<SEC-DOCUMENT>0001193125-25-328743.txt : 20251222
<SEC-HEADER>0001193125-25-328743.hdr.sgml : 20251222
<ACCEPTANCE-DATETIME>20251222161140
ACCESSION NUMBER:		0001193125-25-328743
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20251031
FILED AS OF DATE:		20251222
DATE AS OF CHANGE:		20251222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			enGene Holdings Inc.
		CENTRAL INDEX KEY:			0001980845
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41854
		FILM NUMBER:		251592563

	BUSINESS ADDRESS:	
		STREET 1:		4868 RUE LEVY, SUITE 220
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4R 2P1
		BUSINESS PHONE:		(514) 332-4888

	MAIL ADDRESS:	
		STREET 1:		4868 RUE LEVY, SUITE 220
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4R 2P1
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>engn-20251031.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-12-22T16:09:17.3305+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:engn="http://engene.com/20251031" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_5d4a56b9-586b-4e11-9716-233d70392133" name="dei:EntityCentralIndexKey" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">0001980845</ix:nonNumeric><ix:nonNumeric id="F_b8e47dcb-27f6-41e0-8ad5-35e6889dd47e" name="dei:DocumentFiscalPeriodFocus" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">FY</ix:nonNumeric><ix:nonNumeric id="F_6888b176-5fbf-4c84-9d9c-07293e3092a4" name="dei:AmendmentFlag" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">false</ix:nonNumeric><ix:nonNumeric id="F_ca960d6e-e1b1-404e-8500-f1b61ab7daac" name="dei:EntityIncorporationStateCountryCode" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">A1</ix:nonNumeric><ix:nonNumeric id="F_51d22804-f874-438b-aea4-8e8c33142b8a" name="dei:EntityTaxIdentificationNumber" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">00-0000000</ix:nonNumeric><ix:nonNumeric id="F_19cbb428-9d40-4173-b963-b055e6ae20f0" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_6bb524eb-b790-45cf-97d6-d7746896ad6f" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_e95588c3-c714-4f9f-bfa1-4e84f1995499" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c">http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric id="F_f4615be1-4ad1-4aa9-9576-91c98e5813d6" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73">http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric id="F_d4394cfa-9517-46fa-8508-88aeb275aaf2" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" contextRef="C_09e32747-b91f-4c21-a203-596a312a01af">http://engene.com/20251031#WallStreetJournalMember</ix:nonNumeric><ix:nonNumeric id="F_33e08b81-4198-434a-9055-c3013033bffd" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" contextRef="C_09e32747-b91f-4c21-a203-596a312a01af">http://engene.com/20251031#WallStreetJournalMember</ix:nonNumeric><ix:nonNumeric id="F_0d8e6fbe-0e8d-48be-94c6-063543d24362" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_c36c748c-142e-4749-b840-fae3cd22d5a5" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd">Unlimited</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="engn-20251031.xsd"/></ix:references><ix:resources><xbrli:context id="C_8048b9df-5cd2-4254-af6b-1df01215dbd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_826585ba-14d9-4469-8a8b-c84065002806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82ca66af-1e97-4ce0-adab-8cffb3acd9a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_836b6f28-be7d-407f-8a22-0e6733c24836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8468fb01-e170-4276-bf5a-9ea3008dd3f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84f13fed-94e2-4af5-bddf-2b0f45ef17c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-24</xbrli:startDate><xbrli:endDate>2024-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8544b2e4-4dc3-440f-a656-f66ca9b46e40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8573ef68-8587-44b1-bc31-b24f597df0af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:OctoberPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86803251-d047-4bf0-b674-339fac002c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ab71810-5ab2-4406-b4d3-514255136390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ca9c3a9-bcfe-4cfc-b190-b23c7064bddd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:Personnel-RelatedExpensesExcludingStock-BasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ce99e1b-781b-4b10-a4a6-a47b653599c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d237d2e-9003-4d50-b804-e95a6312f01a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e9a0825-260c-4b9d-90b7-bbd7617e8f5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-10</xbrli:startDate><xbrli:endDate>2025-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f043b0a-21ae-410c-ac96-0271d3d3046e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f0b12b1-19a7-4642-9e3e-cb3fe2551651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90cd8c09-4769-4823-a74e-e5e1dd36b35a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9100563f-205c-44c7-a60a-dd32fc052dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_923c8314-6767-44a6-8d7d-414375566f36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92d33916-bf8e-4140-a042-722d297bdb9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_951877f3-5e88-4367-9785-1d7884a66f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95a2beb8-4e85-43b1-85ca-fbc18197ebed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95fa67fd-790e-4d1c-9cac-d33ccb8066a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96d03257-9ff9-4103-bc83-b064b32da4cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:FebruaryPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97729f6b-370e-489c-98a7-6180fbee0e8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9960e19e-3a5b-4760-a0f1-d9b076862c9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a033399-2b58-4fe0-8140-e6817c28119b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9de67a6b-db13-4cab-b973-3dc0f4942c58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e49cbbf-65d1-430d-a687-9171f3246a39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:IfInterimMilestoneAchievedAndNoDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e58f68c-6bc3-4806-9dbe-08a741a6dfa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ea003c8-a81c-44b8-900c-b2493af5c02e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a090e3b4-1166-4d45-b4d4-8b0b43e3f8be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a09b14e7-c4ab-4158-8d7a-4c0301b562d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a36d4958-0132-4db6-8c04-a6c01658ba4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a38b00d3-e24c-43b5-a082-589eacb61337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9579fc4-c897-4bed-9b7b-0b5cf457408f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:OtherResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa83e563-392e-4d71-8ae7-7474fd972847"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acdf9159-83c9-485f-9bd1-02cedfa90e00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad2092fb-95e1-4908-b08e-8b4a677329ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adfc86f6-5602-4b1b-906a-2f27bffaaf91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af41e941-f65b-47d2-8818-b19e36df5a05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0d9509d-2cde-4f1e-a69c-e980f066e66f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1f2b3cc-0e10-4b83-bbb6-a450052ce673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2244905-4cf1-4e70-8b70-8a3ec973f2f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b291458d-545a-4cdc-a379-778ab2dd0485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:NewLaboratoryAndOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-29</xbrli:startDate><xbrli:endDate>2022-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b57c7e68-7206-43ef-83a4-48c2637e7914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6f75307-46d2-4549-9972-666e9421fcbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b802882b-c5a1-4942-8e3c-1fdf4a877c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba0f02fb-b1f0-4954-bd4f-3c466d2899e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba4e1c8a-00ae-49f4-b36b-9c45988805ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb659fef-c385-43b9-827a-dd3a85171737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc0cb673-5025-437a-86f8-1e9fe06ad733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ClinicalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc14018d-5490-4aba-a323-a2e7f4fe2e46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd2cdf17-9066-447e-bbd3-00fa8ebfeb81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SeveranceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c129c2c8-58f0-43f4-bfdf-85528ac931e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:TwoThousandTwentyFourPipeInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-29</xbrli:startDate><xbrli:endDate>2024-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1ea2072-6521-49ac-9036-975bf2bea853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4f0786b-ed52-43c7-948c-f4930ac10dac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c57bc36e-e49e-472f-83cd-c98e379c32e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-04</xbrli:startDate><xbrli:endDate>2025-06-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c587a04c-25a3-434a-9114-e2f1c6ee0c74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c67c0ca3-bd12-47e1-a7c3-cf98532f1504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7b8ec67-5b1d-4c7f-8db7-8e567d0d0440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c882a3ef-859a-41a2-95d3-51394d6b2ce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9315aeb-75af-4e5d-b506-eb4a1ca94906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9ac9f07-169f-4b39-9e8b-20722b5214f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc2c96fa-b7dc-4174-82d2-d97b5a079517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-29</xbrli:startDate><xbrli:endDate>2024-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdad3c31-b6c0-4967-959f-1627e8533147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce39e6a1-222d-49f4-96cc-9cfa2d2ac439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cebd2d56-16f6-4436-b24a-6359ae1363a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf043049-d331-45c8-a6e7-85747599cf46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d24afdca-87cb-498a-960f-4be785980006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:PhaseIiClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d322beea-35fb-4c80-859d-02cabe66017a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d39e4cc1-c2c2-436d-91fe-df2f1f3ae461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3a16e6c-5f2f-46a8-8d4a-ae4459f30236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4ba6974-9607-41bb-882a-98cb023fc12d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4f15817-44dd-435d-b9a9-e963c46bff1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6033e72-0f44-4d88-8b8a-64261e76903a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6039d83-bedb-4265-a5ba-09c0cc735a4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7356f23-a631-4161-bd89-54fd825f3f25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7458df2-05d3-41ab-b920-651c47e3645b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:TwoThousandTwentyFourPipeInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-20</xbrli:startDate><xbrli:endDate>2024-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8109dad-b66f-4bfb-8c04-ce50e140908e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8f4f613-565b-4dd9-9972-29f9286ff4a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbc9c096-5c22-4cf5-a894-96a9e588ee65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc6a75d1-5e14-43f3-bdf0-8a2ea5c1463f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcdfec87-2888-47ca-a07e-585d35c69c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:OtherResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de15de3c-d6dd-474f-aedc-0db5998ec164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df7d5361-4681-4e11-ba09-2fff4a273c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dffdbdca-904e-4e8d-b739-fd381dc21a3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2f37cd3-8f14-4485-8a97-18812aba3d4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3642777-e12d-430b-aa3d-219b649d5144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3b821c4-4eac-43b3-bad5-9928776d4618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3f5dd26-8cbb-49ba-947e-3a9d2312c431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e634a878-3df9-460e-9159-d57cc1cb247d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-12</xbrli:startDate><xbrli:endDate>2025-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e68a05ca-9f3e-4035-b30c-b74ee7a7e177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6e3703d-5475-4ccd-a165-b5039f0166a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e78a052c-b146-43f0-82ed-460ee1b56df6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e80bdb47-f7b3-430d-b4e8-f25af73e859c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e82b042f-c2f1-4591-a95e-196afa1ab585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e86be109-1a95-4196-ac55-bc2ba9ae5417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec456d2a-f968-4f6c-91e9-ceacc426a74d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee102497-2dad-4531-96db-ff24993a07fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f156578b-8f46-4ad0-9ea8-b91f1797eb52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3d38713-54b7-4d7a-9bcd-88b4b937d366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4a3d6cf-e574-4cf3-b8ec-df2947d5c514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f61eb1b2-4019-491e-996a-2a8485634728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6c04b3e-ddf2-41e5-a4fa-0884f592b542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f955235a-e265-4f5f-9d93-59b1d609f9ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb7a7ff2-f1d8-4421-8eee-75ddcf02c394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd0ed931-526b-4cfb-9b89-94003be94781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe08772b-3b75-4431-99b3-b2403219570c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff785c01-16ce-4fd0-b204-3fe21cdeca9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffb1bf69-b5a8-4516-998f-54b7ad557f99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_019c08b7-c82a-486b-871e-9cb94b318c49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0266c416-4b23-4071-88cb-dd6bf0a921ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:FebruaryPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_038fbf25-9506-4d27-be17-4dc097874279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04e07ed1-3cb5-4c02-a2a7-c7099d04d3e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07c65fa0-4265-4f70-956a-00de275d630a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09e32747-b91f-4c21-a203-596a312a01af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a196932-bb45-4e51-825a-16dde720a445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aad8347-fb07-4df8-ad44-efd7872041dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-14</xbrli:startDate><xbrli:endDate>2025-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0df7a474-8310-4b5a-ad28-db5514624ad7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:Personnel-RelatedExpensesExcludingStock-BasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f0f9870-180f-4dd3-b9c4-ef3ac4ad5d5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:CeoTransitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10beb209-82d9-44f1-a81c-c930ac6ffa93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12fcc884-3c1c-47f6-a197-2a12844cafb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_138b2f29-e2e4-468e-a432-96f0a15a5f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14c30e23-f14f-400e-a50e-517475df9be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16b7f663-ad41-48cc-9a93-5b7ab3af3b3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17444e1c-b04e-4b70-b7f4-f350e405d58b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17725118-e54f-47d5-a64c-c3a544f8f924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17b8691c-0499-4953-869d-643477e53cc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1880048e-dcab-455d-8f72-b54f37487a7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheTwoToTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19e56deb-53a4-4d6b-948d-09e6e90bcf8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ab78818-5433-4a11-a36e-d0983a8bfc04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bd63320-3f8c-40e8-870a-a2cdeaa9bc46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-24</xbrli:startDate><xbrli:endDate>2024-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1be15272-9b4f-4bcf-849e-53caedc2be78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ceadb8f-dcfe-48ff-a395-cc04ab63412f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d3671cc-d989-49b4-adba-e6701da4d6d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ClinicalOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d9d7d3f-3968-47f7-af7e-dd8b5291a3a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e0f6ec7-da3e-436f-8606-34f7da89269a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:RemainingSharesReservedForFutureIssuanceUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ebeba52-1c6c-4bb9-bc2f-7b693e857291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fee1be9-7dcb-46f6-91a8-e987b5b47b59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_222a5d6f-14cb-46e4-a552-efc82189402f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_223bc65f-a711-41ae-93e5-990ae4cc4647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_230bfa79-c42e-4689-8d7a-7064e8c335b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23618105-c2e5-4377-83d6-839699ff1b62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_240506c4-bcce-4242-904f-1aef27639793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_250a9087-119f-4c5b-bf49-75a14a4e74b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2570dccd-3edb-4845-9c23-2fa20a3e119a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25b1651f-4d90-4142-812f-a565d3cf756e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25dc3fbd-7df8-4e6a-9735-4c158848064d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2773bd89-2e98-4a47-a2e5-226327bcbdf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27a237fa-2a01-4b32-b736-267804b23863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a5a88f1-1863-4ab1-bab0-60010f7bda59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cb23464-3212-4cf3-bba9-7c4d415c4691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d00fd55-c9ba-44ab-bd71-904d4195e08b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d71d180-d7f1-445c-a569-e1c8106caa03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e90c670-46cc-4848-9919-7cce02e258fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:CeoTransitionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">engn:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3039a78d-24dd-4c83-bbb1-043d190146b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3070eb61-104a-40f8-be4c-373eeb3fdf18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33a6f084-8206-471e-bfb2-2dda7584d4c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_342954c6-d213-4cd2-9889-aced7e8d67f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3481de95-f470-4b1f-85d0-ee1e20db1594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3538eb76-754e-4b90-b6ae-b9741667f639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36a6765d-a768-434b-b6af-c19baebb16f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37f20ce2-0d85-4e2a-a443-1969a8e12178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_382606a1-c180-49e7-af1d-4f96fb9f4c5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_399413d5-87a5-4355-8641-293745be5095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a4ac89a-0177-4b3c-8437-70136929db99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b8bd64e-b59b-43a4-b1b4-0519c994f6b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:LoanAndSecurityAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fc74f8e-4433-476f-a81c-1803cf2f12f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4051c11c-5290-47d7-8e2a-b368974acadb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_416f76a5-c88c-4d57-baa6-382632288e13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41ba9c19-6515-43e0-a1fc-8f4d1b65dd7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:HerculesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47a4d634-ac1f-4323-9bc5-0785480c857c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47ffee90-525a-4d51-9a91-98932a653084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_496e94d8-a257-4d69-8ba6-932806871284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b5f63d4-ae44-4d1f-a429-c2500140c1cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d87523c-9b2c-422b-88ab-47f28876bac5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d915630-a09a-40c5-956c-ab23b902cf2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d97d0f0-4a5b-489c-b7d4-521214e77828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:PhaseIClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ff723b5-d287-434b-a696-ec3b9aa13f72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_511e94d5-ac9c-4c2e-b367-c6033fb69299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-10</xbrli:startDate><xbrli:endDate>2020-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53d55f9a-d671-4a03-878e-e8d7b35cee90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:PriorLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:AppliedToRefinanceOfAmountOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_545b1b90-fd27-46b0-90e4-68a6f6ffcb9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57ae8deb-9706-4aaa-ab1d-e9fc280a2c06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_585ec894-b0e7-4859-a0a7-ccf1f76d9512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58c8e092-7276-4637-903f-b05e6860130b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cb5ff87-3b6e-4f62-bafd-e58f084904c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e0ae0ab-6ca4-4467-9077-b61b1010d728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6058051e-7700-494e-b243-9c348feb4b05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60b37ed7-9421-4001-bbd1-89a359c2ed0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60ed5f3c-1a4d-4713-9546-b4094d014309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:OctoberPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60f8a68e-e8da-4f5f-bc60-1c69892ea749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61fa00a4-8a04-41ad-8df5-3d8df9828b01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:HerculesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62b3a61d-efba-46df-bdeb-dd04f04c6a18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_631df185-2355-4542-ae58-d1eaa9a937d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6394b714-e543-43ff-9b1c-7ba9b8f9d298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66290f5a-4ebf-4f73-b964-455cb62466aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6691d0be-dbca-4238-ba0d-4650e328c889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dba0949-0813-4fe2-b9df-f3bd190796c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-20</xbrli:startDate><xbrli:endDate>2024-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e273bec-7bf2-4681-92db-741ae2a453db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f8ba018-3c10-4168-9540-f591cd8fe57b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fbe3c27-7c74-4f39-a002-7cb3cad726bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71db83b8-afac-440b-84f1-dbe6aa46e50c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72b405e6-793c-4923-a2ac-fd5c62acce9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72be055a-0ced-4c28-83d8-1cad15ae7d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72c8df98-55d0-47ed-acec-68e231220cf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_737abaae-1e0c-4f1a-8b20-7c57ad401acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7444e3af-f026-4566-9f7c-881accfccf6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7460771b-4637-42ae-b87f-8329a24ece3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:NewLaboratoryAndOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_758f5c72-0590-42c1-b39e-5c9fb4eea3d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_762694e8-c941-454f-ac63-d2e9147b6e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a8c2031-7a18-435b-80ce-180a745a581b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7edc548a-2b6b-40d9-9585-f8a98c0a4267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fc54fca-2826-4f40-b784-cb10a1e8ea92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-02</xbrli:startDate><xbrli:endDate>2025-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_CadPerSquareFoot"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>engn:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_CanadaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>engn:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b05d0bf1-ffe0-4ddd-9149-8871c023e7cc" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_315db525-a1f8-4386-b8c3-c0217a52d495" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25544cb0-53c4-4351-960f-75e51072ec1e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8758164-f9af-4abe-b353-7096b56093e1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93dea500-b646-41ac-81e8-bcab7f7b7c21" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b4464762-2c51-46dc-9562-bb4241caf772" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a4684ec-ec2b-4624-9b9a-442dcf86cb29" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-41854</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1995cff4-ed36-45fc-8da1-e1cbfd6e1069" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enGene Holdings Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_ca960d6e-e1b1-404e-8500-f1b61ab7daac;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">British Columbia, Canada</span></span></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_51d22804-f874-438b-aea4-8e8c33142b8a;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">N/A</span></span></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_c89c60ed-54bb-4b3f-930e-854249732900" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4868 Rue Levy, Suite 220</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_8b6861f2-dfcf-4f97-92bc-45cb9c75f00c" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Saint-Laurent</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_de9451e0-bf38-4dee-8341-27926551a4c7" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_5342f1c3-d3b8-43fb-8732-9ea306cef6cc" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Canada</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0828549b-6816-4878-87fb-ae2a2477f3cf" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">H4R 2P1</span></ix:nonNumeric></span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ce215e4-b0df-421f-8728-5ebf2f391ff9" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">514</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbefdb3d-ea59-4fd7-bfc9-dd7c239f5b02" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">332-4888</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:40%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:40%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_2ba35d0c-467e-4d72-9174-0bcf9c871e18" contextRef="C_e78a052c-b146-43f0-82ed-460ee1b56df6" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Shares</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_de99b655-0838-42b0-abd2-92fbbd9355c3" contextRef="C_e78a052c-b146-43f0-82ed-460ee1b56df6" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ENGN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_19fd1165-8d7a-47a8-9c7c-901a6ae8c972" contextRef="C_e78a052c-b146-43f0-82ed-460ee1b56df6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_a2259443-accf-4595-86c1-cd3e1e3fc7b6" contextRef="C_c4f0786b-ed52-43c7-948c-f4930ac10dac" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_48170895-0633-4144-a9df-c14508864b9f" contextRef="C_c4f0786b-ed52-43c7-948c-f4930ac10dac" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ENGNW</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_554844b6-e245-49ff-9164-8ef0ecbed571" contextRef="C_c4f0786b-ed52-43c7-948c-f4930ac10dac" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="text-indent:2.267%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YES</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3272508f-9578-4635-8332-80298eb88c75" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_324a7963-0136-45c8-bd94-22382b8e3e5c" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad753e47-d127-4bb2-b393-28e7e6775aa6" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e04a339-217b-424a-a9ec-10679c6577d1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:55.84%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:20.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_06a2f29c-e308-4c2f-ac80-a5538574bc6e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c1abd934-56d4-47b8-b7b6-09c9214deb00" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_23973fea-f278-4261-8d0c-0bb70a380ef1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_4f751e7e-af4a-4726-b388-dac04e22bf53" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_15a34eab-166b-4952-9d21-fd2cae5004fe" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6b5c39a2-3a38-4390-bcb0-f4bd86276811" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YES</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9f947ba7-8916-45ea-aae8-a95753f324e9" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the common equity held by non-affiliates of the registrant, based on the closing price of the Common Shares on The Nasdaq Stock Market LLC on April 30, 2025 wa</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_806985e9-4b95-42d5-b2ab-889a28cf3eda" contextRef="C_f61eb1b2-4019-491e-996a-2a8485634728" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">154,176,366</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:2.267%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of the registrant&#8217;s Common Shares outstanding as of</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> December 17, 2025 was </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31d023e9-2f07-45b1-83dc-6f551a5f477e" contextRef="C_a09b14e7-c4ab-4158-8d7a-4c0301b562d5" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">66,984,661</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e656dccf-b2ce-4eed-9640-0bb3c961418c" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the definitive proxy statement of enGene Holdings Inc. to be filed for its 2026 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Auditor Firm Id: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd890491-5e5d-415b-9d78-e398788d1fd3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 					Auditor Name: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61222556-1f80-4f77-8382-5e0265e8c5dd" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			Auditor Location: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac9b222f-a122-4d29-9531-a890966963d3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Montreal, Canada</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:84%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_regarding_forward_look_stmt"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward Looking Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factor_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factor Summary</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_1_business_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_7_managements_discussion_and_anal"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosure About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_8_financial_statements_and_supple"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_9_changes_in_and_disagreements_wit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_10_directors_officers_corporate_gov"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_12_security_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_14_principal_accountant"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_15_exhibits_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
     <td style="padding-top:0.01in;text-indent:12.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="text-indent:-2.319%;padding-left:2.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_16_form"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="special_note_regarding_forward_look_stmt"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REG</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARDING FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain statements in this Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) may constitute &#8220;forward-looking statements&#8221; within the meaning of U.S. securities laws and &#8220;forward-looking information&#8221; within the meaning of Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;). enGene&#8217;s forward-looking statements include, but are not limited to, statements regarding enGene&#8217;s management teams&#8217; expectations, hopes, beliefs, intentions, goals or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;appear,&#8221; &#8220;approximate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;foresee,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Annual Report may include, for example, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance, including financial projections and business metrics and any underlying assumptions thereunder;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain the listing of the Company&#8217;s common shares (&#8220;Common Shares&#8221;) and warrants to purchase Common Shares (&#8220;Warrants&#8221;) on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) or another national securities exchange;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our success in recruiting and retaining, or changes required in, officers, key personnel or directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans and ability to execute product development, manufacturing process development, preclinical and clinical development efforts successfully and on anticipated timelines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to design, initiate and successfully complete clinical trials and other studies for detalimogene voraplasmid, or detalimogene, formerly referred to as EG-70, and any other product candidates we develop and our plans and expectations regarding our ongoing or planned clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impacts and outcomes of our later-stage and pivotal clinical trials and their influence on obtaining the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or comparable foreign regulatory approval to market detalimogene or any future product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans and ability to seek, obtain and maintain marketing approval from the FDA and other regulatory authorities, including the European Medicines Agency (the &#8220;EMA&#8221;), for detalimogene or any other product candidates we develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans and ability to commercialize detalimogene or any other product candidates we develop, if approved by applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the degree of market acceptance of detalimogene or any other product candidates we develop, if approved, and the availability of third-party coverage and reimbursement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our external contract manufacturers to support the manufacturing, release testing, stability analysis, clinical labeling and packaging of detalimogene or any other product candidates that we develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our future financial performance and the sufficiency of our cash and cash equivalents to fund our operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain additional funding on a timely basis;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage the transition of executive-level roles to new leaders, and to attract and retain key executives and employees; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome of any known and unknown litigation and regulatory proceedings, including any legal proceedings that may be instituted against us or any of our directors or officers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to implement and maintain effective internal controls.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are able to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials and acquire technologies complementary to, or necessary for, detalimogene or any other programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are able to enroll, in a timely manner, a sufficient number of patients in each cohort of the Phase 2 LEGEND trial to assess the efficacy and safety of detalimogene including the cohorts with the BCG-na&#239;ve patient population, the BCG-exposed patient population and the BCG-unresponsive, papillary-only Ta/T1 disease;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are able to file our planned Biologics License Application in second half of 2026 with the FDA for approval to market detalimogene in the United States as a monotherapy to treat BCG-unresponsive NMIBC with CIS;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">detalimogene&#8217;s product profile can be integrated seamlessly into community urology clinics where the vast majority of NMIBC patients are treated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are able to retain commercial rights to detalimogene in the United States and commercialize detalimogene independently, while selectively partnering outside of the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are able to execute the &#8220;pipeline-in-a-product&#8221; development strategy for detalimogene; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are able to utilize the DDX gene delivery platform to develop effective, new product candidates for the delivery of genetic medicines to mucosal tissues.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not place undue reliance on these forward-looking statements which speak only as of the date hereof. The forward-looking statements contained in this Annual Report are based primarily on current expectations and projections about future events and trends that may affect our business, financial condition and operating results. The following uncertainties and factors, among other things (including those described in &#8220;Risk Factors&#8221; in this Annual Report), could affect future performance and actual results to differ materially and adversely from those expressed in, anticipated or implied by forward-looking statements:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks applicable to our business, including the heavy dependence on the success of detalimogene and the extensive regulation of all aspects of our business, competition from other existing or newly developed products and treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks associated with the protection of intellectual property, our ability to raise additional capital to fund our product development activity, and our ability to maintain key relationships and to attract and retain talented personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possibility that we may be adversely affected by changes in domestic and foreign laws and regulations, including but not limited to resultant changes in business, market, financial, political, legal or geopolitical conditions, including tariffs, economic sanctions and economic slowdowns or recessions, or prolonged government shutdowns or defunding, and;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect our business; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other risks and uncertainties set forth in the section entitled &#8220;Risk Factors&#8221; in this Annual Report.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements made in this Annual Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report to reflect events or circumstances after the date of this Annual Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="risk_factor_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTORS SUMMARY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to a number of risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report. The principal risks and uncertainties affecting our business includes, among other the following:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend heavily on the success of our lead product candidate, detalimogene voraplasmid, or detalimogene, formerly known as EG-70, which is currently in a clinical trial. Our clinical trial of detalimogene may not be successful. If we are unable to successfully develop, obtain regulatory approval for, and commercialize detalimogene, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to make significant investments in our continued research and development of detalimogene  and other new product candidates, genetic medicines and services we may develop, which, if not successful, would limit our ability to achieve or sustain profitability in the future. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the foreseeable future.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimates of market sizes and forecasts of market growth for the potential demand of our detalimogene product and any other product candidates we develop are based on a number of assumptions and may prove to be inaccurate. The actual market may be smaller than we believe, which would adversely affect our business and results of operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our internal controls over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the trading price of our common stock.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any product revenue, have a history of losses and will need to raise additional capital to fund our operations. If we fail to obtain necessary financing, we will not be able to complete the development and commercialization of detalimogene or our other product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition from other entities, including biotechnology and pharmaceutical companies, which may result in our competitors discovering, developing or commercializing products before us or more successfully than we do. Our business and results of operations could be adversely affected if we fail to compete effectively.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are focusing our research and development efforts on detalimogene, as well as further development of our genetic medicine platform and other product candidates we may develop. As a result, we may forego or delay pursuit of other genetic medicine technologies or other therapeutic product candidates that provide significant advantages over our platform or product candidates, which could materially harm our business and results of operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene and our genetic medicine platform are based on proven novel technologies, which makes it difficult to predict the time and cost of development and the probability or timing of subsequently obtaining regulatory approval.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development of new therapeutics involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs, fail to replicate the positive results from our earlier preclinical or clinical studies of our product candidates in later preclinical studies or clinical trials or experience delays in completing or ultimately be unable to complete, the development and commercialization of any product candidates, including but not limited to detalimogene.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim top-line and preliminary data from our clinical trials will change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have conducted the Phase 1 portion of the LEGEND clinical study of detalimogene, we have not as an organization completed later-stage or pivotal clinical trials or submitted a BLA (as defined below), and we may be unable to do so for detalimogene or any future product candidates in a timely manner or at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our use of third parties to manufacture, develop and test our therapeutic product candidates for preclinical studies and clinical trials increases the risk that we will not have sufficient quantities of our product candidates or products, or necessary quantities of such materials on time or at an acceptable cost.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene is complex to manufacture, and the manufacturing process for any other product candidates we develop may be similarly complex or more complex, and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of our third-party manufacturers with whom we contract encounter these types of difficulties, our ability to supply detalimogene or any other product candidates we develop for clinical trials or as products for patients, if approved, could be constrained, delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market opportunities for detalimogene and any other product candidates we develop may be limited to a small group of patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend on our executive team and key personnel, and if we lose one or more of our executive officers or key employees or are unable to attract and retain highly skilled employees, such events could harm our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development initiatives, manufacturing processes and business depend on our ability to attract and retain highly skilled scientists and other specialized individuals. We may not be able to attract or retain such qualified scientists and other specialized individuals in the future due to the competition for qualified personnel among life science and technology businesses.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nearly all aspects of our activity and our products and services are subject to extensive regulation by various U.S. federal and state agencies and regulatory bodies in non-U.S. jurisdictions, and compliance with existing or future regulations could result in unanticipated expenses or limit our ability to offer our products and services. Regulatory approval is a lengthy, expensive, and inherently unpredictable process with uncertain outcomes and cost and is subject to the potential for substantial delays. We cannot give any assurance whether or when our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict whether or when we will obtain regulatory approval to commercialize detalimogene or any other product candidate we may develop in the United States or any other jurisdiction and any such approval may be for a narrower indication than we seek.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to obtain or if there are delays in obtaining required regulatory approvals for detalimogene or any other product candidates that we may develop, our ability to generate revenue will be adversely affected. Even if we eventually gain approval for detalimogene or any other product candidates, we may be unable to commercialize them.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not obtain or maintain regulatory approval of detalimogene or other product candidates we develop in all jurisdictions in which such approval may be required or otherwise desirable or beneficial from a business perspective, and failure to do so may have a material adverse effect on our business and results of operations. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contract manufacturers are subject to significant regulation with respect to the manufacturing of our current and future product candidates. The manufacturing facilities on which we rely may not meet or continue to meet regulatory requirements and/or may have limited capacity.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug marketing, price controls and reimbursement regulations may materially affect our ability to market and receive coverage for our product candidates, if approved, in the European Union, the United Kingdom, Japan and other non-U.S. jurisdictions.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global economic uncertainty, changes in geopolitical conditions and weakening product demand caused by political instability, changes in trade agreements and disputes, such as armed conflicts between Russia and Ukraine and in the Middle East, and other macroeconomic factors, could adversely affect our business and results of operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain, enforce and defend patent protection for any product candidates we develop or for our novel genetic medicine platform, or if the scope of the patent protection obtained is not sufficiently broad, our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to our Common Shares and Warrants and to Being a Public Company</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of Common Shares, or the perception of such sales, by us or the Selling Holders in the public market or otherwise could cause the market price for our Common Shares to decline and certain Selling Holders still may receive a significant rate of return.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain existing securityholders acquired their securities in our Company at prices that may be below the current trading price of such securities, and may experience a positive rate of return based on such current trading price. Future investors in our Company may not experience a similar rate of return.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that Warrants will be and/or remain &#8220;in the money&#8221; prior to their expiration or that the holders of Warrants will elect to exercise any or all of their Warrants for cash; the Warrants may expire worthless.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will continue to incur increased costs as a result of operating as a public company, and the requirements for public companies may strain resources and divert management&#8217;s attention.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to satisfy Nasdaq&#8217;s continued listing requirements in the future, which could limit investors&#8217; ability to effect transactions in our securities and subject us to additional trading restrictions.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="item_1_business_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span id="part_i_1"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT I</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1. Business.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Background</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enGene Holdings Inc. (together with its consolidated subsidiaries &#8220;enGene&#8221; or the &#8220;Company&#8221;) formed in connection with the Merger Agreement (as defined below), was incorporated as 14963148 Canada Inc. under the federal laws of Canada on April 24, 2023 and changed its name to enGene Holdings Inc. on May 9, 2023. On October 31, 2023, enGene Holdings Inc. continued from being a corporation incorporated under and governed by the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forbion European Acquisition Corporation (&#8220;FEAC&#8221;) was a special purpose acquisition company (&#8220;SPAC&#8221;), incorporated as a Cayman Island exempted company on August 9, 2021 and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the &#8220;Closing Date&#8221;), the Company, FEAC, and enGene Inc., a subsidiary of the Company, consummated the merger (the &#8220;Reverse Recapitalization&#8221; or the &#8220;Business Combination&#8221;) pursuant to a business combination agreement, dated as of May 16, 2023 (the &#8220;Merger Agreement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Reverse Recapitalization, the Company became a publicly traded company and listed its Common Shares and Warrants on the Nasdaq Global Market under the symbols &#8220;ENGN&#8221; and &#8220;ENGNW,&#8221; respectively, commencing trading on November 1, 2023, with enGene Inc. continuing the existing business operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). We are developing non-viral genetic medicines based on our novel and proprietary dually derived chitosan, or &#8220;DDX&#8221;, gene delivery platform, which allows localized delivery of complex genetic cargos directly to mucosal tissues and other organs. Our lead product candidate, detalimogene voraplasmid, or detalimogene, formerly known as EG-70, is a therapy designed to promote a pro-inflammatory, anti-tumor microenvironment throughout the bladder urothelium. We believe this enables the immune system to durably clear the tumor and develop memory to resist recurrence. Because this treatment is designed to work by delivering genetic cargo to the broader tumor tissue environment rather than tumor cells specifically, we believe it has the potential to be utilized across a variety of tumor types. Currently, we are developing detalimogene as a monotherapy to treat non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;) with carcinoma in situ (&#8220;CIS&#8221;) with or without concomitant papillary disease in patients that have been unresponsive to treatment with Bacillus Calmette-Gu&#233;rin, or &#8220;BCG,&#8221; or what is referred to as &#8220;BCG-unresponsive NMIBC with CIS.&#8221; BCG is established as the first-line therapy for patients diagnosed with high-risk NMIBC; however, supply constraints have resulted in a shortage of BCG in the United States for over a decade. We are also exploring the clinical application of detalimogene to various additional NMIBC patient populations, namely, high-risk papillary-only BCG-unresponsive NMIBC (i.e., high-risk NMIBC without CIS), as well as high-risk BCG-na&#239;ve NMIBC patients with CIS and high-risk BCG-exposed NMIBC patients with CIS (i.e., patients who have not received an adequate course of BCG and who do not qualify as BCG-unresponsive in accordance with FDA and urology practice guidelines).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In NMIBC, carcinoma in situ, or CIS, is a flat, high-grade tumor that can invade the deeper layers of the bladder wall if left untreated. A &#8220;high-&#8221; or &#8220;low-&#8221; tumor risk describes the degree to which the tumor pathology appears more likely to grow quickly and invade non-cancerous tissue. NMIBC with CIS, which is high-risk, is typically initially treated with a solution containing the bacterium BCG that is instilled into the bladder multiple times over the course of several months. Despite high initial response rates to this treatment, many of these patients will experience a recurrence that is unresponsive to additional BCG, allowing the cancer to spread throughout, and deeper into, the bladder, often requiring surgical removal of the bladder (this procedure is called a radical cystectomy). We believe patients with BCG-unresponsive NMIBC with CIS are currently underserved with limited FDA-approved treatment options, and that there is a market opportunity for detalimogene as a monotherapy for patients with this condition. While the potential market for detalimogene may not ultimately be limited to these patients, that is our current initial focus in working to bring detalimogene to market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the United States, we estimate that there are approximately 85,000 new patients each year diagnosed with bladder cancer, of which up to 80% present with non-muscle invasive disease. Bladder cancer also poses a long-term management burden with an estimated 730,000 people living with disease. See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;&#8212; Lead Product Candidate and Pipeline Development &#8212; Lead Program: NMIBC Background and Unmet Need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for further information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene is currently being studied in a combined Phase 1/2 open-label trial, referred to as &#8220;LEGEND&#8221; (ClinicalTrials.gov identifier NCT04752722). The Phase 2 portion of LEGEND is comprised of three cohorts: Cohort 1 is a pivotal cohort studying detalimogene in patients with high-risk BCG-unresponsive NMIBC with CIS with or without concomitant papillary disease for which we have completed enrollment with 125 patients; Cohort 2 is evaluating detalimogene in patients with high-risk BCG-na&#239;ve NMIBC with CIS (Cohort 2a, with 30 enrolled patients as of November 11, 2025) and patients with high-risk BCG-exposed NMIBC with CIS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Cohort 2b, with 45 enrolled patients as of November 11, 2025); and Cohort 3 is evaluating detalimogene in  patients with high-risk BCG-unresponsive NMIBC who have papillary disease only (i.e., no CIS, with 36 enrolled patients as of November 11, 2025). In addition, our preclinical research is focused on expanding the cancer indications that can be treated with detalimogene as well as discovering new opportunities to apply our DDX technology platform to treat other indications with high unmet medical needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Competitive Strengths</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene Product Candidate Demonstrated Compelling Preliminary Data in Phase 2 of LEGEND</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; We are developing detalimogene, which has received FDA Regenerative Medicines Advanced Therapy (RMAT) and Fast Track designations, as a monotherapy for patients with BCG-unresponsive NMIBC with CIS who we believe are underserved with limited FDA-approved treatment options. In addition, the LEGEND study has been selected for the U.S. Food and Drug Administration&#8217; (&#8220;FDA&#8221;) Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;) Development and Readiness Pilot (&#8220;CDRP&#8221;) Program. We have released preliminary data from the pivotal arm of the LEGEND study (Cohort 1) on two occasions; the first occasion in which we released Phase 2 LEGEND Cohort c1 data (cut-off date of September 13, 2024) demonstrated that detalimogene was generally well-tolerated across all patients dosed, with no patients experiencing a Grade 3, 4 or 5 treatment-related adverse event (&#8220;TRAE&#8221;) and no drug-related discontinuations. Based on preliminary data corresponding to the September 13, 2024 data cut-off, detalimogene also demonstrated promising clinical activity. Across 21 patients included in the preliminary data, a 71% complete response rate (&#8220;CR&#8221; rate) at any time was observed (15/21), along with a 3-month CR rate of 67% (14/21), a 6-month CR rate of 47% (8/17), and a 6-month Kaplan-Meier CR rate estimate of 51%. Our most recent data update (released on November 11, 2025 and reflective of an October 24, 2025 data cut-off) provided an updated view of preliminary activity and tolerability following implementation of a protocol amendment designed to better align LEGEND with the standard of care amongst urological practitioners treating NMIBC with CIS. Among patients treated under the amended protocol, 62% of patients remained in CR at six months after initiation of treatment, with all evaluable patients at nine months also demonstrating continued CR. Detalimogene continued to demonstrate a generally well-tolerated safety profile in Cohort 1, with treatment-related adverse events primarily Grades 1&#8211;2 in severity and a limited number of Grade 3 events, and no Grade 4 or Grade 5 TRAEs reported at the time of data cut-off. We believe these updated results illustrate the intended benefits of the protocol amendments.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Profile Tailored to the Practical Needs of Clinicians and Patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8212; Gene therapy and genetic medicines products, such as oncolytic viruses, have historically been associated with specific handling or dosing requirements designed for safety reasons to minimize patient, physician, or environmental exposure or risk. These can include use of enhanced personal protective equipment during preparation and administration, required virucidal decontamination of drug product-exposed bodily fluids, such as urine, after exposure to the genetic medicine product, preparative treatment of tissues with a solvent or wash agent, enhanced refrigeration/cold chain on-site storage requirements, and guidance to avoid close personal contact with the patient during the treatment period. By contrast, we believe detalimogene can be handled in accordance with biosafety level 1 guidelines, should not require the aforementioned precautions in handling or decontamination of fluids or bodily surfaces following dosing when handled in accordance with most institutional or standardized guidelines, and has no ultra cold chain on-site storage requirements. We believe these product characteristics, among others, will position detalimogene, if approved, as a preferred choice among both physicians and patients. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Pipeline-in-a-Product&#8221; Potential </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212; Through the combined data generated in the LEGEND study and corresponding preclinical studies, we have demonstrated that detalimogene is able to traverse the mucosal barrier and transfect the underlying epithelial tissues, drive expression of multiple cargos in transfected tissues, and simultaneously activate multiple arms of the immune system. We have further demonstrated in preclinical models the potential for expanding detalimogene to treat solid tumors.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scalable, Proprietary Manufacturing Process </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212; We developed the DDX platform in-house, and in addition, have developed manufacturing processes to produce detalimogene that we believe are robust, cost-effective, and scalable. These manufacturing processes, which involve incorporation of plasmid DNA with the DDX carrier at a defined concentration and mixing rate using commercially available equipment, are patent-protected and involve proprietary know-how. We also have a global, royalty-bearing, non-exclusive license to use certain patents and know-how relating to a proprietary plasmid DNA backbone for high-yield production and efficient transgene expression in target tissues. We believe we have scaled up our manufacturing processes to a level that will be able to meet the needs of a potential commercial launch for detalimogene. We believe our manufacturing process is in accordance with current Good Manufacturing Practice (cGMP) and quality system regulations for drugs and biologics. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary &#8220;Next-Generation&#8221; DDX Platform </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212; We believe our DDX platform has the potential to be the next-generation platform that takes genetic medicine beyond rare diseases and into the mainstream of patient care for larger disease indications. The platform has a high degree of payload flexibility, including the ability to conveniently deliver multiple genes (including DNA and RNA) in a single drug product, and has been demonstrated in preclinical animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> models to effectively induce expression of therapeutic genes in mucosal tissues following delivery to the urinary tract, lung, and gastrointestinal tract, among other organs, all without integration of the genetic cargo into the host&#8217;s genomic DNA. We believe products developed using the DDX platform can overcome many of the significant challenges that have historically faced genetic medicines, including immunogenicity, safety concerns, limited efficacy, high cost of goods, lack </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of commercially viable manufacturing technology, limited ability to effectively target localized diseases, systemic toxicity, and difficulties with effective administration.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Experienced Management Team </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management team has extensive experience across oncology, urology and multiple other therapeutic areas and modalities and is well-equipped to lead our drug development and commercialization efforts.  </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Focus on advancing our lead product candidate detalimogene through late-stage clinical development and seek regulatory marketing approval in the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are focused on bringing detalimogene to market as a monotherapy for patients with BCG-unresponsive NMIBC with CIS who we believe are currently underserved by the recommended standard-of-care of radical cystectomy, a major surgery that carries a high mortality rate, a reduced quality of life, and other significant negative clinical outcomes. In response to this urgent unmet need, the FDA has issued guidance and subsequently updated and maintained this guidance for the design of clinical studies for development of novel NMIBC treatments for patients with CIS who are unresponsive to BCG, with a goal of encouraging development of alternative treatments to this drastic surgery. We have followed this guidance and discussed our detalimogene development plan with the FDA and, after these discussions, the FDA cleared us to initiate the Phase 2 portion of the LEGEND clinical trial, including the pivotal portion (Cohort 1). We currently plan to file a Biologics License Application (&#8220;BLA&#8221;) with the FDA in the second half of 2026 for approval to market detalimogene in the United States as a monotherapy for BCG-unresponsive NMIBC with CIS, and we believe detalimogene&#8217;s product profile will integrate seamlessly into community urology clinics where the vast majority of urologists practice. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Build a fully integrated company by independently commercializing approved products in indications and key geographies where we believe we can maximize the value of detalimogene and any other product candidates we develop</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We currently own all development and commercialization rights for our detalimogene. To bolster our potential return on investment, we currently plan to retain commercial rights to detalimogene in the United States and to commercialize detalimogene independently, while selectively partnering outside of the United States, with the goal of leveraging a potential partner&#8217;s regional expertise and existing sales force to the extent appropriate.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Explore additional clinical applications of detalimogene within high-risk NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Given the persistent high unmet need in high-risk NMIBC outside of the BCG-unresponsive population with CIS, the Phase 2 LEGEND trial is also assessing detalimogene in other indications such as BCG-Na&#239;ve NMIBC with CIS, BCG-exposed NMIBC with CIS, and BCG-unresponsive, papillary-only NMIBC.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe we can potentially develop detalimogene as a treatment for other forms and stages of bladder cancer, including applications within NMIBC and beyond. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we have shown in a murine preclinical orthotopic model of locally advanced bladder cancer that i) administration of detalimogene drives profound and durable anti-tumor immunity, and ii) cured mice exhibit resistance to subsequent local or distal re-challenge with bladder tumor cells due to detalimogene&#8217;s potentiation of a T-cell mediated response within the adaptive immune system. These preclinical observations support detalimogene&#8217;s immunostimulatory mechanism of action and speaks to its potential in more aggressive or advanced diseases where the bladder remains intact, such as locally advanced or metastatic bladder cancer. We further believe that to the extent detalimogene proves to be both safe and effective in more aggressive, high-risk NMIBC populations, it also will have the potential for use in earlier stage low- and intermediate-risk NMIBC populations.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Apply our proprietary DDX platform to other mucosal tissues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We believe that our clinical data to date demonstrate the value and breadth of our DDX platform in delivering genetic medicines to mucosal tissues, especially when combined with our preclinical proof-of-concept studies. We believe this could allow us to use our DDX platform to develop safe and effective new agents beyond detalimogene, thereby unlocking better outcomes for historically difficult-to-treat conditions. Our belief is driven by our DDX platform&#8217;s numerous advantages and points of differentiation relative to other approaches to genetic medicine, which we believe will enable us to apply such medicines beyond their traditional tissues of application such as the liver, muscle, and central nervous system. Importantly, we have also developed a streamlined, end-to-end cGMP manufacturing process that we believe can support commercial launch of detalimogene and can be readily applied to new drug products. </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lead Product Candidate and Pipeline Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidate is detalimogene voraplasmid, which we are developing as a monotherapy for the treatment of NMIBC via the LEGEND study, a multi-cohort Phase 2 open-label study comprised of single-arm cohorts (ClinicalTrials.gov identifier NCT04752722). Cohort 1 of LEGEND, which has enrolled BCG-unresponsive NMIBC patients with CIS, is pivotal, and we plan to incorporate the data from this study in a BLA that we plan to submit no later than immediately following the conclusion of the Phase 2 portion of Cohort 1. In addition to this pivotal cohort, LEGEND has two additional cohorts and three patient groups: Cohort 2a is evaluating detalimogene in patients with BCG-na&#239;ve NMIBC with CIS; Cohort 2b is evaluating detalimogene in patients with BCG-exposed NMIBC with CIS; and Cohort 3 is evaluating detalimogene in patients with BCG-unresponsive NMIBC who have papillary disease only (i.e., no CIS).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following chart shows the enrollment status of each LEGEND cohort as of November 11, 2025, the date of our most recent LEGEND trial update:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_0.jpg" alt="img209334158_0.jpg" style="width:720px;height:251px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All NMIBC cohorts refer to high-risk NMIBC unless otherwise specified.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Detalimogene voraplasmid Mechanism of action</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene consists of a small plasmid DNA encapsulated in nanoparticles using enGene&#8217;s proprietary DDX carrier. These nanoparticles are further coated with a modified polyethylene glycol (PEG) polymer, forming a reversible PEG corona that enhances diffusion through the glycosaminoglycan layer that lines the bladder wall while preserving the particles&#8217; potency. Detalimogene is formulated as an aqueous nanoparticle dispersion in mannitol, then filter-sterilized and lyophilized into a dry powder that can be stably stored under standard refrigeration or freezing conditions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The DDX delivery vehicle is a novel chemical entity proprietary to enGene. It consists of a highly derivatized short-chain chitosan polymer which complexes with DNA to form consistent nanoparticles. The plasmid DNA drug substance encodes three distinct genes: a single-chain interleukin-12 (IL-12) protein and two non-coding RNAs, eRNA11a and VA1, which together activate the retinoic acid-inducible gene I (RIG-I) pathway. The coordinated effects of IL-12 secretion and RIG-I activation stimulate both innate and adaptive immunity, establishing a pro-inflammatory, tumor-killing environment:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_1.jpg" alt="img209334158_1.jpg" style="width:720px;height:374px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mechanistically, detalimogene&#8217;s dual RIG-I agonists work by initiating a signaling cascade that results in the production of Type I interferons (IFN) and proinflammatory cytokines upon recognizing certain double stranded RNA molecules typically associated with cellular pathogens. This in turn stimulates a potent inflammatory response that results in direct tumor cell killing, cytokine-mediated activation of innate immune cells, and the recruitment and cross-priming of T cells. Detalimogene&#8217;s third genetic cargo, IL-12, is an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immunomodulatory cytokine that signals primarily through the IL-12 receptor complex, which is expressed on natural killer (NK), NK-T, and activated effector CD4+ and CD8+ T cells. For these cells, receptor engagement of IL-12 enhances cytotoxicity, e.g., by driving T cell proliferation, polarization to a type 1 helper (Th1) phenotype, and interferon-gamma (IFN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) production. In summary, the activation of RIG-I is intended to induce an innate immune response that will trigger T cell recruitment and cross-presentation of tumor antigens to T cells through induction of mediators such as C-X-C motif chemokine ligand 10 (CXCL10) and Type I IFNs, respectively. The expression of the IL-12 protein is intended to synergistically augment the anti-tumor activity of indwelling effector T cells. Together, RIG-I agonism and IL-12 receptor stimulation function in a two-step mechanism to recruit and activate immune cells to the tumor microenvironment (&#8220;TME&#8221;). Importantly, detalimogene does not need to transfect tumor cells specifically to drive the above effects and can exert its anti-tumor effect by transfecting healthy epithelial cells within the tumor or bladder microenvironment. Importantly, we believe restricting expression of IL-12 to the bladder and tumor microenvironment yields meaningful safety advances. This is important as historically, clinical trials using systemic administration of IL-12 to treat various solid malignancies have resulted in severe dose-limiting toxicities, resulting in a marginal therapeutic index. We believe the clinical data observed to date demonstrate that coupling the potent stimulation of the innate immune system by RIG-I agonism and stimulation of the adaptive immune response by IL-12 provides robust and persistent anti-tumor activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lead Program: NMIBC Background and Unmet Need</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disease Background</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bladder cancer represents a serious, life-threatening condition. Based on data reported through 2020, bladder cancer was projected to result in an estimated 2.7% of all cancer deaths in 2023 while comprising an estimated 4.2% of all new cancer cases according to the National Institute of Health. Overall, according to the American Cancer Society and the National Institute of Health, the chance men will develop this cancer during their life is about 1 in 28; for women, the chance is about 1 in 91. Fortunately, due to early warning signals such as hematuria (the presence of blood in the urine), many instances of bladder cancer are diagnosed while still localized to the bladder urothelium. These tumors, referred to as non-muscle invasive bladder cancer (NMIBC), represent approximately 80% of newly diagnosed bladder tumors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unmet Medical Need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When diagnosed at the non-muscle invasive stage, the goal of treatment is to prevent further tissue invasion (i.e., into the muscle layers of the bladder or beyond), thereby potentially reducing the intensity of needed treatment regimens (e.g., allowing local/intravesical treatment versus systemic/intravenous treatment), improving disease prognosis, and forestalling surgical bladder removal, if indicated. Since the 1970s, the primary therapy for high-risk NMIBC has been intravesical BCG therapy and/or transurethral resection of bladder tumor surgery (TURBT), despite the adverse effects of both treatment approaches. Due to the increased use of BCG in the high-risk setting and loss of several manufacturers of BCG, supply constraints have resulted in a shortage of BCG for commercial use. To manage the limited supply available in the United States, as of February 2019, the American Urological Association and their collaborative physician groups have introduced rationing guidelines that limit use of BCG to high-risk NMIBC patients only. This situation is projected to continue late into the current decade and has brought urgency to the unmet medical need for effective intravesical treatments for patients with high grade NMIBC, according to the American Urological Association.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate that there are approximately 85,000 new patients each year diagnosed with bladder cancer in the United States, of which up to 80% are initially diagnosed with NMIBC. Within this group, we estimate approximately 30% present with high-risk NMIBC (where risk level describes the risk of disease progression to muscle invasion), 35% present with intermediate-risk disease, and 35% present with low-risk disease. NMIBC lesions are further characterized as CIS, Ta, and T1 based on their physical attributes. Ta and T1 lesions are papillary urothelial carcinomas which have not yet penetrated the muscle wall of the bladder. These tumor types are not mutually exclusive within the bladder; at any given time, an NMIBC patient can have papillary lesions only, CIS and papillary lesions, or CIS lesions only. In general, while most NMIBC patients respond favorably to treatment (e.g., transurethral resection of bladder tumor surgery (&#8220;TURBT&#8221;) and/or treatment with BCG), it is estimated that as many as 60% will experience a recurrence within one year, depending on the patient and tumor characteristics. For patients with BCG-unresponsive NMIBC, standard therapy has been radical cystectomy or treatment with systemic therapy, both of which have been associated with significant toxicities and complications, including a lower quality of life, and increased treatment-related morbidity and mortality. No salvage medical or intravesical treatments have been shown to have durable efficacy in BCG-unresponsive NMIBC patients and therefore, we believe there is an unmet medical need for novel non-systemic therapies to treat these patients. This recurrent population represents a population of patients with a need to keep their cancer from becoming invasive while being able to preserve their bladders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Importantly, we believe that the frequency of newly incident high-risk NMIBC per year does not fully capture the number of patients living with this disease. This is because there are multiple channels through which a patient previously diagnosed with low- or intermediate-risk NMIBC may, through the course of their treatment and disease evolution, ultimately present with high-risk disease. For example, a patient whose tumor was initially diagnosed and treated as low- or intermediate-risk NMIBC may recur as high-risk NMIBC. Similarly, a patient treated for BCG-unresponsive high-risk NMIBC with CIS may recur a second time with another high-risk NMIBC lesion and be eligible for another round of treatment. Thus, we believe that the real-world high-risk NMIBC burden is best understood as a combination of both incident and prevalent disease. Unfortunately, for individuals with BCG-unresponsive NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with CIS, which represents the focus of LEGEND&#8217;s pivotal cohort, FDA-approved non-surgical treatment options are few in number and each suffer from significant limitations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Study Design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LEGEND is a Phase 1/2, open-label, multicenter global study with a pivotal Phase 2 study cohort focused on adult patients with NMIBC with CIS who have failed BCG therapy.  The study consists of two phases, beginning with a (completed) Dose-Escalation Phase (Phase 1). The key objective for the Phase 1 portion of the study was evaluation of safety and tolerability and selection of a dose for the Phase 2 portion, and it was not designed to evaluate efficacy in a statistically meaningful way. While not statistically powered for efficacy, an evaluation of efficacy was a secondary objective, with a Phase 2 study to be conducted at the recommended dose. Eligible patients with BCG-unresponsive NMIBC with CIS were enrolled in Phase 1 and additional patients meeting these criteria were enrolled in Cohort 1 of Phase 2, which has now completed enrollment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the pivotal cohort 1, the Phase 2 portion of LEGEND has two additional cohorts: Cohort 2 is evaluating detalimogene in patients with BCG-na&#239;ve NMIBC patients with CIS (Cohort 2a) and BCG-exposed NMIBC patients with CIS (Cohort 2b); and Cohort 3 is evaluating detalimogene in patients with BCG-unresponsive NMIBC who have papillary disease only (i.e., no CIS).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 portion of the study was an open-label, multi-dose study designed to evaluate the safety of detalimogene in high-risk BCG-unresponsive NMIBC patients with CIS, with or without co-occurring papillary disease, and to help determine an appropriate dose for the Phase 2 portion of LEGEND.  This study enrolled a total of 24 patients across multiple dose groups.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Study Design</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patients in Phase 1 received at least one cycle of treatment with detalimogene. A cycle is 12 weeks or approximately three months in duration, which corresponds to the exploratory three-month efficacy endpoint of the Phase 1 study (see below). Those patients who experience CR or stable disease (&#8220;SD&#8221;) at the end of the first three-month treatment cycle could (in association and consultation with their physician) optionally elect to continue receiving treatment for up to a total of four cycles, provided they did not have progressive disease (&#8220;PD&#8221;) on evaluation for response at the end of each cycle. Patients who complete cycle 1 and the additional 3 cycles without PD are followed until PD or for approximately 2 years following their End-of-Treatment Visit, whichever occurs first. In general, we use the terminology &#8220;3-month,&#8221; &#8220;6-month,&#8221; &#8220;9-month,&#8221; and &#8220;12-month&#8221; timepoint to refer to 12-week, 24-week, 36-week, and 48-week timepoints, respectively. We use these terms interchangeably.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Study Endpoints</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint of the Phase 1 study was safety (i.e., characterizing the nature, incidence, relatedness and severity of all observed adverse events (&#8220;AEs&#8221;) and severe adverse events (&#8220;SAEs&#8221;)), with complete response at 3 months and pharmacodynamics of biomarkers assessed as exploratory endpoints.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Results: Safety</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Twenty-four patients received at least one dose of detalimogene in the Phase 1 study, with the total number of treatment-related adverse events (TRAEs) and most commonly reported TRAEs across all 24 patients defined in the table below. The majority (75%) of TRAEs experienced by patients were Grade 1 or 2 and largely consistent with the same events seen with instrumentation, catheterization, and instillation of any intravesical agent. One Grade 3 TRAE was observed in Phase 1. However, on review, it was observed that the patient had a history of renal failure and recurrent obstructive uropathy prior to treatment that was present at screening, and the enrollment criteria for LEGEND were subsequently modified to exclude patients with similar medical history. There was no association between the severity or incidence of AEs and the dose level. In addition, TRAEs were not more frequent or severe in later cycles of dosing. The following table summarizes the Phase 1 safety results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_2.jpg" alt="img209334158_2.jpg" style="width:702px;height:174px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 Results: Efficacy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efficacy at 3 months was assessed by the standard three-criteria efficacy evaluation used for NMIBC, namely urinary cytology, cystoscopic appearance (i.e., an inspection with a cystoscope&#8212;a thin tube with video camera that is inserted into the bladder), and biopsy results of suspicious areas. Biopsies in the former area of CIS were required even if the appearance was normal. In Phase 1, patients without progressive disease were allowed to electively continue study drug after the 3-month visit. In total, 22 patients were dosed with the study drug and evaluable for efficacy at the 3-month visit. One patient included in evaluations for safety evaluation was excluded from efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_3.jpg" alt="img209334158_3.jpg" style="width:643px;height:261px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overall, across all doses, patients dosed with detalimogene achieved a CR, corresponding to a CR rate at any time of 73%. At the 3-month timepoint, this CR rate was 68%, with 82% of patients continuing to receive additional doses of the study drug beyond 3 months. The 6-month CR rate across all doses was 45%. Within the dose selected for the pivotal portion of the study, the CR rates at 3 and 6 months were 70% and 60%, respectively, with 90% of patients continuing on the study drug beyond 3 months.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study Design</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 2 portion of the study is open-label and is comprised of three independent single arm cohorts of patients. Cohort 1, the pivotal cohort, enrolled 125 patients with high-risk BCG-unresponsive NMIBC with CIS, with or without co-occurring papillary disease. Cohort 2 is evaluating detalimogene in high-risk, BCG-na&#239;ve NMIBC patients with CIS (Cohort 2a) or high-risk BCG-exposed NMIBC patients with CIS (Cohort 2b). Cohort 3 is evaluating detalimogene in high-risk BCG-unresponsive papillary only NMIBC patients. Although the treatment is the same for each cohort, an independent set of analysis will occur for each cohort. As of November 11, 2025, Cohorts 2a, 2b, and 3 had enrolled 30 patients, 45 patients, and 36 patients, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Phase 2, treatment cycles are 12 weeks in duration and dosing occurs at weeks 1, 2, 5 and 6 of each 12-week cycle. Patients are administered 800&#181;g/ml intravesically at each dosing. In addition to urine cytology and cystoscopic inspection, a bladder mapping biopsy to confirm a CR is required at the 12-month evaluation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all subsequent evaluation cycles beyond week 12 (e.g., weeks 24, 36, 48, and beyond), the presence of any high-risk tumor in the bladder will render a patient ineligible to continue on-study. More specifically, (i) patients with no evidence of high-risk tumor will be classified as in CR, remain on-study, and enter the next 12-week course of therapy as specified in the protocol, whereas (ii) patients with biopsy-confirmed evidence of CIS, high-risk Ta, or high-risk T1 disease or greater will be classified as non-CR and will discontinue the study. Patients who remain in CR at week 48 will enter maintenance treatment for up to four 12-week cycles through week 96. Maintenance treatment will consist of 2 detalimogene instillations per 12-week cycle, administered at week 1 and at week 2. Patients in CR at the end of the 8 cycles (week 96) can choose to continue in maintenance treatment for up to 4 more cycles (through week 144) or enter a follow-up period for quarterly visits (every 12 weeks) through week 144 or until non-response.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study Endpoints</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the second half of 2025, following discussions with FDA, the Company announced the primary endpoint for Cohort 1 will change to percentage of patients with CR at any time, based on cystoscopic exam, urine cytology, and biopsies, from its previous primary endpoint of landmark CR rate at 48 weeks. This updated primary endpoint is consistent with recently approved products for BCG-unresponsive NMIBC registered with FDA. Key secondary endpoints include duration of response of the responding patients and percentage of patients with duration of response &#8805;1 year, CR rates at landmark timepoints, progression-free survival, and cystectomy-free survival.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study: Preliminary Efficacy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 26, 2024, we shared preliminary data from the first 21 patients who had reached their 12-week evaluation in the ongoing pivotal cohort of the LEGEND study, including 17 patients who were also assessed at six months. The CR rate at any time was 71%, the CR rate at three months was 67% and the CR rate at six months was 47% (Kaplan Meier estimate of 51%). The data cut-off date was September 13, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study: Preliminary Safety</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene&#8217;s overall tolerability profile as presented in September 2024 was favorable, and there were no drug-related discontinuations in the study as of this date. Of the 42 patients assessed for safety, inclusive of all Phase 2 cohorts, 48% experienced at least one treatment-related adverse event (TRAE), which were mainly Grade 1/2 in severity. The most common TRAEs were dysuria (21.4%), bladder spasm (19%), pollakiuria (11.9%) and fatigue (11.9%). There were no Grade 4 or Grade 5 TRAEs reported.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study: Protocol Amendment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with the preliminary data presented on September 26, 2024, we announced an important amendment to the LEGEND Phase 2 protocol that, among other changes, modified how patients are evaluated and treated at key points during the trial. The amended LEGEND protocol stipulates that patients who present with CIS plus T1 disease at screening must undergo an initial TURBT to remove the T1 lesion, followed by a secondary resection at the lesion site. Should residual T1 disease be present following the second resection, the patient is ineligible to enter the LEGEND trial. Regarding patient assessment at the end of the first 12-week cycle, patients will be evaluated as follows: (i) patients with no evidence of high-risk tumor will be classified as being in CR, will remain on-study, and will enter the next 12-week course of therapy; (ii) patients with disease that has not responded to therapy but not progressed in stage will be classified as not in CR, will have any papillary lesions resected via TURBT, will remain on-study, and will enter the next 12-week course of therapy; and (iii) patients with disease that has progressed in stage will be required to come off-study. If a patient is suspected of having persistent or recurrent disease at 6 months, or recurrent disease at 9 months, biopsy confirmation is required to remove a patient from the study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_4.jpg" alt="img209334158_4.jpg" style="width:646px;height:201px;"/></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study: Updated Preliminary Efficacy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 11, 2025, the Company announced updated preliminary efficacy data from two patient subpopulations of the intent-to-treat ("ITT&#8221;) patient population of Cohort 1, which the Company defines as of (i) patients who received at least one dose of detalimogene and had at least one post-baseline disease assessment and were enrolled prior to the amendment of the protocol in the fourth quarter of 2024 (the "Pre-Protocol Amendment Patients&#8221;) and (ii) patients who received at least one dose of detalimogene and had at least one post-baseline disease assessment and were enrolled following the amendment of the protocol in the fourth quarter of 2024 (the "Post-Protocol Amendment Patients&#8221;). As of October 24, 2025, the ITT population consisted of 31 Pre-Protocol Amendment Patients and 62 Post-Protocol Amendment Patients. An additional 10 patients who were enrolled prior to the protocol amendment in the fourth quarter of 2024 were included in the updated data for the Pre-Protocol Amendment Patient subpopulation. The table below summarizes preliminary efficacy results from the two separate patient subpopulations:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_5.jpg" alt="img209334158_5.jpg" style="width:602px;height:245px;"/></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data as of October 24, 2025.</span><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* ITT: Intent-To-Treat population includes all Pre-Protocol Amendment Patients and Post-Protocol Amendment Patients, respectively, who received at least 1 dose of treatment and had at least 1 post-baseline disease assessment.</span><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** CR rates at 6 months include only patients who were evaluable at the 6-month timepoint or had disease progression prior to the 6-month assessment.</span><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CI: 95% Confidence Interval</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preliminary efficacy data for Pre-Protocol Amendment Patients demonstrated a markedly lower 12-month CR rate than those of FDA-approved products for BCG-unresponsive NMIBC patients.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among the Post-Protocol Amendment Patients, four patients that did not have a CR at the 3-month assessment converted to a CR at the 6-month assessment. In addition, of the 23 patients in this subpopulation that had a CR at the 6-month assessment, five patients remained in CR at the 9-month assessment, 17 patients were pending their 9-month assessment and one patient dropped out of the study prior to the 9-month assessment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2 Study: Preliminary Safety Update</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene&#8217;s overall tolerability profile was favorable. Of the 125 patients assessed for safety in Cohort 1, as of October 24, 2025, 42% experienced at least one TRAE, which were mainly Grade 1/2 in severity, except for three patients (2.4%) that experienced Grade 3 TRAEs. The following table contains an overview of this preliminary safety data:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><img src="img209334158_6.jpg" alt="img209334158_6.jpg" style="width:720px;height:340px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* 2 patients experienced urinary tract infection, 1 experienced pyelonephritis.</span><span style="color:#7f7f7f;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#7f7f7f;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data as of October 24, 2025; Data collection and cleaning is ongoing, TRAE = Treatment-Related Adverse Event.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Detalimogene voraplasmid: Design and Mechanism of Action</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene contains a non-integrative plasmid DNA (pDNA) packaged in our proprietary DDX delivery platform that is further combined with the excipient polyethylene glycol-b-poly-L-glutamic acid (PEG-b-PLE), a di-block co-polymer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_7.jpg" alt="img209334158_7.jpg" style="width:480px;height:94px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pDNA component of detalimogene encodes the two linked subunits (p40 and p35) of the human (h) IL-12 cytokine. Also encoded within the same plasmid are two RNA products (adenoviral VA RNA1 (VA1) and eRNA11a; annotated together as eRNA41H) that coordinate to activate RIG-I. The dsRNA directly agonizes the intracellular protein RIG-I, while VA1 is an inhibitor of adenosine deaminase acting on RNA (ADAR), an RNA editing enzyme, and the double-stranded RNA-dependent protein kinase (PKR), a protein translation inhibitor. Together, VA1 and eRNA11a synergistically boost RIG-I activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Analysis of intravesical mEG-70 treatment in an orthotopic bladder cancer model</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To evaluate the therapeutic benefit of detalimogene preclinically, an orthotopic model of murine bladder cancer was established by implanting syngeneic MB49 urothelial carcinoma cells that stably express luciferase (MB49luc) into murine bladders. Baseline tumor burden was confirmed by bioluminescence using in vivo imaging before two weekly IVI of mEG-70, a murine-reactive surrogate for detalimogene voraplasmid, with the study design captured in the top panel of the figure below. mEG-70 mediated a dose-dependent reduction of pre-existing tumor burden as evidenced by diminished bioluminescent signal on Day 29 of the study. Note in the figure below, the right panel displays individual animals, with the color scale indicating the intensity of the tumor signal, from blue (lowest) to red (highest), and areas without color indicating a lack of tumor. The graph on the left displays the geometric mean across all animals, &#177; 95% confidence interval.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_8.jpg" alt="img209334158_8.jpg" style="width:480px;height:192px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We further examined the durability of the anti-tumor response by monitoring long-term survival until all mice succumbed to bladder cancer or were deemed cured, which was defined as no evidence of bioluminescent signal with no clinical signs of bladder cancer, including palpable bladder mass and hematuria. Over 90% of mice treated with mEG-70 had durable anti-tumor responses as demonstrated by long-term disease-free survival with no disease relapse during the 100-day monitoring period. In contrast, about 90% of sham-treated animals had succumbed to disease during the same period. We believe these data demonstrate the rapid, robust, and durable anti-tumor effects of mEG-70 in the orthotopic model of bladder cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Long-term effects, immunological memory, and systemic immunity mediated by mEG-70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the long-term survival benefit and lack of relapse in mEG-70-treated animals suggested that immunological memory may have been established. To further explore this, we examined protective immunity against tumor re-challenge, wherein mEG-70-treated mice with complete disease regression and no relapse (&#8216;mEG-70-cured&#8217;) were re-challenged orthotopically with MB49luc cells to assess protection from recurring disease. All mEG-70-cured mice were resistant to tumor recurrence, as shown by negative bioluminescence signal up to 3 weeks after re-challenge. In contrast, indicative of tumor burden, all age-matched na&#239;ve controls had positive bioluminescence signal following cell implantation (figure below; bottom panel displays luminescence from each individual animal reflecting tumor burden from luciferase expression with the color scale indicating the intensity of the tumor signal, from blue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(lowest) to red (highest), and areas without color indicating a lack of tumor; top panel reflects geometric means &#177; 95% confidence interval).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_9.jpg" alt="img209334158_9.jpg" style="width:384px;height:318px;"/></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As shown in the figure below, to determine if local treatment to the bladder results in systemic anti-tumor immunity, mice cured of orthotopic bladder cancer by mEG-70 were challenged with MB49luc cells subcutaneously on the flank and tumor growth was monitored. Although age-matched na&#239;ve controls showed rapid tumor growth, all mEG-70-cured mice remained tumor free up to 50 days post-rechallenge. To investigate whether the abscopal anti-tumor immunity was specific to MB49luc cells, a separate cohort of mice was re-challenged with antigenically distinct melanoma tumor cells (B16-F10). Although mEG-70-cured mice were resistant to re-challenge with MB49luc cells, the B16-F10 tumors grew on the mouse flank, suggesting that long-term anti-tumor effect is antigen-driven and specific to the primary tumor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img209334158_10.jpg" alt="img209334158_10.jpg" style="width:480px;height:197px;"/></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Bladder Cancer Indications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our preclinical data package utilizes the MB49 cancer cell line, which, when instilled into the bladder of a mouse, can generate tumors reflective of muscle invasive bladder cancer. We believe that the preclinical data we have gathered using this murine model system, especially the data suggesting mEG-70 drives a potent immune memory effect that renders the host resistant to tumor re-challenge, could potentially support the use of detalimogene in other forms of bladder cancer, such as muscle invasive disease, as well as other forms of NMIBC such as intermediate-risk disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with our clinical development plan, we are planning to file a BLA for detalimogene for the treatment of NMIBC patients who are BCG-unresponsive with CIS in the second half of 2026 based on the expected Phase 2 results from the pivotal cohort of the LEGEND study, if the results support filing. If the FDA grants us marketing approval for detalimogene in the United States, we currently plan to commercialize detalimogene in the United States ourselves. Our current plan is to establish a U.S.-focused sales and marketing organization to coordinate with high-prescribing community urology centers in the United States. As part of our commercialization strategy, our plan is to also establish a specialty urologic medical science liaison team to support scientific exchange</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with and education of physicians and scientists about detalimogene. To proactively support these efforts, we will seek to continue expanding our relationships with key opinion leaders as well as our trial investigators while expanding physician and patient education about the potential benefits of detalimogene versus alternative therapies. We have not yet determined our commercialization strategy outside of the United States.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene voraplasmid is a nanoparticle suspension containing the plasmid deoxyribonucleic acid (pDNA) drug substance encapsulated in a proprietary polymer, DDX, and further combined with a custom-manufactured methoxy-poly(ethylene glycol)-block-poly(L-glutamic acid) diblock co-polymer (abbreviated as PEG-b-PLE). DDX and PEG-b-PLE are novel excipients. The drug product is formulated as an aqueous nanoparticle dispersion, filter sterilized, lyophilized to a dry powder, and stored at -20&#176;C.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently own or operate any manufacturing facilities for the clinical or commercial production of drug product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have leveraged our internal expertise and know-how to develop and scale up the manufacturing processes for our proprietary DDX and drug product before transferring them to qualified external contract manufacturers or contract manufacturing organizations (&#8220;CMO&#8221;). Additionally, we are conducting studies to understand and establish controls for all critical process parameters and critical quality attributes for our drug product. The PEG-b-PLE excipient and pDNA drug substance are custom manufactured and purchased from qualified cGMP manufacturers located in the European Union. All critical excipients, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of detalimogene for the BCG-unresponsive NIMBC indication in the United States if approved by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our manufacturing processes are robust, cost-effective and scalable. These manufacturing processes are patent-protected and involve significant proprietary know-how. We also have a global, royalty-bearing, non-exclusive license to use certain patents and know-how relating to a proprietary plasmid DNA backbone for high-yield production and efficient expression of transgene in target tissues. Our manufacturing process is in accordance with current Good Manufacturing Practice (cGMP) and quality system regulations for drugs and biologics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely on our commercial relationships with independent CMOs to supply our clinical trials. We have performed detailed quality audits in the past and will continue to conduct periodic quality audits of their facilities per existing quality agreements. We believe that our suppliers will be capable of providing sufficient quantities of each component to meet our clinical trial supply needs, as well as our commercial launch within the United States if and when approved by the FDA. We have supply agreements in place with multiple CMOs to support manufacturing, release testing, stability analysis, clinical labeling and packaging of detalimogene for the Phase 2 portion of the LEGEND study. We plan to enter into long term commercial supply agreements with selected qualified CMOs to supply detalimogene in the event that we are granted marketing approval in the United States. Other CMOs may be used in the future for commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability to protect, obtain, enforce and maintain exclusivity around our gene delivery technology and product candidates through intellectual property protection, as well as our ability to operate without infringing, misappropriating or otherwise violating the proprietary rights of others and to prevent others from infringing, misappropriating or otherwise violating our proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect, maintain, enforce and enhance the proprietary technology, inventions and improvements that are commercially material to our business, including by seeking, maintaining and defending our patent rights. We have and are expecting to maintain granted patents, and we continue to file and prosecute patent applications directed to our modified oligomeric chitosan-based nanoparticle gene delivery technology independently or in combination with therapeutic genes in an effort to establish intellectual property positions relating to new compositions of matter and novel treatments of various indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely, in part, on trade secrets and know-how to maintain exclusivity to our technology. We strive to protect our proprietary information that is not covered by registered intellectual property instruments by entering into confidentiality and invention assignment agreements with employees, collaborators and consultants. While protecting trade secrets and know-how presents challenges due to, for example, movement of personnel and the natural evolution of the knowledge in the field of our technology over time, we strive to actively manage exchanges of information with third parties to minimize the risks of dissemination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Portfolio</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio includes composition of matter, method of treatment and manufacturing process protection for our lead product candidate detalimogene. We have taken a multi-tiered approach to our patent strategy, and in doing so we have captured a series of sequential technical developments leading to and incorporated within detalimogene.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First, as of October 31, 2025, we own two patent families comprising seven granted U.S. patents, two pending U.S. non-provisional applications, and 85 corresponding granted foreign patents and pending foreign patent applications in jurisdictions including Australia, Brazil, Canada, China, Eurasian Patent Organization, the European Patent Office, Austria, Belgium, Switzerland, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hong Kong, Hungary, Ireland, Italy, Luxembourg, Latvia, Macedonia, Netherlands, Norway, Poland, Portugal, Sweden, Slovenia, Slovakia, Turkey, Israel, India, Japan, Philippines, Republic of Korea, Mexico, New Zealand, Singapore and South Africa with claims directed to the dual-derivatization scheme that constitutes the core of our DDX-based gene delivery platform, including granted and pending composition of matter claims relating to the nature of the hydrophilic polyol used in the dual derivatization scheme, as well as methods of use and treatment. The U.S. and foreign patents directed to this subject matter will expire between 2033 and 2034, absent any applicable patent term extension or patent term adjustment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second, as of October 31, 2025, we own one patent family comprising one U.S. non-provisional application and 15 corresponding granted foreign patents and pending foreign patent applications pending in jurisdictions including Australia, Brazil, Canada, China, the European Patent Office, Hong Kong, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Philippines, Singapore and South Africa with claims directed to the non-covalent, reversible coating of our nanoparticle technology for enhanced delivery, which enhances transfection and gene expression in detalimogene. The pending claims include compositions of matter and methods of use, and the patents issuing from this patent family will expire in 2040, absent any applicable patent term extension or patent term adjustment. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third, as of October 31, 2025, we own one patent family comprising one U.S. non-provisional application and 15 corresponding foreign patent applications pending in jurisdictions including Australia, Brazil, Canada, China, the European Patent Office, Hong Kong, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Philippines, Singapore and South Africa with claims directed to the unique combination of immunological cargos, IL-12 and RIG-1 agonists, that are delivered in detalimogene, including composition of matter claims relating to alternatives to our RIG-I agonists, as well as methods of using same in the treatment of mucosal cancers. The patents issuing from this patent family, if any, will also expire in 2040, absent any applicable patent term extension or patent term adjustment. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth, as of October 31, 2025, we own one patent family comprising one granted U.S. patent, one pending U.S. non-provisional application, and six corresponding granted foreign patents and pending foreign patent applications in jurisdictions including Australia, Canada, China, the European Patent Office, Israel and Japan with claims directed to the use of our chitosan-based nanoparticle gene delivery technology in the treatment of various inflammatory gut disorders. The patents issuing from this patent family will expire in 2037, absent any applicable patent term extension or patent term adjustment. In this patent family, U.S. Patent No. 11,603,398 received a patent term adjustment of 154 days thereby extending the expiry date to at least April 12, 2038. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fifth, as of October 31, 2025, we own one patent family comprising one U.S. non-provisional application and four corresponding foreign patent applications pending in jurisdictions including Australia, Canada, the European Patent Office and Hong Kong with claims directed to the use of our chitosan-based nanoparticle gene delivery technology in the treatment of various lung disorders. The patents issuing from this patent family, if any, will expire in 2041, absent any applicable patent term extension or patent term adjustment. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sixth, as of October 31, 2025, we own one patent family comprising one U.S. non-provisional application and 15 corresponding foreign patent applications pending in jurisdictions including Australia, Brazil, Canada, China, the European Patent Office, Hong Kong, Israel, India, Japan, Republic of Korea, Mexico, New Zealand, Philippines, Singapore and South Africa with claims directed to the use of detalimogene in the treatment of various metastatic cancers, based on data obtained in one of the cancer models. The patents issuing from this patent family, if any, will expire in 2042, absent any applicable patent term extension or patent term adjustment. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seventh, as of October 31, 2025, we own one patent family comprising two granted U.S. patents and corresponding granted foreign patents in jurisdictions including Australia, the European Patent Office, Belgium, Switzerland, Germany, France, United Kingdom, Ireland, Liechtenstein, Netherlands, Hong Kong, and New Zealand with claims directed to the use of low molecular weight chitosan in oral gene delivery, including composition of matter and method of use claims. The US and foreign patents directed to this subject matter will generally expire in 2027, absent any applicable patent term extension or patent term adjustment. In this patent family, U.S. Patent No. 8,846,102 received a patent term adjustment of 1737 days thereby extending the expiry date to at least December 31, 2031, and U.S. Patent No. 9,404,088 received a patent term adjustment of 736 days thereby extending the expiry date to at least April 4, 2029.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eighth, as of October 31, 2025, we own one patent family comprising three granted U.S. patents and 28 corresponding granted foreign patents in jurisdictions including Australia, Canada, China, the European Patent Office, Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Iceland, Italy, Netherlands, Norway, Poland, Portugal, Sweden, Slovenia, Hong Kong, Israel, Japan, Republic of Korea, Mexico, India and Singapore with claims </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">directed to certain methods of manufacturing our nanoparticles, including composition of matter, methods of making, and product-by-process claims. The US and foreign patents directed to this subject matter will expire in 2028, absent any applicable patent term extension or patent term adjustment. In this patent family, U.S. Patent No. 8,722,646 received a patent term adjustment of 327 days thereby extending the expiry date to at least August 19, 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.926%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.070513494751457%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ninth, as of October 31, 2025, we have one pending PCT application directed to the optimized clinical treatment protocol for detalimogene in the treatment of bladder cancer, based on the LEGEND study (NCT04752722). The patents issuing from this patent family, if any, will expire in 2044, absent any applicable patent term extension or patent term adjustment.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.926%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.070513494751457%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tenth, as of October 31, 2025, we have one pending U.S. provisional application directed to improved compositions and methods for expressing genetic medicines in the bladder. The patents issuing from this patent family, if any, will expire in 2046, absent any applicable patent term extension or patent term adjustment. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.926%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.87%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.070513494751457%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, as of October 31, 2025, we have one pending U.S. provisional application directed to the treatment of bladder cancer with immunomodulatory antibodies. The patents issuing from this patent family, if any, will expire in 2046, absent any applicable patent term extension or patent term adjustment. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional patent application to which priority is claimed. In the United States, patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years beyond the expiration of the patent under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. There is no guarantee that the applicable authorities will agree with our assessment of whether any extensions should be granted, and if granted, the length of these extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our general filing strategy regarding registrable intellectual property is to seek patent protection in major markets. For example, our core DDX-based gene delivery technology is protected by issued patents in the United States, Europe (with country coverage within Europe), Japan, China, Hong Kong, India, Eurasia, South Korea, Canada, Australia, New Zealand, Brazil, Mexico and several other jurisdictions. Our filing strategy typically involves the filing of an international PCT patent application followed by national filings in specific countries. The selection of countries is made on a case-by-case basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent portfolio currently comprises eleven patent families, which include approximately 135 issued patents and 64 pending patent applications, including 13 issued U.S. patents, four issued European patents (with country coverage within Europe), seven non-provisional pending U.S. applications, six European pending applications, one pending PCT application, and two pending U.S. provisional applications. enGene exclusively owns all eleven patent families in its patent portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies like us are generally uncertain and involve complex legal, scientific, and factual questions. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents or will be commercially useful in protecting our commercial products and methods of using and manufacturing the same. We also cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold or control may be challenged, circumvented or invalidated by third parties. In addition, our agreements and security measures protecting our trade secrets and know-how may be breached, and we may not have adequate remedies for any such breach. Further, our trade secrets may otherwise become known or independently discovered by competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for important information about risk related to our intellectual property.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 10, 2020, we entered into a non-exclusive license agreement (the &#8220;License Agreement&#8221;) with Nature Technology Corporation (&#8220;NTC&#8221;) pursuant to which NTC granted enGene a worldwide non-exclusive, royalty-bearing and sublicensable license to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain patents and know-how relating to the Nanoplasmid</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vector backbone that is used in detalimogene voraplasmid to research, develop, make, use, import, sell and offer to sell, any gene and cell therapy products incorporating the Nanoplasmid</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vector backbone (excluding any such products in the field of dermatology). The licensed intellectual property includes 10 patent families (inclusive of all related divisional, continuation, continuation-in part, substitutes, counterparts and/or any foreign equivalents filed in any country within such family) and certain know-how. NTC is solely responsible for the preparation, filing, prosecution, cost and maintenance of all patent applications and patents included in the licensed intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless terminated earlier, the License Agreement will continue until no valid claim of any licensed patent exists in any country. NTC may terminate the License Agreement if we fail to make any payments within a specified period after receiving written notice of such failure. Either party may terminate the License Agreement in the event either party commits a material breach and fails to cure such breach within a certain period. We can terminate the License Agreement for convenience with prior notice to NTC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the License Agreement, we are obligated to make annual payments of $50 thousand until the first sale of a product for which a royalty is due and make a payment to NTC of $50 thousand upon assigning the License Agreement to a third-party. We are also required to make a one-time payment of $50 thousand for the first dose of a product covered by a valid claim of a licensed patent (a &#8220;Milestone Product&#8221;) in the first patient in a Phase 1 clinical trial or, if there is no Phase 1 clinical trial, in a Phase 2 clinical trial, as well as a one-time payment of $450 thousand upon regulatory approval of a Milestone Product by the FDA. The first milestone related to the first dose of a Milestone Product was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a Milestone Product, has not been achieved as of the year ended October 31, 2025. We are also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by us, our affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the License Agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. In the event that we or any of our affiliates or sublicensees manufacture any GMP lot of a licensed product, then we or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. Such manufacturing payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory. Under the License Agreement, enGene is permitted to sublicense our rights to third parties and we are not required to share any of the license revenue with NTC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NTC was acquired by Aldevron, LLC in January 2022. The terms of the existing License Agreement described above remained the same. See "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements - Note 7, License Agreement and Clinical Research Organization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">" for additional information about the License Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition, and strong defense of intellectual property. While we believe that detalimogene and our knowledge, experience and scientific resources provide us with competitive advantages, we may face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among other things.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either independently or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than we are in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval for treatments and achieving widespread market acceptance. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than products we may develop. In geographic locations that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of other drugs. The key competitive factors affecting the success of any products we may develop are likely to be their efficacy, safety, convenience, price and availability of reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are five FDA-approved products for the treatment of high risk NMIBC patients that are unresponsive to BCG, and multiple companies have therapies in clinical development for such treatment. While many of these products are neither intravesical nor monotherapy, they may nonetheless compete with us for patient recruitment in clinical trials as well as for commercial sales, if detalimogene is approved. Furthermore, to the extent Merck &amp; Co. (&#8220;Merck&#8221;) or another manufacturer increases the supply of BCG, there may be less demand for alternative treatments such as detalimogene in BCG-na&#239;ve or BCG-exposed patients. In addition, there are numerous companies that have commercialized or are developing treatments for NMIBC, including Aura Biosciences, Inc.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AstraZeneca, Bristol Meyers Squibb, CG Oncology Inc., Hoffman-La Roche AG (Roche), ImmunityBio Inc., Johnson &amp; Johnson Inc., Merck, Protara Therapeutics, Inc., Pfizer, Inc., and UroGen Pharma, Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competing products include, among other things, the following FDA-approved products:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adstiladrin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (nadofaragene firadenovec), a non-replicating adenoviral vector-based genetic medicine that is manufactured and marketed by Ferring Pharmaceuticals A/S. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Keytruda</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pembrolizumab), a Merck product, for the treatment of patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VALSTAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (valrubicin), marketed by Endo Pharmaceuticals, an anthracycline topoisomerase inhibitor for intravesical treatment of BCG-refractory CIS of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anktiva</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (nogapendekin alfa inbakicept-pmln), marketed by ImmunityBio, an engineered IL-15 superagonist protein complex that is approved for use in patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors, when administered in combination with BCG. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inlexzo&#153; (gemcitabine intravesical system), marketed by Johnson &amp; Johnson, intravesical drug-releasing system that is placed into the bladder and slowly releases gemcitabine, a chemotherapeutic agent, that is approved for use in patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors &#8212; Risks Related to Our Business &#8212; We face significant competition from other biotechnology and pharmaceutical companies, which may result in our competitors discovering, developing or commercializing products before us or more successfully than we do. Our business and results of operations could be adversely affected if we fail to compete effectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for important information about risks respecting competition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development, production, testing, distribution, and marketing of biologics like the ones we are developing are subject to strict regulations by various U.S. federal, state, and local agencies in addition to foreign regulatory authorities. These regulations cover a wide range of aspects, including research, safety, efficacy, labeling, packaging, storage, distribution, and advertising, as well as post-approval monitoring and reporting. Our Company, as well as our vendors, partners, contract research organizations (CROs), and manufacturers, will need to comply with these regulations. To gain approval for our product candidate, we need to comply with the regulatory requirements of various governing agencies, including those related to preclinical and clinical trials, manufacturing, and commercialization. This process requires a significant investment of time and financial resources. In the United States, our focus market, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and other federal, state, and local regulations also apply. Our lead product candidate, detalimogene, is not yet approved for marketing in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors &#8212; Regulatory Risks</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for important information about risks respecting regulatory matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain approval for our product candidates for therapeutic use in the United States, we must follow a series of steps regulated by the FDA. This includes conducting preclinical studies in compliance with regulations, meetings with the FDA, submitting an investigational new drug application, or &#8220;IND,&#8221; to the FDA, obtaining institutional review board, or &#8220;IRB,&#8221; or ethics committee approval at each clinical trial site, conducting clinical trials in compliance with Good Clinical Practice (&#8220;GCP&#8221;) requirements, preparing and submitting a BLA accompanied by fees, undergoing FDA pre-approval inspections of manufacturing facilities, and having potential FDA audits of the clinical trial sites. Finally, the FDA will review and approve the BLA and provide any recommendations before the biologic drug can be sold commercially in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical and clinical testing of biological drug products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to test a drug or biologic in humans, it must first undergo extensive preclinical testing, which includes laboratory evaluations and animal studies to determine safety and efficacy. These studies must comply with federal and state regulations, including Good Laboratory Practices (&#8220;GLP&#8221;) requirements for safety and toxicology studies. The results of these studies, as well as manufacturing and analytical data, must be submitted to the FDA as part of an IND. The IND is a request for authorization to administer the product to humans and must be approved before clinical trials can begin. The IND submission focuses on the protocol for the initial clinical study and includes results of animal and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">studies, as well as any available human data to support the use of the investigational product. The IND becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the study, in which case a clinical hold is imposed until the concerns are resolved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the clinical stage of development, the product candidate is administered to patients or healthy volunteers under the supervision of qualified investigators in accordance with GCP requirements. Each clinical trial must be reviewed and approved by an IRB to ensure that the risks to individuals participating in the clinical trial are minimized and reasonable in relation to the anticipated benefits. The FDA, IRB, or sponsor may suspend or discontinue a clinical trial at any time on various grounds. Some studies also include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">oversight by a data safety monitoring board. Clinical trials must be reported to public registries within specific timeframes. While international clinical trials can be conducted under an IND, the FDA does not require that all foreign clinical trials be conducted under United States INDs. The FDA will accept a well-designed and conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials that are carried out to determine the safety and efficacy of a drug for the purpose of obtaining marketing approval through a BLA are typically carried out in three phases that can occur simultaneously, in combination, or staggered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Phase 1 of clinical trials involves administering the investigational product to healthy human volunteers or patients with the target disease or condition for the first time. The primary objective of these studies is to evaluate the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, identify any side effects associated with increasing doses, and potentially gather preliminary evidence of effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Phase 2 clinical trials usually involve giving the investigational product to a small group of patients with a particular disease or condition to assess its effectiveness, determine the best dosage and dosing schedule, and detect any potential risks or side effects. To gather data before conducting more extensive and costly Phase 3 trials, several Phase 2 studies may be conducted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Phase 3 trials usually involve testing the investigational product in a larger group of patients to confirm its efficacy and safety. The trials are conducted at multiple locations and aim to establish the overall risk-benefit profile of the product. Typically, the FDA requires two well-controlled Phase 3 clinical trials to approve a BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After marketing approval, Phase 4 clinical trials, also known as post-approval trials, may be conducted to gain more experience with the product in its intended use and to gather additional safety or efficacy data. The FDA may require these trials as a condition of approval. The results of clinical trials and safety reports for serious adverse events must be submitted to the FDA annually and within 15 days of the sponsor&#8217;s determination. Fatal or life-threatening adverse reactions must be reported within seven days. Along with clinical trials, companies must complete additional animal studies, develop information about the product&#8217;s biological characteristics, and establish a commercial manufacturing process that adheres to cGMP requirements. The manufacturing process must consistently produce quality batches of the product, and appropriate packaging and storage conditions must be identified through stability studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expanded Access</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expanded access, also known as &#8220;compassionate use,&#8221; refers to the use of investigational products outside of their intended clinical development to treat patients suffering from serious or life-threatening diseases or conditions when no satisfactory alternative treatment options are available. FDA regulations permit access to investigational products through an IND by the treating physician or the company for treatment purposes, including individual patients, intermediate-size patient populations, and larger populations for use under a treatment protocol or treatment IND application. It is important to note that companies are not obligated to provide expanded access to their investigational products.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA Submission and marketing authorization by the FDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to apply for either data exclusivity or market exclusivity for our product candidates. If the necessary clinical testing is completed successfully, we will submit the results of preclinical studies and clinical trials, as well as detailed information on the product&#8217;s manufacturing, labeling, and other aspects, to the FDA in the form of a BLA. This application seeks approval to market a new biologic for one or more specific indications. The BLA must contain all relevant data from both positive and negative studies. The BLA should incorporate all important information accessible from relevant preclinical and clinical examinations, including negative or questionable outcomes as well as certain discoveries, along with itemized data on the product candidate&#8217;s science, chemistry, manufacturing and controls, and proposed naming, in addition to other things. The data submitted must be of sufficient quality and quantity to satisfy the FDA regarding the investigational product&#8217;s safety, purity, and potency in order to support marketing approval. A BLA must be approved by the FDA before a biologic can be sold in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A BLA or supplement to a BLA must also include data to assess the biological product candidate&#8217;s safety and effectiveness for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, as required by the Pediatric Research Equity Act, or PREA. An initial Pediatric Study Plan (PSP) must be submitted within sixty days of an end-of-Phase 2 meeting or as agreed upon between the sponsor and FDA by a sponsor planning to submit a marketing application for a biological product that includes a new clinically active component, new indication, new dosage form, new dosing regimen, or new route of administration. PREA does not apply to any biological product for an indication for which an orphan designation has been granted, unless otherwise required by regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may also request additional information before deciding whether or not to accept the BLA for filing. Within 60 days of receiving a BLA, the FDA must decide whether or not to accept it for filing. This decision may include refusing to file. The FDA begins a comprehensive substantive review of the BLA as soon as the submission is accepted for filing. A BLA is reviewed by the FDA to see, among other things, if the product is safe, pure, and effective, and if the facility where it is manufactured,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processed, packaged, or stored satisfies standards designed to guarantee the product&#8217;s continued safety, quality, and purity. Under the objectives and policies consented to by the FDA under the Prescription Drug Users Fee Act, or PDUFA, once a BLA has been submitted, the FDA&#8217;s goal for novel biological products generally is to review the application within ten months after it accepts the application for filing, or, if the application is granted priority review, six months after the FDA accepts the application for filing. The FDA does not always meet its PDUFA goal dates, and the review process may be extended. For example, the review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant otherwise provides additional data, analysis or information that the FDA deems a major amendment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, under PDUFA, as changed, each BLA should be joined by a client charge, and the patron of an endorsed BLA is likewise dependent upon a yearly program expense. FDA changes the PDUFA client expenses on a yearly premise. In some cases, fees may be reduced or waived. For example, a small business may not have to pay the application fee for the first time. In addition, unless the product also includes a non-orphan indication, there are no user fees associated with BLAs for products designated as orphan drugs. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan drug designation and exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA might refer an application for a biologic to any advisory committee, which is a panel of independent experts, such as clinicians and other scientific experts. It reviews, evaluates, and offers a recommendation, such as whether the biologic is sufficiently safe and effective in a particular indication for a particular population and under what conditions. While an advisory committee&#8217;s recommendations do not bind the FDA, they are carefully taken into consideration when deciding whether or not to grant marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA will typically conduct an inspection of the facility or facilities where the product is manufactured prior to approving a BLA. The FDA will not approve an application unless it finds that the manufacturing facilities and processes are adequate to guarantee consistent product production in accordance with the required specifications. Furthermore, prior to approving a BLA, the FDA might investigate at least one clinical preliminary destination to guarantee consistence with GCP and different necessities and the uprightness of the clinical information submitted to the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to be submitted as a condition for approving a BLA to ensure that the product&#8217;s benefits outweigh its risks. The REMS may include medication guides, communication plans, assessment plans, or other risk-minimization tools.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once the BLA and all related information, including advisory committee recommendations and inspection reports, have been evaluated, the FDA may issue an approval letter or a Complete Response Letter. A Complete Response Letter indicates that the application is not ready for approval and lists all deficiencies found in the BLA, which need to be addressed to achieve approval. Even with additional information, the FDA may still reject the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA approves a product, it may impose restrictions, require additional studies, or limit approved indications for use. The FDA can also impose distribution and use restrictions or other risk management mechanisms under a REMS, which may affect the product&#8217;s market and profitability. Post-marketing studies or surveillance programs may result in the FDA limiting or preventing further marketing of the product. Changes to the approved product may also require further testing and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited drug development and review programs at the FDA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has programs to speed up the development, review, and potential approval of new drugs and biologics for serious or life-threatening diseases. These programs include Regenerative Medicine Advanced Therapy (RMAT) designation, the CMC Development and Readiness Pilot (CDRP) Program, Fast Track designation, Breakthrough Therapy designation, priority review, and Accelerated Approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RMAT program is intended to expedite the development and review of regenerative medicine therapies for serious or life-threatening conditions, where preliminary clinical evidence suggests potential to address unmet medical needs. This designation provides several regulatory advantages, including early and frequent engagement with the FDA, and potential for rolling review and priority review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s CDRP Program is designed to support accelerated development of products addressing serious conditions by providing enhanced, earlier CMC engagement during the clinical development lifecycle. The program enables sponsors to obtain timely feedback on manufacturing strategy, analytical readiness, control systems, and comparability plans to reduce CMC-related delays at the time of marketing application. Participation is limited and prioritized for products with significant potential public health impact, with the goal of ensuring CMC readiness aligns with expedited clinical and regulatory pathways.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A biologic can get Fast Track designation if it is meant to treat a serious or life-threatening disease and has the potential to address unmet medical needs for that disease. This applies to the product and the specific indication for which it is being studied. Similar to RMAT, Fast Track designation also allows sponsors to interact more with the FDA during preclinical and clinical development. There</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is also potential for rolling review, where the FDA can review parts of the BLA on a rolling basis if the sponsor provides a schedule, the FDA accepts the schedule, and the sponsor pays required fees when submitting the first section of the BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that detalimogene&#8217;s RMAT or Fast Track designations or participation in the CDRP program will lead to a faster development, regulatory review or approval process or increase the likelihood that detalimogene will receive marketing approval. Breakthrough Therapy designation is given to drugs that demonstrate a substantial improvement over existing therapies on clinically significant endpoints, and this designation provides intensive guidance for an efficient development program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products with Fast Track or Breakthrough Therapy designation may also be eligible for priority review and Accelerated Approval. Priority review is given to drugs that provide significant improvement in safety or effectiveness for serious or life-threatening diseases or conditions. Under priority review, FDA&#8217;s PDUFA goal for the review of the application is shortened to six months from the application filing date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accelerated Approval is given when a drug has an effect on a surrogate or early clinical endpoint that is likely to predict clinical benefit. Sponsors must agree to conduct additional post-approval studies to verify clinical benefit, and the FDA may withdraw approval if those studies fail.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While these programs may expedite the development or review process, they do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA heavily regulates drugs and biologics that are manufactured or distributed with their approval. This includes requirements related to recordkeeping, reporting, and product distribution. Companies must comply with promotion and advertising restrictions and are prohibited from marketing or promoting products for unapproved, off-label uses. Failure to comply with these requirements can result in penalties and liability under the False Claims Act (the &#8220;FCA&#8221;). Post-approval requirements may include post-market testing and surveillance to assess the product&#8217;s safety and effectiveness. Manufacturers and their subcontractors must register with the FDA and undergo periodic inspections for compliance. Changes to the manufacturing process may require FDA approval. Failure to comply can result in legal or regulatory action, and the FDA can withdraw approval if regulatory standards are not maintained. Revisions to approved labeling and other restrictions may also be imposed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, post approval, a pediatric study is typically required unless a waiver is granted. In the case of detalimogene, due to the rare incidence of bladder cancer in children, we plan to request a waiver of this requirement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consequences of failing to comply with FDA regulations include various restrictions such as limitations on marketing or manufacturing, product recalls, safety alerts, and mandated modifications of promotional materials and labeling. Companies may also face fines, warning letters, untitled letters, or holds on clinical trials and refusal of FDA approvals. The FDA can also take more serious actions such as product seizure or detention, injunctions, or civil or criminal penalties. In addition, companies may face consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan drug designation and exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Orphan Drug Act allows the FDA to give orphan drug designation (&#8220;ODD&#8221;) to drugs or biologics meant to treat rare diseases or conditions, which are defined as having a patient population of fewer than 200,000 individuals in the United States or a patient population greater than 200,000 individuals in the United States when it is not reasonable to expect that the cost of developing and making the drug available in the United States will be recovered from sales in the United States. To receive ODD, it must be requested before submitting a BLA, and the identity of the therapeutic agent and its potential orphan use are publicly disclosed after ODD is granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product receives ODD and later becomes the first FDA-approved drug for a particular clinically active component for the disease it was designated for, it is entitled to orphan drug exclusivity, meaning the FDA cannot approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years from the approval of the BLA, except under specific circumstances. These circumstances include showing clinical superiority to the product with orphan drug exclusivity or if the holder of the exclusivity cannot assure the availability of sufficient quantities of the drug for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. ODD also offers benefits like tax credits for certain research and a waiver of the BLA application user fee. However, a product with ODD may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received ODD. Moreover, the exclusive marketing rights in the United States may be lost if the FDA later finds that the request for designation was materially defective or if the manufacturer can&#8217;t assure sufficient quantities of the product for patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Biosimilars and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which simplified approval process for biological products that are similar to an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining how to review and approve biosimilars. Biosimilarity requires that the biological product and the reference product be the same in terms of safety, purity, and potency. This can be proven through analytical studies, animal studies, and clinical studies. Interchangeability requires that a product be biosimilar to the reference product and that the biologic, and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An application for a biosimilar product cannot be submitted to the FDA until four years after the reference product was licensed by the FDA. Also, the approval of a biosimilar product cannot be made effective until 12 years after the reference product was licensed. During this period, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product that shows the safety, purity, and potency of its product. The BPCIA also created exclusivity periods for biosimilars approved as interchangeable products. It is not yet clear if products deemed &#8220;interchangeable&#8221; by the FDA will be readily substituted by pharmacies, which are governed by state pharmacy law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, a biological product may receive additional market exclusivity for six months if the manufacturer voluntarily completes a pediatric study in accordance with an FDA-issued &#8220;Written Request.&#8221; The BPCIA, which created an abbreviated approval pathway for biosimilar products, is complex and continues to be interpreted and implemented by the FDA. Recently, government proposals have sought to decrease the 12-year reference product exclusivity period. Some aspects of the BPCIA, which could affect its exclusivity provisions, have been the subject of litigation. Therefore, the impact, implementation, and regulatory interpretation of the BPCIA remain uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of combination drug products in the US</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Combination products are those that are made up of different components, such as biological and device components, that are typically regulated by different FDA centers. According to FDA regulations, a combination product can be a single entity made up of two or more regulated components that are combined in some way, two or more separate products packaged together, or a product that requires the use of an approved drug, device or biological product to achieve the intended effect. The FDA assigns a lead center for review of combination products based on the product&#8217;s primary mode of action. The Office of Combination Products has been established to address issues related to combination products and provide guidance and regulations for their regulation. Combination products with a biologic primary mode of action are generally reviewed through the biologic approval process, with input from the device center to ensure the device component meets safety and performance requirements. Combination products are subject to current Good Manufacturing Practice (cGMP) regulations for drugs, biologics, and devices, including quality system regulations for medical devices. Our manufacturing process is cGMP compliant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other regulatory considerations for drug products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After a product candidate has been approved or commercialized, its manufacturing, sales, promotion, and other related activities are subject to regulation by various regulatory bodies in the United States. In addition to the FDA, these regulatory authorities may include the Centers for Medicare &amp; Medicaid Services (the &#8220;CMS&#8221;), other divisions of the Department of Health and Human Services (the &#8220;HHS&#8221;), the Drug Enforcement Administration (the &#8220;DEA&#8221;), the Consumer Product Safety Commission, the Federal Trade Commission (the &#8220;FTC&#8221;), the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, as well as state and local governments and agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug coverage and reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and many other countries, patients rely on third-party payors to cover part or all of the costs of their treatment. Having sufficient coverage and reimbursement from government healthcare programs and private insurers is critical for the success of new products. The availability of coverage and reimbursement will impact our ability to commercialize our product candidates, and the amount of reimbursement provided may not be enough for us to make a profit. Government authorities and third-party payors determine which medications they will pay for and at what level. New products may not be covered or may have limited coverage, and the reimbursement level may be lower than necessary to cover our costs. The COVID-19 pandemic has also caused uncertainty regarding insurance coverage, as many people have lost their employer-based coverage. The factors that payors consider when determining reimbursement include whether the product is covered by the plan, safe, effective, medically necessary, appropriate for the patient, and cost-effective. Discounts and rebates required by government programs and private payors may reduce the net price for drugs, and there is increasing pressure on drug companies to offer predetermined discounts. We cannot be certain that reimbursement will be available for our products or what the reimbursement level will be, and we may be subject to penalties if we do not report pricing metrics accurately and in a timely manner. We also cannot be certain that if we obtain reimbursement arrangements with payors that such arrangements will not be subject to recoupment actions or overpayment challenges, which can be time-consuming and expensive to resolve.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health care laws and regulations in the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies must comply with various healthcare regulations enforced by the federal government and state and foreign authorities where they do business. These regulations limit financial arrangements and relationships involving the research, sale, marketing, and distribution of products authorized for sale. The laws include the federal Anti-Kickback Statute (&#8220;AKS&#8221;), which prohibits offering or receiving remuneration for referrals or purchases that may be paid under federal and state healthcare programs. The FCA and Civil Monetary Penalties Law prohibit submitting false claims for payment to the government. The federal Health Insurance Portability and Accountability Act of 1996 imposes liability for executing schemes to defraud healthcare benefit programs or falsifying information related to healthcare delivery and payment. The &#8220;Sunshine Act&#8221; requires manufacturers of reimbursable drugs, devices, biologics, and medical supplies to report physician payments and other transfers of value. The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes privacy and security obligations on certain healthcare providers, health plans, and healthcare clearinghouses. Similar state laws may apply to sales and marketing arrangements involving healthcare items or services reimbursed by non-governmental third-party payors, reporting requirements related to financial arrangements with clinicians, and state privacy and security laws governing health information can be different from HIPAA. Noncompliance with these laws can lead to significant penalties, including administrative, civil, and criminal penalties, damages, fines, disgorgement, restructuring of operations, oversight and reporting obligations, and exclusion from participation in federal and state healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare payors, whether they are government or private entities, are using more sophisticated methods to control costs, but these methods are not always suitable for new technologies like genetic medicine and treatments for rare diseases. Legislative and regulatory changes to the healthcare system in the United States and many other countries could affect our ability to sell our products profitably. The ACA, which became law in 2010, introduced a range of changes, including subjecting biologic products to competition from lower-cost biosimilars, increasing minimum Medicaid rebates, and imposing new annual fees and taxes on certain branded prescription drugs. The ACA has faced legal and political challenges. Other healthcare reform measures may also impact our business. Since the ACA was enacted, other legislative changes have been proposed and adopted in the United States, including spending reductions under the Budget Control Act of 2011 and the Right to Try Act, which provides a federal framework for certain patients to access investigational new drug products. There has also been growing interest in specialty drug pricing practices and efforts to control pharmaceutical and biological product pricing at the federal and state levels, including transparency measures and importation from other countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in Montreal, Canada, where we lease and occupy approximately 10,620 sq. feet of laboratory and office space at 4868 Rue Levy, Montreal, QC H4R 2P1. We also maintain office space in the United States at 99 High Street, 26</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Floor, Boston, Massachusetts 02110 and 200 5</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Street Waltham, Massachusetts 02451.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our current facilities are sufficient for our current needs. To meet the future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, we had 82 employees, including 81 full-time employees, 51 of whom were primarily engaged in research and development activities. Of these employees, 22 are based in Canada and 60 in the United States. None of our employees are represented by a labor organization or are party to a collective bargaining arrangement. We consider our relationship with our employees to be excellent.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in legal proceedings that arise in the regular course of our business. Our management believes that we are not currently involved in any legal proceedings that are likely to have a significant negative effect on our business. However, legal proceedings can negatively affect our business, financial condition, results of operations, and future prospects, regardless of the outcome, due to costs associated with defense and/or settlement, as well as the diversion of management attention and resources, among other factors.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in our securities involves risks. Before you make a decision to buy our securities, in addition to the risks and uncertainties discussed above under &#8220;Special Note Regarding Forward-Looking Statements,&#8221; you should carefully consider the specific risks set forth herein. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this Annual Report or our other filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) are not the only risks and uncertainties that we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may become material and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend heavily on the success of our lead product candidate, detalimogene voraplasmid, or detalimogene, formerly known as EG-70, which is currently in a clinical trial. Our clinical trial of detalimogene may not be successful. If we are unable to successfully develop, obtain regulatory approval for, and commercialize detalimogene, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently only have one product candidate, detalimogene, in clinical development. We invested and continue to invest a significant portion of our efforts and financial resources in the research and development of detalimogene. Our ability to generate revenues from the sale of drugs that treat bladder cancer and other diseases in humans, which may not occur for several years, if ever, will depend heavily on the successful clinical development, regulatory approval for, and eventual commercialization of detalimogene. This may make an investment in our Company riskier than similar companies that have multiple product candidates in active development and may be able to better sustain the delay or failure of a lead product candidate. The success of detalimogene will depend on several factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful initiation and enrollment of clinical trials and completion of clinical trials with favorable results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.407%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.796%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.017103762827823%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of regulatory submissions by the FDA or comparable foreign regulatory authorities for the conduct of clinical trials of detalimogene and of our proposed designs of planned clinical trials of detalimogene, including protocol amendments or other changes we may make to ongoing clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the frequency and severity of adverse events observed in clinical trials and preclinical studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and establishing relationships with CROs and clinical sites for the clinical development of detalimogene, and the ability of such CROs and clinical sites to comply with clinical trial protocols, GCPs and other applicable requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrating the safety, purity and potency (or efficacy) of detalimogene to the satisfaction of applicable regulatory authorities, including by establishing a safety database of a size satisfactory to regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt and maintenance of regulatory approvals from applicable regulatory authorities, including approvals of BLAs from the FDA; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining relationships with our third-party CMOs and the CMOs' ability to comply with cGMPs as well as entering into agreements with our third-party CMOs for, or establishing our own, commercial manufacturing capabilities at a cost and scale sufficient to support commercialization;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of detalimogene, if and when approved by the FDA, whether alone or in collaboration with others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining, maintaining, protecting and enforcing patent and any potential trade secret protection or regulatory exclusivity for detalimogene;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining an acceptable safety profile of detalimogene following regulatory approval, if any;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and growing an organization of people who can develop and, if approved, commercialize, market and sell detalimogene; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance and coverage of our products, if approved, by patients, the medical community and federal healthcare programs and other third-party payors.</span></div></div><p style="margin-left:3.333%;text-indent:3.448%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to develop, obtain regulatory approval for, or if approved, successfully manufacture and commercialize detalimogene, or if we experience delays as a result of any of the above factors or otherwise, our business would be materially harmed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to make significant investments in our continued research and development of detalimogene and other new product candidates and genetic medicines and services we may develop, which may not be successful, and if they are not successful, we may not be able to achieve or sustain profitability in the future. As an organization, we do not have experience in any such new lines of business, and failure to identify other product candidates and/or execute on the expansion of our business would adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biotechnology product development is expensive, takes years to complete, and has uncertain outcomes. Failure can occur at any stage of product development. In addition, if we determine that any of our current or future products or services are unlikely to succeed, we may abandon them without any return on our investment. We expect to incur significant expenses to advance our genetic medicine development efforts, which may be unsuccessful. Developing new product candidates, such as detalimogene, is a speculative, risky and highly competitive endeavor. Product candidates that initially show promise may fail to achieve the desired results in development and clinical studies and may ultimately not prove to be safe and effective or meet expectations for clinical utility. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. We may need to alter our offerings in development and repeat clinical studies before we develop a potentially successful product. If, after development, a product appears successful, we will still need to obtain FDA and other regulatory approvals before we can market it. The FDA&#8217;s approval pathways are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not clear, authorize or approve any product we develop. Even if we develop a product that receives regulatory clearance, authorization or approval, we would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product may never be commercially successful. Additionally, development of any product or service may be disrupted or made less viable by the development or announcement of competing products or services, which could occur at any time. Because of the numerous risks and uncertainties associated with developing product candidates, we are unable to predict whether or when our therapeutics business may successfully commercialize a product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company and have incurred net losses in each reporting period since our inception, have not generated any revenue from product sales to date and have financed our operations principally through third-party investments in our debt and equity instruments. Our net losses were $117.3 million and $55.1 million for the fiscal years ended October 31, 2025 and October 31, 2024, respectively. As of October 31, 2025, we had an accumulated deficit of $372.0 million. Our lead product candidate, detalimogene, is in clinical trials. Our other programs are in preclinical research. Although we could potentially achieve our first commercial product as early as the second half of 2027, there is no guarantee we will do so, and delays or successful development efforts could prevent or significantly postpone commercialization. As a result, we may not generate revenue from product sales for some time, if at all. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial costs for commercialization as well as substantial research and development and other expenses in order to discover, develop and market additional potential products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the pace of our development activities and the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our Common Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The estimates of market sizes and forecasts of market growth for the potential demand of  detalimogene and any other product candidates we develop, as provided in this Annual Report and as may be provided in our future public filings and press releases are based on a number of assumptions and may prove to be inaccurate. The actual market may be smaller than we believe, which would adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make estimates of total addressable markets and forecasts of market growth for detalimogene and any other product candidates we develop in this Annual Report, and we may also make such estimates and forecasts in future public filings and press releases. Our estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third-party estimates in published literature, and other business data, including assumptions and estimates relating to our ability to manage operating expenses of, invest in, and develop and generate revenue from detalimogene or any other product candidates we develop in the future. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and metrics. Consequently, our estimates of the total addressable markets and our forecasts of market growth may prove to be incorrect. For example, if the annual total addressable markets or the potential market growth is smaller than we have estimated or if the key business metrics we utilize to forecast commercial opportunities are inaccurate, it may have an adverse effect on our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our internal controls over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the trading price of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are required to maintain internal control over financial reporting and disclosure controls and procedures. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis. Our management has performed an evaluation of our internal controls over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, however, an independent registered public accounting firm has never performed an evaluation because no such evaluation is currently required. Had our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, material weaknesses may have been identified. If we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to certify that our internal control over financial reporting is effective, our consolidated financial statements may contain material misstatements and we could be required to revise or restate our financial results. This could materially and adversely affect our business, results of operations and financial condition, restrict our ability to access the capital markets, require us to expend significant resources to correct the material weakness, subject us to fines, penalties or judgments, harm our reputation, adversely affect the trading price of our common stock, or otherwise cause a decline in investor confidence. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 9A. Controls and Procedures&#8212;Remediation Efforts to Address Material Weakness</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; of this Annual Report for information related to material weakness remediation and mitigation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">To date, we have not generated any product revenue, have a history of losses and will need to raise additional capital to fund our operations. If we fail to obtain necessary financing, we will not be able to complete the development and commercialization of detalimogene or our other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development of biopharmaceutical product candidates, including conducting preclinical studies and clinical trials, is a very time-consuming, capital-intensive and uncertain process. Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to conduct further research and development and preclinical or nonclinical testing and studies and clinical trials of our current and future programs, to seek regulatory approvals for our product candidates and to prepare for potential launch and commercialization of any products for which we may receive regulatory approval. As of October 31, 2025, we had $50.2 million in cash and cash equivalents and $152.1 million in marketable securities. Although we have a detailed current operating plan, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect. We will in any event require additional capital in order to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for product development and any approved marketing and commercialization activities. Our funding requirements, both near- and long-term, as well as the timing and amount of our operating expenditures, will depend largely on:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, progress, scope, timing, costs and results of preclinical or nonclinical testing and studies and clinical trials for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical development plans we establish for these product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we develop or may in-license; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any collaboration agreements we may choose to execute; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable regulatory authorities outside of the United States; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of resolving intellectual property disputes, including any patent infringement actions that may be brought by third parties in the future against us or our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of formulation development and manufacturing of our product candidates, including the completion of commercial-scale outsourced manufacturing activities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own or with a partner; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs related to any domestic and/or international expansion. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offerings, debt financings, collaborations, strategic alliances, licensing arrangements, royalty revenues, sales or monetization of future revenue streams, marketing or distribution arrangements or other strategic transactions. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our shareholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of our Common Shares or securities convertible or exchangeable into our Common Shares, your ownership interest will be diluted. We are party to the Amended Loan Agreement (as defined herein) with Hercules Capital, Inc. (&#8220;Hercules&#8221; or the &#8220;Lender&#8221;), as agent and lender, and several financial institutions. The Amended Loan Agreement subjects us to fixed payment obligation covenants that limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. For additional information, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Hercules Loan Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 18, Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for additional information on the Hercules Loan Agreement.  If we raise additional capital through debt financing, we may be subject to similar or more restrictive conditions than the conditions of the Amended Loan Agreement. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances, licensing arrangements, royalty revenues, sales or monetization of future revenue streams, or strategic transactions with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our products or product candidates or one or more of our other research or development initiatives. Any of the above events could significantly harm our business, financial condition, results of operations and prospects and cause the price of our common shares to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition from other entities, including biotechnology and pharmaceutical companies, which may result in our competitors discovering, developing or commercializing products before us or more successfully than we do. Our business and results of operations could be adversely affected if we fail to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries, including the development of non-viral genetic medicines for administration into mucosal tissues as well as the development of novel therapies for bladder cancer and non-muscle invasive bladder cancer, or &#8220;NMIBC,&#8221; specifically, are characterized by rapid growth, a dynamic landscape of competitive product candidates and a strong reliance on intellectual property. We face competition from a variety of organizations, including larger pharmaceutical companies, specialty biotechnology companies, specialty medical device companies, academic research institutions, governmental agencies, as well as public and private institutions. There are several companies that are currently developing gene-based therapeutics for use in a variety of indications, from cancer (including bladder cancer and NMIBC specifically) to rare disease, to regenerative medicine. There are also companies and institutions developing non-gene based therapies such as, but not limited to, drug/device combinations that may be effective in the clinical indications we choose to pursue and oncology drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DDX is our proprietary carrier for genetic medicines to mucosal tissues and is the foundation for our nanoparticle formulations. We developed DDX and our patented non-viral genetic medicines to penetrate mucus barriers and to deliver genes to mucosal epithelial cells in a way that is re-dosable, scalable, and designed to integrate into existing clinical practice. Our genetic medicine platform&#8217;s leading program, detalimogene, is in the area of immuno-oncology.  We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of indications for which we are developing detalimogene, including NMIBC. Competitors using genetic medicines for mucosal tissues include CG Oncology, Inc. and Ferring Pharmaceuticals Inc, both of which are developing products that will compete directly with detalimogene, if approved. More generally, if detalimogene or any future product candidates that we develop are approved, they will compete with surgery, radiation, and drug therapy, including chemotherapy, BCG, hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, antibody-drug conjugates, radiopharmaceuticals, immunotherapy, cell-based therapy, and targeted therapy, or a combination of any such methods, either approved or under development, which are intended to treat the same indications that we are targeting or may target, including through approaches that may prove to be more effective, have fewer side effects, be less costly to manufacture, be more convenient to administer or have other advantages over detalimogene and any future product candidates that we develop. To the extent Merck or another manufacturer increases the supply of BCG, there may be less demand for alternative treatments such as detalimogene, if approved, in earlier lines of treatment for NMIBC. There are numerous companies that have commercialized or are developing treatments for NMIBC that detalimogene will compete with, if approved, including Bristol Meyers Squibb, Gilead Sciences, Inc., Hoffman-La Roche AG (Roche), CG Oncology, Inc., Ferring Pharmaceuticals Inc., ImmunityBio Inc., Johnson &amp; Johnson Inc., Merck, Protara Therapeutics, Inc., Pfizer, Inc., Aura Biosciences Inc., and UroGen Pharma, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. Mergers and acquisitions in the biotechnology and pharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for and participation in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">more effective, have fewer or less severe side effects, are more convenient, are more shelf-stable or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if we successfully enter it at all. The key competitive factors affecting the success of all of our programs, including detalimogene, are likely to be their efficacy, safety, convenience and availability of reimbursement. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make detalimogene or any future product candidates we develop obsolete or noncompetitive before we generate sufficient revenue to recover the expense of their development and commercialization. If we are unable to compete effectively, our opportunity to generate revenue from the sale of detalimogene or any future product candidates we may develop, if approved, could be adversely affected.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If detalimogene or other product candidates that we may develop are approved for the indications for which we are currently conducting or planning clinical trials, they may compete with other products currently under development. We may not be aware of all competitive or potentially competitive products under development by other market participants, and information relating to such products may not be publicly accessible. Competition with other related products currently under development may include competition for clinical trial sites, patient recruitment and product sales. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business&#8212;Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The genetic medicine field is relatively new and evolving rapidly. Because of our limited technical, financial and human resources, we are focusing our research and development efforts on detalimogene, as well as further development of our genetic medicine platform and other product candidates we may develop. As a result, we may forego or delay pursuit of other genetic medicine technologies or other therapeutic product candidates that provide significant advantages over our platform or product candidates, which could materially harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Genetic medicine is an emerging field of product development with only a small number of genetic medicines having received FDA or EMA approval to date. Our genetic medicine research programs are still at an early stage, and there remain several areas of product development risk, which pose particular uncertainty for our programs given the relatively limited development history of, and our limited prior experience with, genetic medicines. Translational science, manufacturing materials and processes, safety concerns, regulatory pathway and clinical trial design and execution all pose particular risk to our product development activities. Furthermore, the medical community&#8217;s understanding of the causes of many diseases continues to evolve and further research may change the medical community&#8217;s views on what therapies and approaches are most effective for addressing certain diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an organization, we have limited experience conducting IND-enabling studies or clinical trials, including later stage or pivotal clinical trials. In pursuing our new technologies, we have begun to establish our own genetic medicine technical capabilities, but we will need to continue to expand those capabilities by either hiring internally or seeking assistance from outside service providers. Genetic medicine is an area of significant investment by biotechnology and pharmaceutical companies and there may be a scarcity of talent available to us in these areas. If we are not able to expand our genetic medicine capabilities, we may not be able to develop in the way we intend or desire any promising product candidates that emerge from our program, including detalimogene, which would limit our prospects for future growth. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of detalimogene or other product candidates that we may develop. We may also rely on third-party vendors or service providers, including CROs, among others who may fail to meet their commitments to us or deliver their products to us. We may also be forced to rely on a single such provider with no redundancy or alternative. Failure to commence or complete, or delays in our clinical trials, could prevent us from or delay us in commercializing detalimogene or other product candidates that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and on genetic medicine technologies and product candidates that we identify for specific indications among many potential options, such as detalimogene in high-risk BCG-unresponsive NMBIC with CIS or other NMIBC indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential, or we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. For example, in June 2024, we announced that, as a result of our prioritization of exploring potential bladder cancer indications for detalimogene, we deprioritized preclinical development of another product candidate, EG-i08 for cystic fibrosis.  Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to pursue opportunities with greater commercial potential or relinquishing valuable rights to product candidates may have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Detalimogene and our genetic medicine platform are based on novel technologies that are unproven, which makes it difficult to predict the time and cost of development and the probability or timing of subsequently obtaining regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our research and development efforts on our genetic medicine platform, and our future success depends on the successful development and maintenance of our platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, the technologies that comprise our platform and detalimogene are new and largely unproven. These technologies have been neither extensively studied nor extensively clinically tested, and the scientific and clinical evidence to support the feasibility of developing product candidates based on those technologies in pursuit of regulatory approval and potential commercial viability and success may be considered preliminary and limited. Successful development of product candidates by us will require solving several issues, including proving the safety and efficacy of detalimogene for BCG-unresponsive NMIBC and expanding our mucosal tissue delivery system to treat patient tissues beyond the bladder, such as urogenital and gastrointestinal mucosal tissues. There can be no assurance we will be successful in solving any or all of these issues. We have concentrated our research efforts to date on developing the components of our genetic medicine platform, and our future success is highly dependent on the successful development of our proprietary carrier for genetic medicines to mucosal tissues, therapeutic applications of such technology and the advancement of additional programs focused on diseases of the urogenital and gastrointestinal mucosal tissues. We may decide to alter or abandon our initial programs as new data become available and we gain experience in developing our therapeutics. We cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in any indication we pursue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that any development problems we experience in the future related to our genetic medicine platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing sustainable, reproducible and scalable manufacturing processes or transferring such processes to any commercial partners, which may prevent us from initiating or conducting clinical trials or commercializing our products on a timely or profitable basis, if at all. We may also fail to build redundancy in these manufacturing processes, such that we will be vulnerable to third-party provider failures that may impair the supply of or manufacture of critical materials, products, or reagents. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. FDA&#8217;s regulatory guidance documents, including those that may be applicable to our programs, may change, be cancelled or evolve. Only a small number of genetic medicines have successfully reached the clinical trial phase of development or beyond, limiting insight into the regulatory review process for this field of genetic medicine. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals in either the United States or the European Union for any product candidates we may develop or how long it will take to commercialize any product candidate that receives marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development of new therapeutics involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs, fail to replicate the positive results from our earlier preclinical or clinical studies of our product candidates in later preclinical studies or clinical trials or experience delays in completing or ultimately be unable to complete, the development and commercialization of any product candidates, including, but not limited to, detalimogene.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain the requisite regulatory approvals to commercialize detalimogene or any other product candidate that we may develop, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective. Our product candidates are in preclinical development and clinical trial stages and thus their risk of failure is high. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our filed and planned INDs in the United States, or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support the further development of our product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, including detalimogene, we must conduct extensive clinical trials to demonstrate the safety and efficacy of any of these product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete, and their outcome is inherently uncertain. Failure can occur at any time during, or even after, the clinical trial process and our ongoing and future clinical results may not be successful. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful and a clinical trial can fail at any stage of testing. Similarly, if regulatory authorities agree, implicitly or explicitly, that a certain set of clinical endpoints is clinically meaningful or adequate to demonstrate safety and efficacy, they may change their determination at a later date. The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials and interim or preliminary results of a clinical trial do not necessarily predict final results. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful completion of clinical trials is a prerequisite to submitting a BLA to the FDA and similar marketing applications to other regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We do not know whether any of our clinical trials will be completed on schedule, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience delays in initiating or completing clinical trials and preclinical studies. We also may experience numerous unforeseen events during, or as a result of, any ongoing and future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to generate sufficient preclinical, toxicology, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo, in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or other data to support the initiation of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience delays in our discussions with the FDA and other regulatory authorities regarding trial design or other aspects of our trial and study; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">positive results from our preclinical studies of our product candidates may not necessarily be predictive of the results from required later preclinical studies and clinical trials and positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of any product candidates may fail to show safety or efficacy, or produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities may require us to enroll more patients in clinical trials than we had planned, including if they determine that patients we have enrolled did not meet the eligibility criteria for the clinical trial or, in the case of detalimogene for BCG-unresponsive NMIBC with CIS, did not meet the requirements of the FDA&#8217;s 2018 Guidance Document entitled &#8220;Bacillus Calmette-Gu&#233;rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry&#8221; (the &#8220;Guidance Document&#8221;) and the FDA&#8217;s August 2024 update in draft form of the Guidance Document; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may need to add new or additional clinical trial sites; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended, placed on clinical hold or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or other regulatory authorities or recommended for suspension or termination by the Data Safety Monitoring Board, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs will increase if we experience delays in clinical testing or marketing approvals, which will correspondingly increase our operating costs. Our preclinical studies or clinical trials may not begin as planned, may need to be restructured or may not be completed on schedule, or at all. Significant preclinical studies or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our preclinical or clinical development programs may harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time will change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim, topline and preliminary data from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues, data is further analyzed, and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary, topline or interim results also remain subject to audit and verification procedures that may result in the final data being materially different from the data we have previously published. As a result, interim, topline and preliminary data should be expected to change as additional patient data become available and as such new data and/or existing data is audited and verified; all data should be viewed with caution until the final data and analyses are available. Adverse differences between preliminary, topline or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common shares to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program (for example, detalimogene), the approvability or commercialization of the particular product candidate or product, and our Company in general. Moreover, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions we reached, our ability to obtain approval for, and commercialize detalimogene and any future product candidates we develop may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We have from time to time experienced and may in the future experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of a sizeable population of eligible patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to study sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing clinical trials for similar therapies or other new therapeutics; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of our product candidate being studied in relation to other available therapies or surgical procedures; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of patients to complete a clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of approved therapies that are similar in mechanism to our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost to, or lack of adequate compensation for, prospective patients; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will not complete such trials for any reason, including due to health crises, including pandemics, geopolitical conflicts, acts of terrorism, and/or &#8220;acts of God&#8221; that affect our contract manufacturing organizations (&#8220;CMOs&#8221;), suppliers, clinical investigator sites and governing regulatory bodies. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which would reduce the number of patients who are available for our clinical trials at such clinical trial sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we have conducted the Phase 1 portion of the LEGEND clinical study of detalimogene, we have not as an organization completed later-stage or pivotal clinical trials or submitted a BLA, and we may be unable to do so for detalimogene or any future product candidates in a timely manner or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to successfully complete later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market detalimogene or any future product candidates we develop. Carrying out pivotal and later-stage clinical trials and the submission of a successful BLA or other comparable foreign regulatory submission are complicated processes. As an organization, we have conducted the Phase 1 portion of the combined Phase 1/2, open-label study of detalimogene referred to as the &#8220;LEGEND&#8221; study and are conducting the Phase 2 multi-cohort portion of the LEGEND study consisting of three cohorts, including the pivotal cohort evaluating detalimogene in patients with BCG-unresponsive NMIBC with CIS. We have not yet completed any later-stage or pivotal clinical trials for detalimogene or any other product candidate. We also have limited experience as a company in preparing and submitting marketing applications and have not previously submitted a BLA or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many additional clinical trials of detalimogene or any other product candidates we develop will be required or how such additional trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to submission of a BLA and regulatory approval of detalimogene or any of the other product candidates we develop. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of detalimogene or any of other product candidates we develop. Failure to commence or complete, or delays in, our ongoing or future clinical trials could prevent us from or delay us in submitting BLAs or other comparable foreign regulatory submissions for and commercializing detalimogene or any of other product candidates we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of our novel genetic medicine platform, detalimogene and other therapeutic product candidates we may develop could result in or be associated with harmful side effects, adverse events or other safety risks, which could cause us to delay, suspend or discontinue their clinical trials and/or development or abandon them, delay or prevent their regulatory approval, limit their commercial potential, if approved, or result in other significant negative consequences (including voluntary corrective actions or agency enforcement actions) that could severely harm our business and results of operations. In addition, these harmful side effects, adverse events or other safety risks may not be appropriately recognized or managed by our treating staff, which could result in litigation and reputational damage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene and other product candidates we may develop may be associated with harmful side effects, adverse events or other safety risks. Results of clinical trials could reveal severe or recurring side effects, toxicities or unexpected events, including death. There may also be delayed adverse events that may not be appropriately recognized or managed by our treating staff, which could result in litigation and reputational damage. We expect to have to train medical personnel using detalimogene or any other product candidates we may develop to understand the side effect profiles for our clinical trials and upon any commercialization of such product candidates. Inadequate training in recognizing or managing the potential side effects of such product candidates could result in patient injury or death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any such events occur, clinical trials or commercial distribution of detalimogene or any other product candidates or products we develop could be suspended or terminated, and our business and reputation may be substantially harmed. Treatment-related side effects could affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us to cease further development of, deny approval of or require us to cease selling detalimogene or any other product candidates or products we develop for any or all targeted indications. If we elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if we successfully develop detalimogene or any other product candidate and it receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we and others later identify undesirable side effects caused by any product that we develop. Such identification could also have several additional significant negative consequences, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, &#8220;Dear Healthcare Provider&#8221; letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way a product is administered or conduct additional trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product may become less competitive; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may decide to remove the product from the marketplace; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and be held liable for harm caused to patients; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation could be harmed. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of any potential product. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if detalimogene or any other therapeutic product candidates that we develop receives regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors (including government health administration authorities and private health insurers) and others in the medical community necessary for commercial success, in which case we may not generate significant revenues and become profitable, which could adversely affect our ability to conduct our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of detalimogene or any other product candidates that we develop will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if detalimogene or any other product candidates developed by us receives regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of detalimogene and any other product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the wider acceptance by patients of products derived from or involving RNA or DNA manufacturing processes; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials published in peer-reviewed journals or otherwise made available to the public (e.g., through FDA advisory committee meetings); </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages compared to alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to offer our products for sale at competitive prices and to obtain coverage by third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to offer appropriate patient access programs, such as co-pay assistance; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which physicians recommend our products to their patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convenience and ease of handling, dosing and administration compared to alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which the product candidate is approved by the FDA, EMA or other comparable non-U.S. regulatory agencies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA, EMA or other comparable non-U.S. regulatory authorities, including any limitations, contraindications or warnings contained in a product&#8217;s approved labeling; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on how the product is distributed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity concerning our products or competing products and treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of marketing and distribution efforts by us and other licenses and distributors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shortages or lack thereof of competitive or potentially competitive products, or products utilized in the standard-of-care for our patients, such as BCG; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient governmental third-party coverage or reimbursement; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If detalimogene or any other product candidate developed by us does not achieve an adequate level of acceptance by physicians, healthcare payors, patients and the medical community, we will not be able to generate significant revenue and may not become or remain profitable. The failure of detalimogene or any other product candidates we develop to find market acceptance could harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent of any actions taken by us, negative developments in the field of genetic medicine, intravesical or NMIBC therapeutic development could damage public perception of detalimogene and any other product candidates that we develop, which could adversely affect our ability to conduct our business and our results of operations, or to obtain and retain regulatory approvals for such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our novel genetic medicine platform and detalimogene are comprised of new and largely unproven technologies, and we have no gene therapeutic product candidates approved to date. Gene therapeutics may not gain the acceptance of the public or the medical community and/or they may not gain the acceptance of the public or medical community within our indications of interest or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development areas. To date, several other efforts to leverage genetic medicine technologies have generally demonstrated an inability to generate predictable results or to manufacture products at suitable scale to treat more than a small number of patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will depend on our ability to demonstrate that our genetic medicine platform, detalimogene and any other product candidates we develop and related services can overcome these challenges.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If detalimogene or any other product candidate that we develop is unable to successfully treat the intended organ or lesion and establish proof of concept in a certain disease, it may indicate that we will not be able to apply our genetic medicine platform to other diseases affecting the intended tissue area or other areas. This may also indicate a decrease in the probability of our success for other targets using the same modality in the same or different cell types, as well as our engineered approach and delivery approach, more generally. Such failures could negatively affect the public or medical community&#8217;s perception of our genetic medicine platform and gene therapeutics in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our success will depend upon physicians who specialize in the treatment of diseases targeted by detalimogene or any other product candidates that we develop, if approved, prescribing treatments that involve the use of those product candidates, if approved, in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. Adverse events in clinical trials of detalimogene or any other product candidates that we develop or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of gene therapeutics, could result in a decrease in demand for detalimogene, if approved, or any other product that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of, or modification to, our clinical trials. Any future negative developments in the field of genetic medicine could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for detalimogene or any other product candidates that we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to utilize our novel genetic medicine platform to identify and develop additional product candidates. Due to our limited technical, financial and human resources and access to capital, we may choose to prioritize development of certain product candidates, such as our initial focus on developing detalimogene, which may prove to be the wrong choice and may adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An important element of our strategy is utilizing our genetic medicine platform to generate multiple product candidates. Although we intend to develop numerous product candidates targeting various cell types and indications and carrying different biologically active drug molecules, in addition to detalimogene, we may fail to identify viable new product candidates for clinical development for a number of reasons. For example, while we believe our genetic therapy platform is capable of transfecting many different tissue types with varied genetic cargos, such as nucleic acid therapeutics (e.g., DNA), antisense oligonucleotides, siRNA, miRNA, mRNA, genetic medicine and gene editing mechanisms, we have not yet successfully advanced any proprietary enGene-developed drug candidate incorporating these cargoes into clinical trials beyond detalimogene, and we may not be successful in developing products to effectively employ these types of cargoes or molecules. If we fail to identify additional potential product candidates, our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research programs to pursue the development of our product candidates and using our genetic medicine platform to design and identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our genetic medicine platform and research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs, or that make the product candidates impracticable to manufacture, unmarketable or unlikely to receive marketing approval; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these events occur, we may be forced to abandon our research or development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful, which would be costly and time-consuming.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our use of third parties to manufacture, develop and test our therapeutic product candidates for preclinical studies and clinical trials increases the risk that we will not have sufficient quantities of our product candidates or products, or necessary quantities of such materials on time or at an acceptable cost.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture drug supplies for our ongoing clinical trials or any future clinical trials that we may conduct, and we lack the resources to internally manufacture detalimogene or any other product candidates we develop on a commercial scale. We rely, and expect to continue to rely, on third-party manufacturers to produce detalimogene or other product candidates that we may identify for clinical trials, as well as for commercial manufacture if detalimogene or any other product candidates we develop receive marketing authorization and approval. We rely entirely on numerous third-party suppliers to provide us with various product components. We may not have alternative suppliers for certain of these product components. Any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer or testing laboratory could considerably delay the clinical development and potential regulatory authorization and commercial launch of such product candidate, which could harm our business, financial condition, results of operations and prospects. We currently do not have relationships with alternate third-party contract manufacturers and testing laboratories for our critical raw materials and product candidates that could sustain our operations in the event we experience a disruption of service from our existing third-party contract manufacturers and testing laboratories. As a result, we are materially reliant on our existing contract manufacturers and testing laboratories and susceptible to material operational disruptions due to factors that may be unknown to us and unforeseeable. Our providers may also materially change the terms of our commercial arrangements for any reason or no reason, which could adversely affect our materials costs, ability to manufacture the drug at a sustainable cost, and profit margin on any sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to identify and appropriately qualify third-party manufacturers and testing laboratories or establish agreements with third-party manufacturers and testing laboratories or do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers and testing laboratories, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third-party for sourcing of raw materials, components, testing and such other goods as may be required for execution of our overall manufacturing process; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk of single sourced critical raw materials, drug substance and drug product, where secondary back-up vendors are not yet available; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk of increased and/or extended lead times for critical raw materials, reagents and equipment, thus requiring significant investment in building adequate inventory to avoid significant disruptions to manufacturing processes; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on third-party to ensure availability of adequate manufacturing capacity to meet product demand based on the needs of their other clients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third-party for regulatory compliance and quality assurance for the manufacturing and/or testing activities each performs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on third-party to adequately validate processes for timely approval of the BLA required for commercialization of product; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing and/or testing agreement by the third-party; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible misappropriation of proprietary information, including trade secrets and know-how; and the possible termination or non-renewal of the agreement by the third-party at a time that is costly or inconvenient for us. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, our contract manufacturing organizations (&#8220;CMOs&#8221;) and testing laboratories are engaged with other companies to supply and/or manufacture and/or test materials or products, which exposes our manufacturers and testing laboratories to regulatory risks for the production and testing of such materials and products. The facilities used by our CMOs to manufacture and/or test detalimogene or any other product candidates we develop are subject to review by the FDA and other non-U.S. authorities pursuant to inspections that will be conducted after we submit a BLA, or other marketing application to the FDA and other non-U.S. authorities. We do not directly conduct the manufacturing and testing of any material or products. Therefore, we are materially dependent on our CMO partners and contract testing laboratories to operate in compliance with the regulatory requirements, known as current good manufacturing practice (&#8220;cGMP&#8221;) requirements for manufacture of drug and device products or similar requirements outside the United States. If our CMOs and contract testing laboratories cannot successfully manufacture and/or test material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure or maintain regulatory authorization for detalimogene or any other product candidates we develop that are manufactured at these manufacturing facilities, resulting in delay or failure in the clinical development and commercialization of our products, which would have a material adverse effect on us. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or another non-U.S. regulatory agency does not approve these facilities for the manufacture and/or testing of detalimogene or any other product candidates we develop, if any agency withdraws its approval in the future, or if we identify material gaps in quality control and compliance at our selected CMOs, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop and deliver our products to markets around the world could delay product supply to patients in clinical studies or to commercial customers for any approved products, and may increase the overall cost of manufacturing our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene or any other product candidates we develop may compete with other product candidates and marketed products for access to manufacturing and/or testing facilities. Any performance failure on the part of our existing or future CMOs could delay clinical development, marketing approval or commercialization. Our current and anticipated future dependence upon others for the manufacturing of detalimogene or any other product candidates we develop may adversely affect our future profit margins and our ability to commercialize detalimogene or any other product candidates we develop that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Detalimogene is complex to manufacture, and the manufacturing process for any other product candidates we develop may be similarly complex or more complex, and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of our third-party manufacturers with whom we contract encounter these types of difficulties, our ability to supply detalimogene or any other product candidates we develop for clinical trials or as products for patients, if approved, could be constrained, delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing processes used to produce detalimogene are complex and novel and have not been validated for clinical or commercial production. The manufacturing processes used to produce any future product candidates that we develop may be similarly or more complex and novel. As a result of these complexities, the cost to manufacture our product candidates is generally higher than traditional biopharmaceutical compounds and the manufacturing processes may prove to be less reliable and may be more difficult to reproduce. For example, for detalimogene we must separately manufacture a novel plasmid DNA drug substance (DS), a novel co-polymer excipient (DDX) and a novel block co-polymer excipient (PEG-b-PLE). We then combine those ingredients in the drug product manufacturing process. There are many points throughout this process, and the manufacturing processes of other product candidates we develop, that can lead to failure. Failure in the production of any of our product components or candidates could have a material adverse effect on our business, financial condition, results of operations and prospects. Some examples of manufacturing challenges and potential failure we may encounter follow:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the manufacturing process of DS, bacterial cells are inoculated to a fermenter and expanded. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These bacteria produce the plasmid DNA DS, which is purified from the cells by an extensive purification process. At any stage, any or all of these processes can fail, including the biological or purification processes, which would result in batch failure. These processes can fail due to contamination, inadequate purification or other reasons. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of DDX and PEG-b-PLE involves multiple complex chemical synthesis and purification steps to produce final products with target specifications and yield. At any stage, any or all of these processes can fail, including the chemical or purification processes. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of detalimogene requires careful and complex combination of DS with DDX and PEG-b-PLE followed by sterile filtration, filling and lyophilization to yield the drug product. At any stage, any or all of the processes involved can fail, including the mixing, sterilization, filling, lyophilization or storage processes. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing processes are also susceptible to product loss or failure due to logistical issues associated with multiple outsourced activities across the range of manufacturing, shipping of materials to analytical laboratories, cold chain distribution to where products will be administered to patients, interruptions in the manufacturing processes, contamination, equipment or reagent failure, improper installation or operation of equipment, vendor or operator error, and variability of product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, lot failures, product defects, product recalls, product liability claims and other supply disruptions. If microbial, viral or other contaminations are discovered in detalimogene or other product candidates we develop or in the manufacturing facilities in which detalimogene or those other product candidates are made, the manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could result in our inability to timely produce or ship product. Further, as product candidates are developed through preclinical to later-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered in an effort to optimize processes and results. If we make these types of changes, we may not achieve our intended objectives, and any of these changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we continue to optimize our manufacturing processes, doing so is difficult and uncertain. There are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among other things, cost overruns, production delays, potential problems with process scale-out, process reproducibility, stability issues, lot consistency and timely availability of reagents or raw materials. If we are unable to adequately validate or scale-up our manufacturing processes with our current manufacturing partners, we will need to transfer such processes to another manufacturing partner and complete the manufacturing validation process, which can be a lengthy process. We ultimately may not be successful completing the transfer of our manufacturing processes to one or more of the manufacturers on whom we rely. The manufacturers who become responsible for our processes may not have the necessary capabilities to complete the implementation and development processes to our specifications or standards. If we are able to adequately validate and scale-up a particular manufacturing process for detalimogene and other product candidates we develop with a contract manufacturer, we will still need to negotiate an agreement for commercial supply with that contract manufacturer and it is not certain we will be able to come to agreement on commercially reasonable terms, or at all. As a result, we may ultimately be unable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to manage the cost of goods for detalimogene or other product candidates we develop to levels that will allow for an attractive return on investment if and when detalimogene or those other product candidates are approved and commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing processes and facilities used for any products that we may develop are subject to the FDA and non-U.S. regulatory authority approval processes, and we will need to contract with manufacturers who we believe can meet applicable FDA and non-U.S. regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, or if the facilities used to manufacture our products are found to be non-compliant for any reason, we may not obtain or maintain the approvals we need to commercialize our products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications and under required good manufacturing practices acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to manufacture our products on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, we could incur higher manufacturing costs if manufacturing processes or standards change, and we could need to replace, modify, design or build and install equipment, all of which would require additional capital expenditures. Specifically, because our product candidates may have a higher cost of goods than conventional therapies, and may require long-term follow up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA, the EMA and other non-U.S. regulatory authorities may require us to submit samples of any lot of any approved product, together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other non-U.S. regulatory authorities may require that we not distribute a lot until the relevant agency authorizes its release. Slight deviations in our manufacturing processes, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. Problems in our manufacturing processes could restrict our ability to meet market demand for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any problems in our manufacturing processes or facilities at our CMOs, or the perception of the possibility of problems in such processes or facilities, could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have no experience in developing a manufacturing facility for our biologic products and may never be successful in developing our own manufacturing facility or capability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to evaluate the possibility of establishing our own capabilities and infrastructure, including a manufacturing facility. If we choose to build our own manufacturing facility, we will need significant funding and will need to select an adequate location. We expect that development of our own manufacturing facility would provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term margins. However, we have no experience in developing a manufacturing facility and may never be successful in developing our own manufacturing facility or capability. If we determine to establish our own manufacturing capabilities and infrastructure, we will also need to hire additional personnel to manage our operations and facilities and develop the necessary infrastructure to continue the research and development, and eventual commercialization, if approved, of our product candidates. If we fail to select the correct location, complete the construction in an efficient manner, recruit the required personnel and generally manage our growth effectively, the development and production of our product candidates could be curtailed or delayed. We may establish multiple manufacturing facilities as we expand our commercial footprint to multiple geographies, which may lead to regulatory delays or could prove costly. Even if we are successful, any manufacturing capabilities we develop could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the manufacturing or formulation of detalimogene or any other product candidate we develop may result in additional costs or delay, which could adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods or formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause detalimogene or any other product candidates that we develop to perform differently and affect the results of ongoing or planned clinical trials or other future clinical trials conducted with the altered materials. In addition, such changes and any other similar changes in the future may also require additional testing or notification to or approval by the FDA or other regulatory authorities. This could delay completion of clinical trials, require</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of detalimogene or any other product candidates that we develop and/or jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Detalimogene is, and any other product candidates we develop may be, complex to analyze and we may encounter difficulties in product release testing, particularly with respect to bioassay potency testing. If we or any of our contract testing laboratories encounter difficulties, our ability to provide supply of detalimogene or any other product candidates that we develop for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The analytical methods used to test detalimogene are complex and many are novel and have not been validated for clinical or commercial production. The manufacturing processes used to produce any future product candidates that we develop may be similarly complex and novel. For example, in addition to several complex physio-chemical tests for detalimogene, drug substance (DS) and novel excipients, we also test detalimogene and the DS for biological potency using multiple unique cell-based assays. We rely on third-party laboratories to develop and conduct these assays. These assays may be subject to inherent variability and limitations such as, but not limited to, variations in assay conditions, reagents, equipment, or interpretation of results that could lead to inconsistent or inaccurate measurements of potency. Inaccurate potency assessments may affect our ability to demonstrate adequate control of the efficacy and safety of our drug product to regulatory authorities, potentially resulting in regulatory delays, additional testing requirements, or even rejection of our product. Furthermore, changes in regulatory guidelines or evolving scientific understanding may necessitate modifications to the biological potency assays, requiring additional validation studies and potential delays in the development or commercialization of detalimogene or any other product candidates we develop. It is important to note that despite our efforts to ensure the accuracy and reliability of these assays, there may be factors beyond our control that could impact their effectiveness, thereby affecting the overall success of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we continue to optimize our testing methods, doing so is a difficult and uncertain task, and there are risks associated with developing these methods to the level required for advanced clinical trials and commercialization, including, among other things, cost overruns, potential problems with reproducibility, stability issues, consistency and timely availability of reagents or raw materials needed to execute the testing. If we are unable to adequately validate testing methods with our current testing laboratories, we will need to transfer to another laboratory and repeat the analytical validation process, which can be a lengthy process. We ultimately may not be successful in transferring the analytical methods to contract testing laboratories and the selected contract laboratories may not have the necessary capabilities to complete the implementation and validation process for the assays. If we are able to adequately transfer and validate testing methods for detalimogene or any other product candidates we develop with a contract laboratory, we will still need to negotiate a service agreement with that contract laboratory and it is not certain we will be able to come to agreement on terms acceptable to us. As a result, we may ultimately be unable to manage the cost of goods for detalimogene or any other product candidates we develop to levels that will allow for an attractive return on investment if and when those product candidates are approved and commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The analytical testing methods for any products that we may develop are subject to the FDA and non-U.S. regulatory authority approval processes, and we will need to contract with laboratories we believe can meet applicable FDA and non-U.S. regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably test products in a manner acceptable to the FDA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize our products. Even if we obtain regulatory approval for detalimogene or any other product candidates we develop, there is no assurance that either we or our CMOs will be able to test the approved product in a manner required by good manufacturing practices acceptable to the FDA or other regulatory authorities, to test products with sufficient throughput to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of detalimogene or any other product candidates we develop, impair commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to test our products on a timely basis with acceptable costs, while at the same time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, we could incur higher testing costs if testing methods or standards change, and we could need to replace, modify, design or build and install equipment, all of which would require additional capital expenditure. Specifically, because detalimogene or any other product candidates we develop may have a higher testing requirement than conventional therapies, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market opportunities for detalimogene and any other product candidates we develop may be limited to a small group of patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancer and other disease therapies are sometimes characterized as first-line, second-line or third-line and the FDA often approves new therapies initially only for third-line use. When cancers are detected they are treated with first-line of therapy with the intention of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">curing the cancer. This treatment generally consists of chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. If the patient&#8217;s cancer relapses, then the patient is given a second-line or third line therapy, which can consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Generally, the later the line of therapy, the lower the chance of a cure. With third or higher line, the goal of the therapy is to control the growth of the tumor and extend the life of the patient, as a cure is unlikely to happen. Patients are generally referred to clinical trials in these situations. Initial approvals for new cancer and other disease therapies are often restricted to later lines of therapy for patients with advanced or metastatic disease, limiting the number of patients who may be eligible for such new therapies, which may include our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidate, detalimogene, is being developed to treat patients with BCG-unresponsive NMIBC with CIS with or without concomitant papillary disease. Our projections of both the number of people who have the disease we are targeting, as well as the subset of people with these diseases in a position to receive our therapies, if approved, are based on our beliefs, research and estimates. These estimates have been derived from a variety of sources, including scientific literature, input from key opinion leaders, patient foundations or secondary market research databases and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for detalimogene or any other product candidates we develop may be limited or may not be amenable to treatment with such product candidates. Even if we obtain significant market share for detalimogene or any other product candidates we develop, because certain of the potential target populations may be small, we may never achieve profitability without obtaining regulatory approval for additional indications.  If the market opportunities for detalimogene or any other product candidates we may develop are smaller than what we believe they are, our potential revenues may be lower than projected and our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on our executive team and key personnel, and if we lose one or more of our executive officers or key employees or are unable to attract and retain highly skilled employees, such events could harm our business.</span></p><p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our success depends on the skills, experience and performance of members of our senior management team and key personnel as well as their continued service. The individual and collective efforts of our senior management team and key personnel are important as we continue to develop product candidates, establish strategic partnerships, build out our operations and prepare for potential regulatory approval and commercialization of detalimogene, if approved. In the past two years, we have had several transitions of our executive officers, including our Chief Executive Officer transition in July 2024, the departure of our Chief Medical Officer in June 2025 and the hiring of a new Chief Medical Officer in September 2025. If we are unable to effectively manage such transitions or if we have any future transition or loss of the services of any of our executives or highly skilled technical and managerial personnel, it could have a disruptive impact on our ability to implement our business strategy and to meet our financial and operational goals, and as a result our strategic plans and financial performance may be adversely impacted. The loss or incapacity of existing members of our executive management team and key personnel could adversely affect our operations if we experience difficulties in hiring qualified successors. If we are not successful in attracting and retaining highly qualified personnel, our business, financial condition, results of operations and prospects may be harmed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our research and development initiatives, manufacturing processes and business depend on our ability to attract and retain highly skilled scientists and other specialized individuals. We may not be able to attract or retain such qualified scientists and other specialized individuals in the future due to the competition for qualified personnel among life science and technology businesses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development initiatives, laboratory operations and manufacturing processes depend on our ability to attract and retain highly skilled and experienced scientists, clinical personnel, technicians, engineers, quality-control and manufacturing personnel. We may not be able to attract or retain qualified scientists, clinical personnel, technicians or engineers in the future due to the competition for qualified personnel among life science and technology businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, we may be unable to identify, hire and retain the experienced scientific, quality-control and manufacturing personnel needed to transfer our manufacturing processes and test methods to CMOs and external testing laboratories. Further, if we endeavor to conduct manufacturing processes internally, we may be unable to identify, hire or retain the personnel needed to conduct our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. We may have difficulties locating, recruiting or retaining qualified personnel across functions that we deem critical to our success. Recruiting, training and retention difficulties can limit our ability to support our research and development and commercialization efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory and commercialization strategy. Our consultants and advisors may provide services to other organizations and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current consultants or advisors might impede the achievement of our research, development, regulatory and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that we will be able to adequately address these additional risks. If we are unable to do so, our operations might suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face risks related to epidemics and other outbreaks of communicable diseases which could significantly disrupt our operations, including our clinical trials and preclinical studies, and adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public health crises could have an adverse effect our business. Quarantines, travel restrictions and other public health and safety measures implemented in response to a pandemic could adversely impact our operations, and the ultimate impact is highly uncertain and cannot be predicted with confidence. Effects of a pandemic that may delay or otherwise adversely affect our ongoing and planned preclinical activities, our planned clinical trials as well as our business generally, include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays related to disruptions at CROs and contract manufacturers, or in the supply chain; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in receiving approval from regulatory authorities to initiate our planned clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff who, as healthcare providers, may have heightened exposure; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties in enrolling and retaining patients in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in clinical sites receiving the supplies and materials needed to conduct our planned clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties interpreting data from clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; and interruptions, difficulties or delays arising in our existing operations and company culture as a result of many of our employees working remotely. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these effects, and other effects of a pandemic could have a material adverse effect on our business, financial condition, results of operations and prospects. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States, Canada, and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by risks beyond our control, such as natural disasters, political crises, acts of terrorism, epidemics and other outbreaks of communicable diseases, war or other catastrophic events and our business continuity and disaster recovery plans may not adequately protect us from the adverse effects of such events.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, our suppliers and third-party service providers are vulnerable to damage from natural disasters, including but not limited to earthquakes, fires or floods, power loss, communications failures, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict and similar events. If any such disaster were to occur, our ability to operate our business at any of our or our third party facilities could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or other facilities, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, since February 2022, Russian military forces have continued their significant military invasion of Ukraine. Since October 2023, with the launch of the Israel-Hamas war, there has been increased hostilities in the Middle East. The impact to these countries and regions, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union and other countries and organizations against certain officials, individuals, regions, and industries in the affected areas, and each country&#8217;s potential response to such sanctions, tensions, and military actions could continue to have a material adverse effect on the global economy and political situation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date of this Annual Report, we (i) are not conducting clinical or nonclinical studies in Ukraine, Belarus, Russia, or the Middle East, (ii) are not relying upon service providers or vendors from any of these regions to advance our product development programs, (iii) do not source biomanufacturing critical raw materials, equipment, or other supplies directly from these regions, and (iv) are not aware nor have we received notification from our supply vendors that the sourcing of any general laboratory or manufacturing materials may be negatively impacted due to such conflict and related sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nearly all aspects of our activity and our products and services are subject to extensive regulation by various U.S. federal and state agencies and regulatory bodies in non-U.S. jurisdictions, and compliance with existing or future regulations could result in unanticipated expenses or limit our ability to offer our products and services. Once developed, detalimogene, and any future product candidates developed using our genetic medicine platform will require regulatory approval, which is a lengthy, expensive, and inherently unpredictable process with uncertain outcomes and cost and is subject to the potential for substantial delays. We cannot give any assurance whether or when detalimogene or any other product candidates we develop will receive regulatory approval, which is necessary before they can be commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements governing gene and cell therapy products, and in particular any novel genetic medicine products we may develop, have changed frequently and may continue to change in the future. We are aware of a limited number of genetic medicine products that have received marketing authorization from the FDA and EMA. Even with respect to more established products in the genetic medicine field, the regulatory landscape is still developing. In 2016, the FDA established the Office of Tissues and Advanced Therapies (&#8220;OTAT&#8221;) within its Center for Biologics Evaluation and Research to consolidate the review of genetic medicine and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee, among others, to advise this review. In September 2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products (&#8220;OTP&#8221;) and elevation of OTP to a &#8220;Super Office&#8221; to meet its growing cell and genetic medicine workload. Genetic medicine clinical trials conducted at institutions that receive funding for recombinant DNA research from the U.S. National Institutes of Health (&#8220;NIH&#8221;), also are potentially subject to review by the Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee (&#8220;RAC&#8221;); however, the NIH announced that the RAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same applies in the European Union. The EMA&#8217;s Committee for Advanced Therapies (&#8220;CAT&#8221;), is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. The role of CAT is to prepare a draft opinion on an application for marketing authorization for a genetic medicine medicinal candidate that is submitted to the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;), before CHMP adopts its final opinion. In the European Union, the development and evaluation of a genetic medicine medicinal product must be considered in the context of the relevant European Union guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for genetic medicine medicinal products and require that we comply with these new guidelines. As a result, the procedures and standards applied to genetic medicine products and cell therapy products may be applied to any product candidates we may develop, but that remains uncertain at this point.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of detalimogene and any other product candidates we may develop, or lead to significant post-approval limitations or restrictions. As we advance detalimogene and any other product candidates we may develop, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of these product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA decides whether individual genetic medicine protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage an NIH-funded institution to conduct a clinical trial, now or in the future, that institution&#8217;s institutional biosafety committee, as well as its IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of genetic medicine products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of detalimogene or any other product candidates we may develop. Similarly, the EMA, FDA, and other regulatory bodies may issue new guidelines concerning the development and marketing authorization for genetic medicine products and require that we comply with these new guidelines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we are initially seeking to identify and develop product candidates to treat diseases using novel technologies, there is heightened risk that the FDA, the EMA or other regulatory authority may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. Even if the endpoints are deemed clinically meaningful, we may not achieve these endpoints to a degree of statistical significance, particularly because many of the diseases we are targeting with our platform have small patient populations, making development of large and rigorous clinical trials more difficult.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments in post-marketing experience or in clinical trials conducted by others of genetic medicine products or products developed or marketed for indications of interest to us, such as NMIBC,  may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of detalimogene or any other product candidates we may develop or limit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of products utilizing non-viral genetic medicine technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as detalimogene or other  product candidates we may develop can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing non-viral genetic medicine technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the commercialization of resulting products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, ethical, social and legal concerns about genetic medicine, genetic testing and genetic research could result in additional regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and non-U.S. governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that detalimogene and any other product candidates we may develop are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of detalimogene and any other product candidates we may develop. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance detalimogene and any other product candidates we may develop through clinical development, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of detalimogene and any other product candidates we may develop or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have designed and are currently conducting the clinical trials for detalimogene in accordance with the Guidance Document. This document, which was updated in draft form in August 2024, sets forth guidance for patient selection and describes a potentially abbreviated regulatory path for approval provided certain recruitment, efficacy, and safety data are met. The FDA may review, revoke, or otherwise modify these guidelines at any time, for any reason, which would have a material adverse effect on our approval timelines or process. In addition, the Guidance Document is in draft form subsequent to FDA&#8217;s 2024 revisions, and it is possible that some or all of its key provisions may be modified prior to the document&#8217;s finalization. Furthermore, approval of other competitive products treating the same indication may reduce the agency&#8217;s propensity to support abbreviated approval pathways, which could cause our programs to be delayed in achieving regulatory approval or contribute to our failure to achieve approval at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot predict whether or when we will obtain regulatory approval to commercialize detalimogene or any other product candidate we may develop in the United States or any other jurisdiction and any such approval may be for a narrower indication than we seek.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate and our application to commercialize it. Even if detalimogene or any other product candidates we may develop meet their safety and efficacy endpoints in clinical trials, regulatory authorities may not complete their review processes in a timely manner or we may not be able to obtain regulatory approval. Additional delays may result if an FDA panel of experts (&#8220;Advisory Committee&#8221;) or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require labeling that includes precautions, boxed warnings or contra-indications with respect to conditions of use, or they may grant approval subject to the performance of costly post-marketing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of detalimogene or any other product candidates we may develop. Any of the foregoing scenarios could materially harm the commercial prospects for detalimogene or any other product candidates we may develop and materially adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to obtain or if there are delays in obtaining required regulatory approvals for detalimogene or any other product candidates that we may develop, we will not be able to commercialize or will be delayed in commercializing detalimogene or any other product candidates that we may develop and our ability to generate revenue will be adversely affected. Even if we eventually gain approval for detalimogene or any of other product candidates, we may be unable to commercialize them.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize detalimogene or any other product candidates that we may develops, we must obtain marketing approval. Detalimogene or any other product candidates that we may develop in the future, require research and development, preclinical studies, nonclinical testing, and clinical trials prior to seeking regulatory approval, and commencing commercial sales. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction and it is possible that neither detalimogene nor any other product candidates we may seek to develop in the future will ever obtain regulatory approval. In certain instances, we may need to rely on third-party CROs and/or regulatory consultants to assist us in this process, and we may have limited control over those third parties and their conduct with respect to our development programs and product candidates. To date, we have focused substantially all of our efforts and financial resources on identifying and developing our product candidates, including conducting lead optimization, nonclinical studies, preclinical studies and clinical trials, and providing general and administrative support for these operations. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#8217;s safety, purity, efficacy and potency. Securing regulatory approval also requires the submission of information about the manufacturing processes for the biologic product candidate to, and inspection of manufacturing facilities by, the relevant regulatory authority. Manufacturing facilities must comply with cGMP regulations, which include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports. In addition, given the novelty of our therapeutics approach and technologies, detalimogene and any other product candidates that we may develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use of such products if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. FDA and other regulatory bodies may continually change the requirements for Chemistry, Manufacturing and Controls (CMC) and other aspects of product manufacturing such that the approval to continue a clinical trial and/or commercially sell a product may never occur. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted IND, BLA or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Detalimogene and any other product candidates that we may develop could be delayed in receiving or fail to receive regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that detalimogene or any other product candidates that we may develop is safe and effective for its proposed indication or that a potential related companion diagnostic, should we develop one, is suitable to identify appropriate patient populations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA or other regulatory authorities for biologic product approval or continued clinical development; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of detalimogene or any other product candidates that we may develop may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA or other regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of drugs and biologics in development, only a small percentage successfully complete the FDA or non-U.S. regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results may result in our failing to obtain regulatory approval to market detalimogene or any other product candidates that we may develop, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the novel nature of detalimogene or any other product candidates that we may develop to create further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the general approach for FDA approval of a new biologic or drug is for sponsors to seek licensure or approval based on dispositive data from well-controlled, Phase 3 clinical trials of the relevant product candidate in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. We believe that we may be able to utilize the requirements defined in the FDA&#8217;s guidance for industry on developing detalimogene or other product candidates for BCG-unresponsive high-risk NMIBC given the limited alternatives for treatments for cancer and other serious diseases, but the FDA may not agree with our plans or permit us to proceed under such alternative guidance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may also require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support BLA approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of detalimogene or any other product candidates that we develop based on the completed clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, approval of genetic or biomarker diagnostic tests may be necessary in order to advance some of our product candidates to clinical trials or potential commercialization. In the future, regulatory agencies may require the development and approval of such tests. Accordingly, the regulatory approval pathway for such product candidates may be uncertain, complex, expensive and lengthy and approval may not be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve detalimogene or any other product candidates that we may develop for fewer or more limited indications than we request, may not approve the price we intend to charge for our products (where such regulatory approvals are required), may grant approval contingent on the performance of costly post-marketing clinical trials or may approve that product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for detalimogene or any other product candidates that we may develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of detalimogene or any other product candidates that we may develop, the commercial prospects for those product candidates may be harmed and our ability to generate revenues will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not obtain or maintain regulatory approval in all jurisdictions in which such approval may be required or otherwise desirable or beneficial from a business perspective. Obtaining and maintaining regulatory approval of detalimogene or any other product candidates we develop in one jurisdiction does not mean that we will obtain and/or maintain regulatory approval of such product candidates in other jurisdictions, while a failure or delay in obtaining or maintaining regulatory approval of such product candidates in one jurisdiction may have a material adverse effect on the regulatory approval or maintenance process in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of detalimogene or any other product candidates that we may develops in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in non-U.S. jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many non-U.S. jurisdictions, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions and such regulatory requirements can vary widely from country to country. Obtaining other regulatory approvals and compliance with other regulatory requirements could result in significant delays, difficulties and costs for us and could require additional preclinical studies or clinical trials, which could be costly and time-consuming and could delay or prevent the introduction of our products in certain countries. The non-U.S. regulatory approval process involves all of the risks associated with FDA approval, and may not offer certain potentially expedited development and approval pathways that exist in the United States. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with the regulatory requirements in international markets and/or obtain and maintain applicable marketing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approvals, our target market will be reduced and our ability to realize the full market potential of detalimogene or any other product candidates that we may develop will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast Track designation and Regenerative Medicine Advanced Therapy designation by the FDA for detalimogene and our participation in the FDA&#8217;s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (&#8220;CDRP&#8221;) Program may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that detalimogene or any future product candidate that may receive these designations or is selected for the CDRP Program will receive regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted a Fast Track designation and Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation for detalimogene for the treatment of BCG-unresponsive, high-risk NMIBC patients with CIS, and we may seek such designations for other indications or future product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing product candidates that meet certain criteria. Specifically, biologics are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. A BLA submitted for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. Similarly, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine products, including genetic therapies. A regenerative medicine advanced therapy is eligible for RMAT designation if it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or therapy has the potential to address unmet medical needs for such disease or condition. Similar to breakthrough therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with the FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of a BLA, and other opportunities to expedite development and review. In addition, the LEGEND study has been selected for the FDA&#8217;s Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;) Development and Readiness Pilot (&#8220;CDRP&#8221;) Program, a voluntary program designed to accelerate the development of certain drugs and biologics that have expedited clinical development pathways by increasing communication between the FDA and sponsors. The program&#8217;s stated goal is to align and derisk CMC strategies early in the process, which can lead to faster patient access to new treatments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has broad discretion whether or not to grant these designations or select a development program for participation in the CDRP Program. Even if we believe a particular product candidate or development program is eligible for these designations or the CDRP Program, we cannot assure you that the FDA would decide to grant any of them. Although we have received Fast Track designation and RMAT designation for detalimogene for the treatment of BCG-unresponsive, high-risk NMIBC patients with CIS and the LEGEND study has been selected for the CDRP Program, and even if we receive additional Fast Track or RMAT designations or are selected for the CDRP Program for other indications or any future product candidates, such product candidates may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track and RMAT designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also decide that we are no longer eligible for the CDRP Program. Furthermore, these designations and the CDRP Program do not increase the likelihood that detalimogene or any future product candidate that may be granted Fast Track or RMAT designation or selected for the CDRP Program will receive marketing approval in the United States. Many product candidates that have received Fast Track designation and/or RMAT designation or other designations have ultimately failed to obtain approval.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek priority review designation for detalimogene or any other product candidates we develop, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness of the treatment, the FDA may designate the marketing application for that product candidate for priority review. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the goal for the FDA to review an application to six months, rather than the standard review period of ten months. We may request priority review for one or more original BLAs for detalimogene or any other product candidates that we may develop s in the future. The FDA has broad discretion with respect to whether or not to grant priority review status to a marketing application, so even if we believe an application for a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle, or at all. Many product candidates that have received priority review designation have ultimately failed to obtain approval.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of detalimogene or any other product candidates or therapies that we may develop, we will be subject to ongoing regulatory obligations, reporting requirements and continued regulatory review, which may result in significant additional expenses. If we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates, we may be subject to substantial penalties, fines, delays, suspensions, refusals and withdrawals of approvals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If detalimogene or any other product candidates that we may develop are approved, they will be subject to ongoing regulatory requirements and reporting requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, recordkeeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable non-U.S. regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities of CMOs and testing laboratories are required to comply with extensive FDA, and non-U.S. regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP, and in certain cases, current Good Tissue Practices (&#8220;cGTP&#8221;), regulations. As a result, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work with must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for detalimogene or any other product candidates that we may develop may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require that we implement a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable non-U.S. regulatory authority approves detalimogene or any other product candidates that we may develop, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and establishment registration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may seek consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers, manufacturing processes or testing laboratories, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning or untitled letters or holds on clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in regulatory requirements could result in delays or the discontinuation of development of detalimogene or other product candidates or therapies that we may develop, or unexpected costs in obtaining or maintaining regulatory approval, and thereby adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy and durability of effect must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are developing novel genetic medicine product candidates, the regulatory requirements that we will be subject to are continually evolving and may not be clear. Even with respect to more established products that fit into the category of genetic medicines, the regulatory landscape is still developing. For example, regulatory requirements governing genetic medicine products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing cell therapy products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union a special committee called the CAT was established within the EMA in accordance with Regulation (&#8220;EC&#8221;) No 1394/2007 on advanced-therapy medicinal products (&#8220;ATMPs&#8221;) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include genetic medicine products. These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our genetic medicines and product candidates is new, we may face even more cumbersome and complex regulations than those emerging for cell therapy products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, even if detalimogene or other product candidates that we may develop obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our contract manufacturers are subject to significant regulation with respect to the manufacturing of our current and future product candidates. The manufacturing facilities on which we rely may not meet or continue to meet regulatory requirements and/or may have limited capacity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract manufacturers and their facilities are required to comply with extensive regulatory requirements, including ensuring that quality control and manufacturing procedures conform to cGMP requirements. These regulations cover all aspects of manufacturing relating to our product candidates and components used in clinical studies and commercial production. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational product candidates and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We and our contract manufacturers must supply all necessary documentation in support of a BLA or Market Authorization Application (&#8220;MAA&#8221;) on a timely basis and must adhere to Good Laboratory Practices (&#8220;GLP&#8221;) and cGMP regulations enforced by the FDA and other regulatory authorities through their facilities inspection program. The facilities and quality systems of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. Moreover, if our contract manufacturers fail to achieve and maintain high manufacturing standards, in accordance with applicable regulatory requirements, or there are substantial manufacturing errors, this could result in patient injury or death, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns, revocation of regulatory approvals, or other problems that could seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ongoing healthcare legislative and regulatory reform measures, including the U.S. federal government&#8217;s determination that any of our product candidates, including detalimogene, is an &#8220;essential&#8221; biologic medicine, may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and many non-U.S. jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physicians. The CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The ACA is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the ACA expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended Medicaid rebates, previously due only on fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. On February 1, 2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate Program under the ACA. These regulations became effective on April 1, 2016. Since that time, there have been significant ongoing efforts to modify or eliminate the ACA. The Tax Cuts and Jobs Act, enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) or the individual mandate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted since the passage of the ACA. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction (the &#8220;Joint Select Committee&#8221;), to provide recommendations and legislative language that would significantly improve the short-term and long-term fiscal imbalance of the U.S. federal government. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022. Under the Consolidated Appropriations Act, 2023, the 2% Medicare sequester is extended for the first six months of fiscal year 2032 and revises the sequester percentage up to 2% for fiscal years 2030 and 2031. These across-the-board spending cuts could adversely affect our future revenues, earnings, and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;). The IRA contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the IRA. The IRA could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effect of the IRA on our business and the pharmaceutical industry in general is not yet known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA, has also been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire ACA. An appeal was taken to the U.S. Supreme Court. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further changes to and under the ACA remain possible but it is unknown what form any such changes or any law proposed to replace or revise the ACA would take, and how or whether it may affect our business in the future. We expect that changes to the ACA, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional federal, state and non-U.S. healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, including detalimogene, if approved, or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidates we develop, including detalimogene, may become subject to unfavorable or unprofitable third-party coverage and reimbursement practices, as well as pricing regulations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients rely on insurance coverage by third-party payors (third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.), to pay for products. The availability and extent of coverage and adequate reimbursement by third- party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Private insurance companies, commercial payors and various other healthcare intermediaries such as pharmacy benefit managers may take steps to thwart physician and/or patient access to our products including not covering the product, blocking access to our products or adding step edits or prior approval requirements before reimbursing patients or health care providers for using our products. This could result in reduced or failure to achieve revenues and/or margins. In addition, third-party organizations that purport to study and issue reports regarding the pricing of certain therapeutic medicines may issue reports regarding our products that negatively affect pricing and our product use and uptake by physicians and patients. Additionally, private insurance companies are increasingly imposing utilization management tools, such as requiring prior authorization for a proprietary product if a generic product or less expensive product is available or requiring the patient to first fail on one or more generic or less expensive products before permitting access to a proprietary medicine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. Factors payors consider in determining reimbursement are based on whether the product is: (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No uniform policy exists for coverage and reimbursement in the United States. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As U.S. federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products, if approved, will be covered by private or public payors, and if covered, whether the reimbursement will be adequate or competitive with other marketed products. Such other actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our products if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in the European Union, the United Kingdom, Japan and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates, including detalimogene, from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future or subject to recoupment or overpayment challenges.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Drug marketing, price controls and reimbursement regulations may materially affect our ability to market and receive coverage for our product candidates, if approved, in the European Union, the United Kingdom, Japan and other non-U.S. jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to seek approval to market our product candidates, including detalimogene if approved, in both the United States and in selected non-U.S. jurisdictions. If we obtain approval in one or more non-U.S. jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some countries outside of the United States, particularly those in the European Union and United Kingdom, the pricing of pharmaceutical products is subject to governmental control and other market regulations,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If required to execute such a trial, we cannot be sure of a favorable outcome. In general, product prices under such systems are substantially lower than in the United States. Price controls in non-U.S. jurisdictions or changes in pricing regulations in such jurisdictions could reduce the amount we are able to charge for our product candidates. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Much like the federal AKS prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products are also prohibited in the European Union and United Kingdom. The provision of benefits or advantages to physicians is governed by both the rules on medicinal products and the national anti-bribery laws in the relevant countries, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, their competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in most countries outside of the United States, including the European Economic Area (&#8220;EEA&#8221;) and United Kingdom, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, and in some countries include retrospective rebates to the government. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally, prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us and the potential profitability of any of our product candidates in those countries would be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guidelines and recommendations published by various organizations may impact the use or reimbursement of detalimogene, if approved, as well as other future products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities promulgate regulations and guidelines that may be directly applicable to us and any approved products. However, professional societies, practice management groups, insurance carriers, physicians&#8217; groups, private health and science foundations and organizations involved in various diseases also publish guidelines and recommendations to healthcare providers, administrators and payors, as well as patient communities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recommendations by government authorities or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapies, and a growing number of organizations are providing assessments of the value and pricing of pharmaceutical products. These assessments may come from private organizations, such as the Institute for Clinical and Economic Review (&#8220;ICER&#8221;), which publish their findings and offer recommendations relating to the products&#8217; reimbursement by government and private payors. On December 17, 2020, ICER published its final report assessing the effectiveness and value of nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive NMIBC, both of which are potential competitors to detalimogene. The guidance was updated on January 15, 2021. Nadofargene firadenovec, sold under the brand name Adstiladrin, is a FDA-approved genetic medicine approved in 2022 for the treatment of adult patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors; oportuzumab monatox, also known as Vicineum, is an experimental therapy that has been studied in a highly similar patient group. The findings of this or any future ICER report or similar recommendations or guidelines from ICER or similar third parties may affect our reputation as well as the perception of our value, and any recommendations or guidelines that result in decreased use or reimbursement of detalimogene, if approved or adopted into commercial or clinical practice, could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, the occurrence of any of the foregoing, or the perception by the investment community or shareholders that such recommendations or guidelines will result in decreased use or reimbursement of detalimogene, if approved, could adversely affect the market price of our securities. The effect, if any, of any ICER report, recommendations or guidelines on our any of our products relating to usage, dosage, administration, pricing, reimbursement or other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">matters is not foreseeable and we make no assurance regarding the effect of any current or future ICER report, recommendations or guidelines on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to data privacy and protection laws, rules and regulations, as well as contractual obligations, that apply to the collection, transmission, storage, use and other processing of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are numerous U.S. federal and state laws, rules and regulations governing the collection, sharing, use, retention, disclosure, security, transfer, storage and other processing of personal information, including federal and state data privacy and security laws, data breach notification laws, and data disposal laws. In particular, at the federal level, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future. At the federal level, we are also subject to, among other laws and regulations, the rules and regulations promulgated under the authority of the FTC (which has the authority to regulate and enforce against unfair or deceptive acts or practices in or affecting commerce, including acts and practices with respect to data privacy and security), as well as the Electronic Communication Privacy Act. The United States Congress also has considered, is currently considering, and may in the future consider, various proposals for comprehensive federal data privacy and security legislation, to which we may become subject if passed. If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached certain contracts or obligations. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, we are subject to similar and sometimes more onerous data protection and privacy laws and regulations such as the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act (the &#8220;CPRA&#8221;) (collectively, the &#8220;CCPA&#8221;). The CCPA imposes many requirements on certain businesses that process the personal information of California residents, including requirements similar to those found in the General Data Protection Regulation (&#8220;GDPR&#8221;). For example, the CCPA requires covered businesses to provide notice to California residents regarding the information collected about them and how such information is used and shared, provides California residents the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of certain &#8220;sales&#8221; of their personal information. The CCPA provides for significant civil penalties and statutory damages for companies that violate its requirements, and also provides for a private right of action for certain data breaches that result in the loss of unencrypted personal information. This private right of action is expected to increase the likelihood of, and risks associated with, data breach litigation. The CPRA significantly expands the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed comprehensive state-level data privacy and security laws, rules and regulations that share similarities with the CCPA. Other states are in the process of enacting or will be considering these laws in the future. Moreover, laws in all 50 U.S. states require businesses to provide notice under certain circumstances to consumers whose personal information has been disclosed as a result of a data breach. These laws, and other similar laws that may be enacted in the future, may impact our business activities, including our identification of research subjects and ultimately the marketing and distribution of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA is regulated by the GDPR, which went into effect in May 2018 and imposes obligations on companies that operate in our industry with respect to the processing of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations, including requiring data controllers and processors to maintain a record of their data processing and policies. Following the withdrawal of the United Kingdom from the European Union, the United Kingdom&#8217;s Data Protection Act 2018 (the &#8220;U.K. GDPR&#8221;), which &#8220;implements&#8221; and complements the GDPR and achieved formal approval by United Kingdom&#8217;s monarchy on May 23, 2018, applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the GDPR and U.K. GDPR remain substantially similar for the time being, the U.K. government has announced that it would seek to chart its own path on data protection and reform its relevant laws, including in ways that may differ from the GDPR. While these developments increase uncertainty with regard to data protection regulation in the United Kingdom, even in their current, substantially similar form, the GDPR and U.K. GDPR can expose businesses to divergent parallel regimes that may be subject to potentially different interpretations and enforcement actions for certain violations and related uncertainty. If our or our service providers&#8217; privacy or data security measures fail to comply with the GDPR and U.K. GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros (or GBP17.5 million under the U.K. GDPR) or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR places restrictions on the cross-border transfer of personal data from the EEA to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the EEA to other countries. Similar complexities and uncertainties also apply to transfers from the U.K. to third countries. In July 2020, the Court of Justice of the European Union (&#8220;CJEU&#8221;), invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU&#8217;s decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses (&#8220;SCCs&#8221;), for transfers of personal data from the EEA to the United States. While we were not self-certified under the EU-U.S. Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors. While we may take steps to mitigate the impact on us, such as implementing SCCs, the efficacy and longevity of these mechanisms remains uncertain. Moreover, in 2021, the European Commission adopted new SCCs, which impose on companies additional obligations relating to personal data transfers out of the EEA, including the obligation to update internal privacy practices, conduct transfer impact assessments and, as required, implement additional security measures. The new SCCs may increase the legal risks and liabilities under European Union laws associated with cross-border data transfers, and result in material increased compliance and operational costs. While the European Commission announced in March 2022 that an agreement in principle had been reached between European Union and U.S. authorities regarding a new transatlantic data privacy framework, no formal agreement has been finalized, and any such agreement, if formalized, is likely to face challenge at the CJEU. Moreover, while the U.K. GDPR is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under the GDPR. The United Kingdom has already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union and EEA remain unaffected. In addition, a decision from the European Commission appears to deem the United Kingdom as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EEA to the United Kingdom, such that SCCs are not required for the transfer of personal data from the EEA to the United Kingdom, although such decision will sunset in June 2025 unless extended and it may be revoked in the future by the European Commission if the United Kingdom data protection regime is reformed in ways that deviate substantially from the GDPR. Adding further complexity for international data flows, in March 2022, the United Kingdom adopted its own International Data Transfer Agreement for transfers of personal data out of the United Kingdom to so-called third countries, as well as an international data transfer addendum that can be used with the SCCs for the same purpose. The European Union has also proposed legislation that would regulate non-personal data and establish new cybersecurity standards, and other countries, including the United Kingdom, may similarly do so in the future. If we are otherwise unable to transfer data, including personal data, between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond the GDPR and U.K. GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow the GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Any failure, actual or perceived, to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, any failure, actual or perceived, to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cyber-attacks or other failures in our or our third-party vendors&#8217;, contractors&#8217; or consultants&#8217; telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, our programs, our CROs, third-party logistics providers, distributors and other contractors and consultants utilize information technology (&#8220;IT&#8221;), systems and networks to process, transmit and store electronic information, including but not limited to intellectual property, proprietary business information and personal information, in connection with our business activities. Our internal IT systems and those of current and future third parties on which we rely may fail and are vulnerable to breakdown, breach, interruption or damage from cyber incidents, employee error or malfeasance, theft or misuse, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromises. As use of digital technologies has increased, cyber incidents, including third parties gaining access to employee accounts using stolen or inferred credentials, computer malware (e.g., ransomware), viruses, spamming, phishing attacks, denial-of-service attacks or other means, and deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency, intensity, and sophistication. These threats pose a risk to the security of our, our programs&#8217;, our CROs&#8217;, third-party logistics providers&#8217;, distributors&#8217; and other contractors&#8217; and consultants&#8217; systems and networks, and the confidentiality, availability and integrity of our intellectual property, confidential information, preclinical and clinical trial data, proprietary business information, personal data, and health-related information. There can be no assurance that we or any of our third-party partners will be successful in preventing cyberattacks or successfully mitigating their effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advances in computer and software capabilities, encryption technology, and other discoveries increase the complexity of our technological environment, including how each interacts with our various software platforms. Such advances could delay or hinder our ability to conduct business or could compromise the integrity of our data, resulting in a material adverse impact on our financial condition and results of operations. The risk of system disruption is increased when significant system changes are undertaken. If we fail to timely integrate and update our information technology systems and processes, we may fail to realize the cost savings or operational benefits anticipated to be derived from these initiatives. We also may experience occasional system interruptions and delays that make our information technology systems unavailable or slow to respond, including the interaction of our information technology systems with those of third parties. A lack of sophistication or reliability of our information technology systems could adversely impact our operations and consumer service and could require major repairs, replacements or remodelings, resulting in significant costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, non-U.S. governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. In addition, varying parts of our workforce are currently working remotely on a part or full time basis. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile non-U.S. governments or agencies. We may also experience security incidents that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Similarly, there can be no assurance that our CROs, third-party logistics providers, distributors and other contractors, consultants and third parties will be successful in protecting our clinical and other data that is stored on their systems. Any loss of clinical trial data from our completed or ongoing clinical trials for any of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. We have experienced and expect to continue to experience actual and attempted cyberattacks of our IT networks, such as through phishing scams and ransomware. Although we do not believe that we have experienced any significant system failure, accident or security incidents to date, we cannot guarantee that we will not experience such incidents in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any cyberattack that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding clinical trial participants or employees, data breach or destruction or loss of data could result in a violation of applicable U.S. and international privacy, data protection and other laws and regulations, require us to notify affected individuals or supervisory authorities, subject us to litigation and governmental investigations, proceedings and regulatory actions by federal, state and local regulatory entities in the United States and by international regulatory entities, cause our exposure to material civil and/or criminal liability and cause us to breach our contractual obligations, which could result in significant legal and financial exposure and reputational damages. Further, we could be forced to expend significant financial and operational resources in response to a security breach, including repairing system damage, increasing security protection costs by deploying additional personnel and modifying or enhancing our protection technologies, investigating and remediating any information security vulnerabilities and defending against and resolving legal and regulatory claims, all of which could divert resources and the attention of our management and key personnel away from our business operations and adversely affect our business, financial condition and results of operations. As cyber threats continue to evolve, we may be required to incur significant additional expenses in order to implement further data protection measures or to remediate any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information security vulnerability. Further, we do not maintain separate cyber liability insurance and our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above. We also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim. Accordingly, if our cybersecurity measures, and those of our service providers, fail to protect against unauthorized access, attacks and the mishandling of data by our employees and third-party service providers, then our business, financial condition, results of operations and prospects could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inadequate funding for, or changes in leadership at, or disruptions at the FDA, the SEC and other government agencies could hinder their ability to hire and retain key personnel, prevent new products and services from being developed, approved or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or take action with respect to other regulatory matters can be affected by a variety of factors, including government budget and funding levels, passage of federal FDA user fee legislation every five years, ability to hire and retain key personnel and accept the payment of user fees, public health emergencies, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies or for the FDA to take action with respect to other regulatory matters, which could adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, including for 43 days beginning in October 2025, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown or other disruption occurs again in the future, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Similarly, a prolonged government shutdown or other disruption could prevent the timely review of patent applications by the United States Patent and Trademark Office, or USPTO, which could delay the issuance of any U.S. patents to which we might otherwise be entitled. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors and contract manufacturers, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws enforced by the FDA, the Office of Inspector General at HHS (&#8220;HHS-OIG&#8221;), the U.S. Department of Justice (&#8220;DOJ&#8221;) and other regulatory bodies in non-U.S. jurisdictions, fails to provide true, complete and accurate information to the FDA, CMS, HHS-OIG, DOJ and other similar regulatory bodies in non-U.S. jurisdictions, fails to comply with manufacturing standards we have established, fails to comply with healthcare fraud and abuse laws in the United States and similar non-U.S. laws, or fails to report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly and our costs associated with compliance with these laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with healthcare providers and physicians and third-party payors are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and result in diminished profits and future earnings and thereby adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the AKS and the FCA, which may constrain our business or financial arrangements and relationships through which we sell, market and distribute our products. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry (e.g., healthcare providers, physicians and third-party payors), are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. We also may be subject to patient information and privacy and security regulation by both the federal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government and the states and non-U.S. jurisdictions in which we conduct our business. The applicable federal, state and non-U.S. healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The AKS, which prohibits the knowing and willful offer, solicitation, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including but not limited to cash, improper discounts, and free or reduced price items and services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, courts have found that if &#8220;one purpose&#8221; of remuneration is to induce referrals, the AKS is violated. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. A claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from participation in federal health care programs, suspension and debarment from government procurement and non-procurement programs, refusal of orders under existing government contracts, and substantial civil and criminal sanctions.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the AKS and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the AKS and FCA laws are inapplicable. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the AKS, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their implementing regulations, and as amended again by the Final HIPAA Omnibus Rule, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information also implicate our business. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition to other federal laws, state laws and non-U.S. laws, such as the General Data Protection Regulation in the European Union, create the potential for substantial penalties in the event of any non-compliance with the applicable data privacy and data protection laws. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. For the data submitted on or after January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners. States may also have similar reporting requirements related to payments made to clinical providers, and failure to comply with such requirements can adversely impact the business. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulatory guidance. Federal and state enforcement bodies have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recently increased their scrutiny of interactions between healthcare companies, healthcare providers and other third parties, including charitable foundations, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from our business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, loss of eligibility to obtain approvals from the FDA, the exclusion from participation in federal and state healthcare programs, suspension and debarment from government procurement and non-procurement programs, refusal of orders under existing government contracts, individual imprisonment, reputational harm and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar worldwide anti-bribery laws, including the Canadian Corruption of Foreign Public Officials Act, generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. For additional information regarding the compliance of our operations with the FCPA and non-U.S. laws and regulations, see the Risk Factor entitled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional laws and regulations governing international operations may preclude or delay us from developing, manufacturing or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to certain U.S. and non-U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations thereof.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among other matters, U.S. and non-U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, the &#8220;Trade Laws&#8221;) prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of the Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time, including when and if we conduct clinical trials outside the United States. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to International Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an international organization and we plan to expand operations internationally where we have limited operating experience and where we may be subject to increased regulatory risks and local competition. If we are unsuccessful in any efforts to expand internationally, our business and results of operations may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are already an international organization and we plan to further expand our operations internationally. We currently source drug product excipients and other product components that are critical to our manufacturing processes from CMOs located in the European Union. In the future, we expect to opportunistically engage with CMOs located in other non-U.S. jurisdictions to facilitate the manufacture of our products on a basis that is cost effective and responsive to customer demand. As part of our business strategy, we plan to commercialize detalimogene and other products we may develop for sale in the United States and non-U.S. jurisdictions. Our business strategy incorporates potential international operational expansion, independently and through third parties as we seek to obtain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory approval for, and commercialize, our product candidates in patient populations outside the United States. If approved, we may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rejection or qualification of non-U.S. clinical trial data by the competent authorities of other countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or interruptions in the supply of clinical trial materials resulting from any events affecting raw material supply or manufacturing capabilities abroad; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional potentially relevant third-party patent and other intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in staffing and managing non-U.S. operations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limits in our ability to penetrate international markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our product candidates and exposure to non-U.S. currency exchange rate fluctuations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, including a COVID-19 resurgence, and related shelter-in-place orders, travel, social distancing and quarantine policies, boycotts, curtailment of trade and other business restrictions; certain expenses including, among other things, expenses for travel, translation and insurance; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory and compliance risks that relate to anti-corruption compliance and recordkeeping that may fall within the purview of the FCPA, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors could harm our future international expansion and operations and, consequently, our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Global economic uncertainty, changes in geopolitical conditions and weakening product demand caused by political instability, changes in trade agreements and disputes, such as the armed conflicts between Russia and Ukraine and in the Middle East and other macroeconomic factors, could adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations and performance depend on global, regional and U.S. economic and geopolitical conditions. General worldwide economic conditions have experienced significant instability in recent years, including due to recent global economic uncertainty and turbulent financial market conditions. The armed conflict in the Middle East has created volatility in the global capital markets and is expected to have further global economic consequences. Russia&#8217;s ongoing military invasion of Ukraine has triggered significant sanctions from U.S. and European leaders and disruptions to financial markets around the world. Resulting changes in U.S. trade policy could trigger retaliatory actions by Russia, its allies and other affected countries, including China, resulting in a &#8220;trade war.&#8221; In addition, changes in political conditions in China and changes in the state of China-U.S. relations, including any tensions relating to potential military conflict between China and Taiwan, are difficult to predict and could adversely affect our business. Furthermore, if other countries, including the United States, become further involved in the conflict, we could face significant adverse effects to our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values could impact our business in the future. For example, increasing inflation has raised operating costs for us and many businesses, and, in the future, could impact demand, pricing or the cost we incur to manufacture our product candidates, foreign exchange rates (including in particular U.S. dollar and Canadian dollar exchange rates) or employee wages. Among other potential effects, continued increased inflation or interest rates may result in reduced liquidity and limits on our ability to access credit or otherwise raise capital. The Federal Reserve has previously raised, and may again raise, interest rates in response to concerns about inflation, which coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks and creating new, unforeseen risks to our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual events involving reduced or limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These conditions make it extremely difficult for us to accurately forecast and plan future business activities. The above factors, including a number of other known and unknown economic and geopolitical factors in the United States and abroad, could ultimately have material adverse effects on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect certain of our research and development and manufacturing activities may take place in non-U.S. jurisdictions, such as China, through third-party CROs, collaborators or manufacturers. A significant disruption in the operation of those CROs, collaborators or manufacturers could materially adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may contract many of our research, manufacturing and preclinical activities to third parties outside the United States, including without limitation, in China. Any disruption in the operations of such third parties or in their ability to meet our needs, whether as a result of a natural disaster, war or other causes, could impair our ability to operate our business on a day-to-day basis and to continue development of our programs. Furthermore, since many of these third parties are located outside the United States, we are exposed to the possibility of disruption and increased costs in the event of changes in the policies of the United States or non-U.S. governments, war, political unrest or unstable economic conditions in any of the countries where we conduct such activities. For example, a war or trade war could lead to tariffs, embargoes, sanctions or other limitations on trade, including without limitation those placed on Russia as a result of its ongoing military invasion of Ukraine, that may affect our ability to source from affected third parties the reagents and raw materials used in our product candidates. Additionally, a natural disaster, war, civil or political unrest or similar circumstances could hinder our ability to maintain or initiate clinical studies at our preferred sites, causing trial initiation or implementation delays. Any of these matters could materially and adversely affect our product development timelines, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional laws and regulations governing international operations may preclude or delay us from developing, manufacturing or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an international company with operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we operate. The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any non-U.S. official, political party or candidate for the purpose of influencing any act or decision of the non-U.S. entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government and doctors and other hospital employees are considered non-U.S. officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. As we continue to expand our presence outside of the United States, we will need to dedicate additional resources to complying with these laws, and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. securities exchanges for violations of the FCPA&#8217;s accounting provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain, enforce and defend patent protection for any product candidates we develop or for our novel genetic medicine platform, or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products or technology similar or identical to ours and our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our and our licensors&#8217; ability to seek, obtain and maintain patent and other intellectual property protection in the United States, Canada and other jurisdictions with respect to any product candidates we may develop and our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">technology, including our genetic medicine platform, manufacturing processes and their respective components, formulations, combination therapies, methods of treatment, processes and development that are important to our business, as well as successfully defending these patents and other intellectual property against third-party challenges. The risks associated with patent rights generally apply to patent rights that we in-license now or in the future, as well as patent rights that we may own now or in the future. We have sought, and will seek, to protect our proprietary position by filing patent applications in the United States and abroad related to certain technologies and our genetic medicine platform that are important to our business. However, elements of our patent portfolio are at an early stage and there can be no assurance as to whether or when such patent applications will issue as granted patents. Our ability to stop third parties from making, using, selling, marketing, offering to sell, importing and commercializing any product candidates we may develop and our technology is dependent upon the extent to which we and our licensors have rights under valid and enforceable patents and other intellectual property that cover our genetic medicine platform and proprietary technology. If we are or our licensors are unable to secure, maintain, defend and enforce patents and other intellectual property with respect to any product candidates or technology that we may develop, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own certain granted patents and pending patent applications which cover our genetic medicine platform, use and/or function, product candidates and their use, and manufacturing processes, as applicable. Our pending Patent Cooperation Treaty (&#8220;PCT&#8221;) patent application, and any PCT application we may file in the future, is not eligible to become issued patents until, among other things, we file one or more national stage patent applications within 30 to 32 months, depending on the jurisdiction, from such application&#8217;s priority date in the jurisdictions in which we are seeking patent protection. Similarly, should we in the future file a pending provisional patent application such application would not be eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of such provisional patent application&#8217;s filing date. If we do not timely file such national stage patent applications or non-provisional patent applications, we may lose our priority date with respect to such PCT or provisional patent applications, respectively, and any patent protection on the inventions disclosed in such PCT or provisional patent applications, respectively. While we and our licensors intend to timely file national stage and non-provisional patent applications relating to our PCT and provisional patent applications, respectively, we cannot predict whether any such patent applications will result in the issuance of patents. If we or our licensors do not successfully obtain issued patents, or, if the scope of any patent protection we or our licensors obtain is not sufficiently broad, we will be unable to prevent others from using any product candidates we may develop or our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies. Any failure to obtain or maintain patent protection with respect to genetic medicine platform, manufacturing processes or our product candidates and technology would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute, maintain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We and our licensors may not be able to obtain, maintain or defend patents and patent applications due to the subject matter claimed in such patents and patent applications being in the public domain. For example, in some cases, the work of certain academic researchers in the genetic medicine field has entered or will enter the public domain, which may compromise our and our licensors&#8217; ability to obtain patent protection for certain inventions related to or building upon such prior work. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not be able to prevent any third-party from using any of our technology that is in the public domain to compete with our product candidates and technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of patent rights are highly uncertain. Our pending and future owned and licensed patent applications may not result in patents being issued which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and products or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all, and even if such patent applications do issue as patents, they may not issue in a form, or with a scope of claims, that will provide us with any meaningful protection, prevent others from competing with us or otherwise provide us with any competitive advantage. In addition, the scope of claims in a patent application can be significantly reduced before the patent is issued, and such scope of an issued patent can be reinterpreted after issuance, and changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patent rights or narrow the scope of our patent protection. Furthermore, our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties have developed technologies that may be related or competitive to our own technologies and product candidates and may have filed or may file patent applications, or may have obtained or may obtain issued patents, claiming inventions that may overlap or conflict with those claimed in our owned or licensed patent applications or issued patents. We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates and technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know for certain whether the inventors of our owned or licensed patents and patent applications were the first to make the inventions claimed in any owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If a third-party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patent applications may not issue as patents and even if issued, may be challenged and invalidated or ruled unenforceable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, inventorship disputes may arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and other jurisdictions. For example, we may be subject to a third-party submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) challenging the validity of one or more claims of our owned or licensed patents. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our owned or licensed pending patent applications. We may become involved in opposition, derivation, re-examination, inter partes review, post-grant review or interference proceedings and similar proceedings in non-U.S. jurisdictions (for example, opposition proceedings) challenging the validity, priority or other features of patentability of our owned or licensed patent rights. In addition, a third-party may claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse result in any litigation or patent office proceeding could put one or more of our owned or licensed patents at risk of being invalidated, ruled unenforceable or interpreted narrowly and could allow third parties to commercialize products identical or similar to any product candidates we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a non-U.S. patent office, that challenge priority of invention or other features of patentability. Such challenges and proceedings may result in loss of patent rights, exclusivity, freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the scope and duration of the patent protection of our technology and any product candidates we may develop. Such challenges and proceedings may also result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other interim proceedings or developments related to such challenges and proceedings and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future co-own intellectual property rights relating to our genetic medicine platform and our future product candidates with third parties. In addition, our licensors may co-own the patent rights we in-license with other third parties with whom we do not have a direct relationship. If we or our licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patent rights or we or our licensors are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patent rights in order to enforce such patent rights against third parties and such cooperation may not be provided to us. Further, any such co-owner may be able to license a co-owned patent to a third-party we believe infringes such patent, preventing us from obtaining compensation or other remedies from such third-party through litigation or settlement arrangements. We may also become engaged in disputes with our co-owners related to patent prosecution strategy or the apportionment of costs associated with the prosecution, maintenance or enforcement of co-owned patents or patent applications. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents covering our product candidates or genetic medicine platform could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we initiated legal proceedings against a third-party to enforce a patent covering our genetic medicine platform, product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our owned or in-licensed patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in non-U.S. jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or amendment to our patents in such a way that they no longer cover our product candidates or other technologies or prevent third parties from competing with us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third-party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the genetic medicine platform, our product candidates or other technologies. Such a loss of patent protection would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will be due to be paid to the USPTO and various non-U.S. government patent agencies over the lifetime of our owned or licensed patents and patent applications. In certain circumstances, we may rely on our licensing partners to pay these fees due to the USPTO and non-U.S. patent agencies. The USPTO and non-U.S. patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We may also be dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technologies, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in either patent laws or interpretation of the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and genetic medicine platform.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Prior to March 2013, in the United States, the first to invent an invention was entitled to a patent claiming the invention, while outside the United States, the first to file a patent application was entitled to the patent, assuming that other requirements for patentability were met. After March 2013, under the Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention, regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO after the date of invention but before the filing date of our owned or in-licensed patent application could therefore be awarded a patent covering an invention of ours, even if we had made the invention before it was made by the third-party. This will require us and our licensors to be aware going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technologies and the prior art allow our technologies to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (1) file any patent application related to our technologies or product candidates or (2) invent any of the inventions claimed in our patents or patent applications. The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These include allowing third-party submissions of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because the evidentiary standard in USPTO proceedings is lower than the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid, even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use USPTO proceedings to invalidate our owned or in-licensed patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the enforcement or defense of our owned and in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents. We cannot predict how decisions by the courts, the U.S. Congress or the USPTO may impact the value of our owned or in-licensed patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position, product candidates or genetic medicine platform for an adequate amount of time, and we may need to obtain patent term extension and equivalent extensions outside of the United States for our product candidates or genetic medicine platform.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest filing date of the first U.S. non-provisional patent application to which the patent claims priority. Various adjustments and extensions may be available, but the life of a patent and the protection it affords is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidates or genetic medicine platform, one or more U.S. patents that we own or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;the Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or biologic. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. In Europe, supplementary protection certificates are available to extend a patent term up to five years to compensate for patent term lost during regulatory review, and can be extended for an additional six months if data from clinical trials is obtained in accordance with an agreed-upon pediatric investigation plan. Although all countries in Europe must provide supplementary protection certificates, there is no unified legislation among European countries and so supplementary protection certificates must be applied for and granted on a country-by-country basis. This can lead to a substantial cost to apply for and receive these certificates, which may vary among countries or not be provided at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be granted any extensions for which we apply in the United States or any other jurisdiction because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third-party, we would need the cooperation of that third-party. If we are unable to obtain patent term extension, or the foreign equivalent, or if the term of any such extension is less than we request, our competitors may be able to enter the market sooner, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, recent judicial decisions in the U.S. raised questions regarding the award of patent term adjustment (PTA) for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will be viewed in the future and whether patent expiration dates may be impacted.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our rights to develop and commercialize our product candidates and genetic medicine platform may be subject, in part, to the terms and conditions of licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are reliant upon licenses to certain intellectual property and proprietary technologies from third parties that are important or necessary to the development of our technologies and product candidates. We have entered into license agreements with third parties and may need to obtain additional licenses from others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain or maintain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technologies, product candidates, or the methods for manufacturing them or to develop or license replacement technologies, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, or may be significantly delayed in doing so, which could significantly harm our competitive position, business, financial condition, results of operations and prospects. We cannot provide any assurances that third-party patents do not exist which might be enforced against our technologies and product candidates resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and future licenses may not provide exclusive rights to use such intellectual property and proprietary technologies in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technologies and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technologies that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business or in compliance with applicable laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and regulations, or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technologies. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate our license agreements, thereby removing our ability to develop and commercialize products and technologies covered by these license agreements. If these license agreements are terminated for this reason or any other reason, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to acquire or in-license intellectual property rights from third parties relating to, or necessary for, the development of our product candidates on commercially reasonable terms, or at all. In that event, we may be unable to develop or commercialize such product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. We may be required by the FDA or comparable non-U.S. regulatory authorities to provide a companion diagnostic test or tests with our product candidates, which test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights and seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive area and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a non-exclusive license under certain patents and/or know-how to develop and commercialize certain elements or components of our potential product candidates which may not be available elsewhere. Our existing license agreements impose, and we expect that any future license agreements will impose on us, various obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. If any of our licenses are terminated and we are not able to negotiate other agreements for use of the intellectual property protections underlying these product candidates, we would not be able to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture and market these potential products, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial or other obligations under the license agreement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by any licensors or partners&#8217; licensors; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain provisions in our license agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. In addition, certain of these license agreements, may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions. Moreover, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside of the United States and Canada are less extensive than those in the United States and Canada. In addition, the laws of countries outside the United States and Canada may not protect our or our licensors&#8217; rights to the same extent as the laws of the United States and Canada, even in jurisdictions where we or our licensors do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in all countries outside the United States and Canada, even in jurisdictions where we or our licensors do pursue patent protection, or from selling or importing products made using our inventions in and into the United States, Canada or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States and Canada. These products may compete with our products and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in non-U.S. jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our or our licensors&#8217; intellectual property and proprietary rights in non-U.S. jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could put our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be harmed and our business, financial condition, results of operations and prospects may be adversely affected. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries and we will not have the benefit of patent protection in such countries,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which could have an adverse effect on our operations or commercial prospects within those countries or ability to pursue action against potential competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in Europe, a new unitary patent system came into effect on June 1, 2023. Under the unitary patent system, European patent applications and patents may be subjected to the jurisdiction of the Unified Patent Court (UPC). European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in legal proceedings in relation to intellectual property rights and to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming, and we may not have the financial resources to do so. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these types of claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-examination, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office (&#8220;EPO&#8221;), or another non-U.S. patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications are typically not published in the United States until 18 months after their respective filing dates. Further, publications in the scientific literature often lag behind actual discoveries. Consequently, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. It is possible that our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours and that those patent applications may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome in an interference proceeding could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection, confidentiality agreements, and license and other agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some countries outside of the United States do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. Some courts both within and outside the United States and Canada are sometimes less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For example, significant elements of our genetic medicine platform and product candidates, including aspects of sample preparation, methods of manufacturing, cell culturing conditions, computational-biological algorithms and related processes are based on unpatented trade secrets that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that certain information and data concerning our business made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. However, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. However, we cannot provide assurance that these agreements and policies will not be breached by our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors and that our trade secrets and other proprietary and confidential information will not be disclosed to publicly or to competitors. If any of the employees, consultants, outside scientific collaborators, sponsored researchers and other advisors who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other third parties. Competitors or third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside the scope of our intellectual property rights. We will have limited recourse if this occurs. Furthermore, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our novel genetic medicine platform, our product candidates and other technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The field of biotherapeutics, including the development of genetic medicines, is competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux and it may remain uncertain in the future. As such, there may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed and other third-party intellectual property and proprietary rights in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our and our licensors&#8217; ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in jurisdictions outside of the United States. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S., Canadian and other foreign issued patents and pending patent applications owned by third parties exist relating to genetic medicine technologies and products and in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our genetic medicine platform, product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot be sure that our genetic medicine platform, product candidates and other technologies that we have developed, are developing or may develop in the future do not infringe existing patents or will not infringe future patents owned by third parties. Many companies and institutions have filed, and continue to file, patent applications related to genetic medicine and related manufacturing methods. Some of these patent applications have already been allowed or issued and others may issue in the future. It is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our genetic medicine platform, product candidates and other technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may not be aware of patents that have already been issued and that a third-party, for example, a competitor in the fields in which we are developing our genetic medicine platform, product candidates and other technologies might assert are infringed by our current or future product candidates, genetic medicine platform or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our genetic medicine platform, product candidates and other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our genetic medicine platform, product candidates and other technologies, could be found to be infringed by our genetic medicine platform, product candidates and other technologies. In addition, because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be currently pending patent applications that may later result in issued patents that our genetic medicine platform, product candidates and other technologies may infringe. Furthermore, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or technologies. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our genetic medicine platform, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties have patents and may obtain patents in the future and may claim that the manufacture, use or sale of our genetic medicine platform, product candidates or other technologies infringes upon these patents. Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our genetic medicine platform, product candidates or other technologies. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent or find that our product candidates or technology did not infringe any such claims. Further, even if we were successful in defending against any such claims, such claims could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. If we are found to infringe, misappropriate or otherwise violate a third-party&#8217;s valid and enforceable patent rights, the holders of such patents may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay substantial license fees or royalties or both and the rights granted to us might be non-exclusive, which could result in our competitors and other third parties gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our genetic medicine platform, product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing, manufacturing or commercializing our infringing genetic medicine platform, product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize the genetic medicine platform, our product candidates or other technologies, which could harm our business significantly. Moreover, we may face patent infringement claims from nonpracticing entities that have no relevant product revenue and against whom our owned or licensed patent portfolio may therefore have no deterrent effect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could have an adverse effect on our ability to raise additional funds and attract collaborators and could impair our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. In many cases we rely on our employees&#8217; and contractors&#8217; representations and warranties that they will not engage in practices that could subject us to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or be required to obtain licenses to such intellectual property rights, which may not be available on commercially reasonable terms or at all. An inability to incorporate such intellectual property rights would harm our business and may prevent us from successfully commercializing any product candidates we may develop or at all. In addition, we may lose personnel as a result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize any product candidates we may develop and our technology, which would have a material adverse effect on our business, results of operations, financial condition and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our scientific and management personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have pre-existing or competing obligations to a third-party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we own may have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we or our licensors may in the future be subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patent rights. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration of the patent protection covering our technology and any product candidates we may develop. Such challenges may also result in our inability to develop, manufacture or commercialize our technology and product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or licensed patent rights are threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future technology and product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make next generation immunotherapies for cancer or other diseases that are similar to ours but that are not covered by the claims of the patents that we own or have licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our pending patent applications or those that we license will not lead to issued patents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or have licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may have access to the same intellectual property rights licensed to us in the future on a nonexclusive basis; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent for certain trade secrets or know-how, and a third-party may subsequently file a patent covering such intellectual property; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and future trademark applications in the United States and in foreign jurisdictions may not be allowed or may subsequently be opposed. Once filed and registered, our registered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Acquisitions and Collaborations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to grow the size of our organization, both organically and through acquisitions, and we may experience difficulties identifying and hiring the right employees and successfully managing this growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, we had 82 employees.  As our development and commercialization plans and strategies develop, we may experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of technology research, product development and manufacturing, regulatory affairs and, if any product candidates are submitted for or receive marketing approval, sales, marketing and distribution. Our management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our preclinical studies and clinical trials effectively; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors, licensors and other third parties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expanding our facilities. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates may depend, in part, on our ability to effectively manage any future growth and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, contractors and consultants to provide certain services, including substantially all aspects of regulatory approval, clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">management and manufacturing. There can be no assurance that the services of independent organizations, advisors, contractors and consultants will continue to be available to us on a timely basis when needed or that we will be able to find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by independent organizations, advisors, contractors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing independent organizations, advisors, contractors or consultants or find other competent resources on economically reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding the roster of independent organizations, advisors and consultants on whom we rely on an outsourced basis, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisitions, collaborations or other strategic partnerships may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may from time to time evaluate collaborations and strategic partnerships or potential acquisitions, including licensing or acquiring molecules, biologics, or gene therapies, etc., for use in our genetic medicine platform, intellectual property rights, technologies or businesses. For example, we may seek collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. Collaboration, strategic partnerships or acquisitions entail numerous risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced control over the development of certain of aspects of detalimogene, our genetic medicine platform or other product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of indebtedness or contingent liabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of our equity securities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our internal product development efforts and initiatives in pursuing such a strategic merger or acquisition; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status and their existing products or product candidates and marketing approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to recognize the synergies or other benefits intended for the acquisition, partnership or collaboration; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Any of the foregoing may materially harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may make acquisitions to expand our business and as a result, our results of operations may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to expand our current business through the acquisition of other businesses, products or technologies, or through strategic alliances. Acquisitions involve numerous risks, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possibility that we will pay more than the value derived from the acquisition which could result in future non-cash impairment charges, and incremental operating losses; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in integration of the operations, technologies and products of the acquired companies, which may require significant attention of our management that otherwise would be available for the ongoing development of our business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of certain known and unknown liabilities of the acquired companies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in retaining key relationships with employees, customers, collaborators, vendors and suppliers of the acquired company; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and in the case of acquisitions outside of the jurisdictions we currently operate in, the need to address the particular economic, currency, political, and regulatory risks associated with specific countries, particularly those related to our </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collection of sensitive data, regulatory approvals, and tax management, which may result in significant additional costs or management overhead for our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Investment in our Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we are a Canadian company, shareholder protections differ from shareholder protections in the United States and elsewhere, and we are subject to a variety of additional risks that may negatively impact our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are organized and exist under the laws of British Columbia, Canada and, accordingly, are governed by the BCBCA and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction. We are subject to special considerations or risks associated with companies operating in Canada that may, at any time differ from the considerations and risks of companies operating in the United States, including any of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">political regimes, rules and regulations or currency conversion or corporate withholding taxes on individuals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tariffs and trade barriers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations related to customs and import/export matters; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">longer payment cycles; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax issues, such as tax law changes and variations in tax laws as compared to the United States; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to maintain a company nexus with Canada or a particular province of Canada; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">currency fluctuations and exchange controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges in collecting accounts receivable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cultural and language differences; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employment regulations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">crime, strikes, riots, civil disturbances, terrorist attacks and wars; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">deterioration of political relations with the United States, which could result in uncertainty and/or changes in or to existing trade treaties. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In particular, we are subject to the risk of changes in economic conditions, social conditions and political conditions inherent in Canada, including changes in laws and policies that govern international investment, as well as changes in U.S. laws and regulations relating to international trade and investment, including the new trilateral trade agreement among the United States, Mexico and Canada called the United States-Mexico- Canada Agreement (the &#8220;USMCA&#8221;), which has been ratified by all three countries. The USMCA entered into force on July 1, 2020 and superseded the North American Free Trade Agreement. The USMCA is subject to review and renewal in 2026. There can be no assurance that any newly negotiated terms in the USMCA will not adversely affect our business or operations. It remains unclear what specific actions the current U.S. administration may take to resolve trade-related issues with Canada, Mexico and other countries. Although we believe that there have been no immediate effects on our operations with respect to the USMCA, we cannot predict future developments in the political climate involving the United States, Mexico and Canada and such developments may have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Articles and certain Canadian legislation contain provisions that may have the effect of delaying, preventing or making undesirable an acquisition of all or a significant portion of our shares or assets or preventing a change in control.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain provisions of our Articles and certain provisions under the BCBCA, together or separately, could discourage, delay or prevent a merger, acquisition or other change in control of us that shareholders may consider favorable, including transactions in which they might otherwise receive a premium for their common shares. These provisions include the establishment of a staggered board of directors, which divides the board into three groups, with directors in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or remove incumbent members of our Board of Directors. As such, these provisions could also limit the price that investors might be willing to pay in the future for our common shares, thereby depressing the market price of our common shares. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace members of our Board of Directors. Among other things, these provisions include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shareholders cannot amend our Articles unless such amendment is approved by shareholders holding at least 66 2/3% of the shares entitled to vote on such approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Board of Directors may, without shareholder approval, issue preferred shares in one or more series having any terms, conditions, rights, preferences and privileges as the board of directors may determine; and </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shareholders must give advance notice to nominate directors or to submit proposals for consideration at shareholders&#8217; meetings. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A non-Canadian must file an application for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a &#8220;Canadian business&#8221; within the meaning of the Investment Canada Act, where prescribed financial thresholds are exceeded. A reviewable acquisition may not proceed unless the Minister is satisfied that the investment is likely to be of net benefit to Canada. If the applicable financial thresholds were exceeded such that a net benefit to Canada review would be required, this could prevent or delay a change of control and may eliminate or limit strategic opportunities for shareholders to sell their common shares. Furthermore, limitations on the ability to acquire and hold our common shares may be imposed under the Competition Act (Canada). This legislation has a pre-merger notification regime and mandatory waiting period that applies to certain types of transactions that meet specified financial thresholds, and permits the Commissioner of Competition to review any acquisition, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Articles designate specific courts in Canada and the United States as the exclusive forum for certain litigation that may be initiated by our shareholders without our prior written consent, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Articles, unless we consent in writing to the selection of an alternative forum, the courts of the Province of British Columbia and the appellate courts therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us; (c) any action or proceeding asserting a claim arising out of any provision of the BCBCA or the Articles (as either may be amended from time to time); or (d) any action or proceeding asserting a claim or otherwise related to our affairs (the &#8220;Canadian Forum Provision&#8221;). In addition, the Articles further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving any complaint filed in the United States asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or the Exchange Act (the &#8220;U.S. Forum Provision&#8221;). In addition, the Articles provide that any person or entity purchasing or otherwise acquiring any interest in our common shares is deemed to have notice of and consented to the Canadian Forum Provision and the U.S. Forum Provision; provided, however, that shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Canadian Forum Provision and the U.S. Forum Provision in the Articles may impose additional litigation costs on shareholders in pursuing any such claims. Additionally, the forum selection clauses in the Articles may limit our shareholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including courts in Canada and other courts within the United States, will enforce our U.S. Forum Provision. If the U.S. Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The U.S. Forum Provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The courts of the Province of British Columbia and the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we are a Canadian company, it may be difficult to serve legal process or enforce judgments against us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are incorporated and maintain operations in Canada. In addition, certain of our directors reside in the United States, while others reside outside of the United States. Accordingly, service of process upon us may be difficult to obtain within the United States. Furthermore, because substantially all of our assets are located outside the United States, any judgment obtained in the United States against us, including one predicated on the civil liability provisions of the U.S. federal securities laws, may not be collectible within the United States. Therefore, it may not be possible to enforce those actions against us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, it may be difficult to assert U.S. securities law claims in original actions instituted in Canada. Canadian courts may refuse to hear a claim based on an alleged violation of U.S. securities laws against us or these persons on the grounds that Canada is not the most appropriate forum in which to bring such a claim. Even if a Canadian court agrees to hear a claim, it may determine that Canadian law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Canadian law. Furthermore, it may not be possible to subject foreign persons or entities to the jurisdiction of the courts in Canada. Similarly, to the extent that our assets are located in Canada, investors may have difficulty collecting from us any judgments obtained in the U.S. courts and predicated on the civil liability provisions of U.S. securities provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use net operating loss carry-forwards and certain other tax attributes are limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general terms, where control of a corporation is acquired or deemed to be acquired, which for our Company as a result of the Reverse Recapitalization, the corporation is subject to a &#8220;loss restriction event&#8221;, and the corporation&#8217;s non-capital loss carryforwards, other losses and certain other tax attributes are subject to limitation and possibly expiry after the loss restriction event. Similar rules apply for Canadian provincial purposes. Consequently, we may not be able to utilize a material portion of our non-capital loss carryforwards and certain other tax attributes in certain circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	For U.S. tax purposes, net operating loss carryforwards allow companies to use past year net operating losses to offset against future years&#8217; profits, if any, to reduce future tax liabilities. Sections 382 and 383 of the Code limit a corporation&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. An ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change and any increased liabilities could adversely affect the corporation&#8217;s business, results of operations, financial condition and cash flow. Even if another ownership change has not occurred and does not occur as a result of this offering, additional ownership changes may occur in the future as a result of additional equity offerings or events over we will have little or no control, including purchases and sales of its equity by its five percent security holders, the emergence of new five percent security holders, redemptions of its securities or certain changes in the ownership of any of its five percent security holders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We believe that we are and there is a significant risk that we may continue to be a passive foreign investment company (a &#8220;PFIC&#8221;), which could result in adverse U.S. federal income tax consequences to U.S. Holders of our Common Shares or Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general and as relevant here, a non-U.S. corporation is a PFIC for U.S. federal income tax purposes for any taxable year in which (i) 50% or more of the value of its assets (generally determined on the basis of a quarterly average) consists of assets, including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, that produce, or are held for the production of, passive income, or (ii) 75% or more of its gross income, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, consists of passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. Cash and cash equivalents are generally passive assets. The value of goodwill will generally be treated as an active or passive asset based on the nature of the income produced in the activity to which the goodwill is attributable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the commercialization of our drug candidates, our income may be primarily passive. Accordingly, we believe we may have met the definition of PFIC for U.S. federal income tax purposes for the tax year ended October 31, 2024 and the tax year ended October 31, 2025 and there is a significant risk that we will be a PFIC for our current or any future taxable year. If we are a PFIC for any taxable year during which a U.S. Holder (as defined below) owns Common Shares, the U.S. Holder generally will be subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and certain &#8220;excess distributions&#8221; and additional reporting requirements, unless the U.S. Holder makes (a) a qualified electing fund (&#8220;QEF&#8221;) election or a mark-to-market election for the first taxable year for which we are or were a PFIC and in which such U.S. Holder held (or was deemed to hold) such Common Shares and maintain such election or (b) a QEF election along with an applicable purging election (collectively, the &#8220;PFIC Elections&#8221;). Under proposed Treasury regulations relating to PFICs which have a retroactive effective date, the PFIC rules may apply to rights to acquire shares of a PFIC as if they were shares, and thus could apply to dispositions (other than exercises) of Warrants. PFIC Elections may not be made with respect to Warrants. U.S. Holders of Common Shares or Warrants should consult their tax advisors regarding the application of the PFIC rules to us and the risks of owning equity securities, including warrants, in a company that may be a PFIC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of making and maintaining a timely and valid QEF election (if eligible to do so), a U.S. Holder of Common Shares must include in income such U.S. Holder&#8217;s pro rata share of our net capital gains (as long-term capital gain) and other earnings and profits (as ordinary income), on a current basis, whether or not distributed. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge. A subsequent distribution of such earnings and profits that were previously included in income should generally not be taxable as a dividend to such U.S. Holder. The tax basis of a U.S. Holder&#8217;s shares in a PFIC with respect to which a QEF election has been made will be increased by amounts that are included in income, and decreased by amounts distributed but not taxed as dividends, under the above rules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The QEF election is made on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes a QEF election by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund), including the information provided in a PFIC Annual Information Statement from us, to a timely filed U.S. federal income tax return for the tax year to which the election relates. In the event that we determine that we are a PFIC for U.S. federal income tax purposes for any taxable year, we will, upon request of a holder of Common Shares, provide a PFIC Annual Information Statement to such holder. Retroactive QEF elections generally may be made only by filing a protective statement with such federal income tax return and if certain other conditions are met or with the consent of the IRS. U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders are urged to consult their tax advisors regarding the availability and tax consequences of a retroactive QEF election under their particular circumstances.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an alternative to a QEF election, if a U.S. Holder owns shares in a company that is a PFIC and the shares are &#8220;regularly traded&#8221; on a &#8220;qualified exchange,&#8221; such U.S. Holder could make a mark-to-market election that would result in tax treatment different from that under the interest charge rules described above. The Common Shares will be treated as regularly traded for any calendar year in which more than a de minimis quantity of the Common Shares are traded on a qualified exchange on at least 15 days during each calendar quarter. Nasdaq, where the Common Shares are listed, is a qualified exchange for this purpose.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such electing U.S. Holder generally will include for each of its taxable years as ordinary income the excess, if any, of the fair market value of its Common Shares at the end of such year over its adjusted basis in its Common Shares. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis of its Common Shares over the fair market value of its Common Shares at the end of its taxable year (but only to the extent of the net amount of previously included in income as a result of the mark-to-market election). The U.S. Holder&#8217;s basis in its Common Shares will be adjusted to reflect any such income or loss amounts. Any gain recognized on a sale or other taxable disposition of its Common Shares will be treated as ordinary income, and any loss will be treated as an ordinary loss (but only to the extent of the net amount previously included in income as a result of the mark-to-market election, with any excess treated as a capital loss).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Risk Factor, a &#8220;U.S. Holder&#8221; is a beneficial holder of securities who or that, for U.S. federal income tax purposes is (i) an individual who is a United States citizen or resident of the United States; (ii) a corporation or other entity treated as a corporation for United States federal income tax purposes created in, or organized under the law of, the United States or any state or political subdivision thereof; (iii) an estate the income of which is includible in gross income for United States federal income tax purposes regardless of its source; or (iv) a trust (A) the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (B) that has in effect a valid election under applicable Treasury regulations to be treated as a United States person.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Articles include provisions that may discourage takeover attempts, including a classified or &#8220;staggered&#8221; board.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain provisions in our articles (together with the articles of incorporation and notice of articles, the &#8220;Articles&#8221;) may have the effect of deterring coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the bidder and by encouraging prospective acquirers to negotiate with our Board of Directors rather than to attempt a hostile takeover. These provisions include, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the existence of a classified or &#8220;staggered&#8221; board; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the right of our Board of Directors to issue preferred stock and to determine the voting, dividend, and other rights of preferred stock without shareholder approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our directors, and not shareholders, to fill vacancies on our Board in most circumstances and to determine the size of our  Board of Directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement for two-thirds of the votes cast by shareholders on a special resolution in order to remove directors or amend certain provisions of the Articles; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the absence of cumulative rights in the election of directors. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While these provisions are not intended to make us immune from takeovers, they will apply even if the offer may be considered beneficial by some shareholders and may delay or prevent an acquisition that our Board of Directors determines is not in the best interests of us and our shareholders. These provisions may also prevent or discourage attempts to remove and replace incumbent directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Shares and Warrants and to Being a Public Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of Common Shares, or the perception of such sales, by us or the Selling Holders in the public market or otherwise could cause the market price for our Common Shares to decline and certain Selling Holders still may receive a significant rate of return.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 13, 2024, we filed (i) a registration statement on Form S-3 (File No. 333-283202) (the &#8220;resale registration statement&#8221;) with the SEC to register the issuance of up to an aggregate of 8,511,968 Common Shares upon the exercise of a like number of Warrants as well as the resale from time to time by the selling securityholders named in the resale registration statement (the &#8220;Selling Holders&#8221;) of (a) up to 46,977,183 of our Common Shares (which includes 6,289,198 Common Shares that may be issued upon exercise of the Warrants); and (b) up to 6,289,198 of our Warrants and (ii) a universal shelf registration statement on Form S-3 (File No. 333-283201) (the &#8220;shelf registration statement&#8221;) with the SEC to register the issuance by us of up to $300 million of securities.  The resale registration statement and the shelf registration statement each became effective November 21, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 14, 2025, we issued 12,558,823 of our Common Shares and 2,735,295 pre-funded warrants to purchase Common Shares under our shelf registration statement pursuant to an underwritten public offering, and on November 18, 2025 we issued an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional 2,294,117 Common Shares pursuant to a greenshoe option granted to the underwriters in the offering, for an aggregate public offering price of approximately $149.5 million of securities, prior to deducting underwriting discounts and commissions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sale of Common Shares in the public market or otherwise, including sales pursuant to the resale registration statement or the shelf registration statement, or the perception that such sales could occur, could harm the prevailing market price of our Common Shares. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Resales of Common Shares may cause the market price of our securities to drop significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have agreed, at our expense, to prepare and file the resale registration statement with the SEC. The Common Shares and Warrants being offered for resale in the prospectus which forms a part of the resale registration statement, represent approximately 92.2% of our total outstanding Common Shares and approximately 73.9% of our outstanding Warrants, respectively, as of the date of such prospectus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The resale, or expected or potential resale, of a substantial number of our Common Shares in the public market could adversely affect the market price for our Common Shares and make it more difficult for you to sell your Common Shares at times and prices that you feel are appropriate. Furthermore, we expect that, because there will be a large number of shares registered pursuant to the resale registration statement, Selling Holders will continue to offer the securities covered by the resale registration statement for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to a resale registration statement may continue for an extended period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain existing securityholders acquired their securities in our Company at prices that may be below the current trading price of such securities, and may experience a positive rate of return based on such current trading price. Future investors in our Company may not experience a similar rate of return.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain securityholders in the Company, including certain of the Selling Holders, acquired Common Shares or Warrants at prices that may be below the current trading price of such securities and may experience a positive rate of return based on such current trading price. On December 17, 2025, the closing price of our Common Shares was $7.80 per share and the closing price for our Warrants was $2.40 per warrant. Selling Holders in some instances may earn a significant positive rate of return on their investment depending on the market price of our Common Shares and Warrants at the time that such Selling Holders choose to sell their securities. The Selling Holders acquired the securities offered for resale in exchange for non cash consideration or at effective purchase prices that may range from significantly below to above current trading prices. Investors who purchase our Common Shares and Warrants on the Nasdaq may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There is no assurance that Warrants will be and/or remain &#8220;in the money&#8221; prior to their expiration or that the holders of Warrants will elect to exercise any or all of their Warrants for cash; the Warrants may expire worthless.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise price for our Warrants is $11.50 per Common Share. The Warrants will expire on October 31, 2028, the date that is five years after the completion of the Reverse Recapitalization (as defined herein).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrants&#8217; cashless exercise period ended when the Company&#8217;s registration statement on Form S-1 (File No. 333-275700) was declared effective on March 5, 2024. We will receive proceeds from Warrants only in the event that such Warrants are exercised for cash. We believe the likelihood that holders will exercise their Warrants will depend on the trading price of our Common Shares. If the market price for our Common Shares is less than the exercise price of Warrants, we believe the holders of Warrants will be unlikely to exercise them. If the market price for our Common Shares exceeds the exercise price of the Warrants, it is more likely that holders of the Warrants will exercise them.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that Warrants will be &#8220;in the money&#8221; prior to their expiration or that the holders of Warrants will elect to exercise any or all of their Warrants for cash. As such, the Warrants may expire worthless.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will continue to incur increased costs as a result of operating as a public company, and the requirements for public companies may strain resources and divert management&#8217;s attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with public company requirements places significant additional demands on management and will require them to enhance investor relations, legal, financial reporting and corporate communications functions. Our management is required to devote substantial time to maintaining and improving its internal controls over financial reporting and the requirements of being a public company. These additional efforts may strain resources and divert management&#8217;s attention from other business concerns and affect its ability to accurately report its financial results and prevent fraud, which could adversely affect our business and profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to satisfy Nasdaq&#8217;s continued listing requirements in the future, which could limit investors&#8217; ability to effect transactions in our securities and subject it to additional trading restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Common Shares and Warrants commenced trading on Nasdaq under the tickers &#8220;ENGN&#8221; and &#8220;ENGNW&#8221;, respectively, on November 1, 2023. We are required to meet Nasdaq&#8217;s continued listing requirements and may be unable to meet those requirements. Although our securities are listed on the Nasdaq as of the date of this Annual Report, we may be unable to maintain the listing of our securities in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to meet the continued listing requirements and the Nasdaq delists our securities from its exchange, there could be significant material adverse consequences, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a limited availability of market quotations for our securities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced liquidity for our securities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination that our Common Shares are a &#8220;penny stock&#8221; which will require brokers trading in our Common Shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a limited amount of news and analyst coverage for us; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decreased ability to obtain capital or pursue acquisitions by issuing additional equity or convertible securities. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will continue to incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a publicly traded company, we will continue to incur significant legal, accounting and other expenses. In addition, new and changing laws, regulations and standards relating to corporate governance and public disclosure for public companies, including the Dodd-Frank Act, the Sarbanes-Oxley Act, regulations related thereto and the rules and regulations of the SEC and Nasdaq, have increased the costs and the time that must be devoted to compliance matters. We expect these rules and regulations will increase our legal and financial costs and lead to a diversion of management time and attention from revenue-generating activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A market for our securities may not develop or be sustained, which would adversely affect the liquidity and price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The price of our securities may fluctuate significantly due to the market&#8217;s reaction to general market and economic conditions. An active trading market for our securities may never develop or, if it develops, it may not be sustained, which could have a material adverse effect on the liquidity and price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of our Common Shares could be highly volatile, and purchasers of our Common Shares could incur substantial losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The price of our Common Shares is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their Common Shares at or above the price at which they paid. The market price for our Common Shares may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of our clinical trials and preclinical studies, and the results of trials of our competitors or those of other companies in our market sector; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enroll patients in our future clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of detalimogene or any other product candidates we develop or additional indications thereof, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and foreign countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success or failure of our efforts to develop, acquire, or license detalimogene or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">innovations, clinical trial results, product approvals and other developments regarding our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or capital commitments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing, supply, or distribution delays or shortages; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achievement of expected product sales and profitability; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or development timelines or those of companies that are perceived to be similar to us, including variations from expectations of securities analysts or investors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our Common Shares; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to obtain additional funding; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our Common Shares by us, our insiders or our shareholders; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry, geopolitical and market conditions, such as military conflict or war, inflation and financial institution instability, or pandemic or epidemic disease outbreaks, many of which are beyond our control; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of senior management, directors or key personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intellectual property, product liability or other litigation against us or our inability to enforce our intellectual property; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting standards, policies, guidelines, interpretations or principles.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be a target of securities class action and derivative lawsuits, which could result in substantial costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our share price may be volatile and, in the past, companies that have experienced volatility in the market price of their shares have from time to time been subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any adverse determination in litigation could also subject us to significant liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research about us at all or publish inaccurate or unfavorable research about us or our business, the market price and/or the trading volume of our Common Shares could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our Common Shares will depend in part on the research and reports that securities or industry analysts publish about us or our business. If no or few securities or industry analysts cover us, then the market price for our Common Shares and Warrants could be adversely affected. If one or more of the analysts who cover us downgrade a recommendation with regard to our Common Shares, publish inaccurate or unfavorable research about us or our business, cease to cover us or fail to publish reports on it regularly, the market price and/or the trading volume of our Common Shares and Warrants could decline.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1B. Unresolved Staff Comments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><div><ix:nonNumeric id="F_9bc462af-fb52-4370-ae8a-bbf37b046ba3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented cybersecurity risk management procedures, in accordance with our risk profile and business size, that are designed to identify, assess, and mitigate risks from current and emerging cybersecurity threats. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91198544-053e-421a-8995-4ba19d532b2b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity procedures, which are informed by the National Institute of Standards and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e653a0ee-437f-4b20-a206-6f343231e531" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Technology cybersecurity framework, are supported by a third-party managed services provider that assists us in managing our IT systems.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks, and other related breaches.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity procedures are comprised of a variety of tools designed to protect our data and information technology systems, including but not limited to endpoint protection and network security measures, that are supported by our third-party service providers. We also have a process to require our employees to undergo cybersecurity awareness training. Further, we have implemented a process to review risks to our Company in connection with certain third-party providers and vendors, which involves assessments through vendor questionnaires, as appropriate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c28677e0-f174-4300-9361-736a407ab8f1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party IT service providers and vendors have from time to time experienced threats that could affect our information or systems. For more information, see, &#8220;Risk Factors,&#8221; in this Annual Report.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div><ix:nonNumeric id="F_784bee8f-3b31-4262-a54d-dedcc96db76e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab96fb10-2786-48e7-8403-a00119adb28e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Vice President,  IT reports to our Chief Financial Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a6c7f00-00df-4340-9cf5-609482187412" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bed5dde7-8caf-4a02-82e7-3efd725c0d7b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our Board of Directors is informed oversight of our risk management process.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b9cb85b-0ac4-4be6-a60b-51b350bfc8ff" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true" continuedAt="F_9b9cb85b-0ac4-4be6-a60b-51b350bfc8ff_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors does not have a standing risk management committee, and</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8cd0c53-e25a-4a89-82f5-545f87e4ee83" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.</span></ix:nonNumeric></span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9b9cb85b-0ac4-4be6-a60b-51b350bfc8ff_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2eec362-240f-4294-908c-7f28d53ea6ae" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9512552f-4712-40e7-a090-feaa1dc3b0cf" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" continuedAt="F_9512552f-4712-40e7-a090-feaa1dc3b0cf_1" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is responsible for overseeing the Company&#8217;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9512552f-4712-40e7-a090-feaa1dc3b0cf_1"></ix:continuation></span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_868d1a64-427c-40cb-b854-497f9b70d864" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> responsible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for managing cybersecurity risks.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Prop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">erties.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, we have leased approximately 10,620 sq. feet of laboratory and office space at 4868 Rue Levy Montreal, QC H4R 2P1, 6,450 sq. feet of office space at 200 Fifth Avenue, Waltham, Massachusetts 02451 and 26,355 sq. feet of office space at 99 High Street, Boston, Massachusetts, 02110.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe our current facilities are sufficient for our current needs. To meet future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 3. Legal Proceedings.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in legal proceedings that arise in the regular course of our business. Our management believes that we are not currently involved in any legal proceedings that are likely to have a significant negative effect on our business. However, legal proceedings can negatively affect our business, financial condition, results, and future prospects, regardless of the outcome, due to costs associated with defense and settlement, as well as the diversion of management resources, among other factors.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 4. Mine Safety Disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Common Shares and Warrants commenced trading on the Nasdaq Global Market under the symbols &#8220;ENGN&#8221; and &#8220;ENGNW,&#8221; respectively on November 1, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 17, 2025, there were approximately 66,984,661 Common Shares issued and outstanding held of record by 45 holders, and approximately 8,511,968 Warrants held of record by 15 holders, each exercisable for one Common Share at a price of $11.50 per share. The actual number of holders of our Common Shares is greater than this number of record holders, and includes shareholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include shareholders whose shares may be held in trust by other entities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we previously agreed to issue to the Lenders (as defined herein) Warrants to purchase up to 138,696 Common Shares, of which 62,413 have been issued as of December 17, 2025.  See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 8, Notes Payable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for additional details.  On November 14, 2025, we also issued pre-funded warrants to purchase 2,735,295 Common Shares (the &#8220;Pre-Funded Warrants&#8221;) at an offering price of $8.4999 per Pre-Funded Warrant to a certain investor in an underwritten public offering.  Each Pre-Funded Warrant has an initial exercise price per share of $0.0001, subject to certain adjustments. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 17, Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; for additional details.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not paid any cash dividends on our Common Shares to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of the Board of Directors at such time.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information as of October 31, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:31.966%;box-sizing:content-box;"/>
     <td style="width:7.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.503%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.26%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.462%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:21.144%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan category</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities to be issued upon exercise of outstanding options, warrants, and rights</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-average exercise price of outstanding options, warrants, and rights</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(b)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(c)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,717,948</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.81</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,933,304</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security holders </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,315,350</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.15</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,033,298</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.93</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,933,304</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)  On October 31, 2023, upon completion of the Business Combination, the enGene Holdings Inc. 2023 Incentive Equity Plan became effective, which authorized enGene to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue 2,607,943 Common Shares under the plan, plus 2,706,941 Common Shares that are subject to outstanding grants under the enGene Inc. employee share option and equity incentive plans. On May 15, 2024, the Company&#8217;s shareholders approved the adoption of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan, which authorizes enGene to issue 4,554,169 Common Shares under the plan, plus 2,706,941 Common Shares that are subject to outstanding grants</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the enGene Inc. employee share option and equity incentive plans. On January 2, 2025, 2,548,833 Common Shares were added to the Plan under the evergreen provision.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) As part of the Business Combination, the 2,706,941 Common Shares subject to outstanding grants under the enGene Inc. employee share option and equity incentive plans were modified to have the exercises price converted from the Canadian Dollar to the United States Dollar, at the exchange rate in effect on the date immediately prior to the close of the Business Combination.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Consists of Common Shares issuable upon exercise of outstanding stock options granted pursuant to the Nasdaq inducement grant exception as a component of employment compensation for employees. The inducement grants were approved by our compensation committee and were made as an inducement material to employees entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not sell unregistered Common Shares or other equity securities during the quarter or fiscal year ended October 31, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not purchase any of our Common Shares or other equity securities during the quarter or fiscal year ended October 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 6. [Reserved]</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7_managements_discussion_and_anal"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Throughout this section, unless otherwise noted, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221;, &#8220;enGene&#8221; and the &#8220;Company&#8221; refer to enGene Holdings Inc. and all of its subsidiaries following the consummation of the Reverse Recapitalization (as defined below). enGene Holdings Inc. is the publicly traded parent company resulting from  the Reverse Recapitalization, in which shareholders of enGene Inc. and Forbion European Acquisition Company exchanged their shares for shares in enGene Holdings Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements as of October 31, 2025 and 2024 and for the fiscal years ended October 31, 2025 and 2024, and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See the sections titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in this Annual Report for a discussion of forward-looking statements and important factors that could cause actual results to differ materially from the results described in or implied by these forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We operate as a single operating segment focused on research, discovery, and clinical development of human genetic medicine products. Our fiscal year is the year ended October 31.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing genetic medicines to improve the lives of patients suffering from bladder cancer. We are developing non-viral genetic medicines based on our novel and proprietary dually derivatized chitosan, or &#8220;DDX&#8221;, gene delivery platform, which allows localized delivery of complex genetic cargos directly to mucosal tissues and other organs. Our lead product candidate, detalimogene voraplasmid, or detalimogene, formerly known as EG-70, is a therapy designed to generate a local immune reaction in proximity to tumors. We believe this enables the immune system to durably clear the tumor and develop memory to resist recurrence. Because this treatment is designed to work by delivering genetic cargo to the broader tumor tissue environment rather than tumor cells specifically, we believe it has the potential to be widely utilized across tumor types. Currently, we are developing detalimogene as a monotherapy to treat patients that have non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;) with carcinoma in situ (&#8220;CIS&#8221;) that have been unresponsive to treatment with Bacillus Calmette-Gu&#233;rin, or &#8220;BCG,&#8221; or what is referred to as &#8220;BCG-unresponsive NMIBC with CIS.&#8221; We are also exploring the clinical application of detalimogene to other forms of NMIBC, namely, in patients with papillary-only BCG-unresponsive NMIBC (i.e., NMIBC without CIS), as well as in patients with BCG-na&#239;ve NMIBC with CIS and in patients with BCG-exposed NMIBC with CIS (i.e., patients who have been treated with some BCG but who do not qualify as BCG-unresponsive in accordance with FDA and urology practice guidelines).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Detalimogene is currently being studied in a combined Phase 1/2 open-label trial, referred to as &#8220;LEGEND&#8221; (ClinicalTrials.gov identifier NCT04752722). The Phase 2 portion of LEGEND is comprised of three cohorts: Cohort 1 is a pivotal cohort studying detalimogene in patients with high-risk BCG-unresponsive NMIBC with CIS with or without concomitant papillary disease for which we have completed enrollment with 125 patients; Cohort 2 is evaluating detalimogene in patients with high-risk BCG-na&#239;ve NMIBC with CIS (Cohort 2a, with 30 enrolled patients as of November 11, 2025) and patients with high-risk BCG-exposed NMIBC with CIS (Cohort 2b, with 45 enrolled patients as of November 11, 2025); and Cohort 3 is evaluating detalimogene in  patients with high-risk BCG-unresponsive NMIBC who have papillary disease only (i.e., no CIS, with 36 enrolled patients as of November 11, 2025). In addition, our preclinical research is focused on expanding the cancer indications that can be treated with detalimogene as well as discovering new opportunities to apply our DDX technology platform to treat other indications with high unmet medical needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have devoted substantially all of our efforts to organizing and staffing our Company, business planning, raising capital, establishing our intellectual property portfolio, acquiring or discovering product candidates, research and development activities for our primary program, detalimogene voraplasmid, or detalimogene. We do not have any products approved for sale and have not generated any revenue from product sales. We operate as a single operating segment focused on research, discovery, and clinical development of detalimogene. Since our merger with Forbion European Acquisition Company (&#8220;FEAC&#8221;) (the &#8220;Reverse Recapitalization&#8221;), we have financed the Company through a series of private investment in public equity (&#8220;PIPE&#8221;) financings, debt arrangements, and issuance of warrants.  In addition, in November 2025, we issued Common Shares and pre-funded warrants pursuant to an underwritten public offering, as further described in &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 17, Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never been profitable and have incurred net losses since inception. Our net losses were $117.3 million and $55.1 million for the years ended October 31, 2025 and 2024, respectively. As of October 31, 2025 and 2024, we had an accumulated deficit of $372.0 million and $254.7 million, respectively, and cash, cash equivalents and marketable securities of $202.3 million and $297.9 million, respectively. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the ongoing LEGEND study of detalimogene, including the pivotal cohort of patients with BCG-unresponsive NMIBC, to completion; execute on our plan to file a Biologics License Application with the FDA in the second half of 2026; and pursue potential pipeline expansion via additional detalimogene development opportunities and other compounds. In addition, we expect to incur significant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses as we establish medical affairs, sales, marketing and distribution infrastructure and capabilities to support the potential commercial launch of detalimogene and significant additional commercialization-related expenses, if and when detalimogene is approved. As a result, we expect to need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, or other capital sources, which could include potential collaboration agreements, strategic alliances, or licensing arrangements. We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, we had $50.2 million in cash and cash equivalents and $152.1 million in marketable securities, mainly US Treasury Bonds. We believe that our existing cash and cash equivalents and marketable securities as of October 31, 2025 will be sufficient to fund our operating expenses, debt obligations, and capital expenditure requirements for at least the next 12 months from the issuance date of the consolidated financial statements included within this Annual Report. In addition, as discussed under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 17, Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;, we received aggregate net proceeds of approximately $140.1 million in November 2025 in connection with an underwritten public offering of our Common Shares and pre-funded warrants. While we have historically been successful in securing financing, raising additional funds is dependent on a number of factors outside of our control, and as such there is no assurance that we will be able to do so in the future. See </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Liquidity and Capital Resources&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">below.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Our Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any product candidates approved for sale, have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products or from other sources in the near future, if at all. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate, if ever. If our development efforts for our current lead product candidate, detalimogene, or additional product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales and payments from such collaboration or license agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses account for a significant portion of our operating expenses and consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing registration and validation batches;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with CROs that are primarily engaged in the oversight and conduct of our clinical trials; CMOs that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants that conduct our clinical trials, nonclinical studies and other scientific development services; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personnel-related expenses including, salaries, benefits, share-based compensation, and other related costs for individuals involved in research and development activities; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with other research and development expenses including costs related to outside consultants, costs related to compliance with quality and regulatory requirements, payments made under third-party licensing agreements, and costs related to facilities, supplies, rent, insurance, certain legal fees.  </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development costs as incurred. We recognize direct development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting date. Payments for these development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid expenses or accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant portion of our research and development costs to date have been third-party costs, which we track on an individual product candidate basis after a clinical product candidate has been identified. Currently, our main clinical product candidate is detalimogene. Our indirect research and development costs are primarily personnel-related costs, facilities, and other costs. Employees and infrastructure are not directly tied to any one program and are deployed across our programs. As such, we do not track these costs on a specific program basis. We utilize third party contractors for our research and development activities and CMOs for our manufacturing activities and we do not have our own laboratory or manufacturing facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business model. Currently, the Company&#8217;s sole laboratory facility is located in Montreal, Quebec, Canada, and as such, a portion of the Company&#8217;s research and development and other operating expenses are incurred in Canada and denominated in the Canadian dollar. We expect that our research and development expenses will continue to increase for the foreseeable future as we progress our ongoing Phase 1/2 clinical trial for detalimogene, continue to discover and develop additional product candidates, expand our headcount and maintain, expand and enforce our intellectual property portfolio. If detalimogene or any future product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. There are numerous factors associated with the successful development and commercialization of any product candidates we may develop in the future, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development program and plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The duration, costs, and timing of clinical studies and development of our product candidate will depend on a variety of factors, any of which could mean a significant change in the costs and timing associated with the development of our product candidate including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress, and expense of our ongoing as well as any additional clinical studies and other research and development activities we undertake; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future clinical study results; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties in clinical study enrollment rates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new manufacturing processes or protocols that we may choose to or be required to implement in the manufacture of our drug substance and drug product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory feedback on requirements for regulatory approval, as well as changing standards for regulatory approval; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and receipt of any regulatory approvals.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any changes in the outcome of any of these variables with respect to the development of detalimogene or any future product candidates in nonclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any clinical trials following the applicable regulatory authority&#8217;s acceptance and clearance, we could be required to expend significant additional financial resources and time to complete clinical development than we currently expect. We may never obtain regulatory approval for any product candidates that we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development of detalimogene or any product candidates we may develop in the future is highly uncertain. Therefore, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development and commercialization of detalimogene and any other product candidates we may develop. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of detalimogene or any future product candidate, if approved. This is due to the numerous risks and uncertainties associated with product development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits, and share-based compensation expenses for personnel in executive and other administrative functions. Other significant general and administrative expenses include professional services, including legal, accounting and audit services, and other consulting fees, as well as facility costs not otherwise included in research and development expenses, insurance, and other operating costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our general and administrative expenses will continue to increase in the foreseeable future as our business expands to support our continued research and development activities, including our clinical trials. These increases will likely include increased costs related to the hiring of additional personnel and fees for outside consultants, among other expenses. In addition, if we obtain regulatory approval for our current product candidate or any product candidates we may develop in the future and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing, and distribution activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other (Income) Expense, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense consists of interest paid on our convertible notes and third-party debt, as well as non-cash interest expense for amortization of our debt discounts.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income is associated with our interest-bearing cash and cash equivalents and marketable securities.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other expense, net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other expense, net primarily consists of foreign exchange gains and losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each period or for deductible temporary differences, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be realized. As of October 31, 2025 and 2024, we have recorded a full valuation allowance against our deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended October 31, 2025 and 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for each of the periods presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.863%;box-sizing:content-box;"/>
     <td style="width:1.281%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.764000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.281%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.764000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.281%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.764000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,480</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,315</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,165</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,685</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,982</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,703</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,165</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,297</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,868</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,165</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,297</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,868</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (income) expenses, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,426</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,413</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,994</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,798</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on extinguishment of debt</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">366</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(366</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expenses, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">569</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">456</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,863</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7,136</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,161</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,141</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for (recovery of) income tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,142</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,160</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses for each of the periods presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:82.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:48.181%;box-sizing:content-box;"/>
     <td style="width:1.599%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.775%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.299%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.775%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.599%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.775%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and Development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, Manufacturing and Controls</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,578</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,994</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,584</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical Operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,915</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,036</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,879</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, including stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,935</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,687</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,248</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,052</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,598</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,454</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,480</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,315</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,165</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Certain amounts reported in prior years have been reclassified to conform to the current year's presentation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $56.2 million from $38.3 million for the year ended October 31, 2024 to $94.5 million for the year ended October 31, 2025. This increase was attributable to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $37.6 million increase in detalimogene manufacturing activities is primarily attributable to the preparation for our planned Biologics License Application ("BLA") submission in the second half of 2026</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $9.2 million increase in personnel-related costs, including a $1.5 million increase in stock-based compensation, as the Company hired a number of key personnel to ramp up its clinical operations, quality, medical affairs and manufacturing functions to support our LEGEND study of detalimogene;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $6.9 million increase in clinical operations is a result of our increasing clinical trial activities including complete enrollment of the pivotal cohort of the Phase 2 LEGEND study of detalimogene in BCG-unresponsive NMIBC</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $2.5 million increase in other research and development expenses is a result of regulatory and medical affairs professional service fees incurred in preparation for our planning BLA submission and research as the Company focuses on advancing the clinical and preclinical pipelines.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.863%;box-sizing:content-box;"/>
     <td style="width:1.281%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.764000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.281%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.764000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.281%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.764000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024*</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, including stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,214</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,031</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,183</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,471</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,951</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(480</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total general and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,685</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,982</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,703</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Certain amounts reported in prior years have been reclassified to conform to the current year's presentation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses increased by $4.7 million from $24.0 million for the year ended October 31, 2024 to $28.7 million for the year ended October 31, 2025. This increase was primarily attributable to the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $5.2 million increase in personnel-related expenses, including a $2.8 million increase in stock-based compensation, driven by the hiring of key general and administrative personnel; partially offset by</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $0.5 million decrease in other general and administrative expenses primarily driven by decreased professional fees as work has transitioned to internal resources, partially offset by increased facilities expense.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other (Income) Expense, Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other (income) expenses, decreased by approximately $1.3 million from income of $7.1 million for the year ended October 31, 2024 to income of $5.9 million for the year ended October 31, 2025 primarily due to a $1.0 million decrease in interest income earned in the current period, a $0.2 million increase in interest expense, $0.4 million gain on extinguishment of debt that was incurred during the prior year and $0.5 million increase in other expense primarily related to foreign currency fluctuations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant losses in each period and on an aggregate basis. We have not yet commercialized any product candidates, and we do not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. As of October 31, 2025, we had $50.2 million in cash and cash equivalents and $152.1 million in marketable securities, and we had an accumulated deficit of $372.0 million. Based on our current operating plans, we expect our cash, cash equivalents and marketable securities as of October 31, 2025 will be sufficient to fund the Company&#8217;s operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of the consolidated financial statements included within this Annual Report.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From the Reverse Recapitalization through October 31, 2025, we have financed our operations primarily through proceeds received through PIPE and public financings and debt facility with Hercules. Those sources of liquidity include the $200.0 million from the February 2024 PIPE Financing, net of issuance costs of $12.4 million, and the $60.1 million from the October 2024 PIPE Financing, net of issuance costs of $3.8 million. Subsequent to October 31, 2025, we received gross proceeds of $149.5 million, net of issuance costs of $9.4 million, from the public offering of Common Shares and pre-funded warrants that closed in November 2025, as further described in &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 17, Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s other sources of liquidity include $27.5 million that we may be eligible to drawdown further under our debt facility with Hercules, as well as the $100.0 million limit under our Open Market Sale Agreement with Jefferies LLC, which was entered into in December 2024. Our current operating plan is based on various assumptions. If we use our capital resources sooner than expected, we will evaluate reductions in expense or obtaining additional financing. This may include pursuing a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurance that such financing will be available in sufficient amounts or on acceptable terms, if at all, and some could be dilutive to existing stockholders. If we are unable to obtain additional funding on a timely basis, we may be forced to significantly curtail, delay, or discontinue one or more of our planned research or development programs or be unable to expand our operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary uses of capital are, and we expect will continue to be, research and development activities, compensation and related expenses and general overhead costs. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development, and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, timing, costs, progress and results of our planned clinical trials of detalimogene and any other product candidates we develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results, and costs of our earlier-stage research programs, including the progress of preclinical development and possible clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of our research programs and preclinical development of any future product candidates we may pursue;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of regulatory submissions and timing of regulatory approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress of the development efforts of parties with whom we may in the future enter into collaborations and/or research and development agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and amount of milestone and other payments we are obligated to make under our Nature Technology Corporation License Agreement or any future license agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cash requirements of any future acquisitions or discovery of product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs to acquire or in-license any products, product candidates or technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with maintaining, expanding and protecting our intellectual property portfolio, including costs involved in prosecuting and enforcing patent and other intellectual property claims; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing detalimogene and any other product candidates we develop by third parties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing commercial launch capabilities in anticipation of a potential regulatory approval of detalimogene or any other product candidates we develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of commercialization activities if detalimogene or any future product candidates we develop are approved for sale, including marketing, sales and distribution costs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to add operational, financial and management information systems, enhance existing operational, financial and management information systems and hire additional personnel, including personnel to support development of our product candidates, commercial launch preparation and commercialization efforts and our other operations as a public company; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of operating as a public company. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of our lead candidates or any product or development candidate we may develop in the future could significantly change the costs and timing associated with our development plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, which could include collaborations, strategic alliances or licensing arrangements. Adequate additional financing, if available, may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of such shareholders. Debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research program or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ourselves. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the credit and financial markets in the United States and worldwide. Because of the numerous risks and uncertainties associated with product development, there is no assurance that we will ever be profitable or generate positive cash flow from operating activities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the years ended October 31, 2025 and 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides information regarding our cash flows for each of the periods presented (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(99,239</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,281</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25,138</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(125,953</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,524</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">265,716</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(122,852</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,483</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the fiscal year ended October 31, 2025 was $99.2 million and was primarily due to our net loss of $117.3 million, partially offset by adjustments for non-cash charges totaling $8.3 million. Further changes were driven by an increase of $0.6 million in investment tax credits receivable and a $10.3 million increase in other net working capital adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities for the fiscal year ended October 31, 2024 was $48.3 million and was primarily due to our net loss of $55.1 million, partially offset by adjustments for non-cash charges totaling $6.8 million. Further changes were driven by the receipt of a $2.0 million refundable investment tax credit and a $1.9 million decrease in other net working capital adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Used in Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for each of the fiscal years ended October 31, 2025 and 2024 was $25.1 million and $126.0 million, respectively, primarily consisting of purchases, net of maturities, of marketable securities and purchases of property and equipment during each year.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Cash Provided by Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the fiscal year ended October 31, 2025 was $1.5 million, primarily resulting from proceeds from exercise of stock options of $2.2 million, which were partially offset by $0.7 million in principal repayments of the Prior Term Loan (as defined herein).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the fiscal year ended October 31, 2024 was $265.7 million, primarily resulting from $260.1 million received from the 2024 PIPE Financings, which were partially offset by issuance costs of $12.4 million, $22.5 million received from the Term Loan (as defined herein), which was offset by $9.4 million in principal repayments of the Prior Term Loan, $6.1 million from exercise of common share warrants and stock options, offset by $0.6 million in debt issuance costs paid as part of the Term Loan, and $0.6 million of SPAC transaction costs paid to FEAC in connection with the Reverse Recapitalization.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hercules Loan Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 30, 2021, we entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. ("Hercules") for the issuance of a term loan facility with an aggregate principal amount of up to $20.0 million (the &#8220;Prior Term Loan&#8221;). On December 22, 2023 (the "Hercules Closing Date"), we entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement&#8221;), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (the "Lenders"). The Amended Loan Agreement amended and restated in its entirety the Prior Loan Agreement. The Amended Loan Agreement provided for a term loan facility of up to $50.0 million available in multiple tranches (the &#8220;Term Loan&#8221;), as follows: (i) an initial term loan advance (the &#8220;Tranche 1 Advance&#8221;) that was made on the Tranche 1 Advance closing date of $22.5 million, approximately $8.6 million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the &#8220;Interim Milestone&#8221;), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical evaluation of detalimogene in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances in an aggregate principal amount of up to $7.5 million from the date of achievement of the Interim Milestone through the earlier of (x) 60 days following the achievement of the Interim Milestone and (y) March 31, 2025, and (iii) an uncommitted tranche subject to the Lenders&#8217; investment committee approval and satisfaction of certain other conditions precedent (including payment of a 0.75% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (as defined below) that the Lenders make additional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">term loan advances to the Company in an aggregate principal amount of up to $20.0 million. The Company is required to pay upon the earlier of January 1, 2028 ( the &#8220;Maturity Date&#8221;) or payment in full of the Term Loan, an end of term fee equal to 5.50% of the aggregate principal amount of the Term Loan (the &#8220;End of Term Charge&#8221;). The Amended Loan Agreement also required us to pay on July 1, 2025 or, if earlier, the date we prepaid the Term Loan, $0.7 million representing the Prior Term Loan End of Term Charge (the "Prior Term Loan End of Term Charge" and "End of Term Charge", collectively the &#8220;End of Term Charges&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan.  As a result of the extinguishment, we recorded a loss of $0.4 million as a component within other income and expense in our consolidated statement of operations during the year ended October 31, 2024, which represented the difference between the reacquisition price of the debt, including fees, and the initial fair value of the warrants paid directly to Hercules, and the carrying value of the Prior Term Loan at the time of extinguishment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 18, 2024, we entered into a First Amendment to Amended and Restated Loan and Security Agreement (the "First Amendment") with the Lenders. The First Amendment modified the Amended Loan Agreement to reallocate the $7.5 million previously available under Tranche 2 (as defined in the Amended Loan Agreement), which was not drawn by the Company upon achievement of Interim Milestone, to Tranche 3 (as defined in the Amended Loan Agreement). Pursuant to the First Amendment, the $7.5 million advance originally available upon achievement of the Interim Milestone was added to the uncommitted tranche subject to the Lenders' investment committee approval and satisfaction of certain other conditions precedent (including payment of a 0.75% facility charge on the amount borrowed), pursuant to which the Company may request from time to time that the Lenders make additional loan advances to the Company in an aggregate principal amount of up to $27.5 million. The First Amendment did not change the total term loan facility available to us of up to $50.0 million. The First Amendment further provided for certain administrative changes in accordance with the foregoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At our option, we may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date (as defined in the Amended Loan Agreement); (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) 1.0% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, we had borrowed $22.5 million under the Amended Loan Agreement and incurred $2.2 million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan.  The remaining $27.5 million of the uncommitted tranche subject to the Lenders&#8217; investment committee approval and satisfaction of certain other conditions precedent described above remains undrawn and available to us. The Prior Term Loan End of Term Charge of $0.7 million has been paid as of October 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the Wall Street Journal plus 0.75% (capped at 9.75%) and (b) 9.25%. The Term Loan also bears additional payment-in-kind interest at an annual rate of 1.15%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement, as amended by the First Amendment, are repayable in monthly interest-only payments through the "Amortization Date", which is either: (x) if the Interim Milestone is achieved and there has been no default, January 1, 2026, or (y) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, July 1, 2026. After the Amortization Date, the outstanding Term Loan and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. Through October 31, 2025, we have achieved the Interim Milestone but have not yet achieved certain clinical milestones. Amounts payable on January 1, 2026 were classified as current liabilities on the consolidated balance sheet for the year ended October 31, 2025. The effective interest rate of the Term Loan was 11.63% as of October 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Amended Loan Agreement, as amended by the First Amendment, we granted Hercules a security interest senior to any current and future debts and to any security interest in all of our right, title, and interest in, to and under all of our property and other assets, subject to limited exceptions including our intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Loan Agreement, as amended by the First Amendment, contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement, as amended by the First Amendment, also contains certain events of default and representations, warranties and non-financial covenants of the Company. The Company was in compliance with these financial covenants at October 31, 2025.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025 and 2024 the carrying value of the note payable consists of the following (in thousands):</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:68.366%;box-sizing:content-box;"/>
     <td style="width:1.66%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.197000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.698%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, including End of Term Charge</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,231</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,663</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount, net of accretion</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,088</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,673</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, net of discount</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,326</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,172</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, we classified $8.0 million of the note payable as current. As of October 31, 2024, we classified $0.7 million of the note payable as current, which represents the back-end fee associated with the refinancing of the Prior Term Loan. During the years ended October 31, 2025 and 2024, we recognized $2.4 million and $2.2 million of interest expense related to the Amended Loan Agreement, respectively, and $0.6 million each year related to the amortization of the debt discount.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated future principal payments due under the Term Loan, including the contractual End of Term Charges and payment-in-kind interest as of October 31, 2025 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:80.444%;box-sizing:content-box;"/>
     <td style="width:1.8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.757%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,417</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,987</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,161</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal payments, including End of Term Charge</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,565</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Hercules Term Loan is our only outstanding debt instrument at October 31, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Other Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement with Nature Technology Corporation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 10, 2020, we entered into the License Agreement with NTC pursuant to which NTC granted us a worldwide non-exclusive, royalty-bearing and sublicensable license to certain patents and know-how relating to the Nanoplasmid&#153; vector backbone that is used in detalimogene voraplasmid to research, develop, make, use, import, sell and offer to sell, any gene and cell therapy products incorporating the Nanoplasmid&#153; vector backbone (excluding any such products in the field of dermatology). Unless terminated earlier, the License Agreement will continue until no valid claim of any licensed patent exists in any country. We can voluntarily terminate the License Agreement with prior notice to NTC.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We paid NTC an initial, upfront fee of $50 thousand which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, we are required to pay NTC a $50 thousand annual maintenance fee until the first sale of a product for which a royalty is due. We are also required to make a payment to NTC of $50 thousand upon assigning the License Agreement to a third-party. The License Agreement provides for a one-time payment of $50 thousand for the first dose of a product covered by a valid claim of a licensed patent (a &#8220;Milestone Product&#8221;) in the first patient in a Phase 1 clinical trial or, if there is no Phase 1 clinical trial, in a Phase 2 clinical trial, as well as a one-time payment of $450 thousand upon regulatory approval of a Milestone Product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a Milestone Product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a Milestone Product, has not yet been achieved as of the year ended October 31, 2025. We are also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by us, our affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the License Agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. In the event that we or any of our affiliates or sublicensees manufactures any GMP lot of a licensed product, then we or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. Such manufacturing payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a more detailed description of this agreement, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Item 1. Business&#8212;Intellectual Property&#8212;Strategic License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 7, License Agreement and Clinical Research Organization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; included elsewhere in this Annual Report.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our leases are comprised of all operating leases for Montreal, Canada, Boston, MA USA and Waltham, MA USA office space and Montreal, Canada lab space. Please refer to Note 13 to our consolidated financial statements included elsewhere in this Annual Report for expenses related to the lease obligations in the twelve months ended October 31, 2025, future payment requirements, and the guaranty obligations under the lease agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into contracts in the normal course of business with CROs, CMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not have material capital expenditure commitments at October 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Estimates for the years ended October 31, 2025 and 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This management&#8217;s discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make judgments and estimates that affect the reported amounts of assets, liabilities and expenses, as well as related disclosures during the reported periods. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report, we believe the following accounting policies used in the preparation of our financial statements require the most significant judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued and Prepaid Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued and prepaid third-party research and development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued and prepaid expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued and prepaid research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure all share-based awards granted to employees, officers, directors and non-employees based on the fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Our share-based payments related only to stock options issued to date. We account for forfeitures of our share-based awards as they occur. We have historically issued share-based awards with only service-based vesting conditions. In July 2023, we issued 1,046,764 stock options which have performance conditions tied to the closing of the Reverse Recapitalization and the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">filing of an effective registration statement. For share-based awards with service-based vesting conditions, we record the expense using the straight-line method including when such awards have graded vesting. For performance-based awards, we record the expense when achievement of the performance condition is deemed probable using an accelerated attribution method, as if each vesting tranche was treated as an individual award.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all stock options granted at fair value of the underlying Common Shares at the time of the grant with service-based vesting, the fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of our Common Shares (prior to the Reverse Recapitalization) expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. We determine the volatility for awards granted based on an analysis of reported data for a group of guideline companies that have issued options with substantially similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The expected option term for share-based awards with only service-based vesting was calculated based on the simplified method, which uses the midpoint between the vesting date and the contractual term, as we do not have sufficient historical data to develop an estimate based on participant behavior. The expected option term for performance-based awards has been determined considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, and comparison to expected terms used by peers. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, cash dividends on our Common Shares; therefore, the expected dividend yield is assumed to be zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the Reverse Recapitalization, because there was no public market for enGene Inc.&#8217;s common shares, its Board of Directors approved the fair value of its common share based on third-party valuations of its common shares. Initially, the enterprise equity value of enGene Inc. was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#8217;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering, or sale of our Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. In addition, various objective and subjective factors were considered to determine the fair value of our Common Shares as of each grant date of stock options, including, among other factors:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prices at which we sold shares of preferred shares and the superior rights and preferences of the preferred shares relative to its Common Shares at the time of each grant,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the estimated value of each security both outstanding and anticipated,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the anticipated capital structure that will directly impact the value of the currently outstanding securities,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial position, including cash on hand, and our historical and forecasted performance and operating results,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress of our research and development programs,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our stage of development and business strategy and the material risks related to our business and industry,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood of achieving a liquidity event for the holders of our Common Shares, such as an initial public offering or a sale of our Company, given prevailing market conditions,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">external market conditions affecting the biotechnology industry sectors,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">local and global economic conditions, and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lack of an active public market for our Common Shares and redeemable convertible preferred shares. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if we had used different assumptions or estimates, or if there are changes to the unobservable inputs, the fair value of its Common Shares and share-based compensation expense could have been materially different.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to the consummation of the Reverse Recapitalization, the fair value of the Common Shares used in the Black-Scholes option-pricing model to determine the fair value of the stock option is determined based on the quoted price of our Common Shares. Further, there were no performance conditions outstanding subsequent to the consummation of the Reverse Recapitalization.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our share-based compensation expense is recorded in general and administrative and research and development expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. We recorded share-based compensation expense of $9.6 million and $5.3 million for the fiscal years ended October 31, 2025 and 2024, respectively. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements&#8212;Note 10, Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">" for additional information.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined by the JOBS Act. Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected to opt out of such extended transition period. In addition, for so long as we are an emerging growth company, we are permitted and intend to take advantage of exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will remain an emerging growth company until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of FEAC&#8217;s IPO, which occurred on December 14, 2021, (b) in which we have total annual revenue of at least $1.23 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700 million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2) the date on which we have issued more than $1.00 billion in non-convertible debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common shares held by non-affiliates exceeds $250 million as of the prior April 30, or (2) our annual revenues exceed $100 million during such completed fiscal year and the market value of our common shares held by non-affiliates exceeds $700 million as of the prior April 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial reporting with that of other public companies difficult or impossible. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations including regarding executive compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have reviewed all recently issued accounting pronouncements and have determined that, other than as disclosed in Note 2 to our annual consolidated financial statements included elsewhere in this Annual Report and disclosed above, such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative an</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Qualitative Disclosures About Market Risk.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item 7A.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_8_financial_statements_and_supple"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 8. Financial Statements and Supplementary Data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements, together with the reports of our independent registered public accounting firm, appear beginning on page F-1 of this Annual Report, and such information is incorporated by reference herein.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9_changes_in_and_disagreements_wit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9A. Controls and Procedures.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the end of the period covered by this Annual Report, management, under the supervision of and with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and principal accounting officer), carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) to determine whether such disclosure controls and procedures provide reasonable assurance that information to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and such information is accumulated and communicated to management, including our principal executive and principal financial officers or persons performing similar functions, as appropriate to allow timely decisions regarding disclosure. Based on our assessment, management concluded that, as of October 31, 2025, our disclosure controls and procedures were effective.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with U.S. GAAP. Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of our internal control over financial reporting based on the framework in Internal Control&#8212;Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that, as of October 31, 2025, our internal control over financial reporting was effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This annual report does not include an attestation report of the Company&#8217;s registered public accounting firm as the Company&#8217;s status as an &#8220;emerging growth company&#8221; and a &#8220;non-accelerated filer&#8221; exempts it from such requirement, pursuant to established rules of the SEC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remediation Efforts to Address the Material Weakness</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously reported, in connection with our preparation and the audit of our consolidated financial statements as of and for the years ended October 31, 2024 and 2023, we identified material weaknesses, as defined under the Exchange Act, in our internal control over financial reporting. The material weaknesses related to a lack of formal policies, procedures, and controls over financial reporting, a lack of sufficient accounting and financial reporting personnel with requisite knowledge of GAAP, general information technology controls that were not designed appropriately, and a lack of appropriate segregation of duties. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the remediation efforts described below, these material weaknesses have been tested and determined to be remediated as of October 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remediation efforts included the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hiring finance and accounting personnel with adequate experience and U.S. GAAP knowledge, including a Chief Financial Officer;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing adequate review and approval processes and procedures based on the roles and responsibilities of each accounting members; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implementing a risk assessment over financial reporting controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">designing and implementing policies, procedures and controls around key business and financial reporting process and general information technology controls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enhancing software tools to ensure segregation of duties; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaging a professional accounting services firm to assist with the documentation and assessment of our internal controls for compliance with the Sarbanes-Oxley Act.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, concluded that, as of October 31, 2025, our disclosure controls and procedures and internal control over financial reporting were effective at a reasonable assurance level. However, our management does not expect that effective disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Furthermore, the design of a control system must reflect the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the items discussed above with respect to the remediation of previously identified material weaknesses, there were no other changes in our internal control over financial reporting during the fourth quarter ended October 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9B. Other Information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e2a3559-0df4-430c-90b6-7394d12f9085" contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a9441941-51de-4e00-bbcd-5fcfe0e5a1bf" contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_bc7fa81d-21e9-4501-80af-535187f87fd3" contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_68db896a-6347-4862-a1d8-26e1b7479960" contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;" id="part_iii"><span id="item_10_directors_officers_corporate_gov"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain information required by Part III is omitted from this Annual Report and will be incorporated by reference from our definitive proxy statement relating to our 2026 annual meeting of shareholders, pursuant to Regulation 14A of the Exchange Act, which we refer to as our 2026 Proxy Statement. We expect to file our 2026 Proxy Statement with the SEC within 120 days of October 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 10 of Form 10-K regarding executive compensation will be included in our 2026 Proxy Statement and, other than the information required by Item 402(v) of Regulation S-K, is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 11 of Form 10-K regarding executive compensation will be included in our 2026 Proxy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement and, other than the information required by Item 402(v) of Regulation S-K, is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="item_12_security_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Owne</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rship of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 12 of Form 10-K regarding security ownership of certain beneficial owners and management will be included in our 2026 Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Regulation S-K Item 201(d) is set forth herein under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Part II, Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities&#8212;Securities Authorized for Issuance under Equity Compensation Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 13 of Form 10-K regarding certain relationships and related transactions and director independence will be included in our 2026 Proxy Statement and is incorporated herein by refer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;" id="item_14_principal_accountant"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accountant Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 14 of Form 10-K regarding principal accountant fees and services will be included in our 2026 Proxy Statement and is incorporated herein by reference.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT IV</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report, incorporated into this Item by reference.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits:</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:91%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business Combination Agreement, dated May 16, 2023, by and among FEAC, enGene Inc. and enGene (incorporated by reference to Exhibit 2.1 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023). &#134;</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">3.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Articles of enGene Holdings Inc. (incorporated by reference to Exhibit 3.1 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523224097/d459793dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523224097/d459793dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Common Share Certificate of enGene (incorporated by reference to Exhibit 4.1 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.2</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Warrant Certificate of enGene (incorporated by reference to Exhibit 4.3 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span></a><span style="color:#212529;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.3</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex43.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant Assignment, Assumption and Amendment Agreement, dated as of October 30, 2023, among FEAC, enGene Inc., enGene and Continental Stock Transfer &amp; Trust Company (incorporated herein by reference to Exhibit 4.3 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1874495/000119312521356920/d251150dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.4</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1874495/000119312521356920/d251150dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Warrant Agreement, dated December 9, 2021, between FEAC and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated herein by reference to Exhibit 4.1 of FEAC&#8217;s Current Report on Form 8-K filed with the SEC on December 14, 2021).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/d680407dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.5</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/d680407dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Closing Date Warrant to Purchase Common Shares of enGene Holdings Inc., pursuant to the Amended and Restated Loan and Security Agreement dated December 22, 2023 (incorporated herein by reference to Exhibit 4.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on December 28, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024008125/engn-ex4_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.6</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024008125/engn-ex4_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated herein by reference to Exhibit 4.6 to enGene&#8217;s Annual Report on Form 10-K filed with the SEC on  January 29, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024126446/engn-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.7</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024126446/engn-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indenture (incorporated by reference to Exhibit 4.1 to enGene&#8217;s Form S-3 Registration Statement Registration No.: 333-283201 filed with the SEC on November 13, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4.8</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312525283182/d876714dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to enGene&#8217;s Current Report on Form 8-K filed with the SEC on November 14, 2025).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sponsor and Insiders Letter Agreement, dated May 16, 2023, by and among FEAC, the Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A., enGene Inc., enGene and the other parties named therein (incorporated by reference to Exhibit 10.1 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.2</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Subscription Agreement (incorporated by reference to Exhibit 10.2 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.3</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Subscription Agreement Side Letter Agreement (incorporated by reference to Exhibit 10.3 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.4</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of enGene Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.5</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated October 31, 2023, by and among enGene Holdings Inc., Forbion European Acquisition Corp. and each of the Holders identified therein (incorporated herein by reference to Exhibit 10.8 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1874495/000119312521356920/d251150dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.6</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1874495/000119312521356920/d251150dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Private Placement Warrants Purchase Agreement, dated December 9, 2021, by and between FEAC and the Company and the Sponsor (incorporated by reference to Exhibit 10.4 to FEAC&#8217;s Current Report on Form 8-K filed on December 14, 2021).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523224097/d459793dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.7</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523224097/d459793dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Exclusive License Agreement, dated April 10, 2020, by and between enGene and Nature Technology Corporation (incorporated by reference to Exhibit 10.14 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023). +&#134;</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.8</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Service Agreement, dated November 11, 2019, by and between enGene and BioAgilytix Labs, LLC (incorporated by reference to Exhibit 10.15 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023). +&#134;</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:91%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.9</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, dated May 16, 2023, by and among enGene, IQ, FEAC and enGene (incorporated by reference to Exhibit 10.16 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023). +&#134;</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.10</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement, dated December 29, 2022, by and between enGene and Are-Canada No. 5 Holdings, ULC (incorporated by reference to Exhibit 10.21 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523241581/d459793dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.11</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523241581/d459793dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Waiver and Consent Letter, dated September 13, 2023, by and among FEAC, enGene Inc. and enGene Holdings Inc. (incorporated by reference to Exhibit 10.22 to enGene&#8217;s Form S-4/A Registration Statement Registration No.: 333-273851 filed with the SEC on September 26, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.12</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.20 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.13</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1021.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Nonqualified Stock Option Grant Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.21 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.14</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1022.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Incentive Stock Option Grant Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.22 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.15</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1023.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Award Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.23 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1024.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.16</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1024.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Award Agreement under enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated herein by reference to Exhibit 10.24 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1025.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.17</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex1025.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.25 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/engn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.18</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/engn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (incorporated by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on May 15, 2024)</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000092963825002215/exhibit10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.19</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000092963825002215/exhibit10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">enGene Holdings Inc. 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2025).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/d597787dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.20(a)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/d597787dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated July 22, 2024, by and between enGene USA, Inc. and Ronald H. W. Cooper. (incorporated herein by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on July 24, 2024).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex10_20b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.20(b)*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex10_20b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Employment Agreement, dated October 2, 2025, by and between enGene USA, Inc. and Ronald H.W. Cooper.#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024105180/engn-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.21</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024105180/engn-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Inducement Grant Agreement, dated July 22, 2024, by and between enGene Holdings Inc. and Ronald H. W. Cooper (incorporated herein by reference to Exhibit 10.5 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on September 10, 2024).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.22(a)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000092963823003423/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated December 13, 2023, by and between enGene USA, Inc. and Ryan Daws (incorporated herein by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on December 13, 2023).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025085143/engn-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.22(b)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025085143/engn-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended Employment Agreement, dated June 10, 2025, by and between enGene USA, Inc. and Ryan Daws (incorporated by reference to Exhibit 10.3 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on June 12, 2025).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024073330/engn-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.23</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024073330/engn-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated April 22, 2024, by and between enGene USA, Inc. and Lee Giguere (incorporated by reference to Exhibit 10.2 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on June 14, 2024).#</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/engn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.24</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/engn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated October 16, 2024, by and between enGene USA, Inc. and Alexander Nichols (incorporated herein by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 21, 2024).#</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.25</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement, dated October 21, 2024, by and between enGene Inc. and Anthony T. Cheung (incorporated herein by reference to Exhibit 10.32 of enGene&#8217;s Annual Report on Form 10-K filed with the SEC on December 19, 2024).#</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex10_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.26</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex10_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated October 21, 2024, by and between enGene USA, Inc. and Joan Connolly (incorporated herein by reference to Exhibit 10.33 of enGene&#8217;s Annual Report on Form 10-K filed with the SEC on December 19, 2024)#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025085143/engn-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.27</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025085143/engn-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated May 21, 2025, by and between enGene USA, Inc. and Amy Pott (incorporated by reference to Exhibit 10.2 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on June 12, 2025).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114224/engn-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.28</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114224/engn-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated July 8, 2025, by and between enGene USA, Inc. and Jill Buck (incorporated by reference to Exhibit 10.6 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114224/engn-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.29</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025114224/engn-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated July 8, 2025, by and between enGene USA, Inc. and Matthew Boyd (incorporated by reference to Exhibit 10.7 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on September 11, 2025).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.30(a)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated November 8, 2023, by and between EnGene USA, Inc. and Jason D. Hanson (incorporated herein by reference to Exhibit 10.01 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on November 9, 2023).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.30(b)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Transition and Modification Agreement, dated February 13, 2024 by and between enGene USA, Inc. and Jason D. Hanson (incorporated herein by reference to Exhibit 10.2 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on February 14, 2024).#</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:91%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/d597787dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.30(c)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524183292/d597787dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Transition and Modification Agreement, dated July 23, 2024 by and between enGene USA, Inc. and Jason D. Hanson (incorporated herein by reference to Exhibit 10.2 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on July 24, 2024).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024105180/engn-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.31</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024105180/engn-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated July 22, 2024, by and between enGene USA, Inc. and Raj Pruthi (incorporated herein by reference to Exhibit 10.3 of enGene&#8217;s Quarterly Report on Form 10-Q filed with the SEC on September 10, 2024).#</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.32*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex10_32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated September 15, 2025, by and between enGene USA, Inc. and Hussein Sweti</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/d680407dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.33</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/d680407dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Loan and Security Agreement, dated December 22, 2023, by and among enGene Holdings Inc., enGene Inc. and enGene USA, Inc., as borrower, Hercules Capital, Inc., as agent, and the lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 to enGene&#8217;s Current Report on Form 8-K filed with the SEC on December 28, 2023). &#134;+</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.34</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex10_36.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Amended and Restated Loan and Security Agreement, dated December 18, 2024 (incorporated herein by reference to Exhibit 10.36 of enGene&#8217;s Annual Report on Form 10-K filed with the SEC on December 19, 2024). &#134;+</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.35</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Subscription Agreement, dated February 13, 2024 (incorporated by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on February 14, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524243481/d863566dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.36</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312524243481/d863566dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Subscription Agreement, dated October 24, 2024 (incorporated by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 25, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138767/engn-ex1_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.37</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138767/engn-ex1_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Open Market Sale Agreement</span><span style="color:#0000ff;top:-4.6899999999999995pt;white-space:pre-wrap;text-decoration:underline solid;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">SM</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">, dated December 20, 2024, by and between enGene Holdings Inc. and Jefferies LLC (incorporated by reference to Exhibit 1.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on December 20, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025083444/engn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.38</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025083444/engn-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">99 High Street Office Lease, dated June 4, 2025, by and between 99 High Street Owner LLC and enGene USA, Inc. (incorporated by reference to Exhibit 10.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on June 9, 2025).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025083444/engn-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">10.39</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017025083444/engn-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement Guaranty, dated June 4, 2025, by enGene Holdings Inc. in favor of 99 High Street Owner LLC (incorporated by reference to Exhibit 10.2 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on June 9, 2025).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">19.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy (incorporated herein by reference to Exhibit 19.1 of enGene&#8217;s Annual Report on Form 10-K filed with the SEC on December 19, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">21.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant (incorporated herein by reference to Exhibit 21.1 of enGene&#8217;s Current Report on Form 8-K filed with the SEC on October 31, 2023).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">23.1*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="engn-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">31.1*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="engn-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">31.2*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="engn-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">32.1*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="engn-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="engn-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">32.2*</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="engn-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">97.1</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1980845/000095017024138472/engn-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy Relating to Recovery of Erroneously Awarded Compensation (incorporated herein by reference to Exhibit 97.1 of enGene&#8217;s Annual Report on Form 10-K filed with the SEC on December 19, 2024).</span></a></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Certain of the exhibits and schedules to these exhibits have been omitted in accordance with Regulation S-K Item 601(a)(5). The   registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Portions of this exhibit are redacted in accordance with Regulation S-K Item 601(b)(10)(iv).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates a management contract or compensatory plan or arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 10-K</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Summary</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.369%;box-sizing:content-box;"/>
     <td style="width:2.701%;box-sizing:content-box;"/>
     <td style="width:5.541%;box-sizing:content-box;"/>
     <td style="width:46.389%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">enGene Holdings Inc.</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: December 22, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ronald H. W. Cooper</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Ronald H. W. Cooper</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Chief Executive Officer and President</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">          Pursuant to the requirements of the Securities Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:30%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ronald H. W. Cooper</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer, President and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Ronald H. W. Cooper</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ryan Daws</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ryan Daws</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Philip Astley-Sparke</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Philip Astley-Sparke</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Heffernan</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Heffernan</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gerald Brunk</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gerald Brunk</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dr. Richard Glickman</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dr. Richard Glickman</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dr. William Grossman</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dr. William Grossman</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Paul Hastings</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul Hastings</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:30%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Wouter Joustra</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wouter Joustra</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lota Zoth</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 22, 2025</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lota Zoth</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:93.7%;box-sizing:content-box;"/>
     <td style="width:6.3%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of October 31, 2025 and 202</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#operations_and_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended October 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#shares_and_shareholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Shareholders&#8217; Equity for the Years Ended October 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#tatement_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statement of Cash Flows for the Years ended October 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_the_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> REPORT OF INDEPENDENT RE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Shareholders and Board of Directors<br/>enGene Holdings Inc.:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28d94ea8-1080-4bb1-8c41-6cdfe6384a5a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of enGene Holdings Inc. (the Company) as of October 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2021.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Montreal, Canada<br/>December 22, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D BALANCE SHEETS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.993%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.883000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78dacc63-a09e-42ad-b680-aa863b1b5633" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,152</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d2a431-5b3e-4cf8-8788-b031dee5d766" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,004</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities - short term</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde71be8-9ba6-4e4f-8448-f0e71b8dea6c" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,584</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70b380da-2bfc-4b5b-b8eb-23e99739d63e" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,328</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted investments</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9564da49-c643-417e-82b9-0c8a600e55f2" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:RestrictedInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e382171-b4e4-498e-bbe0-12934e898ec7" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:RestrictedInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits receivable</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d18c391-3d2f-4992-9d76-26eae0a724ee" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:InvestmentTaxCreditsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a9f9520-cd60-4e1d-9a4b-528df4c68009" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:InvestmentTaxCreditsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae15e74f-d7ab-4cce-93d0-82683a90a6b3" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,649</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_969124eb-755f-4688-83b0-562c6101225f" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5adccdec-1077-4751-b1bd-c5e3d2749046" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201,391</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c25eea-cfc8-4be0-b14b-c50eb2f62be2" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,362</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities - long term</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_663533e9-3f76-4058-9f65-d0f91f23acda" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79943bff-0b80-4bc1-8c57-10ddd7784e65" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,527</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_913a5b44-f53a-4268-a780-04a114cb25fd" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ef1bc90-4385-45cd-aa8f-7184724a2ca6" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,169</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right of use asset</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf6ec85-f8ec-481f-8bbe-1730dd8a5676" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,716</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc796bd2-2118-4cef-ba0c-57fff29afe71" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,741</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1687a059-83ab-44b7-b22f-c90bc7bbac66" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,362</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06372059-ecf7-45ed-853f-31e003c6b2a0" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95c925ab-e047-4ee4-968c-ba9c4dbf11c5" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,468</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_690076e3-0689-4c8c-9ecb-249ee9ce9d67" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and shareholders&#8217; equity</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7722a732-b1fc-4222-99ec-d3d16f2aab94" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,688</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d382e5-0836-4020-a585-d356084683ea" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,411</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65a9bc2f-90ac-443c-b460-3e51d86f1d5a" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,275</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db7ed336-9321-4635-ab0c-44a4994cc694" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,128</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e38ac593-0601-42b4-85cb-98ae15a6280d" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,014</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7f49625-5d7f-4e79-8f33-10541ebac026" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">423</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of note payable</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51d0b15b-bead-446a-91ec-c8818a6e1bff" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,002</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcd064f8-1c17-41b8-bd2c-727317de8eaa" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">699</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d450460-89fe-4cbd-b812-bc4cbeab64db" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,979</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7029862-3cff-415c-b6a0-23926ddbc5cb" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,661</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, net of current portion</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3562fbd6-4916-467a-a055-e1854df538d0" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54c60e9a-6913-49d2-bee0-36ba1efe7436" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,473</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbcd5ca4-593b-46a7-a17f-cc1f204c526c" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,455</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bd4137d-232e-4081-a335-590701d8b2f9" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,427</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1371660e-f510-48cc-83a0-ae19ccc324f6" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,758</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffd8a399-dd67-4c5a-8a73-211df46d53aa" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,561</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shareholders&#8217; equity:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_866ce0b1-4a32-48ea-81c5-385f22923b8a" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_811619bf-07b4-4f83-a079-b8de67ebe54e" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span><span style="-sec-ix-hidden:F_19cbb428-9d40-4173-b963-b055e6ae20f0;"><span style="-sec-ix-hidden:F_6bb524eb-b790-45cf-97d6-d7746896ad6f;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">unlimited</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8090ca60-4d2d-4870-8c51-fa2862d9d2e8" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_35428661-28da-4562-9dd1-51f80bb1ef1b" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">52,018,658</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2811be0a-dc5d-4ce6-b1d3-ff31a8a58223" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fe506b86-ccc8-47f7-b2c9-15f5c7811eca" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,976,676</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and  outstanding as of October 31, 2025 and October 31, 2024, respectively.</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8e9bc43-6318-48da-b24f-6b9c487ada87" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">513,281</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa4cc177-42c1-412f-9dec-81154c77112a" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">509,811</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb20a01c-05d8-4b06-8dd9-8004578e787a" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,349</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3adb0a43-9092-4c0d-a77f-70d1185439ab" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,950</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd01748-56d5-4dc5-9a54-933eaa361172" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">888</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2b97aa7-b36b-43f8-9d5d-f6ba2c0e4ca5" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,419</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31001fcb-0401-44c4-a92f-6730d99f54c9" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">372,032</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1172526-0a10-4da2-b418-8eeb1a0b39e4" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">254,730</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shareholders&#8217; equity</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4658a729-fb1a-4e11-865a-39c1c1969d0b" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,710</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0e9d210-1e79-4393-b3c9-898e33cac629" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,612</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and shareholders&#8217; equity</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b5fe477-0728-4a1f-b0fc-377887d34510" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,468</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aee81a67-075b-4306-b29b-9cb7eb9a8415" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,173</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="operations_and_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RATIONS AND COMPREHENSIVE LOSS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.94%;box-sizing:content-box;"/>
     <td style="width:2.04%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.76%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.76%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b24cb9ed-69de-4201-ba21-68e6be99b589" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,480</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebebb52d-8fdc-412c-b058-f738e0ce8c7e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,315</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da768e01-14ec-4f5f-a193-215c86f473b3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566dcfad-c9cb-45c6-a5c7-48ff02ec8cd2" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,982</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe0a945d-2f89-4c79-94e8-4e61f501dd73" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19198112-1a94-4ae5-9859-af3125154f19" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,297</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d280e82-45f9-46cb-ba16-c06e4b7a2f0a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">123,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2894348-d920-45b2-8e77-64ead832f8f1" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,297</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other (income) expenses, net:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62ff4948-b69f-4c97-be7e-05aa8abd2872" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49240a54-d6f1-4c07-b265-86613a92474d" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,413</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b371d423-8fd6-4e13-945e-1c760318a198" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,994</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe05804d-3865-4335-803c-5a8a76de9b6d" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,798</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gain on extinguishment of debt</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e7f8ac5-6214-4bb8-b46b-20e3db5448ef" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f7b7ecf-189f-4876-a148-39615a94076e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">366</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expenses (income), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7dd9f9e-4f5d-45d1-b399-a12c1a45f94a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">569</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8350d046-4266-47e8-bd8b-be94eaf6d43b" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_916edc97-3e40-40c5-bc79-9437f14ff192" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0de0671a-04ac-4555-888a-2f33389bf3b0" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,136</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c2f242a-3289-4ae9-b6ed-6e8cfde9846b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f5463b0-d7bc-4c55-ab66-337de540060e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for (recovery of) income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_817bb8fa-1414-4096-a90f-5af97bdcb260" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce6b088-3e29-420a-905d-deeb34bf8faa" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ba40860-a2fc-4d12-9c41-7a16e19c10a3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e724b10-7936-4ef7-b907-4b74a7f3a361" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized (gain) loss on available-for-sale investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b0e2a17-d0e1-419d-80e3-2fd8abc751bb" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">531</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d619159b-3fa2-4561-b731-decee39324c4" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0df746e-295f-4867-bb86-f3a242342003" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,771</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69ade8e3-19ec-48db-8a05-4d3406e55c7c" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,739</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share of common shares, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bda413f-8551-4b43-adac-69b4d751c666" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ae861c53-3516-4d25-baca-880381ed09d8" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.29</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63d65ae9-03da-4e7c-b090-66fbcc589546" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bff533af-96e4-415d-881d-c538799832c7" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.46</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f9c2f34-f2a6-4aa9-a375-0c9afdea57fe" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_741d1d3e-4cec-4a5a-8a96-a534a4ecf79a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,119,479</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c711fa68-195d-42e2-9077-a703f0ebd8d1" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4953149d-7606-4dfa-8c03-71c83c81e4df" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,782,346</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="shares_and_shareholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHAREHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:22.12%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.12%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional Paid in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other <br/>Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shareholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at October 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fbe8d30-daab-49bd-b0be-5630c0cfca6d" contextRef="C_6691d0be-dbca-4238-ba0d-4650e328c889" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,197,976</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c59bc29-f5d3-4ab9-bc3d-ad501f646f55" contextRef="C_6691d0be-dbca-4238-ba0d-4650e328c889" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,373</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d2b7157-833c-4ed5-b205-72699e648117" contextRef="C_df7d5361-4681-4e11-ba09-2fff4a273c7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,717</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5149349f-e8c2-4d05-921e-930e5b8d76c9" contextRef="C_382606a1-c180-49e7-af1d-4f96fb9f4c5f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,016</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3734487a-79df-44c8-b4ac-6f03785d7d9b" contextRef="C_1ebeba52-1c6c-4bb9-bc2f-7b693e857291" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">199,588</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e37b54d9-d5bb-42f9-bd34-2fd8b6b77179" contextRef="C_86803251-d047-4bf0-b674-339fac002c30" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,486</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3128dec0-ef1a-48e4-a7af-d2f2a11d0ee4" contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">116,752</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25a917ed-58f0-4ed9-82b3-e50fd6c93447" contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0ac69f8-c295-40c0-9ef7-5cec2bb2b186" contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be7f9dd9-154d-403c-90ac-957d4083621f" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf8c091d-ec57-40c3-bcff-30e455073867" contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f4d8da6-8e01-41ff-b1c9-2a5e313830ce" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares in connection with February PIPE Financing, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d62c2e2-964a-4722-92dc-5051c41ec358" contextRef="C_96d03257-9ff9-4103-bc83-b064b32da4cf" name="engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_402fc750-9a9f-4ae4-a002-71991e69c80d" contextRef="C_96d03257-9ff9-4103-bc83-b064b32da4cf" name="engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,614</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c81919-9373-4ca9-a7a1-b0111eb1056b" contextRef="C_0266c416-4b23-4071-88cb-dd6bf0a921ee" name="engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,614</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common share in connection with October PIPE Financing, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6a5eb1f-ed9b-4e82-9fc7-fcc1e68178f9" contextRef="C_60ed5f3c-1a4d-4713-9546-b4094d014309" name="engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,758,311</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7c9f0a1-3fa0-4846-9e84-83995cde0698" contextRef="C_60ed5f3c-1a4d-4713-9546-b4094d014309" name="engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,318</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c997d822-c321-4df6-afe0-40bb636265bf" contextRef="C_8573ef68-8587-44b1-bc31-b24f597df0af" name="engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,318</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of warrants in connection with Amended Term Loan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71022b05-4171-4815-9f17-c09ca3e8c8a5" contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0978732d-c5de-4181-9047-978a875c3927" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares upon exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9d52324-750f-49ca-b743-149e169c27b8" contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f" name="engn:StockIssuedDuringPeriodSharesWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">520,282</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ba84ea-fea6-4a36-b2be-8e8a596ba2f9" contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f" name="engn:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,114</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d50efd93-29a1-4122-841d-18e0c2f91ccc" contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c" name="engn:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fb9d518-e88d-436e-832a-60f0f22b0443" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,983</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares upon cashless exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1aee10d-ee8e-4002-a703-496fe46d7884" contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f" name="engn:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">383,355</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bae644b1-2553-4b49-9167-1c92cda141bd" contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f" name="engn:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fc3139c-5bee-4f2a-b2c6-129906f58f60" contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c" name="engn:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79c6dd72-cdc6-46be-864f-e675cf0b300a" contextRef="C_ffb1bf69-b5a8-4516-998f-54b7ad557f99" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d569f02-42fd-4c79-8a14-3a22388a1885" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850e2f3f-6a19-4dd5-ade0-cee3426d68ed" contextRef="C_c9315aeb-75af-4e5d-b506-eb4a1ca94906" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c777e56b-b339-4b1b-b1a2-c5ff31c1ebd0" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at October 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d625301-a999-4939-a4c6-cfe505fe2c10" contextRef="C_cf043049-d331-45c8-a6e7-85747599cf46" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,976,676</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b32932b6-decc-4c43-a041-8abafc586f4b" contextRef="C_cf043049-d331-45c8-a6e7-85747599cf46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">509,811</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cca0ecb1-628e-4017-911f-171af265c589" contextRef="C_72b405e6-793c-4923-a2ac-fd5c62acce9f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,950</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b19c9388-838b-4b0d-b849-9b3a8d47bc39" contextRef="C_2d00fd55-c9ba-44ab-bd71-904d4195e08b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,419</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54148e02-de3b-42a1-979b-9b8c21a9f7e9" contextRef="C_545b1b90-fd27-46b0-90e4-68a6f6ffcb9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">254,730</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da0d58d-ee91-469a-8ad0-3e58ae0e57d5" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,612</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56a5d35e-ca83-4c80-9afc-169a1a0e4da5" contextRef="C_8ab71810-5ab2-4406-b4d3-514255136390" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,041,982</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9c87ad9-d2ea-40e7-98f1-64852b8652f6" contextRef="C_8ab71810-5ab2-4406-b4d3-514255136390" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,470</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be0c9bf4-6d1a-4caa-bc57-91c35f98fdb3" contextRef="C_c67c0ca3-bd12-47e1-a7c3-cf98532f1504" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,247</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12d9e60e-c4af-4c45-b918-00875a477a67" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,223</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aed49b3-bf50-42ca-bd3c-57d402fe3c8b" contextRef="C_c67c0ca3-bd12-47e1-a7c3-cf98532f1504" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,646</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eebdded7-ada9-44dc-8e53-fdd55d18d5f2" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,646</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a63b40b-1e4c-4cee-bb7a-6820312b4a0c" contextRef="C_97729f6b-370e-489c-98a7-6180fbee0e8f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">531</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1547eeac-7d4d-4d2b-80e9-44f7ee3fe3e9" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">531</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca133d4-2a57-4910-921d-ebad3977e201" contextRef="C_bd2cdf17-9066-447e-bbd3-00fa8ebfeb81" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871d56e8-bfd7-46f3-bf69-faa403f0480a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at October 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d93aff8d-64d5-4047-8214-0567d4398019" contextRef="C_758f5c72-0590-42c1-b39e-5c9fb4eea3d9" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">52,018,658</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e910b6b5-b077-4cbb-b98b-6c88c2aa3113" contextRef="C_758f5c72-0590-42c1-b39e-5c9fb4eea3d9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">513,281</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66ac4be2-a112-4fe5-919b-ac745077c545" contextRef="C_2773bd89-2e98-4a47-a2e5-226327bcbdf3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,349</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1e43f5b-4f89-4c40-a80f-a15f6bf8c745" contextRef="C_ff785c01-16ce-4fd0-b204-3fe21cdeca9f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">888</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7dc2c65-703a-4b40-a3a1-2cb433a0c0c8" contextRef="C_27a237fa-2a01-4b32-b736-267804b23863" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">372,032</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e15411a8-2ba0-4d62-8ab9-be1a9cf44914" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,710</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tatement_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENT OF CASH FLOWS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.313%;box-sizing:content-box;"/>
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.103%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.103%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a491815-c878-4311-af7f-b88897ae9743" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c952f03-f12b-4b8b-a6ac-59158223c375" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Non-cash interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baabcdf0-186d-4f5b-a666-6187d0a7588a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3102dc10-3e6c-4eaf-8cfb-e877ae8e20fd" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:NonCashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">806</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Gain on extinguishment of debt</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0640d5a-ff95-4e70-9a1b-bd2ec26477ed" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">366</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Non-cash lease expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6374327b-af1e-4bbb-be1a-e3e6b7d3d79d" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:NonCashLeaseExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">378</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30ca0058-112a-4b51-925b-3f2cbd20020f" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:NonCashLeaseExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Loss on the disposal of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe6439f8-b44d-433f-8f63-88ee6e428614" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Net amortization of premiums (accretion of discounts) on marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79c07900-9619-405e-8c9a-88eee3e2a63f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3424a450-974e-46c0-84db-ce64f47c25c7" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Unrealized foreign currency losses (gains)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a03f1b71-a53a-4ea5-9abf-e6d23e078690" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f89ef982-b2de-491c-be0b-8c34d82a55fc" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Share-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a47d2504-3616-465d-b13d-fe9fd9309fc0" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,646</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cfa3b8b-917d-4eee-b3ac-bc7b65698d87" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Depreciation of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87d9522b-c801-4fca-a553-29af9604e60b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">509</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94dcc7c0-a2c0-4906-9e43-e5eb629d38e3" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Investment tax credit receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fbb2416-7d64-4730-836d-efc94b7f6c10" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:IncreaseDecreaseInInvestmentTaxCreditReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30769e06-d241-4b71-ab67-446058962aa1" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:IncreaseDecreaseInInvestmentTaxCreditReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,011</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6ac0456-7594-484b-8750-fa0ece2d4526" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,989</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22df02c-2444-4f91-b60f-d9c74beb025f" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,566</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c6a876-2844-4bde-b19b-c8b93f79dc03" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,942</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6128b3aa-52be-4c15-9e9f-5e7ac1f7dd3c" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e1693b4-da51-48e2-95fe-6aed178044eb" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,130</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71f80481-5a98-47a4-9fd9-cbd838937d03" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,225</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a407916c-3792-4f30-8a44-452da85169fa" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63addfdb-2f86-493b-bed8-0a7635af56e6" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd39c192-bc68-4564-a1d7-5fb06a44ec4d" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">99,239</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be3cfb6e-b4d9-4d44-9ca2-72ae339432df" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,281</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24888f05-f3c6-4cf3-a80e-f0e28a7021d5" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,485</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b28a6c4-90d3-4e60-9c0d-dbb551409432" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">925</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8fc8ed9-18d0-44bb-b8fd-0260b5d19471" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">160,843</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af5e08a9-9de5-49fc-8565-7eb41ac81c65" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_827eb1fb-440a-4eed-ab56-52fa25caa54a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,190</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3706e1f4-168b-41e4-a3cd-3c1e1269b548" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,138</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7a103fa-b642-499d-b2ab-a80acec20ff4" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,953</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of Reverse Recapitalization and PIPE Financing costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4db88bad-812f-43da-aff4-136a4dc74ede" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:PaymentOfReverseRecapitalizationAndPipeFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">613</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the February 2024 PIPE Financing</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7bb3b84-88fb-499c-aecc-d99fc9413a4e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260,149</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of issuance costs associated with the 2024 PIPE Financing</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fdc47d2-bd07-440b-9931-87f731fa4589" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,386</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of common share warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd774ff4-73ad-46c4-976d-e160bc634a9a" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,983</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4689a3e6-b994-402e-a1cd-b8dbe35c9214" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,223</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cc20a48-fd95-477f-93dd-de25512847a9" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repayments of term loan principal</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5977c7c9-f009-4677-abde-c4459e8c94f6" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:RepaymentsOfTermLoanPrincipal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">699</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd98944f-5aca-4b82-8136-b58f07dc861c" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:RepaymentsOfTermLoanPrincipal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,445</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of term loan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d9f20ad-6587-43af-b6c6-fdb53d69fa8e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of debt issuance costs associated with the term loan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3bfad08-2d87-4575-bfca-b8923547299e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_840167cc-d242-4daa-8fcb-8f9b49189379" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,524</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_399f0ebb-ee09-4afb-8c1d-d135729fc965" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,716</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93da665b-61c2-45f6-bba7-7eac6e17a0aa" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1598c306-3539-4dd5-aaf3-99a8bbde63c1" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa37d81b-5ad8-4422-a2d7-3a891dc18dd8" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">122,852</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86137dc6-3b7f-4008-87da-56f5ef487ad9" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,483</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b42b5f39-7f80-404b-ba0c-3d9cfd6936b1" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,004</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f29052f-5185-45dc-9ed6-6f891bf6531f" contextRef="C_86803251-d047-4bf0-b674-339fac002c30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,521</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b86e7e6c-e8cc-4693-a4f9-b5cd1db9c2db" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,152</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_128fba2c-427e-45dc-ab6d-443640a01f4c" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,004</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental cash flow information:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_464492c6-aeea-4016-9ae9-3a57aa0ecda4" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,289</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c62ce29-fedb-4860-8e9a-f498102db600" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,925</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash investing and financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reverse Recapitalization and PIPE financing transaction costs included within accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddd3b04-5339-4cb3-891c-e157598b0392" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant value issued as part of Amended Term Loan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7c4dc80-39ed-439e-b233-7c937d2ca47d" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:WarrantValueIssuedAsPartOfAmendedTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use assets obtained in exchange for lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d865f176-79ec-4d29-a437-0590f272636f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,352</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_349609ba-7a59-4518-a689-3fbfb1e193cd" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,904</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment included in accrued expenses and accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73aab4b1-0e2c-40ee-ada5-af4a792e8b1e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ab49f1f-c782-4bdd-a400-727704fd5b59" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="notes_to_the_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enGene Holdings Inc., together with its consolidated subsidiaries enGene Inc. and enGene USA, Inc. (&#8220;enGene&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on developing genetic medicines to improve the lives of patients, and its head office is located in Montreal, Quebec, Canada. The Company is developing non-viral genetic medicines based on its novel and proprietary dually derived chitosan, or &#8220;DDX&#8221;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Merger with Forbion European Acquisition Corp.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forbion European Acquisition Corporation (&#8220;FEAC&#8221;) was a special purpose acquisition company (&#8220;SPAC&#8221;) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the &#8220;Closing Date&#8221;), the Company, FEAC, and enGene Inc., consummated the merger (the &#8220;Reverse Recapitalization&#8221;) pursuant to a business combination agreement, dated as of May 16, 2023 (the &#8220;Merger Agreement&#8221;). As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its Common Shares and warrants on the Nasdaq Capital Market under the symbols &#8220;ENGN&#8221; and &#8220;ENGNW,&#8221; respectively, commencing trading on November 1, 2023, with enGene Inc., a subsidiary of the Company, continuing the existing business operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for developing non-viral genetic medicines and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3cb96e7-97a4-44d8-aeed-0d9c2a1d6f34" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">117.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and negative cash flows from operating activities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0978479a-f0fa-4e78-ac3b-18af9b900e9f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">99.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended October 31, 2025, and, as of that date, has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_cae043f2-a171-4ecd-b167-405764d6f5ed" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">372.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.  The Company has not yet commercialized any product candidates and does not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. The Company will need additional funding to support its continuing operations and pursue its development strategy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any revenues and has financed its liquidity needs primarily through PIPE  financings, offering debt, and issuance of redeemable convertible preferred shares and warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In November 2025, the Company closed a public offering of its Common Shares and pre-funded warrants to purchase Common Shares which resulted in aggregate gross proceeds to the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f82416e3-36f4-477b-a15e-e8919d2ec9ae" contextRef="C_e86be109-1a95-4196-ac55-bc2ba9ae5417" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">149.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting the underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3316815-41e5-41cd-ae9f-6e07d7e386df" contextRef="C_e86be109-1a95-4196-ac55-bc2ba9ae5417" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of outstanding loans.  As of the issuance date of these consolidated financial statements, the Company expects that its existing cash and cash equivalents as of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d264e2e-3d70-4456-a41b-df5a17dbaa83" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8217;s&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are expressed in US dollars. The consolidated financial statements have been prepared on a historical cost basis, except for items that are required to be accounted for at fair value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50de1d4b-f312-443c-8765-63bc00c33c75" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the accrual of research and development expenses, share-based payments and the recoverability of investment tax credits receivable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b60fb994-9f6a-4e82-8dad-e6a030fd3d9c" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considered the Company&#8217;s organizational structure and the information regularly reviewed and evaluated by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) when deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. Based on this factor, the Company determined that it operates and manages its business as a single operating segment. As of October 31, 2025, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d55b1d13-9773-4e10-9fe6-7904e5aafa88" contextRef="C_dbc9c096-5c22-4cf5-a894-96a9e588ee65" name="us-gaap:NoncurrentAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd59a7c1-3f0f-4488-859d-3513a183611d" contextRef="C_95a2beb8-4e85-43b1-85ca-fbc18197ebed" name="us-gaap:NoncurrentAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in long-lived assets held in the United States and in Canada, respectively. As of October 31, 2024, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70a9dae2-f5ac-43d3-8c25-8ceeb3c1d14c" contextRef="C_a090e3b4-1166-4d45-b4d4-8b0b43e3f8be" name="us-gaap:NoncurrentAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca96c2cc-07f7-43eb-95d7-0a625fc0f5ed" contextRef="C_fb7a7ff2-f1d8-4421-8eee-75ddcf02c394" name="us-gaap:NoncurrentAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in long-lived assets held in the United States and in Canada, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7311aaa3-47a5-4678-af91-6fd5f7ec37bc" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk of Concentrations of Credit and Off-Balance Sheet Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. Management believes that the Company is not currently exposed to significant credit risk as the Company&#8217;s deposits were held in custody at third-party financial institutions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's investment policy limits investments to certain types of securities issued by the U.S. Government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Consolidated Balance Sheets. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78e69ec6-6adf-4dba-9e42-8b090052191a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b7bdcc-342e-41d2-9a40-b9950fb303ba" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:ConcentrationRiskCreditRiskOffBalanceSheetRisk" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_433ff012-c7f6-4ed0-8a88-198827ba8b7f" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:ConcentrationRiskCreditRiskOffBalanceSheetRisk" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> off-balance sheet concentrations of credit risk</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party CMOs and CRO with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4a5b82fa-da40-46d8-8ce7-210490764fd5" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_4a5b82fa-da40-46d8-8ce7-210490764fd5_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company&#8217;s cash and cash equivalents include bank balances, demand deposits and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_1" continuedAt="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4a5b82fa-da40-46d8-8ce7-210490764fd5_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other short-term, highly liquid investments. The fair value of cash and cash equivalents approximate the amortized cost. The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77eff14c-160a-45ff-bf4e-697dd913a97d" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents as of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19af5cc1-a8d5-4a13-9d7f-11700e1ac1bc" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">173.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents as of October 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 17, Subsequent Events, for additional discussion on the Company&#8217;s cash position following the closing of an underwritten public offering in November 2025.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52ad8183-120e-45fd-85cc-1378ee9a11d9" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's marketable securities are maintained by investment managers and consist of money market funds, U.S. government agency securities and treasuries. If the remaining contractual maturity is within one year from the balance sheet date, the marketable securities are classified as current and otherwise, they are classified as non-current assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in marketable securities is classified as available-for-sale and is reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders' equity in other comprehensive loss. Premium or discounts from par value are amortized to investment income over the life of the underlying investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically evaluates the need for an allowance for credit losses. The evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of the asset, an estimate of expected credit losses is made. The Company records credit losses in the consolidated statements of operations and comprehensive loss as a credit loss expense within other income, net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable related to the Company's available-for-sale securities is presented within prepaids and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivable associated with its marketable securities.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d554e2c5-9e24-432d-8678-1c7f9bcfa4a6" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_d554e2c5-9e24-432d-8678-1c7f9bcfa4a6_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are comprised mainly of research and development equipment, computer hardware and software, office furniture and equipment, and leasehold improvements. Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if applicable. </span><span><ix:nonNumeric id="F_e315501a-d84a-47a7-bf9e-5a22e87bce0f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" escape="true" continuedAt="F_e315501a-d84a-47a7-bf9e-5a22e87bce0f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e315501a-d84a-47a7-bf9e-5a22e87bce0f_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:56.6%;box-sizing:content-box;"/>
           <td style="width:2.48%;box-sizing:content-box;"/>
           <td style="width:40.92%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f1abe194-7ef3-4448-865d-603681a79f6b" contextRef="C_90cd8c09-4769-4823-a74e-e5e1dd36b35a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_22e3662b-fc77-4daa-9fb4-ae4df6e08cb8" contextRef="C_92d33916-bf8e-4140-a042-722d297bdb9e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_10e29c40-4622-434f-8660-d11ccf779b83" contextRef="C_1d9d7d3f-3968-47f7-af7e-dd8b5291a3a5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_84463090-482a-456d-899e-093e105cda55" contextRef="C_12fcc884-3c1c-47f6-a197-2a12844cafb2" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bc99783d-1ebf-4eca-9a63-cff208db000b" contextRef="C_3481de95-f470-4b1f-85d0-ee1e20db1594" name="engn:PropertyPlantAndEquipmentEstimatedUsefulLive"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or useful life</span></ix:nonNumeric></span></p></td>
          </tr>
         </table></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_2" continuedAt="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_3"><div><ix:continuation id="F_d554e2c5-9e24-432d-8678-1c7f9bcfa4a6_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected undiscounted cash flows are less than the carrying value of the assets, then the assets are considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_401e2cca-20d2-44a2-b463-7bdfc6e2f10f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a right-of-use (&#8220;ROU&#8221;) asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_797b38fe-a132-4931-bbe5-0eca9769ad4b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_797b38fe-a132-4931-bbe5-0eca9769ad4b_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.269%;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.13%;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></div></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_3" continuedAt="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_797b38fe-a132-4931-bbe5-0eca9769ad4b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, financial instruments measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable Securities, and Note 3, Fair Value Measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b17f7c4b-f09f-4d76-8f6a-94c5f435e01a" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:DebtIssuanceCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:12.13%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with the issuance of debt not accounted for using the fair value option as debt issuance costs. Debt issuance costs are recorded as a direct reduction of the carrying amount of the associated debt on the Company&#8217;s consolidated balance sheets and amortized as interest expense on the Company&#8217;s consolidated statements of operations and comprehensive loss using the effective interest method.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e448b552-9299-44db-b532-02398870c53b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are comprised primarily of costs incurred for our drug discovery efforts and development of our product candidates. These expenses include salaries, employee benefits, and share-based compensation expense for our research and development personnel, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside CROs and consultants to conduct research and development activities including costs of clinical trials and manufacturing, and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management estimates the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2b762cc-737e-464b-8320-0f609a59d405" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:PatentCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#8217;s consolidated statements of operations.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4c3d58ab-235b-4c30-a88b-5c8329207bef" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_4c3d58ab-235b-4c30-a88b-5c8329207bef_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an incentive equity plan (the &#8220;2023 Incentive Equity Plan&#8221; or the &#8220;2023 Plan&#8221;), whereby employees render services as consideration for equity instruments.  The 2023 Plan was adopted on October 31, 2023 upon the completion of the Reverse Recapitalization and superseded enGene Inc.&#8217;s employee stock option plan (the &#8220;ESOP&#8221;) and equity incentive plan (the &#8220;EIP&#8221;) (collectively, the &#8220;Old Plans&#8221;). The 2023 Plan was amended and restated in May 2024 and is now the Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which supersedes all prior plans. The Company measures all share-based awards granted to employees, officers, directors and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of its share-based awards as they occur. The Company issues share-based awards with service-based vesting conditions and awards with both performance and service-based vesting conditions. For share-based awards with service-based vesting conditions, the Company records the expense using the straight-line method including when such awards have graded vesting. For share-based awards with both performance and service-based vesting conditions, the Company records the expense using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management&#8217;s best estimate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company&#8217;s common shares, expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_4" continuedAt="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4c3d58ab-235b-4c30-a88b-5c8329207bef_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s expected dividend yield. The Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies with similar characteristics including market capitalization, stage of development, therapeutic focus and certain financial measures. The expected volatility has been determined using an average of the historical volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method for awards with only service based vesting conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on participant behavior. For awards with both performance and service based vesting conditions, the expected term has been determined using management&#8217;s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers.  The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the consummation of the Reverse Recapitalization, because there was no public market for the Company&#8217;s common shares, the Board of Directors has determined the fair value of the Company&#8217;s common shares based on third-party valuations of the Company&#8217;s common shares. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#8217;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering (&#8220;IPO&#8221;), or sale of the Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. In addition, the Company&#8217;s Board of Directors considered various objective and subjective factors to determine the fair value of the Company&#8217;s common shares as of each grant date, including the prices at which enGene Inc. sold shares of redeemable convertible preferred shares and the superior rights and preferences of the redeemable convertible preferred shares relative to its common shares at the time of each grant, external market conditions, the progress of the Company&#8217;s research and development programs, the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company&#8217;s common shares and redeemable convertible preferred shares, among other factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if the Company had used different assumptions or estimates or if there are changes to the unobservable inputs, the fair value of its common shares and share-based compensation expense could have been materially different.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to becoming a publicly traded Company upon the consummation of the Reverse Recapitalization, the fair value of common shares underlying equity awards is based on the market price of the Company&#8217;s common stock at the date of the grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s share-based compensation expense is recorded in general and administrative and research and development expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_5" continuedAt="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af8bdbf4-8649-4754-a543-c80fc958af25" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax basis of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8f7109e-2763-4a97-9e86-655048c0e2a7" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffb1ceb1-d4aa-4874-9d12-7ed9c390e247" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; deficit that result from transactions and economic events other than those with shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21bd9abf-192d-41fd-9670-9b625a9581fc" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if dilutive, the weighted-average number of potential shares of common shares. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and warrants. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted net loss per share attributable to common shareholders is generally the same as basic net loss per share attributable to common shareholders because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. See Note 11, Net Loss per Share, for further detail.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd350ff7-7eda-4743-9556-82027801fd4e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Transaction Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that were directly associated with PIPE or public financings as deferred transaction costs until such transaction was consummated. After the consummation of such transaction, these costs are recorded within equity as a reduction of the common share and warrants value within additional paid in capital. Costs are allocated to each equity instrument on a relative fair value basis for transactions that include both instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4834d508-0d6f-44dd-a2f4-66b71ab12627" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" escape="true" continuedAt="F_4834d508-0d6f-44dd-a2f4-66b71ab12627_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Assistance Programs for Research and Development Expenditures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (&#8220;CCPC&#8221;) on eligible scientific research and experimental development (&#8220;SR&amp;ED&#8221;) expenditures through September 2023, at which time the Company lost its status as a CCPC. In addition, effective for fiscal 2023, the Company&#8217;s maximum refundable tax credits were reduced due to the Company&#8217;s taxable capital, as defined in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Canada), which reduction in credits has been recorded in the fourth quarter.  The Canadian federal government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#8217;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. Following the loss of CCPC status, the Company&#8217;s SR&amp;ED tax credits will be earned at a lower rate and some will no longer be refundable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts received or receivable resulting from government assistance programs, including investment tax credits for SR&amp;ED, are recognized when there is reasonable assurance that the amount will be received, and all attached conditions will be complied with. Reimbursements of eligible SR&amp;ED expenditures pursuant to government assistance programs are received in cash. The amounts</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_4834d508-0d6f-44dd-a2f4-66b71ab12627_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receivable are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. During the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49bb48f1-77be-466a-904c-022698d54386" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:ResearchAndDevelopmentInvestmentTaxCredits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4d9eedb-3110-4a8c-9d22-112343011c34" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:ResearchAndDevelopmentInvestmentTaxCredits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, as a reduction of research and development expense associated with SR&amp;ED investment tax credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00c6b363-65a3-4c14-a945-229f3ed2d4c5" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-07, Segment Reporting (Topic 280: Improvements to Reportable Segment Disclosures) (&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bd69b37-e839-4332-849e-a0d6cd575d75" contextRef="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this accounting standard during the year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_388d6f61-a389-4538-8512-e790c64cd5ba" contextRef="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and there was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80c2b497-5c56-48b8-829c-33781b556a46" contextRef="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impact on the Company&#8217;s reportable segments identified. Required disclosures have been included in Note 15 "Segment Reporting".</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements &#8211; Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  which removes references to project stages and clarified when the Company is required to begin capitalizing eligible costs. The new guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. ASU 2025-06 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as further clarified by ASU 2025-01, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  issued in January, 2025, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. This ASU is effective for annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740) - Improvements to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which improves transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU No 2023-09 is effective for the Company's annual financial statements for the year ending October 31, 2026. The Company is currently evaluating the impact of the guidance on the financial statements and related disclosures.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which amends GAAP to reflect updates and simplifications to certain disclosure and presentation requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 is effective on the date on which the SEC's removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective but will not be effective if the SEC has not removed the applicable disclosure requirements by June 30, 2027. Early adoption is prohibited. The Company is currently evaluating the impact of the amendments on its financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_22e3e41f-1f79-40ee-9d2a-390d3be18c50" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_22e3e41f-1f79-40ee-9d2a-390d3be18c50_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><div><ix:nonNumeric id="F_908f696b-9f1e-479b-ba09-8f5f943b71ab" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_908f696b-9f1e-479b-ba09-8f5f943b71ab_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025:</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_22e3e41f-1f79-40ee-9d2a-390d3be18c50_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_908f696b-9f1e-479b-ba09-8f5f943b71ab_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.187%;box-sizing:content-box;"/>
         <td style="width:1.501%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.952%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.501%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.952%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.501%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.952%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.501%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.952%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable<br/>Inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd1886d1-2c04-40e2-8c64-22e79f21cf9f" contextRef="C_07c65fa0-4265-4f70-956a-00de275d630a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,642</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6fb0c0-0168-442e-944f-abdbb8a46151" contextRef="C_2cb23464-3212-4cf3-bba9-7c4d415c4691" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,642</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9565738d-d1f6-441e-b6e7-545da36c675c" contextRef="C_e68a05ca-9f3e-4035-b30c-b74ee7a7e177" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,623</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca60acd-20b3-44a8-87a7-327f124b25c3" contextRef="C_b2244905-4cf1-4e70-8b70-8a3ec973f2f0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,623</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f5548d-b794-4ee3-b145-83750c0da3fc" contextRef="C_72be055a-0ced-4c28-83d8-1cad15ae7d7f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a09f065-0757-4b79-bf28-9965cbe5e666" contextRef="C_adfc86f6-5602-4b1b-906a-2f27bffaaf91" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Short term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95315ead-a872-4941-88b8-66de4db6db3f" contextRef="C_8468fb01-e170-4276-bf5a-9ea3008dd3f2" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,467</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28e89e5e-3a30-4ef7-bded-32ee94ffe3f8" contextRef="C_72c8df98-55d0-47ed-acec-68e231220cf1" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,467</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77ca7349-33af-4640-8ac7-f8c8cc4dba11" contextRef="C_9960e19e-3a5b-4760-a0f1-d9b076862c9c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,117</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1e18db2-997f-490f-a421-7ef77ad2beb6" contextRef="C_b802882b-c5a1-4942-8e3c-1fdf4a877c1b" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,117</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Long term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04330d45-6aee-4365-809a-1f07d65881b5" contextRef="C_8f043b0a-21ae-410c-ac96-0271d3d3046e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8729a765-eea1-418c-b0bb-99e75a12325b" contextRef="C_acdf9159-83c9-485f-9bd1-02cedfa90e00" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa56693c-c372-4c55-af04-2655018b1f63" contextRef="C_ba0f02fb-b1f0-4954-bd4f-3c466d2899e1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,620</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2b3c78c-e554-4dd5-ab73-30f9fdd66fbf" contextRef="C_23618105-c2e5-4377-83d6-839699ff1b62" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,254</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0241dbd-d7f9-43c4-a524-6ea843de4b4e" contextRef="C_17b8691c-0499-4953-869d-643477e53cc9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,366</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of October 31, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.101%;box-sizing:content-box;"/>
         <td style="width:2.214%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.604000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.107%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.903000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.129%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.154%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.129%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.659%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable<br/>Inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_821517ed-2d27-43dc-b0be-8e3451b62a53" contextRef="C_2a5a88f1-1863-4ab1-bab0-60010f7bda59" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fe895f0-9c63-453d-9e16-58e77cea3531" contextRef="C_6f8ba018-3c10-4168-9540-f591cd8fe57b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98fddb90-b42f-4a16-9f2d-bc54ce60f4ae" contextRef="C_826585ba-14d9-4469-8a8b-c84065002806" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,236</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae90dbdd-de3a-498d-9942-a986a3801801" contextRef="C_b0d9509d-2cde-4f1e-a69c-e980f066e66f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,236</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a81bfa-3b0e-410d-940e-2919ba9eaed7" contextRef="C_f955235a-e265-4f5f-9d93-59b1d609f9ba" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d36c93-42c8-4325-a3ea-d285dacf5e71" contextRef="C_aa83e563-392e-4d71-8ae7-7474fd972847" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Short term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b369f127-e75c-43a8-a8d2-a8b4770b6753" contextRef="C_8544b2e4-4dc3-440f-a656-f66ca9b46e40" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,574</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad0274c9-e3a5-473f-913c-104271bb8cd9" contextRef="C_9100563f-205c-44c7-a60a-dd32fc052dd4" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,574</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7af952b1-cfd6-4df2-89fe-4a25e964289f" contextRef="C_836b6f28-be7d-407f-8a22-0e6733c24836" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,754</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77bea73c-df23-47ea-96eb-4ca99baf0912" contextRef="C_737abaae-1e0c-4f1a-8b20-7c57ad401acc" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,754</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Long term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b476333e-378e-4799-ba4e-ee89fb94cd36" contextRef="C_14c30e23-f14f-400e-a50e-517475df9be4" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49233bf7-074e-4e8d-bcb1-a2b814c1cf75" contextRef="C_3070eb61-104a-40f8-be4c-373eeb3fdf18" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ae8da9f-fb22-4dbb-a5b1-1220629900c2" contextRef="C_d6033e72-0f44-4d88-8b8a-64261e76903a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,900</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9986a295-22a1-44cb-9824-4395176669b1" contextRef="C_bc14018d-5490-4aba-a323-a2e7f4fe2e46" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,900</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e08c45a0-a23a-4560-be55-6a2aa191f604" contextRef="C_d6039d83-bedb-4265-a5ba-09c0cc735a4e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d40db76-e2ac-4b52-8190-e7c4e703a7ca" contextRef="C_6058051e-7700-494e-b243-9c348feb4b05" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,558</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ecfa440-9c07-4a94-9d16-2a4040b65cf4" contextRef="C_dc6a75d1-5e14-43f3-bdf0-8a2ea5c1463f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,609</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="bookmark_id_4d34og8"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025 and 2024, the Company classified its government agency </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arketable securities as Level 2 within the valuation hierarchy. The Company estimates the fair value of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly to estimate fair value. These inputs include market pricing based on real time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ceac9e-2bf9-4adb-8202-c752ce48b9d4" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_618c97cb-ee76-4685-a520-71ddc47b75b5" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers or reclassifications between fair value measure levels of assets or liabilities. The carrying values of all other financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span><span><ix:nonNumeric id="F_e031c48f-6a76-4e95-afd4-a99aaf19eceb" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_e031c48f-6a76-4e95-afd4-a99aaf19eceb_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Marketable securities</span></ix:nonNumeric></span></p><div><ix:continuation id="F_e031c48f-6a76-4e95-afd4-a99aaf19eceb_1" continuedAt="F_e031c48f-6a76-4e95-afd4-a99aaf19eceb_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests in money market funds, U.S. Treasury and government agency debt securities; all marketable securities are classified as available-for-sale and carried at fair value, with unrealized changes in fair value reflected in the other comprehensive income (loss) in the consolidated statements of shareholders' equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d83b0fa-2668-41ba-a5df-cf908ef5f843" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:MarketableSecuritiesTextBlock" escape="true" continuedAt="F_7d83b0fa-2668-41ba-a5df-cf908ef5f843_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the marketable securities consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.866%;box-sizing:content-box;"/>
         <td style="width:12.482%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.902000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.842%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.182%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.482000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents and short-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4dabae-5bb2-4971-9a97-0dd78f05b0bd" contextRef="C_95fa67fd-790e-4d1c-9cac-d33ccb8066a1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,642</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24ef5268-42c5-44cc-9b17-f55e2472806e" contextRef="C_95fa67fd-790e-4d1c-9cac-d33ccb8066a1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,642</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d28e0c9-f4e6-4c69-a6b6-6d2dc659e697" contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,984</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfb52b23-d952-4a02-bd89-49e75c8486fb" contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8f8cc20-5b41-441f-89b4-d078f4b0ee6a" contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ee2e013-0cc6-4c4f-8625-d47b9223e30f" contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,090</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba941484-277e-4268-a142-9c5bf0236f8c" contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,368</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f524b4-712b-408a-9154-ca7afb64df97" contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76af443d-519d-4ee9-9fea-e28d801fdc83" contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53f3ea58-fb23-4d8e-afa9-77c32bfd371a" contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,366</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40bb006b-c6ea-4450-93e1-f65af7c69a2d" contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,994</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b1d29e1-323e-45ab-90d3-065d7fbbba12" contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaff7d8d-e96e-4f91-9cfb-7549c446d027" contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd40a7a7-646d-4eec-8d97-9ac2cfb8376b" contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177,098</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe059b7-a029-4ce4-8a4a-d4c86c35c099" contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7bc2628-68c1-4d78-918c-fc6db6848e7d" contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47ec31a6-4e72-47b7-9591-650fd9d7fbfd" contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fffac9b-55d2-44f3-86b9-754fe1faf3d4" contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_275ac7f2-caea-4738-b418-2b166112b8f6" contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,498</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e1932cb-1ce3-4458-a263-11727165dffb" contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05b5e210-9d8c-4e5f-a55a-fc98d5217522" contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d00535b-dd1f-4045-93d6-84c810b5e372" contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_863b8995-9492-4199-8474-0f19015b7c06" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0513d23b-4f0b-4bf2-b5c7-91caafd80672" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf268560-7f37-45b0-8ccf-e96a9a6879e5" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a735adc1-b52c-4e83-b1af-8b12c5c92258" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,620</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government securities that had maturities of one to two years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_995c0e98-c10a-4dfc-8a2a-2e67efa9e0c1" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:NumberOfSecuritiesHeld" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_793e26e9-ff6c-4168-a641-2a4f412d94a1" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which, with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8abd8114-2922-4dfc-b5c2-e397e0528f9a" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were in unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company does not intend to sell its investments before recovery of the amortized cost basis of its debt securities at maturity and no allowance for credit losses was recorded as of October 31, 2025 because the decline in fair value below amortized cost is not related to credit losses. Securities are evaluated at the end of each reporting period. The unrealized losses on U.S. Treasury and Government agency securities range fr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">om </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c891dc0f-5208-44ba-8841-adcd2a246bab" contextRef="C_ce39e6a1-222d-49f4-96cc-9cfa2d2ac439" name="engn:DebtSecuritiesUnrealizedLosses" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84efb795-c486-4200-8922-fa405ee62ad5" contextRef="C_d39e4cc1-c2c2-436d-91fe-df2f1f3ae461" name="engn:DebtSecuritiesUnrealizedLosses" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their amortized cos</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_7d83b0fa-2668-41ba-a5df-cf908ef5f843_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024, the marketable securities consisted of the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:45.851%;box-sizing:content-box;"/>
         <td style="width:5.972%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.467%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.588%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.205%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.677%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.773%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.677%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.786000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents and short-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cf91dc5-f6d7-4cd3-986d-04ff0030a72d" contextRef="C_9a033399-2b58-4fe0-8140-e6817c28119b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a22628ab-f3e1-411e-8cc3-2e28b9ab5c3d" contextRef="C_9a033399-2b58-4fe0-8140-e6817c28119b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40931a6b-6106-4b4c-9877-3e9da78dd045" contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,832</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eeeb7ee-6927-43cf-8d5f-48d79cf54cd7" contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a89858d7-3de1-4da0-8197-c92b96477e9f" contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a715fec-14c6-4cac-908d-6476d4a2a313" contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,814</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26792223-5564-4197-9823-41ba099c8b99" contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,714</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bafeaaa-e124-4950-adef-f5533dbe3a72" contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24fcb385-cbc9-4bb8-af5d-0616979b0c0e" contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f70bb10b-b7c5-46bc-8ddf-75f44be6193b" contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,709</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bae295cc-0ead-466f-8c3a-e9d2999918b8" contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,667</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2304e518-f627-4a36-af99-d1d5f02ef3ed" contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_976ca6fd-f833-4845-9ace-e3f2b3bfd222" contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b80e80d8-ec8f-437f-91bb-cb9b3afe702e" contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,644</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50dd1d04-fd4f-4399-9a9f-3cb7390afccd" contextRef="C_8048b9df-5cd2-4254-af6b-1df01215dbd0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,931</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ffedba5-92cb-4bba-9d5b-933f193d0a64" contextRef="C_8048b9df-5cd2-4254-af6b-1df01215dbd0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19e198db-b901-45dd-b5bb-43356d18ced0" contextRef="C_8048b9df-5cd2-4254-af6b-1df01215dbd0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ec1b2fc-d337-42f3-87f0-fc72e918af9e" contextRef="C_2e90c670-46cc-4848-9919-7cce02e258fc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,972</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36ce65e8-8546-4a18-99ea-78e408fc8910" contextRef="C_2e90c670-46cc-4848-9919-7cce02e258fc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c319bb0-8dc5-4875-9b83-d7abf06480cd" contextRef="C_2e90c670-46cc-4848-9919-7cce02e258fc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,898</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f01b62ec-6a63-4563-b2b8-16601e65851e" contextRef="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,903</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdff65a3-4ee6-4f77-91bb-52c86150d1c9" contextRef="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">380</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0330b0d-8a3c-43ae-9711-63fae975805b" contextRef="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,523</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ae65f6c-151b-4715-a28e-c0043184dee4" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,570</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e534ffd-60a6-42bc-ae81-ea9d9712f7a6" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c1a5ec9-3e25-4a40-9da6-8a75e1450f31" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">418</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5dca2d1-7791-43b3-8909-883a74a434d3" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e031c48f-6a76-4e95-afd4-a99aaf19eceb_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for certain government agency securities that had maturities of one to two years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a360d5-9726-4847-8c6c-e06bd90847d4" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:NumberOfSecuritiesHeld" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01dbbc0d-9da0-453e-a0d2-565c332e80d7" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which were in an unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company does not intend to sell its investments before recovery of the amortized cost basis of its debt securities at maturity and no allowance for credit losses was recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024 because the decline in fair value below amortized cost is not related to credit losses. Securities are evaluated at the end of each reporting period. The unrealized losses on U.S. Treasury and Government agency securities range fr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">om </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a40153b-fe27-4cc8-9628-f2733c654147" contextRef="C_9de67a6b-db13-4cab-b973-3dc0f4942c58" name="engn:DebtSecuritiesUnrealizedLosses" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7803da37-d7a7-4faa-8918-c8682aaaf402" contextRef="C_8d237d2e-9003-4d50-b804-e95a6312f01a" name="engn:DebtSecuritiesUnrealizedLosses" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their amortized cos</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable on the Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e95588c3-c714-4f9f-bfa1-4e84f1995499;"><span style="-sec-ix-hidden:F_f4615be1-4ad1-4aa9-9576-91c98e5813d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available-for-sale</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> debt securities totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f3e6d6-553f-4c32-bb46-43ba7abac3f5" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67e1a8d1-e826-4ee9-8ee5-51b2b9ac136f" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and was presented within prepaids and other current assets on the Company's consolidated balance sheets. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833d56dd-2671-4c0c-8fa6-e57d7a86ca43" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="engn:AccruedInterestReceivableWrittenOff" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a231c574-fa2c-44c9-817f-ab7a3745336f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:AccruedInterestReceivableWrittenOff" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest receivable was written off during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended October 31, 2025 or 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d69636eb-cc26-4265-90b1-d9e2af5f7b2c" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_72a94009-6075-426d-b789-38b416241c66" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> material realized gains or losses recognized on the sale or maturity of available-for-sale securities during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 or 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2d313ff-33c7-4b7c-9f8f-ceea983c59ee" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49987718-3698-4a69-b3d4-de250bd712ff" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, property and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f285437-b0b5-44e1-b949-d7f0e0356944" contextRef="C_496e94d8-a257-4d69-8ba6-932806871284" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,134</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eefd6f7-ecd3-4e69-87b0-349c27e4dbdd" contextRef="C_7edc548a-2b6b-40d9-9585-f8a98c0a4267" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,191</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b97f7e3-3fad-4bb3-b65c-43630dbad9a7" contextRef="C_92d33916-bf8e-4140-a042-722d297bdb9e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_551ca416-20d2-4d07-bbfa-346fe8f6c0ee" contextRef="C_951877f3-5e88-4367-9785-1d7884a66f77" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1751257c-61d0-4b1b-8941-7f3240bd3b9b" contextRef="C_1d9d7d3f-3968-47f7-af7e-dd8b5291a3a5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b45aa7a2-6319-42e7-9d71-762574b19696" contextRef="C_57ae8deb-9706-4aaa-ab1d-e9fc280a2c06" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45b7d78c-9de9-4634-8eff-cad1ebade39c" contextRef="C_12fcc884-3c1c-47f6-a197-2a12844cafb2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_855eaa39-328b-478a-88f4-8bd6e917cc1c" contextRef="C_250a9087-119f-4c5b-bf49-75a14a4e74b9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4daaa366-b817-4e13-8f90-5c629a1fe90d" contextRef="C_f4a3d6cf-e574-4cf3-b8ec-df2947d5c514" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dd2a806-f54a-4f02-9d61-d5b57b55f788" contextRef="C_e3642777-e12d-430b-aa3d-219b649d5144" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a51d241-5114-47e0-b702-965860ec8fb2" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,580</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_167a078c-8445-47bc-8482-160dfc8a8786" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,779</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f34b2bfd-079b-486b-9b3d-8cf6b2cf06f8" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,103</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dabff87f-0877-4945-820d-92e3526f429a" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,610</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e1918b4-24ac-410d-aedf-e420ff1fc511" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af5ab5b5-145b-422f-8342-eb665bfa5128" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,169</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense related to property and equipment was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0032fd1-8e1d-4a35-803d-07d6e1e5273d" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ef83346-8211-414f-96e8-a36caae26a97" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_6ce767ca-f131-4acb-bb83-592adaa4833e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f98531a7-c321-477b-bd0d-de334bb037a5" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_f98531a7-c321-477b-bd0d-de334bb037a5_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, accrued expenses and other current liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbb51fa0-f7b2-4f88-b2e0-8a427e9892f3" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,397</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e371f566-c75f-4fb3-8035-d2f79dd693fd" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,773</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d001346-6355-4a81-8298-3bacf72b1255" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,053</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b73f32d5-007c-42ce-ae68-807f916694f3" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,475</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_990c2ba9-433e-48ca-8f25-c76a574d364a" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,229</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8d4368-add4-4453-8ea4-64837f31ceee" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">824</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income taxes payable</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d115ea0-0193-4248-bafd-c33e6d5a7edd" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued financing costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_979422fb-fcc6-4ec9-8c0a-29492e938521" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:AccruedFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b70203d-e608-4266-9fac-eb2d87fdd651" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">577</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8b8ab7f-4057-4fa2-9a47-8435c75ca867" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e1b53ce-5c48-4b3d-807b-e4c8229439f9" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,275</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a31c1c1-a01e-4e8c-aa6e-8216972bdbe6" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,128</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_f98531a7-c321-477b-bd0d-de334bb037a5_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_c08ac348-dbb7-439f-9998-0392fe2bf744" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock" escape="true" continuedAt="F_c08ac348-dbb7-439f-9998-0392fe2bf744_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. License Agreement and Clinical Research Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement &#8211; Nature Technology Corporation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 10, 2020, the Company entered into a Non-Exclusive License Agreement (the &#8220;License Agreement&#8221;) with Nature Technology Corporation (&#8220;NTC&#8221;) whereby the Company licenses certain rights to Nanoplasmid</span><span style="color:#231f20;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> technology from NTC for commercialization. Under the terms of the License Agreement, NTC granted to the Company and its affiliates a non-exclusive, royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c08ac348-dbb7-439f-9998-0392fe2bf744_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can voluntarily terminate the license agreement with prior notice to NTC.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid NTC an initial, upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3eeee6b-bc4f-48ad-82d8-bbb03d4aa868" contextRef="C_511e94d5-ac9c-4c2e-b367-c6033fb69299" name="engn:UpfrontFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33832838-7f86-4b30-b0f3-3e84bd188777" contextRef="C_019c08b7-c82a-486b-871e-9cb94b318c49" name="us-gaap:CostMaintenance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand annual maintenance fee. The Company is also required to make a payment to NTC of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49e4cd7c-7afb-4db2-9739-f5320aca7af9" contextRef="C_019c08b7-c82a-486b-871e-9cb94b318c49" name="engn:PaymentOnAssigningLicenseToThirdParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand upon assigning the License Agreement to a third party.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The License Agreement provides for a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f814160-a41c-48ab-af09-697d053244bc" contextRef="C_4d97d0f0-4a5b-489c-b7d4-521214e77828" name="engn:MilestoneProductPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand for the first dose of a milestone product, as defined in the License Agreement, in the first patient in a Phase 1 clinical trial or, if there is no Phase 1 clinical trial, in a Phase 2 clinical trial, as well as a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1afd68e5-99ae-4a93-b0f0-378cd11733b9" contextRef="C_d24afdca-87cb-498a-960f-4be785980006" name="engn:MilestoneProductPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a milestone product, has not yet been achieved as of the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> year ended October 31, 2025. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by the Company, its affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (&#8220;GMP&#8221;) lot of a product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During each of the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8edda7d-9fc1-4094-853a-d7b83f354dd7" contextRef="C_d7356f23-a631-4161-bd89-54fd825f3f25" name="engn:AnnualMaintenanceFeeUnderLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e649768b-6947-488e-b564-4c088e22abb3" contextRef="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3" name="engn:AnnualMaintenanceFeeUnderLicenseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand of expenses related to the annual maintenance fee u</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nder the License Agreement. During the year ended October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred a fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faa4aff0-d91d-4960-a7e2-8d0d2a40de9b" contextRef="C_d7356f23-a631-4161-bd89-54fd825f3f25" name="engn:ManufacturingPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to the manufacturing payment under the License Agreement. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb076f8d-b8ff-427a-a1c0-799bfbb8a99b" contextRef="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3" name="engn:ManufacturingPaymentFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fees related to the manufacturing payment incurred during the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">year ended October 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All expenses related to License Agreement are recorded within research and development expenses.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_41bbb02e-2a66-4784-87f7-646fcfd9e383" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_41bbb02e-2a66-4784-87f7-646fcfd9e383_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Notes Payable</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended Loan and Security Agreement and the First Amendment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 30, 2021, the Company entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. ("Hercules") for the issuance of a term loan facility with an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8e78777-7f58-464d-b516-8ae52488f7ae" contextRef="C_33a6f084-8206-471e-bfb2-2dda7584d4c7" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Prior Term Loan&#8221;). On December 22, 2023 (the "Hercules Closing Date"), the Company entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement&#8221;), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (the "Lenders"). The Amended Loan Agreement amended and restated in its entirety the Prior Loan Agreement. The Amended Loan Agreement provides for a term loan facility of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34bc8c69-8476-4488-a0e3-f16a2cb6d0b7" contextRef="C_82ca66af-1e97-4ce0-adab-8cffb3acd9a1" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available in multiple tranches (the &#8220;Term Loan&#8221;), as follows: (i) an initial term loan advance (the &#8220;Tranche 1 Advance&#8221;) that was made on the Tranche 1 Advance closing of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a934d2ac-c7e5-41f3-8c41-979d57885701" contextRef="C_585ec894-b0e7-4859-a0a7-ccf1f76d9512" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e6796f4-12dd-4385-860c-63e27d1e7c9b" contextRef="C_53d55f9a-d671-4a03-878e-e8d7b35cee90" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the &#8220;Interim Milestone&#8221;), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical evaluation of detalimogene in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36d663a2-2624-4989-abe1-63d27007aaab" contextRef="C_d8109dad-b66f-4bfb-8c04-ce50e140908e" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the date of achievement of the Interim Milestone through the earlier of (x) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b55ce675-4857-4445-a218-5e781adfe0a6" contextRef="C_7a8c2031-7a18-435b-80ce-180a745a581b" name="engn:PeriodWithinLoanDisbursementsToBeMade" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days following the achievement of the Interim Milestone and (y) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1081b53e-19b2-45fd-856f-c51e10b53e74" contextRef="C_7a8c2031-7a18-435b-80ce-180a745a581b" name="us-gaap:LineOfCreditFacilityExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) an uncommitted tranche subject to the Lenders&#8217; investment committee approval and satisfaction of certain other conditions precedent (including payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ebf5d91-f8c3-466a-bb9c-00cf0cf7491e" contextRef="C_4b5f63d4-ae44-4d1f-a429-c2500140c1cd" name="engn:PercentageOfFacilityChargeOnAmountBorrowed" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (as defined below) that the Lenders make additional term loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_826d3b68-ada2-4145-964a-0d3bc02cd2b6" contextRef="C_b1f2b3cc-0e10-4b83-bbb6-a450052ce673" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company is required to pay upon the earlier of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f819d7d0-0fbe-426d-b07d-e9ae4ec89519" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="us-gaap:LineOfCreditFacilityExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ( the &#8220;Maturity Date&#8221;) or payment in full of the Term Loan, an end of term fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_781e0a65-31bb-462d-9e52-278c355404e2" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:EndOfTermFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate principal amount of the Term Loan (the &#8220;End of Term Charge&#8221;). The Company was also required to pay on July 1, 2025 or, if earlier, the date the Company prepays the Term Loan, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b7a01ba-f789-4db6-bb8d-4d0859822163" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:EndOfTermCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million representing the Prior Term Loan End of Term Charge (the "Prior Term Loan End of Term Charge" and "End of Term Charge", collectively the &#8220;End of Term Charges&#8221;).</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_41bbb02e-2a66-4784-87f7-646fcfd9e383_1" continuedAt="F_41bbb02e-2a66-4784-87f7-646fcfd9e383_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan.  As a result of the extinguishment, the Company recorded a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc6952e5-3c14-4943-a015-392ec1d69b55" contextRef="C_2d71d180-d7f1-445c-a569-e1c8106caa03" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as a component within other income and expense in the Company's consolidated statement of operations during the year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> October 31, 2024, which represented the difference between the reacquisition price of the debt, including fees and the initial fair value of the warrants paid directly to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 18, 2024, the Company entered into a First Amendment to Amended and Restated Loan and Security Agreement (the "First Amendment") with the Lenders. The First Amendment modified the Amended Loan Agreement to reallocate the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_920dc01b-0c09-492f-8360-c064355ac401" contextRef="C_1880048e-dcab-455d-8f72-b54f37487a7f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million previously available under Tranche 2 (as defined in the Amended Loan Agreement), which was not drawn by the Company upon achievement of Interim Milestone, to Tranche 3 (as defined in the Amended Loan Agreement). Pursuant to the First Amendment, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dfc6a7f-00bd-4bc7-89de-7bf5e2704e39" contextRef="C_1ab78818-5433-4a11-a36e-d0983a8bfc04" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million advance originally available upon achievement of the Interim Milestone was added to the uncommitted tranche subject to the Lenders' investment committee approval and satisfaction of certain other conditions precedent (including payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb09036e-b1f6-4860-a0a2-7929e1c43b34" contextRef="C_16b7f663-ad41-48cc-9a93-5b7ab3af3b3d" name="engn:PercentageOfFacilityChargeOnAmountBorrowed" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% facility charge on the amount borrowed), pursuant to which the Company may request from time to time that the Lenders make additional loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_965e0b12-8569-4c2a-b63b-337a47561f87" contextRef="C_ba4e1c8a-00ae-49f4-b36b-9c45988805ec" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The First Amendment did not change the total term loan facility available to the Company of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75009499-d7b1-438e-920a-b2027053a5d7" contextRef="C_2570dccd-3edb-4845-9c23-2fa20a3e119a" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The First Amendment further provided for certain administrative changes in accordance with the foregoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49accc30-7191-42d0-a88e-b4205a8b5f56" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date (as defined in the Amended Loan Agreement); (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_216cc0bd-350c-42ea-9bb5-3f25a86218a4" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32a44552-8a84-49f8-be6d-5868e887a099" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31418db8-add9-4511-94c7-3f48476f8c79" contextRef="C_c587a04c-25a3-434a-9114-e2f1c6ee0c74" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Amended Loan Agreement and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_087e442c-18f4-44b4-932d-3374cc18da4f" contextRef="C_c587a04c-25a3-434a-9114-e2f1c6ee0c74" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The remaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae8157a4-5024-4a86-9dec-4df139da9d54" contextRef="C_10beb209-82d9-44f1-a81c-c930ac6ffa93" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the uncommitted tranche subject to the Lenders&#8217; investment committee approval and satisfaction of certain other conditions precedent described above remains undrawn and available to the Company. The Prior Term Loan End of Term Charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e62069-e997-44ef-958c-82238000fd7a" contextRef="C_3a4ac89a-0177-4b3c-8437-70136929db99" name="engn:EndOfTermCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid during the year ended October 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4394cfa-9517-46fa-8508-88aeb275aaf2;"><span style="-sec-ix-hidden:F_33e08b81-4198-434a-9055-c3013033bffd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wall Street Journal</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_214ae661-02b8-43f5-8f44-4759fbf42214" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (capped at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4bab882-571d-46f5-be29-b523772b04fb" contextRef="C_7460771b-4637-42ae-b87f-8329a24ece3d" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66cb87d9-518f-41d7-9e67-21d83e6163a2" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The Term Loan also bears additional payment-in-kind interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13269210-9b7d-42a1-8c37-ea0e41c59f6f" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:PaidInKindInterestPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement, as amended by the First Amendment, are repayable in monthly interest-only payments through the "Amortization Date", which is either: (x) if the Interim Milestone is achieved and there has been no default, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4c04645-8587-4c17-9ae4-59adfd7ed81b" contextRef="C_9e49cbbf-65d1-430d-a687-9171f3246a39" name="engn:LoanAmortizationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (y) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e48f793a-bd15-4435-8070-335db50578be" contextRef="C_4051c11c-5290-47d7-8e2a-b368974acadb" name="engn:LoanAmortizationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 1, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. After the Amortization Date, the outstanding Term Loan and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the Company has achieved the Interim Milestone but has not yet achieved certain clinical milestones. Amounts payable on January 1, 2026 were classified as current liabilities on the consolidated balance sheet for the year ended October 31, 2025. The effective interest rate of the Term Loan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc7622ee-07ee-426e-b4bf-56363e1c0704" contextRef="C_5cb5ff87-3b6e-4f62-bafd-e58f084904c6" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dfdd88eb-1b3d-4064-92ec-232fced0b996" contextRef="C_9e58f68c-6bc3-4806-9dbe-08a741a6dfa0" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">11.63</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of October 31, 2025 and October 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Amended Loan Agreement, as amended by the First Amendment, the Company granted Hercules a security interest senior to any current and future debts and to any security interest in all of the Company&#8217;s right, title, and interest in, to and under all of the Company&#8217;s property and other assets, subject to limited exceptions including the Company&#8217;s intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Loan Agreement, as amended by the First Amendment, contains negative covenants that, among other things and subject to certain exceptions, could restrict the Company's ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement, as amended by the First Amendment, also contains certain events of default and representations, warranties and non-financial covenants of the Company. The Company is in compliance with the financial covenants at October 31, 2025 and October 31, 2024.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_41bbb02e-2a66-4784-87f7-646fcfd9e383_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hercules Common Share Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Amended Loan Agreement, as amended by the First Amendment, the Company also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of the Company&#8217;s common shares, as shall be equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd22e2d5-2349-4b8f-8c9d-0aa9cac0d685" contextRef="C_60f8a68e-e8da-4f5f-bc60-1c69892ea749" name="engn:PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate principal amount of such Term Loan advance divided by the Warrants per share exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c76abd2-55e2-4773-8c9c-39f2a54cedad" contextRef="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (which exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary adjustments under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_350594af-ecf7-40c1-aeaa-62fd200c22f5" contextRef="C_60f8a68e-e8da-4f5f-bc60-1c69892ea749" name="engn:ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Amended Loan Agreement, as amended by the First Amendment, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_576e003e-6916-42c7-86af-c8fb90190b7a" contextRef="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">138,696</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (i.e. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8084523-0b85-46c0-a9bd-205b19897fd3" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:PercentageOfCommitmentAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96028f8f-9ed3-47f8-957f-ddf496a6a8c1" contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2" name="engn:CommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million total commitment amount divided by the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b21e44-cfc1-443c-a777-f322710e7bb1" contextRef="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> price specified in the Closing Date Warrant), assuming no adjustments are made under the terms of the Hercules Common Share Warrants and further assuming the full amount of Term Loans are drawn. On the Hercules Closing Date, the Company issued to the Lenders </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8658d3b0-9570-47fe-b877-af758d62a659" contextRef="C_82ca66af-1e97-4ce0-adab-8cffb3acd9a1" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">62,413</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans (the "Closing Date Warrants"). </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Closing Date Warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#8217;s common shares as prescribed by ASC 815. Upon entering into the Amended Loan Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f54619-d0ab-4d26-b7dc-b6c751a421de" contextRef="C_41ba9c19-6515-43e0-a1fc-8f4d1b65dd7a" name="engn:AdvanceOnLoanAllocatedToWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_091d9848-9e54-46d7-814a-6243f749328b" contextRef="C_61fa00a4-8a04-41ad-8df5-3d8df9828b01" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million Tranche 1 Advance was allocated to the warrants, on a relative fair value basis, and recorded within additional paid in capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequently issued Hercules Common Share Warrants shall be substantially in the form of the Closing Date Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a957f75f-63ff-464f-9678-7ce984f6ec84" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, the carrying value of the Term Loan consists of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, including End of Term Charge</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3698c055-b94e-4ea0-9c7c-07a975274959" contextRef="C_0a196932-bb45-4e51-825a-16dde720a445" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,231</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d5a7939-208f-48f4-9732-3a7396bc4ccf" contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,663</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount, net of accretion</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c64a7fc0-15b7-4962-9f84-5c8e1c7b1a37" contextRef="C_0a196932-bb45-4e51-825a-16dde720a445" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,088</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04301955-ced4-4787-b7b1-ed842b2eac33" contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eed63f5f-bde9-4f6c-af0e-f88b7db29b1a" contextRef="C_0a196932-bb45-4e51-825a-16dde720a445" name="engn:DebtInstrumentAccruedInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4615a15-face-420c-85b5-0a215e7de725" contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57" name="engn:DebtInstrumentAccruedInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, net of discount</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34c5b482-9911-4c6f-b65f-5a3730b7a59e" contextRef="C_0a196932-bb45-4e51-825a-16dde720a445" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,326</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72a8877-08b9-4897-a501-b21bc2b47206" contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,172</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company classified </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f4273d4-6965-4c78-9bd4-484951c21e05" contextRef="C_3b8bd64e-b59b-43a4-b1b4-0519c994f6b0" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the note payable as current. As of October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company classified $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2937af0-00f2-413a-8668-7c9cc730f26b" contextRef="C_e80bdb47-f7b3-430d-b4e8-f25af73e859c" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the note payable as current, which represented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the back-end fee associated with the refinancing of the Prior Term Loan. During the years ended October 31, 2025 and 2024, the Company recogni</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">zed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7e84173-8ff7-4e6d-b2e6-c4d9f3fec416" contextRef="C_d4f15817-44dd-435d-b9a9-e963c46bff1a" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9e63aad-8f86-41da-ab6d-fa173fb80dea" contextRef="C_e2f37cd3-8f14-4485-8a97-18812aba3d4b" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense related to the Amended Loan Agreement, respectively, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42aeebc5-4f4f-4c44-9228-8f73f4c86c09" contextRef="C_d4f15817-44dd-435d-b9a9-e963c46bff1a" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d7dd9fee-d8e5-4442-9a3d-3c5d7b0471c1" contextRef="C_e2f37cd3-8f14-4485-8a97-18812aba3d4b" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million each year rel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ated to the amortization of the debt discount.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea05e68e-cdd0-4aba-9a8b-f7d4c7b8eada" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge, are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.757%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Note Principal<br/>Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0132ce15-d30e-4d23-b731-154939b7c52d" contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,417</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6da7f249-e5b9-4253-bcc2-a23b3d3be88b" contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,987</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9259d12-719a-4866-b0b7-030890d2bf88" contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal payments, including End of Term Charge</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3227fb0d-ff3f-4f47-acc4-5118675658df" contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,565</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, management believes that the carrying value of the Company&#8217;s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value based on the consideration of the Company&#8217;s credit risk and terms of the borrowing from Hercules.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_0120a786-9495-4129-af76-0ee33334521e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_0120a786-9495-4129-af76-0ee33334521e_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0d8e6fbe-0e8d-48be-94c6-063543d24362;"><span style="-sec-ix-hidden:F_c36c748c-142e-4749-b840-fae3cd22d5a5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unlimited</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> number of authorized shares of Common Shares, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390373e5-d1a4-4244-a3b7-2233b24f7e26" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8dbebe7a-a647-4b09-b7b2-60a24c7eebf7" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value.  As of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024 there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b66649e4-6bf8-4fcb-93be-76b4ac4d9b3c" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">52,018,658</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a75bbede-c41f-469b-a0d8-b903df383ab1" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,976,676</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares outstanding, respectively.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0120a786-9495-4129-af76-0ee33334521e_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a800d77-ca24-4b19-9596-d6197375145b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Shares are entitled to one vote</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each Common Share held on all matters submitted to a vote of shareholders. Common shareholders are entitled to receive dividends, as may be declared by the Board of Directors, if any, subject to the preferential dividend rights of preferred stock. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eecdbf5d-4184-40f1-a5e6-b739998667a2" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_820f45ad-97ea-4e78-845b-0223982b1f1c" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CommonStockDividendsPerShareCashPaid" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends had been declared or paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2024, the Company entered into subscription agreements (collectively, the &#8220;February 2024 Subscription Agreements&#8221;) with the investors named therein, for the private placement (the &#8220;February 2024 PIPE Financing&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5495583b-8f32-42b9-995c-154066cb1d83" contextRef="C_d3a16e6c-5f2f-46a8-8d4a-ae4459f30236" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares of the Company, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ac1afd9-6ba0-4c6b-94af-df2d4fe27b22" contextRef="C_4d87523c-9b2c-422b-88ab-47f28876bac5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The aggregate gross proceeds from the February 2024 PIPE Financing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e90723d8-38ff-4c12-933f-819697e1edff" contextRef="C_de15de3c-d6dd-474f-aedc-0db5998ec164" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32eb44e7-ea23-4473-b6b1-53dcd3e274c7" contextRef="C_de15de3c-d6dd-474f-aedc-0db5998ec164" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The February 2024 PIPE Financing closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ce4449f-1541-4471-8325-a3c9043b3754" contextRef="C_25dc3fbd-7df8-4e6a-9735-4c158848064d" name="engn:DateOfClosedPrivatePlacement" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 20, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 24, 2024, the Company entered into subscription agreements (collectively, the &#8220;October 2024 Subscription Agreements&#8221;) with the investors named therein, for the private placement (the &#8220;October 2024 PIPE Financing&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6220781-7984-4ac5-a0cc-c2a3ccd9ce2d" contextRef="C_84f13fed-94e2-4af5-bddf-2b0f45ef17c7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,758,311</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares of the Company, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cc66096-0948-4738-b8be-fe6798517550" contextRef="C_223bc65f-a711-41ae-93e5-990ae4cc4647" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The aggregate gross proceeds from the October 2024 PIPE Financing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_949299e9-a441-4850-ae7c-ff5c4522247f" contextRef="C_1bd63320-3f8c-40e8-870a-a2cdeaa9bc46" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b00a970f-006e-42ad-b3a7-03bf9e7fae2c" contextRef="C_1bd63320-3f8c-40e8-870a-a2cdeaa9bc46" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The October 2024 PIPE Financing closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0428955-3bf1-456a-8f92-5b3254b12d70" contextRef="C_3fc74f8e-4433-476f-a81c-1803cf2f12f5" name="engn:DateOfClosedPrivatePlacement" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 29, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 20, 2024, the Company entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Jefferies, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeb39b11-4f46-402f-aefa-bb1e7f832188" contextRef="C_cdad3c31-b6c0-4967-959f-1627e8533147" name="engn:MaximumAmountOfCommonSharesToBeSold" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Common Shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay Jefferies a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2be7e234-8d4b-444f-a4cd-4b0b7196c9d7" contextRef="C_cdad3c31-b6c0-4967-959f-1627e8533147" name="engn:PaymentOfMaximumCommissionPercentageOfSharesSold" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of Shares sold pursuant to the Sale Agreement, and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any Shares under the Sale Agreement. The offering of the Shares pursuant to the Sale Agreement will terminate upon the termination of the Sale Agreement by Jefferies or the Company, as permitted therein</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Through October 31, 2025, the Company sold no Common Shares under the Sale Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants to Purchase Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e170192b-d238-405a-b5b3-564375350a23" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f681d19a-9ded-4748-8f88-143e49b551cf" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,511,968</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase common shares outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the warrants to purchase Common Shares outstanding as of October 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9120922d-14a0-4367-81eb-995fc07d045d" contextRef="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,449,555</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_205f8788-3f25-41c2-bc18-7d3a96332ffa" contextRef="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and are exercisable through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1be12e7f-c0d7-474a-97a6-f6a539047e8e" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company may elect to call in the warrants for redemption if the share price of the Company equals or exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38493243-540a-4a61-86d8-7032f02c6ba9" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for any twenty (20) trading days within the thirty (30) trading-day period ending on the third (3rd) trading day prior to the date on which notice of the redemption is given, subject to adjustments as provided in the terms of the warrant agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#8217;s common shares as prescribed by ASC 815.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The additional</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dea4462e-e8b1-47a1-ad6f-b831b59bb6c1" contextRef="C_e3f5dd26-8cbb-49ba-947e-3a9d2312c431" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">62,413</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the warrants to purchase Common Shares outstanding as of October 31, 2025, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were issued as part of the Amended Loan Agreement on December 22, 2023, have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d831c59b-c0f7-47f2-963e-e6c2325cc9c6" contextRef="C_6e273bec-7bf2-4681-92db-741ae2a453db" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.21</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are exercisable at any time beginning on December 22, 2023, and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_258b8932-f7b5-40c0-9227-113343afa494" contextRef="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 22, 2030</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4baf0293-0e88-44c4-9cbd-b6f227889e5a" contextRef="C_416f76a5-c88c-4d57-baa6-382632288e13" name="engn:WarrantsAndRightsOutstandingMaturityPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the issuance date. The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#8217;s common shares as prescribed by ASC 815. Please refer to Note 10, Share-Based Compensation, below for the summary of the Common Shares reserved for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under and outside the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 17, Subsequent Events, for a discussion of Common Shares and pre-funded warrants to purchase Common Shares issued by the Company pursuant to an underwritten public offering in November 2025.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan") was adopted on May 15, 2024 and superseded all prior plans. The 2023 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board, (the "Committee"). The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b63fc562-d2e9-4450-874a-2c0aace5bdd8" contextRef="C_f3d38713-54b7-4d7a-9bcd-88b4b937d366" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the fair market value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_1" continuedAt="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Common Shares on the date of grant and the term of stock option may not be greater than ten years. Common Shares that are expired, terminated, surrendered or cancelled under the 2023 Plan without having been fully exercised will be available for future awards. The Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Stock Units, Stock Appreciation Rights, or SARs, and other share-based awards including performance awards and share bonus awards. The Plan contains the evergreen provision (the "Evergreen Provision") pursuant to which on the first business day of each calendar year, the aggregate number of Common Shares that could be issued or transferred thereunder (the "Plan Share Reserve") and the number of Common Shares available for options intended to qualify as incentive stock options (the "ISO Sublimit") each increase by such number of Common Shares  as equals </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e0bca04-cc69-4968-85e5-6708c6cdf156" contextRef="C_230bfa79-c42e-4689-8d7a-7064e8c335b7" name="engn:CommonSharesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of Common Shares outstanding on the final day of the immediately preceding calendar year (or such smaller number of shares as is determined by the compensation committee), and the ISO Sublimit by the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2789cf0d-e611-4352-8c4c-7f8abcdce967" contextRef="C_230bfa79-c42e-4689-8d7a-7064e8c335b7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares and the increase in the Plan Share Reserve (or such smaller number of shares may be determined by the compensation committee of the Company&#8217;s board of directors). On January 2, 2025 the Committee allowed the full </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37d8be66-4336-40bd-84f7-241beb84620a" contextRef="C_7fc54fca-2826-4f40-b784-cb10a1e8ea92" name="engn:CommonSharesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% increase for 2025 under the Evergreen Provision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, inclusive of (i) the common shares subject to the outstanding grants under the prior plans, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16b6364f-6c62-4f58-9895-c8da2578aa21" contextRef="C_19e56deb-53a4-4d6b-948d-09e6e90bcf8f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,548,833</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares added on January 2, 2025 under the Evergreen Provision, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">re were </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_641a52b4-3497-4f31-9c94-e17d34d3d587" contextRef="C_19e56deb-53a4-4d6b-948d-09e6e90bcf8f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,651,209</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Common Shares reserved for issuance under the Plan and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81503c32-f5f4-4bcf-91f6-7d6151a14f8c" contextRef="C_04e07ed1-3cb5-4c02-a2a7-c7099d04d3e7" name="engn:CommonStockCapitalSharesReservedForRemainingFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,933,304</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining for issuance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 10, 2025, at its 2025 Annual General Meeting of shareholders, the shareholders of enGene Holdings Inc. approved the adoption of the 2025 Employee Stock Purchase Plan  (the "ESPP&#8221;), pursuant to which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36068c67-c47e-446e-9741-6932e9abbb25" contextRef="C_4ff723b5-d287-434b-a696-ec3b9aa13f72" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares of the Company, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81c465e5-5ba7-479b-be65-773a0da7db7a" contextRef="C_4ff723b5-d287-434b-a696-ec3b9aa13f72" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value, were reserved for issuance. The price of common shares purchased under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b918822f-7ecd-4d1c-9365-7fb0b5b4de87" contextRef="C_8e9a0825-260c-4b9d-90b7-bbd7617e8f5d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the common shares on the first trading day of the offering period or the relevant purchase date and is subject to change by a Plan Administrator prior to each purchase period. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deb243ba-ed74-49b0-8fb8-8d1f76666c68" contextRef="C_6394b714-e543-43ff-9b1c-7ba9b8f9d298" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9094f252-03fe-4ecb-bc30-df743db15173" contextRef="C_6394b714-e543-43ff-9b1c-7ba9b8f9d298" name="engn:CommonStockCapitalSharesReservedForRemainingFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may grant inducement equity award consisting of a non-qualified stock option to purchase Common Shares to newly hired employees as an inducement material to the employee's entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4), which, if made, are granted outside of the 2023 Plan. During year ended October 31, 2025, the Company issued options to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3e73d4e-69ad-40c1-8f58-b2196a75d769" contextRef="C_58c8e092-7276-4637-903f-b05e6860130b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,709,550</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares to certain new hire employees at a weighted-average exercise price o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_897ca5b3-78e0-4f35-a955-ff86a3989b5f" contextRef="C_17444e1c-b04e-4b70-b7f4-f350e405d58b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The options awarded have an exercise price equal to the closing stock price of the Company on the date of the grant and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36e566e0-7eee-4ab0-aa71-314167d970d6" contextRef="C_58c8e092-7276-4637-903f-b05e6860130b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f7a0015-45bd-4506-8885-07f0911f8a46" contextRef="C_e3b821c4-4eac-43b3-bad5-9928776d4618" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal amounts monthly for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f4867d6-d09d-476f-b067-7ba8297edabb" contextRef="C_cebd2d56-16f6-4436-b24a-6359ae1363a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thereafter, subject continued service as an employee.  The options have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae02d86d-8726-42c5-85da-10e7665ad659" contextRef="C_58c8e092-7276-4637-903f-b05e6860130b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the date of the grant. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024, the Company issued options to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d89b5b7-214e-4b1b-9671-73dd2ca609bc" contextRef="C_fd0ed931-526b-4cfb-9b89-94003be94781" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,643,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares to certain new hire employees at a weighted-average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36eaf546-30e7-4f64-8367-54fe4aa63e3d" contextRef="C_c9ac9f07-169f-4b39-9e8b-20722b5214f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87880b90-49ce-4c02-b9ea-89ab21d64973" contextRef="C_58c8e092-7276-4637-903f-b05e6860130b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">493,851</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the inducement grant stock options have vested, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_670ae747-0386-4967-a921-8e0398564615" contextRef="C_58c8e092-7276-4637-903f-b05e6860130b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hav</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e been forfeited and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_556dde59-22c3-48dc-8b59-2d3383e84b08" contextRef="C_58c8e092-7276-4637-903f-b05e6860130b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne have expired, and, other than forfeited options, all options remain outstanding.</span></p><div><ix:nonNumeric id="F_eca34943-4e40-4831-b331-82c3575d42b7" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" escape="true" continuedAt="F_eca34943-4e40-4831-b331-82c3575d42b7_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the 2023 Plan and options granted outside of the 2023 Plan as part of the inducement grants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_2" continuedAt="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_eca34943-4e40-4831-b331-82c3575d42b7_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0be4ec97-544f-4594-91f6-4bd1a5e819c0" contextRef="C_66290f5a-4ebf-4f73-b964-455cb62466aa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,511,968</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ccecf9e-76a6-4146-8635-e93400aaee7a" contextRef="C_399413d5-87a5-4355-8641-293745be5095" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,511,968</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incentive options to purchase common shares awarded pursuant to the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e40c3c-862b-4ed3-a4ac-295c5ec8ec11" contextRef="C_60b37ed7-9421-4001-bbd1-89a359c2ed0a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,717,948</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9c70726-cc27-453d-b52b-2fab5661fcee" contextRef="C_631df185-2355-4542-ae58-d1eaa9a937d7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,391,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inducement grant stock options awarded outside of the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ca64fe-0481-4841-ba9e-2012b59af138" contextRef="C_36a6765d-a768-434b-b6af-c19baebb16f9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,315,350</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6916a5f-542e-4afc-b83b-57906e2d27cc" contextRef="C_240506c4-bcce-4242-904f-1aef27639793" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,643,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under<br/>&#160;&#160;&#160;the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7747eda-7734-440f-a706-0903e1bbedcc" contextRef="C_b6f75307-46d2-4549-9972-666e9421fcbc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,933,304</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006f4e9b-463c-4690-bf8c-7bc51d72845e" contextRef="C_6fbe3c27-7c74-4f39-a002-7cb3cad726bb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,752,889</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_193f3b8f-37d7-4919-bb5c-eecc96b3acee" contextRef="C_1e0f6ec7-da3e-436f-8606-34f7da89269a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5820deb3-7c13-4a43-af5a-f33f842c18ae" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">22,478,570</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_977682bd-4305-47f5-96d4-a4c193990a62" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,299,369</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_105cb8a7-cbeb-4647-b338-b9456699c7c0" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions that the Company used to determine the grant-date fair value of stock options during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.209%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.376%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.376%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="7" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6614cd5e-d807-46db-9ba1-8988744acecb" contextRef="C_e82b042f-c2f1-4591-a95e-196afa1ab585" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_423dbc64-b9d9-46d1-bd0b-b62c04a39e0b" contextRef="C_bb659fef-c385-43b9-827a-dd3a85171737" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cebde12f-3ad2-447d-a28d-2976365789fa" contextRef="C_038fbf25-9506-4d27-be17-4dc097874279" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_1945412c-0abc-4e70-b5da-430a4edcd5e1" contextRef="C_7444e3af-f026-4566-9f7c-881accfccf6d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_305404d7-c110-46bb-8841-f18b3d9f1e3c" contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">78.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a989d747-18eb-46a8-9913-87ed261940c8" contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">83.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da762271-6623-4a10-ae48-67da2f30f01d" contextRef="C_47ffee90-525a-4d51-9a91-98932a653084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">78.24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_352314df-86d6-4550-83d9-f266c45fd488" contextRef="C_47ffee90-525a-4d51-9a91-98932a653084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">82.33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b5318ce-2738-4b15-be39-22825be7e508" contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7730e619-a4a0-40d9-a84a-9dc4f3c9cf7c" contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.49</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45135fa0-12ff-46ae-98cf-6fb8e363226d" contextRef="C_47ffee90-525a-4d51-9a91-98932a653084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1.78</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c5080d6-080c-46b8-8bdf-fa7df7c57d87" contextRef="C_47ffee90-525a-4d51-9a91-98932a653084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common shares and exercise price of options (USD)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_795c24c5-4e7b-40a8-b463-888b1d3a0f97" contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c" name="engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_248ad6a7-9922-4f63-baad-46165345fbed" contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c" name="engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.39</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12f3cc1f-4194-4b40-8cfd-a1e6c375ea96" contextRef="C_47ffee90-525a-4d51-9a91-98932a653084" name="engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80671efb-7cd8-442b-8fb1-cb8de9e71811" contextRef="C_47ffee90-525a-4d51-9a91-98932a653084" name="engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.60</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36903d64-23a2-4ff9-849a-a3d3f990ea73" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"/>
         <td style="width:1.001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.668%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.121%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.187%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.121%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.187%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.121%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.187%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price (USD)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eabc655-46fe-4027-95b5-d548b3e1d596" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,034,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faee6ce4-a4c4-4e03-ba89-bd9bea9a09d8" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.88</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_531bf77e-75f3-423b-8594-afd36898bba6" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23afe600-5a7d-42a5-9b7e-4ed078079627" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,809</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4ac7d46-9b42-4802-93bc-81c83f38c6e7" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,926,875</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d124ecb4-74b8-4335-aa6d-c3c218629fc4" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.41</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c555015-7e04-42e9-ada7-415540657702" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,041,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dac0586-49be-4e6a-a80e-1b06a1188b6d" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.13</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07b1c428-bf68-42b4-9828-0dcae75d263b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">886,107</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d095113-8830-4a6e-a078-ce4c168dd2b3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.86</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dcd6e2a-8235-46ce-b637-fee36963a4db" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,033,298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fc63eb0-efbb-4b5a-8943-1231feb67a2e" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.93</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8eb0fbcb-e00a-4143-b20d-0eefb36d4c38" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cfb0e78-868b-4282-b36f-5ecff884f868" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,979</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29d6fb50-b8ee-4752-a25d-86cecd65ce2e" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,935,183</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c374fa7-b713-413f-a544-a4535fa98f08" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.07</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_376d05f2-cd14-4aed-853a-4cfc302aaf44" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61ff1b9f-c125-4bca-94bb-127b0cfde7fd" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,497</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options unvested as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_765896ca-bed8-4bc5-8bd4-3595ed92a829" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,098,115</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e0e04d-a85c-43ee-b9ce-f31ccdb89337" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_94dae84e-b923-428f-8c2d-095fc3089886" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51e4efec-b669-4388-ad11-575a114f477e" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,482</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s common share as of each reporting date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant-date fair value per share of share options granted during the years ended October 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc1f028f-714e-450f-a4ba-de66ac34eae4" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_CanadaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.62</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06c8803b-0fee-46f3-b97c-b076f9ab3f28" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_CanadaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Modification of Employment Agreements</span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2024, the Company entered into a Transition and Modified Employment Agreement (the &#8220;Transition Agreement&#8221;) with the Company's former Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_3" continuedAt="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dated November 8, 2023 (the &#8220;Amended Employment Agreement&#8221;). Under the terms of the Amended Employment Agreement Mr. Hanson will be entitled to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months of continued health insurance benefits; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of a 2024 target annual bonus in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53ccbb4c-f8d4-4ce4-8a99-a8db4eea0a6a" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="engn:PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">390,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, less applicable taxes and withholdings; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceleration and vesting of any then unvested time-based equity awards that would have vested in the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8ab550a-13de-4f55-aaff-59aee5c0d76b" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period following such termination; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of the CEO&#8217;s vested equity awards extend beyond the respective applicable term thereof.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Transition Agreement further provided that, in the event Mr. Hanson were to resign upon the appointment by the Company of a new chief executive officer, Mr. Hanson would be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of resignation (the &#8220;Consulting Period&#8221;) in exchange for a monthly fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35fd3b02-6de4-4614-ade7-118c0ed6c129" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="engn:AmountOfMonthlyFeeForConsultingPeriod" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the initial </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc72b02c-5010-4a9e-8f9c-2d991656c130" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="engn:InitialConsultingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consulting Period, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a88bdf1-a283-4686-9a23-2ad50ea6099c" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="engn:TransitionServicesForConsultingFeePerHour" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per hour thereafter, provided that Mr. Hanson need not devote more than fifteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c744fb9f-915c-42d1-b5ff-d686e2b3e27b" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="engn:MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" format="ixt-sec:durhour"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) hours per week to providing such transition services.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Transition Agreement, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b71f7b4-609b-4a92-bc2f-3df61626994c" contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,216,266</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock option awards issued to Mr. Hanson were modified to allow for an extended exercise period as described above. The modification resulted in an incremental share-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef08b47e-32d0-4ba6-89b9-59d3b483c113" contextRef="C_0f0f9870-180f-4dd3-b9c4-ef3ac4ad5d5c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which was recorded upon the effective date of the Transition Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Hanson resigned effective as of July 19, 2024 in connection with the Company&#8217;s appointment of a new chief executive officer. On July 20, 2024, enGene appointed Ronald H. W. Cooper as Chief Executive Officer of the Company and as director of the Company's Board of Directors.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in 2024, the Company entered into a Severance Agreement with each of three former employees, including the former Chief Medical Officer and the former Chief Scientific Officer. Under the terms of Severance Agreement, the employees are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e410fe5-64f9-4a8c-8b34-b35e59d6544a" contextRef="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527" name="engn:EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of continued pay and health insurance benefits; a payment of a 2024 target annual bonus prorated through the last day of employment, acceleration and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination and an extended expiry period, which resulted in a stock-based compensation modification. Under the terms of the agreements, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98181379-171e-4f68-bd80-1a86fd42eb9d" contextRef="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">231,684</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock option awards were modified to allow for an extended exercise period as described above. As of October 31, 2024, the Company recognized incremental stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73775c42-fdf8-458b-a624-6d9241903e94" contextRef="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the severance agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25f1a560-3a97-49b7-8b6e-a72865bb6c20" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94b6ebd3-ce7e-409b-9430-ca9a38ffe6ea" contextRef="C_d7356f23-a631-4161-bd89-54fd825f3f25" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,282</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0330c11-56a9-4df8-9e6f-5884cc5f7c41" contextRef="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,794</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_784c80e0-20f9-410d-968f-244b74917e1a" contextRef="C_923c8314-6767-44a6-8d7d-414375566f36" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,364</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f813c06-7e17-4156-8aca-2b48a676bf5d" contextRef="C_d4ba6974-9607-41bb-882a-98cb023fc12d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,530</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5809434-b42c-414d-893e-4f16c1ccca16" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,646</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc8e1f3-08d0-4452-aa41-adac2d03b2f2" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,324</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82_4"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6e19c81-72a8-4977-831e-1c9578869e5d" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a05b7f2e-12b0-41c3-a758-bf96dea67c96" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_f3b1dfaa-2ae1-4a3b-9a55-e77623c924ed" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00da6c29-866f-446e-ab87-15c855539b59" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the reverse recapitalization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.32%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.52%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b5ab190-b16c-44a1-a7f2-2ccc3f9fcab1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_961f1f6d-af71-4e0c-a37b-3c93b7e7453e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82644f1a-aa37-4033-a9c3-e55e90882cdd" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b0a9eb7c-e9ad-45ba-8305-63b4c22347c8" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,142</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_587406ab-a027-4ab2-a071-55a711ebf636" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_986d48df-4dcb-4096-8df2-51cd22afccc6" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">51,119,479</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17efc0b-57a0-42bd-8dca-5459d8d85ba8" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a8891af-03e5-45a4-8e6a-fb8e7aa891eb" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">37,782,346</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a9b3060-86d3-4bb7-aae2-372743d298f3" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ee609f86-ea12-46c0-8cd7-4f5978af944e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.29</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b035b87e-9ee6-4485-b779-fde6fb2268e6" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_42362633-d9f3-4df3-b50d-102f49649ba5" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.46</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32974f61-9799-48ed-ad15-c96c74912389" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_32974f61-9799-48ed-ad15-c96c74912389_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024 because including them would have had an anti-dilutive effect:</span></p><p style="text-indent:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.86%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.06%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_560b01fb-aa8d-4710-899f-6384e580d9b5" contextRef="C_138b2f29-e2e4-468e-a432-96f0a15a5f12" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,511,968</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b903dd92-1b85-4fa8-9d0a-b800b96d5282" contextRef="C_3538eb76-754e-4b90-b6ae-b9741667f639" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,511,968</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6941a7c4-14d0-4443-87b4-fff0bcdb566a" contextRef="C_342954c6-d213-4cd2-9889-aced7e8d67f5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,033,298</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93f41cf5-44cd-4f1d-866d-61e43320ed45" contextRef="C_b57c7e68-7206-43ef-83a4-48c2637e7914" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,034,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f375870a-a165-4c5d-a0b9-bd77f931a1eb" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,545,266</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca7c7caf-74df-4d50-8ab6-275fb2a594e2" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,546,480</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_32974f61-9799-48ed-ad15-c96c74912389_1"></ix:continuation></div><p style="text-indent:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_afdb251c-e8b9-4503-a324-0daf53e9f874" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_afdb251c-e8b9-4503-a324-0daf53e9f874_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f323e41f-06c5-4fb8-9c91-9083b24871d1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss before provision for income taxes consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ca992e-206e-4da0-941d-0ae8fe595ed7" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">103,727</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55187ba3-00d5-4f98-89d1-03a3ecdc42f2" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,460</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51bf229f-61e0-4c71-b69c-7f0d4c328cf8" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,575</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb471aaa-2af0-4b1c-b7b4-fc9eb010afba" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,701</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff11fe22-eac2-4010-9caa-f1e093e7176f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13cdcde8-d976-4022-9cd1-5a8690dc7fb4" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95a4e6de-f2db-46b4-89d6-73bba55f3242" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the provision for (recovery of) income taxes is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current expense (benefit):</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebdacb8f-54f1-4dae-b429-f0ef78d8ffd2" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2381c7-2153-4d9f-9bc0-895147b852fa" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred expense (benefit)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9f8074f-d637-4afa-aede-0127ad72777b" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_afdb251c-e8b9-4503-a324-0daf53e9f874_1" continuedAt="F_afdb251c-e8b9-4503-a324-0daf53e9f874_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd1ff19c-872c-4260-b954-8d490571d09e" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.322000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.322000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income at Canadian statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d803d6-d738-4943-8557-062fe1b60896" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">26.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fbeeada-d215-4fa9-b70d-6ba687f11d6d" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">26.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_860ad6a9-2999-4dc5-86fc-289aa512bef5" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.66</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1694ad3a-b596-47d9-849c-63f26ce3996a" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.18</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1564f7ee-053e-4bd1-bb9d-43702ffbabeb" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.29</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf158c01-1804-4cc7-a7d8-337b9edde544" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">2.77</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8481a15-5c43-487a-9b91-b0c3d79c652b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.60</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c398386-6fdd-45a7-9dae-7d89abfe4745" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.07</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5c2e975-5dc8-4658-a608-188827908ebd" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.64</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73f1a7e8-425f-48c1-9b2a-e69ae8cc05c5" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e14c0c-ea85-42c0-82f9-8cadf2331596" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">26.82</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e55694-9d36-4825-85a7-afddedd8d1fc" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">25.02</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7e7d877-778d-4df4-abfa-45fceaf07ab6" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f7ba66f-2d3d-462f-860e-284fbf1223f8" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77cbbc4f-b765-4cb1-ad78-fe1a5f93b649" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66c6c216-1b4a-4ffb-84b7-a56194e20e8e" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.03</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb634c14-5f67-4cbd-b3fb-9b799e058bc1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net deferred income tax balances related to the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D expenditures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ecd3c32-bbf1-49cb-acf6-667bcf083d39" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,021</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed4afef-306f-4d10-bf6a-f4194860fa89" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,172</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss (NOL) carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_068ebf72-d2d3-46b4-bd8e-86e4ce8515fb" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,127</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb4a4397-638d-421d-a974-06f71cb83a56" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,661</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51e0d254-5191-47e1-b577-fd4e92d7d0ea" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">285</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d586f9a9-ea9e-4f21-9285-f928aa28d379" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2364138f-27ee-4153-ac01-dac763abc05c" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,688</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45711c57-7d1c-4e2c-a7b3-fdf369912d0f" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,934</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c92edcce-a46e-49c8-8e9e-6b94b0ea90c4" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fef20e7-27ac-4596-aa92-0bda745fa069" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea30cbf7-91ce-4e62-9091-ead7cc204b90" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:DeferredTaxAssetsFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98b06ffa-1f29-4f36-9093-1930e36fd647" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:DeferredTaxAssetsFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05496e70-305c-4ef7-b91d-de6a89ef70a8" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b14bd100-1dd0-494f-82cd-68a9a1e5a3c2" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">747</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71700296-ce39-435c-ba3a-f18733fbdfed" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,270</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56aa2cff-05da-4d41-9bfa-58777cc2bcd6" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_559094b3-b944-4975-8177-60913e7b1cda" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:DeferredTaxAssetsNotePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecfd70e0-85c7-49d4-886c-f50c4009519e" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:DeferredTaxAssetsNotePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ce6f9b4-1598-460b-8893-62ab959c4797" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ade78b-26aa-4252-98d1-0a7e49466a13" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a71ff491-3b35-45aa-b6a6-82859242b507" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,494</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59166b67-2233-45e5-8bfe-9e1a55587e90" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,369</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease-right of use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8aed3c5-9df1-4012-b84d-366116712080" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,068</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fad00604-927f-4f2b-8462-2759ad3f714c" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="engn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_404c85f4-d410-40e6-b928-79c56d3676e1" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,068</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3175032f-3760-4b77-81d9-4e99517d4300" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b411d54-d2ef-439d-b061-4b726d958a93" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,426</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49437946-99ba-4a01-89d4-31cf171b92df" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,992</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liability)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#8217;s judgment changes as a result of evaluating new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03833c8f-e062-4d1e-a06a-f68116b4ac91" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1cb9d8d0-d2a3-4b9e-9c47-51595b8cfff5" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uncertain tax positions have been recorded in the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7de0962-d782-4735-b4d3-a8885f5a4df1" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f108775c-fae3-4fce-9030-131388aa972f" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2356a0eb-b315-48a4-8e0d-d15d039c0de2" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f839c65b-040b-4bda-b07f-74f66a991db9" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:11pt;font-family:Times New Roman;"><ix:continuation id="F_afdb251c-e8b9-4503-a324-0daf53e9f874_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company has Canadian Federal NOL carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48848722-94b3-4dd3-87a9-31c0b82b2524" contextRef="C_a38b00d3-e24c-43b5-a082-589eacb61337" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">220.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, that expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d83b5fd0-d849-4b36-9556-dd08a1b374df" contextRef="C_1fee1be9-7dcb-46f6-91a8-e987b5b47b59" name="engn:NetOperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2bbd59d-e1a6-4461-bb58-6a5afbdb8b10" contextRef="C_f156578b-8f46-4ad0-9ea8-b91f1797eb52" name="engn:NetOperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Canadian provincial NOL carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1521957d-37f5-41d4-bf6f-5f3dd3362452" contextRef="C_95a2beb8-4e85-43b1-85ca-fbc18197ebed" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">214.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, that expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0aa3758-7667-4f94-93c1-331b1dbceda7" contextRef="C_3039a78d-24dd-4c83-bbb1-043d190146b7" name="engn:NetOperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ecae9627-d944-40db-8e73-6a0ad78fd732" contextRef="C_1ceadb8f-dcfe-48ff-a395-cc04ab63412f" name="engn:NetOperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These losses are available to offset future taxable income in Canada and Quebec.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company has a U.S. Federal NOL carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d5dcc06-5153-4243-9053-2e0fb75db761" contextRef="C_17725118-e54f-47d5-a64c-c3a544f8f924" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, that may be carried forward indefinitely, and a U.S. state NOL carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77f2ee19-94a8-4409-af70-99b7cba5531b" contextRef="C_f6c04b3e-ddf2-41e5-a4fa-0884f592b542" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which are available to offset against future taxable income in the U.S and Massachusetts. The U.S. State tax loss carryforward will expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7186720f-cd43-4ca7-a872-4cf06f6bccdf" contextRef="C_37f20ce2-0d85-4e2a-a443-1969a8e12178" name="engn:InvestmentTaxCreditsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2041</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c316364a-37bf-4f9c-809c-8d6910188cdc" contextRef="C_9ea003c8-a81c-44b8-900c-b2493af5c02e" name="engn:InvestmentTaxCreditsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has not recognized the tax benefit of these losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company also has non-refundable Canadian investment tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b97c070f-6709-4873-8d7e-37f3f27b6327" contextRef="C_c7b8ec67-5b1d-4c7f-8db7-8e567d0d0440" name="us-gaap:InvestmentTaxCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5d80931-2d6f-44cf-95cb-37d358775e55" contextRef="C_3039a78d-24dd-4c83-bbb1-043d190146b7" name="engn:InvestmentTaxCreditsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3630b09-481e-4d83-8f8f-a2eec5ce32e1" contextRef="C_1ceadb8f-dcfe-48ff-a395-cc04ab63412f" name="engn:InvestmentTaxCreditsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These credits may be utilized to reduce Canadian federal income taxes payable. The Company has not recognized the tax benefits related to these non-refundable investment tax credits.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company also has capital losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b7d33dc-a726-4042-9652-c124da15288c" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:CapitalLossCarryforward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which are available to be used indefinitely against future capital gains.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company had Scientific Research and Experimental Development (&#8220;SR&amp;ED&#8221;) expenditures of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0195b803-34a4-4b2a-bd05-f71da481e62d" contextRef="C_a38b00d3-e24c-43b5-a082-589eacb61337" name="engn:ScientificResearchAndExperimentalDevelopmentExpenditures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for Canadian federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_227c6da9-4bfd-43d5-90f6-97c30d1594ff" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="engn:ScientificResearchAndExperimentalDevelopmentExpenditures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for Qu&#233;bec provincial purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carryforward period. SR&amp;ED expenditures are subject to verification by the tax authorities and, accordingly, the amounts may vary.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_a39c6799-6c17-40fa-b576-a00ab8b14760" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_a39c6799-6c17-40fa-b576-a00ab8b14760_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases are comprised of all operating leases for office and lab space.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 29, 2022, the Company signed a new lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_317396c1-97bd-4832-a0c1-bca5c4e66ed7" contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc" name="engn:AreaOfSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">10,620</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ddab124f-d45b-4d36-8b8e-f6b288b97e19" contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, beginning on the commencement date, and requires an annual initial base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16ea78f5-dcfa-4b93-9b6a-d918ecb9ebdf" contextRef="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323" name="engn:InitialAnnualBaseRentPerSquareFoot" unitRef="U_CadPerSquareFoot" scale="0" decimals="2">36.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAD per square foot, which is subject to annual increases of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f8ad4bd-6ae0-4813-aa21-67defa8dc191" contextRef="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323" name="engn:PercentageOfIncreaseInAnnualBaseRent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afe909cf-8340-4c50-bfa1-d871e32dfeae" contextRef="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323" name="engn:OperatingLeaseCommencementPeriod" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61ab2f75-7b16-4b0c-8999-5e81b248e57f" contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9ff77756-c969-4e0e-8ac6-cfc72f50036e" contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2024, enGene USA entered into a lease agreement, in which the Company is sub-leasing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acbe86e4-da49-4372-92d5-4687a474b433" contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05" name="engn:AreaOfSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">6,450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23d25158-a0f3-46bc-b117-d04fc776ed2a" contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05" name="engn:AggregateAmountOfBaseRentalPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the initial term of the lease, which is set to expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28d59553-61c2-4f6a-b4cd-b2624758d8cd" contextRef="C_d8f4f613-565b-4dd9-9972-29f9286ff4a9" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 30, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and does </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_283fa3eb-4a55-4d4b-ab80-54d0ec7286d9" contextRef="C_d8f4f613-565b-4dd9-9972-29f9286ff4a9" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13841423-2411-43c2-84c8-d7081982a92d" contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f51ede4e-f72c-4cf9-99a7-42b37b055074" contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 4, 2025, enGene USA, Inc entered into a lease agreement, pursuant to which the Company agreed to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32ed2478-8b4d-44b9-9737-22473edb65cf" contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e" name="engn:AreaOfSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">26,335</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space located at 99 High Street, Boston, Massachusetts. The Company is expected to make an aggregate amount of base rental payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45a77e01-db9b-47a3-924f-6e9683114b7d" contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e" name="engn:AggregateAmountOfBaseRentalPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, under the initial term of the lease, which is set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_702ac242-a386-4667-a227-c8edcee4ff12" contextRef="C_c57bc36e-e49e-472f-83cd-c98e379c32e8" name="engn:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the lease, enGene Holdings Inc. has delivered a guaranty, dated June 4, 2025, pursuant to which the Company guaranteed enGene USA's payment and performance. The lease commenced in June 2025 and upon commencement, the Company recognized an initial lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e99d488-3bf9-4a86-b8cf-9b80435734e0" contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abbe426f-ba29-4672-900d-6f6973c4f278" contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91d6d8fb-9238-4f74-b91e-728b6663daaa" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.493%;box-sizing:content-box;"/>
         <td style="width:2.701%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.663%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.663%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Cost:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13af8ce8-0beb-45c8-bb86-3860071a025b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,266</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e2a4935-681b-4776-94da-014d7beac128" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e32f1d0b-ee54-4cb0-973a-b9a22c48fb55" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e366180-2e2a-487d-978c-4c14a512d495" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,266</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45ab9539-aa22-4527-a305-6c2ce98fb553" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_5e76abda-2bc5-417c-b6a8-deadeaeae07b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="engn:SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" escape="true" continuedAt="F_5e76abda-2bc5-417c-b6a8-deadeaeae07b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the cash paid for amounts included in the measurement of the Company&#8217;s operating lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a39c6799-6c17-40fa-b576-a00ab8b14760_1" continuedAt="F_a39c6799-6c17-40fa-b576-a00ab8b14760_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5e76abda-2bc5-417c-b6a8-deadeaeae07b_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement<br/>&#160;&#160;&#160;of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65aa103e-13cc-4dcd-9f86-42ef1548b446" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">620</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_327a3d96-8e21-49e7-ae29-6a7bbf7e826b" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">365</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3fa654e-2318-457f-a2f5-ba871bb48838" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of the Company's operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.7%;box-sizing:content-box;"/>
         <td style="width:5.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:31.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3270e4e8-0f68-49eb-a479-d4c39159bf04" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,191</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1704983-efe6-4461-bd0e-a4f11554aaeb" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,391</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2b32df6-2f61-42bc-8069-6c8078e58ebf" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1c0723a-4f0e-4d53-8680-a5050d652cb1" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,457</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cc0f0e4-3583-4aa5-a3ac-4609c999fa34" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,502</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f97430b5-a53c-465d-81a6-5bd02e2fecc4" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,081</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16923f92-2d83-4283-a35d-c7642066dec5" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,031</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf9d8937-950c-4632-ba1d-55a4ba2020bd" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,562</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2233221-fe1e-4699-82b7-9181d2f2bc54" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,469</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a39c6799-6c17-40fa-b576-a00ab8b14760_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e64c6960-6f27-4628-b13b-9662b0a34b76" contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded on the balance sheet. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96209361-12f9-402a-bafe-b0eb4ab224d4" contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded on the balance sheet.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19187141-2945-4b97-af74-e022a84d5436" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_19187141-2945-4b97-af74-e022a84d5436_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of  October 31, 2025 and 2024, there were no material claims outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span><ix:continuation id="F_19187141-2945-4b97-af74-e022a84d5436_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs, CMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_fcaa193a-9dad-4648-a780-f0c44f1e7422" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_fcaa193a-9dad-4648-a780-f0c44f1e7422_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b862b90-5eef-45ab-9327-11a1625aa5ed" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a132c9ae-785a-488b-9f1d-887988dc7c69" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is focused on developing genetic medicines to improve the lives of patients suffering from bladder cancer. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ec3e0a2-2ecf-430b-a808-f4ee35d46d39" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated net loss to evaluate the Company&#8217;s spend, deploy resources across research and development activities and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing the performance of the operating segment and in establishing resource allocation across the organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies. The measure of segment assets used in determining how to manage and allocate resources is reported within the Company's consolidated balance sheets as cash and cash equivalents and marketable securities.</span></p><div><ix:nonNumeric id="F_94145496-f12c-410d-9c2c-007b19f7aaea" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_94145496-f12c-410d-9c2c-007b19f7aaea_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_fcaa193a-9dad-4648-a780-f0c44f1e7422_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_94145496-f12c-410d-9c2c-007b19f7aaea_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.962%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.538%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:3.807%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.690999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, Manufacturing and Controls</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_267d421b-afcb-49fc-8245-0ac1aee4ac37" contextRef="C_8f0b12b1-19a7-4642-9e3e-cb3fe2551651" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,578</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0908186b-4e9c-433b-8b36-484d9521976e" contextRef="C_c882a3ef-859a-41a2-95d3-51394d6b2ce6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,994</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical operations</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f5e1b71-025a-4441-99c8-c2e6b9cc4656" contextRef="C_bc0cb673-5025-437a-86f8-1e9fe06ad733" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,915</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2c6a16d-d2ed-4b24-9136-e0e04882ffc9" contextRef="C_1d3671cc-d989-49b4-adba-e6701da4d6d1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,036</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eda4af0-a79e-45af-b956-61a7cd0e3132" contextRef="C_a9579fc4-c897-4bed-9b7b-0b5cf457408f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,052</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f090770c-f3b8-4735-9089-4a8f1c3716f0" contextRef="C_dcdfec87-2888-47ca-a07e-585d35c69c6b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,598</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66d24940-cdef-4afd-8974-0ae5986c7eb7" contextRef="C_0df7a474-8310-4b5a-ad28-db5514624ad7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,653</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_732edc76-5515-4f28-96bf-f15e144ddc4b" contextRef="C_8ca9c3a9-bcfe-4cfc-b190-b23c7064bddd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,893</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05d47619-0ece-4d67-baa8-4c45c1a6a6de" contextRef="C_dffdbdca-904e-4e8d-b739-fd381dc21a3f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,282</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2499efc-2baf-4c35-a7cc-957d460bac2d" contextRef="C_62b3a61d-efba-46df-bdeb-dd04f04c6a18" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,794</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_497de29d-45d1-488c-99f5-9eab7f9a912b" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,480</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc35c81e-9379-4de9-9684-a3d01746e763" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,315</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c660443-09ff-4b28-a96c-bb5ee9accd75" contextRef="C_0df7a474-8310-4b5a-ad28-db5514624ad7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,850</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3caf5e65-a00a-44a7-869f-ba1d8c44ce71" contextRef="C_8ca9c3a9-bcfe-4cfc-b190-b23c7064bddd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee41fcd-c3a7-4252-85f6-2af86b0a3f59" contextRef="C_dffdbdca-904e-4e8d-b739-fd381dc21a3f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,364</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eda3de3-726f-40ae-ab3b-2b3d622fe900" contextRef="C_62b3a61d-efba-46df-bdeb-dd04f04c6a18" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,530</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d99df33c-04fc-4736-9be3-7b2f7bc93e3f" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,471</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f5fb77d-a713-40d9-80f8-d5c0e4fc8be3" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:OtherGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,951</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_072551ee-fe1d-4361-b454-331b8c9106e1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f5e22f-1928-47b2-ac80-b43b6eb535d6" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,982</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6813fb78-a017-4527-a60a-dbb3a2971143" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,863</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a30f2e29-baec-4c63-8020-2cc47eb27df9" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,155</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5153f3b2-86ce-44c3-ba37-8e18148372e1" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117,302</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b02924a7-91bd-48e6-b243-11805706a3fa" contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,142</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) For the year ended October 31, 2025, other segment items consist of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d527fd83-38a0-40f2-9987-8e9a9d6f6dc7" contextRef="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest income, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99a395bf-b227-4e43-af07-887d4169e77d" contextRef="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of interest expense, and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d88f51-71f8-4bd2-8528-e72285a28c24" contextRef="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense, net. For the year ended October 31, 2024, other segment items consists of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df1de18-a9bf-45bd-b161-c994d6155628" contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest income, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_331945cc-e6fd-43f5-9670-78c2419d61e0" contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_272c9d23-846c-47f5-8c4e-cfe036d950c0" contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on extinguishment of debt, and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92dcc9aa-3cd1-4eb0-b0b8-32aadfb282bf" contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.</span></p></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee25632a-9a5e-4138-b54a-85ddc931d944" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company did not have transactions with shareholders that hold more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e7ed842-b948-4569-8c46-13e7885e538b" contextRef="C_ec456d2a-f968-4f6c-91e9-ceacc426a74d" name="engn:PercentageOfSharesOwnedByShareholders" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total outstanding shares of the Company. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had the following transactions with shareholders that hold more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d083b92b-0166-4422-84e7-abb8556c5c18" contextRef="C_8ce99e1b-781b-4b10-a4a6-a47b653599c2" name="engn:PercentageOfSharesOwnedByShareholders" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total outstanding shares of the Company:</span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 20, 2024, the Company completed the February 2024 PIPE Financing, which provided for the private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef012032-2110-45db-9006-6364abaaf5a8" contextRef="C_6dba0949-0813-4fe2-b9df-f3bd190796c3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fa4713c-086e-45f5-a577-bfdb200c8a28" contextRef="C_e6e3703d-5475-4ccd-a165-b5039f0166a2" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and included both new and existing investors. One of the Company&#8217;s directors, Mr. Gerald Brunk, is a managing director of Lumira Ventures (&#8220;Lumira&#8221;), and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_415070ba-b5cb-470c-900c-3f2988464e8a" contextRef="C_d7458df2-05d3-41ab-b920-651c47e3645b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">800,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for a total price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1cda6f8-a23f-4ada-8c06-7156e5210325" contextRef="C_d7458df2-05d3-41ab-b920-651c47e3645b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the February 2024 PIPE Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 29, 2024, the Company completed the October 2024 PIPE Financing, which provided for the private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ce39d2a-1cad-405c-90ae-eb1a00f923e1" contextRef="C_cc2c96fa-b7dc-4174-82d2-d97b5a079517" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,758,311</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c31075b4-93c5-47b9-92f1-086bfad8f223" contextRef="C_ee102497-2dad-4531-96db-ff24993a07fb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and included both new and existing investors. One of the Company&#8217;s current directors and one former director, Messrs. Wouter Joustra and Jasper Bos, respectively, are general partners of FEAC, and an entity affiliated with FEAC was party to one of the October 2024 Subscription Agreements, purchasing an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70a459f8-3286-4abd-9908-bfb4a9d8b8ea" contextRef="C_c129c2c8-58f0-43f4-bfdf-85528ac931e9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">561,797</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for a total price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_255f9742-9d78-4e83-b21b-a9e5a27630f5" contextRef="C_c129c2c8-58f0-43f4-bfdf-85528ac931e9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the October 2024 PIPE Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d1a0a97f-ce10-434d-87ed-6a6a25f83681" contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_d1a0a97f-ce10-434d-87ed-6a6a25f83681_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Subsequent Events</span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated subsequent events through the date these financial statements were issued. Except as noted below, the Company concluded that no subsequent events have occurred that require disclosure.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Offering of Common Shares and Pre-Funded Warrants</span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 12, 2025, the Company entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;) relating to the issuance and sale by the Company, in an underwritten public offering, of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c0714f5-a572-4936-927d-9b2db797ae35" contextRef="C_e634a878-3df9-460e-9159-d57cc1cb247d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,558,823</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7e55c35-908f-4a8b-a144-9ccdc15452c1" contextRef="C_5e0ae0ab-6ca4-4467-9077-b61b1010d728" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Common Share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d287aa7-c86f-48f3-ba32-1c97a215b187" contextRef="C_71db83b8-afac-440b-84f1-dbe6aa46e50c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,735,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a5e3d41-196d-4c55-93b1-0522c5961ecd" contextRef="C_5e0ae0ab-6ca4-4467-9077-b61b1010d728" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.4999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-funded warrant,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE HOLDINGS INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d1a0a97f-ce10-434d-87ed-6a6a25f83681_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each case before underwriting discounts and commissions. The offering closed on November 14, 2025. The aggregate gross proceeds from the offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d002aac-9b08-4c75-aea8-48170c86a375" contextRef="C_e634a878-3df9-460e-9159-d57cc1cb247d" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">130.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting the underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10b67764-55df-44e0-bc10-31180365a84a" contextRef="C_e634a878-3df9-460e-9159-d57cc1cb247d" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Company also granted to the Underwriters a 30-day option to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dce0b189-96ff-4a3b-9340-ab87d418bf1d" contextRef="C_222a5d6f-14cb-46e4-a552-efc82189402f" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,294,117</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional Common Shares at the public offering price, less underwriting discounts and commissions (the &#8220;Option&#8221;), which the Underwriters exercised in full pursuant to a Notice of Exercise dated November 14, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The aggregate gross proceeds from the Option exercise were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_401c92fd-6c79-4c71-b80c-0e9e59b30771" contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting the underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0b77a19-d36a-4821-b993-ba7afaee59af" contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering closed on November 18, 2025, with respect to the Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2c6fb55-7a09-41cd-ae88-a5de148643ec" contextRef="C_c1ea2072-6521-49ac-9036-975bf2bea853" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and do not expire. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a pre-funded warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9abd894f-9eb1-40df-8d71-217a2a39776c" contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc" name="engn:PercentageOfOutstandingCommonSharesOwnedByTheHolder" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding Common Shares immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48904250-c5a9-46b0-933a-5984f8bdebff" contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to the Company, subject to the terms of the pre-funded warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>2
<FILENAME>engn-ex10_32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.2491+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.32</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT FOR HUSSEIN SWEITI</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS EMPLOYMENT AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into by and between enGene USA, Inc., its successors and assigns (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Hussein Sweiti (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as of the date first written below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Company desires to employ the Executive to serve as the Company&#x2019;s Chief Medical Officer and the Executive desires to serve in such capacity on behalf of the Company.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Executive hereby agree as follows:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The term of this Agreement shall begin on September 29, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and shall continue until the termination of the Executive&#x2019;s employment.  The period commencing on the Effective Date and ending on the date on which the term of this Agreement terminates is referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;  The Executive&#x2019;s employment during the Term shall be as an &#x201c;at-will&#x201d; employee; the Executive may resign from employment at any time, and the Company may terminate the Executive&#x2019;s employment at any time, for any reason or no reason, subject to the provisions of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, the Executive shall serve as the Chief Medical Officer, with such duties, responsibilities, and authority commensurate therewith, and shall report to the Chief Executive Officer of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Executive shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned to the Executive by the CEO that are consistent with and within the scope of Executive&#x2019;s position.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Best Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, the Executive shall devote the Executive&#x2019;s best efforts and full business time and attention to promote the business and affairs of the Company and its affiliated entities, and shall be engaged in other business activities only to the extent that such activities do not materially interfere or conflict with the Executive&#x2019;s obligations to the Company hereunder, including, without limitation, obligations pursuant to Section 15 below.  The foregoing shall not be construed as preventing the Executive from (i) serving on civic, educational, philanthropic or charitable boards or committees, or, with the prior written consent of the CEO, which shall not be unreasonably withheld,  on corporate, advisory or scientific advisory boards, or service in an advisory capacity to a corporate entity and (ii) managing personal investments, so long as such activities are permitted under the Company&#x2019;s Code of Conduct and employment policies and do not violate the provisions of Section 15 below.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Place of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive understands and agrees that the Executive&#x2019;s principal place of employment will be in the Executive&#x2019;s home in Pennsylvania and that employment will remain remote but the Executive will be required to travel the Company&#x2019;s headquarters in or around Boston, Massachusetts (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principal Place of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) on an as needed basis. The Executive&#x2019;s employment and all services hereunder shall be provided in the United States and the Executive shall not be required to work in Canada during the Term of this Agreement.  Executive will be required to travel for business in the course of performing the Executive&#x2019;s duties for the Company.   </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, the Company shall pay the Executive a base salary (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at the annual rate of $525,000.00, which shall be paid in installments in accordance with the Company&#x2019;s normal payroll practices.  The Executive&#x2019;s Base Salary shall be reviewed annually by the Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parent Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of enGene Holdings Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and may be increased, but not decreased.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sign-on Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Executive will be eligible to receive a one-time sign-on bonus in the amount of $150,000.00, less applicable deductions and withholdings, (the &#x201c;Sign-On Bonus&#x201d;), which will be paid to the Executive in the first regular payroll period following the Effective Date. The Sign-On Bonus will not actually be deemed earned until the Executive has completed one full year of active employment with the Company in good standing, and shall be deemed an unearned advance until this condition has been satisfied. In the event that the Executive voluntarily resigns from employment with the Company for any reason within the Executive&#x2019;s first year of employment, or is terminated by the Company for Cause (as defined in Section 13 below), the Executive agrees to repay to the Company the entire value of the Sign-On Bonus, with such repayment occurring within thirty (30) days following the Executive&#x2019;s last day of employment with the Company. The Executive further agrees that the Company may make any deduction necessary from the Executive&#x2019;s last paycheck(s) to satisfy this repayment obligation, and the Executive hereby (i) consents to any such deduction and any other action that may be taken by the Company and as permitted by law, and (ii) agrees that, at the time of such separation, the Executive will sign any additional agreement or document that the Company deems necessary with respect to making this deduction or otherwise enforcing its right to receive the repayment amount.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive shall be eligible to receive an annual bonus for each calendar year during the Term, commencing with the 2026 calendar year, based on the attainment of individual and corporate performance goals and targets established by the Compensation Committee (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The target amount of the Executive&#x2019;s Annual Bonus for any calendar year during the Term is 40% of the Executive&#x2019;s annual Base Salary (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Target Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Any Annual Bonus shall be paid after the end of the fiscal year to which it relates, at the same time and under the same terms and conditions as the bonuses are paid to other executives of the Company; provided, that, in no event shall the Executive&#x2019;s Annual Bonus be paid later than two and a half months after the last day of the fiscal year to which the Annual Bonus relates. For the 2025 calendar year, the Executive shall be paid a one-time cash bonus in the amount of $50,000.00 during the second regular payroll cycle in February 2026, provided that the Executive remains employed by the Company and in good standing through the payment date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to the approval of the Parent Board, as an inducement for the Executive to join the Company in the role of Chief Medical Officer and agree to the restrictive covenants set forth below, the Executive will be granted the Option (as further described below), which is intended to be an inducement award under Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules and will be granted outside of the enGene Holdings Inc. Amended and Restated 2023 Incentive Equity Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Although granted as an inducement award outside of the Plan, the Option shall be subject to the terms of the Equity Plan as if issued thereunder.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Executive will be granted a nonqualified stock option to purchase 600,000 common shares of the Company, subject to the terms of the nonqualified stock option agreement for inducement grants provided by the Company (the &#x201c;Option&#x201d;). Vesting and exercisability of the Option will be over four years with 25% vesting and becoming exercisable on the first anniversary of the Effective Date, and the remainder vesting and becoming exercisable in substantially equal amounts monthly for three years thereafter. The exercise price of the Option will be the closing price of the Company&#x2019;s common shares on the date the Option is granted.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Equity Compensation. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Executive shall be eligible to participate in the Equity Plan at a level commensurate with similarly situated C-Suite executives of the Company, as determined in the sole discretion of the Compensation Committee and/or Parent Board; provided, however, that Executive shall not be eligible to participate in the Equity Plan in connection with the annual year-end compensation process for 2025.  </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retirement and Welfare Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, the Executive shall be eligible to participate in the Company&#x2019;s health, life insurance, long-term disability, retirement and welfare benefit plans and programs, pursuant to their respective terms and conditions.  Nothing in this Agreement shall preclude the Company or any Affiliate of the Company from terminating or amending any employee benefit plan or program from time to time after the Effective Date. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vacation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term, the Executive shall be eligible to vacation each year and holiday and sick leave at levels commensurate with those provided to similarly situated US executives of the Company, in accordance with the Company&#x2019;s policy and/or practice which as of the Effective Date is a flexible policy.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall reimburse the Executive for all necessary and reasonable travel (which does not include commuting to Executive&#x2019;s Principal Place of Employment) and other business expenses incurred by the Executive in the performance of his duties hereunder in accordance with such policies and procedures as the Company may adopt generally from time to time for executives. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Employment Without Cause; Resignation for Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If the Executive&#x2019;s employment is terminated by the Company without Cause or by the Executive for Good Reason, the provisions of this Section 6 shall apply.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Executive&#x2019;s employment with the Company at any time without Cause upon not less than thirty (30) days&#x2019; prior written notice to the Executive and the Executive may resign for Good Reason. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the Executive complies with the provisions of Section 6(c) below, upon termination of employment under Section 6(a) above, no other payments or benefits shall be due under this Agreement to the Executive other than the Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the provisions of Section 6(b) above, upon termination of employment under Section 6(a) above, if the Executive executes and does not revoke the Release, and so long as the Executive continues to comply with the provisions of Section 15 below, in addition to the Accrued Obligations, the Executive shall be entitled to receive the following: </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continuation of the Executive&#x2019;s Base Salary for a twelve (12) month period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at the rate in effect for the year in which the Executive&#x2019;s date of termination of employment occurs, which amount shall be paid in regular payroll installments over the Severance Term.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then continued health (including hospitalization, medical, dental, vision etc.) insurance coverage substantially similar in all material respects as the coverage provided to other Company employees for the Severance Term; provided that the Executive shall pay the employee portion of such coverage, if any, the period of COBRA health care continuation coverage provided under section 4980B of the Code shall run concurrently with the Severance Term, and notwithstanding the foregoing, the amount of any benefits provided by this subsection (ii) shall be reduced or eliminated to the extent the Executive obtains duplicative benefits by virtue of the Executive&#x2019;s subsequent or other employment. Notwithstanding the foregoing, if the Company&#x2019;s making payments under this Section 6(c) would violate any nondiscrimination rules applicable to the Company&#x2019;s group health plan under which such coverage is made available, or result in the imposition of penalties under the Code or the Affordable Care Act, the Parties agree to reform this Section 6(c) in a manner as is necessary to comply with such requirements and avoid such penalties. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination, payable within forty-five (45) days of Executive&#x2019;s termination of employment; provided, that such termination occurs six months or more into the applicable performance period for such Annual Bonus.</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any time-based equity awards shall accelerate and vest with respect to the number of shares underlying the equity awards that would vest over the Severance Term had the Executive remained employed for such Severance Term and any equity awards that are subject to performance-based vesting shall vest and become exercisable, if at all, subject to the terms of such equity awards. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Notwithstanding anything to the contrary herein, if there is a CIC Termination, then the provisions of this Section 7 shall apply.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the Executive complies with the provisions of Section 7(b) below, upon CIC Termination, no other payments or benefits shall be due under this Agreement to the Executive other than the Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the provisions of Section 7(a) above, upon CIC Termination, if the Executive executes and does not revoke the Release, and so long as the Executive continues to comply with the provisions of Section 15 below, then, in addition to the Accrued Obligations, the Executive shall be entitled to receive the following: </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continuation of the Executive&#x2019;s Base Salary for a twelve (12) month period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC Severance Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at the rate in effect for the year in which the Executive&#x2019;s date </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of termination of employment occurs, which amount shall be paid in regular payroll installments over the CIC Severance Term;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An amount equal to the Annual Target Bonus, payable within forty-five (45) days of Executive&#x2019;s termination of employment;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA continuation benefits as set forth in Section 6(c)(iii), except that the Severance Term shall be the CIC Severance Term; and </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All time-based equity awards shall accelerate and become fully vested and any equity awards that are subject to performance-based vesting shall vest, if at all, subject to the terms of such equity awards. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company may terminate the Executive&#x2019;s employment at any time for Cause upon written notice to the Executive, in which event all payments under this Agreement shall cease, except for any Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voluntary Resignation Without Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive may voluntarily terminate employment without Good Reason upon 30 days&#x2019; prior written notice to the Company.  In such event, after the effective date of such termination, no payments shall be due under this Agreement, except that the Executive shall be entitled to any Accrued Obligations. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If the Executive incurs a Disability during the Term, the Company may terminate the Executive&#x2019;s employment on or after the date of Disability.  If the Executive&#x2019;s employment terminates on account of Disability, the Executive shall be entitled to receive any Accrued Obligations and if the Executive executes and does not revoke the Release, an amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination for Disability; provided, that such termination occurs six months or more into the applicable performance period.  For purposes of this Agreement, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the Executive is eligible to receive long-term disability benefits under the Company&#x2019;s long-term disability plan and if the Company does not have a long-term disability plan, shall mean the Executive&#x2019;s inability, due to physical or mental incapacity, to perform the essential functions of Executive&#x2019;s position, with or without reasonable accommodation, for 120 days out of any 365 day period.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Death</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If the Executive dies during the Term, the Executive&#x2019;s employment shall terminate on the date of death and the Company shall pay to the Executive&#x2019;s executor, legal representative, administrator or designated beneficiary, as applicable, any Accrued Obligations.  The Company shall have no further liability or obligation under this Agreement to the Executive&#x2019;s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through the Executive. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resignation of Positions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Effective as of the date of any termination of employment, the Executive will resign from all Company-related positions, including as an officer and director of the Company and its parent(s), subsidiaries, and Affiliates.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes of this Agreement, the following terms shall have the following meanings:</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean (i) any Base Salary earned through the Executive&#x2019;s termination of employment that remains unpaid; (ii) any Annual Bonus payable with respect to any calendar year which ended prior to the effective date of the Executive&#x2019;s termination of employment, which remains unpaid; (iii) in the event of a termination of employment as a result of death, an amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination; provided, that such termination occurs six months or more into the applicable performance period for such Annual Bonus; or (iv) any accrued, unused personal time off days, if required to be paid out under the Company policies.  The Accrued Obligations shall be paid following the Executive&#x2019;s termination of employment at such times and in accordance with such policies as would normally apply to such amounts and regardless of whether the Executive executes or revokes the Release.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any of the following grounds for the Executive&#x2019;s termination of employment listed: (i) the Executive&#x2019;s knowing and material dishonesty or fraud committed in connection with the Executive&#x2019;s employment; (ii) theft, misappropriation, or embezzlement by the Executive of the Company&#x2019;s funds; (iii) the Executive repeatedly negligently performing or failing to perform, or willfully refusing to perform, the Executive&#x2019;s duties to the Company (other than a failure resulting from Executive&#x2019;s incapacity due to physical or mental illness); (iv) the Executive&#x2019;s conviction of or a plea of guilty or </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nolo contendere</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to any felony, a crime involving fraud or misrepresentation, or any other crime (whether or not connected with his employment) the effect of which is likely to adversely affect the Company or its Affiliates; (v) a material breach by the Executive of any of the provisions or covenants set forth in this Agreement; (vi) a material breach by the Executive of the Company&#x2019;s Code of Conduct and Business Ethics; or (vii) any other act or omission by the Executive that has a material adverse effect on the Company&#x2019;s ability to operate.  Prior to any termination of employment for Cause pursuant to each such event listed in (i), (iii), (v), (vi), or (vii) above, to the extent such event(s) is capable of being cured by the Executive, the Company shall give the Executive written notice thereof describing in reasonable detail the circumstances constituting Cause and the Executive shall have the opportunity to remedy same within thirty (30) days after receiving written notice.  If the circumstances alleged to constitute Cause are remedied within the thirty (30) day cure period, no Cause shall exist to terminate Executive.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Equity Plan.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the period commencing 90 days prior to a Change in Control and ending on the first anniversary of such Change in Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIC Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean termination of the Executive&#x2019;s employment by the Company without Cause or by the Executive for Good Reason during the Change in Control Period, provided that, in either case, a Change in Control actually occurs.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the occurrence of one or more of the following without the Executive&#x2019;s consent, other than on account of the Executive&#x2019;s Disability:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material diminution by the Company of the Executive&#x2019;s title authority, reporting structure, duties or responsibilities;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A material change in the geographic location at which the Executive must perform services under this Agreement (which, for purposes of this Agreement, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:left;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means relocation of the Executive&#x2019;s Principal Place of Employment to a location that increases the Executive&#x2019;s commute to work by more than 35 miles);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reduction in the Executive&#x2019;s Base Salary (other than an across the board reduction of base salary for similarly situated senior level executives); or</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.667%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any action or inaction that constitutes a material breach by the Company of this Agreement.</font></div></div><p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive must provide written notice of termination for Good Reason to the Company within 30 days after the event constituting Good Reason.  The Company shall have a period of 30 days in which it may correct the act or failure to act that constitutes the grounds for Good Reason as set forth in the Executive&#x2019;s notice of termination.  If the Company does not correct the act or failure to act, the Executive&#x2019;s employment will terminate for Good Reason on the first business day following the Company&#x2019;s 30-day cure period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean a separation agreement and general release of any and all claims against the Company and its Affiliates with respect to all matters arising out of the Executive&#x2019;s employment by the Company, and the termination thereof (other than claims for any entitlements under the terms of this Agreement or under any plans or programs of the Company under which the Executive has accrued and is due a benefit).  The Release will be in form and substance specified by and acceptable to the Company and Executive, and will include provisions in which the Executive shall reaffirm and agree to remain bound by the restrictive covenants set forth in Section 15 below. Such general release shall be executed and delivered (and no longer subject to the 7 business day revocation period) by the Executive within sixty (60) days following delivery of the general release to the Executive.  </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement is intended to comply with section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and its corresponding regulations, or an exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by section 409A of the Code, to the extent applicable.  Severance benefits under this Agreement are intended to be exempt from section 409A of the Code under the &#x201c;short-term deferral&#x201d; exception, to the maximum extent applicable, and then under the &#x201c;separation pay&#x201d; exception, to the maximum extent applicable.  Notwithstanding anything in this Agreement to the contrary, if required by section 409A of the Code, if the Executive is considered a &#x201c;specified employee&#x201d; for purposes of section 409A of the Code and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to section 409A of the Code, payment of such amounts shall be delayed as required by section 409A of the Code, and the accumulated amounts shall be paid in a lump-sum payment within 10 days after the end of the six-month period.  If the Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of section 409A of the Code shall be paid to the personal representative of the Executive&#x2019;s estate within 60 days after the date of the Executive&#x2019;s death.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All payments to be made upon a termination of employment under this Agreement may only be made upon a &#x201c;separation from service&#x201d; under section 409A of the Code.  For purposes of section 409A of the Code, each payment hereunder shall be treated as a separate payment, and </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.  In no event may the Executive, directly or indirectly, designate the fiscal year of a payment.  Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Executive&#x2019;s execution of the Release, directly or indirectly, result in the Executive&#x2019;s designating the fiscal year of payment of any amounts of deferred compensation subject to section 409A of the Code, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement be for expenses incurred during the period specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a fiscal year not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other fiscal year, (iii) the reimbursement of an eligible expense be made no later than the last day of the fiscal year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits not be subject to liquidation or exchange for another benefit.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Noncompetition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive agrees that during the Executive&#x2019;s employment with the Company and its Affiliates and (i) the CIC Severance Term after a CIC Termination and (ii) for any other termination of employment, including a termination of employment where severance is not payable to the Executive, the number of calendar months during the period of the Severance Term (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restriction Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Executive will not, without the Parent Board&#x2019;s express written consent, engage (directly or indirectly) in any Competitive Business in the United States or Canada.  The term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitive Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person, concern or entity which is engaged in or conducts a business substantially the same as the Business of the Company and its Affiliates. The term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the discovery, research, development and commercialization of gene therapy treatments currently under active discovery, development or commercialization at the Company (generally referred to internally as &#x201c;Programs&#x201d; and &#x201c;Pipeline&#x201d;), including material external sponsored research agreements. The Executive understands and agrees that, given the nature of the business of the Company and its Affiliates and the Executive&#x2019;s position with the Company, the foregoing scope is reasonable and appropriate, and necessary to protect the Company&#x2019;s legitimate business interests.  For purposes of this Agreement, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any subsidiary of the Company or Parent or any other entity under common control with the Company.  The Executive and the Company agree that the terms set forth in this Agreement, including without limitation, the Base Salary, the Annual Bonus opportunity and severance rights that the Company is awarding the Executive as consideration for the covenants in this Section 15(a) are mutually-agreed upon consideration for the Executive&#x2019;s compliance with this Section 15(a).</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonsolicitation of Company Personnel</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive agrees that during the Restriction Period, the Executive will not, either directly or through others, hire or attempt to hire any employee of the Company or its Affiliates, or solicit or attempt to solicit any such person to change or terminate his or her relationship with the Company or an Affiliate or otherwise to become an employee, consultant or independent contractor to, for or of any other person or business entity; provided that the foregoing does not prohibit general solicitation or recruitment </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">activities not directed at employees of the Company or soliciting, recruiting or hiring any person who responds thereto.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonsolicitation of Customers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive agrees that during the Restriction Period, the Executive will not, either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate, any customer of the Company or an Affiliate for the purpose of providing such customer  with services or products competitive with those offered by the Company or an Affiliate during the Executive&#x2019;s employment with the Company or an Affiliate.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  At all times, the Executive will hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such disclosure, use or publication may be required in connection with the Executive&#x2019;s work for the Company or as described in Section 15(e) below, or unless the Company expressly authorizes such disclosure in writing.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any and all confidential and/or proprietary knowledge, data or information of the Company and its Affiliates and shareholders, including but not limited to information relating to financial matters, investments, budgets, business plans, marketing plans, personnel matters, business contacts, products, processes, know-how, designs, methods, improvements, discoveries, inventions, ideas, data, programs, and other works of authorship.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall not include information which is or becomes publicly available without breach of: (i) this Agreement; (ii) any other agreement or instrument to which the Company or an Affiliate is a party or a beneficiary; or (iii) any duty owed to the Company or an Affiliate by the Executive or by any third party.  It shall also not include any information that was known to Executive prior to Executive&#x2019;s employment with the Company and which was communicated to the Company in writing; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the Executive shall desire or seek to disclose, use, lecture upon, or publish any Proprietary Information, the Executive shall bear the burden of proving that any such information shall have become publicly available without any such breach.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reports to Government Entities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Nothing in this Agreement shall prohibit or restrict the Executive from initiating communications directly with, responding to any inquiry from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, Congress, any agency Inspector General or any other federal, state or local regulatory authority (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulators</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation.  The Executive does not need the prior authorization of the Company to engage in conduct protected by this subsection, and the Executive does not need to notify the Company that the Executive has engaged in such conduct.  Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose trade secrets to their attorneys, courts, or government officials in certain, confidential circumstances that are set forth at 18 U.S.C. &#167;&#167; 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:6pt;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventions Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive agrees that all inventions, innovations, improvements, developments, methods, designs, analyses, reports, and all related information which relates to the Company&#x2019;s or its Affiliates&#x2019; actual  business, research and development of existing or future products or services and which are  actually being developed or made by the Executive while employed by the Company, on Company time and using Company resources (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Work Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) belong to the Company.  The Executive will perform all actions reasonably requested by the Parent Board (whether during or after the Term) to establish and confirm such ownership (including, without limitation, assignments, consents, limited powers of attorney and other instruments).  If requested by the Company, the Executive agrees to execute any inventions assignment and confidentiality agreement that is required to be signed by Company employees generally.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Property</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Within a reasonable time after termination of the Executive&#x2019;s employment with the Company for any reason, and at any earlier time the Company requests, the Executive will deliver to the person designated by the Company all originals and copies of all documents and property of the Company or an Affiliate that are in the Executive&#x2019;s possession or under the Executive&#x2019;s control or to which the Executive may have access.  The Executive will not reproduce or appropriate for the Executive&#x2019;s own use, or for the use of others, any property, proprietary information, or Work Product.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenant Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive acknowledges and agrees that the foregoing restrictions contained in Section 15 are reasonable, proper and necessitated by the legitimate business interests of the Company and will not prevent the Executive from earning a living or pursuing a career. In the event that a court of competent jurisdiction determines that any of the provisions of this Agreement (including, without limitation, the provisions of Section 15) would be unenforceable as written because they cover too extensive a geographic area, too broad a range of activities, too long a period of time, insufficient consideration, or otherwise, then such provisions automatically shall be modified to cover the maximum geographic area, range of activities, and period of time as may be enforceable, and the minimum amount of required consideration as may be enforceable, and in addition, such court is hereby expressly authorized so to modify this Agreement and to enforce it as so modified.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal and Equitable Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Because the Executive&#x2019;s services are personal and unique and the Executive has had and will continue to have access to and has become and will continue to become acquainted with the proprietary information of the Company and its Affiliates, and because any breach by the Executive of any of the restrictive covenants contained in Section 15 would result in irreparable injury and damage for which money damages would not provide an adequate remedy, the Company shall have the right to seek to enforce Section 15 and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set forth in Section 15.  The Executive agrees that in any action in which the Company seeks injunction, specific performance or other equitable relief, the Executive will not assert or contend that any of the provisions of Section 15 are unreasonable or otherwise unenforceable.  </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The respective rights and obligations of the parties under this Agreement (including, but not limited to, under Sections 15 and 16) shall survive any termination of the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s employment or termination or expiration of this Agreement to the extent necessary to the intended preservation of such rights and obligations.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Mitigation or Set-Off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not be reduced regardless of whether the Executive obtains other employment.  The Company&#x2019;s obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right which the Company may have against the Executive or others.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 280G</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event of a change in ownership or control under section 280G of the Code, if it shall be determined that any payment or distribution in the nature of compensation (within the meaning of section 280G(b)(2) of the Code) to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), would constitute an &#x201c;excess parachute payment&#x201d; within the meaning of section 280G of the Code, the aggregate present value of the Payments under this Agreement shall be reduced (but not below zero) to the Reduced Amount (defined below) if and only if the Accounting Firm (described below) determines that the reduction will provide the Executive with a greater net after-tax benefit than would no reduction.  No reduction shall be made unless the reduction would provide Executive with a greater net after-tax benefit.  The determinations under this Section shall be made as follows:</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall be an amount expressed in present value which maximizes the aggregate present value of Payments under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax (defined below), determined in accordance with section 280G(d)(4) of the Code.  The term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the excise tax imposed under section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments under this Agreement shall be reduced on a nondiscretionary basis in such a way as to minimize the reduction in the economic value deliverable to the Executive.  Where more than one payment has the same value for this purpose and they are payable at different times, they will be reduced on a pro rata basis.  Only amounts payable under this Agreement shall be reduced pursuant to this Section. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All determinations to be made under this Section shall be made by an independent certified public accounting firm selected by the Company and agreed to by the Executive immediately prior to the change-in-ownership or -control transaction (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and the Executive within 10 days of the transaction.  Any such determination by the Accounting Firm shall be binding upon the Company and the Executive.  All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be borne solely by the Company.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">20.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Equalization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will reimburse the Executive for all reasonable and necessary costs incurred in connection with any cross-border tax filings that may be required, as well as the cost of joining the NEXUS program and any other visa or related issues with respect to the Executive&#x2019;s employment with the Company. To the extent the Executive is subject to </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional taxes in respect of services performed in Canada (whenever such services were performed on the Company&#x2019;s behalf), the Company will reimburse the Executive for such additional taxes with an appropriate gross up calculation such that the Executive pays no more income taxes in respect of compensation from the Company then the Executive would have paid had the services solely been performed in the United States. Without limiting any of the foregoing provisions of this Section 20, the Company hereby agrees to fully indemnify the Executive against: (i) any and all tax liability that the Executive incurs in Canada arising with respect to any services that Executive performs in Canada for and on behalf of the Company, Parent or any of their respective subsidiaries, (ii) any and all tax liability that Executive incurs in the United States by virtue of Parent or any of its subsidiaries being a Passive Foreign Investment Company and that Executive would not have incurred if each of Parent and its subsidiaries were a corporation incorporated and existing under the laws of a State in the United States, and (iii) any other tax liability or penalties that Executive incurs in the United States or Canada by virtue of the Parent or any of its subsidiaries being a Canadian corporation and that Executive would not have incurred if each of Parent and its subsidiaries were a corporation incorporated and existing under the laws of a State in the United States.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">21.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when emailed, hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received):</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If to the Company, to:</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">200 Fifth Avenue</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 4020</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waltham, MA 02451</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn: Chief Legal Officer</font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or the Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this Section.</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">22.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation.  The Executive shall bear all expense of, and be solely responsible for, all federal, state and local taxes due with respect to any payment received under this Agreement. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">23.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies Cumulative; No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity.  No delay or omission by a party in exercising any right, remedy or power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">24.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Binding Arbitration and Waiver of Right to Participate in Class Actions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for disputes relating to, or arising out of, the Executive&#x2019;s obligations set forth in Section 15, including the Company&#x2019;s right to independently seek and obtain injunctive relief in state or federal courts, </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the parties agree to arbitrate any and all claims, disputes or controversies relating to, or arising out of, or concerning, this Agreement and/or the Executive&#x2019;s employment with the Company, including termination of the Executive&#x2019;s employment.  If either party initiates arbitration, the initiating party must notify the other party in writing via U.S. mail, or hand delivery within the applicable statute of limitations period under Massachusetts law.  The parties&#x2019; agreement to arbitrate employment-related claims is intended to include, but is not limited to, claims concerning compensation, benefits or other terms and conditions of employment, or any other claims whether arising by statute or otherwise including, but not limited to, employment claims of wrongful discharge, discrimination, harassment or retaliation under federal, state or local laws including, without limitation, Commonwealth of Massachusetts; Title VII of the Civil Rights Act as amended, the Equal Pay Act, the Americans With Disabilities Act (as amended), the Age Discrimination in Employment Act, the Older Workers Benefits Protection Act; the Patient Protection and Affordable Care Act, and claims arising under the Fair Labor Standards Acts, or any other national, federal, state or local employment or discrimination laws, rules or regulations.  The Executive&#x2019;s agreement to arbitrate also includes claims for breach of contract, violation of internal procedure or policy, wrongful termination in violation of public policy, wrongful discharge or termination, tort claims including negligence, defamation, loss of reputation, interference with contractual relations or prospective economic advantage, retaliation, and negligent or intentional infliction of emotional distress.  The Executive agrees that all such claims will be fully and finally resolved by mandatory, binding arbitration conducted by the American Arbitration Association (&#x201c;AAA&#x201d;) located within thirty miles of the Executive&#x2019;s Principal Place of Employment, pursuant to the AAA then-current Employment Arbitration Rules and Mediation Procedures.  A copy of those rules is available online at www.adr.org/aaa. The Company as the employer will bear the administrative costs and arbitrator fees, and the arbitrator in such action may award whatever remedies would be available to the parties in a court of law.  The purpose of this provision is to require binding arbitration of such disputes, claims or controversies that are or may be arbitrable, and the inclusion of any claim in this provision as to which a jury trial or civil action may not be waived will not taint or invalidate the remainder of this provision.  To be clear, this agreement to arbitrate does not apply to any lawsuit to enforce this arbitration clause, or, as referenced above, to seek relief as set forth in Section 15 of this Agreement.  Those lawsuits will be commenced in the state or federal courts sitting in the Commonwealth of Massachusetts and the Executive consents to the jurisdiction of the federal or state courts of Massachusetts.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">25.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that the duties and responsibilities of the Executive under this Agreement are of a personal nature and shall not be assignable or delegable in whole or in part by the Executive.  The Company may assign its rights, together with its obligations hereunder, in connection with any sale, transfer or other disposition of all or substantially all of its business and assets, and such rights and obligations shall inure to, and be binding upon, any successor to the business or any successor to substantially all of the assets of the Company, whether by merger, purchase of stock or assets or otherwise, which successor shall expressly assume such obligations, and the Executive acknowledges that in such event the obligations of the Executive hereunder, including but not limited to those under Section 15, will continue to apply in favor of the successor. </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">26.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement and the compensation payable hereunder shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may be implemented by the Parent Board from time to time with respect to officers of the Company.  </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">27.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event the Executive is made, or threatened to be made, a party to any legal action or proceeding, whether civil or criminal, including any governmental or regulatory proceedings or investigations, by reason of the fact that the Executive is or was a director or officer of the Company or any of its Affiliates, the Executive shall be fully indemnified by the Company, and the Company shall pay the Executive&#x2019;s related expenses (including reasonable attorneys&#x2019; fees, judgments, fines, settlements and other amounts incurred in connection with any proceeding arising out of) when and as incurred, to the fullest extent permitted by applicable law and the Company&#x2019;s articles of incorporation and bylaws.  During the Executive&#x2019;s employment with the Company or any of its Affiliates and after termination of employment for any reason, the Company shall cover the Executive under the Company&#x2019;s directors&#x2019; and officers&#x2019; insurance policy applicable to other officers and directors according to the terms of such policy.  Such obligations shall be binding upon the Company&#x2019;s successors and assigns and shall inure to the benefit of the Executive&#x2019;s heirs and personal representatives.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">28.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement sets forth the entire agreement of the parties hereto and supersedes any and all prior agreements and understandings concerning the Executive&#x2019;s employment by the Company, including, without limitation, that certain Employment Agreement by and between the Executive and the Company executed on May 2, 2025.  This Agreement may be changed only by a written document signed by the Executive and the Company.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">29.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement, which can be given effect without the invalid or unenforceable provision or application, and shall not invalidate or render unenforceable such provision or application in any other jurisdiction.  If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">30.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed by, and construed and enforced in accordance with, the substantive and procedural laws of the Commonwealth of Massachusetts without regard to rules governing conflicts of law.    </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">31.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts (including facsimile counterparts), each of which shall be an original, but all of which together shall constitute one instrument.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">32.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acknowledgments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Executive acknowledges that (a) the Executive has the right to consult with counsel prior to signing this Agreement and has had a full and adequate opportunity to read, understand and discuss with the Executive&#x2019;s advisors, including counsel, the terms and conditions contained in this Agreement prior to signing hereunder, (b) this Agreement is supported by fair and reasonable consideration independent from the continuation of employment, and (c) the Executive received notice of this Agreement at least ten business days before it is to be effective.  </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Signature Page Follows)</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</font></p><p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			ENGENE USA, INC.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				 </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ronald H. W. Cooper			</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				Name: Ronald H. W. Cooper</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				Title: Chief Executive Officer</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				Date:  14-Sep-2025</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				EXECUTIVE</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				 				</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Hussein Sweiti				</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				Name: Hussein Sweiti</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				Date:  15-Sep-2025</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20(B)
<SEQUENCE>3
<FILENAME>engn-ex10_20b.htm
<DESCRIPTION>EX-10.20(B)
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.1046+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.20(b)</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.20(b)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENT TO EMPLOYMENT AGREEMENT FOR RONALD H. W. COOPER</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This AMENDMENT TO EMPLOYMENT AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made by and between enGene USA, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Ronald H. W. Cooper (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Company and Executive are parties to an Employment Agreement, effective as of July 22, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the parties desire to amend the Agreement as set forth herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7(b)(ii) of the Agreement is hereby deleted in its entirety and restated to read as follows:</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;(ii) An amount equal to 1.5 times the Annual Target Bonus, payable within forty-five (45) days of Executive&#x2019;s termination of employment;&#x201d;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General.  Except as set forth in this Amendment, the Agreement shall remain in full force and effect according to its terms. The Agreement, as superseded in part and amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter therein. Except as set forth herein, any extension, amendment or other modification to the Agreement or this Amendment must be mutually agreed upon by the parties, in writing and executed by both parties. This Amendment may be signed in counterparts, each of which shall be an original with the same effect as if the signatures were upon the same instrument.</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Amendment.</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ENGENE USA, INC.</font></h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ Gerald Brunk			</font></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name: Gerald Brunk</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:  October 2, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE</font></h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h2><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ronald H. W. Cooper		</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ronald H. W. Cooper</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:  October 2, 2025</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>engn-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.1225+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-283201 and No. 333-283202) on Form S-3 and registration statements (No. 333-277378, No. 333-285679 and No. 333-290197) on Form S-8 of our report dated December 22, 2025, with respect to the consolidated balance sheets as of October 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders&#x2019; equity and cash flows for the years then ended, and the related notes, of enGene Holdings Inc.</font></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ KPMG LLP</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Montr&eacute;al, Canada</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 22, 2025</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>engn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.1472+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Ronald H. W. Cooper, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of enGene Holdings Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.451%;box-sizing:content-box;"></td>
     <td style="width:5.059%;box-sizing:content-box;"></td>
     <td style="width:3.039%;box-sizing:content-box;"></td>
     <td style="width:46.451%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: December 22, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ronald H. W. Cooper</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ronald H. W. Cooper</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>engn-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.1471+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Ryan Daws, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of enGene Holdings Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: December 22, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ryan Daws</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ryan Daws</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>engn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.2085+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of enGene Holdings Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending October 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: December 22, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ronald H. W. Cooper</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ronald H. W. Cooper</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>engn-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-12-22T16:09:16.1896+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of enGene Holdings Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending October 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: December 22, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ryan Daws</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ryan Daws</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img209334158_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_0.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Z X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^/OV]_VSOAU
M_P $^?V3/B]^UU\4]&U_Q+X.^$>EZ+>7?ACPJVF+XE\2:AXC\3Z+X2T71M%.
ML7EAIPN[O5M=LS(]U=1I#:1W,X$K1")_L&OY9?\ @Z\^*7@;2/V/OV5/V?\
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M>_\ ?VV_^+H^J8C_ )]2^^/^?G^?9A_:>!_Z"(_^ 5/_ )#S_/LST>BO./\
MA8]E_P! N]_[^VW_ ,71_P +'LO^@7>_]_;;_P"+H^J8C_GU+[X_Y^?Y]F']
MIX'_ *"(_P#@%3_Y#S_/LST>BO./^%CV7_0+O?\ O[;?_%T?\+'LO^@7>_\
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MA_Z,]TG_ ,/?=?\ SKJ/^(E3Q#_T9[I/_A[[K_YUU'_$%O$C_HGX?^'?)/\
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M=?\ SKJ/^(E3Q#_T9[I/_A[[K_YUU'_$%O$C_HGX?^'?)/\ YXA_Q-+X'?\
M195?_$;XI_\ G+Y_GV9_5E17\IO_ !$J>(?^C/=)_P##WW7_ ,ZZC_B)4\0_
M]&>Z3_X>^Z_^==1_Q!;Q(_Z)^'_AWR3_ .>(?\32^!W_ $657_Q&^*?_ )R^
M?Y]F?U945_*;_P 1*GB'_HSW2?\ P]]U_P#.NH_XB5/$/_1GND_^'ONO_G74
M?\06\2/^B?A_X=\D_P#GB'_$TO@=_P!%E5_\1OBG_P"<OG^?9G]65%?RF_\
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MWR3_ .>(?\32^!W_ $657_Q&^*?_ )R^?Y]F?U945_*;_P 1*GB'_HSW2?\
MP]]U_P#.NH_XB5/$/_1GND_^'ONO_G74?\06\2/^B?A_X=\D_P#GB'_$TO@=
M_P!%E5_\1OBG_P"<OG^?9G]65%?RF_\ $2IXA_Z,]TG_ ,/?=?\ SKJ/^(E3
MQ#_T9[I/_A[[K_YUU'_$%O$C_HGX?^'?)/\ YXA_Q-+X'?\ 195?_$;XI_\
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M]_\ GP7_ ,"3_P#&* .VHKB?^$O?_GP7_P "3_\ &*/^$O?_ )\%_P# D_\
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MS_\ H58U;/B+_D/:O_U_S_\ H58U?24?X5+_ *]P_P#24?"5_P"/6_Z^U/\
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MR#R".A'K47GP;]GG1;\XV>8F_/IMW9S^%?T;7'[$_P"S)^T?_P %K/'GP/\
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M^*_#FI:1#;C389M6LK9UU&SFM@EYK^A>*9=LV)2ODYCQYA\MXEQO#U?+ZO\
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MK0:^U6"PAACM?%?@9^US\._VX?V[_P!@J;6OV7?A-\*OB/X>^(GB^Q^)>L^
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M)C+2_)0!KT4@(8!E(96 964AE96&596&0RL""K D,"""00:6@ HHHH ****
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M9I85BEDD5$B=E_)S_@B%^T%\+/A/^TG\?/!7Q2\2>%?"LWQX\%WOAWPAXO\
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MW,^!LE62X;&R<,%RXRCC*4JM:>#G&BJ-24(NM6C!\W]2_P"TWXJ\.7?_  <
M_LPZY!XFT2XT73]"\!6\^L1ZY82Z58$^%?B(9+:74%NFM+1I'NHRUNTL9D>[
MC)1FN5\S\6_^"H%[8ZI_P4!_:MO=.O;34+&[^)TK6][87,-Y:7$?_".: A>"
MYMWDAE575D8QNP61'C;#HRCX-$<84H(T"'J@10I[\KC!Y]J<JJH"J JC@!0
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M%.3SQ%&"YG&.9Y%[3%4IM:QA&675LSC*6G-.-"+O[MOW1HHHK^.S_3,****
M"BBB@ HHHH **** "OY OV[O@_\ &/XZ?\'.?P5^'WP'_:C\8?L@?$*X_P""
M;XU6W^,O@7P1X4^(?B"QTK2]3^(=SJ?AZ/PUXRGM]%EMM?@7R)[R207-J(5D
MMANRR_U^UYQ<?!WX17?Q5T_X[77PN^'US\;M)\*7'@32_C#/X1T27XFZ=X(N
MII;BY\'V/C9[,^(+;PU<3SSS3:+%?K8/)-*S0$R/D _EI_;VFD_8]_X*U?\
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M:X!9I1QE3),PSC)>)N*\DX;^HXG&Y?1R7AF68O'X?&Y_B,93Q&%Q<XY/F?\
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MS<75@D.JW%^+25[Y([&%#ZM^T9^T;\0OV*OVK_A3^QK^SKX!^%<?P!T#P_\
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M_&;]IOXS:]JWCZ]G\=^)_#5WXC\)Z+!X;\&:/IES:>&M#\0:Q=+;MI'@O1+
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M_7M'_*BC1O\ D%6'_7M'_*B@#POQ%_R'M7_Z_P"?_P!"K&K9\1?\A[5_^O\
MG_\ 0JQJ^DH_PJ7_ %[A_P"DH^$K_P >M_U]J?\ I<@HHHK0R"BBB@ HHHH
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M7Q!++?W]_9W$5S?M(T=T\D9Q7HND_MJ_M%:'XV_9[^(>G>+]*B\4_LM^#!X
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MP_Z]H_Y44 >%^(O^0]J__7_/_P"A5C5L^(O^0]J__7_/_P"A5C5])1_A4O\
MKW#_ -)1\)7_ (];_K[4_P#2Y!1116AD%%%% !1110 4444 %%%% !1110 4
M444 >\>#/^1;T[_MZ_\ 2VXJYXG_ .1:\0_]@/5O_2"XJGX,_P"1;T[_ +>O
M_2VXJYXG_P"1:\0_]@/5O_2"XKYZ7^\O_K^__3A]I1_Y%]+_ + X?^F$?Y=9
M^\__ %TD_P#1C44A/S/\K_ZR3^!_^>C?[-&?]E_^_;__ !-?Z<+9>B/\%&G=
MZ/=_G_P5]XM%)G_9?_OV_P#\31G_ &7_ ._;_P#Q-,5GV?\ 7_#K[Q:*3/\
MLO\ ]^W_ /B:,_[+_P#?M_\ XF@+/L_Z_P"'7WBT4F?]E_\ OV__ ,31G_9?
M_OV__P 30%GV?]?\.OO%HI,_[+_]^W_^)HS_ ++_ /?M_P#XF@+/L_Z_X=?>
M+129_P!E_P#OV_\ \31G_9?_ +]O_P#$T!9]G_7_  Z^\6BDS_LO_P!^W_\
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M=?>+129_V7_[]O\ _$T9_P!E_P#OV_\ \30%GV?]?\.OO%HI,_[+_P#?M_\
MXFC/^R__ '[?_P")H"S[/^O^'7WBT4F?]E_^_;__ !-&?]E_^_;_ /Q- 6?9
M_P!?\.OO%HI,_P"R_P#W[?\ ^)HS_LO_ -^W_P#B: L^S_K_ (=?>+129_V7
M_P"_;_\ Q-&?]E_^_;__ !- 6?9_U_PZ^\6BDS_LO_W[?_XFC/\ LO\ ]^W_
M /B: L^S_K_AU]XM%)G_ &7_ ._;_P#Q-&?]E_\ OV__ ,30%GV?]?\ #K[Q
M:*3/^R__ '[?_P")HS_LO_W[?_XF@+/L_P"O^'7WBT4F?]E_^_;_ /Q-&?\
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M\;_B=\>]4LV?3/A)X47PIX;GFA81'QC\0@\-W+!(P"FXTWPMIFH+( "T*ZQ
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M\5GJT231R0M)I\UPBRQR1E@Z,H_E=\0?"7PE=_\ !._Q[\08SX9^*W@SP/\
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M?^"NQ_\ C%<]_P +-\ _]#5I/_?]O_B*/^%F^ ?^AJTG_O\ M_\ $4>TJ?\
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M?_@4O\P]A0_Y\TO_  7#_(Z'_A'/#W_0"T;_ ,%=C_\ &*/^$<\/?] +1O\
MP5V/_P 8KGO^%F^ ?^AJTG_O^W_Q%'_"S? /_0U:3_W_ &_^(H]I4_Y^3_\
M I?YA["A_P ^:7_@N'^1T/\ PCGA[_H!:-_X*['_ .,4?\(YX>_Z 6C?^"NQ
M_P#C%<]_PLWP#_T-6D_]_P!O_B*/^%F^ ?\ H:M)_P"_[?\ Q%'M*G_/R?\
MX%+_ ##V%#_GS2_\%P_R.A_X1SP]_P! +1O_  5V/_QBC_A'/#W_ $ M&_\
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M^8>PH?\ /FE_X+A_D=#_ ,(YX>_Z 6C?^"NQ_P#C%'_".>'O^@%HW_@KL?\
MXQ7/?\+-\ _]#5I/_?\ ;_XBC_A9O@'_ *&K2?\ O^W_ ,11[2I_S\G_ .!2
M_P P]A0_Y\TO_!</\CH?^$<\/?\ 0"T;_P %=C_\8H_X1SP]_P! +1O_  5V
M/_QBN>_X6;X!_P"AJTG_ +_M_P#$4?\ "S? /_0U:3_W_;_XBCVE3_GY/_P*
M7^8>PH?\^:7_ (+A_D=#_P (YX>_Z 6C?^"NQ_\ C%'_  CGA[_H!:-_X*['
M_P",5SW_  LWP#_T-6D_]_V_^(H_X6;X!_Z&K2?^_P"W_P 11[2I_P _)_\
M@4O\P]A0_P"?-+_P7#_(Z'_A'/#W_0"T;_P5V/\ \8H_X1SP]_T M&_\%=C_
M /&*Y[_A9O@'_H:M)_[_ +?_ !%'_"S? /\ T-6D_P#?]O\ XBCVE3_GY/\
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MH]I4_P"?D_\ P*7^8>PH?\^:7_@N'^0?\(YX>_Z 6C?^"NQ_^,4?\(YX>_Z
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M9+4Q3 '[*45\'>&_VZ_"]_\ MH?MB?LH>,?#NC_#OPU^Q[\'OA!\7_%7QO\
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M%]AI.N>)_!I\-CP]IP\,ZS<>&+^]\2:%;)X@UN2_L=,DAE6WN9E1 #]A:*_
MCXG?\%R9/ /['WQ%_:ET?]E74?&&M>#OV^O%G["GA[X66OQ26SG\6ZIX;>_6
MS\=?\)''X&O9=/N-;:SCMH/"5OH.I&*^N4B77)H5\YOIR_\ ^"L7PG@_X)=Z
M5_P4QTSP5JFKZ;K^@Z7IVA_!*WUR-O$VH?&S5/&9^'*?!A-<ATJ9CJ=KXRCN
MK>YU2+P_+<+HMG-JJZ,3BVH _5NBOP-\._\ !<5M7_9;_8Q_:,U7]EN[T'5?
MVL_VY+[]BC5/AW+\5H[E_AAJFE^((M"U#QM_PD(\#1'Q28))T8>''TC00T\5
MS VM+&L-Q+1^/?\ P6C^/'PH^-?[=7A+X=_\$ZM>^.'P'_X)W^*M T?]H_XY
M:'^T/X3\*ZIX<\.^(+)[NT\3V_PVU[PBU_J G-CK0AL='U?5Q!!IJW.J76GK
M<!4 /Z **_)[]HO_ (*Q> ?A1\/?V0;WX*_!/XE_M+_'O]O'PEH_C;]F?]G+
MPK<:9X7\4:OX:U30;'7[K7?'GB+4DOM*\':-HL6H165]?&"_1Y[?4K]?*T72
M=2U&W^J?V0/CC^T=\<O#/C&;]IC]CKQ3^QS\0/"?B.RT:S\(ZQ\2?"GQ;T'Q
MII6H6#7L?B'P?XV\'V]KINHVMG*O]G:I;- );6]:-%>3<P0 ^N**^:'_ &SO
MV1X_A0?CM+^TC\(8O@NOCMOA<WQ0E\66\7@Y/B0E\=,?P-)J<D:F/Q(E^#;/
MI[PJR%6E9Q;JTP\V_;%_:FTGX6?#/]H#P;\(?CG^SKX(_:U^&_P1A^,^B>'?
MCOX@DL_!O@SP;/XJT3P_%\1?B;!9Q2R:?X&N&O[C2].OWD,<^O7>CK+"]E,[
MD ^X**_)/0/^"O\ ^RQX8_:4^"G[%?QG^*OPVM_C?XU^!?@#QQXY^*?@_P 6
M:9_PHS3_ (M^+K+018_"70UO6;Q/_P )%XZ?6['Q-X!MY[7[+=^%M;T.:XN%
MFN'6/ _94_X*]?!3XE^-/VF?AW^U#\3/V=_V;_''PI_;;^,7[*OP=\):Q\0O
M[$\0_%3PW\--3TO2--\67FF>)]3N)H-7U/4M233[VZMAIOAEK\Q6EEY<_F14
M ?L717GOQ=^*G@3X%?"WXB?&?XI:XGAKX=?"OPAKGCGQKKKP2W;:?X?\/V4E
M[>R6UG #/?WTZQK:Z=86X,]_?3VUK#\\RFORU_91_P""E7[5_P"U9XN^$OBO
M1/\ @EU\9/!?[''QKUE+7P7^TSXA^,'P^G\0V?A:\-PNE?$3Q1\%+:S3Q)IG
M@N]:WWC5[;4[VRDMY8KG3[S4+=XI90#]C**_GXT+_@O'IGB7]DCX6_'WP[^R
MCXF\1?&'X^?M;^,OV/O@?^S]I/Q3\/6=IXJ\<^%AI$EOKOB/XI^(]"T71_"F
MCZD-=TRS>.;1KPVFI7:*;F338KK48/UK_90^,/QW^-/PZUC7OVCOV4_%W['W
MQ/\ #WC'4O"FH_##Q5XV\-_$6UU2QL]-TG4;3QCX2\:>%HK?2]>\,:DVISZ;
M!="V@D&HZ3J$:B2)8Y6 /IRBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT?35:SOHK_1XO#@UU?[#MO$5Q?RP1S 'WU1110 4444 %%%% !1110 4444
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MI@,+E.>Y)EV%Q]'%XC!XG!4<?@L?E6,QF.ITLTR?#XW!X>E7H*>.P$*E.O\
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M_@?P,;PPZUK4)%F"LMC8RK@W9!!2XN$89%L",QQG!F(W,/+QN /<000""""
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MV<*J;;3KZ9T@/TW+&T,DD3XWQ.\;[3E=R,5;!P,C(.#@9'.* &4444 %%%%
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MFG:+\0M)33M!LO#UQ/<3OIT^E/<:I8Z?:R7,MM96KVURKM9M'%+)$_*^#O\
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M9!@W9'*7%PIY%L#AHXR 9^&;$?#^X          8  X  '  '  X X%+M88
M1@   !&P  X  "@  <  8 X%&UO[C_\ ?#?X4 )12[6_N/\ ]\-_A1M;^X__
M 'PW^% "44NUO[C_ /?#?X4;6_N/_P!\-_A0 E%+M;^X_P#WPW^%&UO[C_\
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MDHHL^+2US_S[0?\ HI:* / ?$7_(>U?_ *_Y_P#T*L:MGQ%_R'M7_P"O^?\
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M4?\ \>H_X7?\0/\ G\TK_P %4?\ \>H ^IO^%?\ @C_H4] _\%=I_P#&J/\
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M4?\ \>H_X7?\0/\ G\TK_P %4?\ \>H ^IO^%?\ @C_H4] _\%=I_P#&J/\
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MRG_^.T >@45Y_P#\)9J'_/M9_E/_ /':/^$LU#_GVL_RG_\ CM 'H%%>?_\
M"6:A_P ^UG^4_P#\=H_X2S4/^?:S_*?_ ..T >@45Y__ ,)9J'_/M9_E/_\
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M_P =H_X2S4/^?:S_ "G_ /CM 'H%%>?_ /"6:A_S[6?Y3_\ QVC_ (2S4/\
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MXZ\,^!/B!X4\6^(/!=W'>SZ;);>*]&T'5;_4?#\T>HVUQI[QZI;VK)>P36K
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M0?RC_P""6'QZ_:@UK]HG_@H]^QE^U!\<9_VF=9_8S^*WP]TOP3\<M6\&>'?
M7B;Q+X:^(6B:SJ<FEZ[X?\+QII<;:?)I]I);'S;R6U>6[MH[VXM#;B+X\^%/
MP=^#G[;O_!>+_@H_X1_;3\#^$OC5+^SA\+O@[X8_93^"GQ5M(/$_@VR^'WB#
M2=,U'QCXR\.> M4>31]9U!I[G2M6O;PZ=>O:7/C&[O9%6>WMY[4 _H:L/CE\
M$M5U?X?:!I/QC^%>JZ[\6M,U/6OA3HNF?$'PIJ&J_$[1]$CEEUK5?A]86FJS
M77C+3M'B@GDU2\\/1:A;Z>D$YNY(O)DVT;3]H7]G^_\ B7<?!:P^.WP9OOC'
M:-(EU\)[+XG^";KXDV\L,?G30S>"8-;D\1QSPQ R30-IPFB0,SHH5L?@!^T!
M\(_@_P# ;_@MU_P0_P#A=\#O"/A?X<_"WPM\-?VRGT+PMX*DC7PYX:NM8\/_
M !=UGQ"-+5KR\BT\IKNHZG>SV2W$<&FW4D]ND-I''Y,?RE\ _@-;_P#!(7]I
MG]GCP/\ MG?L@_ #]H7X?_'C]KF_'[+'_!3SX>WRW/[0&F_%'Q]J@N/"]A\3
MK26>37]=AMY-0EN;RVMY3H-C'-J%[97?BF:'  /["Z*?)&T4DD3C#Q.\;@$$
M!D8JPR.#@@\C@]J90 4444 %%%% !1110 4444 %%%% !1110 4444 %7-/U
M"[TN[AOK&9H+F!LHZ]&!X:.1>CQ..'0\,/< BG10!]/^%O%-IXEL]Z[8-0@4
M?;++=RAS@30YY>WD(X;&4/R/@X)ZFOD/3]0N]+O(;^QF:"Y@8,CKT8?Q1R#H
M\3CY70\$>A (^D_"WBFT\2V>]-L&H0*HO;,MRAZ>=#GE[>0@[6ZH?E?!&2 =
M31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5YG%\:_@S/\4K[X&0?%WX8S_&W2_#P\6ZG\'(?'GA>7XIZ;X5,
M%M<CQ-J'@"/4V\4V6@&VO+.Y&K7.EQV/V>[M9_/\JXB=[WQ7\=7?PN^%OQ*^
M)EAX,\2?$?4/AYX"\6^-=.^'G@ZREU+Q;X\U'PSH5]J]AX.\-6$"23WFM^);
MRT@T?3H(8Y96N+M#'%*X$;?Q2_\ !.[XEZ?IO_!8S]EGXG_''P%^T/X3_:C_
M &EOV.?VM_'?[6?B3XK?LU_&?X8PZ7\8_BO\1IM9TW3K:7QYX3T=[7]GSX#_
M  VT/0OA98_$N(M\.=#C\*[9]9M)]8:) #^P/X8_MG_L=?&WQL?AI\&/VLOV
M:OB[\1ULM0U)OA_\,?CC\-?'?C9=-TE%DU74#X6\,>)-3UL66F1NDFH71LO(
MLT=6N'C5@3]*U_*+_P $X=<\<?\ !,C]I+_@GQ_P3!OYOV"OVO/ 7[0'PW^/
M&I>!OVE_V4_#%YI?[0/PRTWPPNM_%*]\2?&W6I=>\8V'B/X?^+IM<_X1CPWK
M=C/X76\M;*:T<WCZ&D.H_:__  40_:$^-_A__@IS^P7^R+X2_;9N?V*_@K^T
MG^SS^TGJWQ&\86FF_"B;5KOQ;X%O]*U'PC/X,UKXLZ-JWA[P_P".Y(K.XTG2
MM0O+;5+5=(N];A@T"^U:XL+FT /W9N+_ $^TFL[:\U'3K.ZU*5[?3+6\O[2T
MNM3N(XS+);Z9;7$T<^HW$42F:6"RCGFCB!E=%0;JM5_"1)\7?V@OVWI?^"(/
MQ@^./[9WQ)\*ZI8_\%!?VO?V:= _:,\ :?\ !OP7HWBKP_\ "FTURU\+_M0Z
M&?%/P^\0>$;?XB>.]%G3P#K%Q>1:MX"U73/#ZR6'A*#Q#)J&I7?Z\>!_VOOV
MEOAO_P %:;3X0_M-_M,>-M6^!WQL^-'Q+^''[(6C?!+4OV8_B1^S+XH\&_#G
MX=7=WJG@#]H?0M&L8OVD?@]^T5X4U.SD\3>+_'EQJK^"KC5H+O1X_#5EH9DO
MK4 _H_HKR'X$_'[X+?M/?"_0/C5^SW\2O#/Q<^$_BFYUJS\/^//"$]U<:'JE
MWX<U:[T'7;6!KZTL;Q)]+UBQN["ZBN+2%UEAWH'ADBED]>H **** "BBB@ H
MHHH **** "I[7_CZM?\ KYM__1R5!4]K_P ?5K_U\V__ *.2@#V&BBB@#YX\
M1?\ (>U?_K_G_P#0JQJV?$7_ "'M7_Z_Y_\ T*L:OI*/\*E_U[A_Z2CX2O\
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ML:MIFDZY>^&=8CU;POJT.M:+J.EZ_IN+[3+NVO8=DCP96YLI[NRG1[>YD4^
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MRKJ>*_DTIHXIK$P7,,4Z?J;10 $DDDG)/))ZD^IHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KI_"-EK5YK5LVB.UO<6["2:[(/D6\!.'^
MT8X>.0?*(3S(V  ",BEH6A7WB&^2RLDP!AKBY8'R;6'.#)(>A8](XP=SMP.,
MD?2^AZ)8Z!8QV-C'@##3SL!YUS,0-TLS#J<\(H^5%X4=20#6&<#)!; #$# +
M #<0N3M!.2%R=H.,G&:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!02I#*2"#D$$@@CH01R"/45PVH_#'X:ZQ
M\0],^+FK_#[P9JOQ6T7PAJWP]T?XE:EX;TJ^\<Z7X!U^]34==\$V'B:ZMI=5
MMO"FM:A''>ZKH,5RNFW]TBS7-O(XS7\[_P"WM_P42^,?PF_X*I>(/V1;S]O[
M0OV$O@%I/['/PP^-7A_Q'_PQKI'[56O>+/BIXL\>ZSX;U/P_.O\ 8.LZUHFF
M3:):-J<=S.T>FP3::EK"8I;MQ/\ ;7QZ_P""OWP>_98^(OQD^ GBSX-_M9?M
M ?$3]E;X)?"SXS_'WQQ\$_A)X+OO"5G\,O&'AF35-:^,&HF^^('AVQ\-:9I
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M)^;J?<7_ '5_D*=7T&O[/.M  ?\ "2:7P /^/&[[#_KK2_\ #/6M?]#)I?\
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MNW/BK5O&?Q/\6VM];BZENK;0O!NF0Z)965KJK)JE[=_M3_PSUK7_ $,FE_\
M@#=__':/^&>M:_Z&32__  !N_P#X[0!^./CC]B?Q7K?QG^)GQ]\(_$WPWH_C
M_5OVI?@I^U!\*]/\0^%]6U3PIHU]\+O@'=?L_>)O 7Q'AL-5M=1UC2/'/A?6
MO$=S9:_X8DL-3\)7]SI-];VFI36$\-R[PQ^Q3XIM/C7\.OVA/%GQ*\,ZA\1;
M']H[XF?M"_%2Q\.>&-8T_P )ZN?%_P"S\?V>/!OP_P#AW'J.K7.JZ9I'@?PM
M8Z)?7NO^*I-0U7Q1J*ZS<36VG"[LK>S_ &,_X9ZUK_H9-+_\ ;O_ ..T?\,]
M:U_T,FE_^ -W_P#': /SF^$7P0\4?"GXV?M,>.X_$OAC6OA[^T3XZT#XJC1W
MTO6K3Q]X1\<:7\/_  9\.M0TG^T5O)?#&K^"[W3/""ZQ9R_8[3Q#9ZG>FSF-
MQ91><WF/A3]GOX]:=^V%XM_:<\=>,/@7\1M+NXX? ?PDTK4M&^)NF>*/V??@
M1*UE=>)O"/PZLH-1NO!ES\1_B-J]G%K?Q)^)6K1B\\2_8]#\,6]OI'A/0K?3
M)_UG_P"&>M:_Z&32_P#P!N__ ([1_P ,]:U_T,FE_P#@#=__ !V@#\,?A;^Q
M;\8?@WX3^ ^E>-?B3X7^+_@;]CWQS\>OV@/AEX/^&_P]U/P[\4?B1\0O'VG_
M !-3P9\/M6O?$7BFX\+1Z!X-M?B=XDL](O['^SM7\6:[+H4GB"YTK3-.O'O_
M 'OXE?!7XR_M._L10_!SXQZYX#\ ?'CXA^"?AO=?$O5?".D:QJ7P]\->.-&\
M6>&/&_B#3/#^E3ZO-K%QIEL^BOH$$DFM7+?;=]^ES/9A$?\ 5/\ X9ZUK_H9
M-+_\ ;O_ ..T?\,]:U_T,FE_^ -W_P#': /S[\$?!2^\(_M-?M(_M S^);2_
ML/CUX8^ ?AZP\,6^G7-OJ7A:3X+Z'XQTB]N[W5I;F2UU-/$4GBF.ZLHK:UM6
MTY;*5+E[EYT9/ /"G[)?Q \,_M#Z'\:= O/A+\']$3Q'KFI_$'PE\ _%/QS\
M+^'_ (O:3K%K?QE/B+\(==N]0^"FK^*7OY=/UBX\9:7X=\/^*HM1M[V2#Q#+
M#J5_!>?L'_PSUK7_ $,FE_\ @#=__':/^&>M:_Z&32__  !N_P#X[0!^<WQ9
M^ >H_%WXZ?LR_$37?%.G)\,?V<==\=?$V+X:'2KN74/&'QOU3PW_ ,(?\,?&
MU_K'VQ=.AT3X5Z)K/C;4],T>73I[VX\7:WI&M07MJNB^5<?._CS]A?Q5XNU#
MX^^ K/XE>#[#]F[]I[X_^ OVB?BMX8O_  CJ]Y\6--U[PP? U[XR\!^!_$$&
MJ0^$/^$-^)NM?#3PK?:CK'B'2KGQ-X5MM2\6VFBF\:ZT:;3?VA_X9ZUK_H9-
M+_\  &[_ /CM'_#/6M?]#)I?_@#=_P#QV@#Y_ED,LLDI 4R.SE1G"[F+8&<G
M S@9)..IS4=?0G_#/6M?]#)I?_@#=_\ QVC_ (9ZUK_H9-+_ / &[_\ CM '
MSW17T)_PSUK7_0R:7_X W?\ \=H_X9ZUK_H9-+_\ ;O_ ..T ?/=%?0G_#/6
MM?\ 0R:7_P" -W_\=H_X9ZUK_H9-+_\  &[_ /CM 'SW17T)_P ,]:U_T,FE
M_P#@#=__ !VC_AGK6O\ H9-+_P# &[_^.T ?/=%?0G_#/6M?]#)I?_@#=_\
MQVC_ (9ZUK_H9-+_ / &[_\ CM 'SW17T)_PSUK7_0R:7_X W?\ \=H_X9ZU
MK_H9-+_\ ;O_ ..T ?/=%?0G_#/6M?\ 0R:7_P" -W_\=H_X9ZUK_H9-+_\
M &[_ /CM 'SW17T)_P ,]:U_T,FE_P#@#=__ !VC_AGK6O\ H9-+_P# &[_^
M.T ?/=%?0G_#/6M?]#)I?_@#=_\ QVC_ (9ZUK_H9-+_ / &[_\ CM 'SW17
MT)_PSUK7_0R:7_X W?\ \=H_X9ZUK_H9-+_\ ;O_ ..T ?/=%?0G_#/6M?\
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M\_%I_P!]3?\ QF@#EJ*ZG_A$[[_GXM/^^IO_ (S1_P (G??\_%I_WU-_\9H
MY:BNI_X1.^_Y^+3_ +ZF_P#C-'_")WW_ #\6G_?4W_QF@#EJ*ZG_ (1.^_Y^
M+3_OJ;_XS1_PB=]_S\6G_?4W_P 9H Y:BNI_X1.^_P"?BT_[ZF_^,T?\(G??
M\_%I_P!]3?\ QF@#EJ*ZG_A$[[_GXM/^^IO_ (S1_P (G??\_%I_WU-_\9H
MY:BNI_X1.^_Y^+3_ +ZF_P#C-'_")WW_ #\6G_?4W_QF@#EJ*ZG_ (1.^_Y^
M+3_OJ;_XS1_PB=]_S\6G_?4W_P 9H Y:BNI_X1.^_P"?BT_[ZF_^,T?\(G??
M\_%I_P!]3?\ QF@#EJ*ZG_A$[[_GXM/^^IO_ (S1_P (G??\_%I_WU-_\9H
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M9)0I.2HD=G"DC )&<$@#/6ND_P"$3OO^?BT_[ZF_^,T?\(G??\_%I_WU-_\
M&: .6HKJ?^$3OO\ GXM/^^IO_C-'_")WW_/Q:?\ ?4W_ ,9H Y:BNI_X1.^_
MY^+3_OJ;_P",T?\ ")WW_/Q:?]]3?_&: .6HKJ?^$3OO^?BT_P"^IO\ XS1_
MPB=]_P _%I_WU-_\9H Y:BNI_P"$3OO^?BT_[ZF_^,T?\(G??\_%I_WU-_\
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MI10!]U_\+:^'?_0SVG_@-J'_ ,AT?\+:^'?_ $,]I_X#:A_\AU\*44 ?=?\
MPMKX=_\ 0SVG_@-J'_R'1_PMKX=_]#/:?^ VH?\ R'7PI10!]U_\+:^'?_0S
MVG_@-J'_ ,AT?\+:^'?_ $,]I_X#:A_\AU\*44 ?=?\ PMKX=_\ 0SVG_@-J
M'_R'1_PMKX=_]#/:?^ VH?\ R'7PI10!]U_\+:^'?_0SVG_@-J'_ ,AT?\+:
M^'?_ $,]I_X#:A_\AU\*44 ?=?\ PMKX=_\ 0SVG_@-J'_R'1_PMKX=_]#/:
M?^ VH?\ R'7PI10!]U_\+:^'?_0SVG_@-J'_ ,AT?\+:^'?_ $,]I_X#:A_\
MAU\*44 ?=?\ PMKX=_\ 0SVG_@-J'_R'1_PMKX=_]#/:?^ VH?\ R'7PI10!
M]U_\+:^'?_0SVG_@-J'_ ,AT?\+:^'?_ $,]I_X#:A_\AU\*44 ?=?\ PMKX
M=_\ 0SVG_@-J'_R'1_PMKX=_]#/:?^ VH?\ R'7PI10!]U_\+:^'?_0SVG_@
M-J'_ ,AT?\+:^'?_ $,]I_X#:A_\AU\*44 ?=?\ PMKX=_\ 0SVG_@-J'_R'
M1_PMKX=_]#/:?^ VH?\ R'7PI10!]U_\+:^'?_0SVG_@-J'_ ,AT?\+:^'?_
M $,]I_X#:A_\AU\*44 ?=?\ PMKX=_\ 0SVG_@-J'_R'1_PMKX=_]#/:?^ V
MH?\ R'7PI10!]U_\+:^'?_0SVG_@-J'_ ,AT?\+:^'?_ $,]I_X#:A_\AU\*
M44 ?=?\ PMKX=_\ 0SVG_@-J'_R'1_PMKX=_]#/:?^ VH?\ R'7PI10!]V#X
ML_#LD >)[/)( S;WX&2<<DV@ 'J20 .20.:ZM?$.BNJNFH0NCJKHZ"5E=&&5
M966,AE8$$$$@CI7YT5Z7X(\;MI#1Z5JLC/I3MM@G;+/ISL>_4M9L3ETY,))=
M/DW* #[-_M_1_P#G^C_[XF_^-T?V_H__ #_1_P#?$W_QNO+E97571E='4.CH
M0R.C#*LK#(96!!!!P12T >H?V_H__/\ 1_\ ?$W_ ,;H_M_1_P#G^C_[XF_^
M-UY?10!ZA_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C=>7T4 >H?V_H_\
MS_1_]\3?_&Z/[?T?_G^C_P"^)O\ XW7E]% 'J']OZ/\ \_T?_?$W_P ;H_M_
M1_\ G^C_ .^)O_C=>7T4 >H?V_H__/\ 1_\ ?$W_ ,;H_M_1_P#G^C_[XF_^
M-UY?10!ZA_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C=>7T4 >H?V_H_\
MS_1_]\3?_&Z/[?T?_G^C_P"^)O\ XW7E]% 'J']OZ/\ \_T?_?$W_P ;H_M_
M1_\ G^C_ .^)O_C=>7T4 >H?V_H__/\ 1_\ ?$W_ ,;H_M_1_P#G^C_[XF_^
M-UY?10!ZA_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C=>7T4 >H?V_H_\
MS_1_]\3?_&Z/[?T?_G^C_P"^)O\ XW7E]% 'J']OZ/\ \_T?_?$W_P ;H_M_
M1_\ G^C_ .^)O_C=>7T4 >H?V_H__/\ 1_\ ?$W_ ,;H_M_1_P#G^C_[XF_^
M-UY?10!ZA_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C=>7T4 >H?V_H_\
MS_1_]\3?_&Z/[?T?_G^C_P"^)O\ XW7E]% 'J']OZ/\ \_T?_?$W_P ;H_M_
M1_\ G^C_ .^)O_C=>7T4 >H?V_H__/\ 1_\ ?$W_ ,;H_M_1_P#G^C_[XF_^
M-UY?10!ZA_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C=>7T4 >H?V_H_\
MS_1_]\3?_&Z/[?T?_G^C_P"^)O\ XW7E]% 'J']OZ/\ \_T?_?$W_P ;H_M_
M1_\ G^C_ .^)O_C=>7T4 >H?V_H__/\ 1_\ ?$W_ ,;H_M_1_P#G^C_[XF_^
M-UY?10!ZA_;^C_\ /]'_ -\3?_&Z/[?T?_G^C_[XF_\ C=>7T4 >R0S1W$4<
MT+!XI5#QN 0&4]" P!&?< T50T;_ )!5A_U[1_RHH \+\1?\A[5_^O\ G_\
M0JQJV?$7_(>U?_K_ )__ $*L:OI*/\*E_P!>X?\ I*/A*_\ 'K?]?:G_ *7(
M****T,@HHHH **** "BBB@ HHHH **** "BBB@#WCP9_R+>G?]O7_I;<5<\3
M_P#(M>(?^P'JW_I!<53\&?\ (MZ=_P!O7_I;<5<\3_\ (M>(?^P'JW_I!<5\
MW6_BU?\ KY/_ -*9]QA/]TPO_8/1_P#3<3\Z4^XO^ZO\A3J:GW%_W5_D*=69
MT'S)^VE\?]2_93_9(_:*_:5T;PUIWC+5O@?\+/$'Q"TWPIJ][=Z=I7B"]TAK
M6.WTW4K^P!OK6REDN@]Q+9@7!CC*1,CN)%_+?]E#_@JM^UA\0/VCOV,_@5^U
M7^R-\)OAGHO[??P=U?XQ?L\^._@=\8;_ .(%U9Z%I?AC_A*T/Q*\):M]LO\
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MQ2M6_MKQ'XJ\0>']5L].FTFSO)+BZLK46]C!-<):Z=IOV]\1OV,?BGXGNO\
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M%I45R]_+:7*6[02?S#_![_@G?\:_%/\ P4%T7XX?!+]A?7_^"5_P,U_]G/\
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M/+9/B'X1^'MSK+6VJZ WQ!LKB/PS]LU+5M0M/"^A&6[T/3I/$"Q7;^&>#_\
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M]DM/^?:W_P"_,?\ \31]DM/^?:W_ ._,?_Q- 'DV1ZC\Q1D>H_,5ZS]DM/\
MGVM_^_,?_P 31]DM/^?:W_[\Q_\ Q- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_P"_
M,?\ \31]DM/^?:W_ ._,?_Q- 'DV1ZC\Q1D>H_,5ZS]DM/\ GVM_^_,?_P 3
M1]DM/^?:W_[\Q_\ Q- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_P"_,?\ \31]DM/^
M?:W_ ._,?_Q- 'DV1ZC\Q1D>H_,5ZS]DM/\ GVM_^_,?_P 31]DM/^?:W_[\
MQ_\ Q- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_P"_,?\ \31]DM/^?:W_ ._,?_Q-
M 'DV1ZC\Q1D>H_,5ZS]DM/\ GVM_^_,?_P 31]DM/^?:W_[\Q_\ Q- 'DV1Z
MC\Q1D>H_,5ZS]DM/^?:W_P"_,?\ \31]DM/^?:W_ ._,?_Q- 'DV1ZC\Q1D>
MH_,5ZS]DM/\ GVM_^_,?_P 31]DM/^?:W_[\Q_\ Q- 'DV1ZC\Q1D>H_,5ZS
M]DM/^?:W_P"_,?\ \31]DM/^?:W_ ._,?_Q- 'YJ_M _\$Y_V#/VKO'</Q0_
M:4_9.^"_QL^(MOX?TSPI#XU\>>'9]2\0Q^&M&FO9])T,7UOJ%H3IVGS:C?2V
ML#(1&]U*<G(QZ4?V2?V73/\ $BY/P&^&C7'QA^$WA[X#_%69]#WR?$'X+^$M
M#D\,^&?ACXI=[AFU+PCH?AZ5]%T_3G*M'I^(7F?:&'W!]DM/^?:W_P"_,?\
M\31]DM/^?:W_ ._,?_Q- 'Q?X&_9>_9P^&/C3PE\1OAW\%?AYX*\?> O@WH_
M[._@GQAX>T1;#7O"OP)\/7L.I:'\)=%O5F9K/P1I-_!#>66DJK"&>-7$I(K@
M="_8)_8@\+_'B[_:B\.?LF? '1/VB;[4[O7+CXQZ=\.=!M_&Q\0:AC[?XD@O
M5@-I9>)KT@M=>([&RMM<FD:25[\RRR2/^AWV2T_Y]K?_ +\Q_P#Q-'V2T_Y]
MK?\ [\Q__$T ? X_8H_9 %Z=2'[-_P )1?G]H9OVM?M@\-H)_P#AIY[4V3?'
MCS/M&1\2C:DP'7A\VSCR>]9$'[ _[$%K\?I/VJ;7]E#X#6W[2$NM'Q/)\:+?
MP!I$'CAO%)SGQ6;Z)$M!XJ))D/B1;$:WYY:Z^W?:B9S^A_V2T_Y]K?\ [\Q_
M_$T?9+3_ )]K?_OS'_\ $T ?FEJO_!-__@G[KGQ*\1?&35_V-/V==0^+'BSQ
MAX?^(/B+XAS_  XT9?%6I^.O"VM6_B/0O%[:E"D36GB"TU^UMM8N-1T]+2?5
M=0A2XU@Z@^[/VLTA=F=WW.[%G8D$LS$EF)]222?<UZO]DM/^?:W_ ._,?_Q-
M'V2T_P"?:W_[\Q__ !- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_[\Q_\ Q-'V2T_Y
M]K?_ +\Q_P#Q- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_ ._,?_Q-'V2T_P"?:W_[
M\Q__ !- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_[\Q_\ Q-'V2T_Y]K?_ +\Q_P#Q
M- 'DV1ZC\Q1D>H_,5ZS]DM/^?:W_ ._,?_Q-'V2T_P"?:W_[\Q__ !- 'DV1
MZC\Q1D>H_,5ZS]DM/^?:W_[\Q_\ Q-'V2T_Y]K?_ +\Q_P#Q- #-&_Y!5A_U
;[1_RHJVH"*%0!54855^50!T  P !Z 44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img209334158_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_1.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '3 X0# 2(  A$! Q$!_\0
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MH **** "OQT_X+N_\HZ?B-_V//PN_P#4OLJ_8NOA/_@H[^RMXR_;,_97\6?
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ME/X1UGQ+JLB:.EIILNB/#?KK%I DM[JEF]L4N)6AG"11R^_D?%^1X# \(O\
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M/>#_ ("7'A"7Q5H/B%/$#>)=73PU\1I?&TW_  CZZ;IEUI<C7=G(+&(:C?V
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M,MO%(UQ)'KCZU\+A +B,+=W278AWFW)'U[^V#X8_82_94T[]B/\ 9Y^+_P
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M5\-6VHW%E?Z3X>NI)XM*OYWU&5;QK6=;1DCC^S6EL[W+W&;^U_\ \$N_B_\
M%?X^> OVR?V9_CKH?P0_:DT30M!L/&NH:AINH7/@OQ'K.CZ$F@OK>FR6EEJ-
M]8K=:4T^@ZGI6J:)K&FZYH2V<-S!:317#771Z3^PE^VKXU^!O[6WAS]I;]KG
M2/BY\5/VB/A++\,?!^DVFD:EH'P:^&H0:A.FJ6ND:=IVGG[3J5U?"/4;K2_"
M-A=):6Z*_P#:3&-(/%Q7$&7XC#\'8G \84<NRO*<LX;RS->%O^%2$ZV.R[-<
M/6S#$_5Z6&_L^OAZSIK,98ZM6567L(P<75<8+ZG+N#LYP6-\3,%FWAOB<ZS_
M (BS[C;/LAX^:R*K3P^4YSP]B\+D^"6,Q&-6<8;&855'DL,IPV&="'UJ=93A
M04ZDO@'_ ((V_P#!/[]GOXB_L_>#_P!LSXDZ9XP\;?%WPA\2M3USP+'%XDU6
MRTSPO#\(]24Z!H^F:)97,5IK*ZA>6KSW4.LK=0$2V]E806"132W7GG_!(G]G
MKX3_ /!0;XJ_M>_M)_M<^'+3XT>,HO&FBVFFZ!XONKV[T?2/^$O_ .$EU.\N
MCI4=S#%)%IUG8Z?X?\,VLI:QT*RTZ=+"UBG$,T/[P?\ !-[]E#QC^Q?^RUX;
M^!?CWQ+X9\6>)=*\3>,-?O-6\(KJ@T(Q>(]7DO[:UMGUFRT^_F>W@*K/)+96
MZF5F6-611(_YUW__  2=_:M_9V^.OQ)^+/\ P3L_:G\)?![PW\5[F]N_$7P^
M^)'ANXU;2]*^VWM[J":;9"/0/%VE:Q8:/=ZC>R>&;N]T73M8T*WN9+%+Z[C+
MS2]E;C7#YMF?B-A/]:WEN(S2OAZ/">>XBICX83"Y9A,SGB,3EU"OA*%7$Y=A
M\?AU1?-2H1C6E3?MKSDN?R\+X68SAW(O!+,8^'T<[P?#^$QF)\1.$\%0RFKF
M689]F.14,'@L[Q>%S'%8?!9UB\HQOUE*&(Q4YX:-:/U;EIP?L_DW]C'PE+^S
M'_P6=_:+_91^!>LZKX8^$GC#P9XY@3P^+Z\U"PT"ZB\!Z1XW\+Z@$EFF:>[\
M':SJESI6DWU[(U\FEWLEC-=222GS/C;P;\._!O[ _BSXD^ ?^"G'[!.L_&CP
MMX\\:7,EE^TGIUUK&IW$<-VS)/=^%M>6\LM*U2/5F-SX@>*'Q!X<\:B[N+F#
M4(;N6VBM(?Z!/V(/^"7>I_LZ^*/C#\=?C9\:-1^,'[4/QKT+7M!UGXE:=9S:
M=;>#[?Q(6EUB^\-2WSG4+W7;ZZBTV9]7N(-+AM+;2[/3--TNSM1.UQ\I?$3_
M ()??\%-/BUX"_X9O^)7[?\ X,\<?LW-K&G3W%SXE\%ZAJ7Q2U'2](OH;O2H
M]6O9]&?4=4FL&MK:ZAL[WXB36K7L$;2SO$NT^MA^-,AQ&=8VE6XAP/\ 9M3)
MN%\LSW-:E7/\JS7-\9D]+$_6<ZR7,,MPTL5.O1J5(T_JF80I1QZC3?,J<7)_
M.8SPPXPP?#&58O#\&YL\]H<3<?9[PIP_1H<)<0Y!P[EO$V(R]8'A?B?)L[QT
M,!3PF(H8>I5_M#)YUI91SUO<>(G&$/,?^"GG[/WC3XY^'OV&_P!IK]ESX8R_
MM0?LE?"?X=:'''\%=-O/$-TU]X3M)=,O].N+O1;>X3Q7>Z=K/A72[?PKX@O=
M/%WXDT>32$7489(YIF7ZQ_X)+?'#]@SXG>,?BW:?LZ?L]W?[+/Q\?P[H@^*W
MPNO)=0^R7^@^&=5O+.VU#0%:[72GCT/6]=FL=8C_ + \-ZY;7&H6JW]A-"T<
MR>C_ !0_8)_:Q^'^D?L_6'[!'[6S?!O3_@E\(=/^$-]X&^)&E2>(? OC6WTW
M4;K5$\:ZIIL6E^(-)'BF]NK^\6^=_"TI$*6<%G?VMO"]O+:_8 _X)M^.?V:_
MC+\6OVI?VB?C#IOQG_:+^+UE=Z5JVJ>'-&DT?PQI-GJ>HZ?JFMWD)N;:PN-0
MU;59](TJU22+2-%LM+TRQ:SM[2<W<LR?+X[/,AQ? N,RNOGZJ2P=/%4^'L/@
M\3G6&S7%>WSF6+6%XDRR6'628V#A;%RS&-955-0C",JT=?O\IX3XOR_Q9RW/
ML)P?+#PS.M@*W&>+S/ \,8WA[ _5>&Z6 >/X)SZ&,GQ1EM2-7GRZGDCP\\/*
MG*I*I.&%DN3]=:_EJ^$W_*QY\3_^P5XT_P#5#>'J_J5K\=O!?_!./XI>&/\
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MCOXX^('@?QMX9T70_%VB?"#2M M]=7Q!IC>)=06SAU?Q,NJZ9:Z?;7UEX/\
MM6DF/2KW44:ZU*Z=)EAC1I/UC'<?\*U<RXLS"KCJ6*Q.19E_;O!%50J.&,QV
M.X<IY57PT%.B^6CA\?2H8Z2G[-^VIQJQE*--I_SOE'@]XA8?(_#K*,/E=?+\
M%Q9D4.$?%6A*I1A6RS*\HXSJ<087'3<,0E+$XS*:V+RJ$J;K1^JU98><(RJT
MVOE[X)Z-I?AS_@X=\8^'-#LHM.T3P[X$U;0-&T^W!$%CI.B_L^^%=,TZTA!R
M1';6=K#$@))"H,D]:X;QYX__ &#_ !?^TM^T7I'P)_X)L?&#_@H/\0]4\?\
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M3=4FL[<B$7OVBZB0-<SO)]W^"O\ @E9_P4A_9W\+>-O@A^S#^W9X(\/?L_\
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M#\7>(Y+OP+XCNWT.9HHO#GAS78K.&P\ ^&]"T-Q=&T:9-=U%8XYA-<D>F?\
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M)Q]*=-8;)G7E+#Y/]?C)^T:SS,:=;+L![-.^)I34[)'[BT5\%?%3]O\ \$^
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M=NI[A/!_@2;7K:UA^,MK+;7,&O:A/>1Z;=:; ]M9ZE,^[=[OX^_;6^$O@?\
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MAY^U-\*=(^+OPU.MV^B:AJ.M:#JFA^*-,;1/%7A3Q3X:U&;2?$7A;Q/I#37
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M$!O]#T[6O'FD%[QO"6GZY>6^=&DUF>VDO(Y[91&D\Z0GJ?V5?AOX^\/>)?\
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MBL'B\5FM;"8O!4OJM"MAX1Y533<#^<KX1?LS?''Q'^Q)_P %5?AO:?!WXO\
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M3V\*V\K2Q=G\-+?XC_M3_M[> /VHQ\%/BI\#_@W\ _@AX\^'FD7_ ,:_"S^
M/'GQ1\9_$S4],FN[:P\$7=Q-K=EX2\*:=IKW"ZIJZ0)=ZO.5LH&5VE3]9:*T
MEQ4E@UAZ&5X>E6H9;F.28'%RQ.)J3PN49GB<9B*^'E2<HT<1B8K'XRC3Q<X1
MM2KMRHRK4Z-6GE#P_F\SECL3Q!C:^&Q>>9-Q3FV70P6!HTL?Q'DF RW X7&0
MQ"IU,3@L%/\ L?+<36RZC4DI8C"I0Q,*%;$T:WYH_P#!1SX?_$#]H6S_ &??
MV3_"VA>.X_ /QL^+^F:E\>/B1X3TNY:Q\!_"?X8PCQG>VMYXBET[4-#T/6_%
MOB&ST+3O#0U>&XAN[NUGB:QO(?-B/S;^T]^QI\3O@-JGP%_:N^%/Q9_:W_:E
M^(7[/GQD\*WES\._'OB#1/B1?7GPC\;W*^$?BQ8^$-%\*> O#NL+J,NA7EG>
M3+%->VD=AIL\[:>9+>*:+]P**G+>+\?E5#+<'AJ.'^HX/Z[]<PLX0FLT_M)S
MI8_V]65-UJ'UG+_8Y=/ZO.'[C#TY-N;;'GOAME'$&,SO-,=B<9_:V9?V5_9F
M84JM:G+(?["5+$91]4P\*T<-BOJ6<K$YS3^MTJG^U8RK!<L%%GXN^ O%WQ2_
M8D_:*_;,/B+]F/\ :"^-'@_]I#XIVGQV^$?CCX&> 6\<VU]<ZUX9L=*O_AYX
MWQ?64G@;4]$U.P%O:7FOF'2_L4KWDDL$+H'Z7]I/5OBWX7_:4_8+_:_UC]G/
MXP^)?#WA3X5?&SPS\5?A[\(-!B^*_CWX:^*OBIX7\(W&BZ7?Z;H4]LNLV=GJ
M>GWNBZCK>FD:=%<VS7)D6!X1+^OM%6N*J;QE''U,GPT\5++JV59C56*Q</KV
M%JY++(I<D%4=/"57A)*M*=.$T\5%3A&G1<J$L_\ B']>&6XC**/$V.I9?#.<
M-GV2X=Y?EM3^R<?AN)J?%<?:59457S&A_:%-X>%*M5I2C@*DJ4ZE7%*&,C^8
M/@GP#XQUW_@IW\5_B=K7PY\7:?\ "_QG^P[\./"R:[XA\/75MH%QKUUX\OM0
MU7P1=Z@RRZ7-XBL-,N&_MC18;JXFM8][2@Q,CO\ &/[*/[,OQYLOVGOAO^S?
M\2_A]XKT[]F'_@G_ /$/XW_%7X-_$/6M,U&/PS\4I?B-J$/_  H_1](U2Y1K
M'4KSX6Z/XF\67=PEE<W#Z;>PQ6EUY4D42C^@RBKI<9XVC0Q5"GA,,H5\GP65
M47*564L'4P6!Q.64\QH/F5L6\NQ^88;WDXQ^MNK%*I1I266(\+\LQ.+R_&5L
MQQSJX3B;,^(<2H0P\(9E1S3-<OSVMDN*2@W_ &<LYR?)L<U!J=3ZA]7J-T<1
M6B_YF?VA?"/[1OQ%\)_MG^$OC7\-?^"@GQ)^/NM^(OBQH_P-\._"35O&V@?L
MG1_"*ZM)U^'E];S>#]6TCP)XDMX-*,DWBOPQXQBU_P 7>)=3$6A6NB3W5Y,(
MOJ?XA>%_BK\*+3_@D=\=W^"GQ>^(>B?LY_#KQ)X7^,'@OX:^#+[Q-\3O"EU\
M0OV?]"\%Z?<S>!XFBU:>/2M<M9[76[9(UFT]X_*N#"[(#^W]%=M3CRM4IX2A
M_9.$AAJ"Q\:N&IU\1"A.CF>23R+&4,+3BU# T7A:DZM!4HSG3Q,I5*LZZM%>
M72\(</2KYEB_]8LPJX[&/)YX?'5L'@ZN*IXG(.*L/Q=EF,S"M-2GFV)CF&&H
MX?$RKRI4ZN!A&C1I862=1_@/\??A+K^F?MC^(?VH?''P<_;8\2?!;]H7X'_"
MJ"V/[+GB;XB^%_BM\*?''A&SF@NO!WQ5\!?"[QCH'B*_L+O3KNVNHIA+K-AH
M6O#4+4(LLEU/7Z'_ +!O@+X=^$O ?Q#\0_#_ .#O[0OPA7X@_$J^\1>((_VG
M-9U_5_BEXZU6WT/1=+7QOJ \4^+/%WB2QLK^VM8]/M;?7+RSU*0Z;)<S6,<<
MT3O]TT5Y>9<5XK,LJHY94I5:4:.'P6"O2Q^,^JU,)ET84\)&I@'-X>5:%.E1
MA.L_=G*E&LJ,:\IU9>]D?AY@<CXAQ6?4L30Q,\3C<TS/DKY1EOUZEF.=2E4S
M*K2S>-)8R.&JUJV)J4L,K3I1Q$L,\14PL*="/XV?M.WFM_"[_@I7\-/CIK_[
M/WQN^,7PHA_9&\2?#RZU#X2_!K6OBY'I_C+4?B8NLV=E?6NFVTUO83KIEI+.
MTDLL<Z0W$.Q'BN&(\"TS]D_XL?M(6W_!3+QG\.O@]XE_9=^&_P"T]\'_  EX
M#^$_PO\ B)HMG\/];\;_ !(\(V4U_JOQ#\0> [&Y:'P/;>)+B*W\-_:=2CBO
M]2AU:\U*_B_T6=9/Z$**[,-QMB<%A<+3PF!HT\;A<#E^7?7*E>O6I3P^6YK1
MSC#R6 ;AAUB'BL/2C.M-U;4N=4HTJDE4AYV-\*\#F>8YC7S'-L36RO,,VSC.
MGEM#!X3#8FGC<[X?K\-XN#S=1J8R6#C@,37G3PU-4%+$.E.O4KTJ;HS_  0^
M,7C_ ../[6/['6C?L-^'_P!C+]HCX<?%KQKH'PQ^&?C_ ,3?$?P%%X:^"7PN
MTOP=JGAFZ\4>-=-^([W\NC>*K&V@\.22^$K#P\DNI7LES:%(HIH%BF]U^.VG
M^/O@'_P4!^!?[0L7P;^,_P 9/A</V4O$7P"O=0^#/@JX\>Z]H7C7_A.-,U[3
M)?$FD6EW!/IVCZK8IQK5S)%I]O.)VN;A4@D8?KU14+B^%-JA0R;"T,MG'.WB
M<#'%8N<J];/\/A<-C:L<75G.K1C3IX'"+"TXJ2IJE+VTJ\ZDYO27AK4K1>*Q
MG$V.Q6=TI\*K YK++\NHPPN&X/QN.QV54)Y?0IT\/B95:V9YA+'UI2INM*O#
MV$,+2H4Z2_-_X#^!?'.F?\%'?VY_B)J_@SQ/HW@;QM\,?V5['PGXJU31[NTT
M#Q%J/A_PIXCAU_3]&U9X_L&IWF@7%S%;:O#97$YL+B5(Y]AD3=%_P3'\ ^.?
MA[\,OVAM.\>^#_$O@N_US]LW]HWQ7HMEXGT:^T2YU;PQKOB6QGT7Q#IT%_#
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M^T#V_3_XJBS[/^O^'7WA[3S?WQ_^1\U]Y?WKZ_H?\*-Z^OZ'_"J'V@>WZ?\
MQ5'V@>WZ?_%46?9_U_PZ^\/:>;^^/_R/FOO+^]?7]#_A1O7U_0_X50^T#V_3
M_P"*H^T#V_3_ .*HL^S_ *_X=?>'M/-_?'_Y'S7WE_>OK^A_PHWKZ_H?\*H?
M:![?I_\ %4?:![?I_P#%46?9_P!?\.OO#VGF_OC_ /(^:^\O[U]?T/\ A1N7
MU_0_X51$X) &"20 ..2> /O5^%O[?/\ P5.TGP-K>H_!/X&^,K/0]=M]6O\
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M]G_7_#K[P]IYO[X__(^:^\O[U]?T/^%&]?7]#_A5#[0/;]/_ (JC[0/;]/\
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MIO"G_"(Z[K4DVC[X+/4(;R3V[0_V;O\ @IG\6OC=_P $R/%O[1?AK]D[P'X
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M#OP^^"GP?_X)P^)?V3;WP%\+KW4--T7PI\0]4^*O@+QMIVA_#KPK>Z/:S?\
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M_P!O]?\ ZU'VS_;_ %_^M1;R_#T_X'X>0*NM-5TZ_P"'S\U_2UZ/[0/;]/\
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M2\*Z_P"(4AN93#%>7.E:7=7EI8;DWRM)?W4,5G%'!')<2R3+'!&\K*I_SO\
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M@Z&-2P6!QF8?5,;5E5C2]EEKQ>7QK5JF+K-QI>SI5:LU.<73I*]1RU:.3/\
M,,UR[A?B/'9)0EB\YP61YGB\HPD</4Q<L3F>'P&)K8'#QPM)JKB95L5"C3CA
MZ;YZKE[.%I21]%?!?]M#X6?&?QYK'PH_X1WXI_"3XJZ1X5@\=K\.OCCX%E^'
MWB36_ LTJ0-XP\-/_:>L:)KVAVL\L,.H36&L27&GO*OVNVB5)FBZWQY^UM^S
M;\-_AIXG^,'B;XT_#V;X=>#M4LM"\1>(?"WB72O&RV&O:A<+;6>@"Q\)7FL:
MA<Z].YDE&C6UM+J0M+:]O6MA:V5U+%^6_P 7_P!G+]J_]K_7?$_C77?AS:_L
MPMX#_8\^)_[/WPATCQ#\1/"WB?QKXW\=_$VUTBWU;4_$>J?#J\U;2?#/@Z/3
M='ET>U5M6O+U)]5>_-O;I+=Q0_->A_\ !.KX[:_^S]^TQH5[\+=>\,?$CQ?\
M"_A-\/\ PGX9\=Z]^S-:^$?$WBOX9>++'78[KPII?P1\*Z+I>E7=GI%KJFC:
M%\0_'5[#XNU.UUV;3M>81275VWP=+A;A"M*A7Q/$&%R^*Q&4T<?EE',\OQD\
M-]:QE&CBYX7,>:5'$48X.?UIU:<<6LOJQG0Q3K*G*<?RW$>(/B/A:.*PF X/
MQN=U/J7$&)RC/<5D6<973QCP&6UL1EU+'Y,X4\3@\5/,:/U"-'$5,N><49X?
M$8".&E4A3J_T&P_'OX(7"^$FB^,OPG)\?6L5[X&B?XC>#HI_&-K/,UM%-X8M
MY-:6;74>[1[/.EI=8O(Y;4XN(WC7YKE_;M\.R^/?BA\/=(^%7C36M5^%'[2G
MPL_9NU^ZAU[P9IUI<ZA\4=$FUJV\<6 UC5]/DN-!T"*W>'4M%@%QXFO9)(CI
M6G7:B;R_R-_;!_90_;)^/"7\'P^_99\)_#KPWJGPO^#]MX0\->%6_9=LM<\+
M>(_ VOO?^(] ^(WCR_MY?%MI/:R1MJ?@FW^"VLZ)X>8ZE)!KVI2;KZ.;VKQ9
M^Q[^T?K?Q1^)WBE? L%W9>*/^"D/['7[0^GW\GB?PJ'O?AE\*_!U]IWQ#\7&
M*355F@GTG5+D0C2)HH=;U%GDETS3[F >8U87A;A2AAZ=?%Y]EF(K8G#SE'"/
M,\+.6 JT\PR>*5:6#Q=.-6<\)B\;3E",W33P53$TJLH7A1C'>(?B#BL;6PN7
M<(YYA,/@,91A+,(Y#F%.GF]"ME7$,I/"4\SP%>="G1S#+,JK1JSIJKRYGA\#
MB*-.IRU<3^TK_'#X+)?W6EGXQ_";^TK&VUF]O+ _$?P:M]:V/AV>>VU^]N;-
MM;%S;VFASVMU#K-Q-&D6ERVUQ%?-!)#(JVK[XP_"?3/"-C\0=2^*7PVT[P!J
M;(FF>.K_ ,=^%;/P9J4DCR1I'I_BFXU>/0[V1Y(I8U2VOY6+Q2H!NC<#\(?#
M/_!.SQM-J/P4U?QC\ _ NH:I8?\ !2SXP?&OXKZGJ3> M2U#4?V=/$EWK%UX
M8FUR[:\N)_$6@W<DFG2_\(,)+ZYA<(;[0HR;DU4\&_L6_M _#6]^#WBW6/V;
MO#GQN\ ?"']H_P#;2U]/V89_%7PQL=-F\#?&VZTL_"KQUX;LO%%Z_P /732(
M+6_C;P[JUQ9ZGH-G<H]E9V]W+)&O++A/A9M1H\54IS@ZSE"I/*Z,:[HT\S<*
M-"O4S"-&E/%5\#A*5*OB73P]*&.I5JC:<(2]*/B+Q]!2GB> *].C46%5.K0I
M9]B9X6.)KY#&KB<7A*.3SQ5>EE^%S/'UZ^%P,*V+KU<JK8:A%.,ZD/WH\0_&
M+X3>$='T/Q%XL^*?PT\+>'O$ZJ_AG7O$?CSPIH>B>)$>(3*_A_5=3U>UL-:1
MH664-IMQ<KY;*^=K D_X7%\)?MGA/3O^%J?#0:CX^M8K[P'IY\>>%/MWC>RN
M&*6][X/L_P"U_M'B>TN75DM[G1([Z&=P5B=F!%?R0_M ?"SQ'\"E^%/P1^*E
MMX0TV\TW]F+]I#QCX]\$6US\*_%D/PC^&OQ=^-=UXC@\$_">^^-WBSP;X5N?
M&OA3PY:I9>&M:^'U]K_C6WU(W-II?AZ_LHHYY?JG7_V)_B;\:/'4GQ-^&W@O
MXC:_^SU\=OAW^RSJ_P '-;T6_P#V=_ WBOX5>'/AQX;\,PV6C>-Y/B=X5U?X
MB?#VXT&[TJ7Q!!<? XP#Q#<W=PVI6UR;]Y(_4J>'F18>AAL3B.)Z='"XN.85
M,/C:M+#T<+7AAL=3PV%C2G4Q'LI5\3@Y5,RHTUB)0Q5#"U(4*L85(8B'SU'Q
MJXLQ>,QV!P/ 5;%8[+YY/1Q>68>MCJ^/PM7&Y5/&X^K7HTL%]8CA,#F4*&28
MFK+!TZN7XK'4*F*H3J4*F#J?T<+\7?A5)XBMO!\?Q/\ AP_B^\U+4=&M/":>
M.O"S>)[K6='\L:OH]MH"ZN=6GU72C+$-2TZ*T:\L6DC6ZAB9U!OVOQ)^'U]X
MNO?A]9>/?!%[X_TVU-]J/@2T\6>'[GQII]DJJ[7E]X5@U*37;2U1'1WGGL(X
MD5U9F (-?A-J'[!WQ:EU'XP>-5^$7AVX^).L_P#!3_X:_'SP3XW_ +4\&#Q?
M)\!-#UC2[GQ'K]IXC;4H]0TRSDMQJ=Q=^%I;NTU;4II9F.C3S&&J?[/7["7Q
M^\"?M5^'?%7Q'T+QG=Z9X+_:;^*GQKLOC-X>\1_L_P!IX2\0Z!XSCU][1=:N
ME\,/^TIK^H:]::A9:%KO@76]:3P?IZ%KS3[B!=/@BE\>?"G#*PV+KT^+,+[7
M"X"=:&'F\&JF)Q<,+2Q"AA^7%2]I3]I5IX14K+$SJ1JU*<9>RE17TU+Q%XY^
MO9;A:WAYCU1Q^;T<+/&48YE*C@L!4QU7!NIC.? 0="LJ.'GF+Q+<L#2H3PU*
MO.FJ\,4_Z$_M ]OT_P#BJ/M ]OT_^*KG/MG^W^O_ -:C[9_M_K_]:OSRWE^'
MI_P/P\C]D]NNZZ=?\/GYK\.VO1_:![?I_P#%4?:![?I_\57.?;/]O]?_ *U'
MVS_;_7_ZU%O+\/3_ ('X>0E76FJZ=?\ #Y^:_I:]']H'M^G_ ,51]H'M^G_Q
M5<Y]L_V_U_\ K4?;/]O]?_K46\OP]/\ @?AY JZTU73K_A\_-?TM>C^T#V_3
M_P"*H^T#V_3_ .*KG/MG^W^O_P!:C[9_M_K_ /6HMY?AZ?\  _#R!5UIJNG7
M_#Y^:_I:]']H'M^G_P 51]H'M^G_ ,57.?;/]O\ 7_ZU'VS_ &_U_P#K46\O
MP]/^!^'D"KK35=.O^'S\U_2UZ/[0/;]/_BJ/M ]OT_\ BJYS[9_M_K_]:C[9
M_M_K_P#6HMY?AZ?\#\/(%76FJZ=?\/GYK^EKT?V@>WZ?_%4?:![?I_\ %5SG
MVS_;_7_ZU'VS_;_7_P"M1;R_#T_X'X>0*NM-5TZ_X?/S7]+7H_M ]OT_^*H^
MT#V_3_XJN<^V?[?Z_P#UJ/MG^W^O_P!:BWE^'I_P/P\@5=::KIU_P^?FOZ6O
M1_:![?I_\51]H'M^G_Q5<Y]L_P!O]?\ ZU'VS_;_ %_^M1;R_#T_X'X>0*NM
M-5TZ_P"'S\U_2UZ/[0/;]/\ XJC[0/;]/_BJYS[9_M_K_P#6H^V?[?Z__6HM
MY?AZ?\#\/(%76FJZ=?\ #Y^:_I:]']H'M^G_ ,51]H'M^G_Q5<Y]L_V_U_\
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M5[#11];I?] &#_\  L;_ /-GDON#_5['?]%;Q)_X*X8_^AOR7W'CWVSXO_\
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MIJNG7_#Y^:_I:]']H'M^G_Q5%<Y]L_V_U_\ K446\OP]/^!^'D"KK35=.O\
MA\_-?TM?"/\ A?/P6_Z+1\(O_#G>!O\ Y?T?\+Y^"W_1:/A%_P"'.\#?_+^O
M\^P:Y !TAR.YC7^B_P!:D&MVYZ>3_P!\)7]2?\2^8+IQ'B^G_,MHWZ-:?6U_
MP++T7^:'_$\W$_\ T;7+>FW$.+_N[?\ "5;JNO;MK_H'_P#"^?@M_P!%H^$7
M_ASO W_R_H_X7Q\%O^BT?"+_ ,.=X&_^7]?Y^7]MP^D/_?J/_"G?VY!W2'_O
MV@_H:7_$ON#_ .BDQ73_ )EM'^[_ -1?]679VE_3GXG5O^-:Y9T_YJ'%_P!W
M7_D5;6UWZ)=#_0,_X7O\%_\ HL_PC_\ #F^!O_E_2_\ "]O@S_T6;X2?^'-\
M#_\ R_K_ #]EUN$X.V'!_P!A<_RZ_I4BZW!D82+/^ZG^&*/^)?<$O^:DQ=_+
M+*-NG7ZWY?EV(_XGIXG7_-M<L_\ $AQ?]W_J5=+K[C_0%_X7M\&?^BS?"3_P
MYO@?_P"7]'_"]O@S_P!%F^$G_AS? _\ \OZ_S_AK4/I%_P!\J?YBG#6X.ZPG
M_@"_Y_2C_B7W!_\ 11XKI_S+:/E??%]+?@NQ/_$]?%'_ $;3+.G_ #46+7\O
M_4J_JWW?W_\ _"]O@S_T6;X2?^'-\#__ "_H_P"%[?!G_HLWPD_\.;X'_P#E
M_7\ 8UR#H%B_[Y3^H_2GC6XB1E(L>RI_A2_XE^P?_11XKIOEM%/=+_H*?7M?
MIO;6/^)[>*%_S;3*^G_-18N_3_J4_CMIY*_]_/\ PO;X,_\ 19OA)_X<SP/_
M /+ZC_A>WP9_Z++\)O\ PY?@G_Y?5_ 4-9ASD)'QZH@_FHIXUN+NL9_X#$/_
M &6A?1^P?_11XKI_S+:7EVQ3[?EVU7_$]_$__1M,KZ?\U%C/[NULI?3]%T/[
M\O\ A>WP9_Z++\)O_#E^"?\ Y?4?\+V^#/\ T67X3?\ AR_!/_R^K^! :Y#_
M '$STSA.!^GY8IPUR'IMC/\ P%<_H*2^C_@_^BBQ?3_F6T?+_J+\OR[:Q_Q/
MAQ0K?\:SROI_S4>,_N_]2G^K7Z:_WV_\+U^#1Z?&3X3'_NI7@G_Y>TO_  O3
MX-_]%D^$_P#X<KP3_P#+VOX%1K<)'W8Q]8T_R?K3UUN ?P1$_P#7-./T_7Z4
M?\2_X+_HI,2]M%EM'RV_VKR_+MK+^GEQ1T\,\JZ?\U'B_P"[_P!2GS7W+?I_
M?/\ \+T^#?\ T63X3_\ ARO!/_R]H_X7I\&_^BR?"?\ \.5X)_\ E[7\#O\
M;</]V/\ [XC_ ,:<-;@_NQ@_[B?T']:/^)?\&M^(L7_X;:/]W_J*MZ>GD3_Q
M/IQ3_P!&RROI_P U'C/[O_4HZ77W>A_?!_PO3X-_]%C^$_\ X<KP3_\ +VE_
MX7G\'/\ HL7PH_\ #D^"O_E[7\$']N0?W8_R%/&MPGG;#]"J_K@4O^( 8/\
MZ*/%?^&VCY?]1?IZ:$OZ>W%*_P";8Y5T_P":DQG]W_J4=-%ZI?+^]S_A>?P<
M_P"BQ?"C_P .3X*_^7M'_"\_@Y_T6+X4?^')\%?_ "]K^"8:W!W2'VPJ_KD4
M\:Y!QQ"/JH./S&*2\ ,'UXCQ73;+:/E_U%_IT\K*7]/CBE?\VQRKI_S4F,\K
M?\RG^K+MK_>M_P +S^#G_18OA1_X<GP5_P#+VC_A>?P<_P"BQ?"C_P .3X*_
M^7M?P7#7(3WC/T5*7^VX/1/R0?TQ1_Q '!=.(L5\\MHKMU^M>7Y=B/\ B?KB
MI?\ -L,IZ?\ -2XS^[_U*/-?AVU_O1_X7C\'?^BP_"G_ ,.1X*_^7M'_  O'
MX/?]%A^%/_AR/!7_ ,O:_@R&MQ=-D6/]U/YX)J0:W!T&SCV0?S%'_$ ,&O\
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M>1M=\&^*[74I)+/6+6PO=-MENC+=PV+Q"Y0?TMK\:_@^BJB?%WX6!4554?\
M"QO!A.U0 ,DZYEF(&68\LV6.237\*(UV)CG$1(ZEE!)XP,G&3Q[YIXUR'NL7
MX ?UKX;B'PFK\38V&-S+B.I"<*4:5/#X?+(1P]%74I*G"6,>LI/WIVBYJ,+I
M<L3_ #_Q/[0;B1UZJPOA7EL<+&K4^K*OQ-B7B/8.:]E[=T\G4'6]FX*IR+DY
MT^16W_NL_P"%V_"'_HKWPL_\.-X,_P#EY1_PNWX0_P#17OA9_P"'&\&?_+RO
MX51KD.<[(S_P$8_D!_A3QKD0_P"6</UVK_2O!_X@'@_^BBQ7_ANH?_-?DON.
M9_M!N*UMX693_P")-C?[O7^QK=?P78_NG_X7;\(?^BO?"S_PXW@S_P"7E+_P
MNSX1?]%=^%O_ (<7P9_\O*_A:&NPG^"(?E_AC]:D&N1= L>.^ G\^<4?\0#P
M?_118K_PW4/_ )K\E]Q+_:$<6+_FU>4]/^:FQJWY?^I,]OOT7;7^Z'_A=GPC
M_P"BN?"W_P .+X,_^7E+_P +K^$8Z_%SX7#_ +J+X-_^7=?PPC6X/]C\E/ZE
M:4:[ .HC(_W(_P">VE_Q /"?]%%B?_#=1\O^HOR_!$?\5"N*]/\ C5>4=/\
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M"7_HK7PO_P##A^#O_EW7\.XUR'_IG_WPHJ1=<A/18N/55_GC^M/_ (@+@_\
MHH<5_P"&VEY?]1/E^"^4O]HCQ:O^;4Y/TU_UHQJ_E_ZDO?;Y=F?W"_\ "Z/A
M/_T5GX8?^'#\'?\ R[H_X71\)_\ HK/PP_\ #A^#O_EW7\/XUR'NL7X ?UI_
M]NP>D(_X O\ 1:G_ (@+A%OQ#B5M_P RZEY?]17]6797G_BHGQ8K?\:HR?\
M\2K&+^7ODO9I[]/N_M^_X7/\)_\ HK'PQ_\ #A>#O_EW1_PN;X4?]%8^&/\
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M3QAI_P :AR7IMQ9C_P"[VR-]U^';7^S;_A</PN_Z*E\-_P#PO?"?_P N*/\
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MI7EA8:\ES<BU6R\&^(/#OB/4XR8WD:YGLHM5MC%9)LV277F,J2,B%?F!J/\
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M_P#BJ-QA_P!&:R5;?\U?C_[O_4A\_P#R7[OZW?\ A;?PT_Z*7\/?_"W\+_\
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M?4H\19'^M_7_ .O3U\1<??W?Y_&OEU?'4 _Y?(?^_P @Q]#O _,5*/'EN?\
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MR.YL[G3]0O;*:TNU,=W;M;7$D7DW,;+&8[B,*%F0HI60,I (JJ/$8'_+0_\
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M_ '_ ';O2+_%=O*WT4/$1/\ RT'7^]G^1_J*D'B%3T?_ ,>_^O7SL/&=H?\
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M_P"^Q_C3QXB;_GMCZ,?\17S_ /\ "51?\_,?_?U/_BJ</%$1_P"7F+_OZO\
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M >*(NUPA_P"VH/\ [-3E\41'K<1CZR+S_P"/"I>&:Z7]+OMZ=_NMW(?",O\
MGS+IM%_W/*_X]=]SW\>(O5A_WV?_ *_\Z>/$6.CCG_;!_K7@0\3Q?\_$6/\
M?!_]F/Z5(/$\1_Y>H_\ OL?U(H^K/2T=-.ZTLO\ /;^ED^$9?\^)=-.5_P!W
M^ZUVW[=F>_#Q$!_RT(]MW^&*?_PDG_33_P >_P#KUX!_PD\0_P"7J+_OM#_-
MJ=_PE4?_ #\Q?]]K_P#%4OJSZ1OKY^2Z7ZV_#Y9OA&7_ #YE;1_!?^5]OG^N
MKM_=I_P2AG^T_L+?!N?.?,_X2UL_]S;K(_I7Z,D @@C(/!!Z$>AK\S_^"04Z
MW7_!/WX&7"L'66#Q8X8'(.?%^MC@]^E?IA7^??&JMQAQ0NV?YLONQU<_Z"/
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M/_DO)?<?]+7]FX'_ *!,)_X34?\ Y'R7W'SE_P ,C_LI?]&O?LX_^&/^&/\
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M\-ZU=ZSKMY/H_AZYNM.EE*Z2)(+:7K_VWOVU-#^ ?[/_ .W;JWP?\2>$M?\
MVF/V./V==*^-^M?#SQ-H^NZAI/AZ'QQ;:E<_#*_\4QP?V-9ZQI'B>+0M=E6Q
MT/Q']O@73R-0.GF:V$Y]>Q/+S?6L1:U_X]2^U[6YM[)Z!_8N%YU3^HX5R<E%
M/ZI2:UE&-[\FW-**;V3:\CWG_ADS]E8=/V8OV=!_W1'X9_\ S+T?\,E_LK?]
M&Q?LZ?\ AD?AG_\ ,O7DGQ,_X*'_ +(_[/EIX(TS]H?XU:+X \:^(/A=X)^)
MOB'1[/PA\1?%=KX2\/\ BO2+6Z7Q1XRN_!'A+Q5I_P //!\U^=06SUSQQJ.B
MZ:MG9W%S)?-;6MQ<KT_QV_;V_8W_ &9G\(1?&_X_>$?!=Q\0_!(^(WP[LX+'
MQ3XPO_B%X*;4-,TQ-<\!Z?X$\/>)[WQDDL^L6%S%8^';?4=4DTA[C7DLCH=A
M?ZC;/Z]B=?\ :ZZM:_[^HK=K^_IK;?J2LFPKY;9=AVY7Y;8*G[W+:_+^[UMI
M>VVAVO\ PR;^RO\ ]&Q_LZ_^&2^&?_S+TO\ PR;^RP.G[,?[.H_[HE\-/_F8
MKWS3KFTU;3M/U;3IOM.G:K866J:?<JKQK<V&HVL5Y97"QS)'-&)[:>*41S1Q
MS('V2QI(&07/)/O^8I_7,7TQ6(_\'U?_ )+T,_[*R_\ Z L'_P"$M'_Y ^=_
M^&3OV61T_9D_9V'_ '1/X:?_ #,4O_#)_P"RU_T;+^SO_P"&3^&G_P S%?0_
MDGW_ #%'DGW_ #%/ZYB_^@K$_P#@^K_\EY+[@_LK+_\ H"P?_A)0_P#D#YX_
MX9/_ &6O^C9?V=__  R?PT_^9BC_ (9/_9:_Z-E_9W_\,G\-/_F8KZ'\D^_Y
MBCR3[_F*/KF+_P"@K$_^#ZO_ ,EY(7]E9?\ ] 6"_P#"2A_\AY+[CYY_X91_
M9;_Z-F_9X_\ #*?#7_YF*/\ AE']EO\ Z-F_9X_\,I\-?_F8KZ&\D^_YBCR3
M[_F*/KN,_P"@O$_^#ZO_ ,F']DY=_P! ."_\)*'_ ,@?/7_#*7[+G_1L_P"S
MS_X97X:__,Q1_P ,I?LN?]&S_L\_^&5^&W_S,5]"^2??\Q1Y)]_S%'UW&?\
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M&8OV;/\ HW;X#?\ AH/A[_\ ,[1_PS%^S9_T;M\!O_#0?#W_ .9VO>O)/O\
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M8H_M',?^@_&_^%>(Z6_Z>>7]78?ZMY!_T),G_P##7@?+_ISY(\:_X9_^ _\
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M'6E^$]3/AO0],\*Z[<^#M+U#PMJGB#4]'UJ37X8;6Z]-_9$^ 'Q3\/?M,?\
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M(HHU+RRN2<*D:*SNQP JDD@"CFET^6B\K=/)?<@Y5_3:_7R7W'QY^T)GQO\
M$7X-?!RU)DBU+7AXQ\31I\PCT;2=_E"=<'Y'AAU%P&(!S'@Y89^N2B9^5 JC
MA5!.%4<*H]E& /I7R9\!HY/B7\4?BC\=+F-GTQKQO G@5I <+H^G>6+NZ@W
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M+[BGL7T_4_XT;%]/U/\ C5S8WI^H_P :-C>GZC_&CF?E]R_R\E]P<J\_O?\
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M\E]P<J\_O?\ GY+[BGL7T_4_XT;%]/U/^-7-C>GZC_&C8WI^H_QHYGY?<O\
M+R7W!RKS^]_Y^2^XI[%]/U/^-&Q?3]3_ (U<V-Z?J/\ &C8WI^H_QHYGY?<O
M\O)?<'*O/[W_ )^2^XI[%]/U/^-&Q?3]3_C5S8WI^H_QHV-Z?J/\:7,_+[E_
MEY+[AJ*NK=UU?EY^2^XZCX"<>$_$/_91O'O_ *?[BO;J\4^! (\+>(P?^BC>
M//\ T_7%>UUGF/\ OV*_Z^R_0]#@C_DD\A7_ % 4_P#TJ85\8_MS^+KSPO\
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M,?EW=B>FUU.1DG@_[78=OOC\F_IEB.TA,(DB :1#@EMV588PQ ('ROD,",#
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MYNR"'*#<J9/1C@A%&>G)SEL$D9!ZO5_>^MOZ\_NU4CN"J(,X4$G/=F.6/X<
M>P'%*DQC5DC!\V3/S?> !SU&.Y)QD\D\<CAK1R(!YNT.V20#R!GJ0,X';G!)
M!XI8Y%C!8*'?C8=PV@=SQG/U&>,X&: 7_ V_K_,1HHX8C"(UDGG!W$J!M9P2
M67.<>N1E@,!>U95S8"V57\S>Y&) V 5R?E"X)!&.2!SU.36J)8X"]Q+(OF.&
M&'PJQJ>05)^^6ZL ,D 8P !549F?S7'[M<F,..7W#+2NIZ C!0'G&68#.* T
M_K^NO^>FQ[7\(?"L%]X(^*WB>;Q.^GM9>'KW31HME);H9%%I!J.G:EJHO+-I
M?-MM7@!TB;2;Z*$1M>P:K#*\MKL]B_8>\;/X;^-'P]@3PQ9ZC%K'B?1M%T35
M[V\UB*#1H_$VD>(-,UZ[T:PAGBL1>O&+J-H[R.X"VUW 6BCE6.2OF_PQ:VEK
MX#^*.M37J6-Q?0:%X2ME6V:YN6CUN=[NY2TA$\*O)=+:0VKQD@K%*\@*A7KZ
M:_8D\+KXO^,?@E[;Q-I&FW&@?$"P\0V7A_5Y[L7.H6?A[1M8NM:TSPR\<,L-
MY+9Q1R79C/V>"*WCF!ES!NE_$\ZP6,PG'%6K5S7$9C''U\'B\)AJ].,(Y1AO
M90H?V=AW[65.5#VM"IC(RC1P\I3Q3=15J_M,15_=.&9X6IX2<4SQ&$IT,-#^
MT,/4J0=7_:J]+"8:3QE5TX1G[24:U/"R4JE6FJ.%E%^SI2A2C_111117WA_*
M1Y!\>AGX1^,AZVFG#\];TRO/Y$7S)./XV[G^\?>O0OCQ_P DF\8_]>VF_P#I
M[TRN)D1O,DX_C;N/[Q]Z]6FVLOP]O^@S'=NE'+3\]QZOQCF_;_5KA7JU_P S
M3C.VWH4-B^GZG_&C8OI^I_QJYL;T_4?XT;&]/U'^-1S/R^Y?Y>2^XZ.5>?WO
M_/R7W%/8OI^I_P :-B^GZG_&KFQO3]1_C1L;T_4?XT<S\ON7^7DON#E7G][_
M ,_)?<4]B^GZG_&C8OI^I_QJYL;T_4?XT;&]/U'^-',_+[E_EY+[@Y5Y_>_\
M_)?<4]B^GZG_ !HJYL;T_4?XT4<S\ON7^7DON#E7G][_ ,_)?<6O+]_T_P#K
MT>7[_I_]>M#R_?\ 3_Z]'E^_Z?\ UZDZK>7X>G_ _#R,_P OW_3_ .O1Y?O^
MG_UZT/+]_P!/_KT>7[_I_P#7H"WE^'I_P/P\C/\ +]_T_P#KT>7[_I_]>M#R
M_?\ 3_Z]'E^_Z?\ UZ MY?AZ?\#\/(S_ "_?]/\ Z]'E^_Z?_7K0\OW_ $_^
MO1Y?O^G_ ->@+>7X>G_ _#R,_P OW_3_ .O1Y?O^G_UZT/+]_P!/_KT>7[_I
M_P#7H"WE^'I_P/P\C/\ +]_T_P#KT>7[_I_]>M#R_?\ 3_Z]'E^_Z?\ UZ M
MY?AZ?\#\/(S_ "_?]/\ Z]'E^_Z?_7K0\OW_ $_^O1Y?O^G_ ->@+>7X>G_
M_#R,_P OW_3_ .O1Y?O^G_UZT/+]_P!/_KT>7[_I_P#7H"WE^'I_P/P\C/\
M+]_T_P#KT>7[_I_]>M#R_?\ 3_Z]'E^_Z?\ UZ MY?AZ?\#\/(S_ "_?]/\
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M.02-O(89QTR.1D>N<X(SQ@!WFP9SYD><]0PYP".2#SP>,YJ=E3)"@%<Y (Z
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MSA[_ /&-<*JUO^IIQGK]YF>7[_I_]>CR_?\ 3_Z]:'E^_P"G_P!>CR_?]/\
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M[*VUU=[]#2G2E-M*ZLF];ZOHOG;?;>^^O], C#$*JEF8A549)9F. H Y))(
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M7T_-G]#FQ?3]3_C3UA9E=UC=DCVF1U5BL8<[4+L.$W-\J[B-QX&37XT^$_\
M@H/K7QLA\5?$_0?BG/\ "7X%Z_;?LH?!3X-V/@?X-:?\:?BWX\_:Q^*?P^UG
MXV_&?X>^ ])OHM0AU+Q1X'\&ZCX5\'7>GZYHVK^'?"LWAKXA:QJVGMJ&FO=6
M?S3\-OC3^T#^U=\;_P#@E+XEU[XV>*_ WB"R_:E_X*6_!+Q-+H'PW\$^&!X]
MMO@%X*^).@:9XI\;?#K6['Q#I6A^+/$7A;P]9Z;XJ\*PRW6@^&=<.J:]X4L=
M#U:"SELQU$K:/^FE^J''"S=_>2:Z>\W>R:2Z.^UTWKZNW]%.Q?3]3_C59;JP
M>[FT]+RR?4+>"&ZN-.2\MWU&VM;AI([:[N+!93=V]I<R131VUU-"D%Q)#*D,
MCM$X7\A_V1?VH/VX/VCO%OPF^,)\"&W_ &>/B/\ &;]H;P!\1?#VM1_ '1/!
M_P +_!/PXUWXC^"_ EW\-M?TGXDWW[1'BSXN6'BWX=6%I\3/"OQ!\%06$Z^(
M_%5QI>B>%M.\,:7<3\-^VS^TG\5/@'\=/VV_$'P9T_X1^&_B-X+_ &:_^"=+
M>&/B%K_PLT7Q%XFN9OC-^UQXM^%NNZ3X[UJ.ZTO7_&?@C2=!O+B?POX2N=7L
MK;PWJE_JVJ:+<V=_J,LZOG6_GKWV_P [(CV$N;E>]H[-M)N48V?71OMJM=FS
M]O$A,A*QQL[!6<J@9B$0;G8A<D*J@EFZ*!DD"F[5]/U/^-?SY_ME?$7]I'6(
M_C[^SMKW[0NK1WO[.W[?'_!+F/PK\5O"GP[^'WA3Q5K_ (5_:(\:^ +^Y\'^
M+-&M-,G\,7%KX/\ &5MJ.JZ+=:?86#>*=&O].\'^-H/$-C%J$NK?6TG[1?QB
M\*_'+_@HHWQ<_:>\*?#C]G3]A?PO\#XK;7]1^"/AG7M;U/6OB5\!K3Q=XI\:
M?$*31ULK_6;6U\4W-EJO@[P/\/K3PW?:EXCU&7PY<3WOAY]-T93G\OQ_K^NQ
M3PTK733:U>LGI[EEHF[OF6EN^MKM_JML7T_4_P"-&Q?3]3_C7X1Z9^WM^T=;
M^(_C%\"I?%6IV_B*+]LK]A_]FSX?_&7XY? O0?A;\2?AMX7_ &N/ UWXD\0:
MOXU^$FFV^E^"-9\3Z%J'A?4M-^$D^KZ'HFE:WJOCOPO9>*=+UJ/35CU;V_XX
M?&K]LSPQ\?\ 0?V0/A!XMUWXF>.-,_9I^(_[0UU\4O"OPY_9EL/%OBK7;?XG
M2_#OP-X%\7^$OBO\0O OPYL?!W@22XTZ;XN:S\,[*U\;WUUJWAL0:?X#MKR:
M;4A5$]=?PZZ_U\NXWAIIV;2UZ\VRMJWJEJTK-W>KUU/U?FU+2+>2:&YU72;:
M:W-FMS#<ZI8V\ULVHRF'35N8IKE)+=M3G!@TQ9E0ZC,K0V0GD4J+VP9QM.>F
M.<Y],=<]L8SGBOYE?VA-3\<>)OB!^TGX@^+GASP[X4^*>OV__!OGJOQ,\,>%
MM8M?$?ACP]X[OOVA];N_%.B^'/$5K=7]MKF@Z7KTM];:'JUO?WL-[81V]Q%>
M7(D\Y_O&']N3XT1VOA"6]\6>!K;Q+XA_X+;^)_V&ETV?P[H=O>WWP'T3QOXG
MMQX<L=*DN%N)/&5KX3TW3]3NO%L$3ZNEA_Q-Y8DM;E92>T79B>'EIRN^RW?5
M0?W7EOV5WNT?KE;7%E>PK<V-W9W]L[2(EU87<%[:N\,C0S(ES:RS0.\$T<D$
MZ+(6AGCDAE"RQNBS[%]/U/\ C7\WOPE_:9U_X#_\$Y?"^D_";XO^)/!OQD\.
M>"/^"AG[0.@_#OP/^SWIOQTNM7\/?#+]IGXPPKXZ^*5YK*R:9X&^"6F>*;C3
MO#GB2]M9O#GB34M0U,OI'BNQ33KJ$_H/^R_^T1^T)^TC^U+XOT[4/''A?P3\
M$? _[+'[$WQS_P"%9>'? NBZGX@\0>./VEO /CGQ)XLT/4?B#KHOM4M/ FDR
MZ+93Z/'I,-EXH^WV\:/K@TE[JQNTJB=N[2;2MI=)]_/J$L/*,7*ZY4VDVY)N
MS25EKN_5;ZN[/T[V+Z?J?\:-BGM^I_QJYL;T_4?XTH0Y&1QGGD=/SJ[KNOO1
MBHNZT?X^7^7Y]V'P1&/#OB<#_HI'CS_T^SU[+7CGP4_Y%_Q2/^JD^/?_ $_3
MU['49A_ON(_Z^/\ )"X*_P"25R/_ + 8?^ES"BBBN,^H/@#]N3X"7OQ!\,_\
M)MX=2\FO=/LTTGQ;96T\@:+P["US>67B_3[96 FU7PG?OC48%PVH>$-2U],3
M7NGZ7 _X<&]N_ /B;7/#NI6]O<P7UQI3>*=,\022:CHOB?3H9TGNA;Z>$A>#
M4;>8+?:+JME,=4^SJGV*X:&]\N;^L.6*.>.2&:-)H9D>*6*5%DCECD4I)')&
MX*NCJ2KHP*LI((()%?C?^V;^RS9>%G3Q+X/TV?3?!E^HM[6>SNY(;7P=K<UT
M9;/0;F[D227P_P"&-3OI(3X7O/M T#2=1:3PO>PZ7IU[H,T'Q_$6557..:8)
MRA7I.,JGLVU-./PU8-:IK[335G[ST<FOZ%\(>/,+2IRX-XA5.ME^+YJ>"EB%
M&5+WY1<L+5YVU)OE2H0<6FK1A*%2E14_ASXE^'/A';?"K0?%7A*RL[#4]8OX
M;?1S!J^I:E=7<"73'4[?4UG*)+>VMOB.6Y>"%+&58T9"M[;-7S/ ]L&V2Q_N
MV;<7 !=6QC((VG'0CG(//T]*M+*WMM'N?#/BVTU?2DU369(HI;B"UU"]\*^,
M[.*&U?Q#9Z>8;2[GTO74C?2_%>G:<WVHP1"[$:WNF0E^<\4_#OQ5X9-Q<W-F
MVH:) R+'XGT,MJ?ANZ@F=UM[E-0MMPL_M.QBEIJBV5]$$836T>-S>UX>XVE#
M 8K!8G-L=C<=5S+%8R-/-<5/$5Z-+%*E+ZKA*V(E*O4PM.K&M5ITISJ3H>VE
M23]E"%H\1N%JV2YFL3@\'!9-5HPAAL5A:2]C>FW'EQ$J2=*-:,94Z2J>XL1&
M$:J3<W*6?]E5TPEP),8,9+8E0KW61N6]"&]QD< 1M/,NV*XY16(2;&!D]%D_
MNGTZK[]ZSK:2!%$<B*@' E4$$ \D.R_/U[J<X)!%;"V_FH3'+'<(P (5@3@X
MP#G!]\$9&..E?HQ^;;[+[K_\$C_7Z<C\^]'UZ#DGT Y)_ 57"M;/L;/DDX5F
MSF)CT1O]EN-K'CD<]0;BDQ.5D&5?:-N.Q&00PSS_ !*?7CG(P"(^O3TS^&,Y
M^F.?I02 ,G@#D_0=:6VN/"]EKUK;>,IM5C\.SZ5KKQ?V-]L^VR^(;@Z7I/@^
M-_[/S=_V<-?UFVFOXT,<;1QJ;IC91W$<G/>%M1GU7PWX;U342IGO-%TW4+]X
MT 62ZEM8W?8B851),'D**-HRJJ-N*R5:#K.AKS^S=1::.,94XRL^Z=6&EMF^
MQ%.?M)8E13MA98:%63:2Y\7"O4I**NY/W,/4<G:R=EK<Z 9P"1C(R!STR<=0
M#G'7CKGZU')*L>T')=SA$7EF/L/0=R>G7L:=<S_9H]\HW7$Y&V+(&P?P1C!/
M;#2GD@ *,<"DMU2UC-S<,CW4GS \,(5Z!%7GY^N$49.02>I.I8C+-(ZO<GE0
M"D0/RJ,D@M_>(R-O0#'0U('*$,"H8$;=Q &3TP&!#'OM')[8/-2PJVTW-P""
MQS'"S8)&?E9^3ECU;LHXXYS3N7:94GD*06L<A(E8 >88^<1# ^48(W$9;D@G
M&*!VT_3_ #[>7?\ .6=0R^;-(]Q*[(D4" DO)*ZQQQ+&F 7DD94126+,PR,8
M ]"\63V?A#0;;P1+9L]TWV/7/&<T=Y$\,_B?RG?2/!\D-H9'NH-$MW_XF5E'
M+$!?/,TCJ& 6:S@A\!Z7IGB.^LWO/&FJFWG\.Z/):--%X5L;LJ(?$.JV\P!.
MLW%O(+K18IH9+;3K=DOW\RYGM3'[G^SS^S]K7Q<\?:9#+;:<L]U))JGVF:QN
M=:M]$TS[;<"^\?:LL]P]K>7&H20E-,AU60:=XA\20QV%M;W6EZ?KS0?G'&.=
M2Q4O]7,L;J5ZM2$<PJ0LX0@G&2PJDGK)RM+$ZI04%0DW*=:-/]A\/<@PV3X=
M\?\ $G+ALLP5"M6R:C5;C6Q5=1<7F"INTHTJ=/GC@6XSE6G-XRG!1H82>*^@
M?V'OV<+CQ?X@M/%'BJ/[?H7AJ73=0\0&_BESJM]'=Q>)?"OA00O'<VJ"PU*.
M#7?%FEO=>9#80^&=)N[<QZGJ%O'^WU<KX)\&Z)\/_"VC^$?#Z70TO1K;R(IK
M^ZDOM1O9Y'::[U'4[V7]Y=ZCJ%U)->7EP0BO/,XBBAA$<,?55KE>7T\MPD*$
M;.;2E6G_ #3MKKNXQU2OOK*R<FC\4XVXLQ7&&>8C,ZW-##IRI8'#MI*CAT]&
MXKW8U*ME*:5^2*IT5.<:49,HHHKTCY \E^.O/PI\6CUATO\ ]/NEUE2(OF2<
M?QMW/]X^]:OQTY^%7BW_ *XZ5_Z?=+JM(C>9)Q_&W<?WC[UZ<&E@,.G9?[9C
MGJ_^G.7?Y'P]=7XPSFR;_P",:X5V_P"QIQG_ )?\/<H;%]/U/^-&Q?3]3_C5
MS8WI^H_QHV-Z?J/\:SNNZ^]'H<K[2_'^NGY]V4]B^GZG_&C8OI^I_P :N;&]
M/U'^-&QO3]1_C1==U]Z#E?:7X_UT_/NRGL7T_4_XT;%]/U/^-7-C>GZC_&C8
MWI^H_P :+KNOO0<K[2_'^NGY]V4]B^GZG_&BKFQO3]1_C11==U]Z#E?:7X_U
MT_/NRYL7T_4_XT;%]/U/^-6J*QN^[^]F_*OY5]W]=U]Y5V+Z?J?\:-B^GZG_
M !JU11=]W][#E7\J^[^NZ^\J[%]/U/\ C1L7T_4_XU:HHN^[^]ARK^5?=_7=
M?>5=B^GZG_&C8OI^I_QJU11=]W][#E7\J^[^NZ^\J[%]/U/^-&Q?3]3_ (U:
MHHN^[^]ARK^5?=_7=?>5=B^GZG_&C8OI^I_QJU11=]W][#E7\J^[^NZ^\J[%
M]/U/^-&Q?3]3_C5JBB[[O[V'*OY5]W]=U]Y5V+Z?J?\ &C8OI^I_QJU11=]W
M][#E7\J^[^NZ^\^-OVZ_C;JW[/O[-GC'Q[X=OH-*\17-[H_A;1M4ETZ^UJ32
M[G7YIHYM2M-$TU6OM7NK6TMYUAM();(1O.MY+J-BEJ9J_B.^+?[0.L>++WQU
M!XTU'7+^/4=0AN[?Q%XDM-/_ +=@\2:5]MU33M1U.^L5U2Y2PUO2-1O]"BL]
M4<3ZKI.HWFCZAJ]O>6C%_P"EO_@MUXO*^&O@O\/]8\,>(M2\+S:YJ7C)M0\/
M2Z<DM]?VVG:AHMQ97#:A;W\-O!H5O=V^KR"33Y4OEN/)6ZM9(EBN?Y!O&E]H
M,<OBVUT_Q$R7VDW-U&]_%IT6G6M]%>30+:3Z]%=^'C)=Z;I=M<V)U&YEO4CL
M8&>?3],N A1OZI\%,CPD<BEF%:FJF)QV-J3=54HRG1P]"4*4*;JQ<I\C<:DW
M#1IUFO9NS<HJ^[%*S5_>LM%*.FZZ[>>[O9%H:[<KK&@^'[K3M+T>STB\T^"\
MN[?^T;G41;6UAX?OK>SGT^[%EJ6N17M]?:9<QW%QJD,MOI%S=VMK>QV!05]!
M?#[4(RDEUJ.OPZ%INF&PUV_UB":P^R6%SJ%J+N[AT_4?$1$^D:M!!_9^E3^'
M+8W5RDM[/XCEBU#48+33D_-UM+U;S[^QO+TZE:3WFEO8QWOCEO#.G[8+;3;Z
MXFURUT#3=0N;C3]/BN+FWNY?#>L6DXNU>&>5)-+?3S[OX*^'6IR7FKQ?V5\.
M[;5I=0TBYFGMO#OQ)^(^CM9_:+DW\;7E_KN@Z')>"YGM#J,\EQ?R7>B2PVNE
MWGF)/;P?NF89=A_9>]72NKVC"G6@G+V2J.49XF-6.LG'GY)1@J=OL2<>.$[2
M3<-M=;[V]&M'KT?GT/[-/^"0O[2ND>*_#&M_!K7/[.L-9AD;Q!X1NK?Q!J^H
M6&M6*K&UUHU@FL^3;OJ]I:WUMJ]X^A6UM%?Q7+W-Q:+Y$<A_;G8IZ#^?^-?R
M5_\ !(".^\)?M5:#X _X1>]\3:G;Z5>ZCJEQI6D^"])\+^#M/^RRF[U+2+NZ
M^).O>,=/>R>[TZ]U3P[;V-^K6-Q'I)(BM,1?ULW$*W$$]NTDT:3PRP-+;RO!
M<(LJ-&SP3H1)#,JL3'*A#QN%=2&4&OXA\2\NP^6\68R&%<HT<73HXZST:EB.
M;VDN1SE*'/.,I\DN6SD^5<MF=RO.*FXWD^F^L4DEKJM+)W6][7V7Y^?M:?M,
M+X7BU#X6_#W4!_PDMS$UKXLU^SER?#UM,F)-'L)T)"ZS<1,1=RHV[3H7\L%;
ME_W?Y@:/K&I>'=6TW7M&N9+/5M&OK?4]-NX]K2P7UI*)X)@) RNPD4%ED#+(
M"RR!E9@?V/U7]B/X#ZI+-<"R\7V-U<22337%OXLO)VEFF<R2S2B_ANC++)(S
M2222.SNS$L23FN&U#_@G]\,I@3IOC/QQI['.%G_L74(QSQP]A;RG'_749]NM
M>MD?$?"F58*.#@\4G-)XNMB,)>6)J-<LG45*=?\ =V;C"GK&$-'S2<Y2_#^)
MN#^.L]S.685%@)1I2M@</A<P<8X.E&:E"-)UZ.&?M6^6I4KVC*I42?NQC3A#
M0^%G[.WA[Q]:>'?B[\6?&6J_&;6->TZTUK3+;57DM_"NF1W:"86L>DB3_2#:
M2[H);9A;Z>)HG0V3JH)^TXK>"WABMX(8H+>WC2&WMX(TA@@AC&V.&"&()%%%
M&H"I'&JHJ@!0!7G7P;^&<GPB\$6W@8>);OQ18Z=?WUSI5Y?6$-A<V5E?2"X;
M362"XN(YHH+IKB6&4>5M2<Q>7A Q]3K\_P WQ]7&8RJEBY8G"4:E2&!M#V%&
MGAN9^SC2PT:=&G0]SE4XQI0O)7=]&?JV0951R[+Z'_"?#!X[$4:-3,KU/K>(
MJXSDC[:5?&RJUZN*_>.3IRG7J6C)*/+\*J[%]/U/^-&U1T'ZG_&K5* 6(506
M9B JCJ23@ >Y/ KRKON_O9[?*OY5]W]=U]YD-I6E,S,VEZ8S,2S,VGV99F8Y
M9F8PDLS$DL226))))--_LG2?^@5I?_@NL_\ XQ7AFH?M>_LLZ3J%_I6J?M _
M"S3]3TN_N]+U&QN_$]M#<V>I6%S+9WMA/&RY6ZMKJ&:WEA&666)UP=IJI_PV
M;^R7G'_#1?PEW8W;?^$JMMVW.-VW9NVYXW8VYXSGBJ^IU'K]5F[ZW]A+7S^$
M^@CDO%+47'*.('%I.+CE^8M-67*XM4;-6:LUI;;1'OW]DZ3_ - K2^.G_$NL
M_P#XS1_9.D_] K2^>O\ Q+K/_P",UX!_PV;^R6<D?M&?"4A20Q'BNU(4KRP<
MA<*5'+!L%1R0*7_ALW]DO@_\-&?"0 D!2?%=J Q;[H1MN'+?P!22_P##FCZE
M4_Z!)_\ @B7_ ,@/^Q.*O^A/Q#_X;\R\O^G/I_29[]_9&D_] G2__!=9_P#Q
MBC^R-)_Z!.E_^"ZS_P#C%> _\-F_LEYQ_P -&?"7=C(7_A*K7<5SC<%V;MH/
M!;&T'C.>*/\ ALW]DOG'[1GPE.TD,1XKM2$(Y(<A<(0.6#8(') '-'U*I_T"
M3_\ !$O_ ) /[$XJ_P"A1Q#_ .&_,O+_ *<^GW>1[]_9.D_] K2__!=9_P#Q
MBC^R-)_Z!.E_^"ZRQ^7D5X!_PV;^R5@'_AHSX28; 5O^$KM=K$_="-MVN6Q\
MH4G=_#F@_MF_LEC(/[1GPE! +;3XJM@VT=6V[-VT="V, X!.2*/J53_H$G_X
M(E_\@']B<5?]"CB'_P -^9>7_3GT_I'T6L4<:JD<:1HBA4CC4(B*. J(N%15
M'"JH"@<  4[8OI^I_P :KZ-K.D^(M(TOQ!H.HVFKZ'KFGVFK:/JUA*)['4],
MOX4N;*_LYUPLUK=V\D<T$@X>-U8=:TJF\EI=JVEM5:W2W2W8\"<)1G*-2$HU
M(RE&<9Q:G&:=I1FI)24E+22DDT]&KGP-^T+\9/A-\!?VK/V=?&_QK^(7A;X5
M^"];^#/Q]\$:7XN\<:FNA>&;KQ??>)/A/J]EX<.NW:KIEIJUWI>FZCJ%K;7M
MS;&ZMK&Z:W,C0L@^Q/!/CCP/\2_#.G>-/AUXN\->//!^L?:?[)\5>$-;T_Q%
MX>U(V=Q)9W8L=7TJXNK&Z-K=PS6MRL,[&"XBDAD"R(RCY_\ '>DZ3JW[:_[/
MW]K:3I6K"P_9X_:'O+#^U=-LM2%A>_\ "9?!J(WEC]M@G^QW9A9H&N;;RIV@
M=X&D,3NC?6:(D:A(XXXD485(D6-%'HJ(%51[  47?=_>P<5:/NZV?1-6;TTM
MY]^OW>8?%;X0?#?XW^#Y? 7Q2\,0>*?##:UX>\36ML=1UC1-4T7Q3X1U>U\0
M>%/%GAGQ+X<U#2/$OA7Q5X9UNRMM3T+Q)X<U?2]9TRZB+6M[&LDJ2>"VW[ G
M[)UAX7\4>#]%^&.K>'-(\<^+_$?C[QO/X3^*WQE\*^)/&GC'QGX2TWP-XWUW
MQ9XQ\._$'3?%WB*Y\<>%]'TZP\:0ZMK=W9^*9[8ZOK=M>:S-<:A+VW[4/[0%
M_P# #PO\-&\,^#(OB!\1_C?\<?AY^SS\*?#&HZX_ACPS)X[^(:ZWJ*:YXV\2
M0:=K-_H_@OPCX5\+>*?%>OR:/HFL:YJ$&BIHNC6#ZCJ=O+%^4_[6O[6'[3_C
MZ\^''[..@Z/X7^$'Q3\+?\%)OV<OV;?V@5\'?&'XG^'O#'Q'^'WQ4^&6L?&_
MX=CX>_%+P5X:T3XG^&?"'CW1;2TTSXF6\<7AWQGH&K^'=0\/Z?=:SX:ULZC=
M)OOKT?7M_FO.VQI3I3ER\KY4VVM6MK-R27RU[M*ZNC]5Y?V0_P!F:72?BKX?
M/P9\(1>'OC=\'/!?[/?Q1\.6T6H6?A_Q3\%?ASX?\2>%? OPY.AVM_#IFB:!
MX6\/>+O$6E:2/#MKI%]#!J.][V2>TL);6\G[*_[/8T7XQ>';CX8:+JFA_M!^
M!/"WPR^-FFZ[?:]X@M_B5X$\%> Y?ACX8\/>)O[;U;4)+B'3/ LTN@?;;=[;
M5+Y'.HZC?7>K@:@/CC_@H!\6_''PG^)G[ G@#0/'G[0?@SX??$_QW\==%^+5
MO^S5X;?XB?&#Q-H?PV_9T\1>-O#=MI=O>>#/B#XKU*TTKQ+I%KJ^M7FF:5+K
MFI64,QU":8SS(_R7X'_;L_:/\)?#S]@GXL_$7QQ9_$KPYXZ_9(_X*<?M&^,M
M,\/Q^#(I/CCX$_9]T7PEXT_9@UCQGJ'AFSN],\/?%.7X:WUC+\1].\&7.E:-
M8?$36_$UC=Z1$=-CTNP3DE\M-.FR_)K\2E2J24&I:S:WE*_1Q;:NWLO/1=#]
M?/@A^RQ^S[^S=/#=?!#X9:1X NK;X7_"WX*6MS9:CXAUB>T^$_P4CUR/X6^!
M+27Q)K&LO:Z'X1;Q-X@N;9(#'=:E?ZO>ZEK=SJ=_(+E:4'[(_P"SA;? ?7OV
M88/A3HL7P#\2ZIXFUO4_AHNI>(QH\6K>+?'ES\4-7U#1+XZR=>\,7%O\0KN3
MQ=X<;PUJVDKX-UB*RF\(KHD>G6$5M\3_  E^+/B/PM%^QQXZ_:0_:B_:0N?B
M7^U+;_##7(]-\)_"C0!^Q-JOBSXQ>"]6\8Z-\"/#^H:=\/=9'A2RTO1[2XM=
M"\1:S\2)/%VH/H%MXHU/7C/X@?3W]1^.?[5FFZK\5O\ @G]IG[.OQN\%>+O!
M_P 3_P!M>_\ @[\:_P#A7'B/P=XYTW6/"Z?LP?'OXAVW@S7M0T]M:.AS_P#"
M2^#_  YXAC%E<Z5K#_V5&GVAM/FNX)R^BMTT7I*WW+7;\!2I3YDF[N5I7]Y>
M]':[:NVK63_0Y'X^?\$UO /BFR\$7GP3\/\ @&'5-,_:1T7]HSXQ>&?CWKWQ
M9^(.A?M'Z_HOPA\6_!S29?B)\0[OQ)XI^)6G^(O#.C^)-/U?1]8MWUG3]9E\
M-V6B>*='U'39_,@ZSX._\$]? VD_"WPYX9^/UX_Q \>>&/'GQJ\7^"/$7PW\
M:?%WX:)\$_!OQNUB2^UC]G[X0^-M"\<:-\4Q\$](TM;#2V\-^(O$1TK7;NR@
MU-O#>CPZ?H.F:-^CM%.Q///EY;O>]]>9[:7ZK;SU2O:R/GK3/V6?V>=#EBET
M+X3>%] 2W^ 3?LMVEGH2ZAH^EV/[/K7=Q?GX7V&DZ??6^F6.A_;+JYN1>6MI
M%KOFSR-_:QW&N<LOV,?V:M)L9+'0/AQ/X5)\$_!CX<V^J>#_ !Y\2?"'B73/
M!O[/-IJNG_!?1]%\5^&O&&E^)-$;P'I^NZS8V&IZ3JMGJVI6FIW<&OW^K1R
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MJ\QX@@ZM2=5PI9YF-.E!SFIN%*G"LHTZ<7[L(12C"/+%*R1\6_\ "#?MI?\
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MG[\-_P!K?]K[XN^*?@[\ D^%?@']G_X_^*/AS^T7\6O'FM_&CP+\0;SPU<^
M/@Q\5="^$WPWUSP3\'H/''A'Q]HZ?'*X\5Z+XXN;/Q7XTN=1^&'A^UOM'N;3
MQ7J-_IUXG.VO[>?[3OBSXX>-O"'PS_9ZO_'W@WX-_M5^"?V6_B/H7A?X1_%/
M6YO$$1L_ T'QL^+^A_M ?V_IWPQ\ :9\+M2\>-K^C?#[Q7X0UW5?$_@OP9J#
M:AXBT/7/%&DVVGBEYZ76_?1K?K;_ "'[&HWWDM]7=)-)7;Z72MZ+R/T@\4_
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M.FW^FV^LZQJFG>%[V^OES7[O^E;\&O07L)\M]-7MS=K)MZVTY4GKT/U:T?\
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M*Y 6+PM>LY7X:MQ3GF>.6&RG"_V=AYW4L4Y.IB%3=E=5FH4Z+:;?[J+J1?\
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MOQ%J\NOW'B#POK6HWTVDZ.NG1O%;F_2W6:!S="!;>\L=/M%U%+R8A/VGTO\
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M(]*APUUIW@C_ (;LT6,6/@K["?V1O$3NGV7P[]A^V#XS>'51BNS[*;KR"0K
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M  ;>0>%='\#Z-I'A_P +Z3H>D:19Z7IUD;:>2Z^T_+/]T?I1Y9_NC]*++?\
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ML_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\
M"C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7
M_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\
M/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/
M4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8
M?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0
M[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_
MA4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K
M_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG
M]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP
M^H_7_"C8?4?K_A0'L_/\/^"0[!ZG]/\ "C8/4_I_A4VP^H_7_"C8?4?K_A0"
MA9IWV=]O^"<E\'QC2?& '_13?'__ *?IZ]:KR;X0\:5XQ'I\3?'_ /Z?IZ]9
MK3,/]]Q'_7Q_DCS>#?\ DE\E_P"P./\ Z7,****XSZ8**** "BBB@#$\2[/^
M$<U_S&*Q_P!B:KO9?O*GV&?<RY(&0N2.1SW'6OPY\/)J5YX-\ 7T<5S/*GA;
M1RNJZGXLF\,-<A+?;:I);0B47-Q':QV[S&6,H$>(*\RKD?N[+%%/%+!/&DL,
MT;Q312*'CEBD4I)&Z,"K(Z,592"&4D$8-?CI\2?!%SX1\1>)_#FHZ=X;N!X8
MUG4;S3;GQ0NZT;PCJ(%[I=Y;QZ596-AIT,%H\-A;Z=96DMK86EE!927<VI17
MJK\QQ)2E*.&JI-QA[6#M;24W1G%N\9K:E*WNW;5DUU_6_"S&4:=3-<%)Q56M
M/ XF%W)2E2HPQN&J1BH5:$Y)U,;AU./M>6SC)PFH^[@6^@W%K8S7L\ GU@SI
M=?:KI_#\]Y&$_>.ZZJ^FPPR1<(L?VI/,1%0K)&=QKROXCZOJ.F?#72KW3;[4
MX#K7Q$T'2YGEU&UNKB2QU+^V+74H)+W3&,$L%R\>)+??+&JQA"H'RUU'A_4%
MN[\PV.H6=U*L$D<K:3X+EALE:6!I!"=6U*Z%FEG($:(RW=O"LV #Y8)%<3\8
MEE'@#37N#(LQ^+G@N*:W-_%J$5H]O%JJ^5"MM:6MG:ED=)9;:T2:(.X#S/*K
MY^5NG'FC=6C*/Q1DF_<N^:%TY;IQ;Z75^4_9:5*I#&4:5=TIREB\'4:=&M0G
M&G*3BJ<:%?EDJ.BE&I&,N65XR=ZMSE/"J>7>^"XB!F+X0?$Z,D-NR1\%M$R2
MQ"ENO!9$)'.T5C_%%@=#^$"%$5E\)>!FCD"_O7#_ !*\"+,@?8"B1A(F94EQ
M)YO[V+"1M6OX4V_;_!VPEE_X5#\3=I*>62O_  I/0MI\O9'LR,';L3;G;M7&
M!@?$IWFTOX8+MWQV7A7X<PH^(\PRW/Q"\#7,RAL^=^_B,!9=HBQ IR7!Q\UA
MOAX?\\=XA_\ J[R-_I^IX&21;\3>,7_)0RZ4K[I/"8A?^E32=]=7;6Q]7:G"
M\_BR_L&6>[$WV>]D@NKO0WL1:B9U3R=,O(I;Q) !*CSPPAYHT?,X.*R]6T/4
M+2:Y2QBCBTNZE++:_P#"2VGA.S\R/:8GMHM+T^.X=RA*2K=7$CLJ(Y5CTU]0
M^U17_B1H'N&^SW%Q+)/'%;>(IHEN4R+*/298;;4K:$I(LAMK&>YMVAD<+*K!
ME/"::UMK5T-/MW\&:K<$RQ?V=K_AO4=!NXI(\>8]E#Y]R;IEC\Q7021R1[#P
M0"P^FFXWY;-RG*7+K!:<UG%*2;FF[W]V6M_.WKX6-1PA5C*FJ.'PU!58QI5Z
ME[4J<U6J5*52G2H3C%4Y1O7A:#LTG9'V;^RDGA\?%&X_M&TM[/Q;#\-Y(=!@
MN[TWVI1Z(/$,*Z^UI<J[1W5K-<IH<MU,^9B6L]VTEP?T8KX?_9-\%W@U3Q1X
M]NH--&BQ6=IX1\'A+0-=P"U99_$MS9W<JK/9V-W/%I=C+90/=6=W)I45X+E+
MD7-M']P5]UDE.5/+Z?-%1YYU)QTLW!RM&3M9/F2O%I)<CCHC^>N/<12Q'$>(
M]E-S]AA\+0J>_*<858TE.I2ASN4H^RE4Y*L92G)5XUN:<G=A1117K'Q@4444
M %%%% 'E/QOY^%WBD?[.C_\ I_TJNGF0>;+R?]8_I_>/M7,_&W_DF'B?Z:-_
MZD&E5UDR'S9>1_K']?[Q]J[_ /F!PW_87C__ $SEQ\C%<W%V=J]O^,;X4?\
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M0H @HJ? ]!^0HP/0?D* (**GP/0?D*,#T'Y"@""BI\#T'Y"C ]!^0H @HJ?
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MHP/0?D* (**GP/0?D*,#T'Y"@""BI\#T'Y"C ]!^0H @HJ? ]!^0HP/0?D*
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M $%%3X'H/R%% #]C>GZC_&C8WI^H_P :FHK#3L_O7^1OKW7W/_,AV-Z?J/\
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MI-C>GZC_ !J<G))]23^9I*_#-.S^]?Y']6Z]U]S_ ,R'8WI^H_QHV-Z?J/\
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M_L<^ -&\4V=QIOBKQS>:M\3M>TN[C\JYTJ3Q8\#:3IUQ&0K1SV^@6>EO<1R
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M9_X;WQ)_\AT?V?C?^@:K_P" ^G^:#_7#AC_H=X#_ ,&O_P"1\U]YZE17EO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\3S>'=-\97-Q]CA\):KX^@T.7P'IGB(WN+&32K[Q'!=6]^WV&Y2&[5X5T?\
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MOQ/;0?\ ")>'6V:[XD\-ZCJ.AV>G>,]%TMVB2ZU#PC=:U;@W%LT;R1W$+O\
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MG6\LM[:S76S.>7<*9<XTJU/ 2QE;+L1&G1Q688F5/VE?(\-C*%?%NT(X&O\
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M>>"=+\ 3VTM_J/@*PTK3VTW7=3U%=/MQI[ZI?PV2?;+M+RT0VUM-)\3>'_\
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MX*\*2ZAIX\5ZS<:MH0TJPU#P]X5E_LK3?"]C;6DNNW>H->ZIJ,,MDLLGZ/\
M_!6C]D'XN?MI?L\_#_X9?!F7PE'XG\,_M"?"WXEZE_PF6M7>A:8?#/A.361K
M)MKRSTK6))=11=0@>ULVMHTN0LBFYB95W9XA\-4,ZX9HTGE<LMP^)QRQO+7^
MO4'AY8VI+#3QE6O33G*KAW2J2IU%*-.4I02ARNE#;"+C?&<,<;8C$1SZ.=XS
M"9.\MY\(\IQ2Q4,!0CCZ>74,+6<:<*.+]O2C6I2ISK0A&I/GYE5J<O\  G]I
M?XU^,?\ @KO^VW^S+XB\9G4/@C\)O@7\$?%_P_\ !7]A^'[9?#_B+Q5X<\!Z
MAX@U%=<M=,A\1:@=1NM>U*1[;5-5O;2 2QI:06ZPH*_4+Q3JVL0^'/$Y\$1:
M%K?CBTT#6I_"^A:OJO\ 9^FZCXDMM/N'T;3]8O+:.ZN].TRZU1;6VU&]BM9Y
MK.UEEF2&1T5&_$/XC?LP?\%'_A)_P4@_:7_;'_9/\#_LO_$'PI\>?AM\*/ ,
M&G_&GXB^-O#.H:7#X&\(^$--U&?^S_"_A^<QW$NM^')Q [ZA=0RZ=+%)Y<,Y
M=%^W/A__ ,$_?@+\'/'/C']K/X6?!#PGH7[9WB_PAXUU75M=G^(GQ2U#P5J?
MQ,\=Z;_:GB.PFLM5\2:CI=EX7U?Q>D<,U]8>&X+ZRTG=+I]O;2_N3X.:X?*)
M/ 8FGBL-!3R3*(4\/@J>&K*>:4<!A88R&:16+PE3!QJ8CVGML3R8BI4G[27(
MVG)_5Y!B^)(+-\%7R_&U'3XGXBJU<9FF(QN'E3R/$9IC)Y;4R&7]GYC2S*=+
M">S6&P,JN"HTJ?L81JJ+4%\L?\$X/VA?VQ?'W[:?[?/P%_:P^)O@[QQ=? W3
M/@1>Z'H/P[\(V'AKP%X*U;Q_I/B;6?$&C>%+R>Q3QCKNEV21:;I2ZIXOU2_O
MM0DTQ]22&P^VR05\S_'KXV?\%+_V._VP?V*_!WBG]K3P!^TO-^U5\7[WPQXE
M_9F\,_!#PIX*M/"/P_BUO3HKO7_#VO6CZEXYFTO2="O[J9_%&MWEC%:ZCH=Z
M]U;:I8QWY@]+_8W_ &;O^"HOPI_;E^-W[2WQ:^&O[)&G^%?VL+SP!'\:(/"'
MQ0^(&LZCX'T[X;>&-=T[1I?AUI][X=M/[2N]6U&_M?[5C\07DD4<.][-K<*4
M;R7X!_LE_P#!7'X7?M5_$']K#XB_"C]B[XV_&+XFZ_::-+\3_'GQ>^(YU;X4
M?!\WR6USX"^$/AK2/"MGH/AK3X-$>;$GD2ZIJ<J+:ZAJ$D5WJ;7WTJ64T\SS
M'$JKPM5PD\BRV/U!++/9XK,I95'"UZ>&K3I_\)\:&81KXS%5L+4IXFK[/#J/
MM/;J<?B&N(JN1Y+@'0X]H9C#BO.ZCS=U<Z=; 9)#/YX_#5L?AZ=?_A8EB\IE
MALNP&%S"E7P5#VN+E-4OJJA/^EBBBBORT_>PHHHH **** "BBB@ HHHH ***
M^=?A[\2?C%XC^-?Q5\#^+_A'-X3^&GA**W?P+\1'N9Y(_&,CS6T;(B2?Z-+Y
MT$L]V/L>/[/%L;2]W3RH1U8?!U<32Q=6G*BH8*@L1657$4:,Y4W5IT4J,*LX
M3KU.>I%NE14Y\BE+ELCP,XXDR_(\=P]E^-I9G4K\3YK/)LNG@,HS+,L-1Q=/
M+\;F;GFF*P.&KX?*,&\/@:T(X[,:F&PLL1*CAU5]K5C%_15%%?B!_P %@OVE
M_&OA*Z^$O[-'P2_:*TW]G'XS>)? _P ;?VHW\:W/CSPEX%>Y\/?LX^%(Y_ /
MPSU*Z\7SP6>HZ#\<?C?XH\"^#=>TJR)U#4?!NC^-XX9+9()+A>4]\_;^BOR?
M^'/[?7Q%_:PU3]GC0OV1M*^$T!^+7[&'A#]M/Q+XM^+DOB;5] L-"\<Z\O@[
MPU\*=%TCP5JNEZO!XF;Q7IWBVU\5>+KRZU33O!L/AE;5?"_B34-8BBL?B#Q]
M\?OVC=$^&'_!6?Q'\;_$/A7XO?#/X0?MP? [X;^!OAYH'B+XU_"GQ!X4M_$V
MH?L43V&D>'_B=X&^(^E>(M)\%Z%'X]U37K[0M*@L+CQ;XRFUQ=:NH_ OB*Z\
M&Q@']']%?DQI?_!0/XI:A\1M.^ \_P //A_IGQKT[]M[XX? KQW8:SK.O:3X
M5\/_ +-/PE^&%Y\>],^/K7DRSWMB/%'PH\4_!;3FGNQ<:!8^.O'FHV]N=1M=
M&%E-\-?M'?\ !3#XZ>,_@;^WS\._A)\5?@%=^._A7^Q9H7[3GPW_ &AO@%!\
M2)/#NB6.O>-/%W@OQ!X1LF\0ZRDNN^)])3P]IVM^!?BIX>U0>%/$%KK27=YX
M,LX[3[+=@'])E%?BG\7OV_\ ]J3X;^+?%GP6^'_PGT?XV?%WX#_L^?#WXT_$
MJ/P/\#?VC_&.C?&+Q)\3-0\=7/@KX-_#EOAZGCJ+X,:[J_A?X=ZE%_PL/XP^
M(M?T2?Q1KNEF+PV-$TS7KNT]_P# /[:GQ$\0?MHZC^SM\2O"GAOX#^'-2LM)
MNO@_X7^)_ACX@Z=\0_CQH]Q\(/#WQ#\2>,/AG\2K<R?!S5=4\#^+]9U;X>>+
M/@D"_P 1=*M?!7BKQY<:@FBP65A=@'Z6T5^ W[2W[3'[0O[/O_!47Q9\4H_B
M=XBU']C'X*? 7]EW1_VE_@==>5=>%O"W@S]HKXF_&?PC=?M2^'X([5]0L->^
M#/BSPGX&O?B-+"]U%>?!FZ\8W8LTNM!@GKX$O/\ @H=^UU\,_A?^P;XNTKXK
M^)?$MU\8_A3_ ,%'O#WQ"^*_C:>#Q3\)O@Y'I7[=/PJ^%'P__:V^..BV,<.H
M^+_AW^S=X)\0W=KIUCH[06KVFLZ>OB34]$\&CQ#XGTD _KTHKX2^,WQ.UG]A
M_P#8V\,:CH6N>(/VB/'FFW_P2^"W@?Q9\7/&"RZC\2?B=\;?B5X-^$?A#QG\
M2O%^F:>4CT6?Q;XZLO$OB5O#VE1K'H5O<:3X6L+;_B601>$?'']L/]I[X)?$
M+X3_ +.&H>'?AGXI^-OQ+\+_ !B^*S_$'X>_!+]I+XI_#_1?A=\,9_AYX?TN
MVU'X._#&7Q7\3+'Q7XH\;_$>RT>XU5_&5UX/T#0]"N=;FO;[6->TWPG:@'ZR
M45_++^UW^T?\=_'6C?'?XCZ_IGQ<_9J\:>(/^"6O[(WQ UKX+W?BWQ5X?U?X
M3?$;6OVYO%/ASQ0L5K:W&BSZ=K=YIEFNF/KATO1_$&I^%I+#3]7@MX@^GQ?K
M_P#"G]L7Q_XM_;5^*?[,OQ,T+P=\'(_#VJ^*H_A)X$\::!\1=+^)'QN^''AS
M0?"]_:_';X6_$>XMV^#WQ'\,ZCK.H>)-*\1?#;PPR>.OAI::/;ZIXNNQ]ICL
M[@ _1NO!_@!^S-\$OV7O#WBGPO\  _P5'X,TGQOXZ\0?$OQ:&UGQ!XAU'Q!X
MW\4O ^MZ]J>L>)]5UG5KB>[-M J0->BSM439:6\"NX;XC_;!_;]UK]F/XT>
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M_B/3?AQ\3?&[>&O%FAWNN?%4>'F?P[XKTB[?X2WVEZ%JE[=:IQGI']#5%?S
MZ%\:_$NB>,?'Q\7W7C+XDZ5>>-/^#>WPKI6AZI\8?BSX2MO#FL?&;5[+0/$7
MC/3[SP5XJTB_NKU]1U"#Q-XD\-7\TWA3XGWFFPZ/\2=-\1:%=WMG+]O^ _\
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M2_#E]#\&=1OTNK[1?#?B5]7US3-,^'VO^?X[U=KB_FTWZ>^*?[17_!07X2?
M;XN^,(_C1H5CI6NZK_P3^L/@[\1O%^M_LU?&CXA:)XA^._[6?@WX1_%;6XO#
M'P:\*^%OA]JGP6\;_#CQ+9WGP[DUR.77;/Q-'XCM])\47MDNFW&E@']%+,J
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M^VE#^SY^UQ_P2%^,?P5M_$MQ\,?!GCK5OC'\0OVB-<>[_9N\3>.O!/A;PIX
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M?"SX[>$KG6O%&AZ+J6E2^*M!L?AYXDO?#WC>YTO4))M) /Z;**_ #XU?'/\
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MM7&FZA8:@=-U%+:\%E?6=WY/D7,,C_Q<>./&US\3/V3KKX@^*(?!\.O>,_\
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M\,].\'65AX)UK0WTZROW\7+J=]X@GDU:>T6T,-OHMV9-R<Y[!TFG_P#!-_\
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MA\5ZQK47BGQ?9:9XJU1)]?TO3M0M>!\?_P#!3S]F3X=>-OBAX/U=?BAJ>G_
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M#XC>&/$#:E/K^K:;>:_K&A67AS2%\+Q>*/$$7B'P_J.FZ%-I>M:=>W&[K?\
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M:Q>>(/@[H_C'[:;N?Q=82^&O%&D+=S:'!X3OO$GAC7/#&G>);SQ!9C3I/*_
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M++#PY:Z@7;Q'_9ET(]9O;V_^CY/V%?V;H_@_\"_@EHWA/Q!X3\*?LRPZ;#\
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M>KIH]]#'+-I^L3W^G:J 8]7M;Z-W5OG[2/\ @G'^R!H.B3>&-%^%T^F>%O\
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MO@/X@Z3HW@WX0Q>$IK/4_&>FZ)X-O?&T^EZYKLWA+P_KFD>"K.:TU;]IJ**
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M*5'O=4U2\NM0OIY[NXFF?F?&_P (OA/\3+W0M1^)'PP^'GQ U#PL=0/AF_\
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MQ-XKT"/3/#&CZ[XM.M>%IM8U)+/2)FUS]]Z* /Q^UC_@EMYWP,_8!\#GQ/\
M";XC?$+]@WP1J7@+3(?C?\(!X]^"?Q:T'Q9\/]+\!>,(_$OP^E\21:MX=U2%
M]"\/>+?!6OZ7XBO[WP]J^A#2[N#5=(UK4D&O\;/^"<'B'XO>$?V?/">CZE^S
M=\%[_P"#FJZ-XJTKXE_ WX#ZK\+_ (G?!;Q;#\0'\:^+;C]F#7/#GQ!BM/!?
MA[Q[I5W?^$/%/ACQA9^*-%UT22>*?$]EXDOKZ?2H?UJHH _+7X'_ /!.?3O@
M9\:_$'B_2-!_9=\4^!]4^/'Q0^/NB>+_ !;^SKIFI?M.^$]7^*GB37?'.J>$
M-(^+R:Y#:M8^'_&/B;6F\+>,KC1)/%.F^#Y;3PK.MY-:?V[-D_"G_@FAJ/P\
MT#_@GSX?U+XOVFMP?L3>&_VEO#FM3VG@V?39OB3%^T%X'UWP;%<Z7YWB2_3P
ME)X676C>NMR/$(U00?9U^PB3S%_6"B@#\1+W_@E[^T%<_LY?LX_LV']IKPK/
MX#_9Z^"OC+]GB#PZOA?XM^&?"7C7PU>^'O!/A3X9_&OQ3H_P_P#C5X/U;5_C
M/\-M!\-^);/_ (1S5O$6I?";Q!_PGNM3CPYHU[9:7>6WJ?@;_@G#XX^&VI_#
M*?PW\8O"VHZ?I7_!-SPC_P $\?BA'KG@+4TO-5TWX=6?B>Y\(?%+P#)IWBZ*
M#0M0O/$'B_5W\3>%_$$7B"TFT:WTN#2M6L+V&[N;O]:** /QWT/_ ()M_&CX
M8>$=2\'_  6_:%\$:!;_ !9_8P^ '['WQYU7QE\*=6\37L3_  "^'WB'X7:'
M\9/@W;67C[1K7P_XFU+P=XR\00W/@_QHWBSPPNL:;X6U5I98[?7;#7+WBC_@
ME9:W/PC_ &RO@QX)^*T?ASPE^TMX0_9.\"^!!JWA:XUZ]^&7AS]EOX<?#[X<
MZ?#K=PGB'3/^$TO/$>G^ X;F2Z@3PX+*2]*R17GE%I/UZHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BOG3XI_%3XK^#?BK\(_!G@SX,ZMX\\%^-K
MZ6W\;>.[*YGCM/ \ NH8!-="*UEM8!;VSR:C))J=Q:Q7D4?V.Q9[O<%^BZZJ
M^#K8:CA*]7V7L\;2G6H>SKT*L^2G5G1E[:G2J3J8>7/3ERPKQISE&TXIQ=SY
M_*.)<LSO,^(\IP,<Q6+X6S'#97FKQF49IE^%EBL7EV%S2D\MQN.PF'PF<8=8
M7&455Q65UL7AZ-?GP]6I"M!P"BOS._X*J_$CQ[\-/@%\);WX?^)/BEX<N_%_
M[8O[)?PU\3CX*7-M9_%+Q%X"\??&;P[X=\:>#_!=W<M"+;6O%&AW=SI5K-!>
M:==QM/NMM1LY0LR_G-X-_:+^,NJZS\,?AGXA^)?QHTC5/AO_ ,%I?AI\+;+P
M%\5]5;2/C]H/[.'CO]GGQGX^\%^$OCQ>>';E;/QMH'C?66USQ?X)FU/4O$K:
MCX#C\(VWB/4;KQ#H5W:Z=RGT!_2517XJ^+/^"L,?PE^*GQB\-^.9O@%\6?!?
MP_\ V7/VJ?VF8Q^S?\0-?\5>+/!9_94E\-W'B/X:>/;S7-'MO#NL:OXMTSQ1
M#;:7XDT$:-#H?B;P]KVC:OX=DMS;ZBGSG\1OVX/VH_V<_P!I+Q5\;?VB/#7A
M*_M=#_X):6'Q3\(?!'X0?$OQH_PVUSXG_$7]IWX5>!/#6B^)4\5Z4EIIWB'P
MUXH\8:;X0U+XL66BWYU+P5JMWJ]AX?TDVEUX;F /Z-J*_GI\2_MD?M,?LN_M
M1?ML^)?CWI?A[QKXBT'X*_\ !./P#\)_AO\ "OQ)\4]9^$NJ>/\ ]I#X\_'+
MX8Z5XLL_!$V@^)?&7AV\AUV^MK/QS;>$_#WBGQ7XRT#P%I<VBV\NI:CIF@Z5
M[1JO_!1?]JC3-'\#>%XOV<M ?XC?$3]MKX;_ +*/@7QWXZ\.?'3X&_!_Q_X0
M^)OP6\<?%9_B_P"&?#OQ8\#Z+\4DE^%VH^#=5\)>-_!TNGWMIKNIZ)/%X9\8
MH_B"R.C@'[745^;/[7/[?NE_LY?LZ_&CQ;X#N/AC\:_VEO@7H_P[;Q5\%[/Q
M7?>$M,N?$'BOXD?#WX<:I#<ZG<6FMZEX8T9-1\;I+87E];ZI+:!K%;Y;@&9F
M\%^-O_!0_P#:3^%7Q \??!;PQ\%?#?Q9^,7P"^$'@GXO?%;P]\._AU^TOXYT
MSXFZI\2M8\>WG@SX*?![4?AQ\.O'4'@CQA?>#?A]?Q0^-_C#=:=H&J>+];T2
M"T\-V^A0Z]J&C@'[045^1GBS]N;XQ:O\:?V@/@'#H7@#]G_7]%^%'B3Q#\ =
M)^.&F?$W2/B%\9+>V^!OA[XE7'Q5^'VIZ?I</PX\5Z-X+\6Z[KGPZ\8?"O0?
M$D_Q)\-7W@'Q5XPU>XL](L[/3-1\:_9D_;&_;4O/A%_P2C^&6J6'P7^*/Q5_
M;+_9LU_XG^,?C#XJU/QKHEMX7T'X9_";X-^+&\1^(?#EJD][XX\>>,K[QQJ&
MG>(+70[_ ,*Z+;ZY?6FLZ;';Z%8WMG( ?NQ17XF_!3]K[XD:KXMF^ 7P*\!Z
M#:?$WXH_M>?\%&K7_A(OC9\6/BI\3?!WAKP-^RE\4-#\->*?$T<.K:A/XM@F
M\9>)_'_@;2_"?PI\(ZGHG@/X=:7J6L3:+LTG0+/1-5XW6OVU/VG/V<_VC/\
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M ,%7/CCH'PH^(?Q?^(/[+^IZCX4MOV=O"'QG^'^KZ%X.^//PR\):9\2_'WQ
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M0\9^*]1\.:?H]]K5S<'5\ ?L0_L[?#)/V9(_"'A75[!?V0;3XDV7P*%QXO\
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MWK>--1MO'M[-+XNT&XM[6Z@TSP@^@:OIK>"-*T?0+'PL=+AT73Q!8\-?L/\
MPO\ !?Q4UOXO>#/'?Q[\+>(_%NK?#K7?'>E:3\9_&'_")?$#5_A?X)\*_#KP
MY?\ C+PW?W5[9:O<77@[P7H&C^(Y!]G;Q$MO/=ZJ;B^N[FYD^R:* /F;X6?L
MF?"?X3?$_7_C)I$_C_Q7\1]:\)2?#O3_ !1\3/B+XM^(VI>#OAK)XED\7O\
M#KP5<^+-3U*?0/",GB$VFHW-G'+/>7[Z1H4>H7]W#HNF1VWTS110 4444 %%
M%% !1110 4444 0[V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
M'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T'^%&]O7]!_A110 ;V]?T
('^%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img209334158_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_2.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &I!K # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB?M!7\IW@N_/QX_X.)]>U'6H/[3T;X4:SXML--T^Y/VBUTP?"WX+W?A?39X
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MCAZ5Y2>K****_/#]I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KY4_;)_:\^&W[$OP8N?C3\3K'7M9TH^(]#\):-X=\+QZ;)K_B
M#7]<:ZFBLM.75M0TO3U^QZ5IVK:U>R7%['LT_2KKR5FN##!)]5U_,7_P6#UC
M4/VLOVZ_V/O^"?OA:\G?3+?6=)\2_$7^SF9I+"[\=7:MJ%W=Q<_Z5X'^%.@:
MOXJMFC51]B\53[W<D"#[#@3(,-Q%Q'AL)F#G#*,)0Q>:YS6A)P=+*\NH3Q&(
M;G%.4%5E&GAU..L95HM--77YGXN<88_@K@C'9CDD:57B3,<7EO#_  OAJL(U
M8XG/\[QM+!8**I3:A5="$ZV-=*5XU(86491DFXO]>OV$O^"B'P=_;[T?X@W_
M ,,M \8^$=5^&NHZ':>(?#OC>+08M2>R\26^H3:-K&GMH6M:Q#<:?<S:1JMG
M*96MYK>ZLBK1M'-#(_WU7\F7[-L%K_P3N_X+;>./@9#$OA_X0?'R\O?"WA6Q
MB'DZ/::+\3H[3QQ\*[73892/,7P_XR@B^&5G,6\V%9=44/,&<3?I[_P6:_;$
M^._[''P=^$7BWX"^(]+\-:]XN^)MYX=UN\U3PUHGB9;C1[;PMJ>II:16VNV=
M]:VY>\AAEDN(84N2(EC29(VE63Z+B#@2G7XOR7*>%G&GEG%N68#-<@GF%>I*
M%.CB<'*K6HXG$0IUZGM*5;#U[Q5.<X1G2A)/XG\3P9XO5\)X:\4\1>(49UL^
M\.<^S;AWC"ED^%H1JUL5@LRIX?"XG X*I6PM'V-?#8W"*,W5I4JLJ.(J4[6]
MFOV0HK^5GX\?ML?\%FQ\)3^VUX;\)^%_@9^S$TVBZCI'@9O#WP]\5>)&\&:]
M>VFE>'_%/BRW\6Z1J/C>32]8OKJP!U/2SX5,L.K6>K6>BV_AZ6+4E]I_:A_X
M*4_M7ZK_ ,$\?V9_VW_V>;[0/A[)K_BSQ!X#^/6@'PAHWBNRL_$45W?:%I>J
MZ2WB>#6)=*\,?V]X2U9;5?/FOF3QCX>LKZ\FNK61VP_XA7G\I95&GF7#E>.:
M9K4R*57#9J\51RS.886IBEEF9U,/AJL:6*J1I2IPCA7BZ?MG"$ZD%4A*77_Q
M,)P=&'$,JV1\;X2>0</T>+88?'</1P&)SWA>KC\/E[S[(:&,QU">(R^C/$TZ
M]6>.67UGA8UJM*C5="K"']'M%?EA\<?^"@<'A?\ X)?1_MK>"KK3+7QAXW^&
M'A5/!5I)%;W]MIWQ:\7W5IX6U#34L[H26FI-X#\2'Q#>WUE<+);W5MX4OHY4
MEC+1/Z3_ ,$P?BM^T!\=?V0/ OQC_:.UO3]<\:_$76/%&NZ%-8>'M)\,_9O
MUMJCZ'X>BNM.T6UL[!Y;Z32-1UNVNT@$D^EZMI_F,63CYC$<*YI@\EQ>>8M8
M?#8;!Y[4X<G0JU)QQE3,Z-&5;$0HT52<)TL/"#5:I*K#EG[D8R=[??8+Q"X?
MS/BG+>$LN>,QN/S/A&CQO1Q>'HTI9;1R'$XFGA<'5Q.(>(C5IXC&U*L98:A#
M#U.>E>I.<(N+?Z SSP6L$UU=316UM;123W%Q/(D,$$$*-)+--+(RQQ111JSR
M2.RHB*S,P4$U^*OQ]_X+Q_L7?!OQ/J_@WPA!X^^.VL:.TUO<:Y\-K#0%^'IU
M"!I(Y;*#QAK^OZ9+JJ)*J[=5\-:'K^A7$3&6RU2ZVA'ZG_@N1\<?$OP7_84U
MZP\):O/HFK_&3QSH'P>NKVS)6]_X1G7=&\3>(/%=I!*IS;Q:OH7A>[T&_FQ\
MUAJUS;*4EN8W7Q+_ ()W?"?]E3]@+_@GYX*_;&^-6E:1;>)/'OA_PSX_\9?$
M^^\)W7BWQ)H^G>/-<L[+X?>%O"EKIUAK&K:5IL5KJN@->KI$4+7VK7-YK&L3
M):VMG#I?UG#7#.24N&Z?%&?X+,\[JYEG4<AX>X=RJN\+6S#&*$9U:M?$0H5Z
MZIN3]A1IX:$JLJUH\L_:1</SKCKCOBO$<<5N .#LUR'A2AD7"\^+^-.-N(<+
M',,/DN6RJRI8?#X/!5<7A,)*MR+ZWBJV/JPP\,+S352DZ,O;>V_LE_\ !:S]
MEK]JKXD^&_@[#X=^)/PN^(OC"Z_L_P +VGC#2]'U'PSKVK&SENQH]CXC\.:O
MJ4UKJ$HMKI+?^W=&T:QNF%K!;WTE]=I8I^PU?CGX!_;G_P""4?[5?[0/PGT[
MP_'X>\0_'V/Q8+_X5^)]6^#'B_P[XDA\61V]Y=)#!XT;PQ921&Y0W=Q]DUO4
MET:[O$BDG1[];,GY0_X*+?\ !3;]JO\ 94_;RT/X.?":ST?QMX)U'X9Z!+I'
MPMF\*V%_J'B;XA^.-.\6Z)X:D&KV=F_BRX%MXLD\-W_]A:/J-DVKP:8VCPR6
MSZE-=56+X'Q&?9]2RK(.',SX4Q3R7$9I7ROB?%58PDL+6E"4\OQE?!T*M2E5
M4J=.+Q5.G3C7C54Z\*:O&,M\5\'PCP?B.(.,>-\A\1,OCQ1@N'\)Q!P%E^'E
M4IO,,-3JTX9SEF%S+%8>CB</.-:K..7UJ]6>$J8=TL+5K2Y9?T=T5^&_P9\3
M_P#!:KPG^SY^T!K?Q4\">$?B/\>]7U_X41_L_>'=:N_@UI^D:)I7B2^U:T^)
M5SJ4/@#6O"]B8?"5C)H-Q;VOBC6(G2\%S>+=:Q9V^HVUS\F?M&_$;_@NE^QW
M\+O^&E_BQ\>?@5XK\ :+KNA1>*/AUH/A'P%J4^A1>(M4ATC3;77OL_PA\'W\
M^COJUYI^E2S^%?B+J.KQ2WUK*;IH%NKR#S\'X>5\=CZF78?BO@F>)^NT\!@U
M#/*E99IBJN&PV(C#+_J^!K3G!SQ4,(JN(AAJ<\9"MAZ<IRIR9[.8^-.$RK**
M&=XSP[\5*6!_LNOG&:3J<*4,-+A_ 8?&XW"5*F<O&9MAJ=.HJ>!J9C+#X&IC
MJ]+*ZN&QE>G2C7A$_I[KSOXO^-KGX9_"7XH_$>SL(-4N_A_\.O&WC:UTRYFD
MM[;4;GPIX:U/78+"XGB5Y8(+R6P6WEFC1Y(XY&=%9E /YM_$'_@IU8>"O^"9
MG@W]NC_A$]-D\9_$/0='T'PKX$EN;QM G^+5_J>K>'=4L)+N%S?-X9T._P##
M?BGQ"T+W5MJ5]H>B'2_M]GJEXES'^1Z_M&_\%I_&'[*GC?\ ::\9Z5X2^)O[
M,OQ)^''CG3=7\$CPIX T;Q'I'P\\1:+K'A74/B%HFE^$](TGQ[#I&D+<SZW:
MW^IZMKX73;/_ (2#4=&F\*&743ID?ASG&/E4Q.-Q&3Y7A<)G_P#8,J6<9BL%
M4S+-,/52Q66Y<XTZD*]=*,J:E.K0I3FW&G6<HSY,>*_&[AG*(T,!E6#XFX@Q
M^9\'KC"GB.&LDEFE'(\@QN'YLOSS.U.M1JX3"2E.%5PIX?%XBG32G6PT85*7
MM?V?_P""6G[=/CC]O3X-^/OB)X^\%^%/!6L^#?B5<>"H;3P?/J\NF7]@/#>@
MZ]!=RQ:U=W]U!>1OJ\MM,4O)(9EBCE2* EDK].:_G%_X-\O$^B>"?V-?VEO&
M?B:^33/#?A'XO:[XG\0:E*LCQZ?HF@?"OPGJNK7TB1*\KI:6%I<7#K&CR,L9
M"*S$ X/P?_:L_P""K/\ P4HUGXJ_$?\ 8]\;?"/]FKX(?#[Q$?#7ANQ\<>'=
M#\0:KXHU-;,ZK;Z-J&L:Q\/?B1)/KHTJ\TF^\2W%A:^&]'TE=7TBVTQ;]S>W
M+^GQ+P)[?BSC"GE<\JR#A[(<;A:-7&9IBL10R_"SQM*E]7PM.<*6-Q5:M6J.
MI)0ITJBIQ3E4E3@X7\'@7Q=>$\.O#.MQ!2XAXQXTXPRO,,30RS(,!@\9G./I
M97B,1]=S"M3JXG*\OPV&PU%482JUL10=:;4*$*]2-7E_I8HK\;/^"5O_  4!
M^*W[3>M?&K]G?]I71M&TO]H;]G[4KJVUS5=!M(=.M/%.G:=XBO\ PIXB&H:7
M8M)I.GZYX3\26UMIM]/I+6VE:M:ZKI\UCI]M)9WTMQ^R=?GV?9%C^',TQ&49
ME&DL3AU2G[3#U%6PU>C7I0KX?$8:LDE4H5Z-2%2$G&,DFXU(0J1E"/[-P?Q;
MD_''#^"XDR.>(>!QKQ%-T<90EA<=@\5A,14PF,P6.PTG)T,7A,31J4:L%*<&
MXJI2J5:,Z=291117CGTP4444 %%%% !1110 4444 %%%% !1110 5^.'[1__
M  7&_8N^ /BK5? NBW/C3XY>)]&:2VU*X^$]CH%]X*T_5(93'-I=UXTUSQ!H
M]E?S0J,RW7A2S\3Z?%*?LDMU'=Q74%OZW_P5\^./B7X"_L%?&'Q%X+U>?0?%
M_BY_#?PST+6+4E+NPC\:ZW:V'B66RF0K):W[>"XO$L6GW\#QW.G7TEO?VLB7
M%M$:^ /^"3/P0_9D_97_ &"!^WA\;=%T:?Q#XG@\3^)]=\=:SX9F\5ZIX&\$
M:/XVO? V@>'_  II]K8ZI>6K:Q?Z3!K-]=:39QZAJ%SKEM:ZE<MI^CVGV7]-
MX7X:R1<-UN+.(<+F6:TZV=T.',CR#*ZWU:OF>:5:$<3)U\2J->K"A[.7LZ,<
M/!U9UXRA9MTXR_!N/^.^*9<<87PYX+Q^1\.U\+PKBN-N+>,>(,,L?@\@R"AB
MG@Z:PN"EB<+AZN+=6/ML3+&U8X>EA*D*O-%1JU*?T-^S3_P73_92_:"^(OA#
MX4ZMX5^)WPG\8>.]=TKPOX8NO$^G:)K7A'4/$>NW\.EZ)HSZ[X>UB[U*PNM4
MU"YM+2WNM1\.VFDQ33C[;J5K$OFG]K:_%RP_X*!_\$DOVI_C!\(/#M\=!\6_
M%JX^)W@AOA/X@\0_!+QIINNV'Q*'B73Y/!*6/C'_ (1:"^TUKSQ0-,A\J^U&
M+0;N=X4UU6T_SF7Q#_@JI_P4G_:,_8L_:X^"_@CX7-H^M_#S6OA1IGC3Q%\/
M[SP]IEY>>,?$.H^,?'GAVWT\:^]A=Z_IEK<#1-&B\K0Y8+HXN3!NN+A=NV-X
M)K9[GN!RG(.%\VX3Q^)R[&XVIEO$F*K.A56#O+FR_&5\%0KS52*=.2Q%.-.-
M;DYJM.#E)<N5>*F&X2X2S?B/C#C_ (<\1LHP&=Y5E5'/>!LOPL<9AWF?+3Y,
MZRS"9IBL)2E2J25>+P5:=:>&]IR8>M5C"F_Z$J*_"W]GKQG_ ,%I]&^%G[2G
MQ!^-/P]\-^-_'VK>#/ NN_LU?#+5?^%1Z'86/BG7_$SV?B71[^S\(:QX?\06
M%OX7\)75OK-YI'COQ%!=2W&G6^GIK']LW&NFOFKX]>)O^"\W[.?PA\0_M-_$
M+X[_  +D\&^#Y-,UCQ5\*/#WA;X<:KK6AZ1J&I6FFM'<&3X0V<5]I=E=7EM'
M?_V-\4=2UM896GLY[E(I9(O-PWA[6Q685,NI\6<$NNL7A\!AI+/*E6GF&+Q%
M##UHT<%]7P-:K-0GB886=:M2H8=XR-7#TZLY4IV]S&^-&%P&3T,[K^'/BLL)
M++<9G&.C+A.AAZN39;@L7C<-/$YJ\;FV%H4I5:6!JYA3PN&KXO&++9X?%U</
M2IUZ?-_3/63K^IMHNA:UK"PBX;2=)U+4U@9S&L[6%G-="%I KF,2F((7",5#
M;@K8P?RJ\'_\%.["X_X)B#]O+QCX3TZ+Q9I^C:AH%]X%TNXN[71=8^*UGXLE
M\":;I^FSROJFH:=X=UW639:\XN)=0O\ 1/#UU<QRW&HW%@;FY_+;X5_M5_\
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M[.Z,L7E&68.G4I5<=F&)H4\1A576'RY8FMAXRQ-*A+$*C[>?L/:7_,7X5?\
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M_/VH/VROVD_&_P#P5=^!O[%/[-'Q-NO!?@SP[=^#Y?C4NEZ#X2UO^U)!!/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZC?$1Y^6GI/V[P_OZ*\?>.;./"//LQH^.].CF.40?BG')UD;J5,8E@7EV5+
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M6:YMF6<4>*<IS2A6^N8S&RP6+G7P-?+_ *W"==UJF+^L3P]%X=T*,:D?C?\
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MPL%@>(\;Q'1_U5S%NLJ^;9/EF4IY;C\3BHU(R>(S&4*F'JQIOV>)H8=8>M^
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MW_X-Y+N?P[;W-XW@?XTZMXZUJTM07EE\.Z5\2KC3=6N&B4%I+;2HM936[TC
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M5@Z<<NJ0K0SK(HX2GAZN+KPJ+EIX3'O 4)PIWJRYL0U0_$O_ ((!^&-2\6?
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M%'Q3#XQ2/PVUU<V=A<^)/AOXMTW1M/US2;FYAN+FSTBX:%+:V\0Z/?/]+_\
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MG,\\Q6=1C2Q=3%TE6E6K04:D:D</0H4Z6#I0HT^XHHHK\Z/VP**** "BBB@
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M+H/BK2K;5+)+VU8M:W]IYZ&:PU"V+.+?4+&6VO(5DE2.=4ED5OABW_X([_\
M!-RVUH:_'^S%H37RRI,(+CQY\6KO1=Z!  WANZ\?3>'6B(1=\#:48')=GC8R
M2%OVW ^(/"N,Q?#V>\083B?!\1\/T,MPM3$</5\"\!GM#*JM*MA8YG1QE7#U
M*:JRIJ&)A0E*,X.23M[*-#^4\U\&/$++,MXTX1X-S'@+,^".,L7G>/HX/C3!
MYM'-^$L7Q%AZV%S">0XK+,/C*%9X>G6=3 5<5"G.E54&XIK$3Q?Y5?!7_E72
M^)?_ &"_B7_ZO85]\?\ !", ?\$[_ 6 !GX@?%(G ZG_ (2RZ&3ZG  R>P Z
M"OTFU']GCX(:G\&KW]GF7X8^$K'X):AI#Z%<_#70=-7PSX8.ERWXU6:W@L_#
MK:6]H]QJ@.IW-U:2P7ESJ+RWT\\EU--*^E\&?@C\+/V>O 6G_##X->#K#P+X
M$TJ\U/4+#P]IUUJ=[;P7FL7DNH:E<&ZUB^U'4)I+J[FDE8SWDH0%8HA'#''&
MOSF?<;8#-\AXDRVGA,71Q.=\>8CBNC*?L94*."K8:K16'JU(U%4>*C.:;4*+
MI.-W[2]HO[CA#PKS?AKB[@;/*V99;BL!PKX0X/P\Q4:7UJGB\5FF&QV&Q+QN
M'HSH.C' 3IT9).IB8XA3<4Z#BW)?RM:5\;?$G[;?[<_[2/PW_:^_;E\??LA?
M"+X8:U\0M+\'> ?#?Q&T[X-Z)=VWA3QA)X4_X1F;5-;OX_"TWB&TT&UN-2UJ
MZUZR\0ZQK%S+J<FE1VNDV\]I!Q__  3)LOACIO\ P64U;3O@U\0?%?Q6^&.G
MZ3\6+#PA\1?&^I'6?%'BW3[/P,;:;5M3U;^Q] 74A)?Q7<5C?1Z/8PW.G16D
MT,;Q.DTG])/QF_X)M_L0_M!>/Y?BC\6OV?O#'B7Q[=&)]3\0V6L^,O"4VNS0
M1QPQ77B2R\&>)/#VF>)KU8(8;?[=X@LM2O&MH8;9IV@BCC7T#P)^Q9^RQ\+_
M (FZ7\8OAW\$_!W@SXBZ)X6A\%Z/K_AV+4=,BTWPU!I<6BIIMGH=M?IX=@+Z
M9"MM<7L>DC4+K=//<W<MQ<W$LOU=?Q,X;629IEV!P.<X-9GPG+(H932PN3T<
MFR['/#PI3Q=*M0G''XU8BI&52KB,3R5H*53]S6=2/L?SG"> W',N*N'\[S?-
M^%\SED/B+2XNJ\18C'\3XKB?.LIAC:F(IY;B,/BJ=3*,K>"H.%'#X/ ^TPU5
MPHOZUA8T)K%?S.?L2?&_X??L*?\ !5W]LC1/VE]=_P"$!TGQ?JGQ<\,V?C'6
MK:]GL;>^U3XFZ5\0?"6H:J]I:W=U:Z1XQ\*)_:5GJDBB$37ND+=*D=XT]KR/
M[4_[3OPH_:L_X++?L=>.?@OJ]UXE\#^$/BW^RQ\,X_%;V%UI^F>)-9T'X[)X
M@U6_T!+Z."^GTBW/BNWTV*[N[2T:\N+*XN[2*;2Y]/O;O^GK]H']A']DC]J7
M7-.\3_'?X)>&_'7B;2[6UL+7Q)_:'B3PQX@;3[*>6XM-.O=:\':WX>U+5-.M
MIIYVAL-3NKNS19IHUA$<LB-7M_V!?V.K+4/@_JFG? 'P1I-]\!-5@USX2S:,
MNK:,OA+6K?Q!9^*H]62#2]4M+?6M1/B*PM-7EO/$46KW$]Y$7GDD$LJR.EXD
M\)/'QXBQ&5<0?ZQ8GAB?#N.A2JY>\HIR6 >%CC<+"4XXJK*K.G1A.C5E0IT*
M,JDXK$58Q4ROX&>(\,HGP5@N(.#O]2L#Q[2XURFKB,/G$>(Z]-YQ',)Y5F%2
M%*IE^'IX>G5Q-6GB</#%5L7BH4:4WA,-4FZ7\Y'_  6W^'.CZ%_P47^ /Q"^
M,=[XY\/? /XD>#O .BZ_XZ\%2PV_B#0-.\*>+]6TWXA1>$[F?3-;C&N^%]#U
MK1?%'V9](OS<?VY!'!;W$LS(GH?BK]AO_@BC;^'=,\0^)?\ @HW\4?$VDW$D
M$]EI%E\?/A-XZ\0"2?:J))X(\.?!K6_&5C<2*_DR12Z):W:!FC81N#C^EWXQ
M_ WX0_M!>#KGP!\:?A[X9^(WA*YE2Y_LGQ)8+<_8KR,$1ZCI%_$T.IZ'J<:,
M\4>IZ->V.H)#)-"MR(II4?XY\(?\$C_^"=/@?Q);>*]"_9B\+RZO9WB7]LGB
M3Q5\2/&NBQW,<IFC;_A&?&?C/7_#3QQR'<EO)I#VZA458@D:*O/EGB=@H</Y
M%EN*Q_%N38W(L)/ ?\8XLIGA,RP\)N6%J59YA)5L%B80?L:DZ=+%0DE[10;D
MJ<.W/_ 7-:W&7%N>9?D_AOQ1E?%N9TLX_P",W?$E/,LCQE6G"./HX>EDL)87
M-,%5K0>)H4J^(P%6#DJ+JI0E5J_?WA;PYIG@[PQX<\(Z*LZ:/X6T'2/#FDI<
MS-<W*:9H>GV^F6"W%PX#SSK:VL0EF8!I9 SL,L:^5?VH/VO?V3_V?M?\"?#+
M]J#Q%I/AZR^*]AK>I^'I/%OA*^\2^";MO"5]HHN(-<GMM+UBTTNX2ZU6RN=/
MN-5M(=/5[>1WO[:X2V2;[(KP3X]_LN_L_?M0Z%IWAWX^?"KPO\2M.T:2[ET2
M768+JUUG0GU!8$U Z#XDT>ZTWQ'H8U!;2T%^FE:K9I>FSLVNEE:TMS%^3936
MRQ9I1K9[_:<\!*5:6)GE56A3S*-25.HZ5;#SQ494)3IXATZDXU''VD%.*J0E
M)37]%\1X;/GD&)PW"/\ 85+.(0PU/ 4N(:&+K9'.A3KT5B,)C*> E'%0I5L%
M&M0IU**J.C4E3J.C5A&5.7\FW_!:+QW_ ,$\O'*?"1_V1(OA???%:/5=8?QY
MK'P7\/VFB>%I_"$FGV\>EVOB*;1-,TWP_K?B235EB.DS68O=6T_3[;4K;59;
M>"YTF*3^IG]AJQ^)FF?L>_LW6/QB?5W^)-M\(?!B>)U\0QW$7B&WG.DPO867
MB%+TM??\)!8:2VGV6MMJ!_M!]5M[M[\"\:8#S7X2?\$P/V"O@?XFL/&/PZ_9
MN\'V7B;2KG[;I6K>)]5\8_$6?2KX>3Y5]ID?Q'\2^++?3[ZU:".6QO;.&&ZL
M)]]Q92P3RRR/]ZU]MQAQCE&;</9#PQDM/.L1@\FQ&*Q;S3B.IAJF:5IXGGMA
MJ<<+4KTZ.$IJH[05:7,H4(\L71YI_E7AGX9<1\.\:<7\?<45^%\'F7%&"R_+
MH\/\$4,?1X?PU+ JC?'5IYA1PM?$YC6E1C>H\+#D=7%S522Q/LZ11117YH?N
MX4444 %%%% !1110 4444 %%%% !1110 4444 <+\4/ ]G\3?AI\1/AMJ$JP
M6'Q"\"^+? ]],\7GI#9^+- U#0;F5X-Z><L<-^[M%O3S "F]<Y'\C_\ P36_
M:OA_X)6?'_X[_LK?M@:5K'@WPQXA\0Z=Y_BNRT;4M8M?#/BKPZ]YIUCXF^QV
M4;:IJ_P_\;^'KN*\MM<T33-7O1]AT*>#3VL[O4I[+^QJOG[XZ_LJ?LZ?M,VN
MEVOQW^$'@WXDG0UN(]%O]=T]X];TF&[5ENK;3?$&FS6&NV-I<,PFFL[;48[6
M2ZC@NVA-U;P31_=\(\4Y=E6 SOA[B# 8G,.'N((8:6*6 JTZ.8X+%X*HZN%Q
MN"E63HRG&32J4JKC":C!RE*$:E&M^1>)'A]G?$6<<*<:<&YQ@<EXTX-JXZ.7
MRS?#U\5DN:Y;FM*%#,,KS6GA9+%4Z4Z:E*EB,,IU:;J5HQC"I4I8G#?RB?\
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MO@JVW_"FZN],\^PA^&UMX8;R? @GTR3S? -QF^99'\VZQJ"_W35\Y:C^R/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]172=9AL@#^RZBOY5?VM_P!M#_@II^TS_P %,/VT?V*?V%/VG_A[^Q;\-?\
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M5M:\=:MJ.NR>%('T7X=^+_#EM9C^R[>3X@:Q=0F.VU"P$H!_6_1110 4444
M%%%% !1110 4444 %%%% !1110 445^<G_!1S_@H5;?L%^"/AS#X4^ 7Q?\
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MKQ:9;);0_#WQ'Y\=Q)%+#8PO)JMC_3)0 45_.+_P6!_X+;_&']C?]H_X)?\
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M^UO^VA_P4T_:9_X*8?MH_L4_L*?M/_#W]BWX:_\ !/']E[1_CAXW\<:M\ ?
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M[:3PG8>-?B#X)U;Q+X&O?B3HZ37.D>*IO"?B:ZTS5)[.'6'\-^ [J^G\'Z2
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MX'\&Z=)\0_%:^ ?"&J7T?@C1+#2=(\9^#_"<NN^'="T^>9?!NL->.+J^U)9
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M/B*GAS2/V)OV;?!/@8Z5:ZCX?^-6KV5W#I_Q7\.6UAINN2>+-(DUKPUI&O\
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M-$^"T'Q5_9)^*^H_$!=)\1^.?$;^);WPO\%?B#%H5Q=3>-_%'B::V:P37]7
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M9V6MS_M ?#[_ (5QIMLEOI.KBTU5?%]]J5_>^)=!AM[6PT]?!?V*_P#@G?\
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M+],/V^?V$OBY^U/^V!_P2V_: ^'WB+X<:/X-_8C^/WCWXJ?%;3/&6K^)M/\
M$WB#P]XI\*Z+H>GV?P]LM$\(>(=*U768;O39Y+RW\2:UX3L8[=XG@U&XE9X8
MP#\+_P#@J9_P3-_8:^)__!?_ /X);:'X[^ 6C>(-)_;:TS]L7Q1^U'83>+/B
M)9P?%K7_ (2_!6WU/X?:EJBZ;XOLCH4WA^]M+68)X1;P]#J@@BAUJ+48$$5>
MY?\ !PO^S)\-/V<?^"4G[)7[,G[+.DVOP%\!>%?^"@'[,OASX70:,-3\5P_#
MK4?%'BGXAZNFOVD7BS6-0U'79=-\4:]=>(5LM8UJ1+J7_0#<6]GY:0_H?_P5
M-_X)Z_M5?M%?'S]A[]MS]A3XG? WP1^U9^P[XA^*"^%_"O[3-A\0)O@A\1/!
M?QD\/Z;X:\8:7XIU3X80ZAXUTJXL=,L+J"UMM'TIFUJ'6KF)]<\/2V%O<W&#
M^WK^P7^W/^WU^PK^RQ\)?B?XT_95T[]JKX<_M5? []H3XV:MX+F^+'A+X S:
M1\-/%?BC5M6\/?"S^V/#GQ"^(5Y>6^@ZKHVEZ,_BZSTQ-;O[*^O]2OM!CN(K
M= #\A?\ @LC_ ,$K/@O_ ,$T?V-]4_X*?_LM_$S]HVR_X*%?L]_$SX+^+_%W
M[5_CW]H+XI>,/B!^T(OB7XF^$?!GBK1_B]HVIZ_/X%O/#^M)K5K/<>&?"7A;
MPAHMSIVEV_AO48;[P_)=:==?V5>%M8?Q#X8\.:_+ EM+KF@Z1K$EM&YD2W?4
M]/M[UX$D8*SI$TYC5V4%@H8@$XK\V/\ @LO^Q+\5?^"B/_!.[XY?LD?!7Q!\
M/O"_Q'^)E]\,;G0=;^*.J^(]$\$6D?@OXI^#?'&JC5]2\)^%/&VO0/<:3X>O
M;?3Q9^&[]9=1EM8KEK6V>6[@_2/PAI%SH'A/POH-X\$MYHGAW1-(NI+9I'MI
M+G3=-MK.=[=Y8H97@>6%VB:2&*1HRI>*-B5 !\3_ /!0?]K;_@G]^S5\%];T
M7]O_ ,<?"*/X;_$G3)]#'P7^(6B67Q*U[XRV\T\4/_".^&/@A!IGB/Q+\1S-
MJ)M('BTSPOJ5AIMX]K<ZE=:=&@NH_P %_P#@EC^RM^V%X=_;DT/XX?L4?!S]
MIG_@G+_P2$U?_A+=7\=_LF?MC_%&TUV_^+.KZIIGB&'3==^ W[*VMZ'XX\;?
MLJ0W'CB;3?%>O3^(?B3HUWXGT5+9_#URGA9;3P;+]R_M6?L9?\%*;#]OGQQ^
MV#^P7\#O^",6H:OXK\%^ _#\'QJ_;8T[]L7Q+^T]IMSX;\.Q:'J>D:#J/P\N
M=4\!^ /"*I;PQ6-G\.[?PY<:W%YM]XK34-5FFN9/<_V:O^(@/_A=W@3_ (;"
M_P"'.G_#.'VS4_\ A9O_  S5_P -K?\ "[O[/_L+5/[&_P"$$_X6C_Q0GVS_
M (2;^Q?[3_X2#]Q_87]J?9?^)A]DH _8JOYF?^#FK_DEW_!+S_M+I^R7_P"D
M_CJOZ9J_E'_X*2_\$_\ _@O[_P %!=;^'7A_5?$7_!'KPI\)_P!GG]KCP]^T
M[\!_[/U_]M/3OB)?O\-=5\1+\--%^+EW<^!?%7AK5$N/#^LPKXYM?!MAX<-Y
MK,4KZ!K&EV02-P#^KBBOCW]BK_AOW_A6.O\ _#Q;_ACW_A<W_"<7_P#PBW_#
M%7_"Z?\ A6/_  K;^P_#_P#9?]O_ /"\_P#BJO\ A./^$E_X2K[?_9W_ !(?
M[#_X1_[/_I_]HU]A4 ?S,_\ !NS_ ,E1_P""X7_:73]H+_THKR3_ (+!_P##
M6G_#\G_@D;_PQ#_PSK_PT?\ \,__ +8G_"%?\-5?\+*_X4C]B_X1S_BJ?^$I
M_P"%1_\ %=_:O^$9_M7^P/[)_=?V[_9_]H_\2_[37Z@_\$I_^"?WQD_89\9_
M\%&?$7Q:\2_#+Q%9?M>?MT_%']ISX:Q?#K6?%6K76B> O&\N_2M(\<)XE\&>
M$8=-\7VXXU"PT&?Q-HT1_P"/;7[L<UN_M#_L(_%WXM_\%8O^"?W[=OASQ'\.
M++X1?LI_"G]H[P+\0_#FMZOXFMOB/K.K_%_PO=:)X:N/!FD6'A#4O#.HZ=8W
M4Z2:Y-KGB_P[<VUN&>PL]3D B(!^*_[,J_M*?M+?\%U/ 7@+_@M/XD\ ^"?V
MI/V-OA/XE^,__!/WX#_LU>&=0T?]DKXIZ'XRC/AKX@?'3PQ\1?&'C3Q'\6?%
M_BVP/AIIHOAUXVTSP]=Z8?!UWKZPV=EH>L^'+GVG_@Y:_:Y^ WA.]_X)_P#[
M!_Q^^(>D_#CX+?M,_M*^$OBS^U9XJU2WUS5;'2/V8OV>_$>B>*=8\-:GHOAC
M2M9UVY;XH^,)-,T?09[33[J*.^\+WWVN'[(L\]O^B/\ P4Y_X)Y_&W]ICX\_
M\$_OVP_V2?&'PT\"_M-?L0?'.?7Y9OBKK7B[PWX/^(7P \=V,>F_%[X;7VL>
M!O!_C77TU36]/L8--T6.721I']GZ]XK@O;BW:]AD&K\&OV!/C7:_\%?/VI?^
M"DGQ]\5?#?7_  AJOP"^'O[,_P"QIX,\)Z]XMUSQ+\.OAK;7T'BCXJ7_ (ZT
M_P 0>#?#N@>'/$/B/QK8#4=(C\(:WXMADT_Q-XDM;^_LR(UO@#^?WXY?\%=/
M^"=R?\%T?^"<_P"V!^Q_^U%X8^(?AKXU>"?$O[#G[8.B:!X8^)/A:VL?!_B+
M6+2?X%>,=97Q7X.\-:==V>B?$7Q)82ZA=P/>W6FZ-X2MX_)AM&:6/[\_X.1O
M^%P?\)O_ ,$:/^&??^%:_P#"\?\ AY?X#_X5+_PN3_A*/^%4?\+ _P"$<O?^
M$7_X6+_PA/\ Q5__  AW]K?9O[?_ .$:_P")U_9WG_V=_I/EU^K?_!7+]A&]
M_P""C_[ _P ;_P!EGPWK'A[PQ\2O$UMX<\6?!SQCXHNM4T_0_"/Q8\ ^)-,\
M5>$-6U/5-#TC7];TG2[R?3KGP[K>IZ/H>KZI::#KFJ266G7EQL@D^&/^"@W_
M  3W_P""CG[4_P  /^"6FM_#;X@?LC7'[;'["_Q=^$WQW^*FM?&76_B_;? 3
MXB?$WP'\/$TC7[_19O /PY;QWJ>BZ_XZ@75&TN?1? =S)HE]=+%J6DWEM!;S
M 'U?^R'_ ,/RO^%RV7_#>W_#J#_AGO\ X1_7O[2_X9#_ .&OO^%R_P#"5>1%
M_P (Q]B_X7-_Q1'_  C_ -J\[^WO/_XF/D>5_9_[S?7ZOU^*OP/_ .(BW_A;
MWPZ_X:2_X<J_\*$_X2S2?^%M_P#"C_\ AN?_ (6]_P (-]H7^W?^%=?\)[_Q
M1G_"6?9-_P#9/_"3?\2?[1M^V?NLU^U5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!_+I_P=^?\H=/$7_9QOP,_]*_$E?L%_P $
ME/\ E%K_ ,$YO^S(/V7/_5+>#*_GS_X*[?\ !(K_ (+^_P#!27QC\;?A/I_[
M;/[%Q_8(\2_%BR\=_!WX'>/;:_\ "WC'PII'AX,_A2V\1>*_ ?[&>K^,9]2T
MN>ZU!Y89/BGXEM;H3J+R\O@D:Q?;_P#P2P_8&_X+3?L\?"'XI?LT?MT_MQ?
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M2?#;38/'/QETCPMXW\?6_AOXB^"I/&6H:'K]EIEDVG:S=^"],U.WTZ.WU*$
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MC3XAZ9?OI?B"S^'EK_4)_P %!_\ @FW\>O\ @I#^UO\ LV>'?C=X^^&6F_\
M!*[X%26_Q8^(7P!T+6O',WQ>_:;^/FE7-W_PC6@_%'3QX;TSP/IOP4\-P/83
MVUO9>+]:UO4'_P"$JM+O1DN/$VA:YX!G_P""M7_!-'XU_M@Z[^Q3^T1^QO\
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M\3?M!_ ;0]5DD6X2>WD633=%LX%CDMWC(,HF69&5$^F?^#L#]OJ7X/\ P8^
MW_!/?3?B"WP1T[]NKQ'):_'GX]WVD>*]:T?X:_LV^$O$7AVR\;6XTGP#:ZOX
MXUR;Q1?ZM:1^(-#\.^']8GUOP-H_B;PI)9S?\)7&(_.?^#P3X9>)O"'P_P#^
M">?[?WA#0;C6KO\ 9$_:<CL?$0ALS-9VNF^,[GPIXY\,7VO7JI</INCKXO\
MA#9>'8[B2UDM'U3Q=96DK&ZN;&WN/Z=_%/P"_8J_;S\"_"'XO?&+]G#]G']I
MOP[J_@;2_&'PIU_XT?!GX:_%YM'\*?$?2=%\2"3PM>>//#.O2Z/9Z_9KHUWJ
M$>F&TCOWL[*2[CD>UA\L _SK_P!OW]N#_@D[IW[8?_!!VP_81^-;^(_V3/\
M@GGXK^'5M\4O%-S\*_C;X<U+PEH'A[X]?#3QYXD\7:[I/C+X8>%?$_C;Q'XA
ML]&\4^-O$<_@OPYK5SJ>N7-^MK8)>WMGI[_Z8GP>^+GP\^/GPI^'/QN^$GB.
M+QA\+_BUX+\.?$/X?^*8=/U?2$U_PAXMTJUUO0-5_LGQ!I^DZ]I,EYIMY;S2
MZ7K>EZ;J^GRL]GJ5A9WL,]O'_,O_ ,%$O^#<;P3^T7^V_P#\$_?C7^RA\#/V
M!?@-^S9^S_XZT3Q!^U1\)H?A5I'PX?XV^'--^)G@_P 57N@GX?\ PV^"NI^
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M[N\&EZ=#;VEEIF@>&-(-AX6\):'8V/A_PIHNBZ)96NGP_2]% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?PL_\$!_[5_X
MB-_^"WO_  F&_P#X2O\ M3]H?9_:?D_VG]@_X:QT+R/LF?G_ +/_ ++_ +(\
MG[)_HGV'^S_+_<?9ZF^/5LMQ_P 'JO[-#^#H)YM2M?A'I5SXU:**PD2W8?LH
M_%V'4)Y6C5FA@'A2?1(FEU K?BXF6.U;RY-,!^Y/V^O^"#O[:\G_  4,\2_\
M%/?^"0G[8?P\_97_ &AOBAI$>F?%;PA\5]$U!O!.J:E<Z98:/XG\0V>J6O@/
MXR:)KNF^,K71?#VJ:SX"\6_"2_TZ#QGI$OC*U\1&_O[.UT+W/_@DE_P0^^,W
M[*G[5'Q:_P""C_\ P4._:2T#]K/]O?XNZ%=>'?[?\)Z-<P> ?AU::K!8:=XA
MU30-8U?0?"-]K.MZGX=T?1O!VAC2O 'PYT+P3X+BUCPSIFB:C9:VCZ4 ?H-_
MP6Q\2ZOX2_X)(_\ !1'6M#N/LFHC]E#XNZ4D^"2EIXB\,W?AW4@H#+\[Z;JM
MW'&3E5=E9TD0,C?@C_P2%T?5=+_X-)_CU=>"([U/%.O?L]_\%$M8B;3EA749
M=65_BQHXDLFBBCE>[72](MH;9BTU\'BCCM90R6L47]3_ .V1\#HOVFOV2OVF
M?V=Y"B-\;O@/\5OA=:S/'%*MKJ/C;P1K6@:7>B.>2&%WL=1OK6\C6:6.(R0+
MYCJFXU_-'_P:+?$'2OB1_P $S?CY^QI\3O#T-MXI_9U_:#^*7PX^(WP[UZWD
M@U1/!GQ9TN+5+BP\4Z/<6]O<V<MSXH'Q/\*WUG<&65/[!G@E:%U,$8!VW_!G
M']A_X=&:WY'V3[1_PUG\9?[2\KR?.\W_ (13X7>3]NV?/YGV/R/+\_YOLWE;
M?W6ROAC_ (-$;;'[6O\ P6FN_#$%P/AW)\7?AW;:/=/%8"%_)^)?[2<N@P":
MR7[,UQ%H<\DDL6FL;!$FC?:(Y+(GJ/#/_!O-_P %GOV%->^./PJ_X)0_\%-O
MA'\+?V0OCUXBU/5]>\)_%G3==T?XB^&M.U5)-(AM](>'X*_'"UB\9:'X2>TT
M";XG>!O%_P *O$?BQM$TJ]N[70#;:?!I/[F?\$MO^";7P0_X(6?L,?%"PUGX
MB+X]UZWM?%W[0'[3GQWO]!A\,QZVO@WPO=W[VFDZ0^HZI=Z9X*\!>%=*O8]&
MLM3UW4;N[U6^\3>))9=.D\2/I&F@'X8?\&U$USX7_P""Q'_!>WX>:1%=IX3/
MQL\4:HRJ(TLK:^\._M)?&C3M&@ECM[2*W28V/B/6%L51[=8[:VNDCMYEW/;_
M -O5?Q@_\&@GPM\3^.M!_P""B_\ P46\7Z6=+E_:\_:0GTGPO;2I,[+;>&-7
M\7_$7QM>65Y<SW%Q=Z==>)_BS:Z'YLT]S(U_X1NQ)<231RL_]GU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\
M^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#
M_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/
M_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9
MOVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\
MS6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;
M_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^
M;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*
M/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H
M_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W
M_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11
MW_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_
M !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\
M11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\
M0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA_
M_0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA
M_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'
M_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_Y
MK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S
M?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-
M_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?
M-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@
MA1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_
M ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^
M"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H
M[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!
M_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#
M\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /
MP!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB
M@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K
M]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H
M?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A
M]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP_
M_H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]
ML/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P U
MF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6
M;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CY
MO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"C
MYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C
M_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"
MC_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'
M?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_
M  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?
M\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T
M?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T
M/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0
M^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V
M'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S
M?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":
MS?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK
M-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T
M?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4
M?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_
M $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A
M1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(
MH[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^
M(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_J* /P!_X
MBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\
M?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J*
M /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#_P#H?:_?
MZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/_P"A]K]_
MJ* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9OVP__H?:
M_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\ S6;]L/\
M^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;_P UF_;#
M_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^;_S6;]L/
M_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*/^CYO_-9
MOVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H_P"CYO\
MS6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W_!"C_H^;
M_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11W_!"C_H^
M;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_ !%'?\$*
M/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\11W_  0H
M_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\ 0^T?\11W
M_!"C_H^;_P UF_;#_P#H?:_?ZB@#\ ?^(H[_ ((4?]'S?^:S?MA__0^T?\11
MW_!"C_H^;_S6;]L/_P"A]K]_J* /P!_XBCO^"%'_ $?-_P":S?MA_P#T/M'_
M !%'?\$*/^CYO_-9OVP__H?:_?ZB@#\ ?^(H[_@A1_T?-_YK-^V'_P#0^T?\
M11W_  0H_P"CYO\ S6;]L/\ ^A]K]_J* /P!_P"(H[_@A1_T?-_YK-^V'_\
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M!KPO_P ,8^&?V?\ PU^SYXE^V>+/!?\ PS%HWPZT;X-:_P#VQ.?[0\3>%_\
MA55M;>"=5_M6YMF^V:SI7G_;I[<^?<RR1': =I\6_C3\'/@!X+O/B3\=_BS\
M,_@I\.]/O-/TZ_\ 'WQ;\>>%OAOX+L=0U:X6STJQO/%/C'5=&T.VO-3NW6UT
M^UFODGO+AE@MDDE8*?'OA'^WA^P[\?\ Q2O@;X#_ +9G[*7QL\;/;O=IX/\
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MT6@^$M.^&?PJN]0BL/&WQ@N["+1[+3GB\3)H;:+'J<VE_/WP@_X*V_'GP_\
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M+TJ*P?Q'<:CJ^K:)>@']''P%^.OPP_::^#WP^^/GP6UW4?%/PH^*?AZU\6>
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M"#XW?"SP=I]M\18M,\.0C5K_ ,&?\(_IWAWQ!:>)KCPUKTSK83//^AW[?_\
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MO;9=.N #] Z*^:OV._CA\0OVD_V9?@[\<_BM\ O&W[+?Q$^)/A7^W_%7[/\
M\1I=2F\;?##4O[3U"Q&@>()-9\+>"-7:ZDMK.WU2(:IX0\.:@MIJ%NMYI%G<
M+)$OTK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC:%<7G@[Q3?PW'B.#7-/&E7UQ87PB\;1V%]JEWX-URUT;[=^'7[ GQ \1?\
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M.8Q&:TO=2\#^%M"O;JVE,$!D@GFDB<PQ%D/EI@ _F_\ V.OVDO@1_P $[_\
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M7B&UUCX3_LJZK>6ER0+Z>&_^-GPU\06T3V4UP$N8G_IEHH ^)O"E_P#LB_\
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MNIH!+((99[)WB$CA&7>V<WX._ 3X%_L[^%G\#_L__!?X3? OP5+?3:I+X/\
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M_P#A(/&VN>&_"VF^5I6E7]UYVL:WI\#^1Y$<KW,L,,@!^8^O?\%R/^"8]O\
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M?##-]EU"RN(/-BCD\O?&I !_")^V%IG[+WA/_@HI_P $;O"/P8_X*Y_M4_\
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MRWO;RWT_QCI$-GXBLH;NYBMM1B2>57]2^,'P-^"?[0O@]_AY\?O@]\+/CCX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;<?K_P#\$U_V(/VH]/\ ^%,?MU?M9_\ !1C]K#XV?&OXB?"JWU_Q5^SKX?\
MB0-&_8/T30/'_@NVE\*>'_#/P1O_  U_;-]XE\ Z9=Z1(OQ1UGQ)'XJ\5>(;
M"\UW7[:>]U74)KL ^[OV"?VJ/BK^V!\%-5^*GQ?_ &1/C-^Q7XHT_P")/C+P
M-:_"7XYPW%OXQU31/"\EA%8>/+2&\T#PS>#P_P"))+JYBTR6321:7+Z;=7.D
MZEK.DS66J77VQ7\Z/_!"7XG?M"?M%?\ !*+XVZYXR_:<\?P_&6^^.O[9G@OP
M7^T5\6]6N_C=KGPFDTW7=1TOP-XGDLOBCK=Y8^(O#WPPGDMM9T_P9KFJ6OAB
M:RTUM)N/L>FW$Y7\._VY_P!JK]D#]E7X8_%+XH_LN_\ !RM^WC\=/V_/A=%I
M/C3P;X&UK]H"[^-O[*OQ9\:Z=JWAV76/ I^%'@'X,3?L^P^%=;L;'68='TFQ
M\6R:1H%YJ 7Q/J.NZ5%<VTP!_?E17@W[+'Q:U#X]_LR?L[?'+5K&WTS5OC'\
M#?A1\4=5TVS1X[/3]3\>^!-"\4ZA96:23W,BVEK>:I-!;+)<3R"!(Q)*[Y8^
M\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '@_[47[0GA']D[]G/XV_M,^/M(\2Z_X*
M^!/PS\7?%+Q1HG@VUTR]\5ZKHG@[1[G6;^P\/6FM:MH6DW&K74%JT5E%J.LZ
M;:-,RB:\A3+C^4GXE?\ !V#\<O@NFA_$CXR?\$/?VSOA-^RYX@U[3=.TSX]_
M$KQ!XO\  R:IIFK)+/87&AZ3XI_9QTCX=ZSKU_:0R7.F^'[?XS1V]^D<IAUS
MRHVFK^RN0N(Y#& T@1C&IZ,X4[ >5X+8!^8<=QUK_.G_ ."V/[0?_!R'\3?V
M//%7@K_@H+^Q%\)/V>_V'KSX@>#I_C1X]_9?L/ GQ.\87'A+1O%NGZKH0\4*
MO[4?QZO/".B0Z[8Z)J=OKJZ?\/+*Y\26VC:!J_BZVTW5[K1]1 /[UOV4/VG_
M (3_ +:'[.GPC_:B^!VIZAJGPO\ C-X2M/%OAA]9LH]-U[3EDFN+#5O#_B+3
MH+J_MK#Q'X9URRU+P]K]I::AJ-C!J^F7B6&I:C9"WO9_R8_X.+O^"F7Q#_X)
MD?\ !/\ N/'WP)UR/PY^T?\ &7XD>&?A!\%O$4WAWP_XKM_"6H7$5]XL\8>,
M;G0?%=EJGAO4%TKP?X;U32M.BUC2-9L1XC\0:%)=:3=VB7)B^A/^"&WC?]D7
MQM_P2[_97'[$-QX[?X!^$/"6I^"--LOBI%ID'Q2TSQEH7B'56^(4'Q%AT.>Y
MT%/%>H>,;S5M?O&\/3R>')[76;*Y\/"'19K""+^>C_@Z:U*?QW_P4:_X(9_
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M;/0?&7AFX:\\-^+=&MM<L;Z'2_$_A^[9KK1->L4@U72;AFGL+NWE)8_Q.?\
M!)[_ )6U?^"NG_9+?CM_ZM[]FJ@#^A;_ (*D_P#!5^__ ."=6I?!KX<_#?\
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M/ GA4>&_[%U5C;>-;#Q"'TB+2O$%G?:OJ>NIX)TWYQ_8;_X*[?\ !7#]D_\
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M1/B!/IWVF0)I4OQT_9/73H-5N_">F6MNF@Z7\3_#B71 ALF&NSC> ?T3W_\
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MG@<WOQN\?V5Y:#PM;:AX@O-+T6[U?PZNI^'M6LKSQ-?^"_DG_@XM_;V_;?\
M^"9'_##G[6G[/OQ.2R_9F7X]6WPT_:H^"4G@'X8:Y)\3M/OUM_&^BVEGXV\6
M^$=>\8^$)-8\(>#OB-X:>Y\(:MHDMI>W6D:D)6GA-?F5^Q_^WMJ7_!)#PQ^V
M3X'^$'[#'Q._X*#^+/V;O'/A_P")7_!:G_@H=_POWX?>!=87]HKQ]J-W)\0=
M*\ >&_%?A?6_%_QN\+_!^];Q7H6F:9;:SX5:VU_3/&7B;7M/\.6'BG5/'&J?
MHI_P<>_$'X:?M8?\&\?CK]HSX>74VI^ _'5A^RE\=_AGJ.JZ:]IJJ:1XU^)7
MP^;2VO+!KC=I&L_\([XOO=-U.VD>Y:QGFOK)A(R^:H!_39X6\2Z-XT\,>'/&
M/AR\74?#WBS0=(\2Z#J"*R)?:-KNGV^J:7>(CA75;JQNH)U5U#*' 8 @BMZO
MRX_X(E>-M1^(7_!)'_@GGXFU:>:YU _LL_"WP]<7%P,3S_\ "%Z'%X,BED;S
MIVE:2'0(V^T22&6Y!%Q,D4LCQ)^H] !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?DY_P5G_X*_?L[_P#!(_X3>#O&WQ;T
M'Q;\3?B3\6-9U3PY\&?@GX -A%XH\=:IHMK:SZQJ5_JFIR"S\-^$-$FU/1+'
M6-<%IK6J+?Z_I-IHWAO7+B:XCMOUCK^%C_@M=>7WC/\ X.@_^"-7PY\6P#5_
M .A6G[.^O:'X?U&"271SJ^L_M#_$6ZUC58X)BUO-=7%WX1\-QW,D:A&&@Z?%
M,K-;G(!]T?LU?\'1^EZ_^TQ\+/V9/^"@O_!.O]HS_@FYX@^.NH^']'^$WBWX
MJZGXAU[PWJ=[XIU!='\.ZGXLL_'?P>^!/B;P]X,UG7)+?0K;QMH.B>--#L-1
MO+>Y\0RZ'X?@U?7M*_J_K^'C_@]KT718O@3^P'XWB$,'C?1?CK\2M%T2^AM9
M5U5-%U/P=H&KZH+;5H61K6&WU?P_X=F-KGS9[EX+FV:,V<Q?^V/P;=7M]X0\
M*7NI1&#4+SPWH=U?P-'+$T-[<:7:RW4313L\\9CG>1#',[2H5VR,SAB0#^:V
M]_X*0_M9_M$_\''>E?\ !.S]G/XI#P)^R5^RC\'[_P <_M:Z%%X ^&VMW_Q2
M\3VWAS3M9FL+;Q=XK\+^(/%^@:/I_B+XE?"CP5+_ ,(=JWA.\6ZM?&$S2W(;
M3[U/3_\ @I?_ ,'"G@3]B+]IG3/V'_V;_P!DOXS_ /!0/]LB32]+UOQ)\&O@
MU<ZAI=OX5LM6TEO$=OHUQJGASP)\5_&6M>-5\*FU\67/A[P]\-=3T[3_  ]J
M%C=ZKXBTZYDGL[?\I_\ @V9U*?XJ?\%<O^"[OQN\2+%+XLO/B]J>E1RLLD\U
MEI?BK]H+XR:A=:=;7;R+LLHD\%Z!;" 6X1TTZS\K[-%;K W+_P#!!F\OO'W_
M  <C_P#!:_QQXZ@&J>--#N_V@=!TK4]2@D;4-$TBP_:@\,^%;/2K%KDO/:6M
MKX;\.Z'HL,>[>FG:=;6P;RU(8 _:W_@E#_P7Y^#W_!2KXO\ C_\ 95\?? #X
MI?L9_MD?#;2-6U_7_@)\5[IM734=+T"_MM/\2V7A_P 2WOASP)X@_P"$M\)2
MWMC<^)_!WB[X>>#M9M]-O5U/1(_$%EI?B:;P_P#.7_!-[_@HY^V-!_P6U_X*
M&?\ !*[]MKXM0_%ZP\)VM]\5?V3O$0^'_P ,_ ,OASP!;W6C^,=,\$W"?#GP
MAX<N/$=UK'PJ^*'A749-5\5WNL:C:7GP]U?;>-)K4@;\V_C?I]EX/_X/5_V<
M[WP;!%'?^-OA=INH>-X-/L;NU^T7M[^R9\5] OY]3-O(BZG*OAO0=#U*2^8&
MTB$%HMS'))ITS-V/[>=^?A1_P>%?\$X?%NA.;6Y^)OP.\&:#XD2U@(:_'B?1
M?VC_ (7RM?%KM$NP=*ATE/,94%K'IMK+';W-Q:Q^8 ?V]4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?DY_P
M5G_X*_?L[_\ !(_X3>#O&WQ;T'Q;\3?B3\6-9U3PY\&?@GX -A%XH\=:IHMK
M:SZQJ5_JFIR"S\-^$-$FU/1+'6-<%IK6J+?Z_I-IHWAO7+B:XCMOUCK^%C_@
MM=>7WC/_ (.@_P#@C5\.?%L U?P#H5I^SOKVA^']1@DET<ZOK/[0_P 1;K6-
M5C@F+6\UU<7?A'PW'<R1J$8:#I\4RLUN<@'W1^S5_P '1^EZ_P#M,?"S]F3_
M (*"_P#!.O\ :,_X)N>(/CKJ/A_1_A-XM^*NI^(=>\-ZG>^*=071_#NI^++/
MQW\'O@3XF\/>#-9UR2WT*V\;:#HGC30[#4;RWN?$,NA^'X-7U[2OZOZ_AX_X
M/:]%T6+X$_L!^-XA#!XWT7XZ_$K1=$OH;65=531=3\':!J^J"VU:%D:UAM]7
M\/\ AV8VN?-GN7@N;9HS9S%_[8_!MU>WWA#PI>ZE$8-0O/#>AW5_ T<L30WM
MQI=K+=1-%.SSQF.=Y$,<SM*A7;(S.&) /YK;W_@I#^UG^T3_ ,''>E?\$[/V
M<_BD/ G[)7[*/P?O_'/[6NA1> /AMK=_\4O$]MX<T[69K"V\7>*_"_B#Q?H&
MCZ?XB^)7PH\%2_\ "':MX3O%NK7QA,TMR&T^]3T__@I?_P '"G@3]B+]IG3/
MV'_V;_V2_C/_ ,% _P!LB32]+UOQ)\&O@U<ZAI=OX5LM6TEO$=OHUQJGASP)
M\5_&6M>-5\*FU\67/A[P]\-=3T[3_#VH6-WJOB+3KF2>SM_RG_X-F=2G^*G_
M  5R_P""[OQN\2+%+XLO/B]J>E1RLLD\UEI?BK]H+XR:A=:=;7;R+LLHD\%Z
M!;" 6X1TTZS\K[-%;K W+_\ !!F\OO'W_!R/_P %K_''CJ :IXTT.[_:!T'2
MM3U*"1M0T32+#]J#PSX5L]*L6N2\]I:VOAOP[H>BPQ[MZ:=IUM;!O+4A@#]K
M?^"4/_!?GX/?\%*OB_X__95\?? #XI?L9_MD?#;2-6U_7_@)\5[IM734=+T"
M_MM/\2V7A_Q+>^'/ GB#_A+?"4M[8W/B?P=XN^'G@[6;?3;U=3T2/Q!9:7XF
MF\/_ #E_P3>_X*.?MC0?\%M?^"AG_!*[]MKXM0_%ZP\)VM]\5?V3O$0^'_PS
M\ R^'/ %O=:/XQTSP3<)\.?"'ARX\1W6L?"KXH>%=1DU7Q7>ZQJ-I>?#W5]M
MXTFM2!OS;^-^GV7@_P#X/5_V<[WP;!%'?^-OA=INH>-X-/L;NU^T7M[^R9\5
M] OY]3-O(BZG*OAO0=#U*2^8&TB$%HMS'))ITS-V/[>=^?A1_P 'A7_!.'Q;
MH3FUN?B;\#O!F@^)$M8"&OQXGT7]H_X7RM?%KM$NP=*ATE/,94%K'IMK+';W
M-Q:Q^8 ?V]4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?SL?\%+_^#A3P)^Q%^TSIG[#_ .S?^R7\9_\ @H'^
MV1)I>EZWXD^#7P:N=0TNW\*V6K:2WB.WT:XU3PYX$^*_C+6O&J^%3:^++GP]
MX>^&NIZ=I_A[4+&[U7Q%IUS)/9V_6_\ !*'_ (+\_![_ (*5?%_Q_P#LJ^/O
M@!\4OV,_VR/AMI&K:_K_ ,!/BO=-JZ:CI>@7]MI_B6R\/^);WPYX$\0?\);X
M2EO;&Y\3^#O%WP\\':S;Z;>KJ>B1^(++2_$TWA_\4O\ @@S>7WC[_@Y'_P""
MU_CCQU -4\::'=_M Z#I6IZE!(VH:)I%A^U!X9\*V>E6+7)>>TM;7PWX=T/1
M88]V]-.TZVM@WEJ0T?QOT^R\'_\ !ZO^SG>^#8(H[_QM\+M-U#QO!I]C=VOV
MB]O?V3/BOH%_/J9MY$74Y5\-Z#H>I27S VD0@M%N8Y)-.F9@#^Y;7=;TOPUH
MFL>(];NX[#1= TK4-;U>^E#&*RTO2K2:^O[N0(&<QVUI!+,X56;:AV@G K^:
M_P#X-]/^"AG[87_!3OQ5_P % _VL/C+\3%'[(.B?'%OAC^R?\'9/ GPR\,+\
M/=&T^&Z\9:Q<Z_XKT'PS;>.->U?3O NO?#:WU"3Q3XTU_3QJFJ>(;BV2.&.Q
M%K^F_P#P65\<ZQ\./^"4G_!0GQ=H#F+6++]D[XS:;93K(\+VK^)/!^H^&9+R
M*6/]XD]G!K$MU T;(_G1)LEB;$J?S[?\$:CJOPI_X-//VA/B#\/Y9=,\9ZA\
M%/\ @H1X_@U33()X]1M?$>EVGQ$\-66L1R03-+)?Z7I?A32Y+:\00B!+"VWQ
M,ML[R@'H'Q@_X.O[2[^)OQ>T']@[_@F;^TM^WI\%?@%=:A;?%O\ :'\%:SXE
M\*^"] LM+NK^*X\76]EX1^"7QI6R\ WUGI6J:GH7B;X@:S\/)M4L;*2YDTBR
MM1)<Q_JK^S!_P4QT#_@K_P#\$YOCW\9O^"=OC7Q)\$?VB-$\(>._ ^CZ5\0/
M"O@SQ#XN^"_Q\L?";:WX,&L>'=93Q3X%\8>%-?N9M,N] U]X-1T;6=&N[N&^
MT_2O$^C:_P"&]%_-K_@SB\.Z%;_\$DO%=_#I-@E[XH_:O^,'_"17(MXS-K(L
MO!WPPTNT34'8$W,=OI\:VD4<F8TAW*%^=RWP_P#\&@UK;^&/VJ_^"SO@/PLH
M/P_T#XJ_#6UT$6UI>66FVUOH_P 1_P!I'1M#6SL996@TT7>B1+MM)D:\$%C!
M"92EG(" ?LY_P;=_\%,_BU_P4M_83USQ)^TAXA3Q5^TM\"OB[XI^%7Q7\4+H
M'A;PL?%]I>0VGC'P/XI/ASP1H/AOPGHK?V'KLO@V>TT;2+2*>^\%7FJS1B74
MBS?T%U_$+_P;)7Y\ _\ !6#_ (+P? K27,?A2U^..N:]IFGP0&&PLSX*_:%^
M-?AJS6WB>[F-H4TWQ5%:+&B3&XAM(S/<(;6!)/[>J "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\4_^"__ .RA^T7^V;_P3D\7
M?!C]ECX;I\6OC%_PM_X&>.='\!OXR\$^ 6UK2O OQ$TG7M>6+Q/\0M>\->%;
M![;3;>:Y(O\ 5X99HXI$LH+V\,%G/^UE% '\[_B#]J7_ (.&?CIX7U#X6_#'
M_@DU\"_V%_%7B*Q&A6_[1_Q^_;[^$W[1/A+X?VM_"UC>>)-.^&7P+\)V_BO5
M?$FC6[OJ&@_;%U318M6CL7U30]=T]+O3I_T"_P""6'_!.GP9_P $QOV3M&_9
MXT#QEJOQ2\::YXL\1_%?XW_%[7K3[#JWQ6^,GCA; >+/%LVGM=ZC+I^GBUTO
M2=#T33[K4M4OH=&T>RDU74]3U>?4-1NOT>HH _A2_9=_82\<C_@X#^(7[!5O
MJ6FZM^P+^P[^TGXJ_P""M'AKP=HQFU"U\'?%_P"//@3X?+\(OAWXCNKF2YMM
M&/@SQ/.VN^"?"IM8+Z;0='\3:\]]?Q:]NLOZCOVT?C#_ ,%$_A%XT\/W/[+O
M[#'PM_;I^!7B3P;)HWC?P.O[1GA/]GSXU^&?&LFJ:DE]J9G^+VEW7PE\:?#7
M4_#$VEV*Z(FJ:-XH@U=-9GNI+S3)+&TD[G]E+_@G]\&OV1/C#^V!\>? _B3X
ME^-_BG^VW\6;/XL_&'Q3\3]8\+:S=V4^BP:M:^%/ G@H>&/!G@\:1\//!EGK
MFIV?AK2-6_X2#6+:VN?+OO$&H>5"8_N:@#^;3_@FE_P2S^.'A>#_ (*F_$OX
M_?"CX:?L+:'_ ,%,] T?PEX:_8L^ OC+1OB5X8_9MTBU^&GB_P "^(_%FJ:_
MX7TOPY\+M9\?^*M2\8WFN7%GX$T:+P] UM-(VH'^V#I>B^'?L;_#/_@OK^S+
M^ROH'_!+'2/V0?V9[+PQ\.=(\7_"7P-_P4P\1?M'^%-7^&UA\)M6U75FT[Q)
M:?LHZ)IS?%_Q1\0-$T+7;A?"]KXCN/"/A_4M5TO3K?QE:Q6C7^I:C_5Y10!_
M)SX%_P""9'[:WAS_ (-=/%'_  3?N_@WG]L.Y\+_ !'T?3?A-_PL/X3#[=<:
MS^UUK7Q,T4_\)W%X^G^%UK_:'@.YMO$&)_'*I:>=_95W+%K,<E@O],?[/WA7
M7_!'[/WP2\$>*+#^S/%'A#X.?#;PKXBTS[597O\ 9^OZ!X)T72-7L/MNG7%W
MIUW]DU&TN+?[58W=S93^7YMM<30.DK>QT4 ?S#?L:?\ !+#]JY?^"&?[8O\
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M-]\4?BGX2OO&G@7P;J":E>^#+31;K6M'_MB!M?URXO=6T[PG>:?Q7[&7BO\
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MXWTHWB>,-?&KZE\4?V>5U6R\2O=6=Q:BY^)WBNVMK6P:VMO#6AW4;W&M?O\
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M0 4444 ?B5_P5 U/_@N?\/\ XI_#[XH_\$JO#_[,OQR^%5K\.;_0/B3^S?\
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M?\&\?[,'_!/>'Q0?&/CC7]8_9L_9UL;S1XKC3Y?&D_PCTR/X@^./%%CHD_\
M:-^-!O/$O@_2H(-,-Z+BRG\3Z#:RW5P ]O<_VFU^9W[:O_!*7]FK]OO]H3]D
M/]H7]H37/BQJE[^Q?XKU#QK\-/A5H?B+PI9?!WQ7XAU'7/"GB*6[^)OAO5?
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M>QOTUK5K^6WT=-3UN^CT32TM0#],:*** "BBB@ HHHH **** "BBB@ HHHH
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M6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\
MA;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/
M^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_
M (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*
MC_A;/PK_ .BE_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH
M_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_  LO#G_R
MRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P L
MJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_
M\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\
M+*C_ (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.
M?_+*C_A;/PK_ .BE_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI?P__ /"R\.?_
M "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_  LO
M#G_RRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G
M_P LJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P +
M+PY_\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++P
MY_\ +*C_ (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\
M"R\.?_+*C_A;/PK_ .BE_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI?P__ /"R
M\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_
M  LO#G_RRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#P
MLO#G_P LJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\
M_P ++PY_\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\
M\++PY_\ +*C_ (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_
M /\ "R\.?_+*C_A;/PK_ .BE_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI?P__
M /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P
M_P#_  LO#G_RRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/
M_P#PLO#G_P LJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7
M\/\ _P ++PY_\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_
M#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"B
ME_#_ /\ "R\.?_+*C_A;/PK_ .BE_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI
M?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\ X6S\*_\
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M%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\
MX6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\
M_A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__
M .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_
M /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/
M_P#A;/PK_P"BE_#_ /\ "R\.?_+*C_A;/PK_ .BE_#__ ,++PY_\LJ /0**\
M_P#^%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HK
MS_\ X6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"B
MO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0*
M*\__ .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ]
MHKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\++PY_P#+*@#T
M"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*C_A;/PK_ .BE_#__ ,++PY_\LJ /
M0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\ RRH
M] HKS_\ X6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#HI?P__P#"R\.?_+*@
M#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ
M /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\ Z*7\/_\ PLO#G_RR
MH ] HKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\++PY_P#+
M*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*C_A;/PK_ .BE_#__ ,++PY_\
MLJ /0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\.?\
MRRH ] HKS_\ X6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#HI?P__P#"R\.?
M_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*7\/_ /PLO#G_
M ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\ Z*7\/_\ PLO#
MG_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\++PY
M_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*C_A;/PK_ .BE_#__ ,++
MPY_\LJ /0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\ _"R\
M.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#HI?P__P#"
MR\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*7\/_ /PL
MO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\ Z*7\/_\
MPLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#_P#\
M++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*C_A;/PK_ .BE_#__
M ,++PY_\LJ /0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?P_\
M_"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#HI?P_
M_P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*7\/_
M /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\ Z*7\
M/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_ (6S\*_^BE_#
M_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*C_A;/PK_ .BE
M_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH_P"%L_"O_HI?
MP_\ _"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_  LO#G_RRH_X6S\*_P#H
MI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\ A;/PK_Z*
M7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/^%L_"O\
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M6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P LJ/\
MA;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_\LJ/
M^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\ +*C_
M (6S\*_^BE_#_P#\++PY_P#+*@#T"BO/_P#A;/PK_P"BE_#_ /\ "R\.?_+*
MC_A;/PK_ .BE_#__ ,++PY_\LJ /0**\_P#^%L_"O_HI?P__ /"R\.?_ "RH
M_P"%L_"O_HI?P_\ _"R\.?\ RRH ] HKS_\ X6S\*_\ HI?P_P#_  LO#G_R
MRH_X6S\*_P#HI?P__P#"R\.?_+*@#T"BO/\ _A;/PK_Z*7\/_P#PLO#G_P L
MJ/\ A;/PK_Z*7\/_ /PLO#G_ ,LJ /0**\__ .%L_"O_ **7\/\ _P ++PY_
M\LJ/^%L_"O\ Z*7\/_\ PLO#G_RRH ] HKS_ /X6S\*_^BE_#_\ \++PY_\
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M44 ?B#_Q#>_\$2O^C"/A_P#^'!^.'_ST*/\ B&]_X(E?]&$?#_\ \.#\</\
MYZ%?M]10!^(/_$-[_P $2O\ HPCX?_\ AP?CA_\ /0H_XAO?^")7_1A'P_\
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MZ,(^'_\ X<'XX?\ ST*/^(;W_@B5_P!&$?#_ /\ #@_'#_YZ%?M]10!^(/\
MQ#>_\$2O^C"/A_\ ^'!^.'_ST*/^(;W_ ((E?]&$?#__ ,.#\</_ )Z%?M]1
M0!^(/_$-[_P1*_Z,(^'_ /X<'XX?_/0H_P"(;W_@B5_T81\/_P#PX/QP_P#G
MH5^WU% 'X@_\0WO_  1*_P"C"/A__P"'!^.'_P ]"C_B&]_X(E?]&$?#_P#\
M.#\</_GH5^WU% 'X@_\ $-[_ ,$2O^C"/A__ .'!^.'_ ,]"C_B&]_X(E?\
M1A'P_P#_  X/QP_^>A7[?44 ?B#_ ,0WO_!$K_HPCX?_ /AP?CA_\]"C_B&]
M_P"")7_1A'P__P##@_'#_P">A7[?44 ?B#_Q#>_\$2O^C"/A_P#^'!^.'_ST
M*/\ B&]_X(E?]&$?#_\ \.#\</\ YZ%?M]10!^(/_$-[_P $2O\ HPCX?_\
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M\/\ _P .#\</_GH5^WU% 'X@_P#$-[_P1*_Z,(^'_P#X<'XX?_/0H_XAO?\
M@B5_T81\/_\ PX/QP_\ GH5^WU% 'X@_\0WO_!$K_HPCX?\ _AP?CA_\]"C_
M (AO?^")7_1A'P__ /#@_'#_ .>A7[?44 ?B#_Q#>_\ !$K_ *,(^'__ (<'
MXX?_ #T*/^(;W_@B5_T81\/_ /PX/QP_^>A7[?5R?COQ[X%^%W@_Q%\0_B;X
MT\)_#KP!X0TNXUOQ;XY\=^(]'\(^#_"^BV@#7>K^(O$WB"\T_1=$TNU4AKB_
MU.]MK2$$&25010!^-O\ Q#>_\$2O^C"/A_\ ^'!^.'_ST*/^(;W_ ((E?]&$
M?#__ ,.#\</_ )Z%?L'\-/BE\,OC3X(T+XF?!WXB^!/BS\-_%$5U/X9^(/PT
M\7>'_'?@CQ%!8W]UI=[-H7BOPMJ&JZ#J\5GJ=C>Z==2:??W"6]_9W5G,4N+>
M6-.[H _$'_B&]_X(E?\ 1A'P_P#_  X/QP_^>A1_Q#>_\$2O^C"/A_\ ^'!^
M.'_ST*_;ZB@#\0?^(;W_ ((E?]&$?#__ ,.#\</_ )Z%'_$-[_P1*_Z,(^'_
M /X<'XX?_/0K]OJ* /Q!_P"(;W_@B5_T81\/_P#PX/QP_P#GH4?\0WO_  1*
M_P"C"/A__P"'!^.'_P ]"OV^HH _$'_B&]_X(E?]&$?#_P#\.#\</_GH4?\
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M?"KQA\3/!?AGXD?$<0S26\Q\!>!M:UNR\3^,!%/#+!(?#VEZCY<T4D;8=&4
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M_P"C"/A__P"'!^.'_P ]"C_B&]_X(E?]&$?#_P#\.#\</_GH5^WU% 'X@_\
M$-[_ ,$2O^C"/A__ .'!^.'_ ,]"C_B&]_X(E?\ 1A'P_P#_  X/QP_^>A7[
M?44 ?B#_ ,0WO_!$K_HPCX?_ /AP?CA_\]"C_B&]_P"")7_1A'P__P##@_'#
M_P">A7[?44 ?B#_Q#>_\$2O^C"/A_P#^'!^.'_ST*/\ B&]_X(E?]&$?#_\
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MO?\ @B5_T81\/_\ PX/QP_\ GH4?\0WO_!$K_HPCX?\ _AP?CA_\]"OV^HH
M_$'_ (AO?^")7_1A'P__ /#@_'#_ .>A1_Q#>_\ !$K_ *,(^'__ (<'XX?_
M #T*_;ZB@#\0?^(;W_@B5_T81\/_ /PX/QP_^>A1_P 0WO\ P1*_Z,(^'_\
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MZ%?M]10!^(/_ !#>_P#!$K_HPCX?_P#AP?CA_P#/0H_XAO?^")7_ $81\/\
M_P .#\</_GH5^WU% 'X@_P#$-[_P1*_Z,(^'_P#X<'XX?_/0H_XAO?\ @B5_
MT81\/_\ PX/QP_\ GH5^WU% 'X@_\0WO_!$K_HPCX?\ _AP?CA_\]"C_ (AO
M?^")7_1A'P__ /#@_'#_ .>A7[?44 ?B#_Q#>_\ !$K_ *,(^'__ (<'XX?_
M #T*/^(;W_@B5_T81\/_ /PX/QP_^>A7[?44 ?B#_P 0WO\ P1*_Z,(^'_\
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MJ=[;6D((,DJ@B@#\;?\ B&]_X(E?]&$?#_\ \.#\</\ YZ%'_$-[_P $2O\
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MW+W4'V= )A!MC /Z9OCIX!_:N_98_8.^&?P$_P""8/PN^%?C/XQ^ /#OPB^
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MX@BU'Q'9W^GV_AWPOI%]X:-I81Z.L?B66_\ :?\ @SO3Q+\?_P#@F?\ M=_
M+X]:':?$[]F*T^-NI_#[PGX-\<VB>(/"EWI/C_X?:?K'Q@^'RZ5J5I)9-X9N
M)]9T7Q!=Z4EQ/;_VQXPUF_\ LEG=7\US>^??M$_\$Z?V(_%_[<=__P $@?\
M@D%\#-"^ OB/QQX9M/$G_!5O]K;PUXN\??$76O@M^S!?:OIU_J7[-'@#Q3\3
M?%_Q%E\%>//C"Z:5'XG\(^%H?#NEZEI=QX8\+^(X=8\(W/Q(T_PT ?=_[/\
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MUO=0DF&Y@BN(BPVL8YHUD0LIY4E6&0>AXK^''_@\P\7Z!\4/#_\ P3B_97\
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M?"/Q)\$;],MI9[.+4=,\+:9JMQ:2K%?7UW]EL&M/W-HH _(+_@FQ_P $-_\
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MQU9K$B>(? 7C$Z9KEI874AMK&XD@U/1-6LEU+2M%UFWMH-:T32-0LOF_X?\
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M:M&R1RPNZM8:I."J31,P.%D0D,/Y0?\ @TN\9>,?@EX,_;Z_X);_ !I+Z?\
M&3]C']IK6];.D3I)#;S^%?&D2>$=7N?#L=W:6=]=^'5\7^ +GQ+:W]Q$1=6'
MQ!T:\C"07T"5_8/10!_,5^T;_P &DO\ P2:_:'^,GB#XRP0?M%? NY\6:_?^
M*/$WP^^!OQ,\(Z3\--5UW5]3DU?6[JVT/XA_#+XE:QX8L]4O9[G.A>#/$/AO
MP[H]M<&S\-Z3HEI;V4-K^IY^'_[*_P#P1A_X)S?%^\^ 7PST_P"'OP2_9B^$
MGQ0^+_\ PC-G>:IJVL^,?%&D^'[[7;B]\2>)-8N[[7_$OBWQIK-GINC-J^KZ
MC/)!"^E:/8MIV@:1I>GV'Z344 ?R:?\ !HQ^RSXS^'O[$_QF_;3^+%IJ"?$[
M]OCXSZG\0DU+5EFCU'6_AQX'O=>TWP_X@N8KEVN1_P )+X\\1?%#7[.YG4'5
M-&OM(U6W>XLKVUN9_P"LNBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\
M&/$/_!7#]N'1M?US1[#_ ((6?MY^(+#2M8U/3;+7M.\4_"--/UNTL;V>UMM7
ML4FU59EL]2AB2]MEE E6"9!( X(K'_X?!?MV?](%?V__ /PJ_@]_\MJ /W_H
MK\ /^'P7[=G_ $@5_;__ /"K^#W_ ,MJ/^'P7[=G_2!7]O\ _P#"K^#W_P M
MJ /W_HK\ /\ A\%^W9_T@5_;_P#_  J_@]_\MJ/^'P7[=G_2!7]O_P#\*OX/
M?_+:@#]_Z*_ #_A\%^W9_P!(%?V__P#PJ_@]_P#+:C_A\%^W9_T@5_;_ /\
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MV_\ _P *OX/?_+:C_A\%^W9_T@5_;_\ _"K^#W_RVH _?^BOP _X?!?MV?\
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M]_\ +:@#]_Z*_ #_ (?!?MV?](%?V_\ _P *OX/?_+:C_A\%^W9_T@5_;_\
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M_P#+:C_A\%^W9_T@5_;_ /\ PJ_@]_\ +:@#]_Z*_ #_ (?!?MV?](%?V_\
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MZ*_ #_A\%^W9_P!(%?V__P#PJ_@]_P#+:C_A\%^W9_T@5_;_ /\ PJ_@]_\
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MOX/?_+:C_A\%^W9_T@5_;_\ _"K^#W_RVH _?^BOP _X?!?MV?\ 2!7]O_\
M\*OX/?\ RVH_X?!?MV?](%?V_P#_ ,*OX/?_ "VH _?^BOP _P"'P7[=G_2!
M7]O_ /\ "K^#W_RVH_X?!?MV?](%?V__ /PJ_@]_\MJ /W_HK\ /^'P7[=G_
M $@5_;__ /"K^#W_ ,MJ/^'P7[=G_2!7]O\ _P#"K^#W_P MJ /W_HK\ /\
MA\%^W9_T@5_;_P#_  J_@]_\MJ/^'P7[=G_2!7]O_P#\*OX/?_+:@#]_Z*_
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M_@]_\MJ /W_HK\ /^'P7[=G_ $@5_;__ /"K^#W_ ,MJ/^'P7[=G_2!7]O\
M_P#"K^#W_P MJ /W_HK\ /\ A\%^W9_T@5_;_P#_  J_@]_\MJ/^'P7[=G_2
M!7]O_P#\*OX/?_+:@#]_Z*_ #_A\%^W9_P!(%?V__P#PJ_@]_P#+:C_A\%^W
M9_T@5_;_ /\ PJ_@]_\ +:@#]_Z*_ #_ (?!?MV?](%?V_\ _P *OX/?_+:C
M_A\%^W9_T@5_;_\ _"K^#W_RVH _?^BOP _X?!?MV?\ 2!7]O_\ \*OX/?\
MRVH_X?!?MV?](%?V_P#_ ,*OX/?_ "VH _?^BOP _P"'P7[=G_2!7]O_ /\
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MBOP _P"'P7[=G_2!7]O_ /\ "K^#W_RVH_X?!?MV?](%?V__ /PJ_@]_\MJ
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MV?\ 2!7]O_\ \*OX/?\ RVH_X?!?MV?](%?V_P#_ ,*OX/?_ "VH _?^BOP
M_P"'P7[=G_2!7]O_ /\ "K^#W_RVH_X?!?MV?](%?V__ /PJ_@]_\MJ /W_H
MK\ /^'P7[=G_ $@5_;__ /"K^#W_ ,MJ/^'P7[=G_2!7]O\ _P#"K^#W_P M
MJ /W_HK\ /\ A\%^W9_T@5_;_P#_  J_@]_\MJ/^'P7[=G_2!7]O_P#\*OX/
M?_+:@#]_Z*_ #_A\%^W9_P!(%?V__P#PJ_@]_P#+:C_A\%^W9_T@5_;_ /\
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MV_\ _P *OX/?_+:C_A\%^W9_T@5_;_\ _"K^#W_RVH _?^BOP _X?!?MV?\
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MRY^P'\(#\>/VN?BQIWP>^%;>)]%\%V_B.]\/^,?%MUJ'BKQ"E]/I.A:1X8\
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MB@ HHHH **** "BBB@ HHHH **^,_P!L'_@H9^Q3^P)H.B>(OVO_ -HSX>_
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M7OB?P0@/CCP?!%<7":HUQ  ?LY17S!^UC^VC^RS^PQ\,IOC#^UG\;?!GP3\
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M(0M?Z)K%E-';:MX=\1::MQ;MJ?ASQ#I^EZ[IHN+<WVGVXGBW@'NM%(2%!8G
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M7;R '[6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?LNJV/A2?X@ZYXINM#U.*QD2/+_9;_9B\9_ ?_@WG_;O^+7QIB>;]IK]N?\
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M32[Q-,&F/X/\/HU_,NE^ O#DGVQK_P#$_P#X.NM)?X6?MH_\$5/VN=8D:V\
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M&_@#0I-+B^PRM>7!\1+<(CQ-;6EUN8)_G>?L1?\ !=?]D?\ 9K_X+B_MT_\
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M ?Z0M?(/QD_8-_8'^-GBO6?BS^T%^QC^R%\7/'-SIUJOB#XE?&+]G7X,^/\
MQ9<:3H&GK:V2ZQXQ\:^#M6UF;3]&TNV2WM5O-1:WTZPMTAA$-O$JK^<?[9O_
M  6D_P"&+_\ @IK^Q9_P34_X91\=_%K_ (:ML/APO_"Z]#\<?V4_@[_A.?'O
MB'X>_:M.^'G_  @&N?\ "=V7A'_A'O\ A*/'5]_PG7A/^PO#]Q=7GD77V'%U
M\^_\'3O_  4'N/V+/^";FO\ PK\"Z]-H_P ;OVSK[4_@AX-:P\Q=4TWX<BSM
MKCXW>)+26*:"6U,?A/4[+P1!>0.UY9ZIX_TR]M(]]H\T !^&'_!&3X"?!;_@
MI?\ \%]/VCOVZO@S\!OA#\%/V)?V'-2^S_ ?P/\ !_X8^$OAIX$UKQ?&NJ^!
M?@QXC.C?#_0_#_AR]\2Z[::3XS^.NNZI=/J.JZ9K/_")Z*LE[HUOI<UAZ=\:
M_@M^W-^REJ'_  7I_8DM/^"?'[6O[2NH?\%4_B[K'Q!_9?\ VD/@+\-$\7_!
M1+'XIZSXEO;^T^.?Q-N-:@T_X7VW@JR\4I D>O/+-_;]CXA.H0Z+X9U#3?%5
MQ_1A_P &_?[ "_\ !/'_ ()F_!'X<>(M&&D_&/XL6:_'SXZI)*D]W;_$#XCZ
M;IES9^&KJ2,>5'+X%\%67A7P9=V]M)-9C5M$U2\M[BY^VO<S^&_\%E/VP/CE
M\1OB-\./^"-7_!/_ %2ZLOVROVO_  U+JWQC^+=C;ZA)I'[(?[)5Q=3Z=XY^
M*7B/5K6RFM]*\0>,--M-8\,^&5@O+;7M/BN4?1IM*\:^+/A;=:D ?@)#\7?@
M/\?_ (>?LL?LQ_MA?'WPA\-_^"-7_!'#1/@G\,/VJ_B:MUX@\1Z#^WQ^WOX.
M\%K#!\!?A-9^%[7QCXC^+GPH^&UU8ZS?:M:>"=$U676O!\'B#Q1:V2>'M?\
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M6VAV?AB^NENK5+V*'5].D"6RW,T+?V_4 %%%% !1110 4444 %%%% !1110
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M.*Z\&Q:?K7A Z9XC_L@>)_#MU_:UY]L^SC\L?CC_ ,'<'P#U3X3>/O@'>?\
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M?6K/5OB=9>+/$UO:7.G:^EE9Z;HW@FV\2^(?&VD:'X<\.2W>J_JS_P &JO[
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MK+X[^,GQD^(<L6EW%SY(G%MH=GX8OKI;JU2]BAU?3I ELMS-"W]OU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?PJ_\
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M)U6#^S_".L_&34_"VBPM:B6)OM=OX-^ GAC3([E[1I!;K>"62VENI(I_!O\
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MUS2XKIY6N;BTB /[?Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\!S>,/"?Q#TGQ%X;U[P!JWC7P[JA\.:KI/BZSVZ?=Z+9:G[G_P $M?#OQ?\
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MQ<^2)Q;:'9^&+ZZ6ZM4O8H=7TZ0);+<S0M_;]0 4444 %%%% !1110 4444
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MX?U><7=G;C[#,A<5]%44 ?C]_P $/?\ @F)<_P#!*+]A7PU^SKXLU[PGXO\
MC)XB\9>*OBA\;O&'@:35+CPAK'CCQ#+:Z7IUCX7O=?T3P[K]YH'AOP5H7A?0
M;:ZUC1M,NKZ_LM4U4:=IT>HK8V_[ T44 %%%% !1110 4444 %%%% !1110
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MC/\ ;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\ !3[_ ,*RQ_\
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M7E ']'U%?S@_\.,_VRO^D_?_  4^_P#"LL?_ )>4?\.,_P!LK_I/W_P4^_\
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MW_P4^_\ "LL?_EY0!_1]17\X/_#C/]LK_I/W_P %/O\ PK+'_P"7E'_#C/\
M;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\ !3[_ ,*RQ_\ EY1_
MPXS_ &RO^D_?_!3[_P *RQ_^7E ']'U%?S@_\.,_VRO^D_?_  4^_P#"LL?_
M )>4?\.,_P!LK_I/W_P4^_\ "LL?_EY0!_1]17\X/_#C/]LK_I/W_P %/O\
MPK+'_P"7E'_#C/\ ;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\
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MC/\ ;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\ !3[_ ,*RQ_\
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M7E ']'U%?S@_\.,_VRO^D_?_  4^_P#"LL?_ )>4?\.,_P!LK_I/W_P4^_\
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MW_P4^_\ "LL?_EY0!_1]17\X/_#C/]LK_I/W_P %/O\ PK+'_P"7E'_#C/\
M;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\ !3[_ ,*RQ_\ EY1_
MPXS_ &RO^D_?_!3[_P *RQ_^7E ']'U%?S@_\.,_VRO^D_?_  4^_P#"LL?_
M )>4?\.,_P!LK_I/W_P4^_\ "LL?_EY0!_1]17\X/_#C/]LK_I/W_P %/O\
MPK+'_P"7E'_#C/\ ;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\
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MC/\ ;*_Z3]_\%/O_  K+'_Y>4 ?T?45_.#_PXS_;*_Z3]_\ !3[_ ,*RQ_\
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M7E ']'U%?S@_\.,_VRO^D_?_  4^_P#"LL?_ )>4?\.,_P!LK_I/W_P4^_\
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M#: -!\.^+M:.J^(KR&+3K,:7X8UZ^,LRBVTR[D*Q-_(/^TY_P6T_X.1OV-/
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MQQ\+> /&'C6;2OA+\3O$?AWXG?#SXM?L\R6_CGQG\*K?QW\/O^$>UOQ)X?\
M''AC37M]%N["TT6Z\3>&?&'A^]U'0M$U9[S0=/ /Z6:*_%+_ (-\/VW/%'[>
M?_!+#]GGXK_$?Q!=>*/B]X&AU[X'_%OQ!J>JSZUKGB#Q=\+K_P#LC3O%'B34
MKZ[O-3O?$OC'P-/X0\6^([[5)1=ZAKNMZC?8:"XADD_:V@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO!_VHOBMXX^!
M?[.?QM^,GPS^$/B3X_?$+X9?#/Q=XU\%_!+P?_:W_"4_%3Q)H&CW.H:1X&T
M:#X=\7:T=5\17D,6G68TOPQKU\99E%MIEW(5B8 ]XHK^(_\ :<_X+:?\'(W[
M&G@6+]JG]I;_ ()/?LS?#3]D2V\0>'H=<\[Q5J/B;XBZ'I/B:^BL-'T[Q-K?
M@K]I;Q-JG@?4-0OKFSTA/$?BSX#V.E66LWEEIU[HR7U]:64O]6'[ G[8G@_]
MOW]CWX#_ +7W@;PYJO@[0?C9X-'B"3PAK5TFH:AX4U_3-5U+PUXL\-/JL5II
M\6MVVA^*=$UC3=/UZ+3].CUW3[>UU9=-T[[8;&W /L"BOYI_^#I']OSXK?L5
M?L ^&_!'[._B_P 7>!/VA/VKOBYH'PD\#^,/AWXCU#PS\1/"/AG2(F\6^.-?
M\&:EH4D7B2WUJ^^P^'? 4-WH$UGJ-B/'37=IJ-M?16<-U^@GC7]H6W_X).?\
M$W/@EXA_:$N/VA/VJ/B=X*\&_!_X.26?AU/$_P :?C_^T)^T3XPTVVTY-*L[
MWQ#J-[KFL:OXL\9?VM,E[K.IS2:?I<:V=C!?W<.F:-=@'ZJ45_*E_P $C?\
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MZ2, _IXHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBOPJ_X+9_\%F!_P $L?"_P1\ _"CX-3?M&?M<_M2>);[PK\#/A+]N
MU"STA#976DZ,_B/Q%#H=M=^(==-WXH\2>'/#OAGP9H?]EZCXNU&]U".#Q#HR
MZ3*]P ?NK17\8OA3_@X4_P""H7[%7[4?P!^"/_!;K]@/X1_L\_#?]IC5=.TG
MP5\5O@=KUS%%X-M+S5=-T.^\5ZY#_P +H_:!\,>+M-\+:IK>AOX[\+V_BSP1
MXS\)^'M3_P"$@&EZU=1Z9X>UW^SE65E5E8,K ,K*0592,AE(R"""""#@CD4
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M&I1^HZ1_P2#_ &E+#_@WBNO^"2DWC?X'-^T;/\.-6\()XUB\2^/6^"8U._\
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MAS0?AUX>O(HO"GP?T:[T>T\#Z+H>F75Y>:)X==]<CM+_ %%#I$W>_!CX)_\
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MQ-K'AK7M;MO^$(\1?L&ZO\.M#^VZMX/\.7?G>&_".CW%M_9WD6DMO;7=]#=
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M_P#A&M!^*.GCPWIG@?3?@IX;@>PGMK>R\7ZUK>H/_P )5:7>C)<>)M"USP"
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M:A_8H\(>*?\ @D_^T#\)_@A\;?B4_P +OB3X)^+'Q7TS3/$'@:[^$WB+2?\
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M.\3ZCH]S'I[O<K!$P%Y/!J<\%I^)G[(/[3/_  5*_P""3W_!=#X,_P#!+?\
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M7?AW;:/=/%8"%_)^)?[2<N@P":R7[,UQ%H<\DDL6FL;!$FC?:(Y+(GJ/#/\
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MW,C7_A&[$EQ)-'*S_P!GU !1110 4444 %%%% !1110 4444 %%%% !1110
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M:K8WEK%-:7D+J2?<J* /*?@;\$OAI^S=\(/AW\!O@UH%UX4^%7PH\+Z;X*\
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MXB0O^")7_1^_P_\ _#??'#_YU]>>T4 >A?\ $2%_P1*_Z/W^'_\ X;[XX?\
MSKZ/^(D+_@B5_P!'[_#_ /\ #??'#_YU]>>T4 >A?\1(7_!$K_H_?X?_ /AO
MOCA_\Z^C_B)"_P"")7_1^_P__P##??'#_P"=?7GM% 'H7_$2%_P1*_Z/W^'_
M /X;[XX?_.OH_P"(D+_@B5_T?O\ #_\ \-]\</\ YU]>>T4 >A?\1(7_  1*
M_P"C]_A__P"&^^.'_P Z^C_B)"_X(E?]'[_#_P#\-]\</_G7UY[10!Z%_P 1
M(7_!$K_H_?X?_P#AOOCA_P#.OH_XB0O^")7_ $?O\/\ _P -]\</_G7UY[10
M!Z%_Q$A?\$2O^C]_A_\ ^&^^.'_SKZ/^(D+_ ((E?]'[_#__ ,-]\</_ )U]
M>>T4 >A?\1(7_!$K_H_?X?\ _AOOCA_\Z^C_ (B0O^")7_1^_P /_P#PWWQP
M_P#G7UY[10!Z%_Q$A?\ !$K_ */W^'__ (;[XX?_ #KZ/^(D+_@B5_T?O\/_
M /PWWQP_^=?7GM% 'H7_ !$A?\$2O^C]_A__ .&^^.'_ ,Z^C_B)"_X(E?\
M1^_P_P#_  WWQP_^=?7GM% 'H7_$2%_P1*_Z/W^'_P#X;[XX?_.OH_XB0O\
M@B5_T?O\/_\ PWWQP_\ G7UY[10!Z%_Q$A?\$2O^C]_A_P#^&^^.'_SKZ/\
MB)"_X(E?]'[_  __ /#??'#_ .=?7GM% 'H7_$2%_P $2O\ H_?X?_\ AOOC
MA_\ .OH_XB0O^")7_1^_P_\ _#??'#_YU]>>T4 >A?\ $2%_P1*_Z/W^'_\
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M/_G7UY[10!Z%_P 1(7_!$K_H_?X?_P#AOOCA_P#.OH_XB0O^")7_ $?O\/\
M_P -]\</_G7UY[10!Z%_Q$A?\$2O^C]_A_\ ^&^^.'_SKZ/^(D+_ ((E?]'[
M_#__ ,-]\</_ )U]>>T4 >A?\1(7_!$K_H_?X?\ _AOOCA_\Z^C_ (B0O^")
M7_1^_P /_P#PWWQP_P#G7UY[10!Z%_Q$A?\ !$K_ */W^'__ (;[XX?_ #KZ
M/^(D+_@B5_T?O\/_ /PWWQP_^=?7GM% 'H7_ !$A?\$2O^C]_A__ .&^^.'_
M ,Z^C_B)"_X(E?\ 1^_P_P#_  WWQP_^=?7GM% 'H7_$2%_P1*_Z/W^'_P#X
M;[XX?_.OH_XB0O\ @B5_T?O\/_\ PWWQP_\ G7UY[10!Z%_Q$A?\$2O^C]_A
M_P#^&^^.'_SKZ/\ B)"_X(E?]'[_  __ /#??'#_ .=?7GM% 'H7_$2%_P $
M2O\ H_?X?_\ AOOCA_\ .OH_XB0O^")7_1^_P_\ _#??'#_YU]>>T4 >A?\
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M??'#_P"=?7GM% 'H7_$2%_P1*_Z/W^'_ /X;[XX?_.OH_P"(D+_@B5_T?O\
M#_\ \-]\</\ YU]>>T4 >A?\1(7_  1*_P"C]_A__P"&^^.'_P Z^C_B)"_X
M(E?]'[_#_P#\-]\</_G7UY[10!Z%_P 1(7_!$K_H_?X?_P#AOOCA_P#.OH_X
MB0O^")7_ $?O\/\ _P -]\</_G7UY[10!Z%_Q$A?\$2O^C]_A_\ ^&^^.'_S
MKZ/^(D+_ ((E?]'[_#__ ,-]\</_ )U]>>T4 >A?\1(7_!$K_H_?X?\ _AOO
MCA_\Z^C_ (B0O^")7_1^_P /_P#PWWQP_P#G7UY[10!Z%_Q$A?\ !$K_ */W
M^'__ (;[XX?_ #KZ/^(D+_@B5_T?O\/_ /PWWQP_^=?7GM% 'H7_ !$A?\$2
MO^C]_A__ .&^^.'_ ,Z^C_B)"_X(E?\ 1^_P_P#_  WWQP_^=?7GM% 'H7_$
M2%_P1*_Z/W^'_P#X;[XX?_.OH_XB0O\ @B5_T?O\/_\ PWWQP_\ G7UY[10!
MZ%_Q$A?\$2O^C]_A_P#^&^^.'_SKZ/\ B)"_X(E?]'[_  __ /#??'#_ .=?
M7GM% 'H7_$2%_P $2O\ H_?X?_\ AOOCA_\ .OH_XB0O^")7_1^_P_\ _#??
M'#_YU]>>T4 >A?\ $2%_P1*_Z/W^'_\ X;[XX?\ SKZ/^(D+_@B5_P!'[_#_
M /\ #??'#_YU]>>T4 >A?\1(7_!$K_H_?X?_ /AOOCA_\Z^C_B)"_P"")7_1
M^_P__P##??'#_P"=?7GM% 'H7_$2%_P1*_Z/W^'_ /X;[XX?_.OH_P"(D+_@
MB5_T?O\ #_\ \-]\</\ YU]>>T4 >A?\1(7_  1*_P"C]_A__P"&^^.'_P Z
M^C_B)"_X(E?]'[_#_P#\-]\</_G7UY[10!Z%_P 1(7_!$K_H_?X?_P#AOOCA
M_P#.OH_XB0O^")7_ $?O\/\ _P -]\</_G7UY[10!Z%_Q$A?\$2O^C]_A_\
M^&^^.'_SKZ/^(D+_ ((E?]'[_#__ ,-]\</_ )U]>>T4 >A?\1(7_!$K_H_?
MX?\ _AOOCA_\Z^C_ (B0O^")7_1^_P /_P#PWWQP_P#G7UY[10!Z%_Q$A?\
M!$K_ */W^'__ (;[XX?_ #KZ/^(D+_@B5_T?O\/_ /PWWQP_^=?7GM% 'H7_
M !$A?\$2O^C]_A__ .&^^.'_ ,Z^C_B)"_X(E?\ 1^_P_P#_  WWQP_^=?7G
MM% 'H7_$2%_P1*_Z/W^'_P#X;[XX?_.OH_XB0O\ @B5_T?O\/_\ PWWQP_\
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MQP_^=?7GM% 'H7_$2%_P1*_Z/W^'_P#X;[XX?_.OH_XB0O\ @B5_T?O\/_\
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MX(E?]'[_  __ /#??'#_ .=?7GM% 'H7_$2%_P $2O\ H_?X?_\ AOOCA_\
M.OH_XB0O^")7_1^_P_\ _#??'#_YU]>>T4 >A?\ $2%_P1*_Z/W^'_\ X;[X
MX?\ SKZ]P_9P_P""V7_!+C]KGXS^#?V>?V<_VN?!_P 3_C+\0?\ A(O^$.\#
M:5X/^*FE7^N?\(GX4USQOXA\B_\ $G@/1=%@_LSPKX:US6)?MNI6WFPZ?)#;
=^==R06\OR;7T!^RW_P EV\"_]S/_ .H=XAH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img209334158_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +<!PP# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Y]_X?U?\
M!6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\ S!G[-O\ \YZOR!HH _7[
M_A_5_P %8?\ HZS_ ,P9^S;_ /.>H_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ_(
M&B@#]?O^']7_  5A_P"CK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_
M /.>K\@:* /U^_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\
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MK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_ /.>K\@:* /U^_X?U?\
M!6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\ S!G[-O\ \YZOR!HH _7[
M_A_5_P %8?\ HZS_ ,P9^S;_ /.>H_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ_(
M&B@#]?O^']7_  5A_P"CK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_
M /.>K\@:* /U^_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\
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MK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_ /.>K\@:* /U^_X?U?\
M!6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\ S!G[-O\ \YZOR!HH _7[
M_A_5_P %8?\ HZS_ ,P9^S;_ /.>H_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ_(
M&B@#]?O^']7_  5A_P"CK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_
M /.>K\@:* /U^_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\
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MK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_ /.>K\@:* /U^_X?U?\
M!6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\ S!G[-O\ \YZOR!HH _7[
M_A_5_P %8?\ HZS_ ,P9^S;_ /.>H_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ_(
M&B@#]?O^']7_  5A_P"CK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_
M /.>K\@:* /U^_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\
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MK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_ /.>K\@:* /U^_X?U?\
M!6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\ S!G[-O\ \YZOR!HH _7[
M_A_5_P %8?\ HZS_ ,P9^S;_ /.>H_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ_(
M&B@#]?O^']7_  5A_P"CK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_
M /.>K\@:* /U^_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\
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MK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_ /.>K\@:* /U^_X?U?\
M!6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\ S!G[-O\ \YZOR!HH _7[
M_A_5_P %8?\ HZS_ ,P9^S;_ /.>H_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ_(
M&B@#]?O^']7_  5A_P"CK/\ S!G[-O\ \YZC_A_5_P %8?\ HZS_ ,P9^S;_
M /.>K\@:* /U^_X?U?\ !6'_ *.L_P#,&?LV_P#SGJ/^']7_  5A_P"CK/\
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MS5*,J%>M^IG_  ^J_P""F?\ T<K_ .8;^ '_ ,ZJC_A]5_P4S_Z.5_\ ,-_
M#_YU5?EG17UO^H_!?_1(<+_^&#*?_F0_./\ B*_BE_T<KC__ ,3+B+_YXGZF
M?\/JO^"F?_1RO_F&_@!_\ZJC_A]5_P %,_\ HY7_ ,PW\ /_ )U5?EG11_J/
MP7_T2'"__A@RG_YD#_B*_BE_T<KC_P#\3+B+_P">)^IG_#ZK_@IG_P!'*_\
MF&_@!_\ .JH_X?5?\%,_^CE?_,-_ #_YU5?EG11_J/P7_P!$APO_ .&#*?\
MYD#_ (BOXI?]'*X__P#$RXB_^>)^IG_#ZK_@IG_T<K_YAOX ?_.JH_X?5?\
M!3/_ *.5_P#,-_ #_P"=57Y9T4?ZC\%_]$APO_X8,I_^9 _XBOXI?]'*X_\
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MX ?_ #JJ/^'U7_!3/_HY7_S#?P _^=57Y9T4?ZC\%_\ 1(<+_P#A@RG_ .9
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M_P ZJC_A]5_P4S_Z.5_\PW\ /_G55^6=%'^H_!?_ $2'"_\ X8,I_P#F0/\
MB*_BE_T<KC__ ,3+B+_YXGZF?\/JO^"F?_1RO_F&_@!_\ZJC_A]5_P %,_\
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M_A@RG_YD#_B*_BE_T<KC_P#\3+B+_P">)^IG_#ZK_@IG_P!'*_\ F&_@!_\
M.JH_X?5?\%,_^CE?_,-_ #_YU5?EG11_J/P7_P!$APO_ .&#*?\ YD#_ (BO
MXI?]'*X__P#$RXB_^>)^IG_#ZK_@IG_T<K_YAOX ?_.JH_X?5?\ !3/_ *.5
M_P#,-_ #_P"=57Y9T4?ZC\%_]$APO_X8,I_^9 _XBOXI?]'*X_\ _$RXB_\
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M_1RN/_\ Q,N(O_GB?J9_P^J_X*9_]'*_^8;^ '_SJJ/^'U7_  4S_P"CE?\
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MJ_X*9_\ 1RO_ )AOX ?_ #JJ/^'U7_!3/_HY7_S#?P _^=57Y9T4?ZC\%_\
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MN#QV%Q&"Q=!J-;"XNA5PV(HR<5-1JT*T85:;<)1DE.*;C)26C3"BBO7?A+\
M?C=\>K[6-.^"OPG^('Q2O/#]M:W>O1>!O"NL>(UT2WOY)XK"35IM,M9X-.%_
M):W26*WDD+WK6ET+99?LT_EJOB*&%I3Q&*KT<-0II.I6KU(4:5-.2BG.I4E&
M$4Y244Y25Y-):M#P>#QF88FE@\!A<3CL77<HT<+@Z%7$XFM*,93DJ5"C"=6H
MXPC*<E"+:C&4GHFUY%17UQK'[ G[<&A1I-J'[(O[1WDND\IEL/@YX]U>.&.V
M5&FDNWTG0[Y;-%5PRO=F%9%64Q%Q#*4^5M4TK4]$U"\TC6M.O](U73YWM;_3
M-4L[C3]0L;F,XDM[RRNXXKFVGC/#PS1)(AX90:QPN8Y?CN9X''8/&**O+ZKB
M:.(Y4VTG+V,YV3::N[:IK='5F&2YSE#@LURG,\L=1M4UF& Q6"<VHJ34/K-*
MES-1E&34;M1:>S10HHHKL/,"BBB@ HHHH **** "BBOT*_8"_P"">7CO_@H!
MK7Q.T?P3X_\ "7@)OACHWAW5+^?Q59:S?+JDOB:[U:UT^UM(](@E,,<1T6[>
M\N9G+1![98+:Y\R4P^?FN:Y?DF Q&:9IB88/ 810EB,34C4E"DJM6%"FW&E"
M=1\U6K""Y8-WDKV5VO9X?X>SGBK.,%D'#^ J9GG&8RK1P6!HSHTZE>5##U<5
M649UZE*E'DP]"K5?/4BN6#2O)I/\]:*T-7TV;1M5U/2+AXI+C2M0O=-GDA+F
M&2:QN9;65XC(D;F)GB9HRZ(Y0@LBG(&?7>FI)23NI)-/NFKI_-'CRC*$I0DF
MI1DXR3W4HNS3\TU8****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#].
M?^"8W_!0_P 4?L)_%P+K,FHZ]\ _B!>V5G\4O!T#//)IS I;6OQ!\+VQ.R/Q
M/X?A.+JU39%XFT19M&NREY%H>IZ/_>EX-\8^%OB'X3\.^.O!&NZ=XG\(>+='
ML-?\-^(=(N%NM-U?1]3MTNK&^M)EQNCF@D5BCJDL3[HIHXYD>-?\O2OWA_X(
MY_\ !3R3]F/Q79?LY_'#77/[/GC?5]OAGQ#J=R?(^#GB_5;EF>^::5MMMX"\
M27LY/B6!BMMH6J2KXIA-M#+XD.H?@7C'X9?V]AZO%&18>^=X2DGF&$HQ][-<
M)2C95:<8J\\?A:<4H))SQ.'C[%<U6EAX3_L;Z,?CR^#\;A^ .+L9;A7,<0XY
M+F6)J>YP[F.)J7="M4F[4LGQ]:3=23:I8#&3>)DH8?$8RK3_ +3Z*9%+'-''
M-#(DL,J)+%+$ZR1RQR*&22-U)5T=2&1U)5E(()!!I]?QX?Z9)IJZ=T]4ULUW
M/\@>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K]V?^#<V&&7_@IAX2>6**1[;X1_%J:W>2-7>"9M$M;=I868
M$Q2M;SSP&1"K&&:6(G9(ZM^$U?N]_P &Y7_*2WPQ_P!D?^+'_IJT^@#[D_X*
M"?\ !<[]NC]EO]N+]H+X)_#FZ^$=_P##SX;>+[?0_#6D^+/A[)J5TME/X;T+
M4V-]JNF:]HNI7<Z7=_<,DGVF)=C*CHX05]Z_LK_&OX%_\'!7[*OQB^%_[1_P
M=\)>#OCS\)8-,M/^$J\,VLTB>$[_ ,;6/B,^!/B/\,-4U*_N?%FEPVNK>']5
M@\4^"M0U?5-)NX[.SMM6OM6L?$"VEG_/Q_P5D_95_:@^(G_!2;]J?7/A_P#L
MW_'KQSHGB+XBV$GA_6/!WP?^(7B;2]=C_P"$0\-0>9H^H:+X=OK34T\^*6'=
M933KYL4D>=Z,!^XW_!$O]D;Q=_P31_9\_:8_;$_;4MT^"MOXJ\-^'I[?POXH
MFLK7Q'X7^'O@>/6=6GU#7K/[838^)/'&N:[8:/X?\%71M_$HOM(L[*>Q34==
MM+&, _ES_8R\'ZK\//\ @IE^RCX UWRO[;\#?MU? OP?K/DB00_VKX9^/_A;
M1=1\H31Q3"+[793>6)8HY-N-\:-E1^KO_!SE8WNI_P#!0;X,:=IUG=:AJ%]^
MR1\.[.QL;*WEN[R\N[CXU_'V*WM;6U@22>XN)Y72*&"%'EED94169@#^6?[)
M/CJ_^*/_  5(_9E^)FJ*R:G\1?V^_@QXZU%&;>RW_B[]HCPWX@O%9R6W,MQJ
M$@+;FW$$Y.<U_7=_P5X_;M_9R_X)[?&#PS\7?#_P>\*_%K_@H%XR^#>C^$?A
MSJ?C.WN[K0/A/\'=)\6_$.XM/%5RZ/#=63^(O%/B+QGI']G^$KW1]=\5V^EW
M-IK/B'2M(T:TM]4 /X<?&_P!^._PRTB/Q!\2/@I\6_A]H,T\=K#K?C?X<>,?
M"FD2W4N/*MH]2U[1K"S>>3(\N%9C(^1M4YKR2O[7O^"5'_!8'QC_ ,%'/BCX
MU_8P_;3^%WPD\4Z;\3/ OB;4?"L^@>%+RW\/^(+?1(3J/B;P)XV\+:]J_B73
M=2L[CP]]JU;0]7MVT^6PD\/SVE_#JEYJ5E?Z=_+3_P %!_V=M+_9/_;1_:'^
M &@SO/X:\ ^/[@>$_-9Y)[;P=XHTS3?&GA#3[J:26:2YO-,\,^(]*TZ\NWDW
MW=U:S7+)$93$@!\T>"?AW\0/B7JQT#X<>!?&/Q UU86N&T7P3X8UOQ7JPMT!
M+SG3M"L;^\$*!6+2F'8H4DL #71>//@7\;?A98VNI_$[X._%3X<Z;>W'V6RU
M#QY\/?%OA"QN[HJSBVM;OQ!I&GV]Q<%$=_)BD>3:C-MPI(_<G2?^"^_BG]GW
MX'?##X$?L-?LP_"+X$Z-X2\$^&=+\9>*_%-B_B[7/%WC6ST.TM/$GBFWTW19
M/#&G+?:MK,=U?W&M>+9_&>L:QYOVF]-E-(\"?IM_P25_X*R_$G_@H[\4/'?[
M&W[:?PY^%'Q'T#QG\.O$7B71=0L_!EO::;J<6@W&F#6O"?C+POJ-]J>@ZKI]
MUIM[)J6CZE96-E?:=>Z:\5RM^+VVN]* /XK:[OP+\+?B;\4+RXT_X9_#KQW\
M1-0M!&;NQ\"^$?$'BZ\M1-'<S1&XMM T_4)H!+%9W<L9E1=\=K<NN5@E*^V_
MMJ_ S1OV<OVO_P!H7X#>'KJ=?"_PW^+OBSPOX7NM6F>YNH?"::M)/X9;5;F&
M.66YNK;0+K3UU"YC@,MQ-'-,MNKN(1_6I_P4U_:#^(__  1?_9K_ &5_@I^P
M3\._!W@SP3XOM/$5GXL^-6H>#K#Q1/J'B;PQIGACR)]1ED0Z%?\ CGQ^NHZK
MXDU'6O%%KJ4E_8Z4]GX:M8K'2KM=. /XN?'/PT^(_P +]2AT7XE_#_QM\.]8
MN8/M-OI/CGPIKOA+4I[;Y#]HAL=?L-/NI8,2(?-2)H_G3YOF&>)K]?/VH_\
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MQ[JUG8SW"L T^H^'M<CC,<9CME_>B7[5_:J_Y5F/@#_V!_@=_P"K)N:_CKH
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M>5<)XGQ"HX:E0HU/[=J-N%7,J>%C&A3S6K1YGB:<8IPH1PD8_P"S_5V_C_\
M;:^&7Q(^*W_!0O\ :W\,_"[X?>-OB1XC_P"%[?$JY_L#P%X5UWQ?K0MD\27B
MO<'2_#]AJ%Z+=&(#S& 1(2-S#-?('Q'^#7Q=^#NH1:3\6OA=\0_AEJ5PTJVM
MEX^\&^(O"-Q>>3M,KV4>O:=8&]B59(W\ZU\Z)HY(Y%<I(C-_2+^WG_P5:L?V
M0_C)\5_@7^P[\._!7AGQC+\0O$GB']H+XQ^)_#KZSJOB3XIZMJ$]]KNGZ+97
MMQ$+]/#]U<2:9)K/B,:GI\.R30_#&B6.D:9;:MJGU!^QW\>8/^"S'[&G[0WP
M6_:*\'^$3\4O $5II]OXHT31(XK"SU/QCH7B1_AE\1M!L;^XO9= \6Z/K/A_
M7K758M.N8K"^L[7RX_)T_6[_ $FW^FP_''$V0\.9'G>8\+4,/PE2PV3X/$8B
MIF7_  N4,+6AAL'2S:K@(T'0IX>K5G3E3PGMYXEQJ4U4=)R;A\%C/"?@3C#C
M?BOA3)/$#%8WQ'Q&/XES/!X.ED:7">*Q^&JXW,L1P]0S>>+CC*V-H4*=:%;,
M/JE/ J="LZ,:ZIQ]I_&C7M_PY_9G_:,^+]BNJ?"GX"_&/XCZ2S.O]L>"/AKX
MQ\3:,K(TD;"35]'T>[TV(B2&6+][=)F:-H1F0;:Y?X2>+/#_ ,._BS\-_&_C
M3P59_$'POX*\?>%/$OBCX?:LT4%AXQT3P_KUCJ6L>%-0:[L[^VCM];LK6XTN
MY%YIU];!+AA=6-W!YEO)^O?Q8_X+W_MD>)]7C@^"VG?#C]G[P)I:P6GA_P +
M:#X2T3QIJ%OI5I(GV6RU76?%^F7FESE+6-;$?\(_X8\,6D5H%2VLX9T6YK]'
MSW&\4TJ^'PW#>39=C55I3JXC,LVS.6#P.%E&2C3PZP^&H8K'8BK53E/GA3A1
MIQBE*<I2M'\0X2ROP^Q&%QN/XXXHSK*WAZ].A@\DX=R&.:9KF$)P<ZN+^N8_
M&8#*<%AZ$N6E[.K7JXFM.3<:4(0YI_CY\0/A1\4OA-J%MI'Q4^&OC_X::K>I
M/)9Z9\0/!WB+P;J%W':R)%<R6UEXCT[3;F=+>5TCG>*)UAD=$D*LP!X"O[%?
MV5_CI=_\%=_V /VF?AW^TEX6\+ZI\3/AG9WMMI?BK0]&MM)!U6[\+7WB#X=^
M-M-BE-W%H'BJQ\0:'J=EK8T9;+2]0TB)+-K-+'5M2L6_G%_X)P_"CP'\;_VW
M_P!G;X8_$Z&UO/ WB'QK<7&NZ7?-(MCKJ>'/#FN>*;#PW>>3^\DM?$NJ:)8Z
M#<0*R?:(M1>!I8ED,J>+DG&M?$83BQ9]EBR[-.#%.IF^%P.(^O4*^&^HU,PP
M^)P-2<*$VL3AZ53V=&K%234.:2<W"G]5Q5X587!9CX=2X1SZ6=</^*+HT>',
M?FN#658O"8[^U:&38W!9M0IUL51B\#C,31]KB:%25.495%"FXTHU:WC?P^_9
M;_:7^+.CCQ%\+_V?/C5\0_#[07%Q'KW@SX7^-?$FB3QVKSQ3+;:MI&BW>GW,
MXFM;FWCMK>XDN9KJ"6VABDN$:,>5^+/!WB[P%KM[X6\=>%?$G@OQ-IK*FH^'
M/%FAZGX<UVP=UW(M[I&L6MGJ%JS*0RK/;QEE.0".:_IE_P""KG_!2+]N']E#
M]J.Y^"OP5O\ 2O@E\(?#7A3P9=^ +BT^&O@G6X/'^D7?A[3[C5+^"[\8^'-?
ML;;2]$\0/JO@^'3O#,.E1Z>N@;9F,\N^OQ=_;._;Y^*W[<]G\'Y_C%X;\"V7
MBWX3Z/XHT1_%_A#2KK1[WQE;>([O1;J.37K&:]O;2WETQM'=[:#2OLFFBYU7
M5+BVT^R6Y\A:X7S_ (LSV.5YIBLFR.AP]G&&>+H5,'G-?$YG@*-3#RKX5XVC
M4P-'#5YU9*GAZM/"UE4P]2HW5BO95(&?'_!_ASPC//\ A_ <4<68OC/AG'++
ML50S/AC"8#(<XQ-'%T\+CUE>)HYOBL?A*="$JV-P]?,,,Z.,H48PH3?UBC5E
M\-HCR.L<:L[NRHB(I9W=B%55502S,2 J@$DD #)KZ8L/V*_VP]5T!?%6F_LJ
M_M%W_AV2&*YAUBS^"WQ&N+&YLY89KA;^UEB\..+O35A@D>74;82V, \L3W$;
M30A_VW_X)/?!#X/?LX_LB?%__@J%\;?"=KXSUSP.OB:+X.:1J$44T&EQ^&9;
M?0(]2T4W$%U;V/BSQI\0+T>"K'7I[2>7PS9Z?)=V<D2:IJ KY(U+_@O'_P %
M [KX@OXNL/%W@'2O"@U,W<'PJ3X<>%[SPD-/6\%Q'I-SK=U9/\0YXVM5^P7%
MY!XSL[N2-Y)X'M;@Q2185N*N(\VS7.,NX/R?*\7A\@Q/U',<SSK,,1@\/7S.
M,(U*^79?2PF%Q-2=7#1G"-:O7E2I1JSY>5149U>S#>'G!'#O#W#6=^)G$V?9
M;C>,L#_:V1Y%PMDV#S/&83(JE65'"9WG.)S',,#0IT,=.%2IAL)A(U\1.A3Y
M^=U'4HT?QOO;&]TR\N].U*SNM/U"PN9K.^L;VWEM+RSN[:1H;BUN[6=(Y[>Y
M@E1XIH)D26*161U5E(%6OZ9_^"K7PT^&'[5?[#?P-_X*:_#KP9I?@7QSKR^&
M[3XM6NGVL<<GB"S\23R>$KE=9OK:*-=:U/P-X^TA?#^BZ]>6]O?:KX=U.1=0
ME46&CZ=:_P S%>_PGQ)3XHRIX_ZI4R_%X7&8O+,TR^K.-6>!S/ 5/98K#>V@
MHPK1BW"I3J1C'FIU(<T83YH1^,\1>!ZW /$,<H_M"CG&6X_*\MS_ "#.</2G
MAZ6;Y%F]#ZQE^.6&JRE4PU2252C6H3E/V=>C44)U*3A4G;L+:*\O[*TFNH;&
M&ZN[:VEO;C/V>SBGF2*2ZGV_-Y-NK&:7'.Q&QS7]1?PM_:,_X)Q?\$Z?&_P^
M^"_[('A^Q_:E_:&\<^,?"'@/QO\ M&:A?6=[X?T6W\3Z]I^CZJ^@>++2&YL+
MFS^SZD[6?AOX8)'H.H6\=NGBCQQJFJZ:1<?RTU[/^SA_R</\!O\ LL_PN_\
M4XT*N?B[AO#\18-1Q^-S".783#8ZKB,JPF)EA<)FE5TX2P_]HSHJ.(K4,*Z<
MY0PT*U.E5J5%*LIJG&+[_#7CC&<%YGSY/E>35,[S/'Y3AL)Q#F."AC\QR##+
M$5(8U9)2Q+G@L+B\?&O3IU<?4PU;$T*-%T\+*DZTYK]WO^#D/_DMO[-O_9+/
M%G_J6Q5_-U7](O\ P<A_\EM_9M_[)9XL_P#4MBK^;JO'\)/^3=<,?]@N*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(Y-:2QM[V)E.@PN ?S64444 %?J%_P $[/\ @J5^TO\ L+?$7PA8>'O&FO\
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M]L+,"!Y)3+;?LP?#_4?LRQQ))(US-;A/L\03,CS0@E5?</RU_P""AG_!/_\
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MKX.OX;ADL#-;3W>B:OX@LK2=+N[A#?N!^TE_P3R_X(S_ +5_Q'\1_M8^#_\
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MMK_@GY^Q]_P47^&&D?:K[3[7PWIWBNSTN)[N[LO#'QEAT^RFT2^DA2:6ZN_
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M\PS3-,8DKNJY5<3C<;BZEKMOFJ5J]75N\I79\O?\%&/^3\/VN/\ LOGQ(_\
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M.39CBL]RGV-;%3RC!X>C@,%@K>S_ +2PV IX7%1P=;,<+/$4)?69_LS\(?\
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M]KX6T"6='MIO&'B=;>XMM,22.XATFTCO=>OK:ZM]/2PO_P"^SX=_#SP7\)O
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M0UC5[TJLVJZ_KFH37.K:[J]UNNM3U2\NKR=M\I _/C_@JG_P4AT/]A[X8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^%>$_R#_B2/BG_HM^'_ /PW9C_\EZ_T]/\ -UHK_2*_X89_8F_Z,\_99_\
M$??A+_\ ,C1_PPS^Q-_T9Y^RS_XC[\)?_F1H_P")C,E_Z)S-/_"O"?Y!_P 2
M1\4_]%OP_P#^&[,?_DO7^GI_FZT5_I%?\,,_L3?]&>?LL_\ B/OPE_\ F1H_
MX89_8F_Z,\_99_\ $??A+_\ ,C1_Q,9DO_1.9I_X5X3_ "#_ (DCXI_Z+?A_
M_P -V8__ "7K_3T_S=:*_P!(K_AAG]B;_HSS]EG_ ,1]^$O_ ,R-'_##/[$W
M_1GG[+/_ (C[\)?_ )D:/^)C,E_Z)S-/_"O"?Y!_Q)'Q3_T6_#__ (;LQ_\
MDO7^GI_FZT5_I%?\,,_L3?\ 1GG[+/\ XC[\)?\ YD:/^&&?V)O^C//V6?\
MQ'WX2_\ S(T?\3&9+_T3F:?^%>$_R#_B2/BG_HM^'_\ PW9C_P#)>O\ 3T_S
M=:*_TBO^&&?V)O\ HSS]EG_Q'WX2_P#S(T?\,,_L3?\ 1GG[+/\ XC[\)?\
MYD:/^)C,E_Z)S-/_  KPG^0?\21\4_\ 1;\/_P#ANS'_ .2]?Z>G^;K17^D5
M_P ,,_L3?]&>?LL_^(^_"7_YD:/^&&?V)O\ HSS]EG_Q'WX2_P#S(T?\3&9+
M_P!$YFG_ (5X3_(/^)(^*?\ HM^'_P#PW9C_ /)>O]/3_-UHK_2*_P"&&?V)
MO^C//V6?_$??A+_\R-'_  PS^Q-_T9Y^RS_XC[\)?_F1H_XF,R7_ *)S-/\
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MQ)'Q3_T6_#__ (;LQ_\ DO7^GI_FZT5_I%?\,,_L3?\ 1GG[+/\ XC[\)?\
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M\,,_L3?]&>?LL_\ B/OPE_\ F1H_XF,R7_HG,T_\*\)_D'_$D?%/_1;\/_\
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M (89_8F_Z,\_99_\1]^$O_S(T?\ ##/[$W_1GG[+/_B/OPE_^9&C_B8S)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#$T?VUJO\ S^S?FO\ \30!ZI17E?\ ;6J_\_LWYK_\31_;6J_\_LWYK_\
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MS?FO_P 30!ZI17E?]M:K_P _LWYK_P#$T?VUJO\ S^S?FO\ \30!ZI17E?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AJO_(-O_\ KTN/
M_135Y-7K.J_\@V__ .O2X_\ 135Y-0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4L'^OA_P"NL?\ Z&M15+!_KX?^NL?_ *&M &EKW_(7O?\ ?C_]$QUD
M5KZ]_P A>]_WX_\ T3'610 4444 %%%% !1110 4444 %%%% !1110 4444
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MH!_3?17XM?LA?\'!_P#P2;_;7\<:'\+?A)^U#IGA_P"*?B:]M-,\-_#WXO\
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M>)M#U"(36.K:%KND7%WINJ:?=1G=#=6=S-"^" VY6 _,G]NS_@M[_P $T_\
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MCKPCJ5MIAU3Q!'(MOX0TGQEKAL]-U&7^QA*=-@U'];* "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5P='B.=;,,/3ADE;,)JE@:>9RE-+"3Q=22IT(UG%U)ODC>5T?6M%?F!\9_\
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MO_P3;^#'_!2[X^_\)-X ^&OQQ^%?PB^('@;X8V,.F^(OBCXC\3?&'P38^-]
M^&'A33WOM%TKQ!XFM=,N-0N;S4)M0T?0K?1M$U3Q%J%[INEVTLB?S;+_ ,'K
M>BM>1^)_^'7GQ<_X4;_;!TNX^*:_'NT:\BVW"1211Z%_PHH>$)=81)[8G2'^
M)\'^D7"6[7JAHYY/T1_X.G?^";WQ^_;=_8*^%0_9,\%WWC?Q-^RU\2)O'=S\
M#_!EJD>J>*/AU<^"=1\,:@O@#PO9+''KOBCP8L6E2Z#X0TJV;5-1T&YU_3_#
M-K>ZQ_9^B:I_/_\ \$FO^#H+P_\ L4_!'X=_\$[_ /@H'^R1?2?"GX/Z7/\
M"?\ X3GP'H=O9>,O#OAT:A?"[T?XP? 7QG:6%CXJOK6XU&X'BC5],UW0M;N[
M6"XGOO!7B?Q)=W=S? ']\'@#]LOX->/_ -B;P]^WU!-XB\/? ;7/V<$_:CO'
MU[28QXL\.?#:'X?2?$G6(=:T31[S5H'\1:!H5O>V^HZ?HVI:M:3:E930Z5J.
MHV[V]W/^<O\ P2@_X+Y_LE?\%=?B+\6/A1\#_ /QK^&OCKX5>%+;Q_<:5\6]
M'\'6L'B;P/<:[9^&Y]9T2^\'>,O%L,5WI.L:IH]MJ^EZF+)XDUG3YM.NM44:
M@+#]+O -A^R]^U'^R'HGAWX2P>!_%_[(/QR^!DW@KPGI?P[LT\,^!-4^"/C7
MPA<>%#X:\.:3HUMHLGA/2XO"][<: NA6MCHM_P"%WAETB6PTJ_TZ2UM_@_\
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M(\4:>+/7_#%I//>W<>B>*M*TG5;J[U""_=@#\*_^" '[&VG?\%L_VKOVN_\
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M*<OPL^+/Q9TSPCX/TFTT?3K.WU3Q5JNB^&=&\(Z(PL9+W4[[[$]Z]Y>S33S
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MWQC\$:RWP_\ $7BBZT"Z\2:?HFMZKXD\'_#BZTF^O-/LKBVDMM#LO%USI&K
M6.O0:5%;ZG=Z;\@_\%\OV._VZ/ ?_!0#]B?_ (+-_L1_!E_VJM3_ &2O!$'P
M_P#B1^SU96%_K_B1="T7Q#\2-=B\4^'?"NGO=:[XAB\0Z-\5O%'A^]F\%:3J
M7BGP7K>C>%O%EMH>N6@OYM&^[O\ @FU_P<4?L+_\%%?'^C_L]ZIIOCC]E[]K
M:>2YM1^S_P#'?3(+.36/%6C1S2ZSH7P[\=VZQZ1XCUC2DBE,.A^(M-\!>/-0
M$%])IW@N:#3[V6$ [_\ X*J?\%"OV2OV-OVF?^"<GPG_ &A_V2M._:*\??M/
M?%^_\*?!3Q_?>%OAIKL_P'\06OC;X1>$)?%NE7WCBPO=:TJ_FU+XCZ'J'F^$
MYM,O3#X?=FO?/%FJ=7_P4[_X++_"G_@EA\8/V2?A_P#'#X.?$77_  !^U3XE
MU+PVGQJ\.:IX=M?!_P ,Y="\1^#M&\0W/B>RU.>/4+P:)I?C33_%-S!;/:O<
MZ/;7O]G->7-K=16_X;?\'1?_ "DC_P"#?/\ [.?UW_U?/[']?I__ ,'0/[%W
M_#7_ /P2:^,^M:%I/]H_$;]E6\LOVG_!;0P[KQM(\ 6.I6?Q6L!+'^_-G)\)
MM:\8:VUB@ECO=7\.Z&7A:6WMY80#^AT$, RD,K %6!!!!&001P01R"."*_(/
M]CS_ (+ _"W]M;_@H#^V-^PI\*/A'\0!;_L8QZ]I_CKX_7NI^'I_AYKOC'PY
MXUTCP!?^#]*TRSFDUJVOKOQ$?&HT6]N#+9ZEIWP_UN^)MC<V4#?'W[%G_!6_
M2)O^#=73/^"AOBC5K?5/B#^SI^S)XD\ ^-8=7GCDGUK]H;X06H^%'@VSUV1G
M,0O/BUXO_P"%?^(<*S$6WQ!L_P!PLY:S3PS_ (-0_P!F'4/V?O\ @F?XZ_;&
M^)5MJ6I_%;]MGXA>,/CEXCU>ZB:?Q1JWPU\ SZ]X>\"P7OF*)[Z\UO6X_B1\
M0-.G:9EU"S^(-C,JHTC,X!]I_P#!0'_@OQ^S5^Q7\>]/_8^^&'PB^.G[<?[9
M%W"LVI?L\?LN>%9O&'B#P>UQI4&M:;I_B^_M8=0N8=>U32KJ'5(O#?A70O%V
MOZ;I+)J?B+3=%M+W2'U/R/\ 97_X./?@C\4/VE_!O['7[9/[*?[3/_!-W]H?
MXDS:98?#CP[^TWX6N]*\)^,]<U[58]%\,Z!IWB/4='\*:]97GBS4FDLO"VKZ
MOX*T_P 'ZU?0G3;;Q1_:EWIME??RX?\ !O\ _P#!2OXM_ 77_P!N#]J\_P#!
M,;]N'_@H3\>OVHOC0VH_$'X^_LX_"SQ-\1-*\)13-?>.M8\ ZCK^B^$/$,6B
MZQKOB3QA)XGUG1K>73EO-,M?!LEQ:26^EZ4+7Z+_ ."Z7[4?[7W_  5P^ /P
M<\ ?#G_@AE_P5+^#'QL^#'QLTWXC>"_B]XI_9C^+E_=Z/X8N?#/B'1O%?A'3
M+[0?AS:ZII2Z_KDW@;Q+)=1SK%%?^!M*F9HI(8Y5 /\ 0^HKRWX'7GCG4?@I
M\']0^)UA=:5\2K[X6_#^\^(>EWQC:]TWQS<^$](G\66%XT),1NK/7WU"WN#$
M3&9HW*$KBO4J /D#_@H3_P F"_MP_P#9H'[2W_JF/&M?SP_\&87_ "B@^*'_
M &>_\7/_ %3_ .SW7]#W_!0G_DP7]N'_ +- _:6_]4QXUK_/W_X-^?\ @C)\
M:O\ @H+^Q)XR^-WP\_X*@?M1_L::%HW[1?CGX<S_  I^"\OBQ/">J:EH7@/X
M6:]<>-[I=#^+_@.S_MS5[?Q5::/>%]&FN/L?A_3M^H3H(H+4 _NH_P""P_\
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MPYJ<8KB3(*U&K'+:63YQ2PV*Q."KY3AW0PU*CA:E'V&+A'V<X8K"3A1_0?\
MX)+7OQ N/V$/@UIWQ)TSQ#I>N^&F\8>%]/A\3V-[IVK-X7T7QAK5OX91K34(
M+:ZBL=-T<VVB:6&B"?V;I=KY;-'M8^'?\%U+;4Y_V&)9;!96M+/XP?#VYULQ
MJS(FF-;^([.)IR.$B.LW6D(&;Y3.\*#YF6OTK_9W\9_$KXA_!/X<^-_C#X(7
MX;_$KQ-X>BU7Q9X&6VU"R/AN_GN;GR;"2RU6>XU.RG^P+:3W%EJ$K7EI/-);
M7*QRQ/&EWX[?!CP9^T+\(O'GP9^(%HUUX5\>Z%-I%\\.W[7IUVDL5]H^N:<S
M@HFJ>']9M-/UO3'D5X5O["W,\<L/F1/^&X?/X9?XBKB/&86C1IX?BJKF.,PN
M"JPQ5&E!YC.IBH8.M'EIXB-.,JCP]2'+3JN,)1Y825OZSQO!U;.O!%\$99F&
M)Q-?&>'N&R7+<PS7#U,OQ.)JK):5' 5,RPM1SK8*=>4*,<;1J.I6PRG5A4]I
M4A+F_+S_ ((N7ZZU_P $\)=(\"WUCI_C32O&GQ8T>>]G,5Q%I_C*^\G5- O]
M1MA'.1%!INJ^'97AF@E\ZV@R(Y$<)7YA?M2?$[_@LK^Q[X1\/^-_C/\ M!06
M6@^)O$@\*:5+X>D^&>O7,FK'3+_5PLUM!X(A>&W-GIMRWGL<>8$C*Y?CB?!7
MA3_@HY_P2*^)WB^3PG\-=0^)'PM\27$4.JWVF^%]=\:?"?QQ::<UU#H&N7%[
MX;9=:\!^);:.\N5@M-2N]%U&1C/;75IKVE06LS<K^U_^V;^U'_P4D\->!?A/
MI/[*VN:<OA7Q5#XI6#P%X>\?>,M<U'7)-&U'1(U<C2X[?3=(-OJ%_<-#-9W$
MRM'%(^J+#;7'G?O>6\.5)<:YCG^&H\&<3<$<2YA_:V-S7,/[,QN*RVE4I8BM
M/#THXNHJF%FL36]G4A&G63IPI.K&A4A4IP_C[/>-Z,/"S).#\=B/%#@3Q7X&
MR9<.Y7P]DKSW*L!GF(I5\%AJ6-Q$LMHNCCZ4L!AE6HU*E;#2C7JXE8>6*H5*
M-:K^K_Q\^)OC7XR?\$+=5^)?Q%U@^(?&WBKX<_#ZZ\0ZV]I96,FJ7ME\=?"N
ME+>SVNG6]K91W,]M80/<M;6T$<LYDF\M3(17RC_P1R_X)\?L[?'SX+>-/CC\
M<_"J?$J^O?&6M?#OP[X7U2\U6PT+PWIVCZ1HU[J&L1#1]2T^XO=<U:?7S##<
MSR;-%@T^*?31'?W4MS%]@_%CX+_%+P7_ ,$/+KX/Z[X)UT?$[1/AEX)&J^"M
M*LWU_7K.1?C1X=\3W4#V>A_V@\D^F:)(]]JR0&7^S8K:\-X8A9W!C]"_X(?>
M%?%'A']BV^T_Q7X;U[PQ?W7QG\=:A;6/B'1]0T6\N+"31_!]JE[!;:E;VTTU
MH]U9W=LES&C0M/:W$(<R02JOQE;.9Y1X=<;OA_,8Y?[;Q/Q]'"SRO$0P\_[,
MG1PDZ2P<\-*,Z>%G"A34)X9QA*C%TXR=*4HO]1PG#%/B7QJ\)X\9Y+/.?JO@
M%D^*Q]+B#!U,93_MZEB<?3Q$LSI8Z$Z=;'TJN+K3JT\=&I4AB9QK2@L1"G./
MYP_\%[O&E[X5U7]FO]FKPL\^B?#+PG\.V\7VWAFU,QTV2XM;RY\"^%%EN+AY
MKB[?PUH>@:E96*S7$DD$6L7,L[2RW22+^R$7_!+_ /9 B_9V7X&O\&/AZVHC
MP5_8LOQ1D\,:9_PLIO%G]G,K^-V\<F!_$Z:B-:=]56S753I,-L?[#BL%T%5T
MP?)/_!:/]AOXD?M)^$?A_P#&'X,:'?>,/'/PJM=;T3Q%X(TT0R:OK_@G56CU
M5=1\/6\DD<VI:QX=U.TG']@V8N-0UFTUJ9M-ADO=.BLM0^*%_P""MG[:MW\$
MW_9^M/V3O%K_ !U'@P^"I/B3!IGCV;7$C%@= D\3#X7Q^#_M\?BY8,W"WS>)
MVTB/Q$!?-H368.C'?!X;.N)N!.!J'!>;4L+B\FQ^:5.):2S:AEV)H8ROC85L
M-FV-56O1J8FG2@J]537MJDH8B,*<*DH5(T^/,\=PKP)XN^+6,\4N',3F&7<3
MY-D%'@7$/AS%9U@<9EF#RNIA<?P[E<J&$Q5' UZ]5X3#.$GA:%.I@I5*]6C"
MK1G5=_P;V_$'Q%#\3?CW\*C>WLGA+4? FD?$%-.;+Z;9>(M&\0:?X<DO8MRE
M;6]U/3->B@N/+9#?P:3:^<LHTZ P\S_P;WLO_"__ ([+D;C\'M/8+D;BJ^-=
M'#$#J0I902. 64'J*_17_@C=^PC\0/V6O!/CGXI?&;29?#/Q+^*\6CZ;IO@V
M>XMI[[PMX'TG?J-N==6V,BV7B'7M3O&N+W2#<2RZ39:9ID-\MMJLVH6%E^._
MA1/VJ?\ @DY^V;\0-9T;X*ZQX[\.^(9?$O@[2!)H6O2>%_B/X!UWQ%:ZWX:O
M?#7B+0[348;#Q KZ1I$SV2#4+[2KA=1T74=-9Y'8?28W%Y7Q;F_C!DN08S+Z
MN,SK+>&HY?)XJA1H9GB<EC76/EAZ\Y1I5.6<Z5#VRFZ<FE5<_9-U%\-E>6Y_
MX<\-?1IXHXQRW.,/EG"^>\<U,Y@L!B\5B\AP'%%3!RR>.,PE.$\10<Z5'$8K
MZLZ:K4U)X=4EB4J#]U_X+H?\GQ?L\?\ 9(/ O_JWOB#7N7_!Q+_R!OV2_P#L
M)_&S_P!)?A77Y\_M=^%?V[_V@/BM\$OVE/C[\'/$6ACXF:I!X;^&_@'PUX/\
M127O@GP9X-U[1;RTM=7T5+*_U?1EU[4?%VHZGIS^*;P>(=:N4UF^33]/T)-$
MA/Z#?\'$O_(&_9+_ .PG\;/_ $E^%==&4X:& S_P0RSZY@<97R[!<8X7%3P&
M)IXNA#$4\OG"M256G[LG1K1JT)R2Y'4I5.24XI2?)Q)CJF<<'?2OSU99FN68
M/.LU\,,?E]+.,!6R[%U<%6SFC4PN(EAZR4Z<<3AIT,73A)^TC0Q%%U8TYR<%
M]7_!'_@EG^R)JW[$'AG2M3^'6F:QX\^(_P &M+\:7_Q:UI#<>.-(\7^+O!]K
MK]MJ.B:E"\(TC2_#E_=V\6FZ'9+'IUS8V*QZU'JMS>ZG=WOYI_\ !"O5?%?B
M;4?VNO@=I.M7.DZ?X[^"IU73[W+&VT+Q7%/>>$-/UJ)E226WN5@\6^;*8%+7
M,>EP&1)6L[<)7_X>#?\ !0+X,_LVZ%^R[XE^ >HZCXB\4?"[2M!^$_QDL]'U
M^\U*^^&7B7PO:)X;O-!M/#UA=Z#XJUW2O#6H6MEIVKVE];WFESP6L/B;1[KQ
M#8ZB]Q]I?\$D_P!D'XX?LP_ 'X^?'SQ#X%N-.^-/Q&\#W(^$GPT\40S6U^]G
MX7T35];\.P^*='CET_4])G\:>++K3[271[N]T_5[73--@DF739[X%/'S..<Y
M-PAQU_K1GN"S*IQ%G>6/A2%3-J.84ZU2EF?MIX[#Q=2<<-A(P5"<Z<H4HT(8
M*4*E*G'V:G]-D4^&.*/$GPC_ -0.$LTR.EP3PMGR\0ZM+AW%9+6PU"OD*PU+
M*L;.-&G+'9C4JRQ=.E6A5Q$\74S6G4I8BM)594ORR_93^,2?\$Q_BM\2?AS^
MU_\ LC+XM7Q=)I5E/J>LZ!H=YXIT.Q\/W&I1W%]X#N/%%E<>&?&GA37OM\4L
MPTK6](L;^>RT^Z;6YUMTM5_J;_8O\9_LK_$+X0S^,_V1=+\,:!\.O$OBO5-7
MU_P[X9T%/"8T/Q[<6&D0ZY8:UX4BCAM_#^LQV-MH_FVEC!'I=S:?8]1TJ2[L
M+V"^N?PF^/W_  5#\?\ QO\ @IXU_9U^-/\ P3U\0W/Q;\0^&M:\.QQ:C:^)
M#8>'/%MW875E9^,]"\&ZUX$N?%VC:MX=>235M,M+;7I-0BN[!(U\0112RS0_
M>?\ P14_9=^+7[.OP'\?:Y\7]!U3P7K/Q:\7:7K>C>!]<BGLM>T30?#^ESZ;
M;ZCKVCW,<5QHFJZW=7EVQTR[1+^/3;#39[R*"2<6\7F>).#EC^&L7Q)Q!AGP
MYQ14QN78;ZC@^(*&9Y5Q/2ITZ=%8["X&EB<0\+'#4(NK3:M&$:;]I*M5KNI#
MW? S,HY/QWEO _!N/CQOP#0RK.L?_:V9<&8K(>(N \17J5<3_96/S;$8'!K,
M*F.Q4XX>LGS3JRK+V4,-A\+&E4^_?VV[VZT_]C?]JR[L]XN8OV=?C,(GC++)
M"9?A[XAA:XC9&5D>V21IU<'Y&C#8(&#^,_\ P;PV5K'X$_:@U%-GVRZ\6_#*
MRG("^9]EL-'\83VF\A0Q3S=2O?+!9E#&0JJEF+_O5\:_ Y^)OP:^+?PV4;F^
M(7PR\>^!U7>(]Q\6>%=5T$#S&(5,F_QO8@+]XG K^<;_ (-\?&HT/X@_M.?!
MW5BUGK6J>'_!/C*TTJZ0P7ENW@?6?$'AGQ,K0N%E62&Y\9:!!=1.-T+QH-J$
MR9^5X8_VCPE\1L+1UQ&&Q_#N-K0CK*6%>.H+F:WY:?U>M4D]DH-MGZ%Q]_L7
MTC?!#,,5[N#QN3\:Y5A:LM*<<P658M\B;T52LL=A:,5>\I58I(R/^"[7_)V/
M[+7_ &(UE_ZLF\K._P""SO[/7B']G7]HGX<_MO\ PA:?0D\9>*=&N]:U'3X@
MD7AGXS^#8[74]#U@A0L*IXQTG2#?/ 4<7>J^'O$-U?.[ZJJOZ-_P6V^&WQ%\
M9?M2?LN:CX0\!>-/%6GIX4M-,>]\-^%];UVT34D^(<MPU@]QI=C=1)>BWN;>
M;[,S";RIXI FQU)_>S]J#X!>&_VGO@/\2/@CXG,4%KXVT">VTK5I(1._A[Q1
M8NFI>%O$<*#$C-HNO6EA>S0Q/$U[9QW.GO((+N4'ZK#<6T^%LJ\(,;.=.O@*
MF6\1Y;GN%3C54\LQN8X*%>-6BN9N5%QCBJ=.27M)X=4V^24T?GN8>'%;Q!XA
M^DME5*E5PN<T<]X'SOA',)1G0=+/LKR3,ZN%>&Q,N10CBHSG@*]:$I*A2QGM
MTO:4Z37\J'[4/QUT+]I?]NO]@?XY:$8(3\0/"/[,E_K^DV\HE3P]XOTSXX>*
MO#_BSP^"7>;RM,UW2+Z*TDN0D]S8FUO#&L=S'G^RNOX,O@O^R?\ M*> OVQ_
M@UX"\3_!?XDVVN>$?CM\/X]2>/PEK]SHB:9H/C[3;K4=?L=>6P_L>Z\*+:6E
MYJ\?B."[.C3:8LFIK=_9BTM?WFUY7C5ALLP%/@O+<IQ='%X'!93CH86=&M3K
M\N$J8NG/")SISGS)46H0J-_O53<U:[2^A^BQCL]SBKXI9WQ%EV*R[-<TXCRB
MIF%/$X:MA7/,J&6UJ68R5.M3IN$I8E2K5*"3>'=:--MI1E+\E_\ @HY\%/\
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MOM.TK2)[R74->OM0NTC&FZ)IEK%9P2PV4(MVG2W%S<W<\Z_M4^-/B/\ #O\
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MI'1K_6M6EB98HP5M[*TBO-6U.>STC3M0O;;^7']E'X#_ !/_ ."KW[9OBO\
M:>^,NC/8?!31_%]CJWC $2G1;VVT&WM%\'_!3PS-+%$-26+2+72K?Q9>P1Q2
M6^B/>:IJ$MIKGB/2A>T/^"KD/[7OQU_:[\8Z#J?PC^-/BCX0?"O6+;0?AOHO
MA3P%XSN?#$NB3:;I-YJVO:=J=CH&I:;>:UXHF>26YUXQ7SP0)8::B/9:7!;#
MZ0^%7_!2+]KOX)^ /#7PP^&'_!,[5O"?@GPGIZ:?HVC:?X*^-(1$#-)<7EY<
M2>'7N=1U74;EY;[5=5OI9[_4[^>XO;VXFN9I)&KAKA;,N%^#WCN&9Y9C^+^*
M<!"%;,*F;Y=A*7#V4XJE3KK#X98G$TJM7,*O-"52I&/LZ5>G%WMA:?UJ..O$
M'(^/_$Q93QW2S[*/#;P^SBK4PV2T>&\[S+$<:<1X"O6PCQF.>!P.(P^'R;#N
M%:%&C.I[;$82O*/(I9A6>7_TN>,K.UOO!WBO3[LQ1V5YX:UVSN6E0-"EK<:7
M=03&2,LBM$L3L70L@* J64'(_EV_X-Z;Z[C^,/[1.F)YGV&[^&OA2^N<-B'[
M7IWBBXM[+S$ZM)Y.J7_E-_"OG#^.OW/UW]H+Q)<?\$__ !9^T7\1/"%Q\,?&
M$O[/?B_QCJW@O4(M1M;G0O$[>&M5BTO1C!JUM9:G!)J&K?V?%:6]]!%<QF^@
MBF9F!E;\C?\ @WD^'MU#HW[2WQ6N;:066H:GX ^'NBWF,1/=:-:Z_P")/%%L
M&R=\D46N^$)2-J^6LH.7\W"?&\-X>IE?AKXJQQB@KXWA_*H*,X5:<\=A<RJ*
MO&C4A)TZOLU6IU>>G*473C[2+<;-_J''&,H9_P".GT>9Y6ZCY<JXQXAJRG2J
MT*M/*,?DE&6$GB*-6,*V']L\-6H>SK4X3C6J>RFHSNH_THT445^-']/A1110
M 4444 %%%% !1110 5+!_KX?^NL?_H:U%4L'^OA_ZZQ_^AK0!I:]_P A>]_W
MX_\ T3'616OKW_(7O?\ ?C_]$QUD4 ?QH73_ /"/?\%QC)XR:(+)^V1 UN\K
M;(TB\0ZY&?!3,TSD*8X]3T$@[@N]1Y:JNQ!_9?7\W'_!7/\ X)M?%[QU\4YO
MVM_V;-!U#Q9K%]IVB2_$?P7X7:=O'=OXB\+6UIIFB^-?!>EVBK=:Z\ND6&DV
MFHZ5HI?Q#;:EI<.K6%EJ@U&_DTOR7PC_ ,%AO^"@_AC0]-^&_B?]EJ+QG\4K
M/3HK&'6=9^'?Q,TCQ'K-PC?9H-3UKP5HR6"7=].^Q+I=%30K.YNMQM[6UW^4
M/Z'XDR&MXEY'P;F_#&-RNOB,KR'#Y-G&6XC'X?!8C 8C"Q@Y5'3KSBO8\[K>
M\W&4J*P]2E&K&;]G_%/ O%^%\".+/$[AKC[*L_PF"X@XOQO$_#&?8+)\;FF#
MSC"9A4J*GAXUL)2J2>*]BL,^2*J0IXEXVAB)X>I2A[?]EO\ @JU_RCY_:5_[
M%CPS_P"K"\(5_,[^Q7I7_!2ZS_9T^)GCK]C/Q/J5G\*O#OC?69/&WAOPY/X(
ME\477B>S\(^'+W5]4TK1_$FE7.KZF\?AM]"BCMM#O)+ZYF@\K3=-GO Y?]E?
M''_#9WQ8_P""3/[36I_M/^$M>E^-'C;6)M<\*>!=.\)V^G^(=(^'</B?X<3Z
M7I'_  AV@6;:IIQTZ;3?$^H?8]9BN?$D.E!+W6[B21GD7>_X(/>#O%_@W]E?
MXF6WB_PKXD\*7.I?'K7=1TZW\2:'J>ASW^GCP#\/+$WUE%JEK:R75F+VSN[,
MW,"R0BZM;FW+^=!*BF0YA'@OPXXHI3I\.<08C <<4,/4PV*C3S3*\9'ZIED*
MM2A&?LG547"I&EB8P]R<)3BGRM%<7Y/+Q2\;^ <12K<;<&X/./"?%XVCCL!.
MMP_Q!EM3^TL]J8>CBZE/V\:#FJE&>(P4JMZM*K3A*4'--? W_!$?P7\"?C!\
M>/&WQ>^*'C#Q?XS_ &K?"DFK^-M#TGQ=+%/H][9>('.EZ[\1K?59K^^U?QAX
MOL[O5Y;;4FUE+&#17UVRU2SM=6U'RM4T;^K.OY$?C'\*/BI_P3__ ."IUC\5
MOA=\-_'.N_"W5_'5KX_TR'P7X1U_6M.O?A[\299['XB^"+./1[&YLQ?:)-?^
M)=,T/23)++:+:^&-3:W0S6BU_7:I#*&&<, 1N5E;!&1E6 93ZJP# \$ \5\M
MXP*..S;).)<)CIXO*>(<CPN(RZA.K2E_92H1C[?*J=*DHJA2P\J].KR.,9*O
M7KPE>4)-_?\ T9W/*>'.*N!LQRFGEO$?!?%>/P>>8NE0KP_UA>+G-X/B"MB,
M1*<L77QD,+6H>UC4E!X7"82I#EIU80C_ "5?\'!?_)ROP6_[(;'_ .I]XPKP
M;]N>Z_X*A_#GP'X8\&_M@_$3Q9??!3QY?:9;6]WX7OO!M_X6UJ?3HH-6BT75
M?^$2MM N;N_LK>W&K:?X?\5R6=EJ-UI9U"Q,[Z5)?67UC_P7E^&/Q)\:_M$_
M!34/!OP]\;^+;!_@^FC)>^&?"FO:]:MK"^.?$TYTI;C2K"[B.HB&^LY?L0?[
M3Y=W;/Y6V:,M^Y_[;/[.2?M/_L@_$3X1)8QR^+)_"-KX@\!&XC"36?Q!\)VT
M>K^'(HY) &LFU6[MI?#6H3A2\6EZUJ*&-P[1M^A9?QA@.&N'?!Y8O!9/C\)B
M?[4IX[$XS#4<3C\FC#'8.%/'8"M)RE@JE&59UZW[N3KPP\8+EG",X_C&<^&F
M;\=<;_27EEN:<391F6!605\IP66X[$X'*.)YU,IS&K6RK.,+",8YK0Q%/"QP
MN%2K06%JXV=27M*=2=*?"?\ !,WX8_LW_##]DSP;K?[.>L:EX@\'?$".?QMX
MF\:^*C9VWBC5_%$<2Z1KEOXFMK2633]!F\*S:5+H']@V,\VFZ5_9]Q-'>:G<
M7M[K6I_F4W[6/_!&O]F75-4^&?P@_9G;X[:G:7&JVMYXC\,?"SP[\3H;R]M9
M\WME%XZ^+^OQ>(M4T?SHY&MKKPQ!J_A>:"T6[TZ6>R:TN)N$_P""0<OQPU3X
M/_M=_L9>)/"?C[P*?%?PV\:>(OAMXF\4>%?$N@Z7X4\6>)=!D^'OB&PN=3U'
M34CLKF2^U#PMKFG:;&@G#Z3XGO8[::7S]OS#^PI\=OC%_P $S_'7QB^'WQ$_
M8P^(?CGQ]XXDT?3M).GZ=J6B>)[>[\+G5B^DZ3J<?A#Q+'XD\)>(FU6QU%-0
M\/SRVB_8K34K:#78;ZV:RXZ7"<UGOB(J^:YKQ#F%'%Y;C<%DN%XFH9'+B#!X
MMSK4L=F&-=J5995A\14IVIQIPH5*=:G"-..(H1/2Q'B+3EPEX*/"\.\/<%Y-
MB,MSO*<UXIS#@/&<60X.S/+HT,/B<IR?*H\U?#2XBQF#H5W*O.O6Q=&OA:U6
MI6G@\74>+_P3]\;^$-3_ ."O7A+Q#\(O!VI?#/X=>./%GQ=&D?#[4[6WTVY\
M.^']7^%_C75AX?FTW3[B:RL;;3]4MH;C3M.M99+.QAM;&"!5BMXT7VW_ (+Z
M_##X=^!/B=\#_$G@SP5X:\+Z_P#$;3_BAK_CS5]#TBSTV_\ %VMPZKX0\O5O
M$%S;11R:G?J;V\;[5<F28O=7#LQ>5V;+_98\#?M,ZO\ \%?OAU\7?CE\%/$_
MPZUWQ[KGC7XE:[I\'A_6'\/^%]*\6?![QF^AV=[JQ6]MK&>VMKC3M-O[;4[Z
M+4K+5VDTW5K73]86XTVW^UO^"\G[-WQ-^*O@KX(?%CX;^$=;\96WPPN_'.A>
M.-/\-Z=>ZUK-AI/C!?"MWHFNC2M/BGNWTC3KSPYJ=IJUW##*+1]5TZ6X$5JL
MTT?T.)S;!X3Q<X JO'T:&&Q/!E#!XJ<,SCC,-4KRHY[##4,1CU-0QS^M>QA2
MQ%6[Q%9TJJ2E.+7Q>!X=S',?HV^,>&64XK%X_ ^*.*S/ 4JN0SRW'4L+#$\(
M5<;B\'D\J<JV4Q^H?6:V(P=!I8/#1Q.&E)QIS3_0CX=?"SX+?LP?LN:]\<OA
M+\(_ /@GQO8?LR2^+M9U[PSX5TRPU?7YM!^'@\7F#4KBTMEN=0BNM7L([R>V
MD9TNKI4>1'D5"/Y=_P#@GU^T-X&^%OQ&^+GQA^,'[-/CK]J[QYXFDL7TS6M.
MT2R\4P>%]2UV_P!<U;QEK6KVNJ:5JMI_PD/BFZ;3OL.IB*&[MK6TUN""3RM2
MN5K]UO\ @G!^UK\5_P!L3P?XA_9]^*_P'U'P/X$\%? 2T\#ZS\2"NO)'XPUC
M[%IG@6ZLA'JF@66C:5J6IZ-)JVKRZ7#<ZE)!-;2[5^RQLE?EY\$]3_:Y_P""
M-OQM^*VE:Y^S]XB^,'PB\=BULIM<T>'5+#P_XKT[PG?ZXW@WQAH?C31M&\6Z
M=X?U6#3]8U675_">MV+:C'!J7V>^ALFAL=1KPN%\+BL%'Q&X:S>%',^*\>\J
MK87 5>)(8+$9MEM.O4JO"8;.Z=>4Z+IT)1J3PSK0YX5*>'Q$*=*565/Z[C[,
M,OS6?@EQSPU5Q.1>'>4+B#"8_-\-P-4S;!<.9[5PF'H+,<=PM7P<(8E5\53G
M0I8]86I[.KAZV,P=2MB(8>-;SC3_ !7K/C'_ (*5_ KX]_LZ?LP?%+X#>'=4
M^*7PJM_$/A*/P;?Z;IHFU+7;;PQ\0;B!='T6VT31=$\4^$[ZY@UE(X;>W62[
MUG4;C8US+*?[-Z_%']G?_@J!^T'^U'\;_AQX(\!?L6^+?"'PJU767A^(OQ+\
M37/B;7K+0-%BLKZ2>[@U2V\*^%_#6CW,5Y!!! FHZCJTNH2>9:6]BMS(AB_:
MZOSGQ1QN95\5P_@LUR7#Y+B,KR=82C0AGE+/L6\'&O-8>&.Q=.=24:M)PJ.%
M.M4G5Y:CG)IRL?M_@!E61X/+^,<UX?XIQO%6"X@XFEF.)Q=7A/$<(9;',Y8.
MC+&U,IRVM3HTZE"NJM%5J^&H4L.JE"-*":I\S_DH_P""R?\ Q.O^"E/P.T?4
M_P#D&KX"^"NDA9OFA-A?_%'QG/=MLE\R+8TE]=)(-FQMA#HQ#%OZE/BS\+?!
M7QM^&_C'X4?$32O[:\%^.M%N="U[3UFDMIVMIRDL-U9W41$MGJ.G7D-MJ.FW
MD?[RTO[6VN4!:( _S+?\%^/!^K^$_P!H7]GCXVZ=!)''JWP^F\,VM\4,EHFO
M?#7QE>>)H%F X29H/'-HRH[(;F&U<1;OLTQ3^HCP=XITKQOX/\*^-M%F2;1/
M%_AK0_%.DW"N'CETK7]+M=6L)EE 5722TNXG#@*&4A@ #BO1XWKU?]2/"3,\
M%5G36%R_-J%.O1E*$\-C\#B\#%SC.#3IUE6HRG3DI*:E1<E9QN>)X4X3#_\
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MW!I^M:;X7\0:7<1W-QI\4KW%_"OC+2?!^K6MK:W=C>V)U**T34?UP_X)?_\
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M.LXQ#:6&GVT%G96L0)(BM[6V2."",$DA(HU4$DXR30!<HHHH **** "BBB@
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M6%EB)YCA72AAZ&)IXNG&.%7L9T9JS11117SY]F%?A7_P4I_8M_:<_;9_:E^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AJO_(-O_\ KTN/_135
MY-3OCYXR^)'@3X2_$_Q3\*/A'=_&[Q]X;^%OQ \4^"?AC9>+=-\$W/Q%\=>'
MM)BNO"/PUM_$VK:?J>G^'KGQU?RRZ9!XDOK*\L-":$W-Y974;A!_/G_P\K_X
M+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\
M^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#
M_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\
M@MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_05
M17\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\
MG04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*Z
MGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X
M+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\
M^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#
M_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\
M@MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_05
M17\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\
MG04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*Z
MGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X
M+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\
M^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#
M_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\
M@MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_05
M17\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\
MG04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*Z
MGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X
M+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\
M^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#
M_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\
M@MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_05
M17\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\
MG04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*Z
MGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X
M+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\
M^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_0517\^O_#RO_@MK_TKJ?$#
M_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\ G04 ?T%45_/K_P /*_\
M@MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!0!_05
M17\^O_#RO_@MK_TKJ?$#_P 6'? __P"=!1_P\K_X+:_]*ZGQ _\ %AWP/_\
MG04 ?T%45_/K_P /*_\ @MK_ -*ZGQ _\6'? _\ ^=!1_P /*_\ @MK_ -*Z
MGQ _\6'? _\ ^=!0!_054L'^OA_ZZQ_^AK7\^'_#RO\ X+:_]*ZGQ _\6'?
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M4?\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04 ?T%45_/K_P\K_X+:_]*ZGQ _\
M%AWP/_\ G04?\/*_^"VO_2NI\0/_ !8=\#__ )T% ']!5%?SZ_\ #RO_ (+:
M_P#2NI\0/_%AWP/_ /G04?\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04 ?T%45_
M/K_P\K_X+:_]*ZGQ _\ %AWP/_\ G04?\/*_^"VO_2NI\0/_ !8=\#__ )T%
M ']!5%?SZ_\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04?\ #RO_ (+:_P#2NI\0
M/_%AWP/_ /G04 ?T%45_/K_P\K_X+:_]*ZGQ _\ %AWP/_\ G04?\/*_^"VO
M_2NI\0/_ !8=\#__ )T% ']!5%?SZ_\ #RO_ (+:_P#2NI\0/_%AWP/_ /G0
M4?\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04 ?T%45_/K_P\K_X+:_]*ZGQ _\
M%AWP/_\ G04?\/*_^"VO_2NI\0/_ !8=\#__ )T% ']!5%?SZ_\ #RO_ (+:
M_P#2NI\0/_%AWP/_ /G04?\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04 ?T%45_
M/K_P\K_X+:_]*ZGQ _\ %AWP/_\ G04?\/*_^"VO_2NI\0/_ !8=\#__ )T%
M ']!5%?SZ_\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04?\ #RO_ (+:_P#2NI\0
M/_%AWP/_ /G04 ?T%45_/K_P\K_X+:_]*ZGQ _\ %AWP/_\ G04?\/*_^"VO
M_2NI\0/_ !8=\#__ )T% ']!5%?SZ_\ #RO_ (+:_P#2NI\0/_%AWP/_ /G0
M4?\ #RO_ (+:_P#2NI\0/_%AWP/_ /G04 ?T%45_/K_P\K_X+:_]*ZGQ _\
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M.CZO;(\GV#Q!X>U%+W0/$>F.[2Z5KNF:CITY\ZUD _CS_P"#;+_E-#_P7_\
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M_M >%[CQ!<I+83:YKWC'XT^-/"FGV=_!<HD%SJFL_'WX<_##Q#:- T0D\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^JZ /$ T6_FN+JPEGD^Q* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK^:3]M+_@KW_P %9OV?OVGO
MBW\'/@+_ ,$/?C1^T9\(_ FNV>E^"?CAH'B;QU/HOQ)TR?0]+U*3Q#IJ>&?A
M)X@TBSMFO;VZL181:UJ-S9O9O!?RQ7R7%K!^>_QW_P"#F?\ X*F_LO> 9OBG
M^T7_ ,$+O'_P4^'$&K:;H,OC;XE?$7XB^$_#:ZUK#2KI>E#5-6^"EM;-J%^;
M>X-K:([33)!.ZH4AD90#^V.BOR:^,O\ P59\-_L^_P#!-C]G[]O[XE? #XLZ
MKXJ_:+\#? 2\\"?LN_"VT?QY\3-3^+G[0'@FT\7>&OA/IUX^FZ&]X^G&348-
M0UV7P_::B]EI4\MGX3N==N+/PU<?C?\ %[_@X#_X*S?LV^"&_:3_ &C/^"#G
MQ&^&7[)]I<:3+XC\17?QV-SX\\#Z'JNKMIJ:QXRTZ'X:27_AAMUYI=I#;^,_
M!/@[3VUEHM.N];L6UNQ>S /Z]:*^//V7/VZ?V>?VMOV.?!O[='PV\52:9\!O
M%/P_U_XA:KJWBZ&#2]3\ 6/@K^UH/B)I'CBTM+K4K73=8^'^I>']?TSQ&+&^
MU+36ETF>^T?4=5TFXL-0N_P1OO\ @XI_:AO_ (&:W_P4)\!?\$G_ !YXK_X)
M7Z!XVN_#TO[15U^T=\/]%^-VK^!=)\>/\/M=^+VF?L^-X<O;^+1=*\0K/H[>
M'I?$L]@=3L;AM1\?:1I::GJ.A@']6-%>7_#+XR?#KXN?!GP%^T!X+\26-U\)
M_B3\-?#7Q<\,>++^:'3=/D\ ^+/#-GXOTK7=0FNI4@TVW70;Z&]OFNYD2P59
MA<NGDR$?EQ_P3-_X*3?%S_@I9\;/VK_'_P ._A=X0\/_ /!./X2>*Y/A%^SM
M\;]1C\21?$W]H_XD^'KBRC\<^--"MKC4E\/6OPETI(KX:9*VA0:O?'7O#44F
MHQZSI?C+P_HH!^R]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#G[34T_[3'[+6FNC0Z3#+:6EU\1])\,>%XV91)'!\*/%WBOPMK=\%?S[_P"
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MXPNKF\M=&TG7/$*S:MXBU;QSK>HZ]J;ZA%%<>5I=M;:=:+922W7[,4 %%%%
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M)Q)9?";P_P",M3OO$MSH0F=KC3=#\7?%0:GI%OHS VEMX=^%/@F73"M@\*D
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M$P-=V\%EX;L+N'Q-XG\.078!^ GQIN/VA?'WP)_X)]_\&S/[-OBB70OCM/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!I_B[7?#6MZX-2\2Z9KO@ZY@T"_\)3"T2[?ZB?\ X)O_ !=\:_\ !*[XK?\
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MX;C\!/ '_! O_@I=^S9X?L_@_P#L@?\ !?/]H#X6?LY6#:EIOAGX>>/OV?\
M0?BEKOPV\+/.9M+T;PEK^H_%33;-%@4B.2'PMI/PTTNUG%U?:;IUM_:,]G%_
M5E10!\!?\$Z_V'_$?["7P>\7^ /''[5OQ_\ VR/B!\1?B9JOQ5\<_&+]H;Q'
M/KOB.YU_5/#GA?PM_8WA>SNK[6+KPUX-L=-\):?-I_A^XU_76M=0N]3EAU".
MSGM;"R^_:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_LUY%X@B^(FE:VDC/KFDW0B6%_ZSJ* /D?\ 8=_8A_9^_P"">7[.?@S]E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAB_V-?\ H[G_ (*??^)D7W_S!T?\0Q?[&O\ T=S_ ,%/O_$R+[_Y@Z_H^HH
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MAB_V-?\ H[G_ (*??^)D7W_S!T?\0Q?[&O\ T=S_ ,%/O_$R+[_Y@Z_H^HH
M_G!_XAB_V-?^CN?^"GW_ (F1??\ S!T?\0Q?[&O_ $=S_P %/O\ Q,B^_P#F
M#K^CZB@#^<'_ (AB_P!C7_H[G_@I]_XF1??_ #!T?\0Q?[&O_1W/_!3[_P 3
M(OO_ )@Z_H^HH _G!_XAB_V-?^CN?^"GW_B9%]_\P='_ !#%_L:_]'<_\%/O
M_$R+[_Y@Z_H^HH _G!_XAB_V-?\ H[G_ (*??^)D7W_S!T?\0Q?[&O\ T=S_
M ,%/O_$R+[_Y@Z_H^HH _G!_XAB_V-?^CN?^"GW_ (F1??\ S!T?\0Q?[&O_
M $=S_P %/O\ Q,B^_P#F#K^CZB@#^<'_ (AB_P!C7_H[G_@I]_XF1??_ #!T
M?\0Q?[&O_1W/_!3[_P 3(OO_ )@Z_H^HH _G!_XAB_V-?^CN?^"GW_B9%]_\
MP='_ !#%_L:_]'<_\%/O_$R+[_Y@Z_H^HH _G!_XAB_V-?\ H[G_ (*??^)D
M7W_S!T?\0Q?[&O\ T=S_ ,%/O_$R+[_Y@Z_H^HH _G!_XAB_V-?^CN?^"GW_
M (F1??\ S!T?\0Q?[&O_ $=S_P %/O\ Q,B^_P#F#K^CZB@#^<'_ (AB_P!C
M7_H[G_@I]_XF1??_ #!T?\0Q?[&O_1W/_!3[_P 3(OO_ )@Z_H^HH _G!_XA
MB_V-?^CN?^"GW_B9%]_\P='_ !#%_L:_]'<_\%/O_$R+[_Y@Z_H^HH _G!_X
MAB_V-?\ H[G_ (*??^)D7W_S!T?\0Q?[&O\ T=S_ ,%/O_$R+[_Y@Z_H^HH
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MAB_V-?\ H[G_ (*??^)D7W_S!T?\0Q?[&O\ T=S_ ,%/O_$R+[_Y@Z_H^HH
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M (+>_P#!?O\ X+*_M(_&#P;_ ,$CM ^'/P(^%?PLL7\0166J^'?@=JGB+2_
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MOANTUT^%[Y9(XFAO?"T.J0^';NV"M':W&F26\4UQ%$D\GZ-4 %%?R4_M*_\
M!:C_ (*"_M<?MW_$S_@GC_P1 ^"7PJ\;ZE^SQ?ZMH_[1/[6'QP:?4/AAX;UW
M2IY=&U.R\.BTU73](TG1M$\4VNI>%[;6-2MO&VO?$'Q!IFKGP?X+B\+^'KCQ
M/K7SI\;_ /@IW_P<&_\ !&?5_AU\3_\ @I_\+?V</VP?V/\ Q+XJA\'>-/B=
M^SE9KH/B/PSJ&JA;NP6WUJST'X?V7A_6A +R/0+3QM\+8?#'B^?3+CPXOBK1
M=7OK/6T /[8:*_/;]J?]LBUT7_@EY^T#^WC^R]XD\.^*H-)_8R^)7[27P.\4
M7]BVK>'=2FL/A/J_CKP3J.J:09[26>&.YALFU71+N6VN(+B&YTO4(X9XKB%?
MY-_V5?\ @M9_P79_X*N_!#X6_"__ ()T?"WX76GQW^%?AKQ+K_[:_P"U)XY\
M*>#O#?PPL_%6M?$_QW#\(_AM\.M&\976L^%+6>[^$FF^$]4\12Q:3XC\2:UX
M@O-9>QTCP?H7AJYUK7P#^]&BOE7]B"Y_:KNOV4?@G+^W!8>&M-_:N'A26#XU
MVW@]] D\-MXJM=:U6UAO-+;PM>W_ (>\K4M$ATG49DTBX6SCN;J=$M; JUA;
M?5)(4%F(55!+,2   ,DDG@ #DD\ 4 ?F+_P5Q_X*7^ /^"5G['/BW]I'Q/I-
MGXU\>7VK:5X!^"'PHFU.72[KXG_%'Q"TK:?HPN;:VO+JUT70M'M-7\7>*+Z&
MV9XM#T.YL;)FUK4M(M;KX#_X(+?\%M/C%_P5M\3?M=^"OC/^SKX0^ 7B3]E^
M?X66TEKX7\1^)-4N;^_\>:A\3])UO1=?TGQ+80W.DZCX;O\ X=>6S1W;-))?
M7%M<6<$EF))O@OX)!_\ @OY_P6UUO]I6^$GB+_@F9_P23\1'PA\!X7>.Y\&?
M'7]IU+V#4I/&T$3B2UUK2QK>D67CEIK:6: ^"?!GP8MM6L;>'Q]K%I<>&_\
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M=G6+<^))=/O+BVE@LKT6L=U#I^G^8ULOV?;_ /!/;]CGX$>+_P!K/]JWX;?
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MN2*UL=/L+.":[O;RYEBM[:VBDFFD2-&8 'Y)?\$<?^"Q/P1_X+!? CQ+\1O
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M\47_  ;5?\I=_P#@X9_[.?\ $7_K3?[3M?J=_P %>O\ @L'\7_V5/CA\"_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_\ :%_Y(#\<
M?^R/_$S_ -0O6Z_S9/\ @RI_Y2F_'S_LP#XI_P#K17[*M?Z8/Q1\+WGCCX9_
M$3P5IT]O:ZAXO\"^+O"]A<W9D%K;WGB#0-0TFUGN3$DDHMXI[M))C'&\@C5M
MB,V%/^7;^R=_P1%_X.=_V!?BEXC^*_[(?P U'X2_$+7?!VL?#'5O&OAKX_\
M[#>L'6_ NI^(O#GB2_TJ.R\=_%S5H8;#4M<\&^&M62:31[#5XSIL$3M:I+>6
ML@!_I9?MF_M-> _V-_V5_CS^TW\2-;M-"\+_  <^&GBCQ>9KIH?,U/7;/39H
M_"GAG3(+AXX[[7?%?BB;2/#>@Z<77[?J^J6=J6196=?\V'_@SN^"?BCXE?\
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MITIG5-1O-<^&_C+2_B'83.A51%=>&[SPA QA=9U$SERH,)K\YOCU_P $./\
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MX:U&\5'BOH;_ .,WAS5?$32Q0/XGM&G-W;R 'ZA_\&Z?_!P1XR_X*JZKX_\
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M]GQ27J@'R-_P>X_\GH?L;_\ 9L&O?^K6\2U_<MX#\&^$=)_X)8^%_ ^D^&-
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MCB]^+?PI\30Z?I=EX!\=^*[Z[T_^Q?!^MW9\0);_ /"/R>3;PP:G--=VZ/\
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MZEINI^'Y=/\  EM##X-UG2;O7O$FH:G[KX6_:?\ ^#O_ ,#^&?#_ (+\%_\
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MW^GF]CMY$A\56/Q3\!7/@N:#[2CI'>)XMCT86<D86X6X:,6SI.R,/Q,\8?\
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MU"1_B'IVK?$OPU>6CK;_ !3\/A+7P3#XZOKB:RUB"UM9Y8M.74_]1ROY//\
M@W)_X)T?MD_L0_M1?\%9/'G[4'P9O?A;X1^/?Q8\%7GP>UJ[\5^!/$,/CS3?
M#_Q!_:$UO4]5TRU\)>)]>U"RTZ+2_&_A:[AN-<M-*^UC51#:I+<V6HPV8!_6
M'7\/_P#P=Q)8ZO\ M6_\$._"WQ!M+:3X,ZO\?/BBGC3[3MFL]0L;GXD?LFZ=
MXHM-6MK@1V7V:T\*W5S]E\Z=%N8M3U:.8+%!OK^X"OPV_P""^?\ P23N/^"M
M7['NG_#_ , :UX>\)_M%_!7Q7<?$OX%>)/$L<L6C:GJ%QH]SI/BKX::YJ]M'
M/=Z#H'CZR_LN:36+>UNQI_B7PQX4OKRVETVTO4(!^Y  4!5 55 "J    ,
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M4D\6:MH^JRWD<O\ 8JZ?&MSXNMY+^VG:*WE_:;_@AK_P3]_:\_9,_P""D?\
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M+;Q7::[ITOVJTOK6WMOAM!>6^G6EXTDMC8Q:^NJV<;_NO$1O U\_Y(ZAI/\
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M#;P_\6OV;/VC/&9_X*-_&ZSUOPK_ ,$'/^"'>B>&?@;^P'\*1I[ZE<_M:?M
M>"(O#?@#P[\2[;PUJTNGGQJ=.U.U\+VGA,:U)I>G?:$\(?VU<Z7#:?':V?\
M:;X,?\%Z-6O_ (]_LQ_!K]LS_@GK^TA^PAX<_;5O;?1/V6OB[\4O$'A+Q=X1
M\=>*]732'\+^$O&-AH%KIVK_  T\1^)GUS2-.L]&UF&_U:PU;6=&CUG3].TF
MZO-:TT _H7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_@S_ &AO^#9/_@I%^R_^
MW'XX_;<_X(_?M7?#_P &7?B;QEX\\;^'/#?C76;WP)X_\!P^/9[[6]=^'2M+
MX)\:?#'XF>!9=0N9]+TVU\8V^BVS6!T&VUW1]1GTRZ\2/_>910!_ Q\7O^"&
M_P#P<>?\%2[SP)X&_P""G'[=OP9T/X'^%?$/]OS:3I3>&=2ETW4K>UN=/MO$
M>E?"'X$_"SX6_#[QGXIALM4U&STO4?&'C'2+O2]/O=6CM]4MA=O97W]F'["O
M[&/PB_X)]?LJ_"+]DGX(0ZDW@/X3Z'=6::QKD_VKQ#XM\2Z[JM]XD\9>-/$%
MP/W7]K>*_%.K:MK4]G:+#I>D17<&B:+:V6BZ;I]E;_6]% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7)>/KKQE8^!/&M]\.=)TC7OB%9^$O$=UX$T+Q!J,FD:#K7C*W
MT>\F\+Z3K>K0PW$NF:1J.MI8V>I:C%;SR65G--<I#*T01NMHH _FS_X-XO\
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MXC?L]?&K5/'6DW]I"K2Z=<ZC\+/!7Q'^';SR71EL8&B\=%%GA=K[[!"5D/\
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MOE\9Z?H)-CHT2Q_1O_!8WX__ !5_;L_:-\"_\$&_V*_%%UHGB[XOZ/:>._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R'XY?&&Q^!7PN^(_Q3U'P-\2?B+9_#;X9^//B==>
M#OA/X9A\7>/_ !7:> M+AU2Y\(^"/#T^IZ1%KOCOQ(DPL_"&@2:C81:Q?QRV
M\FH687S#^#__ !$F_"O_ *11?\%OO_$%O#G_ ,_6OZ/J* /YP?\ B)-^%?\
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M_B"WAS_Y^M'_ !$F_"O_ *11?\%OO_$%O#G_ ,_6OZ/J* /YP?\ B)-^%?\
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M_B"WAS_Y^M'_ !$F_"O_ *11?\%OO_$%O#G_ ,_6OZ/J* /YP?\ B)-^%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LK7-=T3PQI&
MH>(/$FLZ5X>T'2;:2]U76]<U&TTG2-,LXL>;=ZAJ5_-;V=E;1Y'F3W,T<29&
MYQFLSQOXT\+_  W\%^+_ (B>-]8M?#W@OP%X7U_QIXOU^^\P66A^%_"VDW>N
M:_K%X8DDE%KIFE6-W>W'EQR2>5 ^Q&;"G_)[_:)_:C_X*!_\'./_  4=TO\
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M ."P/A76_P!C?]O[Q8G_  3XTSQE^S/%=P^%-"?3O $OA2&#P?<_&TZGX?\
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MEX=\?_#GQ?X7\?\ @3Q?I-GKWA/QKX*U_2?%7A+Q1H6H1">PUKP[XDT*[O\
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M4=4FO[J1+>T2:9U0_:W[17[3/P%_9)^&-_\ &;]I+XH^%_@_\+M+U32-$O\
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M5X-,\7^&[?5#:7B:7<ZWH=A;ZE)97T=E+/)972P@'C'P1_X*B_L[_'+]O?\
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M2VK?#[58?#\-[%:W5PS)>ZOXA^%/B'X-^)I]+TV22.RU+PQ\1;AQ)/::G+&
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M1-*AU#7M,TC0],:^T:'6-4NUM6\16.IOHNC>(P#_ $9Z*_E?_9(_X+@_MT^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+!83ZWXP3P[\-K7S'??-=)XYNHH;>*=XUN+@06MQ^27_  7F\;>-/^"Q7_!
M[]D/_@J1X ^"U[\/X/AU\;?BEXH\9_#G_A('\:ZQX'^#EU\1?B/\ +WQ.^N0
M>'_#W]L03>(_A[\-]?USR-#L[?2=-U^[O#--IF@W&HS@!_P0&_X-L_V$/VJO
M^">_@']KC]M;PCXU^*WCO]H>7QGJG@GPUIWQ'\9?#WP]\,_ WASQ=X@\#Z#>
MV4'@+5/#VH:WXI\07'AZ^\47-[XBU/6=!CTN_P! T^V\/VT]GJMSJOXE_$[X
M>>)?^#>;_@X)\'>&?@5\0M9O_ACX-^)?PJU/2[WQ/= WGBG]FWXZVNBP^-?
M/Q#CL%L-.U:YT72-9\2^'XM7^RI!)K7ACP_\0+33]+U:"TLM._H6_P"#>_\
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MDG\0>&&GOI+[2[6-OL27EU_390!\;_MZ>+/VW?!7[-?BS7_^">7PP^$7Q?\
MVH[?6?",/@_P1\<-5N=(^'E[H=UXBL(?&5YJ5Q:^./AO++>Z=X:;4+G2[?\
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M2:7X*UK[5K]U9_V9ITPMFU&>UM));J  _D^_;<_:-_X/"-;^"GC'PM>_L3_
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M6FP-!=0V]UYWQ.UCP%XW^.J6TEO#J=E'8Z=-XBM]-O\ 5;>UN #^[ROXC/\
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M9I29)'<LQ_I(_:8_X+1_\$V_V9/V;K[]IG6?VJ_@U\2_#%WHDU_\._!_P?\
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MGHUIINFZ-H\\6E:7'=0VF@Z=:P""W'\6G_!#WXG_ /!%_P 6>%?B_P#MU_\
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MAW4M2\;>(/%++<PQ2>$M*\/W/B2SN&D@O],M9+:Z$'X&?\'._P"W%\0?%_\
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MA+P[:WV@^)$O_"^@^$-(NK*?3H?A/_@S3UOPKXEF_P""L?B/P)I*:!X(U_\
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M]_3+_@X$^,T7[1O_  ;0>,?VA(;.UTZ+X[?"O]A3XQQZ=8RR3V>GK\3?BY\
M_&HL+6>8F:6WL_[;^S0R3'S7CB5I?G+5\2?\'2/[=_P9_:T^%'P"_P""57[&
MOCSP;^TI^T[\?_VD?AQ=ZUX;^$?B?3?'&G^#;'1Y-;T7PWX<\1:YX;DU/0-/
M\5>)O&NN:1<'1+C5DU/PYX=T#5==\1V&FZ;?:+>7GVO_ ,%__@O'^SA_P;.>
M+?V>HKBSO$^!/PI_83^#HO=/\[[#>GX:?%OX!^#'O;0W,-O<M;WCZ*US$]S!
M#<.DH>>))6=0 >7?\$.?^"%?[%/CO]A?X _M8_MF^!M,_;6^.O[1OP+^%^M6
M>K_'B*\\8>%OA'\(;#P7HN@?";X0?#CPGJU[<Z3IMEX#^'^C>&]!'B&YM[G6
M8GL7T[P[<Z'X:AM=)'Q7_P $^O@[X?\ ^"8O_!UC\<?V)_V:Y]4\+?LQ_M!?
M W5/$D?PPEO[O5M)T*";X2:9\;]'TZ.?4[RZO)E\$^,M(\6Z1X-U.[DN=9TW
MPAX@GT"YNKP7FHZC=_T^_P#!%+_E$?\ \$Y?^S0/@?\ ^H3I=?SQ:S_RNL>$
MO^S7[G_UDKQ-0!_:Y7\/7_!T?=I\2/\ @IS_ ,$(_P!GO6)%N_"FM?'>RN]8
MT29G2RO4^)G[07[/_@BYDO?)C$DJMIOAR[M(F\R5[:*XO?L\<+74S7']PM?Q
M ?\ !VK#-\&?VK/^"+W[9ETO_%)_"+X^ZY#XKNEDDM7L9O!?Q'^!GQ4T-1=@
MR1Q_;]-T+QE(LGEQR6ITLRYN5DVVP!_;K?7UEIEE>:EJ5Y:Z?IVGVMQ?7]_?
M7$5I96-E:1/<75Y>75P\<%M:VT$<DUQ<32)%#$CR2.J*S#^./]B6TN_^"\O_
M  64^('_  4A\76D^K?\$]O^":>NW/P;_8CT'4XYVT#XF?'&TDMM7O\ XL16
MKJ+6YELKDV'Q6O)I(M/U.TAN_P!GK1;V/45\,:T@_J>_:W^!-U^U+^RS^T/^
MS=I_C[4?A?<?'SX+?$?X1P_$;1]-&N7_ (.7XA^$]4\+OX@M]&&JZ&=92PBU
M1YI]*CUS19-2MA+9Q:QIDDZ7T'\H'PE_X-7OV[?@'X)L/AK\"O\ @X:_:U^"
MWPYTJZU"^TSP!\)?AI\8OASX)TZ]U>[EU#5;RP\*^#OVZM&T*SNM3OYIKW4+
MBWL(Y;V[EEN;EY9I&<@'E/[17_*ZQ^R-_P!D@MO_ %DCX^5_<[7^6!\5O^"8
M_P"UMX8_X.%_@7^P?J__  55_:+\5?M&>-/ D.MZ#_P4&U&V^)8^-?@;3W^!
MOQ.\9KH6D07/[1>H^.FLTT'PYJG@<&R^->D0_P!D>)M0868LQ<:1J'^E'^QG
M\"_B1^S1^S#\'_@5\7?VA?&_[5OQ'^&_ARYT3Q3^T)\1[:_M/&WQ-O)M<U74
M[;5]?@U7Q1XVU47-AIU_9Z#!+JOB[Q'JEQ9:3;7&HZQ>WLL\S 'R1_P6X_:T
M\:_L/_\ !+']L3]H_P"&M^NE?$CPK\/='\)?#_65F:&\\/\ B_XN^._"?P?T
M7Q5I6P[GUCP==>.QXNTM"LD/VW0XGNXWLTN!7XB_\&_?_!##]ASQA_P3M^%?
M[4?[8'P#\#_M/?M ?M<:?K7Q?\2^)_C39R>/8_#GA7Q-KVI_\(;I'AFUUEWM
MK'4-3\/6]EXO\2>)W@F\5ZCXF\2ZM#-KTVE66E6UK^NO_!P;^SAXO_:H_P""
M/O[:OPN^'VCMKWCK3O ?AOXK>&M*@CDFU"_?X)?$/PA\6]?T_1[:&&XGO-<U
M;PAX-\1:/HVGV\33ZEJ.H6^GPE)+I77X5_X-RO\ @JE^R!\0_P#@EA^S]\+/
MB)^T1\'OA9\8OV6_!.H_"KXF>!_B=\2_"?@;6+#PSX&U+4AX/\<:;#XOU;1Y
MM5\%ZA\/G\.SW?B"QCETC1=;M]:\/W5TDNDEY0#^>[]JC_@FY\)/^"9__!R5
M_P $K_AC^S[K_BP? OXJ?&7X'_&/P!\+O$^M:IX@M?@K+K?QQUK0?$O@?PIK
M&KW]]?W_ (5N-9\/2>(-*EU)GUJ%=5?3]8U#6[NQ_MJ^_:C_ (.S?VH_C7H'
MPD_8W_X)V? 'Q'-X3\6?\%%OC%J7@/QEKNG:I?:9J%QX&\-:W\./"]EX#OKC
M3 VH6WAGXA>-/BIH#>)&M TFK:#X/U?PS<07VCZYJ]A<_D9^V[^W_P# O_@H
M/_P<L?\ !*WQI^S3<ZOXQ^#WP3^-?P5^ MI\9187%MX%^*GC?P_\9[KQIXRN
M/AO?3P1_VUX<\,Q^/-!TE]7+)_:MQ*-6T^V?PWJ/A[6M<_1?_@[P^%WQ)^'=
MS_P36_X*4_#SPG_PD>C_ +%_Q[N8_B/+!<R07%G/K?C#X5?$#X1SZA)%:W1T
M[P[-XI^&GB;PU>:Y)')%8Z[XO\-67D37&J6\; '[*? ;_@WD_P""2'P4^ GA
M_P"!VJ_L:_!SXQ75IH%EIWBSXL_%CPI9>*OBYXRUQ8_,U;Q(_CVZ \1^$Y]4
MOWGN(=+\$:CX=TC2;9X--TRSM[.UB0?S]_\ !++P[KO_  1]_P"#CSXZ_P#!
M)[X:>+-=UG]D+]J+P9J/Q#^&GA'Q7K-_J<_AC5M,^#]]\;_"FJ6<MPL<,GB'
MPYI6@?$#X5:GJL8DN?&7AVPT#5?$5W=ZQHFGPV']4_P3_P""L?\ P3F^/7P*
MT3]HCP?^V-^SUH_P]U+PY9^(M;7Q[\6_ /@3Q-\/S<1YN="^(_ACQ-XAT_5_
M!?B'3;E9;*ZTW6;:W-Q+&ESI<NH:==V-[=?RX_\ !.KQ%9_\%:O^#G#X]?\
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M_P"'?'L&DZW-/IMMJ<"VOQ"^'ANK;2M0DDM+/Q);:K;3PP_R*_LU_"_X+?L
M_P#!T1\#?V;?^"2_Q<U#Q7^S;\;/AGJ5[^U+\)?"OQ%G^)GPX\!S6WA/XP:Q
MXB\ ZQXE&H:\^H+\/;;POX'^(GAJY\3:OJ7BCPOXD\5+X/DU\Q:M=:3. =!_
MP5X_:/\ V:OVP?\ @X-\"?L7?\%#OC=H_P )_P#@G'^PUX'TGQ3XT\+:SXK\
M0:!X1^+/Q=\5_"_0/B2+76+SPZ\5_'K6IW?C[P=X'N&M"VH:3X/\&^,K+0[_
M $/4?%.LWJ^Q_P#!4>__ .#73]H#]@_XV^"_V?O&O["'PM_:"^'WPE\8>*OV
M</$OP"\":1\,/'UW\3_!OA_4M?\ !O@O4=9\)^$?#TOC#1_'VMVH\*ZSI_C:
MYUJT\WQ->^)(!;^*(+368/&?V^? _P"S#^P__P '0<7Q\_X*+?!WX4>-OV&_
MV[?A)IZZ+XD^-GPS\,?%GX4^$O&FE?"_P)\.-3\1:MH'BWPUXETVSU?PQ\2?
MA[H[^(]3@LA?>$?"GQ5LO$EU>V^A7EW _P#2[JW[._\ P;S:#X*_X63K?P)_
MX(S:3\/#:S7R^.]1^%W[$=GX/DL[>.REGN8O$D^A)H\L,4>I::[R17CJJZA8
MDG_3+?S #RK_ (-H?VK?B)^UO_P2+^ /BKXKZY>^*?'OPKU?QK\!-6\5:G/=
M7>K>(M*^&6JQVW@J^UB^O))KG4M7MO 6I^%](U/5;B>>ZU>^TR?4[V9[Z[NC
M7[XU\P?L;ZG^R+KW[/'@?Q%^PMI7P9TK]F+7;CQ5=?#U?@!X.\/>!?A5>SZ?
MXMUO0/%E]X:\/^%M%T#1$63Q?H^N07U_9:9'%JE];SWR3W<4\=U+]/T ?Q1?
M\&U7_*7?_@X9_P"SG_$7_K3?[3M?,W_!7C]H_P#9J_;!_P"#@WP)^Q=_P4.^
M-VC_  G_ ."<?[#7@?2?%/C3PMK/BOQ!H'A'XL_%WQ7\+] ^)(M=8O/#KQ7\
M>M:G=^/O!W@>X:T+:AI/@_P;XRLM#O\ 0]1\4ZS>K],_\&U7_*7?_@X9_P"S
MG_$7_K3?[3M?,?[?/@?]F']A_P#X.@XOCY_P46^#OPH\;?L-_MV_"33UT7Q)
M\;/AGX8^+/PI\)>--*^%_@3X<:GXBU;0/%OAKQ+IMGJ_ACXD_#W1W\1ZG!9"
M^\(^%/BK9>)+J]M]"O+N!P#V;_@J/?\ _!KI^T!^P?\ &WP7^S]XU_80^%O[
M07P^^$OC#Q5^SAXE^ 7@32/AAX^N_B?X-\/ZEK_@WP7J.L^$_"/AZ7QAH_C[
M6[4>%=9T_P ;7.M6GF^)KWQ) +?Q1!::S!]=?\$TM/\ &'_!:?\ X-F?$?[/
MGQFU1O%_Q/?P#\4OV=_#OC'Q#--=7M[X]^"&K6OB7]G3Q3KNHZA+)<7VH>'K
MFT^&-OKVK37AO-;.BZA>7UX+S4;QQ^GNK?L[_P#!O-H/@K_A9.M_ G_@C-I/
MP\-K-?+X[U'X7?L1V?@^2SMX[*6>YB\23Z$FCRPQ1ZEIKO)%>.JKJ%B2?],M
M_,^_?V-]3_9%U[]GCP/XB_86TKX,Z5^S%KMQXJNOAZOP \'>'O OPJO9]/\
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MGX>&UFOE\=ZC\+OV([/P?)9V\=E+/<Q>))]"31Y88H]2TUWDBO'55U"Q)/\
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M8:.4TR#P==26-G;!_&BV<UUI<@!^8?[-7_!7?_@I3^Q=^VA^SE_P3H_X+7_
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M^VF\$:-I7@+6?">IV;CQSI44\FO>-O#4T!MM0>.WN/+MEN@#]&O@GXW^"_\
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MT6Y,PMTT;X?Z?X1T_3K6&&'1H--P[2?IU^Q5_P $Y/V*/^"=WA/7/!W['7P
M\)?!O3_%-S;W?BS6+*\\1>*_&_BR6T\PV47B;XA>.]:\3^.=:T[37GNI=(T6
M_P#$,VB:))>WS:-IUA]LN1+]M44 ?!/[>W_!,W]C;_@IAX-\#^!OVPOAA?\
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M_B#5/M5E:^*]>UFT\/6,.H^*_$=W#IVA06%L'U:6*19+:UTZ&S^S:* /B/\
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MSXI_X$-_\:H_X2Z3_GQ3_P "&_\ C5 ';T5Q'_"72?\ /BG_ ($-_P#&J/\
MA+I/^?%/_ AO_C5 ';T5Q'_"72?\^*?^!#?_ !JC_A+I/^?%/_ AO_C5 ';T
M5Q'_  ETG_/BG_@0W_QJC_A+I/\ GQ3_ ,"&_P#C5 ';T5Q'_"72?\^*?^!#
M?_&J/^$ND_Y\4_\  AO_ (U0!V]%<1_PETG_ #XI_P"!#?\ QJC_ (2Z3_GQ
M3_P(;_XU0!V]%<1_PETG_/BG_@0W_P :H_X2Z3_GQ3_P(;_XU0!V]%<1_P )
M=)_SXI_X$-_\:H_X2Z3_ )\4_P# AO\ XU0!V]%<1_PETG_/BG_@0W_QJC_A
M+I/^?%/_  (;_P"-4 =O17$?\)=)_P ^*?\ @0W_ ,:H_P"$ND_Y\4_\"&_^
M-4 =O17$?\)=)_SXI_X$-_\ &J/^$ND_Y\4_\"&_^-4 =O17$?\ "72?\^*?
M^!#?_&J/^$ND_P"?%/\ P(;_ .-4 =O17$?\)=)_SXI_X$-_\:H_X2Z3_GQ3
M_P "&_\ C5 ';T5Q'_"72?\ /BG_ ($-_P#&J/\ A+I/^?%/_ AO_C5 ';T5
MQ'_"72?\^*?^!#?_ !JC_A+I/^?%/_ AO_C5 ';T5Q'_  ETG_/BG_@0W_QJ
MC_A+I/\ GQ3_ ,"&_P#C5 ';T5Q'_"72?\^*?^!#?_&J/^$ND_Y\4_\  AO_
M (U0!V]%<1_PETG_ #XI_P"!#?\ QJC_ (2Z3_GQ3_P(;_XU0!V]%<1_PETG
M_/BG_@0W_P :H_X2Z3_GQ3_P(;_XU0!V]%<1_P )=)_SXI_X$-_\:I\?BR1W
M1/L*#>ZKGSV.-S 9QY7.,T =I17*:AXD>RO)[46BR"%E <S%2VY%?[HC;&-V
M.IZ9JG_PETG_ #XI_P"!#?\ QJ@#MZ*XC_A+I/\ GQ3_ ,"&_P#C5'_"72?\
M^*?^!#?_ !J@#MZ*XC_A+I/^?%/_  (;_P"-4?\ "72?\^*?^!#?_&J .WHK
MB/\ A+I/^?%/_ AO_C5'_"72?\^*?^!#?_&J .WHKB/^$ND_Y\4_\"&_^-4?
M\)=)_P ^*?\ @0W_ ,:H [>BN(_X2Z3_ )\4_P# AO\ XU1_PETG_/BG_@0W
M_P :H [>BN(_X2Z3_GQ3_P "&_\ C5'_  ETG_/BG_@0W_QJ@#MZ*XC_ (2Z
M3_GQ3_P(;_XU1_PETG_/BG_@0W_QJ@#MZ*XC_A+I/^?%/_ AO_C5'_"72?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!0U7_D&W__ %Z7'_HIJ\FKUG5?^0;?_P#7I<?^BFKR:@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *&J_\@V__P"O2X_]%-7DU>LZK_R#;_\
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M&(HRJ>TT5RGBKQWX'\"6BW_C?QEX4\&V#DA+WQ5XBTCP]:.0&)"W.KWEG"Q
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MIXC%X3+:.)G64<%+$XA9<_:UH4I5:V)P%*EBYJG#EY:MXI132VZ*X_2OB'X
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M]^/_ -$QUD4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAAHEY^S[J.G+XJM?"UOXH\3W7QRO_"DL*7-O]C\)P^+1\21J-S:W-K<6K'X
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MA_PUX0U2?4+6SU-]6UKPG:I9ZC= '[5T5_$O\3/^#AO_ (+6?L567AOXP?\
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M&^.!\4^"K[2=?\,>)+JPDOM3\'67A:W^(&AWB->>&5U.ZU;0K^?P>)K1)=+
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MFOM>"YAOKJZ\&#QC80Z8\=Y#<I9:'80)<I+$)A]%?\%6O^4?/[2O_8L>&?\
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MM*H+:VM[*VM[.T@BM;2T@BMK6V@C6*"WMX(UBA@AB0*D444:+''&BA41550
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M%^([S6O 7C"WLI[>.YU/P1XZ\/ZAX6\206EQ#;WTVEW,^G736-U:7;_SR_\
M!L)_P66_;O\ ^"FWQO\ VIOA]^UYX]\'>.- ^&WPP\'^-O!A\/\ PV\(^!;[
M2-4U?Q=<:)?6S7/A/3]+34-.ELBA6+4X;RZCFB22.\4&5)*W_!NL/$X_X-J_
MVJ3KX TIH/V[#X(($@+>&/\ A4L2W98O\I/_  F:^+ES#^[V@ _O1+7Y<?\
M!D-_R=/^W!_V;_\ #S_U8LU 'M/[4/\ P=$?MC?L2?\ !7/]L+X0_$ZRT#XM
M?LI?!3QC\7OASX ^!_AKP9X1\+Z_J'B/1]!EL_AE<ZG\4);6X\4V-I_PEHT^
M[\9:H[>(1_8DNJIH_A6>\.G6]O\ &G[1G_!=_P#X.<_V9M0\(?M-?'WP!?\
MP"^ OQ:U6(_#KX>^/OV2_!NB?!Z9[NS.NZ?X63Q#KGAYOC38:G>:':7=]:Z7
MXH^*-IXDU'3(-4U&RB,5E)-9>4P^'?#_ (K_ .#O^_T/Q1H>D>(]%N?^"DVN
M7-QI&NZ;9ZMIEQ<:7]NU;39Y["_AN+6:73]4L;/4;-Y(F:VOK2VNH2DT,;K_
M %E?\'<6GV-[_P $8OBA<W=I;W-QI/QL^ >H:9--$DDEA?2>-DTJ2[M'8%H+
MA]-U/4+!I8RKFUO;F GRYG4@'O7PS_X*7?M(?\%!_P#@B#XM_;>_8$^'6GVW
M[:&H^ =>T+0?A*D%GXNMO#7QL\&>+[#P_P".--T*U\41V&F>(]WAH7WC?P'I
MVKB\ANX-5\.:7J\>I7RWUG-_FG^"OB1_P4MM/^"N-Y\3?"/A+5Y_^"HC_M#>
M/M<N_!Z>!O!MSK*_':]@\1CQMII\ W%L?!*W-O!/KYDTA;7^R[7RF-M&IABQ
M_>7_ ,&9%W<W'_!)SXBPSSR2Q6'[:_Q>M+.-V++;6S_"GX"7SP0@_<C:\O;N
MY*C@RW$K]6-?S:_!2:*#_@\1UEYI8X4;_@I'\?H5>5UC4RW%K\2(((@SD R3
MSR1PPH#NDED2- SNJD _IQ^#7_!5/_@I!^PQ_P $<_VE_P!M7_@KY\';O_AI
M3P+\<[GP#\ _ASJ/AKP9\+]0^(6D^+_#?PWT_P"'I\0:?X(==*LO#UCX[U7Q
MY?ZWJUO8P>(I_"OAC5Q:6-Y<P:9-=_CU^S=^W-_P=R?\%)/AAJO[8?[(.H_"
M;1_@;-XM\2:5X9\"Z%X,_9(\.:1XFN_#ETT>MZ!X1A^.UEXB^(M[I6B7:_V%
M_:VN>.]/>]OQ<VUKK=_=V5]+9_V4_P#!4G_@G[X._P""G/[%/Q7_ &1?%WBB
MY\"7/C,:%X@\$>/[33EUB7P1\0?!VKVVN^%M=GT=[JR75]*DN;>;1O$&F+>V
M5S>^'M6U6"QOK#4'M;ZW_P ]=O#?_!PO_P &QRZIJ^E;-6_9%E\:VTVJWM@+
M+XZ?LB^+-:U>XMK&"\U33YETGX@?!G4?%5Q;:?I;ZK);?![Q-XCNTL-+BU+4
MRUI%* ?Z%/\ P2U^,7[8WQU_8E^%7Q _;Y^#Z_ _]JJ74OB)X:^)O@>/PW?^
M#X'?P;\1/%'A;PYXFM_#>HZIK4NG0^*_#&DZ1KHGL]4N]"UM[Q_$7A?[/X8U
M?1[2W_FD_P""-7_!R'^VA_P4(_X*GWO['_QC^#/P;\-?!OQG9_&R^\-0>"_#
MGC+3OB!\*A\-M+UKQ'H,/BKQ)JOB[5=,\1QSVFD+X4\1RS^%]#>Z\2:EI^H:
M8-%@231+O^@K_@C9_P %0O"G_!6G]C+1OVE=)\&GX<>-_#WC'6?A-\9/ $>H
M2:MIGASXF>&='\.Z]?2^&M4GAMKO4?"GB#P_XK\.^(]$EO+<76G+JESX=O+G
M4;[0[O4;K[U\%_LY?L]?#;Q[XK^*GP[^!'P9\ _$_P =_:_^$X^(_@OX7^"/
M"WCWQE]ONXM0OO\ A*_&&AZ'8>(?$/VR_MX+V[_M?4;S[1=PQ7,V^:-'4 ]E
MKXR?_@GM^QS=_M>:O^WAK'P*\(^)OVK-4\.^%?"]I\6/%JW_ (IU'PIIO@VR
MDTW1+GP%HVO7E_X<\":\EA(;*\\3^$](TGQ'?6@-K<ZK);37$4WV;10!_$%_
MP:^_\I3?^"^?_9?[G_UHK]I2O["OVE_V<OA+^UU\!?BG^S7\=?#8\6?"?XP^
M%+SPCXQT9;F2RNVLYY(+RPU32=0A!FTO7_#^L6>G>(/#NK0AIM*UW2].U&)6
MDME4_P >O_!K[_RE-_X+Y_\ 9?[G_P!:*_:4K^WV@#^<7X2?\&Y_PZ\/>,OV
M?X?VC?VY/VO_ -L?]G+]DCQ)I7BK]F?]E/XV^(_#[_"?P/J_A>..W\#R>,(=
M&T^!_B#;^"K%7T[0;![+P[IL&CE?#!LCX-FU7PSJO]'5%% !17Y@?\%-?A[_
M ,%8?B%X5^%-G_P2K^.O[,WP+\5:=X@\2W/QAU3]H_1=4UBWU[P_+IVF1>$M
M/\(_8?A%\8+:WFM=1&LW&M_:=&TJ>9&TO[)J9CBO+6?XF_8K^!W_  <G^$/V
MFOAAXA_;F_;)_8$^*/[*UA=>)#\6? WPF\):W:_$76[&X\'>(;7PTGA:Y/[+
M_P +HH+RS\:S>&[^[FN/&VEP1:7;7\DEOK&T:+J !_0Q7\:__!XC^S1\=/''
MP*_8X_;$^$OAB_\ '7A/]BOXF_$#7/BSX9M;"?6[/1] ^('_  K/5-%^(7B+
M0H+:0W/@[P]J_P +O^$?\5:C),(=*M/%]I/=0II;ZI?V/]E%5[NTM+^UN;"_
MMK>]L;VWFM+RSNX8[FUN[2YC:&XMKFWF5X9[>>%WBFAE1XY8W9'5E8@@'XZ_
M\$S_ /@NE^P/_P %./#/A?3_ (9?%/0_AQ^T+J6EVC^)?V9/B9J]IX>^)FFZ
M^MD)]8L?!)U$:?I_Q:T.RD2XEMM?\"-J,XTM;>\\1:+X8OYIM)M?UY\1ZE>:
M+X>UW6-.T>[\0ZAI.C:IJ5AH%@\<5]KEY86,]U:Z/923?NH[O4YXDLK9Y?W:
M33HS_*#7\J'_  5M_P"#7S]C3]H/P!\2?V@OV+?#EI^R'^U;X4TK6?B+H-M\
M.I[C0O@K\0/$/AZVFUU-(U?P%:'^SOAQJ>IRV2V^C>*OA@GABTT75IEUC6?#
MGB1O,"ZW_!M=_P %7_'O[0__  2T^//Q*_;5^(.H^)=0_8+U?Q=;^-OC-K_V
M_6?%.O? SPW\-H/B;8>(/&EVD4U[XG\6^%]*L?%NBW6JH+G6_$.D:'H5UJYU
M+Q)=:CJNJ@'-:;XP_P"#M7]LJ.7XF_#KPO\ L/?\$UO %ZUW>^#_ (3_ !L6
MZ\7?$ZZT21H?[/C\8SGX=_'6^M]>VM)YBZEX:^$\^Z*5KWPII@:U2;TS_@DI
M_P %>OVW_'/[??QK_P""3/\ P50^%WPZ\&_M8?#3PIJ7CSP+\1?A3;267A?X
M@:+96NA>)6TNZL;34-6T2\35? WB>R\9>#_%&B'0[>71-+U/0?%.A:;XPLY(
M[KR7X#?\%8O^"XO_  5>M/&'Q8_X)=_L=_LC? O]D73?%FL>"O!OQG_;;\5^
M.M:\8^/-1\.ZI8QWM_H>E?#?7],@T]H[*95\16$'@/QOX:T:^GU/PUI/Q%UW
MQ#H-W(OYY?LM:;^VQI'_  =K_!ZV_;_UG]G+7?VC)OV9?&4VLZG^RO!X[MOA
M1<^%C^SQ\0$\*I"GQ&T?0O$TFO064!CUE[BP%IYD5LMG+)'&"H!Y+_P=ZV'_
M  4SMM(T>[^/_B?X 7__  3_ +[]J'3V_9?\/>!+?48/C#I_B:+X0^)PD_Q'
M-UI$-O/#%IK^-XGEAUJ_1KRZLWM;>VMI?)M_Z?\ _@F)IO\ P6]\*>.?$FK?
M\%0_'O[%VH?LTV/P1FN/ X^!L.H:7XOT7QY9:QX0N=)U#Q!?7WAKPWI-IX-L
MO ,/C/\ MM[FYG>+4QHDT/DVT-[(WY'_ /![1_R8+^RA_P!G?V__ *ICXHU_
M0Q_P4YOO$VF_\$D/V[[_ ,'1L_B*V_8$_:&DL#&9!<01_P#"A_%*ZA=V7E?O
M&U"RTTWEYIR(&:2^@MT"ONVD _"+PG_P5._X+"?\%AOC'\9-+_X(Q>$?V=OV
M?_V-?@GXOU#X;W/[7O[45GJ.N7_Q*\7Z<8;Z2Y\)Z%:Z#XRCL!J7A^[TW7-(
M\))\-_$,^E:/J>BZEXY\8^&[WQ-IWA[3NZ_9W_X*Z?\ !2']BW_@H-\'/^"<
M?_!:SP!\#+Q/VG9=-T;]G#]KW]GU[W2/ /B;Q1?W<NAZ;IVN6>HVVE0:I::_
MXPGT;P5)&?"'PT\3>"]=UC0=1UGPQJGA3Q/IVO6GY1_\$!?A?_P7SUW_ ()Q
M>!=:_P""=7QZ_P""<7P]_9RU+XD?%:6U\.?'S0_BA=?%>+QK;>*)=/\ %-WX
MHN?#?P2\::/,MTUG8-H9M?$%VR>'5TF*XCM;B.6VB^Q?VJ?^"+__  <"?\%"
MOC#^R!XX_;1_:>_X)K7.B_LH?%J+Q_X4U;X0-\;M#\6Z-8ZWXE^'NL>,Y-/T
MZ;]GK1=,\1:E-!\.?#\^CZ=JFN:)9G4+&..75;&&XFG0 N?\':^F?\%,V_9G
M^,FJ:1XC_9Z3_@F+':_L_P /BGPW+;:B/VA9?B<?B5I:V]U;W$NC36+:*/%K
M^')&^SZY:Q?V)'/&UFUVL[7/LG_!$CP]_P ' $?PH_X)SZGXQ\=?L2S?\$X#
M\$?@W<6?AVRL=8/QS7X 2_"RR_X06Q>:#PE:P_\ "=P::_AX7\K:^UH-0CN7
MN+B\M1)'/]8_\'8'_*$K]HW_ +*!^SO_ .KP\$5^C_\ P1X_Y10?\$W/^S(/
MV8__ %3_ (2H _)K_@FU_P %9?VN?&?_  66_;N_X)5_MT7'P[_M3X;S>+_%
M'[,>L>%/!8\%7FK^$_#6N6?B30],O%75+Z36KCQO\#?''A7XCZ:UU')<6%EX
M8U[S=2N'N4$OZ+_\%O\ _@H1J_\ P3-_X)T?&3]I3P1/X?'QADOO"?PT^!MC
MXFLQJ6DZA\3?'>LQ6L,\^F-/;)J?_"+>#[+QAX\;39)?)OH?"<MM<*\$DJG^
M>_\ X.1_"6N?\$]O^"EW_!-#_@MC\.=-NH=%T+X@:!\$_P!H;^R(I(I-6M?#
MO]KWT%I<20_-<:M\3?@/KOQ:\ /-(ZK;Z=X'T2$07&YEK5_X+K:[8?\ !4[_
M (*S_P#!*#_@DY\.M;M_%GP=6XTS]J_]H*]\/W7VG2;_ ,"^);*Y\2!Y[Y,P
M6NH:;\ ?!/C#4/"]V"+:\?XSZ#&6N9[RUMT /W6^%'[8'[7WPV_X(A67[=O[
M0_@G0?BE^UGHO[('C']IO6? /A;P[=>#]#U>[U'2?$'Q&^'?A[4/#VES:A?Z
M0NA> +[PE:^.HM/?[>UUI7B"YMH;*ZE2WMY_^"&G_!2+XL_\%3_V'D_:@^,O
MP?T#X.^*X_B[X[^&]MIWA'_A(QX.\8:)X5T_POJ%GXT\++XIFO=333I;OQ#?
M^%KQ5U?6K7^WO"NL&*_B<RZ;I_["6MK;6-M;V5E;P6EG:00VMI:6L,=O;6MM
M;QK%!;V\$2I%!!!$B10PQ(L<<:JB*JJ )Z "BBB@ JB^F:;)J5OK,FG6+ZQ:
M6-YIEKJSVENVI6VFZA<6-W?Z=;WS1FZAL;ZZTS3;F\M(Y5M[FXT^QFFC>2TM
MVCO5QGQ%^(G@7X1^ _%_Q0^)WBS0O GP\\ ^'M5\5^,_&/B;4(-*T#PWX<T2
MTEOM4U?5=0N62&VM+.UADD=B2[D+'$DDKHC 'Y0?\'!'Q.^%WPM_X(Z_MWZA
M\5VTN;2_&/P3UKX8^#]+U$VTD^K?%'XAW%KX9^&BZ197$B27NJ:#XOO=+\8@
M6BRW.F:?X:U#7O+%OI%Q+%\\?\&M7PG\<_"?_@B[^S.GCN"[L+GXCZW\5OBQ
MX9TF],@GT_P-XV^(6N3^$IUB>-%BM/$NDV<7C33A$\\<^G>)K2[,B2W,EO!^
M,WD?&#_@ZU_;GTG4WTWQ=\,?^")/[%OQ">>VFU"WO/#FN?M-_$:PB1;F.)2(
MKX>)O%VDW2VMPL;QGX,_";5IEDETKXD>/1!J?]SNA:%HOA?1-&\->&])T[0?
M#OAW2M/T+0=#TBSM].TG1=%TFTAT_2])TO3[2.*UL=.TZQMX+.RL[:*.WM;:
M&*"&-(T50 ?S@>./^#;+X876L?&_P3\"OVZ_VR_V8?V._P!IKQIJOCGX\_L8
M_"3Q3X=MOA;XCU'Q+- OBW1_"&HZAI<UYX+\*^)]+@70]7T&XTWQ-!?:+'8Z
M%?2WGAS2=+T2T_?OX$_ [X7_ +-/P<^&WP#^"OA2R\$?"KX3>$M)\%>!_#%@
M\TT6F:'H]N(8?M%Y=237NIZG>RF;4=8UC49[G4]9U:[O=5U.ZN;^\N)Y/6:*
M "BN'^)MK\0+WX;?$*S^$VI>'='^*EWX'\66OPSU?Q?!=7/A/2OB!<:#?Q>#
M-2\46UC;7E[<>';'Q&^FW6MP6=G=74NFQ7,=O;3RLD3?R]?\,T_\'@7_ $D)
M_P""8'_A%:U_] ]0!_5[7R!_P4)_Y,%_;A_[- _:6_\ 5,>-:]=_9ZTSXW:+
M\"?@]H_[2WB3P7XP_:$TOX:^#+#XV>*_AS9W>G^ _$7Q0M- L8/&VL^$+2^T
MO0KJ+P_J/B!+^ZTSSM \/F2UDCE7P_H:.NDV?D7_  4)_P"3!?VX?^S0/VEO
M_5,>-: /Y%?^#43_ (*)_L)_LH_\$U_B'\-?VE?VM?@+\#/'^H_M>?$WQ?8^
M#OB=\2/#GA+Q#=^%]3^%WP/TO3M?M],U:]M[F32KW4=#UBRMKQ8S#+<Z;>1(
MQ>"0#^P#]G']N3]CK]K^]\5Z;^RY^TS\%?C[J/@:UTF^\86'PK^('A[QA>^&
M[+79;^WT>\U>UTB]N)[.UU"?3+^&VN)(Q$\ML\9<.45OXUO^#5[_ ()>?\$_
M?VS?^"<7Q!^*_P"U)^RK\+OC9\1=+_:U^)?@C3_%WC2PU.YU:U\)Z1\,?@IK
M&FZ%%)9ZG9Q"QL]3\0ZU>PH8BXFU&X)<AE5?[ _V5O\ @G;^Q)^Q!JOC#7/V
M3OV;OAO\"]7\?Z?I.E>,M1\$6%[;7?B#3="N;R\TFROI;Z_OF-O976H7D\<<
M/E!I)MTN\I'L /X$_P#@NOH__!86+_@IO_P3?LOVEO%W[+>K>.M2_:@UIO\
M@GB? %IJ<7A;09+O]H'X20^#&^-5I?>'X9FB_MC_ (5?_;*H/$,SZ=9:U%+-
M>,J?:/ZE_A_X9_X.7X_V8/VB++XC?$7_ ()\3_M4W/BSX+2?LU:KHFF>(3X%
ML/!\.I>*C\=[?QY_Q1]K!_:5YIC>"O\ A"'31-2\N6+Q*EW+ \^FS6WYC?\
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M+!_KX?\ KK'_ .AK452P?Z^'_KK'_P"AK0!I:]_R%[W_ 'X__1,=9%:^O?\
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MKFJVUE8:1XATGQ)XPTW48;G08-(U.8V?BC7(;:[OKBR&HSFW+5](T4 %%%%
M!1110 5^"7_!6[X?_P#!;S0?C!\'_P!IC_@DM\1/AYXS\,>"O 6H>#OB]^QS
M\3[KPS::!\3-4/B.[UVP\8:;_P )E-X<T2:[ETZXBT/5+C3_ (G_  V\6Z=;
MZ1IL.A:GJEMK&KVMM^]M% '\5GQ;_:&_X.P_VXOAAXH_9@T7_@GC\#/V/K?X
MDZ7>_#SXG?M MXZT70I_#OAOQ)92:?XCO_"5WXB^-_C74M,L;G1=9BLKC5_
MWA+XD^+].9-3G\+36NN6AETC]9OV&?\ @AA\-?V1_P#@DI\;O^"<-_XW35_'
M?[5?PX^*>F_M!?&O1M.FF@E^)?Q4\ OX%AUGP=I.I/973>%/AGIT&AV_A+2-
M2DLO[9FT>^UW4[33+_Q1JMG#^]M% '\//_!/VU_X.)O^".?P:U']@/PK_P $
MQ_AQ^V9\/] \;^,=4^ _QK\,?';P?X6\(Z7'XUO=2U_5#KES>ZYIVH7/A";Q
M5->^(;2R\<Z5\+/$]A+J6JZ3=:K<6>H>''TOT#]B_P#X)A_\%=/!_P#P7K^
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MKN1%*8+?S)1&^S:??Z* /\_#_@F5\%/^#JS_ ()1_L^Z_P#LU_L[_P#!,O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#5?^0;?_\
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M (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_
M7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8
M?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\
M$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\
M$1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=
MG1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:
MO_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A
M!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K
M\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?
M^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\
M!&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_
MQ$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?B
MQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!
M^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G
M0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07
MQJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!
M?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ
M_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^
MCZ_ 7_A!?&K_ .=G0!^T]2P?Z^'_ *ZQ_P#H:U^*?_$1+_P1A_Z/K\!?^$%\
M:O\ YV=21?\ !Q-_P1@66)F_;K\! +(C$_\ "!?&K@!@2?\ DF?8"@#]NM>_
MY"][_OQ_^B8ZR*_&K5_^#BO_ ((N7.I74\/[=O@&2*1D*./ /QK 8")%/#?#
M,'@@CD#I6;_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K
M\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?
M^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\
M!&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_
MQ$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?B
MQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!
M^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G
M0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07
MQJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!
M?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ
M_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^
MCZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9T?\ $1+_
M ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K_P"=G1_Q
M$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^$%\:O_G9
MT?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_ 7_A!?&K
M_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_ */K\!?^
M$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_\$8?^CZ_
M 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]%?BQ_Q$2_\ !&'_
M */K\!?^$%\:O_G9T?\ $1+_ ,$8?^CZ_ 7_ (07QJ_^=G0!^T]%?BQ_Q$2_
M\$8?^CZ_ 7_A!?&K_P"=G1_Q$2_\$8?^CZ_ 7_A!?&K_ .=G0!^T]=]X3_X\
MKG_KZ/\ Z)BK\&O^(B7_ ((P_P#1]?@+_P (+XU?_.SK]+_V)OV[?V3/VX/
MFO>//V5OC+HOQ@\):'X\E^'VJZUHVB^+M&@L_&,/A:V\72:&\'BOP]H%V\Z>
M'9H]4,\5O)9&)Q$+DW(,( /N"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17XS_M"_\ !P9_P2$_95^-'Q!_9Z^//[7<?@?X
MO_"S6E\.^//"47P(_:9\6KH.M-86>I_8#XB\$?!GQ)X5U*1+._M7FDT?7-0A
M@E=[6:6.[@N((O&?^(H[_@A1_P!'S?\ FLW[8?\ ]#[0!^_U%>2^ /CM\(OB
M=\#_  A^TGX/\=Z+=? SQU\,]&^,?ASXDZR;KPCX?E^&.O\ AN#Q?IWC'5SX
MOMM"OO#&ECPW<Q:MJ \3V>CW>C6XF76;:PFMKB*+\6?$O_!T'_P1+\+>/KSP
M!=_M?MJDVGZLNC7GBWPU\&_C;XF\ I=>8(9KBS\6Z)\/KW3]9TF"0X;6]!&J
M:1<1@W-E>W5K^_H _H HK@OA=\4OAS\;?AYX/^+7PC\:^'/B+\-/B!H5EXE\
M%^-_"6J6VL^'O$>AZ@F^VO\ 3=0M'>*5"0\,\+%+BSNXI[*\A@N[>>"/\G_$
M/_!PG_P1X\*_'"]_9^US]M7P5:>-]+\6OX"U;7H_!GQ4O?A)I/C1+T6)T#4O
MC?8^!;GX16H$J7;SZ^_C/_A$[&/3K\:CX@LY;?RG /V=HJO:7=I?VMM?V%S;
MWMC>V\-W9WEI-'<VMW:7,:S6]S;7$+/#/;SPNDL,T3O'+&ZNC,K GX=^"/\
MP40_9X_:+_:Y_:1_8V^#LGC?QKX^_9.TS1I/C?X_TOPU#-\%_"WB[6[V.Q@^
M%R>/X]5<7WQ+LY5U8:IX=ATGR-/F\,>*]/GU(:KX=U/3X #[JHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?'7@OP]\2/!'C'
MX>>+;.34/"GCWPKXA\%^)["&ZN;&6]\/>*=(O-#UJSBO;*6"\LY+G3;ZYA2Z
MM)H;FW9Q-!+'*B./B_X:_P#!.S_@G!^RK\#-3^&GA']E7]F?X?\ P2T7PUJ"
M^,W\8^!/!NL6.I^'H;9)=:U7XH^./B%;:OK'BQ#:644FL:]X]U_5IC:V5O\
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M'[,VF_M:?!CQ/:?$[X-^)/AAJGQ6\'^(=#%Q9CQ)X?TO2;_4YK5;;5;:TO\
M2-7AGTV[T?4]*UFRL]3T/6;:\TS5[*TOK*ZMH_YTOA=_P=1?"7X__![X=77[
M-7[#_P"TG^TK^V!\08O'>KW?['?P-<>/]8^&O@WP9XAO=!M?&?Q3^)FD>$Y+
M+POI7BC[/;WVE6EIX,UK5K2VO+6?5[&PL-3\.ZAKWSU_P:H>*?%VO?\ !"7]
MK31O$+WTV@^"?C7^U'X=\!R7EU/+!;^'[[]G_P"%WB_4].TNUF++::?#XO\
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M]<U.Y((M]/TG2K*[O[V<@B*VMY)""%K^-S_@WC\+^)_^"DO_  47_P""@_\
MP73^+>C:A;:%KWC;5OV>?V2M'UN(;_#/A6#3-%M[]K5$E%M#JG@?X.Z?\-O
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MKOH]QJ]S\<?B!8)/+<1,UJ]Y))\+M;FLV+,\\4VH30G9YN?OW]K3_@C_ /\
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M T74=)\4-IF@^-/"GC_6-)U3Q1X?.D:<+[Y2^-_Q@_X.?OVZ?@[XI_9%L_\
M@G-\#?V')/BEH]Q\,OC-^U'JG[17@3Q+I7A_P=XL2\T7Q;=_#S0M!\>>,/$F
MF?;M!FO;&;6?"ME\5-=TJREGNO#]WI>NWF@ZK9?U[T4 ?E]^Q5_P3G\+_P#!
M/S_@FE:?L/?"6ZC\::_I7PI^)%KXB\8M96WAVX^*/QA^(.CZS<>(O%-U;W>H
M74.DV^J:YJ%OI&A6FHZQ=C0/"NFZ#H]SJEQ%I7VIODO_ (-N/V*/VFOV!?\
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M5;:PL?Z^:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.:?^CB_^"0/_ (:+]I[_ .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\
M)U'_  KO_@YI_P"CB_\ @D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('
M_P -%^T]_P#)U'_"N_\ @YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3
M_P!'%_\ !('_ ,-%^T]_\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\
M ?\ A7?_  <T_P#1Q?\ P2!_\-%^T]_\G4?\*[_X.:?^CB_^"0/_ (:+]I[_
M .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\ )U'_  KO_@YI_P"CB_\
M@D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('_P -%^T]_P#)U'_"N_\
M@YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3_P!'%_\ !('_ ,-%^T]_
M\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\ ?\ A7?_  <T_P#1Q?\
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M.:?^CB_^"0/_ (:+]I[_ .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\
M)U'_  KO_@YI_P"CB_\ @D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('
M_P -%^T]_P#)U'_"N_\ @YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3
M_P!'%_\ !('_ ,-%^T]_\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\
M ?\ A7?_  <T_P#1Q?\ P2!_\-%^T]_\G4?\*[_X.:?^CB_^"0/_ (:+]I[_
M .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\ )U'_  KO_@YI_P"CB_\
M@D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('_P -%^T]_P#)U'_"N_\
M@YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3_P!'%_\ !('_ ,-%^T]_
M\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\ ?\ A7?_  <T_P#1Q?\
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M.:?^CB_^"0/_ (:+]I[_ .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\
M)U'_  KO_@YI_P"CB_\ @D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('
M_P -%^T]_P#)U'_"N_\ @YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3
M_P!'%_\ !('_ ,-%^T]_\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\
M ?\ A7?_  <T_P#1Q?\ P2!_\-%^T]_\G4?\*[_X.:?^CB_^"0/_ (:+]I[_
M .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\ )U'_  KO_@YI_P"CB_\
M@D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('_P -%^T]_P#)U'_"N_\
M@YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3_P!'%_\ !('_ ,-%^T]_
M\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\ ?\ A7?_  <T_P#1Q?\
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M.:?^CB_^"0/_ (:+]I[_ .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\
M)U'_  KO_@YI_P"CB_\ @D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('
M_P -%^T]_P#)U'_"N_\ @YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3
M_P!'%_\ !('_ ,-%^T]_\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\
M ?\ A7?_  <T_P#1Q?\ P2!_\-%^T]_\G4?\*[_X.:?^CB_^"0/_ (:+]I[_
M .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\ )U'_  KO_@YI_P"CB_\
M@D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('_P -%^T]_P#)U'_"N_\
M@YI_Z.+_ ."0/_AHOVGO_DZOW^HH _ '_A7?_!S3_P!'%_\ !('_ ,-%^T]_
M\G4?\*[_ .#FG_HXO_@D#_X:+]I[_P"3J_?ZB@#\ ?\ A7?_  <T_P#1Q?\
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M.:?^CB_^"0/_ (:+]I[_ .3J_?ZB@#\ ?^%=_P#!S3_T<7_P2!_\-%^T]_\
M)U'_  KO_@YI_P"CB_\ @D#_ .&B_:>_^3J_?ZB@#\ ?^%=_\'-/_1Q?_!('
M_P -%^T]_P#)U?I'^Q?H7_!0G0_ ^MV_[?GCS]EOQS\1)/'DMQX>O_V8_"_Q
M$\,^%8/AN?"L,,.GZI:_$&:;49?%J^,A<7<EW;L-,.@-%;JOVT,:^VZ* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQU\99_VR/VE?%5E^VK^V;8^$]"^'7B;Q;?ZCX3_9DEGE^&6C+K/P/MWU;RM
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M7A[Q"FG>'O$5]+K>@>)?#GB3PS?ZCJL&EVGB+6/RGA_X*4?\%U?'?[ NN_\
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M"$>(O 7C+29;3Q%X2UHP@6]U<Z1?P0ZK8&32M9M]2TFXN;&;\8/AK_P:<_\
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MNF^QW-G-?2V%[<VK^9?\%%O^".7[$G_!4#4/A_XH_:3\,>.].^)7PMLKG2?
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M6W\5:@98YT\4:D+[^I/]H?\ 9Z^#G[5WP6^(7[//[0'@;2_B/\(/BEH9\/\
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BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img209334158_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_4.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D MX# 2(  A$! Q$!_\0
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MI(Z[^V]6_P"?^;\HO_C=']MZM_S_ ,WY1?\ QNN#\(>./!'Q"TC_ (2#X?\
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MQ$J5&,FI5:D:%"M7E"FI25&C5JM*%.<H^@_VWJW_ #_S?E%_\;H_MO5O^?\
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M!8? FGW-Q9ZAXWE\7^'H_!]A>6FH?V1=VE[XG;41HEK<VNK Z5<P3WT<L&I
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MD*5.,ISC%^@_VWJW_/\ S?E%_P#&Z/[;U;_G_F_*+_XW6714&IJ?VWJW_/\
MS?E%_P#&Z/[;U;_G_F_*+_XW6710!J?VWJW_ #_S?E%_\;H_MO5O^?\ F_*+
M_P"-UET4 :G]MZM_S_S?E%_\;H_MO5O^?^;\HO\ XW6710!NSZQJBQ6C+>S
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M_"=U;V.E^+8/$<.FM93)HD$R^>EO+Y;\%_B'\?\ ]G/X2?#'1M(\1?M$>/\
MP?XA_P""7=U\6W\!:?8Z2^L_#OXG>'/%NB^'=$M?A3-=^"[FW\(7&F>'-0F:
M_P!*U?3?$]]+I]G<ZY)INHZDD!K^C 7-P$$8N)A&,8C$L@0;2"N%W;1@@$8'
M! (YI//GR3YTN3)YI/F/DRC@2GGF0#^,_-[UWSXZHU:N8SKY'#&4LUS".98S
M"XW'1Q&'AB$L5^ZP">7QJX'!TZF)4L-1C4JU:$*4:3Q%52YH^12\)<30P^2T
ML+Q74R[$</91+(\LQ^5Y1/!8RK@V\ EB,W:SFI0S7,ZU' \F/Q<Z%"AC*E:5
M98*A*+4_YP_!7[0_[5_B7PMX_P#"FD_&/XK3:7_PUM^Q'X7\'_$C0KOQ/XRU
MK3?A[\9X==T[XKZ-HWCCXA?"CP1JGBG0]-O;%9KV^UCP>=&T76+26"TN+O21
M!=7>Y\4OC_\ M1^ [75/@UI_Q(_:!\8G1/VXOVD?A1X?UG29[S3_ (U^,_A1
MX!^#6@^+O!@E\>>'/AMXUU[4M*\.^+O$,FJ:GJ6A_#G4(O$.BZ;-I=_K&CVE
MOYS_ -$37-RYR]Q.QVNN6ED8[7 #KDL?E< !QT8 9!Q7B7Q>_9\^$7QWF\)W
MOQ0\+7.MZMX#DU>3P7XBTCQ3XP\%>*?#"^(+.+3]>MM&\4>"->\.Z_9V&M64
M,-KJNG)J/V&^AB2.X@=00>W#<<Y)/,(U,;PK@J.7OGG*GAZ>#Q>)CB%EM#"4
M*ZE4PV!=2H\31EB:LE7H.,\57K4TZ\8N?F8[PEXIIY-*CEGB!F>)SE>SHPK8
MVOF67X&I@9YY6S+$X-PI8W-U1HPP5>.!P]-X3%QJTL!A,+B&L+4G&E^".K?'
MG]JRXM/A'HGAG]L34QX9N_V=/"7BOP/\?+U_BG?>%?BY\=KGQMJMO\4-/N+/
MPI\$?'FL_$"[\)ZA9#P39_"7Q;9>")-/T>+[7'%)>2EQ]X?"'XN?&1?^"@WB
MCX9>-/B%XZ^*?AS7+;QE<6VD^"1K_AWX7_!*#P[X2T'=X9^)'P[\4_#K3H(O
MM_B%KZ]\ ?$KPM\0]4E\42WHM+[3GM4DAB_3GX=^!?!_PD\%Z!\.OAGX>T_P
M1X'\+V1T_0?#6@K+:Z=I]LTTMS-M5I9)KBXNKJ>XO+V\NYI[N]NYY[FZGEFE
M=SV!GF:,1--*T2XVQF1S&N.F$)VC'; KAS/C+*\7'%T,/PWA84:N#S3!T:TE
M@,/7YL;5I3P^8U(X7+(SI8FBJ$:U7#4,9]4GB:E;V/L,/4G0GZV0^&6?9;4R
MW%XWC?'UL3A\QX?S/%86#S?%8-1RK"UJ..R;#RQ^>3HU\!BGB)X?#8[%Y:\?
M2P5'#_6%B<;3IXJC%1117Y\?L@5;C_X\KS_KK9_^A354JW'_ ,>5Y_UUL_\
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M_5YIX[BR2PALXHX+6.67]#O/G,?DF:4PXQY7F/Y>/39G;CVQ3'=Y&+2,SL0
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M*U?XT_##XQ^&-9TK1I_"EO&+#PW9^+8X=5\%:KI;W+?;X=3NM2#7$<KD_O\
M_:KG?YOVB?S-NSS/.DW[,YV[]V[;GG;G&><9IKS32;A)+*X=E9P\C-N91A6;
M<3N91PI.2!P,"J7B%.C5P]?!Y33PU3"O,/8P=?"5,-*.88!X*HJ]*&4T*E1.
M[J5J%+$8? 5XSJTOJ-+GA.E#\&*>)HXS"YIQ'7QU#,(9,L74AA,PH8Y5,FS6
M.9T987$U.(<51HNR5##XJO@\9FV%E2P]?^U:W)5I5_YE_AOXYT+47_9;^.GQ
M8\$ZKX#\":Y_P4P_;(^)GC72O&_@C6;RW\(:;XP^&FFLL/B+2?[$U&3[+%KU
MT='MKJ2REM[B\MU\N0O$[1_J5_P3OT(VVL_M<^-O!OA/6/ G[.WQ+_:(C\3_
M +/?AK5/#U_X,L;C0H/"6GZ=XW\7^%O!>IVFGWGAOPKXO\61/?Z5$^FZ;#?"
M"6[M[..,[G_2$7=T&+BYN Y54+B:0,47.U2V[)5<G:I.!DX'-0N[R,7D=G<]
M6=BS'MRS$D\<<FN+/.-%G&#Q.$I97+!+$TUAN5YC+%8:CA89Q5SFDJ.'EA*,
MEC*=6HL+]=G7FY83VU-4(RQ$YQ]7A+PNEPQF> S"MG\<T^H5WCE)9-3P&.Q.
M/J<-X;AJN\1C:>88BF\LJX>A+'?V72P=)1S%X>O+%3AA*5*7\XG[,7[.?QB;
M]F7X9_M/1?\ "'_"O_AFCX(?MN77PS7P)HGB6T^/OQ!\6>-M7^)5GI\GQ)FO
M] TNTT_2O"M];_VGX1T2P?Q3-J$AL;P26INV@A]/A\;?'OP/X4_9%NOC[^U?
M^U!HOPC^.7P5\6?%[XE_%W0?#UM:^+O#?QGN?!GA63P1\&8-0\+> M7U#PQX
M4@W:GK6FZ%J.EK?>*/$4EW:WVHRF8V5O^]IED:3S6D=I<JWF%V,FY<;3O)W9
M7 VG.1@8Z"G+<3HS.DTJ.^2[K(ZLY)))9@P+9)).2>2377B?$*KCL7B,1CLG
MP5>G6Q>/K48<N$EB<%A<8\RKPPV%QF*R[&3C5P^89G6S&.)G2G">(C"+PL:4
M*$:'FX#P9H93EN!P65<39GA:V&RW*<+BJC>8PP6:8_+(Y%A*F.QV6X#.LN@\
M/C,GR'#9-/ T:]*I3PDYS>/JUJF*GB_YXO!=U^T#<_'G]B;XX_'#4_B]I'QL
M\7?L6?%C3]%LKBTU#1-#\7_&#1_&3W'PP^&OBK0M,T$V&@GXIZ##H/B/X@^$
M=2N=%@U75)Q>RWFE-&]M4WPS_:$_:^U#0+#6?@]\1?CG\;_BI/\ L??&[QO^
MT9X"^)O@:Y/ASX/?M&:-;V;_  Z\/>!M(O\ P;X<M]&UYM;EUK3-.\ Z7>ZO
M;:UI.E6UY/;SK,LTO]"PFF42!99 )?\ 6@.P$G_70 X?J?O9ZTKW$\@4232N
M$.4#R.P0CH5#,=I'J,45>/,-7C^_X8RRJXTG0HT9NA+!4</]:S3$4\)##RP#
MK0PE".8T_84:&+H2CB,#AL1.K4IKZK%X?PBQV#G%X7CS/:"E66)Q.)A'%1S3
M%8SZCD.%JYA4QL,WAAJF8XN>2UOK>)Q678N$\'FN-PE&A1K/Z[+\*;GXY:[#
M\-_V;+GP_P#M5?M3:W\(O&GQ(T&Q_;"^-.J>'-9B\=?!S5)?A3+K,'@[PWKK
M?"ZSU#PCX;\0^/EFL_$QTS2=<A\)W%K9Z/'JVE1WQBNXOV>M>^-?CW]I3]@/
MQ=\6'\<^)X;%_P#@H%I'@;Q_XV\,W6B>*O%'P=MH=%LOA5XJ\=VRZ3I46GZS
MXCT>-FL[G4;#2[S7+6.VOFMFEG+2?N[]JNMXD^TS^8%*A_.DWA3R5#;MP4D
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MP*O ^(M3!8:E@WE,*U'#SG/#U/K='#XJC*KFE?-L14A.AEL,)&K6Q4,E;=/
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MR_'7_P /U^R!_P#/JH_X7?\ M3_](Y?CK_X?K]D#_P"?57Z-T4 ?G)_PN_\
M:G_Z1R_'7_P_7[('_P ^JC_A=_[4_P#TCE^.O_A^OV0/_GU5^C=% 'YR?\+O
M_:G_ .D<OQU_\/U^R!_\^JIT^.?[4JV\\1_X)S?';,K0,O\ Q?G]D C]TSDY
M/_"ZQCANF#GU&.?T4HH _.3_ (7?^U/_ -(Y?CK_ .'Z_9 _^?51_P +O_:G
M_P"D<OQU_P##]?L@?_/JK]&Z* /SD_X7?^U/_P!(Y?CK_P"'Z_9 _P#GU4?\
M+O\ VI_^D<OQU_\ #]?L@?\ SZJ_1NB@#\Y/^%W_ +4__2.7XZ_^'Z_9 _\
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M_M3_ /2.7XZ_^'Z_9 _^?51_PN_]J?\ Z1R_'7_P_7[('_SZJ_1NB@#\Y/\
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M% 'YR?\ "[_VI_\ I'+\=?\ P_7[('_SZJ/^%W_M3_\ 2.7XZ_\ A^OV0/\
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M_P#I'+\=?_#]?L@?_/JH_P"%W_M3_P#2.7XZ_P#A^OV0/_GU5^C=% 'YR?\
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M:IXD\2?L^>,?&WAWQ+\6OVZK#0/$OA_7;C]FWPMX;\%>!UDTCP3X3U67X/\
MB"[\;>,OAWJL]['>>-M5T_5;".$ _KH\/^+/"WBQ-7D\*^)?#_B:/P_X@U;P
MGKTGA_6=.UE-$\4Z!<"UUWPUJ[Z=<W*Z;X@T6Z(MM6T:],.HZ;<$0WEM#)\M
M;]?RMZ'^UQ\6OV&[#]I+XU>&[:?Q+\(?&O\ P4<_X*D_ ;4OA[;^'K?4WO\
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M? MWI-EIL%UI^G#Q#JJHMKUOPWSN*;EB\K3525-053'5*L_9972SC$2IT:>
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M&O\ 6=#AN7U/2[/5EMKEM,NKZU@@OQ;SFU>412;?Y]?B+^UU^U7\,O@7\/\
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MG%:\<NGE-?"8G%T85\+4KU</]1JXV-:,C^EJBOYD_B]^US\7?V>?!WC7X/\
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M%/P9\0W7PMN[CX9:YK'A?3_!?A3QWH4N@0V?B+2]!\?65EXJ2\EET35+VA\
MOB1^TU'I7PV_9^_9N^._AKX :7\0_BU_P7C^,?C3Q9<_"CPM\5M>GUOX'_\
M!2'Q7:^$[3P]I_BF[@T738)K[Q[JMOXJEO+34A=:3-<V]G#I^N/INMZ8 ?TS
MOH6AR:D=8DT;2GU=DMXVU5].M&U(QVC2/:1F^:$W12U>65[=#+MA:21HPI=B
M;%IING6$E[+86%E92ZC=-?:A):6L%M)?WKHD3WEZ\,:-=73111QM<3F25DC1
M"Y5% _F/U7_@H_\ MZ_!SX)77QE\3>,OAG\>?$'QG_X):6O[<_@CP#X?^$UK
MX)\._ [QW9_$SX#_  _UB#1+NV\4WFN^-OA=I'AGXY7'CSQ7/X_U]K^VN?A]
M=7</B/PYX9UFZLM']&M/VP?V^)/!6D>&[3XT_"RWF^(/[;G[)'P(^&GQIUG_
M (9F^,GCV'P3\</#GBJY^*=AXY\!?LW>/=5^%FGWVBW.C:7KWPCU!M0T+5=9
MT[68HM?M=7LM*N-0U@ _HWHK^8J;X[_M$^*_VEOV,?#?Q<_;1NO @^!/_!0_
M]MG]DKQM\4--\*?"_P"'WA+XV1^%?V>7^('PP'Q"\.:U:WG@>V\<^(=&\20?
M#N'0]+CM--U'7TG\6>"O#VC>)X=,ELOT4_X*'_M0_%#]F?XG? ;Q&/BKIOP\
M_9L$4\OQFA\"6GPC\7_'RX\0:K\0_AYX8\#W$?PO^*-VFO\ C+X+7EMJWB/0
M_&+? S3]4^,NE:[?Z-J.AZ9J5C:7=HP!^L-%?SM^+?V]?C[%\+O^"B_QZMOV
MN_@UX/\ B5^SOI_[>GA;X:_L'7_@7X>W/BOP2?V99?$ND?#+XI>*]1U#7E^*
M^OWOB72_#.C_ !CUZ=["7X=:EX%^(VAZ9I&D:88+;7KO&_:5_:O_ ."@'P-\
M<_#+]GS3?CGX;\1>-=<_9/\ &O[4$7QJUGPY^RO\%O"_CSXD7?C2/1]"^#\U
MA\<O&WA;PO9?!SX7V1L[CQH?!.J:U\;;KP[XN\-:G?\ BG3I+*YU76P#^CVB
MOYQ?%G[?G[?FN?M2:_\ #CPM;?"3P/JGPIU3]BK2KWX1ZO\ $?\ 9OT'X:?%
M&V^-W@OX;^,?CAKLWC7XG>.M.^-WB32K2[\8>./!'P)\0? WP[=:%K/B?X=V
MEIK$/BK4-4UC2=,[_P"%_P"UU^V)-\9OAY\1_&?QR\%^)/@G\1?^"L7[6_\
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M^U7.MU;3-;W%LT7P,\=2">"X1XW@EB*^9'*KHT;*'#*0"/R=^&'B;Q)^SO\
MLJ_"6R_94UC_ ()R_!OXH?'C]K[]CWX'^*_%W[&N@6_Q2\'V?@GXIQCP_+JO
MQ*\.ZQ?:+=WWQ(AMWU^X\-K=:I!;R2QQ,UW/%)JL<@!_2''ING0RQSQ6%E%/
M"UTT4T=K DL37K1M>M'(L8=&NVBB:Z*D&X:*,RERBX^$_@]_P3:_9H^"GC[P
M1X^\-P?$CQ"WPFM?B)8_!+P=X_\ B3XE\9^ ?@E8_%A+NV^(%I\-_#.KW$D-
MA'XATN_O-"FDURXU^YM-"N;C2]/GM+6>9)/S.T7]JO\ ;B\8_%/X,_L?:?\
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MD9AGP(KI%!CEP$D5Z_E4\8?\%$OCM^T#:?M1_#/X<?M!>(-4^''Q;_X)]?\
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M?J:01ZE8:"L%K&-(LM0CMK:.^M=/%O!=I;P+<1R+%&%\X\(_LY_!3P%\1/\
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M )SU?>-% 'P=_P ,.ZY_T?+^WC_X=SX>?_.>H_X8=US_ */E_;Q_\.Y\//\
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M 'P=_P ,.ZY_T?+^WC_X=SX>?_.>H_X8=US_ */E_;Q_\.Y\//\ YSU?>-%
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M[9:C;K+97EM/+^/WQB_X)H?M%?&.R_;;^%_AOQAX)_9Y_9]_:0\,_$+6=/\
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M^LZ)'X[LK'5_'NF_ WXU>!?"V@:9+=6WB74=;^$_CK1KGQGX+\'W#^)-6L6
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MOX<_&WXR?LZ^!/B1X]_:B\.^&_"6I7GPR^,'@KPEKWQ \+1?"#P=\/\ X?\
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M[8:;K'P[\-_$+P+#X @\?^(?!GCS3;'3=(\166B69U2\ /U;\0_MM?LB>$?
MO@+XF>*_VC_@_P"&? 7Q1GU.W^'OBC7_ !OHNCZ7XM.AW;6.OSZ/)J%U;R3V
M/AV\7[-XDU%HTL/#TKPKK-S8F>'S-OQC^UO^R_\ #WXC^$O@_P"-OC_\(_#'
MQ3\>Z0NO^#/A]J_COP]:^+O$NC307EQ9:EI&AM??;[NUU6+3M0_L.2.$C7I;
M&\@T87T]M/&GXZ>)O^"8W[8?BS5OA=\4OBA\4=.^/7C^W_9]^.G[,GQ(\$ZA
M^U#\;O@3;P?"SXA_&>Y^(_PSTZ\^-WPJ^&$OB+XU2^%?!$FG_"[XL77B[X9^
M"KOXJQZ'I'C7?IFMVDMI>_5?P)_8X^/O[+?[0OC'4/A+X7_9N\2?LZ_&B#]E
M@^+G\<>+OB4GQ8^"5E^S;\%O"/P4A\%?#R"X\$>*K;XL>'!I'@C2O$?PZU;Q
MGXZ\#ZOX3\4ZYXNU+6(-=EU%99@#Z=_9E_;J^ O[8G[/VN_M$_L^ZY<>*O"N
M@)XT@U'2-2C@TK7]-U7P;=:U:R:;K%M;7&JV^GMK":-_:FE2QW-V9=%U'3KZ
M6**6:2TBYWX4?\%"/V=_%7P8_94^)'Q<^)/PR^ _C3]JSX1_#3XI^$/A;XS^
M(NAIK4"_$C2=%N;/3+2[OTT674[*'7-:M_#%CX@GTO2K'6-9,5C:QI?SK8K@
M?L5_LW?&WX!?LK>,?V8_B9-\,KV+PYK_ ,;=)^$WC3P3XB\3ZE)XO\#_ !)\
M9>-?&^A:[\0-"USPAH2^!_%-E/XT;1]7\.^']5\<Z4JZ4VI67B.87R6%K^:-
MI_P1X^,&GZ/X)\.>*+GPA\7_  EXO_89_9$_9#^.W@>+]J+]H?\ 9\\*Z7?_
M +-GASQ!X9US4M*M/A?X+U7_ (7#\._&=IXJU+5;?PUXIB^'^N:/XCLFN[;5
MD@\3:B=) /V"^*_[9_P.^'^G?'O2_#OQ&^%?C+XL_L^_#+Q5\3O&WPMO_BOX
M0\"RZ'I/A32;35]0_P"$V\8>(IV\._#S3[6VU+29M:UGQ,\-MX=L-4LM3U:&
M&SGB>3I=9_; _9A\*?%+P=\"/&OQ]^#OA'XY^.;70IO#WPDUGXC^%K?QKJ-U
MXDMWGT+3[+29-0BN;F\UWRIT\-VXBCN/$ODLVB07H(%?E]^T%_P3N_:<^*,O
M[=G@KX1W_P +/@7\'/VJO@%^U'X'USP8?B_\1OB%X5^-/QQ^,/@G1_!WPP^-
M_B?X?ZS\*K"S_9Z\3>'8=/O9_BOJ/PQ\4^-8_B0UY;-J6A:CJEL^NO+\6/\
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MUCEU#07\0Z,!I.M-IERTEH=3TX?8[PQ>?;_NW6NIHHH **** "BBB@ HHHH
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M/W$&GZW>6-W-,1%%"[D+7Y2:[_P3^_:>U/Q_XG\._#.;0O@/X'^+_P"S-/\
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MM^,/#*7<OB3PII$4&HR/J7B3P]'87TFN:'9K-J>DI97;ZA:VZVTQ3!M_C_\
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M.<TRBE.O4G5AB^':\Z6%A2Q-.,_L3P[^VU\(/&?Q\U?X/>"?$7@SQ?X0\+?
MF?XW^-/C;X?^(OA75/A[X4MU\;3>#;7PKJ=_I]Q=V$>J2BQU36[VZGUBV@TO
M3K'-U#FX1ET/B?\ MU?LJ?"CPI\/_&^O_&CP#K'A7XF_$72?AEX3UWPAXO\
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MQKN&"PF$S.4L9_M%&CA<3^YDGQQ^"L/C&7X=R_%_X71_$"#4M/T6?P+)X_\
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MW_X9GX[?_.SH_P"'FO[%/_16M;_\,S\=O_G9T ?>=%?!G_#S7]BG_HK6M_\
MAF?CM_\ .SH_X>:_L4_]%:UO_P ,S\=O_G9T ?>=%?!G_#S7]BG_ **UK?\
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M_.SH_P"'FO[%/_16M;_\,S\=O_G9T ?>=%?!G_#S7]BG_HK6M_\ AF?CM_\
M.SH_X>:_L4_]%:UO_P ,S\=O_G9T ?>=%?!G_#S7]BG_ **UK?\ X9GX[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1/XZ^ OB_P ,>/M(^('@.]\(Z!97P-KK_A#Q?:ZGXDMKRPLKD:-K%EW^J_\
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MV;P5XHD_:93QW9_%[2?V@O\ A4L6J?VF/ +>&F^*^BVEO;_$V0'QA9?#(_\
M"$0:!]NMK7Q,@![O^Q5^WU_PUQX2_:F^+UGX?TR+X4_!?XJ?$_P'X!T?POH/
MQ1E^*6NZ)\(O$'C/PUJVL>*=)\9^#/"6CW&O^.9/"4?B+PCX5\$W&MW6AV&L
MVGAOQ=<V?BJ"ZLXHOV5_^"B5K\</@)8?M1?%_P "_#[X#_ /QL_PA3X5^/\
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M$6C?\$^?VO1^P5XE_8$\0_%7]FL^!_AA\-_A/X"_9>^('A[P'\1-.\5ZW/\
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MA-X!\&>"?B9^SW=>*?V8/VZ/B/\ M6?LT7_BK0/B0=!\;>"/BMXI^/.N>)O
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M+\./!&N^$-0UCX5ZLZW4NC2_9-'\">']"\)W=HL< 22_O-2,+?9K>/1\,_\
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M^QK\-/".O_#2_P#%O[-&LZ]XL\>67B)?B)X5\&_&#QMXO\/:II^M^+[SQ/\
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M->NM2T;P[I1U1K[6X]'O9+>&2XAEA2W^Q7^RC\1OV<?$?QG\0>+_ !5X*L]
M^)^JZ/K&B?!GX4-X[;X3^!O$*2ZQ?^.?&?AFU^(FN:[J_A_4_B9K.K)JFN^&
M=$DM/#6F2Z?;BU%],[7*?,7PW_X)S?'S2->T$?$#XI?!^_\ "GA7]I3XH_ME
MP'PEX3\5V7C#QM^T#XLC\1Q?#U/&^KZIJ,UD/!WPU?7(;BVETNR_M35[?3K'
M1I;2UMK9[R[SH9?P9"OG]"KF<YX:G@,%'*<3.K/ZP\;.BL7B:M.-+ NC5]EB
M*"RZ>'E'V<HXN4Z6.Y(/&1WQ><^)U3!\(XJAD5&GCZV;9G/B# TJ$/J4<LI8
MG^S\#0K3KYJL30]O@\5+.:>+C/V\:F7QIULJ52I_9\_JO0/V]/@QX?\  ]SX
M]^.?Q7^"G@_0_$/Q*^*?AWX6WG@;Q7XE\:P>*? WPWUR70KWQ!J,,GA+2]6M
M-4T6\L=1A\<O8Z5>>$_#,\4"?\))=0S+.WH?CK]N7]D;X:76F6?C?X^_#[0I
M]:\&>&?B-I0DU*>]BO\ P!XQNKBS\.>-+:XTVUO;>3POJ,]M+G7!+_9UG#Y5
MS?W%K;7%O-+^>/A;_@F1\>OA?H?@FP^%_P 8?A+;ZU>_L>7?[*'Q+\1^,?!?
MB?6[SPU-XH\>^*?'WC_XF_"2WM=5L[>XUOQ-J'C"_AGTCQ4+6TN)M(T*^OKJ
M:.&73J\I\*_\$^_C9XR\9?M5?"3PL='^%'[/&I^"_P!GW]C&U\9?$?PCXCO/
MBWK_ .S[\&? WA^Y\8ZS\']2BN-/\,W-G\3]9U?Q#I6M:AJEG/I*ZJDNIV$<
MDNF0VQ]19#P#B:V)K1S^M#"8>4ZU1TZGL$\*\RPN#A[.E6RW$5:>(IX:O/$J
MC"6-GCG0KRA#!4_8JKX+XN\7L%A\%A:G"&'JX_&0H8>C[6A]<<<>LDQV95_:
MXC#YW@</7PM7'86G@77J0RJEE2Q>%C5J9G4CBI8?]:_&7[;7[*?P_P#$?B[P
MGXN^-W@[2->\!:%+XD\96GF:E?P>'=)ATNSUR:34M2TS3[W3(;V'1-0LM:ET
M@7C:O'H]S%JCV*V#?:!Z]X<^+_PT\7>./$GPV\,^,=(USQQX/\.>%/%OB?P]
MI[SSW6B>'O',-Y<>$-2OYE@^QPQ^(+:PN[K3H?M)NIK6$W)@6!XY'_)'XP?L
M5_$?P=8?MC_%#4DM=<\(?%;X _$/X7Q_ ?\ 9Q\._$G7=6^-7C'Q'IUCX.^%
M_P 1/&O@[Q)XAUC0-&^(O@SP_9:%H6H>(/!T-E::A:1ZGXB\0ZE::9;2V2_5
M/[#G[)/C'X(?LYZ[IWQ:\52ZM^T=\<=#L-2^,_CJT:&>72-6M/ ]CX&\&>$]
M$D@^SP2:3\+/"=AINAZ8876"[U2WU;4X9A%J2;/%S#)N%</DZQ^$SC$UL4WA
M<)"A*5.:J8VK2P=?&5E3CA:<X8+ TWC%44:M:<ZE?+*<:JJO&TJ'T^2\3\?X
MSB1Y1F/#>"PV!C#'YC5Q<85Z3H991KYCA<MPKJSQ]>%7,\UKQR^5&4Z&%I0H
M83/*TL/[&&65\7[)%^V_^R5-/\1H4^/GP]V?":TN[WQ]?OJLD>C:'!8:Q;^'
MKWRM>DMTT76I[3Q!=VF@7%KH%_JEU%K=U;:0\(U">*W=MK^W#^R9>?#]?BC'
M\=? \7@0^/;?X72Z[>W-]IOV+XB7=C/J=KX-U33-0L;76-)U^ZT^VFO;:PU/
M3[26>V42Q!TDC+_"^B_\$^_VC++]E_X%? *_^('[/[S?LK_%7X2?$?X4P67@
MSQPOA'XFGX:ZMX@U;4XOC=;W>M37JW/C#4-8M->NX_"]M-;67B739-4E;4Q>
MPQ:;V'A;_@GCX];XI?#'XL?$SXB^"/%VMM^U)XV_:W^.6D:?X;U:P\/ZMX_C
M^%J_#7X(>&?AU9WEW>W%IX;^%5NL=\=4\375UK6K7L":CLAG86\/34RC@:FL
M2_[=Q<U1K8M452K1G/%4L+1]K048O**<*4LRC"7LZDZLH8'$U:."J0Q?+6QE
M/@H\2>+%66#C_JIE]/ZQA<OEB)5\).E2P.(Q^+AAL4YS7$E2I6IY)*JG6H0H
M0K9K@L-B<THU,N<\-EM;L/V@_P#@I7\*?!7@;X(ZI\!=>\%_%KQ7^T3\34^'
M'P[?4KGQC8^#M*CTK4+S3_'7BGQC<^'?">O>([*T\$W=I#IVI^';?1AXGDOM
M3LIDT]=,@O[VV[3PC^WQ\(]!T5]1_:&^+GP \#3^)?B?\0? OPK?P/XV\3>)
M].\:6/PZUGP_X0UX/-K?A'P]=0^++#QEJ\ND:EH&G6NI6MLIM&L]5U'%[);?
M&G[.W[+'Q<\$_M#?L[^ ]3T75M5L?V5?#'[5GQ<^(?QJOO".O^%/AG\1?VDO
MVI==+Z/;^"+C784O?&$/A3PGKNL6NIZQID5W9Z:L5QITUZEXT=@?:?V8_P#@
MG5XE^"GC#X*^+?&_BSP'X^N/@I^S3X\^'?AU)-"U*8I\=_BQ\8-;^*?Q%^*5
ML-322*VTZ_BU&VT"Q15.LBU-^9I(TFCC'HX_+>!<#@Y89XBM4JTXU\7"O3Q/
M-C\PHU\3G2R^G2F\)+#8)/#8+(J]1U\(ZDL/FV(J.A2J4U&/C91GGBUFF8PQ
MZP.'HX>O4PF75<'6P')E638C"X'A:6<UJ])9E#&YI)8[,^+,+26$S'V%/&<.
MX2C'%XFA7E5?TUJ'_!0?]BW2M=UCPSJ'[1?P[MM>T&Y\5V&IZ8]]>M<1ZIX(
MU.32/%&BVWEV#QZCKVF:A&8/[!TU[O6;U7AN-/L;NVG@FDV?$7[<O[(_A/PG
M\/?'/B#X^> -/\*?%71K[Q'X!U@ZA<W,/B#P[I<JV^J^($AL[2XN].T+2;IU
MLM5UC5[>PTW3+\BPOKFWO/W%?%7PM_X)M>/OAU8_LS/)X]^'VI^(/V>_A?\
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M"=W[24_CWQ[\,[77OV>Y_P!F'XC_ /!1+P;_ ,%#=6^*NH'QH?VF]%UKPO\
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M]ES]D^Z_9Z^-7[5_Q"4>$$\-?&^__9UM? =GHC:M>>)=#\)? []GCP1\'8M
M\5:MK5H+V^CM=8\.ZM>^'@=8UMSIFHM>WUS#J]_J,9^)?B'^P#^U;??%OXO:
M1X(U#]EW5?@!\9?^"@'[.?[>6L>-_B"_Q!_X7YX7O?A1J7P$/BWX8>'M TKP
MCJ/@^XNOL/P3 ^'OQ*NO&EM<:5HWB*]\%7_@Z*W6/Q-$ ?>6C_MP? W3]'TB
M\^+GQ#^%7PNUCQ9\9OBS\'/ FA1?%7PYXYE\7ZI\+/B7J7PVO)[.Z\/0H+35
M%U&VTR+QAX?N+<R_#GQ'K$/@_P 3:@NL1J;CTVW_ &I?V<;KXT3?LZVWQM^&
ML_QRMXYVF^%T7BS27\7I/:Z6NNW6EG3%N"YUVUT!U\0W7AY6.NV_A\C79M.3
M2?\ 3*_*K7_^"=/[46A:!X<D^#'BGX5^!?CKHO[0W[7OQ,\)?M.Z9\4?B;X;
M\0_"KX>_M*?M67/QTE\":A\)[#X;ZQX,_:)\(:_X4CT.'Q[\+OB1JWASPU_P
MG?A_2KWP_P"(+;[/#XGMM?X=?\$Q/'?@O]I'Q?XL\07&A>/_ (97_P"V)\6?
MVTOAWXSU?]I#]HG3-6^''Q%^)<7BG5-*C_X98T_3V^!_BOQ%X#USQ9J?AG2O
M%VI>-K.QUKX<M%9ZMX575X3YX!^B>@_MP?L?>)].^)NK^'_VE?@QJNE?!K3%
MUSXGZE:^/M :Q\'Z%)?W6E6^OZE=->+ ^@WFKV-WH^GZW9/=:5J&L6\FDV-W
M<:BOV:D\2?MO?LB^#OAYX%^*_BS]HCX5^&?AY\3+C6+;P#XHU[Q38Z38^*7\
M.W-Q:>)9=*BOF@O);/PQ<6D\?B>_>VCL?#FP/K=Q8I)&S_D%\/O^"77[6=YX
MB\:>,OVG[WX-_M):GKW['ME^SCK>A>)OVDOV@[&Q^)7C_3OC[\/_ (M+\3M"
MU+3_ (5V,'[*GA^"'P@WB#P'X"^"6@:C'\-?&]AH":;K&J06D/B#3^F\1_\
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M6USKFFVNJZX+;XO_ &EO^">WQPT?0/V9_AAX-UZ*X\<?'K]K?]M'X)_';7?
MGAOQ3J^@Q_\ !/7]M;XJ^/\ ]I#XW:9XG\3_ -FZ9%X1\1^&] \%^"])\,ZC
MK<T>DCXA^(M0T#PY<WTGB+[3< '[R>-OVC_@+\-_A%IOQ\\??%WP!X/^#&M:
M5X<UK1?B3XA\2:=I?A36M.\86UM>>$Y=&U.ZFCCU6;Q+;7EK+H5GIXN;W55G
MC%C;SLP6O+]?_;[_ &)_"WPX\$?%[Q#^U1\"])^&7Q+M?$EW\/?&MW\1O#::
M%XU'@UH$\6VGABZ6^;^VM5\,2W$<.OZ+8)/J^DW"SV]]8P36US'%Q'[8O[-/
MQ&^)J?LL^.?V?U^%B^._V1?C9;?%KP7\,_BVVN:/\(O&NG2?"GXA?""Z\.W^
MK>$M"\3:OX&U[PYHGQ!F\0_#WQAIGA+Q,OA[7=$M[*70I;'5+BZLOD;X"?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img209334158_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? B,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BL#Q9XH
MT/P1X6\2>-/$]_'I?AKPCH.K^)O$&IRI))'I^B:#I]QJFJWKQPI)+(MK8VL\
MYCB1Y7";8T9R%._7PU_P4<U+4E_9)^(7@C0)U@\4_&K5/ WP'\+EQ(R/JWQ@
M\:Z%X(E$J0LDTD$.CZKJMW<I$ZR-;6TP5T/SKV9=A'C\PP& 4N5XW&X7!J?\
MCQ->G04WH[*+GS-M623;T1Y^;8Y97E69YG*//'+\OQF.</YUA,/4K\B2:;<_
M9\J2?-)M*.K1Z%\(/VP_@K\:O%6G^!_#-QXY\/>+M<\(_P#"?>&-!^)/PS\>
M?#6]\8>"T>R2X\2>$&\9Z#I%MXDTVR.IZ:U\VE7%S/:1:A9SSPI!,LE?4*NC
M[MCJ^QBC[6#;' !*-@G:P!!*G! ()'(K\:OVH/A9\:/A3\,]3_: ^)7Q@T%?
M%_A3PUX._9Y\!ZE\)?!FH^ _!G[/'PH^+/Q)^'_AGXP?%2VN-9\1>+]?NO%\
M?@ZPMHD\3W=_8:5X,L=+AO;*PC=+J^')V7AWX ^&/C!\8K']F3XNZ%\%/@DG
M[*.I_";XG?';1/'=QJ_P]M?VA?BAXITS3_A#JT_B[5=?N= U[XJ>%](76M6U
MS7H]:_M>"+Q-H]GK>KP7U]:+%]95X<RS&4GB\IQF)6':QM'^!5Q^'AC<$J5=
MTJN+]AE]:G'$X?'Y5AL&J> Q,\3FV(Q&%I)T84*];X3#\7YU@*JP6>9?@_KE
M\OQ#B\50RO%SR_,75PZK4,#]8S7#UI8/%9;G6,Q[JYG@Z>#R3#87&5FJ]6OA
MZ/[*^./'O@_X;>#O$GQ \<:]9>'O!WA#3;O5_$FO7?G2VFE:?8C-U<3I:17%
MRYBX7R8();AY"L<<3R,JGJ8YXY($N5+>3)$LZLZ21MY;H) 6CD594;:061T6
M13E64,"!_.GK=G\%?$/[',G@CQ-\/_A3X'TZ7]M+X$? CX@_%_P-XWUN^^!_
MQ#C\-ZQH-YXB^,FA>,=;U"S46.I>#KOQ+X2\2WFO75^EOXHNM4TV^UW6+RVM
M+V']E/!OA#XC^!M7\+>&?A)9_ [2_P!E73]'BETNQMIO'>I?$0V.I6%YJEQ/
MHFH_VA=>%;BSO-:O8[NQGN);H2:7-*_F-*T(7AS?AZAEF$G46,JO$1QN/HPE
MBJ%'#X6MA<)E^68RG5A.CBL5*.(Q,LPM0PTFYRI0DZRPM6$J4O2R+BW%9QC(
M0>7X=85Y;E^)J0P6)Q.+QM#&8W,\VP%2E.G6P."C/"X6.6-XC%1480JSC]7E
MC*%2-:/,_##]NS]GCXL^(?!OAOP[J_C;2+CXDR:K!\,]7\<?#'Q_X'\*_$>[
MT5;R74;#P/XM\3>'].\.^(=1BMM/O[N'3[/4FO;RUL[F>R@N$@DV_86Y=VW<
M-V-VW(W;<XW8ZXR0,XQGBOQ@_80^ 7Q.^+GP$_8U\6?$CXC>$1\&_@UJUS\5
M/AO\._"'@K4=/\6:OXNTV\\::'X;NOB#XYU?Q+J5O<V7AQ=;U6]33/#'AS1(
M]6O);7[?=&VM/(N/'[3P7:>'?V'/BI\?-/NO&?\ PG/BWX]>._ WQ=^*%KX@
M\2:CXW\*?LU)^U[>Z)\1]"\(7D5U->^&/"^B>!--O[N>+0H8KC2X)=;UF*9)
MR\\?J8_AC*'F=? 9?F-6E/#YK0R:I&I%XR,<5C,RQ."PLJ]=T<M5%1HX?VV-
MC1IXV%%V5&M6G.5"AX^6\9Y]#*,-F>:931KPQ>3XC/:,J4EE\Y8+ Y3A,PQT
M</AH5\W>(4JV)]CE]3$5<!.O&[Q%##PIPQ&)_>3Q#XDT/PIX<U_Q;XAU*#3/
M#GA?1]6\0:_JLHDEM],T?0K.XU#5[Z=;=)IFCL;.UN)YDABDFQ$RI&\F$,FA
M:_HWB70-'\4Z'?PZAX?\0:/I^OZ/JD8DBM[W1M5LH=1T^_07"12QPW-E/#<*
M)HXI$1QYB(P91^&/BSP%\ M;\6?M+_#G]E)="\8? /4/V#_'WB+XK>&?AMXI
MU+Q;\-+?XTZ1JL>I_!/4;2ZTO6=2TVW^)>H:;9>(;C4;'3;U-3U?2--TRX\0
M6ESNM))Z^AP_LQ2^%O\ @GWX1UOQ)X+M_P!CWQ;X$\::U\2VM_'LB_"S7/VG
M+;X<_#BZ\/>&?BQKJZ\=/L+Z"PN?&.JZ=X0\1ZE8:?)XEL;>.;2VOK6TMCE'
MA+#SH1DL7F2KSDJRI5,KA"O1PL<!FF,E2Q.$^NSG2S'$RRJM#+L/[=T\5"M@
MYNK3^M2^K[RX[Q4,1*$L%E#HTXRH.M2SJI5PN(QLLRR7 PKX3'O+84ZV4X2.
M=T)YKB_JRK8*I0QU/V%1X2"Q7[V[EV[LC;C=NR-NW&<YZ8QSGICFFF2,1^:9
M$$6W?YI=1'LQG?OSMVXYW9QCG.*_GXAU/PQ%\/M)\,7GBK58_P#@GW?_ /!1
M;5/"%IX@N_%&N1^"I?@@GPPFO=*\-2>,IM0$S? .Y_:.BGT&SO9M6_X1:XMH
MH-(%^_A^2%)/7?'L/[(<GQ-_9I^'@\2^$;?]A"['[0DKQ#QYJR? C6_VB=%N
MO"!TCPSKOB6_UP^')])TO1+OQOJ?@[PZ-7'@R7Q!!J0T>UEU'38[>'.7"/+4
MIP>*QL_:QQ5=2I95SJC0PF6?VG/#8I?78_5\[E&V&65>_&.(E3C/&*,U):QX
M]<Z56I]2RZFZ,L'AW'$9XJ3KXC&YP\GIXS!VRZ?UGAV,T\8\[_=RE@XU*D,!
M*5-P?ZK?$;XO^'/AEXC^$/AG7++5[N^^,_Q"?X;^&I=,@MIK6QUI/"7B?QD;
MK67GNK>2#3CIOA6_@$MK'=SF\FM4^S^4\DL73_$#QYX6^%W@CQ7\1?&^IKHW
MA+P5H.I>)/$.I&">Z:UTO2K:2ZN7AM+2.:[O;ITC\JTL;2&:[O;J2&UM899Y
MHXV_%#X57%H^J_LWVOA'4]4UGX'Z7_P4[^)NE_LX:C?ZCJ>L6,WPCMOV?_B,
M3;^$]7U::ZN]4\":;XZ?QEIW@V]%W=6<FBVT,>FW,VFQ6CU]H_MU>(?%GBC6
M?@%^SA\.?"MEX_\ $_Q&^(5I\4?&?@V^\31>$M.U+X1? G4='\8:Y9ZSX@DT
MO6AI5AXA\;2^!- #/IETNHPW&H:<J?O)'CQK\.4J6891EZJSMBG6JXVO54,-
M.A@Z'^U8BI6HU:DJ>$Q&!P$:KQ="=><*.(H5:<ZSC!S-\+Q=7K95G^:RH4W+
M!/#X?+L)0<\93Q&/KJ.#PM+#UZ%&%;'87,LSE2^H8BGAX5,3A,3AZL*,95%3
M7V?\+/B=X,^,_P //"7Q2^'FJOK7@OQOH\&MZ!J,ME>:;<2VDS2120WNFZC!
M;:AINH6=U#/9:AIU];07EA?6]Q:74,<\+H.\\R/!;>FT/Y9.Y<!RP0(3G ?>
M0FWKN(7&3BOP \;>(?B#X%^!G[:_[.'CO1;KX.^(X/BW\'/CY\-]$\&^/+G5
M;C1/A;^T'^T)X-B\2VOA+QII.F>'98T\/_$RU\:H39Z=9/HZ^)-/M-LL7E/)
MZQXA_93^"/\ PT3^U'\)E\.ZVGPOT7]E;P1\6],^'Z^-O&9\+VOQ;UK4?BQX
M?OOBF-/?7':?X@-IGAC2$A\2W$\U[#?0SZNA_MBYEOSMB.&,%1^LXBICZ]#"
M.IB:V"A0H8;,Y3P-'"Y+CFYXRGC<)AJU>G2SJ&%D\/%T)XO!XA.=&+2CRX3C
M7,JZPF%I95AL3CH0P>%S&>)Q6+R90S/$XO/<!%0P%;+L=B\-AJM7(JF,C#%2
M6)I8+'85JG7FFY_M0[H@W.RHN57<[!1N=@B+DD#+.RJHZLQ"C)(%*S*JLS,%
M5069F("JH&2S$X   )))P!R:_GK\2ZYXA^(]_P#L5Z9\8O$?P9O_ (?^)/V!
MO ?BS1)OVIO%7C+P]\-_%GQ?OUTF/X@:O%JN@WVFZ=J_Q/L/"\F@75D/$-W)
M?V.E:IJ^K^'HTNY=2N8O:?"GPDT[QSX\_8%^#OQ9^)5K^T#X._X9Y_:9O-9U
M?PKXP\3W'P\^)^GZ'XP^&"^#(-6N$UE[KQWH7AG2+VQTZVGU^]U!=7O=(@U2
M^:Z=Y%D=7A"&&C2>(S-IREFLJBHX&=5+#Y5AL]Q%6I0J2Q%*G4JR_L25)T*L
ML.X5,5"TZD:%>4;H\>5<34Q$,/DT&J:R2G3=?,XT9/%9UC>&\'1IXBE'!UJM
M&A'_ %CA7AB:-/%>TH8.<I4J4L5AHR_:IF5%+LRJB@LS,0JJHY)+$@  <DDX
MKRGX8_&#P[\5=5^*^D:#8ZQ97'P@^)VI_"KQ$^K6]M!%?:]I>@>'/$4][I!M
M[JY:?2I+/Q-8QPSW*6MPT\5P&MEC6.23\3_#UQX+?PE^RM\+_CQXDN+?]E#0
M_P!J?]M?X=>((_''BG4K'P0TOPY\1>,++]GOP-\0/%-_J-MY_AO28(-9A\.V
M'B/5/[-O=3T+0K*Y^TO:6L)Q/">F^!=5^$7CWPS\+_$WBM?A3XG_ ."M_P ,
M/"V@ZWHGB_Q;9ZQJ/@/6K/X;Z?=V.E>,)KV/Q/<>'[NTDNM+T;4/[0F%QX;%
M@VG7T]E]BNVZJ7!M!*M3J8O$SE6="&$Q4<"XX2A"MG^&RJ,\146+=\>Z+KUY
M98E*,*%6C6CC)[+S\1XA8A2PU6E@<'2A06+GC\%/,E+'8F>&X8QF=3AA*+P,
M6LKCB8X?#0SERC*>)HU\// 4[N1_1!YB8!WIAF**=PP7!(* YP6!4@J.<@C&
M0:5G1-H=U4NP1 S!=[D$A%R1N8A6(49) )Q@&OP1^(_[./PFT>+_ (*<Z'I.
MDZ[IGAW]GGX<^%/B+\"_#=AXR\76WA[X1>/];^!U_P"-=7\:^ ]*CU@6^B>)
MM1\2^'M*U.XU.(23(T$\%L+>VU'4H;S!^+TNL?%?XV>-M)^,_C7]G[P[:2_L
MR_ ?6_@]K7[2GC?QUX#@TFT\2>#=1O/B'\0O@]=^'=6T/0F\8V'Q */XDUU+
M@^+-(.F>&+>WGL])=1/S4>$L-B;2H9K7E2AA<+C,0IY;"&(5+'X' 8_"PPM"
M.8U(XFM&ECKXR$JU".'A0K5:<\3")W8CCO&86*CB,EPT*U;%XS!87DS>I/"N
MMEV8X_+<;+&8F64TY8.C.M@5' 3C0Q,\55Q-&C5IX2I*Q_0:S*@W.RJN0,L0
MHR2 !DX&22 /4D <FN0U;Q]X/T/QCX0^'^K:Y;67C'Q[9>)]1\(:%)%=-<ZY
M9>#(=+N/%%Q;2Q0/:QIH\.MZ5)<"YN(&<7L0@69@X7\J;#X+^'/C3^T?H'P[
M^//B.Y^.&D^'_P#@GC\'=5U*\MO$?B/3O!'CSQI)XV\::5<_% Z+INJVUM?Z
MI?QI-J7A_5+XW%SIIU%[ZT9+U;:XMOG7P%H?PD\7W'_!*7XE_M%7>CWG_"1?
M!3XN>$M7\?\ Q$\5W^DQ:UX@\%VWA&?X7Z7J?B"]UC3[.?Q$)(M9N-+2XG74
M?$%T+T3#49HXXXUA^%<).3]KF.)J\E/$NI'!Y>I2E)Y7Q)CL"\-[?$TZE;VE
M3AZHJU"M0PM1QQ%&C"<:DYU*!BN-\P@E['*,%0YZ^#A3J8_-6HPA_:W"F S)
M8SZM@JM+#*E3XHINAB:.)QM)/"UJ]2G*E&G3K_T(4445\2?HX4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0S6]O<",7$$,X
MAFCN(A-$DHBGB.Z*>,.K;)HSS'(N'0\JP-344;;":35FDT]T]4_D<A\0?$WA
MWP5X"\;>,O%\33^$_"/A'Q)XG\3PI8C4WE\/:!H]YJVM1III5AJ#OIUI<JEE
MM;[4Q$&#YF*^*?#W[5_@/5/ ^FV&@?L6_M6#P%X@TBUU&ST&#]F_2[30+O2]
M9MXM0B\W0O\ A((K()=13I--!-:#,C'S4+@U]$?M7?\ )KG[2?\ V0+XQ?\
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MDDP-[' K//[1_@DZ'=>&#^P_^U(?#5]<RWM[X>/[-NB'0[R\N)A<3W=UI/\
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ML_91KVM2E&I-5'I%1HU*E&JY7LX>SJ4JD9*:BUR.37+J>B?\-EM_T:C^V?\
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M0]FVU:JW&$DU*+DJ&%Q2CS1;C>5#&X>K!7O*,W:[A-1U_P#ALMO^C4?VS_\
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M4O[)E2A5:A[&--UWC(5)>W]DJ4:?[Z]^M^+7_!?#]B[P%X"^&GQ+\!Z#\?\
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M?A]J?[6GP@^-_P"Q-H'AW]J+X!_$O]CSX1?#?X<?#?\ :2TSXB_#3XE_$O\
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MVXM;2^TB\AMY&7<[_GMX7_X+8?M(? N3_@EE8?M/?#_P)XV^'_[67[*O@O\
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M?#VV\6);[SJ+QWVF#4_)L_V)K\"OVZ/^"FWQY_9T^/'[?$?PLTWP1XA^&_[
MG_!/3X=?'+7? WBS3Y(AX_\ VA?CW\4];TWP##JWBFQFBUK2/!WA#X=^ M8G
MN]-TB2TDUC5/%:S7E[''I=KMPJJDH8BC4C)PQV&Q=+$6YI<V'P^"K8^M33BW
M4@JE/ <M.-%)RQ#@H\KK59OHH^V=2A4I-*I@\1AJU"_*E'$5\71P5&HTUR3<
M:F,CSRJWBJ/,Y<RIPBO.?%G_  ;T>#/$?B7]H3Q1;_M%ZK93?&_]@-/V1]*\
M/W'P\-[X1^'_ ,:M;^#/P[^ 7Q(_:OTO0%\=6MI=^+O'WPO^%/@SPYJ7A^%=
M+O5M1K2W?C#4?MMN;3TK6O\ @C+\0-0^+?B;3[+]I[P_:?LA_%#]KS]GO]NG
MXL?":;X.7%S\8]4^.?[/VA?#>PMO#7A/XP'XAKH_A_X5^.]?^$_@SQ)KEE=>
M -3\5Z'#:W_AWP_KT-IJ$U_57]F#_@M+KWQQ\>_"_P %^+/@9>Z#K^E_LH_M
M1_$?]JOX4> M(\6_$?XX_"G]I?\ 96^,_P (OA'XP^#O@_P)H,5UJ7BG2]?@
M^(TOC;PDD>GWFO:[X6O_  OJ%I*4EO@_2?MB_P#!:'1_@S\#/!WC#X;?!WXI
M?#7X@?%/]HSX=_LX>#=1_;7^ ?QW^"O@'PYJ'C/P[XN\;:Y\2=4\,P^%X_B1
M\2_#/@_PIX'UB*7PU\-K5]=UGQ5JOAK08[[31J,EW%O*=L1#'<RE7J2HPIU4
MXJ%6/^L-:>#LI<M!X66=KVV%F[854X8649+!4:*AA"$GAWA4FJ#IU9RAO**I
M93&CB4[7JJM#+8SHXB$;UW.6(BU+%5:KGK?#7_@C5'X&F_94.H_M!W&LV_[-
MOCW_ (*8^,KX6/PXBTB[\:6__!15_'(N-.L[F3QCJ2^&;GX51>-7\K4&AUM/
M%TVGK(]CX>2<10<)\%O^",/Q,\&^!/V??"GQ0_:G\,>--1_9T_8'_:I_X)]>
M$=3\+_!&Z\+P:G\,OCI8^ =!^'GBW6+6^^)NN$^*/ASH'@9(O$-M;NEGXTO-
M15[:X\.1V4AU#@?VH?\ @J?^V'\'OV'?@;^W%\!=>_X)\_M3_#W7M4\'>"/%
M%AX.N?C_ .'_ !;^T=\7_&OQKN/AC8?"7]E[P1=SZCJ?A/Q?IFC+]OUK2/B-
MJ/BKQ)8^(]'\5:?<>&;;3O#\ES=_H=^S/^U!\5O%G[?G[>7[)'Q6GTVZTKX3
M>%/V8?CS\"WMM(L-,U?1_AA\=/!.O:-XI\#>([G37,&NW_@[XJ?#?Q1/9:[*
MOVN\TKQ-:6DTLJ:="1,</!JK3Y;1]E5RIPDYQYXX++L115"$)6J.I'*,QQ]6
MG5Y8SA@ZE6I4J4YU<+[6YUZB=*K*5W&M',(32C:-3%9CAZTJDI1]QPEFM#!Q
MG2O*$L3"$(4YPH8CV/U7^R=\"_\ AF']E[]G;]F__A)O^$T/P%^"?PP^#Q\7
MG21H/_"4'X<^#-&\)'7_ .Q!?ZJ-(_M<Z3]O&F#4]1%B)_LWVVZ\OSG^@:**
MVK5:E>K5KU9<U6M4G5J2LES5*DG.<K12BKR;=DDE>R21A2IPHTZ=*FN6G2A"
MG"-V^6$(J,5=MMVBDKMMOJVPKXQ_X)Z?\F:? O\ [%_6_P#U,?$E?9U?&/\
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M6NXTYS@WYMXT_P""+NM:-X_\2_&/]G#X]>$_A;\1/#?[7WP-_:M_9VT#Q/\
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M":7Q:&M?!"YU7Q!?:S\#/"WC;P[\-_C1X*GM_B=IUKX=L6G\>ZQJ/B7P!?\
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M%-R?L:^'RU8>*4>:[ITLIR]8AI_N9T5[=J5:I[3]DZ***P&?&,O_ "D-L?\
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ML_&]K>ZCX7T[Q/;^-=4\/_#WPAJ]E,ES:V_AC4-1O+9+.\U'2[/5Z[KX)_\
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M?L)^ /V>/CAJGA36K/3_ (L^$/BO\$/BCJ^N?#[Q#X3T[6O#FN>']1T7Q%X
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MIQQ4Z\:,%R)PITZ7L\/2]G*$E'V[K.M3K1HT?E+X#?\ )<?VY_\ LO/PO_\
M66O@I7U/7RQ\!O\ DN/[<_\ V7GX7_\ K+7P4KZGJUM\Y?FS"I\2_P %/_TW
M$***\3^+OQ_^'OP1U+P78>/;NXL+;Q?I_P 4/$=WK""+^R_!O@3X-> ;[XA_
M$?Q]XH=G^U1^'?#^E0:;IA33;:^U&\UKQ#H]G:VCB29XU.<*<7.<HPA%7E*3
M48Q2WE*3LHQBKRG)M1A%2G)J,6T0ISJR4*<93F[\L(IRE)I-VC%:RD[6C%)R
ME*T8IR:3^7/^"KMEXSU']@3XZV7@I[^-KB[^$B>/)=-\.:SXQG@^"X^-/P]?
MXX7-UX0\.7FG:_XKT*U^%*^++GQ5X:T>_L[[7/"L6M:9'<1+=.X_,+Q?\3/A
MCXS_ &3/V@/!/B7QA^PAX?\ "6G?%GXE_#?]DW]J#XB_L):U:? SXS>&=1_9
M[\*R?$75?!WPJ\(2?V'I/Q%\*:[KT_PFT;Q_H]S?Z=X\T_P=)IGAWPYXHNM+
MU#3C^S?AC]LSX;ZA<>#SXQ\(_&#X%1^.?#WC;QOX1U7XX^#M+\":5J'@3X?^
M$=(\<>(?&]QJEIXJUZ#0-%M_#NNZ?.]MXA;2?$.G7<DNGZ[HFD7491N_\8_M
M&>'/!WQC^&OP*A\.?$+Q?XY^)WA:?QMI/_"&:;X<O- \/>"=)\2:5X9E\3^)
MK_7?%GAV>#3++5]9M)4A\-Z;XDU2&Q6YU&/3EBB!DY*^$5?ZQAY5'&6-I_5U
M3<+U(S;IU6G&=[*C3P.)<:+A3=.4\=+$2J03I4NW#XJ6'A1FJ3DL-6EBHU54
MY86452<H2BG&3E.K2C*;=53C["-&-.HX57^ VM_!'QU%\,/V2?BY\&='^-W@
M3]HJ?]A7P)\0->^$>M>'[/7OC)\!OAC\!?V9/&/PAUB0_&VZTRT\4V/B[XFZ
M-XVF\&> /A.?#$-QXF^.^K:)\6-5TJSC^&_B#0IOV*_X)X_$>+XB_LSZ%%IG
MP^\%_#[PE\-_$.I_"GP!#\,XO%\7PV\5>"O"6D>'[C2_%?@H>/K*Q\8SV;7>
ML:CX:\0ZAKJ75UJWC;PUXHU;^T+S[:SK]#?"?XY>"OC5XE^,GAGP1%XQ75O@
M=\0+/X?>.W\4>#M=\))<>(+SPSIGB^SU7PU_;EM:ZAXB\+7&DZS;R6'BF*S@
MTW4)1<RZ9)>61AOKCQ#4/VZ_ACHL_P ?%^(_@?XY?#&?]G/X=>'_ (G>/3X^
M\#Z2TNJ^&_%VM^(O#G@;3_!">$O&/B^;Q'XN\<ZQX7U*S\'>#94TS7];,VFO
M!9(FHP&NEU:<:V+Q$IQC#'*IC%%M*,'*I4QBJQJ64JL8X*3C",V[*6(K4U&G
M4IT</BXUJ]+#X>-&3J81T<-S1NYRCRPPT*$H.ZC?$."4E9W]C2FYU74K5_LJ
MBO!?@[^T5X%^-VIW^F>$[+Q%ITD/PN^"GQGTEO$EC;:=-XA^''QY\/:MKG@W
M7;*RAO+NXLYK"[T#7?#7B73;[R[C2]=TQXT:YM+FUN9/>JT:LVNTIQ?^*$Y4
MYJ^UX5(2A)+X9QE%VE%I<O;SC":_PU:<:M.7I.G.$X]XRC):-!7RS^TW_P A
M_P#8\_[/4^&O_JJ/CI7U-7RS^TW_ ,A_]CS_ +/4^&O_ *JCXZ5,ME_BA_Z7
M$J'Q+Y_DSZFHHHJB0I5!+ #J2 ,D 9SQDG 'U) K'\0Z]I/A3P[XA\5^(+R/
M3M \*Z!K7B?7M0E!,=AH?A[3+K6-7O9 OS,EII]E<SLJ_,PCVKR17R7H/[;G
MP^\2/"ND?#/XY:K#I/PW\$_$SXIZMH?@G2M8\.? W3?B)X ;XH^$_#WQ.UD>
M)[*1/%MYX$:R\0ZEI'@[3?%J>';'6-#G\1W.DPZO9R20ZM.#ES3C'V:A*HVT
ME"-15G"4V](1DL/6M*5HMTY*][)Z0HU:EN2G*?,Y*/*K\SBZ<9*/>2=:DK*[
MO4CIJ?F9I\^F_"G]MWXH:!^R=K?P2_:&^+/[0_Q(_;&\4?%"PL?V:KKPS^TK
M^R3XEOOA#X@U;1?$>H_M*F=DO? B_%+PWX3^&6E^%/%.C:4/%(\:Z;<^$=4U
M:TT>YC;Y'_96L/#OC3X 6'PO\0^*OA[=_#'X/?LH? W]I?XY?%#PW^Q7-HWC
M?X5?M4?#;X@6$FL_LK?M!^%_$6JWEQ^U1XD^)^N7'C'7?$O@GQ3JL/CBX^(>
ME)XIN9XX?%?AV-/Z</ OQG^'GQ*\&+XW\-^,=,D\.Q>#_"7CCQ =2OK>PO/!
MWASQ7X&T[XC^'9_'5G).[>&IO^$%U:R\1/;ZDX^QZ7,;A':W'F'YJT[_ (**
M_LX:W\,O@W\6+?5?B$?#OQX^.5Q\!OAKI5[X"U6U\8ZAXVM/'?\ PKR_\1ZO
MX6N)UOO#_@'3]<_LJZU#QMJK0P6FDZ]X8N)[9+W6;'3FY5@_9RCA93;G2HX3
M"QHN-O8NG[? X"%*#;G""QF-HU(*K.KB*V(P^'HRQ4L*I8<[HXV=2+K0HMQJ
M3G4E6C)\U;G<,77E.:@HRJ/!X:K2C[.$*%*A5KUOJ\J\E57YY_L!ZK\6O@9^
MTUX:_9W^)_PU%YXQUKX1?#_P++K7B:Y\5:K\4OA#\!? 'P2;Q_\ "O0K'5+;
M1_\ A6/_  J_P[X@:;X;_%>XTG5(];\3?M1>(_$5[;/-X7T+POIMI^\]>*?%
M#]H3PK\+/B)\-_@QJ&E^,?%7Q&^**WNIZ!X-\)0^'3<:?X:TW6M&\/ZCXSU^
MX\7>*?".EVFB0:WKVF:?:6FFW>K>*=<NGNQX?\.:J-.OVM_GWPW_ ,%#_@3X
MMU35;#1=&^)JZ=HWC;P%X1O?%&L>&M*TOPZVE_$3XR>(?V?M%\=Q3)XAOM2L
M/#MG\7?#L_A?5=&\5Z9X5\=6]I?:?XEB\*3^'Y7OX^N,XSE3A&:G*M6JPHI-
M-U*GMOWD8M*]2:JU92Q%1N<I5_K-6I*/)5C2Y*D*D^>LZ3BH4J$JTO>:2<.2
MG-\S:IQG&FJ>'I1M&-*-"E34FX.I]VT4YE9&9&!5D8JRGJ&4D$'W!!!IM48'
MEOQT_P"2&_&[_LC?Q4_]0+Q!7YY_\$5?^3!_"'_93OBI_P"G?3Z_0SXZ?\D-
M^-W_ &1OXJ?^H%X@K\\_^"*O_)@_A#_LIWQ4_P#3OI]?783_ )(?.O\ LHLC
M_P#4'.#X;&_\G%X?_P"R4XC_ /5ED!^KU%%%?(GW(5^-G_!5'S+;XM_L):QX
MY^(?A#X3_L^Z%XA_:0U+QM\1?B=\#Y?V@_A5X8^,$?POT5?@K/XQ^'DNH6.@
MG5[NQ/Q'L_A]K?B:/4+.R\1RW%CHEG_PEFJ:%<P?>?Q/_:V^&?PH\7^+/!.N
M:5XUU[7_  I8_!V!-+\%:-:>(-:\5>/OCYXB\3Z!\*_A+X0T9]2T^?4_'?B&
MW\(:UXGNC?7&E^&]!\*0KK>NZYI]DL\T/0^ OVF_A]XO\3:KX'U"V\7_  K\
M?:0?AQ9ZGX&^+.E:;X2\0#7?BDGCB\\$>%;$66N:[I.O>(]1M?AMXIU6*RT+
M5-3MWTZRM=2L;R[@N \7/5C'$04(5(I^V5.+UE^_A*WL^6,X-UX-QJ4X7O"<
ML-6E"=.I3C5ZZ+J8:?M9492BJ$IM:+]S6I)*HVXS2I251*4N6TH^UIJ<)QG*
MG^%'Q2^,7P9^.FB?\$^_A!\?/A)\-/V7OVBO%N@?LJ_M*?'7XL2?!+Q%X5O/
M@U\/OA'\2X/%GPJ^#WP(U*W\)ZIXB\,_$'XQ^(=#@ALOAXFN6-E\$OA=XA\;
M3>,I&U2\T?2=8/V@?@U=_!7XQ?&_Q%X&U&U\=? ^R^+_ ,/M*_:3U3XC>!]7
MT#X8WWBWXE?&OQI^T'X4^'?QD\0?#RVU+QC\;?!'P;\1_$BW\2_%WQ@]K9D^
M%F^"'P+NW_LF7XDS-^W7Q,_;=^!_P9^)NN?"+QSXQ\1:5XF\-_!'QI^T/XNN
MM.T75M3\,^&? 7@Z;2EU"VUW6K%VCA\=:_%K-GJ'A;P7%;W.M^(--<7Z)!!<
MV#7GHG@OXOS>,/A+/\7]#^&OQ4M[>&UU2ZT_P(+'P3>_$36TLI?*6WT2U\->
M/=;\'7-]J[EUL[.X\;6DZ7$5S9:N--OK>:V2904INO2J*$Z>*QN.52,%)6Q>
M(AA:D'&*C%+DRV6$FZ+ISJU\-.K%4U];H8C6->=.,*<Z+]E6H8?#*G*I*/-*
MC3^L0J0J3YIZ/%JK3]HYQI4:U*$I3G&A6A=^"_CS7/BG\'?A3\3?$_@Z_P#A
MYXD^(GPY\&^-M>\!ZJ9CJ/@W5_$^@6.KW_AR[^TVUE=>9I5Q=O;*+NRLKQ8D
MC6\L[6Z$L$?I=?#_ (1_;\^$WCK7?#GA+1O GQL3X@>)?B!\0? ,G@+6O"_@
MO1O$^A3_  M\4Z+X)\>^+=9FU'XCQ>&[SPGH_C/78O"]M-X7\1>)/$GB#7]+
M\2Z=H'AO4I_#>L"U^EOA5\4=#^+?A[6]>T2QU+29?#'Q#^(OPN\2Z'K(M?[4
MT3QA\,?%NI>$?$%C<M93W%K+!=2V$&MZ3<0S,MWH>KZ7=.L4DSQ1];G"K+VE
M)+V=6,Z])0ESQ]@I4ESPFOCI0>(H4_:*\>>:@WS\T5P.G.G%JHFI4Y0HU.9<
MK55JK:$HO6,Y+#UI<CUY8.5N6S?I5%%%(1^.'A__ )3WZ/\ ]FV2?^H%+7]"
M4\\%K!-<W,T5O;6\4D]Q<3R)#!!!"ADEFFED*QQ111JSR2.RHB*68A037\ZZ
MZ[H_A?\ X+IMXF\1:E::-X?\.?LK:KKNNZO?RK!8Z5HVD?#:[U#4]2O9V^6&
MTL;*WGN;F5OECAB=SP*_.;_@I7_P5G\2?MCMJGP<^ 5_K'@W]E%BUOJVO1M=
M:/XN_:+MS@I<ZDH,%_X8^#EY&5FTWPN_D:YX\LWCOO%JZ?HEPGAB?]!S/A3-
M>+,TX3P674^6G3X*R"6,QM12^K8*C*>,7/5DOBG*TE2HPO4JR3Y4HQG.'YED
MO&V2\#Y)QQF.;57*K5\0^)X8#+Z,H_6\PKQIY<W3HQ>D:<.:+KXB=J5"$DY-
MSE3IS_HQ_9N_X*1?"']K+]JCXO\ [/7P/LKGQ9X.^#GPZTWQ7J7QLBOH5\*>
M,O$E_P"+[KPO>:#X!L5@:XUWPYHGV*5I_'1N8=(UO4'DMO#D&HZ7:#6[S]%:
M_P [[]E+]K+XT_L6_$G5/B?\"KOP=%JOB#PQIW@SQ-X>\<>%I/$7A?7O#.EZ
MPVMV.G[-+U?P[K6ASV]Y)*D=]HVJPXMI/*DM)Q%#L_H?_9P_X."?A1XGN+#P
M]^U9\+-8^"=_,T-O+\2O EU??$OX6"5V*O=ZUI\&FV7Q"\'68RI>1_#_ (JT
MRT4M+>Z[#"C2+Q\6^%V=Y/B:M7)\!B<SRBE1P]L11E"OBY5(X>G]:JU<)3?M
MH1EB/:RBJ5.<*=/E3F[.3]'@7QHX<S_"4:.?YGA,GSVMB,4Y86O"MAL!"E+%
M5?J=&ACZR^K3E'"NA"<JU:E4JU^=QIKF45_1%17'^ OB%X$^*GA/1O'GPT\8
M^&?'W@KQ#;"\T3Q5X0UO3_$.@:I;DE2]GJFEW%S:3&-PT4\:R^;;SH\$Z1S1
MNB]A7Y6TXMQDG&46U*+3333LTT]4T]&GJF?M<91E&,HR4HR2E&46G&46KJ46
MKIIIIIIV:U04444AA1110 4444 >!?M7?\FN?M)_]D"^,7_JN_$==7\#?^2*
M?![_ +);\/O_ %$](KE/VKO^37/VD_\ L@7QB_\ 5=^(ZZOX&_\ )%/@]_V2
MWX??^HGI% 'Y9?\ !1;X2ZU\3O\ @H-_P1IN'^&.J_$/X;>'?B]^V1:_%BY;
MP7=^+? V@^%O&/[(GC+PS#;?$68Z;J&@:5H'BJ\NQX>BB\2M!IVN75R-(1;J
M:<6[_#W[%_\ P3J^ T'PQ_X+6VGCG]A'X1P7M]^W#^V'!\![;Q;^S#X.BNK_
M .&,7PE^']W\.XOA%#K'@E9;GP$GBA=1N?!:^#%;P^OB 7TNAXU%9V7^H"BL
MIT5.EC:=^5XS XS!.HE[U/ZW4RNHJT=KSHK+'"FFU[N*K:K[6WMGS8*35U@\
M1AJZBW>-3ZO_ &G^[:^S&J\QYIVOKAJ3L_L_SU_LD_LTVWPL_P"#=2?P#X9_
M9]3X<_&3X@?\$Q_%\?Q+\$^&_A5'X0^*7CCXM:A^SGK^CS)XT\.:?H-AXJ\2
M_$K4+Z6/2RNO65[XFNKZ6.Q97F=83^57@C]A?]L#]C?]CSX-_MDV>I7GP9U+
MXT_"C_@F3^S9^TOX#_8)^!?CGX>?%WX.?L5>"[VV\1_'3XT^+M&2'Q+X_P#%
MW[7)MM:T_P *_$'QMX:\"VGB/P+X8A\4OX>T^YGB$^G_ -M-%;U).>-Q>.2B
MJN*K9?44)ISI0IX&KF4IX6<%*'M<-C,/F5;!8BFW%?57.$'&4U*GA3C[/"X?
M!MR=.A2Q5-RB^2I.>(IX)0KQG:7LZ^&K8*GBJ,TI6Q"A*2<8.,_X?/%O[3?[
M1G@ZR_9B\'_%K]IS_@I3X*_8G^*O[=O[?_A+X5_$GP9HGQ0F_;8^*7[%'@?]
MGCPAXK^$VN:II\_P[U;X[:KH6C_&&+Q5'X;\<:MX+C^)4/PR\S6[Q[6Q%OJ\
M5S4OVNO^"K?PH_9N\+CXQ1?MUWWQ<^.__!%WXAZ'\!K?P-\&?B)XS\5R?MEZ
M'^T)\1;SP'XO^(-GX(\+:HWP\^.<?[-D_P .O$7C/6?%LFD.+..]$JS^)U.G
MW/\ 9-XO^"GPJ\??$3X2_%GQCX(T7Q!\1_@1?>,M2^$'B^_CG;5_ -]\0?"\
MW@OQI<Z%)%/'%')XC\*W$^B:C]HBN%>RD946-\./4:RG!SIRIN=2\HPI.HY)
MU94X9)B,FE4J3Y5S8J<L3+,/;1C"$<=!5G2G*5X[1J1C4C/V5.T4Y<B3C3A4
M>;+,U&G#FDHT%"G3P<H2<ISPR5)5(0II3_C'^,&M?M%_"3XB?MR:Q<_#[]KO
MPU%^TG^UK^PUIEW\9?A?J7[0?PET^Q_LW_@FCX136?$_CGQ5\ O@_P#%#XT^
M+/"=_P#%2S/@AM'^&&@:?:M\7'TO1O&_BG1=-M;_ $B_\@^$NB_M::I\6OV8
M_P!HW]I2Y_;HA_:/^+O_  0K_:%^&NBW,G@CXF7&A^*?VHOASXG^) TOX3_&
M#PI:>!;[2='FUCP%IFF_$Z[\._$.UT73_&GQ.70/$)>[U_4K/3;[^Y>BG5BJ
MJK+2$JBA"E*"47AJ4.'L5D"A02LH2Y,74Q:G:_M84J4E*E2BDJ=1TW2;2J>S
MC%34]56FLUPV:.=6]W)2EA:="46W:FZDX2C.;9_#]X[^+'_!1O2/!W@_0;GQ
M=^WG\._VGM!_8M_X)9W'_!-KX3_"7X=?$32/@G\8OB[XA\'^%V_:]M_VF-)\
M-> I/AI-KF@^*WU32/B?X;^..H^#]/\ AYX!MS?>'M-MK@I-7VC\(I/^"BMO
M^V7\,OC'XN^*7[:NK^'?%'_!8G]LK]E[Q?\ !CQ!9Z]+^S?H/[$EE\.?B%XA
M^'OBZV\&GP9:I%X;A\;V&C1^ ?C/J^M7-DUL-+\/:'JILC#:3_U845M*HIXA
MXB4(M/$XJNZ*NJ/)BLSP&.J4N5WD_:8;"5LNJR<G">'QM94Z5&'-2G@HN.&6
M'B[-4*%'VR7[WFH9=B,%"=[V2A7JT\?3BDI0Q-%2G4JMQG#\W/V%?^"6W[-7
M_!/?QG\>O'/P(;QL=9_:#\4+XB\9?\)1XFN];MU6'R[JVMHXKC(N+Z+6+G7]
M4EUN79?W0UZ73Y]UCIVF16WZ1T45FM(4J:^"C2IT:4>D*5**C""ZVC%6UNWN
MVVVS1MRG.;UG4G*I.764YN\I.W5O_@:'YL?L3VMU)^S3X*:.VGD7_A,OC[\R
M0R.O/[1_Q=(Y52.A!^A!Z$5]4_8;W_GSNO\ P'E_^(KX&_8R_8?_ &3?B)^S
M_H?C3QK\"_!?B'Q3XA^(7QZOM:UJ_CU-[O4+QOC]\3XWN)RFI(GF.$4L$1$S
MDJHSBOJ7_AW7^Q)_T;E\/_\ OSJO_P M*[X8U1C&/LV[)*_,O\CQYY7*<YR5
M9)2E*5N1NUW?^;S?X?+U3[#>_P#/G=?^ \O_ ,11]AO?^?.Z_P# >7_XBO*_
M^'=?[$G_ $;E\/\ _OSJO_RTH_X=U_L2?]&Y?#__ +\ZK_\ +2J^O+_GV_\
MP)?_ ")']E2_Y_Q_\ ?_ ,EZ_P!/3U3[#>_\^=U_X#R__$4?8;W_ )\[K_P'
ME_\ B*\K_P"'=?[$G_1N7P__ ._.J_\ RTH_X=U_L2?]&Y?#_P#[\ZK_ /+2
MCZ\O^?;_ / E_P#(A_94O^?\?_ '_P#)>O\ 3T]4^PWO_/G=?^ \O_Q%'V&]
M_P"?.Z_\!Y?_ (BO*_\ AW7^Q)_T;E\/_P#OSJO_ ,M*/^'=?[$G_1N7P_\
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MK3A=-<T8W35T?/\ I?[*'QFN-4^&?BOQ_P#M(77C/QU\&/!GQ.\$?#3Q%:?
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MJ48M--1M&T4FN574>53DGXKX<_9!O'^)?Q^\=?%OQQ<_%O0/CC\2_ ?Q5L_
ML'@74/AA%\/?$_PT\*Z5X&\(&P\5^#?'3:UXJL[/PIHFFVE[9ZY#!9:GJL=S
MJ]S:".X73(,OQ7^PAX*^(&D?%:#QOXO^+-WXJ^*WQWN/C]>?$'P?KM]\//%/
MA[Q#I/@YOAW\+O#&ER^'V>&]\'?"3P.(-*\-:/JOVBWOM72X\57D4&NW;7$/
MOW_#NO\ 8D_Z-R^'_P#WYU7_ .6E'_#NO]B3_HW+X?\ _?G5?_EI63KT7!4W
M0;BJ:I*]1N7*IX>I&3E\3JPEA,-R5W)UH*C",:BBFG:P6(C/GCBN65T[QII+
MX*E-P44U%4I1K55.BDJ,W-N4&[-?/W[,7[)/B#]GOQE>2SZ_K?B[PGX+_9D_
M9O\ V7?AEKGB*]N-4\;>)/#OP??QUXA\3^+O'&+9+?3]1U/Q'XSMM)T32K2Y
MO8++1=!7RIHK>>WMT^U?L-[_ ,^=U_X#R_\ Q%>5_P##NO\ 8D_Z-R^'_P#W
MYU7_ .6E'_#NO]B3_HW+X?\ _?G5?_EI6WUY6M[.37-5G\2^*O6J8BL](JW/
M7K5:C2T4IM12C9+*65SD[NM&_)1IZ4W\-"A2P]-?']FE2A&^\G'F=Y2DSU3[
M#>_\^=U_X#R__$5\K?M.VMTGB#]CL/;3H6_;4^&Q :&120OPH^.A8C*C. 03
MCID9KU7_ (=U_L2?]&Y?#_\ [\ZK_P#+2JEW_P $V_V%K]K%[[]F7X:7CZ9?
MQ:IIKW5A?W#:?J<$-Q;P:C9--J+FUOH;>[NH(KN QW$<-S<1I(J32*R>-35O
M9M:I_$GLT^R[!'*Y)INLNOV'V_Q?U\]/7_L-[_SYW7_@/+_\11]AO?\ GSNO
M_ >7_P"(KRO_ (=U_L2?]&Y?#_\ [\ZK_P#+2C_AW7^Q)_T;E\/_ /OSJO\
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M+/3X4D]6^!?PR_97^"NG:]K47[2GP)U'XPZUXK^)7CG3/B!X6\4^!OAOX&\
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M.:3_ ((6_P#!/1U5U\#_ !"*NJLI/Q2\6 E6 ()#7 (R"." 1T(!IW_#BO\
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M_,'0!]G45\8_\+F_;*_Z,HT'_P 2C\&?_,'1_P +F_;*_P"C*-!_\2C\&?\
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MC0?_ !*/P9_\P='_  N;]LK_ *,HT'_Q*/P9_P#,'0!]G45\8_\ "YOVRO\
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M?_$H_!G_ ,P='_"YOVRO^C*-!_\ $H_!G_S!T ?9U%?&/_"YOVRO^C*-!_\
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M?QZ)XNUMY_ZE?^%S?ME?]&4:#_XE'X,_^8.C_A<W[97_ $91H/\ XE'X,_\
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M^)_@S3IO%.F_!&'0);O#?U7_ /"YOVRO^C*-!_\ $H_!G_S!T?\ "YOVRO\
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MM(I.5E&*4(I)0C&*45^H-%?&/_"YOVRO^C*-!_\ $H_!G_S!T?\ "YOVRO\
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M8'Q7#F3RJ>PEF5;#U)XO#4N>NJ=*&%IU,9P]A<0J]/$PPE>K*BLYQ=2-:=/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ36/%FN>/;VZNM1DLM U_0S+R_[2?_!2[X\_L+_\%:OVR/CG\6OC#X^\3?\
M!/GX.ZA\(_V>?''P.P=6\,_#KQI\8/V-+OX]?!_Q]X5TNTLI+S3=4\8?%OX8
M:K\,=4OM[P//\3;62\9D2VCBR]K%4<'7G>-/&8.&,3BI5)4_;4Z$\-AG3@G5
MEB<1/%X.A"$8<KJXF$X2GA7#$U-?8S=7$T8V<\-6J4GS/DC45&K5I5ZT)O\
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M7X\?$3]I7]EC]H7]ESX[_M7_ +1'[0?QI^ &E_#S_@G+\&/$.K?LB?MU>%O
M/A^]_:9UJ^N_#?Q7\>^//V3;>.+5/CWX'^,'C+6O!FIW=OX;O--O9O!5IKMX
MNDZGITTHTO\ KEKX[TW_ ()Z?L(Z-\1/AS\6](_8[_9KTOXE_"#0-"\+_"SQ
MKIWP9\ V6O\ P]T#PO;R6GA?2_!]];:%&^@6_ABTEDM?#G]FBWDT&V=H-)DL
MXB5K[$K64U*%1-+FGF&88M<L>2$:.+J4ZE.DHIM)TYJK)<JBJ=.I2PZ=58?V
M]7%0Y90:;<88/!8=\S<I2J8:G*G*HV];3A[--MMU*D:E>2@ZSIP****S+"BB
MB@ HHHH **** /D+]GS_ )+_ /MV_P#9=?A?_P"LI? .OKVOD+]GS_DO_P"W
M;_V77X7_ /K*7P#KZ]H 9)&DL;Q2*'CD1HY$895T=2K*P[AE)!'H:\#@_92_
M9HM?AC\//@K;? ;X3V_PD^$OBKP[XY^&'PXA\"^'H_!OP_\ &GA'7Y_%7AGQ
M9X0T%+$:?H'B/0_$MW=Z]IVM:;#;ZA;:M=W=\EP+BYGDD]_KY[_:X\6>+/ /
M[*?[3?CKP%YW_"<^"_V?/C-XL\&?9D,EQ_PE?AWX<^)-7\/&!%!9YAJ]G9F)
M%!+/M4 DXKGQ5:.&PV)Q,H<ZP]&6)<59.;PL9UJ=G9VE"2;IRLW"4G*-FV;8
M>G*M7HT(SY'6JQHJ6MH^WDJ4FTM7%J5II?%'1W1S?A7]F;]EU/#'@W4?@I\-
M?@IX;?X=>%OC#X)^"OC7P)X+\%ZI9?"^W^*^KW3_ !6M?!/V&W?2[6T\1^,K
M%K_QUH=K+#9Z]K>FS6VO1R3QSJN9^P?^QS\/OV _V3O@[^R9\,M1OM=\,?"7
M0]0LG\3:K8Z?INK^+?$/B#7M5\5^*_%6JV.E1QZ?:7FO>)-<U/4#9V@:WL8)
MH+"!V@M8S7\@^E6'QS^&$?\ P2!^(G[&?C+QE>:O^R)_P1*\*?MWZA\"O#?B
M34K3PO\ M-Z7%\5/A0G[3W@/Q#X;MIFT[7/&'Q#\"_%3XGZMX<U2YT^ZU+_A
M8]GH=Q'(=0-O)%]3_L1?MD?MLWO[ O[-'Q#_ &7M7^./C#P=\5O%/[8OCRYU
MFT_88\8?ML:K]GU3]LCXUR>#=/U_QJG[4OP6F\&WVD^#WTG2X?!<^EZ^+>UM
M(YK75K>U$6G6W;*DZ$\125^95\7AJW+'W5#+LWS+ X:J^9KDHXS%4<UJ0C%>
MT]O0J*O3DE2KF5U5I4:SE>,X8:O14V^9SQN7X7%UX25M:V%H5L!"4I)Q5/$K
MV4X-UJ3_ *D%_97_ &;$\+WW@E/@3\*E\(:E\81^T'J'AE?!&@+HE[\<E\76
MWCX?%NYTT6(M9OB"/&MG:>*O^$JDC;5_[=MX=2^U?:8UD&1)^SK^R=\-CH7C
MRY^$?P3\#+\-_&7Q0^)?A[Q=>^&?"GAZ#P5XZ^.QOM/^+WC73];NH+6'0_$/
MQ3.OZA9>--9CN+>[\3G5I[?4IKDW11_Y@OVCOB%\-O"__!:7_@GUX]\)^/\
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M4/$NE^&+N_\ #.BKK6C6#W$-U?P:??Z95:JZ5/ZXHRE)0GB*;G>G7E"6;X[
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MU:W_ #[I?^3?_)>O]+7R_P#X;A\,_P#1NO[:'_B+7Q,_^5]?.>M>-_V<M?\
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M_CE'_#_#P!_T:%^TE_X Z+_\<K]=_/F_YZ/_ -]&CSYO^>C_ /?1I?7N"_\
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M;>GO149+ZS3P;G&3:C*FL35IT95(MTXRG%N2B[GZY45^:NF_\%8/V*-"T?\
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M8>EB:?S=*M!NUTFW&]TPKY9_:;_Y#_['G_9ZGPU_]51\=*^IJ^6?VF_^0_\
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M73KIK'4&T+Q9\*-2T'5Q8WJ*[V=X;"_N!;72H[6\VR558H ?H/PK_P &\O\
MP38\.)#%J'A/XR>,X(%B1(/%'QR\>1Q&.%51(W_X1:_\,.Z;4 96<ALD-D'
M\L\/_P#*>_1_^S;)/_4"EK^A>OJN+\US/+I<,PP&/QF"A6X+R!UHX7$5<.JC
M@\:H.?LIQYG%2DHWO;FE;=W^/X!R7*,UAQA4S/*\!F$\/XA<3JA+&X2ABG15
M2.6NHJ?MH345-P@Y62NXQ;V1\3?!C_@F_P#L)?L^WL&K?";]E?X.^'->MBK6
MWB:^\*VWBWQ7;2*RN);;Q5XR;Q!XAMIBZ*[2V^I1.S %F-?;  4!5 55 "J
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M=>_Z,!_:>_[\:A_\P%'_  ^-U[_HP']I[_OQJ'_S 5_1U177_K/PI_T0L/\
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MAW43@X17M'!4XQ@KE%%%?.'UP4444 %%%% !1110 44W>OK^A_PHWKZ_H?\
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M_1T7[:'_ (D+KW_RKH_X8QL?^CHOVT/_ !(77O\ Y5T ?:5%?%O_  QC8_\
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M?^)"Z]_\JZ/^&,;'_HZ+]M#_ ,2%U[_Y5U)1]I5\)?MK?L$?#[]M/2(YM?\
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:U]?T/^%&]?7]#_A0 ZBF[U]?T/\ A10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img209334158_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_6.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )4!.X# 2(  A$! Q$!_\0
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MGX3_ /#]-_\ .DH_X:C^-_\ T;GX3_\ #]-_\Z2CZAC/^@:K_P" A_:^6?\
M0=AO_!B_KK^?9GW517PK_P -1_&__HW/PG_X?IO_ )TE'_#4?QO_ .C<_"?_
M (?IO_G24?4,9_T#5?\ P$/[7RS_ *#L-_X,7]=?S[,^ZJ*^%?\ AJ/XW_\
M1N?A/_P_3?\ SI*/^&H_C?\ ]&Y^$_\ P_3?_.DH^H8S_H&J_P#@(?VOEG_0
M=AO_  8OZZ_GV9]U45\*_P##4?QO_P"C<_"?_A^F_P#G24?\-1_&_P#Z-S\)
M_P#A^F_^=)1]0QG_ $#5?_ 0_M?+/^@[#?\ @Q?UU_/LS[JHKX5_X:C^-_\
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MB_KK^?9GW517PK_PU'\;_P#HW/PG_P"'Z;_YTE'_  U'\;_^C<_"?_A^F_\
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M_P -1_&__HW/PG_X?IO_ )TE'_#4?QO_ .C<_"?_ (?IO_G24?4,9_T#5?\
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MJ*^%?^&H_C?_ -&Y^$__  _3?_.DH_X:C^-__1N?A/\ \/TW_P Z2CZAC/\
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M]KY9_P!!V&_\&+^NOY]F?=5%?"O_  U'\;_^C<_"?_A^F_\ G24?\-1_&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^A7^-'_B.WQ__P#G9U^K%%']MXO_ )]X?_P"I_\ +0_U3R__ )_XW_P90_\
MF?U_I:_E/_PMSP[_ -"O\:/_ !';X_\ _P [.C_A;GAW_H5_C1_XCM\?_P#Y
MV=?JQ11_;>+_ .?>'_\  *G_ ,M#_5/+_P#G_C?_  90_P#F?U_I:_E/_P +
M<\._]"O\:/\ Q';X_P#_ ,[.C_A;GAW_ *%?XT?^([?'_P#^=G7ZL44?VWB_
M^?>'_P# *G_RT/\ 5/+_ /G_ (W_ ,&4/_F?U_I:_E/_ ,+<\._]"O\ &C_Q
M';X__P#SLZ/^%N>'?^A7^-'_ (CM\?\ _P"=G7ZL44?VWB_^?>'_ / *G_RT
M/]4\O_Y_XW_P90_^9_7^EK^4_P#PMSP[_P!"O\:/_$=OC_\ _.SH_P"%N>'?
M^A7^-'_B.WQ__P#G9U^K%%']MXO_ )]X?_P"I_\ +0_U3R__ )_XW_P90_\
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M^A7^-'_B.WQ__P#G9U^K%%']MXO_ )]X?_P"I_\ +0_U3R__ )_XW_P90_\
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M/]4\O_Y_XW_P90_^9_7^EK^4<OQA\+PJ'F\.?&2)2=H:7]GGX^QJ6()"@O\
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M $!/B[_XC_\ 'G_YVU??=%']MXO_ )]X?_P"I_\ +0_U3R__ )_XW_P90_\
MF?U_I:_ G_"Z_!W_ $!/B[_XC_\ 'G_YVU'_  NOP=_T!/B[_P"(_P#QY_\
MG;5]]T4?VWB_^?>'_P# *G_RT/\ 5/+_ /G_ (W_ ,&4/_F?U_I:_ G_  NO
MP=_T!/B[_P"(_P#QY_\ G;4?\+K\'?\ 0$^+O_B/_P >?_G;5]]T4?VWB_\
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M )]X?_P"I_\ +0_U3R__ )_XW_P90_\ F?U_I:_ G_"Z_!W_ $!/B[_XC_\
M'G_YVU'_  NOP=_T!/B[_P"(_P#QY_\ G;5]]T4?VWB_^?>'_P# *G_RT/\
M5/+_ /G_ (W_ ,&4/_F?U_I:_ G_  NOP=_T!/B[_P"(_P#QY_\ G;4?\+K\
M'?\ 0$^+O_B/_P >?_G;5]]T4?VWB_\ GWA__ *G_P M#_5/+_\ G_C?_!E#
M_P"9_7^EK\"?\+K\'?\ 0$^+O_B/_P >?_G;4?\ "Z_!W_0$^+O_ (C_ /'G
M_P"=M7WW11_;>+_Y]X?_ , J?_+0_P!4\O\ ^?\ C?\ P90_^9_7^EK\"?\
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M&4/_ )G]?Z6OP)_PNOP=_P! 3XN_^(__ !Y_^=M1_P +K\'?] 3XN_\ B/\
M\>?_ )VU??=%']MXO_GWA_\ P"I_\M#_ %3R_P#Y_P"-_P#!E#_YG]?Z6OP)
M_P +K\'?] 3XN_\ B/\ \>?_ )VU'_"Z_!W_ $!/B[_XC_\ 'G_YVU??=%']
MMXO_ )]X?_P"I_\ +0_U3R__ )_XW_P90_\ F?U_I:_ G_"Z_!W_ $!/B[_X
MC_\ 'G_YVU'_  NOP=_T!/B[_P"(_P#QY_\ G;5]]T4?VWB_^?>'_P# *G_R
MT/\ 5/+_ /G_ (W_ ,&4/_F?U_I:_ G_  NOP=_T!/B[_P"(_P#QY_\ G;4?
M\+K\'?\ 0$^+O_B/_P >?_G;5]]T4?VWB_\ GWA__ *G_P M#_5/+_\ G_C?
M_!E#_P"9_7^EK\"?\+K\'?\ 0$^+O_B/_P >?_G;4?\ "Z_!W_0$^+O_ (C_
M /'G_P"=M7WW11_;>+_Y]X?_ , J?_+0_P!4\O\ ^?\ C?\ P90_^9_7^EK\
M"?\ "Z_!W_0$^+O_ (C_ /'G_P"=M1_PNOP=_P! 3XN_^(__ !Y_^=M7WW11
M_;>+_P"?>'_\ J?_ "T/]4\O_P"?^-_\&4/_ )G]?Z6OP)_PNOP=_P! 3XN_
M^(__ !Y_^=M1_P +K\'?] 3XN_\ B/\ \>?_ )VU??=%']MXO_GWA_\ P"I_
M\M#_ %3R_P#Y_P"-_P#!E#_YG]?Z6OP)_P +K\'?] 3XN_\ B/\ \>?_ )VU
M'_"Z_!W_ $!/B[_XC_\ 'G_YVU??=%']MXO_ )]X?_P"I_\ +0_U3R__ )_X
MW_P90_\ F?U_I:_ G_"Z_!W_ $!/B[_XC_\ 'G_YVU'_  NOP=_T!/B[_P"(
M_P#QY_\ G;5]]T4?VWB_^?>'_P# *G_RT/\ 5/+_ /G_ (W_ ,&4/_F?U_I:
M_ G_  NOP=_T!/B[_P"(_P#QY_\ G;4?\+K\'?\ 0$^+O_B/_P >?_G;5]]T
M4?VWB_\ GWA__ *G_P M#_5/+_\ G_C?_!E#_P"9_7^EK\"?\+K\'?\ 0$^+
MO_B/_P >?_G;4?\ "Z_!W_0$^+O_ (C_ /'G_P"=M7WW11_;>+_Y]X?_ , J
M?_+0_P!4\O\ ^?\ C?\ P90_^9_7^EK\"?\ "Z_!W_0$^+O_ (C_ /'G_P"=
MM1_PNOP=_P! 3XN_^(__ !Y_^=M7WW11_;>+_P"?>'_\ J?_ "T/]4\O_P"?
M^-_\&4/_ )G]?Z6OP)_PNOP=_P! 3XN_^(__ !Y_^=M1_P +K\'?] 3XN_\
MB/\ \>?_ )VU??=%']MXO_GWA_\ P"I_\M#_ %3R_P#Y_P"-_P#!E#_YG]?Z
M6OP)_P +K\'?] 3XN_\ B/\ \>?_ )VU'_"Z_!W_ $!/B[_XC_\ 'G_YVU??
M=%']MXO_ )]X?_P"I_\ +0_U3R__ )_XW_P90_\ F?U_I:_ G_"Z_!W_ $!/
MB[_XC_\ 'G_YVU'_  NOP=_T!/B[_P"(_P#QY_\ G;5]]T4?VWB_^?>'_P#
M*G_RT/\ 5/+_ /G_ (W_ ,&4/_F?U_I:_ G_  NOP=_T!/B[_P"(_P#QY_\
MG;4?\+K\'?\ 0$^+O_B/_P >?_G;5]]T4?VWB_\ GWA__ *G_P M#_5/+_\
MG_C?_!E#_P"9_7^EK\"?\+K\'?\ 0$^+O_B/_P >?_G;4?\ "Z_!W_0$^+O_
M (C_ /'G_P"=M7WW11_;>+_Y]X?_ , J?_+0_P!4\O\ ^?\ C?\ P90_^9_7
M^EK\"?\ "Z_!W_0$^+O_ (C_ /'G_P"=M1_PNOP=_P! 3XN_^(__ !Y_^=M7
MWW11_;>+_P"?>'_\ J?_ "T/]4\O_P"?^-_\&4/_ )G]?Z6OP)_PNOP=_P!
M3XN_^(__ !Y_^=M1_P +K\'?] 3XN_\ B/\ \>?_ )VU??=%']MXO_GWA_\
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M5]]T4?VWB_\ GWA__ *G_P M#_5/+_\ G_C?_!E#_P"9_7^EK\"?\+K\'?\
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MA_\ P"I_\M#_ %3R_P#Y_P"-_P#!E#_YG]?Z6OP)_P +K\'?] 3XN_\ B/\
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ME#_YG]?Z6OP)_P +K\'?] 3XN_\ B/\ \>?_ )VU'_"Z_!W_ $!/B[_XC_\
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MW_0$^+O_ (C_ /'G_P"=M7WW11_;>+_Y]X?_ , J?_+0_P!4\O\ ^?\ C?\
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M%A4Q/L,-%4JV,D\'A<5B:.#IXO$1=*C'VJE3C^EM%87BFPUS5?#'B/2_#/B
M>$_$FI:#J]AX>\5'2;77AX:UR\T^XM])\0'0KZ2&QUH:-?R6^HG2;R:*UU$6
MWV.XDCAF=A_-;_P47T_]H_\ X)]#X"_%+X?_ +=/[2/Q%\;>,O$^NV7B'PC\
M2O&1U;P9KL_A^'2=3.HZ#\-[6.+PW9>'(VN[;2=:T.^M=;=GU>P:TU*U\V2)
M^?A/AB/%>84\JHYMA,!F6*E4IX##8C#XZJL34IX>MB9NI7P^'J4<-1C"C*+J
M3G*?,[^QY$YG;XB\>S\.\FK<18GAW,,WR/ 0HULXQ^"QN58=X"EB,=A<!2C1
MPN,Q='%8[$SJXJ,U1I4X4G"+7UGVLHTW_3?16-X<OM0U/P]H6I:M8MIFJZAH
MVEWVIZ:R2QMI^H7=C!/>V+1S_OHVM+F22W*3?O4,>V3YP:V:^6E%PE*+M>,G
M%V::NG9V:T:TT:T>Z/T"G-5(0J1NHU(1G%2BXRM)*2YHNSB[/6+2:>CU"BBB
MI+"BBB@ HHHH **** "BBB@ HHHH **** "BOR\_X*=?M;?%/]GCPK\'?A;\
M K2V/QX_::\=/\/_ (>ZQ?6EKJ$'A_[->^&],OKZSL+V*ZLKO6[K5?%_AO2M
M*6_L[RPMEO[R^GMIY;6V@E^=/$/[.F@?#6*'1OC3_P %H/C-\//VA4L]-U77
MK#7?VG?!WA/P58W&H6$,Q-G\&_%.MZ9J0T:>8RRZ7-<:M8P7EEY4PL(9&?'V
M>6\'SQ>6X'-,=F5++Z6:SQ:RS#TL!F.:8W$T<#6CAL7C:F'R[#UGA\#1Q,OJ
MZJU).K4K0J1IT)1AS/\ +L\\3*>7Y[FV093D5?.<1P]3RZ6?XVOF^2\/Y7@,
M5F^&>.RW*J.-SK&8:.-S7$X"/UUX>C".'HX>I1E7Q=.=7DC^YU%?G_\ &_\
M;K^#/[%GA+]G/3?CAXK\6?$4_%;P=J(TWXN>"= \/ZGX?\1R> ?#?@^XUSQM
MJUM:^*(Y+6U\:R^)]-U/0;;PI#XIAFDOY(4E2UCM[JX\^T'_ (*R_L]>+/AI
MX-^(WA#X<_M&>,;OX@>,_'/@CP=\-?!_PNL_%7Q,US4OAW9>#[[Q->VVBZ!X
MJU'1H]+@A\>^%EMI;GQ%!>W4NHF-+$&VNO)XJ/!W$N*PU''83)\;BLOQ5:M0
MPF.IT9QPV)E0J8NG5=.=54Y15-X'%2J^UC3E1A1G*LJ:5SU<3XF\"X#'8K*<
MRXERK+\YP&%PN+S'*:^*ISQV!IXREEM7#QJPP[K0J2KK-LOAAWAZE:&*JXJG
M3PLJTFTOU!HKXL_9C_;O^#?[4GB7Q_X#\-:'\3OAK\2OAC +SQK\-/C/X.3P
M1XTT2P%V+&:^N["WU;7+&&.TNY+:"^MI]2AU&Q:\M#=V4*SJU?"/[3/_  53
M_9P^)/P(_:N^'O@GPW\<-=\/S?"SXM?"BV^.6F_#2:[^!S>/O%/@+Q)HGA30
MIO&=GK$^IZ;-XDU2XA@T6YU7PY86MW$ZWPG33_\ 2ZUP/!7$F,S265_V3CZ5
M;#U,"L=+ZNYK"4<PG".&KOWX0JJO"3J8:%.JWBHQE[%R49.//FOBIP-EF0T\
M_P#]9,HKX;&4<V>50^NJE+,<5DU.I+'82-Z=2KAY82K"-#'5*]!1P$ZD/K48
M.4(R_<&BOQ<_8$_:1^%O[+O_  29^ GQ:^,FOW.E>&K*\^)FAV,5G:RZKKFO
MZY>?&_XJ?V3X<\/Z:CH]]J=Q:6%U)! \UO:VFGV%U>7=S:6%E//%]-_!+_@I
M+\$OC+\6=%^".I>!/CO\"_B3XLT9M>\#^'_V@/AO%\/Y/'6G"TGU!)O#$UKK
M_B".Y%SI]K>7MA)?G3H-3BM)XM-FN[KR[>2LQX,SS!XK/H83 XO,,OR',\VR
M^MF=+#.G2JQR?$3HXK$1I<]22A2IQA7Q,:<Z\<)3J)UJBBN=SDGBCPGF67\'
MU,QS7+<ESGB_(>',ZPN15\?&M7PT^)<%2Q. P4\1[&A!U*]:=3"8&=>GA)YC
M5HR6&H.;=*/Z$45Y_P#%;1O$'B'X:^.-#\*_$$_"CQ!JGAG5K/3/B4-+L=:;
MP//+:R!O$J:;J=YI]A<OI</FW*?:[ZUAA=%N'F3RLU_-I\8_'_C_ .#?Q\_9
MIT3]BC_@H-\</VS/B'XV\4)%\1?A[?\ Q5M?C1X :R@U#1U:ZDM/#/VSP?X9
MT#5+6ZU:'4=+N#?:GX>T^SFUS^V]-CMH+BJX6X3EQ3*O1H9E1P>)I0Q$XPQ&
M#Q\\-&&'PM3%2K8W,*.'G@LOH3C2G3IU*]9R=2+4J<8N$IY^('B-3X C@\1B
M\CQ69X'$U<'2G5P>9Y/2QU2MC<QH9=##95DV*QM/-,YQE*>(I5ZU'"890C0G
M%PK5*BJTZ?\ 471117R!^E!1110 4444 %%%% !1110 4444 %%%% !117\\
M?PL^*/QN_P""C?B;XW?''Q7^U5XW_8[_ &(_A!XK?PCX<D^&7C'3?A9KVKSV
MQTV\EU#Q-\3;TQ6VFR#1=0T74=8GU:ZU#2[6^\2Z7I>DZ2ENEY<77T>0\.5<
M[I9CC)XRAE^6Y3'"?7<96IXC$3=;'UI8? 8/"83"TZN(Q6,Q=6%14J48P@H4
MJLZE6FHKF^'XPXWP_"N(R3+*66XO.L\XBJ9A_9>686M@\'36%R?#4\7F^9YC
MF.85\/@LORW+</5HRQ%>I.I5E4Q%"E0H595'R?T.45^;'[&7A?P9X:^)7C"+
MX=_\%']<_;"\+3^$)2/A?XR^+G@CXT^*_"-P-<TIK7QE)XL\/:_/JL5I!$UW
MH=Q _AVPTZ[FUFT=[B.:SM8)O//A7_P6=_9)^,'CWX5?#7PIH?QFB\6_%KQ;
M:>#M*LM6\)>%;:#PWJ.I:JFD:3<^*[RT\>7UO;V.J7#B6V.A/X@OH+7$VHV%
MCYD2R=$^#\WKXC'T\FPV,SG#Y90H8C'8FCE^,P;PE.O0KUX_6L/CJ5"M1M#"
MXCW[3HS]E^[JS<HI\='Q,X;PN#R>KQ/CLMX8QN?8O%X+*<#B<ZRS,XYC6PF*
MP>$G_9^-RG$8K"XF]7,,$O9.5+$TO;IU\/24)N/ZU45^5/B;_@KQ^S_X8MKS
MQ+<?!S]K'4/A/8Z\GAVX^.]A\$7B^#BW\EVMI'M\4ZOXFTJ]D6622![>!-&;
M4+J.YM_LME-)*L=?0G[0G[?'[/7[.?P\^%_Q&\2ZIXD\:6?QLM]+O?A'X9^&
M^@C7_&/Q!TW5]/TS4[/4]!T;5+W0(5LGM-:T4E]4OM.E:XU:PL889;Z<6XPJ
M<'\3TZV!P\\CS!5LQJU:&#IJBYRK5J%-5J]%\CDJ56A1:K5Z=9TYT:2=2I&,
M(RDNNCXE\ U\+FN-I<69,\+DE##XK,Z\L4J<,-A<77EAL)B4ZB@Z^&Q>)B\-
MA:^&5:EB<0XT*$ZE648/[2HK^;^P_:*\+?M'?\%KOV1?%7A/0/B-X(F\._!#
MQUX"\:>!?BGX2O? OCKPGXKTWP7^TKXAN] \1^'KF>ZCCN$TS7?#^I*]I>W]
MFZW, 6X-S;RQP_I3\8O^"F_P*^$WQ(\;?"S2? ?Q[^.'B?X8637_ ,4Y/@-\
M-8?'>B_#2WCVFZ;QGJ]WXAT"VTU-/W"/4YX/MEIIMTLMA>W$&H6]Q:1>IF7
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MIR<JE7$5)SDPHHHKR#Z4**** "BBB@ HHHH **** /YX=2U'7/\ @F__ ,%
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M%2R_$0R:-#!TZOL\1@\PE#VLBBBBOCC]-"BBB@ HHHH **** "BBB@ HHHH
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MX6_%C]HWXT_#[4_A?X[LM&^+O[1&H:SJGBWQG#8_#OQ<M_>:!>^(M"T+49_
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M;****DT"BBB@ HHHH **** "BBB@ HHHH **** /QW_X*W? SXS>+K+]F?\
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M!B1I)&2,R;%9W*@%F) /4_\ AJ']F?\ Z.(^!?\ X=OP!_\ -!1_PU#^S/\
M]'$? O\ \.WX _\ F@KIO^%)_!G_ *)'\,?_  @O"O\ \J:/^%)_!G_HD?PQ
M_P#""\*__*F@#F?^&H?V9_\ HXCX%_\ AV_ '_S04?\ #4/[,_\ T<1\"_\
MP[?@#_YH*Z;_ (4G\&?^B1_#'_P@O"O_ ,J:/^%)_!G_ *)'\,?_  @O"O\
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M;\ ?_-!1_P -0_LS_P#1Q'P+_P##M^ /_F@KIO\ A2?P9_Z)'\,?_""\*_\
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M_AV_ '_S04?\-0_LS_\ 1Q'P+_\ #M^ /_F@KIO^%)_!G_HD?PQ_\(+PK_\
M*FC_ (4G\&?^B1_#'_P@O"O_ ,J: ///$/[2?[.M_8QQV/Q\^"M[(EW&[QVG
MQ3\#7#HGDW"[V6'7795W$#<0!D@9R17&_P#"_O@1_P!%K^$G_AR/!W_RYKWV
MW^#WPCM&9[3X6_#FU=UVLUOX(\,PLRYSM9H],4LN0#@DC(SUJW_PJWX9?]$Z
M\"?^$CX?_P#E?0-6ZW^7R_X/X'SO_P +^^!'_1:_A)_X<CP=_P#+FC_A?WP(
M_P"BU_"3_P .1X._^7-?1'_"K?AE_P!$Z\"?^$CX?_\ E?1_PJWX9?\ 1.O
MG_A(^'__ )7TM?+[O^#Z_P!+4T\_P\O^#^'F?.__  O[X$?]%K^$G_AR/!W_
M ,N:/^%_? C_ *+7\)/_  Y'@[_Y<U]$?\*M^&7_ $3KP)_X2/A__P"5]'_"
MK?AE_P!$Z\"?^$CX?_\ E?1KY?=_P?7^EJ:>?X>7_!_#S/G?_A?WP(_Z+7\)
M/_#D>#O_ )<T?\+^^!'_ $6OX2?^'(\'?_+FOHC_ (5;\,O^B=>!/_"1\/\
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M^'(\'?\ RYKZ(_X5;\,O^B=>!/\ PD?#_P#\KZ/^%6_#+_HG7@3_ ,)'P_\
M_*^C7R^[_@^O]+4T\_P\O^#^'F?._P#PO[X$?]%K^$G_ (<CP=_\N:/^%_?
MC_HM?PD_\.1X._\ ES7T1_PJWX9?]$Z\"?\ A(^'_P#Y7T?\*M^&7_1.O G_
M (2/A_\ ^5]&OE]W_!]?Z6IIY_AY?\'\/,^=_P#A?WP(_P"BU_"3_P .1X._
M^7-'_"_O@1_T6OX2?^'(\'?_ "YKZ(_X5;\,O^B=>!/_  D?#_\ \KZ/^%6_
M#+_HG7@3_P )'P__ /*^C7R^[_@^O]+4T\_P\O\ @_AYGSO_ ,+^^!'_ $6O
MX2?^'(\'?_+FC_A?WP(_Z+7\)/\ PY'@[_Y<U]$?\*M^&7_1.O G_A(^'_\
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M_P#^5]&OE]W_  ?7^EJ:>?X>7_!_#S/G?_A?WP(_Z+7\)/\ PY'@[_Y<T?\
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MX5_^5- 'S[_PTA^SO_T7KX+_ /ATO __ ,O:/^&D/V=_^B]?!?\ \.EX'_\
ME[7T%_PI/X,_]$C^&/\ X07A7_Y4T?\ "D_@S_T2/X8_^$%X5_\ E30!\^_\
M-(?L[_\ 1>O@O_X=+P/_ /+VC_AI#]G?_HO7P7_\.EX'_P#E[7T%_P *3^#/
M_1(_AC_X07A7_P"5-'_"D_@S_P!$C^&/_A!>%?\ Y4T ?/O_  TA^SO_ -%Z
M^"__ (=+P/\ _+VC_AI#]G?_ *+U\%__  Z7@?\ ^7M?07_"D_@S_P!$C^&/
M_A!>%?\ Y4T?\*3^#/\ T2/X8_\ A!>%?_E30!\^_P##2'[._P#T7KX+_P#A
MTO __P O:/\ AI#]G?\ Z+U\%_\ PZ7@?_Y>U]!?\*3^#/\ T2/X8_\ A!>%
M?_E31_PI/X,_]$C^&/\ X07A7_Y4T ?/O_#2'[.__1>O@O\ ^'2\#_\ R]H_
MX:0_9W_Z+U\%_P#PZ7@?_P"7M?07_"D_@S_T2/X8_P#A!>%?_E31_P *3^#/
M_1(_AC_X07A7_P"5- 'S[_PTA^SO_P!%Z^"__ATO _\ \O:/^&D/V=_^B]?!
M?_PZ7@?_ .7M?07_  I/X,_]$C^&/_A!>%?_ )4T?\*3^#/_ $2/X8_^$%X5
M_P#E30!\^_\ #2'[._\ T7KX+_\ ATO _P#\O:/^&D/V=_\ HO7P7_\ #I>!
M_P#Y>U]!?\*3^#/_ $2/X8_^$%X5_P#E31_PI/X,_P#1(_AC_P"$%X5_^5-
M'S[_ ,-(?L[_ /1>O@O_ .'2\#__ "]H_P"&D/V=_P#HO7P7_P##I>!__E[7
MT%_PI/X,_P#1(_AC_P"$%X5_^5-'_"D_@S_T2/X8_P#A!>%?_E30!\^_\-(?
ML[_]%Z^"_P#X=+P/_P#+VC_AI#]G?_HO7P7_ /#I>!__ )>U]!?\*3^#/_1(
M_AC_ .$%X5_^5-'_  I/X,_]$C^&/_A!>%?_ )4T ?/O_#2'[.__ $7KX+_^
M'2\#_P#R]H_X:0_9W_Z+U\%__#I>!_\ Y>U]!?\ "D_@S_T2/X8_^$%X5_\
ME31_PI/X,_\ 1(_AC_X07A7_ .5- 'S[_P -(?L[_P#1>O@O_P"'2\#_ /R]
MH_X:0_9W_P"B]?!?_P .EX'_ /E[7T%_PI/X,_\ 1(_AC_X07A7_ .5-'_"D
M_@S_ -$C^&/_ (07A7_Y4T ?/O\ PTA^SO\ ]%Z^"_\ X=+P/_\ +VC_ (:0
M_9W_ .B]?!?_ ,.EX'_^7M?07_"D_@S_ -$C^&/_ (07A7_Y4T?\*3^#/_1(
M_AC_ .$%X5_^5- 'S[_PTA^SO_T7KX+_ /ATO __ ,O:/^&D/V=_^B]?!?\
M\.EX'_\ E[7T%_PI/X,_]$C^&/\ X07A7_Y4T?\ "D_@S_T2/X8_^$%X5_\
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M .5-'_"D_@S_ -$C^&/_ (07A7_Y4T ?/O\ PTA^SO\ ]%Z^"_\ X=+P/_\
M+VC_ (:0_9W_ .B]?!?_ ,.EX'_^7M?07_"D_@S_ -$C^&/_ (07A7_Y4T?\
M*3^#/_1(_AC_ .$%X5_^5- 'S[_PTA^SO_T7KX+_ /ATO __ ,O:/^&D/V=_
M^B]?!?\ \.EX'_\ E[7T%_PI/X,_]$C^&/\ X07A7_Y4T?\ "D_@S_T2/X8_
M^$%X5_\ E30!\^_\-(?L[_\ 1>O@O_X=+P/_ /+VC_AI#]G?_HO7P7_\.EX'
M_P#E[7T%_P *3^#/_1(_AC_X07A7_P"5-'_"D_@S_P!$C^&/_A!>%?\ Y4T
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M!>%?_E31_P *3^#/_1(_AC_X07A7_P"5- 'S[_PTA^SO_P!%Z^"__ATO _\
M\O:/^&D/V=_^B]?!?_PZ7@?_ .7M?07_  I/X,_]$C^&/_A!>%?_ )4T?\*3
M^#/_ $2/X8_^$%X5_P#E30!\^_\ #2'[._\ T7KX+_\ ATO _P#\O:/^&D/V
M=_\ HO7P7_\ #I>!_P#Y>U]!?\*3^#/_ $2/X8_^$%X5_P#E31_PI/X,_P#1
M(_AC_P"$%X5_^5- 'S[_ ,-(?L[_ /1>O@O_ .'2\#__ "]H_P"&D/V=_P#H
MO7P7_P##I>!__E[7T%_PI/X,_P#1(_AC_P"$%X5_^5-'_"D_@S_T2/X8_P#A
M!>%?_E30!\^_\-(?L[_]%Z^"_P#X=+P/_P#+VC_AI#]G?_HO7P7_ /#I>!__
M )>U]!?\*3^#/_1(_AC_ .$%X5_^5-'_  I/X,_]$C^&/_A!>%?_ )4T ?/O
M_#2'[.__ $7KX+_^'2\#_P#R]H_X:0_9W_Z+U\%__#I>!_\ Y>U]!?\ "D_@
MS_T2/X8_^$%X5_\ E31_PI/X,_\ 1(_AC_X07A7_ .5- 'S[_P -(?L[_P#1
M>O@O_P"'2\#_ /R]H_X:0_9W_P"B]?!?_P .EX'_ /E[7T%_PI/X,_\ 1(_A
MC_X07A7_ .5-'_"D_@S_ -$C^&/_ (07A7_Y4T ?/O\ PTA^SO\ ]%Z^"_\
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M#/AKP!X&\<>(-2_LN( _3RBO-/@O\1/^%O?!WX3_ !9_L?\ X1[_ (6A\-/
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M@ HHHH **** "BBB@ HHHH **** "BOQ9_X*&_\ !4G]H3]D[]K?]FG]B_\
M9:_8*;]M[XS_ +2?PT^)?Q,T/13^U'X&_9J32-,^&$HDURV74_B)X \2>%]1
M8:3%?:JTM[XFT"8"T2RL;+4[JY14]]\*_M@?MEZ5^QAX^_:)^/\ _P $T/B;
M\.OVB/#'BZT\,^$?V+?@_P#'7X5_M,^//B%8Z_XD\%>$O"OBBQ^)7@NW\.^!
M=!T*35?%E_JWC>?5U!^'O@?PAXC\8ZM]KLK>.U< _2FBOP5_9._X+.?%SXD_
M\% =)_X)M_MK?\$\_'W["O[1/COX3ZG\:OA+!)\??AO^T=X5\9^ ]+A\174N
MH:MXD^'^A>'-+\.3W4'@_P 66]G%IEUXNBCUGP[JFAZO<:3?Q1)-]C?\%>OV
MSM3_ ."?O_!.']JK]JOPU-9P^/?A]\/XM)^%S7UG::G;1_%3XB^(=%^&WPYO
MY]&O72#6K'0O%OBS2O$>L:8XDCN-#T?4VN(FM8Y\ 'Z245^4>C_MA^)_V'/^
M"1GP^_;"_P""A'CV\\??%;P1^S3X!^(?QGU"+1O!?A/7/'7QG\>:-I=_8?"_
MPSH/@K0?#7@ZVUG4/&WB73/AKX>.DZ!8V3B"WUK5$V+J=\? _P#@F-_P6D\1
M?\%"?V<_VU_C;XE_8H^)?P:\<_L5>)O&7A3Q)^SSX*\:R?'CXL?$'Q%X*\"Z
MCXMU#P5X.TAOAS\)[M_B7J.L:1?>"-%\#OIT\FH>)7T^U&K1R7CP6H!^[%%?
MS>6?_!>KXU?"C]M+]E;]DS]O'_@EY\7/V+=%_;8\8Z7X$_9O^*.H_M _##XV
MW/B/Q%K_ (CT/P9HUGXQ\$?#K0$L_!$\?B_Q9X/TCQ-IDOCK5_$/A*V\3Z5K
M>K:(NDSQ7,O](= !17\WGQ3_ .#B;P-X0_X*I?"O_@G#\./V:-7^*_@CQ[^T
M%IW[+.O_ +5UM\5X_#?A'P_\=+&/PC+\4O _AGP2/AGX@B\<WGP<;XA>!].\
M<9\?^&+FVUS6+G3ELT@M+*_U;S7]LK_@MA^V;\ /VJ?VEC\-_@I^RWK?[$/[
M#W[1/[)?[.'[1*>-O%WQ#'[6GQ"\0?M0Z=X7U:#Q1\%-,T"ZM_AYH>C>&(?$
MYLAIWC33=7O-8?1KG4--NKF)];L?"8!_4;17Y@>'OVW?B5\=_P#@HEKO[*?[
M,7ASP-X@^ /[+.AWS_MT_'KQ-I^OZQ%I7Q=\3:7(_P -_P!F;X*W6C^)O#^D
M#XI:&@B\:_&#7=8LO&NA^$?#TMIX.GTC3?&=\TEC\R?"/]M/]HOP/_P7H_:7
M_P""=_QV^(8\9_ [XL?LI?#_ /:M_8TTVZ\&>"_#5W\.+70M2_X0GXE^ 8==
M\,^&M*\0>.X/$WB"S\<^([;6?&>L:Y<:-9^ UTFQFMY;F\%R ?NU1110 444
M4 %%%% !1110 4444 %%%?DG_P %=_\ @K!X+_X)4?!3PKXY/PJU/]H?XR_$
M;4_%:_#7X >'?%R^"M:\1^$?A?X0U/XC?&GXD:GXC'A3QQ+H/@;X2^ =)N-=
M\4:O'X5U@Q7%]HUE)#:VE[=ZKIH!^ME%?BGX"_X*;_M@?M&?\$\OV4?VX/V+
MO^":LG[3'B_]HMM;N_%WP!E_;%^%?P6;X1>'M%U?Q=X>?7Q\4_BCX'TK2?'\
M=UKGAB"RATW3?"NA:DD.K)>2VZ0V4P?Q_P#8?_X+-?M/?M)_\%'/%_\ P3>_
M:(_X)K)^RA\3?AO\&K[XS?$S7=)_;,^'7[3$/@#1Y4\+MX3TSQ+:_"[X7Z=X
M9T_4/%Q\8:$]I97/CV'7+&UU+3[Z?0I;2]BE !_0917XE?\ !?#]NCXX_L-_
ML2>'[W]E35K+1?VL/VE/VA/A!^R]^SOJUYHGAKQ.FB>-_B'JE_K&H:V_ASQ;
M8ZMX>OXXO"WA37-$M+G6M%U?2-/\0>(-!FO["Y5XH)?9/VL_VM_VWOV8Q\-O
MA3^S3_P3T^,/_!2#XE6_PITCQ3\2/B=#\5/A!^S!\+UN-.>YT#4GN?&OBO2+
MG0=2^)GB&^T/4O$TWPU\#>#4&GZ?JFD&Q@M;;5-/LT /U1HK\,OV4/\ @L-\
M3_V^_P#@GOXQ_; _8E_8-\8_%_X[?#SXVW'P$\9?LA^-/CW\./@K>V?C30++
MP/KWC:YTOXW>-M&/A.^T3PWX5\?:-K-M+J?AG0M6UF[BOM$&CZ??6X+^ _#C
M_@MY^VRG_!1#]F#_ ()V_M2?\$D4_9H^(_[3%GK/BC3]3TO]OKX0_M":MX/^
M&GA[2_%.HZQ\1M:\(_"7X4WD-MHENW@_6[6UB\1^*_"3:K)I^H'2Y[Q[":$@
M'])=%>7?&WXS?#G]G7X0?$SX[_%[Q#%X3^%_PA\$^(_B%X\\12VUW??V3X8\
M+:9<:MJMS!I^GP7.HZG>&VMGBL-+TZVN=1U.]DM["PMKB[N(87_'G]BW_@K#
M^V1^VIXP^$/CGPK_ ,$B_C5X!_82^-^J7$/@G]KKQO\ M%_!NT\60^&)H=2E
M\/\ C_Q#^S EBGQ T_P1KZV$4EKXCTWQ)K6DW%EJ.G:GHM[KNFWMG=7(!^Z]
M%?RY?#G_ (+8?MF^)?VS/AI:^)_@I^RW9?L#_&O_ (*/?&7_ ()F_#^+P[XN
M^(>I_MBZ+\4OA0=8TV+XI^-H9;H?"N+P#KFJ:7;ZA/X=L-%B\1Z-I.HI%<WL
MUNVB>(/$GZG?LC_MN_$K]M;]J+]H2;X,^'/ S?\ !/KX M=?!G1OCG?:?K]]
MXR_:+_:>T358#\1+KX/:S;^)K'PO!\"_A+;"X\%:OK]UX1\03>/?'K3W7A#Q
M/;Z!HUVMX ?I_17X2_\ !+W]M/\ :+\>_MX?\%8_V /VL/B&/B7XY_9+^.?A
M;Q_\"?%4_@SP7X&U&;]F3XWZ$?$G@3P;=:3X%\->&].U*3X>:-)X1FG\5ZQ%
M?Z_XEE\>K-<ZC<VMG;);_NU0 4444 %%%% !1110 4444 %%%% !117S3^UE
M\=O'O[._P?O?'_PN_9P^*W[5OQ"N/$/ASPIX2^#7PA.AV6O:WJWB34%LH]2U
M[Q-XGO;#PYX(\%:+$)K[Q+XRUR9M.T6U2,S0R-.@ !]+45^"W[#'_!:KQQ^T
M/^WCX_\ ^";7[6_["7C[]AC]JSPC\/9_B?HOAN_^,G@[]H'P;XH\*VMIHNIN
M\?CSP1X9\+Z+#>76CZY!J>F7&ACQ3X;NO[.UO2KGQ'8:_IZ:3=>!?M1?\' /
M[0_[%S^&OC#^T]_P2!_:+^#_ .PWXK^)MK\--+_:/\4_'/X3+\5([S4%U>YT
MW4=9_97TW2]1\7^%DU+3-$U#5+&S\7>-_#\EU!;R6D,SZJ8+"< _IFHHK^>S
M_@D?_P %$_V@OVM_A#_P4C_;V^+VK>-/B3^S)X;_ &F_B?X2_8S^"?PI^%7A
M?Q)XRL?@9\#]&:Z:]\#6/@#P_#\0/BMXT^*4GB#2[2XL_$_B+Q&3XI\,74'A
M)- T2]DAG /Z$Z*_$W_@G;_P5_\ $O[=?[9G[7O['OC+]C/Q_P#LI>(_V5?"
MWP_\6SGXH_$WPOXF^(&N6'Q#BLK_ $G3_&/P_P#!V@7/A[X=Z]#HVJ:7JEUI
M>G_%#X@/:F\;3=1FT_4[2ZM8OE_X^_\ !?\ ^*?AOXF_ML:/^R+_ ,$T_B7^
MU[\"O^"<6O>*_#G[9W[0LO[0OPV^!>D?#O4OAW!JUW\2U\#>!?%7ACQ1XE^*
MB^![;POXQ;5H-$FT[40?#AO'L;?0M5TS6IP#^E*BOG/]D3]IGP1^V5^S)\$/
MVIOAOIGB#1?!/QT^'N@_$'0-$\5V]G:^)-%MM9@+3Z/K<.G7FHZ=_:.E7L=S
M87,NGW]Y87#VYN+*ZGMI8I&_.+_@L=_P67\'?\$G/!?PZ;2_@GJ_[3_QN^)2
M^+O$VE?!7P]XW/P^ET3X0?#;0[G6OB3\7_%GB]/ _P 1!H/AGPPW]EZ9:17'
MAIVU[4+^YCL[J%-'U*2( _:FBOYU?CM_P5O_ &M?'WPK_P""3UC^PG\&?V;/
M#?[0_P#P5.^$OQ5^.7AZ/]K[X@>-+[X*?!_PC\$_A#X)^+7C7PKJ^I_#:V\%
M>,/&/B76+'QQ;:5X9UG3;31[&WETB[U#6]"@TRXN+O1J?PZ_X+<?$G]HO]@C
M]@?Q_P#LY_!SP/K7_!0W_@HG-XL\-?"/X!^(K[7[[X7^ 3\(OB%XJ\ ?'?\
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M;]I7PO\ %GQWX3M]7^+OBSP_H[^))/#5W^P_Q=_T3_@X"_8PN+K_ $:#5O\
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M)D:1_P % ;?XN6^A>)/B#JW[2.I_#OP/^PG\+/!UAXHEL;3Q/\5O%GCKPO\
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M_AM^T3X&_P""I'["'[*_Q^O])A\)77Q ^%_[1'P*^/S?"/QEX@&G^)M$\:^
MQXPEO=&TSXH:3IOB#PWXJ\*@>(])@UOP[J>G->Z(W]<_P]^'/P]^$?@OP_\
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M^*= U+PGX$\?:?KK:3 ;;6M"CM-?T:]OOAG_ ((S?MY>.O'7_!-?_@H)=?\
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MO^ G[>O_  23_P""N_PI_9 ^()^-/Q#_ &7]%'@#XY>&O#GA;QSI=]X+\4>
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MDTKQ;;Z?9ZMHLEMX7\+2V6N7THNEA_9*@ HHHH **** "BBB@ HHHH ****
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M^@_^S=_X2/Q/_P#FVH^R?M??]!_]F[_PD?B?_P#-M0!](T5\W?9/VOO^@_\
MLW?^$C\3_P#YMJ/LG[7W_0?_ &;O_"1^)_\ \VU 'TC17S=]D_:^_P"@_P#L
MW?\ A(_$_P#^;:C[)^U]_P!!_P#9N_\ "1^)_P#\VU 'TC17S=]D_:^_Z#_[
M-W_A(_$__P";:C[)^U]_T'_V;O\ PD?B?_\ -M0!](T5\W?9/VOO^@_^S=_X
M2/Q/_P#FVH^R?M??]!_]F[_PD?B?_P#-M0!](T5\W?9/VOO^@_\ LW?^$C\3
M_P#YMJ/LG[7W_0?_ &;O_"1^)_\ \VU 'TC17S=]D_:^_P"@_P#LW?\ A(_$
M_P#^;:C[)^U]_P!!_P#9N_\ "1^)_P#\VU 'TC17S=]D_:^_Z#_[-W_A(_$_
M_P";:C[)^U]_T'_V;O\ PD?B?_\ -M0!](T5\W?9/VOO^@_^S=_X2/Q/_P#F
MVH^R?M??]!_]F[_PD?B?_P#-M0!](T5\URVG[81B/D>(/V:A-YB8,O@_XH-%
MY6V3?D)XX5_,W^5L.=NWS,C.W%3['^VA_P!#%^S!_P"$9\5O_F\H&E?JOG\O
M\_P9]/T5\P?8_P!M#_H8OV8/_",^*W_S>4?8_P!M#_H8OV8/_",^*W_S>4OD
M_P /\_ZL_*Y;S7W^G^?X/L?3]%?,'V/]M#_H8OV8/_",^*W_ ,WE'V/]M#_H
M8OV8/_",^*W_ ,WE'R?X?Y_U9^5RWFOO]/\ /\'V/I^BOF#['^VA_P!#%^S!
M_P"$9\5O_F\H^Q_MH?\ 0Q?LP?\ A&?%;_YO*/D_P_S_ *L_*Y;S7W^G^?X/
ML?3]%?,'V/\ ;0_Z&+]F#_PC/BM_\WE'V/\ ;0_Z&+]F#_PC/BM_\WE'R?X?
MY_U9^5RWFOO]/\_P?8^GZ*^8/L?[:'_0Q?LP?^$9\5O_ )O*/L?[:'_0Q?LP
M?^$9\5O_ )O*/D_P_P _ZL_*Y;S7W^G^?X/L?3]%?,'V/]M#_H8OV8/_  C/
MBM_\WE'V/]M#_H8OV8/_  C/BM_\WE'R?X?Y_P!6?E<MYK[_ $_S_!]CZ?HK
MY@^Q_MH?]#%^S!_X1GQ6_P#F\H^Q_MH?]#%^S!_X1GQ6_P#F\H^3_#_/^K/R
MN6\U]_I_G^#['T_17S!]C_;0_P"AB_9@_P#",^*W_P WE'V/]M#_ *&+]F#_
M ,(SXK?_ #>4?)_A_G_5GY7+>:^_T_S_  ?8^GZ*^8/L?[:'_0Q?LP?^$9\5
MO_F\H^Q_MH?]#%^S!_X1GQ6_^;RCY/\ #_/^K/RN6\U]_I_G^#['T_17S!]C
M_;0_Z&+]F#_PC/BM_P#-Y1]C_;0_Z&+]F#_PC/BM_P#-Y1\G^'^?]6?E<MYK
M[_3_ #_!]CZ?HKY@^Q_MH?\ 0Q?LP?\ A&?%;_YO*/L?[:'_ $,7[,'_ (1G
MQ6_^;RCY/\/\_P"K/RN6\U]_I_G^#['T_17S!]C_ &T/^AB_9@_\(SXK?_-Y
M1]C_ &T/^AB_9@_\(SXK?_-Y1\G^'^?]6?E<MYK[_3_/\'V/I^BOF#['^VA_
MT,7[,'_A&?%;_P";RC['^VA_T,7[,'_A&?%;_P";RCY/\/\ /^K/RN6\U]_I
M_G^#['T_17S!]C_;0_Z&+]F#_P (SXK?_-Y1]C_;0_Z&+]F#_P (SXK?_-Y1
M\G^'^?\ 5GY7+>:^_P!/\_P?8^GZ*^8/L?[:'_0Q?LP?^$9\5O\ YO*/L?[:
M'_0Q?LP?^$9\5O\ YO*/D_P_S_JS\KEO-??Z?Y_@^Q]/T5\P?8_VT/\ H8OV
M8/\ PC/BM_\ -Y1]C_;0_P"AB_9@_P#",^*W_P WE'R?X?Y_U9^5RWFOO]/\
M_P 'V/I^BOF#['^VA_T,7[,'_A&?%;_YO*/L?[:'_0Q?LP?^$9\5O_F\H^3_
M  _S_JS\KEO-??Z?Y_@^Q]/T5\P?8_VT/^AB_9@_\(SXK?\ S>4?8_VT/^AB
M_9@_\(SXK?\ S>4?)_A_G_5GY7+>:^_T_P _P?8^GZ*^8/L?[:'_ $,7[,'_
M (1GQ6_^;RC['^VA_P!#%^S!_P"$9\5O_F\H^3_#_/\ JS\KEO-??Z?Y_@^Q
M]/T5\P?8_P!M#_H8OV8/_",^*W_S>4?8_P!M#_H8OV8/_",^*W_S>4?)_A_G
M_5GY7+>:^_T_S_!]CZ?HKY@^Q_MH?]#%^S!_X1GQ6_\ F\H^Q_MH?]#%^S!_
MX1GQ6_\ F\H^3_#_ #_JS\KEO-??Z?Y_@^Q]/T5\P?8_VT/^AB_9@_\ ",^*
MW_S>4?8_VT/^AB_9@_\ ",^*W_S>4?)_A_G_ %9^5RWFOO\ 3_/\'V/I^BOF
MN*T_;!$(\_Q!^S6;CS)-WE>#_B@L/D[8O*P'\<,_F;_.\PDA=OE;1G?3_LG[
M7W_0?_9N_P#"1^)__P VU,1](T5\W?9/VOO^@_\ LW?^$C\3_P#YMJ/LG[7W
M_0?_ &;O_"1^)_\ \VU 'TC17S=]D_:^_P"@_P#LW?\ A(_$_P#^;:C[)^U]
M_P!!_P#9N_\ "1^)_P#\VU 'TC17S=]D_:^_Z#_[-W_A(_$__P";:C[)^U]_
MT'_V;O\ PD?B?_\ -M0!](T5\W?9/VOO^@_^S=_X2/Q/_P#FVH^R?M??]!_]
MF[_PD?B?_P#-M0!](T5\W?9/VOO^@_\ LW?^$C\3_P#YMJ/LG[7W_0?_ &;O
M_"1^)_\ \VU 'TC17S=]D_:^_P"@_P#LW?\ A(_$_P#^;:C[)^U]_P!!_P#9
MN_\ "1^)_P#\VU 'TC17S=]D_:^_Z#_[-W_A(_$__P";:C[)^U]_T'_V;O\
MPD?B?_\ -M0!](T5\W?9/VOO^@_^S=_X2/Q/_P#FVH^R?M??]!_]F[_PD?B?
M_P#-M0!](T5\W?9/VOO^@_\ LW?^$C\3_P#YMJ/LG[7W_0?_ &;O_"1^)_\
M\VU 'TC17S=]D_:^_P"@_P#LW?\ A(_$_P#^;:C[)^U]_P!!_P#9N_\ "1^)
M_P#\VU 'TC17S=]D_:^_Z#_[-W_A(_$__P";:C[)^U]_T'_V;O\ PD?B?_\
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MO_Z"W[//_A/?$G_YIZ /H:BOGG[/^U?_ -!;]GG_ ,)[XD__ #3T?9_VK_\
MH+?L\_\ A/?$G_YIZ /H:BOGG[/^U?\ ]!;]GG_PGOB3_P#-/1]G_:O_ .@M
M^SS_ .$]\2?_ )IZ /H:BOG.:U_:X,A,&N_LY)%M3"S>%/B9)(&V+YF73QE$
MK*9-Y3]VI"%0V6!)B^R?M??]!_\ 9N_\)'XG_P#S;4 ?2-%?-WV3]K[_ *#_
M .S=_P"$C\3_ /YMJ/LG[7W_ $'_ -F[_P )'XG_ /S;4 ?2-%?-WV3]K[_H
M/_LW?^$C\3__ )MJ/LG[7W_0?_9N_P#"1^)__P VU 'TC17S=]D_:^_Z#_[-
MW_A(_$__ .;:C[)^U]_T'_V;O_"1^)__ ,VU 'TC17S=]D_:^_Z#_P"S=_X2
M/Q/_ /FVH^R?M??]!_\ 9N_\)'XG_P#S;4 ?2-%?-WV3]K[_ *#_ .S=_P"$
MC\3_ /YMJ/LG[7W_ $'_ -F[_P )'XG_ /S;4 ?2-%?-WV3]K[_H/_LW?^$C
M\3__ )MJ/LG[7W_0?_9N_P#"1^)__P VU 'TC17S=]D_:^_Z#_[-W_A(_$__
M .;:C[)^U]_T'_V;O_"1^)__ ,VU 'TC17S=]D_:^_Z#_P"S=_X2/Q/_ /FV
MH^R?M??]!_\ 9N_\)'XG_P#S;4 ?2-%?-WV3]K[_ *#_ .S=_P"$C\3_ /YM
MJ/LG[7W_ $'_ -F[_P )'XG_ /S;4 ?2-%?-WV3]K[_H/_LW?^$C\3__ )MJ
M/LG[7W_0?_9N_P#"1^)__P VU 'TC17S=]D_:^_Z#_[-W_A(_$__ .;:C[)^
MU]_T'_V;O_"1^)__ ,VU 'TC17S=]D_:^_Z#_P"S=_X2/Q/_ /FVH^R?M??]
M!_\ 9N_\)'XG_P#S;4 '[)W_ "1F/_LJO[1'_K0WQ2KZ1KY?_8Y&J+\!],77
M'L)=9'Q)^/XU632HKB#3)-0'[0/Q/^V/I\-W-<745FT^\VT=S/-.D)1997<%
MC]04 %?-W[.7^M^/W_9R/Q)_](_#5?2-?-W[.7^M^/W_ &<C\2?_ $C\-4 ?
M2-%>/_&O1?C[KWA73[/]G/XE_!_X5^-H_$%K<ZIXA^-?P.\:?'[PK>>%4T[5
M8K[1M/\ !W@7]H7]FO5]-\07&KS:'?6OB:X\=:MIUGIVG:KI<WA.^N=9L]8T
M+\J/^">W[1?_  4>_:V\6?M)WGQ!^,W[$F@^!?V3_P!OCXS_ +'_ (O\.>#O
MV+/CM9^+/BOX;^!=YX/?6?&'AOQIK?\ P4(U[1_A;KGC:P\2SVVF6&J> OBG
M8>#[RUBOKIO&$+OI] '[;T5_/=X3_;F_X*2?%3P!_P %,/V@/AUXG_8=TGX?
M?\$_OVN_VM/@EHOP3\<?L]?'+_A+OBO\.OV5[70_%M[<ZO\ M&:9^U[;^'/
M'C+QAX/U2\TFWUU/V</%/AS1/$=E;ZQ=>'KK2+R?3-/^]_%O_!0WPEX?_P""
M5\W_  4WG\*7GAK0-3_8ZT3]J/PO\.?$]TL^I7&M^.?AKIWB_P"'/PRGO].6
M"/4-3\5^*M?\.>"-+OK-;2'4[W6+*YA%G%<CR@#]&J*_+?\ X)>_ME_'3]I[
MPW^T;\*_VO/"_P +_ 7[8?[(WQXO?A)\:/"'PALO$FD^!;SPSXI\(^'/B;\&
M?B+X;T7Q?XM\<^(]+TCQQX$\4QVDEOJ_B>^N3XE\+>)VBAM+#[#$?"/V/?VB
M/^"E/[;MA^TQXX\&_&W]ASX+^$/@Y^VK^U+^R]X5\)>)OV(OCW\7_$EYX;^
MGQ*O_!NA^)?$/C72O^"BGP@TN]US7-+BM9]6@TWP)H]A%?QW$MG%';SQVML
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MS?\ LR>*?VE/C)XWN=7TOPO%+J5KX/\ @9\*;'0=+;Q!XJ^*O[1_Q,G>>_\
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M@V>H>'Y$U*#6?%][X>T4HP@?4%NCY% 'U;1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* /FW_A8W[27_1M.A_\ A]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ*
M/FW_ (6-^TE_T;3H?_A]]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X
M6-^TE_T;3H?_ (??0?\ YC*/^%C?M)?]&TZ'_P"'WT'_ .8ROI*B@#YM_P"%
MC?M)?]&TZ'_X??0?_F,H_P"%C?M)?]&TZ'_X??0?_F,KZ2HH ^;?^%C?M)?]
M&TZ'_P"'WT'_ .8RC_A8W[27_1M.A_\ A]]!_P#F,KZ2HH ^;?\ A8W[27_1
MM.A_^'WT'_YC*/\ A8W[27_1M.A_^'WT'_YC*^DJ* /FW_A8W[27_1M.A_\
MA]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ* /FW_ (6-^TE_T;3H?_A]
M]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X6-^TE_T;3H?_ (??0?\
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M* /FW_A8W[27_1M.A_\ A]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ*
M/FW_ (6-^TE_T;3H?_A]]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X
M6-^TE_T;3H?_ (??0?\ YC*/^%C?M)?]&TZ'_P"'WT'_ .8ROI*B@#YM_P"%
MC?M)?]&TZ'_X??0?_F,H_P"%C?M)?]&TZ'_X??0?_F,KZ2HH ^;?^%C?M)?]
M&TZ'_P"'WT'_ .8RC_A8W[27_1M.A_\ A]]!_P#F,KZ2HH ^;?\ A8W[27_1
MM.A_^'WT'_YC*/\ A8W[27_1M.A_^'WT'_YC*^DJ* /FW_A8W[27_1M.A_\
MA]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ* /FW_ (6-^TE_T;3H?_A]
M]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X6-^TE_T;3H?_ (??0?\
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M* /FW_A8W[27_1M.A_\ A]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ*
M/FW_ (6-^TE_T;3H?_A]]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X
M6-^TE_T;3H?_ (??0?\ YC*/^%C?M)?]&TZ'_P"'WT'_ .8ROI*B@#YM_P"%
MC?M)?]&TZ'_X??0?_F,H_P"%C?M)?]&TZ'_X??0?_F,KZ2HH ^;?^%C?M)?]
M&TZ'_P"'WT'_ .8RC_A8W[27_1M.A_\ A]]!_P#F,KZ2HH ^;?\ A8W[27_1
MM.A_^'WT'_YC*/\ A8W[27_1M.A_^'WT'_YC*^DJ* /FW_A8W[27_1M.A_\
MA]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ* /FW_ (6-^TE_T;3H?_A]
M]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X6-^TE_T;3H?_ (??0?\
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M* /FW_A8W[27_1M.A_\ A]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ*
M/FW_ (6-^TE_T;3H?_A]]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X
M6-^TE_T;3H?_ (??0?\ YC*/^%C?M)?]&TZ'_P"'WT'_ .8ROI*B@#YM_P"%
MC?M)?]&TZ'_X??0?_F,H_P"%C?M)?]&TZ'_X??0?_F,KZ2HH ^;?^%C?M)?]
M&TZ'_P"'WT'_ .8RC_A8W[27_1M.A_\ A]]!_P#F,KZ2HH ^;?\ A8W[27_1
MM.A_^'WT'_YC*/\ A8W[27_1M.A_^'WT'_YC*^DJ* /FW_A8W[27_1M.A_\
MA]]!_P#F,H_X6-^TE_T;3H?_ (??0?\ YC*^DJ* /FW_ (6-^TE_T;3H?_A]
M]!_^8RC_ (6-^TE_T;3H?_A]]!_^8ROI*B@#YM_X6-^TE_T;3H?_ (??0?\
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MPS>^)O#]KK6FV4^LZ='<]O8_M,_LWZG\;=8_9HTW]H+X(ZA^T=X>TZ+6-?\
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MZFM+;[;=16T\MM9^<EM]KN(XF>&V^T2@QP>?(%B\Z0%(M^]P54BOY:_VN_\
M@NW_ ,%/_P!@[X-7_P"T#^UE_P $)]/^$7PET[7]!\+3>*+S_@JI^S5XKN+G
MQ%XFN7MM%T;2?"_@+X4^*?%^N:A=&&ZNY+?1=!OWL=+L-2UF_%KI.F:A>VP!
M_4Y17 ?"?Q;K_C_X6?#7QWXL\&7GPX\4^-? '@WQ;XE^'FHW_P#:NH> ]?\
M$?AW3M8UGP9?ZF=/TDZC>>%]1O+G0[J_.E:9]LGL7N/[/L_,^S1_SF?L'_\
M!6+]HSXF_L9_\%>/^"J'Q0ND^+/[.'P6^,/QQ/[%'P&LK7P%\/;&/X*?LZ>%
M+G5XYXOB5X;\$ZSXJU*_^*MQK>E6?B'Q)XTD\?1:)K?AC4;CPCHMCH]PVFWH
M!_3E17X@_L!_\%'?^"D_[9'B/]GOQ9\1?^"/G_#.O[(OQ_\ A_9_%+3_ -J;
M_AX'\!?BY_87@3Q9\++_ .(WPMUW_A2&A>!O"_Q-U/\ X6!>R^$?#/\ 9D]M
MHVL>%/\ A*_[9\1:?;0Z%J=B/V4\=^./"?PR\$>,OB3X]URR\,>!OA]X5\0^
M./&GB74C(NG>'O"?A/2+S7O$>N7[0QS3"RTG1["\O[HQ12R""WD,<;MA2 =5
M17X"?LK_ /!8[]JW]M3QG\./'O[._P#P21^./B']@'XE?%+3OA_H_P"V?XN_
M:!^#W@+Q GAF?QH/!NL?%V#]F37+(^/-:^''AUUN]9U+5M"\4:A*VG:9JUO;
MPR:O83:;7S5\1_\ @MK^V5X1_;)UV/2_@I^R[/\ L ^!O^"I'@/_ ()0^+HM
M0\7?$"3]LW4OB]XOTS0I[OXN^&=/MKVW^&$?PUTZ771?6>A7NBW7B'54L+C1
M8K^)TU+7M& /ZD**_,#X(?MN_$K]JO\ ;M^,OPE_9Z\/?#[5/V+/V2['4OAK
M^T!^T!K%OKVK>(/B%^UO.8)Y?@?\#+K2_$.E^&;32?@MI,D5U\:?%NMZ5XM>
M3Q/J=EX%T;3-%GMIO$<_S+^Q9^VK^T3+_P %B_\ @IA_P3@_:2^(2?$+0?!'
MAKX<?M2_L=:A-X.\&^#[S0?@/XTM= B\:?#_ ,_PCX8T*7Q?I_@'Q3\0/"?A
M72_$?BN\UGQ;>3Z'KUSJ6K:HL^^Q /W9HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HK'\1>(-%\)^']<\5>)-2MM'\.^&='U/Q!KVKWKF
M.STK1=&LI]1U34KN0!BEM8V-M/=3N%8K%$Y )&*_EK?_ (.;-7L_ OAO]L+5
MO^":'QVTO_@E=XM^,UW\&]#_ &[)/B_\/I_$$UW:^)]2\)MXNN?V8X-";QE9
M>$5U;2;^SFUJY\:)IQU>RO?"UE>W_B^W&@2@']5E%<WJ7B_PYI/A"_\ 'MYJ
MUFGA'3?#=UXONM=29'L%\.6>ER:S/JRW ;RWLQID;7BS!MC0@.&VG-?S%_L0
M?\%I?B%X2_X),?M*_P#!8']OWQ3K?BKX8^.?VFOBLG[)OP7\)^#?A[X>UK0/
MA3;^,H/AO\+O@YH=]X?TG2+GQ#K#^/+#Q?8Z]XR\?:YXFU*PT#P]<:Y<ZI?)
M8W$=Z ?U,45^!/[+W_!:WXH^-?VRO@_^Q)^W3_P3S^)?_!/[XH_M.> -8^(W
M[+^J>(?C5X%^./AGXGZ/HFDZCX@O-$\2WWA'PYX6;X:^-UT72K^2;P9JBZOK
MFD:K';:'XDM]#U#5=%34M[_@D7^VI^T5\6_VD_\ @J9^Q#^UO\0D^)_Q>_8E
M_:F=?AUXYE\&>#O -_X@_9F^*]MJ=_\ !ZUOM!\">&_#/AZ?4M"TWPW)J&HZ
MM]DN-2NHO&&EV][?:BMK!J%T ?NQ1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 45Y7\<OC1\/OV<_@U\4OCW\6-8;P_\ #3X.> O%
M/Q(\<ZQ';2WUQ8^&?"&CW>MZM)9V%N&N=1U![2SDAT[3K96N=0OI+>SMU:>>
M-3_.O\-_^#C7QE=:[^RG\0OVC/\ @FG\9?V9?V(/VX/B5HGPP_9G_:[\0_&_
MX<>-GU_5_%>H-8^%-5^(WP9T+0K#7OACH.L1176M17]_XKU@WWABSO/$WA>+
MQ1HMM->( ?T^45X;^TY\<O#W[,7[.'Q[_:.\5Q&X\.? CX.?$GXO:Q9))''/
MJ5E\//!^L>*Y-)LS))$LFH:N=*73-.MU<2W5]=V]M"&FE13^ W[./_!77XN_
MLL?\$1_@1_P41_X*+:MXD_:#^/O[4'CR[B^#_P */AOX.\!>#-;\7:G\5O%W
MBI?@3\(?!5AX1\/Z)I<6F-\-O"O_  G%WX@UZT\1>+(=.NM3MKJ[\5:U!I.F
MWH!_3717X7_L??\ !8?XC_&+]M-O^"=_[:_[#/C[_@GO^U/XM^#EY\<?@]H.
MK?&SX<_M >%?B7\/[1[V.YGTGQIX,T'0]-L?%EM;Z1XHU)= &DZ_96L?@GQ;
M9:[J6F:QI2:-?0_\$-/VU_VB?VE/"7[;'[._[8OCR+XG?M2?L%_ME?%3]GKQ
MO\0U\'^$/ ,_Q \!6NLZDGPU\;W7A#P%X<\+>$-&_M230O%^CZ<NB:6;?4=#
M\/:5K,U]J%WJ5Q=R@'[K4444 %%%% !1110 4444 %%%% 'S=^R=_P D9C_[
M*K^T1_ZT-\4J^D:^;OV3O^2,Q_\ 95?VB/\ UH;XI5](T %?-W[.7^M^/W_9
MR/Q)_P#2/PU7TC7S=^SE_K?C]_V<C\2?_2/PU0!](T444 %%%% !1110!_-]
M\*_@=X_^-O\ P6B_X+6:=X)_:T_:+_9:M].^%O\ P3$LM=D_9\TO]F>[OO&L
M/B#X)_'6"U?7-4_:#_9R^/FIZ%=^%TL+YO#=_P##F[\"WT4VOZI<:Q<ZS<6G
MAV70OS2TKQ?]J_X(H>&O@AI6F^$K[X?_ +''_!;7X)?LC?"GXR^!K74+7PQ^
MU-X#^%/[<7PSO5_:@A:]UWQ1::AXB^+OBSQ5XKU/XAZWX>\1ZSX6U[XE6?C'
M6O#MU%I=];V5K_5Q\6?V OV$?CWXVU#XE_'3]BC]DGXT?$?5[;3K/5?B!\6?
MV</@Y\1O&VIV>D64.FZ3:ZAXK\8>#=9UV]MM+TZWM[#3H+F_EBLK*"&UMDB@
MB2-?8-1^!'P/UCX>>#OA%JWP:^%.J?"?X>?\(+_PK_X8:C\//"-]\// W_"K
MY--F^&G_  AW@JYT>7PWX9_X5W+HVD2^!?[%TRR_X1*32M-?0/[/:QM3$ ?D
M1^TK^UE8:]\6/^"F/P#^!W[*'[*_B&+X _ 3P''_ ,%!_CG^U-^T'IG[+OAO
M7?"_Q7^!_B?Q7\/M'FF\(_LX?M&^)_BQX.\-?"*[\2P:GXD^+0^&?@?097U[
MP;X:U;6!8^*I='_*/]G>]&O_ +*'_!ID_P :9K;5/V<&^*%QHWB__A*OLUQX
M5?X_:3^S;\4M#_8<T_44U,-I;ZW9_$FR&F_#B&X4WR^);?28="!U=;,5_5+\
M1?V2/V4_B_\ $[P?\;/BS^S)^SW\4?C-\/(_#\/@#XM_$7X+_#CQM\3O T/A
M+Q!?>+?"L7@_Q[XE\-ZGXJ\,Q^&?%6IZEXF\/IHNK62Z-X@U"^UG3A;:C=SW
M,FU?_LV?LZ:K\%8_V;-4^ 7P5U+]G2+2=-T&+X!7_P +/ UY\%8]#T;5;77=
M(T:/X67&A2>!4TG2M;L;+6--TY="%G8ZK9VNH6L,5W;Q3( ?SZA? #?\%\?^
M"B\W[(</@Y?C0/\ @C5;VGQ'G^']M;17DW[7L/QGUNYT:/Q?/I\:077Q'A\
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M)XMUG2OB=XAD\(MJ_CW3=6\5^&O#GB;4['Q5>:M:W_B'0-$UJZBEU+2K&Y@
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M&MM'LO!7B&/XEZQX2O/&::YX/L_#V@6GA;5EUH7_ (?MM#T>#2;BTBTRR2
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M%=0^'WA*\\-_"/Q)\-[!]*^'?B#X8Z'<Z1)I?@+7/ 6F22:;X+U;PK:Z3?\
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M*"YN(;0:[97XMXKB>.'8DL@8 _BU_90/PK_9:_X.*/V8O"7["'[:NK?\%:M
M_:?^#'BC1_VE/B]\9_B#X!_:Y^+WP.\+>'M+\8ZC#JFA_M;>%-,6T\/V]K'I
MNF7>K^'-(O-/&H:>\7A'Q9I]_J'B7P)<Z9^NG_!W%:WMQ_P1B^*,MK#/+!9?
M&OX!W6I/"KF.WLG\;QV4<UT5X6!M1N["W5I/D^U3VRCYV2OWO^"7[*W[,'[-
M$.KV_P"SC^S?\!?V?X/$!B;7H/@E\'_A[\*8=;: Y@;5X_ GAW04U(PGF(WJ
MS&,\I@UXY_P4A_8WT?\ X* _L.?M)?LA:O?Z=HT_QF^'EWI/A7Q#J]O<W6F>
M&/B)H.H:?XO^&?BC4;>R*WL^G^'?B!X>\-ZOJ,%F?M-S86=S;1!S-L8 \L_X
M*6?M(?LT?"+_ ()^?'^/XA?'#X+?"/3_ (Q?LG_'CP]\$=/^(/Q"\&?#5OB1
MJ&H?!375T3PS\-])\5ZKH5QXEU>:#6-%@L_#OA^TN]20ZCIULMBCW-O$_P#,
M'^Q+XC\)_M!_\&?OQ0_9?^"7Q0\%>,_VD/AQ^SI^TSXO^('P3\ ^+_#GBKXR
M>$?#UK^V+\8/B?!:>+/AGHNM2>,_#T/C[P)IMP= &K:3;/XATO6+:XT:VUA+
MNVMKO^H;X _L'^&?%_[$_P"R1\!?^"D_P3_94_:N^+O[._PH\,^ =5UCQ7\.
M_#_QX\ _V]X6T.Q\&MXO\&7GQE^&VDZM9:GXM\->'] O?%%V/"F@W,^KF[LV
M^VV=I:7<_P!-? _]CS]DC]F34=?U?]FW]EK]G/\ 9[U;Q596>F^*-4^!_P $
M?AG\)]1\2:=IT\MUI]AK][X"\,:!<ZQ96-S//<6=KJ,MQ!;3S2S01I)([$ _
MA8_;+_:?_9Z_;M_X(Z?\&_7["W[+OQ6\$_%#]JS_ (7U^P=X2\2? WPAJ]IK
MGQ"\ W/P1_9Z\?\ P2^).M_$7PGI#76M^"-%TWQCK=EJD.J>)+#3[?5_"TE[
MXNTR:]T&POM2B_K;_:D_;FLOB;H'[>_[%W_!/7Q]H_Q$_P""H/P#^ =_K.D_
M!XV%[X:F\&^)_'FB:/;>"O$,?CSXC6?A7X-:CJ.C#QCH>NQVG_"=:A9Z5JKZ
M79^*[.".:>PE^ROAQ^QS^R+\'/B!K'Q9^$7[+'[./PK^*?B);U?$'Q+^''P/
M^&7@?X@:ZNI.TFHKK'C+PSX8TOQ'J:ZA([O>B]U*<73LS3B1F)/H&A?!+X,^
M%_B;XS^-?AKX1_#'P[\9?B/IFDZ+\0OBWH7@'PKI'Q-\>:/H$%M;:%I/C/Q[
MI^DV_BKQ1IFBVUE9V^DV&N:K?6NFP6EM%9Q0QP1*@!_FV?%_PC^WQ^QA\9O^
M#>_X(^-?^"55W\+/B_\  ;]H3XS^./AWI6K_ +='P%^)?B3_ (*#_M#>//%W
M[-OB#XP>(O$WCWPY9ZKI7P,U2^\5:9X8BM=1^(^L>+[.UT'Q=HV@Z=J=YIW@
M&YFG_IH_X*]_LJ?L=:[^T/\  ;QC\*?V/OAO\2?^"T_[56H:)H?P"\3:SKWC
M*^T+X*:?X!TBQM_%/[7WQR\%:-XGM?A9XL\+_LRZ#!82>%]=\<>"?$.H>+/&
MNE>!O"NAVNLVVFSV>E_T4^.?@?\ !;XH>*OAOXZ^)?P@^%_Q#\;_  <UF\\1
M_"'QCXY\ >$_%OBKX5^(=1.G'4->^&_B'7])U#5_ ^LWQT?23>:IX8O-+OKD
MZ7IQGG?[#;>5H)\)OA7%\3KCXVQ_#3X?Q_&:[\&6_P .;KXN)X-\.)\3KGX>
MVFK3Z_:> [CQ\NFCQ5-X,M==NKG6K?PO)JS:)#JUQ/J4=BMY+),P!_"MXD_:
M[_:1_P""5?QS^,G[,7[-O[8OP@\->#OV,_VH?V/?A8?V(?B#\*/ GBC]IC_@
MIQXE_:OL/ WC#]H;]J#QA\4O$NHO\7Y_'6M^)O&FJ7\E[\,H;W0M#T:'PYH5
MZ=(M=(T%_%WZG_M9Q:AJ'_!V-_P2SA\.S0";P_\ L#_'C7/B%#'#NNO^$'U+
M1?VK-#\/-=3+:RE+23QU)8&T+SVR+<6]TBRA[C[->?T4^(_V8OV:_&'Q;\-_
M'[Q;^SU\#O%/QW\&PVMOX0^-?B/X3> M;^+?A6"R,YLH/#?Q'U/0+KQCH<-H
M;FX-K'I>LVJ6YN)_*5/-DW?F]\$O^"=7Q>TO_@LA^UK_ ,%.OCKXL^'&N>&?
M%'P)^'/[-W[('@KP=J_B?4_$G@/X<6,6C:O\3=1^(]IKG@[P_I&E>(]8\9:%
M+?\ AQ/"_B#Q9:C2_&'BFVOKJS=;1)@#]DJ*** "BBB@ HHHH **** "BBB@
M HHHH ^?_P!JS]I#X>_L@?LW_&O]ISXJWL=EX#^"/P\\1^/M<5KA;:?56T>R
M=M)\-:;(\<P;7/%FMR:;X8T"W$,KW>MZOI]K'%)),J-^#/\ P;.? 'X@:E^S
M]\?O^"G_ .T1;)/^TM_P5'^,WB+XX:K=2Q3J?#WP9TC7=?M?AIX8T6&]N+R;
M2M O=3U/Q;XCT*TLYH+27P%??#G39+<IX;L&3^B+XJ_"'X3?';P-J_PP^-_P
MO^'?QD^&OB"339M>^'GQ5\%>&OB'X&UN;1M3M-:T>75_"7B[3-8T#4I-*UG3
M[#5M->\T^9K'4[*TO[4Q75M#*G5^'/#GA[P=X>T'PCX1T'1O"WA3PMHVE^'/
M#'ACPYI=CH?A[PYX>T.Q@TS1=!T'1=,@M=-T?1M'TVUMM/TO2]/MK>QT^QMX
M+2T@A@ACC4 _F5_X.-I+#3_C5_P0AU_Q)'&/!.C_ /!7G]G:3Q7=7MLUWH\%
M@?%GA6]GCU.W\J>.XCETG3M:D^S-#,UQ:VUZB12+YB'T_P#X*W_!?_@F+\8?
MVN_@]X@_:B_X*E_&/_@F[^UK\#?V?-=UOX6ZW\)?VF_ G[*6K7WPJ^*OB?Q=
MH%WK-CXZ\=^ [VX\4WFHZWX%\4Z!J7A/P)X^T_76TF VVM:%'::_HU[??9W_
M  6D_P""=/BG_@IG^Q1J/P0^%WB_PO\ #OX^> _B?\.OCG^SU\0?&<VM6OAK
MPE\4_A]J5S!#=ZQ?^'-*U[7-.M-3\'Z]XMT)-1T[0M<ETR]U2RU3^QM2^PBV
M?[)\:_LN_!C]I?X??#C3?VT_V=/V:_C[XP\.^'M&N=;TWX@_"[P=\9?!.@>.
MKC1[)/%\W@*3XG>#)+N'1IM86\CTS4'T/0M2O=,6UDOM.LIF>TA /YO/^"#_
M /P4U\>^#_V!OVZ?VB/^"A7[4/B_XH_L:_LH?M+7GP[^!_[:WQ9\/^+=<\7_
M !'^&<NKZ5X.LY[VUT30O$/Q#\:FZ\1:[X#FTJXN8O&/BHZ_\0[WPG/J-POA
MV.VL?G[_ (+=>)_AC\5_^"F/_!#+]IZZ_:G^(7[+/['_ ,=/@K\:K;PY^W-\
M,-:LOAMJ/@C2?BO\-GUWPIK&B>._B%X>NM)^&%]XZ\->._#-C_PD/BK1;'5?
M#7A_Q!JNO11:;J/AN:[TS^PK6/@-\#?$/PFN/@'X@^#/PHUSX%W>D0>'[KX+
M:Q\._"&I_":YT&UO(M1MM$N/AS>Z//X/FTBWU"W@OH--DT9K.*\ABNHX5GC1
MUI^-?V=?V??B3\+=+^!WQ%^!7P;\??!30[#0M*T3X/\ C7X8^"?%7PMT?2_"
M]BFE^&=-TOX?Z[H=_P"$]/L/#NF(FG:%9VFD0V^D6*)::?';VZB, '\K/_!'
M/59_VK_C-_P6(_81^,7[2_Q%_P""GW_!*OX<3?#/P[\-?CC^TU\13\8I?$%Q
MXAM]7\1>+?#L?QWMQI4OC&#2Y; 7<FN^']5M]'\/W'@KPUXQ\&P>%;;Q#:2W
M_P &^/O@_P#![X&_LL_M2_\ !2__ ()Y_ +P+\'/V$OV&/'OAI/^"?>A^)S\
M0OBKH'[3'[4'B3XR^#OV??B3_P %(/B<_C[6_&GBOQ[\.OV;-$\8>++3]E+1
MO$-YX@T33=4T#Q+\0K?3]$MQ/H^I?W/^%_@!\!_ _P *K[X$^"O@G\(_!_P0
MU31-:\,ZE\&_"_PW\&^'_A5J/AOQ)8S:7XB\/WWP\TG1K3PC=Z)K^F7%QIVM
M:5<:/)8:I8SS6E];SV\KQMN6WPE^%=E\-+?X+V?PS^'UI\';3PM%X&M?A-;>
M#/#D'PTMO!,%DNFP>#[?P)%IJ>%H?"T.G(FGQ>'X]*728[)5M4M%@41@ _FQ
M_P""?W[;OQU^/7P?_P""T_P&_:"_:[^%/_!0+X<_L>?#'0G^'?[=?PO^'?PZ
M^'?@/XR>'OC1^S1\0/'?C[PJ-#^$ESJ7PTNA\'-3T)?#>IW.AWNI7LMQ?72Z
MQ=3$V<<7O?\ P:R:?X@T_P#X(=?L>C7?,2WO-5_:)U#PY;S(T4MMX?N_VE_B
MZ\6Z-X8G$=[J@U75+5R9EN+._M[F*8P31)']C_MQ?L%ZGXE_X)K?M/?L4?\
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M$TUC^TI_"?C"RM-3ATCQIX1,?B#5O#6O:)H>G3VEYKL<>C:7>M:?V15^+_\
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MOP<^'B:CXN\'^"M6;5_"Z>+O%=IJ:0:0^G#3T\/6D6HZI-I\E[( ?LA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^3W_  72^&_C
MCXL_\$B/V^_!'PYM=8U#Q;=_ '7]=L=,T"RGU+6=7T_P5J>D>-O$6BZ?I]K)
M'=7T^L^&_#NKZ7]DM1/=7"7;Q6UE?S.EC<?R6_ME_M/_ +/7[=O_  1T_P"#
M?K]A;]EWXK>"?BA^U9_POK]@[PEXD^!OA#5[37/B%X!N?@C^SUX_^"7Q)UOX
MB^$](:ZUOP1HNF^,=;LM4AU3Q)8:?;ZOX6DO?%VF37N@V%]J47^AG7SC\./V
M.?V1?@Y\0-8^+/PB_98_9Q^%?Q3\1+>KX@^)?PX^!_PR\#_$#75U)VDU%=8\
M9>&?#&E^(]374)'=[T7NI3BZ=F:<2,Q) /B/_@O!:WMW_P $>/\ @H=%80SS
MSI^S7XTNI$ME=I%LK)K&]U*9@G/D6^G6]U<73'Y%M8IFD^0-7\V__!1:XL_#
M?_!$S_@VR_:=M([^Z^!O[,/Q(_X)P>-OCI/X>T2XO-/\/:9I?P<\-6?B'Q7K
M=K:HLB?V?XM\.ZYX8>\>PGBU/Q-XLMK1;TWFL6::G_;+\:OA-X1^/7P<^*_P
M.\?V?]H>!?C'\-_&_P +?&5C_%=>%_'_ (:U/PKKL"'*E97TS5;D12*R/')M
M='5E##\Z/^"4G["/Q;_9)_X)T>#OV#_VSM0^"O[0%E\.=2^)7@C1KG0K35?&
M7@CQW\#=?\8:KXG\&Z5XZ\,?$3P9H<$.K6%IKUYH&H^$S9^*- T_2=+T>VMO
M$NM_O9(@#\;?$/Q=^$/[>?\ P=&?\$]OBC^Q_P#%/P)^T/\ #3]D_P#8A^,O
MB7XV_$7X2^(M/\=^ O"7_"?^%?C_ .!/#VA7/C'PY-J/A]O$4FL_%KP0+W25
MOS<:>=5-C>"+5;._L+3UW_@BY%?7G_!:K_@XUUK19(O^$+'QR_9OT746@B\J
MVN_&6G6WQQBGCB?[.J37FCS1>(XM6$<X>*YU*&6XCF-W#,O]%'P:_9J_9W_9
MIT36-"_9L_9\^!WP&TK69O[0U/0?@U\+_ _PDT36]3BB9+>YUBT\!>&]*MKF
M89\K[;<6-Y<0Q,Q1),>6WYQ_\$9_^"=/Q8_8#^%'[1FN?M+>+OAYX_\ VK/V
MOOVIOBI^TW\=_%GPLU+Q)K/@3^T_&VJR3Z%X=\-ZMXN\(^!O$E]8Z?'-JWB"
M\?5O#EK/!XA\6:[:6]Q>Z?;V5S( ?L;1110 4444 %%%% !1110 4444 ?-W
M[)W_ "1F/_LJO[1'_K0WQ2KZ1KYN_9._Y(S'_P!E5_:(_P#6AOBE7TC0 5\W
M?LY?ZWX_?]G(_$G_ -(_#5?2-?!'PE^*OBKPIK_[0&DZ7^S]\9O']JO[17Q'
MF'B#P9<?!E-%=FAT&/[.H\8_&'PCK/GHD27#[]'6$17, $QG%Q#  ?>]%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 ?25%?-O
M_"^O'G_1I'[27_@5^S?_ /1$4?\ "^O'G_1I'[27_@5^S?\ _1$4 +^R=_R1
MF/\ [*K^T1_ZT-\4J^D:^7OV.;V;4O@-I>H7.EZAHEQ>_$GX_P!U/H^JG3VU
M/2Y9_P!H'XH2O8:@=*O]4TPWEHS&"Y.GZE?V?G(_V>[N(MLK?4- !7S=^SE_
MK?C]_P!G(_$G_P!(_#5?2-?-W[.7^M^/W_9R/Q)_](_#5 'TC1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445F:UK6C>&]&U;Q%XBU;3- \/Z!IE
M_K6NZ[K5_:Z7HVBZ-I=K+?:GJVK:G?2P66G:9IUE!/>7]_>3PVMG:PRW%Q+'
M#&[@ TZ*XKX=?$GX=?&#P5X?^)7PE\?>"OBC\.O%EI)?^%O'WPZ\5:%XV\%>
M);&&ZN+&6]\/^*O#5_J>A:S:17MI=6<ESIU_<PI=6UQ;LXFAD1>UH **** "
MBBB@ HHKS3PC\:/@[X_\:_$7X:^ _BQ\-/&WQ&^$%WHMA\6O 'A'QWX6\2>-
M?A=?>)+6YOO#ME\1?"NC:K>Z[X)N]>LK*\O-%MO$MAIDVJ6MI<W%BD\4$KH
M>ET444 %%%% !1110 4444 %%%% !1110 4444 %%<9\0OB-\/?A'X+\0?$C
MXK^//!GPQ^'?A*R&I>*O'OQ"\4:)X+\%^&=.,\-J+_Q!XI\27VFZ'HUD;JXM
M[876I7UM 9YX81)YDJ*V]H6NZ)XHT31O$WAG6=*\1>&_$6E:=KOA_P 0:%J-
MIJ^B:[HFKVD.H:3K.C:MI\UQ8:GI6IV%Q;WNG:C97$]I>VD\-S;32PRH[ &K
M1110 4444 %%%% !17FGPR^-'P=^-=GXGU'X-_%CX:?%K3_!/C#6?AYXSO\
MX9>._"WCRS\(^/\ PZMJ_B#P-XGNO"NJZK!H'C#0DO;)M9\,ZJ]IK6F+=VK7
MME +B(OZ70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>;>$?C+\(
M/B!XR^(_PY\!_%7X;>-OB%\';W0M-^+G@3PCXY\,>)/&7PLU'Q1:7NH>&K#X
MC^&-&U2]UOP/>^(K#3M0O="M?$UCI<^K6EA>W.GQW$-K.Z 'I-%%% !1110
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M\/\ 3-+\->$OAUX=O_AK+\6?$^A0:;H4>L^%M0^%<VM6OB#6[>Y328?ZK/\
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MF?X]_ 7P+\.=;^/'C_4?%<NB0W&M_M36'B6_\+^&(VM/!7P]@\4OX7T*;4M
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M^R/_ ,%'-:_;(^.?[.G[;7PC^+'P'_X*(_M)?'K]K;_@HQX_U+QO=_LB>/\
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M&34+*4RB.\L?ACX$U[QM=VLAA_?!+BWT.2)S#^]"N3'\^*_A$\9?$K_@I7X
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MM* /2:*\V_X7+\(/^BK?#;_PN?"__P M*/\ A<OP@_Z*M\-O_"Y\+_\ RTH
M])HKS;_A<OP@_P"BK?#;_P +GPO_ /+2C_A<OP@_Z*M\-O\ PN?"_P#\M* /
M2:^9?A=^QS^S?\&/CY^T'^U#\./AO'H/QZ_:GD\%/\=OB+=>*O&_B/4O&R?#
MO2)-!\&VD&F^*/$NM:!X0TW1M)D6R72_ ^D^&M-ODMK&34[6]FTZPDMO4?\
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M_"Y\+_\ RTH_X7+\(/\ HJWPV_\ "Y\+_P#RTH ])HKS;_A<OP@_Z*M\-O\
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MM* /2:*\V_X7+\(/^BK?#;_PN?"__P M*/\ A<OP@_Z*M\-O_"Y\+_\ RTH
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M "TH_P"%R_"#_HJWPV_\+GPO_P#+2@#TFBO-O^%R_"#_ **M\-O_  N?"_\
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M4 >DT5YM_P +E^$'_15OAM_X7/A?_P"6E'_"Y?A!_P!%6^&W_A<^%_\ Y:4
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MA!_T5;X;?^%SX7_^6E'_  N7X0?]%6^&W_A<^%__ ):4 >DT5YM_PN7X0?\
M15OAM_X7/A?_ .6E'_"Y?A!_T5;X;?\ A<^%_P#Y:4 >DT5YM_PN7X0?]%6^
M&W_A<^%__EI1_P +E^$'_15OAM_X7/A?_P"6E 'I-%>;?\+E^$'_ $5;X;?^
M%SX7_P#EI1_PN7X0?]%6^&W_ (7/A?\ ^6E 'HLT,-Q#+;W$4<\$\;PSP3(L
ML,T,JE)(I8W#))'(C,CHZE74E6!!(KYO_95_9!_9T_8C^&%U\&/V7/AS%\*?
MA;=>,_%/C]/!-EXG\:>)=&TSQ-XSNH;[Q%+X?C\:^(_$L_AG1KR[A6XMO"GA
MV?2_"FDRO<-H^B6!NKGSO2_^%R_"#_HJWPV_\+GPO_\ +2C_ (7+\(/^BK?#
M;_PN?"__ ,M* /19HEGAE@<R*DT;Q.T,TUO,%D4HQBN+=XIX) "2DT$D<T38
M>-T=58?-W[)O['_[.7[#?P=T_P" ?[+/PW@^%OPITW7_ !'XI@\-IXE\9^,[
MRX\1>+-1?5/$&LZKXJ^(7B+Q9XPUO4-0NV4?:-9U^_>UL[>STRR-MIMC9VD'
MIG_"Y?A!_P!%6^&W_A<^%_\ Y:4?\+E^$'_15OAM_P"%SX7_ /EI0!Z317FW
M_"Y?A!_T5;X;?^%SX7_^6E'_  N7X0?]%6^&W_A<^%__ ):4 >DT5YM_PN7X
M0?\ 15OAM_X7/A?_ .6E'_"Y?A!_T5;X;?\ A<^%_P#Y:4 >DT5YM_PN7X0?
M]%6^&W_A<^%__EI1_P +E^$'_15OAM_X7/A?_P"6E 'I-%>;?\+E^$'_ $5;
MX;?^%SX7_P#EI1_PN7X0?]%6^&W_ (7/A?\ ^6E 'I-%>;?\+E^$'_15OAM_
MX7/A?_Y:4?\ "Y?A!_T5;X;?^%SX7_\ EI0!YO\ LG?\D9C_ .RJ_M$?^M#?
M%*OI&OF;]D2[M;_X(6=[8W-O>V5W\3_VA+FTN[2:.XM;JWF_:#^*,D,]O<0L
M\4T,L;*\4L;LDB,&5BI!KZ9H *^/?@;\.OA]XEU+X_:GXC\"^#M?U$_M&?$:
M$ZAK7AC1-5O3#':>'&CA-W?6,\YB1G<I&9-BEV*@%CG["KYN_9R_UOQ^_P"S
MD?B3_P"D?AJ@#TG_ (4W\(?^B5?#?_PAO#'_ ,JZ/^%-_"'_ *)5\-__  AO
M#'_RKKTBB@#S?_A3?PA_Z)5\-_\ PAO#'_RKH_X4W\(?^B5?#?\ \(;PQ_\
M*NO2** /-_\ A3?PA_Z)5\-__"&\,?\ RKH_X4W\(?\ HE7PW_\ "&\,?_*N
MO2** /-_^%-_"'_HE7PW_P#"&\,?_*NC_A3?PA_Z)5\-_P#PAO#'_P JZ](H
MH \W_P"%-_"'_HE7PW_\(;PQ_P#*NC_A3?PA_P"B5?#?_P (;PQ_\JZ](HH
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M'_RKH_X4W\(?^B5?#?\ \(;PQ_\ *NO2** /-_\ A3?PA_Z)5\-__"&\,?\
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M\-__  AO#'_RKKTBB@#S?_A3?PA_Z)5\-_\ PAO#'_RKH_X4W\(?^B5?#?\
M\(;PQ_\ *NO2** /-_\ A3?PA_Z)5\-__"&\,?\ RKH_X4W\(?\ HE7PW_\
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M?_A3?PA_Z)5\-_\ PAO#'_RKH_X4W\(?^B5?#?\ \(;PQ_\ *NO2** /-_\
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MG\5O _@WXE7=]KGP:T:.U\"_$ZST+Q3>V/P\\">/]=T/QEXJ^(FE:KX-\/>
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M\,O%'[1?[;?_  C/Q%^%OC+PY\0/ GB+^Q/V2/BCX=UG^PO%WA/4M7\/ZO\
MV1X@TC5="U/^S]0N/L&L:9J&F77E7ME<P1 'VA\>?^"NG[ ?[->K_$32?BM\
M7O&T5O\ "+Q5H/@'XJ^+?AU^S9^U%\</AG\-OB+XGDTV'0_AIXZ^+7P1^"_Q
M$^&'A3XFW\^M:);CX<:YXNL?&]O<:WHMO=:#!-J^G)<_2OA/]K?X#>-/C)X-
M_9[TGQ/XDT_XV^/?V=F_:M\/?#+QC\+/BS\//%D?P+C\8:#X!N?%7B33?'W@
M?PT_@C7+#QCXFT70=3^''C5O#_Q.TN\NIFU'P;:V]AJ,UI_'IJ'Q(\2?$/X
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M%O[9O_!M-\<O^":?[.WBU_'O[:GPS_9!_;'L_&?P8B\*^-]'N--U3XR?&/\
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M\5/V/]2^)EQ\'?''@--:DT'6= O])^+>H:IXSM-=M;VUUP6^JROI=B]SX/\
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M\5Z%XCT22VU?2"Z^'M)\%7]_H]]8ZS:6?CB2YTVYAFA,\/LO_!57]KO]M/\
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M^P!^UK_P4DTC_@HE_P %"/VM?#^H?\%#?CIXNTC]F?\ 8=_8]\-_!K]HK7/
M_P"RMX6\?^*)OA]X#\+0_$B+X-CP!JGQ$\62>+]0T4^*1XIM_"6D6/CCQ=XH
M\1ZM'K7BV[L_ 0!]4_"__@L9^V=J7_!1OP)9>*/VRO@#K_PR\>_\%.?VAOV%
MO&7_  32T_X6?#[1/B7\!O@-\)%\4V&D_M5>)OB=-J/_  N800P^'U\1^(K[
MQ!:V_P -Y)+?4Q87<=NNI^'_  A^YW[ 7[3O[0?[>WQM^,O[6'A_Q#<>"O\
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M:'\(_B%X&^'UOX*M/AGH,>C^"M/\.W'AKQUI_BZ?7=9,6F:A/I[37=OXB\;
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M<WPI^%W@6S\2>'_'"_$H^,93\)_!/POL]4TWP3J5MH'A:&RT[0?AG%XP\/\
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M@#]T_@?_ ,%1_P#@I+\#O^"@_P"RW^PU_P %5_@/^R1X2A_;E\#^*?$?[/\
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M@^ +G7/%DVDW[ZW%YY\37=O!I6EV-K9V<?Z?44 %%%% !1110 4444 %%%%
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M?$'C?Q-K-_\ "_P7X/\ V=O@IK?A+PA\.[O4=3N;CP5X7\+:UJNJ:OX<\/\
MAJ33-)T35-2O[_3+2UN[RXED /WGKP3Q3\>?^$7_ &A/A5^S[_PICX]^(O\
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M!GX[:7\;=3^#?B6_^(7_  SQ\7_B3\ ?BKI^E>%O%6E:IHGQF^$MOIUQXY\
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MT#_P7B/[-FJ_M*_M%?#W]EW0_P#@E1\._CAXZ^!OP<^,_P 4?@[IWQ&\>O\
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MO>:6UQX7O]1L/#VC0:C=^'O[+>Z33[6)@L$,42?S/?LO:_XP\-?\&3GB/4_
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MP#XJ_9&_9:\'IJOC67]JK5?VV_@Y>?L,_#OPEX(\._$#2OBS^TG!%K6A>&O
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MAU^P#XE^+WP'\(_MAZIXOLOV?/!?Q6UGXE?'O3?%/Q2UG3/ 6FZGXM\3>(=
M\-_#_P *ZGHVBZ'%'J-OJ_AK0O$5G>Z9=:#!?Q ']._[&7[>?[)7_!0CX::O
M\7_V/?C%IOQE^'WA_P 4W/@K7=:LO#7C?P?>:-XIM--TW6)M'U3PY\0_#/A'
MQ/8W']EZOIM]#)<Z-%;W-M=QR6TTP#[??OBI\4OA]\$/AKX\^,/Q8\5Z7X&^
M&?PQ\)Z[XX\=^+]:>5-,\.^%O#>G3ZKK.JW0MXKB[G6ULK:5X[2RMKJ_O9O+
ML["UNKR>"WD_&K_@C/\ \%&OCE^V9XX_;\_9X_:M^#'P8^%G[5/[#/QST#X<
M?&7Q!^SP_B,_"#XFW'B8>.- T3Q%X>3QC>:OXL%Y9R?";6[6>77=<U"\N-!F
M\,226NBSF?2;7\Y_^#A_]O+]G33OVM/V,?\ @F7^UU\69_@%^QIXTT_P]^V'
M^VCXY7PC\0_&]S\6/AGX-\;^+M+^$O[-FCZ'\+O"7C3Q0FF_$'XE?#/5;WXA
M:F=+T^+3='T_P]?66MQ3VMQI.L '[*^'?^"UG_!.'QU^QC\>/V^OAG\=[WXC
M?LU_LXZO;>%_B7XGT3X8_%+P[KUMXUU2;PG9>'?!6C>$/B1X/\#>(-7U[Q1J
MWCOP=HN@RPV::#<:GXALXKO6K.&#4+BRZ']C3_@J]^S5^V3X$_:,\8Q>&OC;
M^R[K7[(\MC-^TI\*_P!L;X>6WP/^*GP:\/:SX3O_ !SX=\9>.?#C>(O$NGZ/
MX3\2>$=(UC7]'U*77#-)INE7ES=V=G%]G:X_DT_X(,^"?V6/^"E7[&'_  6"
M_P"":VE?%_5OA]K_ ,<_VM?$/[2O@*[\#>"O$NGZAX/^$N@^./A!X@^#OQ/T
M5=2T70O"T=GIWQ(\#>'('^'USKNB>*CI=M-:W&E:/93)J$-7X^_#C5/@UXM_
MX*0ZY\<_VB_BU_P4+^$7P\\=_LP>-?\ @L7\=?!_PQ\(_  ?M:?&CX>7_A_X
M+_L3_P#!,OX6^$_!6KZYX8T#2-%UKX@>&M<_:T\3Z)?:M)IGAHZ/X9N;31?$
M[?V7JH!_5%\5/^"IATS_ ():?$;_ (*B? ;]F'XG?$OP9X1\)ZG\3/"'PH^+
MFNZ1\ ?%GQ)^#F@>-8-$UKXNZ7?6FG?%VZ\-^#[WP''K'Q;\&6WB?PS8>*/$
M_@S3[%[OP]X?N-<L,?H%^SI\<O!?[3?P#^#'[1/PYGDN/ OQP^&/@CXI^%3<
M!DNX-%\<>'=/\0V=E?Q/'#)!J6G1W_V#4K:6&&:UO[:YMYHHI8G1?QX^#G[=
M.H?MY_LO_P#!4G]DG]HC]CK4OV,?CQ^RC\!M6^&OQW_9LOOB7X(^-7AC2_AW
M^T'^SKXT\1?"^Y\/_$#P-H.@>$]4T_Q)X&L-46YT&QT4VNA6Z65J;F\6Y:&V
MQO\ @US\6Z_XN_X(@_L=2>(/M,LWAVX^._A+3+^Z+EK_ $#0/VAOBG;Z+Y):
M*)/LVD6+Q>&[<1&5%BT15>4SK,B '] U%%% !1110 4444 %%%% !1110 44
M44 %%%% !7X;ZU_P<D_\$6?#_P 1M6^$NK_MGK:_$#0_&U_\.M3T%/V>/VK;
MM;?QCINNR^&KW2%UBS^!EQH5RL6MPRV:ZE:ZG/I,P474%_+9LMPW[D5_$AXI
M\3?\%A?^#;[]G[XT_&/5_A__ ,$\_P!HW]AOQ+^V;X]^,GC32/#7C?X^V/[3
M&DP_M#^-=.TW2K9-?\0Z)X(^'>F6R2V_AW2RFC^"/B/J&E:I?7EU<P:EH44V
MI:> ?VWU^8__  3S_P""D-C_ ,%#/'_[<5CX%^$K>%?@S^R/^TGJ7[,G@KXR
M/X_B\3?\+Y\7>#[*XN/B-KECX1M_!^CV_@C0-!>Y\+S^&YE\7^-)_%FC>*+7
M5;J/PS+;G3KC[0T?XK6OC_\ 9WTOXX^#([W3;'QK\%['XK>%(M7LQ#J-A:^)
M/ \7B_0H]3T^Y0B*]M8;VU6]L[B,A)XY8)4X9:_CF_X);_MGW7_!-7_@U5\7
M_MK>&M&F\6_%2]^(OQOO]!75_*U"UU#XS_$;XZ-\%O!_BKQ0TS6]SJNB^'YK
M?P_XC\26]W>3:EK=EHEYI<%]#)?6GV4 _IXTG_@JM^P#KW[;LO\ P3ET3]HC
M2-6_;+@NM:T^;X/:=X(^*%XD6I>&_ 5_\3O$&E2?$:#P0_PH35]%\$Z7J6K:
MII+>.AJ-C/87>BW%K'KUO+I:_?U_?V.E6-[JFJ7MIINF:;:7-_J.HW]S#9V-
MA8V<+W%W>WMW</';VMI:V\<D]S<SR1PP0QO+*ZHK,/\ ,5_8F_:9_P""<?P,
M_P""QW_!&_XE?#C]J _&:#2/AA\<(_VU_P!HZ[^$_P ;]'UCQW^VY^U-X4_:
M*T?4)]2TOQ3\,=#\<>)8-7\?_%/P+X(T'Q+9>'[_ $?3_#@TK4O$>JZ;#8^(
M;ZR_M_\ ^"]NO^,/#7_!'/\ X*$:GX&\T:Y)^SWK^C7+0SBVDC\*^)=5T;PY
MX\E64S08\KP-JOB.1HUD,DRJ88XIY)%@D -/X*_\%S_^"3?[1/Q\LOV9/@Y^
MVK\-?&7QFU?6AX;\.^'DT3XB:%H'B_Q!)*L%IHO@;XC>)O!FB_#/QUJFI3ND
M&CV7@_QAK=QK4S"+28[V0A:XGQ7_ ,%TOV-/!_[9<?[&VI>$?VE;B>/X_P#A
MO]D_6OVG-/\ @Q<3?LB>%_VG_%EI:7.B? 3Q%\8I]?MKNS^(UQ-?6EE-86_A
M*[TNSDEDU"[U:'0K._U:U_FQ_P""F'@;P1X,_P"" /\ P;K>+?@MX?T/2OB9
MI'Q[_P"">U_X*USPE8V:>*;7QI\0OV<OB%X_^)QT::SB^UOJ?B#XSZ9I6N^(
MDC622Z\6V%A+>;[U(RWVM_P5+_X)\WO[+/Q2N/CSX4_:Q^)OQ,\+?M)?\%$?
M 7[67[./_!*30_A-X%EO_C[_ ,%,GTW3+/PEK5S\?Y_$EMXT\-_ _3!X:L?%
M'Q@T^30[#P]X>^'^BWR-XDL?$,WA:^B /Z56_;4^$]W^VC'^PGX6T?Q[XZ^,
MFC_"1OC3\4];\(Z+H][\-?@1X/U"\_L_P-:?%_Q7J'B+3+G1/%_Q0NX[H^ /
M!?A[1O%'B34-*LKCQ-K.GZ%X4-MKEQX-^R3_ ,%&X?VC_P!M3]OO]AGQK\'Y
M?@S\6?V(?%W@8:<TGCT>.+7XS_![XFZ/+XA\#_%C384\&>%!X/FO-&N/#UUK
MG@Z2[\4?V))XITBWB\2ZI(+S[-^#O[#?_!0+4/\ @GW\7/%7P>^(7[*/Q+^-
MNF?%K_@HEX>_9-_;W_X*KWGQ9\&0'Q=_P4E^*>EZ'>W_ (+\/_ 2ZT,^.Y?V
M?OA0GB/1_ _P[U.QUG0M#\-_#C3K74+3PM#XEUJ71-8]_L[B;P1_P=UZM;>&
M[*:*#XQ?\$I+:3XA/:C;!=3:+\0K4:9J^IK';NLKP)\./">B6]Q<O'+$&@MX
M[KRW6SF /ZF**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_)*U_P""[O\ P2-O?VB(_P!E:U_;B^%4OQHE\5MX&ATL:;X^7P--XN74FT8>
M'X?C._@]?@M+J4NK+_9EO#'\06^U7[1VMLTL\L:/]:?\% /$7C3PA^P=^VSX
ML^&_F?\ "P_"_P"R-^TCXB\!>3.MM-_PFFB?!OQGJ7A;RKEYK9+>3^W+:QV3
MM<0+$V)&FB"EU_AQ^,'P\^$5I_P95_!3Q)X?\.^%'UZT^(_AWQ[!X@@M[*76
MH/BQJ?[8?B?P3XMUV/4P/MH\3IX6?4_!MS+YIN[7PQ91Z&NS3-/MX80#_1%=
MTB1Y)'6..-6>21V"(B("SN[,0JJJ@LS,0% )) %?D5^PI_P5U^%?[8G[./[5
M/[97C'PSH'[./[)?[/GQX^*7PN\&_&WQQ\4;'6-'^+'PX^&*:0TOQJN;4^$_
M#=IX(TOQ%<:Y9:9HOA:UUKQQ>7>M)<Z18ZOJ%\MK%=^__&#Q5XW\/?\ !+OX
MH^-[O4-3L?B1H?[ _C;Q5=:K>!HM9L_&^F?L\ZGJ\^H7094>/4[?7H&N9PRJ
MR72,"JD8'\1G[0^F'P)_P:#?\$TO"^CF2V^'WQ5_:^\)_P#"^[VYOX=/\SP-
MXD^,G[4'CW5;G4+JW:P9K.S\:Z%X&LK,I'<75E86&G32M+)I\NHQ@']G_P"Q
MU_P6%_X)L?M^?$#7OA3^R9^U5X.^*GQ)\.V%[JMYX)G\-?$;X>^([_2M-D2/
M4M5\,:9\4?!G@FX\::9IQEBDU#4/!ZZ[9V5O+'=74T5M(DK5O^"<O_!1N']N
M_6/VQOA[XH^#TOP"^-?[%7[3OC#]G3XG_#27Q['\28[NRT62:/PA\3-+\31>
M#O!$;:#X_?2O$RZ58#2)_LZ^'KBXAU74[&\LKN3\:O\ @IUX.\.^ O\ @O[_
M ,&]]W\(O#>C>%]9N-*^/7@*];P7IEEI]Q)\(_"?A&PL=*\-2PZ;"BCP=X=\
M*:]XVM],M/+%AIFE7NKBS$,2/Y?7_P#!/6YG\&_\'.?_  7+^&_A^PGM?"'B
MKX+_ +)?Q*UMH5"6*^,8_A+\%=422X6*U6$WNJ7OQ3\;W\#O/'.X&H.R7CO/
M<0 ']3=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M2_O['2K&]U35+VTTW3--M+F_U'4;^YAL[&PL;.%[B[O;V[N'CM[6TM;>.2>Y
MN9Y(X8(8WEE=45F'Y3_!7_@N?_P2;_:)^/EE^S)\'/VU?AKXR^,VKZT/#?AW
MP\FB?$30M \7^())5@M-%\#?$;Q-X,T7X9^.M4U*=T@T>R\'^,-;N-:F81:3
M'>R$+69_P7MU_P 8>&O^".?_  4(U/P-YHUR3]GO7]&N6AG%M)'X5\2ZKHWA
MSQY*LIF@QY7@;5?$<C1K(9)E4PQQ3R2+!)_,=_P4P\#>"/!G_! '_@W6\6_!
M;P_H>E?$S2/CW_P3VO\ P5KGA*QLT\4VOC3XA?LY?$+Q_P#$XZ--9Q?:WU/Q
M!\9],TK7?$21K))=>+;"PEO-]ZD98 _N]\=^-O#/PU\#^,OB-XTU2WT/P=X
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M'\5?!GPY\+_''Q%U\Z>OQ&\4Z/XF\3_ OQC^T!\&M9^+$&FP#Q[JO[/GQO\
MA)JKZE)=>*?"M]X6\97,OB-OTJHH ^*?$/[$/A2[_:\7]M'P!\8OC5\%OB?X
M@\&?#_X<_&3PW\.7^#VI?#K]H/P'\,/$NL>)/!OAOXHZ+\5?@]\3->TMM+/B
M+Q%H0\3?"#Q1\*O&[^'M:N;$>)UFM=*N].\(^)W_  27^"GQ*\3?M12VWQM_
M:?\ AE\(/VV;I]7_ &L?V:_A3X[\ ^%/@_\ &OQ/>>#[?P+K_BK4M;G^%FK?
M'KP%J?C;PUIN@:9\2-.^$'QL^'7A;XF:?H%MHWC_ ,/>)- UCQ9I/B/]3:*
M/SD\%?\ !,/X"> ],_X)P:5I'B[XO7-O_P $O]*U_1_@$^I:_P"#)IO%]MXC
M^#>H? ^^?XP-:^ +--?GB\)ZE/J%JW@N/X?QIXA2*[FBGTU7TF3WGQO^R5\.
M/'O[67P(_;'UC6O&UM\3OV>OAK\8OA9X+T+3=2T*'P)J?A_XW3>#I_%=YXHT
MRZ\-WGB"]UG3W\$:2/#UQI7BC1;*T6XU$:EI^K&6V-I]144 ?#7P@_81\&_
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M7/!OB34]:T:.Z^&7AJ2S@\-ZUX1U"(-J*2ZE/'=(MOW_ (Y_8I^%?Q-_:_\
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MOV<OVB_'&M?M0_LM?M"?#3PK;:W\*/CG^SWX]U/]GK]I_P"%^A^/=(AU/7/
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MXEAN_%6AB37] N=1LYOZ6:* /R9_8B_X(]?LT_L*?%WQ;^TK9?$_]JC]J?\
M:.\0^ HOAHWQ^_;'^,5S\>OBOX>^&-C-97D?@+P??VGACPS9Z7HBR:991PPV
M>A7&LBUA.D6E^NG75Q87'QK_ ,&^G[/_ ,<=('_!1W]NS]I'X3?$'X'?%/\
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M_P"'ZTC_ .8&C_A8G[2O_1M?AO\ \/UI'_S U])44 ?-O_"Q/VE?^C:_#?\
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M_P"%B?M*_P#1M?AO_P /UI'_ ,P-?25% 'S;_P +$_:5_P"C:_#?_A^M(_\
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M_P!&U^&__#]:1_\ ,#7TE10!\V_\+$_:5_Z-K\-_^'ZTC_Y@:/\ A8G[2O\
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M'_S U])44 ?-O_"Q/VE?^C:_#?\ X?K2/_F!H_X6)^TK_P!&U^&__#]:1_\
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M 'S;_P +$_:5_P"C:_#?_A^M(_\ F!H_X6)^TK_T;7X;_P##]:1_\P-?25%
M'S;_ ,+$_:5_Z-K\-_\ A^M(_P#F!H_X6)^TK_T;7X;_ /#]:1_\P-?25% '
MS;_PL3]I7_HVOPW_ .'ZTC_Y@:/^%B?M*_\ 1M?AO_P_6D?_ # U])44 ?-O
M_"Q/VE?^C:_#?_A^M(_^8&C_ (6)^TK_ -&U^&__  _6D?\ S U])44 ?-O_
M  L3]I7_ *-K\-_^'ZTC_P"8&C_A8G[2O_1M?AO_ ,/UI'_S U])44 ?-O\
MPL3]I7_HVOPW_P"'ZTC_ .8&C_A8G[2O_1M?AO\ \/UI'_S U])44 ?-O_"Q
M/VE?^C:_#?\ X?K2/_F!H_X6)^TK_P!&U^&__#]:1_\ ,#7TE10!\V_\+$_:
M5_Z-K\-_^'ZTC_Y@:/\ A8G[2O\ T;7X;_\ #]:1_P#,#7TE10!\V_\ "Q/V
ME?\ HVOPW_X?K2/_ )@:/^%B?M*_]&U^&_\ P_6D?_,#7TE10!\V_P#"Q/VE
M?^C:_#?_ (?K2/\ Y@:/^%B?M*_]&U^&_P#P_6D?_,#7TE10!\V_\+$_:5_Z
M-K\-_P#A^M(_^8&C_A8G[2O_ $;7X;_\/UI'_P P-?25% 'S;_PL3]I7_HVO
MPW_X?K2/_F!H_P"%B?M*_P#1M?AO_P /UI'_ ,P-?25% 'S;_P +$_:5_P"C
M:_#?_A^M(_\ F!H_X6)^TK_T;7X;_P##]:1_\P-?25% 'S;_ ,+$_:5_Z-K\
M-_\ A^M(_P#F!H_X6)^TK_T;7X;_ /#]:1_\P-?25% 'S;_PL3]I7_HVOPW_
M .'ZTC_Y@:/^%B?M*_\ 1M?AO_P_6D?_ # U])44 ?-O_"Q/VE?^C:_#?_A^
MM(_^8&C_ (6)^TK_ -&U^&__  _6D?\ S U])44 ?-O_  L3]I7_ *-K\-_^
M'ZTC_P"8&C_A8G[2O_1M?AO_ ,/UI'_S U])44 ?-O\ PL3]I7_HVOPW_P"'
MZTC_ .8&C_A8G[2O_1M?AO\ \/UI'_S U])44 ?-O_"Q/VE?^C:_#?\ X?K2
M/_F!H_X6)^TK_P!&U^&__#]:1_\ ,#7TE10!\V_\+$_:5_Z-K\-_^'ZTC_Y@
M:/\ A8G[2O\ T;7X;_\ #]:1_P#,#7TE10!\V_\ "Q/VE?\ HVOPW_X?K2/_
M )@:/^%B?M*_]&U^&_\ P_6D?_,#7TE10!\V_P#"Q/VE?^C:_#?_ (?K2/\
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M # U])44 ?-O_"Q/VE?^C:_#?_A^M(_^8&C_ (6)^TK_ -&U^&__  _6D?\
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M5?@+^QE\(=>\>_$WP]\2OVBO#T.H6'Q0\9>)? ?P+7P#H7A'X0ZMXT^'VO\
MB;4/$OA'PGX@^)_@&>S8$ _I@NKJUL;6YOKZYM[.RL[>:ZO+RZFCM[6UM;>-
MIKBYN;B9DB@MX(D>6::5UCBC5G=E521Y%I7[1?[/FNZ/\)O$.B?';X-:QH'Q
M\OVTKX%:YI7Q/\$ZAH_QIU--,U#6WT[X3:G::Y-9?$:_71M(U75VL_!\^LW"
MZ9IFH7YC%I97,L7YS:1^U-^TEX*_:5^*/[!7[7J_!CQUXD\=_LB_$C]IG]G_
M ./_ , /A]X[^#WA#Q7X5\%76B?#_P")_P *?'7P>\??%GX_:SX7\?>"M?\
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MQKG@W6O"%QJMS=:C%=7UY^K7_!2/]@S]B;]KCPG8_$K]OWQ3\0!^SQ^S_P"
M_B-KOBSP*WQY\?\ P:^ SZ;?V^D:MJWQ'^*-I\.M?\'ZOX@UGP1I_AIU\,76
MH^)O[*TNTU/6X)-%U&34AL /TC\0>(- \)Z%K'BCQ5KFD>&?#/A[3+W6M?\
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MQUI,WA-] \2>)I;ZRM]1DUB'0IX;:VNX_P!N/]DOXL_&'XG?L??M3_LV^)O
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MM^U'X0_;1^*W_!3'_@I#\:/@_P#%_P#;#\=_"/2/@!\._!O[.GA_Q;H7P"^
M7P?LM5@\0ZOX?\$W'CR.U\9>);_7M=MQ>_VIXBT^#4-+&H>)E-_JH\2NNF?N
M310!_,-_P="Z;K_PY^ G[!7[<>C6MU>Z7^P7_P %&/V=/CEX\6UABN6TWP1_
M;P@.M"TFCECO)HO'.F^!-"M[1D=9I/$7SH\:LI^N?^"U'["'[2O_  59_9R^
M!/[-?[.OQ9^$'P__ &<O'WQ<\#?$7]J?Q=XKUWQ;#XN\6?!OP[=:+X@\+:+\
M)=)\/> ?%NA^)KR]OKF;QMY?B;Q!X&L_[=\(^"((]8ET[4]9DL?V0^('P\\
M?%CP9XA^'/Q3\#>#OB7\/?%U@VE>*_ ?Q \,Z+XR\&>)]+>6.9]-\0^%_$=E
MJ6B:U8--##*UGJ5C<V[2Q1R&,LBD;/A_P_H/A/0=$\*^%=$TCPSX8\,Z1IOA
M_P .>'/#^FV6C:#X?T'1K.'3M'T31-'TZ&VT_2M(TK3[:WL--TVPM[>RL;.W
MAM;6&*")$4 ^0OVH/@W^T7IG[$7BKX&?\$V_''PS_9R^//A;X?> O 7[-WBW
MX@^'X-<^&GPWTGP9JWA/3?[,OM$G\(>/[7[&GPVT?6/#&A2S^"/%-KI.I76E
MZC-H>H0V3V[_ (N?\%=/^"9/_!73_@H7\!OV(O@?X3_:"_9(U;PM\./ G@+7
M_P!NKP-\5/$OQM^&/P]_:G_:$\*6/@^;4KFZC^!?PO;Q1=?!>_\ $6E^*=7L
M?">F:Q\+;G3KG6;'5K2SM=<T7PQ?>%/Z=Z* /RE_84\&?\%7?A7\,_B-X#_:
MF\#_ /!+#P]HW@+X7Z%X<_8_^'?[$LG[37@3P%IFOZ!I.O65IX5^*EQ\4?#W
MB ^$_AW&;?P9INEWOPZ\*Z[JVCZ>?$-V^@ZK-!IEA<?&OC7_ ((I_$/XJ_\
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MVUC8VUO9V5G;PVMG9VL,=O:VMK;QK#;VUM;PJD4%O!$B10PQ(L<4:JB*JJ
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M\+ZEH4/ABPTW5=%UWR3_ ((\6Z_M'?\ !:/_ (+O_MWZ/:"?X>VOQ/\ A/\
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MW^TS^Q[XK_X)^_\ !/7XI> ?B9\/-/\ @9X6^*TW[0?QRC^#ECJ^@?"GP?\
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M 'S=_P -A?LN_P#1=OAM_P"%)9__ !5'_#87[+O_ $7;X;?^%)9__%5](T4
M?-W_  V%^R[_ -%V^&W_ (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\
MW?\ #87[+O\ T7;X;?\ A26?_P 51_PV%^R[_P!%V^&W_A26?_Q5?2-% 'S=
M_P -A?LN_P#1=OAM_P"%)9__ !5'_#87[+O_ $7;X;?^%)9__%5](T4 ?-W_
M  V%^R[_ -%V^&W_ (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\
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M -%V^&W_ (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\ #87[+O\
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M (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\ #87[+O\ T7;X;?\
MA26?_P 51_PV%^R[_P!%V^&W_A26?_Q5?2-% 'S=_P -A?LN_P#1=OAM_P"%
M)9__ !5'_#87[+O_ $7;X;?^%)9__%5](T4 ?-W_  V%^R[_ -%V^&W_ (4E
MG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\ #87[+O\ T7;X;?\ A26?
M_P 51_PV%^R[_P!%V^&W_A26?_Q5?2-% 'S=_P -A?LN_P#1=OAM_P"%)9__
M !5'_#87[+O_ $7;X;?^%)9__%5](T4 ?-W_  V%^R[_ -%V^&W_ (4EG_\
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M $7;X;?^%)9__%5](T4 ?-W_  V%^R[_ -%V^&W_ (4EG_\ %4?\-A?LN_\
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M 'S=_P -A?LN_P#1=OAM_P"%)9__ !5'_#87[+O_ $7;X;?^%)9__%5](T4
M?-W_  V%^R[_ -%V^&W_ (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\
MW?\ #87[+O\ T7;X;?\ A26?_P 51_PV%^R[_P!%V^&W_A26?_Q5?2-% 'S=
M_P -A?LN_P#1=OAM_P"%)9__ !5'_#87[+O_ $7;X;?^%)9__%5](T4 ?-W_
M  V%^R[_ -%V^&W_ (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\
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M -%V^&W_ (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\ #87[+O\
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M (4EG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\ #87[+O\ T7;X;?\
MA26?_P 51_PV%^R[_P!%V^&W_A26?_Q5?2-% 'S=_P -A?LN_P#1=OAM_P"%
M)9__ !5'_#87[+O_ $7;X;?^%)9__%5](T4 ?-W_  V%^R[_ -%V^&W_ (4E
MG_\ %4?\-A?LN_\ 1=OAM_X4EG_\57TC10!\W?\ #87[+O\ T7;X;?\ A26?
M_P 51_PV%^R[_P!%V^&W_A26?_Q5?2-% 'S=_P -A?LN_P#1=OAM_P"%)9__
M !5'_#87[+O_ $7;X;?^%)9__%5](T4 ?-W_  V%^R[_ -%V^&W_ (4EG_\
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M $7;X;?^%)9__%5](T4 ?-W_  V%^R[_ -%V^&W_ (4EG_\ %4?\-A?LN_\
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M_P"&2^)?_P!$11_PM?\ :X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\
M\L\_S[,/]8,G_P"@Q?\ @G$__*3]$:*_.[_A:_[7'_0Y_LZ?^&2^)?\ ]$11
M_P +7_:X_P"AS_9T_P##)?$O_P"B(H_LO'_\^'_X,H__ "SS_/LP_P!8,G_Z
M#%_X)Q/_ ,I/T1HK\[O^%K_M<?\ 0Y_LZ?\ ADOB7_\ 1$4?\+7_ &N/^AS_
M &=/_#)?$O\ ^B(H_LO'_P#/A_\ @RC_ /+//\^S#_6#)_\ H,7_ ()Q/_RD
M_1&BOSN_X6O^UQ_T.?[.G_ADOB7_ /1$4?\ "U_VN/\ H<_V=/\ PR7Q+_\
MHB*/[+Q__/A_^#*/_P L\_S[,/\ 6#)_^@Q?^"<3_P#*3]$:*_.[_A:_[7'_
M $.?[.G_ (9+XE__ $1%'_"U_P!KC_H<_P!G3_PR7Q+_ /HB*/[+Q_\ SX?_
M (,H_P#RSS_/LP_U@R?_ *#%_P""<3_\I/T1HK\[O^%K_M<?]#G^SI_X9+XE
M_P#T1%'_  M?]KC_ *'/]G3_ ,,E\2__ *(BC^R\?_SX?_@RC_\ +//\^S#_
M %@R?_H,7_@G$_\ RD_1&BOSN_X6O^UQ_P!#G^SI_P"&2^)?_P!$11_PM?\
M:X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\ \L\_S[,/]8,G_P"@Q?\
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M_P"&2^)?_P!$11_PM?\ :X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\
M\L\_S[,/]8,G_P"@Q?\ @G$__*3]$:*_.[_A:_[7'_0Y_LZ?^&2^)?\ ]$11
M_P +7_:X_P"AS_9T_P##)?$O_P"B(H_LO'_\^'_X,H__ "SS_/LP_P!8,G_Z
M#%_X)Q/_ ,I/T1HK\[O^%K_M<?\ 0Y_LZ?\ ADOB7_\ 1$4?\+7_ &N/^AS_
M &=/_#)?$O\ ^B(H_LO'_P#/A_\ @RC_ /+//\^S#_6#)_\ H,7_ ()Q/_RD
M_1&BOSN_X6O^UQ_T.?[.G_ADOB7_ /1$4?\ "U_VN/\ H<_V=/\ PR7Q+_\
MHB*/[+Q__/A_^#*/_P L\_S[,/\ 6#)_^@Q?^"<3_P#*3]$:*_.[_A:_[7'_
M $.?[.G_ (9+XE__ $1%'_"U_P!KC_H<_P!G3_PR7Q+_ /HB*/[+Q_\ SX?_
M (,H_P#RSS_/LP_U@R?_ *#%_P""<3_\I/T1HK\[O^%K_M<?]#G^SI_X9+XE
M_P#T1%'_  M?]KC_ *'/]G3_ ,,E\2__ *(BC^R\?_SX?_@RC_\ +//\^S#_
M %@R?_H,7_@G$_\ RD_1&BOSN_X6O^UQ_P!#G^SI_P"&2^)?_P!$11_PM?\
M:X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\ \L\_S[,/]8,G_P"@Q?\
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M_P"&2^)?_P!$11_PM?\ :X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\
M\L\_S[,/]8,G_P"@Q?\ @G$__*3]$:*_.[_A:_[7'_0Y_LZ?^&2^)?\ ]$11
M_P +7_:X_P"AS_9T_P##)?$O_P"B(H_LO'_\^'_X,H__ "SS_/LP_P!8,G_Z
M#%_X)Q/_ ,I/T1HK\[O^%K_M<?\ 0Y_LZ?\ ADOB7_\ 1$4?\+7_ &N/^AS_
M &=/_#)?$O\ ^B(H_LO'_P#/A_\ @RC_ /+//\^S#_6#)_\ H,7_ ()Q/_RD
M_1&BOSN_X6O^UQ_T.?[.G_ADOB7_ /1$4?\ "U_VN/\ H<_V=/\ PR7Q+_\
MHB*/[+Q__/A_^#*/_P L\_S[,/\ 6#)_^@Q?^"<3_P#*3]$:*_.[_A:_[7'_
M $.?[.G_ (9+XE__ $1%'_"U_P!KC_H<_P!G3_PR7Q+_ /HB*/[+Q_\ SX?_
M (,H_P#RSS_/LP_U@R?_ *#%_P""<3_\I/T1HK\[O^%K_M<?]#G^SI_X9+XE
M_P#T1%'_  M?]KC_ *'/]G3_ ,,E\2__ *(BC^R\?_SX?_@RC_\ +//\^S#_
M %@R?_H,7_@G$_\ RD_1&BOSN_X6O^UQ_P!#G^SI_P"&2^)?_P!$11_PM?\
M:X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\ \L\_S[,/]8,G_P"@Q?\
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M_P"&2^)?_P!$11_PM?\ :X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\
M\L\_S[,/]8,G_P"@Q?\ @G$__*3]$:*_.[_A:_[7'_0Y_LZ?^&2^)?\ ]$11
M_P +7_:X_P"AS_9T_P##)?$O_P"B(H_LO'_\^'_X,H__ "SS_/LP_P!8,G_Z
M#%_X)Q/_ ,I/T1HK\[O^%K_M<?\ 0Y_LZ?\ ADOB7_\ 1$4?\+7_ &N/^AS_
M &=/_#)?$O\ ^B(H_LO'_P#/A_\ @RC_ /+//\^S#_6#)_\ H,7_ ()Q/_RD
M_1&BOSN_X6O^UQ_T.?[.G_ADOB7_ /1$4?\ "U_VN/\ H<_V=/\ PR7Q+_\
MHB*/[+Q__/A_^#*/_P L\_S[,/\ 6#)_^@Q?^"<3_P#*3]$:*_.[_A:_[7'_
M $.?[.G_ (9+XE__ $1%'_"U_P!KC_H<_P!G3_PR7Q+_ /HB*/[+Q_\ SX?_
M (,H_P#RSS_/LP_U@R?_ *#%_P""<3_\I/T1HK\[O^%K_M<?]#G^SI_X9+XE
M_P#T1%'_  M?]KC_ *'/]G3_ ,,E\2__ *(BC^R\?_SX?_@RC_\ +//\^S#_
M %@R?_H,7_@G$_\ RD_1&BOSN_X6O^UQ_P!#G^SI_P"&2^)?_P!$11_PM?\
M:X_Z'/\ 9T_\,E\2_P#Z(BC^R\?_ ,^'_P"#*/\ \L\_S[,/]8,G_P"@Q?\
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MU\?_ %6RO^;&?^#J?_RC^KORM^47_"T;[_HBG[2__B._Q8_^9BC_ (6C??\
M1%/VE_\ Q'?XL?\ S,5^KM%']M8S^7#_ /@N?_RWU_I:G^JV5_S8S_P=3_\
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M?_RC^KORM^47_"T;[_HBG[2__B._Q8_^9BC_ (6C??\ 1%/VE_\ Q'?XL?\
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M:7_\1W^+'_S,4?\ "T;[_HBG[2__ (CO\6/_ )F*_5VBC^VL9_+A_P#P7/\
M^6^O]+4_U6RO^;&?^#J?_P H_J[\K?DY-\6)[90]Q\&OVDX4+! TO[//Q712
MQ!(4%O#(!)"L<=< GM5;_A<L?_1(_P!HS_Q'[XJ?_,U7ZB^+/^0=#_U^Q_\
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MZ"44?VUC/Y</_P""Y_\ RWU_I:G^JV5_S8S_ ,'4_P#Y1_5WY6_/O_A<L?\
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M_P#HD?[1G_B/WQ4_^9JOT$HH_MK&?RX?_P %S_\ EOK_ $M3_5;*_P";&?\
M@ZG_ /*/ZN_*WY]_\+EC_P"B1_M&?^(_?%3_ .9JC_A<L?\ T2/]HS_Q'[XJ
M?_,U7Z"44?VUC/Y</_X+G_\ +?7^EJ?ZK97_ #8S_P '4_\ Y1_5WY6_/O\
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M"44?VUC/Y</_ ."Y_P#RWU_I:G^JV5_S8S_P=3_^4?U=^5OS[_X7+'_T2/\
M:,_\1^^*G_S-4?\ "Y8_^B1_M&?^(_?%3_YFJ_02BC^VL9_+A_\ P7/_ .6^
MO]+4_P!5LK_FQG_@ZG_\H_J[\K?GW_PN6/\ Z)'^T9_XC]\5/_F:H_X7+'_T
M2/\ :,_\1^^*G_S-5^@E%']M8S^7#_\ @N?_ ,M]?Z6I_JME?\V,_P#!U/\
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M7+'_ -$C_:,_\1^^*G_S-5^@E%']M8S^7#_^"Y__ "WU_I:G^JV5_P V,_\
M!U/_ .4?U=^5OS[_ .%RQ_\ 1(_VC/\ Q'[XJ?\ S-4?\+EC_P"B1_M&?^(_
M?%3_ .9JOT$HH_MK&?RX?_P7/_Y;Z_TM3_5;*_YL9_X.I_\ RC^KORM^??\
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M_!<__EOK_2U/]5LK_FQG_@ZG_P#*/ZN_*WY]_P#"Y8_^B1_M&?\ B/WQ4_\
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M_P!5LK_FQG_@ZG_\H_J[\K?GW_PN6/\ Z)'^T9_XC]\5/_F:H_X7+'_T2/\
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MU_V;_P#@D9\9_BW^S]X.\#7/C']H+QO=_M#_  _^'5KX1E\+Z?-J_P 4])^
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M=6%?%4</DM; 2R=T7F2S6.)Q]? 8&C0AB</4CBY9G/#3A52]I&:Y7\Y@_%?
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M1L+F%+JVM[A4$T,;J >??LM_\FR_LZ?]D)^$7_JO_#U?Q.?\$MO^"%_[$_\
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M;2DB\<'78TTW5-1L546M]<Q2_-G_  Z=_P""67_2-/\ 8 _\0W_9U_\ G<T
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M2VJW]Y8DVEQ<26_[N@#\(?\ @C1_RK:?!'_LT+]I3_U)_C77XB>.M;TW0/\
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M4SZ9'I.N_P!.- '\O'_!-/X^? [X!_\ !7?_ (+P?"_XY?&+X8?!SX@_$?\
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M:W_95_Z.5^ G_AWO '_R_KWC^S=._P"?"R_\!8/_ (W1_9NG?\^%E_X"P?\
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M (W1_9NG?\^%E_X"P?\ QN@#P?\ X:W_ &5?^CE?@)_X=[P!_P#+^C_AK?\
M95_Z.5^ G_AWO '_ ,OZ]X_LW3O^?"R_\!8/_C=']FZ=_P ^%E_X"P?_ !N@
M#P?_ (:W_95_Z.5^ G_AWO '_P OZ/\ AK?]E7_HY7X"?^'>\ ?_ "_KWC^S
M=._Y\++_ ,!8/_C=']FZ=_SX67_@+!_\;H \'_X:W_95_P"CE?@)_P"'>\ ?
M_+^C_AK?]E7_ *.5^ G_ (=[P!_\OZ]X_LW3O^?"R_\  6#_ .-T?V;IW_/A
M9?\ @+!_\;H \'_X:W_95_Z.5^ G_AWO '_R_H_X:W_95_Z.5^ G_AWO '_R
M_KWC^S=._P"?"R_\!8/_ (W1_9NG?\^%E_X"P?\ QN@#P?\ X:W_ &5?^CE?
M@)_X=[P!_P#+^C_AK?\ 95_Z.5^ G_AWO '_ ,OZ]X_LW3O^?"R_\!8/_C='
M]FZ=_P ^%E_X"P?_ !N@#P?_ (:W_95_Z.5^ G_AWO '_P OZ/\ AK?]E7_H
MY7X"?^'>\ ?_ "_KWC^S=._Y\++_ ,!8/_C=']FZ=_SX67_@+!_\;H \'_X:
MW_95_P"CE?@)_P"'>\ ?_+^C_AK?]E7_ *.5^ G_ (=[P!_\OZ]X_LW3O^?"
MR_\  6#_ .-T?V;IW_/A9?\ @+!_\;H \'_X:W_95_Z.5^ G_AWO '_R_H_X
M:W_95_Z.5^ G_AWO '_R_KWC^S=._P"?"R_\!8/_ (W1_9NG?\^%E_X"P?\
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M_P##O> /_E_1_P -;_LJ_P#1ROP$_P##O> /_E_7V_\ V9IO_0.L?_ 2W_\
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M *.5^ G_ (=[P!_\OZ^W_P"S--_Z!UC_ . EO_\ &Z/[,TW_ *!UC_X"6_\
M\;HU\ON_X/K_ $M33L_O7^1\0?\ #6_[*O\ T<K\!/\ P[W@#_Y?T?\ #6_[
M*O\ T<K\!/\ P[W@#_Y?U]O_ -F:;_T#K'_P$M__ (W1_9FF_P#0.L?_  $M
M_P#XW1KY?=_P?7^EJ:=G]Z_R/B#_ (:W_95_Z.5^ G_AWO '_P OZ/\ AK?]
ME7_HY7X"?^'>\ ?_ "_K[?\ [,TW_H'6/_@);_\ QNC^S--_Z!UC_P" EO\
M_&Z-?+[O^#Z_TM33L_O7^1\0?\-;_LJ_]'*_ 3_P[W@#_P"7]'_#6_[*O_1R
MOP$_\.]X _\ E_7V_P#V9IO_ $#K'_P$M_\ XW1_9FF_] ZQ_P# 2W_^-T:^
M7W?\'U_I:FG9_>O\CX@_X:W_ &5?^CE?@)_X=[P!_P#+^C_AK?\ 95_Z.5^
MG_AWO '_ ,OZ^W_[,TW_ *!UC_X"6_\ \;H_LS3?^@=8_P#@);__ !NC7R^[
M_@^O]+4T[/[U_D?$'_#6_P"RK_T<K\!/_#O> /\ Y?T?\-;_ +*O_1ROP$_\
M.]X _P#E_7V__9FF_P#0.L?_  $M_P#XW1_9FF_] ZQ_\!+?_P"-T:^7W?\
M!]?Z6IIV?WK_ "/B#_AK?]E7_HY7X"?^'>\ ?_+^C_AK?]E7_HY7X"?^'>\
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MU_D?$'_#6_[*O_1ROP$_\.]X _\ E_1_PUO^RK_T<K\!/_#O> /_ )?U]O\
M]F:;_P! ZQ_\!+?_ .-T?V9IO_0.L?\ P$M__C=&OE]W_!]?Z6IIV?WK_(^(
M/^&M_P!E7_HY7X"?^'>\ ?\ R_H_X:W_ &5?^CE?@)_X=[P!_P#+^OM_^S--
M_P"@=8_^ EO_ /&Z/[,TW_H'6/\ X"6__P ;HU\ON_X/K_2U-.S^]?Y'Q!_P
MUO\ LJ_]'*_ 3_P[W@#_ .7]'_#6_P"RK_T<K\!/_#O> /\ Y?U]O_V9IO\
MT#K'_P !+?\ ^-T?V9IO_0.L?_ 2W_\ C=&OE]W_  ?7^EJ:=G]Z_P CX@_X
M:W_95_Z.5^ G_AWO '_R_H_X:W_95_Z.5^ G_AWO '_R_K[?_LS3?^@=8_\
M@);_ /QNC^S--_Z!UC_X"6__ ,;HU\ON_P"#Z_TM33L_O7^1\0?\-;_LJ_\
M1ROP$_\ #O> /_E_1_PUO^RK_P!'*_ 3_P .]X _^7]?;_\ 9FF_] ZQ_P#
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M--_Z!UC_ . EO_\ &Z-?+[O^#Z_TM33L_O7^1\0?\-;_ +*O_1ROP$_\.]X
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M6_\ \;HU\ON_X/K_ $M33L_O7^1\0?\ #6_[*O\ T<K\!/\ P[W@#_Y?T?\
M#6_[*O\ T<K\!/\ P[W@#_Y?U]O_ -F:;_T#K'_P$M__ (W1_9FF_P#0.L?_
M  $M_P#XW1KY?=_P?7^EJ:=G]Z_R/B#_ (:W_95_Z.5^ G_AWO '_P OZ/\
MAK?]E7_HY7X"?^'>\ ?_ "_K[?\ [,TW_H'6/_@);_\ QNC^S--_Z!UC_P"
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M *.5^ G_ (=[P!_\OZ/^&M_V5?\ HY7X"?\ AWO '_R_K[?_ +,TW_H'6/\
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M_P#C=']F:;_T#K'_ ,!+?_XW1KY?=_P?7^EJ:=G]Z_R/B#_AK?\ 95_Z.5^
MG_AWO '_ ,OZ/^&M_P!E7_HY7X"?^'>\ ?\ R_K[?_LS3?\ H'6/_@);_P#Q
MNC^S--_Z!UC_ . EO_\ &Z-?+[O^#Z_TM33L_O7^1\0?\-;_ +*O_1ROP$_\
M.]X _P#E_1_PUO\ LJ_]'*_ 3_P[W@#_ .7]?;_]F:;_ - ZQ_\  2W_ /C=
M']F:;_T#K'_P$M__ (W1KY?=_P 'U_I:FG9_>O\ (^(/^&M_V5?^CE?@)_X=
M[P!_\OZ/^&M_V5?^CE?@)_X=[P!_\OZ^W_[,TW_H'6/_ ("6_P#\;H_LS3?^
M@=8_^ EO_P#&Z-?+[O\ @^O]+4T[/[U_D?$'_#6_[*O_ $<K\!/_  [W@#_Y
M?T?\-;_LJ_\ 1ROP$_\ #O> /_E_7V__ &9IO_0.L?\ P$M__C=']F:;_P!
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MD:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*^DEACF,_B)A.BSB0#]8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M':7U ']+E%?SO_\ #4'[2_[<?PG_ &"?V&?AQXX\8_"[]I'XY?LB_LR?M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'SA^T]\<_@G\%_AEXG7XQ?&'X6?"=O%G@SQU9>%1\2_B#X2\"'Q->6'
MA^07UIX?'BG5]*.LW-F=1T\7<&G?:9;<WUGYR)]J@W_DE_P;4_&#X2>)_P#@
MD7^Q;\*_#?Q2^'7B'XG^"?A=XROO&?PXT/QOX9U;Q[X1LIOC/X]\F\\3^#[#
M4[CQ#H%K+_:6G>5<:KIUI%)]OLMKG[5!YG[ _'+]E3]E[]I^'PU;_M*_LW?
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MCAAAMX8K>WBC@@@C2&""%%BAAAB4)'%%&@5(XXT541$4*B@*H  %24 %%%%
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M$_\ @!-_\DT ?25%?-O_  Q]^S'_ -$6\$_^ $W_ ,DT?\,??LQ_]$6\$_\
M@!-_\DT ?25%?-O_  Q]^S'_ -$6\$_^ $W_ ,DT?\,??LQ_]$6\$_\ @!-_
M\DT ?25%?-O_  Q]^S'_ -$6\$_^ $W_ ,DT?\,??LQ_]$6\$_\ @!-_\DT
M?25%?-4O['/[+\\1AF^"?@>2(R)+L?3Y2/,19$1O^/C((660<'!W'(.!BI_P
MQ9^RI_T0OP'_ ."Z;_Y)H&N7JVO1)_\ MR/J"BOE_P#X8L_94_Z(7X#_ /!=
M-_\ )-'_  Q9^RI_T0OP'_X+IO\ Y)I:^7W_ / ]?Z>C]WO+_P !7_R7K_3T
M^H**^7_^&+/V5/\ HA?@/_P73?\ R31_PQ9^RI_T0OP'_P""Z;_Y)HU\OO\
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M_P"B%^ __!=-_P#)-'_#%G[*G_1"_ ?_ (+IO_DFC7R^_P#X'K_3T/=[R_\
M 5_\EZ_T]/J"BOE__ABS]E3_ *(7X#_\%TW_ ,DT?\,6?LJ?]$+\!_\ @NF_
M^2:-?+[_ /@>O]/0]WO+_P !7_R7K_3T^H**^7_^&+/V5/\ HA?@/_P73?\
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MR_\  5_\EZ_T]/J"BOE__ABS]E3_ *(7X#_\%TW_ ,DT?\,6?LJ?]$+\!_\
M@NF_^2:-?+[_ /@>O]/0]WO+_P !7_R7K_3T^H**^7_^&+/V5/\ HA?@/_P7
M3?\ R31_PQ9^RI_T0OP'_P""Z;_Y)HU\OO\ ^!Z_T]#W>\O_  %?_)>O]/3Z
M@HKY?_X8L_94_P"B%^ __!=-_P#)-'_#%G[*G_1"_ ?_ (+IO_DFC7R^_P#X
M'K_3T/=[R_\  5_\EZ_T]/J"BOE__ABS]E3_ *(7X#_\%TW_ ,DT?\,6?LJ?
M]$+\!_\ @NF_^2:-?+[_ /@>O]/0]WO+_P !7_R7K_3T^H**^7_^&+/V5/\
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M^H**^7_^&+/V5/\ HA?@/_P73?\ R31_PQ9^RI_T0OP'_P""Z;_Y)HU\OO\
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M_P"B%^ __!=-_P#)-'_#%G[*G_1"_ ?_ (+IO_DFC7R^_P#X'K_3T/=[R_\
M 5_\EZ_T]/J"BOE__ABS]E3_ *(7X#_\%TW_ ,DT?\,6?LJ?]$+\!_\ @NF_
M^2:-?+[_ /@>O]/0]WO+_P !7_R7K_3T^H**^7_^&+/V5/\ HA?@/_P73?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img209334158_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_7.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1.Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $YZ^4"(X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $TUA<G)I
M;W1T+"!'97)A;&1I;F4 .$))300E       01"@ [LX_X76!AXLK4#36$SA"
M24T$.@     !*P   !     !       +<')I;G1/=71P=70    '     $-L
M<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4
M( !2 $< 0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L
M8F]O; $    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4    !@!! %  1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M:X2_(         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ "4S,P  0 "
M )3,S  !  (X0DE-!"8       X             /X   #A"24T$#0
M!    %HX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$1       $
M  (   )    "0      X0DE-!!X       0     .$))300:      -#
M!@             !$0  !7     ' &0 <P!P #0 -@ W #(    !
M                  $             !7    $1
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   $1     %)G:'1L;VYG   %
M<     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   !$0    !29VAT;&]N9P  !7     #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
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MP  1"  ? )X# 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ =P)? P$1  (1 0,1 ?_$ !\  0  !@,! 0
M       !!08'" D" PH$"__$ %40   & 0," P8# P8'"PP#  $" P0%!@<
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M]FHRLJW*0DEP3D8.#5BX8'TY8-N$MD'#V+[Q/,_=TU;L?4ZR2K$"'3!I(34
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MFA:UY%[DBT91BQB9F#>Q3FJ#7+);)$\6XJ1H-XL!$W<JYD9)5V]<;*N(XN8
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M/+- L9B,KSR4:-IN:3?JQ,8LH!'<BE&$34D%&J8\"JFT362.N<O8A5"<B!A
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MQD076Z ,-IPEH6,A5ET=)&CU8,^]A1@#!)<.&YAPX>OOE%S#&Z0YXY /40$
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M ')A1)[1Y*WE@H!A14_=U)Q20H(*5%Z T;=O([/UTR_RYDJF!0.6K*>KT+$
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M?1Z/6K>#&D7R\ E-$GC*XV,B  F,/N23( %!/I(CC^RID_HPY GPDX H"/2
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M3*Q>$3(2E.(G( 3,5VB0%+"EI)"W4I0+E1+1GX;P<\1E*RX9,I8HJ8@%.99
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M1!RU<H'(LW714.FLB<BA#&*8!&8"HLW*/OTB8\O'XKK_ )"F#_\ XI*[V_\
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MD+R:">C+>RD8N;8Q$6P,B^< WC&;]H"Z;ENT9-7SYPX4;*Q7LH^$_B%Q.:C
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MA0$.?](HEX'U'@>1#D0':2I.:]R#8\AMRYQHJ2H)):H!8.YU/05;UIJ>UO\
M  =^X=AY#L \<@'U]?00$!]>.W.MI"@5@:N?, @VIO8D&YK& KF"N@=-+W%@
MW-P]=B,ICM64*!.0$>..# (#SR(#SZ]_0>._;GT[>F<D .>7771GZ>-(@J7,
M 22" 7N#9PYTJY /Y BEI9R0A!#D"CQT]O4>D>0'D?W0 !#GMSV^HAJR%I 4
MZFMN35[<_MT!BIEJ4P <.:N.I\279J/2+3S;D#'( &YX5Y,4.0'CU 0#MVY$
M>0 >P\<\<=L<Q22RM-3<7?>M!9R- PRML2P4J8[@ACIJ]KD^*:!R*4;953(P
M-D<G,8@$@)Q43=Q.GT13PP&Y+W 2]/48!Y$0 /D(\\K$S4NHE] 0!LVV_1GC
MHR4*400 :'G8G]W;>O.//Y^'%746\7#"XG$3=5%SRKU"/J93&EA$3>IAY'CO
MSQZ\ZUI%22"&NPY_@Z=#%L0" QT4QM</;7>/TEY)HL]8NVJ#YS&K.&RR"<@R
M]G]K9'53,4CMJ#MN[9BX;&$%4 =M7385"E!PW72ZDS;,:J3E4%$ @5*3])W<
M"OD?R^O>^6O*<_=IBC3$1G=>JU9:/BJ['8UAC0\YEA3V!JJXM=ER\G^6:A5(
M([A=1HC!P$Y79873-T]?./9G*$,AP<3-QB<3.E"1.F)3+44I00!,(%\YRA/>
MHP+[D.T?3N%8/A&"P."XG(Q/ 9V+Q<E<[$+XG,EXK#<+8D=G*X8H3)F)Q0 )
M FRURE$I S)[PMM(8#W9MS-GSZ>&UG>D<GIA%\XW*O2^"W(.GSJ'(J_;UB1C
M\NN$>N-1F9RUQCUZX0;O(4T?+Q*_M#CF?R[CR M29@:8YEY9I2O"EW0DD%0F
M)#I=1"BQ(8L"KO)^)_X>S42TC #AADA">+IPG!L/C$?$*,B$8A>&E+FH7PN:
MO^HN4F294N4<LTJ2<R$3@L7NJD%G$7*R&6DLVIR"J+2QP,M2Z[MKC(Y-7EC-
MGCG#24FYV,<-0 9&%DH62N"K\56B"L0P.QF4<LJ7QA4I",7,GCB#J3+Q$HH&
M$2X(25);M%!LQ4&*BS)*08PSL5\!H6G$X23PA/PP2E?\OGJG8GXOF !IN&7B
M"A,O"K4Y4B;+4,.@A)45GNGY)W&F[&$*ZF&#.4MV>(^64F8W*B62@C\02<"B
MH916H.L4*O(T\.TD(XPL&\&A R71+)-9J0R%[2F+\M9F&XWA@52EJQ/$"'5B
M5K/RA33NB4X4 I+AF=PY6PS#)AN,? .+Q D+6C _#4^6N7_)YF ES^,RYV1I
M4V;Q9B9BDS%*F!:5A*904A,DEDF<5FYR[VW8K-!Y;S39\JO[Y",<@X[M\$U@
M(N"K)D'AKDG-5.)K#.'A8^+;D$86;"7D2NG01H1MAG$G!%7VUVD\?*J29OS2
MEI[=*QW22Y4K*S)23](S'4 EB3RL5@L,,)QA,W@W",)P>5@)ZN%XS#8@SL1,
MQ&=(PI$Y<Y2YJJ'.@2T;=FEV3LQ;JE,0J?44YR!PH)1 0 P<B(\ (\<CW !X
M,'H)0X$ ]&'U '2W0:TI?1N@^5E*P$E85W@"%$-F HXW!Y.VK7CZM3$0TA%(
MW^5?P-&N,[%F(22A*O/R\>91,%DP>QT4[>-?,1$!!4GGHI]:?;K+R7D.>=7E
MI2N9+2M\JEI"M*%0!]UWK$*<@L6.]?Q6//'3?$=W?3T#AR!G19L[15V:BVX*
MUL:8QC6%Y1S)A"ZYNV[GH9GJ$K%U]XWHD J\MPIQ\NU1M,>@T4:G:K.(\WI5
M\-X>%J(F),M:?Z*05$A4N8F7-[0%B1F!((-C0AHTYDV8A;(22?U$AP7!8@:L
M6V+&FD7TKGB1Y'M9F&.AB B).$_DI.#Y(96)@XE<B)96R)M?KUMBHAN_QR-7
M=3%-;Y;G8W-B,5$1B4$M,TI*I*0CR??N*AJ3.&8>6<W; A2IP"0&RA&< FKD
M+*04%_U!W<0^8F$@A/Z;&Q-'Z'F?_P =2:4NGBY99HD)&.;)BO%L/*W6L8YO
M./E'5[LJT&:)R!"[C3PU3MTB\@X,L;9YZU8 0@4IE$"52JL[XWF9MX]959^Y
ME\DO@<N?VBI:U+$H**JA+Y3+!()+42LG4D!@'($/F%I3F44AU,$MWN=:C70M
MX6WR5=\^DZW 2,H6/))OX:,>2)(EV:0BB/G+-%9V6,?'(0[V.*X.H#)V8A#.
M&P)K"0@G$H<!:0A:D@$!*B "&( -B-#&VDN!9V#L7]8GNJQ:&D(:0AI"&D(X
M"0H\@)2\<@(=OG]1U4I<U-!4 4+Z%_,=-;NCBDDFB0I$TTTB$#I(1,A2%(7M
MP4 *   !P'8 X[!J:N22[ZF_N_5^54=NIA#2$-(0TA#2$-(1 2@8.#  AZ\"
M'(:0@!2E]  -0 P80B.IA#2$-(0TA'69(AQY,0IA 0$!, #P(<<<=OMSZ_WZ
MJ4@D$@$@%B0"Q/@_^MX&H8VT^_@7VZQCKDG;A6<D9<Q/F!_(N6DUBPEA8%BA
M:L9&'L4)8FA2K1T@VD6[@&B[*3;1TFRDF (NT_9UVHF$CA)5KR\9PF1C,9@L
M;-_Y<&HY4M_34D@T*6N"Q<WY&IU9N%ES9B)I^I#Z @@N[N"]2X/JS-CEG#",
M[+[UL#9.C,9,LBU&4H\O1,D.K)&0#^N4B*@Y92?K=DBU95<[QK:!E9==NDBS
MC' O8Y%=--=N<AU$N1CN'O\ $'#\:C#JGHF2NRF A)ERT%0S+(- R&?* H@7
M-8U\3AYDS%8>8F6)DE$M4N8% $(=5%@EPXN$L30LY/=FN)L"76I;M,\WF]5.
M,MU3RG J-*CD9Q86BZE>J15(H1Q$\HJC-N4&JK@K]^$XW]M;.VD:@UD%5'3L
MYQR8'A"L/Q;B&)F2A,D8Y.5"DT$M":Y%I5OERC*3<.6B9.'7*QN(FJ2"B>A*
M4J< IRL,JDFA#6(=S0TH+AX]V38AQ)F-EES%Z<S1B)5^<A)"APLJ^"E2CB:=
M(. EUHETX<)-5V!$U4&;&/*TC$04252:IJMBF4W\+P/!8'%'%81*I2E A<LJ
M)EG,H*) T+A( 8T<O81FE8.5)FJFRW1F04J0"2DDJ!=B6%FH+&C:YA '']0!
M_5S_ /WKLM4G=O!G_<^9C;B.IA#2$8M9+VMP.1LNM,QJW2Y0TG^RZ0P]9Z;'
M!37-&R+CZ1F7<^[K-R9V&F6";(S>R#LY';JLSE??F:%*@#@2B;JV96(,N5V1
M2E0[7M02[I4 $@IJ 2$AN\&J8H0<X5H S>!<T%]ONYC#G$?A54VJ8KQ+5;ID
M>Z*6NMUM&*S$K4I&+4KV:5!RPEFX8RT/;56)2U!$Q=\2*A'R4%)5>?>5H#P[
M]P5H=L@RZ$WC,U<Z8M,J6$*?LPI+F4\LRBI+$)"BE2J,4@EP(P?*HO5ZN 6<
M4+.3J:NP8\KU!@;PS*UC]E2;!DW(]RO&1J<]K;B)6:/H-M4JY&4^7S%*P=4K
M[-*H1<B[KRCO-5LDI)2P+2,^J\]V-4)M*,C2-EZXCC$^:XE(1*2H',*E2RI"
M$DJ))J.S2$E+4#EU5B4X9(-22!1B7!8T)!I>M0?"KS<GA5[>R54*A^8\GC&!
M5&5/\WW]7P>#&,,.8QP@@L94*KT&>C4L3UIV=7R@2&;6DW8(@W7;LVN(<4Q(
M*CW"5$DDBKF8J:2.>91]LTJPTM0HX+BKDBFC4V#UCX;IX6>,L@-Y1A:\TYRF
M8R;R==LIR\<]>XP61?3][/%GDR.%1Q=[2Y-$E@X9A4IF07>V>G04>%<K$[%0
MCIPR/DE\7GRB"E",PE=D"ZJ)T9((2*E1(8@E3J!(K16$2?U$L-@')#$GE6P\
M&BJY_P -G%E@</'JV1LJL7[>_9*R72'C!]304QW;LFYEQ5N!DG]?(ZI;E*42
MA\N8EA;-#-+@G9&P-I:;@I1.2ASQK6-JGBL]( R2R A$LCO,M*$&6D*!)8!!
MR]TIL#>'RJ*,HO6IN"]Q7K2U!SC[:IX;V&*M*L+!^:LD3-A1MN,+],3<I*UP
M'-ENF,,W9&W!-9Z5;,*LR8-E+-D/*-G6LC&';1D9[F.PC()E!@S!=6D[B>(G
MH[-02E#* "= I$M# ERP3+2*DDER3:+HPZ$;^9W?1M>72-A(!P !]  /ZM<Z
M-B/,E^*?7.WV08(52/T*%W7U02&#GD!_9EE(.> [CZ\<<AZAWU5?TGP^XC)*
M_P"5%-7YTY>_6-5O@>6]L1-:/<.S$7+'3O214"E#I">,J/[_ "'PF$.!^0B4
M $0[ZYL^60G,; @-N7/+QM2E7CO2SVB62""Y+FEF?6X\+WCTO/9<JJ9 2,'Q
M"'?J#I$H?/X1[]780$  1#OQZ &K6[@[7=]=GZ$%R7#UBQ24V!-&)%*:@C1Z
MU-@&.KTF]=E4.81.8.>P=0@/\/7Y=A[^OV[\46D*8 LVC.=KT?K6XJJ\9)08
M$FQI1ZORO71@+:B*>7<E((AYG<O(]/KSVX]"E  ]>1Y^G''8 &F0V)##<5%"
M7M87O%S0W 9B!1W?I2H[Q#,* VB5F<DY$QUNX\@)  QN!Y'GGL <CZ<\CP(
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M[,*6%:%[-%>(9-L39@YCTY9\1NX1.DHT(@C[.8APZ1()#$,(!P ?&4 $"B(
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M;UN#AL+)*Y1BE+*\&=@;BQF4Y5E/0KNHBTG&X0@QSI%T#]MWI?"L/-25B:M
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M(4"'-^\8H 4PB  &F1/]HLWAM$%2S^L^9V;?SW'G'#^9*\+0!Y+L^H8>H?\
M"3)8]A^7'YXZ>.>X@(" CWX >^HR(_M2>H>UKQ(6L%PM0\:>SKYWK W@D^%D
M83B;9Y0A%00%036/)(B<0*(%$X_G;DPE 1 HB/)0[%$ #@9"4BR1Y0*UEW62
M_,[]=J#:X8LW ?!&\+ 0(4=G=!$"  $ UBR2/2 "(@!/\M@Z0#D>"AV .0#L
M(\LJ=A[_ #SOSAG709C0N'T]\WZ,P'8/@F>%L(\CM!HPB   =5ER4/' "4./
M\MPXX*(E#Y  B'H(Z9$?VI\A#M)E/ZBKN6)#T(T--]?S$3>";X6QRE(?:!1#
M%)R!2FLN2S%* B(B %&[@4.KD>K@ Y'O]  $)%DCRB3,F%P5J(V<CSK6+Q8&
M\,K8GMBR*QRU@G;G4,=Y&C(R6AX^U1<G;G[]I&SJ!6TNV0).6*4:$!^@0J2Z
M@-_-Z Z2*%#GF0D N QL_I[ZG<Q0N;E_\%Q_GT:,[=3"&D(:0AI"&D(:0AI"
M&D(:0C&;='L]VY;TJ1$XUW-8T8Y2H\'8V]NBH)_.6JOD96-I'R$6VDTGU0G*
M_)BHFPEY%L*1WPMU".C>:BH<B9B(BKOU%]"!^S=(PE#P)/"G(FFD3:FV(DBD
MFBBF3,NX,I$D42]"2*1 RP!$TDR 4A$R@!"$*!2E* :J4)5]20>HBP4L%PM5
MWO32X!'HW..XG@6^%<F @GM:33 >P]&:-PQ0YY$>! ,L^@"(B "/8>WSU14B
M2KZI2#X"VW3E;E%Q/Q #)G*#/S9V._L-L\0'P*O"L-SU;6$C\_\ I9GW"&[<
M@/ <Y8'MR " ?4 'Y:A.'D)^F4@=$B),^<;S%>EM=-=>5(Z3^!'X4RG'7M2:
MGX$>.O,>X,W'/KQ_G8#Y]^_(?;TXR!"10) '3W[Z10J6;K4>;^QZ1T#X#7A/
M& 0/M+CC"(@(]67MP \CWY$0-E<W)AY'D1YY'U[=M"A)ND>4,ZQ9:N>K[7=N
M?+I' ? 5\)L0X':1%B ^O^=K/H<]^?0,K 'U'N41Y$1'GTT"4B@ &K?F(*E%
MW4?N.= Q+DGW<;P%/"8,42CM%BN! 2B'[6L^<"!@$#%$/VJ<"4P")3 //("(
M<ZEAL/(0S* 8*-':QH7I4&E:;1>?;IX3'A[;3,I1.:=O6W"%QSDV#CIF*BK2
MTNV4)]PQ8V"/5BIA%%A;+O/1 B^CUUVBBQX\RZ:2I_(52,(B,P*E'ZE%3;M^
M-OSY94[AL;R^5\16ZDP*[5M./TF$E"'?*'28+35=F6-CB&<@JF!U$6#Z2B6C
M-\L1)<R+1=90J"QB%3'1XCAE8K"S)*" M1!3H"4G, :M4AB2"*U$=[X8XO+X
M'QO!\2G)5,ER"M*TI?-DF(5*60Q!<(F%F(+M>T8-Q^P:X62P6ZWV^\1M=EU\
MB7BV4:.BZ['34?&C.9:JV364A;EA?1ZMR;NSTN$8^XG9& Q"2KSRI!=5..48
M>91\+SIRY^(Q&/6)R\3VR$(0!+R"8A>19"@5)498=)'TNDW#?3U_Q6PO#\+@
M<%POA29\G^58' \05/F3$+[27PKB&#Q'RH*<N'FA>,SC$RN\I2$*'T CC=?#
MM7/0Y2'J]N<R5ML#^A-7LTHBSK9(1H6\Y!E,G3D(#91Z=H$Y5<MW>(8P"1Q(
MT:%8,$'QA$S@ME_#,U,IL/B%2Y_:X<B:X=,H3PJ> "Z67+,U.4 $A3$G6G"_
MXKH3Q"7,XEPO#JX7(PO&,G#V5.1-Q.+X;@<-@BHD.%R,5P[#X@32H,M2U'*]
M:X2\/J,4ODM<Y')$F\CW4O6G<15E(-,T?#PE:R?2\F,ZT4BLTXC31X+4].O)
MC'Q<23W6\!P\;/9%NHZ=[:?AF4,5B,2O%39O;)R(EJ2 F6C.E8 K0@I H #<
MN:QHG^+6-'!I7"9/!\-*7*7B)OS@FD3C-GX'$8(K24ISH4V(5,<S%$$94Y0:
M20WAR,8\XO*YE)=A*%,<C924ID;,PZ#-Y'9-AY- \(>5:)+.%(W)KTD:[]I3
M]VN8QNMY+E!RX:FQ?^U<.%J6G%34%1##*%A@%@%E'**$EK L6TC,/XN3IJE#
M%\$P\V6J>,2>SQ*Y,P3 OADS(F8A 4):SPT=H/U"<O5RJ96K88BRHUBB:)8D
MW-B?52UU2,5GX]BB11G;<3U##QC2\JV!1ZY+#1%5+8$B%3 KN0<': 1N0"+%
MI/\ AD(D3$X:<9DTU0M82A3* 2H%5& 2 >9*J,6BN!_BM.&.P<S&\,E)PF&Q
M_#L<94J8I2'X?QG&<7RIE*!2^(.*^7FG]4J5*224H 3L/@8M.$A(B&2,<Z45
M&LHXAE#=:ATV;9-N4QS<CU&,"8"8>>XB(\!Z!ZN4DHE2T&A2A*35ZA(!KK76
M/D4Y:9DZ=,0"E*YLQ:4FI 4M18GD\3;62,<-(0TA#2$-(0TA#2$-(1 0 >PZ
M0C75O#\/.L;O'EMF)7(4G1K#,4BBU&KST1 HR3^G+U.9R>>=D4A5EF 2S*\4
MW+-LHLW"*F9HIQCLS])VH^*U%GU,!Q69@04"6)LHE1F2U*9*E$#(JW=*&!20
MY<G0TPS9*9A!-"-:@D;./R\6KC/"U;*Y;LN4KMF=.\EG\D4F\%@)3&I :C%4
M;)U[R3#5N4(^O,O N3H'O P*4C!UFL,/9X-E-/:_(6-_,RK_ "S>,%<J7)1A
MTR@@*=25U.9"$$/ES&B'!)*@X 4P:,:<,$ZN"7()?6EPS<OM:+6S?A(R5>H[
M^,IV5HRT.(+%P1M<AY/'3"#M$UD"M[3+KM;K#!')87%P-4QC*P]J_,,W1R5V
M1+^8_:GA;$1B^>LU+2N*I[62J;+9*)N=9"BI.54SM%CLV8J<D!5V-KQ(D-<@
ML0U #U) %J6 MTCMC?"/L<A%U=2=W 1L$X"YU/(-NJ52Q$6O5#WQ3HK;]%UM
MO7(^!R:Q)'R$<RP,U:S<A+K6FM6%]:YF?;4V%EH^O.8O*>-H0N;DP:9B5*7D
M6N8Z\JU3"7"DT']0$!.4@(2EV)$0<.#JSU(Z>!%'\ZZ5N98_"GJ4E3HBJU^]
MUJNNBX:W4X@M=D_9#%O)NR$W-3,?/GN3=TTMD0O&V>F/HXK+VE^YGBV. D9F
M).,*:0*\;:PXS-"UKR$)SH6F7VA*49 P'TVRL2!3, 0S"*G"\][#<DZG2@'W
M:W98O"Z0M%<L%*D,Q,6E9D,@;CKU%2,+BQK'9#+_ "DL;[AZ)8XNWW8;JX)<
M359[N!D)>IR0P,(HVCJVW@'C9RI*+S;4GBRTS4SNS&9)E'+F)1_17+6EDV#F
M6 2 #4N2Y>_8D!GN"'>KD$.2PH'L&Y -&9&TS;BTVP8Q<X];RD)-NY*URUPF
M)> B+G!L9&5EF<4Q7>'CKSDO+$TD]70BFQGAD[6$<JXZU6<7'@=0BFCC\4O'
M8D3RD(##NC*!0'^U*1>OT^-:99<OLTL[VJ222:U-N5'C)_6M&2&D(:0AI"&D
M(:0AI"&D(:0C@H03E$O/'/SXYX^G8>P]^_?MV#D!U!#MR(/E"-7-P\+FD6"Z
M#D>NYAR1C^]*2^Y>8=6.IEBF;MXYW#NLN/XY98#I&,F_Q ]S3=E:#)MUD7R9
M)1ZF[6_PHIF_9D<9G291DF6B9*:4 E?>82@AF>P44)*Q90!#5>-:9A^T65N
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img209334158_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_8.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1MH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &TR^:8@X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $TUA<G)I
M;W1T+"!'97)A;&1I;F4 .$))300E       01"@ [LX_X76!AXLK4#36$SA"
M24T$.@     !*P   !     !       +<')I;G1/=71P=70    '     $-L
M<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4
M( !2 $< 0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L
M8F]O; $    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4    !@!! %  1  M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M# !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M  !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M:XF!(         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ "4S,P  0 "
M )3,S  !  (X0DE-!"8       X             /X   #A"24T$#0
M!    %HX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$1       $
M  (   )    "0      X0DE-!!X       0     .$))300:      -#
M!@             "(@  !5<    ' &0 <P!P #0 -P Q &$    !
M                  $             !5<   (B
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   (B     %)G:'1L;VYG   %
M5P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "(@    !29VAT;&]N9P  !5<    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P     $(@
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
M @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@ , P$  A$#$0 _ /54DDSBX-):)=&@)B3\4E.?U++ZO18&X&&S)9LW.>ZQ
MK-KI^CL='YJ#3U3J[BXOZ<"V'>F*[ZW$N#MOIGW-;_-^_=_86=T_J/1_K-U7
M.PLG$=]IZ:34;=SFM>UKW5OV;'M=7^GJ?]/^=K_[:KM,^KW1KK+?L]#"*GFM
MX-ELAT;WCVV^W^>W)*=G'LMLI8^ZOT;"/=5(=M/]=OTD#J&5D4>BS&;79;<_
M:*['AA( )/IR?>YGTW_\&GQ\>_&I910*F55B&- = 'S<@=2I;;4QF<VI];WM
MK:(?]*S]&WZ+A]+=M24W<6UUV-5:[;N>P%VP[F[B/=L>/I-W*OU+,RL?TF8E
M==UMI<!6^P,,!OTF;OI[';76_P#!(E56336*ZQ4UC>&@.@?BJO4J&VUUG.%3
MF^HQE9&]I#WO8VN'5N:[^<V)*;]5H?0V[0[FAWM.X<3[7-^DN>S,^O,MJR&5
M]4QG;((HK.U["3W]]?\ +WM]ZVJ,?(QZ644BIM58#6#WG0>+G.+G?VE4LZ-E
M66/?]NO8'.+PQECFM:2=[PW^2[^7]#\Q)3F/+W8_J"_K#&E^PM%9+]&[XT;Z
MFS]'_/?X3U?35SI/4:VY+J9SKC8\,?9DL 94^+'MK=]%U+GM]/\ SZ/WTU?2
M;[7WU5]3RII?Z=GZ4DM<6,O&W_K=U:LU=(RZKV7#-N>*SI78]SFF?WO]?H))
M=51LL;76ZQWT6 N,:F )0HS?&K[G?WI1F^-7W._O20T6?6;HKZFV?:(#@"06
MNELC=M?M!:US6^]W\A7,'J&)U"M]N)9ZM=;S4YP! W-C>WW?N[D-]N8'OQJO
M2%_I&RO<RS9/T*][V^SZ>W>S?ZOIJSC^OZ%?VG9Z^QOK>@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ [@)4 P$1  (1 0,1 ?_$ !\  0 ! P4! 0
M   (!@<) 0($!0H#"__$ &L0  $$ @$"! ,#!P(,#PL&#P0" P4& 0<( !$)
M$A,A%!4Q%D%1"A<8(F%QD2-7)"8G*#(X2(&7H;'5)3,V-SE"6'9XEIC!UO#Q
M&4968F9RAZBRM;<T16BXT=@U0T=G<W>"AHB2I::GL\C_Q  < 0$!  (# 0$
M             0($ P4&!PC_Q !%$0 ! P(#!@4#! $# 08#"0 ! !$A,4$"
M46$#!'&!D? %$J&QP0;1X0<3(O$R%$)2@@@C,S9B<A460Q<D)F-S=)*BL__:
M  P# 0 "$0,1 #\ ]_'1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1
M$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(N.7@G(I. U,I+R.]@
M51"%N,))RVK#"GVVW&G'&<.>7+J&W6G%(PI*'$*SA6"+#L)RTYC:[W)NZL<A
M+5Q%@M2\:JSHF\[0LE,U=O1VUVF#W?*WF&B:UKZ-=V=8E9NKLK2V8.!#<A9Y
M<].6.*CA(IXG&6B'8[_I8Y1BES:HF:9B'% +J14MXD>B:_ ,ES-6W;&W-W94
M!J5O3R]/V]_;KUTM]*M=_I88=)#%()D8RWURF6 B$L$>47 J+CCXZ0D@#(V5
M;!).A:]!9W-C4LS.TPZZE_Q/^/[=A9K U1W])2IUZNFIH1N,T9?CF+-N.@MR
MA=FU)7"V8W(LE>(Z(@YF?>&]9B&8A8N3*-F@W8J3'$*RSP#=\IR,<9 U77.>
M)/I=IYJ_.3LB1J(S4^J[>'%1^L]@F;4&M>S.1$OQS!BCX-D1Y;KS&Q16*854
MHZ$?LX4\!*EJ=+C7H]+A*FE'[C.(+9V5PQ/$#U#(5TV3CJ3O.0M\9LL[44KI
MX73UN7M^'O8%.#V,Y'S514*EF'BW=>R,;<A[-)2PU8(AY*/;8F79,P:/>(_L
M^G5N\E&V\>*C6G[ 7':TJ,YFG9X9<@>3R=H7&D7/Y/4+#HZ\#T&;I]ZJ(0\;
M81&*U.A6:-NC89[$P//"PD'%M.NS Q;A0R8J&#$BY=Z9"^1(4J<<\=&HV0G7
M#BKRME&S1-'D[2:H5C_,N/NXQQ@5C5#^R%"8A6;>]*E!UUMI2LQ'VO-&I:IA
M-L>;AU%0#Q?AEI6W,FS <?0_/O1?(>Y5&F4<39D:_L6FVB]ZTG;MK*V4ZK;(
M@*+(0L3>ETN?F@F I@NG2=BAA)D?"FL.X,27#KE(]H@QHJIN=$3HB=$3HB=$
M3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$
M3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$48]8\N]'[:VUR(TK4K.0J^\7)6#BMO
M1DO%&0P\.Y8XE^;C38L\U#0TY$I %?\ C)&/6ZP$2CX<E;;BF\**$L'[[RSC
M-6$KWB>\;[O7=8V36\/N_:0VWHC;-BI$9KG2=XMEA)KND[]%ZSO\_*0,>#\S
MAXH"X3D, &4>,SB0:DPWQF\H>_5!C]^+9 VGU21KTX-4,?S A76L'.WC15N+
M,GS'G[V1$:.B 95X^6E:[/1%E&EX.P&U"5IKU*EX\&T#WD&XQQU1)JA<8Q+L
MV(5^/=8;RTMQ)'+@,7>06#:\,NA+KY7WG3H+7%S-I=CD[>MZN0]%G]AV>%H%
MLG:+JB'V:4H.AF[0M\7&DPU-;L+C;A24R)&78B'2FPV!,17W6I1PE::WRNUP
MU^DTO_";2JD]LV\:D )*7<M?5:AW&QB+!(;#8@]C%W$&L/#2"T_#E/$$42PI
M*&:SZP>&&%O82DIG.2JKSXX+*<*P4/E.7\C85AU&4Y(3WRIC&<9SC+R<8SE3
M?]FGMGOC';/8H"#2[\VC[+:-)1YCQ XAHI+XBDH*88?:==&6M.5(00VA65LK
M6G'F2ES"593V5C'ESC.2JYO1$Z(G1$Z(MJN^$J[?7RY[?O[>WW9^_P#9G]V?
MIT10IX\<YM8\CK!7Z[6JW?*J;;M,"[SJ3EVCZV /:*=]O['K>P#12X:TSJUS
ME+L,+%JM0CK30@0%TJ#XQQBI(E !0F@&8=K7GBS<UV.D>:FN=[W^'HE2KEY$
MQ9X+?]IJ=HFX^ %K5FK/';<53TA:9^(>"L9\JN+LMMM@YU)?*B6,S-> /F"L
M1C3L2S)0?U2FC6]55,?JHG1$Z(G1$Z(HMW/F#I6@[0)U+9I:<!M$?:M*4R4>
M37)%^ BYSD*_> =3IDYY"/@ @K)+Z_FH+!SKB1Q9TVOQ;ZTDS0B%E',QFWY%
M6R9R0FU^8&EM-7*1H=SEYI%AAJWK&US;,/79&7%A8?<>Y(?0VMG94L5*F!'[
M5L:5=CHX52\OJCX6PRSB&P(<I[!":LU6GUI4@<!9X*E)COVQW[=^WOV^G?[^
MW[.BJ=$3HB=$3HBQV\@_#_K_ "%+Y79LUP2Q&<F:7QJK[<<[609@6H3G&6[6
MO8-3F3@9,Q<=<8F7LLY&*G:Q(# "'1,67$O%J;EEO"FU]*<#^,Q(,0.*M>03
M-6<3F=!2*JVFJ/#8=I%DUS=I&<T74IZC<@:MNQ^O<>^.%6TO03P:EI_;NJ@:
MPE@6;G[O)F'O[:D[8?/7.Y6I@ L=<168.""+*?>, S0V0PY-5GBPMS*,]:%W
MYZ4/-7EB.$J8JQZ?L&+]A[.J>8O(;EE@;%<2C,T]OF WA"JI:WOFV5"(KGYY
MG"/G64&+E,P*$J #^.RH9&0O87]LXN A' O!<E@Q=P+\V5BX'POODB8IK&W?
MB&XTC59&<_8_#67LZTY[S_-[&._V@6I.99V;_-YA7Z^ FF/M#Y25N?*FB@!#
MO>:R_E X6X'1=CO;PX)O:U_V!>XS9-0+C=A[_A]U6'4NU*!/W?3UD%C..VMM
M!"P-XJ-<V10GKD57W=>HV!5"):4S!@SDDL:1KLDX())LF#'5W].RDT9H@P[N
M8,EXEY^UKHGPEK#7=?,:[@MYUP:*/XU<QN,=I<1J-N.'?J/*?:1>WXV6J$-#
M76/BJA(:^M"P8W$;Z,Q"3-:&=C0 JV^ZR8+)GFS>E;^F:LY6SOE^5?A7 ^^N
M6,RI+W3%JXSR/)\#EV?KE>OEXV6[LT#:,;O#%/8V:FVXAF]7$;ABA;L\$[KU
MZX(&R]6![4U&N)=9JC'@6(=W;(V?W#ZE7!TIPH_,^OA]G&P%3B>*.L]PZZ1Y
MH!(.;MC;"J6XN77VDRLPJH5=0[?!XS(X/^8*6HD=0^,/%0]^^^7 44\^BJ=$
M3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$
M3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB\[-VXB\HPMY\FKUKNAR0K/
M*/E=L_15_EUS42#\#Q%W7I[CB#*;VCD_,EK?/UG8M77R(K,:X*J95)W UP>.
M0*3DW*:VI;*^>G+_ (N(2*&P!Z&L#ATM?HQN*^U=<7#21Y^EN5Z*%2V_$C@/
M1XE;%A=>7>"%V_S,INQM.-2,F-M'7SI%,L>MH*0FVHMF4+:'+&A%2<>*<,UZ
M!#,PQ;%/7E:T<:4Y<_#YYJ73@M8*T$96HX:FZEYFPVI>,>UJ2)>MM21FY9C9
M35%MESV10]P577YW(^3UG9TU8VW3@%YCHNT7"XV::,LT],R1F7YU]^Q9''+-
M[\J  .?8NJ[Y;<4N4>Q@]PZRI4;MN M7)_2NAJ'LBZZQ&U:YQSOMM@8_-2G;
M3=XG89<QM7236N:XRP/,150N-R>V?6!J_%Q<@F>!E&5N???OP3(U9Y^<C!J(
MN%,*J2'('C3R0VI8;]I[=?*9NZZ'X_5=G:^D:#K&L0<C/:_N'(,V5C9"IVW<
MT05!EQD'>*@+W#+F!Y)Q3QZB1G'70Q9_3CA4O^2S50EJ:F;!Z0(&4 ,'H%88
MC6_)-VYYU9$Z,V-'I5XEUUY/)V\X?2,:\C-2W.!MA<!,,DHN#EA/G(Z;LX$;
M+5=FM_$QRXZ4,<<=!Q&NRE'W-Z/^0_I"$WBF3R: 4=V.1+*[7AYZ:-U;-:IB
M)WA[.ZLVS3=!2M.Y$\CY6PUN('VYL_$]6'9&0;$JLQ-';Z=V#8@K9L<;8U^;
MB9:B GYCA6VIFZV>%BB"\OS=A;\:%I8%9A^BJ=$3HB=$6BL]DJS^&,Y^G?Z8
M_#[_ -WW]$6#(KAMRNI/#?BJWI8>L5WEQHF'V?K&2^8V0-N%SK;?;5KK]P0Y
M.!N.!2.*1.E:PW=%@=R/F,OJYB&&9R9)8ST6)(>9D &L_&7X"FUK'C _J'?W
M&PJBQ0[&F]'<(]C\=&3EFB(DDS\AL#CG+5A#\?E>##7I2#UK99.7E\-NM8D^
MV2WE%2*5.%0>-['[!](?FZGIT53HB=$3HB=$6+#;/%*W;LVKXA49*QIM<@-S
M:'XIP^G-@Y<#6U'[;TZ?O2UP]ACFVWW3AS=>7F5UY8,N/#B_$.>DD)]>4/.,
M%B"((F29?,O#/,LPT<!RK ,Z"Y(;5XL;FW#M'4QU>Y5<E.2'$*W675K<C F'
M:^U1QSY$:/:AJF+*C39L*_%1-4INQ-ROLB2I"LRFPK PSA^07@;,<L2:SK3H
M^E'#45@'-NLR:U<@ 5E]5G-QGOC&>V<=\8SVSV[X[_=GMG..^/O[9SC\,YZJ
MJUZ(G1%#[?FSK.%OSB=H"I39M:?VW8]D; N<X T*X4]K?15<B9>7JHJRFG4"
M.V^XW"A1DD:UCXINJMV44+T33!C@W???XAYT+-GJ;0[/#ZLL4[WB%<IZUP&1
M9]E4S[);!V?PQY(W[1G(")O=>L]AE=GZ;U#9M@BS%VUGC7D17*2]/04.7=*<
MW&35]CBPXGX"UQU:DS&XC,X1.6L]<^:4[S8#E]W4KK+XF#]#W95=.S5&UU(1
M<CMO3^E)"2:WY&%[HQ*;7 JK,=L!>E*OK^QQ</1A9^U  $)NFTJ5<RPVCIT"
MF+C%0R9F\_ORZ&O0RE '-G):(K)_,/+RK+6SQ*]MQTIQTY&V/6+NN^(=UU+R
MGW9&-PM\C+E?-L4+6^LG+;KW%QIDA1:VG6UFL(+05KJT5 7RW@.,3.(VTS4:
M6&H59 +.>)>^LCDT7JNTOOB$;]X_[8VY.<C=80%(A(_17%=6L]25S;H5TIDA
MLW=VZ]KT94Q/;3>U54IJL9!9#A(W83:JG9(NOQ5/?G*HS;7)(9F1?AO4GJ/4
M-4H)_+Q+\R\:4L%6E9\4.][!)I-)UCQUK=^V[<=U6W3C,='[Q/BM-.XJVG4[
MP7>H#;DUIH*<FZP_4&I.&+&)U7"SL5>XLFMO1;HJV)YT\L?R;Y'63E>$G/*T
M5//)YRL2I*\J>:S_ !<FGH.5UB9;CIK1EWV/K)N-M3,7G8>T:C>]::_C]&B.
M'0+H<3/W"8VY2LUZ>?*+2\T[,K<@4M0[KCR(KW_53PXR::UK'.]B.8)EHN6/
MQ?Z0*%5B*E1X"1;V!*:QKE)GKQM JDTEVR6O145R$V*)9K%#:WOTE#Q^JZ3<
M=:Q;Q,)6K7*V>Y7;Y U PK4!+2;4?N.\NH3B11S9C1X-#+4I8NNB$\4UJ4E:
MC>(Z@74HRPZ?FXB,U(Q>*PS1)W=)7+O6O%NJC!6>1UP'/&P,]<[O%GPFU69$
M*%1K"2?F3-7$V)YD6*J,;W,'1ON) 9R,EW6S>:O*]^^ZSUS!Z0K=+VO6>9]+
MTI<*1&[P"GM<;6J%ZXD;NW&#(XV6?IT2Q5:IQ4C#5F:D2&-;.7+XVK&1PT(4
M,2D>3)-7+:#(R&<ER(8>[+O=*<X]Z;VY7<>*.%0ZE1=;V36W- +=57*OKUBF
M8;;'&'>=3TK+/U26;UM'HM%: FW\+KA+Y=.=LL+<)25FHJ!D*5&0]J=^GWCA
M.BIXFM:0](I&M;RRR_X^F/W8_P"OMT56O1$Z(G1$Z(G1$Z(OB20T(.04^M+;
M S+I#SBN_E;:90IQQ:NV,Y[(0E2L]L9SVQ[8Z(H ::\0JF[EL.NFPM(;ZI^K
M]UYDOS(;XMD!25:PV@@"OR]J&>%36;[8[Q2&+#6X*3F*P_LZFTMJ898:CT*9
MF3 HT@H"3ER+N)T#3QNIH.;'H;0,;)KN%9Q'S$$1:(HW,]$I$D:T)\!\3802
ME&X'*@V<RT2ER68=6 VN5C4+(2HX;#A 7GL<9S]PNMB-OZNL$#*6F!V%29JL
MP:U-S5BBK7 2,#$*1GLI,G,!R#\>!E/;]?!1#7E^_.,=LY(#H0VE.F=N!764
M?<E2ND1-2BWF:P_73+4B:AI^=J;DI$PU7M=CJ?VJE,0-@FPXRO39%6E)&(*/
M,&(0 VXQ,"14R!+14<0'.):)L^B[!G<FIW[1&TAK9-"<NLQ'L2T74$7"NJM$
MA%$B8.'DPH!,EF5+CWQ%8)9,'%='='SA]MQ36<+Z(^AZ15JTKTNRXND-NUS?
M6IJ%N*HAS$?6MAUX2RPP4^.(+,C@F^?#34B.";(B,DI\F?40.<2VG/;&'5=$
M#W;E^5=3HJG1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(
MG1$Z(G1$Z(MJU^1.5=LY[?=C&<YS_#&<_P"+]GU]NBA+ G)0>SX@?&ZL1#16
MV=G4"A3#[^Q#$Q,=8)2Y--5+76Q[-KN7N)A<;60WP(6(D*VXBYR1T<-"TF64
M5%2LRXP&W*EC%>Y;W1ZZ?8'Y5R9#F)QKC;R/K8C;555=2R(H$.+&<D#0GYBP
MUQJX5RNXL04>36T6JQU4@2QP%57+)L<U"&A247&%B%CNNDH('*?@'V4.W/%2
MHTKJ.O[CIE%'G86P05;F&JK*W-VNWT?-@Y-:_P".BGEU\BH%CD0,:[?1;&7/
MBR;S69!@>K-B*<,>F "M.XZT5[JEX@VB7Z$)<]JSD=J@Z2O_ "+J$95B2)6W
MS94#QTW7;M-V>^N@UJOD2054436H^;F9DN-:@JI]H0(N4FG'4H*((N"1XA6H
MI'8URUM2R82<-ILWQC#79IBQD0%*L\+R7GHJ,@I6FV8>O3D9/EB@3L(57XYE
M]L>ZR<P!&1TH"+@R7$=.9;O[391SD;^G!X/72K7.%YP<433[?&C;LI+A%'K]
M^M5@>R46U&9@-5)?7LJ4@YI\%J'M@U P,^FY*JITTJLN-K9F$AO8RW@DY6]<
MNW^]:Z<Y/:'W](3T5J'9,!=Y*M1T'-S <7\>R^U7[/F136;,(W) @+EJM8U1
M$JB!L\2DZ EUQIR(^1(4*]A!!P;O\#7,!7[Z*IT1.B)T16LW!C<F:@YC12M;
MHOOQPN6%;5;L[M1^6)5G,BEY-1?'E_F"FL)^ 5AS N',*^(]O)T4.M&+C2)Y
M?*@!Q=YL;3L.C==\C^6^=*Z[UMN:7KE2H3FM([9I;=;MD_:YRJ1[.SI^P(D8
M.L0DW+1T?#PMA.?BH1$[,QD/(R3)LI&L$/3OFH\Z@9@^P>8M:-:YV]SP7':L
MTUM70&K;)MZA[;VW0*5G9)2%4RAU6DV7==)U";?2%V;Y18K&-/E6Y!.KAZQ"
M2@UX"9S:QS&J8SF8(*R3DW,LS\F@WIDQ61=&,X0C"O=6$IPK./IG/;'?M[J^
M_P#\97[\_7HJMW1$Z(G1%QRUDM"DN",-DE-L/+&'=?R,T^^EM2F67",-/Y80
MZYA*%/89=])*LK]-?E\N2+&KK_F/RDL&]MA:=O?%#65*BM,U_6UTVY<HCDU+
MW5R"I>S47UZ'E*Q6AN/D.7;94-G74\LZ#4?"NY4X V,6^LC.&RCPX]OB#][.
MKV6KF11SZSA_CL$'R9V))P.I[16Z'K^?9;%54-T3ZH2F;!N-N;CI>.I.O%"B
M3MED9\P,^037:W-%QL'*$CH$63*/Q'8YJI.,G(F4WNUMN#ME"'UWL/1NSG=5
M;!A(6W(V#3W)_-0JEZ$+J5Y;@*O\]"77[G#-R@IM?A9FO3[4I!2\8P0"EXDJ
MI1=$3HBC%O+3,W<]D\=MQTEZ*:NNCKQ/X):EWB&!)S5FSJX[4MF5QI\88M8\
MDCTJO=81Q3&62IND1\28Z(!*%FC%B7XN]R*4$.VI_ 5AHWPP^-(E+)UY(&;6
MM5):U/LS2]4K=LVC:+!%:[I.Y(IZ$V0W1&2R\YB)FR19+\>W-%+D3H",>=A:
MPN$@G5Q:BN=.X#YT;TLJD(\/'1KUD)G6Y[:@441O"J\DLT0'8,J-0V]V5$ZK
MR(%Y7 )3G)SA;]3BW9*O2Q<A4GB7C9,>!$E'6#1GME:-.G09(VO\K$@1G'>K
MKJ(_PSN,H1<8T:S?;!2Z[5=M42GZGLE_L4IJJE4O=\?(1NR:K5Z@X8VT!#3
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MHUVJ=1.B1$5\R2J4>\8[[X=ND->\<<S-S/V=41_W-#DC,4RNU.=LVF0U4>A
MZNKQT5-W<E,W 0'.;4O)R'LDR.91PU0\L?2*)-PTC"AOS H5H?BQQI@Z)()E
M@@_CD3GSD\#,4/)0E\Q8O6@ UN&R8 KM;7X>W+!V*CZC 7FG2-'D)'EV9.5J
M/W?O71K$1,<A.3E]W+5+E)2NG*X%:=Q@P=*MP%?L&GK+9Z33'9^-))'G)1DM
M,@V5!84/20UX^'K1A'95GP\>2,%$4"EOSFGBJQ$5GPT2[1,LV&XL3S%YX/6Z
MI/W2-K\;FCJ D:O<*K#RI=7G3Y2"EFK#B-C9: "CB294,YC0BYL(?V]7=2K@
M:O&;W,YT<>BZ.5\-_DO9^/\ 2>+4S.Z3CM<\=M.<AM=:2O\ %35W>O\ LR6V
MCH+:.@J(5MBONTP&(UY%PD!LPN<ORJO:=FOVZS1H1\>)#L-_!N*Z/Z>].?-)
M] >$O?Y9FM;(IJ3CM:M?[[&VD=(UYZOL\0=)<>\@Q[AWS7%HUC<-B6"5DDLO
M1HPF*\4';P&8MW!6#UD,&))CA&4,./E0:QKEJQDS,.UZO$R>BJ=$3HB=$6U>
M,Y0K&.W?*<XQWQWQW[>W?'W]$6,@C@#-R_"76W!F?V:,]K88AB#WC,Q=9(CI
MO96K,V.<M4Y0JR\FP/OT,RUF%Q$'+6EDJ9D :VW.-PC8$S(@2T04O:E6->S[
MSG<\/B==GN*= XTV7:4?/OZRO&FCZW>UU'X$^0U]HG<U,V'1J_88H69P*5:W
M*72(FFSMI!>##DIGXBU(KXV'UP^"4)+1&I>A-,LJ,ITI\V4IRK&,*RG'FQC/
M?&%=O?&,_?C&>_;/W]%5KT1.B)T1.B*(\+IO8E/Y#\J]YPJZG+)W#J;1-4U]
M!2$G+ >C:=/#[G<)1;RQH4W,7!3!VQ(-I@^':G)!D065>7&>NT&P86+90[S$
M//'TYPL=.O\ @5S@XV:DWQ1N-NSM$-W7D=.U?:]QO\Z)*Z^DJ#MJPR2FM[1.
MLLUG6UR&1KXZLL AZ.78XPZ2UC+JDS2XJ;8)$9'C:G.6<'2M+*N206-")9Y:
M3,-DY,< LAW"O45^T=J7.N;QKK3NMT0TN2_!@:>O]_V6//HE,8DIVV7FW;)I
ME,M,W?[%8R9.2L<N>S+E3)+WS,V7>+)<99JJF!T1.B)T186F-WW/5WB%;&ID
M"7&IJ^Y^:VE=57?,TR^9D"LM>&]/[, 8@'UF,CPLB9=:37VL/9:(;+:),"0,
MHLULAHH_.#0&H+5MP#G)U;H[FQRPV:":K5FQM3TT2#UUXD6U";&]K5R])GX_
MA]RG;U/K&MQ3>;C&1P@%EJ3J&+K.X6>80ZEPN#8CBBVGP"$!F/"W"+/PY*F;
M!RIY!2S6O8+<)VK-CQ>S!_"XY'54$77\I5A=:9Y#\KX>CV"FB."W,\FT(I[$
M2!.U*T3)#4FF>^(>F )"+6-$"3[ZB_>AX%(DY.(9Z7<00;=678(YZ<N=<42B
M[]O$KK;951VAK/G388K3]>UX94CJU*\4*YL"U4LD6[YM<S(3A5Q&I*XRXB%P
M[ PJI(5VNL,+ +<E:8[U;MGT<H(BLA_Y31WNSDR+W77P7.?G<BJ6N$-@H)=L
MM.N-(;$US-7R-XUZ^L^7]E[<KU(L4!JFC0_*ZZUS8XLU69HI[11FR;9KMF>N
MT2BLS\Y8'Y09M)+\-?GWK8Y*Y.L>9/([=UEUYQ[@]KU[5FQ!X7DU8=I[+V?Q
M]9A;7#3.@K-I6/B]1RVL7=F&45FXOU_= %KV#9:?=;!7":["J)IC</F5<-@"
M7+,0\-ZEW::MZS%J'?$BY7V*VVJRT&O5^XZ[TY:N/5'L!-)B-3#:6VNK:5(U
M%;[!<,;5VKR#U]L^D@6=6S"H[2Z8?4]CB#51<;B2.NY4L?%UM^<M.?"U4@<2
MYXM4Q4O4"LO15Q%\W>6=7&H.Z;A/:^O>N]B;NY]:?!TI6];%P,]%1W%.K\L+
MG19T:^XMTF=-6NS.<= :Y-1RX .#>"L^" @1I.,^+D"1Q,3>8EI$:=!(^&R^
M;'*C2^J]73C^W-+[RO7)^/X^R5*K&O->0\9;=2,;AL28V7L5=@+%MF I^P]?
MM-/!U>AF7S8M,+,V 4*S+S4G&&*BPU?EI(&<]^JMWRM+'IWS9=F5R!W?/Z7"
MVSM*)<A]O\7N?7'K4-?.*1KB'N5ZHNZKKI+5]\A+[1-6[.VW4:E:)"G[UL(!
M=71:WVR9*K5&_"P=>)?C@8XL;$$0Q-R['@[FM.!,+.RGZ8_=C_)T62UZ(G1$
MZ(G1$Z(G1$Z(G1$Z(G1%IE2<9PG.<=\]^V/OSV[=_P"'?'\>B+7HB=$3HB=$
M3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB^+Y#0S2
MWWUI:9;2I;KKBDH;:0G'?*W'%J2A"<??E6<8_;[=$][:E1>VCR"D ;")K'2D
M )LO;$@(LDL+!N&:AKX!UC/PUCV+.#+7B.CTO.#.CP@OGGIH?#B(]IE;PC[F
MKMMMC!_;V &TVF*,.(_X F <1#, 6)9[B&7-L=F,0\^V/[>'" <0+DXH!.$0
M]+Q5W+**<KXE-&T'N@+1_,*_Z%U[:)8=!HTE3;^Y(0U>8*0,D!BZL3;0\M64
MD.*>?7+V@2J".,$@.1 ,Q%AS\[%\.QVN_?O8=GO&PV0P%_\ O=GC)IA<#RFG
MFQ1Q@.SK+:8-D<!VFQQ$@$#RFLEJV;F\4E908B8B9^, FH.2 F(>5#'D(R5B
MS!Y".D0"VDOBF@FB./#%B$LK0\.0.ZXR\TM+C:U(4G*NP6NNRZ(MJE82G*LX
MSG&.WTQWS[YQC';'W_7[N^<_3&,YSVZ*$.*MKDK(6"P\C6)N2'J&K-)S=;:?
MQB(EK'OV\U><.%\B,J>D:_%\;K@!&/I>RXCX<:RR[:FDM/9)2MY3#1 >!X3_
M %PM<KJ/M+RQ_F7X\?=_=-[)^_Z_W)/W?X^B3KZ1/?(9U?:7EE_,OQX[_P#"
M;V3C'\?T2<Y_Q=$#YYVG33.?2Q?:7EE_,MQX_=^DWLC\?IW_ $2?P]^_;HD]
MC3CG]M4^TO++OG^HOQX[?=_7-[)_^Z3G]GMV_'W^G1)[&O'+[Z)]I>67\R_'
MC[O;')O9.?W_ %XD8_Z_A]>BNE->WIPZK3[2\LNV/ZB_'C.>WOC])S9/MG]_
MZ)'O_#'][Z]/3OFI(%RW!S[#V6OVEY9?S+\>/^4WLGO^[^U)[?O]_P!W?HDO
M=N6M?1FU<9/M+RR_F6X\?O\ TF]D?P[?HD_AW^_Z^WT]^B3GU ?TCA&IR7RS
M:N5R74,YTSQWPXM.5X1CDYLC*O+C/92NV>)7?*<9SCOG&/;O_>Z*KZ9LO+/O
MCMI?COG'OW_KF]E?WO[DCHL9 N=(RXCU)^4^TO++W_J+\>/;O_=-[)]_?V_N
M2/P_A]/?WS@LN^^RGVEY9?S+\=\_?V_2;V3C\/\ Z).??O\ P_;[=R+3[2\L
M_;^HOQX_;C])O9'?[_;^U)[9QW[?AGM[_7VZ)SY_+3\\UK]I>67\R_'C/T]_
MTF]D^_M[]OZTG\?^S\"DG3B']BGVEY9=\?U%N/';M[_USFR._?\ '^U(Q^_M
MC^/X$F::=N>OIGM7:.6#:%+5I?CQY4X[YSCDWLG.>V._OVQQ)[Y_=CNK/?MC
M"LY[=$+M5H+].,-QYHW:.5[K:'$:8X[J2O&%)5CDYLC.,I5CV5C..).<=LX]
M\=LY[XST2>QESO;*ZW9LO++^9;CQ_P IO9'M]??WXD_]>_[^Q+W]-.?9T3[2
M\L_;^HMQW_Y3FR?;_P!4C^';^_VZ(7M[?D)]I>66/_R+<>,_A_7.;)_'Z_VI
M'T[>_OGZ^WX=R2V1SCV<T6N++RR]^^E^/'[/ZYO9..__ *I.>W[N_P#?QT1C
MGZ3]O3[JS-YTW>=H1EIAMC\->%MWB[Q+0D_<@K3N>SSS-HG:S'#1%;FIU,CP
MY>S*2T#%!"1<-(F*<,C(YAL()YD5/HY9ZUUXYH1-3ZB(<"8?AF]6'+@=3[!J
MT4Q!UGAOPJK\,+7K=41HJ%V]88F.&J=_EFI^]5D<,#ANR.S 7*=89F;1#MM8
M GI5IJ0E!RBT)>21J//Q,&8<5?\ I<A_66RR<Q*B.(/#0A<%&4>&A5O;HLSF
M8F'UE._:C7,5%J7PY4H&-H5EQBP4T$;#0U9F>TG#-A&X]?HDLTY6Y7J,Y,'.
M><-1MN@-UAD#B?P^#:I:[.NH-";OM8[-67=$&-6]5>:9X=M-PN;2U('M6'Y:
M@?YPV:8W(?$((=2LC0QD1I2EU;"#XTYJ];N] KO O@1"5+97H.7^K1>SI8&$
MM[3#ZGHYNQ18W#!L64&!+0Z3$C&LN#QQ6'B(YMA[SJZ*'+-F@%FK6;2=87TD
MN,+LOKR!U-*\".!<GK.KR;TU7:(=L^9)JT),DJ<R;,QD*]PQ6 '*R?KD)E3F
M&4%2C9134B\4V2^EPJ7+RU&/9G@0 NYEM"66?N]4V5.<(N#TM?Z*+%@4RX2&
MV9XNQU8*"SW@18&8=X;+-C6*^O*W*^V*ZRF"6XZN)P$IUS*B-E#]V(G49<%6
M8-(W!&HKC4=Q0X?@MT^S6BZ5- N\;<,FLW"ZHLC=PM4!ACA[C$/8K4W<;:BQ
M3,?AB1F46>P)D2"<2\AZY0@Q)+6CY(CJ7,NK<1'&DR @[[5X7@;P,BZUM);3
MNQX&/V?,"1%VR.^\4*W9HUGAB@2:8",((+ 8.:=8 ,(?+";8(?=<4#"@'0(Q
MS(I?K4D7XP*L%TQG&S:8\7J&G4OC;Q9USJ[4.R0]L ZPH>^+A6*M8[I!LFD5
M0^=8B^(0V%HKMJ+&OK66FLE25Q@:[)2!:T1[[!15JYRQ8.'>AK<O,J4>+)RQ
MQC&,:7X\>V.V._)K9&,_L]L<2LX_?^M^[OT2?Z;3.ERTTK8OM+RS[?ZRW'?O
M_P )O9.._P#ZI.>B%_?\7'>2U^TO++M_K+\>._X9Y-[)_P#ND_C_ -N.B=>,
M=(GJ.:8LO+'[]+\>,?\ \3>R?X_VI/\ V_L^O15:9LO++O[:7X\8QCZYSR;V
M1^[Z?HD_3[_KCZ=NBD^AM>U_GF%K]I>67M_47X\?\IO9/[/O_1)S^W'TS]/P
MZ)P/1IZO7CS3-EY8]L]M+\>._P!W]<WLGMW_ .23]/\ 'G\,=O<DSZ=_CJM/
MM+RS_F6X\?=_=-[)_O\ ]R5_#_'T2]6S$3KGIR6N;+RR^[2_'C]V>3>R<_?G
MZ?UI&/N[?7^'1)X>_P C2_%;%VCE@VGS*TOQXQC_ (3>R.^<]LY]OZTGW[8Q
MWS]_;&>V,]NB'G/!@V>A[9=7 [#Y-6B%B+' :FXWRT%/1H$S"RH7*#9#P4G%
M28C1T=("/8XD>5X8P1]DEAQ&<X6RXA>/[+&,$#YTK%?6(]^0@1XGNW?$MUYQ
M6E[+QEU-2 =TL[ U>'3DZ@O]OWC<#\R%TC!)F+5KBQ\;*I!R\$=".'M6 V0G
M0F(*)^*F\/,NQ[1#+OOA\0\(*TS-!%9<6Q6<U.I:97!B[<S[[HV#GN<NIM8:
MAW$0EC+U?UG<#[(P4"L9MS!D_$$A$@U&;P]E31,+%76["X4E;N3H]6< -DE]
M&YD]^_29G15.B)T1.B)T1.B)T1.B)T1.B)T1.B)T1.B)T1.B)T1.B)T1.B)T
M1.B)T1.B+X$C#&CO"ECLE"DM.,$#D-(>8?9=3E#K+S3F%(<;<1G*'&UIRE:<
MY2K&<9SCHBBAR'.@>*7$?D;L/3E)JE2.UOIO9^P(&)KT!%PL2JQU^HS$M&%%
M QH;([R&SV&''_596IQAM3*L^GVQC$8<(_QPX</#"!U9N[IBQ8C_ )8L6)V!
M\Q)=RW?)U^9!/VB9NT_-VNS3QUELUDDSIJPV&5,=.E9:7DB,FR)TB:\MQ\@L
MHI:W7W75J6XYC"E>_;&! !+CH*N#I.A!O.:R'^+!AFY;6):V3O>8]AGY,QO.
M^W'5W(32-ADY*;I>IIRD6*A/F$+,8KS.P&[4B=K89#BE>A&K/K#<V#'->5L8
MV1G",^;)GZM]V$]=&CYHL<M7RT9YXVYKU$]5%\W7&V6G'GEH;::;6XZXXK"6
MVVT)RI:UJ5G"4H2G&5+4K*<83C.<YQC'1%87CK9(6Q4ZS.14]&SRQ]P[Y0\Z
M!)C2:F!\[OV$F-;=<'??RVS\"VRD)*U)1\*VTD?'HI3C!8X8K!-N0I XD!V)
M,RK_ '19)T1.B)T1.B)T1.B)T11"+VAKE/-2OT!=[IZ+T_HBRBM4MRS0J+4X
M0JWUB>0TBN+.3,*=7!C%S#;> E*5%#D2"<9$9<>24!<QPZ/?V#BV;&7O15.B
M)T1.B)T1.B*W6W+36J9K.\V*W3\+6( "LR^#INPRH$+$!9+#>#%^+DI,@4(;
MX@M]D9CUGT>J0ZVRWYG%I3DBHKB[:*Y;>.VD)>JST-9(AS55$%;E8&3"EHYP
MF.K4;''CMFQ[Y KCX)XI()S2'5+$-'?$?2V^TXV@L1EE6&G)JMVYE7ZZ+).B
M)T1.B)T1.B)T1:9SVQG/X8SG^'1%#6D[,US)\W][TR.O--D;D)H'C@$55@[-
M"%64,J%OO*0V:'(@VC5R@[L6)/P),DVX,A8;$S$ND)0W(A9?-E+5:W8GAP4<
M0>0CA>;Q4 M0L"IE]%4Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(K?;6V=3=+
MZXN6V-AGFQ5%U] 2%JMLK'P4_9BHNOQ#*BY223!5>+FI^1: $;<*);C(LPAH
M5IXC+6&FG%I*'/*?0]U'%1[\/_<FO=[\-^.^P=72ID[3WM6U"MBRYE=L=9P9
M)4V%$JEA2&#:(F%D200K!#R8#$HR(N,D?A7"(PLP139#A!?L<NQFP=3$SC&?
MKC&?WXQG_+T56O1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1$Z(G1
M$Z(G1$Z(G1$Z(G1$Z(K;;DUZ)MO46T]52!RXL'9>NKI0#)-H8<UV.&N%<DJ\
M^>T&5A0Q3@3<BHEL<C&67EM8;=_45G/1%^7!R+X_2G%C=6T-%VG QQ^OYI^,
M7-P1."(2WP&25OP5IBB4D/84//PF6#UM((<>C5E'1!12SX\CR8LV08/H+EA.
M0B&L075C3E7G FSS[!>V[\GQX;S7%[B]:KY9)J)=G.1\C4;X]38E33[M"B8N
M$+:@(FPF8<41BU2,?-9EIB(<0PB P0+'+:^/1(..4!@!DL7ENX;[A9^NJJJ7
MO$]$U:EVVSSS#I,%7:U.3LT.R.V6\]$Q,82?)-M"NJ0T2XL,=["&'%H0\K.&
MU+1A658*%V+5:.*PG^&9;.('%JKUO6>H],<B-)U7F#M&S;9UE>MWZZBX.I;%
ME=BQQ5VI=!KUNK5GM@<=\FUM'"Q]"@K0_#$3 $'(DAX*FSI!I9#UR$169(UO
M\K*+JKEAI;=.Y=S:.UK:F;=;]# 4\O8AL,SDJL19MRD;C$B5\2P(<4'*S\.?
M1YL:RA@8=9@S,-19A*9=B2CX\@[^>3TTF["2?15.B)T1.B)T1.B*-?(ODS7>
M.?YKPI2@;0V;8]PW63H-&IVIJ_#V&S2D[$TBT[#D<K&G+)5X\< .JTV?.?)<
MDO/YA4--LN+=3CHI.G>GY4%ZW8."]MY$["\1FZ1%@TIO+C9JIK1&UXW=E>S1
M;30(>XR,;8:C*2T"^J3:D9VT1IS]9H-DJLM-M6B)GI*HQ#T@>I4<*01K#VD:
M3<PY>[FA4F2>?.IGM:<?]D4^I;9V6YR<J9=ZU#KVA4MF2V5-T^*@XVPV"QGU
M^2FXF.AHNN1TS#?.'9*<'<;/EXR'#;-ESQ 7R/FPXGBUK_W12BU3LZG;HUQ2
MMKZ^E/G5*V!6XNTUJ4R*6 X5%2PK90_Q,>>R.?'FLX7D<Z..'8-CS6B RV&2
M&7$8(/:O'T5P>BJ=$3HBINY6B-H]0M5UF$DKB*A7)RT2J0VDOEJCH",*E3DB
MLK<90Z1D81W#+2G6DK=\J5.(QG*L$6-60Y:\=N9E"A>/^X-+;\UMK?F;19"J
MZ[F]SZXC:_3=E"VZDF6@".K5K@K+<(F*MY-6:(M-2$L"X20+(BE/0>#)&.4P
MF>CY^T7L%#$Y?UF,^CJKN,.[>+VJJ;>N)7%Z/LVS0.!^L-;0%FA-:PHMB)D7
M9==TA!8*NFM&1\=;]A.S&O;.5>&@GF! K(4^$28J;;F@(NJ"Y8S1X])(=A7H
M("O3Q[Y@U#D5>=I:Z@M9[LU]:M.-5%5Y!VQ1A:FW'E7<$J6@8MDD.?G&GIAZ
M&&;FB8M>63 XB1B)$AM LM'N$E1RSC7WXWR"EOT53HB=$3HBAMMKFQ0M2;3L
M&H']8\@-BVNIT*H[*M2]0:BG=CQE;J5WE[K"UTV5=@7G#L%'FZ^M7IQP4>8;
MEJ.RXAE?JMIR,=_?*ZC\I:8Z9NJ;L/B(\>(ZNTFTU%^][=B;SK$_=0GYH=>V
MJ]GP&IXLU<5(7BW1T9'X,KH(<PP;"+AS&<VLB9B)V+ KQAT%*CBD?T+7[N]&
M]UR)7Q"./4=<8:KC'VZQP\DG4.)3956I-@G-65![?_RW\S(=PNX@RHR%*OZ9
MN!?B\*P^T$'8*\=.NQ <[&/OE'<3#@P\Q6F685'W_4'&#B1OS:OB$&U"PR&Y
M=YUS46B2HVFPB+%9;A8/G[D#5XFEP3.!G7;7>7"JA"SQ1<D'$(B:)"2)Y42'
M'S$@\0C/0\&F9D/2V5'':J\1/5+@<=&1^N=YRNW#KY9-<%<>8[7S+^Z8*R5"
MI0-]LKL[".V!BKA5V)IMLJ5B7:DW!VO2 -NJS$+(R<I-A1JRH>[!@]>-SPI/
M%2WU'M:G[NUW5MHT ]^1J-OCU'19!8!D3(,.C%DQLI%2L3(LL'Q4U"RX,A#S
M44:PT7&2@)81*,/,KQ@KR_.OQR5R>B)T1.B)T1.B)T1.B)T1.B)T1.B)T10&
MW)S9H=5V'MG1)7'_ )$[C_-U5JP=M<_5^LH>^5*'KNR8*5D(P.4%<M04_+9/
MA(Z7R9&1%9ER'4,.BL"EN.H;64-[:JW$3SBX@<<=4ZPJVHJO<I_2U;XZU_=
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M2:'!61B7APY5;\R*$U+/O&+*-J>%174/]K%2?HU"JVN*]'U:GQ;4/!10Z10
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MKG=M#KFTM:FCE(/Q$(Z)OG+BZVJAP<,#79RHX#!S62!FH+%@_P!"0Y<EK+K
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MZZTZXA+C.<X>Z6(%Y][U8Z9!F94@QB/_ *A6;.#$?F[EH.ZBOEMG[D5.1D8
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MB("$ E= P6F)U<>-/'V]G<%FO%<0V&"(.3&)KBZ95;0HLE]2)))Z9/ +3.$
M_#K>]5_T"*TW#7;?)O>VMM<[EW#3M&5"A;:U#0]H4V/UK<+[9+:"N_5^$M4?
M%6=BT4ZO1#* 8B74P61$R)RE23"4LH<%7E[!2]_3^[>O2:G15.B)T1.B)T1.
MB)T1.B)T1.B)T1.B)T1.B)T1.B)T1.B)T1.B+P@_E0Y2&N<>EQB&FGA2^/M
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M,2H9-A=K2+9/^("D/R6X!;%T9J@_;5I:"01&2WP4E%C!.^HD%21'X65<+^7
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MLH^'RX,^EYK/ILN.YX6QXFPG",6$A_-#/;.]N%T9@YI:L^AL]6>ST/"K4&%
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MV<85MG=&K;U;8_-CMS>9:*>-4-&O(GBC71BHE)D*N,7&K('<?DVE+6TMA_)
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M+@2!!V%J-B8LQX),%34E@OC1L>:2.2>9(8P4=*MD@+:*'!1EHO5_33Z'\/\
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MJ36D-:*;E ZO7JU>+D"?6![/ Q5@A8Z8:6/*2$?+(:6$5'Q[GE+/$=];"69
M9ET E"'7F"7&D+6C]6[M^J?@&+P@;;%O>'!M!LL)Q;  _P"?D!Q %B?*,08.
M [7!*ZW:>%;MM=\P[[B!.T'\F_VDDO6H);$(FC$05].:$A/Q>PZ-QW/F7C@.
M/(#>'O.S\$.B7NHQ6P#! &DD$,G,++NRW,'C/$-%#LBXR[AL=I'7YB^I/&,/
MU#XUON_8<(V>':[0;9L+L^!FPRU6 X"*E=FQN9HQ-!!S$Y Q!R(7WUA0[_LO
M0=SIVKX]<O<Y3E3Q@5$QV)..B\O(#U5S",*SF5EI&,C8MM@1@H@@P\M+ XS3
MBLX4GLWGHRX((+'"?,#-128;6^BQ(!B7+-U>DNX[(7,/NU35R[E]:2QR5:6<
MMM<K+UJARX[$K 3,C!P4=8,YD3DMPLC7HF_NS33EG0PV,1"MKF0PU"899Z^H
M>!_JCXKX/N0W';8-EM]G@P-L=KM<6T_<&,  !L/\?*P),2>JI&#'A QX!B.&
M1B/_ "%"11P*7B+K;';9D^.UCW7KC:="EDW.N;1GVZWL."%K%EV!J=N&>.K$
MB/78>P,Q<#+)EX$=C(TA\2(E*#33TAD_,W,(\/XSXWO_ ([OFUWK?=J=H,9?
M9;-R<.S!_P AA>6Q,(R82RI,  >488 #Q^3)ZJG-D4_6^I-(T366H[WL*P5_
M=H+NZ+4F\5]5+EQJN1-OQE#K$C50)F8A</9-@IF<E3F"E!2C&(61C66PS\.O
M=3LL>UV1Q'!M<>$8@V+#+$96_P#Y0<LD!NUCIGD.!TNUKA5BS\?:E5-(;0W=
M/1%_ME,J[%=I=#U<180YT&FU6PR.8BO;0'),1103RWF#U>2%8B;0N$/@I<M^
M40TT/G/!M<>QQ[':;(G9X]CM<.VPXW?$^%B [PQ!G5EB/XXO,SG#_M.@8!M,
MOM%"I790]04[<.R(-J,CME6:^BT.,BD_Z(S414Y=@4XX&,^.)+&B(PR0:@<R
M4BL40B1#('9*)+$DQP/O/TI^K^PW/PT['Q?9;QBVNS/E&/#@.(8\.%@#((AG
M%<4UDDZF_P"X;MXH,.'?-E@VN'" !AQ8,)B(!9R8!M4%FE4[O6 G"]%:TM=2
M!D[#4MELSR+G)0$>LR(U@;!3JXUNG727&+=9C[1+A-M3PD40T.Z9"F!E1BI!
MITA0WEOKK]23]1; >';EN^UP;MM-H^TVI&+^08N,0+ 80Y-2UBY6UNVRV6Z[
M#]C8;+#L\ PD,!8T;6231P'+LJ7*BI.RZ@T_7:M"RUIFIW;&X(6*A8,!V2D9
M@\JK: #&!#$80X^06\MQ+3;#++CKKV<);1G.<95\L!\I!RE4S$,0(AG<UIZT
M%#E<9J,3HC7#=.VC&J"W6YL",C8W7D#88&SR,?KTN$.-DINWB5Q,FS6YIF45
M!B1-?-DV)LX0]\Q44D3(Q*_HGT#]>?\ RD=INF]X-IMMTWC:''AQX!B.TV6T
MQ$$GRX7P^4#":B3B@EV&8V>RV^SQ[+;81BPD  F")J&9^?%V7)V'L&^\>=P1
M,'7%#1-EU[-1)5U?="DQY&!=4:AN8JB6)./$=CYQV%>='+(6*^J-</\ *PE)
MX*W&?2_67ZH[KXYN>W\.W/!M,&RWG98\&TQ[3#B&)W PG"  &#&M"'LL=CL-
MCNNSP[/880  QU()D@N21DW^(BLU(7- [9Y&[+J>D8<R3U1%U.1N ATBI(Y$
M1 U&KRMINUEE<X$2L"(0R%(D^4[T%LL-@^5675+2KHOT]^OL'TKBQ;AOFSVF
MTW/:$8SM,.$G]LDG^6$,02:8Q(I#,3CM<&#>-AM-WV^$;39;3"<)PXB6#U(-
MS0@21K>BJ[/UJX/S]6B[E6M;SI\&:BG6?:CLK 4>0GDHPV)'2UA%C95-6$<Q
ME:QY^?$%KK;K*4R\C%!96:W[?ZN_5_<M]\/V^Y>&8-YQXMKLL6Q_=_;.'R8<
M08XL  (=H#FY)NM'POPK</"L&TP[IN^#!BVLXL3DD2X !(!F(AYA=S 5*V<;
M]9;E@MB0@J9$8+54W%%P5EKMFK]N EW[F^%*UNW5TV7KEAAI%]LS+4K$R)@C
M;K!3)#J2QRF6OG?T%]0;I]/^+;;Q#?-IB VFRQ8I#8CBQ822X:,;EV8RXI7L
M_P"./^.TP#&,6%OY3_DWF(SAV#@1.2HF?MLTQKBO["BX0Z-BK-+V*M0DO,N-
MY'055FHPFPJC&U+>8,:CR)N+9SEE?PZGB4Y?:0MO+6/H_COZS;ABW7#L_#]G
MM?W]JV''BQ['#@ Q @G:8L>$ XB X!Q$D%Q$/I;CX)X5N&VVN\[MN^RV>\[;
M$?W=J,(&/%A+MA@ X<(=W$T#L"J@UQC6=GL,AO\ +NC(EXTE 0MJCM1REKJ5
M !N0D'@86:8;5;(I]BVDR!;@#I-?K\FY99=2\_+(4[.'%C?*OK#??#?%MML_
M$MAO>UVV^;U@P8MK@Q8</EV1 !Q>1I)!IYG(% Z[;>,8VN#" !_& !#B)(HY
MA]0YER>DTPBXGT+=EBE6I6QF4&L@7MMM\@>00 JT6T"JD).?;>!DS(QJT6>!
M3Y1<.?"-%O/N_# M=D<W@GUYXQX/N6/<,.,;;9$#R8L>+&,6#RXG_BSAC0N<
MFDKCP[<@>7RX6@.:@!Y;@[WH KJQVJ+1>M4:&V]L:\1&L@=>&S4K8 MKNJAY
M/:-%7L*9:D+?K 9M\LR<K=2@YM54CH2,K[3A\Q"D#P[DT:XZWCS?B&_;QO\
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MQ6%+OI)]3J@(J&O_ $*]8-G%3\>4.F]TR^Z[?%Q6E-OEU^E#5O5D$X'K&\$
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MX[=\8S],>WMCOCO[>_;'7'M6_;,9 :2,YH#\G.8FF6M0N[B2Y+//V"]:E_\
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M6_\ QYK'^=.HXS'5$_/)J'^=76__ !YK'^=.JB9W)J''UVKK?'[[S6/N^O\
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M<AXAXQNVYEC^]YQQ( 8:O1KY&WSK]5<0P?1'C!-,.RP$QEC!$LP-Q2*5F<7
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MR+A964L5Z)@X&N)1%"1H398FH<$B!)#26XRYHTK'7Q9T19M:^/+SJVS+8?\
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M. _ T+)@L&8*-F@3Z'3_ )T4H5A WPT^ZUEQK"%/J^)4QA3"%)PO#G9.5Z:
MQ2^5VAY9X:32[FC,\<=3J7536+\H&W[7ZK#64K@-P=].47,MJ1G7EA2,GY*[
MZ92F2DV3N[C&%CK6G#.%8P4SC"<]\*ZA,L6(Q/JYRR&KW+*L[R:B(L36,R!R
MM?NJGX_VZ9^-O$DO@1P@<15!XQUC U1F@FB'35"//MNODR!V?,T&6G+:$C(2
MM_"\Y>PE.4YR<P[=?SP#BL0%&:D6&@RYWN>C=-#_ )0_M2<D!Q!N G"EI+HD
M*2XZ[ R&$X5,P04TTU^N.VMO#;)S:%+PEU/F0K&%+2M*\3S1_B#1YJ;$!\XE
MF.4IY3(<YVGTRY-T6LU^40;2C960BV^ O"MQP!1;C:G8(Q2C6&I>,BF4,H;'
M\K;N52*'G%K=RSE">R,H5E.%5])F'DZR9J)@/4"BA&N*M8#V#PWWU8+XO_E#
M^WQI#$4KP_>%62\RYD2EG$#(9=PX#&Q\@Z[V\F&%,N?,6L(4@C+J?*YA3.<)
MPK,=K MF6YG*IIEJJ0[@'T!:EB/?/@N^L'Y03NJLL5]UW@-PS9;L+,.ZR[B"
MDTCH7*R3T>QGS#H<\R$Y0EQ:F<K6C"\=DJSY,+$R TV DO<3-A6."K14U_JS
M9Z\1"Z%W\HQW$P"[(E\"N%XPF!9PH=Y4),K;+S"D-"^@PI&,O868ZO"&%OCL
M8PM:%.)0G"^P6C3H]>#:R>9@#7)XD_TJK<_*!-Y,T]ZU+X#<.?Y*35'J$369
M;*4X2$(8EU\C"\-MX<24K+:4*=6KX=Y*DH_D\KKC1P.+<+S/4L+*M,$W@M(K
M;)O355UQZ\>G:.YKG+5N2X+<08T$#36UMGCF1T!(J<3(4G5UZO,#%%X+:4W@
M23E:F-'R3S:$NM E/+'4DA*%8@O_ $Y'5\M"ZC:D#D?</ZJRIOY1QN,4_,4U
MX?\ PX)D,R\Q%X'8@I-Y>51+,,XM2<)PA#BGES+2&D)<RM66U8RG[^CB6EK#
MOKDKY2[.1Q8UZ5+/1J!E4]G_ "A/==4F H.5X!</0BS3 (]3AU>E64!%F%I&
MQAYC#/Q+S7E6VKV;9>0M7E]-W/9.4#(6-!K\W:_,WKZV^+?=4V_^4=[F"C$2
M:^!7#=D=Z&1-L)Q%2V%/LO34;!--(0.EW"'<D20Y'=Y0^,-(<1G.7,)\PFHT
M,FG/3/+F$;C#.?30<N)A589^4'[_  :>/;BN /$1 A<JY'C*Q!RJ1WTC"%F&
MY;(4[Z67AT-A^9I"W5H23W<;3^IC)ZQ%& >&M)O^0Q4\KL'Q=6>=&X9F\TI6
M/_*/=VR./59X&<-5C-XJF2"$14UZ8_VJ%!*%2YA>4/>9A!S/KI:'=2E2580X
MOMC&; J!SUYC,\7*-#.>+S]N;/JJIIOY0QN^W!6"1&X+<-T"PD1+RK;S<)/K
M1(MQ,D#&NX82KR9;:_H]!JG2,M8P,PM&,Y?RAO,+!W:.![KK755LM'XVDG(3
M ]'/1P/Y1GNB9L$'"*X&\/FUR]FS7G4-PDWE]C#8T8:^2G#G9"LX&/[H\^?+
MYDXSY5>Z%' L*Y@4>/L'&K-$;S%W.M6XD32M'=7"WO\ E VU]1;8VCKT;@]Q
M$D(ZD6NU0<&>1"RR396/A=@/4L DY Z$#LF/LX9,*:1AIA+F7&VUH3V3D:M
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MZ2N["\^LTI3Q$RU""M.I1A2%,ML9A5KPOLK#GK,IPG'?"5APS=WK#.(M4="
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MNT?AUOAZ?@H&PW^Y5T@6#B'I9M1U5K+X2HJ6FUBR(*FA3DO,1Q>, $*>,>:
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M7;UTY2&D?+>'$.8=<;PE2O,I'5;E6C:@>A,$74.GYZ.?MZJ8_*$V"OO"S1%
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M*5U4+6T.GYK'-GJO6K?_ &H5VQ_Y(V3_ -S&]:BQPT' >R_& =]W7,_BM?\
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ME5I"81Z;F S8U3D4F;GA(,3*\K,9)-9-DI<(1>0V"DM$.CX>RTA'G6:C-Z4
M_--0:5H+3RTF"^C/0O!@KB0315HF&X\>>J5-33!+78;+.V@T^.3:7UR((,74
MH%R/"E2B9DQAA(4/'(9&2[Z1!A)P8_KNN',\W<QU8T810(9+E@Y9P&I5@>+L
M?NJH)BYZT'4Z)K;=?Q/E7U @C=WL($%"98%2AU_$M)2Y HP42+Z*$/N'NMH<
M&?)&PI9+K3:8<[%ASH#&9:9 8?Q9T?7DYUBN7H:JW%0'F-FV>2 5;*WKVJQI
M<E(S4Y+"3$U#@"U\4S,<)A57B)VR239$HEZ/7F('6RIWT#"UI8&SC)B:L,CR
M?-Z@01:7J +'N1SL5=^3K%LN9D+1VAO4/MX$?601$S(E9CR22(EGX ]\JQ%"
ML(AWDOBF/&2CHC"$94OXEO#J6\WY[<T.3Y0-4CNMH>G].10*TE+<0UKJR8G2
MB\0D3(UF(.^2+$>DLQPEH&C91Z..=7D$M?PCCRP,N94(I;25K<6UYEY DB+N
M :F0U&'><,^!KG^=!SK?#4&LX<JR7URB6D]53C)&?G:I-6)$6S-/1<:X:? "
MRV 5N13<H]#N /2S(+:0R)AS*!\)&;;\LT,O7(18\68/#N-8K6V5QA[9V4"6
M1%M@C8Z#=CY)%<*JK3&92O?%SL85 'RLR<$=&2H[L>6_B4)%+>%<*%R@-T-O
M!R_ 4,9NTYM-,B95&E9Z,75R*+*'9;J+#=OK[,U%WN2I5=IK\26J6)8.CW)U
M=N(FW!EQ0HIQ;<=">DX1DIIL-E26L,>=S%Z//P<Z!QDZB[/:$+96(RQ1LQ-U
M-#=%KL5+R=:EYAP:QS.)F=7#H,KXZ0EMR)\6\\Y(2 KI 3PT:G$BEHI&/+DP
M<EJ]2U+EF]Y16?KMTF; %7=62>PLZ\UC8I0:PW2Q+@7K(^#&J:%\Y#,2(TJ8
ME7AVQVD"Q$8<'DMQ3Z'"4L=G$STAR6T;4=79N!5U&=.N7+*I:BN"=&V2Q!"U
MROBSMOD7XF2@80*NUPQ<E) PP4M)R+BX +,A(MI5&!%'F)6\2L)D-Y)#^,#K
M=Q2=#TT>SWCUHHN[X%/DNS]B]1;:@1=#<JQ!L^3L_AUKCWM7U59SC/E4UVSA
M7ZV/,E2\8QGWPA%SBGNQZ?W#07PW1R3TG@X448YJH26Z,O[!/LPE1C79M1/V
M-<B?M&^;F$<S!L!_/%M1JA6YDP)<BEYQM:XIDQ(RVGO14B5?I(L:R7!Z?!1C
MI[Y9'OD5)JQ5N/K<1IZU;0L%L!KCQUDD>]4^71\H/,14&[/U53ILQ'&1+HAU
MLE8]R6'#1DCY'B52PMLQX?*!%/N0_ .QI0]1+OCT5ER9JV;!)71JX?6:DG9=
MD"(*)ECXVOQL4HR3=0PB1L)RV Z]6A6UK.E7'D-CI"&:<3Y6FE-8CGFSRS7?
M5M>!#RK#N][.YU&I$\N"JZ3$L4%4U>;,#)F1\>_&8DHF8"EH&6<'/:9%DHN5
M%?;&.8(==8P.^,ZMHIM_#Z<9PE;B&HN1< ![EVBFH@!@I^?QWJ:PJ>(L&W]4
M8MNN %$4&84@6"N<0(Y"R[A1R(<8C H<D([* MLF.R:B5NQQ;B/*8E#1+>6T
M8Q2]N\GTKJ6BZ=]^BNSC7EMJ.C:A9R55=+5TG90>(^0[(J<Y:XDJL@,BS8UC
MKD.0W+PASBS$GI46"AK(RW&OB<8\KKLY3S-6F0'8L^353L]_TK2T6L;$K\W
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M#F39&/9DW,6$IPZ0<8,^*(D"W&O(XV$(D5NTY2&>H#2W>0@*9\OFW*JP#ZZ
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MV!L:/<7"[&%6&#V,<DWGQ(4C,FRTXV%\)A(D<>@\HEYUA;OI*PUEYUM8[MX
M]#+/?_IJ8(S=17W\%[C'M.OZ?'N$TV\("7LFUQQ=?;RT*7'$0[4<RZS*Y(;"
M.:RMKX5]#.&7LD@*8?'=9^)>RU"2Q'"DW'K>UFHZ0[')QQUJUVST8J//C7<2
MYV0J8>URY2#"4O8MD@88 6)+%E"P_D@-B/8)QC+B%+CB8ID-*_40(UB5(2\2
M)G.</6M+N)]7#/#&.*+A>$-N[67&/0LF%LFUF4N\W6VFD/PI%:LDF.Q5&XD&
M.AS2B8B+(9202ZDQ] SKN5CM+%)[)4\\M/M=Q^@?J3Q/P_#OVY[E@Q;''L\.
MTP8OW)Q8,6$8\)\I-P08C##0N1MF ^TVF'9.TXF+DAP7GT=VEF+69\69H^Y6
M_5NTXMYNS:XS>IR/"NL&ZX;7F&W8HQ->#6_W6VDPEH,C"E)^'1AP9QMMC'J(
M\WD]YW+?-RVIV&^[MM-TVN$3AV@()84F0_)B<W6 L0SO EW;_+J<W>S*P-.X
M[YY):NXNT(^R,56LN<I=_NV.9*3ZV!@7J!Q0;RXRQZK*'7FQOBE)]1>4I6XA
MM/Z[^,IUI<&S.#:];$4YYRT?^LEZ?H3A.#K&@"W*CN,1,FY& P$@0T8F(Q%P
ML"EH<5QT!U"4ON8:0A0;3:4MN+=]=U*UNJ5D\D9@4DYEVH*>KPJ.]9$"*_'K
MY@/$GU%CCCR6DP4VT.YQ5NJ, J)="03CY5(BQA;BX%U9">W>-;;[*;0M2A\+
M;9RWA6/*E/\ ;?&65WJHLK/@[:331]!S6U-B'E4^O[)L+YT?,R#F*U'+@(G+
MT.T2N<D7!Q7 "7?,YA25)2V\0ACU,E*\N.78[OMMYQ?M;M@VVTVN >?%@V>R
M.,'!8.!B+P7(HX)JN3#A!#G//\4+M!=Q94;XWH41L&JI6'Z^9$,F%S45M-*=
M1*R,@0]#,"+)4XZD7)(3P<FIY\E2G4-/-(0OUG%(;38X\.(X3L\6S()?!C!P
MXL)%1BAP23QF;K'$&Q$9V-GM.=7U4W/#_P#"_CZOQ+H]E>NL7)2>)BYRVP_L
MFEN5+&FG%1T*Y A/-X6*XQ#Q]>CFW!UH)>>*+?4O V,J&1Q&'<.U:.X]*37*
M*+$^L@.\7Y:_=EC(\3;CY8M@Z=C-XZ^@C)B$T3M64JEW6>VL2:BA0QP);!*6
M'D!+-=8$"D"IW S!"F5DI<0I;#;JD'9SDQ-\Z#1LN3E%AM56C-AU5^!AWQ6R
M9J:JK#11JG$"CX6<4VX\XM"'E=VL^S:O(XWEW+:\X4CVZ&DW#-J>=+,]?]RR
M-II'#(B[,UK9F?7WP"XSD<;]"!B"9BI26D*; YE9.$:4M+JYKX>3;_6=\RC&
MXI7IP[I+V6TY3E+ZNSB<-MC, ]_\7:-346J%B/[_ !1UA?\ %JXT$4C;NEMM
M1<B\@?<K+D'>Q.R$R,6ZB56P#,M85E+;8<D,]'!,,E);RH@-LA"B1GTLMS@&
M9@T0(R>@,"@-='?3OFO0KX>G$/0.I=(TYB@8G(2T20]CE9]VVJ0N;*L![1CI
MC#TOD(!LPUROM"JCWQ&5AKBV2LQ*&0U*2V(,M=B<BS1<B@,'-':PJ*N7LS&&
MN='6*7QXM33K^AM<7G6T2[8ZN5M(J#9:<<:(?')!ILU$X/<<?^'(?C79)8WP
MQ2\*$68M_*7VTO--Y,8?,G.Q@YL2&8Y43[?>/>/N'JOP0^#[,)0+UO2Q3-5G
MK6_9V:@]1X/)),[5(JJB#.R8YSI0([Z<2<O+IP6N/;*CF_E3?]&EK<6PR+LX
M#&Y:1(>&<]Z(2(>+#* YX9ZN5V?C!4NU6+BMM&9K==F+*^9:JE&-Q8HK[Y=;
MCDS Q"WG(YIM\A)#@R<LI5Y6\.X;RMO*WW6V\'ECZU),Q-!H#+S"K?G2T],N
MML#G&<Q),[=#([*\D8XW\I%-Y3GTUMD?HW;/RC"7,Y2G&5+6GRKQV[9SCLKO
M^MUDI:FAIW#S7V"SB^$7P)JE3K16Y\S+\G8WHJ)=CSQEB.1KS!S"G9A\DM:V
M%1^8C/?"Q6_F:W!D8*>+#=4N.'Q,AG)!<,)=X<Z!['5@ KKD[QD\0#,&HK6Z
MG5XK.IZ/=N)>QTVN?B5"@ &6&%*KL['*+BI:/? ^"6AH=MY+S9Q#>7G$Y0,Z
M2,V8TMYE!>'%L-Y!+RQ#C0V>H>( RB+"3X,O$N5O.RKI;+8B',>C*O$@B.$#
MM213PU]LG>,-=;4@H, D6/@L):&?R2YY24D+80E+"W:[5Y:F8Z:R<H19E_$"
MXCV[9R;U2Z'%#D/U;C'<)*,@94E@=LRP "M-MA"O^1#+3YZ?6+%^*R.SF26U
MZ[J,-.9'@><_GBQC*K"N0@-#ZCCQMRI9>>7PI^.FQK]RN$?F]>V1,=H.7D ;
M.8,%AZ.A;-2\,J:84<PV:P6\,^8T^@6,<?6^EP:197@):'EG<4(<1I'Q0-6P
M:55ZD>96O3ME:WDZ/]F6Y--G"7!I^!%40M(:XQY@1Y#C3'J(6AW*6<9\V/AG
M%^9*\LB?RTPU-JEHJ2YUB*YS, O#U18"4HMXE-<V&--A)ZDWS$4]&232F#$L
MM2 RD/K0K/IY0ZO*W6WFEK8?0YA8ZW&4ISC*KBAH&K03Q<JQ+2\B!;/.,JQP
M4AIN@W/='B26*BT9N#<F8SD7?I)O%B)2U%NIQLR2??6]C.,+)2P.WE:A6EY>
M6PEY"<>;.,X@H QH)B-)O&62.030N_J&>(>3<LO7%I*AS%!UIG4MR#C)J1K]
MI*'%L4*UE8IB2"NY"51SS^,9<:SCNZI+CV#V,X=3Y'N_E$.7!%(UX$,SVF:"
M[F@GESK[>Z\F7B*<<9'3_,S9=6K5CC)&@[-OYKC,S')=/-BA#&F9V0<*B<.#
M.?'1C)$BPR"@M"#2(Q:,/#L.H4W>->F5H:;35M%*TCB-?M<-SOZ8O#TX"7F
MX\Z[$A+U\8LJGJL $@J/+%A6GC9N1D3X5X?*W&6"1#33V6$J)'>,&<8+4VTO
M+B&4B&#7MQ#>LODH2!4\K\>'VX+&UXX'%A=>F-8[?AC78N[P0P5$FZ\:#EG%
M@C)^6DHR(6 ^A*48/A18>4E3%GYQZL86"SE3A&&7'0MW-[R];T=S"JGGX.G
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MZRV71O*:/@(ACS_''R,WQ^VFQ$QS*?(EWROE/-L#9SCSX9PTI2N_ZW5!<->
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M;<?&((':?2BQ[!BAM0U5M&5M.H^/7-;!&,#SA;:V< .DMO-K'QE(P/OUJQ:
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MR&N]CE:^-(A$Q9(=@B2JA2]E4RSQ\G'QL=ZH%HH&P:C/*!6VYF)..,B<E'9
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M1S[X,C&/O@::UT&\]&S !,5+1SKH]<;6Z!*1AA<=(A+4H8X H@(IIT9]UI9
M&N3Q+KX-<.>)# )D6QQ>X\LQ<@^&4?&,Z7UPW'G$QR"FP'RPDUO Q+P;9QK8
MKK[:W!TF%894CXE[*XPR'0(W&KU/;:47P3PMX=)[^7B?QKQW^O;1>L/P[?\
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H=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img209334158_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_9.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[20^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ "4S,P  0 " )3,S  !  (X0DE-!"8
M      X             /X   #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$1       $     (   )    "0      X
M0DE-!!X       0     .$))300:      -%    !@             #OP
M!(4    ( '  80!G &4 -  W #, 80    $
M 0             $A0   [\                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   [\     4F=H=&QO;F<   2%    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      9EP    $   "@    A0
M >   /E@   9>P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ A0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M]"P<''OQQ=;O=8Y]FYWJ6?OO'[ZL?LK"_=?_ -N6?^E$NE?T)O\ 7L_\^/5M
M$DV=5-3]E87[K_\ MRS_ -*)?LK"_=?_ -N6?^E%;22L]U-3]E87[K_^W+/_
M $HE^RL+]U__ &Y9_P"E%;5+(ZSTS&O.-=>&WM )J <YT.+6M=M8UW^D:E9[
MJ9?LK"_=?_VY9_Z42_96%^Z__MRS_P!*(U>5C6T#)KM8^@B1:UP+"!I_. [5
M*NVJT%U3VO:#!+2")^25GNIK_LK"_=?_ -N6?^E$OV5A?NO_ .W+/_2BMH8O
MI<_TVV-+Q(+01.G/M2L]U(/V5A?NO_[<L_\ 2B7[*POW7_\ ;EG_ *45M1?9
M6R-[@V>)('Y4K/=36_96%^Z__MRS_P!*)?LK"_=?_P!N6?\ I16@0X @R#J"
M$Z5GNIJ?LK"_=?\ ]N6?^E$OV5A?NO\ ^W+/_2BMI)6>ZFI^RL+]U_\ VY9_
MZ42_96%^Z_\ [<L_]**VDE9[J:G[*POW7_\ ;EG_ *40,S!Q\>EMM0>U[;:8
M/J//-M;3R_\ =6DJG4_Z*/\ C:/_ #]4D">ZG__0]*Z5_0F_U[/_ #X]6U4Z
M5_0F_P!>S_SX]6T3N5*0[[FT467O!+*F.>X-$F&C<=H1%5ZK_P EYDF!Z%FO
M]AWA""DF/E59&)5EMEE5U;;1O]I#7#?[P?H._>63UC(%/5,4,S'8S[FEOI58
MWK66-U<?1R/3L;7]'](QWYBR;\[)=T*S%8&G&HZ-5:3Z6T,R"&FK>^Q[:F-]
M/;;Z7^!V>H]:>6ZRN_IK*OMOHFMH-.&UOHOAIAMEY>ST-OTOYSWL22QZ+9A#
MZNT59+F&K)R+JFNQ!9Z;G/R+MGI&HV6UU6?R[%LXF#1AAPHW@/()#GN?J--/
M4<[:N0JZKE5=,PZ:/2N ?D91N>Q]>YU>5;M H:VKTM_Y^YG_ %M=CA7G)PZ,
MAP#3=6RPM&H!<T/C\4D)3,&.>TK*Z1ATW4T]2>TLR;-SW!EECF2XN_TL;O\
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M]S/TGJ;?4]O^#4'9/6GV5W.Z)6;PTQ:;ZRZLDN:UL[-W\V_W['_Z1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUO$T9W-W@H.5EZ*RMM/8266%AYFCJ,;(U/_$ !P! 0$  @,! 0
M   ! @4#! 8'"/_$ %P1  $" P4$!04*!@X)! (#  $ $0(A,0,$!4%1$F%Q
M@1.1H;'P!A0BP=$'%2,R4E-4DN'Q%A<D,S1")34V0T1%56)C<X*3LK,()G)U
M@X24HM)D=)6CA</"T_+_V@ , P$  A$#$0 _ -NJ]Y"W5W7='D7">#[WABA5
MG'.*<57=V[R+BJU9#EI>5R',Y$C7#9JO!90H;>.;,$:2@H1)1J\4.=XH8RA2
MI@!MY8W;#K+";G?[]8WFVBO%YM+$BPC$#"R,!CAA.Q$T9!(=_@_C1,!+616U
MZM+];6%C%!!!9V8B!C#_ !@0"V;%@1-^:[OXB=HIQS\H3:V(^[Y,^1@]>/V1
M8^7F/7^+5\X\F2_[&XN'_P#7V8TI\&TO:[A<G18E](N[?U<\]X/9G)ZJH47M
M% ZAN$VM\^H?)GR,  'T"&XSD?H ?<//TNG\F''[&XL=QO\ 9$<WLZ\9Y;D-
MGB/TBP_NB>ZJ#1.T4]-PFUL/?^+/D8>?JYW%]/Y^>AM_)C/#<6>7\869=YF0
MLVFQEDIT>(FMXL!_PSZB)'0$F>Y4"B=HKQQ\H3:US[QVS9&_R;C?<''7GJ//
MOT-OY,_R;BXX8A9G_P#6?MY*]%B/TBPF?FS)VS?CN'%E7XB]HF ==P>UL1]_
MR9\C?P#N,XZ?Y.1Z:OG'DR6_8S%I_P#K[,4?2S#5%:LG1XD[><6&5+(]XD[L
M?:7;C\0^T6]-PFUH//SVSY&\O^$7^]U]>..@"Z?R9_DW%M/VPL^&=F^_+4J=
M'B0)_*+OD0UF=-=9"@ &I50H?:*!S^,'M9#IQ^IGR./O$./QC  .!,/3CS\Q
MU.G\F3_%N+C_ /(68[[/<:Z[PKL8E-[Q8:,+,F5.8JW<\E7XB=HIP'.X3:V/
MU;9\C /OZ_C%\?1Z\A^]>G\F0_[&XL>.(69/99RY*"SQ)IWB[C=T1Y,=.0.Y
M5^(O:)?L@]KGU_)HR-T\_P#OBN.GKYCY>>IT_DR/XMQ?_K[,Z:6>;9G,RR5%
MEB,QYQ=]SV9%'SF"^6:X_$3M%>OXPFUL>O3C;-D4. _+N,'G[ 'I]/1YQY,3
M_8S%^=_@=OJ&?#+FG1XB:7BPX16;=M!KGI55^(G:)^NX/:UP/G^+-D;H'EU_
M&,Z^7V>OH%Z?R9'\6XL99XA9G_\ 77P%.CQ(_P (L')F#9FNXTXDL'>>9#1.
MT3[O3<)M;[WGQ\FC(P].?VQ8\?5_'QJ=/Y,D_M;B_P#\A9SS^;?=EUNKL8D7
M'G%@!D.C)'%N.7-YL.(T3M%NGXPFUH/_ "9<C"/'J'/RC0^CKQQ]'(\:AM_)
MH3][L7.[S^S/= &[%.CQ%OTBP)_JCW?:@T3M%?3<)M;Y].=L^1?_ -(OW:R\
MX\F7_:W%N=_LF_RM^? NRO1XDQ_*+ S>=GRI*?WN 4"B=HMSR.X3:U_P9\C!
MY_2&XOH'O\NGO\M.G\F?Y-Q;_P"0LM7^;\2-0%.CQ'Y^P_NSU9!WSV5R-1>T
M4$O3<)M; 1$!'\6?(W'''GS\HSS_ "]?4=06_DS_ ";BV5+_ &-.!LI;AES*
M='B7TB[G_A$=L^Y4&B=HJ/'XPNUL/?QMGR-Y?\(S\OKU'U'5Z?R9$_>W%N/G
M]D[ZRLZ\*9,$Z/$I_E%WS;X(\G/JZD-1.T4_T.X3:X _3MGR,/[WRC #R]/M
MZ\#J=/Y,M^UN+AM+_9=W1A]6Y!J*]'B0EYS8$'2S(&]YGQ5E7XB=HF <?*$V
MN"/^-\F?(WIS_H1W&" =//J/UB.J+QY,L/V,Q:OT^R'9T<A2G/-#98D_Z1=\
MOWO?.8E2@U:BI\0^T4Z?C#;7!_\ )FR,''U_C&#S_/SYT%OY,R_8W%LF?$++
M5\[/@)Z'53H\1?\ 2+#,?FR);F=^,N&KXB=HI^R$VN '[6?(HCQ]?RBPZ_SY
M]=.G\F7_ &MQ:;2]\+)I2^;D[SGEHZ"SQ+Z1=_[LF?-I;N4I/7XA]HISS\H3
M:WQQQUVSY&]./, W%CY]>!Y\_HZ:AM_)EOVMQ>N5_LWINLZ=<QJKT>)/*\6'
M]VU-':O'DSM0:)VBOIN$VM\<_L9\B^G_ )1?/7[/KZ@%%OY,M^UN+<[_ &?#
MYL:/KUNH8,2KT]W?4V9/!V'K]&I>80:+VBO3C<)M;#WC\F?(W[WXQ@Z=/Y,E
M_P!C<6D9O?[.<IULY@ZZE]5=C$I_E%@^^S)]7-A)YOF@T/M%0'@-PNUL?>/R
M9\B]!'_RBNO'[_\ "Z?R9RPW%@[?P^R/&MG)^R7.&SQ&OG%A++HBYGE,"<N\
MR$J?$/M%OV0NUK_@S9'$WUCSN,X^P>??Y]+YQY,_R9BO_7V7'YOM'M5-GB/T
MBPR_>CI/MGPR7/XB]HG^R#VMCT#J&V?(WX0^H]=Q?3GS^T/4-3SCR9'\6XM)
MQ^GV9_\ U%ZR,S*K)T>(G^$7<'^K=N,^(=YG(3 X!1.T5]=P>UL1_:SY&XX_
MX1?G]&G3^3/\FXMRQ"RT']&2^?5*KS8Q/*\V W='$*UF,]"VZDQR"B]HISUW
M![6Q .>@[9\C?_I%@/ C_LO+GCCIIT_DS_)F+%]<0L^T=&TN >AJKT>(_2+"
M57LR7GK(TK69K(I\0^T2Z_C![7 YY'IMHR,'O ?+<6/4>?H\N?I ;QY,?R9B
M^?\ #[/O%GN<3DY"='B65XN[;X-U6<<-[Z"=/B)VBWKN$VM"'3I\F;(P>_U#
M<;_TAZ=/*=/Y,C^+<6SKB%G1]39DTT,V>54-GB/TBPF\^C[Q6J#1.T5'RW![
M6@_\F?(WI]/RC/7ZN.?HTZ?R9=AAN+-6>(6>M'Z,:=5*DIT>),/RBPWCHS75
MN_L.2#1.T4X$/E";6^>O _)FR-^3K\HSIT^@/?U'@ OG'DS/]C<5>OZ?9%I9
M?!SX-Q=TZ/$G_2;"<B>B,_8./!5&B=HIQQ\H/:WU#S#;/D;GG@.OZHS@/7W]
M0]PAQ/./)G^3<7S_ (?9FNXV19LI#<\T%GB+_I%@-/@VXE]_)<0HG:+<\CN#
MVM"'/E\F?(P>@>ORB_7KY?\ 1IT_DR?XMQ;_ .0LNSX-M)SIK-3H\2^D7?\
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M;BW_ %UD=_S=,JSX@D7H\1^D6']T?&O@3J%$[14 _5";6Q$/0=LV10 >OO\
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MVFUGB KPKY(YT2E.EW1$!Y+*S\G[Z;2[V%QQ2SM>BM(H(H[_ &1 B@@,8)]
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MW@7M QO'P>3(O;2,S&(+U.+<WAKG.JQU@M60\9+W+/5<RFI5:"ZDGK!I&1&
MLC(R2M)M;2<ME?>+\5\IWS JTG9_6>JL\^(<\!SY\!S]?KHJJZ(FB*#7:!"
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ME;,+7O\ LZ/? H'\,O> H"!0-QUX >!XY]/3WCYZ*K%UF+M)GN)LH[@,8/<
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M(!_4MVM\?7\"9)X\_41X#H/(#Z<:[%A0\3ZLJGN[$&D\^WERE42R5K"@(G(
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MY_=DL->Z/>/NOPSFG=32#6'&<15*UC7:)-8C?,:P>44QE%;A-U<U@.V9/O\
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M60:&B(ZOQ$5 Q#8K.)A(YE$1;,ACG(TCHULDS9-2'4,=0Q&[9%)$IE#G.)2
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MT1-$31$T1-$31$T1-$31$T1-$31$T109W_@'WGL=<  ?C4[3>> XY =P6/\
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M['0,QE&8O6-&-(<7.H5JCPUJJTO-6*>AF,0#"SUY5FZ=GFHY)P1])_;3EO\
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ME)P]HL;9T5DN4UIFD57:J"!UG210Y%Y N:TGEN)#\#N7T>]E'A9Z>4GB99W
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MM#-I0$YLJXU'6%3VQM^OI?NB?\K1H_F[3ZA4VH?E0U:HKIQ3VQM^OI?NB?\
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M5_&-CDGN>$ZOYI 6TEMSWYC13\%;@_Z1?A4MTT=:Z-R::J/80[2@\\H;H_\
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MB:(FB)HB:(FB)HB_.@U;-A5%LW10%=4RRXHI$3\98_Z-97N 7Q%3=.\<W)A
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MGQ$DGI&P0L#7*TV>.$B'(Y74.R3EH=-TGWSJJNGG]")*)_@D^[X3'TF&7&T
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MR)>\BY(7W'IXP>9$N<L[K,!;0MF)\;T''U8OE:7IE9KD17+4BYQS7KPFNPB
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MQ:X+A<0(:UPO#8VF0-BS$09P!,B;AP\MWYYQF(Q8M?[9_2BOM[M)"GG,1VH
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MRK"1:88#G("7;5GZZCB'MG0Y_KL.T3@.3"([6Z64. X ?PC2PAP ^8^@B <
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MGD2I@)A7.*J[?PD5%$#)$*10404$XF)B:S#C@2W>*SR,LV9%//=AF2<SAB*
MJDO(SCEIB.,-&U=F\F'#P'2"B N'SB234:)"O*D2,*)7*"B:!$C&;E$Z(I)I
M7=QRDVG4>SBBQZE28,:K'/T'_==HV-Y8R =-,#E>M&4*H!/!4,=%0 6,0R9
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M$3<3D.ISB\E!N)]HS8E=0+GPGSM@W>1TO)-#K"NQ; @WD09I).VZ'@+G4>K
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M*R$1*NXA+>OLZD:9*%: X@Y>C,L-;J+''O(6::L6<?/U\6SEF9*6CA5;'<.
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M7-BG ![IG$@AR/'/4#<"/3N]! =?*O=)P<8O<L)LHH3:"RQ$VSB%SM P@;@
M(C/0%?(/=5M!977"HB6_*HY$M)K-SFPF0V<I"AR0;66S=#;YATC:O*U9$N/:
ML)(A9.&2.4YHMJHJ]\.!?24:!)53ORB8IO#N3)O2'?)MGPN6R/T2Z68L;M=[
M,.UG9PP!ZD2#EB0Y,S,YFM/IN&-[WW(LSW:RD6!^("::UWJ0FNTN\FB)HB:(
MFB)HB:(FB)HB:(FB)HB@UV@/Z3V.?+]55M,_Y05 _F/T^>MM@OZ;_P O>?\
M*B6OQ+]'_P")!_CAX]Q)9@)J<G ?3^01X_)U#6FV3J/JA;!01QQS\X+N9Z?X
M/6V+_P#%>?!Y'UZ\_P ^NO1WE_P8PJ7\:X@_]W#O.;'6<UKK+]LKS5^@LCR>
MF;M/L#R4[]>?6Q31$T1-$31$T1-$31$T1-$31$T1-$31%%;=;LOV_;UJA#4+
M<36)JX5&"E5)ME!QEUN%/:*R2C;V4CF1+4IN&-*^S)\G9)2)G*#-P/M39)-T
M!5BE#N9]Z@ZP[!3LP8U($F>!YY( *4HF^_'F ZA@(7N!WCJ7<QNA>0  $ *
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MXS,,78+*WAY&S+2;F@2;1A)V65K\Y*3KZ",3MR:5,CP:7*05_P#M('#9ID7
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M:6(WD1$./G!,+_H@YYZ_$ >1#@1X]  ?=HDJOVRTU9<?ES]L%SP'8L1H]?\
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MW/GQUXZ"!'!D_>#ZCDN ;YNV#X#^LJQQ>H@ #V@F%O/KSP 4$>O/3CD..O/
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M*-T13()E4FZ:)U?"$[@R9$P4452)J!^6^N>X-PSEI,H_3>YS>#&+S+(V[C=
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MQNFKWC)]?&E*#)%\*LR$LRV8KO2M6<8F2/2= W5$X$E9(TL\.?\ HCPUC-W
M 0$R"DKPJGR' **$=XZJ<VKQ19*M\F?&.Y3'>,8ARBE%2>((%6NJ^SM)+PK$
MHZ/&K.Y\P.I60(Q4]FBXY/V1)!$# <2K% K9LF2HL9KV+&0K,E-IK"Z.6QEM
M#U)!-02IK.6LJNY Z9#@9!ND9(H=\RPE*44^\IWS\B]>N<LO&1XHIO\ 9X9;
M+MYR47)3@[5ZYKU>?I+0"A79DW*$E[,+DCAPR?QXHG2:,TN44WAP6$!(JB<Y
MR@F9]9>'&>;5U1>3I;P;-O.Q],^V$%M>]R^([@JLHT=IN',B&04Y8R:1SO')
M"IH+S3]JHFH5PX44(F<'1A%4QX2W+D[59R.NB+T>^Z E$>T0W>Q[TZ4:P4W2
M9YL:3Q;@'A#V:]3S%(J*2;H?&!1JBBHV2.W!4ISJJ*<IB0I1KOE24@?OWF:@
MH. \9=P4QLOYL@7.P:K[480$TCUZQ.;A9I52/1:C)FDQ=K-Q8HF8^V**L7ZI
MQ?.W,N90L:D+--N8/!,B#2;@,^78JKE?<[D%[/VHV'GXO$W2I:3D../X"9DT
MR)5O#%@KZ("'B&(*G<13\8QB@9=03+)@0@&(G0?$Q6OASH=\(?K!ZB#ZEGS^
MZ,UQ;-=J*H#P)C9P*!N?3P\5"(  <A[OPA#W\#^BX^^>X,-K$/*89^]MBW'X
M=G&]F?*M'7D?*L&*[W&$$3O41<AG?9$CD=/:0V>;:.[%SMFP(<TZUL0_>DQ\
MG\)LDFR;<PIU>.(9H ,U5FYCQIB_!JIB*&.*K0XK\+BJ ?#L4^#Q7$("!"?/
M;S9@!SZ5G:QF)RSS=P3E-@O5V0)LH(JA@YE7L$B=#UJ1^NHN1-$31$T1-$31
M$T1-$31$T1-$31%!KM >/O/8Y_;4[3...G4-P>/_ /(' _9T]-M@OZ;_ ,O>
M?\J):_$OT<?UEG_CA4Y=:E;!0/QN/':$;F2B _J=ML8!R(^06W< // B/T>O
M00^G7H+TWX,831_?7$!O_-PM768?27#6V1?%+U*MA9TH&(#-O84?K)4\->?6
MR31$T1:1OW7"(%MNU@1$2B;%F5"D'NB/*@Y&Q.<"B?G@H%2374#NAWBJ%(;D
M Z@3P/'W+7@[.?&-+R#F/%T3/69Z]D[+D6(B'F/6U97E0>49DU5DI276GB/C
MDC3&DDT(UM%MHAZ\=F=G< Y:I$4\2>./&7<BEIVHU I-!R5G6%C;78(%8CR!
M6I562II&4!,E5.HI.L%Y9[((.8A&-BY5LZATF+"1;2BI722JK(Z92J5%B5+/
M2,;4:=)1WLI7ATB))&>LV[],559U\F9=5LZ35:N1(HT()!,@J($ @< 8A!""
M;TS=IYD;\R:F5)HI#;7JS+6_,D%5)"RA&0USFX]K87C6ON;')$3?B9)8L'68
MY,TE)K-4W9BIMRN&C)$J1E';I,J?BBWAG=NT S9Z#[Y(NQRAC3#5-W$6&/N^
M1[A"XWJ<S+(%F(2DLDLBSL>S.NWB!9523G_@^/D)5ZDDDHN]E7;>-:D*LI[0
ML"1-4R?/AZOMU16G@B%R!G\T//7IM3*@>RHQLC>9R(>RC&HUCVQ04I61BX!H
MZE7Z+1($BK,(Y%TNX4.'<(J8H'"9_;PR\-S**>F?,*.H3#>/[W5I1G>(VW)V
MN*CWD8P=0S9=&M298AL[1C9M07Y4Y=L_CY$S%RU(LR 3IN46JY%4BJ:5S-#N
MK49!AGG(O!3U.N^.^STR33<A0;NM6>#W?(K.X9Z=DJZ:(3FVZP2$8*IV+ATU
M4%RUE&"A!(N8P@J)! AQ[FFX"G(:^-Z*.&RG'4/EG),94INTVZ)FYEU$5ZAQ
M=6A&\R@\D)>71;SSNQ)K.6QVT1$USX3?G4;IN'#M\DR;=])$%3D;N[(3;N9%
MD5W\;;\?;:[A><7OLB#',VM 0L<1#N:_(6 LQ-DL2,66L-)TJC0*\_7BE7TX
ML]>M7;<P-5XU-5LNB +#S<NWBCZ/[46(IV[55Q<1=L!1(6P2YVZJ@ 8ADT0C
M$/&'OB813%)(#)B<2B7D1*7DXFTE,9U($CNHV@'!GDBR*=G3B9CG"VP='DK9
M=)>Y6"[J.9S'E?IRDI I49O%%+)6&;N23XQH%V]EG)8Q%D$0Y;'8G.Y*_;.%
M&B"T$LRP#3)RST:LR'WEPBC;O!KM4H,U.U!2.M".4*Q>Y1O+RCV=;*UE]6B>
MRI,6,77"P3:5CI%O+FEDW;YW,R*3EH=HHU3;"?N(WKSKRT['G5%&I=&14LCA
ME'*"99>K5>,:J"^*1%,J[*,1<'3 RZ+<0,5 R:AC<)MTA47-P<A-.OL?AIN]
M>:+)[D?#4U4-K^*\GEGL5VB"=5A&/ U7E)F7<QKB2=/6<W'V95:)B&B,[%/X
MPJ+EG%.9-@DJ9P071SMR^)4738VB,00VRS=.A2\A66VWI8=MLED6!4J*$92J
MJX/DR<%E'5>Q+6!])6%X1!N<\HJXA(U@0R[9-F8Y6YRF(H&X+A[!9TYEQ!4J
MQ6-K7&QY>TR-89N7"-6@U%F3$DU8%$6[DK>+*Z5!N4%O9T5A$A1<)"D0Z<9V
MD^;'@>7?W(I^[@<*Y(QW5Z@D^K[ZR.<HLJF6JMRJ&:H"YO#-3X-ARO.Z9@N\
M0,46KIL=5JD"JWYHY2*T\84A1A)N%&E]S/*J+'5;XZUT:OV_'UJC5X">IMUC
MJQ/Q3LJ0NHN58ISK1TQ57345;G,FF *'(W.9,XB(%4.F&FNLQD^K>L \T7LL
M.56PRV6Z@[AEX\Z'PG#1IY&8?-8V(39"Y:,E7<B_D5R,V2!B**&7[RAP(F)B
MB4H<D%++.?'C(:RSXS<IC;RMMLI0L@,J:2:I,:P>MH*56>QME8V"L-D'S9J*
MTRK8X'QV;J/0D@?OT7T29VFJP$$R HH4 5$4ZN7!CE+*1,PBA-EFHPE?R)2J
MK1LL5G)L+X2+6/R7#Q5BAH%VY4>K>U.4V-F9-9YNWB57BR)ECLS'72: Z:E.
M"H)@(D<M_K197*)M,EW^U;(678&Y8OO]=H-[+5D9^L?&<HOVC=J[8N)1NE.0
M[!T=-\]!-TWY9IF.D51PF)4EDCJU%$#'-;B*Y5,]$8WEQ8YZ?VOS4C;*RM"+
MM3T-TSW<8"80,46:5?O L!I>#30FQ430:@Q"0!DN591(%AG*0UW<=].MT6/^
M/L-B<3,O'0[@Y4):2>N7+85")E74</B*$6/WC"'C)F*F"2H]X4 47[G<(HH5
M1OENY^V4NTHLRU>VLHN-I#W<0GE*DW21B(] 7T)2F%A>J01SE< _AYU:0AHY
MJ29B5BQ29O@LDNR< ]!55VFD!RF3W5XR[&/6BQDJUIO$5A[96>0*[:W=QA+0
MM+5.&";+:*@,198=O'N+4F\CD(M-*Q)B#Z,%E)2*PMD7'M:"!^2G N_.4CP)
MK,=[MD479[;F,1/6=PVF7=Y/?)="%K6)8:EG@6#-[:)JQMVH!9E9)F[5)!-V
M3EXX.WBFZ<F_?F;M@D&2:BS]!VSE33*?'[IHIR;T]KM<P3</B=?;;9*13WE%
M7G8B4:4QS8!?7]S71E6-4D5%YB,]G(YL:DM#3$FS>R)8U1%-4\.L0ZGLZGV[
MSX;J>:+%2UEI!Q$59FS4\-R:RS;LQ$R\J&<)L:XW9@)A)W0-WVQC@!@[HJ""
MBP=T@'*IGJ>$_&O$419V\-;2+BZVFV3*UY"+>.H6H05SIZ\#98B<40K,B^<U
MUZ\EH"#54>)N>\4&"#-WX2R:Z3E19)4!)XC63^M\\IAM=$5L.SU2I#;>]@P\
M#.W"5O$GA/>(.38VS,8QO&P<JVP#F0L$UKR[1PK(.T%8$K920)+().FC\RB"
M:AT#)D('*O%I-7E,G@BQ,/C.E+."3!5=)63C)&#%0A $_>?U6/8@@D(B((J+
M@"C81*<!\%4>G)@#3(RI2C/EX+3H462S 6VEQD-NNRPO9'60VE+H=4D[JY>0
M!*S)5JS3T064LD.I&K/'RTVR@GB[F-:3"9DUY1=FX.1@B@F@=577,5^W)MD-
M]J*$^4BPD)(TB/B'UN5O"*-^-D!C-HPY8)N*:)CP!ZPY8KJR3@JD25965&90
M;J-Y-(2,4 ;%ZLS2FY\]9<-[HK2U9R_DGM9(C*-F[EO()OW#^6<(,XV.6*X,
M@@#Q5RBHDDB@BF=PZ.1-=15/J":BG/+PW5/EIO197<]X0@,;XQ@+#"7:F9$0
MEH9XUM,[49J7?5MP^&27CUWU;E7\5%N3-F:JL6W<'!CPLLU> 5(Z2?C.!G74
M/\DO(AIL-W;FBQCY07H\"I;(7$=EE[!4S'IC567F(5K /GCSX(E"V%!-@E*S
M0#&H2B@HM'@O$U'*)4U5F#%8#%%SWSXOGIV2=%,;9-@:/RVYBJD;(L,:RVZU
M+PSK&+"!LKRSC7B0+ETA;@GV\4K4FB*DBD$8>-=RB4TJ4/:R(*(&+PENG+CN
M^SBB_:\QW"8VW9XN@INTR3"]5G=!@V*B:">"6!JK!+W1$)J34FE7)'4>]8/T
M69BQR\>"#YN]!RW63%%1$C4TX"<NM]TD79[B(IQ=NU"WF-9W(=4Q["QFY_<-
M(KV2\)RZT$W-7[O:@CHL&M?AYV67D)18K2,CR-(MP8[Q9$RJB0?A#45X]RF"
M[W1L7U7*$@^KB$1D!,\74IF.,LJ@X3ADG<8_=$.N@'BM7#A%?D5EUE4@$A@;
ME5[R9"*3'8'0$=3.U[QC6X')T#E"(;U3)Y@LU<9SL7$/GTOAZQ2SEHWC[)'Q
MLJFXAUD'4<[,9L#90Z!56RKA!=-0<0\F:<RY<M7>3,U)UJBSO?='*7C,]IY.
M!_1YP-Y=?P4\4CTY$.3" "'!A /?YCK[Y[@UH(,0\HMH?'N%E"* !HK9WK(C
M1Y#5>;\H;&.V@N@@/YJUZ0R))$@0-#F9=86??:P9\MMQP*>00;MG)<.XU*9)
MLZ4>)>$%-ARMS>.JT9'$ZC?PSK)BW J*XJHD47*F5=3XABS6F+W^T$@;_?+1
MC4BUM(Y-0&$EBTCDR]% ##9B$S(V0[R:'A5A0.10Y*06NHLDT1-$31$T1-$3
M1$T1-$31$T1-$4&NT!_2>QS^VIVF_O[@\?C_ )?\NMM@OZ;_ ,O>?\J):_$O
MT<2_?+/_ !B6D_4IRZU*V"@;C7^V#;E_VO&V,.@?[JL_>?\ /CCZM>@O3_@Q
MA(R&*X@>1LQX&CZ+56(;%+R=;&S?DIY:\^MJFB)HBT>ONO(%?CMLX$IC%(:E
MY41. &  /XEDI)RE$.>]WBG2*H0P%$.4^.0'G1%$GL),54>K7V4W 348G/7"
M)(:OU:(78.UHN+4=+I@\EE$$#C[0]<MT>$A3(D5J0#&:B5PL=9"2._NIU4//
MDBGOVRN"JSD?;38\FR\"B:^5:&&486^+CTDCF+&&="XBG[<X&< S72*N5HX4
M6.='P^ZNJ=0@ET84EFWK;[$6G4Y((5C&K8B:JO(&6,F90QAY)+SK]4Q2 )0'
MNI*@ @3D0$I>>.^0!9MS\:3F*N71;&G8\[-[2C+M]WTBW!TQJ[B3KT#554'1
M$9)R[;-V;AVZ50,=5\R3=OP8"BW(!!?LSBNL#=%PB("33/&:*)W;'5&M/-XE
M?MK2'2APO,6H]F(]H1,C LA&)O&Z3=L<44Q$@I]XR@<$!7O=2E$.[H:'+QJ?
M&\518\<!X.M&X+<TVQ/2023>SK^,>.'#Q=)".CHYE&IRLL_?*KKI FR9LRK+
M'."H?@@4IE"ICWM&UWOO+-.GC*C%MB]H5MLKCG8Y6\-4BM1,'EO&M83M+B6B
MTD6,6_FUO9VJK"!=QH)%>M';=H!VR:#- (Y5LU*\4<$4,*AM)< )=G'K*+64
MCVL@T[,Z_HRCE0'H[Y8YO++',90XK(8?E6+H#K"8 4[ZH&[R@F-WN [P")QY
M&=._1V=F</E[$4[NPDQ3%,<W5_-4\"KGV)99C'L%6B9T?9_;4UP<DD5>3Q)G
MOLR[#Q$TC&4;K+)E4%58$Q#.0EHV@X-E+=HBR.]O'M]C<P4%]G:KQK]A-T]N
MK(R38J"+U)6#;BV0=.7LQ["UX BSAPZ0:)BF3Q%#$\$#JHBF[P=V1KID\N62
M+5$DXM-KBFJMTSG.>66*\,!S#R9:0/"-SI(ID. E3!,$RF,)!Y,00*(B4PEA
MFW%J9"H/%N<MZ+:V[ ?"S;$_WR-QEHKD>8;@D:EUI"6\9TT-"D<$.M*HI)J(
MO53NY%F9LV.*Q4TCLG H )""<+3DU3IGQ]G-%%WMX]I\!$,FVY>N-4&*<RY1
M9V(D8BL=DYD9=VM,-%$B**+E9-T%T'"A/$*=58K\#K+*@1$YGW>/$Y;D6(?:
MOMUB=Q>Z2N8K?2;F$K<S6(UY(/HPS<7:$7'K)MW0L@64!(53%173,=<Q2I%[
MZQS<%* A02;=IW?>BVWMTFWS"B&P5UMFQ[1U&-0KC0$8FYJ. 7DUY$S5Y)3*
MX-GC$ %!6;('CRB#](%7KUVNW*1L#9 SCX;,3EF=9;D6ISA:&?P6T[M!8IZ5
MPG-1RF 6JY5R]Q9--C=9GD>0 H!^;^.=7NB(% "D-P! Y=F_6G?(>'1> [/_
M  C.Y\S?0\=MFLPM3927CI#(R,8Y<,$#5R)EP?J#(NT"'2(8RC,/8#+)N/">
M)IJ)(@9, %G6N5:-U2[\T6T;V[^VEHWVU8VO.(WJ#J/Q?"UM.9:H*+&E6\&Q
MC#-2+J'7457>O$5 %=X)$TR$\$5"D*HHJ832D])=_+JW,TD6EJLJZ>TY,7#E
M10;%>5E#"("HK[3'L$RN5E%!_#5.J$VW[X=[@O< 3B)C .F?+[O7XJ68WLLM
MH_W\LSU<]Y929J/0Y:+L<JQ1;N%6L@LQ7!\W!ZJJ15BDP4/'$(X(NF=5V"J8
M))'3 QB&+O03WN99;MQ[T4N.W3P?7_C!!95HK1TQA8LPU24C456RS6(B73:$
M>MOA08QLS(3V19TY9D 4@6%-5DHLJJ?QSJIY=9''AFSB7<Q8"[%4P&Q8KK<
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MQ(-4VRRXA(JD;IQ;AX"2 M2K+@5;P2D5ANTZV=W7-.W:Y5&BST4D*$Y PL)
M3JCYI'2DZZ35B8]JYLKM,(ANX,]73&, 51<+K-C,TDB'6$5"+!#V(=&D[AO^
MKK22=L8IY7\9VZK/F+TJ*;5W/-W%C(M'.7BY%F**#!5KR],)Q!R)$B-Q.8Q
M-/'7H>6OJ1;E>6L63-GP=:X-S7$C/P+*,6:B2X)H@= Z+%5))%L4'7<*X%V
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MQBF,E^U:WSY%"&92$[5<_P"Z%ZS7<1ZLA[ 27S-/PYWZI&XB<BB4<BJDS57
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M+S%:Q""&*RA )=B( Y9G)D':;<0K^AVC.QD1X^5+ACH(\#\=(WCZ.1$P '>
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M3#ZL<WT]%WW5T"?.,;&?V4N&?]^<<'\)@X_+Q].GO1BA.R+E:DEY2RRS?_\
MUHGOA<V?I@>$,?\ XMPG/)T^<8V,_LI<->?_ &YQO''OY[_EST_Z-9>\V+?0
M;;J0XC<X0YMX=!**N7ZN>7MDJ#VC.QG]E+AD?_'..#R^HP_9ZZGO1B@K<;8#
M66[4C7Q)X,2N!K>(0]/1C>4_DBDZ/VJH=HQL9-Y;I<,^?'6Z1@?1ZG#U]W/\
M(!C[TXI]!M7(IGS !:4]5G#?KK&'AMH2'9VB#'G"/!&JI\XQL:Z\[I<,>H"
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3+$6=F':" .7/HBO4O0:S6:__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img209334158_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img209334158_10.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1FL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &9"^940X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $TUA<G)I
M;W1T+"!'97)A;&1I;F4 .$))300E       01"@ [LX_X76!AXLK4#36$SA"
M24T$.@      [P   !     !       +<')I;G1/=71P=70    %     %!S
M=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13
M:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    !@!! %  1  M
M #(       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ "4S,P  0 " )3,S  !  (X0DE-!"8
M      X             /X   #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$1       $     (   )    "0      X
M0DE-!!X       0     .$))300:      -%    !@             "*P
M!4P    ( '  80!G &4 -  W #, 8@    $
M 0             %3    BL                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   BL     4F=H=&QO;F<   5,    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  (K     %)G:'1L;VYG   %3     -U<FQ415A4     0       &YU;&Q4
M15A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F
M875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D
M969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP
M90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L
M;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E
M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      /!@    $   "?    00
M >   'G@   .Z@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 00"? P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M^^Z7W7-^[^,5<<>[VOVO&_TK?O2^UXW^E;]ZXUW^,?*;(=TB(!)_61PWZ7^
M0_\ QS[/_*K_ -F/_?=(<ME.T;^L5<47MOM>-_I6_>E]KQO]*W[UQ/\ XY]G
M_E5_[,?^^Z1_QG/((/2M#H?UC_WW2^ZYOW?QBKCCW>IZL!E4,9CVU"QE@?N?
M98R!#FRRS%?79O\ =_45"O$M<7A]I8_?LLL;DY-;2TAEGJ8C70
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1U+!\"4S5'9WA[71-3A$1E9B9^'Q-%AF@I*6I[;6_\0 '0$! 0 # 0$! 0$
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MKL4%"QL<X>2CX[5FR4>M29>&9.F1SM.66=SHL>:[K*RJS</3;EL'L&:%RI]
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M,:IU[(%]95T%63.&D\EY$D)6_3-93E'@J.F$=YZ>.=8B4:4O/CEJ=)[AGQ@
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MA[@/D(_5(;IZ^O\ C'T#GI\_?C5_"OMR!?9/?OF_/\HSX)]][-_4L5?XP[L
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MS??S_P"\?J''X#[#TT_"OMS?_=)X_G-A TW>_O4^^MFS'VEDS'>G\8=[/_\
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MCP'M<:U MW2)#B&DNW=TAQ@<H7']ZX$&/;"1(L+$@P8,P!U.HOFG\8?[/WD
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M%R20'9OW48^;M%UE6JQ"^97[)[:PU2I2KLPU)]*I4HU&OQ%,%M2D??;!</>
M(<X18$$@#/H^UTCE)D B!,@B=,N&M^9A8*/;Y[* /9DQJ6YTJE+0.YN!!P<^
M*:JMRS3"MF7L93SH&A")6*4C((XR16W=EY%C'F#S3I%(_;_V![43L\_9*;:>
MU*@I8)SJ@ K/+=X;A@@@M!< -[W0797&O[PPH:\FH :;B'BY+8.[EU($ZFP$
MKOVCMX-G%(3AE+I0]U-13L<<26KZMFP)*P1)R,.D@N5_#GDIEN62:"BZ:+"N
MS%=,J+MLJ)P(ND8TP/8/M/M*K5IX'"TL2ZAO"JVE5;4#2R9!+9(=(+=TP9$0
M392MM'!T/^)5#9$Y:$23>T1)G(B^HFTMNW_V,O(:4L+6!W&N(2$>1$=,2Z6'
M3G8QKZ>))J0K1XX"Q^&BO*)PLL=FF(<K%CW0E#^2'795_AIVQHUJ&'J;/:VO
MB@\T*)J0]XIMWJA:V-XA@(+N&\) ,+!NU<"YAJ-K L !)C*20-=3;JK,I^Z'
M-@/ @#?<$42]1_FD( \<"/' V,>@^P\=>Z/7D!#6T_PK[=>\1L=[MT;Q#'L#
MB ,O\0 1.@.])$9$+ [9V<!)KR)CW6EQGF!E_;BKG!?N@+8Q89B,@(*#W)3L
MY.2#:*AX:*PRH_DI.2>KD;,V+!DTL"CERZ<N5$VZ*"*9U5%C F4@FY O+B?X
M<]L<'A78[%;)K4,,UKGN<]])P#6W<983N@"9+W  7%I*RI;6P%>HVE3K2]T[
MH<TMF+$";3)C7NNI.D.VAVRQEKA:2[Q7NL+9[%'/I>#B4,(G>*RL7%%>*2TD
MQ=M+,NP7CX=./?J33TKD6T,FR=GE%68-ENYX[.S&VJN&?C64&C#TGBD\.>T5
M14(86C<,F'BJP4]7N,"0NHXK#AQ::@W@8/0"3:)@"YX2;+";GV\VR_'LY]&[
MM5-R=9F@9LY(K&5PYX!W,7(H@XCI1@L%E.VD8I^B(*LI./5<L'A.1;.5/4/2
MV9V [5[7P[L5@=GE]"FZHRI[0Q4:YCRQ[7M%VN:X$;I$Q!-B"N>KM3!47L94
MK .J1NCC)A8E_&&]@// );@0 W(EYQ,GR  /7CBQ!Z!QSTZ!T'J \=M/^%_;
MFI9NPZ[M\;S'"I0AS2):YOO P6P1O-+HSN"M;ML[.8XM-8[P<6D;AS!(.4R)
M!O;CQ5R:_N@38NZB9&=;0^XQS#0[N,8RDD3#X&:L'DR#\T4U=+%L8D16D21<
MB=H0W54C)P8.B8ZYW_PW[9TZ]+#5-E5VUJQ/LV&MA@YX!:'%H!!(::C-XQ;>
M .860VM@B-[?> #<FFX 9Q),0#!N8MX+G"_N@78K8IJ+KT%"[BY:;G)%C$0\
M6PQ"5R\DI23<D9QS!F@G8O$7=/G2J+=JB0!.JJJ0I>\)M;:_\,NV>$HOQ-?9
ME2G0I-+JE2K6H[C6C-SB#(%\\A8V&=&UL"XAHJMEQ $3-\IO;OO,@"RY3?[H
M"V+P#ENQF87<9%/'4=%R[=L[P\9%9>*FX]M*Q$@F52Q=XS62C'K1^S6+]E=J
MX16((E4()M6$_AWVNQS0_"[/]NTO=3FG49(>S>#I+H;#7-+7:AUM"%G7VE@\
M.0VK5$N$@-!<8XD 3$*S_P 8:V!CR (;@OL^O\TI"]>>HCS8PX$.#";O<<=T
MP"'V1 .IW\+>W0<ZF-B5WN: 215P]IRUZ@V@<97/]][.B]9PT/N'/EY\1(SX
M<R_NAW8 4"D,VW B8XB!1-B0.OV>]_HV(!'@@"8  !,( (AR!1XP?_#'MJSV
M37[*=2J5WN93:]["XEC0\_DW@00;=\Q$K,;8V>XR*UIB[=TZ38FWPFV<!>K>
MV'<ECC=MA:J9YQ,,^:BW%:P(1 V:)"$F2K5JQRU6E$W<<#AV5 4Y6&>D2$KA
M0%4 26 0!3@/C,7@\1@,36P6+9[/$X9YIUF3.Z\ &/ @]Z[Z55E:FRK3.\QX
MEIXB2/B%/^N=;$T1-$31$T10IN3#G;KGSH'(86RGP(ASQ_B-.]0#U]/;Y]/3
M10_,<.//^_"ZRW%  &+L;    ?0&G= _ZNQVBJ^V3&,S)XXR!&5SS V&1I-J
M8P(-'1&3L9EW!/T(P&SQ19N1HX%ZH@"+DZZ!&ZG=5.LD4@G*1>/,;CC>?681
MM-X7H.5<7D:4_&,>>FW>[8VR-8#Y!@*Y;&>5+E QD[EVV4V(@KLTE*9!-&@6
MA)S\:@)FXC3DY-9(]B*923&O@)\=3\-%=6]E[6 JLZO)5":\L:G4@D3%1<UM
MX<.$WSL^%6]D>IV-RP:D4O;%=?,;V9;+5,*0ZCT2-:ZE'.2U5VJ_?^^7KFDC
MCK&N<3;RY'O5L96+M;O*+)O8&7575I5!6?N5#;<XQ>/EVTABYG=VE68M'DZU
MG+?),@R/+K2<W)5ZIQIE)"-A:Z_%*F2)R2+@'*!Q(T$Y^&@SM=>L^#5,D*X>
MQHIF$4394-2*P.0Q02BD"#<1AF0V$10@GLC!HJ_$Q<BNE"OW<01;Q BUU&'E
MS"57FQVPY"_O?'(]T.1QONX$> ]1_>=9SY$1Z?(/_P"D!]?3OV.2W;>QMTQ.
MT\,3%I(=8GB1Q[EKK@?9<3,067G+\KOHOP8)F-X9>I@^R7D>>!] #T]./L\_
M,/EZ:_T;PI/V?#P3/L*6MS+&YYYQ?.5^.U0/:UK957@"P_F(R,"+6DCE8+D(
MG'_2,/XC[@ "(].>O4!'IT]>0#CGK%\S:2(.]) RSZ&>.1DS&,-.8;G,:$SG
MRCC/#F4[QQ]#& >1Z\CTZB/ISQU#[(CZ\]!#IR$@22<H$SG-[7DZ6O:9D#/'
M<9GN-[@!?K!X7Z<E4#F'J!S?J,/'4?0>1'U'W  'VZ>FK&0,1.4DY:#=BUKB
M77C/,W<9D&-,Q>!,$< 8@WT/ E4 1$.@B7T'CGWY]>@]0'KT'U#Y>NA,6D@&
M&DDF ) UF9U=H2!>R;C,PUAR)(:.Z)'*9 @$\PG>-R("8P\\]>1]!'T .1].
M>H]/O#W$<AH,AR&9(+1-P#,&Y)]Z;&%C/\C,O\K=>@RRLJ]X_(&[XAT_VAX]
MQ^? _,?P].!Z30F;G.(G,#2^0RB;Q!,30QD1N-L<MT1>\"V<Y6-R3:%03F#G
MDQNG'N/SY^?J ??QU]  1#64'+AQSL-0#GO23?,9V";C(_*S.,K^$9=TIWS#
MQR80 .>@F'U]?GUX'KR/O[<@ ZFABYTN3Q@\1O<;"+\BW&?Y&'N$9YF03;06
M.47N0&,/ @<WOUY'D>>.OJ/3UXY^[U]Q,2+Z'07N,[1.L3_-U4+*=_=:;_Y6
MC/E%A\K'-4%0W(?:-QP''!A]1'@/</8./_EY]N@ZMP#&9)(D&,S.6G"(D@92
M0KN,C\K<[G=!/06B#XV/O +D!S>YS>_N;@1Z#SZ_@/W=1Z^NL9-H)UL<Q<9Y
M3<$1,Y"TP193,0QN6H;IQL+S,<HU5!,;D![PCZ![^P=>O(>G7CI]W =0TN0<
M^(,SK !%X!G4WSDA3<9HQO\ I MI:+()AZ^OO[_/@ ^_KZ!QST#K]UX7L>9D
M0+WL-03/.TP4W&?Y6".3<ND"^@O?)<@.8?\ 2, @ \<F$1#KQR/7\_OZ#J&1
MQO'TB9/$F#81D05=QD?D:?\ VC.X(@:R/$9:+B!C<AP8PB'/'7CUX^0@'IQZ
M<B//IR !JW(-XFV1YSG,'.>$<+J;M,$DL98Y[K<R<A;4D3!$Y"3 4HU'$&3+
MM'-YFKU9>7B7$@:-;NOB<(Q\P^(^A(@R+=&2DV3I<@3-GK$**R21FXSEHK,*
M"HRT]%LW?S&T^U6QME8W[#C*[J=<4W5K-J. &[4(WMQKIM3J.@^]NTGU(W*9
M(]/"[-Q=7=?1HTG4B;G<:'$28N;D&Q,2;@29E2F^VLW:-CZ0[=R[)L:Z5J#N
M9'#ZMY'C:]!UJ8QLKEF3>O[D\IJ55E%ZI2VKY]/0]7E)Z<!U&R4=$QDF]9JH
MZ^>H?Q#V?5JXIC</B*PPU9])AIU*)<]XQ P])OLFUM\>UJ.;N.>UM,-<W>>T
M%T][MBG=9O!F\221ND>S&Z+$EL$ "( B-+7AJZ4H:>^A4TI]A.Q,]"M)YA.L
M8^S1K=)@[D'\>'GXZPP<1,-ETUHY=P0J;%PB]8J,WD>N[3=$ OT^RMOMVGAL
M35.&J86OAWU!["H]CG5 UC'AS2UQ:YI+BTF00YK@\!P,^?B=GMH.IC<8=_W6
MD,M><Y!OD;S(Z09=?[;)9-!@>-R-0)H9N+J[V$1:HW^-?RDO=(^TS5.JA8^;
MI,4\CYJSUZIJV&*5E$F,.O%3]0>FE"-K*P5U\Q3_ (@8>HXTJNSL73<,4^B2
M'T-P-HOITJU0U&5G MIO=N/W76<U]K$GMJ[&<RGN#<DAK]YK8_,W>:  )N+Y
M$$V_,+:RF,8#'^T/J;C[7(CU'C@P>H_>'7T$/F/Z,TA[6.@C>8UQOEO!I(.8
ML!F9!,YKPZE)C*KV;C?=>X20"9:;$FY+C%R9AV<9BG(CZB/W=1]/Z@#KUZCS
MSU]NEX 9"9U!&>4Q!U-K&\ A8%C#'NMF9R'GYYCGP(IR?T 3!Z\<F'D>G3YB
M(>HCSZAUZATU9UF><$6UZ$1>#G8B80TV?Y6&UO='*V65SWC*4[QO7OFZ<\ (
MB  'OTZ<]!_7H.!<9@#,WT%Y@$N!T-LX A"Q@/Y&C_VCOSOGG];*O>/UX,;Y
M?9-P'3ISZB/3H C^0>G$%HT$\QE$&18Y2))M%^#<9GN-Z[HM,VN/#7O5.\8!
M_I&Z!R @8?P#WX#CCI[>_0-!.>ITMF+VBXL3.LYAP,&[C3_*W_2.X9:Z#E'"
M:=X>@"(^P!]K[A#KZ#R)?0./EZ>UGG<"X(Y]\P)!()/6RFXT_P K<N  CE87
MZ:SFG>,/3OCSZAU$.0]N0]0YX$1X'I[>IN;E&@OSO)!D]<I$:&X,#39HQI&9
ML,QKEIIR/<JB)N>>1]  .H^HC[\=1#[AX#\^DFW4&Q@'(SE,#^;*8(S-BW&
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M-\'(V,F,P-)@1>;93I>X7+D.. $ XZ<#^0?T@Z"'KP'3I\^-21J1PF8&I/\
M-J1!/.( !!EB+?2\\P9CNN!S3\1+\@#UZ>_'OR;GGTY'^RES08#@+3)<W.X
M/(1%LN"I<+0;7,G6.)F+?";1*KR'7VXYZ<\<AST'[N1^_P!^O/34):(!<+<Q
ME&HG(1)MP(,R4F=9BW,1I!CNT.A5.0#IR'3U#DO' ATXZ\< '3CTY]QX$=-]
MI-B+Q$GF#%R)(F<Y%P09"$S%\N?#.=+&1K&AU0>.>1'GGGIT'U]. #GY!P \
M!UY]=7?;;WVR(U%P)'$;K9,2+B\2 DBQST,9<;D#K!.0*K[\<=.H^O3KSQR
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MUW9.>O53[LP'Z9OC^RI_ 1]F9R(_4990$>H_SYYW#D>1^61_U^WKI^(W;?\
MKM;2/=;Y^[]9U3[MV??_ &5GB?+]]>2K_ 2]F<(@(X-LO(>G\^>=P]/PR/\
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M]?3G(X_/^H/F/,_$7MO_ %VMEJUI@BXCW<ISRX\D^[<!^E;UGE'">?4:#-_
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MJGGR4J$7#8_>V+)+NIUE4)O,]5DYR38R+>U/G4L]9O71TI)JDM)N!(5)KYF
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MF?7?FBF*P8QD7=JR3.OLEU"]M[Q0K@FZ<(T^W8]N#NZ+W:I6:B(#9UI:\Q#
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M4">@SU\;R><:*6#[>\,=1''\-[#_ $WO'7[_ #@CSZ!UZ\]/P9BW=ZLF4SX
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M)J^,F!BJZT3D"BS\W,UJ!N55F[)7#%)8:]$6&'DIR!,=04BEFHIF]6?19C*
M*92O4$#&. E* B'&BD\CEPY3'7RFTROB]R1CZ.F%J^_O%19SS=)\NO!N;)#(
M3"*,8P0E9%96-5>D>)),(QTVD'QU$2E:,7#=VX%)NNFH<DC.\1.1R\/6>2Z:
MN6<7H5-.^K9$HZ-&7.1-"YJVVOIU1<ZKD6B8(6)21+#J@HZ 6Y!3>&*9<#(
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M')A#D #[Q#TX]1Z!UZ:*2+\L_BN*KA!$@J*K)II@ B)SG*4H  "(B)A$
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M8)T]/LATZ '3ITZ  =/8 #VT14,DF8.#)D,'R$H#_NT1<2((D$1(D0HCZB!
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MVWC)-:MDUC>;J&49:^U*F3%\DZXT50J%O@:;.G<,F\30H& 8SJ\R2_7R.9^
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M" ^X"' A]PAH@,_W!^!*Y:*IHB:(FB)HB"/ "/R#G1%I=F7?CA#!%PLM'O\
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MDXFJ+5ZB0P-WL6V4 6[A B@D5\%5(AA,4I6]M-=,P1'H&W'(J1     #T
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M8TBD!0[V(>1:!!'NE4=2Z8Q;1,QN^3@IW+M$IA[Y.Z43&[P" :4[U0";6-^
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M2XR6,J@QE(?%%,!NVGE&;M_'52")$PK%!RJP9%;.)=!N*,:JB#9J[11)WB
M$\+&_*1O&YF;P=,QP*V(;*F7;-US)'0,L@DJ9!3HHB91,IQ24#_;3$>X;IR!
M@'IZZ+)??1$T1-$31$T1-$31$T1-$31$T1-$31$T16F=4*E$2*QNYW46;E4P
MJ$*H0"D04$>\F;DJ@<<\IF*<IP^P8H@;1%X[]A["1$)M-M2,0_4<O9+*+R9L
MR:QW"RD9;9.A41:9C$RN,"X"(T:1[@ ;LXB/BKK#139-)A#7J1CD4&,>4U^>
MF>43GSCZ+"\KX_[55L,8VQQ8KY9'C V[YHM)K2V$:ZSEFLQ?LIK8)L;]XE;(
M9JRL36BIXW:8XK9,;R];;.)%97(LU4GT4Y=+$@=1:TG(:?(\=58&M9[3&.H.
MYMUF>2<M:*;:?F%.&'(K['-F@$FPU;&IZ7#R$=C2PM[.IFN)@6>>&^3;+YI?
M'TC/3-/=U^0L42T191Q(&@'J9^)^%@O<+'O?^@5(\3N]_P"B-;[W=#@O/P9E
MSP'(\!\NHZ*K+]$31$T1-$31$T1-$31$T1-$7$W]$WO]D>GSZ?J_M#1%XZ9J
MW"[\Z;DQQ U.F1UDKC'=LK2FR56Q1>9$]BPN[Q-@>U5F.;S Q%C@$79+!?<@
M%NN0)ZQ4: 'Z"6**KSUM*,&T(N4$'O&1TXV$"V41;(RL3P#NK[0>W9#QM#6S
M#[B;K4Y$3R[QU,X=N^'$+''HQ&9'\G89:=LOQ!OC20I=VJN(<<PU8F8Q20O$
M/D.1NT?&R$>5"0@B&\Z\=?1O(U)BQR/HEL?,L?9_MJ.X2*W<'PS0CKH$4!8B
M*QH!F*J15@(F"I4U!,0J@$(!RE P$* ]T"JVGT1-$31%&*LK8'F1V\(O6Q3K
MT=$HOV]F"3;*).Y!X=]YF-/$D$7[51B5E&.DGBW^"K"Z.@4P&*7Q"G+*-+6\
M)S'EP6#WR<F&F38-ZUCK;.5RN4^SRK^*A&$*XC'D\S!K)1[45W;EM*!8E6[%
M=&&8ICY!RJ9<7"S8[543$GN_M,CC'U695Z,?R=I2N3Z1L#5*:K<<NWI4J#$C
M:KJ(%.(&\%!N9PG,NTY99O,E6D';<%V*:* &*V(<"3>.\_*WC?NU7?)'RTAD
M=6:+/+A7X"MK09ZY\/:^64G95ZWDE)8)$W=>E7:1C-BT\N03-CIOE# 8B@*E
M,3EYS)GOGS\(A9A#!RP26'GO.SK/3<AP;_#%CN4RFX$>!(DHF00$1_H^H^HD
M&7H=+20#TCHKKHJHVL9;&[N]2;-'$/\ 1-!O(N; U<-7AYHTF0Z+FOKQKI)P
M5HDU*>.DDY!-RT6,8ID!143.8!T6)(!DG]LI^1.9C)23HLDT1-$31$T1-$31
M%Y_[D]^T3MRF<G0,AAK)=MD,<5+%-P(XA4&"D9:8K)UNG*LY>PP1RTU/(Q5!
M1KDQ-7.7D:^U:H,F+I*,"15:N#)E+_']O4CZ0A'=KMB>1NK"E)8LR"JM)7N%
MKK6::2%/?0JM,G,SAMY:Y&07;SIG#MB7+@A%!6D&PV1>L\6QNT4;J)L3%5MQ
ML[M,-=*9E6T5YRL\AIK<7FMXP<KL)"+652&VJI&.I'2S5E)-/Y1,X%2>-4%A
M* ' IB&*8Q2W"+96RU_?3);;Z*IHB:(HPRX\.VIZA&[YI'/5Y%BO'O7[5R^8
M-WD&<]F(L_:,UVKMRP1)!J+/T&KINY58IN"-UDUA(8-M$M;4:7?E'YKP=W(P
M2" 8)@D$ W(2"9@3 )CD%\,'1=YAL1X^C\FR$#*Y#0J\4-UE*S&NHB"D+*JV
M(M+NXZ/?.7;IN@N]465,55<1,J90Y4T"&!!-B32=B*CJ#-RD7$,!,D-&0G6>
M)ET9N<;K!@AL1XG/Z<(BT9*19>1;1$:]E'JA464>V6>/%CB $1:MDSK+JF$1
M#HFF0QAZ^WRYUJ DANA,$G("YD\A'59'EGI^_+CY7A:^X3QI7L>V:YFC(U]'
MR]M<2>5K65[-S4VB%SRY9).3M:<8I-2#TT?&(K56+:-(F.38Q+)%D0[%BU\R
MLGKIKXEV(:S?RH 4*1@#_ I- :8:+@EQ()))G@ L6@B 2+"!QN9O-YMZNK]G
M"SVZ)85&"I=$<Y!=7*ZUJO65@RL4+6UZYC]S)H_3J[*KS1R$D6->A1,FXB&
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M0  .1$?N .H_=HBCN4M<+0,:O+A:)-M&0T#6334M*O3G(U1*5GYEPNN<A%#
M"BZGVA*03&,<>X4W !HL18:]# -\LXO>\ZRHAH59FV]HRC;'UT5L%.LZ^*JK
M184K,Q4*S%Q$)&-)[X:X!8Y5F5HDIHS]7NMT2HF;F5.54#%*F3+,@V,Z?..
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MI".FYUV\?+J/(]LY-$OU6\A%*H,U5"*J-3^=4+W3N/Y$L1,FPS-R3,6L+9?
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M&DY-T<Q4&#%P]5 @=]4R;=,RHD1( &%1502@FF0"F$YS%(4HF, #YI;OC=!
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MT]QSB\FI3;%2K) CVCY<&B0W($@ K8-Z '%SB+RZ#$Z"W6<YG@IE      X
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MU'LQM*HW!-K5#6J4:SWM<VH]U1[KM:'9EQNV\ @]9I5BRG2#V@42#( :' 3
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M<4C$,;M-VT#Q40]="G#(-738[UJ8P''4IC8I_,[',J_9@*A#!N-K!W\LD2P
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M^2Y^5E\FY)KT=$6*GH9[NL1*C348APT?04)2HNXM%(.IVB&)(#9(R(C&L7,
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M6%S0G[*QC'DA*C5VDVA$0[YXUB692D64VW:[V@54J"TY$[D+CD*?CXRMM7=
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#(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>engn-20251031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-12-22T16:09:20.1477+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://engene.com/20251031" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:engn="http://engene.com/20251031">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" namespace="http://fasb.org/srt-types/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" namespace="http://fasb.org/us-types/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>75010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>75040 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows" id="StatementConsolidatedStatementOfCashFlows">
        <link:definition>75050 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995455 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusiness1" id="DisclosureDescriptionOfBusiness1">
        <link:definition>995465 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1" id="DisclosureFairValueMeasurements1">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1" id="DisclosureMarketableSecurities1">
        <link:definition>995495 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1" id="DisclosurePropertyAndEquipmentNet1">
        <link:definition>995505 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995515 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization" id="DisclosureLicenseAgreementAndClinicalResearchOrganization">
        <link:definition>995525 - Disclosure - License Agreement and Clinical Research Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1" id="DisclosureNotesPayable1">
        <link:definition>995535 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1" id="DisclosureCommonShares1">
        <link:definition>995545 - Disclosure - Common Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation" id="DisclosureSharebasedCompensation">
        <link:definition>995555 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995565 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995575 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeases1" id="DisclosureLeases1">
        <link:definition>995585 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995595 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995605 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995615 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995625 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995635 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995645 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995655 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>995665 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995675 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables" id="DisclosureNotesPayableTables">
        <link:definition>995695 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesTables" id="DisclosureCommonSharesTables">
        <link:definition>995705 - Disclosure - Common Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables" id="DisclosureSharebasedCompensationTables">
        <link:definition>995715 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995725 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995735 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995745 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995755 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" id="DisclosureDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail">
        <link:definition>995785 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails">
        <link:definition>995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails" id="DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails">
        <link:definition>995815 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
        <link:definition>995825 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
        <link:definition>995845 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995855 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995865 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" id="DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails">
        <link:definition>995875 - Disclosure - License Agreement and Clinical Research Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" id="DisclosureNotesPayableAdditionalInformationDetails">
        <link:definition>995885 - Disclosure - Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" id="DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails">
        <link:definition>995895 - Disclosure - Notes Payable - Schedule of Carrying Value of Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" id="DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails">
        <link:definition>995905 - Disclosure - Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" id="DisclosureCommonSharesAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Common Shares - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" id="DisclosureSharebasedCompensationAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails" id="DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails">
        <link:definition>995935 - Disclosure - Share-Based Compensation - Schedule of Share Reserved For Future Issuance Under The Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" id="DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails">
        <link:definition>995945 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>995955 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" id="DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails">
        <link:definition>995965 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995975 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" id="DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
        <link:definition>995985 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>995995 - Disclosure - Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails" id="DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails">
        <link:definition>996005 - Disclosure - Income Taxes - Summary of Components of Provision for (Recovery of) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails" id="DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails">
        <link:definition>996015 - Disclosure - Income Taxes - Summary of Reconciliation of Company's Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails" id="DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails">
        <link:definition>996025 - Disclosure - Income Taxes - Summary of Net Deferred Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996035 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>996045 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" id="DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails">
        <link:definition>996055 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails">
        <link:definition>996065 - Disclosure - Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>996075 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" id="DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>996085 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>996095 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails" id="DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails">
        <link:definition>996105 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails" id="DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails">
        <link:definition>996115 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>996125 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996135 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="engn-20251031.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:href="engn-20251031.xsd#DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="engn-20251031.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:href="engn-20251031.xsd#StatementConsolidatedStatementOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails" xlink:href="engn-20251031.xsd#DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="engn-20251031.xsd#DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="engn-20251031.xsd#DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="engn-20251031.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" xlink:href="engn-20251031.xsd#DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:href="engn-20251031.xsd#DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" xlink:href="engn-20251031.xsd#DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="engn-20251031.xsd#DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails" xlink:href="engn-20251031.xsd#DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="engn-20251031.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="engn-20251031.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="engn-20251031.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="engn-20251031.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusiness1" xlink:href="engn-20251031.xsd#DisclosureDescriptionOfBusiness1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="engn-20251031.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1" xlink:href="engn-20251031.xsd#DisclosureFairValueMeasurements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1" xlink:href="engn-20251031.xsd#DisclosureMarketableSecurities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:href="engn-20251031.xsd#DisclosurePropertyAndEquipmentNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="engn-20251031.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization" xlink:href="engn-20251031.xsd#DisclosureLicenseAgreementAndClinicalResearchOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1" xlink:href="engn-20251031.xsd#DisclosureNotesPayable1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1" xlink:href="engn-20251031.xsd#DisclosureCommonShares1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare" xlink:href="engn-20251031.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeases1" xlink:href="engn-20251031.xsd#DisclosureLeases1" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="engn-20251031.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting" xlink:href="engn-20251031.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/RelatedPartyTransactions" xlink:href="engn-20251031.xsd#RelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/SubsequentEvents" xlink:href="engn-20251031.xsd#SubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="engn-20251031.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="engn-20251031.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="engn-20251031.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="engn-20251031.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="engn-20251031.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="engn-20251031.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables" xlink:href="engn-20251031.xsd#DisclosureNotesPayableTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesTables" xlink:href="engn-20251031.xsd#DisclosureCommonSharesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="engn-20251031.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables" xlink:href="engn-20251031.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="engn-20251031.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="engn-20251031.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail" xlink:href="engn-20251031.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" xlink:href="engn-20251031.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureNotesPayableAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" xlink:href="engn-20251031.xsd#DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureCommonSharesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:href="engn-20251031.xsd#DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="engn-20251031.xsd#DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails" xlink:href="engn-20251031.xsd#DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails" xlink:href="engn-20251031.xsd#DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="engn-20251031.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DescriptionOfBusinessTable" xlink:label="engn_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsNotePayable" xlink:label="engn_DeferredTaxAssetsNotePayable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LongTermMarketableSecuritiesMember" xlink:label="engn_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MilestoneProductPayment" xlink:label="engn_MilestoneProductPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InitialAnnualBaseRentPerSquareFoot" xlink:label="engn_InitialAnnualBaseRentPerSquareFoot"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="engn_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AppliedToRefinanceOfAmountOutstandingMember" xlink:label="engn_AppliedToRefinanceOfAmountOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTaxCredit" xlink:label="us-gaap_InvestmentTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ManufacturingPaymentFee" xlink:label="engn_ManufacturingPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtSecuritiesUnrealizedLosses" xlink:label="engn_DebtSecuritiesUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AreaOfSpace" xlink:label="engn_AreaOfSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" xlink:label="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" xlink:label="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OtherResearchAndDevelopmentExpensesMember" xlink:label="engn_OtherResearchAndDevelopmentExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="engn_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantToPurchaseCommonStockMember" xlink:label="engn_WarrantToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" xlink:label="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementTable" xlink:label="engn_LicenseAgreementTable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:label="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedFinancingCosts" xlink:label="engn_AccruedFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DescriptionOfBusinessLineItems" xlink:label="engn_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MaximumAmountOfCommonSharesToBeSold" xlink:label="engn_MaximumAmountOfCommonSharesToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" xlink:label="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PriorLoanAgreementMember" xlink:label="engn_PriorLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfSharesOwnedByShareholders" xlink:label="engn_PercentageOfSharesOwnedByShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" xlink:label="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmendedLoanAgreementMember" xlink:label="engn_AmendedLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PrefundedWarrantMember" xlink:label="engn_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EndOfTermCharge" xlink:label="engn_EndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InitialConsultingPeriod" xlink:label="engn_InitialConsultingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" xlink:label="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WallStreetJournalMember" xlink:label="engn_WallStreetJournalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" xlink:label="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" xlink:label="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OperatingLeaseCommencementPeriod" xlink:label="engn_OperatingLeaseCommencementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" xlink:label="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:label="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommitmentAmount" xlink:label="engn_CommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="engn_ScientificResearchAndExperimentalDevelopmentExpenditures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfIncreaseInAnnualBaseRent" xlink:label="engn_PercentageOfIncreaseInAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtInstrumentAccruedInterest" xlink:label="engn_DebtInstrumentAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsFinancingCosts" xlink:label="engn_DeferredTaxAssetsFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TermLoanMember" xlink:label="engn_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InducementGrantsMember" xlink:label="engn_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TwoZeroTwoThreePlanMember" xlink:label="engn_TwoZeroTwoThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OfficeSpaceMember" xlink:label="engn_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheThreeAdvanceMember" xlink:label="engn_TrancheThreeAdvanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UnderwrittenPublicOfferingMember" xlink:label="engn_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="engn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CapitalLossCarryforward" xlink:label="engn_CapitalLossCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LeaseExpirationMonthAndYear" xlink:label="engn_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IfInterimMilestoneAchievedAndNoDefaultMember" xlink:label="engn_IfInterimMilestoneAchievedAndNoDefaultMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LabEquipmentMember" xlink:label="engn_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EndOfTermFeePercentage" xlink:label="engn_EndOfTermFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DateOfClosedPrivatePlacement" xlink:label="engn_DateOfClosedPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TwoThousandTwentyFourPipeInvestorsMember" xlink:label="engn_TwoThousandTwentyFourPipeInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ResearchAndDevelopmentInvestmentTaxCredits" xlink:label="engn_ResearchAndDevelopmentInvestmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_RepaymentsOfTermLoanPrincipal" xlink:label="engn_RepaymentsOfTermLoanPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NumberOfSecuritiesHeld" xlink:label="engn_NumberOfSecuritiesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SeveranceAgreementMember" xlink:label="engn_SeveranceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" xlink:label="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShortTermMarketableSecuritiesMember" xlink:label="engn_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedInterestReceivableWrittenOff" xlink:label="engn_AccruedInterestReceivableWrittenOff"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" xlink:label="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaidInKindInterestPercentage" xlink:label="engn_PaidInKindInterestPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PhaseIiClinicalTrialMember" xlink:label="engn_PhaseIiClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" xlink:label="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:label="engn_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsReceivable" xlink:label="engn_InvestmentTaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommonSharesPercentage" xlink:label="engn_CommonSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" xlink:label="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" xlink:label="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FormerChiefExecutiveOfficerMember" xlink:label="engn_FormerChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" xlink:label="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" xlink:label="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FebruaryPipeFinancingMember" xlink:label="engn_FebruaryPipeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfFacilityChargeOnAmountBorrowed" xlink:label="engn_PercentageOfFacilityChargeOnAmountBorrowed"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="engn_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TransitionServicesForConsultingFeePerHour" xlink:label="engn_TransitionServicesForConsultingFeePerHour"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" xlink:label="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:label="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ClinicalOperationsMember" xlink:label="engn_ClinicalOperationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtIssuanceCostsPolicyTextBlock" xlink:label="engn_DebtIssuanceCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" xlink:label="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheTwoToTrancheThreeMember" xlink:label="engn_TrancheTwoToTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SubscriptionAgreementsMember" xlink:label="engn_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfMaximumCommissionPercentageOfSharesSold" xlink:label="engn_PaymentOfMaximumCommissionPercentageOfSharesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" xlink:label="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PhaseIClinicalTrialMember" xlink:label="engn_PhaseIClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PeriodWithinLoanDisbursementsToBeMade" xlink:label="engn_PeriodWithinLoanDisbursementsToBeMade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantsAndRightsOutstandingMaturityPeriod" xlink:label="engn_WarrantsAndRightsOutstandingMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AggregateAmountOfBaseRentalPayments" xlink:label="engn_AggregateAmountOfBaseRentalPayments"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OpenMarketSaleAgreementMember" xlink:label="engn_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOnAssigningLicenseToThirdParty" xlink:label="engn_PaymentOnAssigningLicenseToThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OldEngenesShareOptionHoldersMember" xlink:label="engn_OldEngenesShareOptionHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OctoberPipeFinancingMember" xlink:label="engn_OctoberPipeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerAxis" xlink:label="engn_AcquirerAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NonCashLeaseExpenses" xlink:label="engn_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FEACMember" xlink:label="engn_FEACMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EvergreenProvisionMember" xlink:label="engn_EvergreenProvisionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CashEquivalentsAndShortTermInvestmentsMember" xlink:label="engn_CashEquivalentsAndShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheOneAdvanceMember" xlink:label="engn_TrancheOneAdvanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CeoTransitionAgreementMember" xlink:label="engn_CeoTransitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" xlink:label="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmountOfMonthlyFeeForConsultingPeriod" xlink:label="engn_AmountOfMonthlyFeeForConsultingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_HerculesWarrantsMember" xlink:label="engn_HerculesWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestments" xlink:label="us-gaap_RestrictedInvestments"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AnnualMaintenanceFeeUnderLicenseAgreement" xlink:label="engn_AnnualMaintenanceFeeUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantValueIssuedAsPartOfAmendedTermLoan" xlink:label="engn_WarrantValueIssuedAsPartOfAmendedTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ChemistryManufacturingAndControlsMember" xlink:label="engn_ChemistryManufacturingAndControlsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="engn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAmortizationDate" xlink:label="engn_LoanAmortizationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="engn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_HerculesCapitalMember" xlink:label="engn_HerculesCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerDomain" xlink:label="engn_AcquirerDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsExpirationYear" xlink:label="engn_InvestmentTaxCreditsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementsMember" xlink:label="engn_LoanAndSecurityAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AdvanceOnLoanAllocatedToWarrants" xlink:label="engn_AdvanceOnLoanAllocatedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfCommitmentAmount" xlink:label="engn_PercentageOfCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementMember" xlink:label="engn_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NonCashInterestExpense" xlink:label="engn_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NetOperatingLossCarryforwardsExpirationYear" xlink:label="engn_NetOperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NewLaboratoryAndOfficeSpaceMember" xlink:label="engn_NewLaboratoryAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockBasedCompensationMember" xlink:label="engn_StockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UpfrontFees" xlink:label="engn_UpfrontFees"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PatentCostsPolicyPolicyTextBlock" xlink:label="engn_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="dei_EntityListingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PrivatePlacementWarrantsMember" xlink:label="engn_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Business [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign (US)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsNotePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, note payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsNotePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Note Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsNotePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MilestoneProductPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time payment for milestone product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MilestoneProductPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Product Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MilestoneProductPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone product payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InitialAnnualBaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InitialAnnualBaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Annual Base Rent Per Square Foot</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InitialAnnualBaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial annual base rent per square foot.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, operating lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of common share warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Future Principal Payments Due Under the Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Note payable current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of note payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common shares issued and sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AppliedToRefinanceOfAmountOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Applied to Refinance of Amount Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AppliedToRefinanceOfAmountOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applied to Refinance of Amount Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AppliedToRefinanceOfAmountOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applied to refinance of amount outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTaxCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets obtained in exchange for lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ManufacturingPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee related to the manufacturing payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ManufacturingPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Payment Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ManufacturingPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing payment fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share of share options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock value on date of grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtSecuritiesUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt securities unrealized losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtSecuritiesUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtSecuritiesUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AreaOfSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Area of office space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AreaOfSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AreaOfSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AreaOfSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Assistance Programs for Research and Development Expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Assistance Programs For Research And Development Expenditures [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government assistance programs for research and development expenditures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment premium of principal amount outstanding of the closing date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Prepayment Premium of Principal Amount Outstanding of the Closing Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium of principal amount outstanding of the closing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholder's equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2043</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income at Canadian statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to purchase common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Recapitalization And Pipe Financing Transaction Costs Included Within Accrued Expenses And Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse recapitalization and pipe financing transaction costs included within accrued expenses and accounts payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Recapitalization and PIPE financing transaction costs included within accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OtherResearchAndDevelopmentExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OtherResearchAndDevelopmentExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OtherResearchAndDevelopmentExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment tax credit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Investment Tax Credit Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in investment tax credit receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance subject to achievement of specified interim milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Subject to Achievement of Specified Interim Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance Subject to Achievement of Specified Interim Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant To Purchase Common Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of target annual bonus netoff taxes and withholdings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Target Annual Bonus Netoff Taxes And Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment Of Target Annual Bonus Netoff Taxes And Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share options granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-balance sheet concentrations of credit risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk credit risk off balance sheet risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Off Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of common shares, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares cashless exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Cashless Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon cashless exercise of warrants (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Business [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MaximumAmountOfCommonSharesToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Common Shares To Be Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MaximumAmountOfCommonSharesToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of common shares to be sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MaximumAmountOfCommonSharesToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of common shares to be sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of debt issuance costs associated with the term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Shares Reserved For Future Issuance Under ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining shares reserved for future issuance under ESPP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining shares reserved for future issuance under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PriorLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PriorLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PriorLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prior loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred shares at a price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common share price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign (US)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfSharesOwnedByShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares owned by shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfSharesOwnedByShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Owned By Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfSharesOwnedByShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares owned by shareholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value cashless exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Cashless Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon cashless exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant issued to purchase preferred shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities into which the class of warrant or right may be converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Shareholder's equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options unvested aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum hours of CEO devote per week to providing transition services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Hours Of CEO Devote Per Week To Providing Transition Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum hours of ceo devote per week to providing transition services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of premium/discount on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrue interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate of outstanding debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets transfers or reclassifications out of level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment to Amended and Restated Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First amendment to amended and restated loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">First Amendment to Amended and Restated Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AmendedLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AmendedLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AmendedLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prefunded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PrefundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares excluded from computation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">End of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">End of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">End of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InitialConsultingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial consulting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InitialConsultingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Consulting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InitialConsultingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial consulting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, operating lease-right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Operating Lease-right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease-right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Year From Which Warrants Or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right year from which warrants or rights exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WallStreetJournalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wall Street Journal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WallStreetJournalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wall Street Journal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WallStreetJournalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wall street journal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting Immediately Upon Grant Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term (in years), Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate principal amount of term loan advance to purchase number of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Principal Amount Of Term Loan Advance To Purchase Number Of Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate principal amount of term loan advance to purchase number of common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Aggregate Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Amortization of Premiums Accretion of Discounts on Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amortization of premiums accretion of discounts on marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net amortization of premiums (accretion of discounts) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OperatingLeaseCommencementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OperatingLeaseCommencementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OperatingLeaseCommencementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of tax benefit to be realized for recognition in the income statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Tax Benefit To Be Realized For Recognition In The Income Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of tax benefit to be realized for recognition in the income statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February two thousand twenty four subscription agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February Two Thousand Twenty Four Subscription Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2024 Subscription Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Holdings Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of common shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total commitment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-balance sheet concentrations of credit risk description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific research and experimental development expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Research And Experimental Development Expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SR&amp;ED expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities - short term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Net Deferred Income Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfIncreaseInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfIncreaseInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Increase in Annual Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfIncreaseInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in annual base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtInstrumentAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtInstrumentAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Accrued Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtInstrumentAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, accrued interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DeferredTaxAssetsFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of vesting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt discount, net of accretion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest related to unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TwoZeroTwoThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TwoZeroTwoThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Two Three Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TwoZeroTwoThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two zero two three plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term (in years), Options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument, basis spread on variable rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, No Par Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock no par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement and Clinical Research Organization [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement and clinical research organization line items.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities - long term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheThreeAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 3 Advance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheThreeAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three Advance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheThreeAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three advance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets included in accrued expenses and accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment included in accrued expenses and accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares used in net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Reconciliation Of Company's Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the February 2024 PIPE Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Note payable, net of discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon exercise of warrants (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D expenditures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholder's equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting on Remaining Years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CapitalLossCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital loss carryforward.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CapitalLossCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Loss Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CapitalLossCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month and Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IfInterimMilestoneAchievedAndNoDefaultMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">If Interim Milestone Achieved and No Default</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IfInterimMilestoneAchievedAndNoDefaultMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">If Interim Milestone Achieved and No Default [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IfInterimMilestoneAchievedAndNoDefaultMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">If interim milestone achieved and no default.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note payable, including End of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current expense (benefit):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EndOfTermFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">End of term fee percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EndOfTermFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">End of Term Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EndOfTermFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">End of term fee percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DateOfClosedPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of closed private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DateOfClosedPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Date of closed private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DateOfClosedPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Date of Closed Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostMaintenance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual maintenance fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostMaintenance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost, Maintenance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, exercise price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on the disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TwoThousandTwentyFourPipeInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2024 PIPE investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TwoThousandTwentyFourPipeInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four PIPE Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TwoThousandTwentyFourPipeInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 PIPE Investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Realized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on sale or maturity of available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ResearchAndDevelopmentInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development investment tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ResearchAndDevelopmentInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Investment Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ResearchAndDevelopmentInvestmentTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development investment tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement and Clinical Research Organization [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement and Clinical Research Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_RepaymentsOfTermLoanPrincipal_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of term loan principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_RepaymentsOfTermLoanPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of term loan principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_RepaymentsOfTermLoanPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of term loan principal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NumberOfSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of securities held.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NumberOfSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Securities Held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NumberOfSecuritiesHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of common shares used in net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Shares in Connection With Pipe Financing Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with pipe financing value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with PIPE Financing, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2023-07 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202307Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2023-07</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment premium of principal amount outstanding prior to twenty-four months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Twenty Four Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium of principal amount outstanding prior to twenty four months.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SeveranceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SeveranceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SeveranceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Shares Reserved for Future Issuance Under the Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Shares Reserved For Future Issuance Under The Plan Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of shares reserved for future issuance under the plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of outstanding common shares owned by the holder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized foreign currency losses (gains)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasuries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">US Treasury</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized increased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Marketable Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedInterestReceivableWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest receivable written off.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedInterestReceivableWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Receivable Written Off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedInterestReceivableWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable written off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">If Interim Milestone and Certain Clinical Milestones Achieved and No Default [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">If Interim Milestone and Certain Clinical Milestones Achieved and No Default</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">If interim milestone and certain clinical milestones achieved and no default.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants in connection with Amended Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of convertible debentures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Exercise Price, Options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements - Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payment of Financing and Stock Issuance Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Financing and Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaidInKindInterestPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment-in-kind interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaidInKindInterestPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paid-in-kind Interest Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaidInKindInterestPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paid-in-kind interest percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic (Canada)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PhaseIiClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase II Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PhaseIiClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase II Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Outstanding Common Shares Owned by The Holder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding common shares owned by the holder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding common shares owned by the holder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease initial term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Live</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment estimated useful live.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets (liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InvestmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InvestmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InvestmentTaxCreditsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credits receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommonSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common shares percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommonSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Shares Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommonSharesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of common shares outstanding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Components Of The Provision For (Recovery Of) Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three Advance Subject To Achievement Of Specified Interim Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three advance subject to achievement of specified interim milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche Three Advance Subject to Achievement of Specified Interim Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Reserved For Future Issuance Under the Two Thousand and Twenty Three Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance under the two thousand and twenty three plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining shares reserved for future issuance under the 2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">StockIssuedDuringPeriodValueNewIssues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel-Related Expenses Excluding Stock-Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel-related expenses, excluding stock-based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel-Related Expenses Excluding Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Useful Life of Each Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FormerChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Former chief executive officer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FormerChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FormerChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Former CEO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Loss Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Grant Stock Options Awarded Outside The Two Thousand and Twenty Three Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement grant stock options awarded outside the two thousand and twenty three plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement grant stock options awarded outside of the 2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares reserved for remaining future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved for Remaining Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock capital shares reserved for remaining future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FebruaryPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February PIPE financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FebruaryPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February PIPE Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FebruaryPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February PIPE Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfFacilityChargeOnAmountBorrowed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of facility charge on amount borrowed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfFacilityChargeOnAmountBorrowed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Facility Charge on Amount Borrowed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfFacilityChargeOnAmountBorrowed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of facility charge on amount borrowed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares upon the exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate gross proceeds from option exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayment premium of principal amount outstanding prior to maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium of principal amount outstanding prior to maturity date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canada</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Canadian</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityListingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Listings [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement and Clinical Research Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement and clinical research organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss attributable to common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TransitionServicesForConsultingFeePerHour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transition services for consulting fee per hour.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TransitionServicesForConsultingFeePerHour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transition Services For Consulting Fee Per Hour</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TransitionServicesForConsultingFeePerHour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transition services for consulting fee per hour</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of issuance costs associated with the pipe financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Issuance Costs Associated With The Pipe Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of issuance costs associated with the 2024 PIPE Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October two thousand twenty four subscription agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October Two Thousand Twenty Four Subscription Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2024 Subscription Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ClinicalOperationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Operations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ClinicalOperationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ClinicalOperationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of cash paid for amounts included in measurement of operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Outstanding, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Outstanding, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee entitled for continued pay and health insurance benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee entitled for continued pay and health insurance benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee entitled for continued pay and health insurance benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee compensation and related benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional lease commitments to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 2 Advance Subject to Achievement of Specified Interim Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two Advance Subject to Achievement of Specified Interim Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two advance subject to achievement of specified interim milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheTwoToTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two to Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheTwoToTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two to tranche three .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheTwoToTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 2 to Tranche 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Policy Acquisition Costs, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2024 Subscription agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Subscription Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2024 Subscription Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfMaximumCommissionPercentageOfSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Maximum Commission Percentage of Shares Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfMaximumCommissionPercentageOfSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of maximum commission percentage of shares sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfMaximumCommissionPercentageOfSharesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of maximum commission percentage of shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic (Canada)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current Federal, State and Local, Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (income) expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of reverse recapitalization and pipe financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Reverse Recapitalization And Pipe Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of Reverse Recapitalization and PIPE Financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PhaseIClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase I Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PhaseIClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase I Clinical Trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note payable, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PeriodWithinLoanDisbursementsToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within loan disbursements to be made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PeriodWithinLoanDisbursementsToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Within Loan Disbursements to be Made</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PeriodWithinLoanDisbursementsToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period within loan disbursements to be made.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantsAndRightsOutstandingMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantsAndRightsOutstandingMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Maturity Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantsAndRightsOutstandingMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants and rights outstanding maturity period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, no par value; unlimited shares authorized, 52,018,658 and 50,976,676 shares issued and outstanding as of October 31, 2025 and October 31, 2024, respectively.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit, maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AggregateAmountOfBaseRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount of base rental payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AggregateAmountOfBaseRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate amount of base rental payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AggregateAmountOfBaseRentalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amount Of Base Rental Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Market Sale Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open Market Sale Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open Market Sale Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss (NOL) carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOnAssigningLicenseToThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to NTC upon assigning the License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOnAssigningLicenseToThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment On Assigning License to Third Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PaymentOnAssigningLicenseToThirdParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment on assigning license to third party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized (gain) loss on available-for-sale investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OldEngenesShareOptionHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Old enGenes Share Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OldEngenesShareOptionHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Old enGenes Share Option Holders Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OldEngenesShareOptionHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Old enGenes Share Option Holders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (income) expense, net:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Carrying Value of Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OctoberPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">October PIPE financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OctoberPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October PIPE Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_OctoberPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October PIPE Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AcquirerAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquirer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AcquirerAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquirer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NonCashLeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NonCashLeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NonCashLeaseExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Holdings Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FEACMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">FEAC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FEACMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FEAC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FEACMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FEAC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_FEACMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FEAC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (income) expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expenses (income), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses (income), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other expenses, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EvergreenProvisionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Evergreen provision.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EvergreenProvisionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Evergreen Provision [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_EvergreenProvisionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Evergreen Provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CashEquivalentsAndShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and short-term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CashEquivalentsAndShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Short-term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CashEquivalentsAndShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Short Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for (recovery of) income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividend paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Cash Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk of Concentrations of Credit and Off-Balance Sheet Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheOneAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche 1 Advance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheOneAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One Advance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_TrancheOneAdvanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one advance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CeoTransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CEO Transition Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CeoTransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CEO Transition Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_CeoTransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CEO Transition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Options To Purchase Common Shares Awarded Pursuant to Two Thousand and Twenty Three Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive options to purchase common shares awarded pursuant to two thousand and twenty three plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive options to purchase common shares awarded pursuant to the 2023 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of new stock issued during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common shares and exercise price of options, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options maximum.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of common shares, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AmountOfMonthlyFeeForConsultingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of monthly fee for consulting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AmountOfMonthlyFeeForConsultingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of monthly fee for consulting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AmountOfMonthlyFeeForConsultingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Monthly Fee For Consulting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Segment Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_HerculesWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_HerculesWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_HerculesWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AnnualMaintenanceFeeUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to the annual maintenance fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AnnualMaintenanceFeeUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Maintenance Fee Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AnnualMaintenanceFeeUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual maintenance fee under license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Lines of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loans aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Line of credit, maximum amount available</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan facility aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credits, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantValueIssuedAsPartOfAmendedTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant value issued as part of amended term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantValueIssuedAsPartOfAmendedTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Value Issued as Part of Amended Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_WarrantValueIssuedAsPartOfAmendedTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant value issued as part of Amended Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ChemistryManufacturingAndControlsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chemistry Manufacturing and Controls [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ChemistryManufacturingAndControlsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chemistry Manufacturing and Controls.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ChemistryManufacturingAndControlsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chemistry, Manufacturing and Controls</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAmortizationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amortization date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAmortizationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Amortization Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAmortizationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan amortization date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign (US)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_HerculesCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_HerculesCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_HerculesCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AcquirerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquirer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AcquirerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquirer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common shares and exercise price of options, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options minimum.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InvestmentTaxCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment tax credits expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InvestmentTaxCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Tax Credits Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_InvestmentTaxCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment tax credits expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAndSecurityAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAndSecurityAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan and Security Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAndSecurityAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AdvanceOnLoanAllocatedToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance on loan allocated to warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AdvanceOnLoanAllocatedToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance on Loan Allocated to Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_AdvanceOnLoanAllocatedToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance on loan allocated to warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Operating Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of total commitment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commitment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PercentageOfCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commitment amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2021 Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NonCashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Shares Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NetOperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NetOperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NetOperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Shares In Connection With Pipe Financing Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common shares in connection with pipe financing shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NewLaboratoryAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Laboratory and Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NewLaboratoryAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Laboratory and Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_NewLaboratoryAndOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New laboratory and office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued penalties related to unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_StockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic (Canada)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Federal, State and Local, Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of unrealized loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_UpfrontFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_UpfrontFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_UpfrontFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityListingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Listings [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived assets held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="engn_PrivatePlacementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private placement warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense weighted-average period of recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized unlimited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term (in years), Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DescriptionOfBusinessTable" xlink:to="engn_DescriptionOfBusinessTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DeferredTaxAssetsNotePayable" xlink:to="engn_DeferredTaxAssetsNotePayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LongTermMarketableSecuritiesMember" xlink:to="engn_LongTermMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_MilestoneProductPayment" xlink:to="engn_MilestoneProductPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_InitialAnnualBaseRentPerSquareFoot" xlink:to="engn_InitialAnnualBaseRentPerSquareFoot_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="engn_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AppliedToRefinanceOfAmountOutstandingMember" xlink:to="engn_AppliedToRefinanceOfAmountOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTaxCredit" xlink:to="us-gaap_InvestmentTaxCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ManufacturingPaymentFee" xlink:to="engn_ManufacturingPaymentFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DebtSecuritiesUnrealizedLosses" xlink:to="engn_DebtSecuritiesUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AreaOfSpace" xlink:to="engn_AreaOfSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" xlink:to="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" xlink:to="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OtherResearchAndDevelopmentExpensesMember" xlink:to="engn_OtherResearchAndDevelopmentExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="engn_StockIssuedDuringPeriodValueWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" xlink:to="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:to="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_WarrantToPurchaseCommonStockMember" xlink:to="engn_WarrantToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" xlink:to="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LicenseAgreementTable" xlink:to="engn_LicenseAgreementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:to="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AccruedFinancingCosts" xlink:to="engn_AccruedFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="engn_DescriptionOfBusinessLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_MaximumAmountOfCommonSharesToBeSold" xlink:to="engn_MaximumAmountOfCommonSharesToBeSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" xlink:to="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PriorLoanAgreementMember" xlink:to="engn_PriorLoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfSharesOwnedByShareholders" xlink:to="engn_PercentageOfSharesOwnedByShareholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" xlink:to="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AmendedLoanAgreementMember" xlink:to="engn_AmendedLoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PrefundedWarrantMember" xlink:to="engn_PrefundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_EndOfTermCharge" xlink:to="engn_EndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_InitialConsultingPeriod" xlink:to="engn_InitialConsultingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" xlink:to="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_WallStreetJournalMember" xlink:to="engn_WallStreetJournalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" xlink:to="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" xlink:to="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OperatingLeaseCommencementPeriod" xlink:to="engn_OperatingLeaseCommencementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" xlink:to="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:to="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_CommitmentAmount" xlink:to="engn_CommitmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:to="engn_ScientificResearchAndExperimentalDevelopmentExpenditures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfIncreaseInAnnualBaseRent" xlink:to="engn_PercentageOfIncreaseInAnnualBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DebtInstrumentAccruedInterest" xlink:to="engn_DebtInstrumentAccruedInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DeferredTaxAssetsFinancingCosts" xlink:to="engn_DeferredTaxAssetsFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TermLoanMember" xlink:to="engn_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_InducementGrantsMember" xlink:to="engn_InducementGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TwoZeroTwoThreePlanMember" xlink:to="engn_TwoZeroTwoThreePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OfficeSpaceMember" xlink:to="engn_OfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TrancheThreeAdvanceMember" xlink:to="engn_TrancheThreeAdvanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_UnderwrittenPublicOfferingMember" xlink:to="engn_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="engn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_CapitalLossCarryforward" xlink:to="engn_CapitalLossCarryforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LeaseExpirationMonthAndYear" xlink:to="engn_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_IfInterimMilestoneAchievedAndNoDefaultMember" xlink:to="engn_IfInterimMilestoneAchievedAndNoDefaultMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LabEquipmentMember" xlink:to="engn_LabEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_EndOfTermFeePercentage" xlink:to="engn_EndOfTermFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DateOfClosedPrivatePlacement" xlink:to="engn_DateOfClosedPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TwoThousandTwentyFourPipeInvestorsMember" xlink:to="engn_TwoThousandTwentyFourPipeInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ResearchAndDevelopmentInvestmentTaxCredits" xlink:to="engn_ResearchAndDevelopmentInvestmentTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" xlink:to="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_RepaymentsOfTermLoanPrincipal" xlink:to="engn_RepaymentsOfTermLoanPrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_NumberOfSecuritiesHeld" xlink:to="engn_NumberOfSecuritiesHeld_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" xlink:to="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202307Member" xlink:to="us-gaap_AccountingStandardsUpdate202307Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_SeveranceAgreementMember" xlink:to="engn_SeveranceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" xlink:to="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ShortTermMarketableSecuritiesMember" xlink:to="engn_ShortTermMarketableSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AccruedInterestReceivableWrittenOff" xlink:to="engn_AccruedInterestReceivableWrittenOff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" xlink:to="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PaidInKindInterestPercentage" xlink:to="engn_PaidInKindInterestPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PhaseIiClinicalTrialMember" xlink:to="engn_PhaseIiClinicalTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" xlink:to="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:to="engn_PropertyPlantAndEquipmentEstimatedUsefulLive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_InvestmentTaxCreditsReceivable" xlink:to="engn_InvestmentTaxCreditsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_CommonSharesPercentage" xlink:to="engn_CommonSharesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:to="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" xlink:to="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" xlink:to="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_FormerChiefExecutiveOfficerMember" xlink:to="engn_FormerChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" xlink:to="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" xlink:to="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_FebruaryPipeFinancingMember" xlink:to="engn_FebruaryPipeFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfFacilityChargeOnAmountBorrowed" xlink:to="engn_PercentageOfFacilityChargeOnAmountBorrowed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="engn_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock" xlink:to="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TransitionServicesForConsultingFeePerHour" xlink:to="engn_TransitionServicesForConsultingFeePerHour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" xlink:to="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:to="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ClinicalOperationsMember" xlink:to="engn_ClinicalOperationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" xlink:to="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_DebtIssuanceCostsPolicyTextBlock" xlink:to="engn_DebtIssuanceCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" xlink:to="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:to="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TrancheTwoToTrancheThreeMember" xlink:to="engn_TrancheTwoToTrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_SubscriptionAgreementsMember" xlink:to="engn_SubscriptionAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PaymentOfMaximumCommissionPercentageOfSharesSold" xlink:to="engn_PaymentOfMaximumCommissionPercentageOfSharesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" xlink:to="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PhaseIClinicalTrialMember" xlink:to="engn_PhaseIClinicalTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PeriodWithinLoanDisbursementsToBeMade" xlink:to="engn_PeriodWithinLoanDisbursementsToBeMade_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_WarrantsAndRightsOutstandingMaturityPeriod" xlink:to="engn_WarrantsAndRightsOutstandingMaturityPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AggregateAmountOfBaseRentalPayments" xlink:to="engn_AggregateAmountOfBaseRentalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OpenMarketSaleAgreementMember" xlink:to="engn_OpenMarketSaleAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PaymentOnAssigningLicenseToThirdParty" xlink:to="engn_PaymentOnAssigningLicenseToThirdParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OldEngenesShareOptionHoldersMember" xlink:to="engn_OldEngenesShareOptionHoldersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_OctoberPipeFinancingMember" xlink:to="engn_OctoberPipeFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AcquirerAxis" xlink:to="engn_AcquirerAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_NonCashLeaseExpenses" xlink:to="engn_NonCashLeaseExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_FEACMember" xlink:to="engn_FEACMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_EvergreenProvisionMember" xlink:to="engn_EvergreenProvisionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="engn_CashEquivalentsAndShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_TrancheOneAdvanceMember" xlink:to="engn_TrancheOneAdvanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_CeoTransitionAgreementMember" xlink:to="engn_CeoTransitionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" xlink:to="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AmountOfMonthlyFeeForConsultingPeriod" xlink:to="engn_AmountOfMonthlyFeeForConsultingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_HerculesWarrantsMember" xlink:to="engn_HerculesWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestments" xlink:to="us-gaap_RestrictedInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AnnualMaintenanceFeeUnderLicenseAgreement" xlink:to="engn_AnnualMaintenanceFeeUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_WarrantValueIssuedAsPartOfAmendedTermLoan" xlink:to="engn_WarrantValueIssuedAsPartOfAmendedTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ChemistryManufacturingAndControlsMember" xlink:to="engn_ChemistryManufacturingAndControlsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="engn_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LoanAmortizationDate" xlink:to="engn_LoanAmortizationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_HerculesCapitalMember" xlink:to="engn_HerculesCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AcquirerDomain" xlink:to="engn_AcquirerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_InvestmentTaxCreditsExpirationYear" xlink:to="engn_InvestmentTaxCreditsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LoanAndSecurityAgreementsMember" xlink:to="engn_LoanAndSecurityAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_AdvanceOnLoanAllocatedToWarrants" xlink:to="engn_AdvanceOnLoanAllocatedToWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PercentageOfCommitmentAmount" xlink:to="engn_PercentageOfCommitmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_LoanAndSecurityAgreementMember" xlink:to="engn_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_NonCashInterestExpense" xlink:to="engn_NonCashInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_NetOperatingLossCarryforwardsExpirationYear" xlink:to="engn_NetOperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" xlink:to="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_NewLaboratoryAndOfficeSpaceMember" xlink:to="engn_NewLaboratoryAndOfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_StockBasedCompensationMember" xlink:to="engn_StockBasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_UpfrontFees" xlink:to="engn_UpfrontFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PatentCostsPolicyPolicyTextBlock" xlink:to="engn_PatentCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsTable" xlink:to="dei_EntityListingsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="engn_PrivatePlacementWarrantsMember" xlink:to="engn_PrivatePlacementWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="dei_EntityListingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsTable" xlink:to="dei_EntityListingsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentAnnualReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentTransitionReport" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_TradingSymbol" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityFileNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityRegistrantName" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityFilerCategory" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityCentralIndexKey" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntitySmallBusiness" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityShellCompany" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_Security12bTitle" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_SecurityExchangeName" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressCountry" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_CityAreaCode" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_LocalPhoneNumber" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityExTransitionPeriod" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityPublicFloat" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorName" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorLocation" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorFirmId" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityListingsTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestments" xlink:label="us-gaap_RestrictedInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsReceivable" xlink:label="engn_InvestmentTaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="engn_InvestmentTaxCreditsReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FebruaryPipeFinancingMember" xlink:label="engn_FebruaryPipeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OctoberPipeFinancingMember" xlink:label="engn_OctoberPipeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="engn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="engn_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_FebruaryPipeFinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_OctoberPipeFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodSharesWarrantsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodValueWarrantsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NonCashInterestExpense" xlink:label="engn_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" xlink:label="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" xlink:label="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantValueIssuedAsPartOfAmendedTermLoan" xlink:label="engn_WarrantValueIssuedAsPartOfAmendedTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NonCashLeaseExpenses" xlink:label="engn_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" xlink:label="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" xlink:label="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_RepaymentsOfTermLoanPrincipal" xlink:label="engn_RepaymentsOfTermLoanPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="engn_NonCashInterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="engn_WarrantValueIssuedAsPartOfAmendedTermLoan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="engn_NonCashLeaseExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="engn_RepaymentsOfTermLoanPrincipal" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusiness1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" xlink:to="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeases1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtIssuanceCostsPolicyTextBlock" xlink:label="engn_DebtIssuanceCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PatentCostsPolicyPolicyTextBlock" xlink:label="engn_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" xlink:label="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="engn_DebtIssuanceCostsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="engn_PatentCostsPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" xlink:label="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" xlink:label="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" xlink:label="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DescriptionOfBusinessTable" xlink:label="engn_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DescriptionOfBusinessLineItems" xlink:label="engn_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PrivatePlacementWarrantsMember" xlink:label="engn_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OldEngenesShareOptionHoldersMember" xlink:label="engn_OldEngenesShareOptionHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UnderwrittenPublicOfferingMember" xlink:label="engn_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="engn_DescriptionOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_PrivatePlacementWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_OldEngenesShareOptionHoldersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessTable" xlink:to="engn_DescriptionOfBusinessLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_UnderwrittenPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="engn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="engn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:label="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" xlink:label="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ResearchAndDevelopmentInvestmentTaxCredits" xlink:label="engn_ResearchAndDevelopmentInvestmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="engn_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="engn_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_ResearchAndDevelopmentInvestmentTaxCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LabEquipmentMember" xlink:label="engn_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:label="engn_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="engn_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="engn_PropertyPlantAndEquipmentEstimatedUsefulLive" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShortTermMarketableSecuritiesMember" xlink:label="engn_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LongTermMarketableSecuritiesMember" xlink:label="engn_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="engn_ShortTermMarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="engn_LongTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CashEquivalentsAndShortTermInvestmentsMember" xlink:label="engn_CashEquivalentsAndShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="engn_CashEquivalentsAndShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_LongTermDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NumberOfSecuritiesHeld" xlink:label="engn_NumberOfSecuritiesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtSecuritiesUnrealizedLosses" xlink:label="engn_DebtSecuritiesUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedInterestReceivableWrittenOff" xlink:label="engn_AccruedInterestReceivableWrittenOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="engn_NumberOfSecuritiesHeld" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="engn_DebtSecuritiesUnrealizedLosses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="engn_AccruedInterestReceivableWrittenOff" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="engn_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedFinancingCosts" xlink:label="engn_AccruedFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="engn_AccruedResearchAndDevelopmentExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="engn_AccruedFinancingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementTable" xlink:label="engn_LicenseAgreementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PhaseIClinicalTrialMember" xlink:label="engn_PhaseIClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UpfrontFees" xlink:label="engn_UpfrontFees"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PhaseIiClinicalTrialMember" xlink:label="engn_PhaseIiClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MilestoneProductPayment" xlink:label="engn_MilestoneProductPayment"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOnAssigningLicenseToThirdParty" xlink:label="engn_PaymentOnAssigningLicenseToThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AnnualMaintenanceFeeUnderLicenseAgreement" xlink:label="engn_AnnualMaintenanceFeeUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ManufacturingPaymentFee" xlink:label="engn_ManufacturingPaymentFee"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_PhaseIClinicalTrialMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_UpfrontFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" xlink:to="engn_LicenseAgreementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_PhaseIiClinicalTrialMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="us-gaap_CostMaintenance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementTable" xlink:to="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_MilestoneProductPayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_PaymentOnAssigningLicenseToThirdParty" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_AnnualMaintenanceFeeUnderLicenseAgreement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_ManufacturingPaymentFee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementsMember" xlink:label="engn_LoanAndSecurityAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_HerculesWarrantsMember" xlink:label="engn_HerculesWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WallStreetJournalMember" xlink:label="engn_WallStreetJournalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementMember" xlink:label="engn_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TermLoanMember" xlink:label="engn_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_HerculesCapitalMember" xlink:label="engn_HerculesCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmendedLoanAgreementMember" xlink:label="engn_AmendedLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheOneAdvanceMember" xlink:label="engn_TrancheOneAdvanceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PriorLoanAgreementMember" xlink:label="engn_PriorLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheThreeAdvanceMember" xlink:label="engn_TrancheThreeAdvanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AppliedToRefinanceOfAmountOutstandingMember" xlink:label="engn_AppliedToRefinanceOfAmountOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheTwoToTrancheThreeMember" xlink:label="engn_TrancheTwoToTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" xlink:label="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IfInterimMilestoneAchievedAndNoDefaultMember" xlink:label="engn_IfInterimMilestoneAchievedAndNoDefaultMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AdvanceOnLoanAllocatedToWarrants" xlink:label="engn_AdvanceOnLoanAllocatedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PeriodWithinLoanDisbursementsToBeMade" xlink:label="engn_PeriodWithinLoanDisbursementsToBeMade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfFacilityChargeOnAmountBorrowed" xlink:label="engn_PercentageOfFacilityChargeOnAmountBorrowed"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EndOfTermFeePercentage" xlink:label="engn_EndOfTermFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EndOfTermCharge" xlink:label="engn_EndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaidInKindInterestPercentage" xlink:label="engn_PaidInKindInterestPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAmortizationDate" xlink:label="engn_LoanAmortizationDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" xlink:label="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" xlink:label="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfCommitmentAmount" xlink:label="engn_PercentageOfCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommitmentAmount" xlink:label="engn_CommitmentAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_LoanAndSecurityAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="engn_HerculesWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="engn_WallStreetJournalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="engn_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="engn_HerculesCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_AmendedLoanAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheOneAdvanceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_PriorLoanAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheThreeAdvanceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_AppliedToRefinanceOfAmountOutstandingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheTwoToTrancheThreeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_IfInterimMilestoneAchievedAndNoDefaultMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_AdvanceOnLoanAllocatedToWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PeriodWithinLoanDisbursementsToBeMade" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfFacilityChargeOnAmountBorrowed" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_EndOfTermFeePercentage" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_EndOfTermCharge" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PaidInKindInterestPercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_LoanAmortizationDate" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfCommitmentAmount" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_CommitmentAmount" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TermLoanMember" xlink:label="engn_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtInstrumentAccruedInterest" xlink:label="engn_DebtInstrumentAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_DebtInstrumentAccruedInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementMember" xlink:label="engn_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmendedLoanAgreementMember" xlink:label="engn_AmendedLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerAxis" xlink:label="engn_AcquirerAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerDomain" xlink:label="engn_AcquirerDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FEACMember" xlink:label="engn_FEACMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:label="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:label="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OpenMarketSaleAgreementMember" xlink:label="engn_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantsAndRightsOutstandingMaturityPeriod" xlink:label="engn_WarrantsAndRightsOutstandingMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DateOfClosedPrivatePlacement" xlink:label="engn_DateOfClosedPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MaximumAmountOfCommonSharesToBeSold" xlink:label="engn_MaximumAmountOfCommonSharesToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfMaximumCommissionPercentageOfSharesSold" xlink:label="engn_PaymentOfMaximumCommissionPercentageOfSharesSold"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_AmendedLoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_AcquirerAxis" xlink:to="engn_AcquirerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="engn_AcquirerDomain" xlink:to="engn_FEACMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="engn_AcquirerAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_OpenMarketSaleAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_WarrantsAndRightsOutstandingMaturityPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_DateOfClosedPrivatePlacement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_MaximumAmountOfCommonSharesToBeSold" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_PaymentOfMaximumCommissionPercentageOfSharesSold" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CeoTransitionAgreementMember" xlink:label="engn_CeoTransitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TwoZeroTwoThreePlanMember" xlink:label="engn_TwoZeroTwoThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FormerChiefExecutiveOfficerMember" xlink:label="engn_FormerChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SeveranceAgreementMember" xlink:label="engn_SeveranceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InducementGrantsMember" xlink:label="engn_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EvergreenProvisionMember" xlink:label="engn_EvergreenProvisionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" xlink:label="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommonSharesPercentage" xlink:label="engn_CommonSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" xlink:label="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmountOfMonthlyFeeForConsultingPeriod" xlink:label="engn_AmountOfMonthlyFeeForConsultingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InitialConsultingPeriod" xlink:label="engn_InitialConsultingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TransitionServicesForConsultingFeePerHour" xlink:label="engn_TransitionServicesForConsultingFeePerHour"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" xlink:label="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" xlink:label="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_CeoTransitionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_TwoZeroTwoThreePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="engn_FormerChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_SeveranceAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_InducementGrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_EvergreenProvisionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_CommonSharesPercentage" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_AmountOfMonthlyFeeForConsultingPeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_InitialConsultingPeriod" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_TransitionServicesForConsultingFeePerHour" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" xlink:label="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantToPurchaseCommonStockMember" xlink:label="engn_WarrantToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" xlink:label="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" xlink:label="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" xlink:label="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="engn_WarrantToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsFinancingCosts" xlink:label="engn_DeferredTaxAssetsFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="engn_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsNotePayable" xlink:label="engn_DeferredTaxAssetsNotePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="engn_DeferredTaxAssetsFinancingCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="engn_DeferredTaxAssetsOperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="engn_DeferredTaxAssetsNotePayable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NetOperatingLossCarryforwardsExpirationYear" xlink:label="engn_NetOperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTaxCredit" xlink:label="us-gaap_InvestmentTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsExpirationYear" xlink:label="engn_InvestmentTaxCreditsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CapitalLossCarryforward" xlink:label="engn_CapitalLossCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="engn_ScientificResearchAndExperimentalDevelopmentExpenditures"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_NetOperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_InvestmentTaxCredit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_InvestmentTaxCreditsExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_CapitalLossCarryforward" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_ScientificResearchAndExperimentalDevelopmentExpenditures" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AreaOfSpace" xlink:label="engn_AreaOfSpace"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OfficeSpaceMember" xlink:label="engn_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OperatingLeaseCommencementPeriod" xlink:label="engn_OperatingLeaseCommencementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NewLaboratoryAndOfficeSpaceMember" xlink:label="engn_NewLaboratoryAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AggregateAmountOfBaseRentalPayments" xlink:label="engn_AggregateAmountOfBaseRentalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LeaseExpirationMonthAndYear" xlink:label="engn_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InitialAnnualBaseRentPerSquareFoot" xlink:label="engn_InitialAnnualBaseRentPerSquareFoot"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfIncreaseInAnnualBaseRent" xlink:label="engn_PercentageOfIncreaseInAnnualBaseRent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_AreaOfSpace" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="engn_OfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_OperatingLeaseCommencementPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="engn_NewLaboratoryAndOfficeSpaceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_AggregateAmountOfBaseRentalPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_LeaseExpirationMonthAndYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_InitialAnnualBaseRentPerSquareFoot" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_PercentageOfIncreaseInAnnualBaseRent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ChemistryManufacturingAndControlsMember" xlink:label="engn_ChemistryManufacturingAndControlsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ClinicalOperationsMember" xlink:label="engn_ClinicalOperationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OtherResearchAndDevelopmentExpensesMember" xlink:label="engn_OtherResearchAndDevelopmentExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" xlink:label="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockBasedCompensationMember" xlink:label="engn_StockBasedCompensationMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_ChemistryManufacturingAndControlsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_ClinicalOperationsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_OtherResearchAndDevelopmentExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_StockBasedCompensationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SubscriptionAgreementsMember" xlink:label="engn_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfSharesOwnedByShareholders" xlink:label="engn_PercentageOfSharesOwnedByShareholders"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TwoThousandTwentyFourPipeInvestorsMember" xlink:label="engn_TwoThousandTwentyFourPipeInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_SubscriptionAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="engn_PercentageOfSharesOwnedByShareholders" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_TwoThousandTwentyFourPipeInvestorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PrefundedWarrantMember" xlink:label="engn_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UnderwrittenPublicOfferingMember" xlink:label="engn_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" xlink:label="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="engn_PrefundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_UnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable" xlink:label="dei_EntityListingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntityListingsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressCountry" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestments" xlink:label="us-gaap_RestrictedInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsReceivable" xlink:label="engn_InvestmentTaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="engn_InvestmentTaxCreditsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FebruaryPipeFinancingMember" xlink:label="engn_FebruaryPipeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OctoberPipeFinancingMember" xlink:label="engn_OctoberPipeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" xlink:label="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="engn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="engn_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_FebruaryPipeFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_OctoberPipeFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodValueWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DescriptionOfBusinessLineItems" xlink:label="engn_DescriptionOfBusinessLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DescriptionOfBusinessTable" xlink:label="engn_DescriptionOfBusinessTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PrivatePlacementWarrantsMember" xlink:label="engn_PrivatePlacementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OldEngenesShareOptionHoldersMember" xlink:label="engn_OldEngenesShareOptionHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UnderwrittenPublicOfferingMember" xlink:label="engn_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="engn_DescriptionOfBusinessTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="engn_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_PrivatePlacementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="engn_DescriptionOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_OldEngenesShareOptionHoldersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_DescriptionOfBusinessLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="engn_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="engn_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" xlink:label="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" xlink:label="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ResearchAndDevelopmentInvestmentTaxCredits" xlink:label="engn_ResearchAndDevelopmentInvestmentTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202307Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="engn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="engn_ResearchAndDevelopmentInvestmentTaxCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LabEquipmentMember" xlink:label="engn_LabEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PropertyPlantAndEquipmentEstimatedUsefulLive" xlink:label="engn_PropertyPlantAndEquipmentEstimatedUsefulLive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="engn_LabEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="engn_PropertyPlantAndEquipmentEstimatedUsefulLive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShortTermMarketableSecuritiesMember" xlink:label="engn_ShortTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LongTermMarketableSecuritiesMember" xlink:label="engn_LongTermMarketableSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="engn_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="engn_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CashEquivalentsAndShortTermInvestmentsMember" xlink:label="engn_CashEquivalentsAndShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="engn_CashEquivalentsAndShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NumberOfSecuritiesHeld" xlink:label="engn_NumberOfSecuritiesHeld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtSecuritiesUnrealizedLosses" xlink:label="engn_DebtSecuritiesUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedInterestReceivableWrittenOff" xlink:label="engn_AccruedInterestReceivableWrittenOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="engn_NumberOfSecuritiesHeld" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="engn_DebtSecuritiesUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="engn_AccruedInterestReceivableWrittenOff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:label="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LicenseAgreementTable" xlink:label="engn_LicenseAgreementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PhaseIClinicalTrialMember" xlink:label="engn_PhaseIClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UpfrontFees" xlink:label="engn_UpfrontFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PhaseIiClinicalTrialMember" xlink:label="engn_PhaseIiClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MilestoneProductPayment" xlink:label="engn_MilestoneProductPayment"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOnAssigningLicenseToThirdParty" xlink:label="engn_PaymentOnAssigningLicenseToThirdParty"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AnnualMaintenanceFeeUnderLicenseAgreement" xlink:label="engn_AnnualMaintenanceFeeUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ManufacturingPaymentFee" xlink:label="engn_ManufacturingPaymentFee"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_LicenseAgreementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="engn_LicenseAgreementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_PhaseIClinicalTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_UpfrontFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="engn_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_PhaseIiClinicalTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="us-gaap_CostMaintenance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_MilestoneProductPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_PaymentOnAssigningLicenseToThirdParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_AnnualMaintenanceFeeUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" xlink:to="engn_ManufacturingPaymentFee" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementsMember" xlink:label="engn_LoanAndSecurityAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_HerculesWarrantsMember" xlink:label="engn_HerculesWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WallStreetJournalMember" xlink:label="engn_WallStreetJournalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementMember" xlink:label="engn_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TermLoanMember" xlink:label="engn_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_HerculesCapitalMember" xlink:label="engn_HerculesCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmendedLoanAgreementMember" xlink:label="engn_AmendedLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheOneAdvanceMember" xlink:label="engn_TrancheOneAdvanceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PriorLoanAgreementMember" xlink:label="engn_PriorLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheThreeAdvanceMember" xlink:label="engn_TrancheThreeAdvanceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AppliedToRefinanceOfAmountOutstandingMember" xlink:label="engn_AppliedToRefinanceOfAmountOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" xlink:label="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheTwoToTrancheThreeMember" xlink:label="engn_TrancheTwoToTrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" xlink:label="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" xlink:label="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IfInterimMilestoneAchievedAndNoDefaultMember" xlink:label="engn_IfInterimMilestoneAchievedAndNoDefaultMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AdvanceOnLoanAllocatedToWarrants" xlink:label="engn_AdvanceOnLoanAllocatedToWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PeriodWithinLoanDisbursementsToBeMade" xlink:label="engn_PeriodWithinLoanDisbursementsToBeMade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfFacilityChargeOnAmountBorrowed" xlink:label="engn_PercentageOfFacilityChargeOnAmountBorrowed"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EndOfTermFeePercentage" xlink:label="engn_EndOfTermFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EndOfTermCharge" xlink:label="engn_EndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaidInKindInterestPercentage" xlink:label="engn_PaidInKindInterestPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAmortizationDate" xlink:label="engn_LoanAmortizationDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" xlink:label="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" xlink:label="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfCommitmentAmount" xlink:label="engn_PercentageOfCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommitmentAmount" xlink:label="engn_CommitmentAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_LoanAndSecurityAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="engn_HerculesWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="engn_WallStreetJournalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="engn_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="engn_HerculesCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_AmendedLoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheOneAdvanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_PriorLoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheThreeAdvanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_AppliedToRefinanceOfAmountOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheTwoToTrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_IfInterimMilestoneAchievedAndNoDefaultMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_AdvanceOnLoanAllocatedToWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PeriodWithinLoanDisbursementsToBeMade" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfFacilityChargeOnAmountBorrowed" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_EndOfTermFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_EndOfTermCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PaidInKindInterestPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_LoanAmortizationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_PercentageOfCommitmentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_CommitmentAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TermLoanMember" xlink:label="engn_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DebtInstrumentAccruedInterest" xlink:label="engn_DebtInstrumentAccruedInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="engn_DebtInstrumentAccruedInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LoanAndSecurityAgreementMember" xlink:label="engn_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="engn_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmendedLoanAgreementMember" xlink:label="engn_AmendedLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerAxis" xlink:label="engn_AcquirerAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerDomain" xlink:label="engn_AcquirerDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AcquirerDomain" xlink:label="engn_AcquirerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FEACMember" xlink:label="engn_FEACMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:label="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" xlink:label="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OpenMarketSaleAgreementMember" xlink:label="engn_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="us-gaap_CommonStockDividendsPerShareCashPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantsAndRightsOutstandingMaturityPeriod" xlink:label="engn_WarrantsAndRightsOutstandingMaturityPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DateOfClosedPrivatePlacement" xlink:label="engn_DateOfClosedPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MaximumAmountOfCommonSharesToBeSold" xlink:label="engn_MaximumAmountOfCommonSharesToBeSold"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfMaximumCommissionPercentageOfSharesSold" xlink:label="engn_PaymentOfMaximumCommissionPercentageOfSharesSold"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_AmendedLoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="engn_AcquirerAxis" xlink:to="engn_AcquirerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="engn_AcquirerAxis" xlink:to="engn_AcquirerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="engn_AcquirerDomain" xlink:to="engn_FEACMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="engn_AcquirerAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNoParValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_OpenMarketSaleAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareCashPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_WarrantsAndRightsOutstandingMaturityPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_DateOfClosedPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_MaximumAmountOfCommonSharesToBeSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="engn_PaymentOfMaximumCommissionPercentageOfSharesSold" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CeoTransitionAgreementMember" xlink:label="engn_CeoTransitionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TwoZeroTwoThreePlanMember" xlink:label="engn_TwoZeroTwoThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_FormerChiefExecutiveOfficerMember" xlink:label="engn_FormerChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SeveranceAgreementMember" xlink:label="engn_SeveranceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InducementGrantsMember" xlink:label="engn_InducementGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EvergreenProvisionMember" xlink:label="engn_EvergreenProvisionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" xlink:label="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CommonSharesPercentage" xlink:label="engn_CommonSharesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" xlink:label="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AmountOfMonthlyFeeForConsultingPeriod" xlink:label="engn_AmountOfMonthlyFeeForConsultingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InitialConsultingPeriod" xlink:label="engn_InitialConsultingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TransitionServicesForConsultingFeePerHour" xlink:label="engn_TransitionServicesForConsultingFeePerHour"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" xlink:label="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" xlink:label="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_CeoTransitionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_TwoZeroTwoThreePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="engn_FormerChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_SeveranceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_InducementGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_EvergreenProvisionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockNoParValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_CommonSharesPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_AmountOfMonthlyFeeForConsultingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_InitialConsultingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_TransitionServicesForConsultingFeePerHour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" xlink:label="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" xlink:label="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WarrantToPurchaseCommonStockMember" xlink:label="engn_WarrantToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" xlink:label="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" xlink:label="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="engn_WarrantToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" xlink:label="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CA" xlink:label="country_CA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NetOperatingLossCarryforwardsExpirationYear" xlink:label="engn_NetOperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTaxCredit" xlink:label="us-gaap_InvestmentTaxCredit"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsExpirationYear" xlink:label="engn_InvestmentTaxCreditsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_CapitalLossCarryforward" xlink:label="engn_CapitalLossCarryforward"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ScientificResearchAndExperimentalDevelopmentExpenditures" xlink:label="engn_ScientificResearchAndExperimentalDevelopmentExpenditures"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_NetOperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_InvestmentTaxCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_InvestmentTaxCreditsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_CapitalLossCarryforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="engn_ScientificResearchAndExperimentalDevelopmentExpenditures" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AreaOfSpace" xlink:label="engn_AreaOfSpace"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OfficeSpaceMember" xlink:label="engn_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OperatingLeaseCommencementPeriod" xlink:label="engn_OperatingLeaseCommencementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NewLaboratoryAndOfficeSpaceMember" xlink:label="engn_NewLaboratoryAndOfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AggregateAmountOfBaseRentalPayments" xlink:label="engn_AggregateAmountOfBaseRentalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_LeaseExpirationMonthAndYear" xlink:label="engn_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InitialAnnualBaseRentPerSquareFoot" xlink:label="engn_InitialAnnualBaseRentPerSquareFoot"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfIncreaseInAnnualBaseRent" xlink:label="engn_PercentageOfIncreaseInAnnualBaseRent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_AreaOfSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="engn_OfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_OperatingLeaseCommencementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="engn_NewLaboratoryAndOfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_AggregateAmountOfBaseRentalPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_InitialAnnualBaseRentPerSquareFoot" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="engn_PercentageOfIncreaseInAnnualBaseRent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ChemistryManufacturingAndControlsMember" xlink:label="engn_ChemistryManufacturingAndControlsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_ClinicalOperationsMember" xlink:label="engn_ClinicalOperationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_OtherResearchAndDevelopmentExpensesMember" xlink:label="engn_OtherResearchAndDevelopmentExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" xlink:label="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_StockBasedCompensationMember" xlink:label="engn_StockBasedCompensationMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_ChemistryManufacturingAndControlsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_ClinicalOperationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_OtherResearchAndDevelopmentExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="engn_StockBasedCompensationMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="us-gaap_AllOtherSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_SubscriptionAgreementsMember" xlink:label="engn_SubscriptionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfSharesOwnedByShareholders" xlink:label="engn_PercentageOfSharesOwnedByShareholders"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_TwoThousandTwentyFourPipeInvestorsMember" xlink:label="engn_TwoThousandTwentyFourPipeInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_SubscriptionAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="engn_PercentageOfSharesOwnedByShareholders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="engn_TwoThousandTwentyFourPipeInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PrefundedWarrantMember" xlink:label="engn_PrefundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_UnderwrittenPublicOfferingMember" xlink:label="engn_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" xlink:label="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="engn_PrefundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="engn_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_WallStreetJournalMember" xlink:label="engn_WallStreetJournalMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="engn_WallStreetJournalMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="engn_InvestmentTaxCreditsReceivable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedInvestments" xlink:label="us-gaap_RestrictedInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_InvestmentTaxCreditsReceivable" xlink:label="engn_InvestmentTaxCreditsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="engn_NonCashInterestExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="engn_RepaymentsOfTermLoanPrincipal" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="engn_NonCashLeaseExpenses" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" order="18" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="19" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="20" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="21" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" xlink:label="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" xlink:label="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" xlink:label="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NonCashInterestExpense" xlink:label="engn_NonCashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_RepaymentsOfTermLoanPrincipal" xlink:label="engn_RepaymentsOfTermLoanPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_NonCashLeaseExpenses" xlink:label="engn_NonCashLeaseExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" xlink:label="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="engn_AccruedResearchAndDevelopmentExpenseCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="engn_AccruedFinancingCosts" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="engn_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_AccruedFinancingCosts" xlink:label="engn_AccruedFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"/>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="engn_DeferredTaxAssetsFinancingCosts" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="engn_DeferredTaxAssetsOperatingLeaseLiability" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="engn_DeferredTaxAssetsNotePayable" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsFinancingCosts" xlink:label="engn_DeferredTaxAssetsFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="engn_DeferredTaxAssetsOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="engn-20251031.xsd#engn_DeferredTaxAssetsNotePayable" xlink:label="engn_DeferredTaxAssetsNotePayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" name="InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder" name="PercentageOfOutstandingCommonSharesOwnedByTheHolder" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ResearchAndDevelopmentInvestmentTaxCredits" name="ResearchAndDevelopmentInvestmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_FormerChiefExecutiveOfficerMember" name="FormerChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" name="IssuanceOfCommonSharesInConnectionWithPipeFinancingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" name="PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_PaymentOnAssigningLicenseToThirdParty" name="PaymentOnAssigningLicenseToThirdParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" name="EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_NewLaboratoryAndOfficeSpaceMember" name="NewLaboratoryAndOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AppliedToRefinanceOfAmountOutstandingMember" name="AppliedToRefinanceOfAmountOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" name="FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PrivatePlacementWarrantsMember" name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PercentageOfFacilityChargeOnAmountBorrowed" name="PercentageOfFacilityChargeOnAmountBorrowed" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_AcquirerAxis" name="AcquirerAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PatentCostsPolicyPolicyTextBlock" name="PatentCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_FEACMember" name="FEACMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_LicenseAgreementAndClinicalResearchOrganizationAbstract" name="LicenseAgreementAndClinicalResearchOrganizationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PaidInKindInterestPercentage" name="PaidInKindInterestPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PropertyPlantAndEquipmentEstimatedUsefulLive" name="PropertyPlantAndEquipmentEstimatedUsefulLive" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance" name="CommonStockCapitalSharesReservedForRemainingFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" name="IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" name="SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_UpfrontFees" name="UpfrontFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PhaseIiClinicalTrialMember" name="PhaseIiClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_EndOfTermCharge" name="EndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_MaximumAmountOfCommonSharesToBeSold" name="MaximumAmountOfCommonSharesToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_ScientificResearchAndExperimentalDevelopmentExpenditures" name="ScientificResearchAndExperimentalDevelopmentExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_OctoberPipeFinancingMember" name="OctoberPipeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AmendedLoanAgreementMember" name="AmendedLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_HerculesWarrantsMember" name="HerculesWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AccruedInterestReceivableWrittenOff" name="AccruedInterestReceivableWrittenOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_InitialConsultingPeriod" name="InitialConsultingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" name="SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_TrancheOneAdvanceMember" name="TrancheOneAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AdvanceOnLoanAllocatedToWarrants" name="AdvanceOnLoanAllocatedToWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk" name="ConcentrationRiskCreditRiskOffBalanceSheetRisk" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_ClinicalOperationsMember" name="ClinicalOperationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" name="PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_TwoThousandTwentyFourPipeInvestorsMember" name="TwoThousandTwentyFourPipeInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_NetOperatingLossCarryforwardsExpirationYear" name="NetOperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" name="PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" name="PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_EvergreenProvisionMember" name="EvergreenProvisionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_DescriptionOfBusinessTable" name="DescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" name="ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" name="TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_DebtInstrumentAccruedInterest" name="DebtInstrumentAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_TransitionServicesForConsultingFeePerHour" name="TransitionServicesForConsultingFeePerHour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember" name="RemainingSharesReservedForFutureIssuanceUnderESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" name="FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_CashEquivalentsAndShortTermInvestmentsMember" name="CashEquivalentsAndShortTermInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" name="PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_MilestoneProductPayment" name="MilestoneProductPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ChemistryManufacturingAndControlsMember" name="ChemistryManufacturingAndControlsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_ManufacturingPaymentFee" name="ManufacturingPaymentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_PercentageOfIncreaseInAnnualBaseRent" name="PercentageOfIncreaseInAnnualBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" name="MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_InducementGrantsMember" name="InducementGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_WarrantValueIssuedAsPartOfAmendedTermLoan" name="WarrantValueIssuedAsPartOfAmendedTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_CommonSharesPercentage" name="CommonSharesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_CapitalLossCarryforward" name="CapitalLossCarryforward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_FebruaryPipeFinancingMember" name="FebruaryPipeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" name="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_PriorLoanAgreementMember" name="PriorLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_NonCashLeaseExpenses" name="NonCashLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_NumberOfSecuritiesHeld" name="NumberOfSecuritiesHeld" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="engn_StockBasedCompensationMember" name="StockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" name="AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PhaseIClinicalTrialMember" name="PhaseIClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_InitialAnnualBaseRentPerSquareFoot" name="InitialAnnualBaseRentPerSquareFoot" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_LoanAndSecurityAgreementsMember" name="LoanAndSecurityAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" name="Personnel-RelatedExpensesExcludingStock-BasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AcquirerDomain" name="AcquirerDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AmountOfMonthlyFeeForConsultingPeriod" name="AmountOfMonthlyFeeForConsultingPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_OldEngenesShareOptionHoldersMember" name="OldEngenesShareOptionHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock" name="LicenseAgreementAndClinicalResearchOrganizationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_DeferredTaxAssetsFinancingCosts" name="DeferredTaxAssetsFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_PaymentOfMaximumCommissionPercentageOfSharesSold" name="PaymentOfMaximumCommissionPercentageOfSharesSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="engn_PercentageOfSharesOwnedByShareholders" name="PercentageOfSharesOwnedByShareholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_CeoTransitionAgreementMember" name="CeoTransitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AggregateAmountOfBaseRentalPayments" name="AggregateAmountOfBaseRentalPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_PercentageOfCommitmentAmount" name="PercentageOfCommitmentAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_LicenseAgreementAndClinicalResearchOrganizationLineItems" name="LicenseAgreementAndClinicalResearchOrganizationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" name="TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" name="GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_DescriptionOfBusinessLineItems" name="DescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_LongTermMarketableSecuritiesMember" name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_LicenseAgreementTable" name="LicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_DeferredTaxAssetsNotePayable" name="DeferredTaxAssetsNotePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_SeveranceAgreementMember" name="SeveranceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_LoanAmortizationDate" name="LoanAmortizationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_DebtIssuanceCostsPolicyTextBlock" name="DebtIssuanceCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_PeriodWithinLoanDisbursementsToBeMade" name="PeriodWithinLoanDisbursementsToBeMade" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_EndOfTermFeePercentage" name="EndOfTermFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AccruedFinancingCosts" name="AccruedFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_InvestmentTaxCreditsExpirationYear" name="InvestmentTaxCreditsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ShortTermMarketableSecuritiesMember" name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_RepaymentsOfTermLoanPrincipal" name="RepaymentsOfTermLoanPrincipal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_WarrantsAndRightsOutstandingMaturityPeriod" name="WarrantsAndRightsOutstandingMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_OtherResearchAndDevelopmentExpensesMember" name="OtherResearchAndDevelopmentExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" name="PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" name="ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_WarrantToPurchaseCommonStockMember" name="WarrantToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" name="IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_IncreaseDecreaseInInvestmentTaxCreditReceivable" name="IncreaseDecreaseInInvestmentTaxCreditReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_InvestmentTaxCreditsReceivable" name="InvestmentTaxCreditsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_TrancheTwoToTrancheThreeMember" name="TrancheTwoToTrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_AreaOfSpace" name="AreaOfSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="engn_AnnualMaintenanceFeeUnderLicenseAgreement" name="AnnualMaintenanceFeeUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_DateOfClosedPrivatePlacement" name="DateOfClosedPrivatePlacement" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_TwoZeroTwoThreePlanMember" name="TwoZeroTwoThreePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_IfInterimMilestoneAchievedAndNoDefaultMember" name="IfInterimMilestoneAchievedAndNoDefaultMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_DebtSecuritiesUnrealizedLosses" name="DebtSecuritiesUnrealizedLosses" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_TrancheThreeAdvanceMember" name="TrancheThreeAdvanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" name="IssuanceOfCommonSharesInConnectionWithPipeFinancingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_OperatingLeaseCommencementPeriod" name="OperatingLeaseCommencementPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="engn_WallStreetJournalMember" name="WallStreetJournalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" name="NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts" name="PaymentOfReverseRecapitalizationAndPipeFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_CommitmentAmount" name="CommitmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="engn_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" name="OctoberTwoThousandTwentyFourSubscriptionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PrefundedWarrantMember" name="PrefundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="engn_HerculesCapitalMember" name="HerculesCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" name="PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Dec. 18, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">enGene Holdings Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--10-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001980845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4868 Rue Levy, Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Saint-Laurent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H4R 2P1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">332-4888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,176,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,984,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the definitive proxy statement of enGene Holdings Inc. to be filed for its 2026 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of enGene Holdings Inc. (the Company) as of October 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Montreal, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENGNW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 50,152<span></span>
</td>
<td class="nump">$ 173,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities - short term</a></td>
<td class="nump">143,584<span></span>
</td>
<td class="nump">65,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted investments</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InvestmentTaxCreditsReceivable', window );">Investment tax credits receivable</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">6,649<span></span>
</td>
<td class="nump">8,626<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">201,391<span></span>
</td>
<td class="nump">247,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities - long term</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">59,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">7,716<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">221,468<span></span>
</td>
<td class="nump">311,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,688<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">15,275<span></span>
</td>
<td class="nump">12,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of note payable</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,979<span></span>
</td>
<td class="nump">14,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net of current portion</a></td>
<td class="nump">15,324<span></span>
</td>
<td class="nump">22,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities, Total</a></td>
<td class="nump">53,758<span></span>
</td>
<td class="nump">38,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value; unlimited shares authorized, 52,018,658 and 50,976,676 shares issued and outstanding as of October 31, 2025 and October 31, 2024, respectively.</a></td>
<td class="nump">513,281<span></span>
</td>
<td class="nump">509,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">27,349<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(888)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(372,032)<span></span>
</td>
<td class="num">(254,730)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholder's equity</a></td>
<td class="nump">167,710<span></span>
</td>
<td class="nump">272,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholder's equity</a></td>
<td class="nump">$ 221,468<span></span>
</td>
<td class="nump">$ 311,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_InvestmentTaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_InvestmentTaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock shares authorized unlimited</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">52,018,658<span></span>
</td>
<td class="nump">50,976,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">52,018,658<span></span>
</td>
<td class="nump">50,976,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 94,480<span></span>
</td>
<td class="nump">$ 38,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,685<span></span>
</td>
<td class="nump">23,982<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">123,165<span></span>
</td>
<td class="nump">62,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">123,165<span></span>
</td>
<td class="nump">62,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(9,426)<span></span>
</td>
<td class="num">(10,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses (income), net</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="num">(5,863)<span></span>
</td>
<td class="num">(7,136)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="nump">117,302<span></span>
</td>
<td class="nump">55,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (recovery of) income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">117,302<span></span>
</td>
<td class="nump">55,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (gain) loss on available-for-sale investments</a></td>
<td class="num">(531)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="nump">$ 116,771<span></span>
</td>
<td class="nump">$ 54,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common shares, basic</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common shares, diluted</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">51,119,479<span></span>
</td>
<td class="nump">37,782,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">51,119,479<span></span>
</td>
<td class="nump">37,782,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>February PIPE Financing</div></th>
<th class="th"><div>October PIPE Financing</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>February PIPE Financing</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>October PIPE Financing</div>
</th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Oct. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,197,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Oct. 31, 2023</a></td>
<td class="nump">$ 72,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,717<span></span>
</td>
<td class="num">$ (1,016)<span></span>
</td>
<td class="num">$ (199,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares', window );">Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">6,758,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue', window );">Issuance of common shares in connection with PIPE Financing, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,614<span></span>
</td>
<td class="nump">$ 56,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,614<span></span>
</td>
<td class="nump">$ 56,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants in connection with Amended Term Loan</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common shares upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common shares upon exercise of warrants</a></td>
<td class="nump">5,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Issuance of common shares upon cashless exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Issuance of common shares upon cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(55,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,142)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Oct. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,976,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 31, 2024</a></td>
<td class="nump">$ 272,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,950<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="num">(254,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,041,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">9,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(117,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,302)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Oct. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,018,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 31, 2025</a></td>
<td class="nump">$ 167,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,349<span></span>
</td>
<td class="num">$ (888)<span></span>
</td>
<td class="num">$ (372,032)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with pipe financing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares in connection with pipe financing value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (117,302)<span></span>
</td>
<td class="num">$ (55,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NonCashLeaseExpenses', window );">Non-cash lease expense</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on the disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities', window );">Net amortization of premiums (accretion of discounts) on marketable securities</a></td>
<td class="num">(3,067)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency losses (gains)</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">9,646<span></span>
</td>
<td class="nump">5,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_IncreaseDecreaseInInvestmentTaxCreditReceivable', window );">Investment tax credit receivable</a></td>
<td class="num">(595)<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,989<span></span>
</td>
<td class="num">(7,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,942<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,130<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">274<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(99,239)<span></span>
</td>
<td class="num">(48,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,485)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(160,843)<span></span>
</td>
<td class="num">(125,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">137,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(25,138)<span></span>
</td>
<td class="num">(125,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts', window );">Payment of Reverse Recapitalization and PIPE Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the February 2024 PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing', window );">Payments of issuance costs associated with the 2024 PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,386)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_RepaymentsOfTermLoanPrincipal', window );">Repayments of term loan principal</a></td>
<td class="num">(699)<span></span>
</td>
<td class="num">(9,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs associated with the term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(585)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">265,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(122,852)<span></span>
</td>
<td class="nump">91,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">173,004<span></span>
</td>
<td class="nump">81,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">50,152<span></span>
</td>
<td class="nump">173,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable', window );">Reverse Recapitalization and PIPE financing transaction costs included within accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_WarrantValueIssuedAsPartOfAmendedTermLoan', window );">Warrant value issued as part of Amended Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">6,352<span></span>
</td>
<td class="nump">$ 1,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accrued expenses and accounts payable</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_IncreaseDecreaseInInvestmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in investment tax credit receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_IncreaseDecreaseInInvestmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amortization of premiums accretion of discounts on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of reverse recapitalization and pipe financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of issuance costs associated with the pipe financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_RepaymentsOfTermLoanPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of term loan principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_RepaymentsOfTermLoanPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization and pipe financing transaction costs included within accrued expenses and accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_WarrantValueIssuedAsPartOfAmendedTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant value issued as part of amended term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_WarrantValueIssuedAsPartOfAmendedTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (117,302)<span></span>
</td>
<td class="num">$ (55,142)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented cybersecurity risk management procedures, in accordance with our risk profile and business size, that are designed to identify, assess, and mitigate risks from current and emerging cybersecurity threats. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity procedures, which are informed by the National Institute of Standards and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Technology cybersecurity framework, are supported by a third-party managed services provider that assists us in managing our IT systems.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks, and other related breaches.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity procedures are comprised of a variety of tools designed to protect our data and information technology systems, including but not limited to endpoint protection and network security measures, that are supported by our third-party service providers. We also have a process to require our employees to undergo cybersecurity awareness training. Further, we have implemented a process to review risks to our Company in connection with certain third-party providers and vendors, which involves assessments through vendor questionnaires, as appropriate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party IT service providers and vendors have from time to time experienced threats that could affect our information or systems. For more information, see, &#8220;Risk Factors,&#8221; in this Annual Report.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Vice President,  IT reports to our Chief Financial Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our Board of Directors is informed oversight of our risk management process.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors does not have a standing risk management committee, and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is responsible for overseeing the Company&#8217;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> responsible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for managing cybersecurity risks.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our Vice President,  IT reports to our Chief Financial Officer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our Board of Directors is informed oversight of our risk management process.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors does not have a standing risk management committee, and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.</span></span></span></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is responsible for overseeing the Company&#8217;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> responsible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for managing cybersecurity risks.</span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is responsible for overseeing the Company&#8217;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> responsible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for managing cybersecurity risks.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our Board of Directors is informed oversight of our risk management process.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors does not have a standing risk management committee, and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.</span></span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors does not have a standing risk management committee, and</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is responsible for overseeing the Company&#8217;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.</span></span></span><span style="font-size:10pt;font-family:Times New Roman;"></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our Board of Directors is informed oversight of our risk management process.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text"><p id="notes_to_the_financial_statements" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Description of Business</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enGene Holdings Inc., together with its consolidated subsidiaries enGene Inc. and enGene USA, Inc. (&#8220;enGene&#8221; or the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on developing genetic medicines to improve the lives of patients, and its head office is located in Montreal, Quebec, Canada. The Company is developing non-viral genetic medicines based on its novel and proprietary dually derived chitosan, or &#8220;DDX&#8221;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Merger with Forbion European Acquisition Corp.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forbion European Acquisition Corporation (&#8220;FEAC&#8221;) was a special purpose acquisition company (&#8220;SPAC&#8221;) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the &#8220;Closing Date&#8221;), the Company, FEAC, and enGene Inc., consummated the merger (the &#8220;Reverse Recapitalization&#8221;) pursuant to a business combination agreement, dated as of May 16, 2023 (the &#8220;Merger Agreement&#8221;). As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its Common Shares and warrants on the Nasdaq Capital Market under the symbols &#8220;ENGN&#8221; and &#8220;ENGNW,&#8221; respectively, commencing trading on November 1, 2023, with enGene Inc., a subsidiary of the Company, continuing the existing business operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for developing non-viral genetic medicines and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred a net loss of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and negative cash flows from operating activities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended October 31, 2025, and, as of that date, has an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">372.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.  The Company has not yet commercialized any product candidates and does not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. The Company will need additional funding to support its continuing operations and pursue its development strategy. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any revenues and has financed its liquidity needs primarily through PIPE  financings, offering debt, and issuance of redeemable convertible preferred shares and warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In November 2025, the Company closed a public offering of its Common Shares and pre-funded warrants to purchase Common Shares which resulted in aggregate gross proceeds to the Company of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting the underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of outstanding loans.  As of the issuance date of these consolidated financial statements, the Company expects that its existing cash and cash equivalents as of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8217;s&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are expressed in US dollars. The consolidated financial statements have been prepared on a historical cost basis, except for items that are required to be accounted for at fair value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the accrual of research and development expenses, share-based payments and the recoverability of investment tax credits receivable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considered the Company&#8217;s organizational structure and the information regularly reviewed and evaluated by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) when deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. Based on this factor, the Company determined that it operates and manages its business as a single operating segment. As of October 31, 2025, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in long-lived assets held in the United States and in Canada, respectively. As of October 31, 2024, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in long-lived assets held in the United States and in Canada, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk of Concentrations of Credit and Off-Balance Sheet Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. Management believes that the Company is not currently exposed to significant credit risk as the Company&#8217;s deposits were held in custody at third-party financial institutions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's investment policy limits investments to certain types of securities issued by the U.S. Government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Consolidated Balance Sheets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> off-balance sheet concentrations of credit risk</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party CMOs and CRO with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company&#8217;s cash and cash equivalents include bank balances, demand deposits and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other short-term, highly liquid investments. The fair value of cash and cash equivalents approximate the amortized cost. The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents as of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents as of October 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 17, Subsequent Events, for additional discussion on the Company&#8217;s cash position following the closing of an underwritten public offering in November 2025.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's marketable securities are maintained by investment managers and consist of money market funds, U.S. government agency securities and treasuries. If the remaining contractual maturity is within one year from the balance sheet date, the marketable securities are classified as current and otherwise, they are classified as non-current assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in marketable securities is classified as available-for-sale and is reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders' equity in other comprehensive loss. Premium or discounts from par value are amortized to investment income over the life of the underlying investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically evaluates the need for an allowance for credit losses. The evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of the asset, an estimate of expected credit losses is made. The Company records credit losses in the consolidated statements of operations and comprehensive loss as a credit loss expense within other income, net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable related to the Company's available-for-sale securities is presented within prepaids and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivable associated with its marketable securities.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are comprised mainly of research and development equipment, computer hardware and software, office furniture and equipment, and leasehold improvements. Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if applicable. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:56.6%;box-sizing:content-box;"></td>
           <td style="width:2.48%;box-sizing:content-box;"></td>
           <td style="width:40.92%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or useful life</span></span></p></td>
          </tr>
         </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal.</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected undiscounted cash flows are less than the carrying value of the assets, then the assets are considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a right-of-use (&#8220;ROU&#8221;) asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.269%;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.13%;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, financial instruments measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable Securities, and Note 3, Fair Value Measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:12.13%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with the issuance of debt not accounted for using the fair value option as debt issuance costs. Debt issuance costs are recorded as a direct reduction of the carrying amount of the associated debt on the Company&#8217;s consolidated balance sheets and amortized as interest expense on the Company&#8217;s consolidated statements of operations and comprehensive loss using the effective interest method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are comprised primarily of costs incurred for our drug discovery efforts and development of our product candidates. These expenses include salaries, employee benefits, and share-based compensation expense for our research and development personnel, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside CROs and consultants to conduct research and development activities including costs of clinical trials and manufacturing, and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management estimates the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#8217;s consolidated statements of operations.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an incentive equity plan (the &#8220;2023 Incentive Equity Plan&#8221; or the &#8220;2023 Plan&#8221;), whereby employees render services as consideration for equity instruments.  The 2023 Plan was adopted on October 31, 2023 upon the completion of the Reverse Recapitalization and superseded enGene Inc.&#8217;s employee stock option plan (the &#8220;ESOP&#8221;) and equity incentive plan (the &#8220;EIP&#8221;) (collectively, the &#8220;Old Plans&#8221;). The 2023 Plan was amended and restated in May 2024 and is now the Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which supersedes all prior plans. The Company measures all share-based awards granted to employees, officers, directors and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of its share-based awards as they occur. The Company issues share-based awards with service-based vesting conditions and awards with both performance and service-based vesting conditions. For share-based awards with service-based vesting conditions, the Company records the expense using the straight-line method including when such awards have graded vesting. For share-based awards with both performance and service-based vesting conditions, the Company records the expense using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management&#8217;s best estimate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company&#8217;s common shares, expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s expected dividend yield. The Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies with similar characteristics including market capitalization, stage of development, therapeutic focus and certain financial measures. The expected volatility has been determined using an average of the historical volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method for awards with only service based vesting conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on participant behavior. For awards with both performance and service based vesting conditions, the expected term has been determined using management&#8217;s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers.  The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the consummation of the Reverse Recapitalization, because there was no public market for the Company&#8217;s common shares, the Board of Directors has determined the fair value of the Company&#8217;s common shares based on third-party valuations of the Company&#8217;s common shares. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#8217;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering (&#8220;IPO&#8221;), or sale of the Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. In addition, the Company&#8217;s Board of Directors considered various objective and subjective factors to determine the fair value of the Company&#8217;s common shares as of each grant date, including the prices at which enGene Inc. sold shares of redeemable convertible preferred shares and the superior rights and preferences of the redeemable convertible preferred shares relative to its common shares at the time of each grant, external market conditions, the progress of the Company&#8217;s research and development programs, the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company&#8217;s common shares and redeemable convertible preferred shares, among other factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if the Company had used different assumptions or estimates or if there are changes to the unobservable inputs, the fair value of its common shares and share-based compensation expense could have been materially different.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to becoming a publicly traded Company upon the consummation of the Reverse Recapitalization, the fair value of common shares underlying equity awards is based on the market price of the Company&#8217;s common stock at the date of the grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s share-based compensation expense is recorded in general and administrative and research and development expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax basis of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; deficit that result from transactions and economic events other than those with shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if dilutive, the weighted-average number of potential shares of common shares. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and warrants. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted net loss per share attributable to common shareholders is generally the same as basic net loss per share attributable to common shareholders because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. See Note 11, Net Loss per Share, for further detail.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Transaction Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that were directly associated with PIPE or public financings as deferred transaction costs until such transaction was consummated. After the consummation of such transaction, these costs are recorded within equity as a reduction of the common share and warrants value within additional paid in capital. Costs are allocated to each equity instrument on a relative fair value basis for transactions that include both instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Assistance Programs for Research and Development Expenditures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (&#8220;CCPC&#8221;) on eligible scientific research and experimental development (&#8220;SR&amp;ED&#8221;) expenditures through September 2023, at which time the Company lost its status as a CCPC. In addition, effective for fiscal 2023, the Company&#8217;s maximum refundable tax credits were reduced due to the Company&#8217;s taxable capital, as defined in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Canada), which reduction in credits has been recorded in the fourth quarter.  The Canadian federal government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#8217;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. Following the loss of CCPC status, the Company&#8217;s SR&amp;ED tax credits will be earned at a lower rate and some will no longer be refundable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts received or receivable resulting from government assistance programs, including investment tax credits for SR&amp;ED, are recognized when there is reasonable assurance that the amount will be received, and all attached conditions will be complied with. Reimbursements of eligible SR&amp;ED expenditures pursuant to government assistance programs are received in cash. The amounts</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receivable are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. During the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, as a reduction of research and development expense associated with SR&amp;ED investment tax credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-07, Segment Reporting (Topic 280: Improvements to Reportable Segment Disclosures) (&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this accounting standard during the year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and there was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impact on the Company&#8217;s reportable segments identified. Required disclosures have been included in Note 15 "Segment Reporting".</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements &#8211; Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  which removes references to project stages and clarified when the Company is required to begin capitalizing eligible costs. The new guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. ASU 2025-06 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as further clarified by ASU 2025-01, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  issued in January, 2025, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. This ASU is effective for annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740) - Improvements to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which improves transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU No 2023-09 is effective for the Company's annual financial statements for the year ending October 31, 2026. The Company is currently evaluating the impact of the guidance on the financial statements and related disclosures.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which amends GAAP to reflect updates and simplifications to certain disclosure and presentation requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 is effective on the date on which the SEC's removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective but will not be effective if the SEC has not removed the applicable disclosure requirements by June 30, 2027. Early adoption is prohibited. The Company is currently evaluating the impact of the amendments on its financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025:</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.187%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable<br/>Inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Short term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,117</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,117</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Long term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,254</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,366</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of October 31, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.101%;box-sizing:content-box;"></td>
         <td style="width:2.214%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.604000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.107%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.903000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.129%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.154%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.129%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.659%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable<br/>Inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,236</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,236</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Short term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,574</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,574</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,754</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,754</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Long term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,558</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,609</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p id="bookmark_id_4d34og8" style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025 and 2024, the Company classified its government agency </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arketable securities as Level 2 within the valuation hierarchy. The Company estimates the fair value of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly to estimate fair value. These inputs include market pricing based on real time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers or reclassifications between fair value measure levels of assets or liabilities. The carrying values of all other financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Marketable securities</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests in money market funds, U.S. Treasury and government agency debt securities; all marketable securities are classified as available-for-sale and carried at fair value, with unrealized changes in fair value reflected in the other comprehensive income (loss) in the consolidated statements of shareholders' equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the marketable securities consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.866%;box-sizing:content-box;"></td>
         <td style="width:12.482%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.902000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.842%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.482000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents and short-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,090</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,366</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177,098</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government securities that had maturities of one to two years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which, with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were in unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company does not intend to sell its investments before recovery of the amortized cost basis of its debt securities at maturity and no allowance for credit losses was recorded as of October 31, 2025 because the decline in fair value below amortized cost is not related to credit losses. Securities are evaluated at the end of each reporting period. The unrealized losses on U.S. Treasury and Government agency securities range fr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">om </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their amortized cos</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024, the marketable securities consisted of the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:45.851%;box-sizing:content-box;"></td>
         <td style="width:5.972%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.467%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.588%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.677%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.773%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.677%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.786000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents and short-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,832</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,814</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,714</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,667</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,931</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,972</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,898</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,903</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">418</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for certain government agency securities that had maturities of one to two years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which were in an unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company does not intend to sell its investments before recovery of the amortized cost basis of its debt securities at maturity and no allowance for credit losses was recorded as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024 because the decline in fair value below amortized cost is not related to credit losses. Securities are evaluated at the end of each reporting period. The unrealized losses on U.S. Treasury and Government agency securities range fr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">om </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their amortized cos</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable on the Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e95588c3-c714-4f9f-bfa1-4e84f1995499;"><span style="-sec-ix-hidden:F_f4615be1-4ad1-4aa9-9576-91c98e5813d6;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available-for-sale</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> debt securities totaled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and was presented within prepaids and other current assets on the Company's consolidated balance sheets. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest receivable was written off during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended October 31, 2025 or 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> material realized gains or losses recognized on the sale or maturity of available-for-sale securities during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 or 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Property and Equipment, Net</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, property and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,134</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,191</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">871</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,580</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,779</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,103</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,610</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,477</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,169</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense related to property and equipment was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, accrued expenses and other current liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,397</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,773</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,053</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,475</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,229</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">824</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income taxes payable</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued financing costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,831</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,275</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,128</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement and Clinical Research Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LicenseAgreementAndClinicalResearchOrganizationAbstract', window );"><strong>License Agreement and Clinical Research Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock', window );">License Agreement and Clinical Research Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. License Agreement and Clinical Research Organization</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreement &#8211; Nature Technology Corporation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 10, 2020, the Company entered into a Non-Exclusive License Agreement (the &#8220;License Agreement&#8221;) with Nature Technology Corporation (&#8220;NTC&#8221;) whereby the Company licenses certain rights to Nanoplasmid</span><span style="color:#231f20;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> technology from NTC for commercialization. Under the terms of the License Agreement, NTC granted to the Company and its affiliates a non-exclusive, royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can voluntarily terminate the license agreement with prior notice to NTC.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company paid NTC an initial, upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand annual maintenance fee. The Company is also required to make a payment to NTC of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand upon assigning the License Agreement to a third party.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The License Agreement provides for a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand for the first dose of a milestone product, as defined in the License Agreement, in the first patient in a Phase 1 clinical trial or, if there is no Phase 1 clinical trial, in a Phase 2 clinical trial, as well as a one-time payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a milestone product, has not yet been achieved as of the</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> year ended October 31, 2025. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by the Company, its affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (&#8220;GMP&#8221;) lot of a product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During each of the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand of expenses related to the annual maintenance fee u</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nder the License Agreement. During the year ended October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred a fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to the manufacturing payment under the License Agreement. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fees related to the manufacturing payment incurred during the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">year ended October 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All expenses related to License Agreement are recorded within research and development expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_LicenseAgreementAndClinicalResearchOrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement and Clinical Research Organization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_LicenseAgreementAndClinicalResearchOrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement and clinical research organization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Notes Payable</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended Loan and Security Agreement and the First Amendment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 30, 2021, the Company entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. ("Hercules") for the issuance of a term loan facility with an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Prior Term Loan&#8221;). On December 22, 2023 (the "Hercules Closing Date"), the Company entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement&#8221;), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (the "Lenders"). The Amended Loan Agreement amended and restated in its entirety the Prior Loan Agreement. The Amended Loan Agreement provides for a term loan facility of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available in multiple tranches (the &#8220;Term Loan&#8221;), as follows: (i) an initial term loan advance (the &#8220;Tranche 1 Advance&#8221;) that was made on the Tranche 1 Advance closing of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the &#8220;Interim Milestone&#8221;), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical evaluation of detalimogene in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from the date of achievement of the Interim Milestone through the earlier of (x) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days following the achievement of the Interim Milestone and (y) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (iii) an uncommitted tranche subject to the Lenders&#8217; investment committee approval and satisfaction of certain other conditions precedent (including payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (as defined below) that the Lenders make additional term loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company is required to pay upon the earlier of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ( the &#8220;Maturity Date&#8221;) or payment in full of the Term Loan, an end of term fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate principal amount of the Term Loan (the &#8220;End of Term Charge&#8221;). The Company was also required to pay on July 1, 2025 or, if earlier, the date the Company prepays the Term Loan, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million representing the Prior Term Loan End of Term Charge (the "Prior Term Loan End of Term Charge" and "End of Term Charge", collectively the &#8220;End of Term Charges&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan.  As a result of the extinguishment, the Company recorded a loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as a component within other income and expense in the Company's consolidated statement of operations during the year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> October 31, 2024, which represented the difference between the reacquisition price of the debt, including fees and the initial fair value of the warrants paid directly to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 18, 2024, the Company entered into a First Amendment to Amended and Restated Loan and Security Agreement (the "First Amendment") with the Lenders. The First Amendment modified the Amended Loan Agreement to reallocate the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million previously available under Tranche 2 (as defined in the Amended Loan Agreement), which was not drawn by the Company upon achievement of Interim Milestone, to Tranche 3 (as defined in the Amended Loan Agreement). Pursuant to the First Amendment, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million advance originally available upon achievement of the Interim Milestone was added to the uncommitted tranche subject to the Lenders' investment committee approval and satisfaction of certain other conditions precedent (including payment of a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% facility charge on the amount borrowed), pursuant to which the Company may request from time to time that the Lenders make additional loan advances to the Company in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The First Amendment did not change the total term loan facility available to the Company of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The First Amendment further provided for certain administrative changes in accordance with the foregoing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date (as defined in the Amended Loan Agreement); (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Amended Loan Agreement and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The remaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the uncommitted tranche subject to the Lenders&#8217; investment committee approval and satisfaction of certain other conditions precedent described above remains undrawn and available to the Company. The Prior Term Loan End of Term Charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was paid during the year ended October 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d4394cfa-9517-46fa-8508-88aeb275aaf2;"><span style="-sec-ix-hidden:F_33e08b81-4198-434a-9055-c3013033bffd;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wall Street Journal</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (capped at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) and (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The Term Loan also bears additional payment-in-kind interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement, as amended by the First Amendment, are repayable in monthly interest-only payments through the "Amortization Date", which is either: (x) if the Interim Milestone is achieved and there has been no default, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (y) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 1, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. After the Amortization Date, the outstanding Term Loan and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the Company has achieved the Interim Milestone but has not yet achieved certain clinical milestones. Amounts payable on January 1, 2026 were classified as current liabilities on the consolidated balance sheet for the year ended October 31, 2025. The effective interest rate of the Term Loan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.63</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of October 31, 2025 and October 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Amended Loan Agreement, as amended by the First Amendment, the Company granted Hercules a security interest senior to any current and future debts and to any security interest in all of the Company&#8217;s right, title, and interest in, to and under all of the Company&#8217;s property and other assets, subject to limited exceptions including the Company&#8217;s intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Loan Agreement, as amended by the First Amendment, contains negative covenants that, among other things and subject to certain exceptions, could restrict the Company's ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement, as amended by the First Amendment, also contains certain events of default and representations, warranties and non-financial covenants of the Company. The Company is in compliance with the financial covenants at October 31, 2025 and October 31, 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hercules Common Share Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Amended Loan Agreement, as amended by the First Amendment, the Company also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of the Company&#8217;s common shares, as shall be equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate principal amount of such Term Loan advance divided by the Warrants per share exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (which exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary adjustments under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from issuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Amended Loan Agreement, as amended by the First Amendment, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,696</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (i.e. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million total commitment amount divided by the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> price specified in the Closing Date Warrant), assuming no adjustments are made under the terms of the Hercules Common Share Warrants and further assuming the full amount of Term Loans are drawn. On the Hercules Closing Date, the Company issued to the Lenders </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,413</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans (the "Closing Date Warrants"). </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Closing Date Warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#8217;s common shares as prescribed by ASC 815. Upon entering into the Amended Loan Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the total $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million Tranche 1 Advance was allocated to the warrants, on a relative fair value basis, and recorded within additional paid in capital.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequently issued Hercules Common Share Warrants shall be substantially in the form of the Closing Date Warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, the carrying value of the Term Loan consists of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, including End of Term Charge</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,231</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,663</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount, net of accretion</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,088</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,673</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, net of discount</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,326</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,172</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company classified </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the note payable as current. As of October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company classified $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the note payable as current, which represented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the back-end fee associated with the refinancing of the Prior Term Loan. During the years ended October 31, 2025 and 2024, the Company recogni</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">zed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense related to the Amended Loan Agreement, respectively, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million each year rel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ated to the amortization of the debt discount.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge, are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Note Principal<br/>Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,417</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,987</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal payments, including End of Term Charge</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,565</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, management believes that the carrying value of the Company&#8217;s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value based on the consideration of the Company&#8217;s credit risk and terms of the borrowing from Hercules.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0d8e6fbe-0e8d-48be-94c6-063543d24362;"><span style="-sec-ix-hidden:F_c36c748c-142e-4749-b840-fae3cd22d5a5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unlimited</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> number of authorized shares of Common Shares, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value.  As of  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024 there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,018,658</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,976,676</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares outstanding, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Shares are entitled to one vote</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each Common Share held on all matters submitted to a vote of shareholders. Common shareholders are entitled to receive dividends, as may be declared by the Board of Directors, if any, subject to the preferential dividend rights of preferred stock. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends had been declared or paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2024, the Company entered into subscription agreements (collectively, the &#8220;February 2024 Subscription Agreements&#8221;) with the investors named therein, for the private placement (the &#8220;February 2024 PIPE Financing&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares of the Company, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The aggregate gross proceeds from the February 2024 PIPE Financing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The February 2024 PIPE Financing closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 20, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 24, 2024, the Company entered into subscription agreements (collectively, the &#8220;October 2024 Subscription Agreements&#8221;) with the investors named therein, for the private placement (the &#8220;October 2024 PIPE Financing&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,758,311</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares of the Company, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The aggregate gross proceeds from the October 2024 PIPE Financing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The October 2024 PIPE Financing closed on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 29, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 20, 2024, the Company entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Jefferies, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Common Shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will pay Jefferies a commission of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of Shares sold pursuant to the Sale Agreement, and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any Shares under the Sale Agreement. The offering of the Shares pursuant to the Sale Agreement will terminate upon the termination of the Sale Agreement by Jefferies or the Company, as permitted therein</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Through October 31, 2025, the Company sold no Common Shares under the Sale Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrants to Purchase Common Shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants to purchase common shares outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the warrants to purchase Common Shares outstanding as of October 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,449,555</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and are exercisable through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company may elect to call in the warrants for redemption if the share price of the Company equals or exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for any twenty (20) trading days within the thirty (30) trading-day period ending on the third (3rd) trading day prior to the date on which notice of the redemption is given, subject to adjustments as provided in the terms of the warrant agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#8217;s common shares as prescribed by ASC 815.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The additional</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,413</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the warrants to purchase Common Shares outstanding as of October 31, 2025, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were issued as part of the Amended Loan Agreement on December 22, 2023, have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.21</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are exercisable at any time beginning on December 22, 2023, and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 22, 2030</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the issuance date. The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#8217;s common shares as prescribed by ASC 815. Please refer to Note 10, Share-Based Compensation, below for the summary of the Common Shares reserved for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under and outside the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 17, Subsequent Events, for a discussion of Common Shares and pre-funded warrants to purchase Common Shares issued by the Company pursuant to an underwritten public offering in November 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Share-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan") was adopted on May 15, 2024 and superseded all prior plans. The 2023 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board, (the "Committee"). The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the fair market value</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Common Shares on the date of grant and the term of stock option may not be greater than ten years. Common Shares that are expired, terminated, surrendered or cancelled under the 2023 Plan without having been fully exercised will be available for future awards. The Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Stock Units, Stock Appreciation Rights, or SARs, and other share-based awards including performance awards and share bonus awards. The Plan contains the evergreen provision (the "Evergreen Provision") pursuant to which on the first business day of each calendar year, the aggregate number of Common Shares that could be issued or transferred thereunder (the "Plan Share Reserve") and the number of Common Shares available for options intended to qualify as incentive stock options (the "ISO Sublimit") each increase by such number of Common Shares  as equals </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of Common Shares outstanding on the final day of the immediately preceding calendar year (or such smaller number of shares as is determined by the compensation committee), and the ISO Sublimit by the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares and the increase in the Plan Share Reserve (or such smaller number of shares may be determined by the compensation committee of the Company&#8217;s board of directors). On January 2, 2025 the Committee allowed the full </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% increase for 2025 under the Evergreen Provision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, inclusive of (i) the common shares subject to the outstanding grants under the prior plans, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,548,833</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares added on January 2, 2025 under the Evergreen Provision, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">re were </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">8,651,209</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Common Shares reserved for issuance under the Plan and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,933,304</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining for issuance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 10, 2025, at its 2025 Annual General Meeting of shareholders, the shareholders of enGene Holdings Inc. approved the adoption of the 2025 Employee Stock Purchase Plan  (the "ESPP&#8221;), pursuant to which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common shares of the Company, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value, were reserved for issuance. The price of common shares purchased under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the common shares on the first trading day of the offering period or the relevant purchase date and is subject to change by a Plan Administrator prior to each purchase period. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remained available for issuance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may grant inducement equity award consisting of a non-qualified stock option to purchase Common Shares to newly hired employees as an inducement material to the employee's entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4), which, if made, are granted outside of the 2023 Plan. During year ended October 31, 2025, the Company issued options to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,709,550</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares to certain new hire employees at a weighted-average exercise price o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The options awarded have an exercise price equal to the closing stock price of the Company on the date of the grant and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal amounts monthly for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thereafter, subject continued service as an employee.  The options have a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the date of the grant. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024, the Company issued options to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,643,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares to certain new hire employees at a weighted-average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">493,851</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the inducement grant stock options have vested, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hav</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e been forfeited and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne have expired, and, other than forfeited options, all options remain outstanding.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the 2023 Plan and options granted outside of the 2023 Plan as part of the inducement grants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incentive options to purchase common shares awarded pursuant to the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,717,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,391,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inducement grant stock options awarded outside of the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,315,350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,643,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under<br/>&#160;&#160;&#160;the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,933,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,752,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,478,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,299,369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions that the Company used to determine the grant-date fair value of stock options during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.209%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.376%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.376%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="7" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.78</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.33</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.84</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.49</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.78</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.66</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common shares and exercise price of options (USD)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.39</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.60</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"></td>
         <td style="width:1.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.668%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.187%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.187%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.187%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price (USD)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,034,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,809</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,926,875</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.41</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,041,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">886,107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,033,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,979</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,935,183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options unvested as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,098,115</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,482</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#8217;s common share as of each reporting date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant-date fair value per share of share options granted during the years ended October 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Modification of Employment Agreements</span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2024, the Company entered into a Transition and Modified Employment Agreement (the &#8220;Transition Agreement&#8221;) with the Company's former Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dated November 8, 2023 (the &#8220;Amended Employment Agreement&#8221;). Under the terms of the Amended Employment Agreement Mr. Hanson will be entitled to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months of continued health insurance benefits; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of a 2024 target annual bonus in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">390,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, less applicable taxes and withholdings; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceleration and vesting of any then unvested time-based equity awards that would have vested in the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period following such termination; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of the CEO&#8217;s vested equity awards extend beyond the respective applicable term thereof.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Transition Agreement further provided that, in the event Mr. Hanson were to resign upon the appointment by the Company of a new chief executive officer, Mr. Hanson would be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of resignation (the &#8220;Consulting Period&#8221;) in exchange for a monthly fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the initial </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consulting Period, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per hour thereafter, provided that Mr. Hanson need not devote more than fifteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) hours per week to providing such transition services.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Transition Agreement, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,216,266</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock option awards issued to Mr. Hanson were modified to allow for an extended exercise period as described above. The modification resulted in an incremental share-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which was recorded upon the effective date of the Transition Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Hanson resigned effective as of July 19, 2024 in connection with the Company&#8217;s appointment of a new chief executive officer. On July 20, 2024, enGene appointed Ronald H. W. Cooper as Chief Executive Officer of the Company and as director of the Company's Board of Directors.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in 2024, the Company entered into a Severance Agreement with each of three former employees, including the former Chief Medical Officer and the former Chief Scientific Officer. Under the terms of Severance Agreement, the employees are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of continued pay and health insurance benefits; a payment of a 2024 target annual bonus prorated through the last day of employment, acceleration and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination and an extended expiry period, which resulted in a stock-based compensation modification. Under the terms of the agreements, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">231,684</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> stock option awards were modified to allow for an extended exercise period as described above. As of October 31, 2024, the Company recognized incremental stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the severance agreements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,282</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,794</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,364</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,530</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,646</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,324</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of unrecognized compensation, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the reverse recapitalization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.52%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,119,479</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,782,346</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.29</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024 because including them would have had an anti-dilutive effect:</span></p><p style="text-indent:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,033,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,034,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,545,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,546,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Income Taxes</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss before provision for income taxes consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,727</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,460</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,575</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,701</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,161</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the provision for (recovery of) income taxes is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current expense (benefit):</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred expense (benefit)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.322000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.322000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income at Canadian statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.29</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.77</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.60</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.07</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.02</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net deferred income tax balances related to the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D expenditures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,021</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,172</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss (NOL) carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,127</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,661</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,934</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">704</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">747</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,270</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease-right of use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,068</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,068</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,992</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liability)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#8217;s judgment changes as a result of evaluating new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> uncertain tax positions have been recorded in the consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company has Canadian Federal NOL carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, that expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Canadian provincial NOL carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">214.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, that expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These losses are available to offset future taxable income in Canada and Quebec.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company has a U.S. Federal NOL carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, that may be carried forward indefinitely, and a U.S. state NOL carryforward of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which are available to offset against future taxable income in the U.S and Massachusetts. The U.S. State tax loss carryforward will expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2041</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has not recognized the tax benefit of these losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company also has non-refundable Canadian investment tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that expire between </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2045</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These credits may be utilized to reduce Canadian federal income taxes payable. The Company has not recognized the tax benefits related to these non-refundable investment tax credits.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company also has capital losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which are available to be used indefinitely against future capital gains.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025, the Company had Scientific Research and Experimental Development (&#8220;SR&amp;ED&#8221;) expenditures of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for Canadian federal and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for Qu&#233;bec provincial purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carryforward period. SR&amp;ED expenditures are subject to verification by the tax authorities and, accordingly, the amounts may vary.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s leases are comprised of all operating leases for office and lab space.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 29, 2022, the Company signed a new lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,620</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, beginning on the commencement date, and requires an annual initial base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> CAD per square foot, which is subject to annual increases of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2024, enGene USA entered into a lease agreement, in which the Company is sub-leasing approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,450</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the initial term of the lease, which is set to expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 30, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and does </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 4, 2025, enGene USA, Inc entered into a lease agreement, pursuant to which the Company agreed to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,335</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space located at 99 High Street, Boston, Massachusetts. The Company is expected to make an aggregate amount of base rental payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, under the initial term of the lease, which is set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the lease, enGene Holdings Inc. has delivered a guaranty, dated June 4, 2025, pursuant to which the Company guaranteed enGene USA's payment and performance. The lease commenced in June 2025 and upon commencement, the Company recognized an initial lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and corresponding right of use asset of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.493%;box-sizing:content-box;"></td>
         <td style="width:2.701%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.663%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.663%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Cost:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the cash paid for amounts included in the measurement of the Company&#8217;s operating lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement<br/>&#160;&#160;&#160;of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of the Company's operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.7%;box-sizing:content-box;"></td>
         <td style="width:5.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:31.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,191</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,391</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,409</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,457</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,502</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,031</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,469</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded on the balance sheet. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had operating lease liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded on the balance sheet.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of  October 31, 2025 and 2024, there were no material claims outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase and Other Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts in the normal course of business with CROs, CMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Segment Reporting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates and manages its business as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is focused on developing genetic medicines to improve the lives of patients suffering from bladder cancer. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated net loss to evaluate the Company&#8217;s spend, deploy resources across research and development activities and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing the performance of the operating segment and in establishing resource allocation across the organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies. The measure of segment assets used in determining how to manage and allocate resources is reported within the Company's consolidated balance sheets as cash and cash equivalents and marketable securities.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.962%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.538%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.807%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.690999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, Manufacturing and Controls</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,578</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical operations</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,036</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,052</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,598</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,893</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,282</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,850</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,364</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,530</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,471</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,951</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) For the year ended October 31, 2025, other segment items consist of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest income, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of interest expense, and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense, net. For the year ended October 31, 2024, other segment items consists of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">10.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest income, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on extinguishment of debt, and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Related Party Transactions</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company did not have transactions with shareholders that hold more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total outstanding shares of the Company. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had the following transactions with shareholders that hold more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total outstanding shares of the Company:</span></p><p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 20, 2024, the Company completed the February 2024 PIPE Financing, which provided for the private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and included both new and existing investors. One of the Company&#8217;s directors, Mr. Gerald Brunk, is a managing director of Lumira Ventures (&#8220;Lumira&#8221;), and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for a total price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the February 2024 PIPE Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 29, 2024, the Company completed the October 2024 PIPE Financing, which provided for the private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,758,311</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and included both new and existing investors. One of the Company&#8217;s current directors and one former director, Messrs. Wouter Joustra and Jasper Bos, respectively, are general partners of FEAC, and an entity affiliated with FEAC was party to one of the October 2024 Subscription Agreements, purchasing an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">561,797</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for a total price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the October 2024 PIPE Financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Subsequent Events</span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated subsequent events through the date these financial statements were issued. Except as noted below, the Company concluded that no subsequent events have occurred that require disclosure.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public Offering of Common Shares and Pre-Funded Warrants</span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 12, 2025, the Company entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;) relating to the issuance and sale by the Company, in an underwritten public offering, of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,558,823</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Common Share and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,735,295</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-funded warrant,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each case before underwriting discounts and commissions. The offering closed on November 14, 2025. The aggregate gross proceeds from the offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting the underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Company also granted to the Underwriters a 30-day option to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,294,117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional Common Shares at the public offering price, less underwriting discounts and commissions (the &#8220;Option&#8221;), which the Underwriters exercised in full pursuant to a Notice of Exercise dated November 14, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The aggregate gross proceeds from the Option exercise were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting the underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The offering closed on November 18, 2025, with respect to the Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and do not expire. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a pre-funded warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s outstanding Common Shares immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to the Company, subject to the terms of the pre-funded warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8217;s&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are expressed in US dollars. The consolidated financial statements have been prepared on a historical cost basis, except for items that are required to be accounted for at fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the accrual of research and development expenses, share-based payments and the recoverability of investment tax credits receivable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considered the Company&#8217;s organizational structure and the information regularly reviewed and evaluated by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) when deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. Based on this factor, the Company determined that it operates and manages its business as a single operating segment. As of October 31, 2025, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in long-lived assets held in the United States and in Canada, respectively. As of October 31, 2024, the Company had </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in long-lived assets held in the United States and in Canada, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risk of Concentrations of Credit and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk of Concentrations of Credit and Off-Balance Sheet Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. Management believes that the Company is not currently exposed to significant credit risk as the Company&#8217;s deposits were held in custody at third-party financial institutions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's investment policy limits investments to certain types of securities issued by the U.S. Government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Consolidated Balance Sheets. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> off-balance sheet concentrations of credit risk</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is dependent on third-party CMOs and CRO with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company&#8217;s cash and cash equivalents include bank balances, demand deposits and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other short-term, highly liquid investments. The fair value of cash and cash equivalents approximate the amortized cost. The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents as of October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of cash and cash equivalents as of October 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 17, Subsequent Events, for additional discussion on the Company&#8217;s cash position following the closing of an underwritten public offering in November 2025.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's marketable securities are maintained by investment managers and consist of money market funds, U.S. government agency securities and treasuries. If the remaining contractual maturity is within one year from the balance sheet date, the marketable securities are classified as current and otherwise, they are classified as non-current assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in marketable securities is classified as available-for-sale and is reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders' equity in other comprehensive loss. Premium or discounts from par value are amortized to investment income over the life of the underlying investment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically evaluates the need for an allowance for credit losses. The evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When the fair value is below the amortized cost of the asset, an estimate of expected credit losses is made. The Company records credit losses in the consolidated statements of operations and comprehensive loss as a credit loss expense within other income, net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued interest receivable related to the Company's available-for-sale securities is presented within prepaids and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivable associated with its marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are comprised mainly of research and development equipment, computer hardware and software, office furniture and equipment, and leasehold improvements. Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if applicable. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:56.6%;box-sizing:content-box;"></td>
           <td style="width:2.48%;box-sizing:content-box;"></td>
           <td style="width:40.92%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or useful life</span></span></p></td>
          </tr>
         </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected undiscounted cash flows are less than the carrying value of the assets, then the assets are considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a right-of-use (&#8220;ROU&#8221;) asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.269%;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.13%;min-width:4.537%;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At October 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, financial instruments measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable Securities, and Note 3, Fair Value Measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DebtIssuanceCostsPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:12.13%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt Issuance Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with the issuance of debt not accounted for using the fair value option as debt issuance costs. Debt issuance costs are recorded as a direct reduction of the carrying amount of the associated debt on the Company&#8217;s consolidated balance sheets and amortized as interest expense on the Company&#8217;s consolidated statements of operations and comprehensive loss using the effective interest method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are comprised primarily of costs incurred for our drug discovery efforts and development of our product candidates. These expenses include salaries, employee benefits, and share-based compensation expense for our research and development personnel, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside CROs and consultants to conduct research and development activities including costs of clinical trials and manufacturing, and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management estimates the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#8217;s consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has an incentive equity plan (the &#8220;2023 Incentive Equity Plan&#8221; or the &#8220;2023 Plan&#8221;), whereby employees render services as consideration for equity instruments.  The 2023 Plan was adopted on October 31, 2023 upon the completion of the Reverse Recapitalization and superseded enGene Inc.&#8217;s employee stock option plan (the &#8220;ESOP&#8221;) and equity incentive plan (the &#8220;EIP&#8221;) (collectively, the &#8220;Old Plans&#8221;). The 2023 Plan was amended and restated in May 2024 and is now the Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which supersedes all prior plans. The Company measures all share-based awards granted to employees, officers, directors and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of its share-based awards as they occur. The Company issues share-based awards with service-based vesting conditions and awards with both performance and service-based vesting conditions. For share-based awards with service-based vesting conditions, the Company records the expense using the straight-line method including when such awards have graded vesting. For share-based awards with both performance and service-based vesting conditions, the Company records the expense using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management&#8217;s best estimate.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company&#8217;s common shares, expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#8217;s expected dividend yield. The Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies with similar characteristics including market capitalization, stage of development, therapeutic focus and certain financial measures. The expected volatility has been determined using an average of the historical volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method for awards with only service based vesting conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on participant behavior. For awards with both performance and service based vesting conditions, the expected term has been determined using management&#8217;s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers.  The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be zero.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to the consummation of the Reverse Recapitalization, because there was no public market for the Company&#8217;s common shares, the Board of Directors has determined the fair value of the Company&#8217;s common shares based on third-party valuations of the Company&#8217;s common shares. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#8217;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering (&#8220;IPO&#8221;), or sale of the Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. In addition, the Company&#8217;s Board of Directors considered various objective and subjective factors to determine the fair value of the Company&#8217;s common shares as of each grant date, including the prices at which enGene Inc. sold shares of redeemable convertible preferred shares and the superior rights and preferences of the redeemable convertible preferred shares relative to its common shares at the time of each grant, external market conditions, the progress of the Company&#8217;s research and development programs, the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company&#8217;s common shares and redeemable convertible preferred shares, among other factors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if the Company had used different assumptions or estimates or if there are changes to the unobservable inputs, the fair value of its common shares and share-based compensation expense could have been materially different.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent to becoming a publicly traded Company upon the consummation of the Reverse Recapitalization, the fair value of common shares underlying equity awards is based on the market price of the Company&#8217;s common stock at the date of the grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s share-based compensation expense is recorded in general and administrative and research and development expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax basis of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in shareholders&#8217; deficit that result from transactions and economic events other than those with shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if dilutive, the weighted-average number of potential shares of common shares. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and warrants. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted net loss per share attributable to common shareholders is generally the same as basic net loss per share attributable to common shareholders because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. See Note 11, Net Loss per Share, for further detail.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Deferred Transaction Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Transaction Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that were directly associated with PIPE or public financings as deferred transaction costs until such transaction was consummated. After the consummation of such transaction, these costs are recorded within equity as a reduction of the common share and warrants value within additional paid in capital. Costs are allocated to each equity instrument on a relative fair value basis for transactions that include both instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock', window );">Government Assistance Programs for Research and Development Expenditures</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Assistance Programs for Research and Development Expenditures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (&#8220;CCPC&#8221;) on eligible scientific research and experimental development (&#8220;SR&amp;ED&#8221;) expenditures through September 2023, at which time the Company lost its status as a CCPC. In addition, effective for fiscal 2023, the Company&#8217;s maximum refundable tax credits were reduced due to the Company&#8217;s taxable capital, as defined in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Canada), which reduction in credits has been recorded in the fourth quarter.  The Canadian federal government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#8217;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. Following the loss of CCPC status, the Company&#8217;s SR&amp;ED tax credits will be earned at a lower rate and some will no longer be refundable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts received or receivable resulting from government assistance programs, including investment tax credits for SR&amp;ED, are recognized when there is reasonable assurance that the amount will be received, and all attached conditions will be complied with. Reimbursements of eligible SR&amp;ED expenditures pursuant to government assistance programs are received in cash. The amounts</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receivable are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. During the years ended October 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, as a reduction of research and development expense associated with SR&amp;ED investment tax credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements - Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-07, Segment Reporting (Topic 280: Improvements to Reportable Segment Disclosures) (&#8220;ASU 2023-07&#8221;), which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this accounting standard during the year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and there was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impact on the Company&#8217;s reportable segments identified. Required disclosures have been included in Note 15 "Segment Reporting".</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements &#8211; Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  which removes references to project stages and clarified when the Company is required to begin capitalizing eligible costs. The new guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. ASU 2025-06 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as further clarified by ASU 2025-01, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,  issued in January, 2025, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. This ASU is effective for annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740) - Improvements to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ncome Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which improves transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU No 2023-09 is effective for the Company's annual financial statements for the year ending October 31, 2026. The Company is currently evaluating the impact of the guidance on the financial statements and related disclosures.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which amends GAAP to reflect updates and simplifications to certain disclosure and presentation requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 is effective on the date on which the SEC's removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective but will not be effective if the SEC has not removed the applicable disclosure requirements by June 30, 2027. Early adoption is prohibited. The Company is currently evaluating the impact of the amendments on its financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DebtIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DebtIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government assistance programs for research and development expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Estimated Useful Life of Each Asset</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:56.6%;box-sizing:content-box;"></td>
           <td style="width:2.48%;box-sizing:content-box;"></td>
           <td style="width:40.92%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Useful Life</span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
          </tr>
          <tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
          </tr>
          <tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease term or useful life</span></span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:34.187%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.501%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.952%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable<br/>Inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Short term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,117</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,117</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Long term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164,254</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,366</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of October 31, 2024:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.101%;box-sizing:content-box;"></td>
         <td style="width:2.214%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.604000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.107%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.903000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.129%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.154%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.129%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.659%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Other<br/>Observable<br/>Inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant Unobservable<br/>Inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,236</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,236</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Short term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,574</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,574</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,754</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,754</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Long term marketable securities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;U.S. government treasuries</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195,558</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,609</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the marketable securities consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30.866%;box-sizing:content-box;"></td>
         <td style="width:12.482%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.902000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.842%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.482000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents and short-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,642</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146,984</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,090</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,366</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177,098</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,498</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,522</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,620</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2024, the marketable securities consisted of the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:45.851%;box-sizing:content-box;"></td>
         <td style="width:5.972%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.467%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.588%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.205%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.677%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.773%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.677%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.786000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Holdings Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents and short-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds, included in cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,832</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,814</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,714</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,667</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,644</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US treasury</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,931</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,972</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,898</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,903</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,523</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">418</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, property and equipment consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,134</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,191</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office furniture</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">871</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,580</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,779</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation and amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,103</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,610</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,477</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,169</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, accrued expenses and other current liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,397</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,773</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,053</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,475</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,229</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">824</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income taxes payable</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued financing costs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,831</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,275</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,128</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Carrying Value of Term Loan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, the carrying value of the Term Loan consists of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, including End of Term Charge</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,231</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,663</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount, net of accretion</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,088</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,673</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable, net of discount</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,326</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,172</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Estimated Future Principal Payments Due Under the Loan Agreement</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, the estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge, are as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Note Principal<br/>Payments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,417</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,987</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal payments, including End of Term Charge</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,565</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock', window );">Schedule of Shares Reserved for Future Issuance Under the Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the 2023 Plan and options granted outside of the 2023 Plan as part of the inducement grants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incentive options to purchase common shares awarded pursuant to the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,717,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,391,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inducement grant stock options awarded outside of the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,315,350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,643,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under<br/>&#160;&#160;&#160;the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,933,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,752,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,478,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,299,369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of shares reserved for future issuance under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock', window );">Schedule of Shares Reserved for Future Issuance Under the Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the 2023 Plan and options granted outside of the 2023 Plan as part of the inducement grants:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incentive options to purchase common shares awarded pursuant to the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,717,948</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,391,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inducement grant stock options awarded outside of the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,315,350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,643,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under<br/>&#160;&#160;&#160;the 2023 Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,933,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,752,889</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remaining shares reserved for future issuance under ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,478,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,299,369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assumptions that the Company used to determine the grant-date fair value of stock options during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:54.209%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.376%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.376%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="7" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.51</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.08</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.78</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82.33</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.84</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.49</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.78</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.66</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fair value of common shares and exercise price of options (USD)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.39</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.60</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.41%;box-sizing:content-box;"></td>
         <td style="width:1.001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.668%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.187%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.187%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.187%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price (USD)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of October 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,034,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,809</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,926,875</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.41</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,041,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.13</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited or expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">886,107</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.86</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,033,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.93</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,979</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,935,183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options unvested as of October 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,098,115</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,482</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,282</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,794</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,364</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,530</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total share-based compensation expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,646</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,324</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of shares reserved for future issuance under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the reverse recapitalization:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:68.32%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.52%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average number of common shares used in net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,119,479</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,782,346</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.29</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Shares Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024 because including them would have had an anti-dilutive effect:</span></p><p style="text-indent:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.86%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.06%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,511,968</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common shares</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,033,298</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,034,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,545,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,546,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Loss Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss before provision for income taxes consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,727</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,460</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,575</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,701</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before income taxes</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,161</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary Of Components Of The Provision For (Recovery Of) Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of the provision for (recovery of) income taxes is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current expense (benefit):</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred expense (benefit)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic (Canada)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign (US)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense (benefit)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary Of Reconciliation Of Company's Statutory Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.322000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.322000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income at Canadian statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent differences</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.29</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.77</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.60</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.07</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign rate differential</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.82</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.02</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary Of Net Deferred Income Tax</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net deferred income tax balances related to the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D expenditures</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,021</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,172</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss (NOL) carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,127</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,661</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment tax credits, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,934</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">704</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">747</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,270</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note payable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,369</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease-right of use asset</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,068</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,068</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,992</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liability)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Operating Lease Cost</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.493%;box-sizing:content-box;"></td>
         <td style="width:2.701%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.663%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.663%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease Cost:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock', window );">Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the cash paid for amounts included in the measurement of the Company&#8217;s operating lease liabilities for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025, and 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement<br/>&#160;&#160;&#160;of operating lease liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of the Company's operating lease liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:61.7%;box-sizing:content-box;"></td>
         <td style="width:5.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:31.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,191</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,391</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,409</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,457</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,502</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,081</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,031</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,469</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of cash paid for amounts included in measurement of operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Significant Segment Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 31, 2025 and 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:70.962%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.538%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:3.807%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.690999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended October 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chemistry, Manufacturing and Controls</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,578</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,994</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical operations</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,915</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,036</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,052</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,598</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,893</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,282</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,794</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,480</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel-related expenses, excluding stock-based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,850</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,364</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,530</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other general and administrative expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,471</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,951</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Total general and administrative expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,982</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,863</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117,302</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,142</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) For the year ended October 31, 2025, other segment items consist of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest income, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of interest expense, and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of other expense, net. For the year ended October 31, 2024, other segment items consists of $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">10.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest income, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of interest expense, $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million gain on extinguishment of debt, and $</span><span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 14, 2025</div></th>
<th class="th"><div>Nov. 12, 2025</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DescriptionOfBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (117,302)<span></span>
</td>
<td class="num">$ (55,142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,239<span></span>
</td>
<td class="nump">48,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,032<span></span>
</td>
<td class="nump">$ 254,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=engn_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DescriptionOfBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 149,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=engn_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=engn_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk', window );">Off-balance sheet concentrations of credit risk description</a></td>
<td class="text">As of October 31, 2025 and 2024, the Company had no off-balance sheet concentrations of credit risk<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk', window );">Off-balance sheet concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 50,152,000<span></span>
</td>
<td class="nump">173,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement', window );">Percentage of tax benefit to be realized for recognition in the income statement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ResearchAndDevelopmentInvestmentTaxCredits', window );">Research and development investment tax credits</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member', window );">ASU 2023-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">Oct. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration risk credit risk off balance sheet risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax benefit to be realized for recognition in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ResearchAndDevelopmentInvestmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ResearchAndDevelopmentInvestmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202307Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets held</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets held</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PropertyPlantAndEquipmentEstimatedUsefulLive', window );">Estimated Useful Life</a></td>
<td class="text">Shorter of remaining lease term or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PropertyPlantAndEquipmentEstimatedUsefulLive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful live.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PropertyPlantAndEquipmentEstimatedUsefulLive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Assets transfers or reclassifications out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value (Details) - Fair Value Measurement Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 185,620<span></span>
</td>
<td class="nump">$ 229,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">8,642<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">21,623<span></span>
</td>
<td class="nump">94,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,249<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short Term Marketable Securities | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">125,467<span></span>
</td>
<td class="nump">51,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short Term Marketable Securities | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">18,117<span></span>
</td>
<td class="nump">13,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long Term Marketable Securities | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">49,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long Term Marketable Securities | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">164,254<span></span>
</td>
<td class="nump">195,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">8,642<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">21,623<span></span>
</td>
<td class="nump">94,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Short Term Marketable Securities | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">125,467<span></span>
</td>
<td class="nump">51,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Long Term Marketable Securities | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">49,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">21,366<span></span>
</td>
<td class="nump">33,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,249<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Short Term Marketable Securities | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">$ 18,117<span></span>
</td>
<td class="nump">13,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Long Term Marketable Securities | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=engn_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=engn_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=engn_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=engn_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 185,492<span></span>
</td>
<td class="nump">$ 229,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holdings Gains</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">185,620<span></span>
</td>
<td class="nump">229,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=engn_CashEquivalentsAndShortTermInvestmentsMember', window );">Cash Equivalents and Short Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">176,994<span></span>
</td>
<td class="nump">169,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holdings Gains</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">177,098<span></span>
</td>
<td class="nump">169,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=engn_CashEquivalentsAndShortTermInvestmentsMember', window );">Cash Equivalents and Short Term Investments | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,642<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">8,642<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=engn_CashEquivalentsAndShortTermInvestmentsMember', window );">Cash Equivalents and Short Term Investments | US Treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">146,984<span></span>
</td>
<td class="nump">145,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holdings Gains</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">147,090<span></span>
</td>
<td class="nump">145,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=engn_CashEquivalentsAndShortTermInvestmentsMember', window );">Cash Equivalents and Short Term Investments | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">21,368<span></span>
</td>
<td class="nump">23,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holdings Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">21,366<span></span>
</td>
<td class="nump">23,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_LongTermDebtMember', window );">Long-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,498<span></span>
</td>
<td class="nump">59,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holdings Gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">59,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_LongTermDebtMember', window );">Long-term Investments | US Treasury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,498<span></span>
</td>
<td class="nump">49,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Holdings Gains</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 8,522<span></span>
</td>
<td class="nump">49,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_LongTermDebtMember', window );">Long-term Investments | Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Holdings Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=engn_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=engn_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NumberOfSecuritiesHeld', window );">Number of securities held | Security</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of unrealized loss position | Security</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Aggregate fair value</a></td>
<td class="nump">$ 55,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList', window );">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Prepaid Expense and Other Assets, Current<span></span>
</td>
<td class="text">Prepaid Expense and Other Assets, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AccruedInterestReceivableWrittenOff', window );">Accrued interest receivable written off</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains or losses on sale or maturity of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DebtSecuritiesUnrealizedLosses', window );">Debt securities unrealized losses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DebtSecuritiesUnrealizedLosses', window );">Debt securities unrealized losses</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AccruedInterestReceivableWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest receivable written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AccruedInterestReceivableWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DebtSecuritiesUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DebtSecuritiesUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_NumberOfSecuritiesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_NumberOfSecuritiesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 4,580<span></span>
</td>
<td class="nump">$ 2,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,134<span></span>
</td>
<td class="nump">2,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 9,397<span></span>
</td>
<td class="nump">$ 3,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and related benefits</a></td>
<td class="nump">4,053<span></span>
</td>
<td class="nump">3,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income tax payable</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AccruedFinancingCosts', window );">Accrued financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 15,275<span></span>
</td>
<td class="nump">$ 12,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AccruedFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AccruedFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement and Clinical Research Organization - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 10, 2020</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LicenseAgreementAndClinicalResearchOrganizationLineItems', window );"><strong>License Agreement and Clinical Research Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PaymentOnAssigningLicenseToThirdParty', window );">Payment to NTC upon assigning the License Agreement</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_PhaseIClinicalTrialMember', window );">Phase I Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LicenseAgreementAndClinicalResearchOrganizationLineItems', window );"><strong>License Agreement and Clinical Research Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_MilestoneProductPayment', window );">One-time payment for milestone product</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_PhaseIiClinicalTrialMember', window );">Phase II Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LicenseAgreementAndClinicalResearchOrganizationLineItems', window );"><strong>License Agreement and Clinical Research Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_MilestoneProductPayment', window );">One-time payment for milestone product</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LicenseAgreementAndClinicalResearchOrganizationLineItems', window );"><strong>License Agreement and Clinical Research Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_UpfrontFees', window );">Upfront fee</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AnnualMaintenanceFeeUnderLicenseAgreement', window );">Expenses related to the annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ManufacturingPaymentFee', window );">Fee related to the manufacturing payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AnnualMaintenanceFeeUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual maintenance fee under license agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AnnualMaintenanceFeeUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_LicenseAgreementAndClinicalResearchOrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement and clinical research organization line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_LicenseAgreementAndClinicalResearchOrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ManufacturingPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ManufacturingPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_MilestoneProductPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone product payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_MilestoneProductPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PaymentOnAssigningLicenseToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on assigning license to third party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PaymentOnAssigningLicenseToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_UpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_UpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_PhaseIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_PhaseIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_PhaseIiClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_PhaseIiClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 18, 2024</div></th>
<th class="th"><div>Dec. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="num">$ (366,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,002,000<span></span>
</td>
<td class="nump">699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">Wall Street Journal [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_AmendedLoanAgreementMember', window );">Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase preferred shares</a></td>
<td class="nump">138,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="nump">$ 7.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares', window );">Percentage of aggregate principal amount of term loan advance to purchase number of common shares</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=engn_HerculesCapitalMember', window );">Hercules Capital | Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=engn_HerculesCapitalMember', window );">Hercules Capital | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=engn_TermLoanMember', window );">Term Loan | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Term loan annual interest rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate', window );">Percentage of prepayment premium of principal amount outstanding of the closing date</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths', window );">Percentage of prepayment premium of principal amount outstanding prior to twenty-four months</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate', window );">Percentage of prepayment premium of principal amount outstanding prior to maturity date</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.63%<span></span>
</td>
<td class="nump">11.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit, maturity date</a></td>
<td class="text">Jan.  01,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_EndOfTermFeePercentage', window );">End of term fee percentage</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_EndOfTermCharge', window );">End of term charge</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PaidInKindInterestPercentage', window );">Payment-in-kind interest rate</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfCommitmentAmount', window );">Percentage of total commitment amount</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_CommitmentAmount', window );">Total commitment amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=engn_TermLoanMember', window );">Term Loan | First Amendment to Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=engn_TermLoanMember', window );">Term Loan | Maximum | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, interest rate</a></td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_LoanAndSecurityAgreementMember', window );">2021 Loan and Security Agreement | Hercules Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheOneAdvanceMember', window );">Tranche 1 Advance | Term Loan | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase preferred shares</a></td>
<td class="nump">62,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheOneAdvanceMember', window );">Tranche 1 Advance | Term Loan | Amended Loan Agreement | Hercules Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AdvanceOnLoanAllocatedToWarrants', window );">Advance on loan allocated to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceMember', window );">Tranche 3 Advance | Term Loan | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfFacilityChargeOnAmountBorrowed', window );">Percentage of facility charge on amount borrowed</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceMember', window );">Tranche 3 Advance | Term Loan | First Amendment to Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfFacilityChargeOnAmountBorrowed', window );">Percentage of facility charge on amount borrowed</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_AppliedToRefinanceOfAmountOutstandingMember', window );">Applied to Refinance of Amount Outstanding | Term Loan | Prior Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheTwoToTrancheThreeMember', window );">Tranche 2 to Tranche 3 | Term Loan | First Amendment to Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember', window );">Tranche 2 Advance Subject to Achievement of Specified Interim Milestone | Term Loan | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PeriodWithinLoanDisbursementsToBeMade', window );">Period Within Loan Disbursements to be Made</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit, maturity date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember', window );">Tranche Three Advance Subject to Achievement of Specified Interim Milestone [Member] | Term Loan | First Amendment to Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember', window );">Advance Subject to Achievement of Specified Interim Milestone [Member] | Term Loan | First Amendment to Amended and Restated Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember', window );">If Interim Milestone and Certain Clinical Milestones Achieved and No Default | Term Loan | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LoanAmortizationDate', window );">Loan amortization date</a></td>
<td class="text">Jul.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=engn_IfInterimMilestoneAchievedAndNoDefaultMember', window );">If Interim Milestone Achieved and No Default | Term Loan | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LoanAmortizationDate', window );">Loan amortization date</a></td>
<td class="text">Jan.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AdvanceOnLoanAllocatedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance on loan allocated to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AdvanceOnLoanAllocatedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right year from which warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_EndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End of term charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_EndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_EndOfTermFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End of term fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_EndOfTermFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_LoanAmortizationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan amortization date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_LoanAmortizationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PaidInKindInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paid-in-kind interest percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PaidInKindInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate principal amount of term loan advance to purchase number of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfFacilityChargeOnAmountBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of facility charge on amount borrowed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfFacilityChargeOnAmountBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment premium of principal amount outstanding of the closing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment premium of principal amount outstanding prior to maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment premium of principal amount outstanding prior to twenty four months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PeriodWithinLoanDisbursementsToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period within loan disbursements to be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PeriodWithinLoanDisbursementsToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=engn_HerculesCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=engn_HerculesCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_LoanAndSecurityAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_LoanAndSecurityAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=engn_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=engn_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_TrancheOneAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_TrancheOneAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=engn_HerculesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=engn_HerculesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_AppliedToRefinanceOfAmountOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_AppliedToRefinanceOfAmountOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_PriorLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_PriorLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_TrancheTwoToTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_TrancheTwoToTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_IfInterimMilestoneAchievedAndNoDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_IfInterimMilestoneAchievedAndNoDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of Carrying Value of Term Loan (Details) - Term Loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Note payable, including End of Term Charge</a></td>
<td class="nump">$ 24,231<span></span>
</td>
<td class="nump">$ 24,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount, net of accretion</a></td>
<td class="num">(1,088)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net of discount</a></td>
<td class="nump">$ 23,326<span></span>
</td>
<td class="nump">$ 23,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details) - 2021 Loan and Security Agreement<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 8,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">10,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">5,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Note payable, net of discount</a></td>
<td class="nump">$ 24,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=engn_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=engn_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Shares - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 24, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock shares authorized unlimited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock no par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,018,658<span></span>
</td>
<td class="nump">50,976,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common Shares are entitled to one vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividend paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,511,968<span></span>
</td>
<td class="nump">8,511,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_AmendedLoanAgreementMember', window );">Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember', window );">February 2024 Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DateOfClosedPrivatePlacement', window );">Date of closed private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 20,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember', window );">February 2024 Subscription Agreements | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember', window );">October 2024 Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds of common stock</a></td>
<td class="nump">$ 60,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DateOfClosedPrivatePlacement', window );">Date of closed private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 29,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember', window );">October 2024 Subscription Agreements | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares price per share</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">6,758,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_MaximumAmountOfCommonSharesToBeSold', window );">Maximum amount of common shares to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PaymentOfMaximumCommissionPercentageOfSharesSold', window );">Payment of maximum commission percentage of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AcquirerAxis=engn_FEACMember', window );">FEAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,449,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 22,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_WarrantsAndRightsOutstandingMaturityPeriod', window );">Warrants, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AcquirerAxis=engn_FEACMember', window );">FEAC | Amended Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DateOfClosedPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of closed private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DateOfClosedPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_MaximumAmountOfCommonSharesToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common shares to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_MaximumAmountOfCommonSharesToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PaymentOfMaximumCommissionPercentageOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of maximum commission percentage of shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PaymentOfMaximumCommissionPercentageOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_WarrantsAndRightsOutstandingMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and rights outstanding maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_WarrantsAndRightsOutstandingMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AcquirerAxis=engn_FEACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AcquirerAxis=engn_FEACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 10, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 02, 2025</div></th>
<th class="th">
<div>May 15, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 13, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>$ / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,478,570<span></span>
</td>
<td class="nump">17,299,369<span></span>
</td>
<td class="nump">17,299,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock no par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,926,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="nump">$ 6.88<span></span>
</td>
<td class="nump">$ 6.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of share options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2025 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock no par value | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance', window );">Common stock capital shares reserved for remaining future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of common stock value on date of grant</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_CeoTransitionAgreementMember', window );">CEO Transition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_CeoTransitionAgreementMember', window );">CEO Transition Agreement | Former CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings', window );">Payment Of Target Annual Bonus Netoff Taxes And Withholdings | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AmountOfMonthlyFeeForConsultingPeriod', window );">Amount of monthly fee for consulting period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InitialConsultingPeriod', window );">Initial consulting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_TransitionServicesForConsultingFeePerHour', window );">Transition services for consulting fee per hour | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices', window );">Maximum hours of ceo devote per week to providing transition services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 hours<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_SeveranceAgreementMember', window );">Severance Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits', window );">Employee entitled for continued pay and health insurance benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_EvergreenProvisionMember', window );">Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_CommonSharesPercentage', window );">Aggregate number of common shares outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=engn_TwoZeroTwoThreePlanMember', window );">2023 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of common stock value on date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=engn_TwoZeroTwoThreePlanMember', window );">2023 Plan | Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,651,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance', window );">Common stock capital shares reserved for remaining future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_CommonSharesPercentage', window );">Aggregate number of common shares outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=engn_InducementGrantsMember', window );">Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,643,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
<td class="nump">$ 8.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock option expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Immediately Upon Grant Date | Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting on Remaining Years | Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AmountOfMonthlyFeeForConsultingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of monthly fee for consulting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AmountOfMonthlyFeeForConsultingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_CommonSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_CommonSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares reserved for remaining future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee entitled for continued pay and health insurance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_InitialConsultingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial consulting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_InitialConsultingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum hours of CEO devote per week to providing transition services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of target annual bonus netoff taxes and withholdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_TransitionServicesForConsultingFeePerHour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transition services for consulting fee per hour.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_TransitionServicesForConsultingFeePerHour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_CeoTransitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_CeoTransitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=engn_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=engn_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_SeveranceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_SeveranceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_EvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_EvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=engn_TwoZeroTwoThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=engn_TwoZeroTwoThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=engn_InducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=engn_InducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Share Reserved For Future Issuance Under The Plan (Details) - shares<br></strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">22,478,570<span></span>
</td>
<td class="nump">17,299,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember', window );">Remaining shares reserved for future issuance under the 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,933,304<span></span>
</td>
<td class="nump">2,752,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember', window );">Remaining shares reserved for future issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember', window );">Incentive options to purchase common shares awarded pursuant to the 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">5,717,948<span></span>
</td>
<td class="nump">4,391,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember', window );">Inducement grant stock options awarded outside of the 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">3,315,350<span></span>
</td>
<td class="nump">1,643,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=engn_WarrantToPurchaseCommonStockMember', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">8,511,968<span></span>
</td>
<td class="nump">8,511,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=engn_WarrantToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=engn_WarrantToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details) - Employee Stock Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">78.78%<span></span>
</td>
<td class="nump">78.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">83.53%<span></span>
</td>
<td class="nump">82.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">3.84%<span></span>
</td>
<td class="nump">1.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.49%<span></span>
</td>
<td class="nump">4.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum', window );">Fair value of common shares and exercise price of options, Minimum</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="nump">$ 4.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum', window );">Fair value of common shares and exercise price of options, Maximum</a></td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, Beginning balance</a></td>
<td class="nump">6,034,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">4,926,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(1,041,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired</a></td>
<td class="num">(886,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, Ending balance</a></td>
<td class="nump">9,033,298<span></span>
</td>
<td class="nump">6,034,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable</a></td>
<td class="nump">2,935,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options unvested</a></td>
<td class="nump">6,098,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, Beginning balance</a></td>
<td class="nump">$ 6.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited or expired</a></td>
<td class="nump">9.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">6.93<span></span>
</td>
<td class="nump">$ 6.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options vested and exercisable</a></td>
<td class="nump">6.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Exercise Price, Options unvested</a></td>
<td class="nump">$ 7.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (in years), Outstanding</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term (in years), Options vested and exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term (in years), Options unvested</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 10,979<span></span>
</td>
<td class="nump">$ 17,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and exercisable</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options unvested</a></td>
<td class="nump">$ 4,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options unvested aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 9,646<span></span>
</td>
<td class="nump">$ 5,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 6,364<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders, basic</a></td>
<td class="nump">$ 117,302<span></span>
</td>
<td class="nump">$ 55,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders, diluted</a></td>
<td class="nump">$ 117,302<span></span>
</td>
<td class="nump">$ 55,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in net loss per share, basic</a></td>
<td class="nump">51,119,479<span></span>
</td>
<td class="nump">37,782,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in net loss per share, diluted</a></td>
<td class="nump">51,119,479<span></span>
</td>
<td class="nump">37,782,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common shares, basic</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common shares, diluted</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">17,545,266<span></span>
</td>
<td class="nump">14,546,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">8,511,968<span></span>
</td>
<td class="nump">8,511,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from computation of diluted net loss per share</a></td>
<td class="nump">9,033,298<span></span>
</td>
<td class="nump">6,034,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Canada)</a></td>
<td class="num">$ (103,727)<span></span>
</td>
<td class="num">$ (53,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign (US)</a></td>
<td class="num">(13,575)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (117,302)<span></span>
</td>
<td class="num">$ (55,161)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Components of Provision for (Recovery of) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign (US)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Company's Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income at Canadian statutory rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.29%)<span></span>
</td>
<td class="num">(2.77%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(0.64%)<span></span>
</td>
<td class="num">(0.17%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(26.82%)<span></span>
</td>
<td class="num">(25.02%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.01%)<span></span>
</td>
<td class="nump">0.24%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Deferred Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D expenditures</a></td>
<td class="nump">$ 10,021<span></span>
</td>
<td class="nump">$ 8,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss (NOL) carryforwards</a></td>
<td class="nump">61,127<span></span>
</td>
<td class="nump">31,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Investment tax credits, net</a></td>
<td class="nump">2,688<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DeferredTaxAssetsFinancingCosts', window );">Financing costs</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">5,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DeferredTaxAssetsNotePayable', window );">Note payable</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">82,494<span></span>
</td>
<td class="nump">49,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease-right of use asset</a></td>
<td class="num">(2,068)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,068)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (80,426)<span></span>
</td>
<td class="num">$ (48,992)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DeferredTaxAssetsFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DeferredTaxAssetsFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DeferredTaxAssetsNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, note payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DeferredTaxAssetsNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, operating lease-right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">No uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued', window );">Accrued penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_CapitalLossCarryforward', window );">Capital losses</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ScientificResearchAndExperimentalDevelopmentExpenditures', window );">SR&amp;ED expenditures</a></td>
<td class="nump">39,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">U.S | Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InvestmentTaxCreditsExpirationYear', window );">Investment tax credits expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">U.S | Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InvestmentTaxCreditsExpirationYear', window );">Investment tax credits expiration year</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canadian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 214,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTaxCredit', window );">Investment tax credits</a></td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canadian | Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InvestmentTaxCreditsExpirationYear', window );">Investment tax credits expiration year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canadian | Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InvestmentTaxCreditsExpirationYear', window );">Investment tax credits expiration year</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canadian | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 220,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_ScientificResearchAndExperimentalDevelopmentExpenditures', window );">SR&amp;ED expenditures</a></td>
<td class="nump">$ 36,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canadian | Federal | Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canadian | Federal | Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_CapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_CapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_InvestmentTaxCreditsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment tax credits expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_InvestmentTaxCreditsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_NetOperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforwards Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_NetOperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_ScientificResearchAndExperimentalDevelopmentExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Scientific research and experimental development expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_ScientificResearchAndExperimentalDevelopmentExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount deducted from an entities' taxes, reflecting a percentage of an amount invested in certain assets spread over the useful life of those assets; includes deferred investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 04, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 29, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,716<span></span>
</td>
<td class="nump">$ 1,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,469<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_OfficeSpaceMember', window );">Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AreaOfSpace', window );">Rentable square feet | ft&#178;</a></td>
<td class="nump">26,335<span></span>
</td>
<td class="nump">6,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AggregateAmountOfBaseRentalPayments', window );">Aggregate amount of base rental payments</a></td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">2030-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_NewLaboratoryAndOfficeSpaceMember', window );">New Laboratory and Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_AreaOfSpace', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_OperatingLeaseCommencementPeriod', window );">Operating lease commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_InitialAnnualBaseRentPerSquareFoot', window );">Initial annual base rent | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfIncreaseInAnnualBaseRent', window );">Percentage of increase in annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AggregateAmountOfBaseRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of base rental payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AggregateAmountOfBaseRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_AreaOfSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_AreaOfSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_InitialAnnualBaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial annual base rent per square foot.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_InitialAnnualBaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_OperatingLeaseCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_OperatingLeaseCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfIncreaseInAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfIncreaseInAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_NewLaboratoryAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=engn_NewLaboratoryAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Operating Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">2,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">13,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(4,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 8,469<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">The CODM manages the Company&#8217;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Significant Segment Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 94,480<span></span>
</td>
<td class="nump">$ 38,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses</a></td>
<td class="nump">11,471<span></span>
</td>
<td class="nump">11,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">28,685<span></span>
</td>
<td class="nump">23,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(5,863)<span></span>
</td>
<td class="num">(7,155)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">117,302<span></span>
</td>
<td class="nump">55,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=engn_ChemistryManufacturingAndControlsMember', window );">Chemistry, Manufacturing and Controls</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">49,578<span></span>
</td>
<td class="nump">11,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=engn_ClinicalOperationsMember', window );">Clinical Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">17,915<span></span>
</td>
<td class="nump">11,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=engn_OtherResearchAndDevelopmentExpensesMember', window );">Other Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">7,052<span></span>
</td>
<td class="nump">4,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember', window );">Personnel-Related Expenses Excluding Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">16,653<span></span>
</td>
<td class="nump">8,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">10,850<span></span>
</td>
<td class="nump">8,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=engn_StockBasedCompensationMember', window );">Stock Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">$ 6,364<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=engn_ChemistryManufacturingAndControlsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=engn_ChemistryManufacturingAndControlsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=engn_ClinicalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=engn_ClinicalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=engn_OtherResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=engn_OtherResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=engn_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=engn_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Significant Segment Expenses (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 9,426<span></span>
</td>
<td class="nump">$ 10,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="num">(569)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">other segment items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2024</div></th>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=engn_TwoThousandTwentyFourPipeInvestorsMember', window );">2024 PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">561,797<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, value</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | 2024 Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">6,758,311<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares price per share</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfSharesOwnedByShareholders', window );">Percentage of shares owned by shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfSharesOwnedByShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares owned by shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfSharesOwnedByShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_TwoThousandTwentyFourPipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_TwoThousandTwentyFourPipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=engn_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=engn_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 14, 2025</div></th>
<th class="th"><div>Nov. 12, 2025</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,511,968<span></span>
</td>
<td class="nump">8,511,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate gross proceeds from option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant issued to purchase common shares</a></td>
<td class="nump">2,294,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,558,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 149,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate gross proceeds from option exercise</a></td>
<td class="nump">$ 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder', window );">Percentage of outstanding common shares owned by the holder</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum percentage of outstanding common shares owned by the holder</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Underwritten Public Offering | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,735,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common shares owned by the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>engn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=engn_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=engn_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=engn_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=engn_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>235</ContextCount>
  <ElementCount>416</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>92</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusiness1</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - License Agreement and Clinical Research Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization</Role>
      <ShortName>License Agreement and Clinical Research Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1</Role>
      <ShortName>Common Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLeases1</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Common Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesTables</Role>
      <ShortName>Common Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureLeases1</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - License Agreement and Clinical Research Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails</Role>
      <ShortName>License Agreement and Clinical Research Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails</Role>
      <ShortName>Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Notes Payable - Schedule of Carrying Value of Term Loan (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails</Role>
      <ShortName>Notes Payable - Schedule of Carrying Value of Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails</Role>
      <ShortName>Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Common Shares - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails</Role>
      <ShortName>Common Shares - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Share-Based Compensation - Schedule of Share Reserved For Future Issuance Under The Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Share Reserved For Future Issuance Under The Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes - Summary of Components of Provision for (Recovery of) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Summary of Components of Provision for (Recovery of) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Income Taxes - Summary of Reconciliation of Company's Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Company's Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes - Summary of Net Deferred Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Summary of Net Deferred Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails</Role>
      <ShortName>Segment Reporting - Summary of Significant Segment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails</Role>
      <ShortName>Segment Reporting - Summary of Significant Segment Expenses (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="engn-20251031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="engn-20251031.htm">engn-20251031.htm</File>
    <File>engn-20251031.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img209334158_0.jpg</File>
    <File>img209334158_1.jpg</File>
    <File>img209334158_10.jpg</File>
    <File>img209334158_2.jpg</File>
    <File>img209334158_3.jpg</File>
    <File>img209334158_4.jpg</File>
    <File>img209334158_5.jpg</File>
    <File>img209334158_6.jpg</File>
    <File>img209334158_7.jpg</File>
    <File>img209334158_8.jpg</File>
    <File>img209334158_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="674">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>104
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "engn-20251031.htm": {
   "nsprefix": "engn",
   "nsuri": "http://engene.com/20251031",
   "dts": {
    "inline": {
     "local": [
      "engn-20251031.htm"
     ]
    },
    "schema": {
     "local": [
      "engn-20251031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 332,
   "keyCustom": 84,
   "axisStandard": 26,
   "axisCustom": 1,
   "memberStandard": 37,
   "memberCustom": 51,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2025": 8,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 235,
   "entityCount": 1,
   "segmentCount": 92,
   "elementCount": 761,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 674,
    "http://xbrl.sec.gov/dei/2025": 44,
    "http://xbrl.sec.gov/cyd/2025": 13,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "longName": "75010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "longName": "75040 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_6691d0be-dbca-4238-ba0d-4650e328c889",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6691d0be-dbca-4238-ba0d-4650e328c889",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows",
     "longName": "75050 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995455 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusiness1",
     "longName": "995465 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1",
     "longName": "995495 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1",
     "longName": "995505 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995515 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization",
     "longName": "995525 - Disclosure - License Agreement and Clinical Research Organization",
     "shortName": "License Agreement and Clinical Research Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1",
     "longName": "995535 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1",
     "longName": "995545 - Disclosure - Common Shares",
     "shortName": "Common Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation",
     "longName": "995555 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995565 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995575 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLeases1",
     "longName": "995585 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995595 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995605 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://engene.com/20251031/taxonomy/role/RelatedPartyTransactions",
     "longName": "995615 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://engene.com/20251031/taxonomy/role/SubsequentEvents",
     "longName": "995625 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995645 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "engn:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "engn:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995655 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "longName": "995665 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "995675 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables",
     "longName": "995695 - Disclosure - Notes Payable (Tables)",
     "shortName": "Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesTables",
     "longName": "995705 - Disclosure - Common Shares (Tables)",
     "shortName": "Common Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables",
     "longName": "995715 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995725 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995735 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables",
     "longName": "995745 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995755 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
     "longName": "995765 - Disclosure - Description of Business - Additional Information (Details)",
     "shortName": "Description of Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail",
     "longName": "995785 - Disclosure - Summary of Significant Accounting Policies - Segment Information - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_dbc9c096-5c22-4cf5-a894-96a9e588ee65",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dbc9c096-5c22-4cf5-a894-96a9e588ee65",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails",
     "longName": "995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_90cd8c09-4769-4823-a74e-e5e1dd36b35a",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_90cd8c09-4769-4823-a74e-e5e1dd36b35a",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995805 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
     "longName": "995815 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_ba0f02fb-b1f0-4954-bd4f-3c466d2899e1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ba0f02fb-b1f0-4954-bd4f-3c466d2899e1",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
     "longName": "995825 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Marketable Securities - Additional Information (Details)",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "engn:NumberOfSecuritiesHeld",
      "unitRef": "U_Security",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "engn:NumberOfSecuritiesHeld",
      "unitRef": "U_Security",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
     "longName": "995845 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995855 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995865 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "engn:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "engn:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails",
     "longName": "995875 - Disclosure - License Agreement and Clinical Research Organization - Additional Information (Details)",
     "shortName": "License Agreement and Clinical Research Organization - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_019c08b7-c82a-486b-871e-9cb94b318c49",
      "name": "us-gaap:CostMaintenance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_019c08b7-c82a-486b-871e-9cb94b318c49",
      "name": "us-gaap:CostMaintenance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
     "longName": "995885 - Disclosure - Notes Payable - Additional Information (Details)",
     "shortName": "Notes Payable - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails",
     "longName": "995895 - Disclosure - Notes Payable - Schedule of Carrying Value of Term Loan (Details)",
     "shortName": "Notes Payable - Schedule of Carrying Value of Term Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_0a196932-bb45-4e51-825a-16dde720a445",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0a196932-bb45-4e51-825a-16dde720a445",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails",
     "longName": "995905 - Disclosure - Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)",
     "shortName": "Notes Payable - Schedule of Estimated Future Principal Payments Due Under the Loan Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_b291458d-545a-4cdc-a379-778ab2dd0485",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b291458d-545a-4cdc-a379-778ab2dd0485",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
     "longName": "995915 - Disclosure - Common Shares - Additional Information (Details)",
     "shortName": "Common Shares - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails",
     "longName": "995935 - Disclosure - Share-Based Compensation - Schedule of Share Reserved For Future Issuance Under The Plan (Details)",
     "shortName": "Share-Based Compensation - Schedule of Share Reserved For Future Issuance Under The Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b6f75307-46d2-4549-9972-666e9421fcbc",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
     "longName": "995945 - Disclosure - Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)",
     "shortName": "Share-Based Compensation - Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_fe08772b-3b75-4431-99b3-b2403219570c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fe08772b-3b75-4431-99b3-b2403219570c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "995955 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails",
     "longName": "995965 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Summary of Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "995975 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
     "longName": "995985 - Disclosure - Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)",
     "shortName": "Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable To Common Shareholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails",
     "longName": "995995 - Disclosure - Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Summary of Loss Before Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails",
     "longName": "996005 - Disclosure - Income Taxes - Summary of Components of Provision for (Recovery of) Income Taxes (Details)",
     "shortName": "Income Taxes - Summary of Components of Provision for (Recovery of) Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails",
     "longName": "996015 - Disclosure - Income Taxes - Summary of Reconciliation of Company's Statutory Income Tax Rate (Details)",
     "shortName": "Income Taxes - Summary of Reconciliation of Company's Statutory Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails",
     "longName": "996025 - Disclosure - Income Taxes - Summary of Net Deferred Income Tax (Details)",
     "shortName": "Income Taxes - Summary of Net Deferred Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996035 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "996045 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_25b1651f-4d90-4142-812f-a565d3cf756e",
      "name": "engn:AreaOfSpace",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails",
     "longName": "996055 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Details)",
     "shortName": "Leases - Schedule of Components of Operating Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails",
     "longName": "996065 - Disclosure - Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details)",
     "shortName": "Leases - Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "longName": "996075 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "996095 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
     "longName": "996105 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Details)",
     "shortName": "Segment Reporting - Summary of Significant Segment Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails",
     "longName": "996115 - Disclosure - Segment Reporting - Summary of Significant Segment Expenses (Parenthetical) (Details)",
     "shortName": "Segment Reporting - Summary of Significant Segment Expenses (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_35984b9c-b42a-47eb-9c9e-3d205962f9d9",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "996125 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_c129c2c8-58f0-43f4-bfdf-85528ac931e9",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c129c2c8-58f0-43f4-bfdf-85528ac931e9",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996135 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_47a4d634-ac1f-4323-9bc5-0785480c857c",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_222a5d6f-14cb-46e4-a552-efc82189402f",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "engn-20251031.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202307Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202307Member",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2023-07 [Member]",
        "terseLabel": "ASU 2023-07",
        "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r54",
      "r1267"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r1016"
     ]
    },
    "engn_AccruedFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AccruedFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued financing costs",
        "documentation": "Accrued financing costs.",
        "label": "Accrued Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r93"
     ]
    },
    "engn_AccruedInterestReceivableWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AccruedInterestReceivableWrittenOff",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest receivable written off.",
        "label": "Accrued Interest Receivable Written Off",
        "terseLabel": "Accrued interest receivable written off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "engn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r135",
      "r779"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r66",
      "r141",
      "r775",
      "r812",
      "r816",
      "r1285"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r15",
      "r578",
      "r581",
      "r674",
      "r807",
      "r808",
      "r1182",
      "r1183",
      "r1184",
      "r1201",
      "r1202",
      "r1203",
      "r1205"
     ]
    },
    "engn_AcquirerAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AcquirerAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquirer.",
        "label": "Acquirer [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "engn_AcquirerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AcquirerDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquirer.",
        "label": "Acquirer [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1201",
      "r1202",
      "r1203",
      "r1205",
      "r1286",
      "r1360"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r157",
      "r158",
      "r159",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r203",
      "r275",
      "r276",
      "r312",
      "r314",
      "r315",
      "r316",
      "r340",
      "r341",
      "r350",
      "r403",
      "r404",
      "r405",
      "r406",
      "r485",
      "r486",
      "r487",
      "r488",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r627",
      "r628",
      "r651",
      "r652",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1239"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants in connection with Amended Term Loan",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r86"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "engn_AdvanceOnLoanAllocatedToWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AdvanceOnLoanAllocatedToWarrants",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance on loan allocated to warrants.",
        "label": "Advance on Loan Allocated to Warrants.",
        "terseLabel": "Advance on loan allocated to warrants"
       }
      }
     },
     "auth_ref": []
    },
    "engn_AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance subject to achievement of specified interim milestone.",
        "label": "Advance Subject to Achievement of Specified Interim Milestone [Member]",
        "terseLabel": "Advance Subject to Achievement of Specified Interim Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "engn_AggregateAmountOfBaseRentalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AggregateAmountOfBaseRentalPayments",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount of base rental payments",
        "documentation": "Aggregate amount of base rental payments.",
        "label": "Aggregate Amount Of Base Rental Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1075",
      "r1085",
      "r1118"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1078",
      "r1088",
      "r1121"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1113",
      "r1122",
      "r1126",
      "r1134"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "other segment items",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r267",
      "r966",
      "r967"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation expense",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r489",
      "r498"
     ]
    },
    "engn_AmendedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AmendedLoanAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Loan Agreement",
        "label": "Amended Loan Agreement [Member]",
        "documentation": "Amended loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Amortization of premium/discount on marketable securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r72",
      "r393",
      "r1305"
     ]
    },
    "engn_AmountOfMonthlyFeeForConsultingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AmountOfMonthlyFeeForConsultingPeriod",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of monthly fee for consulting period",
        "documentation": "Amount of monthly fee for consulting period.",
        "label": "Amount Of Monthly Fee For Consulting Period"
       }
      }
     },
     "auth_ref": []
    },
    "engn_AnnualMaintenanceFeeUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AnnualMaintenanceFeeUnderLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses related to the annual maintenance fee",
        "label": "Annual Maintenance Fee Under License Agreement",
        "documentation": "Annual maintenance fee under license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares excluded from computation of diluted net loss per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "engn_AppliedToRefinanceOfAmountOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AppliedToRefinanceOfAmountOutstandingMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Applied to Refinance of Amount Outstanding",
        "label": "Applied to Refinance of Amount Outstanding [Member]",
        "documentation": "Applied to refinance of amount outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "engn_AreaOfSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "AreaOfSpace",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Area of office space",
        "terseLabel": "Rentable square feet",
        "label": "Area Of Space",
        "documentation": "Area of space."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r103",
      "r137",
      "r171",
      "r174",
      "r175",
      "r224",
      "r237",
      "r262",
      "r266",
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r563",
      "r567",
      "r636",
      "r757",
      "r758",
      "r773",
      "r868",
      "r966",
      "r967",
      "r980",
      "r1016",
      "r1029",
      "r1030",
      "r1042",
      "r1231",
      "r1232",
      "r1311"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r142",
      "r171",
      "r174",
      "r175",
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r563",
      "r567",
      "r636",
      "r1016",
      "r1231",
      "r1232",
      "r1311"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, fair value",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Financial assets",
        "totalLabel": "Total financial assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r1003"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1071"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1071"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1071"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Holdings Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Holdings Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r322",
      "r772"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Aggregate Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r322",
      "r602",
      "r629",
      "r630",
      "r631",
      "r632",
      "r754",
      "r941",
      "r1003",
      "r1006",
      "r1013",
      "r1215",
      "r1290",
      "r1291",
      "r1292"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusiness1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1191"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CA",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada",
        "verboseLabel": "Canadian"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets included in accrued expenses and accounts payable",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Property and equipment included in accrued expenses and accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "engn_CapitalLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "CapitalLossCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital loss carryforward.",
        "label": "Capital Loss Carryforward",
        "terseLabel": "Capital losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizationOfDeferredPolicyAcquisitionCostsPolicy",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Transaction Costs",
        "label": "Deferred Policy Acquisition Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r133",
      "r943"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r75",
      "r168"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75"
     ]
    },
    "engn_CashEquivalentsAndShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short-term investments.",
        "label": "Cash Equivalents and Short-term Investments [Member]",
        "terseLabel": "Cash Equivalents and Short Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "engn_CeoTransitionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "CeoTransitionAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEO Transition Agreement.",
        "label": "CEO Transition Agreement [Member]",
        "terseLabel": "CEO Transition Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r128",
      "r157",
      "r187",
      "r275",
      "r340",
      "r350",
      "r403",
      "r485",
      "r533",
      "r542",
      "r543",
      "r551",
      "r552",
      "r556",
      "r574",
      "r590",
      "r591",
      "r627",
      "r628",
      "r651",
      "r669",
      "r670",
      "r805",
      "r806"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r157",
      "r275",
      "r340",
      "r350",
      "r403",
      "r404",
      "r485",
      "r486",
      "r533",
      "r542",
      "r543",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r574",
      "r575",
      "r590",
      "r591",
      "r592",
      "r595",
      "r627",
      "r628",
      "r651",
      "r669",
      "r670",
      "r805",
      "r806",
      "r1168",
      "r1204"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r188",
      "r202",
      "r313"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "engn_ChemistryManufacturingAndControlsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ChemistryManufacturingAndControlsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chemistry Manufacturing and Controls [Member]",
        "documentation": "Chemistry Manufacturing and Controls.",
        "terseLabel": "Chemistry, Manufacturing and Controls"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails",
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r138",
      "r139",
      "r140",
      "r171",
      "r175",
      "r208",
      "r209",
      "r216",
      "r218",
      "r226",
      "r227",
      "r311",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r407",
      "r408",
      "r410",
      "r411",
      "r413",
      "r415",
      "r418",
      "r419",
      "r422",
      "r425",
      "r432",
      "r636",
      "r821",
      "r822",
      "r823",
      "r824",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r856",
      "r877",
      "r899",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1158",
      "r1194",
      "r1196",
      "r1206"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r226",
      "r410",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r430",
      "r432",
      "r573",
      "r821",
      "r822",
      "r823",
      "r824",
      "r981",
      "r1158",
      "r1192",
      "r1194"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1236"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, exercise price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r178",
      "r433"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued to purchase preferred shares",
        "verboseLabel": "Share warrants issued",
        "terseLabel": "Number of securities into which the class of warrant or right may be converted",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Warrant issued to purchase common shares",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "engn_ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable period",
        "label": "Class Of Warrant Or Right Year From Which Warrants Or Rights Exercisable",
        "documentation": "Class of warrant or right year from which warrants or rights exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "engn_ClinicalOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ClinicalOperationsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Operations [Member]",
        "documentation": "Clinical Operations.",
        "terseLabel": "Clinical Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "engn_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "CommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total commitment amount",
        "label": "Commitment Amount",
        "documentation": "Commitment amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r354",
      "r355",
      "r928",
      "r1223",
      "r1228"
     ]
    },
    "engn_CommonSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "CommonSharesPercentage",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares percentage.",
        "label": "Common Shares Percentage",
        "terseLabel": "Aggregate number of common shares outstanding percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Aggregate number of common shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "engn_CommonStockCapitalSharesReservedForRemainingFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "CommonStockCapitalSharesReservedForRemainingFutureIssuance",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital shares reserved for remaining future issuance.",
        "label": "Common Stock Capital Shares Reserved for Remaining Future Issuance",
        "terseLabel": "Common stock capital shares reserved for remaining future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividend paid",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividends declared",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1033",
      "r1034",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1201",
      "r1202",
      "r1205",
      "r1286",
      "r1355",
      "r1360"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock no par value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares price per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Common stock shares authorized unlimited",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued",
        "verboseLabel": "Common shares issued and sold",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock shares outstanding",
        "verboseLabel": "Total Common Shares outstanding immediately after the Reverse Recapitalization and PIPE Financing",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r856",
      "r874",
      "r1360",
      "r1361"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value; unlimited shares authorized, 52,018,658 and 50,976,676 shares issued and outstanding as of October 31, 2025 and October 31, 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r408",
      "r414",
      "r774",
      "r1016"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r145",
      "r147",
      "r152",
      "r755",
      "r786",
      "r787"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk of Concentrations of Credit and Off-Balance Sheet Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r634"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Financial Instruments, off-Balance-Sheet Risk",
        "terseLabel": "Off-balance sheet concentrations of credit risk description",
        "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "engn_ConcentrationRiskCreditRiskOffBalanceSheetRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ConcentrationRiskCreditRiskOffBalanceSheetRisk",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance sheet concentrations of credit risk",
        "documentation": "Concentration risk credit risk off balance sheet risk.",
        "label": "Concentration Risk Credit Risk Off Balance Sheet Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual maintenance fee",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r181",
      "r182",
      "r375",
      "r420",
      "r680",
      "r701",
      "r771",
      "r944",
      "r945",
      "r946",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1280",
      "r1281",
      "r1282",
      "r1283"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r1229"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r1229"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic (Canada)",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Current Federal, State and Local, Tax Expense (Benefit), Total",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign (US)",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1192",
      "r1198"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current expense (benefit)",
        "terseLabel": "Total current expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r1192",
      "r1198"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current expense (benefit):",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1145"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1145"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1147"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1147"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1060",
      "r1149"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1147"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1140"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1141"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1141"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1139"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1139"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1139"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1142"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1144"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1145"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1148"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1146"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1054",
      "r1143"
     ]
    },
    "engn_DateOfClosedPrivatePlacement": {
     "xbrltype": "dateItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DateOfClosedPrivatePlacement",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of closed private placement",
        "documentation": "Date of closed private placement.",
        "label": "Date of Closed Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r171",
      "r173",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r360",
      "r361",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r387",
      "r394",
      "r395",
      "r397",
      "r573",
      "r649"
     ]
    },
    "engn_DebtInstrumentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DebtInstrumentAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt Instrument, Accrued Interest",
        "documentation": "Debt instrument, accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r48",
      "r49",
      "r92",
      "r95",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1014",
      "r1192",
      "r1193",
      "r1195",
      "r1200",
      "r1224",
      "r1225",
      "r1226",
      "r1304",
      "r1306",
      "r1321"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt instrument, basis spread on variable rate",
        "terseLabel": "Term loan annual interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable, including End of Term Charge",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r95",
      "r398"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowed amount",
        "verboseLabel": "Principal amount",
        "terseLabel": "Term loans aggregate principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r649",
      "r650",
      "r976",
      "r977",
      "r1014"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt instrument, interest rate",
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r390",
      "r1304"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrue interest rate",
        "terseLabel": "Effective interest rate of outstanding debt",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r401",
      "r649",
      "r650",
      "r1014"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r573",
      "r761",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1014",
      "r1192",
      "r1193",
      "r1195",
      "r1200",
      "r1304",
      "r1306"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1014",
      "r1192",
      "r1193",
      "r1195",
      "r1200",
      "r1224",
      "r1225",
      "r1226",
      "r1304",
      "r1306",
      "r1321"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r41",
      "r45",
      "r84",
      "r85",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r573",
      "r761",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1014",
      "r1192",
      "r1193",
      "r1195",
      "r1200",
      "r1304",
      "r1306"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount, net of accretion",
        "label": "Debt Instrument, Unamortized Discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1234",
      "r1303",
      "r1304",
      "r1306"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount and issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r399",
      "r648",
      "r649",
      "r650",
      "r976",
      "r977",
      "r1014"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "engn_DebtIssuanceCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DebtIssuanceCostsPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt Issuance Costs [Policy Text Block]",
        "documentation": "Debt issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r322",
      "r323",
      "r324"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Aggregate fair value",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r327"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of unrealized loss position",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses on sale or maturity of available-for-sale securities",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Credit losses",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r326",
      "r973"
     ]
    },
    "engn_DebtSecuritiesUnrealizedLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DebtSecuritiesUnrealizedLosses",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities unrealized losses.",
        "label": "Debt Securities Unrealized Losses",
        "terseLabel": "Debt securities unrealized losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic (Canada)",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Deferred Federal, State and Local, Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign (US)",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1198",
      "r1277"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred tax expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r114",
      "r1192",
      "r1198"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total Deferred tax liabilities",
        "terseLabel": "Total Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r94",
      "r522"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "engn_DeferredTaxAssetsFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DeferredTaxAssetsFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing costs",
        "label": "Deferred Tax Assets Financing Costs",
        "documentation": "Deferred tax assets financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "terseLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D expenditures",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liability)",
        "terseLabel": "Net deferred tax assets (liability)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "engn_DeferredTaxAssetsNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DeferredTaxAssetsNotePayable",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, note payable",
        "label": "Deferred Tax Assets, Note Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "auth_ref": []
    },
    "engn_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, operating lease liability.",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss (NOL) carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "terseLabel": "Investment tax credits, net",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "engn_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfNetDeferredIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, operating lease-right of use asset.",
        "label": "Deferred Tax Liabilities, Operating Lease-right Of Use Asset",
        "negatedLabel": "Operating lease-right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of property and equipment",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r31",
      "r155",
      "r947",
      "r948",
      "r950",
      "r952"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r156",
      "r224",
      "r242",
      "r266",
      "r947",
      "r966",
      "r967"
     ]
    },
    "engn_DescriptionOfBusinessLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DescriptionOfBusinessLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business [Line Items]",
        "documentation": "Description of business."
       }
      }
     },
     "auth_ref": []
    },
    "engn_DescriptionOfBusinessTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "DescriptionOfBusinessTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business [Table]",
        "documentation": "Description of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r449",
      "r480",
      "r481",
      "r484",
      "r990"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1071"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1071",
      "r1114"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earliest Tax Year",
        "terseLabel": "2028",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common shares, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r153",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r205",
      "r208",
      "r216",
      "r217",
      "r218",
      "r223",
      "r406",
      "r487",
      "r549",
      "r560",
      "r599",
      "r600",
      "r756",
      "r788",
      "r956"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common shares, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r153",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r208",
      "r216",
      "r217",
      "r218",
      "r223",
      "r406",
      "r487",
      "r549",
      "r560",
      "r599",
      "r600",
      "r756",
      "r788",
      "r956"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r220"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r219",
      "r221",
      "r222"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "terseLabel": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r993"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income at Canadian statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177",
      "r507",
      "r536",
      "r993"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r993",
      "r1192",
      "r1199",
      "r1269"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r511",
      "r993",
      "r1192",
      "r1199",
      "r1269"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r515",
      "r1192",
      "r1199",
      "r1269"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r1192",
      "r1199",
      "r1269",
      "r1270"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r993",
      "r1192",
      "r1199",
      "r1269"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfCompanysStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r515",
      "r1192",
      "r1199",
      "r1269"
     ]
    },
    "engn_EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee entitled for continued pay and health insurance benefits.",
        "label": "Employee entitled for continued pay and health insurance benefits",
        "terseLabel": "Employee entitled for continued pay and health insurance benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee compensation and related benefits",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense weighted-average period of recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to purchase common shares",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "engn_EndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "EndOfTermCharge",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of term charge",
        "label": "End of Term Charge",
        "documentation": "End of term charge."
       }
      }
     },
     "auth_ref": []
    },
    "engn_EndOfTermFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "EndOfTermFeePercentage",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "End of term fee percentage",
        "label": "End of Term Fee Percentage",
        "documentation": "End of term fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r120",
      "r127",
      "r128",
      "r149",
      "r150",
      "r151",
      "r184",
      "r185",
      "r186",
      "r189",
      "r197",
      "r199",
      "r201",
      "r225",
      "r312",
      "r316",
      "r341",
      "r405",
      "r434",
      "r487",
      "r531",
      "r532",
      "r545",
      "r546",
      "r547",
      "r550",
      "r559",
      "r560",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r598",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r651",
      "r654",
      "r674",
      "r784",
      "r807",
      "r808",
      "r809",
      "r831",
      "r899"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1075",
      "r1085",
      "r1118"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1072",
      "r1082",
      "r1115"
     ]
    },
    "engn_EvergreenProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "EvergreenProvisionMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evergreen provision.",
        "label": "Evergreen Provision [Member]",
        "terseLabel": "Evergreen Provision"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "engn_FEACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "FEACMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FEAC",
        "documentation": "FEAC.",
        "label": "FEAC [Member]",
        "terseLabel": "FEAC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r617",
      "r1003"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r617",
      "r1003"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets Measured at Fair Value",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1288",
      "r1289"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r618",
      "r941",
      "r1004",
      "r1013"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r618",
      "r941",
      "r1004",
      "r1013"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r615",
      "r617",
      "r619",
      "r630",
      "r688",
      "r689",
      "r690",
      "r941",
      "r976",
      "r977",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r1003",
      "r1006",
      "r1013"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r606",
      "r1003",
      "r1291",
      "r1294"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r611",
      "r613",
      "r614",
      "r615",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r753",
      "r1003",
      "r1007"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r436",
      "r441",
      "r442",
      "r603",
      "r617",
      "r630",
      "r688",
      "r941",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r1003",
      "r1013"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r436",
      "r441",
      "r442",
      "r444",
      "r603",
      "r604",
      "r617",
      "r630",
      "r689",
      "r941",
      "r976",
      "r977",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r1003",
      "r1013"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r603",
      "r604",
      "r605",
      "r606",
      "r617",
      "r630",
      "r690",
      "r941",
      "r976",
      "r977",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r1003",
      "r1006",
      "r1013"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r606",
      "r1003",
      "r1291",
      "r1294"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets transfers or reclassifications out of level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r616",
      "r618",
      "r1004"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r615",
      "r617",
      "r619",
      "r630",
      "r688",
      "r689",
      "r690",
      "r941",
      "r976",
      "r977",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r1003",
      "r1006",
      "r1013"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1294"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "engn_FebruaryPipeFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "FebruaryPipeFinancingMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February PIPE financing.",
        "label": "February PIPE Financing [Member]",
        "terseLabel": "February PIPE Financing"
       }
      }
     },
     "auth_ref": []
    },
    "engn_FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February two thousand twenty four subscription agreements.",
        "label": "February Two Thousand Twenty Four Subscription Agreements [Member]",
        "terseLabel": "February 2024 Subscription Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r325",
      "r328",
      "r329",
      "r396",
      "r430",
      "r573",
      "r588",
      "r624",
      "r635",
      "r638",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r766",
      "r785",
      "r973",
      "r1003",
      "r1004",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1017",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1287",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1296",
      "r1297"
     ]
    },
    "engn_FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Amendment to Amended and Restated Loan and Security Agreement [Member]",
        "documentation": "First amendment to amended and restated loan and security agreement.",
        "terseLabel": "First Amendment",
        "verboseLabel": "First Amendment to Amended and Restated Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Unrealized foreign currency losses (gains)",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r875",
      "r1040",
      "r1301",
      "r1302",
      "r1359"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1122"
     ]
    },
    "engn_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former chief executive officer.",
        "label": "Former Chief Executive Officer [Member]",
        "terseLabel": "Former CEO"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on the disposal of property and equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of convertible debentures",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Loss on extinguishment of debt",
        "negatedLabel": "Gain on extinguishment of debt",
        "label": "Gain on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "Total general and administrative expenses",
        "verboseLabel": "Total general and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r879"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "engn_GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance Programs for Research and Development Expenditures",
        "label": "Government Assistance Programs For Research And Development Expenditures [Policy Text Block]",
        "documentation": "Government assistance programs for research and development expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "engn_HerculesCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "HerculesCapitalMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hercules Capital",
        "label": "Hercules Capital [Member]",
        "documentation": "Hercules capital."
       }
      }
     },
     "auth_ref": []
    },
    "engn_HerculesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "HerculesWarrantsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hercules Warrants",
        "label": "Hercules Warrants [Member]",
        "documentation": "Hercules warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1071"
     ]
    },
    "engn_IfInterimMilestoneAchievedAndNoDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "IfInterimMilestoneAchievedAndNoDefaultMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "If Interim Milestone Achieved and No Default",
        "label": "If Interim Milestone Achieved and No Default [Member]",
        "documentation": "If interim milestone achieved and no default."
       }
      }
     },
     "auth_ref": []
    },
    "engn_IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "If Interim Milestone and Certain Clinical Milestones Achieved and No Default [Member]",
        "terseLabel": "If Interim Milestone and Certain Clinical Milestones Achieved and No Default",
        "documentation": "If interim milestone and certain clinical milestones achieved and no default."
       }
      }
     },
     "auth_ref": []
    },
    "engn_IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Options To Purchase Common Shares Awarded Pursuant to Two Thousand and Twenty Three Plan [Member]",
        "documentation": "Incentive options to purchase common shares awarded pursuant to two thousand and twenty three plan.",
        "terseLabel": "Incentive options to purchase common shares awarded pursuant to the 2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic (Canada)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r506"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "negatedTotalLabel": "Net loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r97",
      "r102",
      "r757",
      "r759",
      "r781",
      "r949",
      "r951",
      "r953",
      "r960",
      "r966",
      "r1208",
      "r1210",
      "r1211",
      "r1212",
      "r1213"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign (US)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r506"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349",
      "r351",
      "r569",
      "r570",
      "r571",
      "r572",
      "r608",
      "r612",
      "r618",
      "r637",
      "r638",
      "r639",
      "r802",
      "r804",
      "r884",
      "r940",
      "r941",
      "r994",
      "r995",
      "r1001",
      "r1002",
      "r1005",
      "r1013",
      "r1278",
      "r1279",
      "r1325"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r351",
      "r569",
      "r570",
      "r571",
      "r572",
      "r608",
      "r612",
      "r618",
      "r637",
      "r638",
      "r639",
      "r802",
      "r804",
      "r884",
      "r940",
      "r941",
      "r994",
      "r995",
      "r1001",
      "r1002",
      "r1005",
      "r1013",
      "r1278",
      "r1279",
      "r1325"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r507",
      "r508",
      "r519",
      "r527",
      "r993",
      "r1274"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r507",
      "r508",
      "r519",
      "r527",
      "r993",
      "r1274"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177",
      "r502",
      "r507",
      "r516",
      "r517",
      "r518",
      "r520",
      "r526",
      "r537",
      "r539",
      "r540",
      "r541",
      "r765",
      "r818",
      "r826",
      "r993"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfProvisionForRecoveryOfIncomeTaxesDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (recovery of) income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r115",
      "r171",
      "r200",
      "r201",
      "r224",
      "r245",
      "r266",
      "r505",
      "r507",
      "r538",
      "r789",
      "r949",
      "r951",
      "r953",
      "r993"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r503",
      "r504",
      "r520",
      "r521",
      "r525",
      "r529",
      "r820"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1190"
     ]
    },
    "engn_IncreaseDecreaseInInvestmentTaxCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "IncreaseDecreaseInInvestmentTaxCreditReceivable",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment tax credit receivable",
        "terseLabel": "Investment tax credit receivable",
        "label": "Increase (Decrease) In Investment Tax Credit Receivable",
        "documentation": "Increase (decrease) in investment tax credit receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1190"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1113",
      "r1122",
      "r1126",
      "r1134"
     ]
    },
    "engn_InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Grant Stock Options Awarded Outside The Two Thousand and Twenty Three Plan [Member]",
        "documentation": "Inducement grant stock options awarded outside the two thousand and twenty three plan.",
        "terseLabel": "Inducement grant stock options awarded outside of the 2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "engn_InducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "InducementGrantsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Grants [Member]",
        "label": "Inducement Grants [Member]",
        "terseLabel": "Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "engn_InitialAnnualBaseRentPerSquareFoot": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "InitialAnnualBaseRentPerSquareFoot",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial annual base rent",
        "label": "Initial Annual Base Rent Per Square Foot",
        "documentation": "Initial annual base rent per square foot."
       }
      }
     },
     "auth_ref": []
    },
    "engn_InitialConsultingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "InitialConsultingPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial consulting period.",
        "label": "Initial Consulting Period",
        "terseLabel": "Initial consulting Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1138"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1138"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1138"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "totalLabel": "Interest Expense, Debt, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r391",
      "r402",
      "r978",
      "r979",
      "r1357"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r949",
      "r953",
      "r1187"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r165",
      "r166"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r240",
      "r266",
      "r966",
      "r1186"
     ]
    },
    "us-gaap_InvestmentTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTaxCredit",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment tax credits",
        "label": "Investment Tax Credit",
        "documentation": "The amount deducted from an entities' taxes, reflecting a percentage of an amount invested in certain assets spread over the useful life of those assets; includes deferred investment tax credits."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "engn_InvestmentTaxCreditsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "InvestmentTaxCreditsExpirationYear",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment tax credits expiration year",
        "label": "Investment Tax Credits Expiration Year",
        "documentation": "Investment tax credits expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "engn_InvestmentTaxCreditsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "InvestmentTaxCreditsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment tax credits receivable.",
        "label": "Investment Tax Credits Receivable",
        "terseLabel": "Investment tax credits receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1288",
      "r1289",
      "r1293",
      "r1296",
      "r1297",
      "r1298",
      "r1299"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecurities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r278",
      "r279",
      "r625",
      "r626",
      "r1320"
     ]
    },
    "engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "IssuanceOfCommonSharesInConnectionWithPipeFinancingShares",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Shares In Connection With Pipe Financing Shares",
        "documentation": "Issuance of common shares in connection with pipe financing shares.",
        "terseLabel": "Issuance of common shares in connection with PIPE Financing, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "engn_IssuanceOfCommonSharesInConnectionWithPipeFinancingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "IssuanceOfCommonSharesInConnectionWithPipeFinancingValue",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Shares in Connection With Pipe Financing Value",
        "documentation": "Issuance of common shares in connection with pipe financing value.",
        "terseLabel": "Issuance of common shares in connection with PIPE Financing, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "engn_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Tax Year",
        "terseLabel": "2043",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r1015"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Operating Lease Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1308"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "engn_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration month and year",
        "label": "Lease Expiration Month and Year",
        "documentation": "Lease expiration month and year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r667"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r668"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r668"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, option to extend",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1309"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional lease commitments to be paid",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1193",
      "r1200",
      "r1321"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest",
        "negatedLabel": "Less: Interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease initial term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeases1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "totalLabel": "Liabilities, Total",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r48",
      "r49",
      "r50",
      "r53",
      "r54",
      "r55",
      "r58",
      "r171",
      "r174",
      "r175",
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r564",
      "r567",
      "r568",
      "r636",
      "r855",
      "r959",
      "r980",
      "r1042",
      "r1231",
      "r1311",
      "r1312"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholder's equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r96",
      "r777",
      "r1016",
      "r1029",
      "r1030",
      "r1192",
      "r1197",
      "r1221",
      "r1300"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholder's equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r132",
      "r171",
      "r174",
      "r175",
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r564",
      "r567",
      "r568",
      "r636",
      "r1016",
      "r1231",
      "r1311",
      "r1312"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "engn_LicenseAgreementAndClinicalResearchOrganizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LicenseAgreementAndClinicalResearchOrganizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement and Clinical Research Organization [Abstract]",
        "documentation": "License Agreement and Clinical Research Organization"
       }
      }
     },
     "auth_ref": []
    },
    "engn_LicenseAgreementAndClinicalResearchOrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LicenseAgreementAndClinicalResearchOrganizationLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement and Clinical Research Organization [Line Items]",
        "documentation": "License agreement and clinical research organization line items."
       }
      }
     },
     "auth_ref": []
    },
    "engn_LicenseAgreementAndClinicalResearchOrganizationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LicenseAgreementAndClinicalResearchOrganizationTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement and Clinical Research Organization",
        "documentation": "License agreement and clinical research organization"
       }
      }
     },
     "auth_ref": []
    },
    "engn_LicenseAgreementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LicenseAgreementTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Table]",
        "documentation": "License Agreement Table"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit, maturity date",
        "label": "Line of Credit Facility, Expiration Date",
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r52"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Line of credit, maximum amount available",
        "terseLabel": "Term loan facility aggregate principal amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r52"
     ]
    },
    "engn_LoanAmortizationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LoanAmortizationDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amortization date",
        "label": "Loan Amortization Date",
        "documentation": "Loan amortization date."
       }
      }
     },
     "auth_ref": []
    },
    "engn_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Loan and Security Agreement",
        "label": "2021 Loan and Security Agreement [Member]",
        "documentation": "2021 loan and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "engn_LoanAndSecurityAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LoanAndSecurityAgreementsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and Security Agreement",
        "label": "Loan and Security Agreements [Member]",
        "documentation": "Loan and security agreements."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Note payable, net of discount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r95",
      "r172",
      "r183",
      "r384",
      "r400",
      "r761",
      "r976",
      "r977",
      "r1014",
      "r1323"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r172",
      "r183",
      "r389",
      "r761"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r172",
      "r183",
      "r389",
      "r761"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfEstimatedFuturePrincipalPaymentsDueUnderTheLoanAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r172",
      "r183",
      "r389",
      "r761"
     ]
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Investments",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "engn_LongTermMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "LongTermMarketableSecuritiesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term marketable securities",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable, net of current portion",
        "label": "Notes Payable, Noncurrent",
        "totalLabel": "Notes Payable, Noncurrent, Total",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "engn_ManufacturingPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ManufacturingPaymentFee",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee related to the manufacturing payment",
        "label": "Manufacturing Payment Fee",
        "documentation": "Manufacturing payment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities - short term",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities - long term",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "engn_MaximumAmountOfCommonSharesToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "MaximumAmountOfCommonSharesToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Amount Of Common Shares To Be Sold",
        "documentation": "Maximum amount of common shares to be sold.",
        "terseLabel": "Maximum amount of common shares to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "engn_MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum hours of CEO devote per week to providing transition services.",
        "label": "Maximum Hours Of CEO Devote Per Week To Providing Transition Services",
        "terseLabel": "Maximum hours of ceo devote per week to providing transition services"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r356",
      "r357",
      "r358",
      "r359",
      "r445",
      "r475",
      "r476",
      "r477",
      "r499",
      "r606",
      "r717",
      "r801",
      "r803",
      "r817",
      "r847",
      "r848",
      "r906",
      "r908",
      "r910",
      "r911",
      "r913",
      "r921",
      "r922",
      "r924",
      "r925",
      "r938",
      "r939",
      "r972",
      "r981",
      "r989",
      "r994",
      "r996",
      "r997",
      "r1006",
      "r1007",
      "r1011",
      "r1012",
      "r1026",
      "r1233",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "engn_MilestoneProductPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "MilestoneProductPayment",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time payment for milestone product",
        "label": "Milestone Product Payment",
        "documentation": "Milestone product payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r356",
      "r357",
      "r358",
      "r359",
      "r445",
      "r475",
      "r476",
      "r477",
      "r499",
      "r606",
      "r717",
      "r801",
      "r803",
      "r817",
      "r847",
      "r848",
      "r906",
      "r908",
      "r910",
      "r911",
      "r913",
      "r921",
      "r922",
      "r924",
      "r925",
      "r938",
      "r939",
      "r972",
      "r981",
      "r989",
      "r994",
      "r996",
      "r997",
      "r1006",
      "r1007",
      "r1011",
      "r1026",
      "r1233",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1238"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "engn_NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Amortization of Premiums Accretion of Discounts on Marketable Securities",
        "documentation": "Net amortization of premiums accretion of discounts on marketable securities.",
        "terseLabel": "Net amortization of premiums (accretion of discounts) on marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "negatedLabel": "Cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash Flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedTotalLabel": "Net loss",
        "totalLabel": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r77",
      "r98",
      "r128",
      "r130",
      "r143",
      "r146",
      "r151",
      "r171",
      "r174",
      "r175",
      "r180",
      "r188",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r214",
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r406",
      "r409",
      "r412",
      "r416",
      "r487",
      "r549",
      "r560",
      "r600",
      "r636",
      "r783",
      "r876",
      "r897",
      "r898",
      "r949",
      "r951",
      "r953",
      "r1040",
      "r1231"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net loss attributable to common shareholders, basic",
        "totalLabel": "Net loss attributable to common stockholders, basic",
        "negatedLabel": "Net loss attributable to common stockholders, basic",
        "terseLabel": "Net loss attributable to common stockholders, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r154",
      "r193",
      "r194",
      "r195",
      "r196",
      "r205",
      "r206",
      "r215",
      "r218",
      "r409",
      "r412",
      "r416",
      "r560"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss attributable to common shareholders, diluted",
        "negatedTotalLabel": "Net loss attributable to common stockholders, diluted",
        "terseLabel": "Net loss attributable to common stockholders, diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r207",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r218"
     ]
    },
    "engn_NetOperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "NetOperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards expiration year",
        "label": "Net Operating Loss Carryforwards Expiration Year",
        "documentation": "Net Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements - Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "engn_NewLaboratoryAndOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "NewLaboratoryAndOfficeSpaceMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Laboratory and Office Space",
        "label": "New Laboratory and Office Space [Member]",
        "documentation": "New laboratory and office space."
       }
      }
     },
     "auth_ref": []
    },
    "engn_NonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "NonCashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Non-cash Interest Expense",
        "documentation": "Non-cash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "engn_NonCashLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "NonCashLeaseExpenses",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash lease expense",
        "label": "Non Cash Lease Expenses",
        "documentation": "Non cash lease expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1079",
      "r1089",
      "r1113",
      "r1122"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets held",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (income) expense, net",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current",
        "verboseLabel": "Note payable current",
        "totalLabel": "Notes Payable, Current, Total",
        "terseLabel": "Current portion of note payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r1209"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r961",
      "r971",
      "r1209"
     ]
    },
    "engn_NumberOfSecuritiesHeld": {
     "xbrltype": "integerItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "NumberOfSecuritiesHeld",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities held.",
        "label": "Number of Securities Held",
        "terseLabel": "Number of securities held"
       }
      }
     },
     "auth_ref": []
    },
    "engn_OctoberPipeFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OctoberPipeFinancingMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October PIPE financing.",
        "label": "October PIPE Financing [Member]",
        "terseLabel": "October PIPE Financing"
       }
      }
     },
     "auth_ref": []
    },
    "engn_OctoberTwoThousandTwentyFourSubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OctoberTwoThousandTwentyFourSubscriptionAgreementsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October two thousand twenty four subscription agreements.",
        "label": "October Two Thousand Twenty Four Subscription Agreements [Member]",
        "terseLabel": "October 2024 Subscription Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "engn_OfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OfficeSpaceMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Space",
        "label": "Office Space [Member]",
        "documentation": "Office space."
       }
      }
     },
     "auth_ref": []
    },
    "engn_OldEngenesShareOptionHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OldEngenesShareOptionHoldersMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Old enGenes Share Option",
        "label": "Old enGenes Share Option Holders Member",
        "documentation": "Old enGenes Share Option Holders."
       }
      }
     },
     "auth_ref": []
    },
    "engn_OpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OpenMarketSaleAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Market Sale Agreement [Member]",
        "documentation": "Open Market Sale Agreement.",
        "terseLabel": "Open Market Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r949",
      "r953",
      "r960",
      "r1208",
      "r1210",
      "r1211",
      "r1212",
      "r1213"
     ]
    },
    "engn_OperatingLeaseCommencementPeriod": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OperatingLeaseCommencementPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease commencement period",
        "label": "Operating Lease Commencement Period",
        "documentation": "Operating lease commencement period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r1015"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesSummaryOfCashPaidForAmountsIncludedInTheMeasurementOfTheOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r664"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale investments",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "negatedLabel": "Unrealized (gain) loss on available-for-sale investments",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r90"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r90",
      "r144",
      "r147",
      "r197"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other general and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1358"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (income) expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expenses (income), net",
        "terseLabel": "Other expenses (income), net",
        "verboseLabel": "Other expenses, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r1000"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (income) expense, net:",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "engn_OtherResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "OtherResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expenses [Member]",
        "documentation": "Other research and development expenses.",
        "terseLabel": "Other Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1077",
      "r1087",
      "r1120"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1080",
      "r1090",
      "r1123"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1080",
      "r1090",
      "r1123"
     ]
    },
    "engn_PaidInKindInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PaidInKindInterestPercentage",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment-in-kind interest rate",
        "label": "Paid-in-kind Interest Percentage",
        "documentation": "Paid-in-kind interest percentage."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PatentCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patent Costs Policy [Policy Text Block]",
        "documentation": "Patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "totalLabel": "Payment of Financing and Stock Issuance Costs, Total",
        "label": "Payment of Financing and Stock Issuance Costs",
        "verboseLabel": "Underwriting discounts and commissions and offering expenses",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "engn_PaymentOfMaximumCommissionPercentageOfSharesSold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PaymentOfMaximumCommissionPercentageOfSharesSold",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Maximum Commission Percentage of Shares Sold",
        "documentation": "Payment of maximum commission percentage of shares sold.",
        "terseLabel": "Payment of maximum commission percentage of shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PaymentOfReverseRecapitalizationAndPipeFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PaymentOfReverseRecapitalizationAndPipeFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of reverse recapitalization and pipe financing costs.",
        "label": "Payment Of Reverse Recapitalization And Pipe Financing Costs",
        "negatedLabel": "Payment of Reverse Recapitalization and PIPE Financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of target annual bonus netoff taxes and withholdings.",
        "label": "Payment Of Target Annual Bonus Netoff Taxes And Withholdings",
        "terseLabel": "Payment Of Target Annual Bonus Netoff Taxes And Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PaymentOnAssigningLicenseToThirdParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PaymentOnAssigningLicenseToThirdParty",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to NTC upon assigning the License Agreement",
        "label": "Payment On Assigning License to Third Party",
        "documentation": "Payment on assigning license to third party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of debt issuance costs associated with the term loan",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "engn_PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of issuance costs associated with the pipe financing.",
        "label": "Payments Of Issuance Costs Associated With The Pipe Financing",
        "negatedLabel": "Payments of issuance costs associated with the 2024 PIPE Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "engn_PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of aggregate principal amount of term loan advance to purchase number of common shares",
        "label": "Percentage Of Aggregate Principal Amount Of Term Loan Advance To Purchase Number Of Common Shares",
        "documentation": "Percentage of aggregate principal amount of term loan advance to purchase number of common shares."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfCommitmentAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfCommitmentAmount",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of total commitment amount",
        "label": "Percentage Of Commitment Amount",
        "documentation": "Percentage of commitment amount."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfFacilityChargeOnAmountBorrowed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfFacilityChargeOnAmountBorrowed",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of facility charge on amount borrowed",
        "label": "Percentage of Facility Charge on Amount Borrowed",
        "documentation": "Percentage of facility charge on amount borrowed."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfIncreaseInAnnualBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfIncreaseInAnnualBaseRent",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of increase in annual base rent",
        "label": "Percentage of Increase in Annual Base Rent",
        "documentation": "Percentage of increase in annual base rent."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfOutstandingCommonSharesOwnedByTheHolder": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfOutstandingCommonSharesOwnedByTheHolder",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Outstanding Common Shares Owned by The Holder",
        "documentation": "Percentage of outstanding common shares owned by the holder.",
        "terseLabel": "Percentage of outstanding common shares owned by the holder"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of prepayment premium of principal amount outstanding of the closing date",
        "label": "Percentage of Prepayment Premium of Principal Amount Outstanding of the Closing Date",
        "documentation": "Percentage of prepayment premium of principal amount outstanding of the closing date."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of prepayment premium of principal amount outstanding prior to maturity date",
        "label": "Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Maturity Date",
        "documentation": "Percentage of prepayment premium of principal amount outstanding prior to maturity date."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of prepayment premium of principal amount outstanding prior to twenty-four months",
        "label": "Percentage of Prepayment Premium of Principal Amount Outstanding Prior to Twenty Four Months",
        "documentation": "Percentage of prepayment premium of principal amount outstanding prior to twenty four months."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfSharesOwnedByShareholders": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfSharesOwnedByShareholders",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of shares owned by shareholders",
        "label": "Percentage Of Shares Owned By Shareholders",
        "documentation": "Percentage of shares owned by shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tax benefit to be realized for recognition in the income statement.",
        "label": "Percentage Of Tax Benefit To Be Realized For Recognition In The Income Statement",
        "terseLabel": "Percentage of tax benefit to be realized for recognition in the income statement"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PeriodWithinLoanDisbursementsToBeMade": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PeriodWithinLoanDisbursementsToBeMade",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period within loan disbursements to be made",
        "label": "Period Within Loan Disbursements to be Made",
        "documentation": "Period within loan disbursements to be made."
       }
      }
     },
     "auth_ref": []
    },
    "engn_Personnel-RelatedExpensesExcludingStock-BasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "Personnel-RelatedExpensesExcludingStock-BasedCompensationMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel-Related Expenses Excluding Stock-Based Compensation [Member]",
        "documentation": "Personnel-related expenses, excluding stock-based compensation.",
        "terseLabel": "Personnel-Related Expenses Excluding Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PhaseIClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PhaseIClinicalTrialMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase I Clinical Trial [Member]",
        "documentation": "Phase I Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "engn_PhaseIiClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PhaseIiClinicalTrialMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase II Clinical Trial [Member]",
        "documentation": "Phase II Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "engn_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrant [Member]",
        "documentation": "Pre-funded warrant.",
        "terseLabel": "Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "engn_PriorLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PriorLoanAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Loan Agreement",
        "label": "Prior Loan Agreement [Member]",
        "documentation": "Prior loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "engn_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants [Member]",
        "label": "Private Placement Warrants [Member]",
        "documentation": "Private placement warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Aggregate gross proceeds of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of term loan",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1189"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from the February 2024 PIPE Financing",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from line of credit",
        "label": "Proceeds from Lines of Credit",
        "totalLabel": "Proceeds from Lines of Credit, Total",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r1192",
      "r1195"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r1216"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares upon the exercise of stock options",
        "verboseLabel": "Proceeds from exercise of stock options",
        "label": "Aggregate gross proceeds from option exercise",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercises of warrants",
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of common share warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1188"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r130",
      "r143",
      "r146",
      "r163",
      "r171",
      "r174",
      "r175",
      "r180",
      "r188",
      "r197",
      "r200",
      "r201",
      "r311",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r406",
      "r487",
      "r549",
      "r560",
      "r562",
      "r565",
      "r566",
      "r600",
      "r636",
      "r757",
      "r759",
      "r782",
      "r830",
      "r876",
      "r897",
      "r898",
      "r998",
      "r999",
      "r1041",
      "r1184",
      "r1231"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r111",
      "r112",
      "r113"
     ]
    },
    "engn_PropertyPlantAndEquipmentEstimatedUsefulLive": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLive",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life",
        "label": "Property Plant And Equipment Estimated Useful Live",
        "documentation": "Property plant and equipment estimated useful live."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r134",
      "r780"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r667",
      "r763",
      "r780",
      "r1016"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r111",
      "r112",
      "r778"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r667"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r356",
      "r357",
      "r358",
      "r359",
      "r435",
      "r445",
      "r475",
      "r476",
      "r477",
      "r484",
      "r499",
      "r606",
      "r691",
      "r700",
      "r717",
      "r801",
      "r803",
      "r817",
      "r847",
      "r848",
      "r906",
      "r908",
      "r910",
      "r911",
      "r913",
      "r921",
      "r922",
      "r924",
      "r925",
      "r938",
      "r939",
      "r972",
      "r981",
      "r989",
      "r994",
      "r996",
      "r997",
      "r1006",
      "r1007",
      "r1011",
      "r1012",
      "r1026",
      "r1034",
      "r1227",
      "r1233",
      "r1291",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r356",
      "r357",
      "r358",
      "r359",
      "r435",
      "r445",
      "r475",
      "r476",
      "r477",
      "r484",
      "r499",
      "r606",
      "r691",
      "r700",
      "r717",
      "r801",
      "r803",
      "r817",
      "r847",
      "r848",
      "r906",
      "r908",
      "r910",
      "r911",
      "r913",
      "r921",
      "r922",
      "r924",
      "r925",
      "r938",
      "r939",
      "r972",
      "r981",
      "r989",
      "r994",
      "r996",
      "r997",
      "r1006",
      "r1007",
      "r1011",
      "r1012",
      "r1026",
      "r1034",
      "r1227",
      "r1233",
      "r1291",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1072",
      "r1082",
      "r1115"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r179",
      "r180",
      "r277",
      "r678",
      "r679",
      "r680",
      "r880",
      "r881",
      "r884"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r679",
      "r681",
      "r827",
      "r828",
      "r829",
      "r882",
      "r883",
      "r884",
      "r903",
      "r905"
     ]
    },
    "engn_RemainingSharesReservedForFutureIssuanceUnderESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "RemainingSharesReservedForFutureIssuanceUnderESPPMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Shares Reserved For Future Issuance Under ESPP [Member]",
        "documentation": "Remaining shares reserved for future issuance under ESPP.",
        "terseLabel": "Remaining shares reserved for future issuance under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "engn_RepaymentsOfTermLoanPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "RepaymentsOfTermLoanPrincipal",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of term loan principal",
        "label": "Repayments of term loan principal",
        "documentation": "Repayments of term loan principal."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r181",
      "r182",
      "r375",
      "r420",
      "r680",
      "r701",
      "r771",
      "r944",
      "r945",
      "r946",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1280",
      "r1281",
      "r1282",
      "r1283"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Total research and development expenses",
        "verboseLabel": "Total research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r940",
      "r949",
      "r950",
      "r966",
      "r1319"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "engn_ResearchAndDevelopmentInvestmentTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ResearchAndDevelopmentInvestmentTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development investment tax credits",
        "label": "Research And Development Investment Tax Credits",
        "documentation": "Research and development investment tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1073",
      "r1083",
      "r1116"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1074",
      "r1084",
      "r1117"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1081",
      "r1091",
      "r1124"
     ]
    },
    "us-gaap_RestrictedInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedInvestments",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted investments",
        "label": "Restricted Investments",
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r927"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r86",
      "r776",
      "r811",
      "r816",
      "r825",
      "r857",
      "r1016"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r127",
      "r128",
      "r184",
      "r185",
      "r186",
      "r189",
      "r197",
      "r199",
      "r201",
      "r312",
      "r316",
      "r341",
      "r405",
      "r487",
      "r531",
      "r532",
      "r545",
      "r546",
      "r547",
      "r550",
      "r559",
      "r560",
      "r576",
      "r579",
      "r580",
      "r583",
      "r598",
      "r651",
      "r654",
      "r807",
      "r809",
      "r831",
      "r1360"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "engn_ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization And Pipe Financing Transaction Costs Included Within Accrued Expenses And Accounts Payable",
        "documentation": "Reverse recapitalization and pipe financing transaction costs included within accrued expenses and accounts payable.",
        "terseLabel": "Reverse Recapitalization and PIPE financing transaction costs included within accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1015"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred shares at a price per share",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Common share price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Shares Excluded from Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary Of Components Of The Provision For (Recovery Of) Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Value of Term Loan",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Net Deferred Income Tax",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Reconciliation Of Company's Statutory Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r993",
      "r1269"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "engn_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Estimated Useful Life of Each Asset",
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]",
        "documentation": "Schedule of estimated useful lives of property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Loss Before Provision for Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1198"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Principal Payments Due Under the Loan Agreement",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r667"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r179",
      "r180",
      "r678",
      "r679",
      "r680",
      "r880",
      "r881",
      "r884"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r67"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Significant Segment Expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r484"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "engn_ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesTables",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares Reserved for Future Issuance Under the Plan",
        "label": "Schedule of Shares Reserved For Future Issuance Under The Plan Table Text Block",
        "documentation": "Schedule of shares reserved for future issuance under the plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r84",
      "r85",
      "r86",
      "r138",
      "r139",
      "r140",
      "r226",
      "r418",
      "r419",
      "r420",
      "r422",
      "r425",
      "r430",
      "r432",
      "r573",
      "r821",
      "r822",
      "r823",
      "r824",
      "r981",
      "r1158",
      "r1192",
      "r1194"
     ]
    },
    "engn_ScientificResearchAndExperimentalDevelopmentExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ScientificResearchAndExperimentalDevelopmentExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific research and experimental development expenditures",
        "label": "Scientific Research And Experimental Development Expenditures",
        "terseLabel": "SR&amp;ED expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r224",
      "r234",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r274",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r352",
      "r353",
      "r554",
      "r555",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r963",
      "r966",
      "r967",
      "r974",
      "r1028",
      "r1324",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1353",
      "r1354"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r272",
      "r273",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r757",
      "r758",
      "r759",
      "r760",
      "r844",
      "r845",
      "r846",
      "r907",
      "r909",
      "r912",
      "r914",
      "r921",
      "r923",
      "r924",
      "r925",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r942",
      "r957",
      "r982",
      "r983",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1027",
      "r1034",
      "r1324",
      "r1326",
      "r1327",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1353",
      "r1354"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r224",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r249",
      "r251",
      "r252",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r274",
      "r961",
      "r964",
      "r965",
      "r966",
      "r968",
      "r970",
      "r971"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r252",
      "r266"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "negatedLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r251",
      "r252",
      "r266",
      "r966"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r269",
      "r272",
      "r962",
      "r963",
      "r969"
     ]
    },
    "engn_SeveranceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "SeveranceAgreementMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Agreement",
        "documentation": "Severance Agreement.",
        "label": "Severance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation expense",
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common shares and exercise price of options, Maximum",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Maximum",
        "documentation": "Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options maximum."
       }
      }
     },
     "auth_ref": []
    },
    "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common shares and exercise price of options, Minimum",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value of Common Shares and Exercise Price of Options Minimum",
        "documentation": "Share based compensation arrangement by share based payment award fair value of common shares and exercise price of options minimum."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized increased",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Stock option expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited or expired",
        "terseLabel": "Forfeited or expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price, Forfeited or expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Stock option forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Shares Granted",
        "terseLabel": "Number of share options granted during the period",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of share options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares outstanding, Ending balance",
        "periodStartLabel": "Number of shares outstanding, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "periodEndLabel": "Weighted-Average Exercise Price Outstanding, Ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Outstanding, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455"
     ]
    },
    "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options unvested",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Aggregate Intrinsic Value",
        "documentation": "Share based compensation arrangement by share based payment award options unvested aggregate intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "engn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Options unvested",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term1",
        "documentation": "Share based compensation arrangement by share based payment award options unvested weighted average remaining contractual term1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price, Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum percentage of outstanding common shares owned by the holder",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental compensation cost",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise price of options granted",
        "terseLabel": "Weighted-Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting Immediately Upon Grant Date",
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "verboseLabel": "Vesting on Remaining Years",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r453",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares",
        "label": "Share Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of vesting rights",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1240"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfAssumptionsUsedToDetermineGrantdateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Exercise Price, Options unvested",
        "terseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years), Options vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Stock options vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock value on date of grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "engn_SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Reserved For Future Issuance Under the Two Thousand and Twenty Three Plan [Member]",
        "documentation": "Shares reserved for future issuance under the two thousand and twenty three plan [Member]",
        "terseLabel": "Remaining shares reserved for future issuance under the 2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "engn_ShortTermMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "ShortTermMarketableSecuritiesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term marketable securities",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r129",
      "r224",
      "r234",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r274",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r343",
      "r352",
      "r353",
      "r554",
      "r555",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r963",
      "r966",
      "r967",
      "r974",
      "r1028",
      "r1324",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1353",
      "r1354"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails",
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r138",
      "r139",
      "r140",
      "r171",
      "r175",
      "r208",
      "r209",
      "r216",
      "r218",
      "r226",
      "r227",
      "r311",
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r407",
      "r408",
      "r410",
      "r411",
      "r413",
      "r415",
      "r418",
      "r419",
      "r422",
      "r425",
      "r432",
      "r636",
      "r821",
      "r822",
      "r823",
      "r824",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r856",
      "r877",
      "r899",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1158",
      "r1194",
      "r1196",
      "r1206"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r63",
      "r64",
      "r120",
      "r127",
      "r128",
      "r149",
      "r150",
      "r151",
      "r184",
      "r185",
      "r186",
      "r189",
      "r197",
      "r199",
      "r201",
      "r225",
      "r312",
      "r316",
      "r341",
      "r405",
      "r434",
      "r487",
      "r531",
      "r532",
      "r545",
      "r546",
      "r547",
      "r550",
      "r559",
      "r560",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r598",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r651",
      "r654",
      "r674",
      "r784",
      "r807",
      "r808",
      "r809",
      "r831",
      "r899"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r229",
      "r272",
      "r273",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r757",
      "r758",
      "r759",
      "r760",
      "r844",
      "r845",
      "r846",
      "r907",
      "r909",
      "r912",
      "r914",
      "r921",
      "r923",
      "r924",
      "r925",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r942",
      "r957",
      "r982",
      "r983",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1027",
      "r1034",
      "r1324",
      "r1326",
      "r1327",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1353",
      "r1354"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r225",
      "r407",
      "r408",
      "r410",
      "r413",
      "r654",
      "r718",
      "r819",
      "r832",
      "r843",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r856",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r878",
      "r879",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r899",
      "r951",
      "r953",
      "r1035",
      "r1356"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r225",
      "r277",
      "r407",
      "r408",
      "r410",
      "r413",
      "r654",
      "r718",
      "r819",
      "r832",
      "r843",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r856",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r878",
      "r879",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r899",
      "r951",
      "r953",
      "r1035",
      "r1356"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1076",
      "r1086",
      "r1119"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "engn_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSegmentReportingSummaryOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Based Compensation",
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "engn_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cashless exercise of warrants.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrants",
        "terseLabel": "Issuance of common shares upon cashless exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of new stock issued during the period",
        "verboseLabel": "Issuance of common shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r60",
      "r86",
      "r821",
      "r899",
      "r916"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationSummaryOfStockOptionActivityDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "label": "Stock options exercised",
        "verboseLabel": "Exercised",
        "terseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r60",
      "r86",
      "r459"
     ]
    },
    "engn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares upon exercise of warrants (in shares)",
        "documentation": "Stock issued during period shares warrants exercised.",
        "label": "Stock Issued During Period Shares Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "engn_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value cashless exercise of warrants.",
        "label": "Stock Issued During Period Value Cashless Exercise Of Warrants",
        "terseLabel": "Issuance of common shares upon cashless exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "StockIssuedDuringPeriodValueNewIssues",
        "verboseLabel": "Issuance of common shares, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r60",
      "r86",
      "r831",
      "r899",
      "r916",
      "r1041"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r60",
      "r63",
      "r64",
      "r86"
     ]
    },
    "engn_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares upon exercise of warrants",
        "documentation": "Stock issued during period value warrants exercised.",
        "label": "Stock Issued During Period Value Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholder's equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r63",
      "r64",
      "r78",
      "r858",
      "r874",
      "r900",
      "r901",
      "r1016",
      "r1042",
      "r1192",
      "r1196",
      "r1197",
      "r1221",
      "r1300",
      "r1360"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonShares1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r417",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r573",
      "r589",
      "r902",
      "r904",
      "r920"
     ]
    },
    "engn_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2024 Subscription agreements.",
        "terseLabel": "2024 Subscription Agreements",
        "label": "2024 Subscription Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r683"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r683"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r683"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r683"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r683"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r684"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "engn_SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash Paid for Amounts Included in the Measurement of the Operating Lease Liabilities",
        "label": "Summary of Cash Paid for Amounts Included in Measurement of Operating Lease Liabilities [Table Text Block]",
        "documentation": "Summary of cash paid for amounts included in measurement of operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "engn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "engn_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No uncertain tax positions",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "engn_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TermLoanMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableScheduleOfCarryingValueOfTermLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Term Loan [Member]",
        "documentation": "Term loan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1310"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1104"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "engn_TrancheOneAdvanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TrancheOneAdvanceMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 1 Advance",
        "label": "Tranche One Advance [Member]",
        "documentation": "Tranche one advance."
       }
      }
     },
     "auth_ref": []
    },
    "engn_TrancheThreeAdvanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TrancheThreeAdvanceMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 3 Advance",
        "label": "Tranche Three Advance [Member]",
        "documentation": "Tranche three advance."
       }
      }
     },
     "auth_ref": []
    },
    "engn_TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Three Advance Subject To Achievement Of Specified Interim Milestone [Member]",
        "documentation": "Tranche three advance subject to achievement of specified interim milestone.",
        "terseLabel": "Tranche Three Advance Subject to Achievement of Specified Interim Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "engn_TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 2 Advance Subject to Achievement of Specified Interim Milestone",
        "label": "Tranche Two Advance Subject to Achievement of Specified Interim Milestone [Member]",
        "documentation": "Tranche two advance subject to achievement of specified interim milestone."
       }
      }
     },
     "auth_ref": []
    },
    "engn_TrancheTwoToTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TrancheTwoToTrancheThreeMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two to Tranche Three [Member]",
        "documentation": "Tranche two to tranche three .",
        "terseLabel": "Tranche 2 to Tranche 3"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r396",
      "r430",
      "r573",
      "r588",
      "r624",
      "r635",
      "r638",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r766",
      "r785",
      "r1003",
      "r1004",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1017",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1287",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1296",
      "r1297"
     ]
    },
    "engn_TransitionServicesForConsultingFeePerHour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TransitionServicesForConsultingFeePerHour",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition services for consulting fee per hour.",
        "label": "Transition Services For Consulting Fee Per Hour",
        "terseLabel": "Transition services for consulting fee per hour"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "engn_TwoThousandTwentyFourPipeInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TwoThousandTwentyFourPipeInvestorsMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2024 PIPE investors.",
        "label": "Two Thousand Twenty Four PIPE Investors [Member]",
        "terseLabel": "2024 PIPE Investors"
       }
      }
     },
     "auth_ref": []
    },
    "engn_TwoZeroTwoThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "TwoZeroTwoThreePlanMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan",
        "label": "Two Zero Two Three Plan [Member]",
        "documentation": "Two zero two three plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r157",
      "r158",
      "r159",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r203",
      "r275",
      "r276",
      "r312",
      "r314",
      "r315",
      "r316",
      "r340",
      "r341",
      "r350",
      "r403",
      "r404",
      "r405",
      "r406",
      "r485",
      "r486",
      "r487",
      "r488",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r627",
      "r628",
      "r651",
      "r652",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Agency Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r955",
      "r984",
      "r986",
      "r1322"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government Agency Securities",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r984",
      "r986",
      "r1017",
      "r1031",
      "r1352"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAtFairValueDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Treasuries",
        "label": "US Treasury Securities [Member]",
        "verboseLabel": "US Treasury",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r955",
      "r984",
      "r986",
      "r988",
      "r1003",
      "r1322"
     ]
    },
    "engn_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails",
      "http://engene.com/20251031/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten public offering.",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued penalties related to unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest related to unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "engn_UpfrontFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "UpfrontFees",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLicenseAgreementAndClinicalResearchOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront fee",
        "label": "Upfront Fees",
        "documentation": "Upfront Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r228",
      "r230",
      "r231",
      "r232",
      "r757",
      "r759",
      "r958"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable operating lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r1015"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1230",
      "r1284"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1230",
      "r1284"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "engn_WallStreetJournalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "WallStreetJournalMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wall Street Journal",
        "label": "Wall Street Journal [Member]",
        "documentation": "Wall street journal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://engene.com/20251031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share",
        "terseLabel": "Warrant Liabilities",
        "verboseLabel": "Warrants to purchase common shares",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1033",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "engn_WarrantToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "WarrantToPurchaseCommonStockMember",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureSharebasedCompensationScheduleOfShareReservedForFutureIssuanceUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common shares",
        "label": "Warrant To Purchase Common Stock [Member]",
        "documentation": "Warrant To Purchase Common Stock."
       }
      }
     },
     "auth_ref": []
    },
    "engn_WarrantValueIssuedAsPartOfAmendedTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "WarrantValueIssuedAsPartOfAmendedTermLoan",
     "crdr": "debit",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant value issued as part of amended term loan.",
        "label": "Warrant Value Issued as Part of Amended Term Loan",
        "terseLabel": "Warrant value issued as part of Amended Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, maturity date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1292"
     ]
    },
    "engn_WarrantsAndRightsOutstandingMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://engene.com/20251031",
     "localname": "WarrantsAndRightsOutstandingMaturityPeriod",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureCommonSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, maturity period",
        "label": "Warrants And Rights Outstanding Maturity Period",
        "documentation": "Warrants and rights outstanding maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average number of common shares used in net loss per share, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r218"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://engene.com/20251031/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://engene.com/20251031/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average number of common shares used in net loss per share, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r218"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>105
<FILENAME>0001193125-25-328743-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-328743-xbrl.zip
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MS_V+,^%#[,<&U?(Y!%].-%#B+40W/7)]?6]^U[L6EU*$*2+RS4__5OQP%&V
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M;GRQ5?BZMLNWZ\'W/G%II6F7$X#F//9.*H9$OBUG0 ]:)IV;_J6(I0V*==:
MGJ-29*_LYW#/G9-)2]Z7&47H/.&8-*ZIW!'=.HML;M)M:52)IT@C[VP)M96N
MO0KIZ=)^6* ^)*)R>(A$G*N8JW0S4.62U=&EZ'1G5>TY<R7V@%S*?@Q3U]/+
MA,04&'61HV1-;G>>!-(1)P32SB=F#!6TL\K.7:KQ/N!=5D'C EWU'7#\>4*-
MIUXCH;/%R[()E4)"6@BJK3<,])/GN'PWMB7,A:[&,76#Z@FX$<_IT+]VZN.6
M,UJ*L^-6T.P,M![PE4EDE' )V!3LC\YJF?>5*VN\ME] \ YC?W?DX&X[*<4V
M?5QY!(W('7X\S?;P5V;0M1/:>FZC<NRDO]E,RL.=:J_\?#1+S+M53*-LF$_.
M6+1_AB!RT:#R,3+>\X25E@[%("B BP=IS[5'B1N&K2<XV,[Z9RYD_&1Q;FC'
ML;#5Z(!8]T(YSV1$D9N(N*)Y9] 'Y(V.3!G/:.QLHDE' B"_;J>"Y^H0>^W4
MQZVB5A9SCZBP#!B06V0(X2C21+R,$7O5V?W=MD,I[GUP]D UZ;"Q.H'5.;^V
MI_B76/E1+]8+RWA>C(_<2^6QA]5W@0 &JTB059XAGPSH D ' G>6!#J=D[XD
M7%9.1UA3)!P!<\LKP.7@%-A<0JJ  ^;=Z_F\E.3P+JR5UM0V,37"6,2)I<B(
MI@4H,SQ(EX-^N[96W^#R77)SH"79RV 1"QL=4L(FQ*,(R.5@N)R42[PUW.#.
MKFDWW5;+6D?K#5@GB$@#Z^A8SJ'6#F7CF3HPGGEW$ZEO"'C:[H?1.'OZEVR2
M/)NBE=Y3;V2RR*G@ 2(51YH&BH)13EBLC"#/TWLX<K6ORF:C]$)!;6V[8(Y6
MD;M5>0J\ :3BG\)YN21O5["!>4:0DSZ'Z^36*@+8F4BJ(FBWC'2WJ,==U+-S
M$OOC[::\OD\3*][$/U#<"E-'9J*T!%%*PS@LQTB?NWHD"\QM/>]>F=%76XEV
M2:IQ=($&(8%54][]8S*7=;1(,E"5(V&2V<YR[G_EPEF@Z5[U##<QY==;I8^C
M:2:13%\&;9'24A2 +E!-[@Z,N<FM@7+UFUP;5$8P?H7B*K=H3]T-OVB]#4QG
M=+@ C)N"MT@K[P#NM06XQUFIC@HL7PWSV=E5N4L*[QX!.V^7T]"F@ZI<L-</
M(\QG^F@_:DT86#$Q6L1$@C7Q&F<G1,C5AJR+4F*BNMOPYO: G(LZNI.8G.PC
M?BZ.V !*$?>>(#!Y\F:8#,B0%%%(-)'$;.2RLP$O"])='J25O> 8T< LD5%Z
M)( F$)<V%\\%K0AH@X-=PS#M;H?6]FW25D!\VN/LQGB0!UGICR<M3!%A\YG*
M5TY]%&EQ9Z51V1++67[$.92]T\AH[X"LDB>T<STNY_)%3T]:;O/?Y3@Q T]$
M:)*;.0<PM%EV1AMK4#0R9RRYE$AGI?Q3E_I8]NYN%\2+Q(Q%11%.G",>-(@7
M!]JZY%22J*3!K+/DL@H8?^T!XYEZ3<AEDV( DX9*@:QP%F'CL?>*"<L[U]CA
M-2\7K(A,.3=&9E\-D02YH T2/ 5-16*)=K:*RUP*QYU%U%^F_%"Y+$\"^9&C
M&#AI.LQ1C*0@GJO()!>=K330\5AQ/+OW<J])<'GJHY93$VR"!9U1RNRM2V[<
MK<1'@2/AV&#=64#M1/;T4BO2?1E,LJ+!B/U']#EY>]P5+I\/YO=)]'F.P_7>
M<0N5'RV6KPM ,1Q'BAC-C80LL\AA$Y$'4T<+(A)Q"S=8GXD5J!-/DC DFEJU
M(4QJ]U"3#-4R)6X[M]W:Y5#M:]5J[T'CV5,?M8J&6*9A 8UT$N@]*.1\)$@$
M)Y+"A'O1V1W1V\'JF;4<#,Z#-6$D$I[27#@3; QMLM/,YE:4.D;9.:5UV<WC
MVMPB\=*JW)I6@/Z1DQ%SU'K*)4MIM,(3+EEWBSMW*KW^%=J;/J3HM4)4:XVX
M\A99K"(2&HP5X:7QLK/&R7-HV[4DW282$7(UNR"SAUOQA&P,'F&0BL;HZ(GL
M;/;*:EMJCO5-*@@F">)2YR+50&/.8H-HRFHK5<RKSG)MU[*3KMIAK>%J2L'E
MZ!Z#>805T@$YQ0Q*@6D2/ 6MM;,R^7Y<;7:IOPK;>Y'>NT@34SXPI%-6KK@6
MH%<9A8C6!$QLRP+O+*N]ZLW"Y4C>[,ZE2BD420[B9M@A"S2"*#%.<A,$X9V5
MO'-Y%2YBR4#KC4>#7M@^/JD&IXL2MHO1>B-SFA(/_!QMTZ(8+"8;!#*&:J5D
MX))T-HWI@7'4._?Z,.>GDU<:1QU9$B$TO4-=CMAU(-US 2YF3:",4,]99T,1
MGUH4C&_L 4&J6,UJ\!\W-I]+Z&F4+%<"UXB%9$#5QA$UK4B#4-X3[RA7G0W^
M>G%5@1X+&>/Z/'1.R)@]]5&0(;5A03E$C0-I8W-E;",S;J1,1<QAV;E-AI?!
MNMIBD<VOQ,#\PDP@Q[ '&XS'J*R*1'5V6Z K79PZ[0)ME58B4YCEZK0JM_WR
M 5DB12Y0P$S"1$I+NTHKKSR9^FJSS+82<:/*X$$!+0C/[7WR5@J-H=$ (G%"
MAM3=?(+[ZZ\M-%>N"VJZQBXXKE!2+E?OP@$Y'C5*5-BD6-3"=+9\WFNNWM6F
M?:^IPYPFY&ENXB@,0=:(B CH7LD2ZT1W>^$MMY7 7,G[SQ47I(L$&T2 %A '
M6D#6"Y#SGCIK;!2\NT535N;<3>;<W"1$$&LE]C,"=F -D.)3S@^.TN3**00%
M':R,U I,%[ZK\^TSA?42F,UST).H1<E(C7B2'AD2#?+1>L^IM(IWSG?RVO 0
MP)!RHQ#-T<Q<,(*,# ZE!-\:9K%*SW)GZ[79/5?J0CU&:TI$2*&T0SKQ)I82
M(Q.M1LZ01)11T8GN&L+V;+=YU6N[5+ .]1 ._CW:JBT2&.^/PTTW1L.C0741
M27^AQ,/1>ECZS7$,81MJVFNL YH8P](QAD0P/OOP,CX1@12AH-5''($JNTJ.
M7?'AW9AIN6GKH[RW>PH EN-NP*R<=J$<I^XL?B^W1?==8F#K&V-0(#D6*K?%
ML298@"YC>> \B=39W@V=SYA;3A!%8H%IE5,SN%.(!P6KZ7Q 6CON#%.!R<XZ
MX)[.?+]C._[@R^#_Q&K0A$DNK"_S]3A(X&DQ'Z%<.?51A,(M"](G%(7B.?&
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MXUR;3<OGOD)/NLW1YM)8877N^T9@#8!Y'$'..HPD3"9.R@7;79_ZJC32$RK
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MI:2 B00*5*MQ2(F51J+H@;.L)0P.=W5)Y@#B*WKX@E4W+%M:$T%(5JH%&(/
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MBLOW<XB@=\/0$1(S"Z2PQ<[VQJ=/OV_\6NQ]W-W9.RAV?]_;_WWCTT%QL%.
MK7, !DU!6+&S5Q#Q7?B^V-DJ#O[RL9@Q@RY,H(W-@WR8&,9;!?=OANQ+LKC
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M3B.W>%6QM#11XU%D6"/N:0(#66-DA6!:*.Z\C.UUBZPV 88^#VXJ!AV;DQJ
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MX[P%6(X3FT\"3&D*SH1FQ'84RN%D7$^$!D18QJ-UB$CI$#>"(A,H02E0;Z/
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MK0.,]+@+I+H2*R2T8YA\U=KYE0D%$M"A(5;:&T5N_%TM&DAK*$:Q;YWH%QL
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M)B6"+2XDIY&X#:J(1S",<;2LB&""K\#XK3)[%*V7FXH7?20%B@[5'3.4JJB
M15*H&V<&*Z-@.[9KHD:++O.E.#O2\IG5F9"5T_PP0+')9[9=MEG'6F3*HK7E
M&XQ\0RRL4T+N)MJX<GAY90L'(33A5N@JNR07VNC2*LZS)IT%2X_WHMZ3E9N;
ME^[%;4)V>>C(#_3"A.[1W%4O> @=V['(+\;5DIO\UB._*F3+E.E"*[C^1KN
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MY.@*0DBQ.+LC'W7;4O!-@[09I,VWD3:_;QEA3I$R($VZ(6T3S/N*1S9-^+@
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MVZPACE@DDNL"--'>BV>OM!TX*+>\6(B235V\9Z.C67.^-2D6N11(6 ;06=%
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M^ .E/,%W:I)7,+;'M3>UQQX>+]<;[ONZS)"]@IDUK5?%$8]*XQ?PYR&@W.C
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M]ECIA49^LB3@0<&RT/@B8#9L5^ZP(ES#>7JQE7F=9"C/R"8E.?$BX)N,FT<
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M<:8S%.HH,,S%)>B8QW.FC9:[=DV_#G:,=XNE1OA"2"G!B#QV+,G<3P'CX\(
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M.)GTR$4GYZ^2,^0T>S82]YBI%3=>^PZBW=VSB7_]1/@BP"\A17K.\'*F@CZ
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M$-2ZDCX%4505_)GU VZ9,-33G9==YC2TG?Z;57ZX'H2F@;=%L>$N9P&9!H)
MRZM[L-LIHT3[A.$JPTX_6#<!$L=<Y=M2*8P<-(X_Y/IS<UG.N6;##IT#E[5V
M+:'O%H^;47FU(<MFZ(<Z84I#H._0U4"G)R.ZFV148J^3*9#<C6'?-@4=\*'9
MH"JM;!8[W+\CIYTB93!W=6AISS[!7[6C\KOS,U.,5Q1>L-/)33U2?!/!>@D
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M6T<,W-"JG&9O()"B2M\A0YK,"$N_*.\D;%=R%62*.RF_1/I9-H([%HW"):M
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M& :HD+*+'1RH;5$$V[9LF)5#DEM<I.#$4/"-1^(X&RVO27%/HL=9 7;3;3=
MC0V DST*+)>@ZO,IC"UTIC\  9,XM:C60 :K2MQ)#8&%:]F431V*SM5\!I4<
M1I$*VHU%NM*J7]\_L3#YYI/">YW"-KJ2#M8>EX)ST7N.Z@&^Z!!4A) <>[9E
M1K2&F=@:)H9P)?=058\Q0(1(!<VBC\T)^G@(RY/<S,A2&\O3<)(XBI+I<4#_
M4JL=[/'0?^%(+S'P>B-.A500R601A63S\[Y5C1H,S?[)R1O),NCY1V_G1$]"
M:>@NNYC,'<W-)NGL[*)I\&BHM'OF%\N7%2TKD=8+8^_@T#3YCG^VR.'!K#0X
M$6>6:F:Q!_WI.&=[" '9AM%7]0Y Q@ EJZ0T_J7TM.[Z!E#.$SJRZ?WH&$58
M%.^_"&S'^A&?^W+>+8>62,B;Z]C(FQ V0^E,T?'P&6?]D:UV^FR]$'7<-(X]
MFYUEH4=F6'0((71\;78/T ?24-]<YNV]$!>[)Q[SOR'"P#9$LF_-"X49L_D\
MPIV5JHFLT"+OMOY3W4-FJ.*)M2S62M8P+,1%J<F1)1JS3IP:4PG 0\R7?+DN
M")Z[+WMSLYO37 1B3.V#[UAX6;B=HGH#3GLD3."P(M73=;OU1@R<)89])IB\
M>:1? @V1D);:[.BPNC7D'95.Z3KHV5@:9RJ)W9=M>0<^ ]>[DWVW;2 ?3FX@
MEB@?^;*:;K4)/W2OC6\O"3VL7B5Z<6\+<1?BF--A04#[EMM.CM%PH9F["K[\
MMM@G1XZZ$TU[PWZ5*N&O?M_.1,NS5DY8'U3'9\"9M^,"#"1:Z?W3]J)GF#E7
M/NQ%=#DG/: ]&Q&O*D@0M&PW_6-7] B<RQ?\CV8U,Q:]LI[YV"* %(;!6/+>
M.7IZC]<>G<I?+@%GCR9*1MU[/G8W: Z$0;K:6W]?NB+>\?:B')<%P1*/7XH:
M?53$Q1!%XI3OTX9%PHU86(E.UGY(XPP>YH/OQ[FLBZ8%XBX\8*"/[JS5T![3
M7ZYI>U=35F67C=?'F^]%'=<:^#5ESAK.?((L' &VFUA#'?+A4VS;<D';YISN
MS80P6U0GTKG7G/_-5J39M3=9DN$II]-S"D9P6JHY=ME, 2Z9*B0?ON7 .TAO
M1V:G?T0*=$4?:JFP35P#RRI6$61"\ .NKOZ3!VP/YI,R#;]"P'U-SRZ>W(%:
M_&97_$/$3]3HJ>C)! *][R#0QQ,(= *!3B#0NY#)6&FQ15TUU5 G>WK%F@:1
M)3B<Q8(_03*U:CH&?=EOU.HNZ,!MU=SCF ]HG</P2SD16"Y4E!5VZ<W5QK/*
M@GA'DB6#N@7_0GAO^>27UH2:"8 #MDH*\^+?-8)L8[$(&OL*:$N!:4J6#=<K
M/$6R\W1"-,IE$58 5"T*\^G05BL5?"=@L9!\#=U[\?:/(MQR6[W)W"(6K1P&
MH(,R?"W%;]<467^E'EZH2@[PCE7*$AW\9C]_\+EY<6_R=IZ3TW'RTZ\5.3YG
MBZT-)JIM%%=YM;,:HT<M%G'!UXXY__T&KBD5FARGH&:;HWZ_"Y)W'O4YKNG0
MXV$Q1E!J?^"OXAX=D'^LYW2%2&6MGYOJS:UO.G/9[5!MR[T<,-GLKK3(3)+@
M45FD[#K3O!%6*UT<$?@ESF^C\U"NW2#"3S6'K>9&BW/BU^*-<=*X<7:#8MMR
MJ!\(T*N&5%QYME?O$NSO83^9GYO\^B6'9T$MAE^X$+L>7(2S[-+D YE'7'+S
MLC(NRHZ&0./3S81[[&J^XZILU_P0@K\Z]"AS12_5C68:XD>))H-MR]/L^WRI
M3_\^(WG/J;RCF1QL"(TD.1B9%ZB="@B_Q)-*%UV$Y;N"Z-B%RO?<H1$PF:!3
M@17#[8)&^'O,3>>/7>W>Z)J*4Q'+\;W"YZ0X6>,[L;.\5$#\>1--NPN88*:/
MX)^,G^+*B"^7< U[[Q0.NBG6.Q0:(D[=#DLO3%G/Z0:I[UC$/+,'@A82X,$,
M\DR*B#V4I&0O1+>JMPY@ >=_Q\=RL16>8D;+GUX@A\,T4W_?+2]$URNJ:M%+
MW&VUJ60P(;?R,&9)LZ3Z/HFC8HZ0\W]P$ 8=JN/6:&(]O*_/."$3S_17X4SG
M0^+1MZ\+(._%N#Q3F :]AS/)E&0O[87]HB_LF,IH)O/&%FQ0?EGQL1>=TC9*
M- T/^M9- WNOM#TN)&TWP2G?LU@GL+)92)4-06F6]]4T\<Q4@NDE,EZ;7J@K
M75][>'R;8[<Z((I9)RLXI]@U.Y6L 4/1]74!ZY;3K=0H^N.E%WA9<\^@E-U'
M 8UJFZ3Z=\.$]U0CN\>!V<]#<,.\;#8XI>CF@)4[S)U'@<4"C0H,R%$UX#]/
MFRH$,*B=2XQ*ADN.\72[-2]AW0PG3"?:E0J=B,UH'-*9^K=S#WC_R75HFWD<
M6;Z&7\KNQ"+O+L>PI[W>+P\@Z<0U&+F>?)$G9K5KM<GE!LB:GQS:4O1:XK2H
MABDWQ!Z>MWZ+'+M$H4>.<9<S'G-1O#U P:I[^0!X19H--HC*\<U841!^O</V
MPIE$N8G6WB4/I TM8T-Z)XKU3U\\.'T4(+0 G^(=\D#P#_AQ=)G@M?[IX1>/
M'.2VM*XBX94**ITI!%5M-XQ>64'@PEH00_D0TA<S#WHPF^WIR3V2!]"N. ^"
M@"KE)4?74GJGE&JSAUC&O%W!O(]@S*XM-\$KEA<O7TH[D 6;:B[NR$'CT9+A
M;#C$ #_2FFF+34-HVBUH->2=PO Z7$"?CA\AU)+1WL@%,I7X&)Y%[:;A\FO$
ME\5^&TPMJI:"*H/AD&C"0='&.VW> =LB8Z3=DL',C'3A6+E,:G("1,%QW853
MUV:<M\Y( ZX!!@+I9,IP.0*,=9/P$Z\]F6"_Z&89G3)H.,_;$[Y,U:".4;3K
MI/>- XIR;?<2&V9STBN3:[M;*JQ6T9%6L+#:-\?D0">'^42"]8%S.I%@.368
M*"@V$TLG0?Z"=LE,]]!,\>P]W-AO<,(?/J GMO-IR=_5DA\]^^'S\.$6N^<5
MB-J-*5).ZW-:GW>U/A6!R :30E/RB\C#[KCGV7&.]-DL'!"OD<X-+*YR 2#@
MM%JGU7I7JQ7.=V>A4TH<[R4>"H4T-@ H<!6"29ZFE3FMS+M:F<KD-/.A(.N
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M-8M7,5RHZ5J<2>(&L\ZR">3L-5"#22YF2R59LOW5>CXL(HHKS(K)[Y<1]+2
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M%$?B"2[4$#B"=;^CQ%NJX4])7<-5-8:PD\M<K(;P-"TMN_#LY5E,"FQ%=>\
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M'<NY0FE4_)K#1C$F^;]V]"(>/7CTN62;ZKI!,+?D2PHUE-6>0_6V9,V:R 5
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M9IOU4L%C]K886%MO:1MO75NE7];DJ2!5R6,)58QV:W)EO F"A0*EAO:0\ Y
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MWX,$WIEDCMNQ*<"<=F#DA;<:SV"]<93FT^(M;*'X:3-/:O(^"FJY.K$H<">
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MJ;S-:->-D@\SE?E,"GY_UU?%_1".!=5)+%!2E5W^UE6\CK) 3&Q8_'VSQZ;
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M-[T<..(]) +9KMH)'$M2$P:5K8@*7*M@);M!RE"[X".M</2 ,K@N^_$[82#
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M'7:&1A5OJHP4)G1F3"4C-74ST3AM(-D;5E(FM-B3UF[JZ'Y"./KEQB:\PUE
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M^W]<?0"72/&<*:-X%2"NBS8OY4SE'$:'3P=!:_]A!+YS"'B_6+^SQ&TZW:/
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MPLZKH^(:(C)Q6M.\2J+F:^D3#2'R,-$PDE?5KFG[X&%4\-RDO041.&S80M9
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M9IN+ON]]1\)7LTZ3<B2$06'">>VVC:,\#I:DL8#,K0SJ@2-V,\* +AUO7OL
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MNNC<H2S!Q_24QU2"*$K'ZNW1;>0!Y*+Q/#RP>/=.=3OOV7Z#>\S%TXLDFZ6
M:MQ<KC ,#*XQ<@M@U4?J#"2A$#QIP>GIZR^(C+<1K*4IPZ,,^1X>K^,-[( I
M$GA86,TKJ@6L>]2*YRT0AY>("%(CO*N,,CF/D&_(7>=DG4XJZ]@5(J6H$ #8
MV$(XF#*(6G:4^D+7G6N(6_@F;&KFTYLF[[DS/5\2Q[ 29\)=JA9UVW"K'D0
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M"T$;Y*@FFB[. @%Z&0#*))Z'+F\%MBV@NU*WN[E-(O-JES-.I[#;U^V1;GV
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M1234Z&DT!(K:M1O"B+OF,2D=NBPT\*+-MJX8'I:@=!XZQ4>8 T Y#6P-&QZ
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ME%,/GL(NSBLS:&_C/I)V 3)!ZU6@=QCG,@-R'$Y'>C]K/K+(DI$<1?N,S%+
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MBM%ARQ( \;^'/4Q<'!8%EF_YC&7*\.09;$LN +/+@6_K9W*7D!P*D2K(18+
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M1/:I&))$/?94"Z(7&Q>EM(6)5$I'HET'[_A/>.13304=6"88"]Q=796:@.$
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M2UGXZ8OIU9!)HHW[PLK:0-Y3.9OY6>%$^F1@9!(5KM&[1-]"NI(1$"70,9G
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MNB[WK)^$?!@D0<ZK_KSJ/\2J=T!>R^>B%Z0.MR7HOKUNYT&[%Z6<'Z\"6-'
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M?[95@-'H5Z@(,)$(S#K^/1V/0JJX7Y8PF;M*O)&'%+;$:LZ7I?4)G'/A\DD
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MME3K=T$O35JF1&X-1W0@O .)NA,M87^XP)CE3Y9TW\:3FQ8VX#R!!B;\(Y*
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M2L,ID],%QL&DRA?[,P(&@:Q11O#H?"L^^DFH*S!O(EISYERB"1B7X;W<Z4Y
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M\4FMZ48IU(T/=F1X:5P.KG@57Y:6XSH9>NY=S1;3U%L1>K.2?6E&!#+)3'S
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M!F7CB_1D#-L'ODB,[$I@RS:A&V;=XJU7RK6/%U>4?<)_TL:L+ <=;T^=^HP
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MH2,OD00Y427$W(S-GW8Y,I9C#%Z;M)J7N78]<$1  8"V X%H2=OOE.6QSV)
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MH7,GC9?,,K?"<0A\L"7XE?,=O?+_J6-7<+Q%^.+ (S?D-:W@!>04\E"L4$+
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MM"FXRM;'[+$DQQ#>$OE:QA(_JOI1G'=2'A(4_B5F48;AU*/HC:*WF\ -5.<
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M%H2'N^ER1&9/Q1)8UH"9''ZRWI0Y=?)ZY* FH\54W'-(4R.$7-?>_FI1V27
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MDH_IX=8;ZG!#PA?@<N]A?F+;8;,"S_FJVAXXV&=87$[1OSVW&(&9A -T<09
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M#^Y=6#X?>@\QK%\N.*Y,5Y$1*B<3W!-<Q9!M&.+EML=O$2_(<<'Z/@6=+^-
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M%[NC.3=-IO#54"%) F!ZO($ .VQ(6U<""383@.J(A^#7)*0.$4):MC&IDO,
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M+.S#,/$:*9@#()6=OFH5;9QT3@?]WNEH>'+6/SX].>T/7MG3JK\+L8"M)AI
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M!ZM-LGR._RQGP@NK/$?O%/[L/PI80Q3P)Q7&=>R[:KR0D\[@^+AU%[*RG=V
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M'(L\SB+M> >*?DTNJ:PJ8)GBS?DCH<AC(<2=K9$-Z/!XAU^+7U' 2B+"NM9
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M!S:(+"F 5I4)[CUN C%7&7Q+/9VF239&;07>F<W))Y!&L:EU!RZ95]QIBOR
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M7%)X?Y(5-*[G9:]WVCE6O_-Y.$R0)#3@J8 'QTLOB!" /$<&=P6'.Z+]AS.
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M6(TK!"-X8S0'599.P_4[$K%)Y,^:UVM,"<V4W*9%%; ENAEB?:B/EQP:35%
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M4I,7"U9TRVCCL?.5Q*=R?.OMLALI7@2T%U@-R.D&8&T278UW2TGSD= IAB%
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M6VVR"/J&3OQR'5B="LB!+,K,4<5^4,7Q_E"%TI;.FU#K&54.@WWE_6=)%-Q
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MM]^>NG>_T=.//?=K]RSOU;=R,SF5A5$#)[32)&K726 I"&=SKM/&M]O4G)
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MQ]QX.;4G#&@."VS13^UO^CP%]<_@I)B,S[/G;R. 3K"=M8DV[=6LMD+"20H
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M&*VPUGG<O-KYNV?RRW&%LK???UKW#0X8IC./]U05B1K9$AU?#>WU[%LHQA2
M>%U O/&%#@?$O>V4 T"\,B#>N%[_ (@_9"/E?G6_ 1 #$%<*2S?O.3 *'C$
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M*P7]MGSK1C%20Q/\NA/\8R?8S_-+6P"2=VH6P7MIJ0PAF@,]?*8,C]2%\\H
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M!]6  2OZ@!5+%KL 5KP,*V8VZ-,=6I7GG]-A_JV%;H6'B'TWON"#']\]2+
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M.\<FY+GB-F%NNOQ;?WU%7S4OP1^<^##5CW;(>+4Z>[\LI0T]V[Y_Y,9VJCF
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ME]\\I\9_?95=C7='DPMD\JJAJ/_$J[\)/"""SCH=S![X;V"AK]8*:D /0 ]
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M:+C OF16QJE%7"<.ZR6A*-'N=ZN2D)NDB2!VKB*J6<>"D4$<@6_1$UMNA="
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M:IP]LN/C]$Q=G>2%'_G>>%QDR63LKSK+3U3A/M)4RS_6PIVA_:U8;0&5;E]
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M7820O0OGIXP!0@!" $( 0I9;UE:7?N,18 A@"& (8,A2&/)QR3-! 4  0 !
M $#^]MZFF<X@D $, 0P!#%D.0PZJ_:D (2V D.<OL76WH>LJH6JU!O.S&JJ1
MMH$:!\=ZG">V"!@9!!13UH+N6BV9 N@$MV:!KUNVT CN[KRNH2T<21,K#</(
M*-_X+$X<YN/$(A$RK+%.M0K-_69I81@3XS]D$JT0ITRB1&&#>"BP951J*>/[
MS=*:[U9*V8#$T2".'FJ(UF8;7Z;_&5@Y$!(0$ASXTB-F$EK$B:8Q2H5AB*LD
M1HEF!BDC,$E#'J9"-,),XUS_,:W[K./6NT>@G+Z_.>2$S3,48H\1E(@'+&+
M3L!.P$[ 3L!.V\1.L:%)1$2$)&,:<6L$2B@6**)A'-N02T(63^E*(R-82!P=
M2?>/)<2S4XRH URN:,1TE*R-G0@;1"0"<@)R G("<@)R:L'I#C<Z\/39>?U0
M0]7UAVJ$QXS'*;)24\2-X\&8$HMBAJU(I(E"'=\G0R9IB$-%D"82(Q[;R!^(
MY$*U- [3)$ZY%FF39%BZZ7&_/<:* TP@G[@9I'G3 J1IB0B!'3NBL\".P(Z/
ML2.+&.<R4BB*38HXUQ(E7&D4.LR.I#"1B9/[[$AL8A,E*"(Z=.%E4B4_:8JB
M)(R9E2*B,=D .\;Q0$@)_ C\"/P(_ C\N)6I3<NB1' 3(R.2!'&:.NXQC".:
M&IF$2121:"&:DZ'$C J"#.:1XZL4HR2,.&(L3I7&F&J&UY;:C.B 2XCB6I#:
M;+B_2ZN+3\,6%)\^K3C[RA8Z*ZT_AZ[T-ACDE]Y EMHV!OY%>_V+E@AS6Q9)
M>NH.,$*EHU:,;$H4XM)RI"*5(D-3J@@QV%I^WQV(0AK&W$JD8TX0%SQ%2H?,
M76-CPET0:\G#R=W#LIQ8\WY2N,&>V"++I^?H5F\>US UPR_SXA)20L)!)&C[
M/ 6PW(Y+#@@$U! (I"80*E1,(FN0D"XLY-9%EI(F#%F!4Q/JF'&^4"K3(('\
MCQI.[./\\8(ZSU@ @VRYZ0*#=%J8VZ*&[6"0K5^QT]B139PZ]G'8CCAVP4]L
MTP@);35-$IH0&=YG+,5"PV,A$2;,U\ D(9(:NU@IU)B$0B:*ZS4RUA,7]"0$
M/[!,!QS6!6'VC<.:DN6+*.R)\I:44%#4+5-4P,M."W-;U!#P$A2U$XH*>-EI
M86Z+&K8C1[+VG$5BHS0V)D9$<(,X9AK%6+E_1&0XEBRD/F-^;T.JY()C2Q&C
MOOF/8@HE.+9(<V.D("(EB6E+EIV0%G92V";3[5.CP,[4:E75#RA1SHZ<[5Y<
MVE&I*J.W5_[WI<ZL!5\ ? 'P!2!V D5MCZ("7G9:F-NBAH"7H*B=4%3 RTX+
M<UO4L*>Y)IU*C6-BD-4B\O4Q#"4Z31'#E@N!(R;#A8K.9>IC]LP_)^7XP@VE
M/,OWG/S]&-3P1&7F<#0]+*^*D'_V ?+^7'P\GXGZ9/\UR4HGAE-;?,VTK1-6
MGZS.OXRJ;VPH0R4&C'+(46VYR0/S=%J8VZ*&X*F#HG9"40$O.RW,;5%#P$M0
MU$XH*N!EIX6Y+6K8T\P&3;F11H5(6DP0)VF*$J)C1)6PC##)L+9-5-% 9@-,
M'CHEM;WZQI>Y5<=RYJFOOKEP,%&W&0FRD0>!D:VQXULV/@\^V*28J.(Z.#D\
M.0@^9"-WI;O#(!C9L?^";/9E.B_'T&L)W(_68E$+U+"G[H<P(=74N1)QR!7B
M$76_4:.1P()H3JQF0MYW/^+0^-:+$8K3-'8N"_:+,=+]@T.>,&H4US>M,NS(
M/>H,U8[3_0K3Z@Y+SNVX ;1_.#P[R2[M#8B=3ILKO?3(3CQPHO/_!V=BRPT8
M>*33PMP6->PICW!,4QT)C&(5IRXD]3W[,*8H(G%,;!AKB1=.=5X'CU2[1)K:
M$"*C04@@+-UV$P8FZ;0PMT4-80$)%+43B@IXV6EA;HL: EZ"HG9"40$O.RW,
M;5%#P$M0U$XH*N!EIX6Y+6K8T\RNC;0D,8E1S"*&N%:Q/XV%H 030FQ"L @7
M#A/%- PU)R'B"777X(@@*76"C F3%"M_5+>%S&[/3!C:_72HX.BA>J-C/<X3
M6T"Y$3@3W4:B%JAA3YT)'2KA?(8461,GB%M)49SJ"*5:$QM*$LETX:37$%LC
M4J814;[/8$08B@4/4<)QS TFG.&X)>5&_G W.6"$@">QY?8+--)I86Z+&O:4
M1E2D8Q='$L12A1&7C@UB*SF2+(Z%-A:'\4+5ZCIHI,F85(2.2"00R99;,!!)
MIX6Y+6H(BT&@J)U05,#+3@MS6]00\!(4M1.*"GC9:6%NBQH"7H*B=D)1 2\[
M+<QM4<.>)G9U'$=&4HHTHP1QDX9(I18CCI,D9"$-1;)PII@4$;-I*)$4,D*<
M)P0EFKE_*$^%^[H4JU9M(X7$;AMKC:"YT5IKC;ZIHE"C\8-]C?8N[,A8$YS9
MXB+XF*M16T$:?(5."[-OO@+$5J"H@)> EWU70\!+4-1.*"K@9:>%N2UJV--<
M5$0PI0D6B).(("Z)0'%*(J1QK!6S4DLEUG7FV#_J<-E'T(V=;\](#$FH+3==
M8)!."W-;U! \;E#43B@JX&6GA;DM:@AX"8K:"44%O.RT,+=%#7N:H<!Q)"-&
M#=+"6,2))"C&/$+N924CH5E,%TY%7]7989"AZ*#I0DN>EI?)W#T#;'+I?K=7
MMM!9>:>*IJVX#.Y!IX4)[D&GW0,5&T$9Y2@2.$4\UH[J(\X0X;$E8:QIE"QT
M28A"&L;<2J1C3I!S%5*D=,B0H38F/$I"2^X6TU:G@]:L_WY2N)'61X+6-;53
MIZ \F&*6>7&''4'Q@$H*;L&6FRPP1Z>%N2UJV%/FL'&B)+<*I5:%/D@,44(3
MBZ252L1AHNABF[:FF*/::O%CXE@^H@P'!-J\;KW5 GET6IC;HH;M((^GTL7-
MM#Y=_*]GDM\H61F!;6IBAFBL'/$02I'DQ" B+=:.J(C6^B5U6JLDJ])-F_OM
ML?;D#!J*/BWU]G1=>M-6U #RZK0P^T9>4(( B@IX"7C9=S4$O 1%[82B EYV
M6IC;HH;M2(ZL/5G!TB0V@DADI32(L] BR:A"(4YQZK>;<<Y>4K*UL<RZ&,22
M09:B7=5:T-1HT]5:6I7G0UN64+8%+D*GP*8%:MA3%T$192W!!EDK+>(84Z0B
MS!"/P]3RT$12\M66;>U/06OF(QRG,Z_AQ?5;3+(!$P(<A2VW7:"03@MS6]2P
MIQ22*!M6C7"I$(XX$AZCF(01(CJFVBC"JXAQA?5;3V20Y</-. (*V7+;!0KI
MM#"W10W;02%;7\6%4\T(BS42B7513TH52J@.$:%QC,-4R#3$*ZWB:H*RGE;.
M!=P%U5Q 8IT09M](#*H30%$!+P$O^ZZ&@)>@J)U05,#+3@MS6]00\!(4%=I-
M=;* Z7A\;@M?NN2N/;>C,OMJ@V%>0G$2,%YK@:0%:M@IQOM68VR2#PU08-\U
M%P"TT\+<%C7L%( "7O9740$O.RW,;5%#P$M0U$XH*N!EIX6Y+6H(=7OK.24S
MUJ$Q$47:Z!#QT'<)#7F*;!@)G>*$8:SNU^VE:4*2-(Q1(I1$7) 0Q;%,D>!)
MI(P041K']\^@J-*4^_-9RL.1SB_LQ[PLC^SX.#U35R=YX4>V-QX763(9JV1H
MS_(35;CQ-UW#QS%L=H8B/F"T+@BS;XP&$0 H*N EX&7?U1 B@+5$ -R(,$XQ
M19RF!G$=Q4@JPA%3E#+I?I52-'$*'40 G4&09B, Z'O4PK(A9W%0)K2%/DCB
M3,06-Z_LB,MQ4.;#S 0SQ6F)N#OHI2PIVT[%?=TN-?K!#-6<@AGH/P U /5V
M*VH?@!IP&=0=<!EPN4N*"K@,N-PC=6^)Y "705$!EP&70=T!EP&7NZ2H*\9E
M6#A_T<*Y%-C2E*4H5"1&W!B!E+$8:6L9IZ$)I5WHTJQC1H2R"8J$2A&WPJ!$
MX!#9A"NB5<QC'-Y?.#^RX]N5\J:7P848$$[;MQ+>(0:$>EF@0J!"H,(>4Z&.
MHLB*,$$)8XX*$^)^(XHB+=*4$4UL8A:Z/R]30P94V"<J[%._J?7-2M.U'S^K
M876 GAH'QWJ<)[8(&!D$%%/> MYHR11LHX-#=ZB'(I-/DJ$%%Z=A%^<9TFV'
MD[-VI\-%V%0P3)"*8^=TQ,[S4%R'2*=68)%:JLF"TZ%3S!GF,3*,^5.2M$0J
MM!&2(N*1B&.=\H7XNSY4[W@R+L=JY*7_XE/T!![$43@(H[#MWL8]+6R;O]%!
M*V^)Y("0.N(:_[D%.@O,],SS^QB-&4U"C_@:<<T94I@3)%6B4BUDF/*D$6;R
MYR&=.W?=%N7!OR;9^+JIT^!Q/)"$ #L!.P$[ 3L!.VT3.VFML-4)02&M#B@G
M$8H)21&)B$II*!Q!Q0NGR]*$8V%#%,7,,5I,':-1I5%JA [=+]K&Z=K8B<A!
M+#"0$Y 3D!.0$Y 3K%R^(%0CL8Z9E$@RF2">8(,2Z<];3YB2AD>)9@MD2 W&
MCO@$TG&B$.<J08F)"(HQ-YS$PF*9-$F&3UN^) -W;R#%%JU? CL".[979X$=
M@1T?8T?!"9<64\<RS+$C58[DHCAQ["@U)2I.([O CH*+A"0Q=K$AC7Q'6>R(
MT7(42A6F89KJ)%ZHZUD].U+!!Q&#H!'X$?@1^!'X<3M3F]@H;(0TR-J8..Z)
M%9+*8,2LD,IB*R*ST,N0)=(0*1G2.J:(8\60U"Q$2B9<)FD8V8BM+;5)(SH(
M2>N+4%M.4XW :9_:%K:A^O1)\W5P90N=E3;(4_?]S@B#_-(;"/0QW#('HR7"
MW)95DI[Z R)4PC!AD5:.X+F6+A95J4;$>09$N:C4J 5_0*HD(I)@)%3B_ &.
M0Y1PPY @G I!6,AB_* _<%B6$VO>3PHWV!-;9+FI*T>K-X]KF)KAEWEQ#2D9
M8$X&L6RAKP"VVW') 86 &@*%3*ME8BTC96)DJ%4N/+01BF5*4,BEH(D,!4W#
M%5+(_ZCAQ#[.(,M'G&S HQ:F1<%X.RXYX!!0PY9RR-8OVR46ZSA).0H-<9RE
ME4*)%K[,4S.1.OHR"5O8?Q!&&FO%4&*(XZS($J0BS9!VGQ>,ID1@OD;.>FK-
M"^41D!>LU@&+=4"8?6,QZ'L)B@IX"7C9=S4$O 1%[82B EYV6IC;HH;MR)*L
M/6M!J(EMB'T'0-\;5W.!DIA(A+&,A.)1I,+H?M8B32E5FB=(:W^";:0,4BFA
M*,$J)"94--*J+9EV.J 4SIQM6<T6= Q<><U6506!$N4LR5GOQ:4=E:HR>WOE
M?[=MA6'P!CHMS+YY ZV(GKI]?"QH;L<E!P *:@@ "IJ[)9H+ -II86Z+&O8T
M'Q4K:WB<,)2D B-.M4*)81J)R'!,4\NT7.SBN405S9[YYZ0<7[BAE&?YGI._
M'X,:GJC,'([VU64V5L,JAO[9A]#[<Q'T?+;JD_W7)"N=&$YM\373MDYJ?;(Z
M_S*JOK&A+%8\"'D+VU:#R7=<<L \H(;@NH/F;HGF H!V6IC;HH8 H*"YW=1<
M -!."W-;U+"GN0]K$V.LB9 R*D:<&XVD%0REQ@AAB#0BI4W4XD#N TP>NBZU
MO8+G>'QNBZIVI[#GS@"SKS;(JG-XVPK;X#UT6IA]\QX@_ +-;9?F H!V6IC;
MHH8 H*"YW=1< -!."W-;U+!3  IXV5]%!;SLM#"W10U[FN_'*F0)QPDBEOL3
MRZU%21(I%$J*&:$)5UC?S_?'443C-$P0B[!%7,8:Q5)%*"02IXFUV,J%,V&K
M3.+^?"+QL,HC?LS+\LB.C],S=762%WYD>^-QD263L4J&]BP_484;?U/'F[,6
M'FT.AMQQR0&?@!IVV_^&! 9H+@#H=@AS6]2PIPXY$3RR5FD4&6X0-S1!$EM?
MBI.ZUUEJV>+)F\L4X(!#W@M#AL8X+2RK<?85#)V=M15ZP0-83IAWSTK$._ZH
MQ#(?9J9M1Z-VT$=84K80AK5!^[?RG%  :@!J4-1> C7@,J@[X#+@<I<4%7 9
M<+E'ZMX2R0$N@Z("+@,N@[H#+@,N=TE15XS+<-+MBY;)C5:$,<,152)"/"88
MQ9089!-E6!Q%EF)R?YD\,52;E$0HQF&(.(]\K:MA".-429ND-I'D_C+YD1W?
MKHLW?HHMB08,T_:M@'>( N&L6^!"X$+@PAYSH8R($:&5*$F-X\(P]9VKP]C)
M3W',4LPE5DV4C $7]HH+H2/3>DO'EJO^^%D-U4C;0(V#8SW.$UL$[/]G[UV;
MXS:2M-'OYU<@'.NS=D07!_>+/.]&T!+EX7MLD2M*.[N?)@JH HEUL]$#=$OB
M_/J3F54%H"^\-RDT68XP17;C4DADY3V?]":.[_K1"!3'2%[!2[1P_ ,?19&H
ME_E46AMGQS;./:@[#BOG^3WP+.!EF0H6AR)BH1LF+/6]D+E1G(@PR%+7VRA4
M3Z*TC(K$AX,RFJSAL3S()(N*K,Q#*7D@LHVIK8@"V9XL%^V"SY#Z*Y9'2]\.
M38[C#^]O*SKW)ZZ73N(H';NUL<:%8[,W]G"7CX1R5B'MB6G\;R/@6:N9[HEA
MG'EN'N<1.+,)^,-%GK,\2W,6%VE:^)P'GA?L1#,A$O$%F.NR:8_^N:P65[OJ
MBO*"B9^.L#/*:B>KG:QVLMK):J>':Z<XQKBK]!GW<%)@*2.6>5G.>)&$$2BL
M(@JC=>WD)TF0BS1COLQ2%G+PM;@/)_I^'/A)7N2B#)Y-._G)) @SJYRL<K+*
MR2HGJYQLZO+ARK#T9!B440YZ$+1;6(0NXZE;@FZ,RC@O4]2)FZG+)(T*UV->
M7$@X4;@L]]V0!:7TO0+4%,\VX.<>HPSOEK],4QM-'%/VTNI&JQO'R[-6-UK=
M>)MNY(DH_"*.6.(&G(4YZL: >\PO\C (N%NX1;KI*'(_2$K.? X*,LP#G^5)
M$#,_3E(WS/T@C7?J*-Y--P:)/W&#T=?V6/UH]:/5CZ/@6:L?]R^P*;TH]#R>
M,C_G+@M%[+.4YQG+I<>SH@S#S O7]568<#@P"!DOO)*%@1^P+"\BYH*+%Z:@
MX**D>+; IA<GD\1SK9KZ_I'-KO84?D'8R:?=/SB*MBJO[JXM^MO?=,?'4.(.
MC^OYM]S_AB?NY=*#3>J[/3Y=^0U.\ZV*>Q#DTX5T>(&#1_GL"HYV9O4"+LX;
M^!CD#1QVWO"I,^?-PJE+9W$A6XFBA0JS^4(*IZQF?%94<%"[@ ]HTO#!"J^)
MZ@NRV%_A7T. ?[%J)N2W-_XOY51^8Z)J)(F -T"9Y>7L%U&U\RF_>H/?;FS4
M@PCV&SZ0KI%6'VC>,L]&IS(Y$[_,ZY9&%+]IY)0OJB\2MODW)"T2I]OQW^ZH
M.^)'\X(^0DDG\Y>6)<_ *'=BB_=LFV?VO583;66GBZY67M.PFDVK&:QH <SZ
MAB\7]2^K7P SJ(_G_%RJNGG&2W@E;_CT*[]J?_GA+^M\NJIPD,UZSMW@P-TR
MVN-TQ7V8['N*WQ7A4$QYV^+KA-/U2?0O_"V;']9E1[2%X$],VL=)\XV^@UV3
M]^C#;T<?CIR_G?S^[OC#;V?.\8>W!_?4=8\F#=FH1A'\HR[_4?#VXA_EM/[:
MCI5L;T\^G)W\?OSN\-/1.^?L$_SSQV.DWS.\YD_.R7OG[>'9WYSWOY_\_>RY
MW_%(Z?+3X1\GGS]\0KYW/OWMY//9X8=W9T@I\%0FSM%_OSTZ_>2\/_GHG/WM
M\..1 ]\ZIT?F+WC[AS]_7T)^1SE,'@ Y &LZE10(*4VMP'!Y>'UX'CR<@956
M+_4AZE99<N#^: X'YICR>2O?M!)L2! +J[J(3OMAH_GM2]56>34%C_.-N<"V
MMC9UOS@Y"+S@QZ&R-<J#M.U?KCO1._##AYSVD'." \]]T!I?[7/MN"MRZ^;:
M]+#O$G+8J^CLCF7VG<2+\Y! S@N@ZA-'O>&EX5?_YX?XAR>AXRB!';X'__Z/
MY(T#WJ(4PU;?YV7JD7;#/S?C6RVPM[O(:H&GU0*^U0)/RK\/17:P,O]I4_Q6
M1%@1,1X1$5H1L1=FX8W3]K8N=#=FX&N&3'K+VPN'0O].V=273CV7#5]@EAD+
M/KY4BTJV;UZ\"O@.]7%/K0 >58WUI$#I+\4JL<2T^]ON[Y?+DB^<F!;2TDY#
MMF+ZF:J61T+,?6Y!&'%[P8MOOXMXF'FI%[$B35(6!I['>)F4+$_3-$NXS))P
M T7L(:C:ITT-RWE5D-I[+AEL0YW55&/B1ZNI7K>F\HLL\DLW8*!J<A;F:<YX
MS L695Z4^GY0!,D&B(I(PRATI<\"G\,Y/."@I#+)BE"(-/*BTLO%\VFJ*)IX
MH554SZ.H;))BA$[PH<!&,>I2<Q:UTTCXJJBFTIEI[Q@_Q=^Q;\%9ME(XU<QF
M+FQD<W^#<3:RN;?$M/O;LN3(6/*%$]-F+D9HM*GW-?SYH9XQLM 0HJ"1[<*1
MW^9RULJQNN@O3I*_+L_PN>GVLB-%SQZYR3G/"U&ZS$MCP4($PN5Q'+/82Q/A
M\B1*TT=-[I0S>%2025CQ=JPETI$22#O"3$JCT(9M7OCFM#IBKXGY4MCPE>J(
MP'-]47@N"V1<L%#RDJ5%F3.9)@F7J?3=4CPFNO\,.L*-K8YX%K2\W43TK7/X
M-,[A;QQ#]C-P"3%DOZS:"XSW(WZ=D/EBK&+7:O^])N9KT_Y/&M_;L8!(?<^W
MC/K"&-7*R[TFYDMAPU?J+95N'+HBXJPLLPB\I<1E&?=RE@M?%GX<)HE\E+=D
M:J'0EFNQ%$JV)[.C%8/NI'P'YMS.9VC$UHD:F1-E,VS?,\,VE;R5-KUFC8&Q
M"Y81L.$K-0;B( EQ/C(FR"0+\SRG821,!C+.$Q&()-LP!AZ:7OL=Q9&.F^Z\
M/CI(1CA<TN[1/:><5166#:VJT%DVM^"N&Z7,\WP<MAAY+/.CG 6E7X#OZ+J^
M6^XJR_:DJL*+ ZLJQN4GVF3;=_ 3U4^,T&#*;7$A'1S>5+=\B@FW>8.M,XLK
MA\^$(_^YK.88N1FK3+:FP5X3\[69!C8%9QG5RDLK+U\[&[Y25ZJ4<1AD9<KR
M,!0L#(*2I64<L#25,I:AG\:;<X ?FH)#^^YD=@8.TTEYJFVZTRF?+8Z,3;=K
M_\JW, 4C<Z]L&NY[I.'DPN&7-1#D7YSV/CE5\K):7K;.3[PH&FD^!K^K@/>U
M:']&3PP>XT^I1[K)8MD09L%8);@U)/::F-:0^!Z>U][B*"59X2:9Z[(L]C(6
MNI%D:9%Q,EQD('T>!QLQX/NG"^7B<" WT6Q14O/0R,R3\IV1F">S/SIQ>=9)
MRYUG%R=NG%BKQJ($6J6V!\2T2LTJM?LD-D,_Y&$$2BT))0OCPF5I*$!?@9=>
MADGA1T7R^,3F^)2:'UA'?2_Q!*W'_C0>^^<9T'@*#R%PX\#KF3FP]QHY*ZX(
M8!"6_M,Y5K5;P\4:+M9P&;OA\NR&!'<#T/N)QW@$]D H><0RGI=,QL(/I)ND
M<>;N @__O1).;[5L^M3P6:L68@+^O23;N2=L3887OGFM#MEK8KX4-AR'#GGQ
MSF^99K+,4E XO@#G-_,*EDLW9VD1A"+U>125Q2Y2T4^CLVY45;8;=*S>K<U'
M?P?O]NR"PV5RCL#X17V)M?4J+VT;1*T]8NV1_;!'GM^G#1/A1V[(@MB+61A'
M(+&]0+!29J7( C<KBYWXM"2=?D7A]'8@FW9D"623.+36P$O?H591[#4Q7PH;
MOE)%D18E#W"P6N8E@H52@JT9</ FBR2/HSA+1?JH+.JS*(IH$O@6K7MDU<LV
M%_H=O,5W$BY35(/*9=L.:DV!?1(T(V##UVH*)"*+?!_\O]3U6%@6G/$H"IB?
M\3*+W5#&;KX+GW$HHW9E +B95?\O?%=:Y;#7Q'PI;/A*E4,6BJ)("I=Q'WZ$
MF1NS3(8!DY',8S\302J#7?B)3Z < M]6OXS,-[PQDVCG;C^-;_CV@L_.87VK
MX[7;5BY:<@^G%<^KJ1VU;4?Q[EI;V5&\EIAV?UN6'#M+OG!BVAC^7MAIFS^/
M9U]DNZ"9:@O^S2D:*:J% WZ2K+Y@L^%8?>47)^*M<VA#-K8F_9H0D5?FN1]Z
M,4M$'+(P"5R6!K%@LBRR,$_*N/ >57-&#=G',Y!^O)7OI/KW>-8+QT_\VUL2
MC1\[R;BK_$(6V1"2A1&Q6FL/B&FUUEXG&@(WB3/IQDR +F$A]>7F<<+",':C
M-(M]SKU'PWH\F1:Y(X3'Q/4\JU#V*"=A?=WG\G5/&SGGE3#M32HU42\N9*-S
M%6.5U]9LV&MB6K-AK\T&&?/"#2-P/J,,G,\47,HTB5QX'A?4N"_"R(]W4;RV
M:3EH@?5.EK(!NT&//SJ<B1,46H<DLW8^"VF2I;;B[:5O9:M1]IJ8+X4-QZ%1
M7GSX%)21*%V_8'X8@@8K,X_EL5LRD15)F,O<]:-'#>I[+@UVH^)*)I$=]SY:
M@ ^;[AV%"WQ8*#Q99\ZO;'K7VB?6/MD#^^39[84B+&*>)C'S4[07<B%9[F78
MO95G09EDHG W*O)WX_$:^72JQ-..3(-PDH46V?JE;U:K,_::F"^%#5^ISH@]
M/\T#SEGDYY*%A1>Q3&8EBV3""Z],A AV AOY;#HCL; ?-HUJ?<BM/F2SE%O3
MJ&HXPF+8[S56,6VMA;TFIK46]MI:"*479T$>,L$CCX4IV !95$H6<RF\)'7#
M4.X$$&2KM8#2Z_=>0IEH](GI7!U\MZL^\8D7N-:<>.%[V:J4O2;F2V'#5ZI2
M$J\$O9%Z+.)9BNHA9 A(S(I<I$&:!8G8#%KNS %]?I4237S?=HZ,S$.U6<Y1
M>*B_X[ZT3NC+M1ARV$^RZ3XYB.8+IZVGE7 ,EXV$W'MH4SR0MJ_4ZN"AFV1>
M7+ @R< I+;$SE6/2-/(%!Q,BSDK^-(YL;UO@W\; N-J1>>&/,?Q] VNJV+ ;
MV(UO-9354"^;4?=:0[WX8N,X .*7(F=^F<8LS(*<Y5*DS.5)'$2\C&*YT2ZS
M&S_\T1KQ;ATRX0C;8_9(,W[O2F2;11Z%CS[\^4$NG(*W%\X21Q&N@HC"!OMB
M?7AK(5D+R5I(+\1"*D60%5X&#G\1IRR,XI!Q3R0L*G,WYF$HP>S91<P Q.I;
MD*JG3?VE$E+\>O49Q.O 3#KL9.NN3:0LF_B!-9/&8R99/6GUI-635D_NE9[,
M95"4>2Q9'HJ,A2(,659PGR4^ET&0A8$O=M*V_/WT9)A._'2$<%VO5D_N..5O
MYXW<(AV^*M+F]53<X]WA;G7*:?VU=<JFOG0J0MA[?+C 6CQV#($=0V"):?>W
MW=_[R9(OG)@VVS/";,_ILBDN.#8"VJG@WUN"VRKOD4><;#SI^\63_#!-T]*-
M6!D4,0N+,F \=24K7>FG/'%]3T2[R+N<\BL4>NVG^K  "=C(4RT43Z=\MCB<
MB2,C%W=4K.E-PM3V@MA,BM5:^T!,J[6LUKI/JWP.RBDN0I:Y(F"AC%V6%:Y@
M(L^CR M=S(/L(@OR[%HKL_V+^YG5L&[SSMUF6,B?<H'P54XKBV5C*QZM_6'M
M#VM_C,#^*-.R2*7(F)<*EX5AGK,\+05S_=C-(^%E8;(Q-6TG7O,?G4P\ZT3B
MKASFV)VD86#-#^LR6Y6U!\2T*LNJK/LTY9>1=%.>L4S(B(596; TBB.6R#ST
M>)%Z1;P1Z-V)R_R4*LN/)JZ?6I4U4H_9)IJ?WF-NZD)*H8O^8*OH'68=Z%=B
MC=A6"-L*,0[8G]0'6\(KP5 (7<Y"D$J,YU',(K_D?E1P'H4[@?TQ(N\]2+PS
ML!H.9^(/)?>N3LK#+[R:HLA[7S?XY>YMCB"9>-D(@6OWJ#]A#T7!2"AG=99E
MU.^JLYZT2';'@!NI[_FC9O87*9=M8G6$;N*CT6=VU4YFU;)5R^.04R]*+=O@
M^*-<UR!Q8^F5(?/B%/Q73X:,!X5@0>%)SX^S/ K3)T2?.3;"]>FZZOUHX@4C
MC)3OD75D$\!63UH]:?7D*]:3(N&>&Y2<Y7$(.B_+P&'#U#!/7;A/X;ME&3XA
M^LPSZ$E,*6?1"*N@7JVBW'':V<+/W"(>=@,_4U8S/BL>'R^P)H^%I[#P%):8
M=G_;_;V?+/G"B6G3/2-,]^@B7"P"_"B!#*V$?PL^KQ:P@']Q\N@0C.;T^/3(
M>=^9:D7=+FQ6Y_M+H)=8B[R'L:CQBO,762AA&77/*6?EI65#&YG_/I'Y4.1I
MFG/!4L\O61@(SGB)">T@YJ$HDE *^9C(O)P!:;59>5)JHW+=ICR<B=-J+CN#
M\BW:DSNJNXZ]$0;E1R(K1AUPMQ[=[ON\%A?2>2_S9LF;*\=W_7#-DQNK,K V
MR5X3\[79)-:'LXQJY:65EZ^=#<?APSV[3\63/ _R-&1IBEVM658P+HN"B2PK
MBRST AX^RJ?:UM!ZW+9+L.'D27G:5%_X0IY.X9EVB##IQ^[$&^.X[I>T9VU2
M;(PNE$:FP:Q8I;>92GDYO&WKHH+=)IROU>*"_"OK5EDS88]$S@C8T+I5EE'W
M@E&MO-QK8KX4-AR'6_7B4V-Q*8HP$3[+A9L@.%'.LBSP6)J42>"5/(S2;%>I
ML?:D-!X<);\..\/R[V!7?KJ0*_FQG<$@3H(TMAZ=S8Z]6M=N)3LFO\FFJ%J)
MCEY17UZ")&@O>".=K[QI^,R6.%J[Q-HEUH^SC+KOC&KEY5X3\Z6PX3C\N&?W
MJPJ1)"'6&"8!%RRD<6Q)+)B$=Y47<1#R; /O];'IL;\K"^Y(6WB[*BZ,)EEJ
MRPMM2LSZ3<9O:A=U\:=3SW$C6'_)ZO_1RI41L.$KU?]AG&8\D#'+LRQDH>M+
MQKT"9'4J<AE$1>9[&V! C\9[1[%THJ22,0+$KBIC)KYOC8"7OEFMSMAK8KX4
M-GRE.L,K"M_E8<I*D44@_Y.298$0((3]*/+\%#3"HW)QSZTS/-N5-C:WT:;;
MGMQM_"CG@UI*$%Z7SK2&>\V;:E94<SX=J]2URG^OB6F5ORW\N8>Q$65)4B1%
MQDK7S5@8)PGCN4##(8PRF1996,:/<5"I\*>7A2?E)Y"$OX,@/#5R<%>][YGM
MUWB>ZIX1" >KH_::F%9'61UU#QV5BRS-PK!D$2\X"_/49ZD7Q"R/TM)-1)'&
M7O'HXM3GT%'9!+2JU5(CK4&UN=1GSJ5V#89#!WFLLMZ:''M-S-=F<MBZ4\NH
M5EY:>?G:V7 <+MKSA_5$5OHN%RR.TH2% 2]9'A<Q*T4>!2+.2IX^(2S+.YGO
M#(K%GT2N:WTFFS]\;:[2('LH8#_=!8[%.E$OU"BPTS2?CE&?>)JF=<1>\!3'
M/63WD5#.RF7+J-]5+MN<W.-P/X.\Y,)-F2_0P8R2B.5E 1YCFOE!%"9^ENW&
MP>R2<NA4KN#&[*JO,1UA2FZ/=*!-VXU1O^[8,D2=</>?'^3"*7#8\5P/)W?R
MJYU-.[;VD+6'K#VT9_;0L]LG:>AZ<8) Y'[HLU!PSM*RR.%'EH>9EV9!LM%$
M\Y#&2Q!U.-;]5 NZ7Z\^MU(<SSKXNL-.UNVJFV82^:$U6%[7WA\)Y:R2LHQJ
ME=3NE%209:4K\YQ)B<T7O 3]5'B""2^(P(,NBRR.=N%$/[N2\N-HDG@CA%M]
M;6K*IG9'Z$X?E:4L:/"\_%9<\-FY=!J^D([ZO75 /J#W/ )Q/A+JOPR[8R3$
MW$.KPMH,O<V0!8+'<92SV"O 28W*F.4Y3U@B>1%++^$NWT 4?(ACJX3427FD
M1=1'D% G,S0C\/^C?RZK+V 8S!;M1]DNFJI82(%?',[$Z@>#(W?E 8_/K+!;
M>\\I9S6,94.K833^4)2E1>#&+(@"\$J%B!CG9<"RC*=Y+F0<%-XNO%*K85[I
MUK8YWA$ZI9BS_0EV -"UE3\[U4S]!K^H5"Z?"?6+[+?;6 6WM1_VFIC6?K"E
M:/<I1>-!(E(O9Q$7*0M#WV?<%PD+>)IYHO!2,$%VX1$_RC(YE4U5BV,M5=]I
M.0M_3Y?(.$,;2-E%=S=E6GCU\-NM ]#\21KYUK*Q&$E6">X!,:T2W&LG.HT]
MT$H%.-%Y4K+0=5.6)H*S*"XC688I:)R=@/B.52G=C(/D34([2V9L3K;-_#ZY
MD_WV.D_:X0LGE[ NO 9FAN>T-<<JU*UM84O/QF9]V-*S>V$JAGX>E4'&DC)U
MP3X!5SCG;L$"D16EB+,@SC>"_$&>"B]- W":,W":71ZPM ABQM,\3/,R3F02
M[-0^Z2R1=U4[KUL^_0T4UAS.@+]Q:=5L*<4)B$I.@PMV%?U/@HGKVAKK5R8_
M1D(YJ^@LHUI%MT,DK-+/W,@O6>2E$0LC4;!,BIC%99IYH+2BP"O7%5T:IV[@
M1QX3;IBP,"]=EL=)R((@*WGANGX1N"] T:782S3"7/=KTW,V'[YOKKJ$SZV3
M;FV7,?'[W>G\;R/@6&O$W,M;3V.9R+A@,BT*%H)[SGA89BR/"N&)/"M\D:\;
M,6'"0Q$'(>.%5[(P\ .6Y47$W"2-PM0MTB@I7H 1$[D3;XQI[==FQ%B%9Q6>
M57A6X>VH!MU/RYS[H.O\1"JOG>>Q8&$8Q*'+7:\,-T;^V/#T:,7(B]1X.\ZP
M;]U'=_/E7X?;_E61-J^GXA[RY6PYGT\E8@CRJ?+ERVG]U:EF:I/!SGGSD)UC
M39>;31=XJ?C5__G!_^'YJ#@*3.;O9A-:8HZ7F'9_6Y8<&4N^<&+:I,I8DRIS
M#BX!6%]@@P'7@7,U N]\),2V\20;3[+QI">()X5Q&&9^$3,N)6>(#<LR+C,6
M\"CAW)6%X.$N>@2/M4@[!1GW0>YL"-K$3S,;\/G> 1^KDJQ*LBK)JJ3=J"30
M1GXA_8R54N0L3&.7I3+CK RSU'-]D<>NNXL.P:=12=XD\^W<E.^NDFP.8N]R
M$*)JBVG=+AN))81P'J.L1#7[ INTPO$H,[&S82G6_+!A3!O&M,2T^]ON[_UD
MR1=.3)NF&&&:XJ.$9V^E\U$6?%Z!T5;]BRI%R#0[/3X]&MAGBX;/6NW8J<GL
M%96%Z;GL%9Q4%,T2_I3?YG+6VJ%W(Y!1KS.VM(=!4#N<W0YG?T7L/A+*6;EL
M8_[C$- O+.:?"2&"W U9%""T?I$'+,V\@DDO2J(LS=T@\Q\3\Y<S>%1MO:X;
MKX<S<5K-93?T[5-ON-(X]6-MMOZ=K-9#9;0>:9L53H9/P U9M*?\BN=3N:,\
M0C!) PM!\-W5G$4+'*$;^G?>P!Y=.%_X="F=JFW1B^2M,^<-38\[O)0S]#,_
MR>;2^;WFLQ'H@Y&\!VO![)\,>E&&B_4LK<H=$[N/A')6+EM&M0[E[AS*,@$W
ML$A=%F12L!!^LMP/ I8469 (O^!A(A[M4&H[]+_0##TF*_00O,!F<5)J"Q0-
M4+0_=^43>K;8^;OO>IN8'*%'^!&?!5V_92O!$VSEHG7J?,&K&;B!U:R?)X[M
M55.:WS:M>%Y-'UQ 9LT0:X:,0R!9,V2\9HA(8S ;DI@EF2Q8*/R,\3!(F!ME
M;NDG?AS$&R"[#VFO(OEW4GYNY2$*OQ,M^HYG9E3-^[K1@#NS\]]1_OVNQ=_5
MCFR3>!)8M+G7)@Q&0CFKM2RC6JVU.ZT5A%GL9CEG"8\R%D9>RGB<9BPH\S+W
MI)<%Q:.<Y_%H+6^26<2X[R\,;)9UA#[U:5/#WEM<47$OXKS/L5&KK^+=4L%+
MAW)=#^',54'$",3_2%[/R[!31D+,/;1"K(W1VQA)P'D>YAX#FP$\8U=*Q@6/
MP-4->9+Y,@5#8S?#R:G6B^JU1+58-A(+NI9-(\6OR\6'>O$_DCK =Q6B#T;H
M!-L=N^>4LXK#LJ&MN+&,^AC7"GY!:_QI;8N>$>\FOOJ[WW3#QQ#B^9_VKEOB
M'L].5WY#->O%/:CQZ4*2-W8)J[N"HYU9O4 GK8&/9X0R>=[P:5<VN[B0K423
MBT(-?"$[N TXJ%W !^@ M@<K?":J+\A>?X5_#0'^Q:J9D-_>^+^44_F-B:J1
M9 B] <HL+V>_B*J=3_G5&_QV8_L=1+#7\(&T^Z\^^-]ENZC**_-L="H#@^Z7
M>=U6=.U&3OFB^B)_R>MO2%HD3A=&^79'FSJ^Y67<S@OZ""5SS%]:CCP#H]R)
M+=XS\P;'L)IX*SM==&$@3<-J-JUFL*(%,.L;OES4OZQ^ <R@/I[S<ZE"0N <
MP"MYPZ=?^57[RP]_6>?3536";-9S[@8'[I;1'BMRGH+--B!\=OVFCS[\=O3A
MR/G;R>_OCC_\=N8<?WA[\,RB>B_I]N'DT]&9\^G$^?2W(^?]\8?##V^/#W]W
MSCX=?CKZX^C#IS-+Q-N)^-/A'R>?@5; =4#'D\]GAQ_>G3DG[QWP]2?.T7^_
M/3K]Y+P_^>B<_>WPXY$#WSJG1^:O=X>?#G\>,95OD];^$QI8*Q9 ,>5MBS(;
M3M<GT;^8UVE^6#<0HBU2%9YL(*+OP0I=H.G#\E(V56'&'/,\S$JO9$62^BS,
MA6 \=%V6^$GBAJ6(\BC;19SIUV4+S]BV[V1;--5<-Q;^RMNJ/2E/&["L@ KX
MZ2>XSZ_3NOCS!P<.Y7.XQJ)9RKOI#2]]N(6B;:A??B#*D"GXCT7]#[#Z_M&9
M>?_HS;RQ;F3O,<;+DZ_NP!DP !K5AB^V2@]Z.[@7P*0-#Z(@^'%]5;LQ3KM7
M/PZ33\Y^DS/I_ W> AS;.L>SXF#B+.IS"<S8$#R,4RW:55>D7>9M)2K>5'!7
M?04\4:6GU-\@U2?JPY\PEN"[OZ@OZ _O%Z=NT,EQ]'=OE6.DO_S9J< U @E6
MS2A( #OA7#IY!?NDN)@!I<ZO'.U*.65=+%M8$[QB(;_(:3U'[^H<[K0 P7,I
M157@2X='<JK+>5-_D73?*0BXEN8C@R3 /3:AQ>.C7DB.DY/+JL"&1@?D SUT
M-7/^ +*!-3N=./^YE+DL)LY;/N."'SCHWNEGP',&*T'PQ"\5^G:;:\JY7CG>
M=@9+F](B8)5S("V8UU>.6/+I%/X!,?H%CBV ,>J6SR9(/TV[=^_^6]-M0O>
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M+V'I9_B&E9C\JKJ36I3U>.D/O!7\GXY.B,+3-'\"?RQA:RLV:Z\N03:UYJ'
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M*+I3$X^Q/O*E$H!83((VP4+)0&V4-%C!3W4>U]3@FP?1[<=, 1#,5?JS'="
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M($N<B#[_F!9YM_C#N/PJ/\R37(!?%82^9*$G?);QT&5YED5NF0=ND&_LC?M
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M6Q"7P_7U@],PW,XI6]3#?5K1"#('-Q_Q_[0J.WP-TK+3*Z53S1F6<:])J"G
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MZ_3I3US*N\V>>F1YQ9;JO(6P)-P3$G95Y*838@XN*KK;UQ!W"R&>H2YU5Q[
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M*CL>@QH'*_FUW1RS.7':)35(X(2$+0TZ"GYKT&3S%6U\&O]%1K+Q(W *7=6
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MJ @3XJ;VF2-,S'Y54?=SG%.]V$JXE6A%N3;17NWD[L&Z69>2RBMP+*Z:SDA
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M?MT6O\M53>/*^IL<$)N:D_K6H3ZV28A/XCJ"LIZB9V88B^=-G$Y>SXV\GB@
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M+)ZR BKM1=4%(,HKFGP"\K0[@0 =$.679NM\48@0#;@C2G^89LRW;T_?=K#
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M32OG' -RJQN'3ONA6P*LH3,S<"@=36J]>F,N,CP2#A4=\>B^07C@I<F/0S/
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MR>8WGRXJ6S"T8.C!*N0>8NBVY@;KE&)P5N1^]7GNE;/(!.&082P1PP*VDF_
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M=\DA[%W7IJQAMPWO$??>1,<H;9G$02"CJ,S=GQ327GH4L73!8/@<GC7G*@Y
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M#8K$:X*EMQ:W0J1_A9TU^SO0)<[.QJ^WR'B6<L?.WOPK?AC^58'^*I WX]A
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M(,^SO#(A)Y+M,.&[;--WZ6&R!-E1ZU2$^)6#G_O$!SS$FW'>,^,:/W'=J_(
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MYWEYI7'(@M&!'.B!D)AFUK7P!!XH 1^!)?# *#F0ZFK,YTZPA*]-@J6-L*;
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M8L22]HCCJ)%6V")+?8C6&@=L^%CNV4U6M<0G'9=BQ^>?.8RM43@AC&5$G-J
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M5>%D4H)AA;@,-(>V#3)&422EC#EIFGP>JO+<5@4=& 8.*N:]5?%2=FVO1HZ
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MDP/,^$ 0NK?:MGY7=WQ7]VKF""BZ+13W5IO?ZYLGT3?)QBA]Y,ARSQ&/.#=
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MDY!DFD>A<3!N:5N6,.UHH@9%&CGB4D=D.:/(R(0M$58D0F_OU#QQ?^;X"QC
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MR^WT[.+DO+HXJRY^.:G>?S@]/GW[X?C7ZOSB^.+DMY/3B_,BQ ?0V./?SOX
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MEF)B<BW_KG7=7G?<C:.+//@7<+.?>P/_]U=5A+E^F8=[.(FOUAU^>H]P'J\
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M#7<,.<,YXD8)I(E22&)#6%2.^/"D:K>K.4.V2Q\;L[2IVA"EN.V+F9P%+0Y
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M&"PPV&(89$0)S&A"3$F 0:<4TB08Q*,Q@JC &=YH!.@68; L"[02!)\WLN!
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MP&18?Q!'TRM/'VS2GYMD\S-T3G1'U47]H+/+9NLPFUW#F'K1U],DCXT?YFH
MC4V(LS_&@_Q-?N=\@]AT[I[9+[ BW4&X,3&W10QO-B?6XWJ"G?GQP,5AQ4BG
MHIB*>N3A%_Z4R(M-ZWBG6O4TC[C5#D)&,-.,>9U0Q)(B'DA$%DN+DM2$2,>M
M-TNYD2E1:CUWR'L,YR@;D$VY)A.VD@1IJ?+V=LA(#A6I)V;6V-%Y'(][L?[U
MN!_^Z$]&$]O[F(%GE&?\<O#(3<C(A]/W"S$C:!1]CAO)"UNCV+_K/8EW)NB
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MO<F7_IO0'5WV[-7K_.W2LN>1Z/9K"4QC7)L/IBQ@)HSZ5!3[X<V,XKRNWQ1
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MX6"38-$DK?C?Z*NRNO$?JY<&.@L[4I_MJ'IK^S9TX7G?3[>W3L]^K;P=#J^
MD7^S>:,!KO,_V^^\<ZVY5I0BPQVXLP'\=JVLR=E\V&D*:D/Y;;_',NTPAB,C
MY1X</">0Q>#Z"VVB]4X2QM1MO^>FCN]@-'H[+Z@[D_CD0A*?N*]H'066TF[O
M!<[OU?N!]5Y*_'X)?D'EXOA;7I9\HJI<C^\T.& ZO$'#Z*2\(JTYS'P'WJD1
M0J(0L+;$,<67DS5)BI&X:) *'EQAF> <8C6*1BLG'(<?9J%R\VD<WSV\)_DU
M:V/T7]$.6S+-85+?D.[;014MTIB\)+D=Q7#4N2!,0)%8B3B7!#DG-))6V.2"
MTXXLU>E*1$BAM$,Z<3C'@EK!A-?(&9*(,BHZ0?=>,;C8%\6XQJ!I,$5WCV&(
M"$J,4 $QE03B)'#DDDQ() :0Q"3E8FF=T0A+770:\:A%AB&"M/ 6)>>))ED=
MX]+.V?9AB/ C5F#HMK7!UC(%YD5)J1!/AB/#/$&,$4>"\S%8M;2ZBIFQ2@=$
M@94@[C4#"P5CC#D+Q&#"I5-[;VVHWA=KLQW%B-Y&(ZE"P7".. X +E$Q@"%L
M@](I*+8T[XF/%@ JH>!31%RG!-Z,$3E0@%LG&2=Y!V;/%6,O8&@6L9.W5:?K
M[]=!-'G+=Y#2*(ZK-!E/AO7&;OW%=)^WVV\0S-;J]7\F8*[]T0_>+J4'O=U]
M3G)S:+[RZ^X8?%#_F(G0)N$_U%6UU1]'YT=W.JI[0A!P$ $FN,RQ-."G4LZ0
MP? ;C3@Y)8)3<FF3F2A%!2'@N0B>$%<!_%0)'JMG5G">=#+9M]TQ02#DZ.ZR
MLFW0JUO\8!HCFU6FFP-DIEJ3UX92%P02>U>=)B2RT;,Z&&-?M4RI1,'Y-<AP
M\&LXQP;9I' N=:2\LT( 7UGRBB3@CF,1?.I$@;I&T#*>+,):\R0,=8+3W6L9
M/L)[HF5-/.9=V&$_V6Y_] ,,R>8.%*]6P=_L:&3]YPF<.&["21N=/*]ULMX"
M!GDO*F8=8;H3$JR(EHKBA'P Z\6]5<AJ!2KC$Y9).N]7%,X"A<0^4H1#]G$B
MM:!<<#8QTE@="25*+W"=#_VOL8D+O+#?WPYCZ(Y;2W'('E"<+7)?SXADDEOP
M>5WNJF8\TCC_"-(03+3V8:FKFHD68^8U: [Q8*# ^S48>^0H-\PFX3&->ZL/
M>T-Y%_A5#LZ?CVS\'!<"W*_C[QN2_".&NWOE+I&MCR34@+Z#Z:CWT3"F23_4
M>'2]%M>]GF^U%OAFQNT)_7%&>:P H:0"YL,U..(ZJ)@7Y5BB"GQKNK1,XY73
MT4N%A"-YF48E.,<I<..%5 $'#"SJ-OU9890VQ'O8GI#K7:Z]B0"PP@BB00+,
M -M 1G@'@QJ8R*&L42PE)3QZ[6V/8.:E[_QX)AEV]?PF$?$ 8ZO!%T86/!\O
M?&1TN5'9HY?<]D@?]H-V/'UA[$$/<P@+8\V:Y QYI^L7DW&WU_"S ;"U,/%S
MF#U+4;Y)0($[7]JK)A?P<7QO(>6E(7ZWJ,)JAG!_DI$\DE(5*K9,Q;R]S H[
M6X7>#ZH% !H8"QY9127BF%-DI*#($X!<2P0%]^\IB16U%7[;2.;V(M.FMCJ/
M[JZ9W08ENN9:=ZPP9:LPBHM+F;?7FV:Z57]:YNCC]Q]"=>Z[<$(W 0'Y'<RA
M'>:Q '8#= !@-MM!D.^[^#7V!I>U5?Q33IFG^,WY[_]JOUR^.7E7_TW>_+E)
M"P1K"2/3E$^XO!P.OM>)YC!T>S#K,<EYP)@AQBU'W%&+7, ")46"S7Q,TO"4
M:+MZUM\(?";OXWZ8E_:<L$_F)+HI%TSNBP^6:Y0LD8"LFGN@290J+X/-,7T)
M/#06!#(X1^HISW @PO"TM)C\:/QX;DTR^X(P69/^S^1?_X4R]L9%/Q^1=3D9
M7@[J^BT-#-6)Z)E#ULGH(5-18(NSG?0%"[>$6%/BNGHO)"MN??&ZWDVO^Z6;
M6>C"7D=3!..HNK:LR_<;3=Q_1S_.=_L*1Z=9S1]W=<UT[63\>3!LJIW 33O3
M0BD@K;P56*=J?QE,^E/N_=4.KQZ42%?_6.6PVIR9J8Q!TA,%5"F!T11*@A7$
M-L<I<B670Q77J![Q:ZZS$V^VYNJJ(A=PS9][ __W5U4$);[,@#^<Q.9^\ HQ
M'(\?^I!_(P]+C2)Z?9+PE/8-6\] (>RH:L3Z](7G)V0JMHQ(7:PH%M1K2MKD
M&5E7,.AFHIH93Z\WJW#0_S0[*EN?08*IVA@!,!=5_=R[+UQ1']Y>29_U@6CZ
M^"435FIJPDH7">L(GCH7&:KK ]7BK:6[2#3;SPX84<R )0(ZX( =:$;!$,&?
MSEOA>90RAJ6%?"6(B=Y(Q%P D^F 8AI#)')1VJB,%]POLH/C8;1GZ3P_^0+@
MC_Z1QC\J/; J6J$C:<OC%4;_F.39F&*L]_1J_;!N #-Q,+RJY]UT"M9/4]EQ
MQ;74U>^3"";O*P#C;W MD%BO4_V?M\VJTC@.O\P*9#6ZUFTF\Y9R08)UA/*$
M A<.\< DTDY'E*2C6CNC(EDJ<? 8I?@1CE[ JYZEMUD$,+C+=0O"9'C5GD5A
M@O=@2;C* @-:Z2(8X'SXK.0! ,:77#VM=J9S68/.M#KC/R;=FN;UX?] OO*"
M)[ X^-=EW1M."^CL@?-#9+1*)Y&W(VRNLY4=&6E1,$1'[TQTRY$TX&LS[SQ'
M@0$MXP*#$B<.VJ^M Y<\>'"';FUAU,(YKD7U,TCH=WBDCW%X7AN"]X/!XI[E
M6QMN?3GU>?"\+:2U?RQ:;NO>'K_+OL*US8/7F;DO8*'F7(1K/;HNR)?V !T)
MC'G@ (Q@PW#>!F/(6DJ05"$FJX,GR^7H'JT^H PYC=E^BF?IPU0^'_J+VK2@
M0. HQFNE0711:^Y9B6VU.OW4H%V#<#/C5)=?VP[.V10--CXAS3@,KQ<8ALH2
M%+0BD=&0HHU/'MY%>'L[9W(_UD[VXHAE*XR^P!T_YTN@;+E178NH#>-S.O@Z
MI<28LCT OJ.J^B.7V%W N?&JLG2AJB-R&I!K].^F!E!3'6X(B @7:XKS9O<W
MF[!<4;7N2K@G>"B)=30I@90#;L8=]D@;8Y"(FCC*=11J"0_787:+2O][%M=9
M^F,4Z_ZL&UKTNZ,'>TI**2$1/+%!/.*(M/7P9_**)H$QDTMS^NEO^.M,6385
ME7W$]ZS@UG2!<P,K"8\I!M+^983_;0''P>]K=KUXIXK]O\9^K/XX/Z[JXB5-
MD3)@2%.[8S\-8VVI.JO+G#>\"N6#LRG:MP4'ZUW4,@)^VEQG@"F8:S0(Q*56
MEBON.&-+&UN)DV@X 0<T^Z,*)JG61",'TY;)D(3%8DL+#K+#V\[!;ZTW+"PN
M] :^*1D_!NW#U?MNRN7)O\;^!'R]_V=[X\_V2Z?Z[7@Q>*7.=/AB_U[O$-A/
MH)"?<EI$LUB?[W'M!N9MBZ;L][Z$4U 6J"!"(XL3 ZUS'M2(*!0P!X10,@9J
MGZY_,YD=UR([2S,>;WL?I^+:$%#L2RD3>-L Q+&IWMO0K*5%K7G/,=9>XS3L
M=; M!X#J((P0#$GB ?B3M,AQ'Y"CDG(E=-!^:9<]Z 0'@B<H:F4(P0!9 "M&
M33)4RY2X-<L+7?!Z-U&-[T SR ]Y?[!7+>/^U\OA#-=(MC>QL74KD&VI#TN6
MQ5R,70""!>Z0!1\0"1YP!+JI95A:)UU/?9;724^^=T?C[-2<I;/+K%07@Y/O
M\,$M?S)UO\< K]4;Q98H4BXVVWK-&5]OD ]JX39[ZOWX[6C9H^R\;)>2,,T)
MIPQ13@@0.C"DFGN-@L*:&$VM61&I] A ?7Z7,@D20\QK/(KZG(29IZQ5B%/'
ME,-"8+5<^>S);[AIEQ(7E_)07,H)^(]\%D5YXT]VJ@]]?Z]3>3D9CB:V7_.K
M9>^R/K .29^>N&?N):- X+G22#L><MHKS%7%%*+P(8O!2>&7%KBH<$2*'.@6
M#$;9F"%-:$(6(#HPGY20<4ON)94=QEK.X!_H7QI3_0)&N3H?@P:!GOT\&(US
MUOZ*5/NYI8P<5N:G21 'ZG%R896*F*#@3(8"RY#)F^LR&JD9(=RI)8!\O$KN
MS.,D^$BV6V&O"T8\Q>?<VJ:3PM1Z"@-JF9:(YS)GEE*%O([!Q\A3(DN%K+Q0
MSC,94>0F@@K1O&4%?JHW.C)E/%B]Q>(.MQS.'%&2(W+K=+J]W&]B^Q!H<00
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M,!52CMI?#/3_MQ^'^-OZ^#8%%=^.ZJ_L,.;';!(B=M>GOF43^V":U),CM68
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MBN_%L !/':,A2403$ !.G4<:RYR3K@'4H]#1I9VS@,_#&#?& S@VI=!^FWE
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MNJ-- 8U6NT]E%ZRM[M-Y=HRJECI&&RT"LA\3;+<@N*: 7PQ,8A&XDL0@'#U
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M+EPIA^2*QJ0E\N<YF5^07)NFSKN5-'%#PGL0<,EJ::YH%A+-@/7K:G9RFD2
M1\,#/C1@6[6\#UJE02LV&2MM:'24Q.>0[']PX1P<A@8+2]#&"^/JXKHS.S<
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MJ[]F\:[?]Z[<;E=N][FCR;.G++?[QW>V\I?__-L_OCN=GHW_^?]02P,$%
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M.'TRC#WGCU)K]^'R-02$$7;[7KK13L"/7-M!VO4G >*3H0<<?J!.&, W0#Q
MII%A:*9>]QV()[IFGT1I(%08XO0=9P(**NIV"!44F62K%#AEIZZ&>*8:]LQ$
M4?:W$7I^U53"-[_FFGW0K"6K8W]X_;+2'UKVJ\',P#?QQ(@O?D5QZRSS[O;9
M-N1Q)V>'N(B(\E^\&+XE'D#L8MM0&QZ=X 3!3BM;@-@L72;EV9[U,[6?MFQW
M+Y[9^GJBEZ_4-^T D /,]"#-HT_3304_\2\26&WIH4F4F:RK7*P%4?[*]W;<
M$31B%UF,8<1C_C7QETT*&_4BOCH0G&Z^O$WX@F@.S]3Q4#'_)8%<EYZ[PO)M
M62@\E7B<.!LF#AL$JE.A.<T_ETK*]]RW:\]] B5MGC4G=_3JUIIN&2@UTAV;
M6#>BN(3A:O79;7X>!2%;L3Z<1,#%M?W,SAT<Y;Q[HB>B/4_:%YM=ZJ'G@C'*
MBLQ0G+EY,U54=++IN:"/H68P?&8"%0P1.SWN#4?Z\2U=-K"LWXL-^W?A.-X+
MJ$]9F7.V+6S466@09@J4Z]8+;*[LD7(4"$\%4SI!1WH9](":WSYYSQ\L:O/Q
M9A_B869__"K#J4W/9P\:KAV#3I[#@]<_G'M6>IG7K=7S.EX">*[A+%PW,AR0
M'N[8,((RZK\C=BY?>5[NDJY1:\J+V =5P07E_RY=X2 1Y)_W]>M-QA(8*VZ,
M'5V\VD%![Q-%)NNH-#8#S%-\I8L'^^(Q"'WVCBW@H%[=H>6"?'73H9:,4%1W
MLNG@*  5XYXJ-.H!*9S#8ZT/H!BEEWAE\>GVI>^9[#F/@LC/!CS&0OEP*MRG
M954F8^3AG@,HX+-1A*\E+^=2,;YV]<D85%M3A2>4;XKB\I.QH,RM2W<?A<$U
MG)&?2Z>EK,9D;)0$3,:JP#5]#<]8^[\5<-:0R(22=NJ*.#?V-B %,:$5W738
M QZT-$6G1?WZ(QW;$C'HBHTRD[%1=73%OLL[LXO+CGK'W&^IXPB8O,*;)5%H
MNE,* J;$LT>S=(EKK^BH*J\TM>Y.7=;HG'S@_Z_:W_7J3G>&&0&(J? /2$_/
M[+$*)U&8\+PK.KIJU9V!ZD8'V9/*)KC449U2.8%-R4S&L.Y#6;[1\DKV>I*9
M!XOWF'V(.\K^^+4I"%:!=-.)U*02 RA"V#+AKI_@RT>M$M$@K_3T,R4U4L'*
MY_)+2&G 7KU[C^NG^&FW]LX\=J-?.<93L]EK3GZJ(<$>@ .43TU&/%BQM1:
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MP,ZHG[>VN4U[V J/D2((H6X$IWZK6%XU5G5NT=ZQ[ASG/F2O]? _O0B@$<H
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M.])*.H='4('<F/U];G&[U1!F>JA&M%.)"]&9_R>/G9MXQ<--))(E%6DVQNM
MSQM53\E\ZTO!0>0YU5!NN9.9=IBQ7SQ_[<6J*7[CY&W@WMOH&RF#POG-3ACU
M_"G6RA66[;M/23BU0(C5%A,$KB* 196G(L**K+>8QJ,T0K,WLA/ZV[&U8\N'
MAHSIJV,UK5/S^$XO?5]INP;5JE^,UR'.JSI-3F=GY%XV?$)-'<A(JBMCJ;G(
MS-B$Q'0 #O=K'\V@AUB>+A4J2BH<W[)/0M@NHG#K^253VG\[DX=6*%5$S<B*
M;/G>$_1X?@BJAKS4 "67:8UJTZU/-&KS[!/&CGW4#H-2O6&-BK.)/:\/$5>G
MYERS[!0Y,%34ZGF3*(QU$99"36H_PYK_F8/"K3:;O$U2I]KP@6JN=4[]D*U=
M:190/P6=@]C:T9[VXFJ3X#V1@3QYNY3=77TW=7PWON"&"6<;RG-"\/SM(GH6
M@/K0*:]O":!VNW/!E"UUZ,DK>GQK06C_$)5RJ'G/;6,^%CQ\O-:UT/'"TZE"
MXT"]M;>P+#13& X$$BQ= 20FW!/X>!>I11O3F=2I,H"G(@U6[N4K"$N1'6RY
M.V$)F'!UO9E:PE(2RF+#_E69B%@9[J71VNC5@/S1R@0W7GYZ4$P:#*XY2E$\
MD*30H /'=V<DI"%^A:.&?>W!5YH>*\5\(E1D(.&B8Z?F%_S\$-!-Y%S;FZ(1
MJU-S.A4+?=% AGW/91]Y!%?0!*^X,9EYNLA(Y\!:T(]M*,TLXK:V4_MU!09<
M;^2/[[#%_PF?>BXZ%X7G]=K$= <A[YCR_D- /P6=#S(*Q%86PD'4K-VWV1?E
MYK_;KA*KRN.Y2\L?WQK-,[N#)_B53Q.P,2-:_<N:/R:8B0OV@6W,HG2$72CV
MO0>V;%Z6ME0ZK@&EL5AO65)ZPF?9WJ>F70Z-I!49T'=$DU=U+ZW5BPMY%M=;
M^B-"_5>YA]0E,RMQ"2Q8X)SFEH44UJ@X(42 2K1>U_6QM,IDC!0(G^7.(165
M9K&[V6>'"E35Q0XL</^JN^L+J_9]&A0]ZV02"4N^[Y[S18PF]:</.Q.I@< 1
M-:1/$#9FY01^MR0R,O0!&JA1H\K-NSF>GH5%YZ,6UR*MBI%LJFKU;4G-B5:+
M+;BY]M'R&M,?K<(Z7O2@R9:;K,OY 83E/@'E=68E=E3FCZFHU'<"&4U>*W],
M%I2< 9X"O.,\ET=.%81W-\R"TIQBWQ $(NT4*T07UC-H%.ZCQW]2,UQ[PKM"
M).3:,XEA8PM#B^:?40)1T!?MZ2$,V$P9P?;*\5ZJ<"U+J_3N5U?+25N#BEA(
MM B<%$S17N)^UQOU"2<P-T<E:E=NZ O^4HQ'4:?N#(ZE?$43=E]8D1: 0%A7
M4=\#X6GG.Y$V\,8+:0,WQMKUI\QFE@30J6"IN/R4"H5]Q$[Z<AC6JM*S?.2U
M3 I22FE":V<8*V0+39EZF>/3]8N#3--/L2E@IWU@FY4.%8.TU[\6-H!(6.=4
M9/&6#R]N;931.:<97DITW1U)#A8+EZ,*"E+ <[KFJ$D\7#?2TS_+\74'ML):
M6DXL.+%9"?0;:/]Y@E"KZPJ+>GF=XSN6RB)_+P"VD[K673&DT_#MSF1)2WR5
M6LM:%9X8P[?B"9DJ-.4^A+! >D'YOY#P'@-E4Y@^R8#9X@W:AEC/=P5[Q>ZH
M?[ZUZ>;RE4EBX("SVFQLD^:G!:Y9:62%_!5[CQ@.X E=L6_2(UY6<DI1$M0A
M[,*$,\0Z.[![U%JZ<8Y9_I $_]Z*Y+3-"4T-]!&P<P?D@0KH[OS"DT/_BWUY
MX[F>/$P+MWAQC1FH2;B(D/(?D=XCD..8!W<WU)&TH]J['<F*N/\H.F0G-#1P
MJU,+WAMLO[37!O;=Q#S-/J6*B#HU)]RNTC 8+%V(F&"]C..FN2Y+"Z)0095K
MWX 7&[]NZRO*!FMNRIP%*'C((/AR&*;\PL/8S&"KB1BFC$[^CD+$.!O1I'*^
MQ*[6AEK?4AA]]"/#/R1 N4KDKY+B _JLR82(YVR4V-\NQQ\Z\WS?>\D$HC6M
M/4SP>.D)E2]^-*X^94B)2:F%GJ'Z]2,C7HIB ZOK39_Z(CX)J^3?TBHS0_\J
MP9[NG_ZD[I$VOPKAGE/Z)W;OQ7-4E0VQ$8U^+1\PMOY!6#_X'YH%A'_QZ_DB
M;="(?Q@5M_+:QF=>4*00+"LY+<!VJ::Y-:U9^1SEP1[?L*ZR)X#S3',A #N3
MFX=U3$4EKSU-SA*6Y#,C*(QX:$IE /\?[K#),<PIP%FP\R>(')@&GI_Q1R\J
M=/"I5[GW^"0)8)T(@V*O"@_<FJD%D*\ 3ZA+C/F!2VT(31IH'X/'EZ!DYQ2<
M_4&!D?NHJLRZ@'>C-=U\J;N;N_I)0XRPF^):R\3=5TF '8E.Y[BRVSO>@5)Q
M5N2;J!30 "J5@K7'GJGZ[\#=C1?^@P+2E??DEB#[#=?>Q.:CG"= J24IKWS/
M!_+*##WV',]-2@7(0J9OXZ-+R3<EL'^M:4T*LV1;MN$?-'"_LDQ7A>6/P#[3
MV2XSI08AF76W5,574'BDQX[0G1X^?7[$=)TYKYQ,D1G86-(PD$MWX_D[/$G/
M#N+'>FD%ZU.:0XA1,DRHZ@*OK->W'EF\).,HZN+3M[#L9,/,WGGTP&T+5Y%K
ME2OF"PI/[\O4Q+124J5OW[EHMV/7$(]5 !0']H#CVK: =0/12):NEE-7 PM.
MR-YL_=;PIANLL1FYR*@N"QM+Q5G0@,#\L)RJ5G*-BCVO9WSWZB_Y<CRF>G6.
MSWLPZV0\ 739[#'*<@[:ZMU:6&-Z(Y+P&W0M[: 4QZFU<N] 7/0Y@A![]?KR
M3U K!F4R67_T)X09S44$+3?QE]:9T8TCC+?:I$@?ROCZK,Q#VIGL],M?DQRN
M?(0R-@^E2/QU:DY\.*EHTFMH!([?8JU"68WIC*-;N"UP-2FX0[3J(G!K?BJS
MA>7A#5*2LK@SV9[E#JEK1,NC@[XT KP*KT:V<WZDAA-NERY;:"!HB.#NW(18
M[8F-I)P03ESWA]VCETXQFOU]?G)K_;=8(Q(ST+\(&\"MP?JLY14)S@Z)7VII
M8)K0.CX1N3;(WC"9LIHV/YW59K.!+)K/L7,S= N,(2XXN$DC"GN[1ZP8^'Z6
M JBT)C>;' JLJ0K5?E[IR:UN8L]J(EMY.$)UO;G9*F*(U(ZQ)&6$C@]"OBRB
M#Q &2^%WAVEP5F^%0#U<2Y^#M:K.)=((L/PRS[?Z4D];:J,Z EZ^QNY'N7E>
M2HO.WANFHP/,3!E\<"VV;F!Q0< G0%YP T ;;@MI#021]>(-!9#5D?)@_*X]
M'<*K#A^Y-:93/G"5G?"9A2PYW/#*%?P+DSWF^*&@J?V+% YM2$V/6\8#L6*4
MN3+)M;1.[W;'9CY!@_C]E#N7KC;B[86^^4' [PX5K\!CI^X])S\2J"F-Z?8(
ME^:OJ 7)+G$1@(;? Q#S-!1AT=YH0F*Z5X,6CLP?G^4OU>+RT[WEDCNS5+F=
M7W9ZR?OL@&:D<\<(RDZCXO(C8RTL7#>"&(P*X.-$L:$.I#LF$O@!:$L2MQ';
M; G_]+R$(AT(#9)7H5%:A5EE5;CVW"=XQ@(PH'PA%8FO>46/3X,0IS2MSJ?9
M"_W)ANCA?NWC\QZ,+#]X;).XE7ZBY77FD+3A)P_NL#MPP2@Z;HM*]Q]0RN87
M8FIL]]HSW L[>(S80832W-H[HU\,JRA2M$;%?@<[\$-MH-E?\2"S/WX5DEWN
MVLC^/FK7[F#'Y5RNR=_F:[,)*CR+I/^0RK \A'=3OYWH>2.)7+;@DL%WJN9L
M):.B<P_KIK5G<7Z5X'!FBAU!..@%9/XK#%MJ3F<Z4<AV(08-LU!(O(OX,@<_
MBR+C0IV:?4-D/#WY] G>IAQ-8 ,;^PZ>XDX!B&#M:GT'4['CB+NP8WYCJ>XH
MB9@JK3"]?Z6&R5GF>E!<?M(7=S5"]2#(U/WD@E>J<W:8G+-C_[#Q?(QTK(Y-
MJ:0P(P!NB"2 ?P-0UECL%WMSX*ZH6)A]!(6T$18F11FPH8&T 2[KA_WDHALF
M8D>LO?76]KE73MGKO[SB=+BNX%H*LIA/MZQ7RD5$78%LW07L>--0Q:Q_1AR#
MC-V9JPU;LK<0*\:DN##T[<<HY!<GXZO8S6'H5F?MMY-0U6HI-3OX[A22G"Y\
M3*'2Q7-X78$F75ZG[^O>L2[ALJ,\:I\_+W@BR[(HZ>I:TV[E0OUYA5-.S<JC
M^AK<1H^.;5XYGI&G \Z6F8$G*$0U-80RS:DR#$Q 3=R_DM*]P^<Q"<ZG?H[.
M)/O[A,BEN0ZY58=99;7)?1/Q45LN8>>4'/4$N*-/-IP\[-8W=GG1^+G%)@4*
MJN_O552ZYUW&#G5PMT0OGH(TD<7EIG.MDY(@$_WA>0V#I4F#IAGM(MQ@/_CL
MA?3@,NG? 908>"]Q6&@F !4YVO5">]2-\)/G1&YH^(<KVV&B1N%.2)>;V!^M
M=HAG8?&^,7 O%^<ED+?QKS.5XEI);[V'73U3'[1=+KIP!Z59BPK+SB6RH#*S
M9%'QOM%"V-D+&JUG=B!Q(\']EKUPP9"MH7Z7((@TJ3\#'9+''?>"E<]16$.*
MF-A[]A4$H+1(VUV'XO1:V5J^746EY^!(E!>V6\^EJ+#F',Q=,LV2RM@HX5*J
M36#%56>!VBU1-A"W4/:Y@*OJ>K/35()4!GKS&OJ-&K7G:YXO,HQ7/41[(#RJ
MJ*LM-NZIJYG)"^7>TDH3'B\N>!US\RK<5MST"I\*3Y7B&L,$'*Q<F26\,M(@
M4W3*P"OY1BO;V-)44/0.;$BE;XF/>G& 5 U[<VGYZ6X:88Z'Z!E4UQ4&[Q==
M.?4)3(P 6[2,NN7,ZU'[7)X8M5(375%]+J LM="BLJ6GEYU7&Z%0!QN=1 DO
M#X"J5W=F0@NWBK$%M,3+C!VFL*+*&6U#J>?S6+4A7 W7WFWDFUM,S(O2!0H6
M(NT:^PFDXW#MM<[L-EAKDSO"-'OL5M6:,)Z/B9/P"J+6103QYMP[D\_,#7W!
MGXH#^VI5GE!!*S).5VIFT^7Z#DKL#.:B'JA\R["+2W<"!CQ3CJB;BRDS31^F
M,_X9/O@@*55%N5=L4>F^#<'"R1-SRSB'*TH3&4V*7:KK59R!9%8+5[NVRT S
M:CU/UH]L7;->!-*=O?B**R@Y:E &8K1#OE@+E'21X4 T"]KF83MN[?W:XQJ$
MW+#.-A1&4I:<LQ87/C7.O4SL3N;G"7TGV)UA P2-9H,H=)C(*]OW28,!HU_8
M/(44Q&G*CHP'UZ)^.A-8[FE3N_)(:V 163:C4> ;H?\Z"T4T*!0#&7]00P&=
M+#^I5T?\YKHR3%J*GE)8?%8!(T(0X9E1.>PY^R7CPMR*Q.3O#^5&#U$-V.=6
M3O@%M<<-*J1[\2Q4I\LY@N_X>_ L@\U=>'/5KSM,G!P*QOP)M C $6ZU6;!.
M6!R0# )*\T[9^I4G6V<_&;X-*C'U-BI84=ER?:N0MW0'GF]L+[K1ACW.(@$%
M#K$\ON>4^0O4K#J=\%PLY%Y7F;SJ5!TJI\<]1'EL;!-TJ#%.,FBL9 :-W!=H
M@^K3Z@QJAAKF%>UYR.$08'<KF^)_J4;RQC:WW/2*ERJ%RY0(7@%D(T^Y%)4G
M]6A6=W[HU#>T1"0MKC*YK'/E^90=&>U4KA65)SDBBP[W5B1F9AFIG\;E)YX>
M$_2( L/5@Z^$5A&N@9NHQ'-_M.8G/:-2ATRL01"'4/(+K21/?,56S(4=[+W
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M3!R_\KQ.1YV@SLYO($] WTG\H0^&_EERDMQPR@1($Z ->A#"J1,@?V3<I4[
MHCDC[/U, L[EAC4SN"J3[0T?C+@7E/^KHC^#'H1^26IHP7\P9F*=!](C7TO*
MWX!F3K$W\,-LN+D"J^UU(QY/")IZAV85 ,X %!1R\K6<-"!!@ ;Y!:@,KFN\
MHP$U?!,\Y33]2LH!I"4ODC;*Z+KV1I!G+(H&CI--_=!(\&IIO%*1"?IOXRI
M"IQ=AE!;J9RYQ,&MZ,C&!KL&!F6Y3*&EFB#8!E&-'"6GB9=GT20.O3/!(S<\
M=#QI.)$1SA,M82+WG5$0N2"?1VU/?2'R"YI$$26<ZN#WEH89+]PSI9FN,4?Z
MHI)TN?*&2I+PBGL17J#'Q)J3QY4@JNR:1\71,_4?O8KI@MDRT4N)!& 7'FWJ
M=)P "0R05(5T5Z_&+1!LXC"B;G4H_L0R?;@G:>Y )Y[2T0RN(Y?<J@M&"%U!
MQR,_OK DP1'%R=Z8R;^"!Y<95<QR#@+9YQZ,%D"'?#ZBWHM%!10)DCPAG.@)
M$<R,ME%BZ*) )!-@2T*<#@H"2 6D='0-D"WALR71UG&SZ=3@D,3MD%^@)8)-
M#3[!&7%>( -G4"WZ?+F(-E"A3A*M'"V[B:4LV'. /7,,]N E<"%>QU=L(1F.
M#!0P6S\#)#W""0HG.H(DAW_1W&^IXP@/[F[O&*1$!*G![V+(/"Z,2O(I;*O8
MADX7,E ^KNX[6L^5I4TC>R+?F",Y7JJ7;&YH=9?)$0T0+37-4?+D)-E1Q$\(
M)TQ^$?^.>$/EIR!9\#1>K&\H(74[K@.N*37A XW;.$K.G!13^"$F?Y0\Z4:6
M(L;8:6*$1#8CY>91+"VQ7](7(Q1/V=5&QR1- MYV.FDT=Z3+(+1W *)-KB+P
M?2<":Q8N:Q%'2BXB2C"K)6&G, &H3*( ,H]]7)SLD,0-P5_HBH7^:JAHX'Y8
M8YY=X+(I+8O=+E&D%%L01[HX>^A_4JNG^[ 2\VB8T ^@_)D8Z:CI@Q?]ZA,Z
M?KSF>038&'[?YL'Z]?SP"!WAF+UW=O#;%\,U>-3//43^TR< AN-*0W#$ZJBA
M2S1'H#T2-P@.3;S)$[Q:XE9'5.-E@F]YNLP.R@8VH4CNA,=0L1N2DSP23M+:
M(=#Y TVN^0^(?4S,)(_!<\V$(1G!E1=XSF <5>PZA<"U\KFF*J04$(SV'G=F
MY(^!M7?F0;H?QW@:8B<J-\J >Q?*?A"M(^)90D*/8%_(+]";P?9G[K!APZO-
MA>U3,_3\8,7F-X#@PLY*PNSH<";9T:Q:(ZJY472%/'W+?N_8$.%]1S?H] K@
MT AGKX5[=]?6BV9@<E5#P#MOBFAM'2NW3E-&QXD<&9#CE-^.QKFO<VYPSKVX
MN<%=-Y71ABN#OU #%/#6RKV#'0@IE,^,P X>7.\QH/XSR$1HB0'T%1?RIB-+
M9P>LCN ?G8)[D0Q!.J/%]RIW]DY!,LHG?N!8E]B/,Y/TK)O_MR2'SF0FSZ)V
M!$PXF?Z#G873&MR-$2Z@U>8AX+MG]<ASY"U=B8MX!9!U?;K!88NGWN:4M<F-
M242V"HZVLEV,V1C=.VZ"84GX?*(XP([1B#'+O2&)IPT.U0<GZ58W=,AE(B>]
MT$Q=T4XZ6U:=71X.*K_8/0*ZK9W>RM#14'WR)19W@II"NF#TCH&'='1:WER0
M#:6SQY7Y ;W)"F!/\$?(-Z_DAAE@G_ >E\*<8!$"'2>Q4\GO?"9R,7T,,6!/
M0/X4DK.1#0S8,[3  XO0ZY =L^(#[RNO,!+.3QO KEM&=&NH)+R:4D,D*NOD
M6:MRG>GNF:BJX0/'_L2Q9+_B0/U^AJF__2Z[QJ&*8"B3*C[1P8%]_W6'T"3
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M T^EPX_);J-/MG2# ]+3X)+->X;2V&9?6QKBEQAFFP,$XQCB!QIW<'@+Z&/
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M3A\ WAQ9OI4!R'=9*G#,FF0M\&A@!!1$K65G="\ESPN*PEUMUOW7UJGH]+
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M+"%'S$/2&)5B9%CQ_L7[+^I["(/H4PI>O-U9^/SQ\W?H$'P<79?2V(M'@*!
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M/_6'2<31BU]7PU+<2WL> 5%<[PA RBW>LY,Q\@Q5+&57%X#+^$)X@#3TYJ(
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M5(/Q$(P67^(TWNPV@U!W..'@35*^"#C=WZ^$^))1D_74(:H9>\'+/M F]<%
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M@:!0$X9"$?.5HA<-RK!Y#KE1@L%[.,JLX3N:E?ZE6_PZ+@!RFC[J!QM:&.5
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M4'N9$9@Y583UUV=NDC8C/@^W'GE5T7%1=-J ]Z?6Z9@#!M_E?K$F/R, WRA
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M&0&\P;&X<!MC%->+@@@RN,Y#-T2SPU3)F\TVR?:$\,M;#X_RD&%D+HDPA+_
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M,E&A:< OGR5GR0&FIDRA-B(:/)"ACB@-V(F3:@^CLE3W?'X/+"5U;K2H$X@
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ME*A]<:N?14VYTX8Y_%3__./G3X%O)N=!E^TACJ:U.H]B=$86$[/EV?JI6.V
M9[D!AKYME%U5$9W@E3,J;Z:'J999JPOR(4O!L' '2&&80(.^LD'%5K+T(QH1
M8D[3MO]T1#Z2!@N"G&TOZ8@L-,X$XVQ8/PR^/O^4O9$\9;AV^3;C8;KT^)N]
MDA02\:HU/NAH__H<5%T%:E]X$(K>:N>'H[>6 R&H>T\1 Y+?.SA&VH509FD9
M8S6E^$TY+&^^@0F51(#># :X'5NB\U6SX-/H-5)8\*'HGX6-*R. -KS(%"1Q
M!QA;+NM>??]B2]KWD#H4==MTRK!=,VR":UIFD<]VY3K+AU8.4;+&_XL*H8CB
MI;/R(2QD#*\#M+R3Z[ ,KP;Y27D4FD(3X'+"X,J-@Y1)\YDN&=1'A<%NT Q)
M:K $^70)PA?!99B@U]M)]@(]/"H7,#U$:@"UXP6VPAFEP.W :;54>W(:XFJ1
MYZ1B5W'1 +NU3IQ&O5IDMZFX^<2V*,%<ST6X2Z^R-"5X(D+=IL=X2Z1'DC4Y
M]=@5)9_GS8R.NS2H.@V@UP"Z59RVSU9K0[L51S,DVE0)&_P]RTHL[R"6+8BE
M<MZRAG;CEYS)I1;G?XQ0'N\>;ZJU(@-G8D$#8,N*X$,L:%A/CS0X]N7.KQS[
M XMY=P0\5,=,_X '!P7!W8FH!:1VFV3O]?S26OB#]0KNMSNJ2I>[G-!WXFW\
M#?XUPNMPOEI!RI4D?CY<\#4L">*[7I!T8[E](.]4C/!^S_(]98@)\WD;+LGP
MF:'$@XHZ<L<G"SLX+\:27CR=Z:RUM+3W(*DSF3$F"^C#OI$MS<DR>TWC?V*%
M# YH5LA7\"-)PP2/QN4RWPT+N.$D@JV@J=8.W"D#P7RM%SZ4<Y> L#&J_($Y
M0'1TH2++R<X"WIO=W&((RVSEU P_C5BX9SLG^VR82;KY<'/TC,E0,TL;&6MG
MJED_;KA:#]U?0\%>DD;2_GA-E@G]S["8/E"^(D$YB#C)<V1+J-W\]0JT+P))
M_:(RDM*_.F)3 FZ2B.JT"5K.Z)T(UK)D5!31:WH>%F6\##Y<A6D8A>Z@1&UP
MQF>R0A1EG5P$V W>^=C1A5MP43>SJJL.=J0 +,<K5:9RVOL=W5TE0G_">3@(
M Y+;RH&E.E5'.(UX."#&QW@H-855V]CPD8N+&YU'2,'?L=:3XMF0MRZ&#'&[
ME4]N)JIJWF;Y<YB0*V:KR78%J*QA @HK6(\?>>7[>U(4BW68?OK\A;9<%VPQ
MSU?B]]-K);Z4BJOP(I #^[C*\H\PM(N@&EQ0C8X[7'G_D#)%_V])AQA\^ARP
M00IL5%C#<J"_,SG7[ 52&KM*C.@)VG+R5E7;K]M53IFZ)<,LMYR,]0+S X:;
MU$<*)'P=:N.-X&S(CU0'@."60E1]&+&J!:.-B4WGQ432'O\$)2NLL-:,Q&<L
MHN/$ 1C/?5R ,7Y0'3&NV0E2MHN%B?OD9K4BRW*^NOFVQ"2M)RJY>3H(8/=4
M >!(,&:'CR6 P0 VP%AHS_QZ!+^)LR19#P2L'EZ5E(F0<@Y29O\N0-H0F6ES
MS^"S['&=I</@\)%,@'0</7Y^)?'K&A#^J98=OA*A/#%O\7Q7%I"["+Z_$3Q^
MUR3--G$*%GSKCCW;?/$)$]T$O!]%?>9Q%$I?%S+ZT;Y/5\GZG&_CE!X*0Z]8
MD?W)R='#W/Z].B(7-0=+G17K?G6)2\(*JP_)8KV/WV"U(1W?Q]W*7DUP\"$2
M"]8DL>NU><SIY5*2QR1<8MRB /<9[K?AE -)6L(6N?%XC,M9\CTRU52>.7-;
MR9QU""VQB]J%F ;>.=I24\Z"A'XB*=BD(:\B B!AZ!;BF[DU>B!OG#I+)ZG1
ME^;NLV>UED>B\!O6^>7I0_9CH," 1H@!4XL#/A;7.P+!K[>4T,G8*=#-11,%
MI@8A5F;!"SV!PCBZP%C; /H[=_X;Z;[_UR4RU:"(_R8LE>70?OFZW&R3;$_(
M,\G?((9("VA*=1-64 TQW MT?*F_@QGF(2O_2LHG&4[RB*5H;K.<_PG:#:JI
M78M5T2'9!N_\?? QY.\#5@X'A)I7@_A]2U3U11V F>4U]'CE-X1AHD,*]J0,
MJD&ARQ^$O*(J_I,[*?-(I,<\6]$3A788)F 3/C&1J%'>59($([YUS7]<5BJ]
M!</::MP V0M7:5%5"B"+&=KC"3?$PLG#39HGI1L[IQ)-PVM6L%0\N@>^IDF\
MB0>@6]6B:;@IHR)_$<@.@M]NXV_@6Z2:RUER7 N+XFD-.(NBEH;L(MB)/NR;
MWV\V)'^EVLA/>?9>KN$<#M.!D/B"9,!H!IRH$\?_R^'"+"_'52!5[&H-6]\3
M 36%_AU,XZ"@[\($8+@&7?6BCX_2TB>["91^ D09@[062 @L?I#E2:<L_WJ6
MPM=H!58+Q-;LM"VSKGFR>\S@+%_6YBS,ET(2])\'A,%;_'&9I4NR+3\RN?#/
M(7&&FT^N2;',XRU+6;_<%7%*^-4F%TQVL"E.TA\G8F.LDL54'5T1S%YA19Q$
M]F9QES+%L+%D:V6>5&%Y,2 _IH2\ E/L :@5D=K BR%751 9H(/PDE954"\)
M?2 0F;] "E[!7L??Z=2\$,9SMBK?,<;ZC239M@+"TLZEJ?&DK/"3BT7& NP$
M>A'HZX_0'6<XYLR-IV=%@(/JX*[:<]/S$S\6FWQE/=$5E.X([IF;;U2=HB^^
MJQW5KJDF6F#H=/J*#BTV/ZW;:AR*T\_UESBA.D:6TA,]BW;+DM\1K0DVM/-B
M5KN#-/G;7D!JS5;TOU!7XQV2O6D;5K<,SD\)(S)?\?3P,!&AFC"C:1%3LO":
MU*T$]Z.85/@J.LVR0K7"T?/"9E=95-LS/3^9?E/<@54.O"LI5:5!=7JBTP')
M0/^SHY?/;9:U]\?A3[S8*E3P.3@1K@G[KX0E+S175>^/O&#MD3Y$'\(-F7V+
M"QT7ZN]>#/B)%/0AOH38,T6?:7CP=)ST^G#Z7=12<@Q^K,/:D>%#+V81 @7+
M?==TU5MX<FASL_83P3I!6("@W!7ZTUK?U@OI4VUD24B$2A>/RA!/5/TAT-'>
M"X94L$B!#EG7+,ROH[[?>L&HW-/\W"JZMI"QL1>LZ*I(?39/4T=S+]BI8/KA
MV<(,"F(U29!T&>RHX_ X"EXPW;ISKL)M#'FO38 WO>K?\^/)#_]K'GMV2Z>!
M/BNXCWS9/OF-#2=G@=U)SVN2)-Q-I+^UU!9>++%YN:9O/O8.O*\J]_';57OL
M=7[A!5/<NBIU VUZ48=9MOM#+UCD^2&-K)!9B3N;CAS/<NTQV.=#+UBLK%A?
MJ&K'=(7Y2BT25*]1UFT)ZT?#"\;![BI>L1T;4=-LTN$O]]'?KO8OX 1F!1Z>
MXN(?7\(T9$Z?9PC4)*\ =L4T0C RZ?2K(72\F+]6U 4@09+(I)1HFOH\CS)/
M?)XSE:HD!!+7MADS K+#<Y%=9E2YN$W"UR/F]FC:_@D*AS9?7<<Y69997LSI
M$BW 7:D]ITXD,;T=9;;=)C&$-SP1!N4*./%8XDH)###X98[XUHO]+-]&3(_^
M0D)X*D3S] DF+:>#O0R+N/B:9B\%R=_@/,97%,12TO=%$J-%^7*/GV/HF]DQ
M;*LO+P0IO0AFSU6MA1>#KNIRT9<4\XCH[=&M9EX,_PD.COGJ:\%6U/REI*L!
M?#XB&?D6<@4/VD!'(#?]H44OFMT*8I%@'W%GX2UI>\(-[;R8SZ'!-3]A%I<A
MD@9_O*9;4!Y#-N)[CAR"/V(_)3#P<9?3C<&#DR3^."A\O%2D4<)6>IM^$]:-
MOW6,HKI]O$=S/]:&K!LBZMIW7FVRU?1S,:/2G*\0=;BMI56_>2%E[ADQF[!K
M#3RQ"-[&"<FOX+V:Y0:38*W)]$M"\=845-$L03U_S+/7/-P4F+AD=/-&+&2S
MP\QFI8/I1::6$W[,R9:=Q_1?FWBW@3]AD?,P:;UQYJO%FEPE]-&;OL*5UY+5
M:)2]V,&*M1A*C<*MM,Z2B#YNF3=:MZD/?>,%8W!'W:5%F>\.W@*&IEZPP6V)
M6 ,0[/MATNG_[&CN"SOH[5MDLR5=*SG1Q8$:&#O\H1<LJH;LRL#]) Z*0CDB
M[K#VTV*=$ZU.?QHE+X1 +P_ZX"SW$$M50L( G;,M4Y(7M&-CZ-7AS_RS+B[6
M,57R0SIL:12D0Z_# &,X"2C'O8RO1U/T8L[OZ9U6@*4%EJ)9)=0T\V+X:L1/
M59L*]MZA^*!Z:R^8T7L4-37L^[LC-1][P6HKI@(&R=[F(FRZ5RA&^S,OV&/
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M?<?L6@4DL#$?-JF9<A<9G"/T)?861^ Q_%K :UIFQ<S T<8B&CN,PS;Z\4*
M1Y4/B=_TT6I'TO""\2.Q&#N?^:?2\D(0]/4+S^ EA]<S>VZU#;U@00W)0B3%
M-.)1D_OYJ@FS>"#:]#12TU],7\)O\6:WX;'G(M<(]:A%=DF>Z5._=3OU^,:/
M^95AKV@AYD%W+;VA1W,OV%$N$[J0'LB[8OS,LY3^DU5Y*TP^Y:,(3+\T)?P\
M6UK@<,SI84B'?KN#'!(Q0U_3B.0WSX^/!K/CB72\F'/PW52S]DS*,B$"_>IK
MNJ,#3U!U*$PQ04<1\(+E=GI(EX9E;CUYS!H'B]J$22)4^&9TFJ:)%W/P1%A&
MN# CT(-BM]DE$#MW35;Q4I\]?_@K+YAK^47I/\3?>/Q"[=&<1I<DI>.GVT?[
MJH8;HI?_=81^IC^5'_,XR^^S,)760,.Q:VKHR;[\E23)7]+L/7VF[XX,T _
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MTH>SO%ZM1E0(:@5V5,58DB1[-Z7*C-R%%V+C.3]J[/T=.VRBRUWYD)5_)27
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MS[Q@[X&\*PCX>9;2?[)TSJ(WDOZQ-+Q@O#,42P32'L8'/H&,%^P/S#JY[P(
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M#E^I.U9<[FN_'+9E'4'(#Q%8QYFU4*7SR+Z]$/3-:@7UR-^JC 88(;BU4H@
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MC1 ^BVRQCG,6UV:TTG1^Y<5&P(AP4$QSLJ8#E,%5\D*GZ[B@QZ@"H1G]?<<
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M.NTD_1,^G]RH=46',LM)>)5%K; 0]3<O=M<3H3=@#%ALBDM*'U2D:3C]SF"
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M"RV7^L'&7LR#$@,C[YD*QT$W)]U?3#\_)GWM2/7.@^76!4?7>6QW?C#]#'%
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MW7?HC<6/Q/T<%9)Z"4>V;PD,] /H9Z!QP-QRF-Y%Q[C!-V!Y<N'0HA1V(_%
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ML7^,-OOR2=?9V$^-4- QKN:UTNL67NJ$P#P+LJ)R1X7>]LAO[X&8^!C5Q9@
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M#.:NLFOG&+KWH:N#F=T+EV2[BU)[_OG7 "7X\=KI(4[.;],+>"M 5]GEO,Q
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MV=>H42R&4,7F9!&A=NA[,=B9UF-E;)J+>.!C7$D0V5J7A;).S>#'11&J:<V
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MK]<62$$L"9\-9P72G^<IZ;??"9XUQ/IKO?EB,-KUQWQ+..L,C;INP>'/%TW
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M%0%.2JH*GL4+^>9295407W4##3FX*C#GZ5T>0J_=%%L55E=U@9Z"K,)G!*7
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M.V("!P?3!G+=+8U$SE+.C65P'W'01>=X+2-2=G ]Y?XNJ45$A?8YK77?UB)
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M<X7<'EKRV%?;=+5B6),.V[[4:DM&>!=ZW1(]T0/5EETM&!:8G7!71C!8./K
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M 'D9:A&J9-]KOXZPXDVZ$/N&%5YP9IY:-4EW7YRJ, )U4E]$R3^#'( M;9E
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M&HC/,3Z).31["ZO$30- H [G- #PC[? NX-LR-[7!G%ZL6TMBW#P #KB&S7
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MV5NZ1X0][-_Y[!W@C[69\DW_XH[6%O6<!!\ \'/H%34TN2R!T=C>CL"9#_S
M2TXUB'DV969[O4M(DZPV??C;9>KPE]]?,!>E3+/YFVL\2V3>%G8S6/?\=0_"
M7KK^%N%7^>0O^S@$(:P]5X6.FF>[^19O]G&>>I&_^09?/^'T;\_!$15:=)QP
MKC;IOA8=/'"0'M,T1_X=B;PM2O$6Z'Y&W\A/;$^/5.?QCRAU1]J_NH;Y;UZ(
M4X+V@KS5U]K2<%'G."*3!':R3HB!KI@=+N"&"8.Q,)F>HQ+2IR *#OF!24K-
MW]W0B[FJ3\.[H:IHS-V4VE/SN@0/<96>19A5934FNO-(22F9.S7**RQU,%D:
MP2*H3ZA1-,A. M_9T]@0>P &LZ40S1TO6>6*6HV5H^8LXG0.O5[EE;!EN(Z&
MGET)KCEWQZ7*>5;5EI?RR$@7&3+TEKFZ,:FFQ,:5VGXM].?KM2H^AFT#B@GR
MF?,I%&^%"?_XU(E1RN0UZ^=6#+-KQ=!:AK2J'H->EN;64RJ0JM"_<_Q2ZH-(
MO+.)K6BM3.198C9WS?;NL+]#Q?H>>FFZWGTENE6V3EZ"]STO^H7=WJTE<'WT
MO!Y6_=LUPL?R+3_0@-G>E25PPPOH;76[C>''''._<JLYF0'I+:_Q)V*0OP!L
MR3>XD^&B><[?PF"[WL$U#+R.#;>PCRLTS UIHC5U9N+P*4%T#*WU-;Q'VPZ(
MXOZ8S5U@.L])L!7YWYG-W1(%UGF69E[DL]^&"KO-/F)L^A$RU#V\_XZ2;9 B
M0I[G']/RU_0'%7H0CF4QK#/>(N2G#Z!:8WW"B_ $:T8&9H2GJ)\32R)361,E
M/ZTVP9=8$KV?O245%2;7NX<@ J2+C)5G]1!C?QNGS )FLKW'C7?ROO/CG1J_
MV[O6\*5$CBWK(KLT,!BW6KM0RC-6]_!N]NA7XM\51;'*#F,7[DY2I)JGIG1G
MDR8E7:^^>8G/6"6A\I*4>!MHZI-NV)E%9K0!/L>Y)U47VK@:MGF>-6GN 2M"
M&U0[$(!B[5E$<(J$S?$2U,,P0BT"*+6P1$E[TC*0XQBB.,?P8O=9 K.ZAF\.
MX^Y,N-@7P<)0XL>B4\_HPA#BBZ),D^)2 MX4V/A"PRI5Z$ELX5U*")<D77&4
MGVNLY/QC)0>?+;$)?=:!:K+'C?ZR9;91CRID)>&>&"]3NCN8R2IT3YU86JTP
MS8&J&!ZB$JZ_7N%2\#Y5L;8S%9]$@<=-C]:8@<<3(:2Z,ZV$Y^\SI145>/I[
M^TH0_W&EL%'\AR7</SOSDL!'NR *6N\(6K'[Y;^JOBZ(MWF1(;KX+W#\^RB#
M%=>>%&AY%I"B[9_?XX^_^"@H',3PAXM?&/[R>_'=IR#%&333SO:7[EQ>2RWN
M;-6)TJ(_6:WL%]PH]3=AY"2SO>W@+3(3F<C]>L,I3OIW./1>'FH*]113=<4!
ML!V?0LZ-GUU(!,5].=!M-Q***\#(QS@]A%X[E+3[NS4<>6\=Z&U&IL)5%.5>
M6&1BYE!CH]G8!P5[!\FE+)QFI^G(4RUB>^XC_P[8.F>>S78C3_(A2+=>^$_D
M)0_P+[1[G]5RI(G"+A)9\71XBT/*])J_CRJ,/ 0A^IQ3#C.UR:A3>T'OI%QN
ME&&G.G-ZK6:C3O$K"L/_B>)OT2ORTAB4+Q+\QH:2U7[42?\6ASFH# G9V$YB
M4W:[42=YFR=8[;M4?P2YDGJTN<U'G3*I((&#/CX0<$&OG!)SRHSF(TWY<;M+
M5KD?P#BK+$-IH4(R9 ].X]&957(+-\Q[G)RX_.K2:J0)EMMWN6#8=R:SJ95K
ML[BYY2[.>MN1C]8V3N!H$[HC*N8MKOZ=G&YCGWTS\'N-R\X PP2G6_#1]_]!
M;-IMMQMUDAOO^Z,/$R#%=3%F L& U7YT.H;-/63W21(GMS&<K2V'E4ET&A7S
MUX,7AE6U,";2S5:C3O#^@))WN%%_2>)OV1X;3;V(3;_TUN,BN@<A2S3/1J.1
MIO>*MCDV"?_PX]L&)U>A3*[39.2IW7_?[K$AG"%P4YN-NKDKWT_@")3_>8+S
MT'YFR6]K8[*W\,=UL@&I7S356DL;$R57Y#IY3N*/(.J\9Q,VMX)M<:$+@2V;
MV9CB<PSR<OB_P9$KJU ;CR6[XN\GR&-,L/'S2%-ZBK&XN0<5F2F#=)J,>RU^
MOYCF"K&8?2=VFXXZU>*9RT,8>VQEM-YF7,'X8F\O?=C,A J2G4:6/M.+EH%]
M[R_8M8N '6[0]^PF[+Z/5^L[EO.A4.[7QR "(N5-G=5RW(DRY)/ZK^-."#,C
MXO%F3NK<8MR)/03)X9'&FYJ_4R9U"1V@AG%<W@W@"?G9_X=S#2+___Z?+,G1
MY1_C* ,:N0^)3_C__I^T*)3)B@(YAS\$4?87/SB<@T! _6G&?ER8 =/OC\,^
MNLU*KSLG/J,W%O_5P6+GA9>R]-*+A3\CN"_BZ$]^P_/+*.G-\LQ3HJ\;[N2)
M0% ZLTU@</:4NXT%F>N?#@V7J_(I:'KI75[O'D9.MOD;^M.9"D2K%A=D[Q*(
MRQ!PMEP<(,)(!ERY[$VLNWL+V"3U5BC%1!>LMM&MN P3:_[1J4VFQWN86/=/
M3JZ[&T1B8NW_[>3:6U$I)A;^5R<7WHET,;'TOSFU]%;LC(D%_]VI!7?C<DRL
M^1\.KKD=\&-BW3\[N&YF%)$1R<4MM801DF1DY6Y)J?PX)R, N"7!\:.FC #@
MEBC'B\$RLGRWI#EJ3)>1=;LES+%#Q8PLWBUQCA-\9F3U+LIV@F@V(SBX*.]U
M@N*,K-Q%B8\9:6?$;N.6Q"<3MF<$!A?%OU;XGY%UNRCU,:(*C:S?+:&/%J1H
M9-EN"7O=X$<CBW9+TJ.'51I9N%M2'B=8T\CJ793R*-&?1M;NHF3'"B@U H"+
M EX[/-6(7\HMN8X7]&ID^6[)<\T@6B,+=DN0ZX;H&EFTB](;+?C7R.+=DN$H
MX<1&5NV6$"<3IVP$!K=$.H5X9R-HN"7B,0.FC:S=+1&O$8-M9+UN272=$&\C
M@39N"7.MZ'&Y%9<YZ9HYY\;+2'>)]8RC- X#GW H+\3Y1U_W".%\TM;3J'40
M9^5/NS2TG_N-6Z>XV<C:9%=IBH15<5N-+"(+E\6>Y.A,[_^=8]5!4,Z7W<&%
ME&J_>6'.(I!.,VL3?@J\MR $WH/2*C^QRAY(=W=A@:6367Y)[0Z6#[+<_.EM
M[9T(+]T#:>#_8)+X\$(L,*^R6R])3G#?<H^)5%][N[+=8EM6^NR=,)^G)S<2
M-+8W>=\/"G'EV0O\Q^C6.P:9%XJ+&$MTM'?8X^A]@Y+#YSA#%=*L8TYK:FWB
MG[SD#Y3A.93^D0OW8<R?U\/FB4ARY#=OA76V1TGMG]@'1**O4SOT.8ZVRIM4
MZV1SG_)#'F)E@"",O:X)VN.'91\(&S,.Z"E.T\\H6^\VWG?VCBF-8FVYZR/"
M@471^Q/R4E21TTFX?>)^UI;T@N!B#[8 _6/T 7\F9BC&,NAM7=L-/KL3=+*V
MF.<DAIEEIV=0J4F^=Y!3CAA@H'K&4KA=+!)4YH%Z[=][283-(+7#?8=VP39@
M+4>BHPO"OUC:[SU-1BGZRV$#YG>;(!";TA>T12#'=L42F1[68*S+2/QC2FOI
M"*,I"A?NOJ2(:$A2?*;=QR'CB+11Q"9O1$=0$>Z_XYHBJ)+F&OHIDT6*>[K
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MY,A_C#*4H#1;[>"_JS",OX'0@MO<)@C4AM[DHC"\9O;>G%=S4SI>:YD>D]_
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M;RA0^ F$C-^\,$<73G$M>+[$@N?-R52DH9 1N=7%D86,4RO8E6IJ,ZO"V1M
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M>.(%ZOH P'$[3[PLF;R]K^:KGGCI*"T4<'%]3[PNDCP:0G_YQ(O_#$/"3O6
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MN\=]##UNFN3S61#\^U7?QJ:NS^*"=%;#.R'S?19$.JND#4F[GP5S;JM8RA(
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M5B[L(H#G?R=;6IN1_3J"TH+=NX#3ZFVBC5NSVF?[=C>1TWD6*6-@A&5N2D7
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MS&:%D;I!'=RB%<L=18Y":B][KW4D9T>!'"Y@MVORR258TLBP<^Z8Q-L60[5
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M,Y8K9:_P0DDA4 Q>;/-M)Y)TRZTAD]=/'NC2Z5_,H4L0DB+LW#26(H758H2
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M[3ZP5^SG$+U4X?>/P4L4[ +?B])B3-G]@)#N=\?2NH*.3-[H@B>\!EAA:77
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M+2;O.IP6,2SBZS<_SY+WN)*@*)W/<!;A2VM -+'%*','O5@9J_GZD<]63=W
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M"QCX!B.1T%L<1KGV2>5-E2[1N?7\B QR<K:RUE'UO!D]=J"6#K+]/2%N@\9
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MJ-Y"(Y0LGR7,-86%.\J42*H&9FX/S@?>-;#9<@'.[:*9\LZ-;50R($(5XP'
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M 0QVFN[/5F]QG@1)'\U>B*3!<E+[@4?8FQMM$I$;VD'M)<L,3X"$TG GP2;
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M<01ZG2EJ5V'><B#GF+6-FQ"/2/MP36&(!PA#G!P]GC $6IM$ZBCD=6,20.V
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MULOIS")?1+46HXQ. ?^E,W$!"+=@H-U!;F;&3=&8!^>! 9^A0!$;!.U9;46
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M&I_IE,7#AKDN'KL".Y*C0^3N7QB#W/!W4FPME.S"0GL-)U?=4($M*LV*_Q
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MQ"!L7IYNP8>KTQ,XTL6D0>6 0>U<FPX&7=?URTHHJ^7$":ULO]#- !@[&'G
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M7S&;+>Z@SO(;&!+92Y4#SH:Z+&P9IRKW<2RU\!RC&:U&LO'^^NN>D6QAG(1
MPN'$J0H@J6>FYU$_TR\:J?>+Y['3MV?GK!]D8@JGP@12FSP%MGOYQQY[-_KC
M/3O501Z#RIC')EF6^(W&;#:KAY%01LL\$UJ9>J#C!O.\XQYU>)("I]/LE&?
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M<R?=)^SS_[D=>#%=JR;M\T73\]".#U[O=,O-V"6W]_=W5O7Z9ONGOQ*3+^W
M>P0F+QCMD+<ENS5+'&U][Q9[RTD]ZA]G0^(><E'GA8@;JM5LUIL[I3PR4O+$
M@&]<&6^QNKE]XK:=W1%/"J3EZ%15=.N]7W902J%8N$#,K4"=^L'A3G4??+FO
MN]@(W\C"3[7MU)L'#VRZ__"F!X?WU1C_2N^@4[P08(UQS(/KJU3G*O2*Q2^R
M_ZIKL/WIT8GU2^(:9&^_D]!LT9L'568T\<24@G5,60N3=F:^$"NMOM*R>#7
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M'T(6/06&(/J_ ?#M+'Q>&LY+S,4=-VCFX)E@-$&52TN!7@+*ZM8['@5]3=7
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MI3]P)DZ>YZSY!TH .C,O35AVY)C^1-LB8+/(1H,YH#T(#DBNC"WYFZOE]W%
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M^MM9V'@;]EMN06=MU>O"/AFZR^ 6<38/[<[*E'(/TJ!_H_%L*0MS0(]"+W)
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M*P5P1Z3MSEZ)Y&[F7_O^%YMR=1GVG2:!_;:,[6CW+Z>7^.*!5+8%$<_"CG)
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M/KZLKR(/>I]V/)=WJBZ*Y\=9&#X&9H+R[Z674/_B@.92^YW9\M1M9;4.8/*
M<;%JZ[AA&_14% \-WI]U/23RU2;8OBV]+(%_X4A')&ISDW+%_HM,>C4'M%<$
M*/,GP\6^LX^PJKIX4):$@5TO+O%$?^Q\WS&'B*-^]>UFE_>SRTBA8BC8EF-3
M5V?AF8:,F6A<<&A=7>B^)?'KWW,FWT$UO51NLC1=.]K[45_9!+/16VE030;:
MH[[DD\RJ7?_5 .T3"O8IS7></,'R%Z4_EP^;.%2:Q$1B]Z*&I)*&KM\<D?0X
M5X_6Z_6P3JL^2[JU&^V_NQB+2^F^4CVDF!YW9(HZ_9K65SD@$Z09\4=C"F=9
MA.@F:NV(D9!,R4)*8E\)L9&"W[A_E[S(C[(AAW9O[?%"K>)":G>47 A?3!KO
M9HJI)VQN:[4M7BRT3>RC=QV9U'N&GWZ>%O"P:=R+*$^^=M*ODKL6]X$>^&!F
M0DDCGH!+P^Z':0+K_<KR-' R1F,!97/Y;A$?'9O::TP\D4_6@B>Y.$<I%/WR
MM*@*.A;@YM1Y)R:AO#I0O[EM4D=5$@&N<$@'[+-#O1W,>RTKZ&@#9V+-JG9'
MG0PEP$?-TSY"U;)./GPRJTHO0%WADGWMT4G,/CV!SC.X>-</'CIYYU-'-&_N
M9IZ0OZI69#=(T*[-&11<K[E <PQ[XKCND [>J*PD:YJ05D=JL(>/XF9P1 NV
M@#IEZP&2M].;\1?3!."2UX6>2X40="QMS<D/ 8=7?XBX^T2APKOFJS](L0ZS
MVG4#F6'A K,WO'8)+A.;A\%;+X?\9:9:6*/W\$NI;%,:'P&;@-$%DAF.F!'D
MOLY06B:7<A328"]2*:@:G+S#DOR%:)TV9+7:KQ$#W]^BN^0<7PLH"^CX:F;@
M.2CR>=/,6M*'C;_YH(< 835;K>WH.]VT:X$HT(2D3J>%R51.]=08SVK<U8:2
MO,K/-QVZ*.TO^+@@CJ(^U:E(TUB.;,C<08K79QUGP@),;>1SK/9IB^I):2O+
M-A]X3W'V3$*E75./+[-,T"P/S"N(/&I96'TQ#)F:Y;*&V&CF[F,U4,9PQG#S
M+'6L2X:;+ =[O,"3&(T@K!C3&YSYLGW<<(L/A26<.#%+Y.85)41?@T=MVFYP
M[KQ.,&F<U)2Q1K:>N*Q7&_PXNG2(]9I;9^1BP5A?/5&T!HT>3\'M98_A16#Z
M01W^<9T0"C;>.ERG?#2U>6R3]%8FN&#+H?EM:M^J-#>E.%R8_ILF.C]T?-TO
M.XLU10RF 5Z7J]_+AB5<?MXWTVLC='0V-D-+C,^^3MFIXKP):MJ1HM$K657D
MVO_A<8'M4R.H-F77 ];VTL,H/5KZM:O'@-Q:Y+'F:*K<AX=E%F"$"$("ZGG!
MO-9>NFHZ7N!TO/6 S(*I8>;'*JW?B6>X\4R$Z9B--B4AY=G3D,;,>QA3H(+P
M<WT7T?W6P;%C"NJB<AAQJ/5R<+-0S&F63OX%LYSR4B#493+8-X.R\1M,[?;#
MYL']<8 :>)"KF;#<"CR@Y($M#H4@K?1CYPITCNN$$KP.VPRQS/O=7C81D\<W
MMTO$5R=T:A,>5;I?=E\[T;$SW#QU:[6C*'MB3F+Y^:T)&F]L]?C@50W_3]:7
MABHG:E.K2,EQWHFXE 3!G".%1?PL'R%MI_,17EHBFZ]I6>05>_V (B!S/_1B
M[]6&IS(8B8^'4D;6KQZ;B]SGLL^^_((?6*^R8+;;Q9%FL)OC+=R5[G&^V\<+
M(F_B4! O?U%7_=NFS.X\XSP'U*,*.\P$L8J8IQCG '\*K@>7B1&ARE;(/J&9
MS9*"OPU_+19N!\\46+YTL ='T=T&F:J[PYO-.6\"CHXW!\/DR]X^N:!?VW>;
M-1L'7TKU@DYU*:/-:<9]6&(A/1PPH(F1\0]&,SKW44,'S<CS0.OE\6^3SZ=U
MKH(-UHC7<S9U0H+AS0.9+X.<"[1;]RA6MSXVE7&GL,5WBZ!1] 6^Q.I4W/W8
M=.%KU3%!(N>-:-+?XC/DR955TIH.M<ZUY_7+!9TTIK+/"O1S?5L\J ^WJ3EG
M0[KA&)9U_/.14+M1<*Z%P(YP9#3I9F3ELM2 %8\;JL;)K"U0[HYK/EESMLPM
M3<,LJT*.K2\D1&^,L;ZA5VB;$=GRQ-Y=ZTF%U:UNF9:[-(DFFP3A\BL!<;5M
MWJ)GG7"?<0EN>H-#BX!J27*3*3J<"B? &W/P#-OK7X1HJH%= C18+0U^=BJR
M) 4C-+XC)F%!+A03UTOP'8M8<%N>='IH12I,OVV[_\/:P)!KYG!+"CP/9L3=
M!GV8+EJ1U0 380_:DKE)!O7&':"(Q>.8BC0AFXE(&S$1K,]Z1T*%=VU@;D%,
MWV]C2SW^EZE5@69/3^2V'O=8I9XRW&^JIQ('!<O[1M9??BFFE-RSM'Y%OWU8
MP2[^QME()-^C\9[907+55+%HO*8,E3IP.I+ZL#(I8M5D*MZM_M9-@U A5*Q0
M[E?Y'(<''W]!3P1G4T=4I33;/)1E73U&4^I-,Q0UNTG?)S[6YZ4Y@\$NNM4(
MH3RGLCBG( V[RL12-021'6B'Q"G+<-GU%]J>EOLW,Y "AKBT1>$:C")FV/]<
M/5#/.(,JGK6GSMZ+P$H&8I0;:2*C\<&&FZ=_;;K<J4O<-Y?IV9[KV#R^W48R
M!A=DZ83[!$=2D"U13*E,LOI&[!(>A'9O!G*I%,IHCU@RN.03&\(-8@VT'TU'
M=WX%WXW>GXM^L&+7=&SM1$',-O%BQ<NUW>RB^4](]XLW?EPY5[$H,O!4+VW0
M^_AG6.CIE\9*-F+N(J<F^WJF7&LT!TBK'\K/'RNWD7(74$M*$&U:)1>=*-^(
MM)*%]W;!AXZG#9X<H'[1S7'*OJJ/NG%;T^BU4[;ZO<'.1OFD> 63@FR:G##L
M2GEL=;YWI5.W9:>O6,T7W<4B/17+-R\BTF_M7[E2_63,-TG^Y"O)0XAC9G*T
M-RCOQM"ZC<W!KC!D*X1Z"B&*NMN';3'.\*&)Q3=!9%_F,V# K,-DQ);XJJQ"
M?\V=+"]5*MK.-G1_:6C8 ?#QL]HM)=>3[;WW]8WS"6A5QV@Q3C-% %^R'G"4
MCRE52!\ X*1::28O"]>EQ53+]**RZM(KU!,CX,E?%&FZ^>4 CE"0\TBD;=*[
MT+FA)7+JQG*+0#3NNY=&[HU/6;@G>;1EB [9(U3,96B- VKX)OE1PT_YBWYI
MTD , IQ9GMUF9CM>BQ2X-S!=YC02B'6NE+%MPFWG0V*!CXS[#<4&O?XFF!N$
M),H3\JVH^*?UKM!Z/U,_!^3)=*?+VA<A GDKIGX0J=.&I9I(SU)3)[LGK;^N
M^,5?.N>;9+EXVT(E+K1,JFG[I%C@G0ZS!$L7A_'L6(U=\7/P(JPGMN'W_<Z]
MW 3FCIQ?M'Y#A<0VBPC]!9C+EKVX#H;)C8<8IL.VHGJ=<V*,+^3T;VR$U)UY
M,F@T_$("H?GY<^)ML!0?DZL!'O2R1[T4:(/<&FLNB/Z8]12M]_(45^_.&_=B
M%*G+1>6 #Z*A?A+1+_=B,MCPG6_+1+!/??.T4;"J^^1&*/W!+/B+_'3=92]7
M/;40:&/?TR-P^%##^;E@#VD#[52]$0T_&?U+18*1OX3KE[=_KM73#?_X'U Z
M<(V")+J5]0YKVBW_CKG Z*X9U%C:6$]YG?]->*+%IC]_4-3E?>45S8G^F9YO
M\ILPY>JG8P5]SN$5VH,RN0Z5\8Z%S^NGYG'JD+M4GY$X>)9?DO73:,S5T%&/
M&R,;E*=7GQY.:T\[EW#VVT,SKA9^99Y(UF+XLDIATLP]P&5N\O_.JL'[Z^T#
M5'NB,)JL7+A?B?#W8FV:/2KH[!.GD@&V*O4F[4+!FT!<L.Z+@@6*-DRM($ 7
M,\T;=")3^OX9%+.95<:$D(3@P"&QC7#R780@RF^V;W91NM,PMTNU92SBE1&C
MKXW&UW^MW:;63^O,5)UJ^[E2F[B";Q.1#_9ENY[BOWBAK/\ [,;K\(K'Y.L.
M@V$7P8DW?U:G/,AZY7/KO5_;A?')W8[ (K1Q0];-SR/GC7ST0B8:MU&9WQFI
MI,5-.2=RFK)NETNW"=M@P$+LWJO5R0'?Z!U1Y8\-,B[KM^PKXP=')2ZZ?G$"
M0PU+=WPQODQJ3-6L">."_&JF&71E4K$*\U:+\1FH#: 1""5->AN+U-FEE0U;
MJA[996..@N3_+HF^ 3S!H:P(!;ZS][^V387>:+Y>$S)2&GJ- _*F?GM;7!G*
M+8>5?'=L"N]7#(;S$7G=,=HH"_H!5CX\  MHXP=P\5T"8[6U<+^M.&=]% <T
MV"4X+ADL]%<7S:O0F_36P(/J_$0P)F4=02U?R30*RC?BW[XO\JJQ8:K&,+IV
M>_Z-8MZ?AE#P,?EXX=MZ2ME#O/$]UTS2V$XWVXNEC+*N>]/">E@(L&7:4<=N
M'YJ,OUB5-TWC+JI5%V5I'//9;OO&<,,-+[O<;P=."<]""FA^0G$^B1]O03&G
M!*[6YZ,;P?E7]&76KJ[ZM5L*B5W$$N4Z%9\0;.8(<U/9Y\K^](/%93\=2>H*
M>WVNL'&U]7;X9DH.OE0OI83J,OI@-[0/>P -GH1?P<VM]&$;<N*C:IG0^G&Q
MQ(BWBH/$E[G/1\.?XY)J],B3=6C]\O*^%GSHQ/:CY\V;34C_;*9EZYMR1!_V
M7HF@(J5BH"0!LO\JS3E[*9^MCAH]3_4M2=F9C]Z*J)7][9Y?V[2*JZU=;BDF
MJ;\-"I*C9*!L/GN>%DYZ\>BWO&5T'OFU:R<FZN$,:0,&$;)1.N\4]@D]X/2Z
ML=RMV<4,9<)PDTO3UC@[2^@(?U/-/U[I=OZ%]Q]CJ9L95KG+^7YVO6C/!(IV
MB#DDZ4.]]/=OJ(\%)AZ].:HB"82JR$;Y&IC6OLSJI(+>JQ2W0AL19]<"$Y29
M?>77)I=UL7M<J?L8+L<,8X0P'5@I?!E,^'-N7!3LA(AE-".3?V/D9GY ]2I1
M=^U:J)^)(OW%CY2^&H]UM1HGS8PL^.'U7^Q>K)%UOW^#]\]*+P0X,MB'3";F
M;I8%D"%)RF @N)S==PEX#$]6H#>7K74T%[=6 I&=SC\#.HS>%@V7#]>_K:=F
M[^PT]_>.].O6D&P"RA_>*Y&G]L:?+R$"40JN!W#Z)=KZ4KE3OPJ:OOMFE_';
M92W3(@,GXC1.'Z_E<RYIKMAGTFK3.P*+O#Z.-DZ-6U_.9]L@B$Z]#HGT3&'O
M-7(C4:K204(A8H97[/3;R[.5)MYKENE(;^>RBL-X<_774SI7FCLZ)K<V@T.S
MBP?6UCZL?9GY(WYORS?,T%J$>$@U?+XSI5U>5:6JJK'AN9;Y&TT5E<8W;\2K
MDE*$S!O%JZJ$#,1!A^\CQV<S,8)H5^ /-90MP$,=I-_G"@(3P'P)FVHHI\L4
M0!4KTN#Q1N;!BJ>!2)*G&YP/?8HF6T_1VTA']L$,QDB-5$R)7H).YW$]J,-=
M>L^^[8EY31Q36H_.RRKA@/PRB8E+R#[X V5SP';)5I-"WMK8(?UBZ 7L3M/+
M:,H:S0BY=[N9?4;-,YW6U6L$0JXJHC7!02?NMLI?%Z).NX@/+7FCSWVH\CF6
M[Z>21<KS(15-$[0A,_IYRAX5Q_M\IU:G^SMU!"9QR<7*98]=H^UZ/T@Y5;_Z
M$+<>DV'>W76P/-?/=)E/ZF+T"0?W^)O 2CX+H3/L"*2J]JPX59,:@&6Y#T[4
M-@57HOZ++R>*M2 *3=\2>]L)W&*%N?SE$W*U522@TA49T'J]:BO@U=SG3YXJ
M)I\S9F;#+(Z7X3ZF7=+*<'PT[(1;GV<+6G.#>1,M=#.;<?4S:O8"ZQE,"*TU
MU7F*.DMP@]R#[J,(#:4N'@!^4'IE.VH'DXP4=?8/K(U>RK2:]/KYY4O,Z0_S
M'@5RE(+H6I4$N9S0;ZKD08(>F"D-9%-&XQ;%M54GH0'4E3YB:SS4VC_4;,&M
MKNS%R%@GW3BPJO5.S(:7$[WHM@1LTB<\U#3#X-#9;0">_C-#K\=[S3MHO"*_
M<[^B4L8'BEFS>FSZW?Y7,Y468@><S)P<RNR;^3^(5[TMNGB^>/77ER,HN[YB
MA>4\HBM3]TB7Q0&*4M8WT^W5L7*$?H[H9%H5Z=75^LAC,M6D;\*V!V":845N
MDO0I3S>O/RNXPV'I$V:6774?RGY=W7>P0"7AE+:?_LQ?:Y=B7)7*:$8L70 F
M=G^1>AX'J(]VXXC*C*5< @>4S@$UAVXZ! =5?0=S0!(U5Z:;D,+?W08>05+L
MA:Z76]?5&D)$47=B]BA93IX.-G:<[;2HW=\U?>5U@MPFVF7)?S.<ND4GL=YP
M0%<JFW%S423C7EP26QE()C,@R7=&[VU7\RQM)>^J;<76J5'[P%V*7:_OOM*%
MFK]R79O5U\7%X RQH7'SB^SO5N 21$:8:T%TB\]]4J>S>F(#;K,JU"S'.[9T
M)V7N"$3*_DWYO<<YZFN18:Z7ERJO/E^!!QV=RI%W2+>VF*\D*;L_J"7D'PD>
M-!$64P@3V\6Y0?6%2X[WQR"$^ET_[M,^K.4W]><FEHA"[X?)%Z&%IS5AO4]7
M+136/V0%8O;_>;0A&8K03DO\_(9_1Z2H[?>PBJUT^\]O&1=NW3;KXJLDVF(]
M%T&8O4Q>6BA3IIHMJ$!<)"PF8-2 1.H\H5AX%@9"&]*<7N;[+C'2[]I1TZM1
MF1Z)A'5?HU@/U[5CJ)"9+:?,\UV%9V/[C'=K3KS\>:8-\6$+T!CDE@-$Q;XO
M,F,P ?8D_O5@+VX./U@ SWA!@R>RCP!\A%:W8%Q2A!)LU'GB!_HD:2% T6FB
MTZ)\X>U.^8^RN[[D@.F,$I_#!4=*#C\;E'=)@LR;C@@=[?FZ:C;G9YM/7B,;
MW)!5?BMH.N(I/"#9<R5PP"1M(D-2YI"-#%+L'<FE #:TX#$?!H[5)V7(#J-R
MCY/]U>)'4;DJ0S<!F/)'6IZ'LVK"K\JODPE!!=[?H$<L4CX&VE<G=WN'8::=
M2C>^KN,"*BA&TG;(,DC"?_J Y@*6L@!?;\+O[C42^9=S0Y%@/<0T9":**:Y(
M*6&JX7E@1]"\4UM["RIZ(7+J*<R3H:K+IY86DU2L=<N2SRTKP?O=8A@PN0VS
M3@LA?,GB>;82=NDA1(FO!S*?2FKN*KU+1PBCO1(X())84EIFPV<;<J8F4F@!
M\;"[$"DS%W T[?:&3?OK;GT^1JJO9K^K=U;VP9V]!\0Q"?B$SJ!WV'K4BF)2
MA>@%W6C+G&#+H07ZM)Z%DB)Q)!1L^5(E**+^6-<J?J?L.VX LHZ(F_,2;$8&
M9)*@%U43]341BR@W0;F:J@JMX"J[(9KA:\?BX:5 M1#GQW9G9?X<8BG_CT^-
MD*D<4 N2*;..9.5C@[<$,=UX?KAW*)>5+9!!,1FF6#U "PJ@X@;9>ZEQ=H#;
MNAUM7_IFTVV,=GW[X^48!1T>G)%BQ9OFY!SVC.*YD,/622#6L^>=?'04,$S&
MI>(%.GDHH:F+^SNM&)IH.UH'*OD'UC\SI4N/>KN>IDYX7QI$+,X.U1HB#?7X
MU/77K#J?P&BTF)V1M/5^L4:_N?::Z-4?+AE=LDEAN!/9 _CZV4T#AMUW!7 B
M3#,(WUAQKW  C!29[Q\+0(:^#7:QF0S>SI1 KMH%[E8DG'G_ZBW1<-?=XV/+
MQX>]'SS'>#>JM&AW25M,&9P#K6(SFANNMUAYD9 'Q0>H]">,6YA>'8;_.@<D
M[@_$HA"]J2^HOU.-YM!B_A6>UV^W*+#30]":U%%RC(/]>,4Y/<P$78*5_1CQ
MJ1)M07IGF,<\!4^&&O,EEI^[EMKG ,1:)1(FRON>"T6E>N7L1.0[DV\=O/^8
M%C=9<N3X!#.+!W?VX*%[OH>R[_ER#]D)3MD)%EI[!%\?/G;PP:G].?<$CS[_
M']I)%TL.Z*%3(NNN%?-5V7]W_DQ,B 9F)C9C=SD@;L8]71,X]P_]W?/PWG(.
MR(O$ ;TH(VEQ0,JMK)A*#JC\W='G*6/O_KT_S_[.W(]]UUJ!G9]EYWQV&I7B
M@-XUDR$,GK7%W5-ACDQY#DCE2Q$'%(K<=0]S@2*XW=DD[ 9?-79U7S]Z&_\%
MR<)B=V\RSL-_ZG'O?N4F!S3)SP'I=L;']-V3I1PN!NU!/T9< ;T_&8\-P39;
M]6X1"RE6R5A?I +[PV++Z'T8#\#7@Q1AFH;2)"<HY)%RG^!JKZ:"X-VU!I26
M=0N>VIKFDVAY69L]3#:?/^HKJD,\TWK$B:TJ]@6[NZK.3@M,W*"OU(AS0(LO
M."!R$(N7W"51W=?V-%?>0I]P1<M7_"-)COPS#1:>V&=A6)I(F%HA7 V3OEYI
M'R^[VCY0M5P0 MLL9QL!861GR/UC4+L<\L\+MT,3R.?S92Y/#:$RP037STH7
M$N53!NSHKI]EI:22LK2F^E[-I)N./8Y3<.C<@JS'DK>8TG"Z'1#, >W# D$4
MEG$?6VFF4S&4*N3$*F&?0%^E#EF\0MT>ZB.N)%-HLO%W3]*SZ:G!@83>QN^[
MEKEUZ[(&7G7YOC4>Q,1\P_WQ&$L S_5<'^KM5MK=@479".R\#SV"6K%104Z/
M\@(2.2"!A$IR4(Q-?Y?"F-'FQ9B08(6) ?-/:#TRK[_25_IN2,L7K7KP^."-
M:Q-=DZI_88O&0'(@D D(!%+..^!XE?_4YT-)QAY)DZ8[(P9>ED*$3LMS5 ?2
MB/J KU/EM4\W<B'V7<C8CS.P#-'F.\"-"QID-7YO?4>UE+[3J>??\MM%K)I)
MIIO>190/0X.[:6[# 6&#/-^>6L3WA9TP3[EU1^["HOZ[8H?4CS<_>>@:['-K
MD90)7#81=CQF<CXO7CUAP+'/LMDW-:ZJW&87"1C4,'DYH >IF!ZL* =T==.*
M?H\ZV#-*A--=:"]R(0)0*TI^<,1;R""1+R%T9PC"OWXG NPB&QQ3L0:3Q#<W
M3D=L:I)CL(3=ND?^5=8^=RO.J7;L1M$SIMC'T4>YAITP,Q Q;#"<.$N"#)2D
M8^!/-C@@4;X$M,LS:VS8L_>O $TMB-"J\\WO7I)3D;7G$.7K=[Z]C[5H#W*_
M6_%KRS=EX07BJ_RC ][3'G>.)T >[75PEGOX325=K.IY);-;)D.5<-1I<*S2
MQNSF!RK30O1P>>[LAV.N-5Y@)6U?;<R)'&1ANWW?TFL4TTG.$9>8KOF(H8_N
M4$)!(('>/],\%9C:%7UR76+5/4:_TB 2?GD'WD"RK;1KLWSSGE(2L[26?D%'
MCP[19(YZZS_!G0]9>S%9N06I_/MG[Z7J$EF,!I-GE@/R'T8LB6TTEEZ'':2>
MS+P? G4GC2;LUN:FW]BX$;P1_,1I$O<#BHA\20RZI99R+F361K\'FFE4(][1
MY\-R MJIHSU8JHO8IVHZ+'>I9! ?!^,%VAE0P'ZTUPL&1-*,O6)$-IOYJ(,)
M4(,Z[?4 Y?+:51HADN0TS33'=)QEY^("7 8,[@9$[4V%_!R\@"K#>!G>,@.?
MO8&Y,EN;N:2][^=GA.BLAVG>M\LYJL<)5RN]<[Q/1X:U6=T?L)"*ZW=.J18$
M0ES5!:?*S]LYQ-J^88X@*+)A0\574+-"NB?>F\2J]GQUW=B'OM&0YJ0-<\\C
M& T%+H4?D%4.B;]PY(1N>16I7GK]]*T*9UUH"SN6NS(OE;6 DPQ3#J@'SET<
M,4#=*A:C!;A3U/OU>%%U$$6T]4RGTJW<#LL'.:ODA8NHY<?$'S]$S-:=9CO=
M6HBP1V'ANB\[8-EAV$HWU^:%DL(?BU3[$AE4D!W7G=*P/=I;-6C$L\6 #MTB
M:H8[8]TVZF+[9%,R7W^ZF4OQSQ^*K4V3[Q,./_IQ)$=IK+?!(.^Y/7Z(6/6,
MF%+5E;(G\QU(8V_8*U_7,2W_FX+/3MSY ;JRTA64*T1:T#8?"K0QQB7U>\-G
M/@ ;MAXZ:MJ#D/ZF@,F!JV^+S%Y7Q"4H.TY5>J\.O/!5/#65>O'6=OV7$V3]
M5&@I(H':!MWO#1$[%FVY/\';Z]+[6YFBZS.5N4M*@=N:,Q\U*8><!B52J\V.
MQU\,?%1^M&TBD1Y-S1R 22:RA1XQ M;M@4;"B=VSLQNEU%WBJ$MAGYEM5V%X
MI.@C:IQ-:- KFVBEFEEQN?* YRE^.3(IEP\[GBO*_1G.YH]GG$)K PB&-1--
M=>G7DT2Y]#:B453/K43T(3('I-2)(%67R 1\.3P5,DD@LDNCHGVEW(#B>:>"
M;Y0W4QN3E]LFR),S.WJA.I>Y00W]*B5.WZK^HM-MW;'HK[K'Q-0?&KRO>,BO
M^9>F)?]!<:M2OC27DQ!A:OV'</3+K@"W6NW9Q#9_E<@ DO?IE\H>1I8W"92K
M17?&7]%DBLPF"4,YQ]+4;(A3*RN9?GJ#G;T5$M1%"9()5B2Q[^9O^;!966VC
M&S$7;(5]8:9]ERI3AXY0$@@7<Z>H4^O>JSXJWS1&&NI>V4?\46=Y8:9VL8.9
M<[_H)UC5AA6I; $;:AEI, -]*(RTB2 L-B+C.@.X>1?"=&Z9^8H0=8<55MB0
MJY541OO%5XGE'^GP@ 9:4F-RR.UE?N(R/ ;@H?Z@N+&*F:I+6_,KY*@-#885
M^YTR!- I#U26!C*K Z6N+\I#>4.@\(H3A<]J/X[#\K]=+PA,UX>>>K%NII>F
M$*1U5G_!"SYWE7UL1NX2-QPA_FLXVO_D?>+MK2,Z<R-;.L;^LR8C,>LIN/CI
M(-^A_;]V#<..?_3/<_SXNEU)4^[3,.GF)S>''K*SM[:7E+REM/H-^WZG]',S
M=*=C$^666>#JA-U3WJ_;IQK5>H!.Y_WR.M#B!*N\,,\;7BYF09#TP=GRO"7?
M)P3=C\<_VEYP4M-^NW3T8A9U2,)*$2'A]99;)SMP0 TN/7K\[#$(U0I)U%H:
MC.O20 61$N,[W1FNJ$4$$$XI2<Z]M=H%*1ZUI;42WEIU%[@D;REM5C0^Z<^A
M*_BE'QX6_BVQII#E&[$^USMW@0/**(8!7!;N_<EZ@E\J+FD$9\". #;DWWW8
M>'@SF%MJ9BC#)IE"Z.*#$]OP_:B[_5^T:5;)ZAF?HW.I 71)5(L01*A\)[MH
M*TFW:?[-4)"0XV65%N8YZLIF/UE,E-V#.<F*DR)]B;]+&E5BGDDEBPSV63?/
M SNU)U#->('UQ N)A*$KNS$?@XWCEEK!M];LLA/H?@PM&^D;BT+/5815-'G?
M\Y>>@K6!'*]TGOP8UIX3Y&#ZL=KN?0EX6?Z'E%:%#9]]"\SI5L=EC.*QRGR'
MI_5RF.M3.(4\ZXGE\#*%G/)-HT5C6O7AH>->D/+>/\I@J;Y%FLC/$.F/X<2V
MM \)X*,)$'CM4\JM0%.EP+#>JZRB"S!)1P,%5*IECDJ$>]VJ+G+]%SESPY\$
M3^. J)?P/-B><YTZC*MH(4CC E?%$4I2%,J_E%)>\25%H#!*U]V<<IFJN\(]
MDV>:QXR2F@C1=W4KJ@.B[DC_WIU^^^5)^$V2HCD]G/6R2Y9YBU6%7<)A93J5
MR$6BHST=LSUZPD!HC]NWF?+@YR6R[BA(=[$NM:]+;:)_>R;787[-A6[O&?!;
M,-5D\N7$U^R#CZ^E855@9TP7OO:_,5WX]C)\_:F_(?U,S)M'[@$??ERZ7>+T
MS@0J:E4>P!7G+9&O#7HH;8^[],?>WX2>S)IB#Q&\9W@UNY?;#@P[U%Y,C]S9
ML+7*]:9N26B,I5TIAU]=4<?X;\>6)0Q?7[Z,X"4U3">3T?-I0$(BG6TN^PMS
M:!B%/?'.UUW(12+^\8?7AJI/*6&/>GIS-!VJC]JCDB8K%#$_,?V[/Q*]N<[%
MU;@/TK_/WNG*#JWV NK+&\;5IS9J=\RWL6),?0]BP,1(KD-J0H+K(_+]OHFS
MAP,]R;[(Z='[>#$U&A]76Y!&!;B9YU27.H8 ;XK:*"Q%@R<CQ?B9=M-&\A'8
M=(Q <I.-P(VFR[K+UMM;P). I!NJM/V)=0'%>L4_1Z:]S-<'KTL!^*/QL5GV
MZ[]=7VGC+555*[\'%%\P;XW6#QF)B@YX VL?"-_RC!Y,^#FLN>P4X)_)JSUX
MLK*($1CM:TJY::1^;XBJG^&9X?K!B9J79,6K46-K_-[.)6*=%#B0)=]#\#*;
M?'>L75E1HC?(*,&Z-ZL-N;;32&SZV3F3#5T\,5P!7='(\4SJ638QF_Q(NNAJ
M-AY9"=4.\@[[%#WS*G=[;\'@_4DVOPZMA*"L1-M?HH-G&F7_9JK>\?Q2$=AU
MJ)WZ@>E)32M0^TR\T3!8"6WX_J@GVL"HH:M'^\>KI&]8)ZQO:&H)+^P8>QC>
M,+K)HCGT?U%.)"=NA%&E*%:Q4.N7BX%N$0I=U34!,,AKZLY&X_RHF>?[N]AR
ME'>SYR&=C9<Y:XS^3XUBAY &0/6GPM8-SZ4KL/$WRH7U3^_Z/>R7O[)LJ*N?
M>+0\P<P[Z=U@".K5,/18:3XI+ +>4F\2^*GK\+#!^ZNK)&_-H7U%OF-#!A>*
M77 R9JA.0\G*E$[?CV5J%@LNG:F#3&?KO&_ Z([[OK3>;TRIA]2FXQ\^[3[J
MA<XF&%3E_[#H>V@CI'ZQSC.]:/6*6T'$PCFH9Y4YU@Y"/3]*M.E%'L#[+\ZK
M+V'3(DON/6:/X>78AJ@22G$^"4F\>Y%-!!"T R@2U"@JQJ<V0"+0S'8T*;A)
MR8'PI'8A/J[W]X6["^JN+7__[%M72_Z9"6B*-M.&2"4;_DOX!\5F;5P'10/P
M'O8AH*=B<94#XH/[+(#[<Q2*,T_D^^* !UB9RAGTZ0[/NLSP5QV$NM10OGF$
M;FGUG(]3*(QL"G]*/Q.6Z!3V_8,<YHS$N4=6RK<MDXO?2+C /7@*UBI((V"Q
MOM&3! KIP(%&;5C@SZHYM!9#VT]1 "' %S< O2"K7%3I\-2AUZGVXD2\YE@<
M$4ID&U-H3_F4)0=\C7SS)]_K/SVI?+!W1>9FM42.3[AF?KKKLFE@CV/.<9S1
MG>WR&[T)"@U9FK,$QVI;:S:%2Q8>HV&IOUB-Z+ H7)";96* W@:+PJ_:,1-I
MKJ1)M!Y-08/5GQSX_6N^[V=2V6,'A?8P8?L/CE;2:5WC7+HF @M+\&1CC"8K
M'7,<*+,=UV&":92_6%4<D!].,D@AOOF% CP# P%^BH3W%X,G<;HO,F04?A1)
M_Z;GO#=)W]A!R"$.V(]J:B^.I*J8$-?JVD?D+81WEQX86/S=K>E$UY0F*ID<
MS#!W\8ONSD-O2?29%.3MYMV9FP$?KHBO1(C).WZHCSY0WU":5JY^.<9G7OO&
MJG.IFN5Q0L?4@6\*/\-^H1#]3'_!*VUZ/%9'RM)ZJ5W>_4:_%&1H3^*5#PVU
M514[(&1R9N-N_D0AJJ%5.:HB*6GUD@GZWC3]<@'2\PK6'<R0ESX5C:6ZAP)'
M99OU4M%ZLJE1U!MNQ'4I5.*YQ/,=':VY)$T/XOS:\2]J3W_+XH37(X4=H#G+
M7R@CCN+G'<!L 0E:ZI)_/W[.#;&'/68VFDB9PGOK9>SB!_029Q7HM167AU^B
M[K@C9=?9"C--VYU/%]9D._;1RRGN83*/K:3A_F,D.T8AUOR/JOX9QT,9QU-N
M5=F=KUQYV-8-+8YM+[\^_B'GS-7.2M^]E3L>L1FQ%>4HURW!FY\^BZH*:*]+
M6-9>X!.\\OI3A]RYWA9)#X,'_;Z3.#%Z2<RR*S1$,VWUURGO:9<M%Y?4W8WJ
M5:FT#[]NB/HHR_207V\;8,7#H;?=4SZJ.8CD$3(,H*VF97&OOO#]#GMO<*&"
M)Z7"Y7%9_X<4C[S+;C:[3H $X[0%;86NQ"7(.-J=YMS^\E,0!P2&(G# $\OQ
M9AWG"9&S$38E^]4R$PQ3%6VJ'X6'*><_)ZX2S];<_O[]IUO>LTN+'5[&]$<T
MO80?V*589'U+?"A9:3_%HQFH(.6TCU^9,5R-3(V,[8/(?"%53*JV!WW/65 ^
MTA9PT&[/L$#6LX*3BR/_A;LS?X?RB^.^OBVR9]]-)=DI2Y:&J800LN\F"2%-
M0@9CINR[4B';)+O!V+<PF3$46;(6668FR5;W).,N8SQZ?GN6Z_D#GA_.=<W]
MPSES7><^Y_-^O>=SSF=6K_HZWG;TV:VQ%X'OF(E#'I?RO[I%.:&W1KGDO7U3
M(Y*WHB7R*?"3RT+:5#AQ8#">6T=PN<O8B$/JC+N_W= #W=O/&[]/(N/^2.L'
MUS1(Y:1WYS3DT/DX*]+!#2N[I+?>&L[4!N3(D9%V3>'<T?-959ZMX>0'U *3
M$'VX7>"LTD21-,6@K'RQ[6\?)@X3C&W!$Q=G*ZB+_3\_SU&M-X9W$4CV)5,B
M_ A2E/00RZ\5A4^9C7%9^UM8UQU6O;C6A()-++T!_-).MP.;Y-:<MC[]LI3K
MLB?>JUP R 8H/(T/5%C9* %^LKC8_6@\DF1#\7;0API_=&&?C:WG'//FQR.B
M"R*(I!/(.HP@,L0%ZSJQ<"?,0/9RRIPE@.[ DQCYRKH_;N173/QV*;/^ZKT!
M^!U0P3I651,+?V/[B&V6[;#8V\-BOP>N1SG%/@(P[.:)4YI0"NW^Y"_W@3,D
M%1&[^,' :I=T9\>JI'ZJEYNPT_G:Q"HK0:**$<,^P!3[^7V'8K1OR.^7'QK$
M6G)O2VDU=@7=DW_?7B*I,I=TGFD4]P*5'0=,UKOX'BN''$I\7]\^J!UH^T$N
M%N[<-XYM8HS=B,W\K4JW9AU_0Q$!2VB8%';&E[U"E-RN2D!G>3?M'=0_BBH9
M9-WO>N$Q;G%^G>/UW.H)#U?0R25[1/EI8,4:@Z68'*:0?5CDR;U2-R?FL0GM
M_,7C(-:*+IJ@+8YI1BE3E2T1I+PN1;G2_JU+4]Z$C]L*3[=4:S*U"UO&97VO
MB<<4-$JLQ)V(;3<Z<:^#_Q\H^9;AQQI5*G2&*J>+"U9^C5*4=%&&,II#YUZB
M[HR7<#ZI4NKI#ZM(QB?;Q>!MRZZ-MRCLZ@M]J=9CG2=_,2.Y3"MSI5(R>!/9
MIQ.413/ZK8JB<GVW^JCGM17LRZP2I[T2RV*(-_W,2^N;JVQ>1%&5HNXZ.!/3
M#D L$-9,V+P,8"F0C=6:@SAMAA8/9$DA#M@2@A9B#1ERMXXW;UI;>=@JU$#]
M=%*8QG[! 3+1-E]327_[&TK76K-FN5+=,#QD2>$G3R')!P,X,J,![Z71#1_Z
M2A_\6)?#ZX">?[_1Q*-LP)#:]2?. 9T>/TH@B4N 3L+*S+V2UM;"'YN__X1F
MLKL9A=81OL]6I-W[G!288\(RZ@M.4).]M*)WOUILI<Z9NV#G_;?X#"VY+"U'
M1-=@=>G7KU\?<:P41<VL_$'$B:F\$7]QX$9;&[3WV9JVY%-JK<I%%+T;-[0:
M.U]>L'&%NV1E0!3PSRGKMI4E.JYVM9'V?WX0O$<-L_Z4AV33CWFVPX_&14P;
M<Q/X/+.];;IP^OT#!B5]7TP38GHO#XGV.7N>[*<T"'E<B_8LA.JH1O:0Y?=$
MT'-%^@#ZZ:X8IE<X++ PRNQ-*V $2KK3#5H+*YW7=&9-L"5(/PIYNEAN.;VE
M[]G<^R#I,F)72.G=9U>!=A?[5]L(4&F@-TB=C&E)W-C>#0;A-)U>_ GFN1EF
MT*X6\K#)6#-&I#>:)FVRBO*)JO8(9(S-E>9=[Q%K&B=W;XZ\UK:^<+1=.=B?
M^_Z?<8QZ+[_+2QN'_)_G;H@3%D[>9FE]%+J4=3I-Y,CYXZ^>1,9<>L_>;A#X
MF8B,AO*@\/SQ(RM6Y?^A++FO9,/-2\_GJLE](#3C*%G99\& W(A*NXS3&I5K
M)AKHD?RLY3\UI/X\ESI!@UY?*46K%JEI['\.O9T1PY':&E]&'S<Z9%$:&N_W
M/J IT!3-:_V75B24TLVNJ+7<Z=W"V.ZS-2^F=.F%'R ,&^N#_E>9LQ_5M#Q@
M5P#AKK]]D<MQG0Z/#87!I-NM.3?<RIN;_676-*8W57Q-WZ0]]^V :](1+,['
M4=[5F-Y+F("Y>7W&Q(V&-V"ALMO")W=2A'\PA"F;]Y]HS+?YKPD.3HXFY]\<
M?2IS@52B &J9BMG&:!V/?&7,&?6KO7=EMJ"Z^K]*SI)'0FQLO]GN*X]3?G E
M7$X=; C^()<2X<=! 5VN./N8SIDDZ*P3/!XXK$7I6;)^KC&;;#QW6C$<E."V
ME!?((14J=VN$RCDN0SJ?^,!(<_"OOBX5>H0? \%POPDT1]<HXA=JX-HZ\C^B
M/=21K,+?Z8<IHDSA3!;'_.Y%E!2PV(])A'$0 B"?38BD2PANE-'DL6<^5:NS
MOH]Z!%^\/N:BK<B$4;LES8$?U3VG/]9L(S8* ZWSKT^&@CO_H5$@QZX$$LZ0
M^9]YTMPNNUTSIASX@JY#A@F@/,)H/SF8AE-!]U 7@8$K$TSQ$$ABW3:,?W%^
MSM,ZA"IMM6O?^%C; ')% .-G<O=5^Y8+#I"C95Q'7$6%+E1_^GM;XK+09?/C
MM..1E<:<:%P:I,^)1^W8@->=;Y\]N9)Q8Y0O$[OW N6+7.+P4-7K/Q*4M(NY
MB0ZRGL[ZNEWV].;ZM4+]NN!T16JAGOW*=K",FH]X@GRB)G/B$9#;HTW9)DYB
M!6Q'0Z145<)XA<G+6\2IJF?$YT#]AV ]--Q:!9_RPA7TL2HS_PTHU?A'P;X/
MT'0V>ODV_]55%-]K85H"F8Q.0/YM9@:,I\L?H-F!-B(5U(0Q"KVE=O11C3>=
MYT<BS>"P8Z;S!/Y?6MC9V6.?S=O_[VK<HOZ:8[#)(<.)@Y$4P6+1Q["E/!GA
MO7Q"0&;&(M<^FS_?G*@-/>-Q]9W.BD<_-K4-3$F=Z!R\-6:?C4.M-CS(W]MP
M\R+Q]3JQ3>)'6=EW'4/YCJD8LA=R#.[9]FOP5E*ED90/N[%"F>G'X,<@IWVZ
M8-S52Y%Q-SJ8CVI**)LN--V <G4#9 '?P5?=MG_K5?+\9J6WP]V*PZ8<$L'#
M%+U;E!SJNBVRR^J8#6Y4/ZML.]-/(D!:@X[C,U6AY8F'<T1;:-,6MS.R@].K
M^EZ6JRL509)"[EK=6K=.K+9-^*\<D>.%&U![^^WY\F6[,A-M5B5NI+G:,$4!
M/Y[92TQ1>/7?_ZN5P^@_L-NS\+W_)!+*Y'>.Z^VS>9P:O6>K/NF-K7P5Z!^)
MKFPK79O->(SSCV1DWF=$]L17.0?J.WRY6I/=6?0BG&<OON^NGE/,CP5Q^XRT
M5S-_E="C$-'0Q4S,?V@!E,_XO 1?4L]A8)\MJ:[DRO&6:;\F"\P)Y];_-J-4
M'\[9M(3.<FH97Z,21NX1\!CPI!]9-82\V#C:QY?06=M".W ]Q]'R9J()VRXV
MZ05Y\(S?-"I7H0A'+G-BU;6E9?OK6,S5&X$7TB[\:<>_93W1DPKN.O]H].1K
MW-=<<+Q*_O8"G^;78MV=9\Z=2!TA_)"X?79J+JOOKSC=YWI3IF:&8)5BE[S0
MUZT^FYAOP1E^3Z.N.RBVU'B)^TPUZ0ZZAEAIG?[Y8V['Y& F:4U[FO]')H]U
MB7#O9^P^FQA+'],[@CF*AJ#8]RJ97KLG45?^N3=$NN,B3?TQBI]BG80^V3#>
MW&U-E1ZIH'QG:M,4-W^[!+6 HN^*?ID=':Z,O]TJV3BTAYXI<$=)@\;A="=K
M<#,,>$/9'NW?E"?FR!P99YT;I4@+P),[PV/4RK.I*[T,PPM1FE0N!(^[-73+
M\C49W<IW9KSITO7,)WS+%0Q&GO6G'1;GU#[;L1TDGM&Y5PX9<.4C97*BIXK$
MP-1=3Y3?!%,3:#.ABR9MIZO;-4_\9-Z<M5]?(K /)I(]I3]J(&XUI@QOX!$_
MWD:]B6-^>T;]24)D[+-Q8I: S-3%XRB/,G"+@L]40Q]>-^2E9Z=LF96 .<:&
M:N +GZ #P+>64@\O71@.NKB:0Q]@!)F,D2-\SDPWD63WV4)AHJPC*+Z]8J@F
M8@F?B3W&$D4% ='E9<>:_"B85)DCP$SF;TD#ST_\QZK\RI'Y5I-!00BJ7;.'
MVX 4^5S:AU>'/ACO*J*'GOA#!)DPQ*X.BK-ES/#"JJ'TF*'&=T<,9Y>HWVNF
MTU@7I")=ENBJWF>@-&.:,$#.<TK0*I-X^-BKIC<LL/0S7]-G8^[;*6RL&RP!
MT(BXR+_/ME1) *[P)7IJ3VQNXX\QKQR\1>YUUC'ZO:>&,M).Q(5SH!N]A/1W
M.RZ%U_7B\%D60T8_I@_R_.F?3>#U$#6\;U00Q;;/%NO=%<V>I&['B#SH7XK<
M)2\*;L]5WE/[/1S%. EZ5WQA>@-3W?.4"Q]K*Y*P'@<.QL=_=^X.A0#4U)^Q
ME73.W_UZ$*K\?CZ:M4Y%0Y"[%J JT&1)GSG >1T2+!ZM40_()ZI";8 Y"JE7
M%0>RO^W\JA\98"@"A+A9&W0 /S(-RK-OYMWI&6YT.8P2!*Q9'&^JD((LSOQ=
MIP,^LS*48YH"F R4*;V$4A%OR(,2 '0247QAE/716"Q?J(7EL2%7!#^8LL9:
MAL*IF!.?03^+EGS[MN;6.\7M4Z<T#?(_N<ZRH:OY.0NS@;+N9B_OUK:THQD+
M"]K\O0B)2LZ&7LY2F^I'U4FOV-B$GO__>Z,6.GX\*^+:N\S1)X][3XG/B6\6
MW"+ U0A+.1B^(&;@$B:FD?6%P/D;.ZM,-7W,%#R TV.HLW13(B$I4J00YXFZ
M/'9K!J5.*0<SCT[74H:"3.W,T.\#?M[]9?E -ODN^0/=%3NP.PHRNO;9ZL(Q
M@^:L#$*@>@JLP?HM=K9DJ:(?GR(CNE>,/H,>@_!@_!8_8\DL83"Z>)^-V//1
MD#U 8B%QB<=PY^U,Y$XR E''O"MHW9.B:FK7W#+FJAD>=.]48-*1!K.]/7)'
M1G \>5D76M1C6'C7\_!%/*?+0R[U?H<^[W,V0X['"C&;G,**-KWZN=5/^R;3
MW97-@Q&"9G)R+'UD8-;]?I@R564BN?ZE >J"1S[0PULG?_'#5EIG I?JAY7\
M?;: F=XNK*!)CZQFNI2TXE+E*%^N\6#!^-N9H%[6&3!VJ2Y]*?,X\T"JXY/I
M1I< IP&^N'TV 5-2%<9O:(_/M9ONE"Q!W L=%01CK>D&!P&(Q\5_0?*-14L1
M5X=$X/>-TJSYB=$FM\Q#"_GA/SUR1_9(]PS"_<1VAM$?0 MJ9A(T8O<0>@'3
M7-?@78PA3DS#[D$>$X1EI^S,&I_[%YV>@IH=J#PT>S9JWFU4R_76HME724??
MC"@/^I<S,?ZQ>Q$8@$89P>[:!, !^TJH_.OWNP9FNY*0V2VSL9%\"/.T*2-]
MLKD8R)ZC^,=[!UIO7NLY^VYV>)CP0LD-_J[1O69D_.CR/IM[@WAHP^\0%6ES
M,,4YS9./;X,N)*ST9QJB_*[!7N.Z1(9 0;$4L<[/8VF-JG0+9TQIX"U=83<O
MA!F#;H]'3SV[]0 ZDB'( 3^:X^N\&!A+MA9,H*!\H\A(*2=A7[5R+\]"L]N_
M-:Z?"9'0U=?E5BE)ZZW6*G:YI33-"I!P?B;Y-5U#0T>_SK3RO3C$?/OG8]@1
M]"GT.$08J@SX40P27N+ W?[T:O7$WWM.KO5C=]6LTDOA@9V)^=5K:ME/(ESO
M%88IL=^:N);*'3"N'_NWEK;/EL&"[B5C;F,_#?3#FJ:QP.YE>N:F-64T&2N.
MUF9Z3:$ED1?[74?3H#X(6F:3^J/:GU"7DG7]>^F4GYR7[S/:#*7'7[<>N_+K
M;MN6&G.?K:?G2.!ARCX;4VB.(4N7?_S[@(R5IPA!\,^BQ$4AF#\DP1,"]#\K
M7S6CI68>!]>=+"VN32!4Y?)[C?J<9BW+ZV=]$\_F1VFU[H0$P/T]+)E?FCQU
M!RB-'P;$XP?KQRS8^\8'SPO3MY5VW9VX]VZ)S63VVO42D9$"V:+\=AP;= >?
M)$9HY2U/N)U F34: CP[V^_W6<8EE\ZK7[9E>"21GW*NPU)%OR0G>&:RVB=5
M85C9U\&?2@].\(HMR62T*YWHW74W46=KRA-35%H<'/[J2US[-?CMFFT4UQ".
MZTF3Z9G ,!]H]@Q_:37Y#)?*7>'G3X82I/@]GP)&;QTQHH8:*'G0+00W7.*"
MN@9F+A'^\UA_Z @L?ED582G1>1*2+Y0%^:F,70X+]I%>=S<*T@+(6D]K'EQ+
M(2>NC6[0Z:F,1G"*;LW(VRO?SLR$<1@*@/"EBICFGQPH>W"5AG^,YJ!W #EQ
M:JCPFCE0EN3) :@E+JW.;I%=%[J#PZ3:IK.GPW/.'_>>TG;B\#H:#:$WPH^A
M3*8/!/$)I/E"X4'DXF,ZT6<R"/Z%\+<+\N#G8J8H[)":X9D[1<? VJ528#<0
M?8C;6X<EG;UV$&%3/=*.MUP5=)]3N?'AM&=:N!BU_M.+%U.]7I2DVD1\8I'Z
MH90!;Z^<;ZFGR'ZAWV=>W,WDRL&-D:HF*E0P,SZ<GR+'AZ9E2BMDKI<0-]Y
M'D6P(-K]![V#P>OV&LQ%M<'&P9?]E\"V0\3M8&=GK_822/X%.G+ JM;9!_[Y
M255BOU=Q_I"HL2V60MA4!++FED0W#]/SEPJ+.H*I;K!X.#_*>BD*?F+!A5SA
M$7AA]EB):H%^^E2:H/ME?X.^.WBM$Z,J-ATW,YR$MR&DS$_*9NW@Y25,!JQY
M8%,;(#$L 6ORXV@841767R1-]\M@AM$VE2V?D\.ISE#)I>]D5B;%,?KUD OA
M9?SL$$+]LU=;5T/>^@AFJ>0F=JZ-T7L8SU0?39;99]N2;*?15^%.F%Z/&KRV
MN@!K@"# A!V=Q!Y!.>R*HD0^HH4#&C2'*+N:E'554Y8 A.NROJ:KZWJDQ8+_
MKX!IT\$W?6/)WHA&0DY7$W14.''I X\*T9GS#PNNXJBC%<\MYVY1)*I,HI8E
M$FW)-K4Q&?+BCETX'3L>UW,DKV#S0K'W_;5J2A''+N=X=]D,X[[6C]SO@A20
MU =!=+GR^>(8^R;N'=%'&3KG:A_U4;;T<Z5:$R3$?"2<-U16,@:6Y-P$%13'
M\'^6=R^A9)I 2=H4D/V2;D$9[8?Q!GC*?$2Y43*3"-PM_F$0GO6\8UW/6IYV
MM'6E\!A=FJD]TUHTYP)\JQ)87 VW^?- J^&]4"/R\4O.BR:KIVY8"9.X&2/C
MP7 <%K F'),G+2826OTVSU>A5.KIB63K1YBFG7A4-*!.PIQ *>2U)AX&M\@[
MAM*3:$TW)-RU95<G^2Z3H\R_+;([H42N>R$C*:?.W?JK-5_Q^J)0RS[;G!V+
M@[1[ ^6Y5Q)*.+H&$3A +4@RYK@JBQ=UZR.4;VF?[?#Z[ Y31=6A>504I=J3
M3^STS?3'NWQ:]8$:23>Y0*>O1+E<)WRG/VVBNIOP"6XKY2*_Z=X]YIWU-2(C
M:#M/%^5P?4#/62X>ESCXG;)BWB,-)1VCAWFG$"O-D8F))/L,B?ONP)*42. C
MES(IG^O/SHUH>)ZE=CU+8)4D]R__?N IGGV+#J+N89+Z[?J\@D,RK%_NL_E2
M5A[U=XZ5Q3IW^8C3[HS N=&S\";?9[OR3&=@A11TL3^\2*-MIH<?I0'FA5G:
M639_K*O] <6\OH ++E4MJYV?M)U;'2].6?C^KG%44C%;.TRNQ]SOJOA#>YF:
M7M-OUX3W;C!O[E6Q3B.-6)S\NU+HX3R=Q!YA&!&? N$E^,!YF$[UTV@QI%%?
MY$Y?-V0@4DI">"\S!6J)]^],:& 82)ICFI /!\S;)S9^[P0F?XOY83%4N,\F
MY>\J$K\KB5(Y0.$,5"2HN(3@#, (L831GZ<)36TDK #81IR%I[\"98$W-E-A
M05=H??J\R74N:Z[:1665U^]V08ZU57_^T-#7^L1((7>89S0QB]YZJ[&KL<CG
M48*\YL!-C<A/G!\'K@AM2;PLNM58.=G?ON1/4OF*5W LN#,Q$.*UO-L^=**G
MAM64@E)XMQ9\+!Q^>B3@Y@,5W 4JU# D/L(XH.6!JYZ(>=/JQT%O.RV<$Y21
MZV#'9^6<UV&;H":*TUW"IV523K^7_&_P^Z!^8^.3\S-G!(X9K(<3.X^5T*R%
M0+_>3K:6]IDN#RH/'TE"NFOGONOE8!R8:M<RKE59WEDX+>E\MJ>[+</BY4NO
M>+$AV2.V@3N'G>C<F.;%C8%=4=8T1$P+<<2%->8(;]N)0[,;4^</]Z)E -0^
MFSA:G%1YQW6C$1EK.J:JM2?JU@YD5/(6A?F,3Y^-W111XVY:%%UEP=#S, FF
M^C[;4=G\)6M2NB;%FJ0>SV+;:]"RYEUUU8DW% 2Y=FT9T6[D!F1@O^')J2[K
MJN\Z>?,C.-I%A&!@CGZE6V6M2D5[D[Z[8Z/_PV?XTG:21I]];6SO[7:_3")E
MJS-W)6G8CUM$I-4RN2RNX(YC1?9D;4:%9UFD9H4ZCN):7DUL+''%-N;$[[.=
M&#C=:TORC< +>4];YWJ#K@EV4A ^8KE_)BGX@D"Y84%#;L#G*6Y#.S<N4Y[D
M,D^(^T"_ QIOQZ5B)8/#\9$0!W3.VV4#8*BF&6A!\-O"X%#_(B_*LAII2GXH
M@2X)JIYU6<_3)KDNSLVMB:1-[SP9T&@LZY,?>B;N2>W![F7 O/;9)%F?#,^T
M-4[TG$1I@=9+W^CW,I?,H#YTOC['"SNN%6G;H,2**9 8 Q4^^M53CMZ6C*B=
MJC,NQPK7Y?O?Q?_+HU(<NOU8G T'X<T1K#CPR\%@( U_XO-:T0E0AXZC6J4"
M.V9MP&A"LUNZI$7[I&IMJ\=:I,E3+]QZ'2-;)%!Z^DU4Y8<KS>_/KGX-_P4#
MS]+3T(O81E[JXWTV2B2H<)9Z."3\)'&EX-GC@3-TC^T0E17^7HT163OV[&_C
M[\I>;HVE-4E!Y:0DR17FNDE>H@:N_MH2S>MV)/O\6.=W=M]P7[T:U41ZP0:+
M!!]3C5'=!U(.UK(,W<ZG[QM>V-/I;]_?DH_%93ZOI.#,S8;XX#QNTB;/ Q1]
MMFI6/_[)H28^KC,48UJ B<#T3YM8ITXPFH81 I56'%MB+-R";#'<@4Z=6IWQ
MW36C9Z;'%@Q>MF<LN)S)$GIB\NNBHO<V=F-^5Q*\2(.]'4V!-^OT_9S5).VS
M-?T[>A+?HP?@'VE+;KI1"*F&I[^L28RF;AI^+-=R+!*:5+VW^<J?T^W>A1GE
M-ZBL]_\I<:!@C+I0Q&P.X]GLX">03K\I7</+QY27^-3;JZMWY.9?B;VS>YDH
M!+!#^<D4V&)TT=7[#OSU7_4!&$?OKCF3OZ4=C,:#;_J*CD_@U=6UIA(&;*.C
MB&F=?;:K(?QA/,UW3W:$_5KYHPS=U?SP_?XWA]1>ASXCZ8S^^]\D2H'07SLI
M!2$JOKP92KIWOMW(]N#<]G(M];<0%#8I*,T/-E^WXGJGH8*0]OOS,#"QUW[P
M04U3^OG)*M^PD*3EWQ59RQT)RH>AH;_T!O2JXHN=^,S#*#'/&[3]R?U*]RQA
M'PB9$+X>/N:%F=]!F@>:LGFT##W6J<K(F/E+2 XE)!JJ@H%!K]:P044+!KR6
M%_L%AR,JA^1J@A<EYTS<;KN,S^<,VUHGU#0T";OPYX8YA*F<GSDIE1:MO+W.
MXAC"HY3^'1X^:@:*1R^-QGB*@I; CDLKW?>E/!$'.[%^@#@P[B<H-;I/3QGR
M+SY=A&;7$>WQZ<O[(VO>#3G'WA4[A#'X_D,%TODVPW<O8GI->B103D F,15^
M!#U*X/ ^6!>B5P$=XK\*-5JH4U-065KR[Z"+5D!V1<DJ$*A>]N4[H\'_;])T
MF+3MCU\Z;[("<[+^_APF$@1I&M6_ >%?3"M5K_LNQ]0U^VGT=D[Q>&'LMT\U
MU2]@U<NYBCY@@8E("V\DC@_.EU@HK.[G&"8+0<PE+''CD^IS"V@<!4L/WGMO
M69T;:I3"RP]NH1PM4[#LP ^//K$4 GRT2<%/5TH&QI,>"OSJ]PK.;;_EH6T;
MIV"%X *O^21)B<NR/_PB>B/\_L.E@A^][-(1,LU:'Q5GQ_MK]Z;#V'^=D=@C
M@&]V+9 SC(=[29B;? <^ SAPS'B^-9@4S \.\8<+HD^!L11\/,J-.F]'S,8*
M0(U?SR&#M2$G5G=PY?XB&.!I0.<P>2K&J/H+/-7,\X]L0SP?#OT1VXSH4_^$
M8^!!NUT)UDC/(= )\E;Z\,'..!3Z;"G:F@*)9<)#=B_A^X)D+W72X4E=;E15
M/Y-)J 75TH@LVME34CX04;;VE,N_UMPHV3O[7#'Y3WI$?[:D+,F\+&)EJ[?Z
MS^@4S>DH";F<XRN6LBWBXJ@;N1WL<'^=/3ZSS<'?OLJ)/XE8K6I>C?1^2E$<
M[(&E!D]^IRC>CU89<;82<^[,14UD:%04?/UT755Q)=?_%O#\G%9PIM; Z-HX
M:;K8/(./(Q.9VXXV0PGN%?Y>3(7]APG,3--!*TUJ62Q^QO9"^* >9=\=.WUJ
ME[&II?2V](&X.I46R=6ZTUB+3.NXU*&(H%,=_LMG]1SX'\S"FW<V)LK1HVCN
MO6RHDS>-:Y]-$+8I# B:@T-5+FL2'G4O(?'J+=*VT8:6Q_JCHG"Q52Y73SME
M,%:#?DBW(>*-E/!KZGW6!W+"U\-M>K#4ET _H%'2 G8(A!,7#Y\>"TT]?-$%
M&1P&2XDT:<)04AW;LUS0HY1-:YNN\=JQ=]0%KCN;]E1.!H9ME2'1]B^+<$1I
M(LQ"4M7:JFLOJROU#8_)^,+?P3418"=SR#C8/TRJ=>OLI9MGTEOU:Y);/CHC
M[6CNKK5NVF5*4QKM]N1O0HU_GY28U !"77I#[5G9O&'1+\S&\_NGJQSMNI8Y
M7\AQC:1Y7]]5,A3V"2%Z(:/X+;A,855&ZN^#Q:<X<VLL)2):,.)-5ESXE^.O
MZ$+^3A52K?%*)RJ&S(45QM/&*UP?U& T3SLGGS035^*X*?V ;>W:R"7I+?.L
M,X^>A][7?W[S;?2ULX1B]4?[;*WJR8;G47)[W8B>,TS)O4*HY6OTT +G.$N)
M->)Y-']I-#8()0J4]$4Z9:AUR9:1*SX[KS)F,Y-"=Q40*F%ZJE#+RK7DJC7]
MP-9ROT2;[A1K!3"VUGCW#NL]H<&/3,B\#YK/4*TZ=L/6X$W6*:RS2&]B'GN,
M>@LB7J*ND++I4QOV!LZY.NN9KSKR3.T5XZ_#EX?!>S%"&I5;/Q ^V/F*?K%9
MY'O*EE2&F+G0^=\/F XHPSL-315NHL^Z5CB_4UC%B6&T;;2K+FZR]#OU3$FB
M\Z"Y@Q-Y"B I]ODTTR/D11P_G$?6O.X)>43TUHU>;L9YU4N9RHA_D$TF[[,%
MWIH6P+B']"TSF\]S"<>6+Z=%W#M]@S1$YQM.:NU5\=E*?S/S,/K"BAZ#K&PA
M(2!QU9;MC&;E29FX&)-#&X%_D\ .^@K##M0\T([KX"'Z,]I,O-=>#DITKP,H
ML=]+"85_0MBFS%P=V_S-H8(RB*+\3#WQI:<EC(;S,/'0(?.C+&*^V=5J&I";
MN7CZ>$3[(#P]>F B(_  ;AW!PU13(I:7:0 1T,;.P:GX6"WUI(7S %\"*I"*
M./I=@ZDWKAW8T:4"M:X(<(W.J*VZ7.ZVFB.ZXQB>Y>8_(SHV>T;CR\MG4O*2
MM(;VNZH![A<]!3\$BSM(=5!QM'IG?6#X/KAAK /UU#Q;+._$P2V0?4%7Q1#&
M(X&L@0+M']Q+5^L^C!*OXQ3[:<"GN@O$R;)G-S6_>(;6BUUOTOQPO^G=^0A'
M@<:RG.4NT]04DJ_@AV7NNH@B3:4!^]K'Y/$!GP[4*8G17VU+X;U8&=9'N!#S
M%.!'\<C(QX$[ T[Z\=B$#6V#6T-7ZSNQU\?5MX?(^0X]8<VM_*N=/E\';]\=
MI-><3\BZ:O>MC1&RFI=04C:?-+UE/JD>.C298E\HVS7QPZ>Y,]TGK?%:%52M
M^KMYYZ/!:Z<)5; #&N+7=H8MO88!EO@43ZEQIOP2_@1K%M/(FTZUGCT]0V2)
MC&G-2_:C3T^$XJ6^[+/=_>Q/LSX/(NPFU9D72^?A\TC,KB%UPXU+[W;6M-GI
M9W^8>Z4L#:;O7CE+,W"V+1/O1U],9FJ'4V$<W^N1B-X\PY<A_I1:OCX)\OA<
MZ].E;H&W'I+6^E3JEDU72WL71T==75=E_T)!:O*6%$VG]@I22D10I2SK9L.4
MCTJ0>>X'0XUR[T(?L-(_+@/"G^CPJXI8L%<N8U-RG J'-JASQ6V!!!(S,T'7
MCR>U)-^W(SL:GM)T_76<UXN/93G>&K,NZEPK>M$FA.: 6T#N:+7?[S7'F)*T
M].N6+DLE&ZM+Q>D#S"&;B+$LMNS3;C\RSS] QT)9P@W%CV:_)1SGKG#[.%EU
MZ,7CR=K'CNPG8S2._VMDC'WDSX%"/[>#5?@6K&"(=((1@"?D<^J Q(\&BKH,
M"M9R0,#O?G0%AE$1L?[4N7TVT766TC/SG+YQL%KZ5E2(5[A?E<NLBXNSJ\O<
M[$D7N6=ODL"L'E/;<\79 ^?L?]U=-R";(Y=C0^_K235N)Z>+[3D);J=9.M.H
MWVV?%5N.Y*>;_Z;!_/D@CT%)=G*SCY-XT>3[9;=DT"_NP5KHKXJ7*E9!9/NM
MY)ORR=@9 &[_]D:1C78:_C@51RSTT1=SW4ILS/GUS'(!NP#?_8Y)#W?JA.KK
M].W^Y%VM7VU[.&O:YS;,;ME*5QTT*O%P6^U1RK%L:*,+?WTV.R"2 [UA+-(4
M)C?<*)?_97#G!-MM^ (6O,Q278$ @QC "/H70YP$^C'JH*=#:WC?<PV?V) R
M\]?]=H77HMS1@D<FO39:G5^2)PDM3E\[XVOF9_7:[1[1438JXT)T[>\6RG@+
M/J>U/U9>>28AE>L5$3>KAFV;BM4<;$=>AZ=/WL9<3!M,&1G@K'8N(BC%F-'P
MAUO0L>!/%L<Z#9& :5Q,W6>[\U,,Y0"Z:_\\ND[@"26<8 H Y4U!-&MQT'>"
M6E(,=+%TIIN5_S1#.-=U'$TL;5 : _8$B^.]W47$;\:M^ 24B]13))[,;QE8
M[&(IFJS]Z5LCT+4:1DG5\YY2R[:PYOE"#HZ0'DW<+-#25Z$O> Q<R,L>E_NP
M1G3<XP7/ 'BF0!OC!ZD?1CM)\#G=IY'Y$M^RE:VW^^&R'C2+KUOJ<NJ'<\T/
MTAS9A;D-E%Y.F\:3QY&182O)I&\N=>Q']6WP>KIC,25)-<M*H66.(:%EYBW"
M'-4MO2Z>EKFWP!RUX<:U3QO&O*+4&K1;LO/@)W-G*4^S)]\ZTI6VB+85$KEY
MC7V4<X,G<,D),H6Z,_%W+YQU\%*2@>P:LD9@QPV5D(Z[_3#1@RT-BR4T^19!
M+73B0PVXR*Z05%0(+3J ,3U@16B?E@<(<133,=2I)ON$Z;F^V6ZF8TXXH[.P
M.?A0Q;!J9/F_ GK+8#IE="Z*LK/A0(5)(ZVF]]FH<9'HAB5\JH1VV8\W%)Z0
MWLC1Q.W1$W<65!HG'*FD&UF2[;\EYPT#V=^DU^)I.8-=;YJNU=5!*QC7]K(A
MC 0Z[QLJ5AK,&*)@-F: [(71/BP$K1E8PY@U3>C27%'&QS,-*>+;HTE%ZL;1
MFL0BZ8GIJ%4U>='1PV3N^U]V,\DP4 &6C'+:#4=&,;I!FZ5\^(9UC"NZD(*-
ME3E,5]'/* LL0YT'K!/"$-RKJE1*Z7SMFD58(&[-4W:Z2/6RUT3=S^&JKL H
MQ 5K>>GDT8H"W_;K.9K(%HLSP_*.\:@+Q\2@);I5IGPL/.4[M20QW8R*&W2@
MBW497FA5.T%2<JBV(UWID=!F9<H/@892ZJ2.'"'@[U A6OE=)86.O/XPR$F3
M>D^JY)^JUHE]L(*KN%?:OO62E5+C4B,OYZ)Z:MT#\0DE;I).'!E5\;\R,R%-
M%1L?@3>]$@D$8("Q"O -+$HX!SZ4N 8&419CL8)0\:K1(S.U@=5K1G Z-+/$
MF#<E:4>02"Y]PV9\E_S9$N4 ;XB\C3V""<)\YF*\!7'5K \$#HP?/N7 .HH\
M7L)(@A@JYNTGE#4%>PP<@8L@7_^T[ +44YC*M>N>)R?*I\*.QTH;_N"QW!9'
MJ*NL&+<F'$O8HH^%2N.F* 7W9/E-SQ&]<;[:(5)-,O7MBYL*RX;3!6M+]<C9
M\R5V<L6)O0ZD(9Z4,D>!%[I4;_UG%1ZFV<?_C)[0J.%E%\[ZYF(B>H;X]27K
MQA8W?I?7_6KE5%GBAR9NO"#4@U>>3-.$&FJ(?>")%);E'.^UKS O=%<I&[6]
M;"SD- 'YOV8<__<F?'Z?+3/T8*K']]F^GYC4_E\>Q[2;NV'VE_J4LN4/73[S
METW#>AD^#V<*1"VY@'R[?*BS$S\W>@:HF.0;'DP/^K6L<SFP 'K%BPOQ@?<U
MK-;YN-SNU!_5G=T\.:L)[\_<: )\MQCQ>Z]9/$SQIO1Y:!1MF,]\RN,0S!?X
M*BIK0]>FG3"9;!E3:1%/O2>FU'4P_5?=+)15+XR/7I^X:>&A<[VI92)TSCGG
M[L-.-!8A79C>'&"X<=^5)'2M^P4;_AN^U 2S41\!X;$I+$O!V>GTDR]JF_*6
M)?2:6-0H35<E%Q85@,[=XVT[\+&*.(,>'S(J+*D,>?/<;R1"I>#%!-G; _K0
M3]>@Q(XOH>1QZ?R/5=J*M%#ARNL4Y3\W]MF,_I?3*03Y?S?](("]"V&IR%-S
M[RE:#$0P/.@KFW9T4\80?3&5)<U4!ZP?HT^"<,KR.)A/'%V*B@K2#S(EZU]H
M\ D+IRK_E%Z=[GR@-U&K&E_X9::-GA ON1U#>+K/!NJE1%V#!1Q\.-650X!X
M[V6K/F/D@(0S^VS-H4W@PWE#CDMYV(U?<F#N%K(U"LY-%HTSXG$T"UNECGL[
M:T:=)G4^@KW*_*S.P(+S='SO@@[=>M-R5Q*<8W'LLX51\ +?]?D2FC'I&-$>
M"60/##*WGCVA&9!GU4')W*C5,;_@FN7VG68YN15>Y;%X(-Y^6F3?9,/>>CI?
M8IB'A=/'9BP_&.XTW04[$XR,-1X/VY2WG];B\+W58%RWZBB:(Y&0>::.TR3O
M17<3]%'_J_8Y>+\I4T2P'RW2?0 "7*C0":;L@6\R:CIXPJZSQ/?J87[#3K;@
M>MGZ(M<];7QBK/UD<33[6PT,L602_WO^@JJAAZ0-W>192)4')G HK&;QO:1<
M6=EKXXT\OXV7@"B+8^#?";Y_-0V9@KMGP!!/,.0U>A+;2!CHUJ3]#D<;TA-3
MU-%JZX80@*^/3Y!,@TE[(O.=I_QF4"ZXP$CC(GS-?'9;8^=DC6J89"#7Q?SP
MK!M\ZZ>'^@UY)NM"=Z4U^]&\DS];_,.N:>7S:)+1,I/J+?Z_]8[H?Y5P>%%4
M9C!29IBLR+]^[K,Q-,^NL&W]'K)B%FPBZLSN+<9M0.$4R7TV$><S67#0=H"L
M?W0E1<7VA$1X%[#<6J+6$E"OK&SEUY#YWI;[S:%A##L&L%C\%$O:6:S/80K9
ML3@1P'.F"YU]D[ZKC;+<(S"5=Q4-TVFU#ZUY4= L&F4!7Q&H":I3OA40O'KH
M5A5E*%.Z8X=0VRV&(_UH1F*E_YC;PFQRV1_!OED84S#_7PE,Q,%$:;/466^Q
M@B?_)=):993!'>#*3W@[X->W*(E,9>30V<FJ"/?I"K"A N4,Y# V_TR@('Q)
M)JE!Q>X!>;Z%/K7^JW=:PSM'L)A:"UWV[0BZ&XM+F3J:L"AU,&##(OL2>)02
MY#G!XO#;O0C*TS )VJO,X%K7>:;O)-1M"<$+=L+YP.Q! YEK4#DOGV J7STY
MHF2XRL,"X;,"O>66_A2=SWJWV#R,W13?%4,/8UH(&:I05: (DG&P<- 0IN-T
MZ '""+E=IF".P\%%L]0;^MPR"G3!5;.PHUTC-YN*=C=VG"YQ][GSP]]#-LT'
M6))P%N_7+4X.#.41BSNBV'Q3$$/,!N^=Y8HQ.5)S:4!,.>/X*&FQQ6.E#R8,
MRK-X-D!3VCZ;(&NH2'+OQ38,/.L4A[*A5&(0, 'F+0"[X8!GAK:.;^?#!?!D
M [>E!=RK0-F^O]8)-X&KA@+1<*?6L=]#\X[DGW5!0=NI+;F']T2#6GCT=ZP2
M71HGFX?F1;Z];U$."ABU:>S\>$]KRO3IMH)V5,37B?*)<=VO3W^6= 3:9^A)
MEW.FF7Z#D+&@ @C(,X6PC--[<5V22XN'F4: ]688,$,3S=2&I$O ,C'-OD#T
M"G$>UM<6_/VO2.$K4A42XRG:)B/CYF'Y8SLJ8@,]NRPKX*;R8)_M-/9$ERH]
M]G^> >)BS<L(@!&[[NC116DT9R"D;:=W&$;.QM;#^]13%T^P>-&C,/8N?X1?
M'>HZ:$/!BC(OCV^VS,&.+*R+PGG==M5-Z.QIH=GU/5DS[C,(;6EOIWA6'LB^
MM C*X?_5SJ(@P+,7T@\X"$\/CX=: )V8?W]GOK?2AS2$(%?(,A>!"X6TY!Y^
MY(;_@_)B*M>\^>AU,+8&:<NC>0-\^FI5IRK8"\>EI[VG;#$MWQ[_%M:1\O]S
MW8J7_+<%34A*FQKGWHL[AMMJZ$D)OOO6[4>3[Q]-(D"@+EXT3(I$=WD;U4"S
MER4$R!4N9S^MN/-D@((]LNI? CX<KOG=KKI9FC?>*Z*(E]$,>4@;;G^ZF/<K
M=@?+ZC3;9RN1.!#5ZPLR<6L?^T;2]6XIV.&LTOVOJ-4JA>T]PW.&!.;Q5W\?
M#Y,5>3ZO&P)_X<:4SM 1M^!)>3M.=JJ((4\7NPG'Q;L,\"7AXAA#7+8M0I-*
MUKP-PGMI%2*KNZX%M2%O_GY+I@]1G1+1W,AU!GI<&^>&B<<*H)PH> F0<"5:
MUK)HRX;.%V>BI5P95E4[9U^?,+?L'Z3RXU9;YVTC_0O'[_4C9D=IRP,;4T&[
MIX=H"9A'V46*,N<2>S?+_!-6PVRJ+&OE&NB'VO1'&6<B)T=Q Z^Y&BK.E@JL
M>O'&]#QXW;'F$Q'DHCCU]N::N>[?B-?/@=]E<B]MRSBU&E8'>6I\]+4HYF+Q
MNY\FXFZ6O\ZZ6$GGC4JL4++73#N8#1_A1@Z[LO0^N[A&J'%D;O4?H[2 ,[]F
M/^6U*$_UMFQ'3%7I#>8_S\=X,07WN@C^F8\,_]MGBW=;.@!"N!T8?JS]7P%]
M"!U"&7C<(_^]1W*FW/],QQ14%4&+%G1&\'WQ&);],G\V_\PYBU#7[T0U&3/(
M*)X0@)UEM]M[=9<0X&%-]>VH9(9/A*W#^%=9%[LME%-3#WS 5(W*W5JM*M6,
MU*!7LZL9?Z\;RL00#60,E,SN.HX9R2;\8:3TZ\E8<INH"W-7J&7(0ZQ:5,+"
M8DC5[9W.&? :N[Y)!FJJ..EK9ENZJ<)T<&IEZ7B;I94:-:\=VJ9>U1?Q!7 Q
MN'M!5HDXI-FO+QZ&DGS6.]T[$=9Q?_L<:NMOS:K"$'>%G'&O6<6.P(%R&&,"
M;H.)U,SD\V B92,2FX$2# *V^EDBUK%8;@+%!3E$;(ULK:J;<T664'#(H"[9
M6KAI3:!KV9]I1//G,!>Y[CP]M84O22:0/OC<(N,5B*M$B4]V!=(\COVU_KS5
M/P[N+NT5O5SB.XH,-P4<6W?TY29%(M&IK^YT/GPAGZBU S!>B.13YE+-M(8N
M!H;'Z*8,*R(R[M1XD5 PJUJEL?<:E8XEUI]M<5+'Q.TK+"G+<??CI@SOD"E^
MT(MFN+%GI3_Y0M>J!MS]7>-1JI[*5,[<NPZ(FEOW?PTWU*4?A$3WBERE%G_]
M+\^R!FPJTE*?P]64.+N"'']%$_H(23VJ8#>=JQ\KU!552<8AYZA\R=IP$1!G
MU];0/'&R9T8;E_.&T!YK59_"I2QV^^4G<F @]_U+^=[I_SV&6S!Y#P+N8_04
MO&GF43[%C_13YOL.@6?"-MK;$K#N4_\/J4.%)_[FL7+,LT@E\'P&)TRF1F+N
ME1<%IJ9&ZU\+.M.1[89M2E[),S,\_[JSP<7**9UH^]9;8T-$^;#1YRBIL[)<
M)JTRF?69<J+FZ=?,A>85HIJ_R(H>7SCO?R$3IDZU.C48HO1GQ*GP6P<Z,.7O
MP'23E,Q%P<3^6^@6F'^R<YJQTM,JEUM*Z%_- >;FI>,%$UF6T5%^NY'HZ8=P
M&768_[4>];5&E.NDUF$*UY[MBMF8/+"\$G.<B!2@O?U9CB&>DH\I/FF!H! V
M@BOFOE1VIVAUSS\(9AF@/Q.:(9NRE&[V7I@@U.&UT1*,9\U)8N'%$H0-E"?"
M>: "G7OC9D(+I[J!Q9C00HCUE/8$=^-ED8K*@;!@!'>67-,5N>>$(7M'K5]2
M6?^N)Y8]6WY.U]6W_^ZE3#J<$.^N*G&^0&&BV%;K>=65YTKV\0J]9+NT%3$7
M<[/?4S0957SL@,\4F&]8^_C#^C395]>\HTZ_'"*=U&=5Z&Z,\E"<N=_GT.=0
M8E(6,67[(N!YE57)\ZK>@54^?M8T5AKE0F^BS&SRU8$55F_ 6J!\CK*'?;Q-
M!D9BCR:\1 "]LM;'!H)?D6YW6I4Q#@FT?.QIS5U3<5Z(>)Q4ETI9V>S=M4"I
M@2_I<"HAEAGFS9[$T@O0+Z^B(ZY-0^4H&'XDWT!X7FM).,[Z;-N2=(A%#]!,
M\"'T=.5;G%L=>U\N-T7N+G@Z-ZIE_2M(V.Z]1L!S="T4IU8D[>458^\72QK,
MZIVHQDV0%/3O*<7K?TP/"!W_&F]?;:Q8=EHQ&"%D0XZ.S#RQ8M^0"7'20E9'
M9*L)+_C >8&6AI&:@*HNA[LJ90DXES;]YW)*FO?R@S$W4"Y[C; [\/2B<R""
M!H. (_UKZTM[C/PJU#E@.I8"YT%:4_XA9&BWZXQ["LT($$W4FM<AG;",J/KL
M^B6@J0>KVE]>;XH(5\E^]U0]"WF@]81,P[-,.SJL'RL2Z(M(EE&GHU@7IU%&
M9;-S=P[ @./ZSM,U=ON)C=^?EEHF9"3?O2Z:OJA+S9BG&0FDO^Y:2YGCR?9I
MUQW/$#P42S))Y\P-L"E.*#&S(TU7XAQ+CAXW-BET_>@0T!O5HH3WUUJI&LZ@
M2NUHO8CXIC?BEY$M+VHDG92M+IG49]ZJR769<O]3=4:MF9X3B9)/&JO<6]."
MA5GV<US]Z\=(VL.C]=%3\B1;9N ,]#R5ZR=7]P9CMC]UB>\8TLA]6CV,2U73
MJG.RRZ$&Z6<Z$<8G%*#N5^I,S-'_L&-R2#(_-&GX[#JL";N92,<Q[*-M:4M?
ML;P;VM)V3A-AI%ID$\7I$3,"OQI9_O3(-$/44&;F8"NLZ5<D,I\7.9U?=7*L
MW.*_J/C\'DSMHPLT1SXBG&$T= [RV;&-\8#XT5DYRCH0@5-0NL HVNM0':Y-
MGQ&F:XSLLTT[8'T7UX].1$P,4#WOS+ZN7[.66(,:Y=2;YVA6H8T#L5?08]CF
M';+U+,;](].,[H$Z>K;E=7E=_2(H3\''L&0L*X?JYN<6 YS0)Q''_?7=D E_
MW7!A>1?GW>>_7!J?%[MM%';_]AKZ$'H6(T/PQ;.#;PY>/TG:].TX4G- _T<.
M%2$ A@Q@N;OXZ;(6W3-:@8Z-$V''-U$^)6L-;A9!A[V@+QQXJQ3^,_Z"MGV=
M?+OC*G!BL")[R2=[_/X+Z)'Z24^!@JHIQN0R)Z_,B)HP(>K8ZX* J,'1&Q5D
M=PM3?5R??=.7Z:)H5^U3;CH)%[I"..MK$_^6.=N3%:N;TMUU?BB9V :$=K^7
M%_7><,'<^SDKAD* T;M7_9VP/%!ENC4E(:?Z#DM@"BH*1%%&XT+OW-U.#;(:
M_]."X+ZCSY.=6#??THJ/YA;MK"T;'JXV$XNYUF>6>1+@VSQTT#?[*1UK!#SL
M]J]8)32SQZMU"=*ME M%+29]9E &$=5F-5]F/X]&!*ETJOR"#YTAW!V?7: X
M,%ON/[Y$SU-(L'AN5[%1M9PK9A=:W^PN&__Z]?>E!NWSN?J6#P*MN5)Q3H)7
M>.EEGJ5KO8KO6QVH=7)XEUO*?I];S =[8$+50Y#D$.>"B<-&JA]P%9M:N(PA
MH!TEHO9Z!T>IG"BQ&2P0<JH"MVBP/O5D-#=H"NRS]4NTE)=0X(][1*:Z)(%9
M(H^\57V.*<!JJ^DA5+DN>'[N%9YNT/I;D*XQOV9K#;6ABLU[B\'L0'469_"N
M+Y*OER4(W$NE0TAM ,AN9"@!B*:@G( !RF(:^C12ULCM84OS1)?Z@2420(;;
MT"_D\+Z\M^"89?OGZ\13;S<_XY1SA/\^6@@^_?II4 CXU(53ZZ.L.N*3RHSX
M8TG3958]9\.4;@40A14'SU<E5;G6K+\_LS98.F]US]\3@,+)+KYJK3 U*O3G
MX?0^ROUV);#KK%\:B:KL=4ZK\F.OUYICF:-FH8JTR@49,6=S2R^:25;9^PT:
MPG<,=@>2ZBD%C [ .#XCJ]V&-1E/F\;OLC3F [,?=O[HH"Y_1%G(IVZJE<ZT
MZ/[0MI"^ C]AH;JWMU?8YZ2S*6L:^LLDV#.UE#5+:'9,I"$^_Z3*%%+WE-2%
M6$-H;ADV4#5"/HYYT: M$7I.->PBK&%-1.!3"SZISK(''RT)7S\_[Y%%A[W\
M9B3)]T(!AWONX]"-J\U>"MA%^&]V ,T^F]&MG'I!<'^D(<(_AZBKN,#\Y%S-
M^SLK.1N2#&9R;&-P?ATM?-51$%R4"OJL#&GM<^E6%ZQQN;+#("/8-J+,T.V!
M]XJ*?9"KE5_=@8FNZ",D1K+W6W,C[5R;ZS_V&"+]47+T*PO1$,N>9VYC.>[6
M_*F!%U-Q$6<_^K"FTWUU]-W</MQ21;P9O'A5!R*)EIU'B8QA_#Z'X;R -R28
M0)AU:J1:)F^.U[$*/]JPMW'BI9ZIQ*33\=J)\<WO3J=('NO<E>MZIW8KW>_0
MP',;-RCAOS5]/'M"F$]264J8M 3JI^"5&.+'/KT'\]-E"2G%5F5_BHV5@@,X
M!U1":A:T'"7TB@QUD4OKR_37#0XOM!^3;RW !&-OK"P[!X"?+41=TSN4;DGB
M%#K:9'^?PBQ5[K.UQMZ9[@S:R>P2KET7\91!<+FAC.BBO:/QKOML9/N/>1\W
M!,Z"J=6@[7I?DX>1[[<%59.H#L0+!^F*"*</^&=X] 64Z22:XSNF:7BA*5"=
MB.=%F4ZQ5/Q=Q<:UOA(2#\)52H_,9(M9V.2C@#:1+7^+KV?S54G.I%.: \=S
MN*&O4[X2O^J=Y5AD?^[3[K2Y2D4D]GI];_',PDDX.#552%H]#YQ)OU"[,150
M+>(@CS&%]$-=\@:>:5*O;YW+G%*^J1?\LDCS1!&?H J4+N:OU%(V;,&O<E;$
M@:9<C><QF@V)DD 13,QVG5$1AF?VL"AX$.WJ!-1B5PWI=!6 ]UK"S3]J14EB
MN9'AI)D9UX1"G\@&EUS4E86P[2].38'!GCW%_L&J92OYAQLA52S) Q W1?F]
M9IJ#^;NF*..&^AG,'0QH.[O/1D0\=C+D!" QT,-+?%QK10:3/S)3F5$T#QTB
M\#T=%ZCO^:)RK<WU=+J.?;[+C/91B>'Y[O32*P1-A9H&E,Y3FJ*^0^.'TU;/
M@9'02MLR!TK@ 1\F$Z.<+]L[W_5PL?\[I?#>I#EPQG:Z9FYMJ'TKM;%SG3]A
MM$G17#?%^=-$WZUUJH+I.>)2]N'#N5&<+7+FSE\ZXQ2BKW31%+U6XHGM"UJG
MA.6:QV>M@T*X;D6Y):D5/WUTUQJA82W9^+2E04E9XVE+QY&;U)X"6"MLDPWC
M3]N]!1%>]:-M!0S58H4Q1.4#_=D@; H!1*3![7VV.+<-^"<99X#I[[\<G8K(
M,YS&C)L]9Q*,(W73>+E$OM*=KQN>&N5*?CL\76*%R^:2W.AIB\N!>@ @ULMT
M[B/F#6ZC:JO?_6E;?,SPEGO'99\_&3I'JGQUI1;RB-2 L1O#&N0DEX?>1ZUL
M;/IO.JH+U>?&!S2+G&XL4]@U6V!45<ZONY97U01HJ,PF-%0NKLW&X22N/H,'
MA(=X+IC7]XOH9ELD+X>E:#O3'(^G"+%IHG()*\\Q.\0#VVAF'%KZ^OFMK#1;
M,[G;68YF:LFJ KH^MB$%U>8/GJ_(ZPV_[S"W18T_+_PQ]RRH#1?Y0ZO21_G=
M47/@_B59*?YWNM]-K:;^*K_"]-H2 M6YD<8H]A*=MX'PXUKZ*N&17.AAS-%O
M$]O^T(OWLF=5&6T(^;@TU_Z*BOZ7;9-A1XI^Z7F:93EDF7K_^6P<\2?!YL6W
MCV7<$^J]W_B+Y?7/]WNMWI(U#R)W3#AXRXE[GD -C@"IW>,&!<^2VQ,35I*J
MGOBY9%M"/;0MA*%O1-TX5(P5JLJLFDH4.DC9M=?:!^G!!=0)6_^]*2"3Q7EQ
MUXYY A"I!4AO)19)=Z#LM2#- TS%4+HQ2S,DA)#_,'64W]TTI#+@Q.7:[Z+!
M<T:"9*E(GX)KK7\M:X)G_5<105+!9PT;]MF._K=7$89(7> "5_F2F#R4T:2%
M_P!&!\5 \ : (2(29<0_UC%UJ%ZG V?_!WMO&M74TJV-!E%1$.E[(2H@TMO0
M&\A6-B(@1$ ! 8GTG1@5D*@A2VFE5U2P@ZCTTO>(F$ :V I(WRLA044Z61&!
MI>F^[/'=[[QG[_.>\]YQ?]QQQQTO@_I1Q5ISU:R:<];S+%;-,DU!'"S&7K44
MH<E;%!YZ&W%9K=D?ZS:1?JKAMVR\_HM7P$B5VCJ4CEI7.\U2;!G-U*EO]\T[
M^?OE U&U4M5:CJTOWYC,C[A^6;]S\5!K_P]@;-KD5[&$,*_ILFC'YR'R<+OO
M:$3&Z1K7CC-GP"MDFIL/V4. 02]](QC6E;YZ_F[-JAGZR+Z"'T0W2,1=X"EC
M5VG3\"&K79YAW=5O9^!)/"$PF+RR?:%U"7L@[!<O:R9"Y7B\#['QO-K FFNT
M:L4SQQT.%A5IWVUDW9_'M9^_,@EWZP:Q%W;"\Z,M,Z43$99:+@5M"V8NZ7X+
MCD5])D^+ J\N92F8O(_$;<BM+2T>[@IJZ0MTBJ-^47PYWCI08&=LGQ[F]O2S
M\NFA,%GF\)Z8;KFKLLXVT?GG_YOS3/]23G?Q+(=XKQWXL&?6IX8KCDUI:\$<
MM+7ZMS$U^HW'AM9L?XCP85OY,,X.@3?FSMK2,),BI^OI)3A]\*G5=K"7FO*P
M+ZWM^KDU)5\_8&R>IS!4Y7]%]KYCX%;;1^C1+?APH$.#MX5P"ZB9([=@EGAO
MF4!J^ T60)V:_?Y-#&JC\6';/C;,U*N.^LC4#]P7;@[O,_RC\"GO_A@HDGIV
MXQ>E2VG:0&:._.>KN\#S%2MRR=W5R?>?K5^J3O5X>M+SHQMR EX@D &4X67
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MK*G;DXSUCBOG[,5>?Z QSX?9C1'W@TV/7FBEK"%E(7]'D%I+,?+9-XRP+O"
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M_+]TE+]) <A'"_BPOAF!!9HB.4'_W$_N /^SE\C^70ITP@CXR8%O?)D36./
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MY'S->^N14!_#4 :[R!.;+<;=0.Y8RTHB'E#3![MN(1QN8*H=*\):95LUKK_
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MY7=8)PRTI'^+,PN0L2,JMN_60+V."A':K2/Y3!KVY2;2F ^+,)P88FHM_PD
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MRM_VK&V0]3H""F<IM+<VT]X8KM\&Y9O!(1IO+S3"1*8HCY;IN3V.23;FVKJ
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M$668*KTYQ-H%Y@CL<B*%<9BURI=3=I.:.I^<X]^C,">9@:_?G1V&:/L'=,0
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M*'[8ZJ*-9N 4#KH%Y+<MZ()ID><2'-OL# MEY5K&57.7"5HF%Z=_Q3;,04/
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MPL#E2XC$S916>XP!R1>8Z4 O@XU :LH\?17\:Z_" O)N&4098+8P6OE(HNQ
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MN0!#18M$\;JQT/*'36FV1>4QO9WM#N32GE^7;;GM]LKI]K4[DZ'_C4I@EF5
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M=P3,;F&8SA7?5OLZ9(D:YTWLTAAZH<BV+CS FTN2M SG7$2.G6RVT.I%5BN
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MMILH]#NFXS?+N"U"7?L'6*XG1)00>7$L5G6.=AQ)UU.R-H[M=7C>Z4"'W%U
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MES^;V\^6R^,1'AWT$W&D>A@>L*P=),ENPM<>*3;#5D/.\68M?"M(0X*].?V
MR)TEW(@JG8]&[Y.D^0?X!^[NLR[+ZYWR=[+9]FS]_2-9[SX^SB*D H&<_NYF
MQ&+.UFHK$]DXA3N\-CI<3$@1S$QTAX/>DNQ;%&.#'""]#BB@V*7R><=I:(5'
ML6!O=9^1H"\[?P#^9>3%TWQI_@WCBU?Z1E?2;@/E_(F7D.M>M<PF0*$O],\8
M_";[07T43;D 2]6#?SY,/,<Y\S+) 9:+A0M:U+,UYKSE/<,2V+G9J3FG(-L
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M<:)"#-RB57LK]+&[X0N@9Z/QH!GT.5F$-B*C)<VS,2ELNX^CICI5F6!5=VN
M(]+?-?4F0KM)=K;O<WNC %\L&9TVWW\I5%=SDG+GB5Y=Q1OSNFU#;[.N'-;*
M^]!H_#;K^-[N2W?=/G OZ>99[RH477>ZE7C*P]U[WMU?,DQ\]@:=VANT^MJJ
M!&*F+=(!Z-2YB$@#MEY*%KY%[@X'R@XJ*[)%PXVE^BV#R\'(>FCM4'!*G3=X
M7\Q)QZ^@;*\$C5*>D&F-%CBXLF@<,*BD+X(C]^(L3P=9T)=:6/=)[803+I[$
MJG&%H8@A,)8%J2?*85C('5S)D!-DOX":$\/09,O@D@Z<U3.ZA9L(8S9^D#S.
MR]6"CXG:?AJ=S&Z&*"NK^J+H\^&(ZO90FCH8)T>QO&RFX)]02KOE[E_;E[09
M9 KN^A4M#_DSM_=7\?'/AI>S/I0OV'COX!TMC;6&'D?Z[-*7]1#'8]EW'[VW
M[[U[D],7[6RSH5D8YGWHQ&C5FF\'<P7O!\>\NQL#"P6+J9WQ<3BCK/*V"W87
MJC]A4BLGK](JC"<PQE)'^990H98]D"KPGA@2*R\UJE"&6[Y$4 Y)V@UV2WB@
M37:S,)6A/VWF<@ P5!PG+O(L#0.6L]=Y#6G7'_#?_&U/CWMQ],/FF6<<'/(A
M8"M\-^(T%"Z[D#;T1A$)7DZ/48/R"%PAGDS+70].<A\0 N!PR*IUKC9T$L[*
MXMI36E-M9]U:$4<W)&!+9Y0V.M5B,?BN\+31RX)=T0LS??IP0-'H]H&KU.^_
M7;]TNT&4<'OWRE,)?ZPM0*_)M.0SB;$*,@1(-T$#38 AL@%IRZ:9E-$JK '2
MY%5&Q6]JQIJJL >5N+D<8^+DUO;^=\3T:J?XL1-P\#[X)USP4WC@1V(2;1GN
MD 2M9?]D.=S^HYJ+[>=7QGGA!D_S(#4O^QE"\PA)G(K<9/DN?YYX,2>2DTY#
M,?%.HU1M.+08[I80FV@+J&_4<]?T"\[6_ U\EI0L4Z&6L\W)LU^_-<16TW&V
MXA!6=;S9ZUZ*U9;BT*=^>^?)/7Z;63##G;][ZM3BS1?>+5NV-?;P8KU/=PRS
M-N2NZ/(YY1,8?O-Q)BG;^O:B[3S]+_YWG#8[?!+PSK=_ID]XB!_X>2@+U;'\
M]C&,H8(F::U4%MMI'P.S4[[@M 2Q+4\I\^"=)2?@VSXCU"4=T>\C2Q_^S#+?
M$![OCD%_"-4M\0_-2:H*[EO_K3UC%I.HP,C#D1:._A1&A[))W4_)"D_Y<3*_
M(8=)QVO!><AR0& FX30S,!0+*.OZH!;<_NB![8\ 6$!Q+AV-+2N'%G$/0([T
M+W5KX\3  N(^\:16:)83JPJ%R6.8X[44MLHGB![YF\B[-6(^S5"Q!;[WF(Z&
MN[E]LZU,\?=I_W4!@K'Y@S;AN^N>]]GQC2\?[TI+Q\L&+WSZY9N#L\8@.9PK
M &[@[,4<+7)LSWMR7%, IA-G(Y9KX/@;N#^ 7[+#\T)DQ-"75R(C\:\*^OW\
MOL\L?W7!,?MSV[H[%3N_#\F8\$N:B/C^FRP7?@-FMLPNS5T/1X#>0YHIN+62
MM@U#KE  /0\>:(BU>/'R@>.8T_II83+.K< SZ-D(7W(HO,C'?S0VGW6$BUL\
M!%30FYEI:NNR6FM!0()M\12FY6QARDTI"Y3YI?;^,5P+'9!=*&:NA/DM@]8@
M/9W%0'-%I6;N-\B:/J;4[.*0&GR-O320F^UP9( G\3^LW;_@%.:1R8[6 R[.
M1VU/#OAMKN_M+7UJ)$B/CE[XHB)PW>K<O=R5%W_X,Z. C;.P5#[BB"_1@NXA
M.U6HIAH5ZD:/8 *H($[(V O4!^>)$P,JE/96:H<7I"]?((#F,A,HK(3PWC;.
MK \XHOZ!&W.Y\G>JWN@1\G=U4!?WP%MV$HKB5 @G*J&+PL.PL?P@^20YC^LT
M2"\*GR5F#$&Y=^.-4VPL0?>2:,NKDSC#?/CQ>)/%^HH[$H0<F/39<]_4* KP
M6GISZ>:S*;XCSZO<<^SC"HXME?2;<$\:'C]^6NNBX2^Y6F^NGMW\5'O;ZF.[
MUF4%7C58>F=? VII)O%=3"O!F!PXA.4RX$W!K;2;@VIB<4-34IA "^+TSZW5
M>F&ICB]CHS@IQ/E1DRLI^IWL512@"O[AIO4T>AF9>5CY\ N3LK-HC+WP17F/
MXAASQ)>45!F2J^T988$5Q.45*TA@< JBI]@'%O(8-[8&P-YNW8H@R.I'/FX;
M*!AH/O)[MW&++XD[N1+V:)WEITV%1U /%9WP'WSSB.QZ5*U,I.R[-9;UX+#G
MY1L:(\G1>^[XK$M?D^CYQN[.8^[R3:BZ3%NM3@W=_'M-2:OWO9I_9U]@*A8?
M^BA5J(=A>>$.#4@H5Q80UCY;=T!KZ^WA-LUM7PP5L]3V.R$YPHEN-38>@R,D
M69V5M*L!V^%NB+\;SGX4+D@="]"!T#=Q&-%DAOI[:M+<;I*O[.U-J@^\,M3F
M,#B\#^2GGJE_ 2VJS@N12 2SGP4?'$@3KPI@RU9B)9H[F8!9$5&W5@*\9^R!
MJA6&[N.RRR"?;F\63Q A#]E:< N8Q\TR,EW@^_%MKG$?BYYD@8(T6_V )-DM
M?A6B ]; ]P^!C/<1K(U?)G8!CXV6/BF9_V3E]MN[%\0F>+T:S76Q$F/A#6H7
M_3%8MD1YGZ0(CB\)R_D9Y*5.L%P()^OK>J9=/,3O[D*VK;/>35;]E2YNGS@]
MTB]X@W[R=B_GP_59<0]<?PQW?AEI&5HW+*^Z:FQ9=B#^TK[,\4EXMM,-M850
MK!C=^/CJ3J(Y;-8H-,#I2]J3A'J4G05SI0V<.^RQ2^#V)M^N]@UT"5$GW&$R
MM"0D]LGE[@'"%D:1X \9_X+;!6U/[;J@I@J-TD<C.8Y)45YFW "SKBBI!C=W
M95?41PWN[#)ZZ"+&DY$<"WKP,L:345/_Q!<>I*#"T"HCT*??MR'%P CDF6X\
M9ECLAC*Q+&[['SH]1"\#^1-"D-2$P:C]34^ !?A,!JRD;B-CFS!HZFJXL5)Y
M>4R'U(1?0/X3;,U&)T>2/H'('1G6P,M>EEWH&R#\-<^XXIW!DAG3C0\7OIH&
M'IC@"[\]>7QU*?+ :G@R"7C!;^ D"%=072A4F"9Z%357TX8U6"QN\QOR3B<I
M7"4ZL?*62[#[:R]G;M;EK-F^O+@@<3W&D_4+;U&:>#S>^<>S&8O75057WRCL
ML#LXSS-S+'3C0PU+?B$A[.#>G>-_X+XN<]DMH@?N<T.1-9M(_9=$I 85*H5H
MP=ZJ=I51 L?F=@&I)38X'>] KCT(&=_$N17!G).=$66E=HDWPVO2%4Z+Z 6-
M<1>K?!<E6##R&LXLR[J6=XO)Z?R/E-MC/\JJ'Z<C(DZ;?JY&!]TG='\BYGG$
M1-W"IR]=:MNU;]&25)RVB/2/3Y_44!F;I\<.?QG5^H.GLV"IR[K;\;W,,_^/
M;R7\(QO%>DC(4Z&N$K7M0UCH5, <6:S8SO]<4=USNH.Z1N$+QXO\(_V=I(6>
M7C_8K&W!K^F*-K&.S!5\BF :O1\X:5\G,3G)744\7%%7T7-N8MK<Z6OWH>Y*
M;<]P)7#P^<OK,N[!YW6)6\Y-/L-&G,D2?'W]57"BS&:+-#]K\//@WN'K^]9$
M75*\H/80%R+K%.H@(N$&8CTB7,I>2FVDF59ZF2&+HT%G[]XIXL!,(WLUQ."V
M8=Q)Z35W;P@XUZTI.\4T@X^^L+BLS'HB:^QSE^#]2,78-OL^V5[&<^5S3AAA
MH-M5602(BFB+.<& ((TKK. T$>;2V9J#GC(&?$D4KR^CPEY#OU<2=?W(:&)/
M)2;Y?!A[4Y?_%#9I<(W3-E:/J)K%[K,;\"2BW41RH8ZO3UA6S>^:4\,GVX37
M<<;%<.T/D.R12+AX#(\'6^\]#0DPAEHFDZ;"VTW@2V[\G U\.Q*:_%CRVBO&
MO:NR.DFC9+0F0EF96]#13#KU6^NOR#F*F?PLK=&#=HXT<$1F#3N"@"P-CI$[
MJDG_L&)YMRQ&R<;;C? !#75TZNYUI-D1P541;E+UX+A+SRJK2AXZ-IM9W538
MRMH\C_?8X+"/3"*G7)P(NM;>)'$N6DVS'R&#L>T-POYN9,D.]<S(OEI&<8:&
MD25^X?*5K]2(VJ]");J"8KN/^N*R/"BFF:C#_U'M-!I7P),7H/;='5%6!%/B
MF&E&N<,UFZQ2G0]L_4K6B:P)C=ECF"J/B5\B!0W4+N(BY /'PD_F$P[ 7JQV
M%E:Z.:O@.Z+QZ\P7C$'66[-,,0%&=)%OD8/AH]N7W'FF%;1.UUUKE>BZLRYY
M#><&+%VK5J(VYJSV=C2,.S FW&SP^HT*I;6"_DEC<]#IJ]MNG[RUU/L#XP5'
M84! EHS*CU$[<LWA=A%!<S",6!'=KC#0;&%4!#=S$G/>"LN3$]@:L*V(D*P@
M71*U[8Y"&X2KZ>64<&#M(65AE%]0)63@X)2<*&QBV][]$J%F2J%KPDDXC=E$
M^!Z4("8T1ECNXK.Q%'>0QG71;Z':@7PN?>G8H%U?*<M9)XZ';*^Y\Z:)JM/U
M9<M-3XX>.>/+IHBI])WH^S'6%S?'MZ[M,O$Q^;FGI,0P"&<8M"-H;?D"W?AQ
M^)BRF!.F]K RWMS]K&"2X,B0L90 RH0-5*S:2D.4K?!.$?-][("8>97EY2E^
MEPP"0_Y(HK@M>!?4RP(51_FXTQ$%A;+"YA"*[VQ5<G0!.=.CMGL"Y[A]ESWF
MRVLY I" \;$A%<K#!77L/]OAUAM%^K[P!(W/HKU.M?N_WZ(@?VKKK->EX^0)
MIKGI[,6RK(H76RU7E5@'G;!H7HXN/4,+#@.FT&P5JL&9CC@2W?^<9;SMS!RC
MV0;<LEWLOHW^PLM]6_KWW+IB*X7+.42%LJ'L^_/Y;\..-^\,_Y9/.LOZ?%<*
M1=5Z*]"_<2HJ,;.:0IK(G/>/'07.AU2HA_$SR+P/-*AFUM&R!SE[BW'D>PY3
MNHG67J3VXR05ZN=I)*M<F8R>U6(@VD1%-G.J\ON;O_X2^(M89M[%>,+G$+6K
MN)<GWT_\-@; :I+T9SPMO_A?8OX_%M,(WKCH)I;B=P;>V60L=<Z[:^IX<O#D
MU@\9ADF[%YQ9>EU+U,O0A\1,W<QN^;_=S>F=DUI0\ZP(^N/QWC^/[UM[WMQ\
MI6%4]+D2JTV;7S<D+;BN93]\X.2W7THC0_<?E[X=J);$'2V6;SXZ:OFVN#O1
M6<#_,S5=6LH,%\QB<D+7Q1G/I,QXP]D=<=UU?ZA0PX]I0D_$?G:]&EZ&DSDC
M&GDT49GZDFX=^K>&A?_><#0'<U_-ZL4JE'ZH:;(ZR'L2DKNNPSZ<]B),@+YI
M]Q'PZ[3W(VY;+]]2^"3LO'_H;&+U?8/#WXTO=[M];EEYW['UE@[1HP.WVS"?
M<]/N@7% ]?/>J(^7FW1(![JGR=;1'TT_D>SB(U^;_Z#]J]3^P1K(:')_;T2?
ML])I]/CGUY+%O^Q0;E"SZ4M<X=3\3@[H':A"M6[\IP:-KXQFH195!^[3'B"9
M4C;"WD-F$9[-:4,V[L(6&EIA+MEACUY1D&ET/1?+3CO1.7GX6\N%D:W<1X4I
M6XY[A=J%_-25-75B3]9X%]FCB;H4ICT>@$D->&.0>8VR,_C"A9A0\>2B$5\@
M<<K*L^35 G[V<0$^.3RPL/%"S-;E'PF&-6\N;%R^_YV"/UJH6)MKH1XP1NES
MU= QR#:/OS?LPMR-13>1$A"CWCI7)DP4$YLF=<+96^A'DEMR^,EU&F(=X^/0
MCTX]7S^&'X0S#W5'I86W733_:4P2]\#7_'!X4:55RN><:<L[WF>]T&++1G7@
M!E\F:9&#_R$(=A_V*8?6MR=&H5&PJSO8R[O)>GFNL$NQ^\+#48%;U5W\R_RV
M@M"*T)RZ*GI1Z-?1ON4^'QIDEUNQO438 ^>B0NVRF5O,=1E0_$3_>\-58*L]
M:3[%A5^*\RX<']0"\2]/#[VR#H)ZLRK$)'185:[C?<_J*E;79RBQ$F%<0*<,
M=]M83TBC^BN;V5E-@JZ^P4YQTJ"!ZW[0DOMQR9NFG,AD$5UC)"?FZJ",,']T
M%DBDN!3XD#?X'S"KC3A U!3TAX*[Q2F55N'R\7CWB&7.)B11?5V2]'/&6'3F
ME J%Z+6C:1W:[G/5A^DJU(J\OS<\1+\MPJT5U1(-A>2O_":UTX;ZBI\,C)@6
MII>R=$R%K:8%B:'61P0A.=DIX@JOBRK47E:.5E!E=^1DP8OJ.RMR5^@]OE5F
M] !DB@^D291')([)R$J%$SC<7'_:?EL1Q;.#@A8I;26&S;/-/]CLE]&,N7FT
MB(\! 1,IDQOJ:U\:MR_]0;DE[XB)\O!_9Q0#XI@&82)#BZH[RM# ;1(/F'&2
M'1RHJZI[IN@&'H$2!RA]\E9E.J&9ZL3'79"-[PZ4Q)-XU'5]TTQ=<M.8K,%O
MW*F@--ZZZD+CYH'"/+\1O&E%+ZTZPLYE?O=)I*4"Y,L^EMTM\!O'@.FC_.7^
MHX,KD9ZDCUB.&-/]I2!GC.LF]Y %/7C;]<'/M\4N0SI[[.]P\$_X<%!SF'0/
MHY@BR$=IK;]C#!76:B+91G2#T!F("<4.:N6(.5A$[V-,:X F6)@:78IRC<WY
MQ>KQ6,Z7N[3X_&=.MPZ%;5M_"UP7 _'(J=4;7]![T?^-@8B-;D=1=D(>*74N
M0T1]6+\A=SU4>./,<IC0:K$:9"3;<PS)OH>B99\RN;EK>J;&2P-=H^I;)B(*
M GQ_G=04Y%D!DU9^S?_7XN0_'.\QB74^7*=W80N_Z(_BL-[$JS6VCW*U?:]_
MT0T2F:KN4:JK'+I]]^7WBSP?=:7VO;H7$KFX+Y3Q8D3=M/I#E@_?_V+,N/]#
M>^-_AL<BZ'S&G_J)'[0?Z$U]J!M^0"K\H'VS57S#UMN_;:-C/NC-_7#\P#0[
MGFNEN;:/:NU#K];H9B]T79@E-;?Y(/?-+/$RH7M1-H%;]US<I"GUZ_VA]2WS
M-#ZL:W\0+_S'X$?J(WOF'XEKY0_;<5W_P_E0-_V0G'0UMW6OW=$_M@_GNGON
MO&CBOGG#GMT;M^4:';MR.+6\-%,RNKIS<?U5>2("UFJ1V 57$0'=/6+?/AS-
MS\]G.LH#9+EM=,S/9W%4:N)0<NF22'+ITIBHW"LJ&F)_IO]?E?K?+_L?QR^*
M_]!74?VO(<K\']>;^A]'Y5&Y#'5E/R?^9SCO\I]AW_0_&9^!3=UYG?\9:O5_
M7'\QG8A"<^Z^E/K/%^W?+_W/(&6#I08C,H7V&]G_?#'_^Z7_#+UUG81C\/8S
M]_\,ML+_?L5_7#SJU5&O KUF_W[A/],W^U@_6&V?O/;UA)[4U,M??K;'+=5[
M-['=KTU"HLI3X??J^'!^OA\U FZMBYLX%'J-3@BX*S0IG%#X8KKPFW?\SV_;
M_S/L-_S/\-&$\<GM]A5_CDK*+?XL^MH^90OHCN[ZWY_E@:TM]YNZ]L]OW?_W
M!^C;(Q?8)Z=4]9\)G/C*WC!N\S=O?R0S:B==_E>[]C_#^S/U?WP9*LW<1PT<
M]@;698$N+_&KOV'\;=W'._8B]IG^-ZT?[#]VOF/;/_G+-IK\O365#V]^U1<X
M_G"M5/;-+W-YXJ-?B;6\O%5SJ_?+M@U&@M)WO8J*#%^Z?_/\.]WG/X.0GO^!
M_+;>PH_M#\W;]S'_"9WYQ?93C>,/_8>Z?/X\/](?]G?%OI/<JL_QHDYNZI=8
M>[^BM7+S.^+2;TG4'L3GSIKX!_DWJ[\5_$A^[,]9X_:C_$/XP^=->VH?Z#=7
MV;]Y_V"^1$6U2S1O]:']P&9E-=_2A7]4+^:'I67;LV2:?W"N3%VR:D-;Q=4C
M2[H>E.C?4/^F\&'_\>[]M[H/S]^4?D!6^%OGOBOOOI[N[ZDJ/SR7[?ZQXT>D
MVNSN/_+0#V/.3'V4?8D[MJ+OV*G;,;/<)H7O-SJMTO]+%J]C^>R3^F\RQ,WU
MJ#O[GX'3]>??A;._;?V=\.$6YW^&A\OG7;EI?KS?^*VDO%#O2@/9BIK;%I^J
MK[G(;[!_XYC]\9?_K677OP7\X,W][>&]5E[XY,=%]P](N<A9Y(O,>7XT[9>*
MM^.C19X3?DS,<=O^?-JNW^6W.N?\:_^+[ !YE)3A(#\K:OT?X?I_G+_7U7A]
M%#_F&__-Y._<4OYN.9V/[>W_%'YT/Y+YS\!GDOHQ;/GC]=S98?^4+^R)NS5%
M4SBJHNER_-9MU_1,96UUU:^6<@0]CK!J?G?^UEG%LO3R.^^.SNUDV6RH.F-^
MD*?ZG>NK\3E"SA>4&-U R;?J/'):O8@:DHQ/;@)3MP@H^8:O&90&,IR5_N<8
M)O_UK?RG16M7<"P,8 V5"(V?ZB#+P,S ^()5A/'_30!02P,$%     @ <(&6
M6QHP]=_6" , Q4X# !(   !I;6<R,#DS,S0Q-3A?,2YJ<&>DNGDT6^L?-ZI'
M5<TUS[1%S=0\A?Q:!T51\\Q!%5$S%6TDIZUY/%5#JT4-$43,015!(DXI:AZ+
M)&V54@G%;D6\^=U[UWO7NNO^\:[WW5E9.VOM9S]K?[[/\_T,>^5L\6R#Y9*-
MI;4ER[D_SK% F1^6LQ46<Y9S_X?'?R?Y/YWCW-D "__%<S.L*:SGKK+\P7^.
ME?_<&8%%EH7E'-O_/8#E_SG._<%ZGNT"^T4.3B[F .PEEC_.L;+^<9Z5C>W\
M>>;59.9UEO/\; )7M&Y<$'0,8+\:(Z3]^%GE1;F;K8/"3E-4>9W V"<<G"*B
M8N(2"M<4E915=/7T#0R-C,W_M+"TNF5MX^SBZN;NX>D5=#?X7DAH&"0N/N%!
M(C3IX=.4U+3TC,RL@N>%1<4E+UZ65E77(&M1=?4-;>T=V,ZN[K<]0WC",''D
MW_>CTS.S<_,+BTO+)#+E\Y>OF]^VMFG[!S\/CXZ!7[__B^L<"^O_A/[_BXN?
MB>N/\^=9S[/_%]>Y/Q+_.X#_/-L5K0L"-QS9 V($KVH_OBAT\UEEZR"'G(X3
M53@P=HI31%Z7I$#[+[3_"]G_&K G_UO(_B>P_Q?7,@LWZSGFXK'RLX!9& RE
M*IPA8@.-Z  /.RP].KI.6Q]N?BJQBTKK349!LP>6]5\VK87V^&<(VF,78+;!
M0?6VO"68Y?4PYU735[;G[9*"$Z3,PFV>):$E4=6%P2]RONN-M>7(UYL+OJ1<
M!R0$FY5OYD#($&*A@MN=5&OBZV#YKR3[6$>'8NT'#@3R[1.VH55P6<RU(&Z+
MVQ<LBH-T?()!\E><A4%F%U)HP@'I*#>,1!Q&Z0;Q-<0-R7ZML.&F0<&I3!7N
M#\1&_CK5,3\7T>&0PY!C3.*P:>^"&F!>,[VFE71[(+RQ.>VG)N<JD#_0@\DM
M(Z*"%%#I]W^.R_QJ5#_T9?>=CL1T #\T?I:Y_=HL)ND>WMUC7&0LXCHT<W ;
M+14=LCOU9%F)I34Z)]7@B9Z=\Q"#UX$+>F^>8C=[_V<^RYIY_)I\Y\Q5FC3E
MY>&X74W6L7-W5T*WZZ6Z-'6<7=X&]X'F!QUZEZ S"SKZR.ZT+Q/#.8=*(P;O
MD@HAP7-NXL;[KPC#%JZI%Y6=,1SV.NFJ  A-M!>8T/;CG;SNTAX6 ,QD5@]Y
M2.G=UI H-U";>!U34&]N_(:&"9"S,50>C4R][6K%N?BP<&NBS _*6)GR$Z2%
M'%6<EIF=]_7T@-T#UJDX4G%EW<CF4EB_#JT\M1+B?EWP<8Q(V:,DZ:VNH']*
M+ISC:@FV"FQDCZ%2R,UX<(Z,=/;P.F=O,HDOHU^LV.UQPOH%:+HM3>1%%\?Q
M+K)G^D=DT),O%\0Q7[4^\!>-1@0K?M[\>\09;R[IS):=QEOMB,HNE^F(GI/?
M"QWJ?5-OW>\>+-ZY<Z+S$Y+4[^PMZZZ*+ V>BS/6BL.4.!-)J'SD^:K5!I*<
M*UEY6'GXK7VIM8TZ+LF_OZH__(PE[=_30JM4NBO%_;2JGW>$!#X/?4:7)D]>
MLJ/L\>*1W_S4<GW7\24+3NM7KW6TCLCCEO[U^S8LU):1$W-K;%N6NU\#I@',
MD#IHZ4,.&7Y\P'-28G?!S$GB(/SR#,B\=B3QDEO!Q*-<;3(IHFE*6C[<.U\E
M1NK9:-#^9TL(IOBKX4,G3,9 4*ACJH5E0GA ^#22LRWK=9A-S1:1OU[)1N=.
MA/5PO<*]EX;W]ZX1%])$V5]]>=%KYZ5-F,:36@&;P^T DI%S&=01Z9:@:*DG
MIQ*+%NNVC"F4*GQN5>7H*7,9.]<<+QTY>6,V+;?)=TNBJ"FW4:]#%(V$+(@X
M6Z @=B'Q!=Z^V9(C:=]6?"RI]E>U;N=*ME4,K0/RLKM+)W_"H #FQ!8^ <:6
M9*O#'&C>)+M]_V\&'*1\;J@-5 UDVK0.U1F1<%Z$!MV:VFV:Q_M(*'P67/W/
ML=9PO7%'/O\-T>J2Z!\FNN\//FQR.'.I2(&YA7T>2+BJJ-VM"PKO!:F2ME2T
MD4Y%XK4T@2)(+$JDIEJU7":1^-;M!J%7$2^>R@V+\0EVUJTLI&Q-5:JUE6NJ
M#.%%G=ESF]5NJWXD!-;;+RKA>;R$MQ79#7673F8LX.*(01=P!'A9E10U<L:R
M9'+D=%I #PHF@;/ XMAO&C!WA&(:2).\M/&1?H/,)<L)]9O;H=O50HXZ]<=C
M9#.QF)O0B(UW(J6Z:NV8=_V,@DE229[<&<N3=_GBMB?)@->FA3_7#5!%*XTV
MT=EO4#[*E_(QK$MDE[KJAQA2D"F*:3 '$\+TO!]9S+[)<R^5#)W7>F *D1+-
M8(SA[W73QS@>(_/_/<@YT,2KB-']-+!J*'Y;[GJR,HDZC7J:9HRT[M5007K>
MN5-MY%:D.FB[V>JGN#&/R"714?(?XB"_'$2BUSE#Q#:S1MOH[W@RR%+"L'CT
M7^@@K2G,2]=192<D]\@Y*SYN9W0&RH$;W3T;?5I?U9\TAPMW6,K_3Q]0A JO
MD&$(;8FNL\NW/267U2(IOKRC");)NE5).[-U FW5SW+9=WQW4;^S\_C<O7+*
ML19Q&H:M;(+/@MOST^ R0")Y) -N!%.=,I.$]LSLK@G3.NLI"+Y%X!&A^'&6
M[F^1RIAD*>,&R^WWUUMU.C0:"U*"+\,6COQ"3G" _0CC=S3*]C2?_V2Y2*G1
MPCC^C"5Q;P+)8=E[17+4Y6[#L*&>W \_Q#](W]X])5LN&R3,-JF81\V4TS S
M0-6M^63ODQ,R.Z4%J^+R)17T9["EG8N]ZJ>Z9G' ^L2"?@$X%*G6'(S* ?/"
ME7(ORT%: ;GA'H.,2-W%SQ'/QI+#4)_&$\*Y"V0UC+ZF7DTR^S-VU9W$MX.D
M.9/AF#,6MME3=+\L!,=/3VJ LCM\A%]%A$!E'6D/<,D;IX9;8]2?B_IEI%?H
M7_'>[.T&!M?6;$V49#0[[(5;=1_WO4:EQKPL,KM:%&:K@<&_U?/YVB\IFH[F
MG*NTQW#"!V_Z3;B$Z/G:Z[SV:@,BY!?&:*(91GY6WD\JTU)T&L$2-#/)M.@7
MJ^\DT]%I>%>"(V'N]VK#S%$'36AKC$<E#F434Z(#WX\).V.Y5>BFF0FSJ +,
M\3W'V2#KNALUP".\L3ZJ^7L/<B:B:Z8C5V8TPMRIK^QO>8OPD"C=R;^](9?>
MO&:E4^B&IUW@#:0_U6DR$W<)04J+@DO")RK:C_'C=O'/:%QDQ70UD#5Z>W_U
MU\R6;5V9MSG-R:YINYC_&DK_*>F4<VT!/R^J7]\0;F!@(#+M:VD^M$AGY 7D
MH#(&@I?NN7,Z?=#Q6>!7TV?E4?MS]?I/GZUI@CO:K_>Y2]W'2K?8<)>WU<G
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MPF_3O$H*1G^:%-Q#[<=<:(T(>LBZXB!OWSE3&7KW@:4*X@9BXW7Y51I[-B(
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M<E&U:?B"LJ^"C6"F_,WHQJ>-B'L.V3T_6DGY:;*R9@+0 X(7&V:.T5H%^(_
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M% OR4N[?TZZI3AM\.^.15?CIEC)\V]$_#=?5GQU':Z94[+C2P*0HNI WZ7B
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MR&]N@^:B95/2A93X:5I=Z00K7TXA>97H]2&5B36:'-=&57^M,QL+BQB\ 8:
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M30:X04LG[1%R'PVF6F7K1EV$5MR>QX+YHMZ];7%&>RQ-*HR7GO9,?_W8,=6
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M=%QY38I^6>O-?5YY=I!$$XH&^]3MTX/JG814/U9;">LVW*0]+X2;9+7U7YD
M9C0HL..AQI7,;H3@P%L<SP;@(.R<1ON5=Z/<=7Q[H?IET'6/G*DOLW)EP0VY
M$HL?KBD*9XY5/M3S)5<Z'SPZ<CY%P;7HS #WY 9\U8L]'>3>."+ZI%^1;@H@
M-B*\UK9)FK KE?2_WG5.T\-$T_<$[OSV[:5Z?UKUL@I3\C4^]NGKQ?([1+<M
M?)O<B6&NWMO3O'X%Q*!VKRFE61(&GM&;S/(7,A."5H\<G[&(-&DVYV>"-)NU
MP]TEK.ARQU?W)4T-'*B;BY@K/2W77R6[>6C:MRP$?LF"/Z8SM?Z)*XP#"#KA
M!RA'UV?U>)P)RXG#ADV'X(P*?KNR\C*RM -Q.CG-3HZP;%$>N?NS#J88@PP#
M4_/"M!T>"=U9U%Z;3-2OK+,##TBPTP6Z&)P!U.^D>[@3#9CN:6\O:RWCP\.=
M4F+I[X3C5#TT0L*+F48%/N5&6<_D>,D@DZH](51FTD-5A3),VF8T4+U]%X]H
MJ_]Z?]-Z'? L1'LRZ!^:GAD?P9T",TM22X!XI@F>>"M5E@2TQ!:&E)#0KD6N
M.=7^LE(X80E'C-K-(GNOMOKWM+<A:;W>>'Z2Q&OO@;E>Z\$ D HQN@R$YO)7
M^N#/2Y-1-2'>TTK9^@KLF'+&!Q>1H]^ZWJ:<,]['6W&HQ/M0:96[8&-PR'HF
M7(N63K\T>31)M<HXM,4XWP"":)JDTY(G;OO6J A):YIF!IT?X_]-/];F0^O6
M@]*N9:RDB2&ULV![X<;-(=K54V;^.3]VF@)G VR/C*CL="%)IPZ:;#8X])/@
M8(4 0PUJY3T'LT+C*P&(PX70-3UJ>GJONF@ZIFG!;O9GN"_8,BNDQ/D)^:?]
ME'F('C*UT2WWJ!_'G+-ANE>!>?I$6]@QHIH,E[J8J=&&?SPGFSXB.^2K1^[L
M@NPH8B KTB=OU[D$;]\+*\[O9N[;OWSC_6WY6D68R!O=%1-OI=KB'_Y8W_$C
MJQW7$X-MIJHC=IY2JX\B@*?UP".B!.I)KVHS-(ZPL"SD/DX:#S1]1#"[//<C
M8E=N+@*CB6P[D>E4"S9X4+QGE.=^G9A7!UI3H.QT=MI6:,A^4"&!.PT9_9K\
M?[]I(,6(,63K"P):%GN*"E)<KB\5:S\M@PB\#C%P+N[3?SNU2]5\NO15- MZ
MTR>X,.!  >_'%]"V*A.1'1_'+>-,U(6BQ?/&OI%6&UR.7JP^5Q^V+)<5Y(Q#
MVN@F4;'N/Y;H!TQ[*@$.]%\Z.5H";$]NTX-/471MN!IP/%PAF"#+;M:*V4[<
M0G\3@,A(3(/<T0#>JA?[+LO;7VA[&9>Y=DLO,[!H9^96UO*LI&>4^N<)9D-H
M0;W^!UE?'LCT_\>O3Y\28B%W[%.N<I8S+/NF3X18D?M8DAP+2<MD;>78W/M$
MB+#*E5ON-!9S? HI9X[L*G(L[SG6N\S\]OG]_OS]L7_VQVOOU_-X'*_77J_W
MU%NZ$I51CCOPBO)F_"96!5CL%<@V4L>5U 2\05J7#G>>A$+CN ]5YGU]I@<T
MQ_JK588^_%M5NF>K+1[/^(?:&K/*9)-3BZ$[)'RXZEZF^>H.-_Z7:Z\RKI99
MO>/*4DMYH10L_RED:2<OMAPJ$V)Y_]MD3CFFVI$+24);#<*/?U$)%3FU/;(J
M+<QSM3#/ >R1F7[!"@M/X <SJ!G6XOA]6%C[/R@7\,,HG:,\MU2-X8^438<2
M+S]9CGJ',?&I/:M%'HDZQN\*;B)'X1Q3NZ.&EKA)>CA(\G%@YV:"^I4F15AK
ML812'L5)['(M@2 KZGTR,:^AYT-8K:5,O5N_;R6?*@J&]RD>'.OQ=N.;]08I
MY>UG808@_4>\=*;U+RRV-%W<']9P^N6U6Y]G7F<&$RHM_T')/7$IV[K7_I(9
M<N)<L>-ZA4 LI'I71*I9&-07JB7ZS"]W9!]FB?9DV(D4,ZZSSQBAA-XU/AC7
M36VR&Q Z6M$!N)"<Y"D0[0R!QDXV:U>$B#6L7_[=^L*'N5#$@$BIHFRL][7%
MLU3NRW.V!F>+?%PZ3GV8VK@PV7B\,6M9HOX3Y/.B0"R0F\"[O9.!1^V*3 _V
MX:4%RBLXPYT7FQQ_&DV93BSAG@,C_V>.$R?3W+-1(Y6A\LHE";&W@MM)B+$?
ML*?7]YNWYPRA-HFKZML'L6=W<H3>AZZ"&YPWY>8E4,ZRH0J^?*]V4J^U/,D'
M+^F)[^G^)&LWYB94\C5W."Z+JUJ:[5VZ@5+GFB^)F8E!GR:#*_JDWTP?]9%O
MCM+Y4140]JV66VZG3M]K3Z^7R&%67EON+PUP#DN/.GQ%Y^Q[ VQAG5%BY]JY
M>)C6B+#'#]$A?=BC1YQEU8&V="/*7:AQR<,^)A#[ PX?F'H;L&A;YM \KU,N
M*\<)&;:]7%H57=E3JD)D+_)EM5GF/=61H(8A)[)$,.ZOQ0VJ>.NWEZ56SZR>
M11Z@GZE/4W#BXE(8;Q: ^OBY'Y[U?'M6W(9<RQ/IZ=B9VLVIR'TU;7EB0![G
M5)5@! ?;R5I#TQ_  8>1%.B?_+T5R_?V8B)YK9/\<W5A=^G!3F$S/2SH(7_$
M\R]>*"[FD;:R0TVQ;F=S\X0!,T[)^X(T].=>WCUALD^#Y!YD0_# VN<-METO
M]<"7%;@\[J@G]G] 6X:UVLQ*'D]-=J)9TIQV^;NY>:O_7XT?(TR/+%L>?+6<
M>ZHTRK&4/BS7.>/W9('8VT('-8C\PW$#5!$]Z@UH,K253M.MC_?_8S0@@4E]
M>(=T$'5I-JS-TK17!H-TX'YH@Q),.&B*54FLXYG',OZ8AJ4QGYFRVE+"Z1]7
M>0TPC^['F&S+X5"NG.6IZOX[T0H.K0&]B@<[RCT!Q>,CT/CNH,-N1T:@/@KB
MXZC186^:3M1"M>.T<T3]X(UY-; HF8%39"Y3%'QD+=646.N>UT[^@A^X,3UQ
M\%>P4I&#DGMP092:)JOQ2(5$WG@/JZ%E_<#.7;?2Y[:-]0Z/A7;XN(#>=0AH
M$SI-1B:]H6* >BA$^>XK;EDS/ D)&>E= 8O9_9*,-T([M[ $,S>HU2#X9)AS
MW'D_M:P>F11C=5:.Y6;C9Y'-Q 2*Z+8:OENM#'R^;0ZJT,AB71K8&/#4MADF
MDH7(A*FB#$BL,_>@BM]_0WF"Y^A*GR%MRYPYRY_)SQ0<EC2T_:C%6HZ$S+]_
MK['@?%DK3[#EOV5GT&O[$%@R\%N-Q)5@1A+YJF;9[%JUD<OC6 V!$?"0>F6C
MIHXUUA)'@H3=O5?$(UL]T5_C)"[=5VUN]-&OH:R]70.U\1S-.MP07@X?9#A+
M9.^*).'TL">GK*$8*'.M>]"06&"2.Y/7\QDF&U7IO]1UU'*^B5DK]=-[8K7.
MCA#XRNFRZ9'0>:B3)6JD<<Y>Z1=YJTVC.B](,&N5V/ :FHQ9'5/*OI)K09DE
M<I5:9:43/76D2V!:6@0E6TQ.8J]S^E^53OTZI94]%5^H4I@J0E3ACD=2F-U)
M%G5_8TV"'BOLTOMG[3%I#=@SZ=T+T!E,U9."V$R(7$;A\X3<P(2RY$IWS]2P
MZ)SC[D70Q=ENO.CL /F5;38#O@_??51@ HZPH*D47;5:YJ[(S/;?D]CSE;XH
MY9TOTY06[HWLLK.,,504T^(J]"I"?*"ZZZEI;A"*,!Z%.\/F+7(K.!8,)*B1
MM^H*(-GH^@P8A$62X9_CMA'X,<_!#U9OH')(T(Y9^Z,4=R2T2X.P))CY?2^T
M;<;V66[,#[60S0PU^\<U)TB?2 0D@$""NG:K&\P] )*!X'"!*AJC*T]_HBVI
MA(MX\,.0XLK<T6(MLU96?\/N";'LRF]EI8HL_"K'JL\I\,\-)Y[KX3B7+LI.
MF= 4>/_D!&S+\,_L%'>9\(/;N<$#)*(8BJ5OS/[R@V"VW&65J>I,OQ0>>"Z3
M95$&3#95A(67^)_=U^OQ:""X?/G5T8Y&'XLSJ\&J7TV:YK*E4X9NPP:T*OHV
M/N3<--!-V;@X)>;<NE>%6)96:V=9IJ-T7]Q4-Z#:8W!].2M=]U("+8!S\1>L
MK<?9H/<6Z3 #4(++?:6X^M#N'3D)@*NB?WQ5VA^0W+,P[6[6A4SJN_7AF&+A
MHEQ*2=( $YCNBK:5J2;TC5=D].-^E:Q7"\2SA14\MY,K5'2@]F("3I^O!=PL
ME@$S&&(XQ>\%%:EZ:(G6#C OE*T[;.PT6<H=5U"0G0WSZ!%\0W\Q^S%I%6LR
M_=S,C!%*.*V_*Q(A[- GY'72VK2YX-\U(KQH&'<)LRT0D]W&8V-!]6"A@GJX
MTP;39'TQ9D80RS]C)0';[)(5LR[);+>QA?B>,7?P>7T%87/M$.IV2)<R:D52
MQJNY7CKLGQ$]<5/'N"@TCSP'F99E?'BS#<,-T?=9'P#)[J-H^B&L,:#VB.F'
M]/AXGO5]ZN?DL7.PWR'C?[5VFB65SLKZ^9PUKEK#!.HW8,V5@CU][?8Q;H<5
M>CFF1M\TEV._VJA';-N$"=UI OE5NF[@]\M%#F%E=A;'M9USPB9.;LZQ[8H$
ME4RB.!OP/[Y0B#A'J^+OH;73I=8IQ;G*;;SSYDBS[@5/?(U#G<*)OFNAEZJ^
M?^+=0BO7IM"8E8&Z.NA3L+1?'"&Z3^+?V^$99#*"2/_=>:TN4"!. J9H5"4X
MHQ':.-6#5!BL/L^$IEC+@I<9:_):*2^'R\(\NE0F87YLSY8,(WV;N91PUOCJ
MJ*-*[D5RTXC6IS>AT/)=D;9=$;XLGE7!B=QVQPU!U2BR;#I1H 2,=,L#G[EF
M&:P<KM(4VN1CU['S; NDC;)SSOV*H2GYLZMLTJ4W8[TQ9[U*0PH??]PIP3.*
MX+)=)OCN"_#@R%G#O[F+#S9)1+HHAW*HZR^@JUK((OW>CP72DUC'JG\+++U#
M&[^3)'^OR/^CT=91]G3V<'O.\T*-RX-K7['(1XR3L&-"TE\*X,9Z[(TB[&]R
M:*Q,&CZ5,^';D<&VGVGQD+-TUN\S>?K8Q^.7E#XPF[J1/MN;)*B[=NHU#L]J
M(TRW*AOE*GT:,CI2+^:2&9WZK0A#E[0Q5=7ADO4*LATD3_APHP7BE[<5L7^"
MYW9%]LGL_-,%X2L#PR,]B#U8]"AE+Y.J\GU^_X3A)J-52*V]<2,BJ(U0!5G?
MD>@@Z]=,@KQW8_/86?S)K!_+)RI>=X2^,01/&*[^!&)X:O]=?, @WZ.O4AE/
MX4E&=%2Q0IY+\T?#EK/AE7-@-,N<T'R]DX)Z,UN=;]B2(>O9.8H]=T<+4NMM
MO<(U63,9%5 $,U0  4VA-T]Q*K>U<:/SLMR1!_PSC%V1!WEJA_+ZO"')KKV2
M+#\_F"E7&:GBM"MRX/=21]!DGKK?]+]ZUY0S=AX0OBKYE2:S_EM[MX4SBJ"'
M\3?))&@CO2_R#\S:6VNY3[C]RU%?,&1G;AB8N%Q0UH$9H15K:I\5#(RV2-C?
M,.LXT]>0=JFX>U_O/VWD;_GB=[[![B?D..\KR^>JACWQ]C7LQ5BK5Z34IU4[
MEQM+VRDA]B!..1O_GK"W^VR;7A47)!SWTNUL+-:>(0A65M.[9F0@1OLT=,KW
M?G<L>9][=\#MWW(OO[5?=/9"FM5G.Q@3>?<5WUU;3$V"5L=%QCJ8'CY6\BM&
MF!<5T(M)$LI6P <^O<&$9)"%4C#1D*4=;ZV B>GC=9B51)7.+W>I9:T-Q'1D
MID_Q:O(.S81]^ER;Q$U))'R(370ZTN6;PB8#ER"?QQCF- 2H UGM!+29'H2(
M+GG^29!=AC7]1(EBTO>&%1"R,BK [/Z.D00^(K+,MV7HI]DI3!J-%^6UW/ K
MR\?WPM@<15*_MQ\QLY9!!YSI0D%Q&,\HI^_=%0D?UAWPWSN&4^6?'(6="*X!
M$9<0A]HR#']0+*!I\F?+]5OSM0A7WX3CQC7:O&LI_]28[WOV3_*DK6"2##C7
M"P=JAG)^;I_$35JK_-<VAGNQTLA]^!XGYG"$X2%XFJDM4)%A&GGXHHEFPUCP
MIV\*DS^!F;_1DK9ONXT<U<5<KQIG<Q?V[G%-"CF7K$EXR\!:#C"B'A^%V=!&
M1XHL=T4\*MS3KS)=Y2L0D-6J=J>S+\M.?ZGPM6.J13YUX4(4/!*>9PQ'1RJO
M%\[J]HV7Q><:4<5LRB$KZ)?7@MW<RO+:)_JW[\$V=RI@<TOO^FX+G 3S0DN[
M*])C^+E$(&XOI "P<^<)1344*-;'^P#2$\UTB-_R'ST_XO I]_")!A%%A@9U
MB^;*(T2T8Y$Q\F[^E%?RK[8ET]XVHQ$.5?J*W:Z(Z%]\O5B1C"" 4/R)\N2L
M%CX8JO*_,J6&(\TO/Y:+Z1][,J5G-D6'ME'YLFTL(B=HVU7P'JI*46#7[\&@
M:,@]Z#-2&WV6\%2%7FW?">8H[J\E_Y/_A.RU'ZVOT<A%62F%2YNJO-GGF)M1
M<$[Z6B&=PQ4^] !8S=W@98+AVTC!(%G9!)) 5N6+57R?\5T'VYS&#>Y8C3%G
M,VR<5/Q:.L?TT/G7J*D#KJ\_F9X10I/-N$EML,-Z0+$C.M/S1\-@.U6SC[%^
MT!I53-L^IR*4*O+ A\#\0%Q;2C%$]0G[\/K$D\DKRU,YF@Z0W"BWU^JF<=KH
MJ2),9)\%+J@/_ !E.I"TWU," 3;)Z&*VGA=.O#@XYRM&]"#WZV<O=QKS!$LU
M[)_%"FTBNLRI;/CX.EGNO\:^@J<)B8%1_.?#H5V1_0<TT -]5%F&0/3TF>33
M7Y77D3,2#/P#:@@=-/S1!.!9.>4E55@8UYP(@[S$5-!^XRIC2OM8J$AQ_A\?
M*8X5WPLZ^](?^0Z6^"[/!"469-2X#&CV'E(L*1 -*H#7;JZ!&G8<NTK!)+VI
M@A/#C>25 FU]NR+)_E)@FG"^1_@WGGI_:@G_XV.HX/#DS348G E/+#![5-KU
M%%7F'<J=MUFI)$.\T]Y-LB0M#VW\(KLX"E.P#CXUY\O=WQ6)+.=./91EDOGJ
M9ATNF)-VK/W<3]0VT#$<6"6*.B$AM27TGM__M"LW#>F][PD_V-LP23S\5<D6
M*G%N7R_F7GMA6\_<MGI)9L\YE;/XR"O#QSUZ/O58?K[GF?S!I4*GW7N]PK[=
M1H[\ZO'CP)$TAI0AZZ([7+8 <#>&/!RQ_N>(:M^3FHI3U;G7"ICB%@;JDD^N
M&>\C]$WU.!<==\\XB),O\K7)\&XY^8ZE+O9.X(:B2V!%MS7PW;%=>S"ZO'O
M#I6&W =2[8'>>P.)FQ9KLC:H2&4,HJ\C)OFF/D>K/>?%6*3FZ$W3.V/I&4'A
MU=VJ$\W2>E&]9#.0/6"YV#\"ZB Y;BQD"KP10L)'5N,)]];2^=),2(*_\A3:
MYXSZVZXC "E5GZ+Y E60D53\D*5!^<AA$KY:YVF6U6:,I&#/:=7>V9C3B&K[
M0>\G@]IVO6LI2,"5'"]D]_TD]LB>SWP8B"X'G>F^0&:%0K)"?XR'M4H3]WQA
M=>E.GE/[QX7XM>VP#YX+E/'5TN2R]Z9O?D7!!.AM&V&1Z0DLO7$3./6=5_@
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M><L/:17>X-,!K@](LV_(HO7F6IKR%93AO>V1=R1"@YJES8KJLB/&8)^AM4C
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MB+6:M]UIV?KN>5<OI+/5#'FX5$^.Z61XZ?Z=\1:1BE /C 7\>Z:361L9HOW
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MNP17F,#:[(A)H07^VU2XE-"&;TEL(8E-"=%@$<!C_?*YM68Q+!?]Z@GF&OI
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M<?K9AV%WN8:62F$_6Y8X)X1.M&+^%;/5J<<6*MPE+]_4#N2'=RQN1<KKS&B
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MFS&'R1WCO^EGO,PG2O=/.^9(8W2+>$4V#(85V<T^\[>22MM2#_O$DZA'R/T
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MYT]W0M?%=G]@E?XCA>!'$VC"IA]=.Y#]6"@#U2U8\OG:1"HOK&\'<LA4Q<^
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MK*7=$\%*>KRW&LACUC7(/,W^J4"XN[6:<<WLG'/'^<;1]:--%Z[9G9R_SZM
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M8-VSW7R_;%DAOIGM%>-U]L7<2N,*3&Y,^MF?5W+G%G:56D>*,_N'< +,N[>
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M 8REV(*87$I<<UOJ6P1I%/HCWJ;E$F8K9%E\T[(^3]4S#+YBJ7T88MT-3$
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M>0S0?J'(7OP!M/^"HR[!>.OXP0)-*R-4H,10< :_G[NR,#^;S+N0ERB N1#
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MF[]V-V?*L.XVT(<O %&D)&JKWP2(/J[]\A6,+\GI+YRH?K"K-C00Y&@26D,
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M/\Q^%U^[U\59_4XK1S)-*FXGW^ZR?JB9(R* .%N3$#W+6JU%$_:IS]VJK'R
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M!F0 ]$#9O.L?-/#1U!'[H9G#8-&,1X05H[C>2#;]@5Q6CP68'_K4 N"X[SM
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MON_?/Z3Z?'QCMI ZJWX]?E3UF6+9JJ/_14(,,]RKE$&@U?\L!D=_K1L^<C7
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MKV'_@S6TR-0N%;36NT"DH,C>/[?)5) .I88+AEFA@H9S9 O^>KUK!-"$_\W
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M]ZW_B[;W#&MZZ=I'8T5!1+KTK8"(E(A2I"5;$1#8$$'I)5N1&B'2 X1$0;J
M@H"B$*4C)0()2$N$4!0V(EUJ2"+2(5&!GZ1PV/MYWO.^S_^4ZSK7.>=+/I P
ML];,FGON>\VZ9@ZJGO;,NZV@P?IU^QM*:1<4I $A<+=W08I"OT+&24/STT-H
MM=SVFPVFG4-?G6?(4TMLZH2E/(7GM_'K$2FG+?N7_J?EHZ>:8@6>Q?UR%#;7
M]KAM(?HK^*P75>S!G30FQO>K?9C^L5<IN?_B!9U@N4[;:=>/LDR;5/6+E-,6
M8H/OCF7VG!:I4ZPX5E.<</#$M8I_T152Y@4;K<"@+#\/V[I'A!FU%I5FQZBP
M:-Q+&T$;OQL5UJH?SUHWV1PU/&OC]O;;TP _R#7WTE^>X1E/6QWB>#+F<W!9
M+$6?][EM "F-EI4G[8*J8TS^M47^@*7LL2.*'X>?@0-\P),*LKN@D16F#U6>
MN"GQ#V_YG-<RBIP)O_+4O:@(0%,=251\3<F_^$V9MO)^R;2GUUH8ZE(FI98;
M5^Y)1>S7TS2[+/5!YSMN+8Y%[28?, (S':T!9 EP>X,.7A-B_\$YS7W>*E.%
MHE-OC!B)S^U)B63S3H.&:@9>Q'=2LZ1PF:242.%),#&D4.0QYY7F?2R^Y'6"
MAB[#=?CNPKMW\-Z!Q%T007+-F7EF8^O;.#YT1K(;OL>I8Y^A,CJP"ICS*# M
ML0N<-GL"V,?,N,;-Y)U<V9'L3%/80GUNC?!DG6'\/LXQ1]#6%+OS^!*,'*N=
M.1JX3H@BR_HCZTQNZ<?HL]^RW*.GRG[]VM+4]CG[0XFML5GO2-HPK?FT-E4)
MQ79>C6T_6;[\7NN 7'#4,;M(3]#:)170CUCSZT+!:K_RN#587WBR-*XK8TJH
M1_X0\)SE%<I5V'+9,Q !E,V9KXDRHQGP9&VA"=B6%ZNGIQ]!MZ\>Z-F0XQC!
M94U5TB#\J S;!N8W(L/P!?DA5/Q6&U/WT=U65X7$-<VRT5=; \DX@D(/=F*!
MQV_,=N)XL?2ZL"=7R+7C]Q6YV;L@'VPZ7+!F4Z"%O!\MC$W?!1UV=&#RK=G.
MM:GW*Y<]7/N)3=.:1-V@=^Y$=1T:C\.<G@ *>9<58B=F8PJ)JVMAVQ#RPE03
M4E#I5V16>#B0/SD_O/!7==OFX R.#'%4NJLOI72K#K1\;5F+.I3U3QPC?GD!
M+]CN'&N6T*K&GBY<!0R+>:-YU [XI)H3-ZG5AQV"ZJ,/))'.]='@(AP3ED([
M7!#KPQ$!O.ADT66#^+;Q-&URAH(4\8$GG2IH'6-4H,YLC-V<L@A8?WV;A0&
MD*UJIF,G[DME^RZHP3&^U8?YXSV$'TAEPO;^(/&3+(FVSKT.WP?HM[J7+&6Y
M.0-YXZ;O&L? -:$:X3L;E" 4PJHYSG[,R!J!H/59,)K;+ ZD7>402/AASH?\
MH^VF+1-]V6CWT1>DCTLD,H9\\S^T"#S9%MMNPXE!E@)3'5$%;4R/'D?FQMH$
M$['U1R.WJ-65V4<OZQA(R(/>YX$Y8JF,EU@1CB-3D2Z40LA0F  R?B<21R"R
M@J=A\GXD4=+HIH9,CR/D]#!'#5G>Y8Y;G6?#>1,X@MPNZ#TR;M;\?<8^C@>
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M8@V]QHSM0R(8!W_)O.>=XA8;09E3O*,]M(%XS%DFMA,YJ=BMP+R&G;Q(QW>
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MC^_>.(1J:=\%B>Z" O90)8XLO;=#N*$RVF?UA\,R!,I6VUD;=+G&.)TU$UB
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M2S/!$7_R B8GW>'3[9Y>B*"8Z%"Z6K3:->7FYG=//MC*ZC*+^M1$@AZ:;#R
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MZ ,9$ W_O)[5$CKL@<)Q@D:(V\@NR$L EB *#'1..F2S^#KEY0GO&@'+7*Q
M*^@.2SXM[(TO5@0?2/#Y'#:@VH=H8(<MD]QM?XHMZ5-S9^I@U2\"E!O=0Z.W
MIKGC!&X^[\ 7M%4;\-&+&4(;Q7>EV1R.LP/B^>()(RRSXKI%79YX3C2;=AP,
M7F 2JQL3:G1<DXI'-4./W+A6\-T*]*?J''2".@?M:,DX.H/6!0R9/]Y'8/;7
MLAQRYZPRCJ%N4RQQ[2ZP]++!FE:O(L#FFB>5QE7HW):78W*:N[-*7K@;+!&L
MS\IX69T5AYZ$'$<' ,.L:+ID!VZBK),L15+Q@YP &MF!V'9W/!I.APFA.AA7
M@4KZQG[>1[@,<HTG@?D++L0[;15TG#B'%9KV<YF.R,L$8+:?.7O;[\9[QRC)
MQ$VJD!.LPC^<&L;AXY;Q#@#[(/HHJ =\,I=66L*L9_ E</8Q% YA/C>7I>Z"
M?*TC*!X:+,>.#4&.R5! JR0]8Q]0M/5PE-J^,Q!/=)7S7ESF77SWMI8E-IE=
M4N7BYT5\;+<V/\2>^/4+2Q$<RIN8F=S1;:B;F5B*1A2YAUEP=<"K9>P+%LQO
M#-H!S)YF/4('[",8T1O)PVCC!J9NLA<-!CA+EQ*A241PDNZ.5SZQ-1RC31ZO
M"20B\*+..B2\SEK_7QGA#O30R-/<'+)W)?8H '\?CML'$?V" K_GZ38!V7-D
M@242_R"A7Z$#*@SVX%F;],A+$X>KU["U:-L*4N6;?$?'X5F!ZIO^4;'^X-#<
MK$H NFK!&#@),.@PCIC_<!=$G264_!,'XDU/;CR$R$^L-,>/KC7&M0HKK&XR
MP9T-!>+,>>+$I[17I;4U_I/-2^>+M;K*_<=_$"R,.XFLB/N[H+DB'%&BC7E@
MZQ*01L?OXUR$)4$;'3O!<JAHVD8B1(1S%FACA5-I"O=YPHMP$8XM0^$D@B<^
M9!3A2=\%I9)46!Z)<VV"!.R111'@@"53N9OXIK\:5=DE(:WH]DD/6? B*F9&
MYY!-\<O,B$8US(^9$@0";UJ6&[(98<K-Q^P#D'1O/ M'H1[FR?IB)<+8^69L
M%R"^!.5J7<O2+2E?D0AOQM17NGFX=CY)\W%Z6T>L']TL?Y7J,+)6I 7W^%1O
MHSS,<GR_1ZP@!F26?"4#'N\!8@66,00OMD>II.H(":/@EJ-X(ZLBM!Y+B70!
MB"Y>R94,_VY1X<?C8X7^0.$Z&AK56;YYJW7^#FKB?;E0'%EP%X3 3K+I&RF8
MXYS]L'C,/BZ.!P6*: -KDBQ$3QZU.V,_YW(K<W3@/N08VOXS212M-VXDRHP2
MDD69]TP:H(/?L3Q2&:DOH.+ T((M<(O&=EV3_S;<%97&RT>]7,.O+;!M@'I&
M8EKK*>; 5A29M1V'$>2-8HYR<WB*BQZ2@#D+YOJB4U@&>N RJY[.2V3_CD4N
M48^A]Y6B-4=:49.\-":["W-B/ PN"H#;\^+\Y4]_WAP0\].=1)4LE(QQ?R(P
M#;N@4VSIM.U,JF-HEH4[*==R-O4#]S<6[#TYEG0ID6Y,?D02Y4!9?T!/%C'_
M@DN(NC-)N>6X9(&YI^G00XV//.B'LUQ?= B(09F/W&8,W19AQRXL94Y9BP6?
M,V$JSN63GC#(0BH=\,3^UQS;SP2H ,=Z2!.M43+KQ#%E+B2@+TK&<O0+4;,"
M'U3D588)X",F? D_GX7%16P9RY^LHGE=M8->Y,GS9G9!1/FF,HXV\)J>P<\;
MJ.6H B]V08?X@1+VP:4]R!G+9:Q0Y?T&?<FB/'4T& AC-5X?"X-)N?HZEH)/
M 'R6$ / .>"UH@<JD'%S#TD9,Z?G:9_5T;E;6MSRO8F\!-U3F4+O>:=8VY2]
M@(5*8Q&XR:*M&L"+!DZF"AMI,$)*T1>8"NT*<IC/\F!6:2.]WPA]@SR.4?</
M J)IW(R'&#' T'R<I^"R:!# >X&L6I$NS:=%3ZW,]V,V=APXTC\EW^(T?HZN
M]4]^;*PFS%NL?.:Z#/[]?OF$#X4GQ")3UD2W4 "T%%"DWUY<82E0)'A\@^G/
M&6/,U4RK/0$I637V?1JQ/2N?8Q;#9SM2HS*B[>"4_B(,L16-5=W;1Q+9ZJC$
M#HP84[.);8Q6'C4Z->?:C[1E!L9'S''UJSDZ,73O)QSKL!*WPC-%!TG*D=(P
MX<"V)V$3!X/]*\.9'8.\&"!B:XU;P4&P*#2^U?9"P''N<#)+S6Y/^=PE3S 8
MX,[J&W^P>+5S3G?)7GLZ_1A/S5=!%",)2/=UNW@3E7O2]E;/19/!36IBP1E6
M51^-*I+OKM$:$./URFQR8[5PG?]UDL^1UQ.7[7WX#]15J-LZU_7&3Q<^+IF.
M[9HQMKWP<&ZS.8 :$5VIQAWC",F/D/9Q!,<"=:RJ7>>V*>YF#%=8PN"*R S*
M\.H3XB62H#^X"GTJA1GS6.DS!SQ:G&7'%%-&DP5F6V#%)?4OQY075MO8NOY0
MX7F@JQQ]$+"*9GD@11=G+V71=<8?$%1;X7ORCIP8H+ZJ#9/NJ6I[_2ZN:R<@
M(;_,R82.")$@*J?%9^?WKVZ-O;U:P#8]N#*T"\K(Y0A1/OS"=\)K=T&KK^EK
M"A2(/,M\=8;I"O^,/FGD5" ^& 9-W#GT*?>U*[#MM@MZB.O1U=4U^WR9F\V
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MW=4G+:61B6%D?HXUX%<&%%FR-?)GF\.@NE>)(]J5246?=:S:+EY_.QHP2>^
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M],?!C_QOIND6/M6?M%!1XL%ME;X3I_MRPV\=O*LU7X-ABP[+V>PSFOLS6R?
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M+Z;,7HR6,YWUL12S<\59ZU:\XPHU?'CAR/&_)([=.'?IU%_/?*7O_D[QRD(
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M@TN.H+.P]&".$M&)14!H&4*OD5(+/*D'L'+U Y8:4A/M[?C#VO0E#OZ W-F
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MNIZZ3S7DL&.WK;<P,$?+6M@.)UT4P,R9W$MXP2TU8%(H5NPO $FFNR_,%);
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MGEVDX,0[%[B][ETT6V+TG2\CW1/HV&[2Y=''Y#,H!8Q XHPFHL)P9KQD=?G
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M?J*PX#M'GB$ZF/BS-%%_2%;T;=W^W5[2^OVJ$6A(>, [Y?&#[4\9CC '-?;
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M&D5%F2(B(&-:$1 !D5D1$Y4&!(3(/),&1(:($06)$!*5>8R"@((0$0,R1H8
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MAA_^.K8Q2G[I-N\1\!)ELGZYI:&^T3+OB@7/9P"J!S3.T)=.;U[':+$K!9H
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M9!Y3_Q-=[T-8B&[G5?0G"Z/*PVS'[*C,EV47-GXXI#HQ8N[XD:I^#RIK^!N
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M1+2^4(=CT!?(83%O 0+X(:"001Q^3)_/B^79<N[%=JPGH,!N,6W@FN"/6Z#
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M)'D>39]$);0IA^P_X7;ULE!DZ?_-6/]='A$(^YY3+_D>55G-ZQ&CT]@@FU3
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M)#(YZX>H0,23[2D0.<-)98*7J>P.2"R$;)S&DV2E(\^-0'=,8O;D,WSN;1H
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M"B/07]#1G1O80D)H:T.FP.:Q;=.@RV#[ER;W+= S/*!%:.]/)AR"S11L@0Y
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M\Z<>B;S<R+P*>#2Z7]C(D^9^0M.0*2:CHA]WX\GU(]40H13!0#MCUN.X6]-
MYP]GFG-I.C'J8)&+@:9OJ,GJ'U?Y+YRB]=N,F4_!X!O7@^_]/NMX\@/[L==5
MU-T<^&.6!H-X_$YXC9NJ0X(QV%.[NE!'TD1_F\O1FSM&(S3,+Y<9\_4QE[<5
MZZF !MDC.#6%_;"-[3 @\E>@U8A8/#>&E6O<7CG5GD$>_4G0#P:V*IT"E8^F
ML#( 23,I>8'2EIFF>8TLG3#S]DQ^GO3^"; R$\F3L9PA+2.8I,FAF=Q[:RN
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MZU&G#%WB+QE0GTT1)A-GG$M[<$*"/CWT1C<\[<_=4(4%A*RI%..,-\R-DHH
M[A"]#*MFDY9-S9"E_P=5WQF7U.+_;]-<4;DGMTS-23E+$;[E55-34G,/,C-7
M2I9>*1$J<Z_;TK*4S!2W.= R!1746V;NA:4"M\Q!GM.@<V/XI]^S_P->/('S
M.GS&>YSS.1^&V94=^YQU@^:'Z_I3DK=:]3=TC<+,7VZP,OEO12620,I_UC$1
M/4,=BB;O;J,KQXP\Q9]CN5M@0957'%/77>.Q+Q)Q"G@_U^D?HA/&NR)R0IR^
M+'JDV&TO>1_R_L2,]1KB.F'W#%$7LN-(KR<!5T)$MW_$UAE+=%)?Y@":ZO2D
MTQ8#4 9T=( O^94+PGV312$:RT%NO'-?A[]\8;>#>M3FEY>&*2%9E)>%'S<@
M0US?IE2!6%O4O"D5)JE1=N;Z3PZ=5=R+;N40? %Z@5@)+_,]B*RQTD%$CS?$
M)<(THFR=7B%5BN^L?'.VL.>8Y\K4-Q G$LYU[ EE?'N I"#J'H5=PN?<I636
MW.R?N1Q0L'7? .>0@Z:)O='1AR?P!/K:5)1G^:YS7-]*0PS+ZNADI2*OU>R/
M=Y>$=OEO@41#GT$'\Z'GM8IO+&*>OP$>O)F+0U[05;Z1[NK_=BXB\0@^SR?F
M86JPO=:?AI>=$DN-OIXF#M$!/WBFV/BYJ$U\F' 5JEP:PLW1V20>AHU-HTL1
MDI8VI7;BR]9C4<K@IP<=.KO=?;4U%D.FK=R=O5]&?*.JMY6:VTFU5I4K/,GN
MHD_ ]A!GX:U-Z2CS-9)4EQNH,_0G5,$>20LD\[8U1944W&V:7_F%Z3-5<:F8
M(H2G<"+'Z6SUC.F>H!&KX;LQFU*LV_,.>J];ONYYC7W;D8T.VYB'<4CKI9M2
M.PQD!$9K9#GB >@;_P/D*#A-L(3VXU*?V-.ZV7%_!*RQ9C*$\(;HF_.,7SS^
M[:J8CK\Z<BOU&KK*]%J[)B[>^N;T?.2[TVWVR/P0MX,W#V+XS6.D<(26<.NK
M:=+2(](^HB)!:X)FZ<:&[UDI)BO5X\)QNU="[:DYL:72KB]FDH9>??Z^*(<O
M.+9_LLU8,\XO^.8B9C+>](]?%Y-W7Q+KMR/V9@RP@<GJ\29I5_6J (TS:V-#
M7P.6[ET--_0MT*_2/5*D3]-1CGZ'O_I&9^1.0G'OQ^#8@:,F^B'I Q'XMW_I
M*F?W3OJLGE?_=VVJE],:KT=YZ.J:9#@HA]0VT?'$[$@?F*H(?'PDL6;*IS3&
M*W-M9/T_25 <1!GTF,*L5@D+*X+SKF A$[O>C?$?%QY+8I.TH$#LWA76G^;!
M,:IEJEU@<D:;*9HY.C?O]/-N8W9RBM'LLXYRA7JO(;B=!/T;1=5$(^(,N:55
M& +U&V1\!',(X=#P4H)!>EN I;;)9^).\%W%DZC_K7S%KIY"J&+:LW%F.]Z9
M7=CIJ121,\/&K:< NOS/H UO1;"-<!Z: X+X;]LG:$I1V+U"!(B3J,4=RXS7
M0A@;HQ+S^[F/*,0!R(%-WA+-0@O_(._"61W9492/JW:XHO!CN#^]\D$6*]@E
M20"7G-I9R %T7BI>#T/<)"(@.29=01A*M"<002E@,6<=W4H-+X<R.=9U-5'7
MJMN_'=R4.C%U4:_@RYNXV1+I *6XLQC8GG_G]+VO#SALR:K(;O#\=^KLQ_P^
M;AW[H]$<3S[$R#]'Z=+[[Q0MZWW=CC^N7;E9YVJE^%.3?]0B^T5%5FLPK0J7
MQCQ;[2F1/X=_^"!;M>^')5S*4$T_<C65X*2HFC,HL/U.*7A[J>U3\_WH,_>U
M')Y.\&\7+AMDDY9:R1WZ#Y^*I\F:B8CKZ!9:D\!6_,^BCM 1*!SXJY/.)*M!
M6([X)64%M3_$_,TRXR^;&9M E;K:X)6?UE?>QO&2-9NHN:8JJYH!)X@Y#I*$
M'YAIW)2*'[F.;J4(]Y>IC1+E"6&BW&51'96LCL]9]LT<)"KBUAO"L>X'OJB9
M.:6IE%*B V,4@H9;BWB1-N:.EVXS;Z/9(2/"?7Y<Z3RQIGAQ4ZH-+CR$5OV\
M2.U@8.<=F"15T@4YG&(TKSJ:I$;3C@XUR&7Z$34R>WY5?IRYU17T!%^DF7]B
MP^5%U_CP1W&-<F-)_$)?;*Z-:/^41%I>$570ERJQK9D#FU)J!'DH%YAGDYA8
M2#\YEZ9%\)QJ:E.>J"<J"?\'BC.Y]L:!4'+M?\7R)@3GBO>Q-XV-MS;>#:(^
M _\9;6U)>5@4TN=A%:JAMFL0=GTX>JK&M:FU!J,L7V?&/#MIV!67E/^HSD_9
M*T-?MMC>?[(/ QMV="7IW8E$Z1J&$;N1+)\C5SM@DQ5.5!C.;>^-NK)E->2
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MR++/D UX7'<B%I''5=7PBC\U)O$*:&5T-!DZ%"E4]&:$:D)7!!CBT*:4 O%
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M5Y3"+7JY5&KT>VJ6G*>C7W+25*RS^JMZ^N.CT$G+\>;W,3,T>,;J^/38!X[
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MIS"%XL3J.&[<RA276PY\#Y'@Y/9R1^ (!^XU/(;.P;Q@N3<A1(-=]8;J2'+
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M8M:Y4DADW.[ -?FSA6NF2N2=EN[J[J(4['7AYI)>C4'435\;PW!7Y_!A>>@
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M' D1$X/ZF $)-R$S!-<^:XZF(02<&720QR"KWN>2$GI7,[PD7',?D4/BF'.
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MIW[?;<)1W?<R+$#L1/N(?8Z?J-PZEWJB(U!&"A1@H4^QK[]-)ULEN+KO"TS
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ME.+F] 2P-43K0>HG$O07?:V"[\%-:HUH2-4_J,L\*#!F5U\D?E''.,X9<DH
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M6F?O,%;[D\SI*%8^YDBF!BDJ)]U:*.&3M-+R<2.H>4 ?;(DMO8ZZFTM"DL+
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M@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@%R
M7(#\+X-@_O4> 3 $)$KM1BTN=CH.2 ,(_\-VIN1_J@/AV\L1MQ'5D!#P?KP<
ML04@!Q  !&0DA%]>DHJ&@(**CHB,@80)YQOC @ J A("*B(J$B8&.@8B&L*W
M%R,"Z'A4&/@$A)R21!K$5ZC-G*+U AYA7KU&0L/ E5$V0DO/QR\EK]FX2<>M
M[>H65-G/*R CIVMN-;/%HV]Y-R8AMVH8KIWL[(6+2.?F_4!'^/'>13A;&0]
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MI0D.4VODL(L)VL+29M*O HU,G4G" NLONA1['F^E4J%.G)!0%]?'$9.)B,B
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M>3W__B>"<RM[BMT'6GS'GE".K]:ZT:YX122GTX>:0,#1L-L-ML(0(B7?R1"
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MA@F 6&Z-.Y)J/D3_0?F(D0)#P?",J(?=9C?7[+?;N+;"N(.[XWID?CD8C[F
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M>[DJQ7FN@=^O2)\4&2CE@^E8Z!\:/A>:KAA1^],U-NA2#P";C+;:;68[4#S
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M9N?&9.;\_0:IW+^D<D-6TX,NFE*W60FU^7(&9H>&*I@9/$%KJH_5]JWF3]P
M67PH2@WJ).T$ +,G.APC.\[ZQG_9"(75R@H9P/[M6];$&T947M_V3.]66D*.
M%$GO4T(V6G2Q/?2O*<6(0>!::.Z:6M\T7'FC,+04=CZ^JI-GU8/)!=P_8'PJ
MG@2C!6,<G;-L]:J"?2L(Y/+;MM)_TV^2AG"$YF,L&?JMGOSOU7.=B<EJ4N^R
MU4^NHGNF\(6C]O[69 .]3O21^R$UG('"W*.!C@2["V,$9]J!][X5"%@;V_)4
M]>"+L>[WM6 !JP9QJ<$^Z=-:%[BY&0EGC,ER39W\=]!(M-MJL^@[?>2*^M&H
M-XSIE)H:JMM&&L!Q.G-\E*M?GKQ78VD*G0*>$/2(.%@KAV XI79/;IZSO_@U
M%;)$GG%WODT"LT.#@0RHY0\VF@?Y#]QMB1=?1#>$6\#C]^WN2%&TLQD:/[]3
M];OVM2X1_[#]?KYKPCJ:Y_;7O<C8N %A\V9;(%]H4T(RN&\).[MAK_)IHWH]
M* [&RT)'"9#RPQAV/5DZ)L^56?<^0S^GHZ-!1 X^]G<Y<JAJ0]T$O;_>2#L
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M5QE?->/?>FAJ4BLL.:SA3ZB>V1/2[^D.MW;\/H]_HX96^%9!XJ /,D,O'<=
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M6<-FOY\=OU&*1R[%6GG'7L_ZIV^"!O,0I/=L HZWH]0E.I'B=H5T)7JT@GH
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M.$Z<&D(KA<?6XJ<(D55>A-0MH.,R Y=$GB(V2E?+T[;\./ X)3K%Z&N*2O%
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MO-&B32P?8)D$J?*8$;YP>28D6<7L\J<:3+_"EY205YM5%\^Y'KL_,K$>JML
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MI$%#!OM;[9XV/L FES<^EN@2AF0]\XY$37NUK#&9OI62&S4'EJD^OU),-JS
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M$P"48/6P+52^6D.4@T.JT$*Y&N9LCW+"!##6Z*VQ3['@2=AK8,WHAN<C''S
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MY+K-$_-V,TU8%?*I.CV468: M:WZ,\N'M G10*NLPJ1,3B>=%X)C2WG42:_
MIXM%T/)#S)7W=!',MBI23&.BCG&B&>DZ: U-#+KSAUL0ALW;AFP?48FC*^F=
M]YQCFC.Z[S_V^>VB4RQ+?G+W96^5(?W]3Q7&?WY_LK9J\38VX#%[[VX,NZ'!
M+;<-Q1O]7O[T]:1$3D*YV%OAG*\SHYM^R9ZG@W+/5!,]_RQ>2R1Q/KVQ3A;F
M1/ADW&H*:0\L)YF/%_U07^N:4[?.^+<=!><%R,I%"_&3^1?;LZH&YYOVP[G
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M_9;9\NYIJ'GX&.*"EQ]QIFY7.N@"B,(5XO'@0O?K*%\M-KNX-"I$&P!X#P
MWK?[,B*5RK@HW@4(U?&G#6CS)#?^"?<($3-W46*63F/]W<A&M8AM.D:2<V><
MF!P*3XW#S#^,W2.!32J'B^*$%.G*^[73NF$80E+VH:&TRW7ATB)VC%'[3JHR
MVDG#G&71,T#\EL8]!R?."J*6P6O+'7F?T$@EZ3PIGZ"ES/#K'1\@0_KHXQKE
MO,W;6ON9$8_#STHE:6U&GVB>>>O:G!ZN<<?IIA-\V+4H'!''91"QZ/8\J.B<
M@G%H[8IY+2RJ=2O8)T \L?_-HJ,41M-_AEHTV 0F2R.3V1DO4#%:7A$Y,$9
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M(2W@4^5''KXOY*]#(8X2?0,CIOND 9I83TQ45^D<]4;.:#_P;*%-,AZ<@^W
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M\<\+?D^ R"PRZA9;-5*7[:@>>- /O\M#PROP9A!JT.EM++,<'TO)@"N:S\Y
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MK\14L\W@F7O00U"@FXZ^\</C?,O"I]I'G$&/\(^YT@P-/A@@E%,$ICY/8?#
M+8',-:I-4.$E3$\JE5P GHXGD>GA@QZ,ACE=G!EDY9HY$5]:9&66*U&0QVSK
MV)1*2]H66-<!QP&5G@R_$#A8$A4FCCS4GUDS\Q%]#5D$VURSEZ$FR5TRG0]^
M6NX.^1YDJIH<[FU1]%6V9?8J4IKW!94QW0.7DPW 7#AU,5[BWWP:X>FNRAGI
MMZ7[=.^%7'@<I^)9I\/_ G14^22/C7WL*(42DYD,*"0$XTLI,);'!-( !O&&
MN/]%;1@QP$;&9E(I\4P2R8Z[4I<-SY?\EYO; MARW[H+']R1?$XN^'!1%L6F
M,E7ST&M0, .=4?LU1" &OCK[^E5T1COD3$+%[ 6!-^9YI7B"<P(V%WAP='QX
MK-0A-0FW4_MH@S60@/-D<,EUY26,><VKM9%:4 T=>5E3.X*B/R5#GOWWQA!]
M+A?_*S3^,?ZHG%] S/_#U?7FIPU1V@]\-1\2$'K>_JOO7=_;JV8%2;19?9)
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M"90./V=-1WQ[2D<SN<+]ZL*^YDV^OEOM3#)GV&H7&X@45R*)G5PW]T1DE]I
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M'*^ #>]R_Z1]>R%Z9[6P?U[.COI(],[ZV_/O/W_?_F1!56.,1OF-@O9+&'R
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M\<)6#MU>U@6T*GK$> [:T 8U2]:A^I9KC&;[JUN5%)G[*SS.V)#FBKH5<6!
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MI)85R&FU^88.VWK2T([9OT_LBAY^?W;6DHH*/G-K2;A$P$(V?\GPA1J_K=9
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M'5ZUG\IFV+O8&>QV;.<G<^4/)*"1JGP(V/H'?#1P3JNAD2WE%C,MDU>UHL-
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M"-S=.M.;6HW2HY/Q-9CCG+,L_Y[2>WW?5B1:ZD,87^\/2>_JOL$B:LO*&O9
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M_5=XA#38;9O,1PVH 7I,M]!\JDEG#MTS-WID*PR$UF!WX"CS.'/Q7/7%%,_
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M]4VSA.BN0D9'<6<$E(H8?#)SB!P( ;5-5LUV[G'=P9!9LA#HV?TP([%A+>X
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M859@>Y$-O2O?_-BX;GFDTFPKZ'AS5TCR:&O+,RHJLISK!?JQ5L]/O/)T#!9
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MQX)[.H$6'C3^\'X^*\27LBLDMQ;!\[SZ^3@Y>7K;^[@PJR\$IIC?9F/5ECV
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M4F9N6F$]/>38=C7#)8JA@7)-;6FSZ+S)5V1?=*:]*S7,9Y-:,O$!3V=USNM
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M+@M$-A9W,V,RQXM.0K!G&#GQW A6B/[86/<XM6A210WH351$U.,]4VS-MSR
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MA[1]-L7J%VTK6K,6)_.2WP;,G08LT]=OM='R)@94']VM6:!",Q)^8420W<#
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MA)L^,SEJ9K]GX_A&&KN$+Y:S(\'_C#T]"CN&<>4502V(:+K7._G6F<1[&0?
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M/HASF-*UM(%&:_P8%R1/P4\D@YRD[^#P"=+*Z \1'32Q<;-@J%H737ZXCWL
MPECW>#)Y^>0[I3!K$!"[OI,:HD+%J.%="Y Q^MG/#2S$\$%3LU-;D]FPY&(%
MZZ5#V$%$^;Q[VL_C*"J>HXRS-<YDZCZ68$PR2@T&P?S6T NX.U);@=HY"KX2
M4+5+74UU!PT_U_P4/[T7=A= 5ES7XC?,OR[JAQN]3TBP<&3BU&"E6Z+K-ZQL
MIF;_-'5I=/!XP7G"M;:_\A5P+\OE4U23L+I=\S.LP#9=$B.VNO\8'N-G*XEA
MT(*WB -]@[(UMLASP)3K,,!SQ$^CO.R'S.@N[G8)YJT2+9#'%'@W&^(G@A B
M!PX+\AEFHGZY.?2Z1Z?VT)^=?P*Y@,I^[?!+M;OF@IZ*'\*"]%]SWK4Q5\Q1
MHDF*5PLR)&LXHE;($C\LXKR$HS)\:7"5>Y:ORU5U);NU/K>8!$%4 +H0^]3T
MF:SBU^@:IDF,S8("^(\Q)PI1M'G^NN/_]?5"8,^1[L8N*V6VG#E*:\@/)SC,
M5Z.K!O'3<.#[RGCVV>==OAZEX1.AK6\N';_ 2$K:6%MX-N'S4+G4JU.Z-FOI
M@SO]2XT9_J"-HQ]9L N@\W%7=9\,J1(J=ZLAPU.00GM.U12C^2IF*G<QR9AR
MJ33"0Z 6M2K2Z#NP:A6;7P^U"A9@C&;(@NM<@GOWE-4.N+]%SD@V]M(WQ!2M
M/5R&I??,ZK]A%6X&8Z8HAYF= .[@I.=QCQNRH&]I9IB3+@D%LQM,]%_R^A6V
MGM0;1<8H7PI9C#NNQC)5M.5C%M[9W LBS.-(UX/LEKS9_IG7W%W*S?%3)D^F
M[2W492]K^N)$]ZO3)W1J4A2=>Z'?P?L-6,*EH75P>2:>!(,W "/\,^$JWG9N
M")I7!XLL6,1Z9";MVS[>>FRX=?1S]%+Q0Y;W+4F%8_6CP,L5XY9WS;:OKU,X
MB!]$7Z,=.LQLCN(#RG%@V E6S#?0XF$A2*HN$;.(U"_D]0IKO=.A*#!ECK*2
M6,>Q@OOK2 'HB"W@;>#8J]IS?!,>L(Z3@O@B:-+Z>*_W35=Q(WTUSUY6'BU*
MCE,E'TX,8NT;W"#05Y.2&I_O_OB & 20([)K/OE-HG2 3.W7Y@K=*RP?C0I"
M/U0_Q7>C4)95LV()01W&-H'+PE['\#Q>2@8ECN^#)^B>=.<7+[I<Q>SL(N.B
M,/;R<<70<=[Z+;Q99QB<C"1+CBTQ2K<GOR6/$TB8E)*I=\&00]AP%V(_HRZM
MCJL0YW2Q[/H$G'U!Y6[#^?1U70-VV:TJ"D3WJ@7IDO78KK;ZM+?I647NB'-N
MG.<<Q7PDHF;PUKC+@XG/ABC@V;Z0CQ7Z,$).0X(9\BABV6E]--$*/"O7 ,B,
MSA4CN7P1:LBO 7,=O=&V2L28%-F.W&/H,!R0R5VGDMF-@53Q"?I&TPKJ$HY;
MF%^2?B/77^6PW:MQ23(MI.]#"9HR<65'?K&>/3F_)$?=14I*93IOX?PF'[S^
M(H?>;;Q-L0=@4;J-T,S7A)U4)FH3">JI.0V'E<!2#DOUU\^/ A.3;''G'-5[
M_-C3O6?=1,:I4]G@*D6S^Q/?[1N^7F!P[&;^S$2^UIH3"L?-\W2D<B-'_Y$;
M]*+><)^@CW#NMGO3S!NL5()%^,YGACS<3.V2E-T$+?5U?LQQ^K+7-^ AEM\<
MNNW9>'U[9D,43+7!*@)0KXGW>UM\?D94 ]."5B:VXY/NN:%T&Q3#Q+:TXU94
MG013H2'JF19H:)?ZN @FA8L%\<5\,D,K>!M81495Z+Y21-8R4%G)F3C>ESCD
MN\7H/62.,U4=K.V&?+9SB]EWXU8.M<7?;J00=>]%2K+XFP:0$7IH>$*:((8<
M? 4:\=PBHH4F%ZDI ')H?C--6U_[)SRR[AFGT=J U> 9=]/7X^XP.X4F!J4G
M>%MCZ+Y(2%;#T4$)K<^1G3%JA=0UAU_R"PCN+48^/&(K?\(/P-IQ%F$2KC_&
MZU;4)DVVN[=KY;M>*:J3KGG1;/&OT%3<HPLZ!PJ*UACNXUXLY/Y.S0.DD)_#
M6XLY'T?=KXMX&]Z/>?UU"W[4X RS*CV.%OWE<!KW5NZJ&,-I#Z[Q;O^_W=_L
M\,97>A"FQ?K(:*ANX!&)-5+SIO@3OSDN,U1 L6P*A]?;(K1I"$)#3KRHQ1)5
MQWV^*80=PJ3/8G02/^Q V<FF>^_E,^GP #<)EF73UW1K?(\]#<-\!K_LFSZ6
M$OA7-F%"^J_%(]BT/I W!%E 2A(J1ZA#H%3X7*1I5 ;9GAB8^A4W><S\74E;
M_08#&=6H>9UJ%;[K"9;=;BMW>UZT'*I#96F)!GNRDC5L40M-PR:\=07I?)W9
M:NZA!89=W:?*!;XQ][C>B/=-8CWGZ4>_7<V$$5*>P8V"@[X\N2[=Q<&X>=;_
MG[J*D=]=6_[39!<VIO.V\NC<=GCSESW[,TRI;P6$68FA!(P1#.\]."^(R0)^
M (JEY0*V8EHZS4+BQW)<B7DC_'::E6]4)6F,5BO!)6,]W+UH*&;<;%<ZQ5O:
MO<VST*F-1T5^J=?R+[K2+^<WU4LCOJB7].7MIDXX9A'.Q62AN $IG\U1ZJB9
MQ"XNB;64/6"3%]T&9QK^ T8U7CW>U; 7I:K]1JL?<[1MWX]M#ZSP?\A).EB%
MC2#[K%&;2E6&<H#,KA,<]Z^P.KC37!'2'63H_%->F%;Y;AS K3J(93%L,MH?
MR*$O$'UV(=(ZM'WRNO[P>[HM&M)$,JJS%,RX(A9FTE=S]"V$!?02BT39*D&+
MV7K%'M0U/>W)^/'>4Z&M%UCE6.J>?MP/9B_O3*@8.AE#;!Y\!10_=OF7E$ZI
M(5"\]B8D;I\$T+TJ;\UVM7 U=Z^A&#P#YM+78Q=@R 8/1/<UPO_3L@K,:I%L
M1BJUN6+(9MR'GR6:+J2UF*IEBZ3TIZK[W=R-#TXL866[/!#,<O[W=LZP7O>]
MH01@,Z^1ZBT$PMS2H,FP^?W]:'65PDPHFGK-$M_=9T_ROK?>521UJ?10G7M2
MY%#+8F35.U8!-]LS84G_.X_WYQ9U[^._'<VD!8NWS!KKUQ'-D /A, XA1R!L
M"Q^W#E0S;D#GH%R@-J#I18,1[&THHJ\OYWL*7M_5Q2&,Z[EW6 \QD.2<LTGF
M0I0IS1NPBW_AG.V9Z24RB[&;H]RH(<N:?'1"GO[B0ME[81PAI3T3M"J&;NO>
MDN>EG-=+]R4-: [S%5AGW,I.I?M@AQ]@ 2$HF2?9#7X/N#X(O5%5&:^ '=*K
M569&^WH2[2L,1T;#M]+,)DB)5M2]Z<</']O.[M\P.ZQ[:[A3XSX,ZKZ<C[[,
M BLBH>L3U0ZF7YFY;ML6&B]TK$I4!1V9_>)##=4BQR9L9+M71[)51'5OHLN(
MF3C(11_[AUP=:/?TI\'OB#=&V'%#;0T5VP#PP3/:;&9-'6Z5K_N</.C:NG:9
M,8<G@]E-;&SKNS0ZC3?<BW_1B$)ITT)J> 37'Q6T,[*%%E.-&W&7ASD+6>Y6
MK%#^M<J+C18BMVFJR9C\W/V\OX3WA<CWPF8P#1 S\!7!2F?-' 7EOPH%,\!8
M-I5K9Q D@LNX@>$AS-ZG^!<\/RQ5M8:,Y:3F8KC]T5Y?5S */C[@+FVMB/:6
M?O-Y@-L=G7W&VCR@E-@(-NT@RUH#N ;X-OPJ82)5B^0!A,FC^;5F9:G(IF%E
M>SI]/;X58;8/$>YX%#)SW7>G,5_B@ %P"E8BU<S_HI;?P#"_52S(HF_$HE2,
M-9SKKB6-M4CNSU%K>BMGWK,U0238:E!W33CY\PQ"%J&]+4*+AEU*0>;H&H,0
MC!(8R;G^W1HQ:(&M[X7S7[FX+XRU26*9==;Q$S5[FT*U&=Q5LV?R>\8N^;26
M99-D>]YL2=R7W1=CKMD_F3]OI+^BOC8B3%1ZKISW&\W(DY'2Q3UF^)'G,@ZL
ML#V TG*Y^XB-C0C4Q,S8'AUB&\Q1M#IN*AAZ8L7L?Q5.#_3\U?O)#&M7JY$_
MU@Z[D\KKW21),DORB#\ *_HBEITL3>*"O5-%-3-3(E:B=>F5/=H6PICDM,M/
MQ^1SE$Q\2WQOV$M.?6^S[LJ(\,:'N ^N'Z84ELRQ*Y6%G>+^F\'M^DPD4BG$
MK0-@[\DH_1'<V  U1.K-8D$K^EK<%+5M$EPG?<T+XW868[F)ES:-V(PDSV1+
MO#@"N*AP4R6]ZLE$_=/LQ*NVUQNLEOQ<=N)U;$BM3V+?[ V?8^4_<8*)I?_&
MH/;$TAQ$39CXZ0]C%=+?88$9;M>%.R2C'JJOY:*,&H8)]QM$D/G4-TRI<,2V
MX\$E'/>0@<D:UQ_\=H2-[#K:T^!%?UGJ$+;W<LWK:6I=VP+\+YR%4?6;.8#2
ML5JM?0T2)J1F-+;  1+9A1C#OP<_AD"ZOU'OR5Y]6 3^-2IK2_X\>>''.4H$
MUI[\" \<:*!6<-BPI]PEE"-O[E6]J3]76#I>\(MD%?)W<*";$)R=WTGG5*^$
M3O1'N) $>=X36H-)X:C)-/V7>#(*9L31MV%W7PT R$UN!.8%SU$RF!3)FG8T
M.PCY;ZCXSDUB":KYY8HPVW?G_=B/,=VQ$0L'/L2)7^Y:[>5@.3HR1]F/FR$O
M"7,_1,2O8:;Z\#4F) ;O#>).JHDP8&D8K]]'*V7(^2&&XFFAZ8F8KICO.>H(
MS.GL8PY+V:!8^4L%RW8'PE%QK1,N+[^49'>JZLT;IOL+GAQ\YMXND ?K?B%#
M$<AE=_N"2.^A9X8;Q':.$ ;:XQBM_!;'%2BU97.BUHB3)/UA'##W=55!RSEU
M7V8?ZTNLW*H_^J(K46:))07V5+JI:JL'V'^>H5!;:<-W"1,-XD(L;=>3(&PB
M%2&+@3F_'6P%T^@>6!-I958;\L$8PZY3V%N4"9O?T1_$3-7.NF:.(!@KCU3+
MK#@_*HZB6XB_^C]4ONU-%ZCT#E%A]'4U"#SA<UR0>)J*6WL0)G?U9EP&>?#S
M=SR;7&L !WQA=\.>!\1P:)0F&Q;(<YO9-MROJE/A 0C)5U9*RA']D7[;(#3Y
M5E<98M"4/FGR73_JR#^ZPM]<;%.R<&G%C NQK$EOC$<87GJ*7E]J5]$R"'OL
M$GNH1#>+&>N/<C02IW'"N<>I7T+C;F.O$*Z()BSIJQ$PFTRAMI#4X[5$6^_T
MC:Z+@3FW#74M/I=>XS*2FU+F'P_V V-%<A?UNTD_?3RO66@E64+ZN"<&/BDD
M]G#=54SY.2F\2+&(OI[CKG;F3RG,.-) ])M'2+/#WK;Z8ZVY/Y].7%Q9*RCU
M8!V:"-E.?Z$:.^_Z(9Y")SU"2@-/*MF),?448OZZ5=VD/>(,O\N (H77H9JD
M&PT']$=YOX'/9UIHUIPDM7LK-.3_% ^'@0R0BAL_/<7)93A@38F,E1.0W*[\
M^I1H!93IZ^\ZDM']8=OM?;GO&!,D06;M)4P6^9Y&TP#E3[/EK8KK1=NKD:>W
M2WE=$%G@W*VYYY'1"D3:4L^KB W(]3V V*ISJ^!=E;;M>68),<H1L!TP2S2$
M-%FY]D3/YF@4&6X;?@6?2]9S=A&FZRXC5*5M)GT5-]J0<E$@US8_@G\'HL%T
MR5;L+/JC5O<E]HQP:@Q #/FIOE%G*V7ZW5SZ'"7M0MGP1LGMBNR@8UQF\B/F
M*):_)WUT0,I@+C9DD8=<.$<1MPHU,Z@1L>PJF:/&&%_O&4YT%V@G#=3)1B7S
M!E0E2Y>L?<VU1^JD+'"U5&V, EF^;)0UJ5C!O:J>^*?Z>4_7FVBYFZ!D*%GL
M.J ;F<H.6FHT 6(NMI-YI)BSQ:U*='6&GY_$=<JRR/P1A$FPRW8O6]IAP?6S
M8NPZTK8C;_V&W-%W[3S;KFW:+,LSO1_B56=N;8@>_A<TE(/G19DTY"@-6P?B
M5DZZ?=@!^"@@)F5Y&)R4"IZ%,B\-GFTKB8K1;Y$F/N9U\3X;7*L_)O[3YG!L
MD0E"S4I\>=(1J'E/_WQ%T#:+\-4N^ES1/\:Z^99JIOA!PQU *:*M!N(8*[G^
M6"3L/F1_ &5H:&B ;A?F?7]\U*4>'6QF9H'BO=B.03CB4<5[G_QK4R*3:#O_
M_+0IR(+C<2!;2NQ M]45?,=A'_I1$=@0M&\)!1]#(<TT2M4]);DND2Q;<Y0A
M=ZE/J4&HR=9_B\=CI A== >-*.1LR&^1. SZFL(=[N;<(X-X\-D7\3\.Z%4V
MUU5]Z(/>Q^+_@I8WZS9MEYPQS"]=^HGKA@A(@SO,)LP>8-N59GZ>(B/N1L/]
MADADL$D>N_7Q:RR2_'P);JJJ7/;ZQK+2XMZ+'6=N75O\QN.7O$W/Z8O(+%LH
MV8P[DX,-8Y!NIH_NS/7ZU9 Y!6:!]E",* 58.%69T!:'&DNAFGP-54DUP<+@
MXR\KL5"VT6L.+:AKXT!<8B>#(>EI )^,)I/3-ZZV,_O/[:-A[KW4X7<Z2^R%
M/IAX34,"V7(CU4R&9$TT86;(( #.#%S>&N?1%@IED@+0BI,J'=V"/,TN'M.!
MU/,UC*4<_L'^Q)_BIX;^;JA#-XE5NU9I1IU3#_]ZIVC5*\"4Q.HC(?*UXC4+
M!N=[R!$F<<685FF3 YLYZ^2]P'GF2E[?)2M.-;SQ%YJ-F%29T.*X:8 OSWM8
MS\Z>S$WSYFOC7,^9J&R0*9][*9L3'XI7K?"/(!6GL2GQI]!L?M_XC<Z3=_2?
M\SI\@D2OF LX(<2R!?K/L0351;O/^O 0JK0RH-5Q"\:O*(-B;+.]<O8>'CS;
MRSTL"N>DG1?GQ'Y5GV^@O D;^C>&^A[$K;T)DXEY%\ND :>UPPFZE5@AXMU$
M$T=-[H)I6:8J<!G1NX.V8A.V#K5J E?[ F48J\V.F97(2%\Q[NC5\W3;Q0[3
MAZYQ-<E;[H;R0U]D3LNH@:?9"1=2]5>()K .T$SKEQ$=-!.>,]:K.]8+Q8KX
M@#CDE59NI3Y7J7PAV<8)5"Z7!T@9UEC)\?X&/Z1:'RD5KI"LBX@(>^_S-*?T
MO0R>\-ON]5+O,F$XJ-^3"[M<I.!I)#!^(T'B,M_VH,D3C$P.)I:!>E?\:T/)
M>4A9S*Q6M,A2"'<T2<-4*^2F</Y-^EI>5S;,S)18(%%9-23/[R@7R91A,NK$
M@<I0V065T(03UFSG^E=AZ3#&/IRNEWX,CQED#H6DB?DH-=UWIZAC85C@TVB?
M?54;:^+/!";U3>FO#E[?\.V3,:MO(D/.+DY)7VN5A;\F#ZR#:(&L0>5] /E&
MF\M\'M#$7,&E(U +F)FO6!Y_T8$-YU; ?E9--K<P=UB8RKWP.(=Y!!&F^<:)
M=L_8,?BBN"DT2O5R.O]PWH!+GKCV<KS2X(2DWTJXQV$TSYJIFUS_R52-6.VO
M_W'HP=48MXLC.^1_)=5=_BX]Y/K;-/FF'U<]B/XC/VO'QMW&+?.7R4'Y,&%B
MT'MQ;0>FF,-SE';:TA*,C3I_+=Q+6TRLB\YC6HJU-VL_,58"2"X6J;QA%Y5!
M&K\UG0_O[G=T]6B>O9-^EZ.K\[DS4&AG^I!D7Q+D><#S.DV:2C%\>R^FTJ_D
MKC&4@<I?(&1_$).P'&&V@\^C- )T7V\XA%57C!=$99SN351<4SROK2O&U&V*
MYP^\';^X&X1&- (9O WO!WG.W4>&<+\?BFS"&$LZ9MPU)_6KP::#YP&V< WO
M-?",^4J+.=D45V"B)IX1@M/LH+B<7;I64L3[E;W!V-*JZ"M%M^Z- U2W1,8"
MS*AY:Q[2&AF%?%!(\^W>1,3-9/4>ZC]7\ \CP5  P6L!+'R49)CTYCD*WP>4
M?I%<'4R6H+MSE.7]<Q2SRCF*Z4L]H#<].K^XYH8582/ #PG/DV_OZFWU#,*2
M^@8\#<8FYQ.;:&?N45\_)LZ!RG]$_VY4(($R?6#Y9/X<Y0'A(QHK@/X+8EO<
MYUL;$:9Z,FZ+!P@'#G@,M<4M)IJ%I/2+$LK54D6-]A4X:0!UO;V2]4Q(&A[2
M$HCT^F,ODA*43&L.ZVB@@#KQF2@WCFM_6B6]_*35Y;U=6_X92V\*\72S2 !^
M)\+8"NPX:3MPWS!BU0QAZXT[D]2#9(-2:[!YC)P:2>S+AO54*<GO( D I&&.
M C\F)Z0F+)G808G"0-972]HD@ 40,D)H*&&>/F3\R8/DY\DYRN^'242K0'DX
M$.UNV"S:0/ZK:8XB#06E'T'E+0AI 9"_(*2;'%4V1ZEUQM<QD7XF\AQ2[3=D
M$Q8R[#&HVD(> BD>K15R2+6:Z"=>$;\;!G5:':@3X(%$+_,A@!P$,>>9-L;K
MJ#80.2RTX(:B[E)WBY.\06$=HY4F3U ]89J+A=:Q@Z'.UQK8;@:7_6@S)[^I
MR()/:L!?U8>>=46A.W(LYBB".-YD0AA4 TPZH4FP K?.GL?^)2RA!33?)K'@
M_0$N Z.U"_&]R#]U%5C!,$ROKL"92.- IJI"L"3&QG%%7X/'P[$![^ '!7_+
MWV7CNQ+BXE=/;IO>2<FXQG,A_JS0'^3U*)!PQ@*.*6'*@!D4S%GWP) CL<+R
MU0!N-:,$)OM5A7L###]*MKSG?7X38\'&[8SEI+?FY_@&H%&MA.LSNEW,?2Q1
M'><A';QR&DD<E3P;&HJ^(N.[)9<3YJ&&ISPCSC<S\^O_2 7+P_@/\"\P5_W7
M1(_$$JO6'^=4'*T;] IS<-)]9RC" ^YSRD\@ ^7WL<B# XG#>5B)VL2SD[:G
MJ)=1G[5+:ZI(?DI[ONW3,)%!,N4WH+((M =C! ( 86B'J;H#*%_*6$B>A"KC
M]IW3_Y[#*BHY+Z4\*I:&&+5?VCX&V4KLF2S')0B8DSC5[]5(;S/S]L\-WQ!#
M&YJ=R5(V_EK'>GW&#EH"?<O(N00A(3)Y/K'L #K3RC2;GJ,LC84H$D?BSSE*
M57FJK[.(4W>*/+&B]-K!+DX)7#I'R25K[ J.M[3>F.^[%P;L7IL%[!<TVRFR
M3]]FH-Z9KFSMY&\Y[&N 4)'+1$)(Y_$#V'219!H2:L:3H/XP)Q*FI9/&U+D%
M>O9.DWH_VG$5=EO%8M&,L>P3-4)ER,W$.R@SM<&K/'SH/8FK Z?=BI.,1D=B
MZKUO5*H_GJXYEP= @/)O-G:*AI ,T&0'J(2@*G2.THR2[)"/40EK=]R-@1T$
M5$?!9E*SW/AAAK  L1,0<F..TLHDYYBDJQN"ZN8H*E+Z9 [JDH2&0N+VV\%Q
M$GP=.HO&^>>["/(/[><H9X5F$XZ.2'N+R"J,D] J-/:-A+,K@QE=N!,:^8J^
MH=?WF,HL++C?T\^).3!5Z/8QV>>=M'ZTO.3]%<FCF'L3!0_R0A/?MOVV 8LD
MEIG-WULE!\_E]<U1*( RKT A96?0GGNU:ZKTIG@X%H0JX#(QFA^&07&(%>S<
MHEB ^P8Y,:'N<PA5FH>.EM^?('RN)^[K>=?--4[8E)E\L2HV-.AMC<TG2C)3
MOX[,\H^0ZH<A4'H5E#X$5//]7&F#4 VD^@_Y3@3]SWKC8W_[DR%H?PVI$L!6
M,O^6SE'D#5J-%B VT0/N&(3ZSNE9B)D%&9&4LUZ!A2G,(=4#2/4'A!0#JFT]
MH"J.'$1 DO$[DB3(6"WUEMOJDPCK0=P90O>!S2=U021K <AML$6HL><-Z9\,
M:H[]_VYK#+H)D:1W>'%O"U-W 3("ID0M=_1D_5KTWSG*?T/GU\-"D[\!9V6&
M(Z/+1>]DQ#(-^1EI.%*(^6O'W$BT3D47ZL\3K>VZI:A[:[:[ ^Z .:B'2:=F
MRFEO+@C@IP)IK@W^,+2 :+L"W8SJJWGQ06R<MYJ^!<L;>/_-_8\?L0TLVWG.
M#:2^MB=,@_2^W'58J=Z3-P+4V;YBKL07/S?<<06B1$/[W(=$!PH4L/$KAZN!
M722WK4)+H>Q(@Y"L$S*;\1\X'LVWR$,^>VJ"_@5*AQZR=NSP21TO",(]QNN^
MI16 R$GF:QEA?AH3(.]T:E))Z5GX,K1\<LO#<:$U-ZR8Z(26/VW8B6C5V43G
MCGJ)Z.E)CM5Q]#Q839-6:+X+<E*]<8E4,\TC\*L# 3<G71/]%L+:=K-']JXA
M6@#S G0EAI_I/F#3%^^P8_I=N/D+@W":,=31WH-%P8-I;-\8H&67T!Z#V@J.
M01F1V.\78/V(RU=0PZ]D(@TEFIZLR:YTDU--@71&>DT08=<S%031N,?(6#/
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MXH1'$_G>$ZQO\^MJKUR=HY0Y-VFSA50ZG;L%2T!?JIPS8)1/RNKL"%/D70O
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MC+OF$6Y_4QUPW(7T QQW]_&SLV5G8C\!1: E^I7ANH0)?(6N0>K@#-W?#+^
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M=U-RM:X#K>@;7%H[)<H/S 58!SBW-]]B6D/3/H1<=4:(J=Z#TXYY=?ALU__
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ML^G&MQ,8UUW15Z1S-V2+EV'OA\B&7R2G^/U92F)&G."RQ-+'^QDK7\FO9Z:
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MHLA+D$(JMA%!UL7L[+0NMY*2%^['W -/#13FVO>FNB>!N] _<';<Y0SPH1^
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MR24V*FR'T.-005D*/+_).F]E3]7$5]ZE)L=@]Y;[3T9J+]A>N+5+%^B52!:
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M7,0P+#V"=LW@[$6N8(7^BO$^DJP*IRV.4]9&RX"\X950<EL"N7L,X[.+3[F
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MI3_KZK0-3#E3INA,LMWF'P#]-G)^<8=G_?W04Y=???4+_EW#%+HPT' 8[:*
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MO GO"A]RY-G"_FU*?(!3U="HL/+!^ZMP6B<5\AHF(A@@IRT:IC,-J%40]N,
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MO=U<>#9O<<#G(_S:.I,72\_N^+1Z&2&;\B_H5SF(@Y,5^'34$)P0TY+Y6T!
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M0*5746OZK&;+H-8ZE7PI/"Z.(UUE$)0)YJ_F-O0@>U0TH^#P2:>T8MD#PPO
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M*:Y2EO#QZ.^8Z7:,]R>I]23C"X?E%LP%B*WN'G#. LY0Z$*].Q!:&7(,E'U
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MG%[74I_#Y0XG>7?4C)'V=25K"K=4=:T[-^K86!9XPO;@.+IPWA3NEXV8_)W
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M'^][E6OPSN/5A:;*)Y>!Q<#CL:]RQ(R(+GRL>P*$ 6;[ZR=$[; ]1<0Q85C
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MHEC!7%F1_)"31EF$&CD)3JG;XEMM]+IKB OH?/3S49"6SK2ACP0);JLH:2O
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ML0YLF<)5LRXSCJJ(&3)-EGT*CY8-+$9\\%FH_7/E@[=U3YZ^BKX5/4 0V1B
M.9R$J$BSR:<@)<E]:VS%KV-WI$X\!Q_2@;JJ"4HZ"?2A799; >?;$SEU0RUR
M$^3_8N]-HYK(OG[A*"("8A00%(2HJ*@(:16D&T-*141$C$,+"D):$9F,Z6Y
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M2"70'D^+IF\XKP?GPYZ3//:YXV$/6&-JGR;:HNUJ4F;^^@[7UR7DQZY+A<Z
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M@VQO<<[J;^%*+2-!-&*_@_82W#OZ0D?&ND*MD6ZX0-F2YL9;B@B\('HJMG(
M"2":1MJT<2E :<QYQR8_P5P9VQ%.NO&D7-4ZNRFXP=Z]-_2#7]^J*E]E^=N3
M503]XOO/P S @FK'MH7(&6)'- CN3>$L1;^%3MU>4ZZ2VR%CC1Z!J>S5RCH7
MQYPUXAZA_LSPZ[U=97]T2IFV \>:USS/LV6)VEP/2-Z#]62$+$?-+;29B%+)
M[WNMF-04*,F+V:%P<891"F6%4L?GTFW93O<1?F/G/L;I\1"#EL%-R,SV!FZ>
M\'-9G%7O]IR6ID.\A2'^3.;]+??<NFOVS-(M\E[\MZ/NR#2A/@Y7Q WYTX_-
M=:#VK+X$B*8A^"0M0<E%"!C8RR;AV<1'FP4+WL6-60YMD7U._0EW-2.I)"74
M&1*V]5>5ODX4K&D+?I;?^\<7\DK1<]\5^XD]OSO!@0H07393FB1>_X!*9GL@
M9E"8]B7N-:]5DB:^5135" &5="1BFB#C227]V-K>,U9=>SJG"2)*(.2W QJ\
MH2U-.X+UEXW8G+DS-^'/@88+3]73A"@Y\FV$=IG^/U0/]C%DQ4,V5?^$ZK9=
MYQ[*2MRG?T1UY;31"6>P5>QY^EPWL@5]FA 1U0/84LZ1,^)L[]B$/V^M[428
MV^'#!=%7!I%3/1]&FO("RNZ^N\#1'*"[L[YJ:_1W.+;8:QN^ID3%SY@R$XVV
M%:'KGB)O^9:,/-7([FZQ?8R'6_X+Y4"P5W4.26,7]+7)*N]F+D-99M[9,7$G
M)J#;56/_>[/_OB^V 7^/-/!%GPOA9,RX145$U@:^E/1QU?:EEM.$N90H6* $
M7I(N3^8O1'QA1U5Q&GMC<;3'FV2*NWAQ-[9QB+JT2^P061/5@YHEQ=J7/(RN
MV7*O()IXK]ZJ-'*9P7A0)OK;3$('Z_?6FN(>^(,^9YPH*ZC'3*8)J2&/<1.6
M*.6-S%2R:@S9]YEJAW0UB,Y.;HS:A(BP1:#ADQ=6E0I]1$,^N;*.)_4(\HE1
M?3L^F?'Y])F3S*[S_S-M_%\NP64\))&0M1&CAW2S(ST<TR4Q^'QN5HZ]U#$M
M6AZV*1D.C8'G<TK5Y,7]G\8B[ 7Q2AH76]PEG*D)F]_EF[N_2]7M4D5>,&PU
MQ19I-X;ZS<\].^+(Q5I Z*@$64/6P.H2\1+.[WRAY*+8@>V[V^7):8PT$HI'
M?*B@.4]?E_J+++^ G$+9"//J\PD]M=%YH;<8L271+0U;@N3: 'Y,?.)#?9Y,
M=BZ,H*?<ST3#$#ZN*G;73$U*P_/(S*GW:\@A:!E*AWE9&.DU;*OF-;W#UO<C
M=#\]/^Z <B"AV4H;Q+NDJ9VE>LU?/+(9"?9OGZ"7AR+\^GG$' II3J"U\2.W
M1@*I\I? /TA"GJ9 MP&3DN87(5+=490!1=0#!.?&FP$>_$P7\ADA<^'P@1UG
M3G:@=DJSV:^/P+G9$XW"P!H&L7YJ[O/2K"-_/=\2NI.Y\C/V&A0"+\%^FB(A
M&8@B]?%QE52(3=G;P87%*13<;>:U7*ZUTS\97 QO*5=HV&##5MP]B*S IK.D
M'^ U%TNC^KI=G5;$:VG51VVSC#5/B@A3)IEHDOX^[O!B.;2;U$=345] /#5=
M\QR/SWL0KI*Q1^<-^W I9DIB%F"S"FI^4?BG;T0I"VP\GUM/Y\H75B49-09Y
MCF\>FFJ^6!IM=;[Y^L/^/X>FLF\(W]>V^TS9XH"MBT\ 8MI2@QR;Q_H*5&W)
MXLWL#?"<WBUY8!9J76(Z\JW0:84I_5->TR\=_=&#=K!5GLA*4X+$-GIP<I\,
MW5?]*8_2JEBB"XEEEBFIAADO]_M2+\R_WN+IZ00%!D\3DN^ "FZH74\\2!P!
MJL?>3229'I)T"(-IR"F)[(MZM.;FK03G&Q,BF3-G%BT&N!H_I_Q<3Y?_G!<)
MT@U7*YX3]"/WQ;,A'W2QA=82N:JS1MHPDT4*/L^#4ZE;B<SN:DJ@KD,$/RDD
MZ=@RK.UZ?>[0@Y'ST2S'IGQB.V=%2(Q9*2VJ\)/,6Y2Z^BW%)^EAU--(JZGK
MT5M.@;],$TX($)>Q4:[N-/LGB#;Z]0&Z4?]8$D'*H"^A&"7"/MIS5?I2;)YC
M0Y*U]@827]Q''^ZUWXPL%0R)G>&<.RK]K'%GIX.]CYE/WG?D'NZ,T^]@K&.>
MZAJ[6TW0E]P7XR^@X@%I-A!.EYEJC^E_$4J(Z'Y$J//A](8ZW=Z!T"%04711
MR3=GE?I!S7F5KU2T+& AJ8FS"=J5I22F<A:+*M^2W00+CPWW>OQ:[0&D,^/\
MC8X(H;;TPD[QH9E"O7A".!Z&OSG$WJ_/'F]+Q^&BL"4'C&B3):HV3!,6H(DZ
M+RE\F+*. =EHVP*@/Q-R9=P+UY5MF9]K3U]%@H.ZV73#JE!'J""D#PD\6G[I
MU#/O*P1.=\?>G)TWS(_<696Y\ZC#M2T+KCE<^.W3\)Z*35=^_WWW#]OG)-/^
M6]@HL4$.!?(01Z,<28S>26L&D30T19L]I]NF6YX>-T+D4@W;*:#:V5$7V!!*
M@HTR*;2"4/0 U)823TL)"GVNU%LWR,:GQ!F/6%_: KH^/UYP(S;"ONRGJ+!O
MC8;,+ /5<M3*"3-1*T%DE;R!EYSOR%5HVC1+X2S<QYJRR*D28VQN%+BP3&P[
M+%X3+CR*>JLV"EXII@FDT#5WE+K;TP2SR%8S?HK0ZD4O.T0Y8AS1I:[5'21P
M&@X<P>QKN\=0X-ZP_<I.1BT@"(V4,3Z\N"<;C@BJZG!+S%KK^';\-B/\L6M1
M=UE5?V_^&SO_JCI7>9/)P&W3S>M$O*\&B@34:@0SCM7Y8EW5TX1R"9Y790)?
M)%GG'3HRZ :]N:-@D)7<9IWGYL,]'/NHJ<$RU4@22;6F$FKS1\(?!P_51'#=
MRG;(#W91PA.*8K:<)?YT;S#Z@-^9S@N<T@YO#H?3)X$. XBC!+503?IT3!-B
MQF0\'%,T$"UB9*>#>JXKSCG7'E +TD5!BYM:6V\(THE2,"V?!.?F:-"MYQ+#
MP/!PP0#KK)V]]NN^MV4,YJEG76-A%PS&%V0B3EH</%_B8_5TZ,!:RMZ9\6M6
M*\8NUW"3C_M)+%DGS,C-]G/AP:RBUS]7'XA)D! YJQ%F??YWM 6O$U<%'&!E
M4RA3EKG7O2+SDH_Y6S*A7LW6:8+1?$S*KS1JH67QY[@1N7)A2_-#X-1(&S%*
M+O1IQA&]PDS>R+M(JOA0J,*3U*C&HT4=P5L-NR3'%NP5?2?*HYM]HJZO8ART
ME<^7_3G JMS3766[D#CPR.G#F#VGEUXID()]88?T0LHA&-A>K;\U+D_=0K*Y
MKLJN/!8292.2MD;LJNQE;RV-/-LAU1>4AK+N=QWLU-2ZW0\*HE:61<N*[A3T
M'7E5,N@5+?=D'=+JWXJ_ >N_G>GS9FB"6.N^0<.Z3_ 5+=E4-]01,8#SOS:0
MC*FKT.^AMC17C<_1]HBTR88:2;.GH]0CH9%A[>\AORAX$M;M9A:XZZTK8_OX
MMRN[&087.%D'Z+=(D"\169=[$50\)I4/7M1]SP)P99<*KZH!:W0KD@T5HB$X
MBAMHD4IL6 &?!S\XKZ%;X9-+5@A[3_2P28^10TW:A'(DPF^WANUCGP][MF;_
MD3W%_"_5J?Q_+0JD8!V2JK%1G6XEVZ5;[(IUD:S9BZ!@95H694M@J#/<4[D@
M-R+^48A7[$_A=S_=_,'O$>MZ8\UEJ\!K0_E+(4U.B6 X*NKGTZ[]_)4A%^PU
MWIQ [!4)"J8CJW,U;; 5*06L)&E2%;1E*$WL>]L;LDY'W6 GI74F^Z"VY_JP
M]=E!DPYL,\M!.?$Q>VQT?"2X=<_D/NAR4+<^_W9XXL.!X*;PB'@*_9$EX0#]
M,FB!)T9!'I@V\P<G&HIK=!.. 3\+VPB#TK\Y#NR?D!>DIF#0= BL_)Q)V?H$
M:1A\?0 *$5V@'(U5U9T"3:-J[$NU3G(+9,4LN"59D:E2NNUZECR,YW#,Y*+.
M (^ME!70W_IR210XAVW[%CT\>Q");8A]APA:2 OCLYT_%Y?;3.1*F6EB>SB7
M]Q?4*0\^]NZ5*DPI;%]95_VL*O>@7_KJ; )UXKZ8K,^6*.X#Y3ZHI;74IC<+
M")/('%[R;4]3-FEC5'<<O3UZN;4,Y<ZW>1\\73XV@0LH,0^0"!4Q;8/;N0T"
M=8?0+E%JDY16OH;_T*?H6(AGJDP*6Z,6DYBI!5,7COT)BHQ&#6!W[;G;VFAD
M2&<WDO#1K\M%[-0"NW&^81GXPHR65"&9-%1B)!7,]E+&1#J\Q>QCK@RMF6S4
M)!2B.[K"N0><BD-J+Y"$50>\"9;_W2NPGE[-1Q<;:(WP4,'R4G[5A7$ZL7F(
M>PGRR+ .^ICRL1RFYU"7C]@$#]!.N(V0T^1F;$\UF?1*62BN?EY^O;%%&G/7
M.Y'Q4Y3+@]R%?C9QDG(1:NFCG3FC>0D)"X(C1A-T.UD6:@8W+;25?>C!I^(@
M:#*[=FW>]6,MA7\B F5+=AQ_/KH=:DH3K+Z!GM]2(&"%T9[VK.J:F#?^.JOX
MZ8LCVZCM]Z]<N5NY\-'=FR>V$69=\Z40C%;E$P3-=!RZHHL_2S$3$)9K91#0
M(+_0JN1?(%70&FV!-,Q27_  *3'*9'"VQB3D23(VA-6V4\S"%69K7DO/;QT*
M79K;>"74!S9H^MFO8(1C<]./13H<7TG0W[XO<< Y$(BX3,Y4W-Z!"!ZB1.1O
M721"E *6XUM?Q;69LPXU#)HCI7 TW3A:V[NR\ZL7G%\*@2^IE/9:6Y6I:?+[
MX2"CS'A_AZ-=U2_D1_H?G'D]X9@-G)88Q8#EM$9^_U;M-E[]-*$Z@HLZ0\4M
M)'/,'J=JHL8[3K0.;'THRWKO6S<S6OU9^^\J.RG!1ESVSLJHH+2LQ+ DY8@F
MV <VK*JQ+RD('OZ)QIAGU/=+X <?U-P+,PE7T!$GH]&$NYQN>R(4B*[7G&2U
M->&8 G-@KP.MP8:$GZ"QYOS%+T3/LWQSFR10%N(<_T[(-QJA6L))=T8Y2SL[
MM](7M137TF+#8ATXM]O_E]9C_[N+_H:+VKD\DD.^<G.GM>%,&4T;%!! *%V'
MU-V[]'C!]CGF\QSF_!@S119\],$6W)@F_$)C\; WA[1'IPG==??V&RW":4+J
M9JP>@ [0<1:'FOL$Z=;P(-&Q'F> .?8NK66+37PNNIYT.==*"UC6&BJ37!;]
MIVIF_VVPIRFMZ_[55?11P'S$N+C_78C/NK_Q>/#1$:5LUM;IJSBD!DTIYPT=
MVB5'UO1JO.%#S9=LTW)W]$X3SI!DUEH03@',QK-^8TS,BGHX@&Y (B+.J;(W
M3905SAPR9P@U-E_6W@XX2+V)8^.T.%XZO^(T6,Y%K4 M"''1U8"EY =RNE<#
MWQK]SFR\QEG0"/0EJ^,K$%H3U1;>57(\/+'D";\0R==*][6/<5X_>H<<!-,]
M/F:>J?+<Y[34G"+I8VI/P/R7(.+.UXXA0KC(\;8V3_]\FG"*WA^L_5-?X.;W
ML+;T[]I8>$0ASZ;XWOO4U:3-4)?3B"R[6O>(+=>CJV^>YPA=1.^/;G=KJK]B
M $BG"38MHR,X![['=D Z.>;L18AFIG;2J#<$'"(92R+'9H$-;<@ZM4."2F(4
MA?.9L8N , Y =E?U'W]X9T]GKRZ@[57WXRI=VT9QZWO@4ZYFIL')Q@I]JN0X
MN2]0Q>=R3*+XEF)/K*M%FX@XZS9A?X@)XBHD02FP9A]'A,HDFR3;AO.']7^=
MKY-<XI!8)_H^[EZJDOCM7MG.]CA3MJ^HIH[_EU&S_.]#=#Q#5Q(1/!"5FBHU
MB8[HXBPEV.Q'>]>%S>O0_<A>B1Q6C>58@1"-E"FO&-,8PHE*KE1CB :JZPXI
MGB&)RGGL6 $2*%T4_-JE_"&+X9IE7!1_TS3)B":NA0-*5HNS[@Z?3[U@-,B?
MC6T!ZW^NM8,#7U*)>J'D%/U=(AZ[.>Y-JC(C*6@I.3%FB<:^G28H;U%B(Q0A
M8)-X 5#5DL)9OT$4NA9RD90.+6*Y'X(3&O0GVO9TN)4HO@H>)(5)M36Y2AYJ
M4=2+F5*G"5# - '9(&-_VX-GNO]LD=NJX.+1."!:Q[=%@K6/ZY##YR50&>5[
MJAVI[T/+=CB-K](X2Y1$FUOP(]3W;?S, I##$9<4>5_4CYV<,<[,N>,08I^U
M5HW40Z6*CZ,KE&/9).&" E72GJ-B=U:7'^*#9V6>E-<7UF!5LWBPA"J$$YKY
MEFP[9=G*KXTV::6+16GLC4KBG%:5.VS_>+)U06543 1C2^'?P="8M@M9BKM?
M%1ZXA\'ZH.-Z$9,="V7MTK]8K<]A']*M1:[U*LE-_'0;6G,&VPSZ,OERZLU%
MQ4<D5@$NKOM02LI  ZTR-HAF]^ZIZ''MUZ_7'1")%TJ7&XT6X\&N4C69#"K*
M)941J$77/FA2FLA/!I: )\D9$E+M 576 *EQ#/9XW<PQP6GV_:&\LQ<?;U?;
M@B8RU@E5/RW-3V?G4Y_WI'35F%/PR-F.7[*=L&Y Q,?#VD4Y]#WNT3ZCVY7
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M^+U!F,=,2W0K;*:4<3#(N..#F?C#8U)9\^WCN@78;R03R7'YK"'[]<+,OL]
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M<^*FJ6=)_!S%8I^X^[\??W)]2(NM[<$<$,>A Q[7?.OE;T[7_'SW@ MK]G)
MU>SY3B0-LT00)W@:,^\T)&'MO+I,9*0$C8:[<MEF(TB V,XU/T<3<4;B=21+
M=:XOR36@_8(BG4$1S'^($_<F=I6*DD5?\D&1V2!TZF;MWM#[(;2TON_/ 1"'
ML<I^T0M @W.M"=QC'AH?B>(IG)FN-FX6KV%:HB5+9HABG2V3;2*('5U[J8Y,
MK['V, G5::#.\JBX OENJ+WX$R1-O;$NR.IPWUGM;AHQU@[(/!H9=T&?NX7
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MRW8 I%0@B"B>9CNEB2<>F C'8TEA]47M?(9*"^Q[).J?6IDXO^]2RL"L3=G
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M8+SG<T9#R03K*)-<6":A+_$)42NRV!\/"2+@K1)'(GRT0.IHTP(/-JI?!1R
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MDIHQ<YGA0!Q]B4)&?FRF#;B-T*5T,_0KGB6V9GR0O1Z)UNBLD-V83L65BC*
MI6XY%\TD#7:VM0_"@TXGV$BK>6I+LQ!H.DNPU?TY/SJZ'"FE$[",^_S79,PR
MTM@LW((-D1_-$O KBCI9'BL:)NK3C=>PSY$<E2P;AZH4J=UTCG #,ZT5<UF.
ME+8U"KT&T?#[XXZ?B ;/@DLI7!^KQ3/-&3G^4/ZUKU96;ZJ^#KQ5__M'V+$X
M')%/W)YMI7HD=/3)QIA[V*"HUE]?>LY$<&W@?5/\2?_QE([AYVOKZ_>6IVYX
M4J1)_Z;PXXZ,:W.P?)<_@!&QGC+;AGN^F?$'-H7]C+PR>J"2905'^=?445=#
M[^4R-; 0N2&>>5ZD!LT0T?;K?]GG!#]@,B0S'C<?NE;]3HM[,++CS%V%RU'%
MRPK"Q:CRQRWI-TH7'*EKB(Y><_-FR<[_$1^_W_$K?XR(6?[Y)'4")_"IW<?"
M:982W A:OS81XO5YS/5[2ZZQ1(MSGZT_^:MF]=6*9=\'' QF;M6?Q-E /G4E
MZMUK(IR@6;*'Z7@L6LFB0.^NB(@L7\-QEA\29? _QAX^1R4VUF*_]_I$)4'O
M!@-UEV;&)#1BW+-$FVPF[S"\V*Y36GF!DR/P5UN&J0V'FHUXU$]-Q-^ BCG.
MKEL )QR\]2R(EB/P@P%)$Q[^P^$ C7,[WRY\9(0YI*&U ^1()UT.MH99['U>
MMV_K*R?AK3MO;9.]\FO!<N2,?\_D5%"RQ*[24_[ZSAQ4@(^Y %1>X]6"VF>&
M+0GD.K+V1C5Z$-'<0SV,%9CO&T6M9VL=<A,FJ;ABVG!',"23M@1(O4P$KN"S
M>ZQ/X8+T/^ 8"6B/B ]Y%=>KZ:2+3:.^]E] NHR0O4\>=VM/$<?!R0(3P64C
M_J@08+)3%*4SNK]QQRG)L@J]-?(+[E.0\?LI[B7 3N /C4FPS_J!6&(>V::D
M7TB*QS8,"K;,UMM6BZO?'#DTRJQM<S0?((75U1E'JTX5;GW1>N:OT'%/F#US
M"P+TRY%?H#YLT5O#24SAI<,!0P3J:+PK)* +D! EP_*MERBK'+E9QN2HDO)_
M8J@MNFQCIXN7/H):\G*9^D-%CIH .+_YXK>Y*UOZZOX*/3 7'W(5KO\8EAW^
M=PZ&4[UP7T]]+5PN[5K%[@27X&9=,NIN*WH<DBY<SQQ2T=MH=N@>>,.MU\?0
M0T@I"'5)(FUA;NX4GQ@[XYAUEVFQYU9$7QW/'$#77[@2=W^O.N7%&D,"MO#&
MW7CZ8T]MYVS]8_Q1";'@4I_C5=AOY,<QV4 ,+U-46WT-)K7+&[-UU,5(L"9
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M]$$Q= I0&W]4)BF(E^U<MBB^MC!J/XYW2%Y[RZY'!IYCTAC&]._5/G %='-
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MD-#9+;D'0 <8\#IB"RXE9"-*GY%_W(&K%)W$B^;AEV(F+C!TD*5J7:BP_D%
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M=[#2:F31 Y67>A4)\@7DK\40.O.;/L$.J+#0\ 88$<@KF*5DR/&.FBUQ2L;
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MXG#AZ<TD(\(<*CF@84UI)TXF3G-X8=O]>0[MI7QQP[.PT^_+'CUZMLM$BAW
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MEGTM4,)%O5S;*6>1[F]N-&P:=,NE#ZRW?$Y,)I-EKN>^<[90EMB.W6**33.
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MS^BXM'8K;!0>%.LN:)@*]YPS?V87@1-!I[A)_E+Y10=#CQX.G.]W:\\6%OH
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MAMMI^OX 6>'=^I'@H6\?[M\O+YKCSG'N(-?^2_6NU0F(#G(U7>A3+8,T&7&
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M)'RD1KHUCY,"/IG:G18C@9YO+LM+_96B%WYRN;[<.D^$NA;N4%$Y:%WN-?3
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MUE3,K92$F80N)\*L/^J+_F\TK]^"B%ZMR4_,H98?BI>R+EY*H."ZL 2O+G
M?S>5&P"#783,F:/UXT;P (#\PP4DB#'O_/=^6OMX05" &2G#F#76[QMB;JZ6
M2]?-./C69R@RN/V#3PQF!D77('3I;T%N$KZX,2N6]6O$'K#'0[$QW81=AG@E
M^@+^S @\!N MT;SI GW@;BESY>S:^E+G'R$M*U53H=!XK.&7].#LP*03>3=W
M@);/*1?$E>@YL>'G,H%O@D9(+2.N#](9#L*J&H'?2VS=6I^%Y6616F=NEXJE
MS4P*-(V9_Y.J8F$>+CJ8N07Q?! 6+N4[59?]37/(KR]W! H>AMT3C_< KR/,
M(9]9)+1:50.V?9PCQ1R*LL$.=G .,K4C5H5J R:PWL//(+H[Y?TB+[Z=B#Y'
MLKA?J"K0K%B<T7[H[:@>_^6I<Y+TGP2S1[_-NYDBMN*RV(KE^.$MR.M6&FJ/
MIQAX"[<@]\D[IM&;":1LL@28R./[ ,TS:03<@\6?>*GZHI5(T**GO@?>2L>7
ML9*;U?++=Q63*0%U"S,WB,:+$N]@$+'MI,3)C9PD,3%)5KK@#V>A>%6AQJD,
MZ8[]3$(Z7L\OT :T"^90Y+&H\PW#S;EJH9N#6;?,$$FBXRB51>\$$<6J/"+Z
M!>Z\R>(-AM>;#-<>V%>RV$-68BND,^H1.4V$'.)^ O-O+2BXRI"M,X 'LABI
M=T66((8='[\2>*$MZ=)PW08&@A.#93*IU_]D!D9^F(,<DKNUGGV._2B4M]F2
MUYH_OVU /-=AV'8!M!1;S;LN+(TZ:XP<%D1RE@A: DONQFS[+PM_O08@3,QD
M$#L752)LW?76HO3# FEJ-@/E!G?\!U]^O:EVJQ46.+0.'EH4S^XO)A$\@!$H
MKD/L=7FCD&UY]L+[>#4(1",/"9%M!J?^G\*2F"^6CUVV^#,WXRJ2USM]J*AM
M(OF%S9(4X"%U<]V\9>8@N0B58$Y0P4[16G@Q<2G-+VO9/L7:]DW-(X9KJV%-
MG1+6PX<,A156M6:#\Q:"?6@>2_C$2E-P2%B.N :E]_<62E!1VW%1G6/-M1(]
M5@9CAS_C]&IZ.(3M=L 2&Y%B-JCH7%D&GF<C9>?;E<8SJI94\LU52$:5H3]?
M,WP6\B>8L(_1A*L4P,''*YH 6O!%4B8! 2WQ;R9XW1_W:-E?;&$T2E"%=LO]
M&O:'LR/-WB ;:0HGX9\3KZ!N"YK%"TPE="'$YB!2&H*[M#G0>XC6_#2^O<";
M"\L1G$8S&6ED12Z":BQO78&S'#45NO_T&.]PF-G6R57\J?#'P>$B1^[."7^%
M88Q-?Q>ZC-%_\FQKD]AB>\1#OB#L1@1ED;((O_?,$G9G 2:<L6ER]4N0Y%8?
MOR:-#>SY,1^)#:05$K(YK?+3YUBYFM@[ABH.1>Z./D5^:C]MFRVKID+4<DJK
M%J["!J8)*(:J4H%(Y@[HO]_+'K7S^-X].BA>^6BQNH0$NDQ?;_Z#]=Y$F5A&
M!H%9! .L$4E6>@]Y?W(+!(JZUMR?[ZK1E1U.S_&#,W+@8R9,'4NBV>_\Z9'!
M!#=@:3\WB;2PR'/RARTU *]Y-=UT@VYI/W1OOG?R<*C<9JM 44(DI<?7$XW#
M %N4\DW&7K'AQ#DI)7"+YD*[_>4!Z#(UC,V0\A'8 Q/4M338_N5EN Z< 35]
M^X1D^E:?DA:W^RD[EC,<Q<^5N1GA7ZP\Z#F*[VZ-.2"Y!=G]VK'B$W,+,E5(
M=0X(8Y=5"O;DHUNONO&M.(Y@CVQBM[%>CL&&:O/3&U>#=OK^\?(PYY/H/V9A
M9UR'-OR0]N-A1C5FV<:7.D::T>KS,_I3A@X?YAS12X[_O* ]F/:9MC&PD/O'
MXL6K1<9QL\TD,8YD_FYK/"?^\$-8@<S!^076HE&[18>Q.*PTF_R@M-W^E>="
M;:5WJ"4L>WW:W*\^M)V41&*]N?[:Q <9\SQ4=*"AJ=AHE27#O\>W)W3!*<S[
M6Y!F HT@)QJW@HK'OB\X#AJS4.F6/7W9(FW0X@*8#1"7?Z"]7_)7XL)V4$5&
M8U&YJN .FO\1BH7X2VGBN$<]6U)+7BH#[XR/SPTZ)N\P$<D4N<,@".;?=5<2
M37#P*[<TRPNZ4(I91\-3'EDJ0_[=[7I;-?B7+N!Q'VX-_.SUEQ>7S.3H_5&Y
M2B",1H?>AY^H_D^$50$;MG>QI7 \ZU7WG1.&^>5!89'[__G%]D?S'PBS$,SG
M*,"1F")2 AE\;?P _AC@T<6X1]QCI?*IZB91F6P$5CL!MO5\&YS#Q$KSRID>
M>N]?XJIM5,LN=I5VTO_/D>^KXU2O\<.CI<-P$^:*>C=9:ZCLK4C^Z Z^K-@.
MW\ S-L(6"I-(K/\I4$2Q4A_PJE>L)JAQ,9G+ZV]*5E?[J;#] 2/++X>,7Z0<
MR5]<>X=2->W'[/+Q+M,()1\;RS=_^J_?%P+@_LEYZK^GZMB)_OGO,8_0:>L@
M#C%36>WL6L_16[-.(U] J[E!MD6/WK_*7["U@G/<1AI=;SBH[4'^CPO#T6@(
MQFHPXK!6FSC2IG%W@$$QCYDL8W];]N(BG%JX-I2N0?6;8O:D688VC_1;,,%:
MT$IT&KF6D\>6T0=P>MQ@ZAK[P:[1!YW3$YFLF[6KS,;.[X2]"&8;H6E!6"Y.
M\U**<FK!JZ*UG3@9\RW(-IR:=D%"'4XB!@_'Q.^YZ/,10]8.M3+<A^J92VBU
M;QE&$$SW^2Q#!'_^WO')5_S?=42)1D02.#%%3HP0C5$ .\8DGW=6^#?E%FD'
M3G[4E"B+O0957:CEH"1!5!]=EL(T5EWTOF^>_1+L'> QEBV3>G9R_;(D2SM&
MZJX5#K.\<@8?W]J"7#4&+:I9?O]PC6D8\&A!)OY(2!S6<0X8N,>5[M[\5"[L
M.'GK31/E->@(M'IRRY><AVUF?>8M2QZ^JD'#'_SJ?VKX[L@6).GJ;SJFP,#Y
M@BR^3VB+4S# [_;?W@GJLJ8=YFQ3-3UZ9W3&!&(@E3,K@7BY=9/W?XZ:W[ K
M^2/5A&-XBE8@WZ<_B<>"/IR*)/QI0E>,0(E;']0ZVB'#@8%')1*GNBWOWV+<
MZ!PRM-(-T5("P]C;A^NNY6!OP2UJ/_@>\PG'M1^.GUB!316(I#T N_/"8B/$
M-6-09PM"S;9FP;J6BK4O 07I9%VG%_VL,Y,X8_Q4=!$T+0[>.E%RA(^Y?S5_
M#J8@#I&OX^23[:D_7*7+[6K\>]B.J+D"Z_$-@@S:&Y$N0+R:GM_\F;;AA/ 9
M,D-+ELQL01S'UJO?8-:G;3^P3VI)OU7OQX:'O3ROI??<SE4J$R)BB^.@'@%<
M@DTV\BX(7W; F*AL(G"1]">C>:"3C4S2TN"FYG+1[+ ^ZOS&5((R016[]H>6
M5))(GO0G2L%L6U!IJ)K.:J6&"YBC'T20@U>6TSO6SGZ;_9DL'O@MHC[MSP[[
MYV#_.P9@8SR9UE5B#$P++$EIN"LLA ).#UC+,-5T_I+?.MKD%VDGS*O9<#(2
M[3Y,C0V,WD7[(R]/CU1MAJ$GB21KQ46]04@D:V#/\*A@:P7^'V(SI?OL_K!:
M\D%LD0?P,TE@%E^]>#?NNK_A*,ZL%INY.MBE=1! 9&[('!IQ>]BE=6A4@& /
MRH0>\)Y7(=TP-LN.F>M'@-HD@7P?:V]_C6@(!G@,IN(-/]<B1NIP%F)NRT*F
MX/P(%7_]<:C?N46L>2BH-KO\X4W=MA&!?O2W$XZ>RM)/6K]"\&<)77:(<"<[
MD90"_\*TZ+/%%D1&S)Q33L!V8X.[U(*3#7!VNEFS+2,=YO3'W3.A_CH)$E08
MG9XR/5>+[;TLCK*5Y;P/[P,+EE^R,:.D+X,BZ2^X@T#\!6$!!4.ZMXE9<0,0
M%X>CUJ0GP<QX*!1--D_JIE^_35^@([-PNAS/J6Z"/*7!X'FFC/'ESC'X"9)M
M?KU]56C<K( 8GL7]R;E(;)!]S \*Q0#>4STSNL+[3<2,&2D_*QEWO[N#/2)=
M,%BL:+M/E9R^.3OFG,O6=QS<UZ2E4W AOGDH^LQ-XUL9K<-'SF'"^,UL$JAC
M(9!;XZ4^%NF(^AG 960::KM [I6UL)4 ;$'8J6^9@_M"M91'/L<6W*:6"^S$
MZ-YMG&&U?R2,3:\TSM'F[IKNJ#9]N!CS0#'GP!X$)A<\8K?LPBWB&8TCF"]0
M@)/?M;7S@$=:F%&'-8>18H*L^7I3_N;FW4KE(C;WQ0+^4-X2S7\[-RUQ-?SP
M:#-19AHU#5X3IQ!O+9+U*FKIRLB1"3A%)$/8@CS<!-]N06[<XZP)Q400HO^5
M@";2EWC[A2D49A%9__?]75$/3#5M19LSF)D7>AQG Q8]G_$.):N,U,)]8BN^
M8K_1++1TAPPI++G1M>A/L LM0' :3I_E9.<EZAUZA@+3O..75(DT!(S0U<Y0
MQ\L*]@A;1=K8(DYPCS$$IPT,=/*/8[]U%WIDD'6PK=8 ,G558!_!M68.4,*>
M;T$P8,Y/Y^$#HT9-N;)+'OFO?6?.3^A7?%+4NCYWZMF.?W/O;\)Z8/*$KD#\
MB7GB3IN_06J". D.@<\H>X^,.M0]#>&\(82$Q7WKWDRMUJY^8>E<5$T-(50A
M#YG>#N%-F%PHETLA7*0 [M D G 1-27!R7\L=A$O6]C0@> ?QT\0=G3L8"5(
M]UC2QA%!0'XU"Z'HT\])@)VCY/;*+="-*JR*K2@)I'GE0KN<E>9.;23W>IE?
MTY@V>:2D[U?W9[@=UXX-%2@3>O"6PAP%*D4>?P";R_L.MG$EF&)MBXQ@$I3F
M"V J<!3[GXUBE&M#WFF[/XT%2KQI'YI:\_VAKU26.852_R!<7IDT_TTDE<'U
M$>UYP,JE;Y>!\A9!E4K!)>%+8G>)ZBC^T%>!8AMWNGGNS^]B*8"'#7>@V4AI
M@0UX@3[&F=_>BX1:5TVA%@&L^UGE.=[(A::WPU<?[6"O8'@=8C_'B%FM+B40
M>9_8^&W9F)NXQ"L3OA A/$,M">FBHUX^=A9IIB'AMT@"P^"Z4/ILLKG:KI=/
MF4*52]Q=WQ+AAJS^0:5%"[PV.<S:O[-U*#JE$_7O'*6&E$AH0 CVZ8ND]-GZ
MC"1"HW(CE\%+ !G5"W&]S2R9'5YC'3Z&*__&7511*_F[,+HU=TUT" RD_76S
M/?I%Z\2FHI;A:Z[.0')!04L!<5XMM4R<@Q:49N+RM!B2)Z&\^R")?PJ[N-EW
MA0OK9LB]?&#4^-+F;&?JVQ>+WOY$MO%>,'%\?,E".0(]LW\\*N&JU\7OG4\[
MS6LC(O[]]1U"<"8"T16"+\'":9B(7TLX(TXMTJ\+B&7'W[W/P.]-6W9I:-Z4
M2/;2;RH03*(?P-.^,1&]@V)VK)J6&K4%R=TD9E!8/MB)_W S@+'6+ K+CBAK
MQSY8BO(OEKXTAF!IC@MJ=:\H%]:@)EL/S0W(E\6P+)85Q+.7%B#$>'"=H(&=
M\AN!&XL9LB1^B+&[PYI-D$=[N'R9WY1->0%N0<YUCIEEN_.NO9X,H4<_,_&;
MF?[X7J:YR15I\L+E+00Z 0-/MXI<H4P$WRPW#;798'5BXD<SZBT"N#W8FYN,
MT! +8*(4MIK92OO-7KR!EH=\2ZPTU4)T%(Q@?U+H+5%/0S5Q*32A]]H%OWAJ
M:WO.P[,K=<3:D!B5XU/^%\?9O*-SDT>Q$T#A__ \XA(",XD!7-B"@/Z%H@Q^
M,'[87_D'7@KT<..CNG*WH_/;FL%Z]LHA+L?*:+PF^*(_#@[DE]]Z'Q1TK+GB
M/MPIE/<3'Y/6Y(1$3HCTQ)%Z6ARI!F9K4WSV9VXKS0GA-DP((J30.QL%Y\<Y
M\=E6F'1+@9[,1D4W19I!"WSFB[(V[&3<CPZSLBFBEF@4R^N_U<3X H):45J)
M)K":Q-+<\0= 2FD*,Z&2]P,S#ROF_6&?37WT$RPN#$7Y'1G6US1Q&%[G7V W
M-XRL\X\>;&YJ:LTY%<;,/%5F8P.!W)KX;B-&G&KQQ$JA,-32%J1^8OD7VW!F
M]["QNC/(XGQ27E85!-=\^<3?@J1N:JZ\W2=2&@IG7^$&">0Y-&^:3.D?MDDO
M&:WIHG_$8_R^#W )P;*]:4E:K@2@M(-6)EB2PW?\$6R_;4?/1#=1.O2UOE':
M2S^?>G,\@FM+U,.<O>[(D,+BY\XZ3P>,FR6H7!I!Y+C:'\[[_??^\'=[W3S[
M1?1F9!=A;V<9E5NP+T!(XW@<>.>>UCOVS"04*/B"]"7+^Z]3I@R>OVXD LCA
MAWVDZ_4SJK?#+7XVN%$C<C IE8*CS:'/SB372@CLJ_LL*YWX#PB3.<YW^H9?
M/G*Q(;C"OOW?'A*\37B=T-7F(>^-4Q?6&I4>< SC0'?X_N$9[G+82IEKFNX5
MG_WAY)D<_>\<&@+P,P:/UK5>NR7F#QEX*>#9Q]A1W%F@L4L!%?;U_F6HP@+^
M</VE*VIG^Z\W'.O7UJZI5GR0@!%+0BMAC3B+89.#++N5,Z4"#-C,(J1NMF9&
M,R07M33JN=*A<I]JO;VQ&%I^S,F0+4A0?;MC:N*<9T"^8J E_/.-XT?2*3]R
M43G7O^KFSSTCL(U,$*QE<ZM,&O"UH<86G=]+UD+SC]5$8"3@5_1<:I5.N603
M@@>5CHZX-;K8K?]4Q&85BXM+4LF>V6>:O4^6RQ0!C4C9@UT +]9-\GZY#DTU
M].F=CPO,$_MHK)<+8SW(W4M5;H]TO2\7916=-68/]B(SB9H=002N! >:BW/B
M*O1:IGM^FX C*YT($4H-)J:6>.(.I<;AJ.IKJP;KQ<?H@Q<;W?70(5*:S9O\
M_TUSD\"")$:/0Y0^XV1BX]I*VBMPB6.7LXY,P^][ UIP,- >$ICHF-[T<SQ:
M!M/U\ZXWX6D8YO;2V4_DXOC#\4.7LNZZLC[H)V"TKOHPK;3?!7TQ9_",#J4J
M[$JD3D^>.^I"9;VROOZXU/F9J<-[6!'6NK#7ROBV;43QG(.^,.0=^\?>$=/>
MPW6+;5=HG(@W[?EO,87EH1O1X=\?3WX72\I $9+*>[,%:?C%U=Z"N)ZA"YO$
MM@M]+YH2ONYUEBT CCXHD50A* ,7%AX\3)K2'9U@P59Z."@I@9WP-24$HX6%
M^31R=9,$/MRBOO:UU TA_,.MZ&S8I0F2;L/H+?I-]H.5NM*@?)6;$Q^S'X^&
M744N;D$$^R+%=8](N5$;S"M^R&GM0<C@3N;V>J.ZS[$RX!=^UMO5M*;5D;7-
M&S5?Y.?'7 BJ]T,[AAQZ4)9G\]8])4CN8^"OG#/O.!%6T(EW+ !;!4X\O#VJ
M+)NC5>OK5JP1[G+LM2?V_!7?2MMGLZ[P@N0 B\./?%"Q+.6PQTQ\WIN+4^I/
M@T!X%1S99U82G-D; /R**\_X .:IQI'4W5\<_U <.U8N91)].O1#[:FN]P-Z
M(D?\)U1C;QO? S]:LEM(%""J>OZ>$?S!S6\,BB0A@XU*M=)*YWEQE RX74U"
MJDH*26>D U&VZ.$^GAT1HC0V>MOG4VRP(BE2935X18?- '4( @7=7CM>W&?"
M-3Z&3N) 4]<'91>M$!-X?32O88$7$S?^N&+),DJED)1A"E,-R:CQGQ]9:!\;
M?\A"0D+(&JD35UKOU=&_ASD,3W$M>%;"\BG>)6$M7D/T>7S35Z0]C--DUT9L
M=*H-1Z C:["./=[^C:S<?=3K/\+2^.=,S]Y9_6F?LQ94/Q960Q[FVJK](60)
M*T5RA"Z]WU+<'X&A/W04=G08 [H]6KJ?FW3 )-:@@J8\U6WL&R!,+6;U2R>Q
MH/L7K50FUAGR]!!S^MTL/-UQB6Y;%O)B:K$PX<4#FU>A!;\B:GTOGB+JEI?4
M:>?NZ,@K*V3-%I9[I.-;'MV<&WXO_]%=?=$!*K/K:*]G 39$PSH7F8+%*3EO
M8WL+#H%:>/V^S/ECF&P=Z@ 6+RT:=/:LTTA3:KN>J]'H=<5S<3BYRGI[6ZBW
M6U?E[P,&=[8)J_"J^%&$Y!8DM-B:15PN!I)X'LU 0DE62.4"15+,(J">5([$
M.,Z,8[]<U\SY&ZO?%?'5=_[!PDA7D$Y/YZ3DJVE5IZK&%\2>X%2X$QNZ"\P]
MQR4D;V1;4V>. F12!5JD-1%5G6%H9@CS'@YGDT>B]:6?I.=)5Y]Y<ZA$4G'V
MNLTI[0-;$%]B@\I*F7A*+<+"#A.QG@@'==A+!&FLQSG@ED4!0TMTR&RLKIY_
M#LMW:9BX91Q8?_ES&*;N%N[$=KK/PMI98MKZ7YNUHW@-X.<7\DC=$N(3<=F^
M$O]A,V9E&VM^"W*K4\5UC+PSE*Z;L>Z'_^9(4)#.E5VDY^=&J*0)'+A82S94
MWM>Z//3\R:$%^U@XTC0F&$G.F5QYP6(>@Q[["+?_&$"-%:D?JT4>Z@F:]+>
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M4Z3<99(@C*OOVS;V$IBNN!?6@6"C$]S^TWASW5@"M)W[=HEKR$A9:VIK,E1
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M[949:--\JXGGU.+/5CG\6\$-\(28]=P6=@H""-R1;D*SL&+Y/1?*5BVB:5D
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M\2@A]/KG.D2K%0RWYW.'-7,P_?.B9<U)G?&"8+8/02+$7=DRO?Z)S:%SG(3
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M'R[HLH)(TIX]F$($G-? PVDKN_A!:+P)<%CL2#-OL-\+,$X+A]O];<\V/$^
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MJ@LU&81<+* .)LF%+TKTPJ9*&"HTV9Y-I_:Q"+Q08*-0?<8%:!KZ5.#* NZ
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ML?N\)T2SWFR+<?GAU1'3[KK5O+BG4<=:F?=HEUB\!_=D4$C@"04?AY8=0Y]
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M,?Y4\ZY9']CP.EH5"27-\Z' T+0&W+\"6TQPE:N[EX)<:Q(;]3ND.D9V\C?
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M1EW5>#O11U^WJP5!$W5;'T:]FB%&^U.")4@YY)"R('^F.F?06LS6ZP0L=/W
MGA=F9>[NKT46[]D]4YPLIK.'#1*%A-(S*?[)4 0V 0<B!& >L4 C&/\S-Y[U
M+^(3X(?7(1KGY[O2Q$?V%.":2$QOQZD$TNZG,E^!E%>]%?JID6N-]4]V+"Q
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M'G675+,QNA1,/,8:FE]!8)$*DT&@C,O>!4"UTB5HXTOY%86JLEA!JB7(J.O
M!8E08^QGPM?4JM>? \FW2.J1 >'I#01QMF=(S4?"A!J8,MGZVBKT!?0O-)KW
MJR<S"S*B]@A5: 0\Z%HM>SW W@^JNX/T4L5ND"C&Y01K 0N9?QBFIS\$<\3(
MOSEU(S?%Q!B?_HL:(4_1Z;V9"XW$?3SOM,^=)E='CP\'J+X8)+Z!J1T%^*+^
M"48HR["B>W 0EGC8C.4C14\B>N6.E$!I;DYTE5O8=C >=EB:"MT:</95B55]
MX;+%]N=L8#2;@GTTTS=AD3K@0GAHU[5EH! ACQ?3^4($)0*,%S&R\6JLP(?@
M=W$SG[3I"V0+8&^P7*XVMZ S71V8_NZ/"0%/&5?6/$^;&2%_Z+"//C_N^3DP
MZ)#*VS/MC-ZI>1BS5/= W8SZ%<2\M@0_IB/[$]20'Z9Q#W,(J/4FH3@I/85V
M$:E!(X&D=FA/'S/M7C79$<Z'JU>79:W5LRUZ#_O]P(?X]:!Y1X!3VN+&(YF/
M(\OX^2TEZ2&K]^:MVZ=\RMZEL(6I]3PMJC>KA=K(Y$HX8^BCRD;*00#O9^OP
MJ?.?Q_Z*_8-4<_+V[R=V69C\H",5[N"]F*O?3NY*/YG[;MFJ(R3,^)0R!-8E
MR=1W>"2$@C$0/2J[U3@P%X?*7G6.G<BL@%XZ)>::2>U45G@?U12L6Q)/I2FV
M89Z%0(-!>IU+O(2I;.^3K2^+RT=804]F;KFHM\;^O7:,$XH##Q3) I0/8*O$
MT:3^RVGH>H43J$(;E?+?R0,+1_I=#<1X ?8WZ!TPE:$(>8IONEU!MH[[.=>@
M0>,M?VU\4DV8,"SJ@-2 KYG,R V"WYW;V!Q,<9D0JJ=QC]$N<U1I7$=L*#V+
MT^1$=]60D#)-#<' .)&E)6<]>&3)<S"N)WBR"Q;(UL WWMS2\MO,D"B-G(6L
M7X<N_W<S[&IC0_[ND&M_'N;TP@[$#5 7+V5R1,4<32PA?^!2;&\.]A=:! XQ
MC=&0*K/<PB1W6=LF9W':[\DI[=HS4C?E@^7S+8O,-%8@*<ID2".DFGS9<O9
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MOL"E/]HEX!L'.(D&+5'S+O(KE*NC&"W*ZB33$4A >]:5^H.3UK*4.P?9*I(
M3FX#_9>9A'<Y3-#7HQFPBF?O!0\!(V_!%/]&J<;7ZHIQPG)%595GU(/(,QHF
M-7^PAV)%2%M0"8^;$;536"><SY9?HK[&F[(L)GO7>LKU*?K]D&4D7BMG*:W1
MB'0C82G#FKK1\X%B)^@OWK"HGA1S6OKY9;24<S3;R_-G;6QU$I9'M9"B,D@-
M2 V"OJ"1Z0^[U=4M7<(.."['P%HI3@P+J^<%G;UCUQ2JP((76"ZF:5-.#8V>
M&J3^"GIX2W<RTQ\P3N8H+,0Q!/+)TA!*=J67Q'I?X#6;<PZ7N.H?5Q 8MH[R
M#K2).H(%KN'FPQ\J_@(Z.#DL:R"*R]X$RDO);F>S! N\@(5<A;H< [UM\;BN
MFM4P7GUM<L0^2.>,U$_Z>X+GW5IF8ZWZT>RS@1]1<@]/#B3?O5:Z%MH(>W<5
M->4M3A1]W A2<P?0(N1<7B7E%_">'$T)9 $%G<(L'ZH>2"@-4B1*5=+YI,R2
MM04=SHWP0\Y9.RA]YF8@E>%&OW(I<:(J@;A8?K7%D]E0W0RI><(M]X/:<$#@
M(AX6T<:PL#A5P>R'QFA-'GR3[:-\9_2<4+Z?'*<X)BEV<N,T#WUMZ*9K?_ ?
MGUG.::JN%DS[)N3?$S.0((D_L=UY2RC?.;^H(J(@X9RL$NR"BV28]@9./Y&8
M(3\ >PS:K!<TV.BDV#(JZII?7?=97<P= -,A=:+\ (QT7?//Y1C*>1#W@*P^
MF?XWRVQ]515Y4GR9\1!4?<5!NGJHE+-OAT@8F\D7.J=P8)2XUS!"N-F^5VV6
MNG508RJ;8BV9-3&"$9$S@L#B.7_@0&N8[.:)\A-=<E-J'PW +0AF9?" U( N
MG::N@.-MZ51[?#_9K@MC"AC+3H-WOE!WC[AB1<2 SS*!R>$)V4 B>F.DJ2&[
MT9..YE==62:R*\$E.:R"WDAH@"==[J@!BPZ8O)O*J9]HW'TTT4O:,[Q"]^2W
MV7;L.M8Q"?87!048R71L8RI^ ;L>^H/A$O?\(M*G@-F YE2;.0>-*![&L=]>
MWOS-8:/"EGE^-B"LR'\"+.-!IKG0B#D$>SX1/(Y;,'L46V#2*>%<X&33UD):
M$PH*^!)8D.FRI:LO8DMIN?J@)6R*KCA6!B;*!*W/^\0O-NY\VY'E,#C=\J?=
M;,+;J[V/(AR7#(<7K^]#T$Z@@',DT&II#A8_ZVJ>@T%BCB$8WLDPP4:@<UH^
MI14 S;++H)N2D22UY!N&C52TN($/EP6?_DLR=WLQ/$9Q$9<'6BKQG<&6M^5(
M7D+0-\+$=DX?[11F,[F+S]!BZU-<I5,WJ";D=#$R2Q$FZM4D%_'QZJZ!2661
MP;O!:S6S">>>ECTFN_"=(%,6I]^FD8$\_^%81:0=H>"VP&&X@>TM(J(ZPQ5&
M1L#2ZB7-YI/(>1,X-?'*)]0]E?.KRP.6S\"BU?7Q==*K=PJI]^169._3=;=Z
MN0%"'D=](BBX+#!J6:,6M@TL XEG1&T-1:443/0&'%.CHJH#P73_$4YSY/_?
MKO+_MY_2)RN(?QUAH=9F@_WA[7O;MV;F_^?^V*%?5(:'&W-J>^;G^8[Y5Z]X
MQ<7'Q6QW(Q&))".O@_SO1WWVEZ;MN+;SYM@9>Y^+VPXY***HO8Q&VBNL 8U[
MVC51'@(-3+B::@*F14_ 03Y'TU3>/K%/>J)@U+&I"?H%Q)=Y5I ]>9 9NYYQ
M&/B]"E:%GP4C QJAAYIV3T>[VOK^@*V,B@N8/HE.ISW'=?I341&8;:.*D,F@
M7:/BBCS5M!^U'C[L9TW2CP,1U&W#?](]FU^V-, .HZ>VR%.4]6QF@%#UN6M'
M_PM%#URB 3#)[66KD<=E!)0V)Y*6_-<LY"#EW(AK%6Z:AFR*.J"M0['HM=.G
M!1&"2/;MT"<1\=I-S.JQJ$*6K_[(U\L_6HOW2$;UWMWJE>/3!_ZMT]20L,UZ
M9R9+/5WN[_=0WU1"=BA2XK7=)3$6(?FV+:=2_9SWG(MT[[34..U^O"R5DZ>X
M6-G!"I/0TBDZW*%]A7=SMY3[\N\GG=Q9?J\[;<).-3-7W2P-X_^GSZ[R$PY^
MDC"U+1?+#X1^:;F5L].[Z+N.3*)\1%5;/8JW#FB>CY'O!+]A#=\KF\5"?E L
M3\PQ(+L3*8EB]<<_BJ/<"[LZ,<; 8D=/>J:]ANJQEJ'+1.NO1'38R"+Y:> [
MNXW8AR1PCVJV/=9T-2H8._(43__""H)'M0-P[6A=,O7G;VN^NTN1?&;:<E-!
M[)KZQ]_G+HL*(JZJ!1KEVN%AO.#B."*8@=:P3.0VD1PM6/<L)(?R2K  *DMQ
MH&;6D;WEI92>Z8#7 O= @73D;$"L\Y'2FJ@CWI43LX8>&5,OZAOD[DV,A\+6
MO4U1R>Q$41!)TM6!!+<Q.G%I 0N\A0P4<)^RA].O4"F;CJ=J2PUGJ=N M *I
MFW@I)[;6X\2@\&1@T2Q*\TM ^=?L*R.GWA1>+1+[O&RS/<*T2Z+N:49*-?%B
MFM:?YYX_H:M)KQ[C^>45G^5Z./BIY'3/A#R13.@^T2E/^Z_<,,[B<;GQV0^3
M/88Y5&*!&.Q._LY$D>VRK[STYI-3Q!S=Z(GUYZT]'!C([OW7+I+<3-QL<D,-
M+DQ+;"?&=;RUCS0\\13\8=%Y_Z7YD7US,-05KB"^I6,%W1"7UN@$527MJ\>*
M8'K]J8.-Q,D-(-T5Q'1UEZX0#N$!BLID+1K:N$WN!0:> ?#9]@LZY!0O9859
M'^5 DKCGPF#0B- ;] HM)U0](NCK1<\8WIXQO&]':/(,(]FV<K("]Z\KT&:%
MFD$;5$1T0S*6BV]H!5O;37<#=9%4"S"R)0JD_S;<X#YDV'5,>JTM4&]HWMI]
MW#][W"[VUWU&T?&7+FXPSZ:A="[L]DQG$6Y$]=]Y(J7B]D3G'#UP-NOMWN8[
MF_,^%U@]E12>KYOK]?QG+_E%=$'_A9AVR38U4Z-H5\MW9_=TVH=;W38L,ZR+
M/G[_T=2Z,B>]#Y);2WDKB-( R!TKRF%\NT7/1LG,*' Q#ZT@VA>5<:/2@X#J
M6>53[ 6:@"=)[^!LHKY>W4@=7^49)S7G>G@-8TP4[G2/6X/^TKBVN<*\BO*'
M7[QK!57]#^4[1KYY$N)4N"4'3#9=HD:ULUSK-4VEYGM*?34V70Z[)=H+.I/O
MG]MD%74NYJW^GJJ,JI,;S7=_/_;ZB&O_Y\@O<OJC78X'G Q!?;Y?C2/FZ;F;
MT4=B<GHL15>VLMK)EUQ#;GD6GKT2&W7NK\)*;/@&[IO*'3]U/EV%ZFF7>KP]
M^CE_X@7)*XC@B".W5A<A.F83'T_=W.[):2:K!S]K'NQ_M&W3<G'/6^>DFO!=
M445W'YYZ*T)->4 ;XFNC, @ /S\KC7QG8=KU"KN!<J!VNQ$)X](6[C9 -2?G
MO]EQXO*+6QMB"?S\_MMMI.V;-[W6BZ$>H,#^)/DIC7NTH8B6LFHB/#+8!HI]
M[.&:RI$?L_BUY+)7ID8CE^WEK4D>.)H!*)?$_><SFB_0X.^=B9XVM%K^JR?&
MI/;M,J:2IG=KNW)8F;Z"",&JK[Y5H]ZF$O#T9S=*G3(A,VY-L.(/Z:Z[=(VG
MS"?D= ]#W<[;I9[Q1!/)%T/-&_I>_0+9AO]>OB1Z!.9W=A*#$S>XS)SF7D&F
M_^0@IPQR@W+?@0RG-S-#;_YZ&V:5^.K32ZJE>D:MK_Z9&^4GBX\#I3YWSER]
M\^1T["??L9&SE,*M]P<[T09DT@UR^,[>?;E;1*;&O5].25R7K/F?M'OJWT[]
MDLL-^1(V%*V=DS!TI=&6G+"X8^!*ZJ8S3#7,^,9%1CL#W#[Z"I7.:0SOI O0
MDQ[SZ@\(>/U&IDIE:N/N'PNF!!E[6W\<:2O%;TA!I%6#S,!^9MGMXR/H^4F@
M?.YJ_G)QS@2#A*FW5C@^QX\11O6>T;BPOP^GI6'K?3OH8PL2YBN&1@3LS./0
M* 'XYO,*PA,PN6-J,!"[H*/8.\3227I$KCXRT/"H:?"'UTD1N4GEWH^BQ/U_
MONQ_P(F@"JV'>[KL@,Y1&4RFR4[4/H8VW$+J-B;E#]!=,GO-/GUXCAB72%('
MIW@!-I6)\6*4CC^YF;=,RKRD0$G:,!.)SVFELRU)BQW7#2NJB+N*[76F"WLN
M@;,\3I.J0L]#E@7&/XE"J3@(DQEK6;I1494FWM[IOEZJ[52=D3C/1*%>U-6)
MW5+3VZ4=DPRCV6>"P'&"S-2TG_@@HN&C!MI>;F1$] XJ^%%IE835*C"FD?X(
M%3?\A?\KN@?H7KL8=JO&N7M;WI.9RF9HL,GVM%]@3,"M@A'KWQ5[[+]EL3=A
M-W*&%(+@ V<E^4].%VB&ED0^[\V$6JV6*ZA "?>/$3=*DU_!7<=2BAM]B)EU
ML!I2FP;2)RN[L&FH.N1\H)BS(2H8 [ 9@.^A-C#[X73+N7=EYJEQ)!W"LNJ-
M3Z,.3"3A<4%_1(#@XWF"8'CQD47XHQ7$A7'NXY[*VN'L[@5AG?Z\_/_DOK)2
M$08P7JT@M#CA* 1E$RA\ *;PXK'J"Z/MP08T-;K1=(%CY:$ZP".WP<OIZ(@"
M2XM['!A8[/+;:(-<8\],2.67UT]F"[,#N$Y#M";?>;JT6K9%2FN?U^?2ZFW*
MI2FR2[BTIH2KY1(4LC+3:I&SB5SFWM8V0(S-9NCX$=C;@:^,,&2ZM;UG=Y1&
M*$]6X-Q0)VPLJ3<,\-+E2# OQ<A,&N!-&H<U/I^3PJA[VBC'DC$C"]P>*;(3
M']*6\GM\GZOGXZC"!3K%0Y)!L1-_U"3I!P5<*[2AAQ"(<;6S3H8[LW#Q!S:O
M("Y22@ZEK2#\]F.1Z;W L]<@;0\WG/PV);N.O8T7$E[ T\FH]O&_&':G:W-E
M1JW%SB.G\U0.G+Y!.+RW..!N)C6[<ZMPT8Y?<]$IY?M&J9-!M&94^[WPK6 T
M PAVL2V_/_1*!-PQ*_GOO+OWFFGQWKZ4Y;?AQKYU:=MCF#[G+$*^A&P;HG'#
M,.8XR>JF;7.>,&W"=G43P0HBC:86NY#6-*#  -)\#6]\>J>O(#Y3022*1W+M
MS,CI'0&N GSZ_&7)YBT,KT');SN:XQQ6$$2TP$R,G-\)[$*F<32PHF+&ZC6A
M0EYAVC\Q(IS!-$?3RI[?=\E>_J)T^$=@/C"55K-HU&/NW3?Q[9?*;JLFCB"[
M<F9?9WC#,=\Y!FC9-1<GG2'E,C2P1,X8CV?8F[/(4 DD^Y!TOY08#ZY_*4%J
M@'1Q4TNA,(452A#/!BTS,QJJ,R;4#P:,GZQO*SIJN,FW(%3NO.Q_:>< S.$O
ML 9Q7OM0&OY4;K#K,-7**"KQXJ ]1XO\9/+$BZ'"W7J>7R@N2)X+8S./:/_M
M9]/RMM:6%[D6?S01K\:3&IVJ;TLJLV!'^5QA?>M4[^P52/VV_G&&'N_7:T<(
M)\LM0LWIKTXV&N[/\IMY4AZ09WFDLK'4O-?@=*W!V9]?=W5/B_9_[[Q4Q->T
M[+QRU>C&]W.^ULQ 7N']"R]N_UI[I.8O@3\FVE,CBR^J_K0_WDWC>*Y>.2HD
M^WK2?7%6^\DMM$-P_V^-<K1LL"'(E(!X?K$=WSFX55PA34_] 5)PH8F5D3WB
M)/U.PV%.VNE:APW63Q\^'XR-(3XDA#S<J"PJ%_R\U#\?*A8"09[$D[3W%_PO
MZ?DTU(-<0#85:%N];]?=$<BL/K/2['K&K%/ X?6D.^^ !S_O1?U@RN*E##XS
M@[8.,@:%D\AD?3&'S]0A)UC[=I2L#R0>_A>\#"46,7:U>UK[).:<?$-[9OUH
M22_@>NTU@NM X/F:O_C2<F&N<+VK@?RP8KMTBLO(T,N)$^--OW@3]'LUA8W3
MHP0K7P'F9:5=<N83,LV_87"QS?8_WU32G/5;:3?RG@YDE-XK+@"S7M -4LN.
ME*"RGGS>_]9&K<;V+.'09[NJK#3-AFL$B=G)?8^!Q6W=)ZMO[#3U.Q:XW&O$
M':YGKL.O"[N79JZ#-Q!_-=K9';-I%.F-YDLB:_+SC%5.=*N??M>D%O=)S;:S
M__&,#\]B.!5'.+/YLX*U>FTE_BEL<-<!!4<!Z\5<QJ2792=#S_[:0KCM>?=*
M\(W\];"]NO+(>X\#VH<J9M@F>>+"C939B'UF-XUW4D.H0PP=CJB.\WSA.@4[
M2;NQ@FC8HA> S&0==;4H]Q1/8PQF1_=%=IW@#+?W$%63MY&)/25%?TTD&E_[
MQ\RR8#(3\$W%BLH8P%%FY@3Z=CM-(PZ9B5*G'(O>XEPK*Q(GQ7<R-BJB"94.
M0\[K7T8GBIN"HEY1=S;E?OOT1\/0TQ]!1X[8C0<%1 G.ZM4[6<KQT!BG$:78
M<IL7K +B'D%O!)_OLW6E9S$6?JXJX@44N?O\4-QK>Z+'[SGG<VQ<DIR..BZG
M*GEN#L7\-_T=9C/9&HU=Q?*)0%[>SLZ7N;2T,NY]+ZZQYUU:5&C,>9[<SBBK
MFW"V/*/6]>!NR<R>N_XU7J3P,]J5_LY7'LUTIAX]6XF<G%O*^<)K?WL[1?J>
MOF6_3@=U_>L"S4^4@[=82WM>A=_-.@?X1?I]^+U.8).+N?-L:UA SO&\9P,Y
M"2_RTO/WI!YW> (Q%12P:!)_@P$<_N@KP?.#_@#3.R?V@#' \BS?>5S@[_?Z
M2? 8)0YX>J>Y7C ](FLZ_:&7&++V0V-C@W;W@5LDZQ/7?=]@ 0\T:-XU-R_]
M+FK.P>Q7Q !/*,?9;=+\1F"!Q]8?1CL$:JCS$J[2'T6,MJ0]U^I?M,9(ELX/
M5XZ^W?NA=U>/G@;&XD>_B7*HV38I11HJXG2@56#9C[1A(V?9&T<]^/,ZXH+D
M(]6BVCT]B\J$=^Y@OUBH\_$W60)*EO(:<^_AT25!W6]A4$^6 )C8FEK,I?=Q
M1.D3NE*/Z[0+X_/8#JK1*,N6%B=E= 6D-M(S8I/<W%DOGMWV )*>!'.)58'C
M7@YE'_T_CN]\&]'7(&O62M]W: ^ST^==^!UR7.="^O>MGZ!QOB+)V.H;Z_>]
MWZ&WQ<8[IJV,@8$;T^)PM2U#YFG1UQ]W#-XHMCB.7C0VW^0MP1NRS.D&_]6_
MHU:+]'!970.2328GPK#S,W[WDUQ_KW?V^W*R^%+2GA<M@]4X$\.\;9GWHXZK
M:ZO%T*>0"OW6S@*V[C#M(F>LNKT7DPETM],TQSMD$P:-=B:.GMF!W8PUX.FP
M%R^N/;41\@),_ZGR]ZL9W7QL74#'V_J&NH\[LN7;]!4P%<I^RY9=Q?_#!$+%
MLY%F7/S[.L7IVSS#<(55A31<%F,)?F3]]0=-I^*A0V72N4NCYYQ/.';)-2U5
M^L[%<K_A%'ITF1%X4WX,]!"O(#I1*88F2S=<X:$=#>QW=1?EV+OM8C)!\W,1
MB^>&* =).V[V5$69F@S-FZ/>.UZ8/#5"=*@J\DKS_.AL:>TF286+OXDJ:*:M
M$\JH#<K;K( 5A(E'"C+Y$7A[_;W)L4;^#3^3-3@=9*H4Q,Y+P9=_]+0+G3+'
MC]+YO^$=KX_\\:6+8FKD++F\3A1IK%]TIEWR[1*5X)U)L!*D!666WF#FI%YR
M).:<B^JORJP\KM9VSF'^R?&M&>WW]QS7-</1[;JN,->06R4C=ATVQOS/!O$Z
M_XVIF*KP,<8=X7[&%_U3WLR$1"M<\MZDZ>AZK UN\[W.VW],'.%=E9QW?#&B
MO=9@.%YA-"Y5Y9]2>(%+P..)B==B:X]7A1[\+8-%Z(HQ<O81Z7J&^#7ZPH=R
M(BGNH%UPECK=^G]"[B/!S^[=@P_V?L<"I$2T KV"R.V^^4)A.OC>YHBD>C+(
MV'9ME9K_(;.__0_-6/[PA39\E&]0_*;,9^FLGDXR:+A'L9.B):P 3%$%Z)B8
M35A@68N2S*EEE^.&F_99%V3$S9^4/D7'ID1;M7CEWZN ):6@1I":6C#)2=61
M5<%!/TD=XV@Y%!N)GCZ?Y&B":?C-H,O1S1$!/TKT0;K())[OTR),8U(<)-::
M@Z?3>'RUY2,W[<9^'4(W5*<.Q09Y>(7??)^TRTD_3WJ9-+G>\W^A^Y9?O)VU
M%C_^](W\9$O$1?+]?(<1C%_"]SN$LY_N3Y^2O;E\O_#<>>7M.'U>V+7+-'&O
M1I(AN>S&7Q\FD?E7V(E=#G9WK=:C=;/_O6)\VEO5JF3_VYW[<=J'WN49'[&<
M>5=8ZW5,/+PS\WC*$AZT25<P].>D*X@_4UYQEIO9OXZ^I''YG&_KE;=6$'/F
M4MA:'J/JCD[USL>+\>,<V=]@+> INP/*@1A^P%;PWI-#8DX:] LPFJ)PW[F0
M3#$0?4QT9S4T#O\X6\<9_A$VVHC2CW0NN0]9L$RWC3SU]F=[87%]MW^_#J7\
M/_W/$>^TM+58P,UJ^;.J =Z&&YVKK^NZ?E>)S77;+=]^MC?N]&&TFA]IB.R[
M?^N_.(NS_]V1W&&8;PY]$FYL\H/9Z^-?^.FNZZP#P$,5#+S;JULW%W1>]]+G
MG!,VV_T27I^\'[V?T-<Q>)W1D+/)7=_'?LI<99'&18$[&7.9U50^;*D:L>D!
M%Y]/KF[G7M_ ,<0K D;^]X$\>51*RV:AHICCD<Z[RM7;[7/0O(*EJU)"B\FM
MKLKS[]_7) PEU/9\K8Q/_%D)4Z_E,,570O20M8 FCV9]G4\R)CG)E><&%_[J
M'#\L/>\]07;#C3P,.[:S^:6?:^#G-W^<&;6=OF*PV:>^>2,>,ET]>K4&M),[
M?L'7+612?YEQIF>P3@.MQ_NH.HH_Z_L7Y3W'Y>*"3 HZHL2(U4=T/1@2_P"L
M#AI@.3P.&",(VLH7VSX7N.H] XL\6J0:N0^74(3_6PS\$Y6+JD>^0M$9*%<W
M46".RR2.3UK[@7Z=H>%Z>M/(Z$*X.$G'=T3A@LR*)7\:7#RXBV9(KIO%-11X
MM+8-+B8&V7DE'ROP*@&W2+_OGSK@M"%Z=+F_1%2_Y[Y[\2=ZZC9OQ[*[WK5G
M\L/G*W-Y'4/WK[P_RCUU?_K-EK+#6RT.E^^)ED72O&[BTO:7\1D;5A!#FIM[
M]CF?UVD?^R;5K+4QZ?BS\=F0Y7^6&IY[.M_9$[I-[@Y56P4YGROUU78-.C%2
M?-PO:^!<F.>W;IDWR&< )VA9PLU48VAT!5&W#VRD!.W*"\-4UGPQ-)G*BG5!
M(3]$GOZ )VM.=NCYFAI(*U,=%IH[K'C'1WYD&_V<:Y!7C$P%QC;B9T@RM)0Q
MQY2JBS=!=LJ;L9Q-$2A-EJ>DS=MW5.$B+E9QW66/-?W@1]":S3<<3=V>:T1#
MSMJ^'X^ B.4WM*?C'1FA0[%5-G/H/]@O%;M6E]E4W.!JZH1AH<1!64RUASGV
M(,4M1DKB8PQ'6"[& 3G,3(WT=-? ^)"XL/#)@^K<EM%_;"A!99$3)M=V##=T
M>Q(3O Y;MJ[+H1S:<J;;'GL-;D$7&R;,QM<S7]%040S]'R;>W(3>#J8^(6$B
M1Y3TE\5<X[S.(0 JP!21'L\*#KZ-/A]1^+0Y[MK5KA.MOW/H7L\&PUE9&\WU
MI-=*=H@^T<4U^,W1ZPV J2UG.S^])ST6@<EIX7G1!_?$3O?[S=FLSS?7 I[S
M3F57>U4?T:Y0/JH^]W3&[2-@MR\7UW6-M!:XC'$EO;+?5S.+4M;>NW+1<IO$
M9BW?M\I71YE'[WF^U=CP[9[0Y]ZYIG64P>H]W6-N&NGMG7DX#HW8.EZ+E3DI
MJVWFEK+O<L+Q-]K-;]2]WE@@7L@(B<H8,_ W'=M!&.;^--S[_M<_(#OXP5F.
M/L]!'=F#(>_P<1M6(/#FS5]K?C+"GO4K0@Y6?-MBBW,ZT_:->_%4Y^$GY7<Y
M"[Z=G+6,3,YZMK7"\?1+]C;*/NG"/\/Q&4LH/;+ON;[?OF]-/5&D(%U8HY1<
ML?S9N;H%C!)IC\W -DQQ/_HUEC3"2IZ+V=<P\/1_W&N7)U1'*(?$#!W+P^(P
M_VTOI?G_J R==#HL?2"X_IJ1)Z;+Z!LI1]K[1[73NH"OC@UF->6IY!GU>[4_
M"<K@QF,';Z40&:712W+] 2?N)I[N5Y'T)=;PDU] W<#]&)6\"\+M)/<S=5TA
M$1W!W_+\'MV@@S:CBF+Z'"S>+S@40#5%;][!2?0.Z@W>IBRF13#2L4TKB'8]
MQF&< ;GR2.M(HPGFUYOD\$EL2FCCT(^#?Z2JJU7>B"W^5>BJ8APTPS:5:@Q_
M;YUYPOPB! )):4)M2IC\#+6[D'[=5642ITN8%GMZV2Y0G,1)I* &KV.8;=U7
M1I#1Y>\__E[P<.+S!*G>;B.K2O*_75UG:(G82.3?P4;*2O9:Q5'03!*S18_M
MV&?>--!(V*;#26>=OC!=10[D7WG OR&P:2.$)-K;NGHEAIN\*_FVP>:3ZLRS
M#X&XU#KF!MOZ8F=0[1Y)^]/+K[K[A[V[;5_FJNE.^F1]OGSV?&A6Y<ECB3 Q
M.?[<:4]-O$N.#N2;;EOV##M;=:Y]RCYF0O4=Z+'W3OBA@=XZUFV[ZE3RI1,O
MMYAEW9CZFQFP^5:II\'\@.S.M(/B,74(:Q*+%N!EL\I_H ,11S;@^,@-T-N"
M9>@V:7>>ZT&)TFXR/8N%E?0BDX,^?VOHB3_*SAKP_-_M#^^+ GF&73&FM+H6
M:!/[_Z8F&RK_YERBI02OD6*YM$Q'P=1UJ@L%2S]#5NQD?OB261&!P0Q>;C2A
M=@4'(N<2F6K6Y>6?F:@,4:NSO>#"ZZI:X5BV)WZ">"W8(:3NK0I&O?NO^T'&
MP:HJ=R9+4XL-AV:_B?=<F.[=<'_Z'>7UZ4BMQ\*%<TX.40WL]"_/<WMCLM@6
MX13W@@MU<Z/V$M>'%2$XG;3:U)BWC\,:JR[N._O_8>T_HYKJPJY1.-X61(30
MNT0!0:DJ32$0$04!(0+2A0B($*I(BQ(2!>E-0>$6A4B7&BDA2HL0BH)T#$U)
M046:["C@OB&$$]]?[WG.=[XQWF]\/U8R1G[L[+W6-><UY]IK76O9H9QYTOM:
M];67.9AH-]U9M+D]Y^^;^$RL..\3R[%A1U,]W#<_@)TQ +5'4D&>UK1V8!;=
M<:9Y)$0O&!)P^_K<<'B%#9,NHD,-?#7DT]PNXJI!U/SXCW5)D-/L[VBNC [W
MH-<NQ,*/%<HYYX3@K ;^4=W,W7F(OX6?F7<'AI.Y9T'5JVP%,E-3;>WB:*2@
M04^A*O"Y'NV<Y\VU5D]NTG3JG?MY]N?'QG>_NWY?'!^JUNH[2.$!FYJ+8! 0
MZU8<Y"XDR8(EM0O1E>BD7D=G?WNF@'K0$Q::_%\LUMBPOC+^0\D3>$-\KF+M
MY;Z#;+U/(18RO7<V4Q"!)Z=/3&O[9'*T6"^VTW329[4!^CO. E]Z[86(<),3
M!)&:;<FB>*K]B]\2#[K:M$D95@YER&DKZZD+>;IE)E$[C5S^96!R\RKH!2 ]
M1G<A/FNP ;82L[F,+>?V:6-8^#J8"Q7SH,Y'C\ UO5XM1CO,+N8;+HZY^SLI
MR+_)LLVQ)>>M3#X*V%^>RCU)^#GS'\\)A.W\:W(8]X%[<*)#@2,,] PGPG5J
M,+F_>[;*VG^VUH*IO_Z@.L:;:A5C/D0*WMN^VGJY]WDQ.K?>M5-#_VI:5(%F
MS^#@Y]_$58=Y)$]_".U"_+33Y_1!LV(/,(T5F@3?6[>D<&BL)B(M2]C3FJA9
MGSJV-&M&2F3%>@;K# ;;Z3)#SW@\UU;T+Y1ZC%QP+9TO9!^/CNN=#WL\J",;
M\7IJY=<UM$] V\7%T0KG4P4RUXIL*GEXZWQC_N)N36T_)8BYY7C6XL'KL,$S
M-=6:A:;9SMT^#86B%2G$ITS:H8P@FR 3:VN)0V>K1I\<W<E0J\^PI#U/TJTK
MWX5HX1FO\<#58!B#0/T2L^D->E3U5&(#0<++@1*P)=;0L:!#%A3KUA\,Q6K-
M:7*1:1R/LF'-S*3R2O<=G<OM.=WC<JIYU-"J 'RG//Y&1NBF'R!4S^YC]3[6
M>LQ.8\UEH"L6.^3;TWLJ,5!F*S*PVJPLX'5#32Y.D6U;$NQ5O3P3-%LV%MQ4
MRX=\8VWL=.36*&*/R1[M574@9[Z)AV"#;N34)&MME9^])U*=*(H>QUH#L!Z#
MAF9V[;>%V9OLYA()2N)"GL?DJHJF_J.M]$&_LKD/.Y42I?D%Y4^C*W!KW$$4
M8+\VJSK/UX=*I N:',5U>RH"T'BL%U'_*0LJ,\ DIAI&>,K5&\:N#F^63N;_
M?""9<UC_MZG($\\!\3OF;LJYYVYF3/[Q/,[$#B=AM"H$;E</U$L?>J(0V/-L
M_3>V(5-=KS:Q8K4LOI-Y/,TE%:-A6/H$?7;;ZG-]F82J@YB#!"?CW0O\(S8Q
M]1K<E"WHA]&8R]2"&S.'#XXSV[;%[C-7M S)GWR>?;^; '_+J/K^[P=O]X)(
MNU%JC*7SB^)7#'\&P@GO3Y]18A)6W@*$;H(45RV0O_R'K+B)36*!P,6MR=0V
MTW#Y"DN G+A2&A&X$^B4J^)2LC]XI5:Q[1/IW,IZAM'5]F;N=;PO[/XN1&P7
MPJBF-X>F[D+0:^DM.E-8\5$.RJ<:\T[DY&AH<)-<S"4 WXD\/*AA)VCI/:89
M48V7].R4MW?_D76W*D!T)K!0:2QA%0JJ?460UOI0,VN]AD(50-8\,M5$&*M.
MTVR")6YI)_#2E!'AL'6Q3?FB07YS>T5 E.&!LO*Y0,\3S[[F+GB>1L&%CR?F
M)V^Z79>D+D(3>$.D/;/&(-R'\^0_,XDC9N0$$.*PJA7EA!+_&7Q<A^[#BX?'
MKGMZ7K=D3KZ=B/0P__:MXU.D^Z(?96)MX4U[^YO\[VCE &:=Y,<WJ/@YHT2_
M7!^0DGI;."&HJSPTS^OD[4V'U#+;%BHS5U7,JO9Z%U'WN'VIS\JB<X54C!=Z
M)^#L<K=\5A;GBBOR""]%90FVF0RI35!O-F%"C3[6RZ.[,8<V7F?)9&+DA92@
M21]>_Y0H,D]?B@DR%VTK>5_VK]-=_/K;>74C]S4^#!'9>MK"]RZS-FKH6]GY
MD;+:WKS(?;V7!Q2;K,7J(S3NOU1S-7W/]: PYIXOO^&>XHX:>M\E>+6"@4SK
MY1?ZQ[8]"UAI:3':IPV;"FTK\=\, .(+1"8E?(,^(]"=!P-XE"N)&\6+P(^%
M 7V]HMQAG#8[LY;1?D'3G+9P@6V$"71,LQY-ER61<BOVY2?6[A DRMK71:[W
MAKY,O77K@!,G@Z>;[IHH?#$KP8W1)>J"2R7=$BL8T*06S>^GQ;[XTUIV(2EP
MNR Y5>SC2W7@!7M]8FY#?-[OVP0Y*N;>,U1BAUJ?]$MB!I-3=4@GP2V\SRM<
M+;7-?^)A@6''H%.%<^&+,BE;DS'-WD%N49]TOPS/SQ,LGGT+*?G6_Z8O.: _
MHFJD&GFB[^L3WX>%BADN7<VP6;A>@,(0Z:RM7E7,R5=#2XBQ#'$[5 9LG/G_
MG[+W?.RBB%T(D(7O#$LO/.,?]V'[YGG:FGI0AB);Z*T,X*!SY>O)3&.DZ=&?
M NT6N56MPGC?#<YG?.=U'E">HZ3:(MFVH3/TS:"12*ADH-1,5(IV-WX_Z%$1
M>F063.NBT?)OI<VC]B]&I9+=E@=*7=#Z^9E/B_/8@LUE9=1J%]> >#M*CO6O
MOVN4.[THC)=<Z9%U>B)7=2>WF$WH43<V5)>.+/!CTKL'E;KO#7893+^<V"#N
M]_]P(R]ZO*.[Q4-"5]WH>6WO'&T2_P11!.8<JV5Y6G2^I1SVN=,"IA./4;].
M][HG]S$!E_0#2@+2YZY%+ ^I3_UNF?L=]N15C;&57;4,Q8_C\*X-E0 HI<%M
MF74F_8T<%8'DLQ2Y;LYIPHT&; @Z?NC4LP2KU$(%O==/JBQ9[:E4D\M5CRI2
M,#/2*<PE^R3RWS*0<;7X?A,\&K4M">>)@&J!+@G.$+?GGC-'O&5X,P)\-D^<
M&N[>>DKH(@J!=-><WCDYX"OW8%Z/E*=J(Y"5I!T9ZV URK$LN[ZT];R/21XI
MSIPU:\O>^NX/KS6P*03.X:=1\GBJ']:%]U=7N.-NA%4$4_,>*D-!GZ8R"3_)
M\##JBMK")T=D)=T&"<SN+<_'NY"#40]NS92_B%ALHHLMP7QHWF_9RH97K;^$
ML"QEOGJL@4?_Q+>A&/1I%,N7G,919R$/75]"*9"^6-B2V2I)E3_"Z8OS[Q!0
M#9N-)VYEM35Y3MZ;0S\_?G[7<$&K-B1XX+\1J]2;YQYBM*F9)\H,L>>ZI=/Y
MY*]2)ZC>)4C=?O;CK7+70Z03YK@/G^QN5\JZ_$O]_.+XV8K^T>NHG($>;3F0
M3\2*+'<[!'H6($AEE&2^LR5#V0?<';:MC2N32M(JD;.]\?F5YIAT\:JY6K4F
MYDG303W @","Z\3_@SN%Q;#)/6NI"J?8?Z?R ^B'+*O!6;,QK(>&PX\_S9Y'
MP\N6*2*U&Z[$-1)>&M,QM.:<.VL?[*MQ8Q3ET?!)8S4RV*+_DV[HTA#E,2P=
M?\A$#=^)X,5T)0TAT2&%-6 /M0)D9_8G8M;Z>ZP4\PC>;9R(4^!8YL; DCL.
M-F99U+]ME)I1GN0>']<U5OZ@T9P6R,RPJ1T9]"?M1%4>+DJ\_4[DK:O[OIN^
M+@<<EFKV[NV$L%&:\_]D&NE_.)O'GUFH?9(EGR60//#*MO8DWE=-)(O<7SE6
M6OS*GMK?;MB6>3J;Z-EV_.X%&Y[M'BT8/LD<4F,$]9VLR&7#]K,]$7R%WHM7
MB="-!-:"03SKT%3ZQ0H-#^S-4Z17,2X33Q2D^!]6"KE%>O%@=1P%W$9Q7A [
M0[>/U>]"EF+G#P&ALX7+W$-)?]>>2P.AJ_%LL9X\^G[XW=AR=_<OH.=V)YDK
M2:L8+XYW2KOT"<\4;1[1"EE;J5WMK:T \3UW7*<##-Q<)S2NK)59QOIN9'&D
M\IA9W019[BABOQ[T ,>834D+@C&V_#_$, F' F<VJ@,%Y@EBMA%E;\9JM%B&
MR8E;0ZAZOFUD7G00UVFZ1'.;L!W$';+<1G+?(T1,1(ZGWP$;\ =GP/AWYJQ3
M.:X<4Z"@Z1XE23'3$A*H\BEDM0R@%9VU9Z/OT8H3#81&R3]<\=(WS@8F815<
MVB2165W>>-+)^?JS'_7D;1$JZ:>GSCKTW5"W['=1>^+K.EF[_=80H/8*Y-Y.
MGP=[PYGEH7W70]?S<MWSP_3MGMUP,D6=[/1]LV++=X)U=Z(_7);44#,O<+#W
M7.WA2W"-VV^N59MZ!<S[V7N.%5B._=T3MF\0]-DVX)S:R8'+U7*'[O66L:!\
MV/.9>#G,\]X.-?VHN1.?.';RUJ6!N5R5YJ9<&X3I\ZY&M/T/V)2^SF#Y(FKZ
MCYC%W<K/GG/+;H3O#G_7!9M3IO.N?3*1X1S=>38[WUR!#JN:F<-D46$"<".V
MH=S K.OO&%^IS [M938F[=HHY\?7P$#B8=-JT--?4W+--C=&I>G-\X<\HC =
M8%.O@8AM#VZOIS) R&H[A'4&9GL+%<%@5J@XQKF[12B/B93$Y)GF,->2@[0B
MC2UL+J_4W>R8@&O6H6>"_%6AI6#AIA&Z[/<FA[I]"!L%]O">>)@]V:N=1!=!
M^$"3<>?8?S*51]=7E1>WHLJ*,85S:UT+3MJEBX8O<,)L#9PRD)?\W+%^PN$J
MP/DUHSU5JZ?NKS<56IL_D)G'/^C7H:CV7UU@][D$>4_WC,Z;;SQ5BAX/))_"
MD TGZJ<3]6:>^C[U8DN<G'F![DJPBJSLTIU/+A(;Z\:DV5X_SBCI M:@MSUM
MD@?"VRKT6"^H]]DO7(6$/O[Z,4)EW7E!4,O2P^J^29.)+_+H;UNF]8P2$VJ=
MRM ,=J2"-D?L3R]7>(('>:*G*!O:I<T7@#K,/8*9[R%(F3\&MAU(Y/$0K!%S
M!\7$9T1Z,?]K^F+""E27"T9<:TZ<MQVO]<T>ZI5SES[JF#JGBPKF=?86YQ08
MS4"FT/=R+!G#^S&!75N[D.Y@!"N1,C^(,AO36)_=A4@%WE[J$/ZU$2I\??:2
M?'[!UO/9WFW'#]G>?YR%/GHZWQK8R84+;E]9XN5DY[4DE!3N'%:<C:#61O>U
M+&3@C@>V8!5@-!B5*S76Y@K$](863<\M]80&U_@U-[\9;YK=#K;=TK0:<$;K
M?G&;1-(DYVW(V^Y<@0_;!E@;L)I!C(-)FLB!%N[LIV2J $7^A^?9<8Y!A>>R
MVV!BSOQ^H'8NI2Y#'9D:0Q[371X6"HC*)WT^U:\)<QPO>R/B5C-NL7[VQ2S?
M0W;X?;6V6%GI(.2!JYVLBL-#/*A9_2HII J:B60Y7.U#U,9(VW<[MG8[1525
MEITEL3$*1SZ&PTI"TS&^3UCU& XT]6S-\!ZK.C,X^8BUP&'D0<=>%G 77MG?
M[ ![%7NK68G/M"R>:B&6^.0%>A QDI6$$C 1P'V$-7QO9P\PM;L0$%"U=Q/6
MJ-RA18M<.PPZ7WG]:>._)EA2?,]W02O6V'1(Y,$Z4LS!-=7FQP5:=4\5+MZ5
M.,C]N[J<@&HR>- AR3$'W[*3YOE6QN>),ZU]A2K9/>N#@;:C&FT.? D;FE&[
MD.N?VGQK S9;RI]6S>"[S%C/R\<[J)7)1:W-I"8:(PZI;O_6;8?&&_;;.!I%
M8A<2A.0#DS9C02( LP,0#^ 2@.CXNZWA[KB67Q;S@CXK;GX/0FH>WBM_X%N"
M=LNM*+&L#OBU>/OSDKVI7E.K\TI]@_.WA4YCY.9;WB7U.<%@;5D@H?%/<L<I
MK")[BM3P_/HH\Y,&',%J-^J*WIK'&/3*PC)T@^5Z6J*3-EQT=WP<\YR!0K+W
M3/KM )1?1^*'HOJ)P"XF5DM]/TSD3:!!@OQP*GM-K3;AG2/K\HUZF69WVW8K
M(G_BT.+DDQ\M$<=E<ZB&(PL)5ACLQ9-C3UT=MGZ:?#S#H>'XPX8%';N_>A[Y
M)I!\ZE\.7?#=)YT@*2$_TNU_[PF<[KM-PLH?2W%D7UNXD&OL%1!C^.;>U,<C
M5E/)7O/N0[J[$(EED].\!WK*.03^V3;DC:!XQUY,]#6P#*BB=YN(9G62MT+R
M529(LZ&'L:9O'D3$2LY>'(U BH.V6]\%?942Y[[<;*5%RF5DA&M4;!L0>V#3
M]+\;[$RY$W@YKCQ&Z1VJ/C0->PRH=J1YPI(IHAR;<%;PO8'SH]X-'=DQ;_2L
M0P^!**J;\4?G1Z;[^%\M&3:U/"ST+6M/_?P^47MFB;/0(Q_BBY*@@AJ3QZE?
MWZ0355VL=(\5V@_7A_+)_G;!^-1'+-C;55MVE208?E)USBUYD7^G?AM_7\;)
M(GX [--C<D_VLIUX<C'?-5-5RODA6_Y8;I].KE!Z/>G,BV:2H>[2U;JJ4<=J
M)B^O5SU1LN*OP@[_=X+7(Q]XU,#+P0Z D06/@[[*=OP#JI<F//_^< K%L6._
M^!/<@#JCF7%\8^RR?E#P0\/3A]VWGH"- +D3)8>3 _N8%MTVZMN!G3C#T9 (
MS1BD:VES06W%20T#IV@[$<W"D@I/L^!7B^3'W%]C7-K,MSW^]Q$?R1RI^<XM
M"B\O^*.FY^=#"O8][JO&FCRGZI-[#N>F$+%Z[*<+*2]=[S-5_.'A_OV9[T.\
M2&&2:XU7'+:2@>C4"*(<B.CJT!^]9=F$E (#S=BV.;?K%,Y%U.*M29]J5%S/
M.T9DC_U4%?HGT5X:(J0^.G]O S^1Q:\#EW ==[E.T2^R;9>Q$J/Z &?;#E^?
M/ZN[2'-\U1_QM;2\[-('U]Z%%*:M&'07(N*^"'OTO>FD<R'B''/%(TA+[46
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MU1DI^C??WQS[OWA^5._;2@\ +_AO=HG]5]"_@OX5]*^@?P7]YQ7T?ZA5 T.
MZ)4.(ZL5?*LJ:S:&_>.?ZS!([ H(?58B (-.Q@)0.E$QY^WH6QTF/1TV7CVP
MMQ60'UT3;OD+_?<Y6N/_*GWUDQGJ,/ *"6) 3HYWE,#N#U1S<;M^_PZ *NR5
MR;JHK:'Q\)9_7E\:_ISS="*O[#^#+OX5]*^@?P7]OQ<4/'U5AU&^&D;X3"0S
M2Y /0 DDV%2"W.Z!KN@PV4805H=YG2(($,A84H[91()J6"[)@/=J NA-YL/C
MNY0&V$P3*N4@:,I5S=Z[;5$FH:TJ,*SM*X12\B:OTNSDV:X6";R#7=!^*IT<
M0#GN?Z3B0GM-]B]S9E;_W^Y>*W=K[,=8G.EQD<I&,0RO')99U3TD)^:.DS1D
MJK-(8.Z04,4URP\ Z\3:$XK(+, \*G)CS6FJC<)P.)7F#HI;)&8IY <5D%3D
M;,I0?_=5&*O/L+^B^)AZ$L'0G+6/Z68ZC#!6APG'9L^XD 6&= <J4ZXG0I7Z
M=N75=^(RZA5!E.W^WMA'I5EAU9)O%JVU$IKK8_'JIUV.$ZY'>NU6VU?(XS#(
M!\$Y8  KSYT(!^?)S29L0(H_\AX*5Q4]KS=CNMDDCMX8VAM6,5"1ZX)GGV?:
MO'7;*Y_PP,4:+QO)F;"_7362EW-OU]?*L_.@K^C0S@L^.!! D@ZCP?W'(="I
M<OK.4[/?/+>I4Z#;FGG(6Q8W%UZ*59?W?<AM%ACP8I2$#-*3H3I:&*>;YAYF
MR FQ45U+EP?9O@ROKWW#MZ8N_'I ^X!F4M3<9LG@")9/.CHCO3W[?=P1PR<Z
MS.]O4!4 .LRX /;48?HJ(?D>K#WZJ(<TOTS[&)#52$'OCOYSRF:_1".6JEN>
M+II,\PW,O;NMK\"\%[^5WAGB (9"-RU,OZ[].C'D8_WQ6[&U]R>'?._(OV\(
M%Y>-3L/FX9I@:K=8\,2FE?361,GHG6*+*9 -LX5!DA?7+VRXU$VNCV]ZG^0O
M"7WS;4M[&[=71'.#KL@G,PH6_=#<-4 %1+5T@\Y"C>-?U2G\C:@1@\"K-BRX
M3ZI910@3:,\SE_LR)[;8P+NDB%$.M$/CT202$9Y,PRO)(A:82O-\=CZ0^JM(
M87R=2S*FNK;>;'?(CYX8?L/?$2G00[93RT_7#]6Z$)J92YOK?&OK_+P7Z:F[
M%:@-4&.>AYBH/'-X9\K[(: IQ #\7*?H6#$V<#W%DK ?'$YW&+P7&M0[6;IK
M6<!(?=B]W@]_7_UYYYE+NVWA7]$87!ROPZS082Y8ZBG%L*F?PFU G2\'!IS5
MD[WT.;0YX.=RV]4.TFLD8[X%F;XNV\?6'E3S%X-E\%:*GC]IY$?/4BDU1R2>
MW$:ZD.61KI'/?B^LPYQG #(B;#)V2/L[?45^I:=R&%YA(^[#UDA3><Y%+\3-
M\5*CEM>Y<:I#/NM[UUA(H8-'RF0ZS%6)[X62"W;(EE<GTZ\N@R[J,'K6B#C$
M2GN%(,MD@8<H_3OV>#L_A;Q5(1_%K8'W,DY0%+C,^NFF#E-JF8*9672K+<?+
M;FHRPUR2P;58D$^K'3BO]@T)]21;80A<'68P>8@(64]/)&V\_GI2LXP&Q,?_
M_/JS= [L__???WN=^]GKW,:;7AO_D7R=O0E[X1G@U6;\9J!_$CZMP_02-+LE
MD],3#3K,YG?:*M047^#Q.LSH-548??:Z]3](7[*,L[#J)!W&C#!%1#IBYWR/
MU%RDMTH7$F0/!."EX0P@C#EP!&=*)BR"O4%<TW3= '"-1DR0-X;T\]9IK <A
MI6==UU1$Z+-;1VJL-ER6OA\8;*H.WMT[YI)I7WJC,1]9C.+F0CG]E0 D4MX.
M*H@34SK,? WT3.-![P"L@+"D9 /Q3+*2%LQ[5MO'N0L?*X*2_((W-%^Z9(Z[
MSMND-'#U^67HDTM!ML*CAG^SG6-;:1X9%S%E@<5H>;Q3FO,0#C'J5J5G$&0%
M D/\<CA(^RB:OAC:AUM M5#&P3,44:.W9[WV!J<-6/TN2G)IB "%.L0'4M+.
M]E*^E9!612I\#AF<C<#UY.]";4!XEG<&7< ?:5':_*E@ S6D_<UMM8SRUGM?
M'\U9B1UP/JR].B6=,VHNSJ29R"V/=[>8L14,]Q-0M>8 ? !47Y$[O1'(-[-(
MK*;M,+XSSM75,+QEY%'D3##']#Y6(H:7V:@;H&Q-'""T$YRE#,0HQD$IC:@2
MI]+\Y)-6Y*612A]F,WT3=$*UHU6ZB(M=V5A!K?'N6/E2=DRQ^VADME&N5?DC
MJ?N9\+*@YKRXLB_=FM.T8&T9(%.R(%ML"Q;:I,,\)S%"UD&6J)Z'M;^7J<QI
MB2I"ZMF[N8JK B.>=[@<9PKE!@9Y15?PHF/8\'X>LTFPR,VB8C3>RIC[YILK
M,ZMK)/%:47A2M/$W)=K)S]H2()3 9($^N*OF MAD>D\?C ,I,DD:FV[B#I:W
MC*P4,^E6*/@+9T[5UK"IH>);_L$^T6PJ*[A!$NT6EJ0(=IFJA$,*MF4W+SI?
M-66;;X ;-D&69'"ZN<2Y@/ @#P >WO,6\ZVA6QK\ /4.^;>-_&@7B2?44ADY
M<[W[QLTX1GASR*:$E(GE/F<:12M][F,?T->C7NM&D-U(+!.IP8)K0"1S"?7)
M;I<D,B7+5[JJTI&TXN5#!].7T8^B$JW*Y09,S/M%X74)PT^Z>9N*W'_)E;QI
M50M4N-PC6A1,4H[16PD<LW%CS?8H5@UE8HZ&.(;EW@7+6IBK0FBKH1N*G5,O
M>%Z%\.+&+AY.+X6W@.VA,/0^W5C'1\$F5)'T1X4=O+=JQ/S(O<=O1\SMX,13
M::7W0F="/3"T0<U1^EML#6X\0.:#5<1/G%#E"P7SX'D*8], R,Q#Y<FHJJIT
M:/=NF;EVHW*L+W!!^4!@B+?U@XM%U)C@GE#F*P-UM/U(&^,REOYFJA';7&]_
M0T$PCKKDTG=%88@C]GW;'7[X6=:T3R\GV;?+0KOC1/?DVO"4SZW(*ZI]I?V9
M^*RDA- [3F?C;%2W$"-+[2WB!$H]YC.TE;25I9%EQU3LIDD]3XT';;=_D4F(
MAP)WY:LS(RX[VF5>*KY(89RN+G ";Q<O^Y@0IEKD'7<S9@WEJR>\S 19;"=_
M'XX83H-^$ZY*K5><A>!MC(S8PDP7K/CYSH<E0Z3Q2GGE@>DFEV-/PP,N./I0
MY O8H@2E%Z:QOF>J)&5[S+9JXB]S-.Y@C'IP]E**"$*VP R92UL):<!AA6<K
M\7+BG9)BVADH3LZ("*'F/@_,82@L!/IC3O7M^1[+[W3"/J$Q]T<[PC:]"[SP
MN+H_Y.7\KX/%C82)39H3] YL];3H$B30'*$%@Q0AZ5I12!?/O@"GXM\?H.<2
M,J:X#;<.=4:[/;Q@SW:T?;L-]_EG#K<N[UAD:%+"^A)N27.U#I.'4@&_5L$:
M0B@ ;>T8U]<<A6-[2IEH)@CZDQ8A;ZS,GJH6O/(^X_2,314KB0RW+67]4N&O
MF0M>/ZJ DZ$84-3LQ)BW?R.HPS0;6GU\TS9<["?@L<"8N-<E&C+R'@ /HMQC
M@PZ3QKZ0-ZC4:VD#<H#5XQ4E>/H]69(V:DRN9BK^4%[S+PUPLT4[V:<MBGOY
M.^]7[Y4\[+F;-DO^F3?5@1@0P"!$GZ Y@[PBU>@PUPFR(H"S0JI/"'^)WT"E
MM)+FT[="X8HE(8N(*\:0G:!5=45DX*G;[R>ON060RR/QMJ!=Z8/R)_Q4RPEN
M3H']^)3/5N(/'>JZ":PF !&C4SW"[+_U/%5!$N/FT?3!=>!\DB$?$V6%Z[/A
MF7_HN,K',J']L>WFD=%30?<N)/E8'.D.OZE6[Y+]X=A .M(5TEH#N!# 1-_<
ML@@ /,SL#_7H'*_DM&_PU'+<#$M&$N-^]UI0P"J+U&%JIL7YWA:V!S?,65?+
MJ;VV>6TFYJ""L6P/9C&2S<?37TE1MR1J-E")GMHB1(^V'7I? IG(%T-UPCN$
MY?"Z(NB)M FQ)EWSB7)L-W0DDYGC$][CXV?(^:%KKE]Q-ZEVN@S\R (I?O":
M>6 5T(]5- %"7X+L/F)!RCE&[RQ X>3J?#B,ER-M'I:[28WHJ]O/J,W Z6N*
MK.@EU)?PN5H6.=(ZY5.(T#B7O&89>S;./QA+],P$9'^0GN1FP(1' 6,NQAF$
M\X(YY$1K=MF1W$!Z>7&4H$8JSM8Z'Z]^EL'Q,XWO.R&*BW8[_])A>7'&H;\<
MOS!A<R+JCC.SUW.226]ME--,(+*CGR@CB0'S3UCN<"9O72&U2,$4"8RI@B 4
M?<A@N*RJAG+??]2\\5Y["_^V465EU,SU2Q?KFW(3&?_(W5__HPU#!U<\XG(N
M%>U:K+W]S<Z$6-,5&VVF[@#M;Q5'!L;Q?//H=TLCI;-:=S7$MW8M.&AW?KQR
M7=; P-"*@_=3'+(<3Q[%Z$TRFP705@IL(E+;@I(F2KJ :SP1 \;(L<T&.DPZ
MR>B"W_/$CHQ-O;SHT#.5U/@CYD<J*R%BDSIQ,L/-M3!JL3DY.(;4S7F_/BCV
MY@B%WK'F)OL]80&RDV:E+<*O@0#%]'-*)G\1) !%+5MB$:Q**I(N&RG8 KY^
MV&<6XQ_E!$;EG6II?]K839GX[* ]TN2;,^TCJ"MX-3,T-+IZ/:F)^38=,9S]
MOB*.BE5'OV%.N(/9[EJN(()TG6[6Q3NCZE"G0]/V#0J!!<1JX6_NE/-[),+Z
M-*3:OD1FB3U$'MGFX-V^<$;2(O%5]]4S,]P\'T>I6F(HW[UFO^O\E%<WGJS#
M+ A')30#0D<:5A$=[ZME(6949K.5 [@PL^JT'9QWNF NQ-:[XK;[T<M?7\^E
MII\ ]1BQEC8M\7U_[2E8_Q1LS8V/-ZSN/A]=A$'DY.^Y:.C*!625TMG2WO=0
M"Q'AK@B>M/S3)^"B/*^";+4*-&THZ1=6D'480UBOL*TX$MFDHJ1S,M?R W@7
M%7:AS8$VJ7BL1?[JXZX-'<O(]1>C0YO4O[S4.OB!LX?32I9218C17^B@=Z.T
MW._ 8%.@7KK@;'+2/NY31MXK94BJNA :5-CJ^]K$>Y7TP43YQ+Q]!1XG,_N:
M!LPRKR]WNX_UI[]@@1&L\4</:3]R(-0Z%VR$LE4B]0UM)=^ZORX+L8OJ(YC&
M)6-%^-4J(..\Q^NB,V5CO[G'*'%64.J!GJI2I$<ESJ9Y Y&*Y$-=MD]YSF=^
MZAXD:5F:Q8!PMNR#\ ?@@D"?%J_-)I %V7GAXZD*'ZRX'IB8I]D '^\ME8S#
MQ$=1(08]G$G,6(%EWS=;GPU[^NS=')7Z#CY'AH"5U!!CTXB\ [D)89%*QKG!
M0$$7:^9 X67" OJ2V<%[$0T!X7G$#07C2%71T3Z!K/0KA#NI,FN>O+*<=@CI
M[*(M*X'80D2_FRM=-4#=0MM-22 _C$)6J(S32NHYC2IZ=5GD&^C&A0H'2R?/
MS'$=)AB(H S$JQ.UM_!6[V!?;0G_1]@-V@"J^SX;NB++F1D%F[IYKJ%)CX/#
MQP<.W+#\IRVABNR\F+W1',^(!AZU+SE!M"QWG_^:]4(PCJK4-A\0[A>,O[5#
M<]$C]-:ICU(P9@VR9C:'6( N?4H '*^MQUM110HFO+R[:6AELDEKR)KN6(TV
M1@C"_I355.4QU2MRO66CM)]KF\V8PS>@WO(%_U$%!</NH%\*:@J&(Y=FND;R
M*CEKL3UZXVUHQR@FI(0A;Z5+'T ^FIU(/V$1?CWLT^A,+J8:3\QT7'4[I?#\
MJ_:.>H:PZ-.0:R=O>Y)2__RXW><X@S]X.%/V1I?DRO=P5NVE.A./&1]2MO3)
M]#@:*.;OT+*YDZD";L?X,3!?O5UEG$U?"*6[JUB7D;5(6[UQ&G\%M>[Y;&&+
MF,)/>91FICZ\/57H,E5=VQDP8>=FH$H5'=Y663EA96?T;B#0C<1QP!SS6/%O
M^_^P^8'HPB[\&7C1BYH-RI*?"#4$8$2LOL?^_"M_J39K]JA^-0LV>?55&8SF
MEK? 0J7\MF1"3U%IVX(FZ&>?JJ3-6'-[[J.(Y=2LX+D#KW!KH*+F8Q&)%Q@X
M%!@VE93FW#EWHOSOW"]#GN2R3;_I?6V8+9Y ?Z'#+$-6CF)K"+"I1'T\Q6>'
M^K(VW2U:EHW-8I?UMVTE2Q<7JBCJ]!2:#WOOV4Z?1Y'XI:IK["19QVK_5[?L
MZU"VI C^$B7Q'3!.,[>!VA!#6TA8BKP1@,>QT#:*> +KQ7OCP,QQ^49:Y5!I
M<"S/@N'NT4VWIE&A<J6WI?6,XIU!PJ3#8/ %6]=']^>N#D\;6E=]1]  F$.V
M3:3E;I8*5OH0'AQB*+'S(*5H0'P5/B,G+/,/&JTWSJ3M4!CBE8?ZOMF%^S1X
MV;&_M9\X4O_T22.GP!FEXL6,GFN.X/"X.^HRCV:W"/X,K&M.3E)OU[(J^$O&
ML*:5#H8$\4 6;1_$5<T=#OP+;'E=F5#H/RAH(5A!4LW"5WUC03WA=[I%J5YU
M_!L3.0\L)>I+]]1'C3_4(09"%%.V 4(#8/RGV?KO4T_<O$@/4187YSGN0YA
M%VE^K8K=@M,?>?(./J7-GM(  SN:IGV7[>K%/D\\Q<DCM"8[V3[\:E=Z+TQ&
M?H;?0'+[R2&79,A!\7&!> PGGH2L<\<C-41Z#[9&,GMGLMRG(YL0@>O_=?A
M ^2LW$R+5\T3J>L7B*_QCN$8L/T,\QK-59%L*PI99V6IHDV;(_>LZDI"Q(X]
M7P*C'CT<\8B=TIQH1LS?T,+E@J40H27P5$&#'#"-2*R[QO-Z,+H]88!><W^L
MULP\I+J$Y'[C8_^H2W)OR[V_ ZS.[G#Y)]QA#D(C@5[8;,!4(!.P0'^@GZU^
M"*D>#+6#-8@^H+&&-S[K?2#P_QS+6D[O,LWS?%OA1DK\:_69:@F<I*I5MI+,
M.-L.6J/D+T8VF?ZM[:.)?_L<30QBC&+P+9R6@=KU\-2D]A1^$WM$H#9&L3.*
MWBH ?8@+H;'GK&I)4SH4]H!V2.53EPU'32,_J,IRN(R84]WC1KE%(GR#LA)H
M=N$$^J;_]%58/.(T?=%_X&720^FJLSUQNP]\&97.GLJ<K]#^!LB*A^:#1!%E
MT%C.&&Z>7$3;K2JD3C?5)Z?G\))E6\;=]FKSXPO?>UF7S.83_-4]%\:G#-?/
M?&[Z_'ITU#_E4)T3*TR0,O!YJ3XA6OK]P/ $ZJ_G]JJF=9B3SMFVH!ZRI$F'
M^?TH[2C*M*70,QWF,:!.8H^6M;*,W2Q5QG)I-GX%5>S!#(22E:P%8U)CMU-R
M24//ML)>GJ4BVFA,E/@Q2S(3_;Z@/-(2R4R*^UERR4Q=?]5@2U[?9X/?<\*^
MB]7KM*F$L$G(QD_8T'&9]80H&A.D8PT=<19C@F5<'Y1?M^)WJ%H^%REQRR)G
MK&\\&C,S[\AQG%P:=2.W$W:\'_G+VX'@H,@W@Y%'7]T!+CP5-#1@$'=D'<T;
MS:5N(<9[&E4=+10L9"-GIG"DEVM]9YC7\>NHY?M 4AI'P_!6;\T2'4F9;K;:
M*.B.S0]@3Y:EO'ZUY;,RJ?Q98=V5LWG[W;4;T; '!K!F]TC&.T&L@I@#)VA.
MT]NE*\P[A/5@-WX)S0EZ!DXKTIN)6<ZY>6':RO34;Z2YD&N()"YS@N9-79@6
M7S7JZUM@TNFKJH*]*R,#S\<$;Q(,3".+DF:]2\NC;Q^BO\%R_<;99U3."J3D
M?@1]=0\<'JD*5XI%Y?=.>(*]O#N):P)+<\$:!3,EUO+0-+$ZKEO1.\DI9YSY
M-D@V="%_/\\96V3'.R&?A"W.H-UZ0*&*=MO6 G-MJMOJAV07AU*R*PD+']?>
MQV^C^GKMU&%^R[U"WP('JG)3'(OGSZTFXZT$F<2MEV\>U/NG#%Y-0>?*%DV^
M9:O_@'J5/L:GP&%1!U-J07/18195<#=?F(CFOM\AK[LV96G1@M_Q9AW/]\[8
MGIZX]CB:#:4\.SNML8=G_'C@LUWIW7/PB/8FXA@)@.<]8=-L-5O[IR"2@6O.
M\QS?H@GS*H1NR<4M#&>1Q#RM](H\B+""R@R 7)69=IRQT(N5GP2&T?!%Y60:
M=N4WZ9*W3M71Y1[83$Z[^22Q^UNC[2D=QCW9S*.3YUP<68 %/]\JC7 QRCP3
M61(Q8)U]AEPR8G[@[IFY0?XC]>?R0U>8^IJ:7NH44R+#R4M\U>"!&^[F!QX7
M#6,'&M1;M;\++A#3.V%[;06R@*JG9*;:V5OSNNS<2*6''%E+2.\REH\=!\.S
MOV4S=K1:Z??BUM5>ZYL^ =YI+)0.!=B\K:H*XX2G77:SF;W:HA$0;HO%87Q4
MKJCWI*33Q88R*/J"_9TQ'^T#^FIR8N]@X#Y[>X>)'4WFN(PIXU51,]]^^6U8
ME!>2FL"NW5>:]_>^OF'8I %9O%N#GZU8A%]!.P0I-3\.P'N -)8Q?Q>5+0MC
M9L* / Q,I>HPQT'F55A?T28PAPB>^<=X?2>$+K<%S/,5L8]HQT+E'2;) N_>
M^[T\Q^*VN0=TF#^M5J/YA#\@RT!6JRR9&>GC155D:?_T@<^&!LU2*[KK*++F
MSIZ ^SF:PT#&#2 R<+#:US3QZK13[CK3W?LL7@3Z_Z,=A(+!,GFN$#L'BI?'
M"SO2AY9  :"TR8G4/V0&VHAFB:35<K @]=S9A"%#W-XW$]LX@]MW-]<$G^8Y
MC6WJ?=?]_C2OSL3;]O*E7+6I2R7C<^ZC_L$H\PLED3%G'OJ'""W;[TTQ_L%1
MXL/CHW_D^9E*?O#:N$.XU>'7YDF+<MNEP$N6HJRUPQ)5SX_(*D 8)9!EF'L4
M"!(>P[]HR_%+J>&RE8QB\[06#74=+^YB.=DEV^$/!IN^#3;OYNM%-&UI\[ZX
ML"1NB2%M4\Z7#FW$V)=!)1->EHWH=V@.(&_YRU''Q-'FH3!?I+X-7JH&-<U.
M(?8D+,VCR\$G* 0Z>9X@#XD:V@0>82KRL8O&ID-6!V_P2-G8XY 0[1AD9W&D
MFZN)#CIRI7(C!J'.UH@DOG4]JKV-_HM) H^0L@"]]=?$"D]X.:E%6H/<)BO*
M=]YMSV%6C."7@4 &?+)+^(&7FR<0LPUHFR2?-]G-/_XN1/HW8\G-UC(39%&-
M:F$'LG@$95D3:.HJ*]]2$N(),M54R 8%>[GS\W++(ZM1B%00,O!&7'!3PTA7
MB,A0E,"W ,O$EL23&7OG5W>HS/6+<UX/?33P(E2S!K!J&N2A\:6M@!@:5S@1
MO&KE!KFK2*(N*%2,7\$ZUOOMXN,12DQTLGY=[S<++2ZHBS+N:&%KY^W3\^W>
M@;:CW5,&KD%MWAFE::NHSN/K_F,K^89 EJ?#+.'Y@+GJO5 X0<1:!'6W[H"F
M6\I.J"C9-$HEE-K\923P4OK*#^I&Y6[RZ1XEI[K+(=_"CG"PNJ#;\XEM?))A
MUFA@:7D2;0XL!X1C.LP71D=_.=(!-)%F'O )?E-G"D?,4"GCRN)/@;\6C9I+
MA+:&ZULV1M_@?BR1':R8\/6<D[6!^./"GRJY7CMWME#K_B."3FE_1R,HL!C>
M 8:J>5 "H+*8?:F#K!T!3.#=)2,%#BK6%?MQM]#B3R'KP7:N#J,67)F2&H_F
M.G5%X&TEW\883J.C9'W?[_8M]:.F@<D?V&]G?.^&%D:B7+5D,#MXQ\&_:KH=
MQHY^>657<=Y.R>'4+7_]I7WMM:'-2F.'FX?D\0<__U.-02Q0@W@].<!6QT ;
M-"OIZ-#T$&<:&74NDGC(4/O0$9=9K[ZBHHCIJZ'HI'!9.UGN)^K0OQ>M4!64
M%'YL.RCA6U'3B:KY+U[7&S9?NC$VMX5=0>_^S (30\I*QP#P,*L_/*"3:V%)
M\NR=/8$];S3Q2&5I\*!TI+X@'] 0X,2&ZI[8L3&O3=S&ZD;N'=M\[X;(L+IG
M=7=V/;BAC N=J=.@S%-8)P /X@;BE3D-FKVPM_:/<S6JX>L\KQB%-..2P!BQ
M1O$I3H[-P*_KL1I-)IU2Z:71UJ$LSKM[RC!QYI_1H;4]-"PVC6L9$Q 0QSC^
M>>QX3US2/<_/N$$;1+]<LX8^I,/,1:R0=BFGH^DE3 *3Y'Y9M.U*8PSDMU?%
M8M#FTUPKJ.Y-]=(4!\?:7IH)^U,@9R:N[BKL61%161H2\B[ R_!OOW/+'KY]
M&S)P.3D8S$>\2"*BQ@8QU&%Z8GS82B:R"%6 [6YT,K\0QDE0K@Y3WBWW 2+K
M_[N7#2J3L6&3;/5^;8$.0S8>F*?NAXC@@$8$<(@3N\(W,=%DQJQ-2;$@FU]H
M6##TJ&@LCZ4&TAP9=(W(944>O^[^2&(E7'\D-THQ^KZHQNE2O)GID\O);:06
M,6R9IK&F_0R2,G684!*T+7Y\N/0T&>^F3>>%R2J=%1X5@4&C-S[A5X%ES0_I
M6VE8Z,K#P<$#N89R@@%\B!6,NO]UWX2/5SV4C8OE&ZJK:_L^2S6>%1.D@UTT
M]^+1O(6"DI&!CVE5D9+Z ]S"4;7OP)U;Y2,NMSFU@3FYCR,EU<3PAY$#:7]^
M#0SI#Q8Y<GLY74*WXQX;'F#@7[49J+'R2>!A8-!3-IG&7R_4'*>90?K*!NU&
M;R4EA8!%MD!8>7PS=MZ8VJFSK6JD4Z2T#-_'4>6DGOM0Y2!=1?7U<??LX=1F
M*3Y%NOP96,HHC;,R0".D A"ZT7'(H%2/\!.E?TP! QQ6*RZ[&MY3G]_"FA?:
MS;L(GI!_9($:>5T6?U/P$%6@:*DMU[OF2)IH,]9__REO&\&H5-7M7C7D/TC-
MY"RZ4%G&>DY'$YMJ%NA!R2[8T>L6\PAYX80L[HU#Z4FC]V'HE,I=(18!>HWO
M__Y"W%@??P7&*5UQBZ!?5_ZX2M[-PQ5%Y!U>^MC3,&7^Z60=1F,*"'\ ?NJ
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M0E]PRZC8D,9\#_ C2Y9$,H/BCX!_7_)U1@E983+]""(B@?L)D#4 F]2UABJ
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M]:'Q'_EG?#O8(2S J4Y?]"@^';SU?4 DRC96P)XJ>_'X4<\%]UZGRXEZA[+
M0']QQ!S(3RY-D8*!_029@F5%V]TM.$_J3Y$BB[%ZXP_"'X\)L-80R00VYT/'
M:=ME+\^ +66I!/DI%W?%_&[KSLI\E-Y?M5X>SGEV2[/_._^L0&(F)F8*P*/
M6S3_%VD.T<YH'R!.\%:(I8F!5T#.*D!\%$;YGLS.121_E\>H:G@< LT-(BT8
MY9N!ZEL)]JGR_'OKQ4>SIIOZ^OSJT_YD7Z0\W'+S\^275%%\7QX%MCJEFCN$
MQ'+R2=J4\8I8_^'W%E&YO\ [P2-EVTP35MU5_M7I2,X=.)3Q;8QWK_-'Y@!K
MMB#/ PVR>),.<TZH,M9A#A;>7TP"?9@#;<KP"3-TD9(@.PV)YB_YU@XH6=EH
M9D7)F'41A071.&+&*C=9P3(*@3Y:_JBB[2H*[(^H_6MCHNF?UD\XG)2!T#5I
M10O].KZRT&YZ9^\L!(1"+.AOW"_U!G/'Q97P2FC=8]K.7AY)3]P!;<:U4J[1
M+9)-2*H##RI\$F24JZ1YB-FG(7V57HJC74P3LJ2A*XY@/EK/2IF*]134F#<.
MI_WYB06RZ!V <+4.\R%XLE^$_*W#*/60/_F;)7]CP? R^,',(/(:4,8C-ZCF
ME_$8R!6U:1XZF$YZ.XN3*YZ$-HHGUH$&383:87C%KW9D41YNG*LR$;K8I//F
M@4J_].:97Z&;2H5S2Z=L8L=S\P5282/VN4O.7>6@7=!^4'PYCF'GH*6(K C\
MS@LM0Y5R?H.Z0OL,168LM#X]&PCO&" BBU>JVM2_:&L(H=)LZ<IM^#7P*="O
M"4"G"T9+FJ*]_;K9L+MUJIRR/$*',<";0_7)!ZGA7BI\B2R:$E*OJLHO?P?A
M-8=4/FE7!Z[EQP,3Y6LB422]=?!%!L-Y?-'&V[=/!0;H73Z^]LO2.?'+/-:<
MR=^V@6'B>FS/-R+D=@LYAI5W:-"9IY)FKL*D^\;]*+@1X!5U<C0?WZ&V4J5/
M,!3!^$%QERL4+B(MI,VSXNHPBS1P ,10/BQM %G7QJ<R';0>WS0;WYR/ZS ?
MDV27OG_?#[DW(6L;:JH;^"E#KP$QRX"V'951CM\.V]5J2R5JL?8W^ERJN+E^
M?@$>9(UON0CJ-066WHHLBS+=07;!BB8M:$=5SBEQDV;4T)8O37V!^]79RFC?
M[L/USP:K(#;Q6:W 5+ 6C9621,^,$G31]@/"G33OZ#B +.M8 B="1D-V]7_]
MA70E6X\=U_[)2[*ZPFX_+WUZMONF)*CF<C#G4IW93.6]U%=/AO;=I&=30Q']
M#;/XJBJ[!N]68O71GEL!;GH&S5;1;NREPEWC[2V&ET,)"27D JSDO-V4CX5_
M-VX==*TS.'*FX%Y<=%)8C(E#S"!QS<-#3QWFJ./A99[(XENSGUAY:O_@'5/B
M,G08XPJZ,=(EG8-LC)(N($1BT_+(HY[>;^#XPB"1F]7:-W;<5*?R$@AH5EF\
ME;_A!FE/G  _-A92F2*)>6V-Z>WHRE&@^C;4@3I-^NR%P^@Z@X=*M ^GR,R!
M$V(L1YP#1*&!ML 28BIG#R,(A/6$*X5U$@<3-"#GMP5;>$G<]M5$#:WOY<54
MCKJH2V>N'CN=$!C,K;T747O<.TZS_7\BDULI!0."CWQ%%O>C.GFD30=D#/S2
M9T][Z?/HKQ-+V!/;-5%.^;^TEQ65,O0RV Z6462_!E.S/%)30Z6SD&[1$S*T
M@ZR0#JS<1BG<<N%FBS:,WB?@E%T6A KZ\Y7,B;TJ)PI.B,*"!90KGN$^.;3V
M65]9Y_C9:+.FF=C27;?CF*9C79$%JSK=6U_,U++/YLS=L0Q^C2[S8Z FE\F+
MD1$':I#%7S7[GP\PQ0)HLU^+=#51SOCYB\WR )KU['XEUW5R^;M/^\+)#&=W
M57S+WD<CIC,[YD5&RZ5I>/W<P[8_@8\P2+E;',IUTED+44]E*YQSXG:;/!<8
M(,;0AF:KG:H#@O@+M?7&5V!]&=&(-(JL[2NP<(UW<O%+YVTOD[X[?,>IY4%W
MY8=KBP(NF@"V 'B* .TD(_H258UZ!Z32;*2W#+GV"LYW#(2JZR _);%?*1>+
M<.G $O[&P4BU&;#*P=+[>2[=5K50H"0M@  / WDR[E3/E-;Y0-?&/L>V]M C
M70]X-9T.06W,Y2."OB.-Q9^L-G0Y$@R@HL.=4^_UFF<NE-P?L[*45%1P?38T
MNQPH"[U(+O]47W#CH>?N.Y6EH^9GZWP'[MR+HUPDQX=N:G8^^O+"ERUPI?:Q
M0)8Q:XV4@1@YD\&S4<U3_ZB]1[<X/6:^\&&V"I ;BXSGT%9!=V4-3[_5I8A;
M[N#=P .9]X/?><LO+C%G5+$4SQP%^J]J;<E5$7DY-S:]_UV&W0 ('06R7,$:
M03@.6DMB"'XB94P[F3M/&*.8"6@??=/&>W$E=E6<CG1DI[:(AE/ZX$0%IFAL
M91*?-79O>@9R[]3)(3>/QQ'39BYN] T^4<'6DR>ZE76]. &&O@80'N8;4['(
MHF4*$K2!D,&WH%V<W<\K$8,:1>YX9JAF5=ES0I:D8'<OZL$=604;@FU;35T8
M@A1IT]RF0='05I^H)%=&HO'*N@Q._AC9T'1F*'A'8 _A)"![0QDP5N:V2-_Z
M*>M$QEEXUUYD*TS0YA$BDMAII+G(.K*S)._W)U0KXJ)/]>^&]+O8W%UAO5B1
ME>G-CV)_L#'G_A=\6B&UM5O49[PPNW@D\0)+@P;A!1?0\3&H?HC^(XW=*&GE
M><XB^EJD$S")\P92@2=,89MMP!1N&>P'#2JZ:OGF73]UQ?9&G],T(58->=)F
MJVW>)O."!X5A\@:#IS0?!6"T]](<2%]5JE2GJ::?LR ;*6RQ0^,$%08;*#DZ
MS!.!, T56 2?!;G#ZM[T<9'&[1.R%.Q!47M)8DGU=B\%D.'LK/3@=-L\[;YU
M$GQ=+A,8O#O@@,TVB7*QF<K5., 6T :-$\T,-![OU^!'!LS2$7/:8K#OKLS0
MH&EFM_;>5%^F4=[-U<6J%7?^OF"MPM<]=$2>*7R(Q_?W3'4L)8W6M][O&AHZ
M_4K:2IIXIMD-HYB:,KNU8D#?3@M4Z34SXA$K+U0SFZ#O(+];/: M==#ZI#-X
MN(NJD.EFNKT$L8)(+2ZG)AZ/6%F!(:FE9*NYS_B=D\M?:?Q5P'6NS]SD'8<%
M8*,@/8D);>Z 38K4%U$1ZVA$]-<3Z07 (RQCJ$$VW1S$'B3)AL?OJ0H'1 JS
MG*D:S4'8";H5=O$AM:!-@6=503=U&._Z>DFN,+"2JRW-#"^,J$Q29">51]OW
M$0VATY^>8P<K_[_.J?]_VK L #Q)?'NKA00>H[PM4G2,)\@I3!/D=:AR/G]I
MC<JF.8F4+E($/P?9Z6ZD0JC.%WQ%C:!*Y?]4ZF5AW;E=<:C%$Z/\O//4763R
MF/=@?L#N!K63]@^WE1I3Y)4.,X<01DRO,WY(]9,11;@E,('3]_%)MD^#ZD!)
M<;\ME=D:F,.:/_U#0!3?0;5M1I U1?:WM[EFZ.U?G[/Z+.,4LZOGJ%XS.CC!
MVW0A !YCO14IF>,)RGO)/,LRVFD0N4<IA$8M%V)-0J@&K2'FJH6W%-*%4&OW
MOOP3;P9]D6:557J9#U L8D<<'PMT'0U<U^< <;=<,/E*40C@I=/-.LSLNXQL
MDJ% =B/D1VWUYSA#/WDYY-3FHRT-AU;4>,?+F>F"Y5RL&60K(H)7:3]G! U2
MDX2W(J1&YZO\%+2*;=\,=D<=#/YPZQ#IT\(LS%=<"F#8+1L6LJ^R%A7U631O
M =ERYF6^12E?/<\[^:*;L3S85F10X?1'7=[E[OP3YOZ-Y#D S6[)QW<AIS/@
M81C-IU)05BJTMA/([I$X3'A%KOIJ'?25T"*%J'[BW3N4V\'KTB5%( [>NOF;
M= U\2?6$>I8\HIQ$TX<FVI>7JOKD75S!.&G!X[+T]<_,=T4?D_VE32^\3$C'
M06Y)LNG+=&<H%]%/ QN>^WX9)=26M4BO\W^ W$'1ONZ_-]</BXB6[Z@[1-,J
M:FG$<>]/ZVNA>^54*XEPTB7YUOB N#EA;8"YA8SUMFS\F89 =5:C3!"_$&DG
M&2L-9#K,%8&!FPDHWO]G\U\=CT1RRX5M!Y]**+W>>KTT]V1*7%74UQJW7)?2
M!_$QMKR;#=@_^5L!(<IBPX@,4IVGD )MCF]N-&C%;]8^0*G\XB#(4[Z'IRI]
MB+>$SG6])JYZUQ]U S+ZH3ZXM2'\(74XJ#=Z:LL_O]97)/IH]DO,/;)%,X9[
ML!T">(4&6116C@Q(N>%-E$&EVD];#2=H%B/]I,4T"]P5O6;V8JH#=<Q+1;DV
M,>'F'5XLPK.BE=BY42%K) M9BHEX4>#04T?<\I&\R=2JG][@X$T_<+SK9C)1
M8\G78<QH9)0N5D&5Z*\*TFBBH$FEM(5R'3#F;Z&ZM@BX'4QXZ<P=/HZ_$4KW
ME6R;7 O%$Y@?(AV,%PQ&F>8M3)??AJY$+NN*?;&6(^B<&#!PQ?5%;9XG([[M
M4*_.5A] 32"!YJA-(3:/X->V@-.H7K.0%5ZJ$\C27O#/O YXTPDH3Q&=[&:B
MP^A[9OH=UEA0;_3MMN,%//Q>'M' 7;'#!)L+"*W0T>:AK'L^2\O\2?N[F=*;
MEK2==D0E:,YTHTF-TIOD&Z!7NTW7%96E>>;PUZ^2^/BLWD$?VOC[D-NX-)2S
M:)G@Q.;[QB^(4-PV$OC=&$H*AW$)SCJ," \TH:EIVCP=9O'+2]]G*YN^E8)W
M@*9N].$5%NZ%=G)VPP&LBD\0?+7L_R*9W==BSK[3F]WP(FMOG$<7/!/OY 7J
MC^/MJ3L4%59NQ'1;E==A_K(NFE^Q4Z9S6I"89-0F?BA4/"HQ3Z'>M*ZYT[6M
M_WUQ5?D,UP-#NZ$2J6VA=9HC]!<NN>,!FKV?"& U?=E_7(8T>_R)=)2TO_=L
MOE!=O_>-&^E!\&!;G',ZSZ=P+,\J7^%C]$6_2E##=3UH2JH+S)0_A>>#>O!2
M'+(X6.-$I7>@VAZ_@@[TJ_8^WI3^VM?P421_-92@G$1)]EZHI IV FM>G^OZ
M1M$GSS!;?)S:31>LW[4.K+T%=GMS_PPF1=;'U:FOJR\"OB>/ZCTG@4<$;X%F
MX*]<X:09-$^,Y5+$.LS@!@6*:YEY[!;2&OAG[0.>)[Y!X7H/. D.I\%V6H8\
MR;5\XN<Q48AA=3=M4UE[&417DB2!DJ,-/1_2C^:\3@HRP DB_N<5U"+8H+93
M30!]B*L!H:\@K!VK/M5)B&QC]><*<TDF,$[9D9G'8#:E08_B519[P*OFC-<,
M6:3=)N@&.&JWO F[XEVDE7VTQW!?=A2RNM-3#=Q>,D3YY/R<E,*?K\U']&F;
MH#F@R =Y"26 H7+I5?QJR$F8Q5-!@##/\DYJF7?2#Z>< V^_,_5.>$PZN&1Z
MYOJT7^Z2KQT;ZBK1L'47M:X3DY U*PV0E0CT$2QD_U59U@KTERN(0E9&J*).
MR&*0YDUU%T%E0OI.*ZL^-WN)WYT1Q[2ALA*?$G)\BK]#<E)3_;C?LN=JJTW5
M5]@3;,&J."GD+$$61ZM218DL(7O $S'2UY;A-R"OZSF^><Z9L-D#VN8>&D$A
MS> OHYZKZX5W*P!3$AS;]R'+<%\_TIY@EK$>RBPA1V[ /RM^O^B.&5+S\+[Q
M#1WFC/1MNIH^Z];TU_0EVEP=YAS;,!@"Y!VI'WJX6]C<\H9DOQ;D1]6!NE_L
MXR;-J<,A==7=?B&J(]7K@T07$VN=+MU)#,O)??!);7XNK3@R,8S5G(KH)Z%I
M438!/(4:IJR(Q66V (:P/TAZSEHX2-VA7JPMB 6,H^[05T-FR8^;&$I<%MW>
MI7'J-4N!R_*;+H^)*1DS]0T)YDW7GU+=')HMKWJYE:FQ0?WK#&K^\[37Z$;_
M<;U$&!;%O2>D5AUFPANW"';G=E_@2%=0J0&X+#=])=8HRG= FN86*7_$-2"7
MG^V9/5KJ6%][![<AX,UG+F \5/\V:CH!+IO="YJ_"YJH@"]J<Y'-@' _NGC_
M45N!(IU+;W9YGYX%A+%2 W.?8]-9\V#G^]2.O9S.2IJ-$L@:D%ZCN2L:XY5Z
M&? /L62#-D-BBXES1E7</:?!XSTT8OR91U#ZGEZ@,/%_T<O3?]N_[3]7F_>"
MOHNV"IP6=Z1)ER$FU*(05=DU#BY3N@1. &L"^GAS%*:@(#N68:(PRC6Z]7@,
M;R99WJ?B4%9&_K:GAIH4%)0P>*@A_%[T1SL.'<V*F[<#U6RM90?*I708D_7H
MSQ\N"!/%LV$]9%VVE@%\^@S(RJ3073,I+.S489:V(*V";_$$%)CAP]F3R$]C
M,W@TD/R)A:[AU(XZ3-'L5R(L0'&6!'S5\X3=S33F.DSGN]EOG 6J'W&"[ZGL
M3S-9&.070+%*\%:"Y PCB]&T-/,&^O.W)5:UA#2.LB[/&!2:T$RU^05?A_EH
M)"@:W3SONU"'R?AY]J.Y&5<6M&4:L?:8UF%^B 7^G<*_4_AW"O\;>V\:U$3:
MOH]&45$1PB*@(,0=%2$N(,J2UD%%1(P[ D+&<6&)D)D!)$I,*PAA$3+J"*\P
M$ 41%"&R*T)"2(!Q&$3V3<C"N &!;L'00SK-O_-6G?/IU/GV.U6GZO<E5:&H
M3C]W7\]]7U<_]_*_2_C?)?SO$OYW"?^[A/]_+4%;C/NR #5IEGN@)NIZBQDQ
M/YZW' CF)652$]EK6N$MDZ<TCP2VWK"7Y&J-9-@P3I3ZY.M Q8!]6D^.10!E
MB-SI8>A<4M$1:GW-[B.Q[LO_RY"!38\,@IH$F\HA(([E/Q)P4"\E&VBP7ME;
M>QP,"U[G%&W&)G64?*<7VMWFKSJH.&MGO7O_O?67#P9,%-T#VG;U8D1_33%Z
M^L7H+L$B? 4L=%V7_$R-H*)=R;H![VRT:$U(J]Z\W*[PPU<+_=AAQ^H!N["2
MRDT5-W;TQ#P\?N]=9UO:$"CD#IACAXC-)/4ZW); =[V>,;0?D/W%^_<PH[E-
MO8V8#,ZVT\J*">R[+.,Y0MS@N$G3;% "$"KL,_>!:)R%0^D\A=",M0ZIFIU,
M0AT=?DUTI!<*S)"Q^N&5WL?67'[EO0-,G'7[>&^PLHCZS-NY15?%46_ ^H!R
MKK(5\M^K>01>XB<[FS>"\<.K<T:HWD&'_ >MW/?WOLBMRCH)5:>XNA0-GJ5C
M)O#1#-./?U3/+A(6G W=[C=\=M1(;)]=>#;@@S;Q=:'VH.,<NPV$3M+Z_15!
M-REK6*Y0=W-3';%^V+8;")HCW-D>8N0QTL:A&=M%^F?Q]&]P TK5N_B%B+M/
MMS)2331'[$<GPDPD%A=TZ8>BB@'W[@JA7(PM^UOSK/8\-(8MU8/=56<SS@HR
MY!E*2\A#PEY/L=BYL\^?=0IQCWXZ-FP-.QC^Z6MWF;) @,3ECAYL7WO_I/IH
M8F_9D<P-R?OG8=D./K!6XQ=H>XM0=J,+-"_(@"Q;"!T!XV>)DCG"@)Y8L!6:
M(]RLC8!MCK\G"S:U 8WZ(6%4='/;;5#?8:41CM85(>8S*@MB4F7JY1MG?9'_
MT-GZE5#L:.:1S [V3RRM&:I 48\0\F:ZKH/%*@5D\) L$IHB/*^JLI<(!Z*I
MK@H05J_YLMD[[,7=M2?5>_1M&BE+NKX7.S=A>I9D<R2G65+FH?]/E9=;ZQ\)
MVXC3R;G"K4+90Q Z#<8*H>-SA+ZCI$&?_65<>6T@L1I.Y\%C\J'AU\1$!ML0
M>2.?^".JS?AK]/7:JWZ'NB.SVO2\\I%.<69YR$",%&$$= KZ0RX\%ST[ZSM'
M6!NH!>XP[BS8<P19F;""VT3$_R):5T'D /,IINC64M#PP*7G2+3LZC.%';F^
MMZ;[$T^N[Z4(NH-1^IB=^^K@WA2_X4.+XF3Z2UN\2\UFDE:9FV4>?*Q(N4F<
M=N8KPL784NU872$/TY,"X[> ^M80\$*4IG02,R :@&*G4+#O+M9:-6R;<: :
M&:9LL__-D><,)K0?@'^I?.UZ"C.;FK!X&_F@ ZW;#O@)94E""T!6@6W!KQD"
M:$?JG@7B_,"$[_SXJ\ R1_ V8%'!7<:T]'B)_"'8^@;^7I 26:H@W:XI_MP
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M5 :]D"FL%]A#=?&M_;_Y#0XSX_9V.63Y3ASQ7)\[O'FBP_/.+[6QCF&)K?'
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M?+2.<&V.T,C[=P-H/$<8YR$M<X3CK8>%OY&1'33LB+FV3*A<^&J.T+T=JA'
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M+C8)O8C\,L*-#W3N')\&TW:99PP;(!QY]LD&BDUYI9"C"M[I>VXH.+-QVC!
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M<83OX[C\_47%[W7Z70[Y(DS^;XP+V%5;V%&59&2G*(G72@P"Q!T&/NV8#74
M.BOQWOI*@@7RQKD&XGNOK35QS><S)/BQYL@FN[R9F?QKYQ.)2YZN/FUTEO37
M,ZQ$B%Q*N0!TBV]P27AHXY1"KO*G]HOFNBO'L28-R&R1?SI;1Z).CBXAQGHM
MEJ#-R/BN)F41)M_[@W#3DA*[IX+:Z<</<_< L]>,_%BY<VW,3PY*J%"S\BX;
MI'5U;U>Z";"GEE/UQCDV8![]I3JPO?#3L#*]#V/M_PM WJ<Z\@(:J R'MV7*
MW!Z4_N><ZR9[%N?=%I8@^6SPV]?>.[-TWFA]Q-D>Q7K5,2CJG_M@=[1AXH2-
MI>=Q-JC+V$XJ)+Q[H &?/H\PH817C7-LA0T- *UCRA3>#*(RI8.NK4="!^X#
M0K9+*C(2F$TCS5@RH=U36R@!9:)]SP+M6$U*)WQ7"&SQ-VBIW 4=DR-%I<J=
M U1SF 8Y:"DF*/4"*0O/4E<H@F3>*+[&&ZI,D"I\^[Y];[-&]S4P#?@I6LA9
M0:2Z<\"EG7FITO>)ZF"4)=UR'M$>*.^V5[""]%6F]Y&R>81F96<SU"5'T\6
M+WVH5)K4V9-%6^8R)4J03W7B,JPW],,&LIY54)Q.OU> %FUL7V(LP97UI/OX
M]YA:C5&:S"'KJ\N7<_L?F@RXFJ0?'7G%8-$D@^+A(S)N%WT()4=.YJIP4&&'
MUDQ$:%/R;ZA7AKZ&-4+>3,RMH75^(V^;#1DL;(N7><<<>OZ\WU6;MBO(MWD,
M0XR%[KGHYP7#^P#[K/J10+OVHK_=-2MCYA&_+<!3(T.9HMD\CQCXKEH:X@FV
M9L)&_IJ5:9 /R,+*BA>JE$N>1NK2,DIV_F9:!RCO@4+Y06 J@^G,KM0++=Z#
MS6ED+*><8A*;$O:<=9G*B]S^^]YGEX$/"-IA1I.#XI@4^3Y-Z:-^P"4BUUJ&
M7L1>%:^@^,@=X[=]E4_FDPOYF_0()4N TTD[K8,^Y\'G'T-)[18I'W^>1X0W
MKEFC=?Q>#&B#>Q[MG).M1E]+A$N:0:;"0;6'<@;T8ZF2813$4T5 36V1Z\"I
MW-/ GZ.F4*44*=((VMR2,,;W@FDKL9FL;J24FTZU(X?LN_9R+-F:44N^Y.0\
M^CK(HL\3)^Z!=@CXFG5JUC_O_3BXPZL^2\\P4TF/J?THLP;<S7E$PU_"#,FX
MM26D(W&L(4U>^+"4L+Y@U'L[;QYABK%Y=>JRR1976@;5X([=MYFE2,D\@H5+
MIWA*\)#GE$;774)?3C"CH@!&&NUG?9H>A-\M^)5?\:7$"ICEX89O[^UUR5T]
M5%Q:+[@X[$GT/'WFYU_;<T*S7B$TW12BG+84=@4865ZIH"5?8P[H7*78E8\0
M2S:#%7F):H=VCC'P-O=T2?17I@QI.-%TR0*36R[R6U$8EE%^.9YP+NUBO<UW
M_%(R4J._\!B=!16#*]'ID8O57&XTVA#Z]OVHH,';]B<6U"WYPQ:T9U6]_I60
M['_=-5=Q8' />+/R\8E7IN6/&-)XW/&6DF_'J^7IM>4W[364A:X 2I$8-GFC
MT<]7+=4&D04<(F,:QHKKS*X"H[/*>^HRV%WJG7"D]QS&AF@6%M.!,Q5!I(X+
M8WT^-B(1.4GZ.</+6YKGMZ:TY9TS9S-T^T3]Z8$MT]GWU3[J.JQDE 39S7:A
MASQE_FWB#-2SGK:%VF:&-50K* >=)C;%F$+.7>TT0R]7<!DOH*49.%=1 U7Y
MW\2N@E0XC\G@8,VZ/DI,JFQ1S9?OD6&Z3E.1/0?K$>JA?I83UD_ G$F-G!/L
M[VNH<JP)/-+/_&K3\$PPK5J]H;F5T]I2++\F[.L3;3KG?,[^8L[JJ,L;$GTW
M4,X_7BB"/X\X&6$K.5"H.A#';72?_%Q![9G[6E\%D7AB,R9U"X09;BNQ YW3
MG#H\NC(H6Y\$/;&!;G<T4PJ:;.0\D46<Q1^K]DV<_N,&#Z!I#-ZIGV(V:(1<
M8 \M)YAF1O%/E4V9:[J#0)7R%Q;H7)^0D,*<L-8%/K=CD>3O+VMJ\"-!+H7?
M8S$H*)LDJ=)O''+\HC$5W)I2F#_[,#I"/:,]PQH4$( =2E*RU+=JYA'$J6'C
MG_ B*E:'X@/E 4D2[$M\KAL7N$4Q@%Q+";-SN!R8(/-$+HH+"2FQ!MUSO%)D
M.*.@A,=!-6.X\O?AH7N.'&#WE^4>JD-H!FG:WQ?)E2?53RFVJ7+N4()<W,ZD
M8TS[SBD:U E'H"BYMSG?2=IZ0-F/#R-@-@FF)RH3<?IQLV:G(_AE4,:;H/Y(
M\6S[\)N_J_X>UN+\1UK;^:[)\V"+<AN$53EH!L0_3'H=T":/-^,J-KY')\!!
MFU]6$V(D9C6/)DEX/ R)!H_G'FZ!$BT(HHHLZ]EC66/)Q15#'^<1@8T%KZ[!
MAP"ZQ(&G-;3^L%4-D*M,5M^:?H4QA9>J6?.(TU.K(6XG5P?V=BE]*?+MYO(8
M-S$_IJ+]^[[^]1NA>;_U3G7Q64I$:?@PNX(WB+$=F+;246UOGXTOVR6&/+8K
M_=2%L*?*A];FC+'Y@D5H3+Z,>BPT"3]7[+D'4LNZM[<EVQ6T@)G^]X*A(Q4]
M%90]_4X*6T:'LGXH,F*XQ_JQ(+OOD[Q[5+#W^.(YL?IWVCGT^UDEMP6,SYQL
M4@7"YI J5>*9:C'5&4S3@U.UE+-Z!#HCZ-@6=_!+H0>?0[^<X'J'4^&67\DG
MN#Q^]L;N]S]6_XB81VQ! ?$5G;CK#,0,"7).XJ-O8HW9BX 4:5,FC331HQ!;
MPT'@I30);3D!G2KCY@8'KQ*3,SL*Y\X5+GU;FN)BYI%8-:)?O&>.O*5:5C(>
M^Y V3E.>5V?2HL1#/TSQM;JL3CS9"^ EIK-TIVDB;DTDQ1% 9L)623(B#AE0
M&?0PG&ANX5W<,-@X=UK$J7 JV];B;U)X>\?A#D/8:V$_B18L"L3U\P@%J(I;
MJ,**<=0*JPF:*<:(VD-K[.K8 3NIT..SHAR*)1C2(38COY&=SY4E=7@O,SC@
MB#:-A/"[!)]Z+UJM_/KR>(^Z*L6^'E-:83-FC*"14/4.BC'5:NI0%SY7&:RN
MH.K#2?U>CGHC9(8/E"2O,0\'W3.K-[06'F@:<.7JV_U)M>V;3AE^?[I)P,H=
M<39 '\ZGO7/^:OH;XRS4!-*E[B^QB DMNKC#^P#W=ES&J/E59Z_=<F869V,O
M&R6-M[,[;]H<,1&F^.M.SHG1 Z^(I\[8$UOW?#M^=O*^=NT>T&29&CT?K65#
M+NRTT$Z60I-DBRVX/Z.7Q(KK671%(OA0(*'SZ1E:N7O6"=X)?#\LF,%GB_4U
MQE#1MYZVQH=6.OZ-8$R:9F<>]GB?2VYXD)%^CQ[!>H/@XCV\L?_YRM%4K3K7
M"26CNPKFQ M]1*]K$YO1Q4#1),6T>J9"IYK,4PY AR3':VM/,7#/!S26[IDL
MYIHQ(')X^$/L7&;:]#PB.W)5GVMQ9!#*IW?&(/D[SX.>/1U*M7F_?Q?V 7Y(
MH-'3VM,EW]0U[/,.//005\F']$&2S(-/.T^2:.W%[#[,UH'XBX^M)XZT O.(
MC)DU6OXS.DX0YK>.J#57"96AHK#2$Q]P:_5.H\@ADD+86-.C6;Y(=0$22Y.T
MY+T81JOSXS$[-#V/\";D<P*I.R_509D$C0#=++Q^'&9I\SSB^F<I(^.B.'-N
M'I'EM3.^%,H]#"CN#.9<1)O!WA;Y@=P5<>86&8R*N!^IRG>+?$T._L\>.M^T
MJ+'TSC^E3>BTILQ)U<*+:-KK>IZR_YX$S\?>*$&2<A@L=\76A^IG[-T 36H9
M2LX\1%OY173GNFXEY'_8>O6[,C!"^>QA7)A#%DN!Z\"O\#*5+K0//4LNQ*<T
M+&P$T9K$TU;.PD&^!4ZQ<$ ; 08;ZAN5$ -^[9'/9CBQ0PBU8WWJ)WUSPM%A
M:8-YP5QBN3S *>]&V-QXXWGN5_9/I,5X[,>;#[18U.9'W:3][!,#1UH=-;I3
M<N8U# (:G$?H^? P*T%SOA; %^]K =W2@01),?,Z[33D:D5[B3%).S!XEL5
M&<3L RHRI[W=@P%AR_T3H1.C-O="&NI3*L"5=Y7FBAX9'=K1HEDN $HUEC2^
M&#A(2F, !]%#PR]+'(%B;A<NG>JN9E , .'WH*=@4_9%^O+8N?3?-"; "#W[
MP3L'T+[I$3E%46(&93[H*8TK&LVC8=-8W>M=T9,2Y !6J\.4'R&Y=IF_+*0/
MD;&*%B->-9X<PE^PB[NA1!7F"]YD5.2H3GD)DJM\03>6#&W],DP8J$\S^O E
M<GG_=#PZ^/G5]7WLW3)/I^!7?J6$4\:4]1(DY#JL3(!:5)Z0H^QS!WJ8J_P(
MTA0D>4]&&*I#GRYZA*+;'A4H* 39B!Z/?V1\SHQ>20C+>$"3Z,X07(;'%$P*
M"9LU4XS=W]"2VUD4_S%_9%A30AWE-J!AXZ1_MFBY?("IZA>)*3WZU$Y40U<;
M-J,$4Y>W(1JJJ""7=LX=*)33,SW0O/ 41V++/7&>M26X955C?@PA*K7,]6M:
M5: LA<A8Q),%B?E=URE8;8KK+W2BK)?U(.%EO=RSWC2-KFG-Q"+8DE ;3MD,
MS"JXYI/D-ZF)*=%2*_NNPR"SHT<7W@FBTIR=I"VY/+/1=0 [.;JFM>=Z=0W5
M>)QCUSAP!7L?"ZW+A$T^*Q^"A;#AE'(6JE?Y0,PCZOM>T=IEG\*B'@+F_.+D
MJ<.@?3D8PF/H:_2"0/R^=XE3ICUVG4WRO)!]_?'EC4'4&?R)5N!1J_0X.KJ5
MDU[["/X*,"<W,1?JEUTS@YHT^D0Y6BL6GCS7?K][@KQ=AE7$E\') HXWU+2O
ME[V#L9*Z&<KP1DO/Y$J"' \V )<8TDV43=(SUPRLNP[4,_: P>5*@[6AY*B@
M1B"=YH<'?M*&0QN:1D!!=DH&D*1<#HRHZ9.3+FA3BB,D!ZIDAJQ,N6O%#9@D
M%9P"=3D[1@@);(_/N924A^.H>'JGQ=(/HV;]TZ%.+EP=3GXY= &[ DKZ_AH-
MK9N"39#2J<DF60]DKV1H<W O8+8 @(]:!B@!CXD'R;F2,_?,%8Y2?)H%XZ9.
M1X\Q[)HF,^VLTKE^MB$WES_P6>B%3TR*.9UV5!A-6S$,A2G8Z\\NFHLPATV[
MVKB+:)(<Q@\TR2-&@]P'FTN)5VVGV(,>9'30\8:(0-EGQ6(Y:5FH/G()V:,M
MGMMKWDG],??@@->$$^;K( ^S@AX,NA1\_R(R_3.S1TNE6=RG=+XXTR*$3X<V
MH12O;VDY%3B$A3:N*"AQ@VX5W6$#;P"4I%5P/ YK0(NAK1R*?.,MSJRYZ&W!
MXR5A-KU[P[._B\F5HI>,&XY\H'AF'NO'&K"Q(%%Y5EWJ=88F*:595L]P]1:8
M&RO)3';(H"[3O*3I^97,W>E1$%2[R#9H V@QCVND8+M6!58P+(H]C[" UHKK
MG2S[PHK4!U[KU:R$<AX!% W-(PB<%;2V9%?B/().JT>U,8>W:W0G5'NI[=9K
MU2Q2_#1NB"B;XJ-7D0/YHX;@8,[,Q3Y4N\8(S,NX2JS0SLS RU\6,^B2Y]'C
M)SS%':AVC8_QHX<*IA7VX]_#!%JV2OY_J//9_W!H5LPC8DF0&TZCYZM":SY0
M=ZB;L!*ZF)6D5:O+(J![G9%>(#?3RUT><6;V90D66(OQ+E&%#U*M' ,E# O*
M5NBN)#11_^YTJ]M@I]N<4_UQJV7#$;TS:Z;?,(VPLW=]$;3%*'.N)&/A#87/
ML*GS]Y<E"S6I?Z>.<)=IW;/&%$0J8=&!WT;7])<+$AU3PHLQPQW)(>VHJUA]
MC!F, 1DYI^H&7"V]T8? S!L7<UO1N-:!TJ8!I_3A(3SM#.HI<S(*R-7HSJ@V
MPS;J6]3E/I7N5S3&7Y*""=7$V^JJ#HP3Z-SR1$R^W1GI BY]J1Y4-N7 1ZKB
M1/W*2[DK"\M\DY9E/Q0-Q3:?8T239EI-$(=\_]>-$#OY!'/-<<BXLTF\\F*Q
M;224'B-%&XZ0C?> RTKM\^]/1&YKZIVR!SBW:\;?\<X[WRV+\Q ='QH/NQ'\
M_55TC,O@IA4UJ_PF8N\C/_5H#&3_%)WH10&X"$ME"S2EBL>3L9%J)I;(S,V6
MH4S&J6:@ VR?2Y"T;H['=S OTV3K3YV*1V6Q$T!DY^BV0=C_5'G-2%F!1\QU
M9^<9W<3E?PD:&&/;_B=OS>^@$? W+.B3*A4&CH7^*H-W@$F=!H%2% ^[&O:I
MAR(DCI>=88)\#'9X,$H,E))6#/,(-!=1)U/I0SCSZ_O1/Z-_75W]];3^$D8Z
M:J4612:1D,U@+MM0)YL2#WZ6X=JPYLMK_<J!0IG[Y Q8=104WJ81]!J:$]^6
M O5M>$.-%?M;Q)JS)V/9%P_%I(M4DZON_#J/V,N2E*#5=[#14UF83?BUT*SR
M'*0CIUENZ/FEY$>0UC:5J37#^TX$TK<E@LOJI<,CH6=N+Z8\G/24G(NZN@OU
MQSQBH>*U,0/:3(/-*Y17_JF)N%@R>%-C2.6/ZD&[Q#H:8_*;KCG7P8Q$4IYF
MH[5!K\94A _K.H?R!WV&QSRP.3-3QK7%3R:"1W_(P&:6K!DX=T98WE2$4IQ[
M\O[]$*'@4O.E>S'$BC&E&R Z_O[X,)\0$T,@6?"7LFJJ==>:*8&?JM;^V)Z]
M]M"3AYL?(\+N(^6Y_X,[8R-8X")V,B)5=53[%[379=#]I3+)1XZ>#&6&4OLC
M$0,-MY1S"FX&C(KW;N*_<?3>LR)"%":"L2_Z*<FO8H,),]Q,CO7&+T 5\HME
M!P,)Z\BM GG)7;EL8RG*-$YCT+^R1FH0TE%BV<OJ#FPOJBQZ*QFG6G+Z)VMK
M&[QW?2"(*)]F PN$'[NC8C;=3JU>4>P]4,.:8?'O*-CFEY)^"2(F$1)7))D-
M!@\:-AP9_K![,_M(F]<!,&C%X]Y7EML\ZIXM60S5:A5G5 /MQD(=*%&I\K5V
MQ46:?B <3_[>(0JY-H^(1J5U;K2Z&.%"#F\KT;LM*ZB4WK/\U7S?-0,'7^AR
MN2B2D&73TL\^!&[6+7</L<A_/JQFT?ZZ@(/LD>JB9:7SB,?NBF'\^\%T+RLI
M:M&72YS5@'LZ>Z>DQ^!XZY\%D=; H\Q'Y"2?^EO?9.%O7CE=++86OFT?^5K[
MJ6C\KP=-?B4R0LQO#76>%H,E/P#.#V1J1YG!PA8\AU3YB#[N7D"O%^FRM-OZ
M,W_.[<Z%IE?G'Q$B[8JZ9XH]<<6NW@%GZAI:,T3'^M%WY*>2=ORZ^.]%VO^5
M?J&9:2/^=SP00GM_6Z-?*"5E6#MIA8\;V5W:/X_0>NBX$<>7R8[C1>*K#7<%
M7:.F#'YS0X]K"2-&)PNV!,-&L4M.C \V1U[W2@"$@SX@,LOE#_:QT@U<7XU0
M&Q13L/&US\I?P(S;*F-X#Y2N"M0(N29>#I5DE"2D#:U#,8!ZR\AYF(WDOK>?
M>27&C YWZRV \]6R$^%?DM4*ED*8*8TXTH'9 .HV9AX 1AGD1$\B-(^H3&D)
M#%2%W]-7$5.&+8<OUZ"W?)7>_"3\VO?)+4,F^C0:38YI*C$G/\HX2OXK;\@J
M]'C:Q\BEZM_G$3'<=)%ZH5GL&E@7<@4F^!ZE;^PK9/@?X!\!_^N):K^ !V[?
MO37U4C42UW]N]+AN1O#S%_EEU__S_C>[V,4 0[.\6"M_U%"N]G-<NX3VY!XI
MO3/5&K^"0H!>2)ET5(,#'[7L0PUWF&)82_XL':C(],)*G0X0"16AKJT."Z]F
M>:VE^)[[LZ:<G",/[MW[*^&AC(;2!I\W]B^D4*Q,F$=8<J=S7PZH]W>O"#$,
M7 +Z>QEW MTK_JCS=3F\*<"FP'W%+7^;K?[^AVO+JG[0->V&?%YJ]*&44H=,
MK\52I#Z$XO6>P"59ITD-%@< PCRK$8%.\XL@M&]#W;/ W()CA$_'E]S>EF:[
M%?%.YYNI*F0>\?J3&-C/5&U#HFCCVC6ZEA:"TZKL"U^H6P%Z.QIRB%'$E)-#
M0D'W*PM]B(=]=H-)'86]\9AA^[R*N&=?PH39*8\W7@QW\CS8S]9QR"SM9UJ+
M@X(20GM=AG.?GV.%FS#FWK0 J*M3<$0YO(L#Q*2C*9<?$@2Q<^B\6MBS[ 34
MLK?OW-(OS_NFN49!9^:Z,XIW]"<N<KU3/AG<EZMZ![J+*KZ[N=:8^X'V^96Q
MUC9]%[M3]@C/UKJ,1/TDK'9*#+(])F#:Q#I/NCJYS6V:G*JN?9"4(1..KSE9
M8A_[5UY^UCI4"?YI$FQ:JES8WE@85X+MY49I>8/!]PZ4XC/9EC)45L&L> 5G
M(XRU-J-WN5O,U&8_.H$#S=LT9HT#K*W8C)FC;.NU]T(%#U:5=CWN6?NX2ZL4
M#,+F$;>T%F=IPSQ"ZU@':#,V$!<_P.#AT[ ZFA7'XY)#VJ;24094$T+RP*RR
MY-DCV!5 I\/ZIZKB\.QY1'9&18PT%1W8Q.6H)[EC28?>G%<-82]_;TQB;Y6@
M?X#L(R[0EI'1[51#1L=<6?/G[#- 5Z9+Z@_X51-'&NB89[4!Y:$B3,V3_=]>
M?QLW5YQ/L@VP]?HS(ANA\5DH1;7P:-?RT$+0ER]47>*S5%=52;2VGQ=V8CJ$
M=/:D<Q=CST[,([)0!A0LV/720YQ#V0JF:RPF2G9 ;GT$#P$YY3B S79FVR[C
MREIHJTR>/^4669*6Q37;->8_"3\QT?SH]@K DB[0RE3D2\V6 2_76G)56XD)
MZ,R2O)D=H*"JH#1>LU_]$_*1H[<" T[WLUT?Q[DEN2>;JMZ<BK(=)22$?7 I
M"+[99]9XO9QF#>^$4L CO,)()/1 @EU&V0OD3507<LS J?1I[&KRA:\_W3Q^
M.+#&N,/-X^;=7R9,OG?4.%75=;D\7AZZ=A520I3Y9V%/H44]&GVMP%["!;4L
MNBJ7MY5A 6%E,? 6]#!/AGW)S(S<#(4"!]!I!9K-P,42F\+0WD1OG;9F[]IG
M5; +*9=J!7ZJ.54ZEHR_\94=+>&N*/;OL-[>6M37I5[FV,VQH%A NX'P@.?O
MJ"LIFZ!XX-X>]AV'EEZJ!=F29[VD[UQ%=D7LI^<"ME/Y6'#"&\L3'[8%;-GR
M9=#XSKHW]E,!_Z<]AOZO#J3,7*-G*D=K?: I32)#:9FA[:A7JJ3'?)SQ#*G@
M 0DXR!44=)7H 1_G^LC(#K=(,R D;29HL[)/>&;X\9AHL!U]'65F,=0G4G5Z
M&'3=J*;8Q=22Z7OZ3^K 9O<T^H=4+K0V;2Q%IXBUA 8;U6*S&(TTA:XJDGQ;
M6IM/T>A!0:!#>[(.;VH9V;-+8P+=J\3'#:*,*9LDBI_$$2>@<+^Z 71IK[B=
MNA+@#^:X3IE#5;R0Y!5N27C1;+;75BES36Q19@;EE%2!Y%,M!TIO6AWA:3;T
MG74=,3Z<LT;6G./D$S#@]+4:;9OS:;FS;6#N95.'C$V_Z=KZK47ST%=1BS5Z
MX1]"80LMKE=(G<I%=1$B>!MT64NVPQ]*_W2V<EX'U-++?;>UOC2N^Z/:XJ3=
M.F[W+E1G(;QVX0G0N-8I8S6Z"Y6/&P :C[D\#M^ Y4U!]I\J 1%2%--F;2I
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MH;+/$'Q-Q"U]XUJOP%M0#CWM=YE(*3;Z&KYC:CJ/UC:ZBH,NA0\-N&*U>OS
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M7:3N[<7?P (DNL(3)"G9VF/X:OZ81ZS1[)P(J\C1. 0]A'<#.EE>Q.IG]XZ
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M5T,Z_E-!YKZ[-N%WSQ7/(QXPH8VCA=J%&U*W8B5WFS_G<..X]$L6J$E;^0-
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MVD-@^8.B(X"BEO,,1P'B 81T2?<]$J#FY''!:%>_]E['>6\%BQ _4<FZ=_E
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MJM-!*7JRYH2#[>[,P<&.<"D?^#<4IF/&=V8)A@[8GXX+W@&Q)!SXC0)TF^.
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M3#]@)VYLK9Z/K6*]!FNY5W&'EO<%:Y*'-',[<D;P]]@;L!;,FC1Y:IC-=*U
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MQYYG!7'4"P?+(E/<?V^L'N78,K).I+7:%+ZI+$,*J%+N+.%7$%D7A3JLU^W
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MAPE<=/4U8$;VNOE8-V6K_B[%)IJU  F$?)5"S4+=81G3XQELF$WW]GC$J#@
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M$A:S-IPVFN;3+]OQB6B#N:6[$5B\35+W[2V=*MC59^T9RZ]<U<8QN?U,[ZU
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M1W>E$+<*T>H0D[= 39X.S!!W^FKV5\TN8!=&B59X<M *$4VB2^&)G7"R]5$
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M^1B!X@Q0TJO"8QD[:@;K,)O'>BL@#]^!07>\L@^.M->AV52@C=KL.TK[1NY
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M&_-*S$?R5S=8WND+&M=T]_9>@FV0^Y^Q?*JF#.MEXB/!+3^J#6IV,K=(],"
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M@09YLON J\@1T)]+D.TB>'1H?4LW1N[%6=[)I70XBK'-FPNQOBM'B 9EHZ_
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MM1S,$^3<78)=0G%<>:5I1/OGA%Y^SO24^"0]B:1$R)CT1^9AGT#=K&_MOKL
M:I*6?12O[^K"!Q3?O*$Z*]^XBK3#=\NN'U\WM?[^)3>M;2C@# 8R,&!A4JB
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M5G74_UI;/JDYT'PWX#7IP-3/LPI?#-Z0(;U B6J@""NE15#'J#SV&\->1=F
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MO=(VLL8HH0<Q:BD4:)05XS;C+)'Y($; [J#H$)P[+R"([A:,=4SP#A(.7LM
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M<&U1HF(AZ@ 7DV5&Q'/2+#D^V"@Y!\8NBJ@I$CR0UBFSAEQ#JR8/XG'O7=T
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MDQ3CE?IUT;MQ:.S<T,#\'%.+8-#*5;'6%YBN(!X'2I.LPWADS0G-1H54B8Y
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M3I;SG076X+72*JBK_9N3K&\H@Q)8CHNTO!;7F/UT;8)_B;<O>I7TD=Q/U#'
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M;::'V2Y"C,I';PC3IK)E2WR$#BTY(AWY>_+3NL":^M?ZA;91KL2UBHR C-:
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M0NF/V2$-[0[HLG83N;:YOLF0V/?]$%G4O?AYH\4*G[B@,UA_Y&6PM[FX4GE
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MTQ^H:F/45/768R,I2^<K[H]U.GU1[5]&M&A6B_O_\\5_169]8E55SB$K]A5
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MUV\X@\0#=8F53XI:-N?M;Q>!$8Y*F>>$M%S='Z>+G#TWZVDAG0LT;CP4GM0
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MD W% PR1;)'J).$W!^.1E+.AZ*0V&O_!F6Q7L++L)4@Z#IC<S?@X]OL,\*.
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MDVSX3\]8IE/W)33#H<P=]I%30&"$]=[W_YWT $B0BC.<*GTQ0QC@%(K+%I\
M(R3F(*L)T@$)0E+\&ZD#F%=(Q"M+384A/AS4!3#M^M.1B=,\,$Y/Z%01(N](
M/I=F^ZX;W3'\[;=-.6VZ@RA1DNC"3D!@1C-YKVEM/ 6H%U,9V811!]V$R%O3
MUM@B,K[%>Z 5F83;6]4S*J+1S#$*Q-DL5"+%K?CG@-HP&.759_8]:_+CM6K'
M#SMK?LUJ[LZ'_H'3:1'UYS#R*P_JB,4M(_K*!-Z(22J!!:+GI%H2\=,NZTA)
M4$SCBB;##HY#"N/ 1XGO_=Y6"U3E^"W()"6L.4;CW:^%.76*HVB@!;^&_/'S
MY&$S[O 'P02DQ@V"-H'1:QNZ&5358(\;&N.)Y=08UNA0)VABV8(&]RS>C$%+
M#64OJK *$YBJMD8=J@KY]N^67,77;[O-D$DLE7J/J)>$?FB[WJ:.ODR:M1W_
M\(7F@1,B,PNKVP3OYU-<S?P7A*QK$8:.I ',7Z!ELQ56JMK6#,GW4/8])>#6
M8;^:8KOS@<+'+SP)D%Z:0P.XYMX(H2)(?,7VO$9ZCZ^O,:?^BI';]5^/->ZF
M8@%_&!.Q?M^*I.J!XB<5#M]]#J5]S6_)#!M:LVWWY4M,*XIR?$^D<XI^O<?B
MO9:V=)_'-R5C-S&7J:,"%GB@3D"7J@T(1A(EZC$MM8%W8*P,HH+VUH>$Z.0\
M=6N/%[9"0VR\1:YQO.!W,QY9;SF:_5_MM6="6>3Q:!1G<:DHP<VU>SY/:>J&
M<EE&7.DD;DO&(AL?AV*0I!JQD,I?H+]$57H>/ MS!!=9MO59 7(09DQ=H(.
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M4/D[S>W^9X!<1E2/6MAF]YV#%@6'CMON^^T Z5(/)Y2-K,?,YHELI0,3*IK
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M$'M&I2,HE6^LYKRM0V/2"9-!6+O^TRJ))QP0'"?XEA&['60C B>FM_VMYLT
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M#A#@DE="X\4NP-AA*!'P.0I>?E!>!E#;BQ!0>R4'\A TW'G<,.CO"*PBA(1
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MA-JP\VPE6*[=F><]H&R#MZRUU-H-TTFB8]CDM-NX.1F0YM1?GB]'W"T^ RA
MFGJA+1SW4J&/&]\CZ7:4CA[K7EWF"5?4W*.ZV+D8K[I^E-BS<I0M&H.)I3(:
M\!C#0 <+I)N^ 5A/R1VQ,6S33NB&*(2 _FB'F]3SXJ$[6)L)-P%2(F-G6>>D
M_[@K9E#I=61L31@GL>>> 7AFF+F][B7X(0>H;1.J3OO59$=7?O*=UM>-0WU$
M7_J/^_!BC?X6&&D#67=8P"G*&$6J0DX?"CPHH3!WX1,F46VTI-OD>W641 J"
MX"M KQ>?!&3OD4*X<A!1U/81Z@I\#KAG36Q4P:[X)-8LSAU9:+?)>#G#-'K=
M*W:<=/,0.<'(\R<*LDD6;I)4HWF/D2\Z9Y>!G\+#T%$22.F0RDG*J^R"!!C%
M*>)N )-$LUA0\  Z!5K)6:^N$6X(T)O#&C3_P-K4YP1%ZM$7A_^(8QJ7UXLV
M6^=Y<_M,E^,M4)IB*P9T8[)9LQ,##*<RE&_PR-KX2$_/R/(9/TWZ8V:"0$_S
M'Y4[19V>SU\S7KP^<WUWPZ/6YYL58]1/R8*[ 2^A(6S"*=@)98C;"2'0VHGR
M><@>&);*&\&_2J'L23>L )?(U,.7=!#U %P;+G&EIE)H$\#XG8,E6@"DU%+P
M 9[D\C%*D?BS=9_X")"<7A6%]5"C*$/6YQN9SU](U"2%JXAP9>B0@I B*790
M=)Y<&#$47I?<(UV6H 7.B=&T3.9V*!%4=H5205P;9?,LO<G-JUU_,Q!<E#,9
M%[B*\  WON ;(1WK60-$M2N 8<INT1&(RBX?6GG7M;(&[A9HWG/,\Z'7<#!=
M:R<63>Q#OG2^9]F,9!/14,)C".L/X:KQ=[\F'*E?J]9$V8;'"5")LY;/NF)-
MG6;<>@DN3_$!=D;5X4/YT9*)G%)L R>1GOE)V#O6!66O59N!TF%\V4C81!H]
M()43B0[#"K-E:L/DZP:DH$=A<U-6$72M5+M;_*:YTUV\F&23:!%FLQ\^1'F3
M.*#Q(\%C4M&^JLY#,<Q'JMO'<-K=^Z2?9G>8'WLX)EH0+'U]Y;'R.V7(3':6
MS%\8@]'QABB0@!PRLP@XX-=+U)S!;"4B\>D81FU?78\2G)2C(E!M.*6)B9G\
M>_=]K^@$UEBL-6I)]V^\'['(58#(_D61GY-I7Y'2S>.2O^QN@$'MK+IO8G7*
M9&!))<0Z_Y&A!_0+#2 C@8?*?!,CF4U18BCSSA'<PH(LOJ?E3BA!,7S472("
MD!9??>DAR=%*B6I*KS4<:Q]>7( 5_ )2$%T@#L";QIV52:GUF74+Y1M)30B1
M#DCHEL"U1PMJMU,++1?O&J#O9D /ZG5*A_)N#OLP=_9:@+R"9O//1_4Z[@H*
MKT45S&D^9UN7P*HT0%]\1>+]Q04\6*.=0O?&;,=FD'I'C#2@@1A?0)P]'N;W
MK9VK&Q[#W ]EWJ*&^]RLM^;4DX,$;N$_?P,FRDC!03'HQ+H(Q5W]BU]234SO
MV&(@(UKGS,(H5BK'%UTE?K0QS)AU0.+9_.393C / T4(YAQ-#1)<H=>&=^F%
M*)[X^AB&'1D4^W2:HFZI+'=EQ8ER"V=?7US)'3W7HW[_DSGE Q*R(D^BYBBB
MH_",]]O9@DW",=B9,AP,\,,"=(=':GY/*TL+/S_1H:PRC9$QV0$,)]<9%E8M
M=IOY5SM@=+^SMLS7N<Y \Z%-O357#6L9>4YQ1CM61%+Y,MC#/L&^&U]"V V=
M%=E")9,3M4 L3Y,,4ELQ:K +6[=*Y7464IGV>.>6E_8?\H#6_@[<)%JY'9AT
MSS[]:.E99A2$[?B9B?4 OA9'E/LS4V#FL$AJ*5($:&S6)KP/?Q5QEX NPWNT
M.,@"7U/YRK*0_Y':=(]>.VL^27&JGN.04!RFN64O.[@\S":@L#HQL^K$BY8(
MG/KQ7YX^5LI=.Q3-^H,&'>H76JQ5R21.<'I:E.^PGG]KQ4&^JX@70X7\<PP<
M2&9S0CM0"5P%3 =+.\(NH-(L[['X-SJ4#KKR)YH$J$U0*-N/>+<:?ZGKJ/F4
MD4 /ZSUHJ8TYWVMW(!)VA, Z&)0\ 6,!1:QW7W2 L!- OB'?10).2,A0B^UQ
MCZMHL0VGA#_04J0++M^=6YPS=F\(S?4-SH7-31AN+*JNF.B.K)QIG'\6&5N-
M3_!K9@W1FT02;^F/'SB8:$.[2>U<R-BCG;*1X+]VL?VYM NY'AV"TOG.- 3&
M62TBY%VI<2_!D8IGMPXWGA47&30.SUG@R.BZ#;<CYM.?^4\!HY\\!!':2ULM
MC8+<Y'S<;!(7IMO_FR(T=XA#:$6&,U@@])64,94A]"P:R!5[0^O ;'Y#(JMN
MWBUW+7PCLV! );>N& H3>5E!84$2:J6?I.:SHU$\]_U#)Y$5A02#6@];*I<#
M>$F5JN"I>DI[X!G/#J_==F@Q7\MI=/!:;6@-@C-X\Z</U UF\V@I!.^B7:!U
MDEB/CQ79NBYLD(YSE2S^7-Q3MXI8/W5@=,SCL>M3YUN13UT<2NS,Q_S]B//$
M-^BZ!K$N!5PO? ;=X".A/1BQ6K_0$4**#,*'BJQA*ID#>O ]R 2CI_C)UKQ<
M_0V@ 947TA=5;2WL@T;C*AVK(6$7.U!GH/HQH+$\NC@>,G/ZP2KB9%*K:YDT
MX_MCY2\TJ<):VB>1U,"T4AG:LXH0JX1.DF=% %$DL&Y=&*4*$_H8;N!PNU6@
M(>">K@P#TCGQ[Y#<I,M2M9<'B$ZU<//W@G.D>[C60(.!G1BE<S,^[AR[H2-C
M<\NW@ZN7EXP<8:*SUG-J/9REL>AK-[A^AS^%,HV(O2S9!>8V,5I22KIB;]C&
M76_G$2T@;9BIIZ@P#D6 6.%#T(XSE!/&)ZEB_6H*0AJULAB[20UMWCJFPV+W
MH#K1/M;+@;FKMV'OL<$*527/6+B%D5 >"9ZV,E]O%=&!2]'?(JFR,YY<V (%
MG00-$^P.Q%SD?2>J$2X"] _-0I8NGLS6"6BGUS0+(G[I$$P,2;$PLW+MOQ(E
M<CLRW[\2_.2.@YVD&'V9)$,<1K^0S5I%!)$S-:MQ?%H:;+<Y!QU\5FQ4PP#*
M#D5K*9[J/ H&/GAV\&73$$-N4N^ "QAXS^_FRSR?CU5^3@]&GN,^IPL= 4.Q
M+HPG&TX#2:]%V\0[)5E255@?A]'!X[+MS!VO(.7)&9PN%.OFH)?0EC=\>VG1
M+S@?IC:4+((I/],U8+"&<;@&"A7(WBNM[R>XQM8<YN.V]92Z"M^R&N7A=,19
M*A< +$CEAP5-+$[,9*A8@]U&4B+8HSJ;T6_T=:&CHAUBTX%9.EJ.V,-4!3X'
MHO7-LK#CZ\^"FBG1-!VRUI1F0\,?^ 6!<@IJCF$=LL)-ZS6U*-QV4KQ1DD(*
M(4-F:/&V?R8].-N$),E?K(LL>5*+TUJE[G22FD\G1M$.R^>F2=7A<!-@ZRL7
MRH^P]0-EFK^(\Q>2EO1\6NH=MM6!\PE5D-5R:[U.!QGW%/+H))>.SCR89HW;
MPZYB#G&E<FM=P_Z6E+%X%4C E0;M:9@C\VB_3-<S=26/HS(Q':N(=5)E**]%
MCL<:\>'EL1>T(%1;HSZE>B:_(4NQL\U# S\C<NYHY*;B[+:AR%]=5Q&;_7S)
M*A\:.Y,8.V' '<=!*+18U02F^?#<)0IOF!M!PV2QG,A)K H&#[=YW-6W $UB
MNIYXQ#X-"ST)AK)96\)MPL]/ZR"3"=&XB.)QC^J1L)6<H6P!4AZZ)*FZ5A5!
MJPZ5M,'8D,%-8M%[Q'HL'BII!3D[6$-JL93*B7^#&IY\UR2J];/"*=J$8U#D
M#>K$N?9P3EP#V>ZR5!_Z)Q18#@0CZ"\:!LV"Z38NS8WT#]4\4V?/5XSGKZ4Y
M:S>8Y.%-BD[ O%1N[5DO_<35CEI%D#%TF_/XF3:N)G/']Q]N5JDWGD%<@58:
M(;@<"CV:'V#XFXL%9OUWG?D<WKCIU3I%99?ZEQ_YM;T6!:;Z$QTJPCGU==)@
M+O![\JP7B&K! +X!*/[R+%NP9Q'.VN)9>$/>0J(X"/AY=.#QO1D'R[Q)Y7@[
MVZ?GH :VD!DG:4A8HJ6P%(C:!%^'':_2-EDB-4:A9OZ?[,?38,.*%?$#=SU#
M"PX6,I"ER(Y@0]=D;H1V UTM& 6Q69)Z4M@B109/9/]6/X#R-F]U\SBC:5H1
MWF#VH_M61<!XP"<WBY\N<%YA3_QEK82*=!BCA>;QR6NWJ#U96%M2\A;B!Y(,
M8_M3R$N(!CZ0)WWMS@JT"TX"P^)? V4;!QCFG+,,![VZ^.&V580:TSA<()5\
MZW/8.;-R\O;NFF)YM\HI2G_W?\GW!Z?^^V93SSPFG=M9R:0-3&W"4>@1Z-HF
M9&X!4&Q6,M$"RIE$;YGPF[;.Y6C=%2N4&U %/5O.^X=YQRPO:ZY89H#GW7#!
M89%Q-J_\7?U3UQU>8[<J:PBQE?1]12P#(ZU6!TUZ,VJ=R,.1:$)J.\:"0_"*
M VL=B2\#/EM%%!8B01646"592J:]P4"'">&KB&^AOR'K%GT$G>)C\$[8 .??
M)3. EG0+1H?USVCOO_+_E?^O_'_E_RO__U'^TG_[+34FC?2?_-=IQU6$K!JI
M9:OFN4>L:ZQUB)<[U581F[0Z:A 77%81#T)'Y!&2QF'69U2L5$Q:,;#YF]91
MC9$JP4$NWNS\M(\76W03VGB\]/*>R3=HG3<7=CC:6;/WX7_-^FW*E_6_IU;_
ME?^O_/\ORU_Z[T^& %CICMWP;MVWBNA=@A3@S8W*Q(AG9Q990@-)$^ERSUC"
MF_QE,CH8E]&(ZE"6NT*TR^,+GU5?X:#2ZZZ8B(.4$ZL9 09) )[&YLB,?2C2
MR[<_U:/!R'4R5%'(_GWSK^OGY?_/UNS__QI[)T;.37L/:_IE%I9)"L?KA#'>
M>?7 N/]YSOFGK@7^*88N._(Y?(0+[[Z.T1F9^^<V^\#8*E_ QTC4/))7$9 3
M%+F*R*%_5S\E2UE%M):O]9,ZU@\CME2%J;N*^!*!!"J8&K#=+-;>I-_#):/_
M\0^\ZXBXM8H0[\4EDA;=')"K"/XV?H_4N_=?R?]*_E?ROY+_E?ROY'\E_ROY
M?[+D8=<G4"B;N.WN',&6+U'^K3Z7-^Z">S)EI7-&-6#KO8U?^"\:XJU?[5LG
M]^CAWY=^L1_;R!G[7\_8_I>.O8?*TR:,0HO.\>(W3825/QHZ6)QFB=KU\N\O
MIP]..IK-SVJH:UY"&+#DB0=(+>]6$8#CPEWN%I3#-GR>\.]>PEE:F,^#<S.W
M\UI)R2QUIBETX$31-G+M"=DL*1)OC0&27KUX^?X'4A[K\.O^4B4];Q?3R;_6
M+X>G_?-,>%KR AV"'DOF.R9W+(PZ3Z+N$2T)%DQ&WLGL *"M0=C ,:O=K+D<
M^5W?%*AO#BK%-[4$[HK_\./="DX)SSKR<6FD"E>%N]P_-"0<"B/F//XE#7(6
M"N"DXI&4S0+<N@WY$W11F/CF<\@T& SR!#7S@!^'[%1 :\'&"D$L;=-8F!;1
M,-9>F1\:S[A1[3]RY09V177:KUI*"2L;.X^U.5LPH=!\9$B.^ >D "[P%N8.
M \EON/I,A/BWC\0]XNU0=BF3SF/I0M=<D_N6"O;@KM5U#>P+'!N=]KM65A8^
MI+7BT/!D>LA*YT-RU=3RBL.+BT$5O@%^;>MF!CPQ>:Q-+%X=$CA)(F/H!,H+
MY59E3@-;WTY2[A, TI(BQ#(E^)V"5[U+;C'\B>PJ+'-_?QTR=9GY2QWD*C"*
MRC1DKXQ_CY/M],NPR;@=+)@ZS755R;J#/O7T21IBSW^,BO%I&V)1A*9TY</?
MW E'ZCF%IC]-,^>+;5QV:5K%AQZ-O&5^]$![A-(_GX^77CZBDH)X[:CQCS6<
M +;#*JR (J7RO@+RF"T[$ E95HL-<"/+DX,+;\:/_#P'YB2GRY(-Z0,$WPM%
MNVOCN]@KVP'Q:8I\EW&85_<SQI$?%CKWF*X6=Y!5#_^++A;\I\-G$KW6T41V
M(ZEE.SH8DXG<0@JED='T3T19B 74^F&4H)^MGH1-DG*"7Z-2W9#F;<J(<@I#
M!0AM*](8*'6U%?GDNR'/#VR/]XGU+<N:5TC9 5*@-%OI)L]5A'/W*B*_6P1G
MPXL.'V47EC0^,Q'0') NB'D#9ZO$/J(R.)$>#1SHQ&Q>Q&40=:'LJ@+:)HB(
M2;)9123Q0&+AI-YYB#EVA ETY-I91VI6/U56&_V^?-ORU:/H JQ<=<V.=#"T
MC05$(<4JJ-8)!P8@PYTC<DHYQ*I&RV_I!$L -XE+9?R2%W@A"9N.UOQ.4:9%
M24)=XH\F#2VJ5(9IJ21$!L=&8T4K".F=/34*_)AV5#)Z&U$?CQ8,MZ)UH$@!
MBNV1HJ.1ETK0FB3)A>=R>I(9SL73<DS.*L)MP%1/D".GO!EXX9IN^XKZDI&D
MT'2+1_Y!:D,#UREBE<E6EBZ*%#H7*1P$SE(S%UF:K#OTB-OHC80SS9!+*=2+
M<DS]:(G*%#K(O(8<PS=4W/PYLS")AH[-!O73.DH$"H<BQ%2$I/#),TX !\,9
MPXR<'YL8F1ACQX3>"K.(L6JXF;>_:FC9:GA++=N> 32Z;NZU[32Y5I/Q[@TE
MF;AI%=%R#!U*YJ"$KR6EI"!<PDL\MX/I(,FNZ];QR)2B^\26F[DR8E/!W#6A
M[58'+4/RY.!Y#,&U-B?Z8B7^II[AW_U?@<ZTQ7^6ME=",5[]/(2H<NV$Q[_C
M__50\ND,5 "6V\@;\)W\;^E7/P_8&4URY:'D%J+A\Z3IKQW^7&4\]3CCX]*S
M@[2K9?$_/K@66JU\56^LR]]6</.&A6KGWIWD=*G.VGDR-.\OY$O:FVX//O4>
M*1@S2N&OE1G78OO%0]WB()['QAE-&TIR<;U+=+6/@)SEL-T_?*4S?0O'U]'@
M!0V_C!DLMZKW7D5<;=8<.F6"CO/Y:2F*@"70N+7*<W1PYZ1A.TV+.,IJ^'I7
M0,IP. 2BV[:1-P80_ %TIL,F".T+VHLY5?F81.*V&>[F)X-7"49ETZ98278Q
M4C>;.E5_/2PW[Z.C8FG]'60!$@BG)M9=(>%HD$E/.BOX;\OC)![%#?P=)R_6
M8"1%.#*T*@O0Z4B5)51B+^3G=ECP0"1"\NV[/FP6#NM\+>#35/!N!,=(Q2'J
M%1SKU3NIW2J"ET&J8\T=$*V'Y^Q"W$UJ87'K9KD*#KOPQF\<-@PX["!VH74<
MU,4[ %R+SP##5BMQD9:BXH^GMD@W]$=EJBY"):U:^34E->&<TML+&764E!79
M%(MJGXX)='^T&_I\_RKB^3N$U)3$F\:LQ_L(2'/P7S8NBBW H?L1 N4-XJ.2
M*J8!M*W#1N:[:6@UY-/.VDJZ&+&^S<:1$Z_@'^[G5'PK^. &-?7Y=1N;E:6*
M?X +Z>C+Y"P,X$F&=OATZ 5.S[237J(Z<%L(YZ!M-RK_[%MN8\F*/2K#.*@4
M2V/C&Y]WEZ<3\N E&8;=_#B6EX_)T!EL>S*^_?@S0ZE2Z"KBX7UXZ?448:QT
M[RIB\*=(QMM:K&6N0(8,4&)-9:G<6I&<1\![U2F*@L..F?I5Q$OJ7()EAHG)
M?)3U\^8^GS:=MO [X?D3Q0#.'U0<2HZPF-D0LXI89V<V_=Q-^_5UY4\HR PW
MQZ$ 'BC(@#2G ?8<'^QW@4H$]NNEZCUOZOW)M5Q6^T+:S6&.?D+EU"Z[$/]5
MQ"_?4P4>J>4(7E<0+WUP798**QT'&;)FK5%B-9%481".B@>@_0)%@PA# 26=
M=,G49Y+4 :%V7+$\2#0F^ *R<^T"/?]C@\47?@D/W   0 \;&U^B2M[H;&OQ
MP&47310$+TN3!2\GG@:OGTBZ2(,,A'>C95-7$2$+(\AC9&&/Y%E)_V>RYT<Z
M1<-.7P^T3F08UYALQ+I*S./,17SK!.\K-=5E2>S)Y(Q)F1J3[5Z=1 [KQVM#
ML9JLM'L]'+ &M@GG'BM_CY7*KU5#=9'DL7@YW(U1K+151)T[5:#H<1YDEI'X
M/0EP^!++EIO10:2 FVX!F88R^@B607;"VQ%)!:7.3\/Z(7);XWPQ]3O'PGHE
MKK([CH;5V9C\3+H?RI,J8: QP)W#%N#F8-:^P4W")(5P1W&G!NJP-Z'EFM%P
MFY+O-M?HE6-3N8W)&>+M N4DAW5]=H;1UZ\5QQUP&F#^*FGR+\SM.2$Z^?)8
M'YXU%U8>MHK08_$6*",'^-3VII!!.UG@J/!D,Y0)U+;>?I_ID/ 4OWP<&.[L
M2;'2-^V/ E%_Y'<\$C0IHGRP0YFAKQJABR7.-[[Y3>6FL(:L.U<1R8'KH2;
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M>E*)1H/B2! I])#D,W_%#[>I';U!P[,[N+\PM?"T=IOQ]N;JYD3&"BO%DJN
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M>=G30MY"^%5_TPL EQX$HMDLN>E 0R@]&E?273H!379(C:1OT\\/,G^=/AW
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M)(NW_P'%47%S-X$"Z*;I_LL?D6ZI$HITTU$$V"G6JI4J*4!E)18]_!XE@O^
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M/$-J&2 9QYR.V)X:'^ 3V'/2,Q5R.OQJ2N]SL"Q[7Z_OTWJ7._>'M=.R'9W
M/HIB6"!S;#'6TA$C?'5W(B8_QX/1/&1#;PO)A&7=Z=H:\I-_)O5R+N6JYV9R
MIH 1[^S_FK[M=*U*'ZO$X^B47=[#H&:=N$KD_7&M^TPX0FTCVV+M(F/];Q3%
M" _YDC_>#<GZPI#5"@"U;/\6B;W[3=K7\4EV@!EKH_[Y9&M6\J'%;X[WL'Q3
MS7OJ2P:W>G)S144IR5O_VOA^?(Z^OX/6.HU:2[607C!E(.#+=K:%Q&9 O(V5
M"!H#T0:";&R'"'XGD<O,QBU;'Z,KD#4D271OODFW\_$SDYQ%+I>A,57R59;O
MXR,[HE2IY/VO6,['E>:1^WH\OW<+V/H.X)!FK_CG:G$-U1,RLG:V%6XK/NP[
M49KN,.H"Y1?#FQ":BM^D3PA'DN'VPY#7>7B^Z(MZJ"+W[?WX:8=5E9WOGKVJ
M *\08;O&X)FFFJ#;JH5W.]_4=#M_2WF6ZP058R8!L\UP83]T:0MF8J4BR=*;
M-O$O>W^#K&X@+6=;LX[60(6_1(?^1+/&[)EKDWY'PQ039:.60_1-L9@=3+Q8
M=VS%XE;ZNHM/1VO2N'RG$'J.1R_EI2.Z"*<X M0J!3/]I+.+%MDC?/P]%OH"
MR@E!'T=IG"GZ$@FI2X6*5<%7W&@R4/L'<EL0ZZ0*2-C5BVU TINV\3)8SE"5
M4I0E&)$Y/[WM>3,ZM&NZ*O=GJ%GT83 &6THP$':8HK--QF\#XN\][? 5T@V3
MQV.5H!6Z&O:0; !.DC@UP(NVK\8:A]9VUFTGG<]__['Q]%:$=X!S2#JUH-=Z
MB+'TB.LVMW)Z\]OU\?U3_L&[(WE0'F;2 EMJ<?1=. :(?XG"?[]!S^B+1>NQ
M?E)YNH8(^1Q!&G7;D'(U[8J0L1B9?B&-9EO"M,QQ<]%]E9=/D^WU6\?MTQLX
M&:(O>NM(!;&+$?] 4-CA>::(GN]0_[PG,8\WVX[Y'1%QQ(TDZ7YDM]"61^G+
M*'2:50A;!E;&<2Y-DM,CUL%QV'TEI?]FR!OD^'V7<LA[<(KA]&U-:>H.EXJ'
MX^.3S:4!VP,J;;;:'?SY!6GX,.WO9-3N&YBO)DGD&0!TI)5ZU4"P9J]C4840
M1=-;/,PVJT32U>!2I$?>8.LT9B!8K4Y=W0 AV8>[[D-83D??D5TR]LW*G&LY
M05>..<4MI'8!R#H*NF1: N(@GLB<%JW3UU%BR0-?4J[FY)L+RSK!Z G;&.^U
M'75S,<N\IL"C,0Z6I5UN)0GC9WE7N.$7!H)K+\32O'O]I,J<#>C#7)(:Q!;J
M=%\#XAW 24 6B9F6Z[:Q7P(5^8]TR]E_RK@:OEINA77Q2-@RHJ,VLU>8PK!#
M Z3H8HBA="AU*(],44:S?*)ES:4J@=417W[EK<CC#/N>1\4[F)[+59N(DV<+
MP/02AW;MG_BTS1Y:_PC^(.BOG-:^1O2Z8U@C !VD+?:#'DO%O(KD+#>J#9,C
M=O#H\CQX'[$B)V9F17P\W)GH%=DHVH)<ACXV_1*+?5$.U3#E.[J%#%,F9T?L
M';)?;^!["O(-6=N&3$#)+10H0-XG5X(:.P'69""84.*)6:*54)7&7!?!//$^
M8%X3:('.4:8"RJ#S+K=QMV0K3CEV2O&G)R_#!EL'>U<MX"N+KV@FO2SL.$OI
MF"6W^=2^.?J#!VD7:&44='%4$V_V--4$2M>>0W"68'1 #XK6L39?2(W\'FF#
M@K6W$&$1BX7$P>]VPL1+;@->2R;\\_9*ZXR*F+2#4J$^;#<<<4?U*)%A&[-E
MH)]*CTRA.Q2YM;*UK_Y;]K&5--3:"3,S*YG]8,"-<0$H)XZ#4"A5QL%,S76'
MPU,YBN 7;^("$@/L=CVOK^]P9G_)'$G,I@,/HW]!TIHG]DL3S0)B&\T>A0T/
M.?6XT98QPW9!]5.3<CL9RP//M)Z73/XI<J+J=@+BS8RIPCM)&R@G['@FR%6O
M+V/G9(3M!.SZT2U"44#XOPNZ!B1PB*LXNOD-ZX3+BROLG:PH_7,A\2(%2N)J
MDN%?# 1M**+!J=$NA P1=R"K=.M1<\1<V<\*4VFV-H<*&JD7BA\QTV8T.3!J
MI;B">JEI6=-#*V&OM(LE3[-.J:/O5G?^5"7J$M8RNCFV@/A/H*)W_)8 <0R:
M=4KX -@:"-&"OG<*#P[.6ICL=G7:>3AL'])?B,0'A.V[B;UL#).>Q)8S5^^I
M[EUYW63*KF2Q9]@#Y@/U;F'/P%[H#O9(V7IG&S)/VXB9XN'6B(B<F2WMU&>R
MPG6AK%,=+FYZGQU5.'M+JW.#WC5,0V'A3)UJ^FK)&\Y.:!>G>-04'ID)&PH=
M/9M?+O"/!4[=9_KX]DS5IJX.J2]-WUV/I:(;U&1D.U_=*VYE#-B(:UK&W: 4
M']@F;9R]EDG2NO34V:P%FWB+D+T?&L)3]KY:2[-D>DBX9QTSW#1;4MT7)I)M
M6 E0?M6*['9&<:M"$_JZK^T=/L#)')8C_+>!@"T\ TE]>S6L8U"@]@\]_QT\
M>I3>:V.#^\NJ2__F*:S/*P=30]:D-7_H,1 ::'9N49WQCIM?>^<]I=GM^3(M
MI1,0OIA[[O'<Q^>LOB40%A (/Q-6$+Z>>XYB#"JR#00H3#"/+0>>X3"4750;
M7^A5O), ?0,!\!\\(=CH9>&UZZVTL0,A-=B"684P</&)6_]+81P.PJ7#$0ZP
M*7W( ;::K!DZKZ)9,+,;/6:N%R_@TE7.D1_R2<@&/]0FN 5XYC);S?0,VE^J
M6X$D: ]WNK"HL-DN_64W6KIH;3?**&:W1Q 1[AE%>&QXC\A57]9[F&:_@WYO
M-/=O>_?PU;ZB5SW XK#A2NY-.F8FF#U7#V01.[U7XNLC"%0,D_HNV%5"<CP@
MT,T]U)2T*9.3FH"WV7=EZ!Y8+L&IY).1HH4GGSS FLJ0P>(L#W]Z2<[V(T\3
M=<&Y\K::+&RAE*)XZCT/?^Q>)!U;&#A;T5.#M!>S$FJAZ2PPRME,6RK%>>9;
M_8TWR'9XGNI$R>,(U*\+6T4]O::"MQ<",I+L;:6-=+,8KKMUSEE]V],[CU*+
MQ<_. 4<-A"^ ..)%A^WZ*W5S="D(]V@E$@EME<C+P32 3EX4,[2Q)EPT%SI1
MI4@AVXU6GM5(*B@C9SEI=ZN?=SY52^,>< ]UC<OD>ZNJ<][V; !<\:AWG59!
MT=3J $2@/8<KG<8Z ;O70^W:M4CU(ZJ"VN>DW=_EZ:P8,/M39(-00\/.S&+(
MGIE&)%9EQ=<=5.?=<5>U[Y+F2::]228/F:+=&]VHYJ&H>[<234:R%/[D ;LF
M'@%47*)88%^%1<NA_41D+;&!>*D&1*W4VGO"GD Q1H2G,T6+AH-N^D 6<DE9
M>!_]K'G1=$;==A5I,;/'?S @L+'F3?J5I%AP]1%D34_-Q&26;A4^83@E_9U6
MX9CA"O9SM=OTC[SG((U-[+G09 0)XC:0YXP^NO>7\65/R_LA.ZS2&^LM#SSK
M*/&D*B?,HS>'?55U84'I@Q%9>%;CIQL#]*JLDW-F]OP/.'K\3Q3CORA5<G$)
M0YNA3P-.,LZ)EET/81V$L[4T/":W-W3XO/ET$^$U\[Y@4>\R3Z]=4K:K(2 &
MD]@[[+[5<?N+T@4?;2 :9FZE?^AI-'M'-$W9WI]KSMA7CE3I5J/^2+F2O!PQ
M??M^2"ZI9"]'LF!2$\^FSD-M=L=D,&E]A3GU>WCZ"NH4][ MOM0^H<&VYX]_
MROHO,T;/@@0PEHRX<S 3ABX,C8,=->8ER&J50$R[FN_1->6<W%+3.SX%;U$K
MM3PU=='8B>&QH97==5Z/AH>^>I4X2&LBG;R-^B0HXRB-K4\']R0\BNF(B,F]
M_BB5->>3GRXHEFVI?X)CZ#VEC_R=/B_)G"*I:1_/@+; 8 S)CNGN[^47 "5B
MEK3KV_#005D:(TMI-8N@:_.](<:YJ>]OTD]THG[PW(&&X,RX1R/3/3F@K(W-
MQ%Z0H+T&0M]%S.26DK8(=W)^R#?'%6W4YE\:';.P56,S^??4Y(RA35>[[A\9
MJ>G-FOH4+SR">O%K3"8-!-,1\R(DXN6,?\DA\^5N86.Z <&K40+V-:AX"WS:
M0T+MZ 9"%*@2Z&F49X?/MJ/V"3I/1+U_MM7&B=E4[L7O+^_ :LQ$#+\3#VT+
M.-TYF/N6G.[M D>EK?9OG1(RWT^%4<U801WL%>&9)AZR$"2%!M?_*XBENQ=\
M9"O8_3@!(_;?UXXB8IT]ZV=DC,CY"0;'/>!='U5R,07YSC,HWZ%S#>PV?<5[
M!;/@[4!S$+$HABB(;B]!-T#'^X3"ZL[XCI/Q)3?U<4*SYX4SC6JNF),.5D2)
MP:N4.>R-PYDJ2AIO69VQBI/N_77'OA*&\T0:&E88'EU3T#^T<BM]YC?W:49"
MT>CI@?C)^EUVX3L[U-655WT)F"=%\1O/DH/:V&!FF3 #,^4!ROKDW?H\RC'!
M>8=YB)_.G1G<-!H1L%K%:6)\,?ILM&J)2Y,TR6SPJ[A(->,*(WYEI;_.&B8V
MVMTNS'CB^N$L8R 8"UZ#N\T?#(3^NS&4F8OL0:%^ R#VHBCN4,K]4$L;A5?[
M.*QSB1:MD:)6CY"!,"1#91_6G/LO>RV<GH'2GO9%S_CVE#P=.S B"ZC3, J0
M%)^.<><2UP$G?W_S+?-W?S%QRA,A+085OQL(90:"A(2LIXCQ))][=2-Z&J!S
MSM$LW(AI#D9<*IS0CRR@$>7]+%]ISE@X=$_Z-OM ]_A)]@;D[Z&7*GE0:?FQ
MU#AGS>5_M=8WF^>@2D#L4W=&.=$7B5D4ZL\#L0Q.[B6VA?Z.MR?69LMK,&-<
M'5I775X*,2Y[_B3SDW#2/;3)9WOXI^(B[XZ(['KJCD'E03"[..E4;&1!M ,E
M.Z3VN6Y3_6&L$(P#9&.*EO%CNJ]8X?H'[$U(:^-9XGG44F&?<J33[A#8.8!9
M"A:WWAMZS?1[@5F6U]6D$2V1[.:97-F( ZG#^:=?1[/#B[?[_<CU.-"KKS 0
M9@<X$#-=#%T%+O"$W(8 ?/HO!HU,><T='7Y-CW"!O.LZ%OI=J3-2.Z\+HRYF
M^H=N.L](2BBDB2V*?_BI4YB7ZK_G>75I'GQ1*4!M9X/R-205GM?H[=[C28;'
M5.\Y"OW..+]&N:G(A?4CMXEF.CX4$. 6_>0=I,U4@N8QN0\XYC*V@?!=MU"G
M61V6MJ< =LZI*&^KF_>6BK@[:=EP+[ZZ5[:W4*R1=WNZ*K[3WZ\+UNU&3T$!
M^04L;@TT'S3V7 6!/CVJ4N>W V%CO7@TG[JSOT&E^KJHVY4^6;+_M?^#HR.]
MEF=[T>4C!L)Z=J6!4,Y#!@V$PH@%@I''8\KIBV^1E"3H:?L.:06)T*X8XQ &
MF%&-03E#I,X*P"0 S[7N=[C:V;O8Q7I9-S3ZG8I\$#H"[6#PQ4LWATI6_%Q
M_EL.4>6(HX'P@H2LXX]_8NA<V6W%:AH2O(G9+G'PW((8"$TWF/RFA#',^>:?
MHU1W/N-!M+:A<YGKF)V_4[0K\MV!,*=_IFT.O3[ZSQQ4SNXV$#Y45Z&63M@_
M%UOD,WR*XFYW"F;Q3_=)E%0"B!W8JV.E?GS$YX6\*BZ_6!5WXNUN15GGN"8>
MLQ\K:TM.V+IFTZX:6KHPI?)F\.Y.IPV%IQ=>\YNT5X/(.NYX&VR)F2Z'@C'3
M4RHSFCU1EJ @-^@3E.3S;Y_!QRJA+T3+>BL8&?FD?'4XE#TBK<=*Z86LHW!]
MT:UN47%D#*7".=YE//Y]Q=@W!>^!>%Z?HS82!VL6:EJGSZ?$M,_U5S,(WN #
M!/R.MZ_'C6B.W!</;>DH$9HYDR7Y2V!K[L;@LT'EL<>*8VI.7O"ME0KMR8%=
MKO5A5% ZX>)<2)CY,'!0.L$"2^4A@Y\J3\NNT4Y47P \J/4?O5M22;]-B%Y.
M_,T=[W7ZW?%#X8<[6G?*KQ.(6RRVEXM:2[%V ^&P@="5J=*S.P&Q&T5QG5+F
MB"YYJE9=OZ=SBV#]V.O&R\QE7'0E6X[1EGFO\E.G#% MF$93(^A6I9P8-C)#
M3*NX0]I35@.[E)_N:'G0FK2Q:H?M<-B.^8MUQN.^L\UA]'F@@E<CUVP08.T0
M,NKEHWV,U*? ?-5YF'^5V_1,HJH=R/IQO)_YXQJIJWS\S@*9FM9=6%51';<7
MS;O+W7:GZ>>PPF])+^7HBN,&PH9D/..+H8Q/3PKT=+"O$KP/#/AK?]9?IL3+
MB7XZ&W9O#;6!DQ$JR*C(Y%S!EB#!)4AC0(?W9KI[36#$<(N*U^@?M_6(E/WE
ML-_N''_]5VK)D.UB^@??=??OQFZ-H'-S<VXG9.B. F)7\ 1C($S=,AZGVX7&
M"&$IND=_&5M/E@@N6#(#)>D[.FA-,,)[$;'E@KSY;.!([YA@&&)F*P67IM8(
M*WE[:ABEK_O;4ITO:]J*/W'1I6'8PC>Z)8#X@!LQ'5NO+T0WJ^NWJX(;!ISN
M.+Z@6;,M$=UAB,B9-%^@_23TKY\3'YEY&'K/?[#GT5;:@(%P$DDX*.I\6E2;
MO:M>FG;OD7.?\4?*(]01P1."!1]P(GH$5.3)RTGC6;IP5A"BU#FPY0:"M3/F
M@-/J+8A$94=<-DHQJ7!.:,%,H'7WU"7KS'84CMC:/Z^%QT5KH*@L5S*1:1?8
M_=[;ELEMC"#7P3DW^*,?/*;#:=<HI41T41AF,JU;B)[,UMZ"B.FBKU@1^GMW
MJ^K+H>EFFHRBBK\/AS5'F N[7759CH<=EA(C[PW;QM][.,)-#CTYM"K/IPYV
MM3T^B'&/E82,U.3SZ6=T7O_7GL'_+T*24"^SDN^Q7X!0\KL6NO?6F*#\Q9 Q
MNC12&P6)SD-<B6A]C;#3=4]=P--ATD*@-.ZZ(&'-Z8)PA@H8GU STFJL"F_Z
M.+\'!4Q@W^+6,TG'U[;(2=!IQV8<N'(BJ. 8"+;>2Q!=**1##R$ZE>"2MRUB
MHRB^/5X$[ZI241>BD0B@;E_*S/Q.ZN]=O"!/23-"@*.V(C#JY,F[U=V3G"]H
M@R\PYXJK[Z9\\( R^UVQ_BI.XOA#"Z%W%X%8X+) 5=L^K_WA4=0;QE/YI#9_
ML8&P&#5R+]5N?M*BE%N.;-G W=>SI.&?&+8#3A]!\Z&VV"C _5=9/H\_)&.M
MU:W'5T0%#=HK[]^N:KDL\J #%MY?H@EX.K1'XX*:/<8Z28N*D+Q")D[S]NV6
M^G:YMAN+[R,)XEZNR.%##V#>+HC>)H:F9L)&:S:5=9]T'1O81'PWC9D=U+FR
M3NK_P+7%-89V4F3&33-&FI;K.,@]@/(W51*&6<R!/0NJ%0.<%<QY+[8-BK(>
MOYY7V2!M\-Z*'%/RTK85K*ZUCPSL\*V^N2SB,#;@:::+P-J Q903X:NU$NA=
M,V4NK[\\&/H"6,)3-1>IS+?N@YYF*@^>J$K^R,P^6%.]V]7<WX?;UCFEMSMT
MTYRZJ]?Y:87_V!'AUVN$#L6PCS*Y49 %$%DTB*>27ZCS@.V4 L[D]G9SI%WL
MX-)9DB2P8'*^ [_ENMOFYYU9\6O \E7K+GQ;[%74=2 BU-]HL&ZK'ZJB >+[
M-&BWG6"QY*$L&JC(YRB43T)B/0"3Q F.; #U[.*7;OU2PDKR(AV".T)*HG*:
M_5MI=K)12+9[)/)1J/^:[*^-_Z% )RTR'K,[P(KIV2TPTUL6W*0BU%E?#,34
MIS2 1@OXQ[SRBY.58T1;9$#%KI!NU#@<P^,JB;6ITS%_V=HT=41I;PEK("5K
MW=LN=C$^I;&@HH"V"#Q.3B-9& C'>?V65(;=_^ZP'!]W!B.R6[U-I;9#*0:"
M4<OCLI&AC8A&-?^.Z*]"!%!.7?ZGG&[[M"+0+[.)'5']6)*LI"Q$VIZ H=[&
MJ#GBJW-G;8"H+R;P')Q8YP%5*3T:2QR\S,0B8ZB(VY>8:BL^D3-ZVFXHME;O
M?PA\7MN=5,_XOKJ^1Z@YH3400GN$9OJ@F0\?@.OL%8!XJ[<9@EML!G,QTT"5
M8!FZ!R?CWZ'^T(D;4/N+*!4>=M(FZDBZ[:RMTB<J83T4);8G[H*&K@TY5/:&
M.*;2@KN>3L7]DMB%[EQPM\J;#!>]RR!0;G.0C<GCVPMQB_$%KGA=2^TO5E:6
M BI[FBI*8P]M^ZCM0<1S7[N#,$_BX-C-\*2IVZW'<K,:O)_)UF!?0^D7/"G*
M3/]'/X&5T,O;!?3<PIDL?4_YF4=Z'(5&<L0$,M.F=H.*-+:G_KK(CN6&G(+S
M&DG005J_7)G^H@794Q#-MNNJ\X&2@X0VN=ST@EJH[5P=3+E("Y36F3$2>].#
MRL( JY@%1]Y1E\;LU,UDZ^_AV8[@(D^8+&9<H96W:^8HXL@J2@/Q:NARR$#(
M\B05U[^VGKF5&RX;#?)PKY*E2O+YA6.V[H)C_+&S%M6%0R$Q,H<J/GVFDGLF
M%HAB> *_D\IXZ"(_[4)]MO<6=#NBN2MHX5W#MB$;^!%T"B%27^CMAG!5TY<Q
MPLCTC<:%58B?TFN_G;E9XZZ&A5>CIVVLS][IX6Q,TP7D]QZ\\/)#USQM_O^
M$LW/\ED^R_\?(1KZ_Q=02P,$%     @ <(&66^G:PO$U0P$ 6V<! !(   !I
M;6<R,#DS,S0Q-3A?-"YJ<&?LNW=04WW7[QU$1 0,2"\2%>E-!*08B<HE" A(
M#46(B)2 $!&0H#%1$)":2ZJB$)$F($UZC9  *BK2!8201$!*)%'!K6DOUW/.
M/._]G+FO^YPYS[Q_O#-WF/T'L_?L_?NLWUK?]5V9;/Y'_@)(PL[:UAHDL$,
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M&]PGZ),EHE\R@D]):N6FFB#UGN8M&H_=,%"9U]+P/'?VO7&34QI1!.-@D'2
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MEQUE@YD8-3 #04O#*<Z'3189UD^$8ZQBF?2^8S<BRJA<^9 \Q:)N]C;+SB3
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MD!-<0PIU&GW8B3<)LG_GYNK):RP+Q/%Z*;NP#"4J8X-368A:\YU$;DN%CO/
M]PAB;<PC'A2CE-C!Q_H;7C7B8GAE*#F7,G35J\QGJEHC!8;ATY[-MV<%RC5.
M-/?ON=\N[^_Z$ZEYI>YI@D?"QP,<X&G\#;IJW4KPX.I_+T?*+O(.CL[QC,8\
MHTY3CY%H*/FDMC\O[;WJ4PY0MJT69W;M!-]O&RH=_)BA4G<V==_MGKU/,H_I
MWG0;&LT.O^+VY-&)C2E=HR($MR!TIG_$"_@>7\6:8_]0;!Q=2;.5S/3\O@I?
M.1JZ]"5]XK=A'8GK^CM$5_A\*V0FV1KV]_:,^"DC"+55= (* W6E_G^+A0U6
MD"5^2E)?D,(&:1\A>J!3(@LXW",9BH* W'O6.!YR.\:#51L7.AZ-3HQH6:@+
M7YW);'2UW_6Q.9YZZ /_IYG4737"EQZ#1MTD>7&>E"H_,11:?7'5Y/:3K5@A
MXAN[<3E1(D\T!RT8G<OQS1Z+>RHEHZQY**!#RUY(-&B%'@,5O&N6Z*T6\!W!
M%YVX!D4G,184>=^0.WG]!;?7B;5\YJ(#RY_EV=06^.-*>V[<*!E>6ESBCI0T
M7#N4?ZH^W:+1)T#;_/JFI%,7L@VHCR_X!%OM>N8^Z/6-Y5Q]Y/18-;=QI)J3
M,E1])0:KUYA^P&WWD3O#-FV527N:[LT<:#S=A>(HOJ-,Y0HX4)'0+Z10;0=!
M#[T1<A+0(+[4/PUPBE):T<)#D*X+?*MDQUSAX>'6XZ!,1_-."1).+5N#=;-W
MA?AI  .=+;%&%X!.Y%:I-*,?;<YU&#&?5G8>(08B2R2LHB8I27(&U$D?UF#;
MJ(B$O#788O$ML!G.4O8$T4FT-9B6Y+W?'M">*KTFX1F)PP1$!TD;1'>ADV6!
M];*M@?KI%@/*\\WVDIJ7T.IO9I'BKZ,BLS+/CKR9MV4PTJ07A&7FW2F(*<5(
MX$/&X06.WTM'PUML##NFSC-BOG5:4F("M\GBPG\_7J<Z@E))X!W<<74>5FJK
M"4QA5N]D$FV*"Q!G"N5J])VMG.^-K+3DH\T6)[0BGC8)+9X(9F[03XT/=>VS
MO5;H8RH8^%D)J@L8:[#[J2$D32B1IXU/1VZ4;)7:_3O2/R^*=,7-MGL@IW:R
MHD@)')#FF!+)K(^'8)E)=B 5,.3M \FA-UY !OP^&:Y.[J:QY;A?SG:71P+I
M"<OMDB/QYN+3SI'54)/P%ND3RY#<;H\,AF\B7@ BBCHHDRB4.&\%D4C>C""I
M8*P$125.0@?1!G&!*(K'?EBD+@K#Q"@^C$!N%JW+XO6W@"?Q\M!5M*)M)1>U
MC9 RX#=>:UPQC#X%$X-M5 "5B#>.$)^<ZFA6*]XS0C0HQWJ\GM,*Y!><G=?>
M!6?>L7JXL'$1OUS:U# 2'A.5W-R<J1WC@]$+MT,DYK;_QKW"TI71\KY'RBK9
M7@O> XD)N68A6MWQL1&E(7>:RTO*OUMZ%V94LMB8R$'?OOWC1;'XB,";KS_;
MF3N)ID1VXN?$6%#&BP'!>616#/?K4B7P6RJCZM9@&^^"C ?(8,9&@L<[DK83
M65/D*7XU#E<1:8+R$QU3+1D)WK-UW%AD.TD%G(DWO2=?E$1MD^D9=_<S='H?
M.&3AQ(+#Z/M((Q?GT/*,H.7)%CXC@0Z3AEUB0FXG2 Y!(UVYR*W6)J"/7Y$/
M!%^#;=H#^E(>+%G;5$#EW^75G>]CEW7F&R6&.3]&7-2]STT<$=R<6^7/-<_\
MLTYL1H\O?E^YZZJS]ME8W\R9(V/H\U3<F9[@89O2ZW^*+>U-_+S\IK>U^&/V
M!7?D7KWAC6F.>)!;_\G3R\OIY;2%H'A_6;7:,'JF>1\J*AKH3HL('[+?B;MU
M+-/]S)!<MOV&/QEC9$[)&JR)TCYPWP.M273F(Q+(.L038)%$%H,5AD&Z[VSA
MD#.64Z0@4@"GBSH'[DHA_E>2N5,+7F4&2S\"^982@OC9/1G6'LB,7P)&XULH
M-B)2,4ETC%MP?;[7806+FI(10%GMW@X)2[;F(N.F?)[BTEOA/N(6" -6>$G)
M\CKTGO^)J PRF86&;Z$*?W[1.E+?C,T820WSFV72GU:VP-[R:_.HN8F'UPCM
MGQ<32Q$Q)H;\"^,P9$FTT9^4?#YC29G'8/D(#@'LKH&ITPOOXC@HD0I2,"G.
M;,6!=LY A10P$V=V0)/P>')0+G0/>$<\"<S2L%&<&/Q.*/$TN ^NP!U<>;-D
M/NV =A1Y<2B*P3/ZB>=R>E=<)5OAP@NB"^*G$GWB9E #JBH768OS-[KV@GGP
M]=Y$79#<TYNQ/82Q7:)#"'CW6TF$@$KN2,'F(5W.SR=D1G=0=)6]P5SLRC?-
MKF5_8Z4GEH>X'\F]\W#=*M.>?)QD(FXCV78!+9*M"'!^2M "64A51S*Z@5XD
MC";X<"F+N\@<=&*3K1'@*'X:")H^!GIYN2F_=MGYH5-6Q<O)X8QMW]9@&K_F
M9CK0B=ZY]TBZP='7'Y=B$N1PT<O:@FQQU=^Y6. ;B&% KX X0CH&X3O]+":0
MU_[BWZ@2,62<>$QH)%(#&!FV^WRA81OX20AID=B#T";X= C0,K;JD]K',[3@
M&^?S)KJG_D[WR/0N6(.EA,\9UT;XWMBP:O."\0RM1F(7-<V^%;I@UV *UB8X
M(.O=:D5'@:O <)A"4IJ7(M(:[+I8AEO1I8U/FY&#\'QXNM;BC 54P*\YSH],
M-J]R8F@0^.WP]<03@"6SR5NM@4=.O).3UVEK.&KA'. X<GP-%K\&HTTL)5MV
MXQ.+E$1!8&\[:1^D#ZI+MG8)?:2NW+I&LHY%W /,)NME $)N8XO0"<-6(-ZV
MU?>9Q_-J['@>B;_P]ZV<"ZM"!Z<@'T\@IRIFTTS<&DS6/D.TS_(*G!'^?QN"
M9W\OD:6)?E2:GH7B9"17ZMFX]F2F,;F#7$5FXLD=[R>E^S%$NPM)R0($9$=<
M7JEA?V( 6>1 <H>9E-CQT#GI+CJ2S])8H80NC#/!ZPU*$H*O)_".EC7E&.@6
M&CS6T=P3;F0<MN]N2><WKVL.FS1EMVW9Y[ZK,9E[C.H!?"E\S)TC6KT<='PN
M90SLMZJ=61:])U<O7\C?GG'3FUL2O)[:5;:;[DT_+.6 TL\6%2+EXY*MVN&Y
MRMXV38LGA&[]3>XC%FU=#?: 68^++.>-0QHG9R_]VNVJDM,?=AY^M$54 /GS
M\#M(_6NP>DJ'#V+2]>][$;=%VE QR!?0Q1DD&8C2Q:ZKO8<'G=H%)%FH0@,0
M-5,Z*0H+ZBR3Z=^=23@V^@W F@YYY//>^):9[X!*7O5M&/G,K;GF\,,]UNYJ
M%U%RON:N#MCU3LI^5%STT+]UB:=;@E]@7Y1J)Z28&=Q.S7@@422W'V%<S[A?
M: LX9+1:RG1F;&_JP**3<I ;6W?QI;5@NQ\LNDN2]11Y2C$G2:U(7F16]=E1
M_@%IS_#RLKE!Z82IA3#?>>LLWVGD*Y56>"WKYW'[O\(T%*$A<H7,A/"_'?;+
M\53$KO?"&-(G<CVE$\[20]SS6S]*1/$5I9)UPQHLL,U2D .X4S# [#Q(W/1<
M=-(--,WBVN OCJS\ CX"<Q-YGX#'V)?5[FPF?NJW( F$]RC&Y4GS41.@H"=L
M]4DS#.4UV#7TWZ92*V/B!NYQ? I<EJY"4.\L4A49VYJ$1"\54I!=4W@M0AB3
MK! .3Z,?F:!-Z0*)%P!RZG_#X?)&Y])_=["^#,HLGWY<0[0$=6K*V,%63?<M
MEFX2HFCR:C_/, 8CG#T)+CYSX1/TX>_&984_)4IS%@?T7V/S'21],=\":::A
MNH3N+Y0$HF7@MG&!'WQP:?>;1[W6:LW.\:UF9T/[GU_+.UHSM.\1N\$O-^*Z
MY;7/65]W_!*-2P]:D]2^!I/+$O@)$9.69.8+DU9&PY_C]+XUF'P?B-:VIA,S
M+".GQ>RG+5"#;V&-E,8VB5_<0&*027F!&4MN0)@; Y*6S"84(+,8Q&5_<D<F
MSLBBDZ6XN)EX=I2T'1.]G!Y*=-!I9>_8.T[2)D3VD,R@FE)"D?W@(E%7,<%V
M%S;']C!JNWG]Y6\<>#-<C023&N]16VT[?MOAU7DF%]^-VD*, B199?.1WD>R
M*HEG .UY=;K2J,@CH()Z$"KL/35!P;5Z8,KF7V"1T%DJ4F&AWF'_]]3K<PL-
MM041UNZ1>S_P9I75RC95\V0KXFN^K->&GF>%/_XGZ%W*G(K&EW>.J@M_+H&)
M(A4G?M/2!HSPHL@,NB4\08B[!-T"\1+97]+36P_U 5-=!PEV'/4XTGZ"'%I<
M\(N]C8 _C504K>/ M0E\OLP]<_+V.;KA!-$D0G%)$1, ZCD)Y8]WZ2CG=I#V
M-(R9.QMY]) ;>[K@DWRF%;(+$:]C  4)70D_F7#  ;&>>'J(?CS$5AFZ545@
MNHRV7A2B(1EN(:URH= &.->LDQL%]'+&4WF^KETZ^E+3W)_+74A#O9LHW /2
MWV)>FM)J3JT3GT&]")[PSLZA191B<JVZ\W<.SK&H K6&$/?MG]?KIWR0G,F;
M'S_&5#*_Z:3UKZR"AO)%3T+,_X9+1O<.K]C G5/="WUJW(_+'_[0;W-^-L+
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MF4<J7K&GJ7<V3U\]\VQF^D. YY#&OZJ7,CH8<,DG!E4O&<S\^HX!%Z&!Y;/
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M[P/4AASWKL'VCS. "RB6SVD(+C0FJD(;0*EA:)C($$4*#2$\#]6!D">:0?)
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MZ,BAN#ZN0E-?Y!Z_-;^LK/W#56Q9GN;#U]]OH;/I._7_PJ^EVX'<=DVF81/
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M-&84/I<%83/@H$BK"H>2A)*(SU#B>>_K)<G4Z/ZB,Q'Z6N'/0A-:?R=F'3U
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M!MTAJ/-'*! Q+4WMG%IN1R;A2JKJ"]B9(]CA)&;?#49XN)6Z!K9$+"AZRSO
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MY=5\$'T0X-ZY E[A9%1?C\]U /PIREQ/5\<#=2A]"G"T6A6>W&JP&>)'*IT
MZ^SY<(N30M#Z[@NIN]PB0!E^>7)H?X+9*MBO9-F+J:"RBW5YK#/]K$\:TX@4
MX>PHI>)Y-FK7_\OU.WQ#+5]!_P'H*%=3,PT_ -S;.+OGG9L;.[-ALLK,J<U@
MUZ<N^+DA?=Z,&M;TIO]:N]1<3$7+]D1^C7JX+W+4\3GG5]ZW%G+HZ51$'))J
M&]I\V/?EZW@8<\:@-_8>HA;O)N6QU!@3BH,ER. H1KHQ@4^K<0%7J@/*N["9
M"4\OQ6.-Q%>EK';9[)/J"6_R0]WQQG1GPQC!C$% LG!'Z3BF]I[!DF@[(=R(
MMT-\Y5O07L*:BXV\ "4_HTPDJEV=E,)<^CD%*2L)+6)G+=C>"J!O58_(5\7\
M-1[BN;#B).?PX/4J^L%2QE5#-PD@2F0BA76V\&=,9KYA/71!'1NHC)K9BX!Q
M&>C4SC2C,&VX\[YQ!Z SNACX:!],54IL)S#K=T"$,AEMH4.^3M7;16L0Y2!J
M=MD(K21LB(J-#PH\D;O=#<7(,PQCZJ/@O0UI/&R6[<(T"/:K.MLTJV@^B#X#
M62ILVR>\3?T=H% IS_CY'L0B#<[0$T!,:^A"CD>0STE=Q#O<5H1UCH'$K.MS
M*9[:9(I1HZ=GB#P08JL:1,35-+\@<.$^+EF)64YS"PG:6X4+5'/7DR-,>_],
MN=HS-I'7S52%5>\9LYOJ.G?KTILGZJ9+EJ(/9I9WF%Y"Q4M2K74'5M;9BE@X
M$[J1SIMN ;VA,)5F#'D+R1J_C='#P$,$%6&X4^U0<F,#$H<XD&@"^2L[<\YT
M-I+2J/$:$YHHZ'6=U'TF5!T&#!0<UOJ='&#(!!6Z,X;_./A"?P-GM,>@<)6K
M7QO!:IZ81JIC33\!_=1':\'E;1]%QZ&<8MA*ZN)!RDSZ&_B<%%'YXC,%OY5?
M^RBL'W9SY7N?B3CITCU:M]>QQZBOR%1?L82Z2LB4?4G#[046M/<@"S77'#[8
MDX"VA$Q$8^N@]PJT!:7($_CXP$,LJ%1AC,G>V$PL%3[RG)QOE?]+C&W- ^JM
MR"B/ZH$0BP[MU^\N]B#*B#K<U3ZV$R& N[ 7J%-P,W&7@"+1J4'&;MJ9(U"I
M(N5,.\=LKGGSV\G%?+:[C_W-%&*;I^T9YYWEM[@C9*UV757^/P[]YP!<_1;Y
M$U$(Q8WMZ,41%<*5=#O@ZGL* J,$D#13D:*BFKKF9:GV&=;0\I62^WSK7[1)
M3_/33ROY-]QH52)"^A^/= YA/CE_%)[-V[_C+K4(CV&V?B^,^96_#/!2HC,9
MFPV_R==5+Z$BA<-,[1MHAY*:RU@&UKRO@$3:!C"JDWLW5--F;W01S&?)E4-W
M;@%-?E*/H).$'/FF_'8'9^C)RTFAY4Q=4[4-]E)MX<5_KIB?4K%A2SOM/N@,
M$*D.Z:P.U-Z%+J@0><"0% 1E5(+!I(PB/$!ESW-,/=]FCMGW8>,Y:,K"F3#*
MV"ZR8X[(^\B4+'RJUKNSW&6:]KL+4U$BK]TNQ'#QIE,82X8E+5+T[1X3PX0>
M E' U';")@9F F\*-2> E9W,C;!1">2HU&CO5UP5;)/6S?@KK[W=W\LS"^(9
M\Z9<\6-]/I4WORZA</ M1(240/F5=*=!@RWLT\-80R?8+J'@#2-!^LSYX/X-
M\<W;EE!JQ)3"_DK)!MK5E."1HT#5Z0C([N1[EKA,*F9;+@H*;ZB<IT9BEY,U
M>U;<%"(B2,%90MDPR<>8US29!@_(#;!HXU@PHTG0CF"6S@EV!1 ED^UBV-(*
M-*A+\TIUQRC6W@D-]Z,@ZO-"[*HCU=!7Y54A)J>.@+X0WET9+:?@-X=Q3"?R
MK;=@7@/P5>C@#=#SBZ)4*":RW.#(VEY6)A=OZ:<FF76!#OT']K9^/U1#-R]X
M1'MHYB)*B-TGS \*C#3[S>)6T<7>VJ1SC)-TC/X)@4QED>KGA)9TMU(H6?D%
ML5J;R'T44EU7#,EBAK$CS-!#V# M,(%\E-(T.$6!9BUPS.HDZQ'G<^?**RC*
M_RWX\<TE<.=4&_Y[@)K^4ST?R"A7^5X>B>@AG!]'/<_>]7^_5J0A$@J;$;$&
MQ-RE8]3$3,%*@)W#V#$9DH05L4UH'/$8I@?GK]9'$NNM&Q9#[L8'A?Q8-P"?
MJ[APX4%B8F1QJ'PT+&P#KG?[88_$!.#+C/.W#8;Z?S$I5#;I+?(C*&HI8&<Q
M7 R=12Z-(*?5]ZI$[&W(*I\H$'<4/Y_ZQ8QYM!_[4S_?/ZH,8HD*K#/=IU(.
MF?\T4/=I\/?"D^^%KYMT]V_C6 A4NY7RX2Z%5X=0ANZPO5F+V&M%5!LUD[,)
M1WP!W73>#Q^L@)C*AK0$YJ8I6P9K=?&M\D]!E6,3BQ[B^L*-,_K<%_D/#S5X
MW>S)?X+_ <A'S/N)YH%Y[&KZ_V+O38.:R+OPT2BCB(AA$9 UHXBH"!EE4PC)
M**.HB%%1PB)DD$&6#&94D" AK;*#D-=QA!%>B8J(B! 1 HHA@2QD9A@,:Y"@
M9)N17;I'B#UFX1]OW:I;=3_?+[?J_="II"I5?7Z_/N<YS]/=YYS3NBJLKUZ,
MVY".O*K'Z1Y@+2G!2G4[>'#(0 4<J2;@Z(%!%GUC% 6ELLW#NL-U"FR1DKY.
MR(1I1&L84**+M;89BKL.T<^AV'OXO'LC/MD!4]SQ#(5Q"9"$>].K9L%F<MM!
M%VBTASM6IV+P@-6'F1-]=4F'E<Q"8!T;KT C?5F/HZ7$MQ'3(0TIZH+C[.L]
M_T23\/Y)\^>=OL+_>PM"JP-U+<L(4J,5G@L/&+!9SNW*-7!3.]H(SHAFH@T$
M)WO,B,KWS9"5*F/>#CPHD_]!D8GTWL1\VJH!JA6HXF,="DX\>P;J;S^D,,^,
ML/"6;V<[:H6YSJBAM+YOC99>\8FMMCPS0$"S@C-Q D:!/;X':4-Q"X'^9G:_
MI+G MF%PJ4U>?=)T8^"BL_- NF[_;,3@O =V8-/HXH%A;X?QZ)#28/SP^=:_
M;8/7\M4O=+\L$8WA2:5-A2:4)I967.5LG&F>(EI24^NT/\#IF0J#CG\[E%WM
MA.KAN+1!CI6X/%;D!]R%U8S&B8AW?;LL#IB^-"7^4KF@M=*HJX>U@!)8K_6J
MV@\CY8"![;9X&\ &2"877=">Q!=&)0J)%OLTFT) JVZL%^C'<V<6V&<4<39H
MPT!4\3)"8=-R2^2\$:Y_D!2["4Z4)\^GT]?/7M%WUF&OQ7#CN5)^.'Q"XR:^
MH-E"$\5:0!5S01!:$?XR#@S>![,RLT"1FM&O704&*<G=+]-+&);HKKM;M.AA
MJMECRN<A):JKSTL8ZPC?Z-C:$/\D:C;#_MC]C(3&\:NTMED<BS#'58A7PF1E
M02&0M(RX*K7EXS=.2ZN;#3A_121<*) F7M.>?CC5N)9DS\C7$K*4&].<+O./
M9%6E#3<MOM(\WAE+"7]_J/*4V21A&=&>,<<E:;Z%B6IB*]RH,".HW,KT)KW0
M0I>_&;T8XYDF=J"X+IF2S#:CS6:'2"<B4J)&BS:]])\LF$NM/+2$,QV;B=UR
M_:]I_^P^'HU$76?(8V>I)_OU&-J?RPA[[$XX2$Y0K[ZF.:"7+2-:1P7HG$K7
MOZK=06*W6:*Z <3Q%TP-[A;,N_44]@INAE(G2OSR6'V71-B=]&_!0#8'#=%+
MT@.1A[,"#T?]H+O-E3.XK>(YE1(8PZIG>3AC=N@#2HC:_\N[[2Y:O"\VL'.0
MS+&*HC!4=\5"1IZS&^C!YJQX52+J,&/F?]\".LGR+3]V$[#VNX,NQ&<!=?M\
M7B%H]V"RNE?'V HR>*GQ2H*0FP.LIA(A@,\QDF@#P'$1SE%OUJ<\S*2YC/>Y
MY7D'.APW!$WI$GD]13)YYF4KMQE4U\A+B0)[O^+SWIH6Q2O=R6UW1.VQU)-P
M0AW#TG094<A9U8PU@Y %;%<EE*F<7_D&)@AC/?4"[ 907/25]#H0!^<(5 *.
M(]9Y@(5[/N,_JM:7Z*I2+^GJXR>7$3@) SR,ND% M>#G5\A1%I00^<%VB"Q<
M1H#!C+%7ZJ_A$*7'R7\"(RA$%9<7:J0:)]T:APN.@S]V%.2SK8QOL$F@+'9
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MPQWY[E^>%^_Y;_B.$WS:FV2<!18UJS<#"CMLR]A.C50L/90KV0));BE3;4^
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M+G'#7W_+E<$C;XAQE5WWOEWY9M9_&5&T-#Z;>G)BFOI-W.#7UY9^>N1P7B5
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MXXXT-[SQL6HW=1.>CC*Z#_V 75FE0O,>L],O7*B)BH8]B86QEG1ARSNX-!Y
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M/UOQS5OAO[>;@.X=!I]G%/ZC'P8LV*$JXAA)SA#22Z/\YD:S[\%NZG00*0A
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MWYQV78-8H@]=@BZ< 6PM=>?G)FOT6 E$MH\A7X W&P#RR1P9%GC[EL9510:
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M#T>N7D%8E3.BB]+/(Z8MG;_-%@\2+C@I+5Y&BXM\: :DC^QGF'38%ICK1F^
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M;>D)[^$=W^"-GZ?,O;'2F7U$YRAG'U=Y\"/,A:8?)"U5 ?E/#)6MS\"(B]G
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M[$1S_R:00OEF_X:]FNA9<TB\H&44HUOC\5C6'[?8>6&X:TKVNZBAMJ5+E-D
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MM'H*'7B8&=":& H@*];PA]].&W,LN.>/I?N\&1^G1T_BK*,,SU-<"\T9F4&
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MWXPS9N"A9S0\G4VINB]+>@RYMC=;(H7.N^J_R>RMN?_)-;OS>A7X<6)NJ<6
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M8<Z&[X+LRCBANR!:5O8NJ+!]IZP'9LPD]1$.  BZTH/H3:M^F"AK*;D)K@S
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M3LPS^>3("J3_X+&J2['#(E[.^9->%W6&)5@''>P\\,T%(Z9%R-FV =T6R\3
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MM%/;UYB<-!SH\T8+'A[??[6A[Z6Y5C]B1K;HZLT>&ZV:/W2;B:[ID@YY)YL
MH-!_\2X:4B+_GE1/(0YYJFG;%7PM.D&&>R>2O@;9Q-ZJ\"4W";)+4W2WD92&
M1!!MZ7HQ89^<(FQ@KTWQHG&7X?QRDP'A/P,>(L@4J\QK=A+B8B/_?[ZV,='-
M,?R"A55-$>2*% <JK*;*SO@ UCYX2?YA3PD?/!2']/3<8? <*,[:??C;;JO]
MMW?%72#]U[21UO\];63@?TT;^0[KIKZ3XCE/(O;CM*DO04SUXU1&XKQ$6^$
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M@J+R;/]8).T?@0'%"FP'.#;@ %#&CNF!'["J!V/8)!I#&6<^4_[7=H-K\Z;
MYPI6D0MK[^E'KD-N164[_KJ@[ZS+DODW@8QD)5$#J>(L;A6JP3/1_/5EBY<A
M%(=:Y8X&LF_AHGLZ_7/"V1=._D93;'H;IG;B7-7M/@L/[:GX8-NH!<D'N4]^
M!NVQ=;D52KY*N5IPZSLB1O (R<RV"!1!7A'^HFNN5EOA=<!'3"1X?#1%!&'^
M#9/KD&5)WQKR!ITXR+B8XM_>JC=R.VN_EK'N6O;RA,935DC@1X]R9\Z;R)!P
M5OH9EXX61\MA.\?&J>4V4"RQ.\P%]_!0X0A#@AJ$3H+)&"/I9\Z!<A7@@@V
MSL0;A7BY85>;*$DP69PCU]2O<;*N0Q('+7U?!1+[H,(_RFP=X\(>WO[N>#+/
MQ]J8>@DY&^CQ0:B\%#&@;-5@K]F/SI0=D'<Y9G^B02PR"@K'4K2FRO/L L]R
M/&,"/=1OOP/WB+OP$W$(?5#:34RM1\9#=M'J0:I0N9T-XQ_-PL:?/1HN,\!&
M@6)Y?T>IJTFKHEN@56T<M4VZO>6:@*D@UPK[P<>5OJZ5KIXIV;GGKAHJ?JS)
MAYL8&O2[7TC1=E0PLQW+NI_PR.5\_#&'&LR$2X*9'3/^(I%V<5+AX]>RQ&X6
M"V-N>LA(0_=-I#Q?K)$[PD#3.N$XBILUQX'V"78Q>15;I_A00:T8T[4P&*8M
MZ$;!3R ;U^ZO9_X+IP=FS1_O!')G^J0-STT8D:1!+Y<9*VDRMA^^#TOJ11P<
M;];S--<;OXL@D*XCF9DDL<!>A?T%:Q'&;>D+9Y&J0A.^C:"J2Q5':,E^16@J
M8G2K(KO5-$ 6]X?MKV?N%SB:O:CD8BE0E<SWFXZF2GA_L(\LZ8YEASJ>(SK5
MI]*F[YPS21P+Q8M+7J*16+2;5M=1X*EWRS&W4)4^7^(XY'Y:;0#FH<,#QRJ?
MQ>WL&5[Z_*-#W^SV%J1W-N79&R6K.*M.G;OCM1*Y=32DQ;'R6L">N^%.6;%S
MWAMZ*IS\?H$;*FO!J?/%1+0*=JT&?^*"[QL$J=+7?_''F'H-+W^ZU22[)F:_
MHW+@B3:W"L^T@ANUQ-Z+P9K:IE:(H\4J,KZ%CT.;5YYC=4Z&OG1)E-GEG!U_
MHTG!^DBA&]DUUWNB("J$M=Q]L_NT\37GYCNN+JGV =@:?Q^M.?J0;'(E G-)
M9Q =@A\F2#1ESE)Y,:#<%N(:U';+!H0!<:R!GE #P8/>S002;6TW1DV!Z))E
MX#V@L;F(OO[0X%;'/R_9G0U40\+_F8]?_DT=J5V^R%7X968C<AVF-#W+6SX7
MV9L/SZKG?IQKL-=/E&_<:ZT3M7BZR$;R1H(9>9">=DRIS_3N]3Q!Z&?\(Z]^
M1G./)?B8=_)=S1SA.FE'>ZCKG O^ "[DQ "$Y7[3&]CE%J#WOZ3T5UV>H@)<
MW!UQ72:C#83B6EN?OS)!7F8TW/3!64[]Z83F=8&$DB4=AB+"Q/]NF5,'>)%;
M_/6: @6O?J&S)I&#:GX8=IT^_^F/4%C1)\<3X=G=D_Z7V]"QCAM&&4&V3OH.
M*0)?3[I Y>[,T#^"?TK_PQ$@_Q)M^*H#\HV;"*+Q[?MW0LRCS4!T*JQI@7_@
MA_>O!_."1^G+;C.XTW3H"FWK-KX'#Q$4(\R"B^6G:]9%D%3$?I "G&%G4.IP
M"*Y,_/IJ"*U@@;BA"NT-@'!GDJ**');6.PIL*UCM^Z.67T=?-":UB7'F_ZP=
M_VZ87 &YR/A/;^!7ZV5=\NJS>IE<,^44Q]IG["H'Y3K?%+F9O!%6H=O]K+1@
MF^&WN*'\ KA,"HVC_:)]O99(-)YPO9\3NN8?.8,&[$9GC[D(FKJ,A/2VYOR4
M#?0!X1BZ$4=MC.D?33#US2B2Z<E,4K8>GKF'8'"&W9R?C]=T.(5P/GC9_%J:
M2R:8GO&8[>>$/%\_?K2=Y!SJ\JGS#E*6RLP@-$0O_,778(G9LVW 6Y")(P ,
M#O4OL:5')C(4A#*UQ*3H46F^+WB[!"3U%"#(E=A(=J&:*4!.B9):VPU.] 4<
MFK$RK%XDHB9KFB_K_OVU-O2SXUO\(++>?Z33-$$ORDEYN2]O^=@%K/,,+PUL
MC6171R?L:%3)E.[F9CB%;=MQ3J-PZ,_B<W_8Z_=:5J6A&^$K<.N%%*,O>GQ=
MDQ)F.%PH]W@W%4-*<0W 'AL)?2"V,T'7J<I[Y^6_7Q%,!J&=D#AJVX6A;VZ;
MY>-$O;.T[+RH3\YAA:7/.)I_G\F+>G^EY(R*JW<*!N%K&/+05D=;H\"M%=Y0
M-0-O^)1SV>S;),UNE]:W-R^H(0D!_7<":N06;MX,Y7,(8C55 #1R19"5*;8,
M$=;"6(T&VOL8C48$J)4-BW3@VAM JN\R&IS@;O4+M;@+_23Z+C=@H3?\?A<<
M>)K-]1I0SDQ9,[JVD;GW2X$U-:%#]_+3+P&*+>.ECK-K78."?.H51@I2AA J
M@LP1>?5@<PW&HHI_!1A=&09,F:VST68;\/VC0#:/ *C5(AHY,H?TBE-+,;Y>
M*5V'<9Y<$23=V'S=^OB>FJA5N/UX><;9859S:S>R?G0EJ:WH:0KN *$E6MI@
MP6]BG0 &D%0RJ@FE/J.8D)C:60R-_::C?:PVK%E*RB_=<_[@B:,ONQKO?57T
M>^:R_C\2;I$FX4K2B8N_*.'C^C3+_8M#5525A6R*0XI[H)]DI=NGDD/6/F/N
MM9(!@X$%+EGYQA;IDSSG\J+"I:K(!&RLC[FI2]M@\7$/S3N-M4[NT2J57G3\
M(Q?T(^K_A)S_!,;6ZY:6IONG/_-XGZ4L+<V.M[6WMQ58QOKY^6'IF*]A8<>O
MI.P^G*SF\S1WVJSLO\HT/E;X"JTHE%\D-.SJMD:Z@D7 MQ[AQ.GILK:&#BXE
ML;:NMCQ<$;P?F!%[N]DH#WJM(N/WK*/U]K+US?<0NMQLWF^"1^N4."JTV1_)
MZJ\,?X8A2'8=6[HE1Q43W4RE]%<2LS/LV[A7XR1"P_^=OWK,_O[5T-LA$2$&
M<8< 1SD#V!L94!/VZ_[))4&E"!)(DL%=!*O#N=LZ BNQ0_WSL+;PO6"#JHQ#
M*)*6/YU7$.&$W%+['OHFQ6OK7.EUA[FS?T@J=K6JL]*JH3F?#W9%%ES^3?X&
M=D5QY_[N/[4Y9$_LH%G5H*O'26\/"86$K+:;[5ECT2#^*.?<LD31I]LPF8\O
M#HW*90[5_TRWO^J3>ZZM2-G[D.W.^+(]KMT<\T_:ER^M3$;%30K)2%84_Y#8
MC30"8H<E-2I%^#;] I42H U*<(-8^;WH!/PQL!E@8F/9Z%]7XT20@-^PWWNZ
M;HQU!+($9V@%)<1;U9E&WDMN?W_O%[QD4X^(W=IKZO,%_A8.+=;*Y%TBB&$3
M@?:0<''T)P^DBJ'S@(PP*,2A _DJNM*]S"VI\:=;M7/4DIT 3=._YIZ:-C5]
MHZ##S\O).)8<%>G&ILAINY,]27N ?X+="G5.HY=MM;^-&*25KGRS)>E.#QM_
M7:J-5.&)=W4?B]O>+B A9+%>O&F0!M#Z2+(XN#B=Z=-49C[L@)4J<RU5;?<4
M7A%+9CY]S)54=:0A]Z]7#]N=J^>:D+B2XMX*Y8'$9DP$K[P9**Z---KO,Q_L
MZ]3R7-@(Q KWB'%VQ[-?-S?XNP6%B*-+7=L$95&DV67:O $P<*\CAIO)+H[3
MS$"?Y8[VP@[@'*97-QQ)VY?5]HV%.8*IO3]6Y9/+!K1:S_Z190]_?*)8K#3[
M; 1$Y,(<6P01'CJ+_%E4$[Y?!.E6)C!):OO'PCOLV8*0@7E98#[OX9M*,+4/
M#5U'27]1ONFH0Y-"+_M.9UY^.IO\-"H1UN1O&R@.?)JEA,6H)O.V<X5OH7WQ
MR\G"*G=Q?W<^+N2:O;^R$/U88]<)S\#,FI^W7?-TREW/-[G;)5O9-QW9MY]5
MH?2M*HK3YSVC5$'LN7AL=]_'X>9#"!DI&\U_WM\ 0E^2-5=$$#GDG]3990YT
M%0H@V0.]I+F%?OQQ$+9ES+\(P ?6[J$;K+J,P.V7 2IKI@^=.*],I 5(M8]W
M1).Q#A,<XX7[369EC]U:@>.5G.4/!O[.O!^K^5Z^UQFSU4']C$8OVF@"LG&4
M+\]&S59S!OY":."GD<#Y@UVZV*JM ;0*7@\K9=?PG&N7CH#!$JC2.!4U"JM(
MW[ <IPL>8?EXPB2NK54$;S;XG;DK/5T6&U-EW4M P$!U3;Y<5'# P;''_5WJ
M_D']TP0Z8L_8'*<U >K)?5IX<>OLI!7LZ>-ML>S47:W_<.>OG4?/V>\VL-,]
MK(YY3_AU+HIY>?.'.]IGK&)",2RE"E+?C!O_TMM+K4#.;SY%MAB<A^'B4:1T
MN2_6])M)T_21$_?:KO]N-3A8=^I5KI87;9(=<#BJVJ7OXC+C""UR1(E4=<*O
MTM6'5EB%6O(V&ZGYN-1O=D?^9\[ATG5R'^+XZ6;EMZQ]2@L5;E*>8JODP[U0
MCXWQ]<;V2&FXN)>="-")(.^H'(RNFOP4K?X17RT<>HO;*7A$O3KZ%[JQ+H&;
MS2HN*<=)@:; '$LOHQP7R<+.N1'%-3[>*%-*3$-6H=5R*DNHI];K2:C7/_9V
M2L12^/JD.-*Z)UX,^:S;K'"A[PS;E=!] 'GQT>4,[Q*P7=UUX%#]69)LZ+SY
MI=P=#QU5*$2'CINV@]RVK+JT@_8[E&/XYE">6$%(X:DB"!AQ6 3Y?*M--_"0
M0D"S[Q0V&QD=XE'DFRD(Z*F>K#0U;S\Q/_CMYBV_@ _&/?FR8+I#KH4[:)?H
MKCV18(9.B0A[&W]9:5F06IL?T'+]U\RT!+%M%J:,TI!\N)48L89\_XU>4>60
M_XGD(%<0.\4;9B)%D%Z">#1&,]&+(81ETV3D^EE@ /6SZF0 >D/C.R$2>2J*
M!,/*]5*!\X*35N:<\-W+:Z8KMVO>G5%+9OM#/;+\ON!/8I1S6B(&+L=:=D[Z
MWK3F/]!YY#JL]BGG= UGK4KHAPPDS3:R\E=H(HA$!4#LR4QXOES)LH8R8Y(Z
MW*[@;*J.UU<3@L',5Z8ASQY1IL='_VG5M4S%_J'[,4WZZR[D9!&VP^,A\]N)
M '_4MG1*9L]G<X2,286?7&+B@:I$ VQ2?^&SGJXCNJ?3KC":[@Q7^VI3RYD9
M&@-<DUW&M8\^O;O>J)*S\(Z?T07;DUIL$E_UI_;%0(OG%#>9Q&S7RH ;CK,:
M0[L'?V2?+4W1_2S3^)_-;%D2BD?OC3QH+8)<:67]$);>L;E)^I]7/;T 4^%9
M<O?:E@95AKHA-ZZU??)9G:58B\7)N/L=/ ,7R5S;:5*]LS6R@I)JY50*1BV)
M461<W^H4VS%U6PW:Y_%K*^03NO_RG?<MPBMW/!^&1E2BFSL+#<YU'2:UB#OD
MIW[S'U+SVDH7T"WOAM+!X<'S8S3IWC?A.\9?6WE[FCU]\?!PBMT1]4?CZB=6
MY*NKFZ.CKTYMV,\/U^4WML:>G*7S;L4BBBSX,_/MI/,N 5Y,2@9U!U[]B]HQ
M+II&22-(=MQEA>]Z-)"*<V12D@)DN9[W6)=#KM!S7W/5&DN"?VS>2@I=_QCR
MLY\<&?)Q5M??O@5R!2H\A/L3M.>F.E.G$;(X5S":B[(?I]@^K@HF[;,*9Y$.
M8>AAI>=?GX"OX0PKE_*F8Y[^=L'WO>.AK6WA\&O#'D7TQK:TJU/-YW-SKDPO
M&83>?//E:\V&PE1V5_H+\MB@9<6'NNKHR75?K=('$@JOL'YL"@U]"-O(AM^S
M4N50)<''_:3=T7?E?@<K6*%R?L\GHQE$.B/9"AG$ILHL!NA/Z%W-6CY-G<89
M/WNWW!;:4G+HP(?%F!L!IRD[4A8B>Q$G@?SX&N-.KSZ$IKC $XT8TMA(-RXQ
MB;(Q?!DU7FL$WW/M^7!$#9;D5;S)WKV^)K-XPV_4I*3&O\GW;N&-P1]0V:J3
M>YJ5OIOD7%"P.3Z>^I2U*O]U_6.48$/WVXO8F4^3P08W/[F$77C?46FJ'Q86
MX!<^//R5/O-Y?.;MER]UL3T(?8"2V:''&CT$JO06P-)P4(ZTC"/7-)[OPTKW
M'+H +"3C+.M\SE1>HW]-J%EL?+^X6?>P:O&'R8\V?,GE".O:3S5CJ!T-?RP-
MW)UU\?F0*RO?V/Z@JNI)WM5+OWN<WZ/^ +(C.Z52<Y>&$9--S\KZ%!$Q[F _
M^[0 0P[Q<W5SM>^KU%9G3U>2&YW"2(YA%BE<5 *RB?@*E7&'E-H4'L> "F$X
M^RG<GBJ3A^Q.9(_:\0GCZMKC7WPQK4.69S"6S?/91LK-22TS-1+SQ.A(]6E/
M>EIK2WX>3SCC6![("U(:.;!HYA1@F$IWR9HV\'(*?GP&0]9JQMB\>&-]Z$I1
MX956)VOE.^27/\NV% AOFD%=X0 \D[$Y#H-6+P7_#.+IB),Q!/ 29*!AU(UR
M!-QK<NJKJU >V9.97<OWI6Y\(VRZB?.VR1"I16"V=BF!-(X,>-QN5>$)3G$,
M%\,.O?1YF14ZVHN2POVV%8L[PT6]LK9D$Q/"A99@3,]Y#$JM-I90R3=IG69W
M3D2U;N$K2J4]!W?DCUZ[PL<(R%UJ^!Y&LQ'A.32!P,Q&;\-#_,#@'[R?0 6Y
MM].0K;ERE^LPP;OT<F8%*3;?#T!]> 9!VIBP#[N/T:];XAW_%A=4A?FN]SFW
M]CVFFNWON>":2#](H%R)2<\=>Z2Z.S#J4DW-OC.Z_Y)\<'O'_E,?W?N_+N;F
MO'=JGGHX,7PC+6/N@\\IR<&U[R\.)Q(>-;R?,7H^]KCRGU7EOPOW:0Q*935B
MK6P56Y_G^G7AC/*4UY^]@%],HB3U:H_2![.7*U)SM28<]-JBZIM*"QD-(LAU
MVDA<U:+O_/RAY8+2+%Y3Y7B%%B7H(.53)FOF?G.ZI5#ZOJ 2+^N#1;(#BKB.
MW8R=U! TD2&+4%S>E-A<FC\ OL%PS_B]Y!+^$H\S?G H$G=L0G_M"2'>T\+*
MZVT?,Z3(Y*!^$#7N_)6?7JP(L5WCRPW]UP3+$#@4]!J [42H@U_AX/%D0-BX
MM0L+%QXD\R+BF#)I.$MH(AF<X'V(93$&5*@) ? Q*Y>86M"/UP[>N\A<@X+3
MLONR8YF=1P<=?U)""4VHIO<'C_T]>C)/PR,%;<Q_G;MM=WW7ZNMG>R3E_WKR
M #*L\^%"U8I?\OVP6[.?NX;']Y[M,PT]_OO9F[87#IG8G'O^/?=.[M39'H_G
M+_&*-9=1/X*5-)*B%91>?C^ME.SE_E-#IWAH=]7;L%J'^E[7%VQVI85!Z8),
M+>=D1*>C(TG!2KWTZ:3U#[NECO=#V72O')T7/?(?E$E]^3WP%%C3:";B!*%;
MG7H-3H=SR*M.^\@L:CH5<%V;7>CI4D\9\LZWY_:32T.*E1_S/ !"K[7M=V98
M7,VR)[7)N.)#)HVR'_<[-_-^ATPT!_6O:VUW!6U\Y(Q>=.V%NV-B!G<2E"-#
MPS-$$.7HH5'Z&9[8J\?/W[5CVJ484^C;>4'<X=&,KUW'<+*"4J.U5)/-,)(I
ML4.[$C],V&.E"D![E,.)%#A?%=G3#DN!R3,"&AO?\M$52UXB"-=@TFWS:DA[
MY4&ZXZ./01YV&(V8JQY[%>ROJB?L[;[]\\QO2GMOSNIKYCJ\,<JHR'UG6+_W
M2[&OY4?^UX?"U8,-@Z2C#SH\U_]<="BLT/9P_^*<E3:'FZA.+-+Y.]G<7-NS
M-JG:2\%G4']?%!"6IN5)&Y5-&FDY:HQQ*"C;[>"6EC.>^HE\R'VY/PUZ] ;9
M.;^1-LZ[&9]SM[UFV:U6V0CO"DJ+(!H#O 41I.$[(,8:GQ!FQ5T4^@1.7)BS
M.%N1(LCL[?]:LJ<9<.TB5_OA/OULE"0=$",(4F"ZOS2%BTREPH1J?-G)#NA%
MSEQ[JE0X=%$$D;>RBZDYG+H%[^[: 1HS5=:2"++\NVQBT)8[7A40YNY\_%1^
M(I32K#(<TFMA751;EGP<.[D@&1%96+;;)L UVR7-==XUNR'M$D7[3;.2C</-
MX).A^\D6#>?)!YW#^,]3;N84.-%/^@XZ3Z>YWLRI52(?S_X9*91L#^18V_%V
M@,N!3#(UO4Y?>$ S4V,"9UX#]F,14IGI2!DT)V%X)M[*_#8Y1*C[MA8O3TG5
MQWFP:M6$(UL7@!K?Z4>JO8Y17Y&_=:"YAJS,-#&%C-*W=R,TN,25(V+HW8-A
M*.(U^*:";$*P3!+U>5XS!C#DF"9&PV;7>AIP-E,X5:"ZYP#AXB)2%J==MSS!
M/S[602A[SUB<MYK@JQY_Q&+LPY8N.TX:<;9,69ESAJRND@CF=PYL-_]/4 &6
M@;/FA*N =AX@A[D*?U7@6<)$$86RXU81;)C*^^"\8IV9)V^-_ C[EMMP:Z%L
MQ7'<&;+_&WU2W9<"F\E %2HW<_4@:W07[C(8 NC ]N%.<PD9>$VL+T$%@P02
M,5V'.MY:63.+-'L+O!(#N<ADR@9#$7L+:S2DA_9IRCT"S#]F.[FJ*+R<O#R1
MIW4O.ZM+UFNS7\WC4& Z>2/:J6?CF,GB%*8_IJ$,M3TYHI3E-)'#'>]U*)>K
M<&R52<E3D[]::7["&'.IS,/]4T*.AZ:6@W:_LUNU@\'C:'?.RC%;HR4S#\)?
M=$8W3-4&H/'LP9= D!WX@8FBZQ#>>;TB[3=>B[\S0US96$LC;>M2XDL('EE=
M!HC>#_BA;1-Z5FZ7V6O);:;I3X&@OQ!RI+UG(MCA&9LMR=S+'N,U'#"<+2T9
M_HX":F;V8KN."O_9E/<-HJU)\!% /HVP?XD@B=LF0S/K0$-IX0I8W1Y?.^)7
M(ZH"J(7='!SH-YQMGJ]_!HK#,;%-;"%;TSN,V>E^6Z>_K]8LKYOV$#("),$I
M-CJM^"#P1\!)?S]F3*\4DCAO29#'6OH#61>P][_3+()25S;0TH0P/]\EM:-
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M+H(TX1YZGP(HM'FKMN? #6)W/D5A.._=:;^[R=QCO(OB9M&XP\!H+U*)[PQ
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MU_-6HUWXOVIKTR0]C<Z/')S37QE8N6GUG3AO]^C*SP_71_=LU S!!\:J\YD
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M-;RU@I>15)>A^'W^@8BC?L="*JM#Q"W*).AE6;8O&J^Z>C_Z_SC4CAGV /_
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ME<+[@!6A)X"[(<M?]7"I0C8P)R2 FJEDT%<VQW\R]J[!.M$&X,L6<*5;Y.J
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M"[N:F:AXENTH![BVX=NAOQRB7C#IWDS=AYF8>5G^%;7/%OW$HY=3=Z]_YLI
M(VY@:U+MSX)/91F]3H-!YT_X,J:'J^L86:YU3WS<*JP;<WFGK]>-N(0^&5+)
MYX1%<C1#@J\'NG>>=\X*<P7UIAQE)LK%L)KMPEPQ[%8/T+[^T(6-ZJX DBK
M!/QP3'*21Y?REJ_YM$/YO1.SE@C%;Q$C-_1O00\M@@,P7#)D5YY))2Q/8R,-
MJ7&5)G_=M-TT%[UAR3Q*Y V0$@C;!'LD2N /7N"BD]M\8CDD*6P,?#MVD=?0
MP1 98B=1$]_^H29? .&])\D+BK[&$WZOFE^#9N-5S6.5+:96B)\/A64=AW&G
M )I ,5^T>XW'V@U)%, 4(8\+V;3!7N!$]2\BXPF47Z<8[!=->B5GM+D!.[RE
M:4DT%>1UFAQ4NBZ1L$[B5!3=/*/ , 7G5X.]L][K\M5]]$)-SV+-@E=E15A
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M$J-.^UGEN3\#/^1$::;K^\3T)]-F*ULN&7"->QV3IN4A?3W\<2:T./H<ODT
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MT/<F5WL_%BVI;G@/F=#;4'BQT+%0*D'Z>)2I-J%#M=K2P-+123(])JM>$3.
MC(?0')"/YL58RIX(X18@9O\/A E0$DGF=^G&\M.22)#$":S ..M<X-[-A!A*
M<M[[B0R*QV[=[:B2X\N_9@8>SS!B9=^,WPJ]^93WRZ<3O^2XV*"%E[ #L>#8
M09PP+DB OS(=K+^ B0NCO*+_2**&0@A[L(R[Y62(@ <\_VM=%@HH\:S/B7K
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M91:4?+6F/ \K#N.I6G<C7->NKE#*=<US#.S#TV!N.V\R])GZPZYSTM@Q78A
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MK%) !@@9-(9*\L<+G]QN:Q@-&J16^##S<GU"KM/N3H@I$!Q(2[O%?L^71&B
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M42S3!FSXT,PH@$'K3R_TJP<(AQJ@P*KSB?_3*[)SAX8+KK5G+LVOM3A8*O?
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M3M8'8,HU>=0[GW)H-5*YE#>?S3S5@G7H\*N7[2N-Q-OMXQQ8 ;$G@:2=*(#
MZ8?CF/F(!_O" *]5 R"Q,!@?JS4"#JIC7 0,7S,T:5=-+I2\A\F2!FJJ@N9I
MJ7 OG[:W<<180=JWG0E,Q73_:YC'S++>J)=9R W8#&2A:$YF."H,4((QA.=^
MN0PU==HN$7HDMU%%<^45[MY0_Y ZQ!_T*&QE2*AQWTG+T+!:M\OU,(+0J_L)
MM2$B^/Z3A^5PCBY#2R:GF)'',KNN]48X5OFV>:B3[^O28PC=U*J1]P%.VBE^
M6J[/%Z>N4)4I,N[/@T83I,_*<TM462K8PB2>PC5_?NY1[->*^0%+)EX'_SD
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M*>6Q^NT[,SGR8%WWIH:&HOLZ-;:I=G<7NSLDJDPUJ%=E8:3G'3@A4HS^P1O
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M(4%? BA'FLN_3_R<"WX&0,U';S>AO5D]MG_I3KS.]^K&A")C#A>ZG"3X^3]
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M<\[!20"4]XW[#J_@1_T>9JMVK&'F-'=4!]NP@I->JP,XL9>DWU(LQ3^.A.5
M7DIR!C:714)BH3/-$\.1W(4L4A$2+/M\QZIGM'JD]K3XWEA>P)CSF-F'Y^6W
M.D[,N.=_Y=L^TKQM9ZF F\F4&OSV]C??RX5["XRVJ_Z4.A=>:A_9P \@KGSQ
ML&;L2W^Q+S&C)/A!^$WMLOWN5W^)^F[5?4GVCV<05U.(MT7)TE[\Z;>P#0)&
M\Y#=CQ\2<]K/7/KFX:N$FZ<3+,-'E??WWO!?<,K-/$WTUTWK?KRX#I9M^+O5
MY]C8_M-5-O2?@5HC\22R=CR!5!.8S'9'YSVNTQ4ZY+7(YIZ=D8Y/)#%@3Y5G
M5NQ)Z5==%#\%.=MF?]K&4+)_XHX-TWNDPS OHZ1><L0U^'5[@@=?7 LV66-6
MK*,(3;ML5PDKM/NSGK PE)FGBLAF'5> "Y'KIUSB0TF-P;592B_?^7_UN/[Q
MYOV/T04K)!1?WF"4]-O@=N?M]=&"G7Y^:_,^YV=#CQKH)J_=J#;-BD=026:K
M8M.OE7LC?NOTR-U^DVT?MU[RQX^=!JF70[XLOO?VX.:*2_>4-G%)==5EMDFG
M#BOY1\GV_NI*D?L?&U0;CYP]?>.[C>>L%QQ4CDB+?U.O4XU)5<X_=9Q9'_&D
MGMJ\J?!@ <FIT*2Z(FNFCE]QX/>B;"<5K>_+_Z4#%[II=NH)5Y<=TQ..DV>7
M:^^_B'#I?M(_N8^-T)_;B=KU8(T15D-LF9DY=<$$.:.0BTG)!4;];. ]+@::
MH+IF&QF[FVO^P=8;]FXA&B/@H2 ;(K&Q>@NW(EJ3%V/IQZ XK4Q=><.X>$&8
MI^FT'>LT!"C+1%S+49#TF6:!&#115_9V3BR#;0SNC14LZ>+'J!><%=A%*CT3
M--;6\]9$K?GATHM'1U[?,_SU9Z*_GI!>."M7WZNHAGJ"<A RTA/<%X.B;[$_
M]82ITZ0O<+^>0 STA'R3$:'2!UVF)Q1Y0V(]83[91$_X6,I!#H+SP/=7T$TX
M/3=M%J+E=Q9&8#89F@@]H3@3L<;9**.1A';-+K6_6^NF)W2WL$SU!%&=@HA%
M.N%2)<T1BL"R2"(2NJ+!24_X(Q_XEUXN;.,BT:0!+G9YM8*.V0D)X*==WJ@'
M<;Q33_ VA\BXZ\@O '_?>7 +6\QMXLZL 1> 4#+$TQ,V1/Y+%X1WH/(>> *<
MV<JY"")GT3EZ0H<A">H%J@'=<N]&(>K%)N@)[Y+K&?\87?$_.S"X^1^(_X'X
M'XC__X'XJ7,1U@-65^DNG7Z%LA"GQ%6A;9-V9:V P='MCM=^?#9P3!IZ/6&1
MYZ)Y^Y:]6-*&#PU#S/6$/3RE([:<8P1^?/=<(U=,-WOMC:A!0J!W?6_.5H<@
MJT4;JUW/\/-W;/)UW;EUS:5+GRM J(*]#.S>#CEB%E22GO VR2!@#,QKQX@*
MUJ2>8*I5>.NLA*E<Y">*G9[0C@\>9,W'!R^%KN%C\DX1_GV&_M4L$3ZN)WPU
MULA%]B&@GG!]ZE^:^!^U0L4,KOO\:8 ([T#Y[O_K'F+>3H--G[$;I05@1AY*
M$OWYMQRSGF[DS+B Q@#T%]-+3\AS!_\!E2 3-T$(U(YE22\"T!5H=LEWI_?_
MUB9M_Z GI(SI7/PH>@*1C  9-S\)4?+D1=)4,&8!*G^'$O0$UUF+ZJ#56 Z]
MF89NLU^(H]J1A'=I4J?,TUGRO@"5JY5Z A;8_2]-O+PW>H*1="8X_QQF3X=
MHMLPB-#E7P#O^>@:W"VO*":QH]W_ MO,:FP)0T2><0R;BWN#MTA/0'G%_])$
M)S_#B+PIOOLGE")48/81+_$ $@KF@MTQB \>#*N;Y.C3XG_ YC'EC6Z0I].G
M]C<8ZPFIG P]X6_ZOS3M%= 34!)])#IJ&#D'-J&4SMMXU/[#HM[_ "WF/0<Y
M+%P@?'^;::DG&).(>%@)_J4IER681*C"GEY))_01-P9RCNOU+^[/^0=HTF[2
M/WS]GRTV?R?)H22PI+R,JWR+6P+Z1$WX%W.2_@$9KPA0!J";\6'&*VCH&A:
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MDR)Y+6F\!!I4TIHG!_-: T 3MAD:KN,*HXGF6/=Y1JI@&_-6L[%Z,IUKQO9
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MXOUL@[OYOD&\FHX0G][QXP7M!R0>MNL5#0^%U04Q(>U'BI[4W=CW@_<*F[C
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M&;+NNX,G)#^WG?5UR+G"]T-+,UK>_1XUY"Z)3^PX-A5S>[=?_=.LS\](QA?
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M;#N^93)$6\ Z/(E&P(*V%_8C1%S\'],3;-F=^?*)&,CW:(_SQ+#/I'NG"7M
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M=-EP%MMA[+RPZ8U!H\#!)OWYO9CSKMP'C9-E3.XWM?N?86:_(0:PP4$=5P"
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M-ZC&GE=HJ\19+ _ 584/I2@/8,(T/(9D00V;O75T];%'VCBJ37O\K?VQ!1^
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M</3<_6DSW_A*7PA2-7TM9W_S^H-TS#JSU<:Y;BA]D9YV/-Q6=XSS SPWTTI
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MOG)8V67-_EGSQ=/GB%73?<P-_<+K,*SQ$PU&I-9;]PD-50PS)KX%3GYXQH^
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M\!1RZ0 :J["CJ 0YL\D&$I$[6EC"!B0R2$I=RX9:6N+A-JZJVB8DNAO-E7H
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MN-\D= -3OHBS2U_DRN#*!!GUP: =(=9,XYI<CM3V"L^+'."$U-BZZK7LYVQ
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M#DBZ_X81<QQZ4,@9A\>UG^MO@::<?8.T'=A&_5T@DI(*66 '!.4J<@9D2C/
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M/1Q?]'UDBF2,:K^=)_&PE%^=S79J^;)PI42:/\2K2P+08ZY)9:X=8<P;>B[
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M=R(3E#D.-8<Z*,4V([Y(A&.*:MT/G>.>W5[4QTR; /V#[M]L<LJ_8]U643(
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MX>^8_4IMK\+-6WY<(BT5IV>V(O;\3P%3G99[:%%#27??.Q=8)DJ+Q%0"_]%
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MB]BQP,T/FQLZQU[X-;O0\A>BPAS_9 M9[=9ZEPVBWR^[%Y.KDTHF^$6B5]5
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M]H>W1 ?*?YQ62"[P1$&=R>.+1EH=\YPNG-7J7!R4FQNYJ2N@CRX:Y>U,@>8
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MEQ8-5INR%P_5>@UU97GPA.Q[8!6M^]RCXZ)KJSM.1ANVX%:)3K<S. M)W,Y
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MW_ZBV^CQAO/+#J^NWQ35Q6-58?HUD<R:U4(DIP&S-?PK1IB<MPB4%*.GD.C
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MY*<(X*/$WL?$A<,;?[H>H#5*J128!;YWB34_'N0IR[NA8>+L.R?]HOIPQV!
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M;4+UMJ2(:YZ@YJ>[D.>=]@?I.V&HL86O,.>YHE_#;_GJG%$#1;(?-#<JB&B
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MQ^- L;T2V6VPP2%-,%V$JV;,NQCKA2IC4?,)9:ZP83PM;\4[S YK$ZT#-Y
MS2$/QO6Z8TKR+-X;YEP:>7A@$]+=0+_.7%!EZW2V*VB*(/=7&R6(3 '3JQK)
M2AGLK#OVB!-ZL.-#U.=C91NJ@K=.$OZFA! Z78B%#TG63:<"SM[8_HENANXW
ME$T1S@JOBHEE=6L?@ZTRP5PH3)$YZ=Y(3Q185^;&[7_:<8I.JC-5DY-YGJW4
MB^>_U6WLBTP^>-6I_,P?SQ*UIS8Y%O^+:XT?>1GZ%:#K5^*!5N?403]-!VN,
MFN@)>4XB<.(AL&.G,RL_][=<%X<?$Q&#BPJ46Z'>&B:(4Q&3O^>N::NLWZ-@
MB+*\VBM?]UM\\*/LB[_L678BS@<*?WB/V-32ZXX97]:OY[U65&;>UG\+BM43
MV@1].*^#9@4;QA-Y9"[;@-]=A.EX)N8.HE1:7T9G=([!67+>2Z4P&KYPKJ6(
M5?O'-<N1[%/"BX5]K$L-$1,>L;I"Y-F06%DK?M*2!IT5@E5\+1,FJC[P+PK1
M@[<:< (A2,RVRYD5X%$MUHBO\5:W8BN&\Q:V*K-WW[\<U&P=8M=11SQ1>Q0Y
MI][QK?*JH-MFS4SX [%G0JJ #RN  WDL*%R_@QLZG>R%-=AM8EP-#+F-M*B@
ME_P4#_&81$.Q!CE'8-IMW#_5[*N\+1SGYBG"_)A^7VF>V:W#[ZI>".8/T9:_
M6Q\U'NW)"_IB,478U_6CF*TWA2264#B]QUOE(./W:K:!C],9Y8H*MDR1[#'8
M\"9 ][WA$6\3@-3DERW&'%]9;59J#'.)!.Y3=2=@2[F;6ZGFD*:OA<3ZR&G>
MWW;?<M3=YMK$7Q<O_5P1\DIONY/ F\-[*X;/,L<HN,<? 5N11:B?X0E^@;XZ
M-A*EX$.GQ+U]ND3#/:*4T2O6749RFQY-_E&32B-QG:O@Y.1]=TN&L]N]RWI]
MREF7/OTPZM:5W55LG5_:Y\45<[G+\0DYSUT G/2Q6#L$[Q?/!4*U+A\IUI7#
M ?%U)HAE [822;KUB+NNM9(_XR@G?%_;6:J5ZED=)4PX?.D:#/S]6'>ZJ$%J
M4]M= G_^ME]:RZMLTR_H/Z01@)&N8MJ3T;F&IU $U).@^PD4JLEI-N[\*<*W
MS!1L+1# + ;L5J_*<&RHQ5ZH1UN2LR8+DZ49].,P.]75D[4K<U25E?2@(J'Q
M4O>U&..$TVLW%%)C=U<;I@B9T'>"1,@2FNY@1J\.D'I"S=A&1/"22. 42,2S
M1(M&LXN3/M#FHIL0<L:'/:!1XY"$.I(2ER.6W%#$*/F.0G(>E 8@F27%D7D+
MJS);OGGGDOY%6+55+!S"[9S.A^#M+3T:7;JAW+5%WMQ,<S44N[RBQFGXUP26
M-&?>6YH9:'=/%H>Q^= ";$[O49Q\S:L+19)5V\&%D8_2VI:DL4_E;K;GBT'I
MCJ>A4>><CWV9%+W84/*1WDB_(EA"CZ" +;::;NUEQ$CE(&7.P%K$3]S'HI2"
M7H&2S*>RE4P+P&RD+Z+&(6ZC^Q%!&M<7K@CNJLQ9:MMTR?V:!A'((!-.:2"L
MU3V,VA#4H*MQ-Y<KY V"UL+_2WV@_U8G"%?1"XF82;-^,R390R-Q&*HLK1&)
M'QW'3Z9M^06/9Z5J=@-S48N2G*:8BRV+O)/E=B'$$?9."ZWH=(IR-3[Q?)/I
MY2#O+I>B^NKVF-7M;PL*([,N".A8$QG>1>\MUKD;[KGRY4T:M4(;J0_".CRR
MX@O!N6*49ZBF;0WF7@"W5,P9[W]]&LQA-4S>!+$-V6<%D=1(G>N+Z<8G+">W
M*"_?]AA;)_JQKO(J<C<>Y+_\-5VHG1[&S,#ES7?B1,$B\2EZ\L!J4*S?P9,R
MJ^@2H;Q -=@HG#7DCCD@_,PR=%5)_Q!O)=R=_&GI:MM<UN'G-?R0=FJDF^!^
M8,@HJ6M@WLUVOR=U=7F.L9-"':X'X[_CO:7#_O_&-92<TFS3K?72._'>"<RH
MCE'EZ!HPJ/<$$_Z&/#&^Q(F39'YT2HSG^9<VU?EEG/# '.\\ET[*I_KP75TH
MA93"=;\(J8/=?M7LNA70_6V=X3L\T-A$,\!RYIB/2MS#U/$-"2Y.WAH9/T',
MXIO+0;<N#8R>1_:/XOQ41E\:R*G9CMSD-$H5EE0?E2%\=UW'8U<ZL6_;P^%D
M24%#;?F= K57";CT88H@"UDI[J3OQ^9P5\#=8P:8H9QXR9[#Y"0<@B$))5%
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MAJTG9X@L#-?JPO1> RS%$^\DS+[\?>P%N4'00(+K114/?0G>O^12O309$:Q
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M!\D]6<%(IY)S@<9/:+CO/FR__QVS7<2>"7_BP4;^/<J>6& +'!&-+47R[@]
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MY]RSC90Y8F &,V8XI)/EIPJC;H7@)-LD^NXNUL:B_J4#_3:!_#/3M-I,+,1
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MDF7W?=]M7>[RSB,.BW+]ZW,]CF =UD+2TE@)!L*=W!GL6]+W?2D&PI\)^IO
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M,.B\Z:"J#JL[UP@Q]_,B.%W#C9ZT/@H*^\_V>C!@QZ)GGJ&^N((U1/"S6'.
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M-,MCY>-H'>GHS';C,$)F;9=7EHVVK[%A]/E0NTP5QWN?O[P-(R$BH3G!XH)
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M*_2[R>E+^[B&_,G=B(TM.@(\X\J5\AGX]23Z2@NYPY4KT\A(WMK\""S32&9
M*Q6V($]'#B5D8262,EP8;V+A/O1A:.8R9!LIB3:9X7IDG.K:A>$ZD<?7_ N&
MLAZ79V@[9&@L<AS);B15;C@8RI$5G.L0 7!S0$0O0U$>*S_QB+BQ>23;DR6
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MBWR,5FF?M<_5M99>556?V$X/BG$&HV(87DBI /#86S94K+_E5J-MK2XH+XO
M6XN@CP-)R\>^P=6 /#H^*][:*":%KP'2$'CX ;JS9$*>]:GI6)>R!E0F([ G
MO#B:;SFSHWNVTF)/R(OE%-W]L_340F"@0P*G1XA[0E!E1MBW782#V(UQ<I0K
MSX%O/,O0+.SL,Q600Z9 BE?N^?#5*P95)0!E;.?6:Q'^2<Q[52%@*QONQW2=
MUQQ0C-B48)$#7O >]^K3/QYF?$R.2SDW8]2G]-K?N;1)KUDO&9)=.KYZ4YZO
M74PI?;XGE+0D#CH 1/H0I=)RY2=E3 !1:&&@^,+[K5ZK)UQ=(.(VUY2.Q5L$
MWVJP^M!3A2>BU&PF8]&&835K!M'RWY%1I0M7O7T2TF_^/'IAUE">>TMP"7]C
M^K$*W   S]80B.=MM #1Q-%6G*.8J:4CO.H:7FZR_23F"%H")-/WA X/-2^M
MDJ0F/ 9VX1@1H*N;OB6S1@!*4,[)E2)P6 3#*0?ND/9\>;64G?:7\*>A#4M6
M#?LTKPZQ\C>Y'4I=7B#PQ5+J^1\0':VO7\##_L8,(@YQXSBJ*#Q?9)$> )'E
M^HP+W^*>8YAS84RDV-<85ADC(B_IP]=@I73G "?\I9E-YC-@"P\S5K'2^8W?
MO_Y?(:^6+XKM=\&NM%1I\.[QY=%HP55@4=H"806<5H0W'0 "NP8L8-T8(G2Z
M#D 6$(P6DK7LF_K 5DK";8PR" U+%\9O<9VM'W?U%.7#@UJ_=HTO_%&&G?>P
M?JA:W+(GY&*TC]N+[3?B6Z,E06$!5OSZK0V AH&?6((4ZA_+1DCM"46[SF<B
MP60Z+-?: AC[LY.0;1&1QU=96\#B/@&ZW;G&5C"^M%BESR46#-=T8K+78J&T
M5G8K!VT>=2-*8I#\Q#ZU2( J7;S'UB)\"J'["U>NF.W#>T8Z(S"]&>!+%I+]
M'YC#"4.K3?%-P$9;,+&:&PSN8[U^4P_JK=._Y*&CTFNC5+541=O;%3'$)U$]
MS=2%V&[%@A;"52Q=A74Q#;'MP43.)[##P!*6Z0!4D:2&&27L1V-9Q?3MTNN@
M&&.V ".%1K!\J,L'G8B!%1^M78^@?@0!.WM"N6AC]2RZZ<V$FN@NYYCK%P&9
M^V5/^2;\M\OMPILPR;L)''O,B$#QL9%'X-9A<8<A!61AOBK7&_]'U&A$W$F$
M"I@2[&ST+O7^O(Z&S?"_X\(K7[C2"32^$N\9>:5[&?" +5+8Z"J(+.;-+N0U
MXA;VN5X.J]'FG.F?&'/T%:"W7#,7'=H("B.[+VR@0XAHZ^<3T@-E/3LU:][M
M_L%@VIZ0PU3=N'&SAE/1ZLV7A,.@=C]9$@U[#$+I6W=Z#5=<#X'1;Y*V)$&;
M_A[)$CI6[*MBFN4_I8HP_+:3DXJFXW.'4_=L.]LZ;A]*5;D34IFS^E3H<>[I
M P]8$=Q, 2JV"F!]VW8D=2<-\G_,:?KUL?_KJ_4LN$A$KOW:U:RW:N%5LE3;
M$$T0AV<0HWJ2LWJ[4Q:R>%M9QC$QEMJ6OE)?7K[J>5%JIKM)MR^->G*!:7=3
M:#=#MEFT)2O->,(]*7JRX?&V>]+GNN(8SPKOF^8L%(H!/&@Z]82N[*U*4O7(
M=7$K2+O^Y)/,=KR6\Y/MGBE^//8R9$&8.;:1P]$: ?R1<U#V&*N(5LHJRD?;
M5G>0#W)MZ01<$>]57'C2BQV"_-JZ7#VQR51.C7/.'E>.4&<O!L-IWGU0.H0K
M7<2^_8(G<#QQ 8@<'T4OXJ8Y)SS:)!@QA3:TKHU)E"RK1_G03)<LW\,1+3'O
MESZL1K6BB('3Z/-ZWT+)+R>3PF:2MKJC#9SCZL6PR[O:V_"4[+F&!TT82^VW
M9Q6\#4U&SRHLQ>2P7S3%70Q6TQZR,>@/F:!Z>CX#3X>&B-LZ&D79U48-E%=B
M+IQ&T)X3#AKL*F!<2R*X3A4LR0#*(_U'0"MD)5AI7\FEX6M^?"]XL='@6U\+
M VKH#<>77HXO+(X_<DX=I[@W^WL"I)F:!O+#CP&#T$Z?(NP*84E%4,[I4=!G
MW9MJ=>C@#.@ 0:(S01DL[A]YC%;H&$<;,GCR0=VL0]U4%<>U88=[/R]U3%[N
MZ.E^53IF/ZE1RF!;Q;CGSBU HWC$/:$(&)XD!EIR#+G[P)<<5?X$MD-V:&#Y
MEH7JW<?\<<+SEC+-;'0$'9'M_?Y#?PL8''=R8N$?8M9@<TP"0T)QG9K0Y._?
M7W^Z8^+)=-R.V*L]H>7R,WM"5-MF5ZGS=1#-ZK)Q7,*#+SNKEV_ 9W G28D/
MQW&J71IF<XR,3E&CKY1Y]_Y! \K;2L=QJKW4Z*,PE%I6XVW:^W=@F73EE35@
MR;X?A-O%_07P8<)WZ(\RY>$WY??!6U"R.-J5&$9=V_'\T>LX ]FO](;+Q,RD
M\GIN&TAA&_)Z2/H"_8-+U?YZE+H CF1ITU,V]S6!S &D&#?FJ6LJRV!])6OY
M3K.1^H1Z^;>=Y,3&5?XI"]JW,GKZ&,S?5>+#\]5:<7^3/.0?F'>( ^1P*Q]F
M0G^&O:"A<(]%L F@%8,, :LHU*7?!.I41D/*]:JO$+)ZB/ACSJ&NLT;"+'SA
M3H!K3FM,T_P<)8P8!&)MTKM+XFWOWSY\BUSMJ!WHFFO>HGVH\'6O\K6D-K/>
M1=GS"G81%?^":8A%D?0TLT=Z00753@:UC@W)7YO\B[VBO0M<H\YW.AI\?HW:
M1WEY,^;^YV?OB ^OG%5(D;RL7_*B^ 2]16-08.:GZXWOT"[?$-_2'KQR'6YW
M,M/WHN?S+P>_NE-<;M?D#HQ3*31LE)6FE\!T1B"+RN7P=<LQ%DN=@ ^CJKAF
M53'HR<_=JL:&M>##L[';/%.7MDZ'^(2$UI;/N)F)B:4SFB\$]1YB?W?:]4=-
M(W\,"KTJ2$5M5 #]*O:@M=X;EC5D83\SD$#OQ4IPK_"M,VVMU5DRF5X5_<,U
M4"E;XO$Z7&*J1ODSI=3'+XZE&IPJX%UT"]:48%5IXX#M:]MG?=$7(UER/E0M
MKVC/O)+8ED*M KCAI??N#6WN][^P;/M/-YID"!(]Y$_FHWAMI;P1_0<*5UYH
M(U9>VD#L"BY0Q B,YUROV.CDY&3@^S!=-&GYV^<&AS=$6>QK+'CZ2S\V7]4<
MU!=T+<8$6A9H99CF&[L>0&6^WF+&60[P15F:V;!>J$IK%EPB+MDT5S>ITN1;
MQGZQ@#SM?_0BIMTGE%*;(PHC['->+_ :T#!6Y@J1*VM(M]],K47O!T=8%+HG
MXDA\KRZ:<*!7-H/9>G1U87,(STVA%X<^C0*4 N+@-)/6VC77Y*=(?]\W=1\-
MSR4;[_26&G/Z;&^N@'M"TEF4RX"7P3L-33'\,%BC0W4OB;4UO_+LD4=.H:8\
M-,K%T5/KTGTU1>,3(ZCEAT$?4Q4(F0^4,9:&(Z>__(<3TQ_\ M]'N+P^.;"R
M3H&]0UOW.QTH<YKSR:_.J\G/<AB3=6S5\HB9?V-G@GVGN2G,.?VF%O-A^:BU
M-3J#)T  S!2V?6RH2/1KL.;[)&SF,Q2)R1"F((XC(TE2_/'G+!B>#T75V/05
M^P#<A?CNZL#5GJI7$=7+B]'>/7U5->J?"FAW5!=;^6,]OV[D60IT5]>2C>+=
M(9WEC_:449W&\%VJJH!\SB^AVA-BC-&"+ >"SP)+M7'-PRL2'MZLA&STZ5V+
M:,QO!49.VGGTY/BR-,*"9@[D+D_8+:@$[C*B-?XFRE7"@R]%O/O='7?C$46/
MZOZ/OEFLG837&V8^?X2](W>LP +,"5F[8<:[4JF%*O1O^Q$)BE% M(\,XS0S
MLG7G<9E<>J"MBP(][>5GB-2@F7B\F&&)I'JI'^_EC@7L+,U[X')U?NT;A2:5
M6%NTO+4J\3/TEK4JR![CBT#2@;=;_<$ZG6"1YH832WJ@?D6L"!(]#K[O=7O*
MA;&L"HIP^*Q_.X(2^,?$7JU7I"ME'!>TX<CA="/OO-AXE5 +*.",Q:F: 5M<
MZ1OTE(%E950H%0'IC3/%8XPC=_%X=-S?:TM*LTD.O4XL5T;<8)E):_7:3&EY
MY_T4BYN-(0V_MR_8_53,F.Z;$F6Y2I-7PV1_H$AGJ(*4']ZW$VW$?,#ZPZS.
M*_3,6\_$L]5%-<I&:K";GG%%CQ[5;G6[:(>/O1A&(UY_FA^TK6BZJ='[' 99
M0V%=(19)='&7PRW:FC0G%?=K/^DY)%<7T4>(E.AI558.MX6K!,QN1@$I[!._
MQH=>KL=>V1,JW/U)'9,%:X9\O)>/QF[O)P@7927K'CC7,9NL"QN\%YM)W?UP
M"?1/ &V3H&+V36\8]3N6%YJ_-6\Q%(.6#W&"4?:#>T(0Q$KIGA#@LBR*>C4@
M,"MWN(G5:#^6;Q^ S]LNL*%8;&;M#'8R-^U=.Z8[FJ\L#5^:]/^V]'F4?NC#
M4?/.E[G7X-W>B!D>^B''CS^X+$:.K3SP&J,"UC2!Z[9M8"KS=&]"C<-*D,_Y
MB9:6';.FNC:3M*;R+5ROD\S"U6?O1D[=O#87G".E:/EU-@WQ50&9ZZD5\4(\
M..(^_3I7C6%*?=FB=@@>KM&E=C;5Q%3[*=VN+W501HMW1;I T<7ZS6 P=ZH5
M.@AF?N7EUPSX=07]Q5)%6+P+[3^Z$@SM#^_XWBLI+U),R;U>=>))PY5G#QP]
M&O,H/+M.<T:BZ&-J/>5GTB-=Q!M8X37^!!*X-+80P#8%=L8V*EGM*\)WK/>C
M1M QK'2:0!)Z378C\-53%?Y 76WK'*A&,S#X2M*;_*T#2)A#6V*)WTC3K9T/
M6N*3TJVLQT=,0UDIMN PQQ+;[P=WXK@-<<RXR> T0!XB"&^/B4=VDP]PI4P+
MONGN= /=>+B1;O*\]^?ABP#WYBX9=RKFO\Z"\^\65TUG%II[4^[B[O!_OD>:
MNE)%W J4593S]CFIU_P5_LCZ^5-&VPC<.K$0%UK8TM;>#'=OAGMIN<C?KW')
MMRIW<9ZR_MR=Z<DRH'[V;=$=82F[Y3!559FF5..S"A?]!X%!+X]3;\\6:=7@
M:LMZ=75(G<E^=D<K8YWM@UX,:.6 M^C8/\G2OV8@'(K@]:)MGH)J@TLJ8!C+
MA^T(A<"-60%NP,W>JOU3R7T1_=!V'%ZWKH@1U:S;H9+@/OEE(ODSP?'9M.J&
M=5;#P+JT7^ #3#BO@NO!<?M%P,];!UOGAJC8-N%-!69KCL4HD:7I# @78J"@
M"9.Z+-QY@9O^V.3/GCHR,T9#KB<,]S!%F%W9/4?[$=V3Q#J7QE=^:5>R)U2;
M>X9"U6JG3+YF/@^41.QS.D Y'AGR)9LV?H\*=,GY7I0S7*2O>53LTK1*U'(I
M;QP?W2][7G+&OK*!)$9?9<9\GK>7^?S2+B%[Y,5/%0\EIT.E#+H.)-L\2V?(
M:#A87NE\YRD@^:M;*;(@,RO2\=@N5?\HH1TYG+(IQ9'@CR-^W2<J1NPGB?JA
MS5D$*B3O.69RABP#CUK!XH.5IWK3Z\'SDX& )BW@4->+HGX@QHXQZ7 [07)A
M7;$W8/M51HI7S/$$C3OS'P+Y?PJ4VI$DC[[(VMH,$K3%%RSH+9(JBCD8K JF
M<VP"US'6LVAMNG,*51%QVR@<+.)8K8DU@J\\)F+U-GI-ZXP+\<W!8KPK,98>
M<4_6/$0NWO21@&YDR3A1\R=:3&'O],UTU&-=A!5HX!NSGH[ZF?K!X\:9-)N[
MYA9)P*7 N:NU9QS?&H=I/"K'WYH_K*0]:A K&?4PY)EY2P"]SN_XJ)'VS, X
M,&:86K6?V)EXNSG Z.D'_>_WSPS(WP>V5\KO8,NWP-.N VU,@>%;EDD>PQ&>
M[0EMYJV,+;2ZLB0)$< B.Q.$1-0'<S5!?$2"1J6,M1ZK-7O[1D0"??$_KG6[
M?\]JZ=UU?63VE5GX'XPWS-:EHOFW%$9+&2!/EZQD#?YGC,B;P4)Z]86IEM/E
M2@\C6/"TH!=3F,7DV)R8E/HAC9/3+9L'_(.B$S]^\!\V[KW[EC]IFZHP*S<[
M>CVPYE25:(F6W\67JU>B&8FHC2!2LY/$3K0LJS-Z:N#3GM"KY)H_B>9N1'\?
MXAN7HT1H+1TI>;871@MTH'FV!]JI25&OL5'YA\0/!]S_]&$YJ+7 =R-87IM"
M__I986RK5#&U+_H:=9IR?KJOUK\DYN+C7.U_72?^OT>M_WH.C%@E!U9'<:YB
M!)Z[]P3@Q/2A;0FC56>^P=V8?X#FP#(2O%4_O["J:@P,/MM-&ZI]W1/7U9@1
M$6495;I (M92;KXGZ;F;U=U#?(S67J8W[:+-RX<,<7)5QCH:(9GUN$;WI!KW
MPM#;K;>:.6]3'JDK)G\Z;43H+1DK8K9($0>Y5AXGZA]XOUU\=SUVM- 4<KY4
MHU;9Q:F<;AAK^DV[T^6)9H#P$<_\\I_JVM%8!+F#]S]CCP]=G"7)<B6!Y8UY
M5B,[GE<)-V<.0U6X+F .YW<P'+H/5<XSX@1\5#R>E'#$-<7XXR:ML*PIIN;B
MQ#;/U3/3:P:VO3CB'2?M.D'N\'@,S@.+3.B&H.,=.C-)CH6*H/>!#UFS*RGY
MUC)16$BGE=H*YA8L'YZP4CH!U_\;M-G(H4<2 X:_=",EOBX4/)KU\%U-Z<'4
MI.^;KNZ=:#F$ =R0MO9%ZR'5]OMP;Y[)7!?U\XZY[ZKIU78/E6L^?=$JEB(;
M<+8D(A>UUGD-9>_2D1IUB8C/4D0E.X^X,O2#)4/:=O3-!Q$Y/_)]CL\R5%48
MCH&N.GH^AS)IUYJ5P^4U7H=<CPSQ1BK7X:#Z[T(#Q(SA=AHDDQ:-+@.O4(=)
M+HQ7;BTK: 6O.-'\"6CWSR)RQ+(\UQ# -0*YG-<$46M)M%, 1 +\PCA<&T<O
M$HML\T.5V4V?["L[WS:UO27^,6#9H7ZUBRWR%%4XL#2:$3[[QXP_DYEP!"T/
MELAOV@+:-'(;9*.:$\K_1[%YB"JFM+4@[002PAJ^+K=/J2HJMA T:B*JU[J_
MCU9ICN/NH\^7E6>\<Y"Y^V%N 0R@S'2[!9CQZR);RJU/,4_[T*9P'IELX^OY
M_ZN]+X]J(NWZ3$LK(B(B @)"5%14P'2KB (FTC:B(D1%V2$B(DO4N"%10DI!
M=B&M-M*"$!4!!3&R!A$2("RMB&&G"4@V-S:I$@@EJ50FO#-_?._[]9GYOCG?
MS)DS!\ZIG),G=2M5MW[W=W^7U'.?]8XW:NW] RRKXKRNU[G7!;R WZZ$MN9D
MVH:5-A14_EG5WGC1-6O?D?M/[GNRU+:\]3>P>NB64(HK"H#O;)$,-.](];NS
MQZXIN*^"'-MZ'GY;NC4W.C])W.WOZ7D\*+[%?.6V;ZCWL2<]+-<==[Z'0NS1
MJ!S:9D4I$(9;1N_&OF U\P4M8J<F4@+'#$X#"YN$I8VJBOKR=#T33(/S&]"-
MU1U3)MA:SL^@[Y+I9(FQB[F7Z8:NL:_;7G$7\R(>[@D/*&RQYH^E([K3XOQH
M="5-FZO2.5@9"3(8O9='+6VV_9S YU$,J7P?B'43)_6Q,O^U&"(F;*8Y/0VK
MXL>?#7<V6;,B$(QM[6/L]]E;G6A8[G7V.?W#HVITE?1M2T+)&\/+F_6&Y+9>
M448<ODWKQ_3N5+]XSZO'-GXH__GV&W!J9._RX1.;]FBOV]26YGTHYTB1%_$O
M$7_A%KP&O_A*CX^'AI=[0_".^[9%/)K-RD\W2JM/%E<F6<-Y=[U,5S6)SW4^
M]4]=%.M[<N5/Y:OC&XXV'N&)Q4000!?9B<>3C+!C$W)]A IR:[FI) -$$\S<
MCW9#%Q%#.$BBG6 4^[(4.I5S27 RV#7.:KV6-SE4FCW8>;1[LMW2ZI/&+[3N
M=_1V?ZSB,5=40%A*7T+[B:VXS\'-/JQ6HL3PE!@C7"JZFLJ6HG$T70E39Z"_
M.3RW<4&FZ IN767FH62'RIZR&AW+O.X 9[[.P/OAC+OIN0VWWRLQNR^YPWC\
MTVN\DZEQ+M%7N-I!E??9&UL+3_Q\S%1_1\%?59V-3FJ&G;RCC1TS'X/BLRCD
M _=?;K+=^KO9V8/\.H$AAY#4@TN<V <*C52"<#JA\J)63,N7YI^>IHM+!G;9
M<ZX\&W)O/M)R7M."5QUDB>L>Z<D;/IRZ_G?S]4J,3C@CEJDO5I7$[X:9!J?I
MR^#/WG"X0:UFOR9AQ6MQT0F^6%;T/)]W[W01L@VUJ^HDU5>PIV?^<+%Z6,FY
MLNKND2!VD+L;>)MF#*?;C.F P4W B^G1Z_) >C-A&8N^IL\7.5\"I<0]S*6W
M7O96EZ7<&=Q\2V+<=[($,H^O9HZ1LSR<LNM;]MQM$D]RE\#^XL$F 6$X.^E+
M'?76S;I-^F_ [IKX):(=YX\4)C='.>O%U1YNZK@QL9)C[:Z--:PF%SSU>/S>
MJ.S1E^X;P>Y;):WV6BT7]TL&*F-,XCS?V;3"[WMY'U]ZR/+43#(E%^X['O#:
M?-'>?L+RT5%IFN6V$;'%$\D+..-68\#PT9RXI\Z@J9:NE#EJK2)17<5CNJT_
MVLHTXA"0E8J<;?>>E^T"9 !X<W!7;YG)@4\3KCV2SJFB>1IG&A/+ND8IDX7?
MK2W&;,V"K.-*\UJ?;'V=>Q?MI>LJ\M#5M%\5\4H,9;:_R5L\@7D(/E8PHH,X
M*NX_V[RZ=[8EE4.G?7B!/WS137\F/(,/1$F8BRV&W8;<;1T;^;%3=JUV![KF
M?XE,K@3H3YYMA!2>@5M&WUU93_+84O_Q]V^^9S=YWKR:&ISF]J;PY#?>41Y/
MQ\@S+.U%6NB;Y^9+<MSZQ5_>W<[5.+'18[1(]'[1O5/AM]PDU9_B'/\([J[,
MW]0BCGG]T6V-Q*C:X88D)/")-$P4G-#<QCOE>;7MX?6FEVW4@Y?7WUTGV<13
M3ZA'ESB(B2E,-@%9OE46I7AX4I%-WT+G$]2 8!.=SY7=J!WLC_N1VM_H/57S
ME5W8-R0SU7G)K63^R>GZ.OG*S/JF(*TH-3.T(,SFZFT_O]"K/M/,%P;UC"3\
M8H6*:$0Y^&U0/(]A GO4H390XWMA-.(A(6B0!>9Q"(ELPT \ )/>V/(:U_I^
M%TCKE1=Q?CMSW\OJQ%79&GYIIQ+88[OTXG"IQ2MN<@U_;V\Y]\?!"LZ>&V)D
MO6F6KZ.7"*ST%>Q\6UC5G6_[QWU7L^4%FTJ8ZW;4A[KE+R%&%FX&&?-CWEW@
MF#4&OTP-R@[8\>IGJ66SL8]6-*^S=>MB8$E+7*@X,+:^,]=)[7I=$/JZ+19'
M]@\/?7-LI$N6_7EBCWPMVL+%?N6*LKG@(4:L-[.>8DIU;A8NM0\N(%&->?X[
MP JV:,RYL3@TXVSB4[4'=1([DYWE*Z;4\ET"\OWZXXM?=OG;!56I7W%M=@1N
M<NQ40;F7YJJXRQ]ER0_";A)2/3]N<&%;#U:?MK%GVY_XU<.]6$.KJ>1,0MS5
ML&WH!H@D<X\-UL\O<*&(X4?E^\W= Q=O[_40MI_1^R*A.3>>@(X5>]YDSM_9
MDK3EN25O@^3G0S// ^X>J@\PL6MR9^W1B:O?=-9Z3=;&[JQ]+ZT7L@SFB]Q)
MZ4&P+U>]X66N[3E0B4F@V3:_\;2?3V1]^/YUZT]O]2)=EW@>/*5I\H?MBRS#
M2H_\7[(,FW32]CM_?PB/@)K2O&(Y0:783;>YF(OXC2YN7G#P\] MM'T=EY28
M>-2BNHMCVA .Q.G>HUT,HN3NORC>D)-,Y-Z^8N]@FOV;55I?5HY\6S^>K2A
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MJM=8$N)O#E'BK*,H^YTC$P*RY[_@L)>V+C[2I"?=:UHD9<:1M%!S^  %@QR
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M7=6U"CX,YO!FFN(?F5^_Y/+SE&+><!/_:(GIO4CY7NJ(A((8#<F=D!#%(_M
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M1B05J79H>OX$:WQ@6,"/_,X58Z2KMW.U"(! ; P<;$A9:D /, 8,  B  8P
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MF^%M7<U)U;W=_-'X)<Z)UH0]-A9CO%_EJ307PCKG8;-)Y7+8RL<8<M9C3:6
M8?FI=/#02RT.%V4FY>)-_[YT:,?Y7K.&+H)_&JW=5V"HS=XW9ZNJR7[EGEL$
M-LI3_MRD#_/L:W(14_:6+LH77 [LUHR\1KR+*D4S#FXA#FZ-O*\^J^KD5S:Q
M>0IAI4L=;QTY00\U%D'?S>\VE"7.Z.+&T39GY.AU:8R\*_,Q;5^,4/29M$ER
M;N16W-*'EOM58'WW&&AM-.T&#Q$S#QV6F'V!B4@UO4^9;A7>J6O/QS(3,%6A
M+,>G[IT: 4OJ+ZP\VV^^^9(V6]6/[W!L\/AT$%._\>FTOFJSS\1YY)$BQVJ
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M9*=-<B6>5ZO@\_ -(IM#'[NSFJXB?A_[35O.^B0078I[/N&AM<E479/%<G+
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M'R\XMUJIMZGYY5F 4Q;+!O\4G$KD= -I-3"T#GX8^7+ZDM9S\!M^X:.?WDW
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M1$.-6*0VE&!U%7Y:"C!]89$?VV<BK%O,U )8\@0XCH_),<0XGB6S!\0$BI@
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M"S6&A_MUUVO3D]0#Y@/V_P!+MV^?I^O8?N.D12KN6(</6]!>CZ> VB  '//
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MJ5O%&-&!?TZ@AM]7 I4N&^<SYH8 'RB<@''/RY$0$!Z1  'CY_8>_/SM70$
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MFQE35[7$EF<ELIZ*.XCGS$RA'T(VI97,H@HV47*9BW$5W!3B1 HG, &=TAP
MQ.VY IM[/622*>#:M4_<:M8CE%X\"8"MF?+;7=Q.XJLRE7IU9D4)[;SMWL29
MD'<"X0()HO,N;(A5,".,IKIK^=2J*\*HRQ&V D@]!YD-R9:I@D"MN3T:MZWW
M=^34BKOTW9NEZ'1B-;WIL_*7I   1$ ^O'^H U:+1'2$?%(,F<BR=L)%NB\8
M/$%&SQHX2(NW<-UB&361714 R:R*J9A352.4Q#D$Q3 (".JJ2%!04 4J3E(-
MB"X(/(@M%5)2H,H!0-P;'J-=(U398S@UV\6V:P7MSVWU2[8WI5./D;,\16FQ
M57;!C:9YW#B2'K; JJ<Q*L'#5:4G(YXF=7W*@1FV%@DW250\3CL<G 39O"^&
M<-EXK#B5,QF(4A05D7]2LZ1J2'J"4H<CNQR,1BE85:Y&$P<J<F4$F>@%(4@3
M&()2Q=TJ"JW2185&@K--4O\ 5;7$9+R%'1]<ELZPZN8HR*C(WV=O'NIMS)(2
M;=]7%&)CP2RSQNK.1[%R@=DX8OB&BS+GCWA6ON/A7XCQ^/X5P].*PF%,XY)L
MG"E^U$A0S2W2P(9)20"7+<J?5O@(8#'\.F8:?BYV#XM,#R&5E2B6;(0DERA(
M9,NCE(!CA6,BR+"$D8%@96&++RT++K.$_*3>L'4.V8-@EF4TR1</QD%471$5
M&Y/9FSAIY+QRY.X6>HN/=R$86;+Q*I663+5)F)<JI5*A=Z4)-/!]=_'29F$G
M8;$3R<7,DS9<V9(0#VI0A86M)3154I8  DDMM'R3-_<C Q*!UO9S#&IJ-D&3
M6"(T0=Q]@<HR"2AFH/5TF;5)Q+/622+N.48MG:AQ,OY:CG6$\(.*5)1(PDR<
M'!,]"<R4I2"HDJ#LZ!L14&MC>3CSAL5C,7B\<B5.$N7FF3,Z$XV5/6F7)PDL
MJ2D%<A:I<Q27<=FH 4 -<;;:IDY1IE;<#0HJISL%B2IR$;:8VY"\F@GHRWLI
M&+FV,1%L#(OG -XQF_: NFY;M&35\^<.%&RL5[*/A/XA<3FHP,SA7#UX6<F6
M O%HFJ!*)0"T+RI+GM 2 *&BEOWFCYQ\3\4E8Y<^7*0DS,--[2>:,$J3,3D4
MP/>5F>@%@I[ [/,98YV#7BS8WQOAG*N6J5DZQQ\ZBM=Z+-S2KB5)*UEJO+8U
MFKU8()=@X0BX.((2"B&:::K%)J;RERO7(%6^;X+#< QBI."X?.Q<G'S92,T]
M&?LT*0GORTJ8)_4H->@T-?*RI?#IID"5-7+6,P69!4,^8 ,LE('=R$  -WB
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MC/5VI%P%'<-4W<Z[5HU*M6EXE:\^4ANZ@@;@.H1$1'IX^0 /U^+Y]0\=O7F
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M0)H)+4OT(/V$6,V/**+;4MNCQ!50ACXBI(D,F(E,4J<0BGTAQW$GP@' @/S
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MJ!R>K 'TB2J1L7%F3\IBD<J9S D5SYJB28F-QR!!4(7J_P![#GI 3<% W/'
MZ1D55F!!<DO<[T!J&?>U[&,\G$K"<H#][3F!KM2E:[;R&=?JJE>*J<"1JQ=J
M)I% 2I *3914.DI0-P(@')1_>Z@ >KN(#JXB0&-0+5Y[D4JU7#UZB-N5.6I9
M)20;,S$,!KJ214G<1H-_#X/"N_%WP\<#=8C6-Q1A'MSR?'=B/\7/?D>LQN_
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M]3&K!8I"9BU25!,I\ZB4@!@#OW@R@72X(+BCQ8+0JR@:/<<]]B/.EXRI >0
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M]1X'D0Y$!VDJ3FO<@V/(;<N<:*DJ"26J 6#N=3T%6]::GM;_   '?N'8>0[
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MD,V\?+N8^]IV^7[4X<LV)K3&2 =#\(3IMTPSF&Z52$K=/W\!X,L\W:A;<CQ
M3^U3H:8=Q:P?.4UOR,SX4K63VL(;KQPX?Z^D-^9)@+K4PV\#-P[U-5KPH2_D
MX:>TF=#'_S!\7E[5TOIWZI>/P ;['C7'#XZEY213@=?)S/A5)@,(JB!:/G)I
ME53UI?#UFJ5*K*GS<6LH.=WE]6T8[S^O WZ;>U,Z4RFF'/N^^[FR5S_@CF=G
M]/,V;+AZ^<!9HBXI(ER(/R&B>&;RV\^O&^DZ>(!&!._3HJ!5@'?&:L9(D+F.
MTPK;@,/;35)7$IX/U:)JHW*41%[9^5,J3#P!^Y,4 .H LLSCDD'N]%KU=!"
MMR\CFJ?0Q-N<L%TS&V ZPHBS1 A_:R*O7!B,'D%>NWJO13!G$.41&Y.< FD-
M&R-.#O0 $=)!7^G/0+Q%7^NYAVL::7P<HOV.+J"D!9ROM&CTFXRDCTAL+;/9
M:$PJ[_(*A4,61]E6_'F96:P[;P7IM[0LQ\(^U9@V$S]*C-6M>I1 YRS]9=R.
MYS:1O\ONC?1X68;H4<X<VDR8:"U#VT)DJ%ADE,&>5U>[Y2]@)/V\=+XA*6KU
MZ[S(O*LYX [(A<#O1C>VN!D!/'/:BM4S?-6/6Z6NU)X>CIEHTG![X\KM\+2F
MZ=LK_-L(;[Y*3/MXI[.DS>7'P=ZD/QGM_G7^-!=V$A&D-]YY*N0]Q\VB'<KF
M#DP:NB8[PY+?KQX?&L]5EXPK!^]:2C*\ZV9_[V?I93U^@MC+(\@>(A"(+"@H
MT5V9BDG->"O$ZC9#FU0A.QZY5%%Q\83=*3?\8*X5E%K_T-WU-!F36BFK<%WN
M9/G9]N(?^M!9&7-=V'XC-MN%HZ_X7:HN\U"K*+;8*MK+WK>I[#XHZ3.7E)OC
MB]9J/M&]GKA<6V2";5[1-+J]4=.*>AHB5_+IX"^@47NX3!.E!29L*6T&+Q?O
M40](RP KSB2:5+@DMFHE+#\5@WRV5$1,O)5?FFXE. =&,WAUMRRX?#I_+6[N
MVYA,?,Z.&K#V'TUI//TJ''Y0:S%ZG&UD1@'/*2O+.+-DQ:A(7N<A"X8' 1>W
MEJ5+COF?S,U[?!32"N7ONJJKM,TJO+/_RIV=96]K\<9*_0^W@?Y$9D;F"F=7
M\*T9"BK6)D_^P^:C7?V:P R9;X>13,;K-_QXIO<Y^TB=KD<$&^91F!!U2C5E
MCC8Q+IL9)\=4\)'&FHN]-!M/!$077'P'^*DC5B"IOV6^Q*I1?GMB)':DFA1J
MZ\#%!SJ"G0/W5^380:)CZ%I[;>_99Z*XQ?13Q?R"S:^A&1I/9CR%GDXSI%20
MJYL:LI3BA> YG5'2$"@,6XAOE 8/P1!-VK3DTK?>SO3 8'V'$PS!_SXR8YEA
MBVXW,<YE9_^4N.?@/3[OXV-=3G3'FL]"ZCWU$<NIWT\<\Y\(9YMPO/'/JGL#
M8U/=*BJ$+\^_Z_AX$S0_-IP\M;<X/3O,:*DSJ. L;,S$K%477";6>H2@EM4I
M7I797'K^?F.Y,_'Q_;A77!#(-_]2\&%A55-:HL\XSCJ?P&F!*)VR%M=\0VJH
M6[9-FLI F5^/5X0Q,FJ]\WQZZN$9',9R-#8H4'C["M9>940^5RK&M'W.HK")
M\^F"%K.W O2*5!'$+,I'ZP".&%)@G>8<EV!BJH& 2HIO"/0!N[S?'%.]D&P-
MHI[BA?$T>Y5Q17E"!OL?8K!JK%8L["$TQ+*B"X8DF$.^"G\IAE%02\RW'>E^
ML9U435K=IGHZ2T\F\=T<K2JPVR[YCHA684J/P:H_&AI=/A2KQ6P\2 K*^S<B
M_>043-_9%YW\1!R^-:+8J%XPKABXR"*)<>]J,&RKQ8I\9:T<R;?IILGU;S9^
M_%IE6\F+BJ,>WNE_I)B)\RF'QP0+1P,LR@^3O)GC=N+HH>1IO43T^7*LH$TA
M/;E< "M1)+!AR<_W7;[ @R_KQ&VV<X^.&MZ'A_V[O"EG)H4Q?)53*K$U@#-S
M "/^X4'E)EG:YN_>G8<[NH[ 4>F+V]7-7%K)Z>8SJ4-=3D-@@ORD;X_X^LJ;
MJ9M-\OQ'A#=:1?;B)!<"ZG3</W]^>?.4Z'!"@/^.9O S^1':*QM[RN12ITI_
M ;813X\[BV]M.2V#@2/8G24N7T8E#\9@<Q@60!8%*GS_NF78R7 IXO.JGNZN
MY(MJUTSE.U[,[*PKL;:K70Y$P22?."T"9W"C95B*IJB*7JM")S\QUANO8]XV
MVDP PS=H0D)DH(#3$V(R[*\;NIQN-6_$SQS& VOL6ZMTD19T!OEC,"4!U*<L
MZ>T*^TZG18Y)-E*TX6^C=BWMBY6F0#Y5C: _>$0F^";HFE:3ST38-?"6[IK1
M&_G9V>'ER-H()1<WKLK$[@'8F.JM@B[#CC:7FERO#-)QZ-32:*.CIL)+IGI]
MN[YM<%0$AZ>.+BIL2"L[_U7!+V!&S_>"BB,!5^")3)H!2%(QV+?*;UTSIVTS
M42F_?E %GA)Q-'**CNZ+,6 H>S/R^,SA8<^NV157!<E$[^RSH051YX"@[/B>
MJ(CCJ&]\/;][5AXK7\140E+/EE^]>?1#,0WL@OR7N7(:^I4A]X/L7WX7>FWT
MOS_[<?MB%"K0 P\EM_2 (64A5?4(%:U$HN?#Y=2H1FR]OL57%!/%XB?C$PKL
M2V]NK) \E 1$]3V&\?HKM:'$BP0MI'4V'FS'S(S'8XGXJMKJ*F&%6>9]K@+X
MY&07[H%&_,)9A@F+4'5<?M4!K4X4[<G'B8YTCW.QIU<5[Y(M5>-WM&5OEL J
M1!C4ZU]L[_H>5*LN'12T*7A$T,=+,F)1^-.AY"Z.1#"A\W%26R''^ 5C9KHX
M@YVRR5)P6UH.SNXJ2>CLPGZ&U8XUU5X@TY(DGT"_ZX%7L1(\@.L*5&4<3E62
M4D,-FN\A%0OT2 #9(H*X3H(H)%R+F+E#A?1:27$I& _9T8P7=Q&XR^U)2?SY
M14Q&Q)ESWBWO)]8]\NC#0(ALQ25U7@6(>%=[F=631+ #1M$<3OO 673>MR8_
M%9B(=(>),5%&KS(3QV943)R&B9-3CZT9NC ]<[];-[&CHE07I46S<<%SR_!G
MEU=O$ !2[44B*&$DNM<*=W]P4A&9VY:)N>*Z\#GNV:Q&=C$=7QN-!#Z923<?
MEHZ.C(V_+(UDM&A>->S$'&&T4A>\#!>2NQ$*]_H%+>D##"7GVZNU!00L6 3P
M<4 "87M=^HHYN=E]*@KH*TIN:OGZ!(X!K9,^:F6INALJ _<FQ^*I02!N+!8;
M/ZFE&P6D*_4'\Y#X1$70(Z2/O_> M<BPM_'<9'R2RN>#=/R<JJO41R5.Z(=Z
M]!3!0+6,(P$:>^P5>0W1]0E=+=_6AD7^LTU[LZ-7_2O_]?18_!^'C0O(?(K
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MNK6H"[.MO>37=R"IRO>.%<F\ZC,UN-HK%OBP@!RHFH^@;]+_5/'WK8?I;MO
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M78C)&IJZ,#3S<;X0;\WY_<N*_-<80XYB87.<1X5[#1YDL^T"!>>?,9OAVCP
MNE;[: Q?IYT]MF(>O@96GXMYK6E^:3D@=M*UVJ&8.?/=B+F?P+K(*(=C:&0-
M.](K3*\.L#I-E!"^0)L1U#L7Z:.9X$;3DYPL)[E/! 7%5_FDJ/;9X^;T9@E
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M>$ QYN0@0E0EIZNPR<.3<']=#@L V.H;U27^S[SB_QW2_Z[]+U!+ P04
M" !P@99;9;_ND>%1 0"!I0$ $@   &EM9S(P.3,S-#$U.%\X+FIP9^R\!U14
MV;,OW(#D) B2D:QDFIR1G"3GJ$W3Q*8;F@P")G*2#)($R3E(D"!*1H*2LTA6
M28($R:]!G7%FG/?=_[MWO?6^M=A*]]E5N^I7NW95G7W.Z75.QTX_ "ZK*"@K
M %!04 "QR'^ TS4J&TT;N O<V0;N2,?'Q0,0EE%6NW0)@&Q4MU[:!OW9!5RG
M1C$&H%$Q*U*C @#(_]2HFH K:B $PA;NXL)!IPA!@*"6MC#(=Q7,YS*7Y6X
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M\Q\==6L7MS\Z\@Y0N3\Z2/?^J5H&;&_]PQ'?#?RY8FCGQY9T=)9P5XN;\ ^
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MCV?L_WG>N2^P?GCT/,Q1;W[_^\&3^X.'^@\>[1\^_-ZG/#M"D_UC9M]=Q@
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MS_/IQG>YLW"6^@+XDTYT?HCRO49=(CGOG2THVGG_;#S@<M /ASU%_MU$'GX
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M6UJ<,CY]LBZ/LMGP*LQW@P6TL98O!OHZ*A:7?P^7QHDT49@NE'4O#(U?4)9
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M,*;RP:3K)M.T=3[W]PU89!-3[,,;(HN#)O7TS%09;ER>:T?<?)>>6#9*66O
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MR/*Z_1_^MB]D$J;FQ3(Y9**AIT1=6^9F7E>GB1=C ^IU$[;W1Z@T[*]AZ),
MU2]-A01#$<!X<Q-#AYDA?>=^LL77G2^E5)S K@[X9+:O.JZ5+J6'F4X1"3,0
MSZ!$ZQ^1YMR(?;Q+(G[$8BCA0!=(&VZD*$>B_3:2L2M44/KA1RY#=1GZ(FE7
ML+K>,BKTZRI9]4;7YFS#*%EMH]U+(Y9,LY2%N^$*WW8$F=4DUW!8N"Y7/V6
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MY:&C8"%;$AF!0M7&FL$R[^Z_4*VZK>H.V<YZU+\7-N.=G1]I%3!!B1LW.,7
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M^]/F2D?M)63_-J#BJ"75[VO5S78B83=S)MD!/D_N78-(5*Z,P8  95?;I*M
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M:!,#N 6',Y4NX\<J5@%#*V<]\-PZH7/CU@#'+JHVR;R6KRC-XEK%-)@4X#?
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M17\IN.*013G-ZX3<@T>]3!-2QQI_B=W48S4J/SD4LFR<FA@/5B#!2-O$+*S
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MJW["E$GO9DNGM*A,74L7%A8>[1,I UB\ER6,=^;!I=C]_K?L>+;5$+'&+=[
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M%&WGCF8HZYEIL[O/DOQS1%@W1U99M0>E7:B)R5JY:X@Y/X_%.-Y6M8N-&[*
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M[:R9>SG^N5DM;:&'6DGX;B;T#< N'V&%L;2@Q\I0+[#/>%-,W;#7Q!CUYX3
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M]]^C54QB!W)?11\>SYN=#M]T4^:>/P',?.2]!JZ'>"\F="\F1)\ '9X7D^:
ME9C-YY?#M37!QR CE'DTRWNK2R!C6E\S'1.C)NH^TGTA5#*F_Y#UKNSE%F_]
MC-,:[J1@U_KB;=;CU#^Z\&K1'5#EUUD;LOP)@%GJ]CTUSO>@;+CM+$]5--!^
M_ 3<P_[C$]XXBN_C#MOG;\(C:Y4287G;U>/WR4\]K1]IAQ_>W0_U,^KUIVL?
M4]>?@*G' )_?#HH>]GC$0K^[]82121X$>'@_ 5^08?\I:?HE=:SX-8](\XZ2
M9+/B$X:FRVS"'ACS7]7[C7=,28N(9(P)GH=GI\D(1<O7T0Q4."L@D3&W)#I
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MKK*E9'G4FS*BW1N'.RVHF% &0C!0Y+2\>#R&OVX? N37Q^#C(\56_NF/?+Y
M]=#YP T7Y.<-*^9'VZ$0OP8N@LRVB%?/B'!8L[W =AJM7G%DD<:1_;_B,8S<
MA/V)R<F]:3+&^7"VL-)QDX1T*(>XI(T"IYXW+<GD7\/1I2=^@9(%M&4 !+T/
M.1\6$>'<UJZ%9VJ_3)!]I:U^AQ13+0I$O>45X  OR!1-Z"4%3<%=8[=DR)6R
MDTYWU1&D<AP931['>IB,9S/N<UHYY72^L9E+-T+XVI\ T'>-O/%E+*]VY-X^
MH3\4>U?I\3)EEG?9J5+^(B#T RVLW^M(24@M*81N^QW4.#[?2H4=8CV8L* 6
ME*'?PU:@4_=)<&B?()=OR:J52PS$I6E5WFF(;81T:W;J5Z8*7++>76(2+<.F
MK][*+>+V)ET[A)KNU;MAK!M36Z&P>6L!8<GYJ@?6I&,_C";)6J<2%KY7%Y*9
MNFND^F2QJB# '_B&D]#)X/I5=(5JX",##/^ +0.3"J\S)GP6EI1'TJH;UU-6
MN'%EQ]U W29]LTJU;#> WW I7ZV"6%/1 Z]N*??_EH]Z7:L<V1BVBE<S5T-5
MHN";K$_0TSKHAM(,SPD/AB;;Y;5].+M8+4A (8/#^1G[_WV<=:-X&'(44MV:
M$]5@"Q:RM-*M(3/>9-(0UA*7F&77=1*M'WX]7.,EG?!S?'?S6O(D:%HG#<7"
MD<G(>BHX]*U5# M_J2EA/;&%>4VIU3 .I)DNGA@83']KP'C>KJL&$P*GN/F-
M\TLTT8![BU'E1!L;L(K^\B0+:O1I\U]ELMU=@W3IG"% Y!7,$\/(5T>Q4;H-
M875R1KL&?O&@!RTS.U8$O:=;W3%/HF &!@5\\TN3<F)WEGZP?8=PW8IV.>EJ
MA&B[U/;BD[<_ DQ?0*N&- X*V;'YO!NH[DDV(B53LXX4G*\ ')?Z&@40S6$[
M^&&SB]838S3=/F$H+6AI.[D@E19X-A%WF(M-R(.)X<\\Y]S?G"))$ZD;&F6%
M=]>ISOPM-C-P*%<C[[1S>C?H$T!S0I6\C7M11'.O' 2B*ME_A2N\-RJ@7P_*
ME^.^XP#_ZD3W&]V7[7,Z=DJT<;8-9-PJ:5XULZDN1J$+2DW5(A,"817Q987-
MU"]%/M"BRVRZ;XAN^#1!.7T7J^EGC#A!347-:D'Z52Q22H$5#.2C^)4D-A@6
M^,4-XOF6F-;2#=&I>3[P5-DVO'-<#'U4M6OE=;@W;%$PP(0\J4_I>F],$%D=
M6L9VB'.W-98$1_:NMVBX3[^ %4.9^!1>.S68;W>BDNY=O?&7#\P.#T=X,60M
M9C7LWL5"9T6=>@.SZ]BW4/WRN>F9:8CS,JJ,/LOLN.>6",<C%Z@X0]]O^W8.
M'3*70&]%I.1O26\45A[3QH+0F;0\^'*H)UH_4M$(BX\@: XYXKUH,H;L6Q:;
MUI!=]_O^$+&_[!YC(, (TM&&B!4%8C$FY'@Q]%'XBL5?,D4)E23DAAE%@>V-
M_+3#[%"G[J&=9%6C)1T8-T@W%(01G[0KB.JT'6P6<3-+16?LE\=URR.EG5T&
M!$-W3*8BS0*^4O^!BI#\CIW4N:D!(?3W"0AT8I T*1PG6+B<D8 YGE$8M?^2
M@V134ZO4;GC#0?PB.1;(KN;+Z3G3&?< *A4=CN6\N>'WMS5J%NAR S?E%9,5
M"42T>!.6(U7G?0VT+![SV9G0G7053YLB?93[Q2LV\LU)_R^[$'9(SGU\,^6A
M[UFQ7J?K/EF1;W,HV@&14P>5["T=$6A?FSO/&Q-:3ZSTL#"WN2SM+9\;X;5W
M OU[*'X$T2EP"24F)2'2 YY=.5T9TNU'%YMAQ H>VPQ) B\L?D4D>5"3D$H!
MO(K<_;#.-^_9U8/LQZU6S4V8*AVN^=0HE)0_:64*I '11NM[? V^M"<DU"]B
M-"A8+:7.8^5&N$ 'SE3,K&)K%8>+N[_3WY%69LKM-*9":J@F+*?AW3&:0Y<D
M&R=#5N>?OPV*^*3\;E/=,Q-J3[X2-5>6%9ZW2F7MP"$,OXYP0 B8^Z-% R\:
MGV0$@PRW)Q(>;4DEN@.W,^[OUBRE-!D-Q1T)_<L+^^?,5RXKM]LZ%WBQ\PE8
M[3 +)/:*O5(_&)--+F"?M-T#5BY%F N=[%]_KDG<^*15F8P![-;%.):X^D4Z
MRV#6#@$G^$I>%X5&6S:R43 H$4ZWBG*1XXS*J*>**9TUG8HY0CS)M5 >*!7E
MKC-F@#)7N6_&&K+1EG(^U>@E")EA8?OL<@_B3W%")A@1+ R#^]M3J7_(6(<M
M4B@;R4-*;L8TG=!K=(^DK4,RC_0E;CFJ!1AE&I\!K"YE\*N=GOX$-,EIC8UM
ME5AM?3DGGO>9R4W\!.3'B+Y5(>O->_76W@VZ-,.0"%<F>9Q5*VM>[E_N@_ZA
MLZW;Y2= +N"V^5? 2Z:\YC,B3B?"K;#&Q9K@94_S^98E"B.!'+.]8HJX5%<Y
MM3\FY8%!H+?N;) *^W8F!U+7R8J3)&MEI;L'-)5\I0)9M_I26I^I$2J5?&LN
M?883,R_X)8C@5)C$^Q-0*?R?74]/\JDTLYE(_-US'WBUO;"I%C4WVTCC D]A
M1X=\B^64TJ)*660\O2I9)KB#0F?_Q-[4![??;<[SE#Z;-U5W 2/*4^6HK6@S
M<?EO<:L*G<:W8H722*XC9L36<?BTDL-')'G]O2-VZ#G[&C=X.Z,*E,:S#%?3
M#L8\U44)4E4CZGZ_X:$(V-1)&F:QHBZS^=)97]]?^Z4 S^UJ+XJJ5&E#<JZ)
MDYF*@B,(:U*2I,5O 0WH2B[XXVED&:5_M(G#D,:80$+,Z >:"9R6I<;.37!6
M6ZCMS6)I4N5:/=DL"C!O$>G:P.@VL1@C1<EC>3NM)8#6&-+SMHV)$+]*"&!L
M'$[$OQ6:SAYE!)5[437)B-;)<Y)CBRCB]](XD<>PUD9@F5T;^[X_5MB)!AG#
M)8AB?\>$J\.LRD1J<WEQB8''"\E+1LO65N,DOO8".#;2(V84@@0)PS-D9H;$
MKWQ9"08;ZV0$08$N+]%=, I),)_F1A"1?727+V>_$07H+[1_V#]*%CN,V,#T
M;? 4HY=QN6I=J7S->U"K1;N>Y1]F:G24/I!=1DHI&P'EJ>BZX:Z4!;7RX-9_
M0QS4X)PU_@1 <1>?;.RZ34P8-/S&AZ0PM_(7B,1S7&T32G<LP6S):0%:(D++
M)<\#@T_NC& 6\A.@L633!9,X)U%5$G;@C2"[R-\\]8=Y$J@K<W(VQSM)[]3_
M:SBAB.-PCKCV"?"X6QFJ#NA[V7>#]?T$^)"$=F_/R+6\$?F_,;/&Y_R;.EO=
M72[)/KN\#V].61ZO']FW,2N7.1L.1I\ M-D>5>YB:S>NY,RFZ'A&W79AB/SP
M$>6E+>M3KRF'>WF)\RVB3\#E2?/]I$O4KK"B_2<@P/=CG'OKKT)^7X^S8#"=
MGAJ3'4INQA"W=[5V\W_J5=9(GBE,/P'K@_>_:_M$>GQ8!B&V/'2G=AH_ ><6
MPK?W0OC3#%!A._.[H*FAZT&.W$OW29<W'S_A6%&?;$[>F/]J?$;WJZN_%\(H
MM)9R 1_LE??*_IX?C+J_]]ZE^E,SU#-**9HGC!MANR^5KQI/'K:666N< *PN
M5H2T+6%K:#T "C@%C.D=E#$FFCJE*),NOL#L:NJ# _/_V'1#X/ 6>MF-MIBF
MI?G+.Z/0L6/  (G3SB=J?\K4U:&\'(ZDQ5=$4X*A]#\T^TAZA^FVEOP&RK?*
M(N\8WS(J P-6<O![5Q[D#[9K*B*V^-6P-1UPM,IU=WZ@1S3W0J5;[1:A#AN#
MEY)XMM!#<,>JO.5+&4 N7P3WWSVYE+TA3@J"M)<$WT2?O6*>'W:ZO_AUWR5.
MD3QWC\3D@?<W8%OW\DK9O5-KR>0WR\#_6XMC65T2X!XP,O-UWV?$\1CF!IBH
ML.["R4?8?/YE)O)'0G3P\"N27I!Q/[V9"GIIE0(Z>@L'].#/,Z>!KJ.+>O*M
M/G#C6)<N ]?)^^C&1(M%\N+Z3)$+6);VU<TX@2NG)E*"!>=OY9'ZTU6)$[2:
MNK$<KA=M(*4L4ROL!GV_N+B^"J0:6(Z]:3J^A@^I[W3JA\NT0T!.ZTG%NM_!
MA,!RF+]$2WK@*0LHFA.ZCN:%<), /8NO)$,U)W54+:V4R J%[RA_&Z]WS4G^
MGEC,&JH=/0<40DV*=OT=/+=?_30N>+D.HA=1W?E5H5/)4:7*@#2R(9O]$X.8
MZ^LWHB3"/'IS*!I:\2($*""R9"XKIW@Z=)OH:(2I:_XA$ZDVAWGMU\>3'09U
M#DRXIM\D]$WO-<DU(HE<]FAI]Z)ES=3W:2'YIZ$RG"Y]FG&FSJ%Q?.+N)NOP
MH=)?#I)J\3Q^3V4BIL+(A%FSUN,6E*8RKN1(:)]5+]"G.R1F=L PI51;49;9
MVJV*:Z\$Q[TK43AKI^HEF:$#8)"RE*Y_<7OVM#W%CQ-BX'$P/0\9+QH(>BI=
M=1)3*7SX+&CJ_<$31G9;<G&!B*)GGMX!JNY3F!M1S\JA8R:@A3*N2Q!K07;>
M.B).2J1)6]3,:JGT EEHB/C]A?$VOSC8$TCNXIT455--&J)Q605';1M'#VW@
M[NYP!%'=P RHT*"PQZHWXVMDTIWONS5KJ_@NNR'()D\?Z^E5IPK+8RG;@* H
M"<4%^O.Q6R$JF_B!?]4*J6;(;,(PX)IZO.8*'1<)D:"(N6S%OYTP8$ "=):Q
MB]A"^5R\_<!6/MGRP4QVPH)VDB,J2_FG7#QNX';&\8D4YV/2BL6I*(B(.S>1
M)!%S:I%,N(319,K$&');+=K>?!%"RRL3%**W$I$#UF,6*4]&HDY@2!!R!;>\
ML\T1RU$5DB[OS2T$\+TCL&5XY72:NQP0[W2K+'?ZC"U@^$=Y5+?GIR1V6LOO
MX2'XA$#E&<U8IOSUN*?X,3$1K]U]S/BB!N?T4>:?3F7K(JYGWV%-G"5'YZ+7
M]+(3@Q-0^.;PS&H0N*W+HN%4ERM&-<(B*//,USFOJ40YA EKN[ 593G@X]T3
MYY2X#/5Z\[)>L7"8II890BFX:A^*2S5.!?WDN/LY,:CEGHD4X%IUD#+_@E?2
MP:7$>/,,L_X"E((I:X.$8FS/H\XOG3@918*=F4O4L,6RRJLO:[2"(FZ+9Y:1
M"@M9L17*##!C6DPNZ#/; ])"A%X*T@C+_4+QLG&<W_M]:0AZL]P.5X&5;:<!
M*RU19DH0U"X6VR@, WT#JKOR]G/K]!_'-%0O2*=?I>VDZ72#]E@9FZ-,6'B*
ME%H2.,8\B&ZC6D_-'A:3&) /YT9]JHD6XH0]\,2/750A-D=&A=N;B7N+6MZK
M2JG+FU1G#'\C<I PEA.XWJ@*2*RH+;>0[XWDQ(HI02\DHHSM(&*).6.(Y1PS
MH!M#7>VVB,8>?=\5&1847%'PE=3R5F0'/WLBIC>M]?<+D*HD:XL:$6>F(2TO
M\&*EMVZ3]H_>U.-1+LHGI,))['$C ,7YA(C'I*6RS0N_%0/>YI2LM!$5F:@1
MCZ9$KPRK*#$EM*D)8HF]B^7E68%Z(6/\EIQ/>ZL&NF&D _-YNK$(:@7F<D9!
MP:B$(9+ KG@8#$>3EXL6%X&-<3<32?3O(< 4%*T>:_7 G3/_D]_4S-[3;GS4
M31L!F/L&2J31&V>D(J)F@2JA!OT-2:V045C271%HKZ%MJX1X-Y*]*<!*[C27
M6J/)'X-F)=^-WK1F[O<.-:OT0\K6U6#35IJ\2+%M*T]7*ZR<53A4$WKEY,5^
M,/FJ<A!28VN$9=?)<(L7Z,?J&\/JT'M,LS86!]9'I674#-_X;N:)X*3^AAQJ
M)3Q3WTJLT&$V%YU9)9@7VH3V,T7'9*<R%TB0#K?XB^I;CBY:$^:1\%0B8%I8
MP!ID!GQ*N3K1F7@^GT!13$)6X:_,/W[GQ4*855D7TSX9"9^-[*>4BS8GO4Q@
ME"JJ)Z3*LUR1*HQQ\X)N?*.(941J388K;DBN'&@\T/^>0'X! 8Z;-]ITG JL
M"LB&Y=M"%JG8'JTST"W05E178)?T=P=S&8OK<"A*#+9874&.&6*W8JT73E\
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MT5TB?&J/W_M$?+])4=[EH& IQUCG4[6Q?_P1&J>2Y%IIQ'S@&LYM<,A,D^*
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MQ@<;B_%-]L'*[\DUM:\U91M\(<LH'M+-'M"<^ -E4B@HZ)FF*YK'G7P!KJC
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MCZ(MS>$@2J77EZ%B="5?>H M=9(5"R95SD2U.@NV+I&+H$.)K'C.N;O_-RE
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M+\Z6TJJ&9\RWUL-G [FAJKE<2A0FAWMP1+0H#GA+D?P=^$LLS\0<VMHDA-*
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M.JE*BFUI+=V4?VEC:E<45RHNP\.85N21S4M%H@M?)K?5N&[/2:%?/_SP1G/
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M;/7O.9(PLRTS\*!OJ:VRUZP@[/C!]_%Z15M-VP[A_2><1[-_")6MIF5Y#6Q
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MVH)<&FT*11Q#8*)W(+AZ>.VVR8LV+HT0J)ZGWM1VS^DS$ZTX.51)$PW=H"6
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M6*6L2ES<ZA"W-V RNU_*?;9(;I78E9QG0ZFKT!3&?P&$F34[][^K_NY/3L)
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MF]_C<O5D_CGNO_A._(OO&LX(J).C*PI+<>JA,\+QISLH=RWA?PRT;5S5_J3
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MNZW"^".<AF&47=)2)GH2OZP/R2OMA^NORK0@ZQ@ES\77\(E!62ZC1&3F>4B
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ML/KNH?1?UN:T6G4@+G_%_B3 H-*_>;Q1DO<'[:^2>/\I2I+WMWI/K+%V@CN
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MMBBNJI24[47MK3.K@O1@*O,HHGV%H( Z6@LGRQ=]/@KWY#;NC;X#L&E.(LU
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M$[5&A]RH0Y.\WYAUV[A/;;W6;9E;2"!1Y_341!&--WP@(?K-QMY+_*21QWL
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M*D#5 NP*<B<.#$)?!4,?<@P;W^V4N%X=O8PQ:&E$7.;^\1-#6$DE/$1VSW/
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M;-QF#(33L!C-7)#1]C8S//LS1VYLO1_/J*ILXX^.(+EA5["($YXM#?+\<Z=
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MC IYN<OD&YEF?[2BKRG2U[>TC7B613TC)QA5#<4-?H.9MAF/==78"I&8WSB
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MO>QQ';?#H3GHC)'$\/LD]1&<<[.4E*2B9*,QKN=>0W(I7ZN/G9F(J;=E(4-
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MNTV;KM%M[&NG\=\XE28&XAE BO_R$KV(?[<6NKI;P&PBJ,:&Q_G5X356Q*M
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M>R0;/EA]%/D4GA:VR,U=D^1/Q#@S5XG[OR(S1GD4$T"8D<>N*[$B6I=)Q>L
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MCTO_KI>*AAXVZZ:<NCY\[:F^BF-BQ:S.1^F(I]KG/!G38A*1.;: .&DYY'>
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MECL4Z\[M0_UV]B*$?C@]$?U>*N?<>M;=:6X?=V"';X2='LC3B;%W015QY]'
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MLHL^S'3<%0JL1C'Y_BVI2ZO8:]0L3NE,#2J*N)5.F.%N?E>&1VQ9%O?BMX]
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MLH'+JVI"T5A[X<3@7.G8=OY2<=?C%I4U=!8Y%#YUO'R@\$!Y2'\^2Z!W42%
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MD!$V?;4*H(:ZIR%053;//&OOM>>,A4UN_]*Y"D;W\XEIL=+2I.G@,+^$@(1
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MP9[;@@85=S.W0TNOT4PTG<S+XFE>BX[_B("_:G\2(NC$H0&WB!G3<6\;^)3
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M(2GT?CR9I=6ZBJL5M4V=NUU^4W=I &[ WC1)&[75;Q'\YGO.7FRARF?C<2<
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M!%&GVT,3G=-IDU4+K,8^4L$A7030&X_9*K[,>X3G.U5K'=ABY>TV-:#A3AF
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MIS.R4/:I@AM_5.(W#N,SJ\6]_5+JE%[G8 $;/4G_C@92NFG,PU=F4>^J:/#
MGVI3MW9,2#1%N5U!WVS.#,HC<ZR-:QU6/XMROJ_V@F*WVA$-CS>F\7'Q,COQ
M3(,0WDF+?H3P;!\-6Y'POU]!7.NY-W=^*MQW_6_S)Y8[E"8=WEGI&JT:6RF-
M[#@X$=X]V+#9N"S5Z+OCT0AVSM8[E_OSR>N4RM^$J>RTJT@*ZA,8V#YAJ&+Y
MG>!0?.#OB/&X>3!Y0_/EFEK.[CF=C(M'5L0SPS]:2XU"AP;IL<,E_JW+%6\I
M@XUSM=8"=W8'+A7VUOT.AE( G?R92]R\\@QI5R\^*BZKJ'>3U+%ERQ0_&Z:1
MK:80-IM25NK0BPP(/=(VMJ3&B7ZSHJB4K<>=IS+WYA5' Y:D2B:!9]/&VXO%
M]L,WJ*;1BIXW_@E$U'*,YXS9G;\*Y!1[?J\G.;.!LSNS$EAS\V'*G>D>1J,!
MB,X(HNGJ3X%AI!Y?"^#=4P*:I987,Y>DZ36..:._0M\WN!!-KA2S>6B?^*+[
MW\O^\9WQ(.6PLU#1X.$?M?'?^$X)XRDAW@%]KR,5Z+59MRPCK9,[7].WS\5?
MC>=&:X[<;1KJPAA6=:K7ORV3<1IV;,;./?PP+C3.:DKV9=HOPYRET-4Q]2Z=
M04ZV86M>JBCB,._G88VEG?PB83>4] N.M* >/3)/4IV M8;DE$5[B!O$L"FT
M,VT25#D>;4YHMK<)1KU[>D=! IA/5;DM-[=MWHM2KO6?@:!C4<XGUS*.BOEN
MWVJWES.39:6;R-D=\?F\2\5;L#A]M6NB^%G#J2$*179QP0>PO)$7''C=^L*N
M"M:I%3F^KXYI)@?,]&<3*$!MHK^L&K?8H9M7$D]^%/2VC(*OZU:L@/9'_$MQ
M2;]I3@7&?'+A%>37A7(JF*%R4;!L?P@O'Y%O0D-^7;?)8AK3T!=0[:^<8_EP
MS9:O&':.AWW)+3,R+:A#I[96$"-XT8&^R^:7AJW51G"=D3:.QN37\Z^?+&3!
M9V+TQJF&!"/-[XQ3WI!-=?-.R "L%A>FNEXUAY\J56=Q9R]Y5;Y()E=.GS.(
M)]GF^[#?U>;C6A4R'\ES''^WD*&VA=FEV>#59_FU2O"KK5? U!7_N]UB=<N+
MU32['"B)].ABKG9Z]!M6X96VB=@9&I_*Q,AG/$2=_2LBS=SX?URW*1P?K\S/
M:,S^KCCGED"96_-/1B,XH1.'H/",NPW>8<OT))K$M@8/D5GL?6F\#^S!BI)D
MWFZ U%*F;TS'JH2$L$\<I);^8<DF22W+Z.IOEX*R[\F%D=3U)Z)Q>H?(S%%,
MIC^^X_I'> 4D\R  P]/-,S*0Q2\J1(Z+WXT KPC[E8IB9M74P[^ S Y44//0
M) B_023R",."M:!'A[][3:V]/L%!XC'.T&G7LQDC^5P-VT.(_<4D^9F*I+Y]
M0I7:[1OB1>.9DL7)[$64-TN-R2RERR(U(\>]-C70)S<<%'6RYKP4)$34";,Z
M41;R"\2:]:J=\;KSP\X,!K!WOK3!U=&@G_#TI+/]WX(I;UOQ]^\+QT'Z6/A>
MGUQ+6+\.X.XU_0M@&^]\]1X@GQ30-HB/>#*;8ZP[$V4_ 'IX8NN3PV(2)I;>
M,7_@/+BX?#S.E7KVN5G-Y9F?"!V^)''+&%2X\!RXB_:R&6+&\V9TO/WC"7TL
MBOOTZ>BI^\MNOQ]02_*RGK5.ACO$X./L_W'MQ/Z>S%D>Y!28+PB4_%_Z*H8O
MNE=$4M#/Z$P !?;M;$W_ /P#P?FB1H2VW$^L2A@U7L29G/^1FMZ-U^[[XEOF
MJL-QTSCSEKN@@V"FJ/22H]HF6S8<#41BZ,59&?,Z9;-[63?S4M8>IIY^0,8U
M@2XJCZG(8:227IS[0.9'(-61)=./M&_8$_R_ [.XKT$>NP;1O=SR224#Y0X-
MM<<MJK<SN1"Q$)")J[P7.\VBUX3Z8@HA@8*%!&Y\Q,@I!G;@";Z0?-- BUPN
M*[:1@.*75LC&GSR3RW!FJ?0T8WFR'6'$?+Z$,-/@K@B^@[W>7M_N-TP.80P(
M9!@.]\QR,6,N&?#!"PC(2ZNRN9K_<G$G,!I*Y-::2!%>[MQL+>/-?2@QWI=C
MK:G3$^%S5Y1").K*XJ.@[>M6@I .W+"2E#96- XM0G:JTQ;W@8C9![8L.-!O
M."NSS@]J,.T8?:*P/#$5Q#!YL,0$Q%<S@+)V=_<?N4,P/NN/D93G& L)&E.J
M:@@K9@-E7$H4$' Y#86[<A:UWRKZ8JT:!I&._F"8%/52US!1N!T@+@T>)#@C
M'JCW3ME%6UBHL\4[+RULBX7,-K_C$"^Y?)=!AG[FO9VJ/JSQ94,<+3H!^]3N
M-V;.[.-YZ4.D%S,,0<1-Q/WA1FNF ':S7P6-4VF=]XA=:7*<=UZM1'^TG<&.
MY2RK/,BY>;GZX4QEF,,0^JA!8R2B*-JG/ZB@N\,^2N9"Q;;M@:PH>L.#N,XD
M/N9:G"@1,/"=MGG;8N'C@ 6HKO]Y=Y10?!5._9F382=!CT?Y)^O@?X\'@U1K
MEUP8WZVXP?I2]/OVZN3%,KI6]^!V@(W_"#7CFH*Y?]Y&A<6N9Z*KT@)AK'2D
M J3H?:OU7P5@@J-@U88TBJQM !%9+ ''&I'Z+KD5.%RYH.CK1<6;R1T/Z2U/
MA'O&QR)A>(Q3M*B9$IA2M7E-;C3,F00,SAN?I+]/Q*^,4!4Q((Q5D5>\!55'
MYG!]7Z1C! UH(&PPV@PL@D4YLL@E^8@@1^2<:N5LK 0"//$M)Y!F<Z^)8;8;
M-:;J4>6*6ZM_ <V9W\,!YYW?&5]!K8OWL^6_1BL"#H<IJ#"P26U% )W"[?K3
MNIS>A7Z\RK0^P3I>QYL=;>^;/E\\NR.:W25N4^E9%#+TTZS4>'H=8?'T@#CC
M 9#J>?4F&W^N_V--AULIG2"E^@CI3?2X!_1BE'9%5B%<W6TF7HS"VF6T *J.
M_/$U[<M*F],7B94\3UE?;]_.^4^\.RLSXCG<M9"#7'7H M*J)D#.F,Y8W*P>
MU\4P5.FT?J+N+7+(-/^8128?W5)OY3$E&*HX@'HX#$@)OE515'JECLXO,(.#
M2]/SU$K?QOI<=EN"2]0QDPJ+LK<%LP>J\O8XC,9XB)?REW<F%SUGL]N7];2:
MI_R\EENSG#)X<VCCIV;@43$G>7Q<(&>:KHEBGTA1BEDRB:?9_)(B<&[&C>/W
MB&%)A?=B%<:_>++W9 _,W;7&A:PW+[M:;K,:P$$V3DN>&=I%#HKEG*!XO'V>
M71X(M?:>C7":UKC/X'XNXA5W(KA'1-5:L7@3IN&I[*AW1:OM+R]_LU;>X""Q
MS&,1,>]_#&.O)3++\2BSZEMU"Y@V2FUMNTOM?NGFA-*7.NZYHH8[E3IB.!-A
MW1C%$S RT5Y!;>][0JL^;VR,N@;%LF'K*TL@R)G(,5CS=. %'H<Y<]?N[MCZ
M@Q@(H-7$"I[3?'@^#-KW6.I2=B)1D^"0;.QN^$II98F%4J)W=%H"?ZS<"AHY
M(>\%0;DDI-#G_F,KJE%FDI@JPT/O8V7+I:Y"K+B/H.1D=U*'#SEV3O/2:\R;
M4UZ9Q;ZN(YT[L1<[Y*A<37J5P/2/=:)-3HG0=E%IN3$%A9ZC<81Z!880@/V%
M@S\'CX("A@C&(1+#@3[JBNS;V?9[ _YF"^5 SHN'*(9FV=R>I::R-I?[*JD-
M+8ML+H-L3(HGH*C+"4,_^=[I.J7;G:B!L5I+0L7#13#[MMT3 ?8R3S.6&QM
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M%O2UY?6[9]WWA_-9^.Z+_TE7*0WI@ZP$7W)E 9>O&GDG;8&OVS,+SSS^1#2
MS=]-.'W*Z/V#_K^TL]KD'FM-B#0]&]Q1\&2?VZYN.^[JK)TE\CGWB_6O$=(
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M1FY?X4>Z=RO:OB L6?CAMW'Y)]B"M;VAG1IHU1&8%VTNF.$5%.OPC*S^1K,
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M_L%)&BS6.!Z*>?.M)Q38T]GHOVE<XL#!4!M4_==^^\OT= %&4&N776#&HAE
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M'X*^KW O)YO#T>(EN(92BCF?P[*RV\$+$M&E7:TFJNF^?T.DA-_\=$KB]"^
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M:5/55C?CX^.J_(HEC[&II-S.@KP=D\T]G<:8ID<*D4<GTTV-2647N1R)-MM
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M]J1E3M,K)ZR\)1A\"'%'7*C&X5.[Y+(SK9 <.(@LMH^^P>_CTHL?-#@=].E
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M:#1KT">4XBD4D.]!GWMNI=JM9/6_AFSP;,*.[P:2O@U["RG_!:3AB_T)>O]
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M>YC6?0=6-1L.K+ZNW;9SIH;6S.KQB[,OYEO/JB()@Y9I*C6&!K3JVN1O3-(
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M8Y5DS/E@^62US@D7?6Q?C)\7^KOK1>@J63KH-<AI'GJZ=P+[MOWSR"3\YU]
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MR6IS^HQ&W9=RF]N]H#)KVK,9+LA*O'9P:IV9G*971T,SL<@VF'AGI5P=BW"
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M1.*3;G@"D2 #?(S.;"NKG80<S8<+BW\%L"1JVN^A?'BM=J4-,4**C\3D 3\
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MG4.E3P;\^>CDX*/B5'?M<AL$2K)B ;ENXS"04)Y;TDI(UR&A7_%R\8>4#$?
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M]C35EP_W;+&99VETE 4C&L^YU"%UK]_OTFP-!*%)(>/(&K1BA(%G@!^689P
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MGQGCDX=>^-&D+RF)-MC46RL+LU56-.']%(&E,4;'=N^"8X^'-+,P)7NCYH(
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M \#R&)^YCDU2$K[G:DO^3SO;6=:A"?8V'0!\/NQ:LD3>.U&4 (F:0^+["\M
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ME[@[N?3!>HBTJ#4249P"X.F.][3:XJ$]H@"%8TH#;J:P;DGUW%.>=! 6&=8
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M6UJ96W5H9,-/[J[-HF=@4XDLO7,%.K>4J=R!XQ3JQ2.JF7]4?MA4!EV;W0\
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M,C R-3$P,S$N:'1M4$L! A0#%     @ <(&66T4L&D2PG0$ :9<7 !$
M         ( !4.\$ &5N9VXM,C R-3$P,S$N>'-D4$L! A0#%     @ <(&6
M6P(=/\%R!P  PC   !$              ( !+XT& &5N9VXM97@Q,%\R,&(N
M:'1M4$L! A0#%     @ <(&66V)N_;PR20  Q$L" !               ( !
MT)0& &5N9VXM97@Q,%\S,BYH=&U02P$"% ,4    " !P@99;G];%VQX$  !_
M$   #P              @ $PW@8 96YG;BUE>#(S7S$N:'1M4$L! A0#%
M  @ <(&66Y8H@@ 0"@  1T4   \              ( !>^(& &5N9VXM97@S
M,5\Q+FAT;5!+ 0(4 Q0    ( '"!EEM%W\8[_PD  !1&   /
M  "  ;CL!@!E;F=N+65X,S%?,BYH=&U02P$"% ,4    " !P@99;^?,9KVL&
M   3*   #P              @ 'D]@8 96YG;BUE>#,R7S$N:'1M4$L! A0#
M%     @ <(&66Y$Z(3E9!@  LR8   \              ( !?/T& &5N9VXM
M97@S,E\R+FAT;5!+ 0(4 Q0    ( '"!EEO,X_><>DD! +F- 0 2
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M              "  07W$0!I;6<R,#DS,S0Q-3A?-"YJ<&=02P$"% ,4
M" !P@99;E0UZL;,D 0 H/ $ $@              @ %J.A, :6UG,C Y,S,T
M,34X7S4N:G!G4$L! A0#%     @ <(&66Y8/BIG[+P( +4L# !(
M     ( !35\4 &EM9S(P.3,S-#$U.%\V+FIP9U!+ 0(4 Q0    ( '"!EEN>
MMI050\    ,. 0 2              "  7B/%@!I;6<R,#DS,S0Q-3A?-RYJ
M<&=02P$"% ,4    " !P@99;9;_ND>%1 0"!I0$ $@              @ 'K
M3Q< :6UG,C Y,S,T,34X7S@N:G!G4$L! A0#%     @ <(&66UB?=FU5CP$
MC.X! !(              ( !_*$8 &EM9S(P.3,S-#$U.%\Y+FIP9U!+!08
1    %  4 .T$  "!,1H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>engn-20251031_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:engn="http://engene.com/20251031"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="engn-20251031.xsd" xlink:type="simple"/>
    <context id="C_8048b9df-5cd2-4254-af6b-1df01215dbd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_826585ba-14d9-4469-8a8b-c84065002806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_82ca66af-1e97-4ce0-adab-8cffb3acd9a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="C_836b6f28-be7d-407f-8a22-0e6733c24836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_8468fb01-e170-4276-bf5a-9ea3008dd3f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_84f13fed-94e2-4af5-bddf-2b0f45ef17c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-24</startDate>
            <endDate>2024-10-24</endDate>
        </period>
    </context>
    <context id="C_8544b2e4-4dc3-440f-a656-f66ca9b46e40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_8573ef68-8587-44b1-bc31-b24f597df0af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:OctoberPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_86803251-d047-4bf0-b674-339fac002c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_8871fa5a-72d5-4807-8b14-7d124187f1b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_8ab71810-5ab2-4406-b4d3-514255136390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_8ca9c3a9-bcfe-4cfc-b190-b23c7064bddd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:Personnel-RelatedExpensesExcludingStock-BasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_8ce99e1b-781b-4b10-a4a6-a47b653599c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_8d237d2e-9003-4d50-b804-e95a6312f01a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_8e9a0825-260c-4b9d-90b7-bbd7617e8f5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-10</startDate>
            <endDate>2025-06-10</endDate>
        </period>
    </context>
    <context id="C_8f043b0a-21ae-410c-ac96-0271d3d3046e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_8f0b12b1-19a7-4642-9e3e-cb3fe2551651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_90cd8c09-4769-4823-a74e-e5e1dd36b35a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_9100563f-205c-44c7-a60a-dd32fc052dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_923c8314-6767-44a6-8d7d-414375566f36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_92d33916-bf8e-4140-a042-722d297bdb9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_951877f3-5e88-4367-9785-1d7884a66f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_95a2beb8-4e85-43b1-85ca-fbc18197ebed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_95fa67fd-790e-4d1c-9cac-d33ccb8066a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_96d03257-9ff9-4103-bc83-b064b32da4cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:FebruaryPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_97729f6b-370e-489c-98a7-6180fbee0e8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_9960e19e-3a5b-4760-a0f1-d9b076862c9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_9a033399-2b58-4fe0-8140-e6817c28119b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_9de67a6b-db13-4cab-b973-3dc0f4942c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_9e49cbbf-65d1-430d-a687-9171f3246a39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:IfInterimMilestoneAchievedAndNoDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_9e58f68c-6bc3-4806-9dbe-08a741a6dfa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_9ea003c8-a81c-44b8-900c-b2493af5c02e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_a090e3b4-1166-4d45-b4d4-8b0b43e3f8be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_a09b14e7-c4ab-4158-8d7a-4c0301b562d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <instant>2025-12-18</instant>
        </period>
    </context>
    <context id="C_a36d4958-0132-4db6-8c04-a6c01658ba4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_a38b00d3-e24c-43b5-a082-589eacb61337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_a9579fc4-c897-4bed-9b7b-0b5cf457408f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:OtherResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_aa83e563-392e-4d71-8ae7-7474fd972847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202307Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_acdf9159-83c9-485f-9bd1-02cedfa90e00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_ad2092fb-95e1-4908-b08e-8b4a677329ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_adfc86f6-5602-4b1b-906a-2f27bffaaf91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_af41e941-f65b-47d2-8818-b19e36df5a05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_b0d9509d-2cde-4f1e-a69c-e980f066e66f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_b1f2b3cc-0e10-4b83-bbb6-a450052ce673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="C_b2244905-4cf1-4e70-8b70-8a3ec973f2f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_b291458d-545a-4cdc-a379-778ab2dd0485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:NewLaboratoryAndOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-29</startDate>
            <endDate>2022-12-29</endDate>
        </period>
    </context>
    <context id="C_b57c7e68-7206-43ef-83a4-48c2637e7914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_b6f75307-46d2-4549-9972-666e9421fcbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_b802882b-c5a1-4942-8e3c-1fdf4a877c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_ba0f02fb-b1f0-4954-bd4f-3c466d2899e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_ba4e1c8a-00ae-49f4-b36b-9c45988805ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="C_bb659fef-c385-43b9-827a-dd3a85171737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_bc0cb673-5025-437a-86f8-1e9fe06ad733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ClinicalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_bc14018d-5490-4aba-a323-a2e7f4fe2e46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_bd2cdf17-9066-447e-bbd3-00fa8ebfeb81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SeveranceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_c129c2c8-58f0-43f4-bfdf-85528ac931e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:TwoThousandTwentyFourPipeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <context id="C_c1ea2072-6521-49ac-9036-975bf2bea853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:PrefundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="C_c4f0786b-ed52-43c7-948c-f4930ac10dac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_c57bc36e-e49e-472f-83cd-c98e379c32e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-04</startDate>
            <endDate>2025-06-04</endDate>
        </period>
    </context>
    <context id="C_c587a04c-25a3-434a-9114-e2f1c6ee0c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_c67c0ca3-bd12-47e1-a7c3-cf98532f1504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_c7b8ec67-5b1d-4c7f-8db7-8e567d0d0440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_c882a3ef-859a-41a2-95d3-51394d6b2ce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ChemistryManufacturingAndControlsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_c9315aeb-75af-4e5d-b506-eb4a1ca94906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_c9ac9f07-169f-4b39-9e8b-20722b5214f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_cc2c96fa-b7dc-4174-82d2-d97b5a079517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <context id="C_cdad3c31-b6c0-4967-959f-1627e8533147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-20</instant>
        </period>
    </context>
    <context id="C_ce39e6a1-222d-49f4-96cc-9cfa2d2ac439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_cebd2d56-16f6-4436-b24a-6359ae1363a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_cf043049-d331-45c8-a6e7-85747599cf46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_d24afdca-87cb-498a-960f-4be785980006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:PhaseIiClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="C_d322beea-35fb-4c80-859d-02cabe66017a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_d39e4cc1-c2c2-436d-91fe-df2f1f3ae461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_d3a16e6c-5f2f-46a8-8d4a-ae4459f30236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="C_d4ba6974-9607-41bb-882a-98cb023fc12d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_d4f15817-44dd-435d-b9a9-e963c46bff1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_d6033e72-0f44-4d88-8b8a-64261e76903a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_d6039d83-bedb-4265-a5ba-09c0cc735a4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_d7356f23-a631-4161-bd89-54fd825f3f25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_d7458df2-05d3-41ab-b920-651c47e3645b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:TwoThousandTwentyFourPipeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-20</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="C_d8109dad-b66f-4bfb-8c04-ce50e140908e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_d8f4f613-565b-4dd9-9972-29f9286ff4a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_dbc9c096-5c22-4cf5-a894-96a9e588ee65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_dc6a75d1-5e14-43f3-bdf0-8a2ea5c1463f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_dcdfec87-2888-47ca-a07e-585d35c69c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:OtherResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_de15de3c-d6dd-474f-aedc-0db5998ec164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="C_df7d5361-4681-4e11-ba09-2fff4a273c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_dffdbdca-904e-4e8d-b739-fd381dc21a3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_e2f37cd3-8f14-4485-8a97-18812aba3d4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_e3642777-e12d-430b-aa3d-219b649d5144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_e3b821c4-4eac-43b3-bad5-9928776d4618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_e3f5dd26-8cbb-49ba-947e-3a9d2312c431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_e634a878-3df9-460e-9159-d57cc1cb247d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-12</startDate>
            <endDate>2025-11-12</endDate>
        </period>
    </context>
    <context id="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_e68a05ca-9f3e-4035-b30c-b74ee7a7e177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_e6e3703d-5475-4ccd-a165-b5039f0166a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="C_e78a052c-b146-43f0-82ed-460ee1b56df6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_e80bdb47-f7b3-430d-b4e8-f25af73e859c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_e82b042f-c2f1-4591-a95e-196afa1ab585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_e86be109-1a95-4196-ac55-bc2ba9ae5417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_ec456d2a-f968-4f6c-91e9-ceacc426a74d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_ee102497-2dad-4531-96db-ff24993a07fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-29</instant>
        </period>
    </context>
    <context id="C_f156578b-8f46-4ad0-9ea8-b91f1797eb52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_f3d38713-54b7-4d7a-9bcd-88b4b937d366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="C_f4a3d6cf-e574-4cf3-b8ec-df2947d5c514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_f61eb1b2-4019-491e-996a-2a8485634728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="C_f6c04b3e-ddf2-41e5-a4fa-0884f592b542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_f955235a-e265-4f5f-9d93-59b1d609f9ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_fb7a7ff2-f1d8-4421-8eee-75ddcf02c394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_fd0ed931-526b-4cfb-9b89-94003be94781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_fe08772b-3b75-4431-99b3-b2403219570c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_ff785c01-16ce-4fd0-b204-3fe21cdeca9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_ffb1bf69-b5a8-4516-998f-54b7ad557f99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_019c08b7-c82a-486b-871e-9cb94b318c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="C_0266c416-4b23-4071-88cb-dd6bf0a921ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:FebruaryPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_038fbf25-9506-4d27-be17-4dc097874279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_04e07ed1-3cb5-4c02-a2a7-c7099d04d3e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_07c65fa0-4265-4f70-956a-00de275d630a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_09e32747-b91f-4c21-a203-596a312a01af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_0a196932-bb45-4e51-825a-16dde720a445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_0aad8347-fb07-4df8-ad44-efd7872041dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-14</startDate>
            <endDate>2025-11-14</endDate>
        </period>
    </context>
    <context id="C_0df7a474-8310-4b5a-ad28-db5514624ad7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:Personnel-RelatedExpensesExcludingStock-BasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_0f0f9870-180f-4dd3-b9c4-ef3ac4ad5d5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:CeoTransitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="C_10beb209-82d9-44f1-a81c-c930ac6ffa93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:AdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_12fcc884-3c1c-47f6-a197-2a12844cafb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_138b2f29-e2e4-468e-a432-96f0a15a5f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_14c30e23-f14f-400e-a50e-517475df9be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_16b7f663-ad41-48cc-9a93-5b7ab3af3b3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_17444e1c-b04e-4b70-b7f4-f350e405d58b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_17725118-e54f-47d5-a64c-c3a544f8f924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_17b8691c-0499-4953-869d-643477e53cc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_1880048e-dcab-455d-8f72-b54f37487a7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheTwoToTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="C_19e56deb-53a4-4d6b-948d-09e6e90bcf8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_1ab78818-5433-4a11-a36e-d0983a8bfc04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="C_1bd63320-3f8c-40e8-870a-a2cdeaa9bc46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-24</startDate>
            <endDate>2024-10-24</endDate>
        </period>
    </context>
    <context id="C_1be15272-9b4f-4bcf-849e-53caedc2be78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_1ceadb8f-dcfe-48ff-a395-cc04ab63412f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_1d3671cc-d989-49b4-adba-e6701da4d6d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:ClinicalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_1d9d7d3f-3968-47f7-af7e-dd8b5291a3a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_1e0f6ec7-da3e-436f-8606-34f7da89269a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:RemainingSharesReservedForFutureIssuanceUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_1ebeba52-1c6c-4bb9-bc2f-7b693e857291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_1fee1be9-7dcb-46f6-91a8-e987b5b47b59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_222a5d6f-14cb-46e4-a552-efc82189402f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="C_223bc65f-a711-41ae-93e5-990ae4cc4647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-24</instant>
        </period>
    </context>
    <context id="C_230bfa79-c42e-4689-8d7a-7064e8c335b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:TwoZeroTwoThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="C_23618105-c2e5-4377-83d6-839699ff1b62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_240506c4-bcce-4242-904f-1aef27639793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_250a9087-119f-4c5b-bf49-75a14a4e74b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_2570dccd-3edb-4845-9c23-2fa20a3e119a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FirstAmendmentToAmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-18</instant>
        </period>
    </context>
    <context id="C_25b1651f-4d90-4142-812f-a565d3cf756e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-04</instant>
        </period>
    </context>
    <context id="C_25dc3fbd-7df8-4e6a-9735-4c158848064d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_2773bd89-2e98-4a47-a2e5-226327bcbdf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_27a237fa-2a01-4b32-b736-267804b23863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_2a5a88f1-1863-4ab1-bab0-60010f7bda59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_2cb23464-3212-4cf3-bba9-7c4d415c4691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_2d00fd55-c9ba-44ab-bd71-904d4195e08b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_2d71d180-d7f1-445c-a569-e1c8106caa03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_2e90c670-46cc-4848-9919-7cce02e258fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">engn:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:CeoTransitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="C_3039a78d-24dd-4c83-bbb1-043d190146b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_3070eb61-104a-40f8-be4c-373eeb3fdf18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_33a6f084-8206-471e-bfb2-2dda7584d4c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="C_342954c6-d213-4cd2-9889-aced7e8d67f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_3481de95-f470-4b1f-85d0-ee1e20db1594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_3538eb76-754e-4b90-b6ae-b9741667f639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_36a6765d-a768-434b-b6af-c19baebb16f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:InducementGrantStockOptionsAwardedOutsideTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_37f20ce2-0d85-4e2a-a443-1969a8e12178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_382606a1-c180-49e7-af1d-4f96fb9f4c5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_399413d5-87a5-4355-8641-293745be5095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_3a4ac89a-0177-4b3c-8437-70136929db99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_3b8bd64e-b59b-43a4-b1b4-0519c994f6b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">engn:HerculesCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:LoanAndSecurityAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_3fc74f8e-4433-476f-a81c-1803cf2f12f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:OctoberTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_4051c11c-5290-47d7-8e2a-b368974acadb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:IfInterimMilestoneAndCertainClinicalMilestonesAchievedAndNoDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_416f76a5-c88c-4d57-baa6-382632288e13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_41ba9c19-6515-43e0-a1fc-8f4d1b65dd7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:HerculesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_47a4d634-ac1f-4323-9bc5-0785480c857c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_47ffee90-525a-4d51-9a91-98932a653084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_496e94d8-a257-4d69-8ba6-932806871284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_4b5f63d4-ae44-4d1f-a429-c2500140c1cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheThreeAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_4d87523c-9b2c-422b-88ab-47f28876bac5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:FebruaryTwoThousandTwentyFourSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="C_4d915630-a09a-40c5-956c-ab23b902cf2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_4d97d0f0-4a5b-489c-b7d4-521214e77828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:PhaseIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-10</instant>
        </period>
    </context>
    <context id="C_4ff723b5-d287-434b-a696-ec3b9aa13f72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-10</instant>
        </period>
    </context>
    <context id="C_511e94d5-ac9c-4c2e-b367-c6033fb69299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-10</startDate>
            <endDate>2020-04-10</endDate>
        </period>
    </context>
    <context id="C_53d55f9a-d671-4a03-878e-e8d7b35cee90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:AppliedToRefinanceOfAmountOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:PriorLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_545b1b90-fd27-46b0-90e4-68a6f6ffcb9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_57ae8deb-9706-4aaa-ab1d-e9fc280a2c06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_585ec894-b0e7-4859-a0a7-ccf1f76d9512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_58c8e092-7276-4637-903f-b05e6860130b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:InducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_5cb5ff87-3b6e-4f62-bafd-e58f084904c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_5e0ae0ab-6ca4-4467-9077-b61b1010d728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-12</instant>
        </period>
    </context>
    <context id="C_6058051e-7700-494e-b243-9c348feb4b05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_60b37ed7-9421-4001-bbd1-89a359c2ed0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_60ed5f3c-1a4d-4713-9546-b4094d014309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:OctoberPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_60f8a68e-e8da-4f5f-bc60-1c69892ea749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_61fa00a4-8a04-41ad-8df5-3d8df9828b01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:HerculesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheOneAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_62b3a61d-efba-46df-bdeb-dd04f04c6a18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">engn:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_631df185-2355-4542-ae58-d1eaa9a937d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">engn:IncentiveOptionsToPurchaseCommonSharesAwardedPursuantToTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_6394b714-e543-43ff-9b1c-7ba9b8f9d298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_66290f5a-4ebf-4f73-b964-455cb62466aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_6691d0be-dbca-4238-ba0d-4650e328c889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_6dba0949-0813-4fe2-b9df-f3bd190796c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-20</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="C_6e273bec-7bf2-4681-92db-741ae2a453db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="engn:AcquirerAxis">engn:FEACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="C_6f8ba018-3c10-4168-9540-f591cd8fe57b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_6fbe3c27-7c74-4f39-a002-7cb3cad726bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">engn:SharesReservedForFutureIssuanceUnderTheTwoThousandAndTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_71db83b8-afac-440b-84f1-dbe6aa46e50c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">engn:PrefundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">engn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-12</instant>
        </period>
    </context>
    <context id="C_72b405e6-793c-4923-a2ac-fd5c62acce9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_72be055a-0ced-4c28-83d8-1cad15ae7d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_72c8df98-55d0-47ed-acec-68e231220cf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_737abaae-1e0c-4f1a-8b20-7c57ad401acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_7444e3af-f026-4566-9f7c-881accfccf6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_7460771b-4637-42ae-b87f-8329a24ece3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">engn:NewLaboratoryAndOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-29</instant>
        </period>
    </context>
    <context id="C_758f5c72-0590-42c1-b39e-5c9fb4eea3d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_762694e8-c941-454f-ac63-d2e9147b6e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_7a8c2031-7a18-435b-80ce-180a745a581b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">engn:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">engn:TrancheTwoAdvanceSubjectToAchievementOfSpecifiedInterimMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">engn:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_7edc548a-2b6b-40d9-9585-f8a98c0a4267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_7fc54fca-2826-4f40-b784-cb10a1e8ea92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">engn:EvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-02</startDate>
            <endDate>2025-01-02</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_CadPerSquareFoot">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>engn:Segment</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_CanadaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Security">
        <measure>engn:Security</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_5d4a56b9-586b-4e11-9716-233d70392133">0001980845</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b8e47dcb-27f6-41e0-8ad5-35e6889dd47e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_6888b176-5fbf-4c84-9d9c-07293e3092a4">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ca960d6e-e1b1-404e-8500-f1b61ab7daac">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_51d22804-f874-438b-aea4-8e8c33142b8a">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      id="F_19cbb428-9d40-4173-b963-b055e6ae20f0">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_6bb524eb-b790-45cf-97d6-d7746896ad6f">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      id="F_e95588c3-c714-4f9f-bfa1-4e84f1995499">http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      id="F_f4615be1-4ad1-4aa9-9576-91c98e5813d6">http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="C_09e32747-b91f-4c21-a203-596a312a01af"
      id="F_d4394cfa-9517-46fa-8508-88aeb275aaf2">http://engene.com/20251031#WallStreetJournalMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="C_09e32747-b91f-4c21-a203-596a312a01af"
      id="F_33e08b81-4198-434a-9055-c3013033bffd">http://engene.com/20251031#WallStreetJournalMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_0d8e6fbe-0e8d-48be-94c6-063543d24362">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      id="F_c36c748c-142e-4749-b840-fae3cd22d5a5">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <dei:DocumentType
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b05d0bf1-ffe0-4ddd-9149-8871c023e7cc">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_315db525-a1f8-4386-b8c3-c0217a52d495">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_25544cb0-53c4-4351-960f-75e51072ec1e">2025-10-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_a8758164-f9af-4abe-b353-7096b56093e1">--10-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_93dea500-b646-41ac-81e8-bcab7f7b7c21">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b4464762-2c51-46dc-9562-bb4241caf772">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_9a4684ec-ec2b-4624-9b9a-442dcf86cb29">001-41854</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_1995cff4-ed36-45fc-8da1-e1cbfd6e1069">enGene Holdings Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_c89c60ed-54bb-4b3f-930e-854249732900">4868 Rue Levy, Suite 220</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_8b6861f2-dfcf-4f97-92bc-45cb9c75f00c">Saint-Laurent</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_de9451e0-bf38-4dee-8341-27926551a4c7">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_5342f1c3-d3b8-43fb-8732-9ea306cef6cc">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_0828549b-6816-4878-87fb-ae2a2477f3cf">H4R 2P1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_5ce215e4-b0df-421f-8728-5ebf2f391ff9">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_fbefdb3d-ea59-4fd7-bfc9-dd7c239f5b02">332-4888</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_e78a052c-b146-43f0-82ed-460ee1b56df6"
      id="F_2ba35d0c-467e-4d72-9174-0bcf9c871e18">Common Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e78a052c-b146-43f0-82ed-460ee1b56df6"
      id="F_de99b655-0838-42b0-abd2-92fbbd9355c3">ENGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e78a052c-b146-43f0-82ed-460ee1b56df6"
      id="F_19fd1165-8d7a-47a8-9c7c-901a6ae8c972">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_c4f0786b-ed52-43c7-948c-f4930ac10dac"
      id="F_a2259443-accf-4595-86c1-cd3e1e3fc7b6">Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c4f0786b-ed52-43c7-948c-f4930ac10dac"
      id="F_48170895-0633-4144-a9df-c14508864b9f">ENGNW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c4f0786b-ed52-43c7-948c-f4930ac10dac"
      id="F_554844b6-e245-49ff-9164-8ef0ecbed571">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_3272508f-9578-4635-8332-80298eb88c75">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_324a7963-0136-45c8-bd94-22382b8e3e5c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ad753e47-d127-4bb2-b393-28e7e6775aa6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_2e04a339-217b-424a-a9ec-10679c6577d1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_06a2f29c-e308-4c2f-ac80-a5538574bc6e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_c1abd934-56d4-47b8-b7b6-09c9214deb00">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_23973fea-f278-4261-8d0c-0bb70a380ef1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_4f751e7e-af4a-4726-b388-dac04e22bf53">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_15a34eab-166b-4952-9d21-fd2cae5004fe">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_6b5c39a2-3a38-4390-bcb0-f4bd86276811">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_9f947ba7-8916-45ea-aae8-a95753f324e9">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_f61eb1b2-4019-491e-996a-2a8485634728"
      decimals="0"
      id="F_806985e9-4b95-42d5-b2ab-889a28cf3eda"
      unitRef="U_USD">154176366</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_a09b14e7-c4ab-4158-8d7a-4c0301b562d5"
      decimals="INF"
      id="F_31d023e9-2f07-45b1-83dc-6f551a5f477e"
      unitRef="U_shares">66984661</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_e656dccf-b2ce-4eed-9640-0bb3c961418c">&lt;p style="text-indent:2.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the definitive proxy statement of enGene Holdings Inc. to be filed for its 2026 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_cd890491-5e5d-415b-9d78-e398788d1fd3">85</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_61222556-1f80-4f77-8382-5e0265e8c5dd">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ac9b222f-a122-4d29-9531-a890966963d3">Montreal, Canada</dei:AuditorLocation>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_9bc462af-fb52-4370-ae8a-bbf37b046ba3">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented cybersecurity risk management procedures, in accordance with our risk profile and business size, that are designed to identify, assess, and mitigate risks from current and emerging cybersecurity threats. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity procedures, which are informed by the National Institute of Standards and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Technology cybersecurity framework, are supported by a third-party managed services provider that assists us in managing our IT systems.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks, and other related breaches.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity procedures are comprised of a variety of tools designed to protect our data and information technology systems, including but not limited to endpoint protection and network security measures, that are supported by our third-party service providers. We also have a process to require our employees to undergo cybersecurity awareness training. Further, we have implemented a process to review risks to our Company in connection with certain third-party providers and vendors, which involves assessments through vendor questionnaires, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, we have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party IT service providers and vendors have from time to time experienced threats that could affect our information or systems. For more information, see, &#x201c;Risk Factors,&#x201d; in this Annual Report.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Vice President,  IT reports to our Chief Financial Officer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our Board of Directors is informed oversight of our risk management process.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board of Directors does not have a standing risk management committee, and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee is responsible for overseeing the Company&#x2019;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; responsible&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for managing cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_91198544-053e-421a-8995-4ba19d532b2b">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_e653a0ee-437f-4b20-a206-6f343231e531">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_c28677e0-f174-4300-9361-736a407ab8f1">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_784bee8f-3b31-4262-a54d-dedcc96db76e">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our Vice President,  IT reports to our Chief Financial Officer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our Board of Directors is informed oversight of our risk management process.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board of Directors does not have a standing risk management committee, and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee is responsible for overseeing the Company&#x2019;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; responsible&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for managing cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ab96fb10-2786-48e7-8403-a00119adb28e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity program is managed and directed by our Vice President, Information Technology, or IT, who has approximately 20 years of experience in information technology and information systems management.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_9a6c7f00-00df-4340-9cf5-609482187412">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our Board of Directors is informed oversight of our risk management process.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board of Directors does not have a standing risk management committee, and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_bed5dde7-8caf-4a02-82e7-3efd725c0d7b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our Board of Directors is informed oversight of our risk management process.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_9b9cb85b-0ac4-4be6-a60b-51b350bfc8ff">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board of Directors does not have a standing risk management committee, and&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; administers this oversight function both directly as a whole, and through various standing committees that address risks inherent in their respective areas of oversight.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee is responsible for overseeing the Company&#x2019;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_c8cd0c53-e25a-4a89-82f5-545f87e4ee83">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_f2eec362-240f-4294-908c-7f28d53ea6ae">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee is responsible for overseeing the Company&#x2019;s enterprise risk management processes as well as our policies with respect to risk assessment and risk management, which includes cybersecurity risk.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_9512552f-4712-40e7-a090-feaa1dc3b0cf">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_868d1a64-427c-40cb-b854-497f9b70d864">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A cybersecurity update is provided at least annually, or more frequently as needed, to the Audit Committee by members of management&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; responsible&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for managing cybersecurity risks.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f"
      id="F_1e2a3559-0df4-430c-90b6-7394d12f9085">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f"
      id="F_a9441941-51de-4e00-bbcd-5fcfe0e5a1bf">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f"
      id="F_bc7fa81d-21e9-4501-80af-535187f87fd3">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_ea1a08f1-cffb-4e69-9591-d8da6e2a502f"
      id="F_68db896a-6347-4862-a1d8-26e1b7479960">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorOpinionTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_28d94ea8-1080-4bb1-8c41-6cdfe6384a5a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Consolidated Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of enGene Holdings Inc. (the Company) as of October 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders&#x2019; equity, and cash flows for each of the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_78dacc63-a09e-42ad-b680-aa863b1b5633"
      unitRef="U_USD">50152000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_19d2a431-5b3e-4cf8-8788-b031dee5d766"
      unitRef="U_USD">173004000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_fde71be8-9ba6-4e4f-8448-f0e71b8dea6c"
      unitRef="U_USD">143584000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_70b380da-2bfc-4b5b-b8eb-23e99739d63e"
      unitRef="U_USD">65328000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedInvestments
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_9564da49-c643-417e-82b9-0c8a600e55f2"
      unitRef="U_USD">79000</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_0e382171-b4e4-498e-bbe0-12934e898ec7"
      unitRef="U_USD">72000</us-gaap:RestrictedInvestments>
    <engn:InvestmentTaxCreditsReceivable
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_5d18c391-3d2f-4992-9d76-26eae0a724ee"
      unitRef="U_USD">927000</engn:InvestmentTaxCreditsReceivable>
    <engn:InvestmentTaxCreditsReceivable
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_5a9f9520-cd60-4e1d-9a4b-528df4c68009"
      unitRef="U_USD">332000</engn:InvestmentTaxCreditsReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_ae15e74f-d7ab-4cce-93d0-82683a90a6b3"
      unitRef="U_USD">6649000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_969124eb-755f-4688-83b0-562c6101225f"
      unitRef="U_USD">8626000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_5adccdec-1077-4751-b1bd-c5e3d2749046"
      unitRef="U_USD">201391000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_e4c25eea-cfc8-4be0-b14b-c50eb2f62be2"
      unitRef="U_USD">247362000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_663533e9-3f76-4058-9f65-d0f91f23acda"
      unitRef="U_USD">8522000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_79943bff-0b80-4bc1-8c57-10ddd7784e65"
      unitRef="U_USD">59527000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_913a5b44-f53a-4268-a780-04a114cb25fd"
      unitRef="U_USD">2477000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_9ef1bc90-4385-45cd-aa8f-7184724a2ca6"
      unitRef="U_USD">1169000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_6cf6ec85-f8ec-481f-8bbe-1730dd8a5676"
      unitRef="U_USD">7716000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_bc796bd2-2118-4cef-ba0c-57fff29afe71"
      unitRef="U_USD">1741000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_1687a059-83ab-44b7-b22f-c90bc7bbac66"
      unitRef="U_USD">1362000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_06372059-ecf7-45ed-853f-31e003c6b2a0"
      unitRef="U_USD">1374000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_95c925ab-e047-4ee4-968c-ba9c4dbf11c5"
      unitRef="U_USD">221468000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_690076e3-0689-4c8c-9ecb-249ee9ce9d67"
      unitRef="U_USD">311173000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_7722a732-b1fc-4222-99ec-d3d16f2aab94"
      unitRef="U_USD">6688000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_39d382e5-0836-4020-a585-d356084683ea"
      unitRef="U_USD">1411000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_65a9bc2f-90ac-443c-b460-3e51d86f1d5a"
      unitRef="U_USD">15275000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_db7ed336-9321-4635-ab0c-44a4994cc694"
      unitRef="U_USD">12128000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_e38ac593-0601-42b4-85cb-98ae15a6280d"
      unitRef="U_USD">2014000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_d7f49625-5d7f-4e79-8f33-10541ebac026"
      unitRef="U_USD">423000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_51d0b15b-bead-446a-91ec-c8818a6e1bff"
      unitRef="U_USD">8002000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_fcd064f8-1c17-41b8-bd2c-727317de8eaa"
      unitRef="U_USD">699000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_6d450460-89fe-4cbd-b812-bc4cbeab64db"
      unitRef="U_USD">31979000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_a7029862-3cff-415c-b6a0-23926ddbc5cb"
      unitRef="U_USD">14661000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_3562fbd6-4916-467a-a055-e1854df538d0"
      unitRef="U_USD">15324000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_54c60e9a-6913-49d2-bee0-36ba1efe7436"
      unitRef="U_USD">22473000</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_dbcd5ca4-593b-46a7-a17f-cc1f204c526c"
      unitRef="U_USD">6455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_2bd4137d-232e-4081-a335-590701d8b2f9"
      unitRef="U_USD">1427000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_1371660e-f510-48cc-83a0-ae19ccc324f6"
      unitRef="U_USD">53758000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_ffd8a399-dd67-4c5a-8a73-211df46d53aa"
      unitRef="U_USD">38561000</us-gaap:Liabilities>
    <us-gaap:CommonStockNoParValue
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_866ce0b1-4a32-48ea-81c5-385f22923b8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_811619bf-07b4-4f83-a079-b8de67ebe54e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_8090ca60-4d2d-4870-8c51-fa2862d9d2e8"
      unitRef="U_shares">52018658</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_35428661-28da-4562-9dd1-51f80bb1ef1b"
      unitRef="U_shares">52018658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_2811be0a-dc5d-4ce6-b1d3-ff31a8a58223"
      unitRef="U_shares">50976676</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_fe506b86-ccc8-47f7-b2c9-15f5c7811eca"
      unitRef="U_shares">50976676</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_d8e9bc43-6318-48da-b24f-6b9c487ada87"
      unitRef="U_USD">513281000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_aa4cc177-42c1-412f-9dec-81154c77112a"
      unitRef="U_USD">509811000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_fb20a01c-05d8-4b06-8dd9-8004578e787a"
      unitRef="U_USD">27349000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_3adb0a43-9092-4c0d-a77f-70d1185439ab"
      unitRef="U_USD">18950000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_1cd01748-56d5-4dc5-9a54-933eaa361172"
      unitRef="U_USD">-888000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_f2b97aa7-b36b-43f8-9d5d-f6ba2c0e4ca5"
      unitRef="U_USD">-1419000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_31001fcb-0401-44c4-a92f-6730d99f54c9"
      unitRef="U_USD">-372032000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_e1172526-0a10-4da2-b418-8eeb1a0b39e4"
      unitRef="U_USD">-254730000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_4658a729-fb1a-4e11-865a-39c1c1969d0b"
      unitRef="U_USD">167710000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_d0e9d210-1e79-4393-b3c9-898e33cac629"
      unitRef="U_USD">272612000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_0b5fe477-0728-4a1f-b0fc-377887d34510"
      unitRef="U_USD">221468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_aee81a67-075b-4306-b29b-9cb7eb9a8415"
      unitRef="U_USD">311173000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_b24cb9ed-69de-4201-ba21-68e6be99b589"
      unitRef="U_USD">94480000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_ebebb52d-8fdc-412c-b058-f738e0ce8c7e"
      unitRef="U_USD">38315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_da768e01-14ec-4f5f-a193-215c86f473b3"
      unitRef="U_USD">28685000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_566dcfad-c9cb-45c6-a5c7-48ff02ec8cd2"
      unitRef="U_USD">23982000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_fe0a945d-2f89-4c79-94e8-4e61f501dd73"
      unitRef="U_USD">123165000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_19198112-1a94-4ae5-9859-af3125154f19"
      unitRef="U_USD">62297000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_2d280e82-45f9-46cb-ba16-c06e4b7a2f0a"
      unitRef="U_USD">-123165000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_c2894348-d920-45b2-8e77-64ead832f8f1"
      unitRef="U_USD">-62297000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_62ff4948-b69f-4c97-be7e-05aa8abd2872"
      unitRef="U_USD">9426000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_49240a54-d6f1-4c07-b265-86613a92474d"
      unitRef="U_USD">10413000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_b371d423-8fd6-4e13-945e-1c760318a198"
      unitRef="U_USD">2994000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_fe05804d-3865-4335-803c-5a8a76de9b6d"
      unitRef="U_USD">2798000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_8e7f8ac5-6214-4bb8-b46b-20e3db5448ef"
      unitRef="U_USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_0f7b7ecf-189f-4876-a148-39615a94076e"
      unitRef="U_USD">-366000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_d7dd9f9e-4f5d-45d1-b399-a12c1a45f94a"
      unitRef="U_USD">-569000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_8350d046-4266-47e8-bd8b-be94eaf6d43b"
      unitRef="U_USD">-113000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_916edc97-3e40-40c5-bc79-9437f14ff192"
      unitRef="U_USD">5863000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_0de0671a-04ac-4555-888a-2f33389bf3b0"
      unitRef="U_USD">7136000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_2c2f242a-3289-4ae9-b6ed-6e8cfde9846b"
      unitRef="U_USD">-117302000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_4f5463b0-d7bc-4c55-ab66-337de540060e"
      unitRef="U_USD">-55161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_817bb8fa-1414-4096-a90f-5af97bdcb260"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_3ce6b088-3e29-420a-905d-deeb34bf8faa"
      unitRef="U_USD">-19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_0ba40860-a2fc-4d12-9c41-7a16e19c10a3"
      unitRef="U_USD">-117302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_4e724b10-7936-4ef7-b907-4b74a7f3a361"
      unitRef="U_USD">-55142000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_4b0e2a17-d0e1-419d-80e3-2fd8abc751bb"
      unitRef="U_USD">531000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_d619159b-3fa2-4561-b731-decee39324c4"
      unitRef="U_USD">403000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_e0df746e-295f-4867-bb86-f3a242342003"
      unitRef="U_USD">-116771000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_69ade8e3-19ec-48db-8a05-4d3406e55c7c"
      unitRef="U_USD">-54739000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_6bda413f-8551-4b43-adac-69b4d751c666"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_ae861c53-3516-4d25-baca-880381ed09d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="2"
      id="F_63d65ae9-03da-4e7c-b090-66fbcc589546"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="2"
      id="F_bff533af-96e4-415d-881d-c538799832c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_5f9c2f34-f2a6-4aa9-a375-0c9afdea57fe"
      unitRef="U_shares">51119479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_741d1d3e-4cec-4a5a-8a96-a534a4ecf79a"
      unitRef="U_shares">51119479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_c711fa68-195d-42e2-9077-a703f0ebd8d1"
      unitRef="U_shares">37782346</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_4953149d-7606-4dfa-8c03-71c83c81e4df"
      unitRef="U_shares">37782346</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_6691d0be-dbca-4238-ba0d-4650e328c889"
      decimals="INF"
      id="F_1fbe8d30-daab-49bd-b0be-5630c0cfca6d"
      unitRef="U_shares">23197976</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6691d0be-dbca-4238-ba0d-4650e328c889"
      decimals="-3"
      id="F_5c59bc29-f5d3-4ab9-bc3d-ad501f646f55"
      unitRef="U_USD">259373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_df7d5361-4681-4e11-ba09-2fff4a273c7b"
      decimals="-3"
      id="F_9d2b7157-833c-4ed5-b205-72699e648117"
      unitRef="U_USD">13717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_382606a1-c180-49e7-af1d-4f96fb9f4c5f"
      decimals="-3"
      id="F_5149349f-e8c2-4d05-921e-930e5b8d76c9"
      unitRef="U_USD">-1016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ebeba52-1c6c-4bb9-bc2f-7b693e857291"
      decimals="-3"
      id="F_3734487a-79df-44c8-b4ac-6f03785d7d9b"
      unitRef="U_USD">-199588000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_86803251-d047-4bf0-b674-339fac002c30"
      decimals="-3"
      id="F_e37b54d9-d5bb-42f9-bd34-2fd8b6b77179"
      unitRef="U_USD">72486000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f"
      decimals="INF"
      id="F_3128dec0-ef1a-48e4-a7af-d2f2a11d0ee4"
      unitRef="U_shares">116752</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f"
      decimals="-3"
      id="F_25a917ed-58f0-4ed9-82b3-e50fd6c93447"
      unitRef="U_USD">295000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c"
      decimals="-3"
      id="F_c0ac69f8-c295-40c0-9ef7-5cec2bb2b186"
      unitRef="U_USD">-182000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_be7f9dd9-154d-403c-90ac-957d4083621f"
      unitRef="U_USD">113000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c"
      decimals="-3"
      id="F_cf8c091d-ec57-40c3-bcff-30e455073867"
      unitRef="U_USD">5324000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_2f4d8da6-8e01-41ff-b1c9-2a5e313830ce"
      unitRef="U_USD">5324000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingShares
      contextRef="C_96d03257-9ff9-4103-bc83-b064b32da4cf"
      decimals="INF"
      id="F_5d62c2e2-964a-4722-92dc-5051c41ec358"
      unitRef="U_shares">20000000</engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingShares>
    <engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue
      contextRef="C_96d03257-9ff9-4103-bc83-b064b32da4cf"
      decimals="-3"
      id="F_402fc750-9a9f-4ae4-a002-71991e69c80d"
      unitRef="U_USD">187614000</engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue>
    <engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue
      contextRef="C_0266c416-4b23-4071-88cb-dd6bf0a921ee"
      decimals="-3"
      id="F_e7c81919-9373-4ca9-a7a1-b0111eb1056b"
      unitRef="U_USD">187614000</engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue>
    <engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingShares
      contextRef="C_60ed5f3c-1a4d-4713-9546-b4094d014309"
      decimals="INF"
      id="F_c6a5eb1f-ed9b-4e82-9fc7-fcc1e68178f9"
      unitRef="U_shares">6758311</engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingShares>
    <engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue
      contextRef="C_60ed5f3c-1a4d-4713-9546-b4094d014309"
      decimals="-3"
      id="F_a7c9f0a1-3fa0-4846-9e84-83995cde0698"
      unitRef="U_USD">56318000</engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue>
    <engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue
      contextRef="C_8573ef68-8587-44b1-bc31-b24f597df0af"
      decimals="-3"
      id="F_c997d822-c321-4df6-afe0-40bb636265bf"
      unitRef="U_USD">56318000</engn:IssuanceOfCommonSharesInConnectionWithPipeFinancingValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c"
      decimals="-3"
      id="F_71022b05-4171-4815-9f17-c09ca3e8c8a5"
      unitRef="U_USD">319000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_0978732d-c5de-4181-9047-978a875c3927"
      unitRef="U_USD">319000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <engn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f"
      decimals="INF"
      id="F_a9d52324-750f-49ca-b743-149e169c27b8"
      unitRef="U_shares">520282</engn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <engn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f"
      decimals="-3"
      id="F_e9ba84ea-fea6-4a36-b2be-8e8a596ba2f9"
      unitRef="U_USD">6114000</engn:StockIssuedDuringPeriodValueWarrantsExercised>
    <engn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c"
      decimals="-3"
      id="F_d50efd93-29a1-4122-841d-18e0c2f91ccc"
      unitRef="U_USD">-131000</engn:StockIssuedDuringPeriodValueWarrantsExercised>
    <engn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_3fb9d518-e88d-436e-832a-60f0f22b0443"
      unitRef="U_USD">5983000</engn:StockIssuedDuringPeriodValueWarrantsExercised>
    <engn:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f"
      decimals="INF"
      id="F_a1aee10d-ee8e-4002-a703-496fe46d7884"
      unitRef="U_shares">383355</engn:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <engn:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="C_762694e8-c941-454f-ac63-d2e9147b6e1f"
      decimals="-3"
      id="F_bae644b1-2553-4b49-9167-1c92cda141bd"
      unitRef="U_USD">97000</engn:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <engn:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="C_a36d4958-0132-4db6-8c04-a6c01658ba4c"
      decimals="-3"
      id="F_0fc3139c-5bee-4f2a-b2c6-129906f58f60"
      unitRef="U_USD">-97000</engn:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_ffb1bf69-b5a8-4516-998f-54b7ad557f99"
      decimals="-3"
      id="F_79c6dd72-cdc6-46be-864f-e675cf0b300a"
      unitRef="U_USD">-403000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_4d569f02-42fd-4c79-8a14-3a22388a1885"
      unitRef="U_USD">-403000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_c9315aeb-75af-4e5d-b506-eb4a1ca94906"
      decimals="-3"
      id="F_850e2f3f-6a19-4dd5-ade0-cee3426d68ed"
      unitRef="U_USD">-55142000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_c777e56b-b339-4b1b-b1a2-c5ff31c1ebd0"
      unitRef="U_USD">-55142000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_cf043049-d331-45c8-a6e7-85747599cf46"
      decimals="INF"
      id="F_6d625301-a999-4939-a4c6-cfe505fe2c10"
      unitRef="U_shares">50976676</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cf043049-d331-45c8-a6e7-85747599cf46"
      decimals="-3"
      id="F_b32932b6-decc-4c43-a041-8abafc586f4b"
      unitRef="U_USD">509811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_72b405e6-793c-4923-a2ac-fd5c62acce9f"
      decimals="-3"
      id="F_cca0ecb1-628e-4017-911f-171af265c589"
      unitRef="U_USD">18950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2d00fd55-c9ba-44ab-bd71-904d4195e08b"
      decimals="-3"
      id="F_b19c9388-838b-4b0d-b849-9b3a8d47bc39"
      unitRef="U_USD">-1419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_545b1b90-fd27-46b0-90e4-68a6f6ffcb9d"
      decimals="-3"
      id="F_54148e02-de3b-42a1-979b-9b8c21a9f7e9"
      unitRef="U_USD">-254730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_0da0d58d-ee91-469a-8ad0-3e58ae0e57d5"
      unitRef="U_USD">272612000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8ab71810-5ab2-4406-b4d3-514255136390"
      decimals="INF"
      id="F_56a5d35e-ca83-4c80-9afc-169a1a0e4da5"
      unitRef="U_shares">1041982</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_8ab71810-5ab2-4406-b4d3-514255136390"
      decimals="-3"
      id="F_c9c87ad9-d2ea-40e7-98f1-64852b8652f6"
      unitRef="U_USD">3470000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c67c0ca3-bd12-47e1-a7c3-cf98532f1504"
      decimals="-3"
      id="F_be0c9bf4-6d1a-4caa-bc57-91c35f98fdb3"
      unitRef="U_USD">-1247000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_12d9e60e-c4af-4c45-b918-00875a477a67"
      unitRef="U_USD">2223000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_c67c0ca3-bd12-47e1-a7c3-cf98532f1504"
      decimals="-3"
      id="F_9aed49b3-bf50-42ca-bd3c-57d402fe3c8b"
      unitRef="U_USD">9646000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_eebdded7-ada9-44dc-8e53-fdd55d18d5f2"
      unitRef="U_USD">9646000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_97729f6b-370e-489c-98a7-6180fbee0e8f"
      decimals="-3"
      id="F_0a63b40b-1e4c-4cee-bb7a-6820312b4a0c"
      unitRef="U_USD">531000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_1547eeac-7d4d-4d2b-80e9-44f7ee3fe3e9"
      unitRef="U_USD">531000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_bd2cdf17-9066-447e-bbd3-00fa8ebfeb81"
      decimals="-3"
      id="F_dca133d4-2a57-4910-921d-ebad3977e201"
      unitRef="U_USD">-117302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_871d56e8-bfd7-46f3-bf69-faa403f0480a"
      unitRef="U_USD">-117302000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_758f5c72-0590-42c1-b39e-5c9fb4eea3d9"
      decimals="INF"
      id="F_d93aff8d-64d5-4047-8214-0567d4398019"
      unitRef="U_shares">52018658</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_758f5c72-0590-42c1-b39e-5c9fb4eea3d9"
      decimals="-3"
      id="F_e910b6b5-b077-4cbb-b98b-6c88c2aa3113"
      unitRef="U_USD">513281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2773bd89-2e98-4a47-a2e5-226327bcbdf3"
      decimals="-3"
      id="F_66ac4be2-a112-4fe5-919b-ac745077c545"
      unitRef="U_USD">27349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ff785c01-16ce-4fd0-b204-3fe21cdeca9f"
      decimals="-3"
      id="F_f1e43f5b-4f89-4c40-a80f-a15f6bf8c745"
      unitRef="U_USD">-888000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_27a237fa-2a01-4b32-b736-267804b23863"
      decimals="-3"
      id="F_a7dc2c65-703a-4b40-a3a1-2cb433a0c0c8"
      unitRef="U_USD">-372032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_e15411a8-2ba0-4d62-8ab9-be1a9cf44914"
      unitRef="U_USD">167710000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_5a491815-c878-4311-af7f-b88897ae9743"
      unitRef="U_USD">-117302000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_2c952f03-f12b-4b8b-a6ac-59158223c375"
      unitRef="U_USD">-55142000</us-gaap:ProfitLoss>
    <engn:NonCashInterestExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_baabcdf0-186d-4f5b-a666-6187d0a7588a"
      unitRef="U_USD">854000</engn:NonCashInterestExpense>
    <engn:NonCashInterestExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_3102dc10-3e6c-4eaf-8cfb-e877ae8e20fd"
      unitRef="U_USD">806000</engn:NonCashInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_f0640d5a-ff95-4e70-9a1b-bd2ec26477ed"
      unitRef="U_USD">-366000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <engn:NonCashLeaseExpenses
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_6374327b-af1e-4bbb-be1a-e3e6b7d3d79d"
      unitRef="U_USD">-378000</engn:NonCashLeaseExpenses>
    <engn:NonCashLeaseExpenses
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_30ca0058-112a-4b51-925b-3f2cbd20020f"
      unitRef="U_USD">-163000</engn:NonCashLeaseExpenses>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_fe6439f8-b44d-433f-8f63-88ee6e428614"
      unitRef="U_USD">-22000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <engn:NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_79c07900-9619-405e-8c9a-88eee3e2a63f"
      unitRef="U_USD">-3067000</engn:NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities>
    <engn:NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_3424a450-974e-46c0-84db-ce64f47c25c7"
      unitRef="U_USD">-232000</engn:NetAmortizationOfPremiumsAccretionOfDiscountsOnMarketableSecurities>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_a03f1b71-a53a-4ea5-9abf-e6d23e078690"
      unitRef="U_USD">-3000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_f89ef982-b2de-491c-be0b-8c34d82a55fc"
      unitRef="U_USD">6000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_a47d2504-3616-465d-b13d-fe9fd9309fc0"
      unitRef="U_USD">9646000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_8cfa3b8b-917d-4eee-b3ac-bc7b65698d87"
      unitRef="U_USD">5324000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_87d9522b-c801-4fca-a553-29af9604e60b"
      unitRef="U_USD">509000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_94dcc7c0-a2c0-4906-9e43-e5eb629d38e3"
      unitRef="U_USD">323000</us-gaap:Depreciation>
    <engn:IncreaseDecreaseInInvestmentTaxCreditReceivable
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_1fbb2416-7d64-4730-836d-efc94b7f6c10"
      unitRef="U_USD">595000</engn:IncreaseDecreaseInInvestmentTaxCreditReceivable>
    <engn:IncreaseDecreaseInInvestmentTaxCreditReceivable
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_30769e06-d241-4b71-ab67-446058962aa1"
      unitRef="U_USD">-2011000</engn:IncreaseDecreaseInInvestmentTaxCreditReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_e6ac0456-7594-484b-8750-fa0ece2d4526"
      unitRef="U_USD">-1989000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_f22df02c-2444-4f91-b60f-d9c74beb025f"
      unitRef="U_USD">7566000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_c4c6a876-2844-4bde-b19b-c8b93f79dc03"
      unitRef="U_USD">4942000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_6128b3aa-52be-4c15-9e9f-5e7ac1f7dd3c"
      unitRef="U_USD">474000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_4e1693b4-da51-48e2-95fe-6aed178044eb"
      unitRef="U_USD">3130000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_71f80481-5a98-47a4-9fd9-cbd838937d03"
      unitRef="U_USD">5225000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_a407916c-3792-4f30-8a44-452da85169fa"
      unitRef="U_USD">274000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_63addfdb-2f86-493b-bed8-0a7635af56e6"
      unitRef="U_USD">-49000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_fd39c192-bc68-4564-a1d7-5fb06a44ec4d"
      unitRef="U_USD">-99239000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_be3cfb6e-b4d9-4d44-9ca2-72ae339432df"
      unitRef="U_USD">-48281000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_24888f05-f3c6-4cf3-a80e-f0e28a7021d5"
      unitRef="U_USD">1485000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_4b28a6c4-90d3-4e60-9c0d-dbb551409432"
      unitRef="U_USD">925000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_f8fc8ed9-18d0-44bb-b8fd-0260b5d19471"
      unitRef="U_USD">160843000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_af5e08a9-9de5-49fc-8565-7eb41ac81c65"
      unitRef="U_USD">125028000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_827eb1fb-440a-4eed-ab56-52fa25caa54a"
      unitRef="U_USD">137190000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_3706e1f4-168b-41e4-a3cd-3c1e1269b548"
      unitRef="U_USD">-25138000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_d7a103fa-b642-499d-b2ab-a80acec20ff4"
      unitRef="U_USD">-125953000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <engn:PaymentOfReverseRecapitalizationAndPipeFinancingCosts
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_4db88bad-812f-43da-aff4-136a4dc74ede"
      unitRef="U_USD">613000</engn:PaymentOfReverseRecapitalizationAndPipeFinancingCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_a7bb3b84-88fb-499c-aecc-d99fc9413a4e"
      unitRef="U_USD">260149000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <engn:PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_6fdc47d2-bd07-440b-9931-87f731fa4589"
      unitRef="U_USD">12386000</engn:PaymentsOfIssuanceCostsAssociatedWithThePipeFinancing>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_cd774ff4-73ad-46c4-976d-e160bc634a9a"
      unitRef="U_USD">5983000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_4689a3e6-b994-402e-a1cd-b8dbe35c9214"
      unitRef="U_USD">2223000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_1cc20a48-fd95-477f-93dd-de25512847a9"
      unitRef="U_USD">113000</us-gaap:ProceedsFromStockOptionsExercised>
    <engn:RepaymentsOfTermLoanPrincipal
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_5977c7c9-f009-4677-abde-c4459e8c94f6"
      unitRef="U_USD">699000</engn:RepaymentsOfTermLoanPrincipal>
    <engn:RepaymentsOfTermLoanPrincipal
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_bd98944f-5aca-4b82-8136-b58f07dc861c"
      unitRef="U_USD">9445000</engn:RepaymentsOfTermLoanPrincipal>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_5d9f20ad-6587-43af-b6c6-fdb53d69fa8e"
      unitRef="U_USD">22500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_a3bfad08-2d87-4575-bfca-b8923547299e"
      unitRef="U_USD">585000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_840167cc-d242-4daa-8fcb-8f9b49189379"
      unitRef="U_USD">1524000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_399f0ebb-ee09-4afb-8c1d-d135729fc965"
      unitRef="U_USD">265716000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_93da665b-61c2-45f6-bba7-7eac6e17a0aa"
      unitRef="U_USD">1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_1598c306-3539-4dd5-aaf3-99a8bbde63c1"
      unitRef="U_USD">1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_aa37d81b-5ad8-4422-a2d7-3a891dc18dd8"
      unitRef="U_USD">-122852000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_86137dc6-3b7f-4008-87da-56f5ef487ad9"
      unitRef="U_USD">91483000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_b42b5f39-7f80-404b-ba0c-3d9cfd6936b1"
      unitRef="U_USD">173004000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_86803251-d047-4bf0-b674-339fac002c30"
      decimals="-3"
      id="F_5f29052f-5185-45dc-9ed6-6f891bf6531f"
      unitRef="U_USD">81521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_b86e7e6c-e8cc-4693-a4f9-b5cd1db9c2db"
      unitRef="U_USD">50152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_128fba2c-427e-45dc-ab6d-443640a01f4c"
      unitRef="U_USD">173004000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_464492c6-aeea-4016-9ae9-3a57aa0ecda4"
      unitRef="U_USD">2289000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_2c62ce29-fedb-4860-8e9a-f498102db600"
      unitRef="U_USD">1925000</us-gaap:InterestPaidNet>
    <engn:ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_9ddd3b04-5339-4cb3-891c-e157598b0392"
      unitRef="U_USD">3831000</engn:ReverseRecapitalizationAndPipeFinancingTransactionCostsIncludedWithinAccruedExpensesAndAccountsPayable>
    <engn:WarrantValueIssuedAsPartOfAmendedTermLoan
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_f7c4dc80-39ed-439e-b233-7c937d2ca47d"
      unitRef="U_USD">319000</engn:WarrantValueIssuedAsPartOfAmendedTermLoan>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_d865f176-79ec-4d29-a437-0590f272636f"
      unitRef="U_USD">6352000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_349609ba-7a59-4518-a689-3fbfb1e193cd"
      unitRef="U_USD">1904000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_73aab4b1-0e2c-40ee-ada5-af4a792e8b1e"
      unitRef="U_USD">332000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_5ab49f1f-c782-4bdd-a400-727704fd5b59">&lt;p id="notes_to_the_financial_statements" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;enGene Holdings Inc., together with its consolidated subsidiaries enGene Inc. and enGene USA, Inc. (&#x201c;enGene&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company focused on developing genetic medicines to improve the lives of patients, and its head office is located in Montreal, Quebec, Canada. The Company is developing non-viral genetic medicines based on its novel and proprietary dually derived chitosan, or &#x201c;DDX&#x201d;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Merger with Forbion European Acquisition Corp.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Forbion European Acquisition Corporation (&#x201c;FEAC&#x201d;) was a special purpose acquisition company (&#x201c;SPAC&#x201d;) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more business or entities. On October 31, 2023 (the &#x201c;Closing Date&#x201d;), the Company, FEAC, and enGene Inc., consummated the merger (the &#x201c;Reverse Recapitalization&#x201d;) pursuant to a business combination agreement, dated as of May 16, 2023 (the &#x201c;Merger Agreement&#x201d;). As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its Common Shares and warrants on the Nasdaq Capital Market under the symbols &#x201c;ENGN&#x201d; and &#x201c;ENGNW,&#x201d; respectively, commencing trading on November 1, 2023, with enGene Inc., a subsidiary of the Company, continuing the existing business operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Going Concern,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As an emerging growth entity, the Company has devoted substantially all of its resources since inception to organizing and staffing the Company, raising capital, establishing its intellectual property portfolio, acquiring or discovering product candidates, research and development activities for developing non-viral genetic medicines and other compounds, establishing arrangements with third parties for the manufacture of its product candidates and component materials, and providing general and administrative support for these operations. As a result, the Company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred a net loss of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and negative cash flows from operating activities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended October 31, 2025, and, as of that date, has an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;372.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.  The Company has not yet commercialized any product candidates and does not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. The Company will need additional funding to support its continuing operations and pursue its development strategy. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Company has not generated any revenues and has financed its liquidity needs primarily through PIPE  financings, offering debt, and issuance of redeemable convertible preferred shares and warrants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In November 2025, the Company closed a public offering of its Common Shares and pre-funded warrants to purchase Common Shares which resulted in aggregate gross proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;149.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting the underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of outstanding loans.  As of the issuance date of these consolidated financial statements, the Company expects that its existing cash and cash equivalents as of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months from the issuance date of these consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-5"
      id="F_b3cb96e7-97a4-44d8-aeed-0d9c2a1d6f34"
      unitRef="U_USD">-117300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-5"
      id="F_0978479a-f0fa-4e78-ac3b-18af9b900e9f"
      unitRef="U_USD">-99200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_cae043f2-a171-4ecd-b167-405764d6f5ed"
      unitRef="U_USD">-372000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e86be109-1a95-4196-ac55-bc2ba9ae5417"
      decimals="-5"
      id="F_f82416e3-36f4-477b-a15e-e8919d2ec9ae"
      unitRef="U_USD">149500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_e86be109-1a95-4196-ac55-bc2ba9ae5417"
      decimals="-5"
      id="F_e3316815-41e5-41cd-ae9f-6e07d7e386df"
      unitRef="U_USD">9400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_d7d0da19-1ef7-4f0a-a631-8999f3c0fed2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x2019;s&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are expressed in US dollars. The consolidated financial statements have been prepared on a historical cost basis, except for items that are required to be accounted for at fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the accrual of research and development expenses, share-based payments and the recoverability of investment tax credits receivable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considered the Company&#x2019;s organizational structure and the information regularly reviewed and evaluated by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) when deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer (&#x201c;CEO&#x201d;). The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. Based on this factor, the Company determined that it operates and manages its business as a single operating segment. As of October 31, 2025, the Company had &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in long-lived assets held in the United States and in Canada, respectively. As of October 31, 2024, the Company had &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in long-lived assets held in the United States and in Canada, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk of Concentrations of Credit and Off-Balance Sheet Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. Management believes that the Company is not currently exposed to significant credit risk as the Company&#x2019;s deposits were held in custody at third-party financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's investment policy limits investments to certain types of securities issued by the U.S. Government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; off-balance sheet concentrations of credit risk&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party CMOs and CRO with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company&#x2019;s cash and cash equivalents include bank balances, demand deposits and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;other short-term, highly liquid investments. The fair value of cash and cash equivalents approximate the amortized cost. The Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash and cash equivalents as of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash and cash equivalents as of October 31, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 17, Subsequent Events, for additional discussion on the Company&#x2019;s cash position following the closing of an underwritten public offering in November 2025.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's marketable securities are maintained by investment managers and consist of money market funds, U.S. government agency securities and treasuries. If the remaining contractual maturity is within one year from the balance sheet date, the marketable securities are classified as current and otherwise, they are classified as non-current assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investment in marketable securities is classified as available-for-sale and is reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders' equity in other comprehensive loss. Premium or discounts from par value are amortized to investment income over the life of the underlying investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company periodically evaluates the need for an allowance for credit losses. The evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the fair value is below the amortized cost of the asset, an estimate of expected credit losses is made. The Company records credit losses in the consolidated statements of operations and comprehensive loss as a credit loss expense within other income, net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued interest receivable related to the Company's available-for-sale securities is presented within prepaids and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivable associated with its marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are comprised mainly of research and development equipment, computer hardware and software, office furniture and equipment, and leasehold improvements. Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if applicable. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:56.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:40.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected undiscounted cash flows are less than the carrying value of the assets, then the assets are considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a right-of-use (&#x201c;ROU&#x201d;) asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.269%;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.13%;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, financial instruments measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable Securities, and Note 3, Fair Value Measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:12.13%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with the issuance of debt not accounted for using the fair value option as debt issuance costs. Debt issuance costs are recorded as a direct reduction of the carrying amount of the associated debt on the Company&#x2019;s consolidated balance sheets and amortized as interest expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses are comprised primarily of costs incurred for our drug discovery efforts and development of our product candidates. These expenses include salaries, employee benefits, and share-based compensation expense for our research and development personnel, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside CROs and consultants to conduct research and development activities including costs of clinical trials and manufacturing, and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management estimates the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an incentive equity plan (the &#x201c;2023 Incentive Equity Plan&#x201d; or the &#x201c;2023 Plan&#x201d;), whereby employees render services as consideration for equity instruments.  The 2023 Plan was adopted on October 31, 2023 upon the completion of the Reverse Recapitalization and superseded enGene Inc.&#x2019;s employee stock option plan (the &#x201c;ESOP&#x201d;) and equity incentive plan (the &#x201c;EIP&#x201d;) (collectively, the &#x201c;Old Plans&#x201d;). The 2023 Plan was amended and restated in May 2024 and is now the Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which supersedes all prior plans. The Company measures all share-based awards granted to employees, officers, directors and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of its share-based awards as they occur. The Company issues share-based awards with service-based vesting conditions and awards with both performance and service-based vesting conditions. For share-based awards with service-based vesting conditions, the Company records the expense using the straight-line method including when such awards have graded vesting. For share-based awards with both performance and service-based vesting conditions, the Company records the expense using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management&#x2019;s best estimate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company&#x2019;s common shares, expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company&#x2019;s expected dividend yield. The Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies with similar characteristics including market capitalization, stage of development, therapeutic focus and certain financial measures. The expected volatility has been determined using an average of the historical volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method for awards with only service based vesting conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on participant behavior. For awards with both performance and service based vesting conditions, the expected term has been determined using management&#x2019;s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers.  The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the consummation of the Reverse Recapitalization, because there was no public market for the Company&#x2019;s common shares, the Board of Directors has determined the fair value of the Company&#x2019;s common shares based on third-party valuations of the Company&#x2019;s common shares. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#x2019;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering (&#x201c;IPO&#x201d;), or sale of the Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. In addition, the Company&#x2019;s Board of Directors considered various objective and subjective factors to determine the fair value of the Company&#x2019;s common shares as of each grant date, including the prices at which enGene Inc. sold shares of redeemable convertible preferred shares and the superior rights and preferences of the redeemable convertible preferred shares relative to its common shares at the time of each grant, external market conditions, the progress of the Company&#x2019;s research and development programs, the Company&#x2019;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company&#x2019;s common shares and redeemable convertible preferred shares, among other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions underlying these valuations represented management&#x2019;s best estimate, which involved inherent uncertainties and the application of management&#x2019;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if the Company had used different assumptions or estimates or if there are changes to the unobservable inputs, the fair value of its common shares and share-based compensation expense could have been materially different.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent to becoming a publicly traded Company upon the consummation of the Reverse Recapitalization, the fair value of common shares underlying equity awards is based on the market price of the Company&#x2019;s common stock at the date of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s share-based compensation expense is recorded in general and administrative and research and development expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax basis of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; deficit that result from transactions and economic events other than those with shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if dilutive, the weighted-average number of potential shares of common shares. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and warrants. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted net loss per share attributable to common shareholders is generally the same as basic net loss per share attributable to common shareholders because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. See Note 11, Net Loss per Share, for further detail.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Transaction Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that were directly associated with PIPE or public financings as deferred transaction costs until such transaction was consummated. After the consummation of such transaction, these costs are recorded within equity as a reduction of the common share and warrants value within additional paid in capital. Costs are allocated to each equity instrument on a relative fair value basis for transactions that include both instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Assistance Programs for Research and Development Expenditures&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company was eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (&#x201c;CCPC&#x201d;) on eligible scientific research and experimental development (&#x201c;SR&amp;amp;ED&#x201d;) expenditures through September 2023, at which time the Company lost its status as a CCPC. In addition, effective for fiscal 2023, the Company&#x2019;s maximum refundable tax credits were reduced due to the Company&#x2019;s taxable capital, as defined in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Tax Act&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Canada), which reduction in credits has been recorded in the fourth quarter.  The Canadian federal government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#x2019;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. Following the loss of CCPC status, the Company&#x2019;s SR&amp;amp;ED tax credits will be earned at a lower rate and some will no longer be refundable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amounts received or receivable resulting from government assistance programs, including investment tax credits for SR&amp;amp;ED, are recognized when there is reasonable assurance that the amount will be received, and all attached conditions will be complied with. Reimbursements of eligible SR&amp;amp;ED expenditures pursuant to government assistance programs are received in cash. The amounts&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;receivable are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. During the years ended October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; respectively, as a reduction of research and development expense associated with SR&amp;amp;ED investment tax credits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-07, Segment Reporting (Topic 280: Improvements to Reportable Segment Disclosures) (&#x201c;ASU 2023-07&#x201d;), which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this accounting standard during the year ended &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impact on the Company&#x2019;s reportable segments identified. Required disclosures have been included in Note 15 "Segment Reporting".&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements &#x2013; Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,  which removes references to project stages and clarified when the Company is required to begin capitalizing eligible costs. The new guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. ASU 2025-06 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as further clarified by ASU 2025-01, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,  issued in January, 2025, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. This ASU is effective for annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740) - Improvements to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ncome Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which improves transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU No 2023-09 is effective for the Company's annual financial statements for the year ending October 31, 2026. The Company is currently evaluating the impact of the guidance on the financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which amends GAAP to reflect updates and simplifications to certain disclosure and presentation requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 is effective on the date on which the SEC's removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective but will not be effective if the SEC has not removed the applicable disclosure requirements by June 30, 2027. Early adoption is prohibited. The Company is currently evaluating the impact of the amendments on its financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_6d264e2e-3d70-4456-a41b-df5a17dbaa83">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly owned subsidiaries.  All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x2019;s&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements are expressed in US dollars. The consolidated financial statements have been prepared on a historical cost basis, except for items that are required to be accounted for at fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_50de1d4b-f312-443c-8765-63bc00c33c75">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to the accrual of research and development expenses, share-based payments and the recoverability of investment tax credits receivable. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b60fb994-9f6a-4e82-8dad-e6a030fd3d9c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considered the Company&#x2019;s organizational structure and the information regularly reviewed and evaluated by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) when deciding how to allocate resources and assess performance. The Company has determined that its CODM is its Chief Executive Officer (&#x201c;CEO&#x201d;). The CODM reviews the financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. Based on this factor, the Company determined that it operates and manages its business as a single operating segment. As of October 31, 2025, the Company had &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in long-lived assets held in the United States and in Canada, respectively. As of October 31, 2024, the Company had &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in long-lived assets held in the United States and in Canada, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="C_dbc9c096-5c22-4cf5-a894-96a9e588ee65"
      decimals="-5"
      id="F_d55b1d13-9773-4e10-9fe6-7904e5aafa88"
      unitRef="U_USD">7200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_95a2beb8-4e85-43b1-85ca-fbc18197ebed"
      decimals="-5"
      id="F_fd59a7c1-3f0f-4488-859d-3513a183611d"
      unitRef="U_USD">3000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_a090e3b4-1166-4d45-b4d4-8b0b43e3f8be"
      decimals="-5"
      id="F_70a9dae2-f5ac-43d3-8c25-8ceeb3c1d14c"
      unitRef="U_USD">400000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_fb7a7ff2-f1d8-4421-8eee-75ddcf02c394"
      decimals="-5"
      id="F_ca96c2cc-07f7-43eb-95d7-0a625fc0f5ed"
      unitRef="U_USD">2500000</us-gaap:NoncurrentAssets>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_7311aaa3-47a5-4678-af91-6fd5f7ec37bc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk of Concentrations of Credit and Off-Balance Sheet Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. Management believes that the Company is not currently exposed to significant credit risk as the Company&#x2019;s deposits were held in custody at third-party financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's investment policy limits investments to certain types of securities issued by the U.S. Government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; off-balance sheet concentrations of credit risk&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is dependent on third-party CMOs and CRO with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_78e69ec6-6adf-4dba-9e42-8b090052191a">As of October 31, 2025 and 2024, the Company had no off-balance sheet concentrations of credit risk</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <engn:ConcentrationRiskCreditRiskOffBalanceSheetRisk
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_24b7bdcc-342e-41d2-9a40-b9950fb303ba"
      unitRef="U_USD">0</engn:ConcentrationRiskCreditRiskOffBalanceSheetRisk>
    <engn:ConcentrationRiskCreditRiskOffBalanceSheetRisk
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_433ff012-c7f6-4ed0-8a88-198827ba8b7f"
      unitRef="U_USD">0</engn:ConcentrationRiskCreditRiskOffBalanceSheetRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_4a5b82fa-da40-46d8-8ce7-210490764fd5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company&#x2019;s cash and cash equivalents include bank balances, demand deposits and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;other short-term, highly liquid investments. The fair value of cash and cash equivalents approximate the amortized cost. The Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash and cash equivalents as of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of cash and cash equivalents as of October 31, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 17, Subsequent Events, for additional discussion on the Company&#x2019;s cash position following the closing of an underwritten public offering in November 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_77eff14c-160a-45ff-bf4e-697dd913a97d"
      unitRef="U_USD">50200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-5"
      id="F_19af5cc1-a8d5-4a13-9d7f-11700e1ac1bc"
      unitRef="U_USD">173000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_52ad8183-120e-45fd-85cc-1378ee9a11d9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's marketable securities are maintained by investment managers and consist of money market funds, U.S. government agency securities and treasuries. If the remaining contractual maturity is within one year from the balance sheet date, the marketable securities are classified as current and otherwise, they are classified as non-current assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investment in marketable securities is classified as available-for-sale and is reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders' equity in other comprehensive loss. Premium or discounts from par value are amortized to investment income over the life of the underlying investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company periodically evaluates the need for an allowance for credit losses. The evaluation includes consideration of several qualitative and quantitative factors, including whether it has plans to sell the security, whether it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company's strategy and intentions for holding the marketable security.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;When the fair value is below the amortized cost of the asset, an estimate of expected credit losses is made. The Company records credit losses in the consolidated statements of operations and comprehensive loss as a credit loss expense within other income, net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued interest receivable related to the Company's available-for-sale securities is presented within prepaids and other current assets on the Company's consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivable associated with its marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_d554e2c5-9e24-432d-8678-1c7f9bcfa4a6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are comprised mainly of research and development equipment, computer hardware and software, office furniture and equipment, and leasehold improvements. Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if applicable. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:56.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:40.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected undiscounted cash flows are less than the carrying value of the assets, then the assets are considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <engn:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_e315501a-d84a-47a7-bf9e-5a22e87bce0f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:56.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:2.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:40.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:33.85pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:7.2pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:9.35pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:6.5pt;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8.65pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;"&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;padding-right:0.075in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease term or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</engn:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_90cd8c09-4769-4823-a74e-e5e1dd36b35a"
      id="F_f1abe194-7ef3-4448-865d-603681a79f6b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_92d33916-bf8e-4140-a042-722d297bdb9e"
      id="F_22e3662b-fc77-4daa-9fb4-ae4df6e08cb8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1d9d7d3f-3968-47f7-af7e-dd8b5291a3a5"
      id="F_10e29c40-4622-434f-8660-d11ccf779b83">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_12fcc884-3c1c-47f6-a197-2a12844cafb2"
      id="F_84463090-482a-456d-899e-093e105cda55">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <engn:PropertyPlantAndEquipmentEstimatedUsefulLive
      contextRef="C_3481de95-f470-4b1f-85d0-ee1e20db1594"
      id="F_bc99783d-1ebf-4eca-9a63-cff208db000b">Shorter of remaining lease term or useful life</engn:PropertyPlantAndEquipmentEstimatedUsefulLive>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_401e2cca-20d2-44a2-b463-7bdfc6e2f10f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a right-of-use (&#x201c;ROU&#x201d;) asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated non-lease components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease if readily determinable. If the rate implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_797b38fe-a132-4931-bbe5-0eca9769ad4b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:10.269%;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:12.13%;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;o&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, financial instruments measured at fair value on a recurring basis include marketable securities (see Note 4, Marketable Securities, and Note 3, Fair Value Measurements). The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <engn:DebtIssuanceCostsPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b17f7c4b-f09f-4d76-8f6a-94c5f435e01a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:12.13%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with the issuance of debt not accounted for using the fair value option as debt issuance costs. Debt issuance costs are recorded as a direct reduction of the carrying amount of the associated debt on the Company&#x2019;s consolidated balance sheets and amortized as interest expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss using the effective interest method.&lt;/span&gt;&lt;/p&gt;</engn:DebtIssuanceCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_e448b552-9299-44db-b532-02398870c53b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses are comprised primarily of costs incurred for our drug discovery efforts and development of our product candidates. These expenses include salaries, employee benefits, and share-based compensation expense for our research and development personnel, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside CROs and consultants to conduct research and development activities including costs of clinical trials and manufacturing, and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management estimates the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <engn:PatentCostsPolicyPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_d2b762cc-737e-464b-8320-0f609a59d405">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</engn:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_4c3d58ab-235b-4c30-a88b-5c8329207bef">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an incentive equity plan (the &#x201c;2023 Incentive Equity Plan&#x201d; or the &#x201c;2023 Plan&#x201d;), whereby employees render services as consideration for equity instruments.  The 2023 Plan was adopted on October 31, 2023 upon the completion of the Reverse Recapitalization and superseded enGene Inc.&#x2019;s employee stock option plan (the &#x201c;ESOP&#x201d;) and equity incentive plan (the &#x201c;EIP&#x201d;) (collectively, the &#x201c;Old Plans&#x201d;). The 2023 Plan was amended and restated in May 2024 and is now the Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan"), which supersedes all prior plans. The Company measures all share-based awards granted to employees, officers, directors and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company accounts for forfeitures of its share-based awards as they occur. The Company issues share-based awards with service-based vesting conditions and awards with both performance and service-based vesting conditions. For share-based awards with service-based vesting conditions, the Company records the expense using the straight-line method including when such awards have graded vesting. For share-based awards with both performance and service-based vesting conditions, the Company records the expense using an accelerated attribution method, once the performance conditions are considered probable of being achieved, using management&#x2019;s best estimate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company&#x2019;s common shares, expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Company&#x2019;s expected dividend yield. The Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline companies with similar characteristics including market capitalization, stage of development, therapeutic focus and certain financial measures. The expected volatility has been determined using an average of the historical volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method for awards with only service based vesting conditions, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient historical data to develop an estimate based on participant behavior. For awards with both performance and service based vesting conditions, the expected term has been determined using management&#x2019;s best estimate considering the characteristics of the award, contractual life, the timing of the expected achievement of the performance conditions, the remaining time-based vesting period, if any, and comparison to expected terms used by peers.  The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to the consummation of the Reverse Recapitalization, because there was no public market for the Company&#x2019;s common shares, the Board of Directors has determined the fair value of the Company&#x2019;s common shares based on third-party valuations of the Company&#x2019;s common shares. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#x2019;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering (&#x201c;IPO&#x201d;), or sale of the Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. In addition, the Company&#x2019;s Board of Directors considered various objective and subjective factors to determine the fair value of the Company&#x2019;s common shares as of each grant date, including the prices at which enGene Inc. sold shares of redeemable convertible preferred shares and the superior rights and preferences of the redeemable convertible preferred shares relative to its common shares at the time of each grant, external market conditions, the progress of the Company&#x2019;s research and development programs, the Company&#x2019;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company&#x2019;s common shares and redeemable convertible preferred shares, among other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions underlying these valuations represented management&#x2019;s best estimate, which involved inherent uncertainties and the application of management&#x2019;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if the Company had used different assumptions or estimates or if there are changes to the unobservable inputs, the fair value of its common shares and share-based compensation expense could have been materially different.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent to becoming a publicly traded Company upon the consummation of the Reverse Recapitalization, the fair value of common shares underlying equity awards is based on the market price of the Company&#x2019;s common stock at the date of the grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s share-based compensation expense is recorded in general and administrative and research and development expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_af8bdbf4-8649-4754-a543-c80fc958af25">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial statement carrying amounts and the tax basis of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of benefit that may be recognized is the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <engn:PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_e8f7109e-2763-4a97-9e86-655048c0e2a7"
      unitRef="U_pure">0.50</engn:PercentageOfTaxBenefitToBeRealizedForRecognitionInTheIncomeStatement>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ffb1ceb1-d4aa-4874-9d12-7ed9c390e247">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in shareholders&#x2019; deficit that result from transactions and economic events other than those with shareholders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_21bd9abf-192d-41fd-9670-9b625a9581fc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if dilutive, the weighted-average number of potential shares of common shares. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and warrants. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted net loss per share attributable to common shareholders is generally the same as basic net loss per share attributable to common shareholders because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. See Note 11, Net Loss per Share, for further detail.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_bd350ff7-7eda-4743-9556-82027801fd4e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Transaction Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that were directly associated with PIPE or public financings as deferred transaction costs until such transaction was consummated. After the consummation of such transaction, these costs are recorded within equity as a reduction of the common share and warrants value within additional paid in capital. Costs are allocated to each equity instrument on a relative fair value basis for transactions that include both instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
    <engn:GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_4834d508-0d6f-44dd-a2f4-66b71ab12627">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Assistance Programs for Research and Development Expenditures&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company was eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (&#x201c;CCPC&#x201d;) on eligible scientific research and experimental development (&#x201c;SR&amp;amp;ED&#x201d;) expenditures through September 2023, at which time the Company lost its status as a CCPC. In addition, effective for fiscal 2023, the Company&#x2019;s maximum refundable tax credits were reduced due to the Company&#x2019;s taxable capital, as defined in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Tax Act&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (Canada), which reduction in credits has been recorded in the fourth quarter.  The Canadian federal government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#x2019;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. Following the loss of CCPC status, the Company&#x2019;s SR&amp;amp;ED tax credits will be earned at a lower rate and some will no longer be refundable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amounts received or receivable resulting from government assistance programs, including investment tax credits for SR&amp;amp;ED, are recognized when there is reasonable assurance that the amount will be received, and all attached conditions will be complied with. Reimbursements of eligible SR&amp;amp;ED expenditures pursuant to government assistance programs are received in cash. The amounts&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;receivable are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. During the years ended October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; respectively, as a reduction of research and development expense associated with SR&amp;amp;ED investment tax credits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</engn:GovernmentAssistanceProgramsForResearchAndDevelopmentExpendituresPolicyTextBlock>
    <engn:ResearchAndDevelopmentInvestmentTaxCredits
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-5"
      id="F_49bb48f1-77be-466a-904c-022698d54386"
      unitRef="U_USD">600000</engn:ResearchAndDevelopmentInvestmentTaxCredits>
    <engn:ResearchAndDevelopmentInvestmentTaxCredits
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-5"
      id="F_b4d9eedb-3110-4a8c-9d22-112343011c34"
      unitRef="U_USD">400000</engn:ResearchAndDevelopmentInvestmentTaxCredits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_00c6b363-65a3-4c14-a945-229f3ed2d4c5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-07, Segment Reporting (Topic 280: Improvements to Reportable Segment Disclosures) (&#x201c;ASU 2023-07&#x201d;), which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for annual periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this accounting standard during the year ended &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impact on the Company&#x2019;s reportable segments identified. Required disclosures have been included in Note 15 "Segment Reporting".&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements &#x2013; Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,  which removes references to project stages and clarified when the Company is required to begin capitalizing eligible costs. The new guidance is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. ASU 2025-06 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as further clarified by ASU 2025-01, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement - Reporting Comprehensive Income- Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,  issued in January, 2025, which requires entities to disclose additional information about specific expense categories in the notes to the financial statements. This ASU is effective for annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the effect of this updated standard on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740) - Improvements to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ncome Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which improves transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. ASU No 2023-09 is effective for the Company's annual financial statements for the year ending October 31, 2026. The Company is currently evaluating the impact of the guidance on the financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2023, the FASB issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which amends GAAP to reflect updates and simplifications to certain disclosure and presentation requirements referred to FASB by the SEC. The targeted amendments incorporate 14 of the 27 disclosures referred by the SEC into codification. Each amendment in ASU 2023-06 is effective on the date on which the SEC's removal of the related disclosure requirement from Regulation S-X or Regulation S-K becomes effective but will not be effective if the SEC has not removed the applicable disclosure requirements by June 30, 2027. Early adoption is prohibited. The Company is currently evaluating the impact of the amendments on its financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8"
      id="F_5bd69b37-e839-4332-849e-a0d6cd575d75">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8"
      id="F_388d6f61-a389-4538-8512-e790c64cd5ba">2025-10-31</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_abfceb4a-8cb1-4526-8c29-9ed003c45af8"
      id="F_80c2b497-5c56-48b8-829c-33781b556a46">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_22e3e41f-1f79-40ee-9d2a-390d3be18c50">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable&lt;br/&gt;Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of October 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.101%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.214%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.604000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.107%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.903000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.129%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.154%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.129%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.659%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable&lt;br/&gt;Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p id="bookmark_id_4d34og8" style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025 and 2024, the Company classified its government agency &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;arketable securities as Level 2 within the valuation hierarchy. The Company estimates the fair value of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly to estimate fair value. These inputs include market pricing based on real time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers or reclassifications between fair value measure levels of assets or liabilities. The carrying values of all other financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_908f696b-9f1e-479b-ba09-8f5f943b71ab">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:34.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.501%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.952%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable&lt;br/&gt;Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the Company's fair value hierarchy for financial assets measured at fair value as of October 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.101%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.214%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.604000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.107%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.903000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.129%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.154%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.129%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.659%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Other&lt;br/&gt;Observable&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant Unobservable&lt;br/&gt;Inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Short term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Long term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;195,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_07c65fa0-4265-4f70-956a-00de275d630a"
      decimals="-3"
      id="F_cd1886d1-2c04-40e2-8c64-22e79f21cf9f"
      unitRef="U_USD">8642000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2cb23464-3212-4cf3-bba9-7c4d415c4691"
      decimals="-3"
      id="F_9a6fb0c0-0168-442e-944f-abdbb8a46151"
      unitRef="U_USD">8642000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e68a05ca-9f3e-4035-b30c-b74ee7a7e177"
      decimals="-3"
      id="F_9565738d-d1f6-441e-b6e7-545da36c675c"
      unitRef="U_USD">21623000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b2244905-4cf1-4e70-8b70-8a3ec973f2f0"
      decimals="-3"
      id="F_eca60acd-20b3-44a8-87a7-327f124b25c3"
      unitRef="U_USD">21623000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_72be055a-0ced-4c28-83d8-1cad15ae7d7f"
      decimals="-3"
      id="F_b6f5548d-b794-4ee3-b145-83750c0da3fc"
      unitRef="U_USD">3249000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_adfc86f6-5602-4b1b-906a-2f27bffaaf91"
      decimals="-3"
      id="F_6a09f065-0757-4b79-bf28-9965cbe5e666"
      unitRef="U_USD">3249000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8468fb01-e170-4276-bf5a-9ea3008dd3f2"
      decimals="-3"
      id="F_95315ead-a872-4941-88b8-66de4db6db3f"
      unitRef="U_USD">125467000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_72c8df98-55d0-47ed-acec-68e231220cf1"
      decimals="-3"
      id="F_28e89e5e-3a30-4ef7-bded-32ee94ffe3f8"
      unitRef="U_USD">125467000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9960e19e-3a5b-4760-a0f1-d9b076862c9c"
      decimals="-3"
      id="F_77ca7349-33af-4640-8ac7-f8c8cc4dba11"
      unitRef="U_USD">18117000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b802882b-c5a1-4942-8e3c-1fdf4a877c1b"
      decimals="-3"
      id="F_e1e18db2-997f-490f-a421-7ef77ad2beb6"
      unitRef="U_USD">18117000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8f043b0a-21ae-410c-ac96-0271d3d3046e"
      decimals="-3"
      id="F_04330d45-6aee-4365-809a-1f07d65881b5"
      unitRef="U_USD">8522000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_acdf9159-83c9-485f-9bd1-02cedfa90e00"
      decimals="-3"
      id="F_8729a765-eea1-418c-b0bb-99e75a12325b"
      unitRef="U_USD">8522000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ba0f02fb-b1f0-4954-bd4f-3c466d2899e1"
      decimals="-3"
      id="F_fa56693c-c372-4c55-af04-2655018b1f63"
      unitRef="U_USD">185620000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_23618105-c2e5-4377-83d6-839699ff1b62"
      decimals="-3"
      id="F_b2b3c78c-e554-4dd5-ab73-30f9fdd66fbf"
      unitRef="U_USD">164254000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_17b8691c-0499-4953-869d-643477e53cc9"
      decimals="-3"
      id="F_b0241dbd-d7f9-43c4-a524-6ea843de4b4e"
      unitRef="U_USD">21366000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2a5a88f1-1863-4ab1-bab0-60010f7bda59"
      decimals="-3"
      id="F_821517ed-2d27-43dc-b0be-8e3451b62a53"
      unitRef="U_USD">121000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6f8ba018-3c10-4168-9540-f591cd8fe57b"
      decimals="-3"
      id="F_7fe895f0-9c63-453d-9e16-58e77cea3531"
      unitRef="U_USD">121000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_826585ba-14d9-4469-8a8b-c84065002806"
      decimals="-3"
      id="F_98fddb90-b42f-4a16-9f2d-bc54ce60f4ae"
      unitRef="U_USD">94236000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b0d9509d-2cde-4f1e-a69c-e980f066e66f"
      decimals="-3"
      id="F_ae90dbdd-de3a-498d-9942-a986a3801801"
      unitRef="U_USD">94236000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f955235a-e265-4f5f-9d93-59b1d609f9ba"
      decimals="-3"
      id="F_e5a81bfa-3b0e-410d-940e-2919ba9eaed7"
      unitRef="U_USD">9955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_aa83e563-392e-4d71-8ae7-7474fd972847"
      decimals="-3"
      id="F_95d36c93-42c8-4325-a3ea-d285dacf5e71"
      unitRef="U_USD">9955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8544b2e4-4dc3-440f-a656-f66ca9b46e40"
      decimals="-3"
      id="F_b369f127-e75c-43a8-a8d2-a8b4770b6753"
      unitRef="U_USD">51574000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_9100563f-205c-44c7-a60a-dd32fc052dd4"
      decimals="-3"
      id="F_ad0274c9-e3a5-473f-913c-104271bb8cd9"
      unitRef="U_USD">51574000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_836b6f28-be7d-407f-8a22-0e6733c24836"
      decimals="-3"
      id="F_7af952b1-cfd6-4df2-89fe-4a25e964289f"
      unitRef="U_USD">13754000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_737abaae-1e0c-4f1a-8b20-7c57ad401acc"
      decimals="-3"
      id="F_77bea73c-df23-47ea-96eb-4ca99baf0912"
      unitRef="U_USD">13754000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_14c30e23-f14f-400e-a50e-517475df9be4"
      decimals="-3"
      id="F_b476333e-378e-4799-ba4e-ee89fb94cd36"
      unitRef="U_USD">49627000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_3070eb61-104a-40f8-be4c-373eeb3fdf18"
      decimals="-3"
      id="F_49233bf7-074e-4e8d-bcb1-a2b814c1cf75"
      unitRef="U_USD">49627000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d6033e72-0f44-4d88-8b8a-64261e76903a"
      decimals="-3"
      id="F_7ae8da9f-fb22-4dbb-a5b1-1220629900c2"
      unitRef="U_USD">9900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_bc14018d-5490-4aba-a323-a2e7f4fe2e46"
      decimals="-3"
      id="F_9986a295-22a1-44cb-9824-4395176669b1"
      unitRef="U_USD">9900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d6039d83-bedb-4265-a5ba-09c0cc735a4e"
      decimals="-3"
      id="F_e08c45a0-a23a-4560-be55-6a2aa191f604"
      unitRef="U_USD">229167000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6058051e-7700-494e-b243-9c348feb4b05"
      decimals="-3"
      id="F_2d40db76-e2ac-4b52-8190-e7c4e703a7ca"
      unitRef="U_USD">195558000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dc6a75d1-5e14-43f3-bdf0-8a2ea5c1463f"
      decimals="-3"
      id="F_4ecfa440-9c07-4a94-9d16-2a4040b65cf4"
      unitRef="U_USD">33609000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_a2ceac9e-2bf9-4adb-8202-c752ce48b9d4"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="INF"
      id="F_618c97cb-ee76-4685-a520-71ddc47b75b5"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_e031c48f-6a76-4e95-afd4-a99aaf19eceb">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Marketable securities&lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company invests in money market funds, U.S. Treasury and government agency debt securities; all marketable securities are classified as available-for-sale and carried at fair value, with unrealized changes in fair value reflected in the other comprehensive income (loss) in the consolidated statements of shareholders' equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, the marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30.866%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.482%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.482000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government securities that had maturities of one to two years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; securities, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of which, with an aggregate fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, were in unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company does not intend to sell its investments before recovery of the amortized cost basis of its debt securities at maturity and no allowance for credit losses was recorded as of October 31, 2025 because the decline in fair value below amortized cost is not related to credit losses. Securities are evaluated at the end of each reporting period. The unrealized losses on U.S. Treasury and Government agency securities range fr&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;om &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their amortized cos&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024, the marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:45.851%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:5.972%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.467%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.588%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.677%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.773%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.677%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.786000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for certain government agency securities that had maturities of one to two years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; securities, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of which were in an unrealized loss position. All investments in an unrealized loss position were in this position for less than 12 months. The Company does not intend to sell its investments before recovery of the amortized cost basis of its debt securities at maturity and no allowance for credit losses was recorded as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024 because the decline in fair value below amortized cost is not related to credit losses. Securities are evaluated at the end of each reporting period. The unrealized losses on U.S. Treasury and Government agency securities range fr&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;om &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their amortized cos&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued interest receivable on the Company's &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e95588c3-c714-4f9f-bfa1-4e84f1995499;"&gt;&lt;span style="-sec-ix-hidden:F_f4615be1-4ad1-4aa9-9576-91c98e5813d6;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;available-for-sale&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; debt securities totaled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and was presented within prepaids and other current assets on the Company's consolidated balance sheets. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest receivable was written off during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended October 31, 2025 or 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; material realized gains or losses recognized on the sale or maturity of available-for-sale securities during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 or 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_7d83b0fa-2668-41ba-a5df-cf908ef5f843">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, the marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30.866%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.482%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.482000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;177,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024, the marketable securities consisted of the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:45.851%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:5.972%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.467%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.588%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.205%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.677%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.773%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.677%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.786000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Holdings Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US treasury&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,931&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_95fa67fd-790e-4d1c-9cac-d33ccb8066a1"
      decimals="-3"
      id="F_5e4dabae-5bb2-4971-9a97-0dd78f05b0bd"
      unitRef="U_USD">8642000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_95fa67fd-790e-4d1c-9cac-d33ccb8066a1"
      decimals="-3"
      id="F_24ef5268-42c5-44cc-9b17-f55e2472806e"
      unitRef="U_USD">8642000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1"
      decimals="-3"
      id="F_3d28e0c9-f4e6-4c69-a6b6-6d2dc659e697"
      unitRef="U_USD">146984000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1"
      decimals="-3"
      id="F_bfb52b23-d952-4a02-bd89-49e75c8486fb"
      unitRef="U_USD">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1"
      decimals="-3"
      id="F_e8f8cc20-5b41-441f-89b4-d078f4b0ee6a"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f3306b33-5d9c-4031-9615-7122f1e0e1f1"
      decimals="-3"
      id="F_7ee2e013-0cc6-4c4f-8625-d47b9223e30f"
      unitRef="U_USD">147090000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78"
      decimals="-3"
      id="F_ba941484-277e-4268-a142-9c5bf0236f8c"
      unitRef="U_USD">21368000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78"
      decimals="-3"
      id="F_a2f524b4-712b-408a-9154-ca7afb64df97"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78"
      decimals="-3"
      id="F_76af443d-519d-4ee9-9fea-e28d801fdc83"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1be15272-9b4f-4bcf-849e-53caedc2be78"
      decimals="-3"
      id="F_53f3ea58-fb23-4d8e-afa9-77c32bfd371a"
      unitRef="U_USD">21366000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef"
      decimals="-3"
      id="F_40bb006b-c6ea-4450-93e1-f65af7c69a2d"
      unitRef="U_USD">176994000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef"
      decimals="-3"
      id="F_4b1d29e1-323e-45ab-90d3-065d7fbbba12"
      unitRef="U_USD">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef"
      decimals="-3"
      id="F_eaff7d8d-e96e-4f91-9cfb-7549c446d027"
      unitRef="U_USD">34000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ad2092fb-95e1-4908-b08e-8b4a677329ef"
      decimals="-3"
      id="F_dd40a7a7-646d-4eec-8d97-9ac2cfb8376b"
      unitRef="U_USD">177098000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91"
      decimals="-3"
      id="F_8fe059b7-a029-4ce4-8a4a-d4c86c35c099"
      unitRef="U_USD">8498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91"
      decimals="-3"
      id="F_d7bc2628-68c1-4d78-918c-fc6db6848e7d"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91"
      decimals="-3"
      id="F_47ec31a6-4e72-47b7-9591-650fd9d7fbfd"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_564037ba-a7ea-4270-bd91-8fb37e3d8e91"
      decimals="-3"
      id="F_6fffac9b-55d2-44f3-86b9-754fe1faf3d4"
      unitRef="U_USD">8522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a"
      decimals="-3"
      id="F_275ac7f2-caea-4738-b418-2b166112b8f6"
      unitRef="U_USD">8498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a"
      decimals="-3"
      id="F_7e1932cb-1ce3-4458-a263-11727165dffb"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a"
      decimals="-3"
      id="F_05b5e210-9d8c-4e5f-a55a-fc98d5217522"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d322beea-35fb-4c80-859d-02cabe66017a"
      decimals="-3"
      id="F_9d00535b-dd1f-4045-93d6-84c810b5e372"
      unitRef="U_USD">8522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_863b8995-9492-4199-8474-0f19015b7c06"
      unitRef="U_USD">185492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_0513d23b-4f0b-4bf2-b5c7-91caafd80672"
      unitRef="U_USD">163000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_cf268560-7f37-45b0-8ccf-e96a9a6879e5"
      unitRef="U_USD">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_a735adc1-b52c-4e83-b1af-8b12c5c92258"
      unitRef="U_USD">185620000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <engn:NumberOfSecuritiesHeld
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_995c0e98-c10a-4dfc-8a2a-2e67efa9e0c1"
      unitRef="U_Security">50</engn:NumberOfSecuritiesHeld>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_793e26e9-ff6c-4168-a641-2a4f412d94a1"
      unitRef="U_Security">14</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_8abd8114-2922-4dfc-b5c2-e397e0528f9a"
      unitRef="U_USD">55900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <engn:DebtSecuritiesUnrealizedLosses
      contextRef="C_ce39e6a1-222d-49f4-96cc-9cfa2d2ac439"
      decimals="2"
      id="F_c891dc0f-5208-44ba-8841-adcd2a246bab"
      unitRef="U_pure">0</engn:DebtSecuritiesUnrealizedLosses>
    <engn:DebtSecuritiesUnrealizedLosses
      contextRef="C_d39e4cc1-c2c2-436d-91fe-df2f1f3ae461"
      decimals="2"
      id="F_84efb795-c486-4200-8922-fa405ee62ad5"
      unitRef="U_pure">0.01</engn:DebtSecuritiesUnrealizedLosses>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a033399-2b58-4fe0-8140-e6817c28119b"
      decimals="-3"
      id="F_9cf91dc5-f6d7-4cd3-986d-04ff0030a72d"
      unitRef="U_USD">121000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a033399-2b58-4fe0-8140-e6817c28119b"
      decimals="-3"
      id="F_a22628ab-f3e1-411e-8cc3-2e28b9ab5c3d"
      unitRef="U_USD">121000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a"
      decimals="-3"
      id="F_40931a6b-6106-4b4c-9877-3e9da78dd045"
      unitRef="U_USD">145832000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a"
      decimals="-3"
      id="F_2eeeb7ee-6927-43cf-8d5f-48d79cf54cd7"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a"
      decimals="-3"
      id="F_a89858d7-3de1-4da0-8197-c92b96477e9f"
      unitRef="U_USD">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_973bbc62-cd34-41f4-92cd-0c92e02fd78a"
      decimals="-3"
      id="F_4a715fec-14c6-4cac-908d-6476d4a2a313"
      unitRef="U_USD">145814000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3"
      decimals="-3"
      id="F_26792223-5564-4197-9823-41ba099c8b99"
      unitRef="U_USD">23714000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3"
      decimals="-3"
      id="F_1bafeaaa-e124-4950-adef-f5533dbe3a72"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3"
      decimals="-3"
      id="F_24fcb385-cbc9-4bb8-af5d-0616979b0c0e"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7e45dcbd-ec3e-4b9c-b33f-9b9b8fca10b3"
      decimals="-3"
      id="F_f70bb10b-b7c5-46bc-8ddf-75f44be6193b"
      unitRef="U_USD">23709000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92"
      decimals="-3"
      id="F_bae295cc-0ead-466f-8c3a-e9d2999918b8"
      unitRef="U_USD">169667000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92"
      decimals="-3"
      id="F_2304e518-f627-4a36-af99-d1d5f02ef3ed"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92"
      decimals="-3"
      id="F_976ca6fd-f833-4845-9ace-e3f2b3bfd222"
      unitRef="U_USD">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_313a26fc-809b-4ba8-a8ed-38bcdb1d1c92"
      decimals="-3"
      id="F_b80e80d8-ec8f-437f-91bb-cb9b3afe702e"
      unitRef="U_USD">169644000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8048b9df-5cd2-4254-af6b-1df01215dbd0"
      decimals="-3"
      id="F_50dd1d04-fd4f-4399-9a9f-3cb7390afccd"
      unitRef="U_USD">49931000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8048b9df-5cd2-4254-af6b-1df01215dbd0"
      decimals="-3"
      id="F_8ffedba5-92cb-4bba-9d5b-933f193d0a64"
      unitRef="U_USD">306000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8048b9df-5cd2-4254-af6b-1df01215dbd0"
      decimals="-3"
      id="F_19e198db-b901-45dd-b5bb-43356d18ced0"
      unitRef="U_USD">49625000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2e90c670-46cc-4848-9919-7cce02e258fc"
      decimals="-3"
      id="F_6ec1b2fc-d337-42f3-87f0-fc72e918af9e"
      unitRef="U_USD">9972000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2e90c670-46cc-4848-9919-7cce02e258fc"
      decimals="-3"
      id="F_36ce65e8-8546-4a18-99ea-78e408fc8910"
      unitRef="U_USD">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2e90c670-46cc-4848-9919-7cce02e258fc"
      decimals="-3"
      id="F_6c319bb0-8dc5-4875-9b83-d7abf06480cd"
      unitRef="U_USD">9898000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e"
      decimals="-3"
      id="F_f01b62ec-6a63-4563-b2b8-16601e65851e"
      unitRef="U_USD">59903000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e"
      decimals="-3"
      id="F_cdff65a3-4ee6-4f77-91bb-52c86150d1c9"
      unitRef="U_USD">380000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1ebf9048-20c8-4c1f-951c-642fd2100d7e"
      decimals="-3"
      id="F_d0330b0d-8a3c-43ae-9711-63fae975805b"
      unitRef="U_USD">59523000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_5ae65f6c-151b-4715-a28e-c0043184dee4"
      unitRef="U_USD">229570000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_5e534ffd-60a6-42bc-ae81-ea9d9712f7a6"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_5c1a5ec9-3e25-4a40-9da6-8a75e1450f31"
      unitRef="U_USD">418000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_f5dca2d1-7791-43b3-8909-883a74a434d3"
      unitRef="U_USD">229167000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <engn:NumberOfSecuritiesHeld
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_68a360d5-9726-4847-8c6c-e06bd90847d4"
      unitRef="U_Security">31</engn:NumberOfSecuritiesHeld>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_01dbbc0d-9da0-453e-a0d2-565c332e80d7"
      unitRef="U_Security">21</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <engn:DebtSecuritiesUnrealizedLosses
      contextRef="C_9de67a6b-db13-4cab-b973-3dc0f4942c58"
      decimals="2"
      id="F_6a40153b-fe27-4cc8-9628-f2733c654147"
      unitRef="U_pure">0</engn:DebtSecuritiesUnrealizedLosses>
    <engn:DebtSecuritiesUnrealizedLosses
      contextRef="C_8d237d2e-9003-4d50-b804-e95a6312f01a"
      decimals="2"
      id="F_7803da37-d7a7-4faa-8918-c8682aaaf402"
      unitRef="U_pure">0.01</engn:DebtSecuritiesUnrealizedLosses>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_41f3e6d6-553f-4c32-bb46-43ba7abac3f5"
      unitRef="U_USD">1300000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-5"
      id="F_67e1a8d1-e826-4ee9-8ee5-51b2b9ac136f"
      unitRef="U_USD">700000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <engn:AccruedInterestReceivableWrittenOff
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_833d56dd-2671-4c0c-8fa6-e57d7a86ca43"
      unitRef="U_USD">0</engn:AccruedInterestReceivableWrittenOff>
    <engn:AccruedInterestReceivableWrittenOff
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="0"
      id="F_a231c574-fa2c-44c9-817f-ab7a3745336f"
      unitRef="U_USD">0</engn:AccruedInterestReceivableWrittenOff>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_d69636eb-cc26-4265-90b1-d9e2af5f7b2c"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="0"
      id="F_72a94009-6075-426d-b789-38b416241c66"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_d2d313ff-33c7-4b7c-9f8f-ceea983c59ee">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, property and equipment consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense related to property and equipment was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_49987718-3698-4a69-b3d4-de250bd712ff">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, property and equipment consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_496e94d8-a257-4d69-8ba6-932806871284"
      decimals="-3"
      id="F_3f285437-b0b5-44e1-b949-d7f0e0356944"
      unitRef="U_USD">3134000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7edc548a-2b6b-40d9-9585-f8a98c0a4267"
      decimals="-3"
      id="F_6eefd6f7-ecd3-4e69-87b0-349c27e4dbdd"
      unitRef="U_USD">2191000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_92d33916-bf8e-4140-a042-722d297bdb9e"
      decimals="-3"
      id="F_0b97f7e3-3fad-4bb3-b65c-43630dbad9a7"
      unitRef="U_USD">169000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_951877f3-5e88-4367-9785-1d7884a66f77"
      decimals="-3"
      id="F_551ca416-20d2-4d07-bbfa-346fe8f6c0ee"
      unitRef="U_USD">62000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1d9d7d3f-3968-47f7-af7e-dd8b5291a3a5"
      decimals="-3"
      id="F_1751257c-61d0-4b1b-8941-7f3240bd3b9b"
      unitRef="U_USD">144000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_57ae8deb-9706-4aaa-ab1d-e9fc280a2c06"
      decimals="-3"
      id="F_b45aa7a2-6319-42e7-9d71-762574b19696"
      unitRef="U_USD">146000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_12fcc884-3c1c-47f6-a197-2a12844cafb2"
      decimals="-3"
      id="F_45b7d78c-9de9-4634-8eff-cad1ebade39c"
      unitRef="U_USD">871000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_250a9087-119f-4c5b-bf49-75a14a4e74b9"
      decimals="-3"
      id="F_855eaa39-328b-478a-88f4-8bd6e917cc1c"
      unitRef="U_USD">141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f4a3d6cf-e574-4cf3-b8ec-df2947d5c514"
      decimals="-3"
      id="F_4daaa366-b817-4e13-8f90-5c629a1fe90d"
      unitRef="U_USD">262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e3642777-e12d-430b-aa3d-219b649d5144"
      decimals="-3"
      id="F_9dd2a806-f54a-4f02-9d61-d5b57b55f788"
      unitRef="U_USD">239000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_6a51d241-5114-47e0-b702-965860ec8fb2"
      unitRef="U_USD">4580000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_167a078c-8445-47bc-8482-160dfc8a8786"
      unitRef="U_USD">2779000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_f34b2bfd-079b-486b-9b3d-8cf6b2cf06f8"
      unitRef="U_USD">2103000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_dabff87f-0877-4945-820d-92e3526f429a"
      unitRef="U_USD">1610000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_5e1918b4-24ac-410d-aedf-e420ff1fc511"
      unitRef="U_USD">2477000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_af5ab5b5-145b-422f-8342-eb665bfa5128"
      unitRef="U_USD">1169000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-5"
      id="F_b0032fd1-8e1d-4a35-803d-07d6e1e5273d"
      unitRef="U_USD">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-5"
      id="F_4ef83346-8211-414f-96e8-a36caae26a97"
      unitRef="U_USD">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_6ce767ca-f131-4acb-bb83-592adaa4833e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income taxes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_f98531a7-c321-477b-bd0d-de334bb037a5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,773&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income taxes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <engn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_bbb51fa0-f7b2-4f88-b2e0-8a427e9892f3"
      unitRef="U_USD">9397000</engn:AccruedResearchAndDevelopmentExpenseCurrent>
    <engn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_e371f566-c75f-4fb3-8035-d2f79dd693fd"
      unitRef="U_USD">3773000</engn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_2d001346-6355-4a81-8298-3bacf72b1255"
      unitRef="U_USD">4053000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_b73f32d5-007c-42ce-ae68-807f916694f3"
      unitRef="U_USD">3475000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_990c2ba9-433e-48ca-8f25-c76a574d364a"
      unitRef="U_USD">1229000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_5c8d4368-add4-4453-8ea4-64837f31ceee"
      unitRef="U_USD">824000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_3d115ea0-0193-4248-bafd-c33e6d5a7edd"
      unitRef="U_USD">19000</us-gaap:AccruedIncomeTaxesCurrent>
    <engn:AccruedFinancingCosts
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_979422fb-fcc6-4ec9-8c0a-29492e938521"
      unitRef="U_USD">3831000</engn:AccruedFinancingCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_6b70203d-e608-4266-9fac-eb2d87fdd651"
      unitRef="U_USD">577000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_a8b8ab7f-4057-4fa2-9a47-8435c75ca867"
      unitRef="U_USD">225000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_2e1b53ce-5c48-4b3d-807b-e4c8229439f9"
      unitRef="U_USD">15275000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_5a31c1c1-a01e-4e8c-aa6e-8216972bdbe6"
      unitRef="U_USD">12128000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_c08ac348-dbb7-439f-9998-0392fe2bf744">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. License Agreement and Clinical Research Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Agreement &#x2013; Nature Technology Corporation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 10, 2020, the Company entered into a Non-Exclusive License Agreement (the &#x201c;License Agreement&#x201d;) with Nature Technology Corporation (&#x201c;NTC&#x201d;) whereby the Company licenses certain rights to Nanoplasmid&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; technology from NTC for commercialization. Under the terms of the License Agreement, NTC granted to the Company and its affiliates a non-exclusive, royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can voluntarily terminate the license agreement with prior notice to NTC.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company paid NTC an initial, upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand which was recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand annual maintenance fee. The Company is also required to make a payment to NTC of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand upon assigning the License Agreement to a third party.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The License Agreement provides for a one-time payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand for the first dose of a milestone product, as defined in the License Agreement, in the first patient in a Phase 1 clinical trial or, if there is no Phase 1 clinical trial, in a Phase 2 clinical trial, as well as a one-time payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October 31, 2021. The second milestone, regulatory approval of a milestone product, has not yet been achieved as of the&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; year ended October 31, 2025. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar year by the Company, its affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (&#x201c;GMP&#x201d;) lot of a product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a product-by-product basis upon receipt of regulatory approval to market a product in any country in the licensed territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During each of the years ended October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand of expenses related to the annual maintenance fee u&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nder the License Agreement. During the year ended October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company incurred a fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related to the manufacturing payment under the License Agreement. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; fees related to the manufacturing payment incurred during the &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;year ended October 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  All expenses related to License Agreement are recorded within research and development expenses.&lt;/span&gt;&lt;/p&gt;</engn:LicenseAgreementAndClinicalResearchOrganizationTextBlock>
    <engn:UpfrontFees
      contextRef="C_511e94d5-ac9c-4c2e-b367-c6033fb69299"
      decimals="-3"
      id="F_c3eeee6b-bc4f-48ad-82d8-bbb03d4aa868"
      unitRef="U_USD">50000</engn:UpfrontFees>
    <us-gaap:CostMaintenance
      contextRef="C_019c08b7-c82a-486b-871e-9cb94b318c49"
      decimals="-3"
      id="F_33832838-7f86-4b30-b0f3-3e84bd188777"
      unitRef="U_USD">50000</us-gaap:CostMaintenance>
    <engn:PaymentOnAssigningLicenseToThirdParty
      contextRef="C_019c08b7-c82a-486b-871e-9cb94b318c49"
      decimals="-3"
      id="F_49e4cd7c-7afb-4db2-9739-f5320aca7af9"
      unitRef="U_USD">50000</engn:PaymentOnAssigningLicenseToThirdParty>
    <engn:MilestoneProductPayment
      contextRef="C_4d97d0f0-4a5b-489c-b7d4-521214e77828"
      decimals="-3"
      id="F_1f814160-a41c-48ab-af09-697d053244bc"
      unitRef="U_USD">50000</engn:MilestoneProductPayment>
    <engn:MilestoneProductPayment
      contextRef="C_d24afdca-87cb-498a-960f-4be785980006"
      decimals="-3"
      id="F_1afd68e5-99ae-4a93-b0f0-378cd11733b9"
      unitRef="U_USD">450000</engn:MilestoneProductPayment>
    <engn:AnnualMaintenanceFeeUnderLicenseAgreement
      contextRef="C_d7356f23-a631-4161-bd89-54fd825f3f25"
      decimals="-3"
      id="F_b8edda7d-9fc1-4094-853a-d7b83f354dd7"
      unitRef="U_USD">50000</engn:AnnualMaintenanceFeeUnderLicenseAgreement>
    <engn:AnnualMaintenanceFeeUnderLicenseAgreement
      contextRef="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3"
      decimals="-3"
      id="F_e649768b-6947-488e-b564-4c088e22abb3"
      unitRef="U_USD">50000</engn:AnnualMaintenanceFeeUnderLicenseAgreement>
    <engn:ManufacturingPaymentFee
      contextRef="C_d7356f23-a631-4161-bd89-54fd825f3f25"
      decimals="-3"
      id="F_faa4aff0-d91d-4960-a7e2-8d0d2a40de9b"
      unitRef="U_USD">235000</engn:ManufacturingPaymentFee>
    <engn:ManufacturingPaymentFee
      contextRef="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3"
      decimals="-3"
      id="F_eb076f8d-b8ff-427a-a1c0-799bfbb8a99b"
      unitRef="U_USD">0</engn:ManufacturingPaymentFee>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_41bbb02e-2a66-4784-87f7-646fcfd9e383">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended Loan and Security Agreement and the First Amendment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 30, 2021, the Company entered into a Loan and Security Agreement (the "Prior Loan Agreement") with Hercules Capital, Inc. ("Hercules") for the issuance of a term loan facility with an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (the &#x201c;Prior Term Loan&#x201d;). On December 22, 2023 (the "Hercules Closing Date"), the Company entered into an amended and restated loan and security Agreement (the "Amended Loan Agreement&#x201d;), with Hercules, as agent and lender, and the several banks and other financial institutions or entities from time to time parties thereto (the "Lenders"). The Amended Loan Agreement amended and restated in its entirety the Prior Loan Agreement. The Amended Loan Agreement provides for a term loan facility of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million available in multiple tranches (the &#x201c;Term Loan&#x201d;), as follows: (i) an initial term loan advance (the &#x201c;Tranche 1 Advance&#x201d;) that was made on the Tranche 1 Advance closing of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of which was applied to refinance in full the term loans outstanding under the Prior Loan Agreement, (ii) subject to the achievement of the specified Interim Milestone (the &#x201c;Interim Milestone&#x201d;), which includes no default or event of default, delivery of written notice to the Lenders that the Company has conducted an analysis of interim efficacy of data from the clinical evaluation of detalimogene in the Phase 2 clinical study, and satisfaction of certain other conditions precedent, a right of the Company to request that the Lenders make additional term loan advances in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from the date of achievement of the Interim Milestone through the earlier of (x) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days following the achievement of the Interim Milestone and (y) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and (iii) an uncommitted tranche subject to the Lenders&#x2019; investment committee approval and satisfaction of certain other conditions precedent (including payment of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% facility charge on the amount borrowed), pursuant to which the Company may request from time to time up to and including the Amortization Date (as defined below) that the Lenders make additional term loan advances to the Company in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company is required to pay upon the earlier of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ( the &#x201c;Maturity Date&#x201d;) or payment in full of the Term Loan, an end of term fee equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate principal amount of the Term Loan (the &#x201c;End of Term Charge&#x201d;). The Company was also required to pay on July 1, 2025 or, if earlier, the date the Company prepays the Term Loan, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million representing the Prior Term Loan End of Term Charge (the "Prior Term Loan End of Term Charge" and "End of Term Charge", collectively the &#x201c;End of Term Charges&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounted for the Amended Loan Agreement as an extinguishment of the Prior Term Loan.  As a result of the extinguishment, the Company recorded a loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as a component within other income and expense in the Company's consolidated statement of operations during the year ended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; October 31, 2024, which represented the difference between the reacquisition price of the debt, including fees and the initial fair value of the warrants paid directly to the lender, and the carrying value of the Prior Term Loan at the time of extinguishment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 18, 2024, the Company entered into a First Amendment to Amended and Restated Loan and Security Agreement (the "First Amendment") with the Lenders. The First Amendment modified the Amended Loan Agreement to reallocate the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million previously available under Tranche 2 (as defined in the Amended Loan Agreement), which was not drawn by the Company upon achievement of Interim Milestone, to Tranche 3 (as defined in the Amended Loan Agreement). Pursuant to the First Amendment, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million advance originally available upon achievement of the Interim Milestone was added to the uncommitted tranche subject to the Lenders' investment committee approval and satisfaction of certain other conditions precedent (including payment of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% facility charge on the amount borrowed), pursuant to which the Company may request from time to time that the Lenders make additional loan advances to the Company in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The First Amendment did not change the total term loan facility available to the Company of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The First Amendment further provided for certain administrative changes in accordance with the foregoing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the Company's option, the Company may elect to prepay all, but not less than all, of the outstanding Term Loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the Closing Date (as defined in the Amended Loan Agreement); (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the principal amount outstanding if the prepayment occurs after the first twelve months following the Closing Date but on or prior to twenty-four months following the Closing Date; and (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the principal amount outstanding if prepayment occurs at any time thereafter but prior to the Maturity Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had borrowed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Amended Loan Agreement and incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of debt discount and issuance costs inclusive of legal fees and End of Term Charges under the Term Loan. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The remaining&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the uncommitted tranche subject to the Lenders&#x2019; investment committee approval and satisfaction of certain other conditions precedent described above remains undrawn and available to the Company. The Prior Term Loan End of Term Charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was paid during the year ended October 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Term Loan bears cash interest payable monthly at an annual rate equal to the greater of (a) the prime rate of interest as reported in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d4394cfa-9517-46fa-8508-88aeb275aaf2;"&gt;&lt;span style="-sec-ix-hidden:F_33e08b81-4198-434a-9055-c3013033bffd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Wall Street Journal&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; plus &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (capped at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%) and (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The Term Loan also bears additional payment-in-kind interest at an annual rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, which is added to the outstanding principal balance of the Term Loan on each monthly interest payment date. Borrowings under the Amended Loan Agreement, as amended by the First Amendment, are repayable in monthly interest-only payments through the "Amortization Date", which is either: (x) if the Interim Milestone is achieved and there has been no default, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or (y) if the Interim Milestone and certain clinical milestones are achieved and there has been no default, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. After the Amortization Date, the outstanding Term Loan and interest shall be repayable in equal monthly payments of principal and accrued interest until the Maturity Date. Through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, the Company has achieved the Interim Milestone but has not yet achieved certain clinical milestones. Amounts payable on January 1, 2026 were classified as current liabilities on the consolidated balance sheet for the year ended October 31, 2025. The effective interest rate of the Term Loan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of October 31, 2025 and October 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Amended Loan Agreement, as amended by the First Amendment, the Company granted Hercules a security interest senior to any current and future debts and to any security interest in all of the Company&#x2019;s right, title, and interest in, to and under all of the Company&#x2019;s property and other assets, subject to limited exceptions including the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Amended Loan Agreement, as amended by the First Amendment, contains negative covenants that, among other things and subject to certain exceptions, could restrict the Company's ability to incur additional liens, incur additional indebtedness, make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. The Amended Loan Agreement, as amended by the First Amendment, also contains certain events of default and representations, warranties and non-financial covenants of the Company. The Company is in compliance with the financial covenants at October 31, 2025 and October 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Hercules Common Share Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Amended Loan Agreement, as amended by the First Amendment, the Company also agreed to issue to the Lenders in connection with each advance of Term Loans warrants to purchase that number of the Company&#x2019;s common shares, as shall be equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate principal amount of such Term Loan advance divided by the Warrants per share exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (which exercise price equals the ten-day volume weighted average price for the ten (10) trading days preceding the Hercules Closing Date and is subject to customary adjustments under the terms of the Warrants) (the "Hercules Common Share Warrants"). The Hercules Common Share Warrants are exercisable for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Amended Loan Agreement, as amended by the First Amendment, the maximum number of Hercules Common Share Warrants and underlying Common Shares of the Company that could be issued is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,696&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (i.e. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million total commitment amount divided by the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; price specified in the Closing Date Warrant), assuming no adjustments are made under the terms of the Hercules Common Share Warrants and further assuming the full amount of Term Loans are drawn. On the Hercules Closing Date, the Company issued to the Lenders &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,413&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Hercules Common Share Warrants in connection with the Tranche 1 Advance of the Term Loans (the "Closing Date Warrants"). &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Closing Date Warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#x2019;s common shares as prescribed by ASC 815. Upon entering into the Amended Loan Agreement, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the total $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million Tranche 1 Advance was allocated to the warrants, on a relative fair value basis, and recorded within additional paid in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequently issued Hercules Common Share Warrants shall be substantially in the form of the Closing Date Warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, the carrying value of the Term Loan consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Note payable, including End of Term Charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Note payable, net of discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company classified &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the note payable as current. As of October 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company classified $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the note payable as current, which represented &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the back-end fee associated with the refinancing of the Prior Term Loan. During the years ended October 31, 2025 and 2024, the Company recogni&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;zed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest expense related to the Amended Loan Agreement, respectively, and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million each year rel&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ated to the amortization of the debt discount.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, the estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Note Principal&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total principal payments, including End of Term Charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, management believes that the carrying value of the Company&#x2019;s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value based on the consideration of the Company&#x2019;s credit risk and terms of the borrowing from Hercules.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_33a6f084-8206-471e-bfb2-2dda7584d4c7"
      decimals="INF"
      id="F_f8e78777-7f58-464d-b516-8ae52488f7ae"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_82ca66af-1e97-4ce0-adab-8cffb3acd9a1"
      decimals="INF"
      id="F_34bc8c69-8476-4488-a0e3-f16a2cb6d0b7"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_585ec894-b0e7-4859-a0a7-ccf1f76d9512"
      decimals="-5"
      id="F_a934d2ac-c7e5-41f3-8c41-979d57885701"
      unitRef="U_USD">22500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_53d55f9a-d671-4a03-878e-e8d7b35cee90"
      decimals="-5"
      id="F_0e6796f4-12dd-4385-860c-63e27d1e7c9b"
      unitRef="U_USD">8600000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d8109dad-b66f-4bfb-8c04-ce50e140908e"
      decimals="INF"
      id="F_36d663a2-2624-4989-abe1-63d27007aaab"
      unitRef="U_USD">7500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <engn:PeriodWithinLoanDisbursementsToBeMade
      contextRef="C_7a8c2031-7a18-435b-80ce-180a745a581b"
      id="F_b55ce675-4857-4445-a218-5e781adfe0a6">P60D</engn:PeriodWithinLoanDisbursementsToBeMade>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_7a8c2031-7a18-435b-80ce-180a745a581b"
      id="F_1081b53e-19b2-45fd-856f-c51e10b53e74">2025-03-31</us-gaap:LineOfCreditFacilityExpirationDate1>
    <engn:PercentageOfFacilityChargeOnAmountBorrowed
      contextRef="C_4b5f63d4-ae44-4d1f-a429-c2500140c1cd"
      decimals="4"
      id="F_6ebf5d91-f8c3-466a-bb9c-00cf0cf7491e"
      unitRef="U_pure">0.0075</engn:PercentageOfFacilityChargeOnAmountBorrowed>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_b1f2b3cc-0e10-4b83-bbb6-a450052ce673"
      decimals="INF"
      id="F_826d3b68-ada2-4145-964a-0d3bc02cd2b6"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      id="F_f819d7d0-0fbe-426d-b07d-e9ae4ec89519">2028-01-01</us-gaap:LineOfCreditFacilityExpirationDate1>
    <engn:EndOfTermFeePercentage
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="4"
      id="F_781e0a65-31bb-462d-9e52-278c355404e2"
      unitRef="U_pure">0.055</engn:EndOfTermFeePercentage>
    <engn:EndOfTermCharge
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="-5"
      id="F_3b7a01ba-f789-4db6-bb8d-4d0859822163"
      unitRef="U_USD">700000</engn:EndOfTermCharge>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_2d71d180-d7f1-445c-a569-e1c8106caa03"
      decimals="-5"
      id="F_cc6952e5-3c14-4943-a015-392ec1d69b55"
      unitRef="U_USD">400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_1880048e-dcab-455d-8f72-b54f37487a7f"
      decimals="INF"
      id="F_920dc01b-0c09-492f-8360-c064355ac401"
      unitRef="U_USD">7500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_1ab78818-5433-4a11-a36e-d0983a8bfc04"
      decimals="INF"
      id="F_0dfc6a7f-00bd-4bc7-89de-7bf5e2704e39"
      unitRef="U_USD">7500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <engn:PercentageOfFacilityChargeOnAmountBorrowed
      contextRef="C_16b7f663-ad41-48cc-9a93-5b7ab3af3b3d"
      decimals="4"
      id="F_fb09036e-b1f6-4860-a0a2-7929e1c43b34"
      unitRef="U_pure">0.0075</engn:PercentageOfFacilityChargeOnAmountBorrowed>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_ba4e1c8a-00ae-49f4-b36b-9c45988805ec"
      decimals="INF"
      id="F_965e0b12-8569-4c2a-b63b-337a47561f87"
      unitRef="U_USD">27500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_2570dccd-3edb-4845-9c23-2fa20a3e119a"
      decimals="INF"
      id="F_75009499-d7b1-438e-920a-b2027053a5d7"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="3"
      id="F_49accc30-7191-42d0-a88e-b4205a8b5f56"
      unitRef="U_pure">0.03</engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingOfTheClosingDate>
    <engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="3"
      id="F_216cc0bd-350c-42ea-9bb5-3f25a86218a4"
      unitRef="U_pure">0.02</engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToTwentyFourMonths>
    <engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="3"
      id="F_32a44552-8a84-49f8-be6d-5868e887a099"
      unitRef="U_pure">0.01</engn:PercentageOfPrepaymentPremiumOfPrincipalAmountOutstandingPriorToMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_c587a04c-25a3-434a-9114-e2f1c6ee0c74"
      decimals="-5"
      id="F_31418db8-add9-4511-94c7-3f48476f8c79"
      unitRef="U_USD">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_c587a04c-25a3-434a-9114-e2f1c6ee0c74"
      decimals="-5"
      id="F_087e442c-18f4-44b4-932d-3374cc18da4f"
      unitRef="U_USD">2200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_10beb209-82d9-44f1-a81c-c930ac6ffa93"
      decimals="INF"
      id="F_ae8157a4-5024-4a86-9dec-4df139da9d54"
      unitRef="U_USD">27500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <engn:EndOfTermCharge
      contextRef="C_3a4ac89a-0177-4b3c-8437-70136929db99"
      decimals="-5"
      id="F_57e62069-e997-44ef-958c-82238000fd7a"
      unitRef="U_USD">700000</engn:EndOfTermCharge>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="4"
      id="F_214ae661-02b8-43f5-8f44-4759fbf42214"
      unitRef="U_pure">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_7460771b-4637-42ae-b87f-8329a24ece3d"
      decimals="4"
      id="F_b4bab882-571d-46f5-be29-b523772b04fb"
      unitRef="U_pure">0.0975</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="4"
      id="F_66cb87d9-518f-41d7-9e67-21d83e6163a2"
      unitRef="U_pure">0.0925</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <engn:PaidInKindInterestPercentage
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="4"
      id="F_13269210-9b7d-42a1-8c37-ea0e41c59f6f"
      unitRef="U_pure">0.0115</engn:PaidInKindInterestPercentage>
    <engn:LoanAmortizationDate
      contextRef="C_9e49cbbf-65d1-430d-a687-9171f3246a39"
      id="F_d4c04645-8587-4c17-9ae4-59adfd7ed81b">2026-01-01</engn:LoanAmortizationDate>
    <engn:LoanAmortizationDate
      contextRef="C_4051c11c-5290-47d7-8e2a-b368974acadb"
      id="F_e48f793a-bd15-4435-8070-335db50578be">2026-07-01</engn:LoanAmortizationDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_5cb5ff87-3b6e-4f62-bafd-e58f084904c6"
      decimals="4"
      id="F_dc7622ee-07ee-426e-b4bf-56363e1c0704"
      unitRef="U_pure">0.1163</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_9e58f68c-6bc3-4806-9dbe-08a741a6dfa0"
      decimals="4"
      id="F_dfdd88eb-1b3d-4064-92ec-232fced0b996"
      unitRef="U_pure">0.1163</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <engn:PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares
      contextRef="C_60f8a68e-e8da-4f5f-bc60-1c69892ea749"
      decimals="2"
      id="F_cd22e2d5-2349-4b8f-8c9d-0aa9cac0d685"
      unitRef="U_pure">0.02</engn:PercentageOfAggregatePrincipalAmountOfTermLoanAdvanceToPurchaseNumberOfCommonShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608"
      decimals="INF"
      id="F_0c76abd2-55e2-4773-8c9c-39f2a54cedad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <engn:ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable
      contextRef="C_60f8a68e-e8da-4f5f-bc60-1c69892ea749"
      id="F_350594af-ecf7-40c1-aeaa-62fd200c22f5">P7Y</engn:ClassOfWarrantOrRightYearFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608"
      decimals="INF"
      id="F_576e003e-6916-42c7-86af-c8fb90190b7a"
      unitRef="U_shares">138696</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <engn:PercentageOfCommitmentAmount
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="2"
      id="F_b8084523-0b85-46c0-a9bd-205b19897fd3"
      unitRef="U_pure">0.02</engn:PercentageOfCommitmentAmount>
    <engn:CommitmentAmount
      contextRef="C_8871fa5a-72d5-4807-8b14-7d124187f1b2"
      decimals="-5"
      id="F_96028f8f-9ed3-47f8-957f-ddf496a6a8c1"
      unitRef="U_USD">50000000</engn:CommitmentAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_7d0a0592-eb6b-413d-a5a1-3b16c4d94608"
      decimals="2"
      id="F_34b21e44-cfc1-443c-a777-f322710e7bb1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_82ca66af-1e97-4ce0-adab-8cffb3acd9a1"
      decimals="INF"
      id="F_8658d3b0-9570-47fe-b877-af758d62a659"
      unitRef="U_shares">62413</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <engn:AdvanceOnLoanAllocatedToWarrants
      contextRef="C_41ba9c19-6515-43e0-a1fc-8f4d1b65dd7a"
      decimals="-5"
      id="F_a5f54619-d0ab-4d26-b7dc-b6c751a421de"
      unitRef="U_USD">300000</engn:AdvanceOnLoanAllocatedToWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_61fa00a4-8a04-41ad-8df5-3d8df9828b01"
      decimals="-5"
      id="F_091d9848-9e54-46d7-814a-6243f749328b"
      unitRef="U_USD">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_a957f75f-63ff-464f-9678-7ce984f6ec84">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, the carrying value of the Term Loan consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Note payable, including End of Term Charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Note payable, net of discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0a196932-bb45-4e51-825a-16dde720a445"
      decimals="-3"
      id="F_3698c055-b94e-4ea0-9c7c-07a975274959"
      unitRef="U_USD">24231000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57"
      decimals="-3"
      id="F_4d5a7939-208f-48f4-9732-3a7396bc4ccf"
      unitRef="U_USD">24663000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_0a196932-bb45-4e51-825a-16dde720a445"
      decimals="-3"
      id="F_c64a7fc0-15b7-4962-9f84-5c8e1c7b1a37"
      unitRef="U_USD">1088000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57"
      decimals="-3"
      id="F_04301955-ced4-4787-b7b1-ed842b2eac33"
      unitRef="U_USD">1673000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <engn:DebtInstrumentAccruedInterest
      contextRef="C_0a196932-bb45-4e51-825a-16dde720a445"
      decimals="-3"
      id="F_eed63f5f-bde9-4f6c-af0e-f88b7db29b1a"
      unitRef="U_USD">183000</engn:DebtInstrumentAccruedInterest>
    <engn:DebtInstrumentAccruedInterest
      contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57"
      decimals="-3"
      id="F_a4615a15-face-420c-85b5-0a215e7de725"
      unitRef="U_USD">182000</engn:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="C_0a196932-bb45-4e51-825a-16dde720a445"
      decimals="-3"
      id="F_34c5b482-9911-4c6f-b65f-5a3730b7a59e"
      unitRef="U_USD">23326000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_d91a385b-96b6-4ad7-bce1-5db5f7014c57"
      decimals="-3"
      id="F_e72a8877-08b9-4897-a501-b21bc2b47206"
      unitRef="U_USD">23172000</us-gaap:LongTermDebt>
    <us-gaap:NotesPayableCurrent
      contextRef="C_3b8bd64e-b59b-43a4-b1b4-0519c994f6b0"
      decimals="-5"
      id="F_3f4273d4-6965-4c78-9bd4-484951c21e05"
      unitRef="U_USD">8000000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_e80bdb47-f7b3-430d-b4e8-f25af73e859c"
      decimals="-5"
      id="F_f2937af0-00f2-413a-8668-7c9cc730f26b"
      unitRef="U_USD">700000</us-gaap:NotesPayableCurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="C_d4f15817-44dd-435d-b9a9-e963c46bff1a"
      decimals="-5"
      id="F_e7e84173-8ff7-4e6d-b2e6-c4d9f3fec416"
      unitRef="U_USD">2400000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_e2f37cd3-8f14-4485-8a97-18812aba3d4b"
      decimals="-5"
      id="F_b9e63aad-8f86-41da-ab6d-fa173fb80dea"
      unitRef="U_USD">2200000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_d4f15817-44dd-435d-b9a9-e963c46bff1a"
      decimals="-5"
      id="F_42aeebc5-4f4f-4c44-9228-8f73f4c86c09"
      unitRef="U_USD">600000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_e2f37cd3-8f14-4485-8a97-18812aba3d4b"
      decimals="-5"
      id="F_d7dd9fee-d8e5-4442-9a3d-3c5d7b0471c1"
      unitRef="U_USD">600000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ea05e68e-cdd0-4aba-9a8b-f7d4c7b8eada">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, the estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge, are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Note Principal&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total principal payments, including End of Term Charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485"
      decimals="-3"
      id="F_0132ce15-d30e-4d23-b731-154939b7c52d"
      unitRef="U_USD">8417000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485"
      decimals="-3"
      id="F_6da7f249-e5b9-4253-bcc2-a23b3d3be88b"
      unitRef="U_USD">10987000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485"
      decimals="-3"
      id="F_b9259d12-719a-4866-b0b7-030890d2bf88"
      unitRef="U_USD">5161000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="C_b291458d-545a-4cdc-a379-778ab2dd0485"
      decimals="-3"
      id="F_3227fb0d-ff3f-4f47-acc4-5118675658df"
      unitRef="U_USD">24565000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_0120a786-9495-4129-af76-0ee33334521e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Common Shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0d8e6fbe-0e8d-48be-94c6-063543d24362;"&gt;&lt;span style="-sec-ix-hidden:F_c36c748c-142e-4749-b840-fae3cd22d5a5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;unlimited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; number of authorized shares of Common Shares, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value.  As of  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024 there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,018,658&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,976,676&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares outstanding, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holders of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Shares are entitled to one vote&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each Common Share held on all matters submitted to a vote of shareholders. Common shareholders are entitled to receive dividends, as may be declared by the Board of Directors, if any, subject to the preferential dividend rights of preferred stock. Through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cash dividends had been declared or paid.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 13, 2024, the Company entered into subscription agreements (collectively, the &#x201c;February 2024 Subscription Agreements&#x201d;) with the investors named therein, for the private placement (the &#x201c;February 2024 PIPE Financing&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares of the Company, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The aggregate gross proceeds from the February 2024 PIPE Financing was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The February 2024 PIPE Financing closed on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 20, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 24, 2024, the Company entered into subscription agreements (collectively, the &#x201c;October 2024 Subscription Agreements&#x201d;) with the investors named therein, for the private placement (the &#x201c;October 2024 PIPE Financing&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,758,311&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares of the Company, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The aggregate gross proceeds from the October 2024 PIPE Financing was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The October 2024 PIPE Financing closed on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 29, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 20, 2024, the Company entered into an Open Market Sale Agreement (the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Jefferies, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Common Shares. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company will pay Jefferies a commission of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds of Shares sold pursuant to the Sale Agreement, and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any Shares under the Sale Agreement. The offering of the Shares pursuant to the Sale Agreement will terminate upon the termination of the Sale Agreement by Jefferies or the Company, as permitted therein&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Through October 31, 2025, the Company sold no Common Shares under the Sale Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrants to Purchase Common Shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants to purchase common shares outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Of the warrants to purchase Common Shares outstanding as of October 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,449,555&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and are exercisable through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company may elect to call in the warrants for redemption if the share price of the Company equals or exceeds $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for any twenty (20) trading days within the thirty (30) trading-day period ending on the third (3rd) trading day prior to the date on which notice of the redemption is given, subject to adjustments as provided in the terms of the warrant agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#x2019;s common shares as prescribed by ASC 815.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The additional&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,413&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the warrants to purchase Common Shares outstanding as of October 31, 2025, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;were issued as part of the Amended Loan Agreement on December 22, 2023, have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.21&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, are exercisable at any time beginning on December 22, 2023, and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 22, 2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the issuance date. The common share warrants have been determined to be equity classified as they do not meet the definition of a liability under ASC 480 and are considered indexed to the Company&#x2019;s common shares as prescribed by ASC 815. Please refer to Note 10, Share-Based Compensation, below for the summary of the Common Shares reserved for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under and outside the Company's &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 17, Subsequent Events, for a discussion of Common Shares and pre-funded warrants to purchase Common Shares issued by the Company pursuant to an underwritten public offering in November 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockNoParValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_390373e5-d1a4-4244-a3b7-2233b24f7e26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_8dbebe7a-a647-4b09-b7b2-60a24c7eebf7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_b66649e4-6bf8-4fcb-93be-76b4ac4d9b3c"
      unitRef="U_shares">52018658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_a75bbede-c41f-469b-a0d8-b903df383ab1"
      unitRef="U_shares">50976676</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_3a800d77-ca24-4b19-9596-d6197375145b">Common Shares are entitled to one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_eecdbf5d-4184-40f1-a5e6-b739998667a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_820f45ad-97ea-4e78-845b-0223982b1f1c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d3a16e6c-5f2f-46a8-8d4a-ae4459f30236"
      decimals="INF"
      id="F_5495583b-8f32-42b9-995c-154066cb1d83"
      unitRef="U_shares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4d87523c-9b2c-422b-88ab-47f28876bac5"
      decimals="2"
      id="F_3ac1afd9-6ba0-4c6b-94af-df2d4fe27b22"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_de15de3c-d6dd-474f-aedc-0db5998ec164"
      decimals="-6"
      id="F_e90723d8-38ff-4c12-933f-819697e1edff"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_de15de3c-d6dd-474f-aedc-0db5998ec164"
      decimals="-5"
      id="F_32eb44e7-ea23-4473-b6b1-53dcd3e274c7"
      unitRef="U_USD">12400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <engn:DateOfClosedPrivatePlacement
      contextRef="C_25dc3fbd-7df8-4e6a-9735-4c158848064d"
      id="F_5ce4449f-1541-4471-8325-a3c9043b3754">2024-02-20</engn:DateOfClosedPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_84f13fed-94e2-4af5-bddf-2b0f45ef17c7"
      decimals="INF"
      id="F_e6220781-7984-4ac5-a0cc-c2a3ccd9ce2d"
      unitRef="U_shares">6758311</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_223bc65f-a711-41ae-93e5-990ae4cc4647"
      decimals="2"
      id="F_9cc66096-0948-4738-b8be-fe6798517550"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.9</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1bd63320-3f8c-40e8-870a-a2cdeaa9bc46"
      decimals="-5"
      id="F_949299e9-a441-4850-ae7c-ff5c4522247f"
      unitRef="U_USD">60100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_1bd63320-3f8c-40e8-870a-a2cdeaa9bc46"
      decimals="-5"
      id="F_b00a970f-006e-42ad-b3a7-03bf9e7fae2c"
      unitRef="U_USD">3800000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <engn:DateOfClosedPrivatePlacement
      contextRef="C_3fc74f8e-4433-476f-a81c-1803cf2f12f5"
      id="F_f0428955-3bf1-456a-8f92-5b3254b12d70">2024-10-29</engn:DateOfClosedPrivatePlacement>
    <engn:MaximumAmountOfCommonSharesToBeSold
      contextRef="C_cdad3c31-b6c0-4967-959f-1627e8533147"
      decimals="INF"
      id="F_aeb39b11-4f46-402f-aefa-bb1e7f832188"
      unitRef="U_USD">100000000</engn:MaximumAmountOfCommonSharesToBeSold>
    <engn:PaymentOfMaximumCommissionPercentageOfSharesSold
      contextRef="C_cdad3c31-b6c0-4967-959f-1627e8533147"
      decimals="3"
      id="F_2be7e234-8d4b-444f-a4cd-4b0b7196c9d7"
      unitRef="U_pure">0.03</engn:PaymentOfMaximumCommissionPercentageOfSharesSold>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_e170192b-d238-405a-b5b3-564375350a23"
      unitRef="U_shares">8511968</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_f681d19a-9ded-4748-8f88-143e49b551cf"
      unitRef="U_shares">8511968</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069"
      decimals="INF"
      id="F_9120922d-14a0-4367-81eb-995fc07d045d"
      unitRef="U_shares">8449555</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069"
      decimals="2"
      id="F_205f8788-3f25-41c2-bc18-7d3a96332ffa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      id="F_1be12e7f-c0d7-474a-97a6-f6a539047e8e">2028-10-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:SharePrice
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="2"
      id="F_38493243-540a-4a61-86d8-7032f02c6ba9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_e3f5dd26-8cbb-49ba-947e-3a9d2312c431"
      decimals="INF"
      id="F_dea4462e-e8b1-47a1-ad6f-b831b59bb6c1"
      unitRef="U_shares">62413</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6e273bec-7bf2-4681-92db-741ae2a453db"
      decimals="2"
      id="F_d831c59b-c0f7-47f2-963e-e6c2325cc9c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_e6893d7b-29b4-4a54-b96a-94fd57c3b069"
      id="F_258b8932-f7b5-40c0-9227-113343afa494">2030-12-22</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <engn:WarrantsAndRightsOutstandingMaturityPeriod
      contextRef="C_416f76a5-c88c-4d57-baa6-382632288e13"
      id="F_4baf0293-0e88-44c4-9cbd-b6f227889e5a">P7Y</engn:WarrantsAndRightsOutstandingMaturityPeriod>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b3d86028-47b8-4fde-8d49-7ad12a5f5c82">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (the "2023 Plan") was adopted on May 15, 2024 and superseded all prior plans. The 2023 Plan is administered by the Board or, at the discretion of the Board, by a committee of the Board, (the "Committee"). The exercise prices, vesting and other restrictions are determined at the discretion of the Board, or its committee if so delegated, except that the exercise price per share of stock options may not be less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the fair market value&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Common Shares on the date of grant and the term of stock option may not be greater than ten years. Common Shares that are expired, terminated, surrendered or cancelled under the 2023 Plan without having been fully exercised will be available for future awards. The Plan authorizes the award of incentive stock options, or ISOs, non-qualified stock options, or NQSOs, Stock Units, Stock Appreciation Rights, or SARs, and other share-based awards including performance awards and share bonus awards. The Plan contains the evergreen provision (the "Evergreen Provision") pursuant to which on the first business day of each calendar year, the aggregate number of Common Shares that could be issued or transferred thereunder (the "Plan Share Reserve") and the number of Common Shares available for options intended to qualify as incentive stock options (the "ISO Sublimit") each increase by such number of Common Shares  as equals &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of Common Shares outstanding on the final day of the immediately preceding calendar year (or such smaller number of shares as is determined by the compensation committee), and the ISO Sublimit by the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares and the increase in the Plan Share Reserve (or such smaller number of shares may be determined by the compensation committee of the Company&#x2019;s board of directors). On January 2, 2025 the Committee allowed the full &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% increase for 2025 under the Evergreen Provision.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, inclusive of (i) the common shares subject to the outstanding grants under the prior plans, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,548,833&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares added on January 2, 2025 under the Evergreen Provision, the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;re were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;8,651,209&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Common Shares reserved for issuance under the Plan and there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,933,304&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remaining for issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2025 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 10, 2025, at its 2025 Annual General Meeting of shareholders, the shareholders of enGene Holdings Inc. approved the adoption of the 2025 Employee Stock Purchase Plan  (the "ESPP&#x201d;), pursuant to which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common shares of the Company, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value, were reserved for issuance. The price of common shares purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market value of the common shares on the first trading day of the offering period or the relevant purchase date and is subject to change by a Plan Administrator prior to each purchase period. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remained available for issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inducement Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may grant inducement equity award consisting of a non-qualified stock option to purchase Common Shares to newly hired employees as an inducement material to the employee's entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4), which, if made, are granted outside of the 2023 Plan. During year ended October 31, 2025, the Company issued options to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,709,550&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares to certain new hire employees at a weighted-average exercise price o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;f $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The options awarded have an exercise price equal to the closing stock price of the Company on the date of the grant and vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal amounts monthly for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thereafter, subject continued service as an employee.  The options have a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from the date of the grant. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024, the Company issued options to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,643,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares to certain new hire employees at a weighted-average exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;493,851&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the inducement grant stock options have vested, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; hav&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e been forfeited and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne have expired, and, other than forfeited options, all options remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, and 2024, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the 2023 Plan and options granted outside of the 2023 Plan as part of the inducement grants:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Incentive options to purchase common shares awarded pursuant to the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,717,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,391,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inducement grant stock options awarded outside of the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,315,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,643,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remaining shares reserved for future issuance under&lt;br/&gt;&#160;&#160;&#160;the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,933,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,752,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remaining shares reserved for future issuance under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,478,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,299,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.209%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.376%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.376%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="7" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common shares and exercise price of options (USD)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.668%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price (USD)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,034,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,926,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,041,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;886,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,033,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and exercisable as of October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,935,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options unvested as of October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,098,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company&#x2019;s common share as of each reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant-date fair value per share of share options granted during the years ended October 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.62&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Modification of Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 13, 2024, the Company entered into a Transition and Modified Employment Agreement (the &#x201c;Transition Agreement&#x201d;) with the Company's former Chief Executive Officer, Jason Hanson, which amends and modifies the CEO's Employment Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;dated November 8, 2023 (the &#x201c;Amended Employment Agreement&#x201d;). Under the terms of the Amended Employment Agreement Mr. Hanson will be entitled to:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(i)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months of continued health insurance benefits; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(ii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;payment of a 2024 target annual bonus in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;390,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, less applicable taxes and withholdings; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;acceleration and vesting of any then unvested time-based equity awards that would have vested in the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period following such termination; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(iv)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;extension of the period to exercise his vested equity awards to three years following the later of date of termination of his employment or the date of termination of the Consulting Period (as defined below), but in no event shall the post-termination exercise period of the CEO&#x2019;s vested equity awards extend beyond the respective applicable term thereof.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Transition Agreement further provided that, in the event Mr. Hanson were to resign upon the appointment by the Company of a new chief executive officer, Mr. Hanson would be immediately engaged in a consulting role to provide transition services as a Senior Strategic Advisor to the Company for a period of at least six months following the effective date of resignation (the &#x201c;Consulting Period&#x201d;) in exchange for a monthly fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the initial &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Consulting Period, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per hour thereafter, provided that Mr. Hanson need not devote more than fifteen (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) hours per week to providing such transition services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Transition Agreement, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,216,266&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock option awards issued to Mr. Hanson were modified to allow for an extended exercise period as described above. The modification resulted in an incremental share-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which was recorded upon the effective date of the Transition Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mr. Hanson resigned effective as of July 19, 2024 in connection with the Company&#x2019;s appointment of a new chief executive officer. On July 20, 2024, enGene appointed Ronald H. W. Cooper as Chief Executive Officer of the Company and as director of the Company's Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, in 2024, the Company entered into a Severance Agreement with each of three former employees, including the former Chief Medical Officer and the former Chief Scientific Officer. Under the terms of Severance Agreement, the employees are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of continued pay and health insurance benefits; a payment of a 2024 target annual bonus prorated through the last day of employment, acceleration and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination and an extended expiry period, which resulted in a stock-based compensation modification. Under the terms of the agreements, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;231,684&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; stock option awards were modified to allow for an extended exercise period as described above. As of October 31, 2024, the Company recognized incremental stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the severance agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of unrecognized compensation, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_f3d38713-54b7-4d7a-9bcd-88b4b937d366"
      decimals="INF"
      id="F_b63fc562-d2e9-4450-874a-2c0aace5bdd8"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <engn:CommonSharesPercentage
      contextRef="C_230bfa79-c42e-4689-8d7a-7064e8c335b7"
      decimals="2"
      id="F_6e0bca04-cc69-4968-85e5-6708c6cdf156"
      unitRef="U_pure">0.05</engn:CommonSharesPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_230bfa79-c42e-4689-8d7a-7064e8c335b7"
      decimals="0"
      id="F_2789cf0d-e611-4352-8c4c-7f8abcdce967"
      unitRef="U_shares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <engn:CommonSharesPercentage
      contextRef="C_7fc54fca-2826-4f40-b784-cb10a1e8ea92"
      decimals="2"
      id="F_37d8be66-4336-40bd-84f7-241beb84620a"
      unitRef="U_pure">0.05</engn:CommonSharesPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_19e56deb-53a4-4d6b-948d-09e6e90bcf8f"
      decimals="INF"
      id="F_16b6364f-6c62-4f58-9895-c8da2578aa21"
      unitRef="U_shares">2548833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_19e56deb-53a4-4d6b-948d-09e6e90bcf8f"
      decimals="INF"
      id="F_641a52b4-3497-4f31-9c94-e17d34d3d587"
      unitRef="U_shares">8651209</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <engn:CommonStockCapitalSharesReservedForRemainingFutureIssuance
      contextRef="C_04e07ed1-3cb5-4c02-a2a7-c7099d04d3e7"
      decimals="INF"
      id="F_81503c32-f5f4-4bcf-91f6-7d6151a14f8c"
      unitRef="U_shares">2933304</engn:CommonStockCapitalSharesReservedForRemainingFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4ff723b5-d287-434b-a696-ec3b9aa13f72"
      decimals="INF"
      id="F_36068c67-c47e-446e-9741-6932e9abbb25"
      unitRef="U_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockNoParValue
      contextRef="C_4ff723b5-d287-434b-a696-ec3b9aa13f72"
      decimals="INF"
      id="F_81c465e5-5ba7-479b-be65-773a0da7db7a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_8e9a0825-260c-4b9d-90b7-bbd7617e8f5d"
      decimals="2"
      id="F_b918822f-7ecd-4d1c-9365-7fb0b5b4de87"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_6394b714-e543-43ff-9b1c-7ba9b8f9d298"
      decimals="INF"
      id="F_deb243ba-ed74-49b0-8fb8-8d1f76666c68"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <engn:CommonStockCapitalSharesReservedForRemainingFutureIssuance
      contextRef="C_6394b714-e543-43ff-9b1c-7ba9b8f9d298"
      decimals="INF"
      id="F_9094f252-03fe-4ecb-bc30-df743db15173"
      unitRef="U_shares">2000000</engn:CommonStockCapitalSharesReservedForRemainingFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_58c8e092-7276-4637-903f-b05e6860130b"
      decimals="0"
      id="F_b3e73d4e-69ad-40c1-8f58-b2196a75d769"
      unitRef="U_shares">1709550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_17444e1c-b04e-4b70-b7f4-f350e405d58b"
      decimals="2"
      id="F_897ca5b3-78e0-4f35-a955-ff86a3989b5f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_58c8e092-7276-4637-903f-b05e6860130b"
      id="F_36e566e0-7eee-4ab0-aa71-314167d970d6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_e3b821c4-4eac-43b3-bad5-9928776d4618"
      decimals="2"
      id="F_4f7a0015-45bd-4506-8885-07f0911f8a46"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_cebd2d56-16f6-4436-b24a-6359ae1363a7"
      id="F_3f4867d6-d09d-476f-b067-7ba8297edabb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_58c8e092-7276-4637-903f-b05e6860130b"
      id="F_ae02d86d-8726-42c5-85da-10e7665ad659">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_fd0ed931-526b-4cfb-9b89-94003be94781"
      decimals="0"
      id="F_8d89b5b7-214e-4b1b-9671-73dd2ca609bc"
      unitRef="U_shares">1643000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_c9ac9f07-169f-4b39-9e8b-20722b5214f8"
      decimals="2"
      id="F_36eaf546-30e7-4f64-8367-54fe4aa63e3d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_58c8e092-7276-4637-903f-b05e6860130b"
      decimals="INF"
      id="F_87880b90-49ce-4c02-b9ea-89ab21d64973"
      unitRef="U_shares">493851</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_58c8e092-7276-4637-903f-b05e6860130b"
      decimals="INF"
      id="F_670ae747-0386-4967-a921-8e0398564615"
      unitRef="U_shares">37200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_58c8e092-7276-4637-903f-b05e6860130b"
      decimals="INF"
      id="F_556dde59-22c3-48dc-8b59-2d3383e84b08"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_eca34943-4e40-4831-b331-82c3575d42b7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, and 2024, the Company has reserved the following Common Shares for the exercise of Common Share warrants, share options, and remaining shares reserved for future issuance under the 2023 Plan and options granted outside of the 2023 Plan as part of the inducement grants:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Incentive options to purchase common shares awarded pursuant to the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,717,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,391,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inducement grant stock options awarded outside of the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,315,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,643,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remaining shares reserved for future issuance under&lt;br/&gt;&#160;&#160;&#160;the 2023 Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,933,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,752,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remaining shares reserved for future issuance under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,478,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,299,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</engn:ScheduleOfSharesReservedForFutureIssuanceUnderThePlanTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_66290f5a-4ebf-4f73-b964-455cb62466aa"
      decimals="INF"
      id="F_0be4ec97-544f-4594-91f6-4bd1a5e819c0"
      unitRef="U_shares">8511968</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_399413d5-87a5-4355-8641-293745be5095"
      decimals="INF"
      id="F_6ccecf9e-76a6-4146-8635-e93400aaee7a"
      unitRef="U_shares">8511968</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_60b37ed7-9421-4001-bbd1-89a359c2ed0a"
      decimals="INF"
      id="F_d5e40c3c-862b-4ed3-a4ac-295c5ec8ec11"
      unitRef="U_shares">5717948</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_631df185-2355-4542-ae58-d1eaa9a937d7"
      decimals="INF"
      id="F_e9c70726-cc27-453d-b52b-2fab5661fcee"
      unitRef="U_shares">4391512</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_36a6765d-a768-434b-b6af-c19baebb16f9"
      decimals="INF"
      id="F_92ca64fe-0481-4841-ba9e-2012b59af138"
      unitRef="U_shares">3315350</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_240506c4-bcce-4242-904f-1aef27639793"
      decimals="INF"
      id="F_e6916a5f-542e-4afc-b83b-57906e2d27cc"
      unitRef="U_shares">1643000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b6f75307-46d2-4549-9972-666e9421fcbc"
      decimals="INF"
      id="F_b7747eda-7734-440f-a706-0903e1bbedcc"
      unitRef="U_shares">2933304</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6fbe3c27-7c74-4f39-a002-7cb3cad726bb"
      decimals="INF"
      id="F_006f4e9b-463c-4690-bf8c-7bc51d72845e"
      unitRef="U_shares">2752889</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1e0f6ec7-da3e-436f-8606-34f7da89269a"
      decimals="INF"
      id="F_193f3b8f-37d7-4919-bb5c-eecc96b3acee"
      unitRef="U_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_5820deb3-7c13-4a43-af5a-f33f842c18ae"
      unitRef="U_shares">22478570</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_977682bd-4305-47f5-96d4-a4c193990a62"
      unitRef="U_shares">17299369</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_105cb8a7-cbeb-4647-b338-b9456699c7c0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The assumptions that the Company used to determine the grant-date fair value of stock options during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:54.209%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.376%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.376%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="7" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.51&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.49&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fair value of common shares and exercise price of options (USD)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e82b042f-c2f1-4591-a95e-196afa1ab585"
      id="F_6614cd5e-d807-46db-9ba1-8988744acecb">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bb659fef-c385-43b9-827a-dd3a85171737"
      id="F_423dbc64-b9d9-46d1-bd0b-b62c04a39e0b">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_038fbf25-9506-4d27-be17-4dc097874279"
      id="F_cebde12f-3ad2-447d-a28d-2976365789fa">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7444e3af-f026-4566-9f7c-881accfccf6d"
      id="F_1945412c-0abc-4e70-b5da-430a4edcd5e1">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c"
      decimals="4"
      id="F_305404d7-c110-46bb-8841-f18b3d9f1e3c"
      unitRef="U_pure">0.7878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c"
      decimals="4"
      id="F_a989d747-18eb-46a8-9913-87ed261940c8"
      unitRef="U_pure">0.8353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_47ffee90-525a-4d51-9a91-98932a653084"
      decimals="4"
      id="F_da762271-6623-4a10-ae48-67da2f30f01d"
      unitRef="U_pure">0.7824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_47ffee90-525a-4d51-9a91-98932a653084"
      decimals="4"
      id="F_352314df-86d6-4550-83d9-f266c45fd488"
      unitRef="U_pure">0.8233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c"
      decimals="4"
      id="F_3b5318ce-2738-4b15-be39-22825be7e508"
      unitRef="U_pure">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c"
      decimals="4"
      id="F_7730e619-a4a0-40d9-a84a-9dc4f3c9cf7c"
      unitRef="U_pure">0.0449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_47ffee90-525a-4d51-9a91-98932a653084"
      decimals="INF"
      id="F_45135fa0-12ff-46ae-98cf-6fb8e363226d"
      unitRef="U_pure">0.0178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_47ffee90-525a-4d51-9a91-98932a653084"
      decimals="INF"
      id="F_4c5080d6-080c-46b8-8bdf-fa7df7c57d87"
      unitRef="U_pure">0.0466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum
      contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c"
      decimals="INF"
      id="F_795c24c5-4e7b-40a8-b463-888b1d3a0f97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.31</engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum>
    <engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum
      contextRef="C_fe08772b-3b75-4431-99b3-b2403219570c"
      decimals="INF"
      id="F_248ad6a7-9922-4f63-baad-46165345fbed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.39</engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum>
    <engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum
      contextRef="C_47ffee90-525a-4d51-9a91-98932a653084"
      decimals="INF"
      id="F_12f3cc1f-4194-4b40-8cfd-a1e6c375ea96"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.73</engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMinimum>
    <engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum
      contextRef="C_47ffee90-525a-4d51-9a91-98932a653084"
      decimals="INF"
      id="F_80671efb-7cd8-442b-8fb1-cb8de9e71811"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.6</engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfCommonSharesAndExercisePriceOfOptionsMaximum>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_36903d64-23a2-4ff9-849a-a3d3f990ea73">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.41%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.668%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.187%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price (USD)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of October 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,034,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,926,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,041,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;886,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,033,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and exercisable as of October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,935,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options unvested as of October 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,098,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_6eabc655-46fe-4027-95b5-d548b3e1d596"
      unitRef="U_shares">6034512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="2"
      id="F_faee6ce4-a4c4-4e03-ba89-bd9bea9a09d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      id="F_531bf77e-75f3-423b-8594-afd36898bba6">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_23afe600-5a7d-42a5-9b7e-4ed078079627"
      unitRef="U_USD">17809000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_d4ac7d46-9b42-4802-93bc-81c83f38c6e7"
      unitRef="U_shares">4926875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_d124ecb4-74b8-4335-aa6d-c3c218629fc4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_8c555015-7e04-42e9-ada7-415540657702"
      unitRef="U_shares">1041982</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_0dac0586-49be-4e6a-a80e-1b06a1188b6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_07b1c428-bf68-42b4-9828-0dcae75d263b"
      unitRef="U_shares">886107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_0d095113-8830-4a6e-a078-ce4c168dd2b3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_9dcd6e2a-8235-46ce-b637-fee36963a4db"
      unitRef="U_shares">9033298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="2"
      id="F_7fc63eb0-efbb-4b5a-8943-1231feb67a2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_8eb0fbcb-e00a-4143-b20d-0eefb36d4c38">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_9cfb0e78-868b-4282-b36f-5ecff884f868"
      unitRef="U_USD">10979000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_29d6fb50-b8ee-4752-a25d-86cecd65ce2e"
      unitRef="U_shares">2935183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="2"
      id="F_7c374fa7-b713-413f-a544-a4535fa98f08"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_376d05f2-cd14-4aed-853a-4cfc302aaf44">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_61ff1b9f-c125-4bca-94bb-127b0cfde7fd"
      unitRef="U_USD">6497000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_765896ca-bed8-4bc5-8bd4-3595ed92a829"
      unitRef="U_shares">6098115</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="2"
      id="F_35e0e04d-a85c-43ee-b9ce-f31ccdb89337"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_94dae84e-b923-428f-8c2d-095fc3089886">P9Y2M12D</engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1>
    <engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_51e4efec-b669-4388-ad11-575a114f477e"
      unitRef="U_USD">4482000</engn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_dc1f028f-714e-450f-a4ba-de66ac34eae4"
      unitRef="U_CanadaDollarsShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="2"
      id="F_06c8803b-0fee-46f3-b97c-b076f9ab3f28"
      unitRef="U_CanadaDollarsShare">7.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <engn:PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      decimals="0"
      id="F_53ccbb4c-f8d4-4ce4-8a99-a8db4eea0a6a"
      unitRef="U_USD">390000</engn:PaymentOfTargetAnnualBonusNetoffTaxesAndWithholdings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      id="F_c8ab550a-13de-4f55-aaff-59aee5c0d76b">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <engn:AmountOfMonthlyFeeForConsultingPeriod
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      decimals="0"
      id="F_35fd3b02-6de4-4614-ade7-118c0ed6c129"
      unitRef="U_USD">25000</engn:AmountOfMonthlyFeeForConsultingPeriod>
    <engn:InitialConsultingPeriod
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      id="F_fc72b02c-5010-4a9e-8f9c-2d991656c130">P6M</engn:InitialConsultingPeriod>
    <engn:TransitionServicesForConsultingFeePerHour
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      decimals="0"
      id="F_5a88bdf1-a283-4686-9a23-2ad50ea6099c"
      unitRef="U_USD">500</engn:TransitionServicesForConsultingFeePerHour>
    <engn:MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      id="F_c744fb9f-915c-42d1-b5ff-d686e2b3e27b">PT15H</engn:MaximumHoursOfCeoDevotePerWeekToProvidingTransitionServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2f23a9ac-e3c9-44c5-a5a3-2bb5059a0bae"
      decimals="INF"
      id="F_3b71f7b4-609b-4a92-bc2f-3df61626994c"
      unitRef="U_shares">1216266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_0f0f9870-180f-4dd3-b9c4-ef3ac4ad5d5c"
      decimals="-5"
      id="F_ef08b47e-32d0-4ba6-89b9-59d3b483c113"
      unitRef="U_USD">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <engn:EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits
      contextRef="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527"
      id="F_9e410fe5-64f9-4a8c-8b34-b35e59d6544a">P12M</engn:EmployeeEntitledForContinuedPayAndHealthInsuranceBenefits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527"
      decimals="INF"
      id="F_98181379-171e-4f68-bd80-1a86fd42eb9d"
      unitRef="U_shares">231684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="C_bfd32be4-fa9d-48f5-8e0f-0cbcf3992527"
      decimals="-5"
      id="F_73775c42-fdf8-458b-a624-6d9241903e94"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_25f1a560-3a97-49b7-8b6e-a72865bb6c20">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation expense included in the Company&#x2019;s consolidated statements of operations and comprehensive loss was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d7356f23-a631-4161-bd89-54fd825f3f25"
      decimals="-3"
      id="F_94b6ebd3-ce7e-409b-9430-ca9a38ffe6ea"
      unitRef="U_USD">3282000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f3b47999-d181-4066-a9da-9e9a4d44f5f3"
      decimals="-3"
      id="F_f0330c11-56a9-4df8-9e6f-5884cc5f7c41"
      unitRef="U_USD">1794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_923c8314-6767-44a6-8d7d-414375566f36"
      decimals="-3"
      id="F_784c80e0-20f9-410d-968f-244b74917e1a"
      unitRef="U_USD">6364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d4ba6974-9607-41bb-882a-98cb023fc12d"
      decimals="-3"
      id="F_8f813c06-7e17-4156-8aca-2b48a676bf5d"
      unitRef="U_USD">3530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_c5809434-b42c-414d-893e-4f16c1ccca16"
      unitRef="U_USD">9646000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_cbc8e1f3-08d0-4452-aa41-adac2d03b2f2"
      unitRef="U_USD">5324000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_d6e19c81-72a8-4977-831e-1c9578869e5d"
      unitRef="U_USD">30700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_a05b7f2e-12b0-41c3-a758-bf96dea67c96">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_f3b1dfaa-2ae1-4a3b-9a55-e77623c924ed">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the reverse recapitalization:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of common shares used in net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,119,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,782,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,033,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,034,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,545,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,546,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_00da6c29-866f-446e-ab87-15c855539b59">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per share for the periods presented, retrospectively restated to reflect the exchange of shares upon the close of the reverse recapitalization:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:68.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average number of common shares used in net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,119,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,782,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_0b5ab190-b16c-44a1-a7f2-2ccc3f9fcab1"
      unitRef="U_USD">-117302000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_961f1f6d-af71-4e0c-a37b-3c93b7e7453e"
      unitRef="U_USD">-117302000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_82644f1a-aa37-4033-a9c3-e55e90882cdd"
      unitRef="U_USD">-55142000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_b0a9eb7c-e9ad-45ba-8305-63b4c22347c8"
      unitRef="U_USD">-55142000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="0"
      id="F_587406ab-a027-4ab2-a071-55a711ebf636"
      unitRef="U_shares">51119479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="0"
      id="F_986d48df-4dcb-4096-8df2-51cd22afccc6"
      unitRef="U_shares">51119479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_e17efc0b-57a0-42bd-8dca-5459d8d85ba8"
      unitRef="U_shares">37782346</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_1a8891af-03e5-45a4-8e6a-fb8e7aa891eb"
      unitRef="U_shares">37782346</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_6a9b3060-86d3-4bb7-aae2-372743d298f3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="2"
      id="F_ee609f86-ea12-46c0-8cd7-4f5978af944e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="2"
      id="F_b035b87e-9ee6-4485-b779-fde6fb2268e6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="2"
      id="F_42362633-d9f3-4df3-b50d-102f49649ba5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_32974f61-9799-48ed-ad15-c96c74912389">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded the following shares from the computation of diluted net loss per share attributable to common shareholders during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, and 2024 because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,511,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,033,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,034,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,545,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,546,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_138b2f29-e2e4-468e-a432-96f0a15a5f12"
      decimals="0"
      id="F_560b01fb-aa8d-4710-899f-6384e580d9b5"
      unitRef="U_shares">8511968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3538eb76-754e-4b90-b6ae-b9741667f639"
      decimals="0"
      id="F_b903dd92-1b85-4fa8-9d0a-b800b96d5282"
      unitRef="U_shares">8511968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_342954c6-d213-4cd2-9889-aced7e8d67f5"
      decimals="0"
      id="F_6941a7c4-14d0-4443-87b4-fff0bcdb566a"
      unitRef="U_shares">9033298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b57c7e68-7206-43ef-83a4-48c2637e7914"
      decimals="0"
      id="F_93f41cf5-44cd-4f1d-866d-61e43320ed45"
      unitRef="U_shares">6034512</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="0"
      id="F_f375870a-a165-4c5d-a0b9-bd77f931a1eb"
      unitRef="U_shares">17545266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="0"
      id="F_ca7c7caf-74df-4d50-8ab6-275fb2a594e2"
      unitRef="U_shares">14546480</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_afdb251c-e8b9-4503-a324-0daf53e9f874">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loss before provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic (Canada)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign (US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the provision for (recovery of) income taxes is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current expense (benefit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic (Canada)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign (US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic (Canada)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign (US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.322000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.322000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income at Canadian statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The net deferred income tax balances related to the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss (NOL) carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment tax credits, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease-right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#x2019;s judgment changes as a result of evaluating new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; uncertain tax positions have been recorded in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of October 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company has Canadian Federal NOL carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, that expire between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2045&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and Canadian provincial NOL carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;214.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, that expire between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2045&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These losses are available to offset future taxable income in Canada and Quebec.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company has a U.S. Federal NOL carryforward of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, that may be carried forward indefinitely, and a U.S. state NOL carryforward of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which are available to offset against future taxable income in the U.S and Massachusetts. The U.S. State tax loss carryforward will expire between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2045&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has not recognized the tax benefit of these losses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company also has non-refundable Canadian investment tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that expire between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2045&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These credits may be utilized to reduce Canadian federal income taxes payable. The Company has not recognized the tax benefits related to these non-refundable investment tax credits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company also has capital losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which are available to be used indefinitely against future capital gains.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025, the Company had Scientific Research and Experimental Development (&#x201c;SR&amp;amp;ED&#x201d;) expenditures of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for Canadian federal and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for Qu&#xe9;bec provincial purposes, which have not been deducted. These expenditures are available to reduce future taxable income and have an unlimited carryforward period. SR&amp;amp;ED expenditures are subject to verification by the tax authorities and, accordingly, the amounts may vary.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_f323e41f-06c5-4fb8-9c91-9083b24871d1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loss before provision for income taxes consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic (Canada)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign (US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_a7ca992e-206e-4da0-941d-0ae8fe595ed7"
      unitRef="U_USD">-103727000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_55187ba3-00d5-4f98-89d1-03a3ecdc42f2"
      unitRef="U_USD">-53460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_51bf229f-61e0-4c71-b69c-7f0d4c328cf8"
      unitRef="U_USD">-13575000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_fb471aaa-2af0-4b1c-b7b4-fc9eb010afba"
      unitRef="U_USD">-1701000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_ff11fe22-eac2-4010-9caa-f1e093e7176f"
      unitRef="U_USD">-117302000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_13cdcde8-d976-4022-9cd1-5a8690dc7fb4"
      unitRef="U_USD">-55161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_95a4e6de-f2db-46b4-89d6-73bba55f3242">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of the provision for (recovery of) income taxes is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current expense (benefit):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic (Canada)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign (US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic (Canada)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign (US)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_ebdacb8f-54f1-4dae-b429-f0ef78d8ffd2"
      unitRef="U_USD">-19000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_3d2381c7-2153-4d9f-9bc0-895147b852fa"
      unitRef="U_USD">-19000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_b9f8074f-d637-4afa-aede-0127ad72777b"
      unitRef="U_USD">-19000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_dd1ff19c-872c-4260-b954-8d490571d09e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.322000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.322000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income at Canadian statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_19d803d6-d738-4943-8557-062fe1b60896"
      unitRef="U_pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="INF"
      id="F_4fbeeada-d215-4fa9-b70d-6ba687f11d6d"
      unitRef="U_pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_860ad6a9-2999-4dc5-86fc-289aa512bef5"
      unitRef="U_pure">0.0066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_1694ad3a-b596-47d9-849c-63f26ce3996a"
      unitRef="U_pure">0.0018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_1564f7ee-053e-4bd1-bb9d-43702ffbabeb"
      unitRef="U_pure">-0.0029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_cf158c01-1804-4cc7-a7d8-337b9edde544"
      unitRef="U_pure">-0.0277</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_d8481a15-5c43-487a-9b91-b0c3d79c652b"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_0c398386-6fdd-45a7-9dae-7d89abfe4745"
      unitRef="U_pure">-0.0107</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_a5c2e975-5dc8-4658-a608-188827908ebd"
      unitRef="U_pure">-0.0064</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_73f1a7e8-425f-48c1-9b2a-e69ae8cc05c5"
      unitRef="U_pure">-0.0017</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_b4e14c0c-ea85-42c0-82f9-8cadf2331596"
      unitRef="U_pure">-0.2682</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_84e55694-9d36-4825-85a7-afddedd8d1fc"
      unitRef="U_pure">-0.2502</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_f7e7d877-778d-4df4-abfa-45fceaf07ab6"
      unitRef="U_pure">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_4f7ba66f-2d3d-462f-860e-284fbf1223f8"
      unitRef="U_pure">0.0024</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="4"
      id="F_77cbbc4f-b765-4cb1-ad78-fe1a5f93b649"
      unitRef="U_pure">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="4"
      id="F_66c6c216-1b4a-4ffb-84b7-a56194e20e8e"
      unitRef="U_pure">0.0003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_cb634c14-5f67-4cbd-b3fb-9b799e058bc1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The net deferred income tax balances related to the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss (NOL) carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investment tax credits, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease-right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liability)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_4ecd3c32-bbf1-49cb-acf6-667bcf083d39"
      unitRef="U_USD">10021000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_3ed4afef-306f-4d10-bf6a-f4194860fa89"
      unitRef="U_USD">8172000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_068ebf72-d2d3-46b4-bd8e-86e4ce8515fb"
      unitRef="U_USD">61127000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_fb4a4397-638d-421d-a974-06f71cb83a56"
      unitRef="U_USD">31661000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_51e0d254-5191-47e1-b577-fd4e92d7d0ea"
      unitRef="U_USD">285000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_d586f9a9-ea9e-4f21-9285-f928aa28d379"
      unitRef="U_USD">97000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_2364138f-27ee-4153-ac01-dac763abc05c"
      unitRef="U_USD">2688000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_45711c57-7d1c-4e2c-a7b3-fdf369912d0f"
      unitRef="U_USD">1934000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_c92edcce-a46e-49c8-8e9e-6b94b0ea90c4"
      unitRef="U_USD">270000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_1fef20e7-27ac-4596-aa92-0bda745fa069"
      unitRef="U_USD">704000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <engn:DeferredTaxAssetsFinancingCosts
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_ea30cbf7-91ce-4e62-9091-ead7cc204b90"
      unitRef="U_USD">4000000</engn:DeferredTaxAssetsFinancingCosts>
    <engn:DeferredTaxAssetsFinancingCosts
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_98b06ffa-1f29-4f36-9093-1930e36fd647"
      unitRef="U_USD">5452000</engn:DeferredTaxAssetsFinancingCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_05496e70-305c-4ef7-b91d-de6a89ef70a8"
      unitRef="U_USD">924000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_b14bd100-1dd0-494f-82cd-68a9a1e5a3c2"
      unitRef="U_USD">747000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <engn:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_71700296-ce39-435c-ba3a-f18733fbdfed"
      unitRef="U_USD">2270000</engn:DeferredTaxAssetsOperatingLeaseLiability>
    <engn:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_56aa2cff-05da-4d41-9bfa-58777cc2bcd6"
      unitRef="U_USD">404000</engn:DeferredTaxAssetsOperatingLeaseLiability>
    <engn:DeferredTaxAssetsNotePayable
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_559094b3-b944-4975-8177-60913e7b1cda"
      unitRef="U_USD">15000</engn:DeferredTaxAssetsNotePayable>
    <engn:DeferredTaxAssetsNotePayable
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_ecfd70e0-85c7-49d4-886c-f50c4009519e"
      unitRef="U_USD">197000</engn:DeferredTaxAssetsNotePayable>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_3ce6f9b4-1598-460b-8893-62ab959c4797"
      unitRef="U_USD">894000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_f4ade78b-26aa-4252-98d1-0a7e49466a13"
      unitRef="U_USD">1000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_a71ff491-3b35-45aa-b6a6-82859242b507"
      unitRef="U_USD">82494000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_59166b67-2233-45e5-8bfe-9e1a55587e90"
      unitRef="U_USD">49369000</us-gaap:DeferredTaxAssetsGross>
    <engn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_a8aed3c5-9df1-4012-b84d-366116712080"
      unitRef="U_USD">2068000</engn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <engn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_fad00604-927f-4f2b-8462-2759ad3f714c"
      unitRef="U_USD">377000</engn:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_404c85f4-d410-40e6-b928-79c56d3676e1"
      unitRef="U_USD">2068000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_3175032f-3760-4b77-81d9-4e99517d4300"
      unitRef="U_USD">377000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_9b411d54-d2ef-439d-b061-4b726d958a93"
      unitRef="U_USD">80426000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-3"
      id="F_49437946-99ba-4a01-89d4-31cf171b92df"
      unitRef="U_USD">48992000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_03833c8f-e062-4d1e-a06a-f68116b4ac91"
      unitRef="U_USD">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="INF"
      id="F_1cb9d8d0-d2a3-4b9e-9c47-51595b8cfff5"
      unitRef="U_USD">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="INF"
      id="F_e7de0962-d782-4735-b4d3-a8885f5a4df1"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="INF"
      id="F_f108775c-fae3-4fce-9030-131388aa972f"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="0"
      id="F_2356a0eb-b315-48a4-8e0d-d15d039c0de2"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="0"
      id="F_f839c65b-040b-4bda-b07f-74f66a991db9"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_a38b00d3-e24c-43b5-a082-589eacb61337"
      decimals="-5"
      id="F_48848722-94b3-4dd3-87a9-31c0b82b2524"
      unitRef="U_USD">220500000</us-gaap:OperatingLossCarryforwards>
    <engn:NetOperatingLossCarryforwardsExpirationYear
      contextRef="C_1fee1be9-7dcb-46f6-91a8-e987b5b47b59"
      id="F_d83b5fd0-d849-4b36-9556-dd08a1b374df">2026</engn:NetOperatingLossCarryforwardsExpirationYear>
    <engn:NetOperatingLossCarryforwardsExpirationYear
      contextRef="C_f156578b-8f46-4ad0-9ea8-b91f1797eb52"
      id="F_b2bbd59d-e1a6-4461-bb58-6a5afbdb8b10">2045</engn:NetOperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_95a2beb8-4e85-43b1-85ca-fbc18197ebed"
      decimals="-5"
      id="F_1521957d-37f5-41d4-bf6f-5f3dd3362452"
      unitRef="U_USD">214300000</us-gaap:OperatingLossCarryforwards>
    <engn:NetOperatingLossCarryforwardsExpirationYear
      contextRef="C_3039a78d-24dd-4c83-bbb1-043d190146b7"
      id="F_b0aa3758-7667-4f94-93c1-331b1dbceda7">2028</engn:NetOperatingLossCarryforwardsExpirationYear>
    <engn:NetOperatingLossCarryforwardsExpirationYear
      contextRef="C_1ceadb8f-dcfe-48ff-a395-cc04ab63412f"
      id="F_ecae9627-d944-40db-8e73-6a0ad78fd732">2045</engn:NetOperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_17725118-e54f-47d5-a64c-c3a544f8f924"
      decimals="-5"
      id="F_0d5dcc06-5153-4243-9053-2e0fb75db761"
      unitRef="U_USD">11700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f6c04b3e-ddf2-41e5-a4fa-0884f592b542"
      decimals="-5"
      id="F_77f2ee19-94a8-4409-af70-99b7cba5531b"
      unitRef="U_USD">10000000</us-gaap:OperatingLossCarryforwards>
    <engn:InvestmentTaxCreditsExpirationYear
      contextRef="C_37f20ce2-0d85-4e2a-a443-1969a8e12178"
      id="F_7186720f-cd43-4ca7-a872-4cf06f6bccdf">2041</engn:InvestmentTaxCreditsExpirationYear>
    <engn:InvestmentTaxCreditsExpirationYear
      contextRef="C_9ea003c8-a81c-44b8-900c-b2493af5c02e"
      id="F_c316364a-37bf-4f9c-809c-8d6910188cdc">2045</engn:InvestmentTaxCreditsExpirationYear>
    <us-gaap:InvestmentTaxCredit
      contextRef="C_c7b8ec67-5b1d-4c7f-8db7-8e567d0d0440"
      decimals="-5"
      id="F_b97c070f-6709-4873-8d7e-37f3f27b6327"
      unitRef="U_USD">3700000</us-gaap:InvestmentTaxCredit>
    <engn:InvestmentTaxCreditsExpirationYear
      contextRef="C_3039a78d-24dd-4c83-bbb1-043d190146b7"
      id="F_b5d80931-2d6f-44cf-95cb-37d358775e55">2026</engn:InvestmentTaxCreditsExpirationYear>
    <engn:InvestmentTaxCreditsExpirationYear
      contextRef="C_1ceadb8f-dcfe-48ff-a395-cc04ab63412f"
      id="F_c3630b09-481e-4d83-8f8f-a2eec5ce32e1">2045</engn:InvestmentTaxCreditsExpirationYear>
    <engn:CapitalLossCarryforward
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_6b7d33dc-a726-4042-9652-c124da15288c"
      unitRef="U_USD">2200000</engn:CapitalLossCarryforward>
    <engn:ScientificResearchAndExperimentalDevelopmentExpenditures
      contextRef="C_a38b00d3-e24c-43b5-a082-589eacb61337"
      decimals="-5"
      id="F_0195b803-34a4-4b2a-bd05-f71da481e62d"
      unitRef="U_USD">36700000</engn:ScientificResearchAndExperimentalDevelopmentExpenditures>
    <engn:ScientificResearchAndExperimentalDevelopmentExpenditures
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_227c6da9-4bfd-43d5-90f6-97c30d1594ff"
      unitRef="U_USD">39200000</engn:ScientificResearchAndExperimentalDevelopmentExpenditures>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_a39c6799-6c17-40fa-b576-a00ab8b14760">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s leases are comprised of all operating leases for office and lab space.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 29, 2022, the Company signed a new lease for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,620&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, beginning on the commencement date, and requires an annual initial base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; CAD per square foot, which is subject to annual increases of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The lease commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.  Upon commencement the Company recognized an initial lease liability and corresponding right of use asset of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 1, 2024, enGene USA entered into a lease agreement, in which the Company is sub-leasing approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space located at 200 Fifth Avenue, Waltham, MA. The Company will make an aggregate amount of base rental payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the initial term of the lease, which is set to expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have an option to renew. Upon commencement, the Company recognized an initial lease liability and corresponding right of use asset of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 4, 2025, enGene USA, Inc entered into a lease agreement, pursuant to which the Company agreed to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,335&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space located at 99 High Street, Boston, Massachusetts. The Company is expected to make an aggregate amount of base rental payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, under the initial term of the lease, which is set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In connection with the lease, enGene Holdings Inc. has delivered a guaranty, dated June 4, 2025, pursuant to which the Company guaranteed enGene USA's payment and performance. The lease commenced in June 2025 and upon commencement, the Company recognized an initial lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and corresponding right of use asset of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.493%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.701%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the cash paid for amounts included in the measurement of the Company&#x2019;s operating lease liabilities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, and 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement&lt;br/&gt;&#160;&#160;&#160;of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturities of the Company's operating lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:5.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:31.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recorded on the balance sheet. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had operating lease liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recorded on the balance sheet.&lt;/span&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <engn:AreaOfSpace
      contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc"
      decimals="INF"
      id="F_317396c1-97bd-4832-a0c1-bca5c4e66ed7"
      unitRef="U_sqft">10620</engn:AreaOfSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc"
      id="F_ddab124f-d45b-4d36-8b8e-f6b288b97e19">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <engn:InitialAnnualBaseRentPerSquareFoot
      contextRef="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323"
      decimals="2"
      id="F_16ea78f5-dcfa-4b93-9b6a-d918ecb9ebdf"
      unitRef="U_CadPerSquareFoot">36.50</engn:InitialAnnualBaseRentPerSquareFoot>
    <engn:PercentageOfIncreaseInAnnualBaseRent
      contextRef="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323"
      decimals="2"
      id="F_1f8ad4bd-6ae0-4813-aa21-67defa8dc191"
      unitRef="U_pure">0.02</engn:PercentageOfIncreaseInAnnualBaseRent>
    <engn:OperatingLeaseCommencementPeriod
      contextRef="C_b2a3cbc4-d376-4506-bf4e-f8abb80dc323"
      id="F_afe909cf-8340-4c50-bfa1-d871e32dfeae">2023-11</engn:OperatingLeaseCommencementPeriod>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc"
      decimals="-5"
      id="F_61ab2f75-7b16-4b0c-8999-5e81b248e57f"
      unitRef="U_USD">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7519ec96-3bd2-4b82-9916-be6ae79c54cc"
      decimals="-5"
      id="F_9ff77756-c969-4e0e-8ac6-cfc72f50036e"
      unitRef="U_USD">1400000</us-gaap:OperatingLeaseLiability>
    <engn:AreaOfSpace
      contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05"
      decimals="INF"
      id="F_acbe86e4-da49-4372-92d5-4687a474b433"
      unitRef="U_sqft">6450</engn:AreaOfSpace>
    <engn:AggregateAmountOfBaseRentalPayments
      contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05"
      decimals="-5"
      id="F_23d25158-a0f3-46bc-b117-d04fc776ed2a"
      unitRef="U_USD">500000</engn:AggregateAmountOfBaseRentalPayments>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_d8f4f613-565b-4dd9-9972-29f9286ff4a9"
      id="F_28d59553-61c2-4f6a-b4cd-b2624758d8cd">2026-12-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_d8f4f613-565b-4dd9-9972-29f9286ff4a9"
      id="F_283fa3eb-4a55-4d4b-ab80-54d0ec7286d9">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05"
      decimals="-5"
      id="F_13841423-2411-43c2-84c8-d7081982a92d"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_af41e941-f65b-47d2-8818-b19e36df5a05"
      decimals="-5"
      id="F_f51ede4e-f72c-4cf9-99a7-42b37b055074"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseLiability>
    <engn:AreaOfSpace
      contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e"
      decimals="INF"
      id="F_32ed2478-8b4d-44b9-9737-22473edb65cf"
      unitRef="U_sqft">26335</engn:AreaOfSpace>
    <engn:AggregateAmountOfBaseRentalPayments
      contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e"
      decimals="-5"
      id="F_45a77e01-db9b-47a3-924f-6e9683114b7d"
      unitRef="U_USD">10600000</engn:AggregateAmountOfBaseRentalPayments>
    <engn:LeaseExpirationMonthAndYear
      contextRef="C_c57bc36e-e49e-472f-83cd-c98e379c32e8"
      id="F_702ac242-a386-4667-a227-c8edcee4ff12">2030-11</engn:LeaseExpirationMonthAndYear>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e"
      decimals="-5"
      id="F_1e99d488-3bf9-4a86-b8cf-9b80435734e0"
      unitRef="U_USD">6400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_25b1651f-4d90-4142-812f-a565d3cf756e"
      decimals="-5"
      id="F_abbe426f-ba29-4672-900d-6f6973c4f278"
      unitRef="U_USD">6500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_91d6d8fb-9238-4f74-b91e-728b6663daaa">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024, the components of operating lease cost were as follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.493%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.701%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.663%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease Cost:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_13af8ce8-0beb-45c8-bb86-3860071a025b"
      unitRef="U_USD">1266000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_3e2a4935-681b-4776-94da-014d7beac128"
      unitRef="U_USD">444000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_e32f1d0b-ee54-4cb0-973a-b9a22c48fb55"
      unitRef="U_USD">24000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_5e366180-2e2a-487d-978c-4c14a512d495"
      unitRef="U_USD">1266000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_45ab9539-aa22-4527-a305-6c2ce98fb553"
      unitRef="U_USD">468000</us-gaap:LeaseCost>
    <engn:SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_5e76abda-2bc5-417c-b6a8-deadeaeae07b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the cash paid for amounts included in the measurement of the Company&#x2019;s operating lease liabilities for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025, and 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement&lt;br/&gt;&#160;&#160;&#160;of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</engn:SummaryOfCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_65aa103e-13cc-4dcd-9f86-42ef1548b446"
      unitRef="U_USD">620000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_327a3d96-8e21-49e7-ae29-6a7bbf7e826b"
      unitRef="U_USD">365000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_b3fa654e-2318-457f-a2f5-ba871bb48838">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturities of the Company's operating lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:5.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:31.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_3270e4e8-0f68-49eb-a479-d4c39159bf04"
      unitRef="U_USD">2191000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_f1704983-efe6-4461-bd0e-a4f11554aaeb"
      unitRef="U_USD">2391000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_c2b32df6-2f61-42bc-8069-6c8078e58ebf"
      unitRef="U_USD">2409000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_f1c0723a-4f0e-4d53-8680-a5050d652cb1"
      unitRef="U_USD">2457000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_6cc0f0e4-3583-4aa5-a3ac-4609c999fa34"
      unitRef="U_USD">2502000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_f97430b5-a53c-465d-81a6-5bd02e2fecc4"
      unitRef="U_USD">1081000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_16923f92-2d83-4283-a35d-c7642066dec5"
      unitRef="U_USD">13031000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_bf9d8937-950c-4632-ba1d-55a4ba2020bd"
      unitRef="U_USD">4562000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-3"
      id="F_d2233221-fe1e-4699-82b7-9181d2f2bc54"
      unitRef="U_USD">8469000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_47a4d634-ac1f-4323-9bc5-0785480c857c"
      decimals="-5"
      id="F_e64c6960-6f27-4628-b13b-9662b0a34b76"
      unitRef="U_USD">8500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3b8d1883-cc92-40a3-8c36-a8b48bf67e73"
      decimals="-5"
      id="F_96209361-12f9-402a-bafe-b0eb4ab224d4"
      unitRef="U_USD">1800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_19187141-2945-4b97-af74-e022a84d5436">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of  October 31, 2025 and 2024, there were no material claims outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Purchase and Other Obligations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into contracts in the normal course of business with CROs, CMOs and other third-party vendors for nonclinical research studies and testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or expenses incurred, including those incurred by subcontractors of our suppliers.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_fcaa193a-9dad-4648-a780-f0c44f1e7422">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which is focused on developing genetic medicines to improve the lives of patients suffering from bladder cancer. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM manages the Company&#x2019;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses consolidated net loss to evaluate the Company&#x2019;s spend, deploy resources across research and development activities and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing the performance of the operating segment and in establishing resource allocation across the organization.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Factors used in determining the reportable segment include the nature of the Company's operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies. The measure of segment assets used in determining how to manage and allocate resources is reported within the Company's consolidated balance sheets as cash and cash equivalents and marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.962%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.538%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.807%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.690999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chemistry, Manufacturing and Controls&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical operations&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses, excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses, excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(5) For the year ended October 31, 2025, other segment items consist of $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest income, $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of interest expense, and $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other expense, net. For the year ended October 31, 2024, other segment items consists of $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest income, $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest expense, $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million gain on extinguishment of debt, and $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_6b862b90-5eef-45ab-9327-11a1625aa5ed"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="INF"
      id="F_a132c9ae-785a-488b-9f1d-887988dc7c69"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_0ec3e0a2-2ecf-430b-a808-f4ee35d46d39">The CODM manages the Company&#x2019;s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_94145496-f12c-410d-9c2c-007b19f7aaea">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2025 and 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.962%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.538%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:3.807%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.690999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended October 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chemistry, Manufacturing and Controls&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical operations&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses, excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel-related expenses, excluding stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other general and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;Total general and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(5) For the year ended October 31, 2025, other segment items consist of $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest income, $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of interest expense, and $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of other expense, net. For the year ended October 31, 2024, other segment items consists of $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest income, $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of interest expense, $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million gain on extinguishment of debt, and $&lt;/span&gt;&lt;span style="font-size:6.7pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;vertical-align:sub;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8f0b12b1-19a7-4642-9e3e-cb3fe2551651"
      decimals="-3"
      id="F_267d421b-afcb-49fc-8245-0ac1aee4ac37"
      unitRef="U_USD">49578000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c882a3ef-859a-41a2-95d3-51394d6b2ce6"
      decimals="-3"
      id="F_0908186b-4e9c-433b-8b36-484d9521976e"
      unitRef="U_USD">11994000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bc0cb673-5025-437a-86f8-1e9fe06ad733"
      decimals="-3"
      id="F_7f5e1b71-025a-4441-99c8-c2e6b9cc4656"
      unitRef="U_USD">17915000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1d3671cc-d989-49b4-adba-e6701da4d6d1"
      decimals="-3"
      id="F_c2c6a16d-d2ed-4b24-9136-e0e04882ffc9"
      unitRef="U_USD">11036000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a9579fc4-c897-4bed-9b7b-0b5cf457408f"
      decimals="-3"
      id="F_1eda4af0-a79e-45af-b956-61a7cd0e3132"
      unitRef="U_USD">7052000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dcdfec87-2888-47ca-a07e-585d35c69c6b"
      decimals="-3"
      id="F_f090770c-f3b8-4735-9089-4a8f1c3716f0"
      unitRef="U_USD">4598000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0df7a474-8310-4b5a-ad28-db5514624ad7"
      decimals="-3"
      id="F_66d24940-cdef-4afd-8974-0ae5986c7eb7"
      unitRef="U_USD">16653000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8ca9c3a9-bcfe-4cfc-b190-b23c7064bddd"
      decimals="-3"
      id="F_732edc76-5515-4f28-96bf-f15e144ddc4b"
      unitRef="U_USD">8893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dffdbdca-904e-4e8d-b739-fd381dc21a3f"
      decimals="-3"
      id="F_05d47619-0ece-4d67-baa8-4c45c1a6a6de"
      unitRef="U_USD">3282000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_62b3a61d-efba-46df-bdeb-dd04f04c6a18"
      decimals="-3"
      id="F_c2499efc-2baf-4c35-a7cc-957d460bac2d"
      unitRef="U_USD">1794000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_497de29d-45d1-488c-99f5-9eab7f9a912b"
      unitRef="U_USD">94480000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_cc35c81e-9379-4de9-9684-a3d01746e763"
      unitRef="U_USD">38315000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0df7a474-8310-4b5a-ad28-db5514624ad7"
      decimals="-3"
      id="F_1c660443-09ff-4b28-a96c-bb5ee9accd75"
      unitRef="U_USD">10850000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8ca9c3a9-bcfe-4cfc-b190-b23c7064bddd"
      decimals="-3"
      id="F_3caf5e65-a00a-44a7-869f-ba1d8c44ce71"
      unitRef="U_USD">8501000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_dffdbdca-904e-4e8d-b739-fd381dc21a3f"
      decimals="-3"
      id="F_4ee41fcd-c3a7-4252-85f6-2af86b0a3f59"
      unitRef="U_USD">6364000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_62b3a61d-efba-46df-bdeb-dd04f04c6a18"
      decimals="-3"
      id="F_5eda3de3-726f-40ae-ab3b-2b3d622fe900"
      unitRef="U_USD">3530000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_d99df33c-04fc-4736-9be3-7b2f7bc93e3f"
      unitRef="U_USD">11471000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_8f5fb77d-a713-40d9-80f8-d5c0e4fc8be3"
      unitRef="U_USD">11951000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_072551ee-fe1d-4361-b454-331b8c9106e1"
      unitRef="U_USD">28685000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_f4f5e22f-1928-47b2-ac80-b43b6eb535d6"
      unitRef="U_USD">23982000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_6813fb78-a017-4527-a60a-dbb3a2971143"
      unitRef="U_USD">5863000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_a30f2e29-baec-4c63-8020-2cc47eb27df9"
      unitRef="U_USD">7155000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      decimals="-3"
      id="F_5153f3b2-86ce-44c3-ba37-8e18148372e1"
      unitRef="U_USD">-117302000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d84540e2-32ab-4a3a-b09e-c4dd8515f1bd"
      decimals="-3"
      id="F_b02924a7-91bd-48e6-b243-11805706a3fa"
      unitRef="U_USD">-55142000</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9"
      decimals="-5"
      id="F_d527fd83-38a0-40f2-9987-8e9a9d6f6dc7"
      unitRef="U_USD">9400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9"
      decimals="-5"
      id="F_99a395bf-b227-4e43-af07-887d4169e77d"
      unitRef="U_USD">3000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_35984b9c-b42a-47eb-9c9e-3d205962f9d9"
      decimals="-5"
      id="F_38d88f51-71f8-4bd2-8528-e72285a28c24"
      unitRef="U_USD">600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b"
      decimals="-5"
      id="F_3df1de18-a9bf-45bd-b161-c994d6155628"
      unitRef="U_USD">10400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b"
      decimals="-5"
      id="F_331945cc-e6fd-43f5-9670-78c2419d61e0"
      unitRef="U_USD">2800000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b"
      decimals="-5"
      id="F_272c9d23-846c-47f5-8c4e-cfe036d950c0"
      unitRef="U_USD">400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_4d915630-a09a-40c5-956c-ab23b902cf2b"
      decimals="-5"
      id="F_92dcc9aa-3cd1-4eb0-b0b8-32aadfb282bf"
      unitRef="U_USD">100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_ee25632a-9a5e-4138-b54a-85ddc931d944">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Related Party Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended October 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company did not have transactions with shareholders that hold more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total outstanding shares of the Company. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had the following transactions with shareholders that hold more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total outstanding shares of the Company:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 20, 2024, the Company completed the February 2024 PIPE Financing, which provided for the private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and included both new and existing investors. One of the Company&#x2019;s directors, Mr. Gerald Brunk, is a managing director of Lumira Ventures (&#x201c;Lumira&#x201d;), and certain entities affiliated with Lumira were party to the 2024 Subscription Agreements, purchasing an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;800,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares for a total price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the February 2024 PIPE Financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 29, 2024, the Company completed the October 2024 PIPE Financing, which provided for the private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,758,311&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and included both new and existing investors. One of the Company&#x2019;s current directors and one former director, Messrs. Wouter Joustra and Jasper Bos, respectively, are general partners of FEAC, and an entity affiliated with FEAC was party to one of the October 2024 Subscription Agreements, purchasing an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;561,797&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares for a total price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the October 2024 PIPE Financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <engn:PercentageOfSharesOwnedByShareholders
      contextRef="C_ec456d2a-f968-4f6c-91e9-ceacc426a74d"
      decimals="INF"
      id="F_5e7ed842-b948-4569-8c46-13e7885e538b"
      unitRef="U_pure">0.10</engn:PercentageOfSharesOwnedByShareholders>
    <engn:PercentageOfSharesOwnedByShareholders
      contextRef="C_8ce99e1b-781b-4b10-a4a6-a47b653599c2"
      decimals="INF"
      id="F_d083b92b-0166-4422-84e7-abb8556c5c18"
      unitRef="U_pure">0.10</engn:PercentageOfSharesOwnedByShareholders>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6dba0949-0813-4fe2-b9df-f3bd190796c3"
      decimals="INF"
      id="F_ef012032-2110-45db-9006-6364abaaf5a8"
      unitRef="U_shares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e6e3703d-5475-4ccd-a165-b5039f0166a2"
      decimals="2"
      id="F_3fa4713c-086e-45f5-a577-bfdb200c8a28"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d7458df2-05d3-41ab-b920-651c47e3645b"
      decimals="INF"
      id="F_415070ba-b5cb-470c-900c-3f2988464e8a"
      unitRef="U_shares">800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d7458df2-05d3-41ab-b920-651c47e3645b"
      decimals="-5"
      id="F_e1cda6f8-a23f-4ada-8c06-7156e5210325"
      unitRef="U_USD">8000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_cc2c96fa-b7dc-4174-82d2-d97b5a079517"
      decimals="INF"
      id="F_9ce39d2a-1cad-405c-90ae-eb1a00f923e1"
      unitRef="U_shares">6758311</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ee102497-2dad-4531-96db-ff24993a07fb"
      decimals="2"
      id="F_c31075b4-93c5-47b9-92f1-086bfad8f223"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.9</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c129c2c8-58f0-43f4-bfdf-85528ac931e9"
      decimals="INF"
      id="F_70a459f8-3286-4abd-9908-bfb4a9d8b8ea"
      unitRef="U_shares">561797</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_c129c2c8-58f0-43f4-bfdf-85528ac931e9"
      decimals="-5"
      id="F_255f9742-9d78-4e83-b21b-a9e5a27630f5"
      unitRef="U_USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_ff22ac4b-cc02-47ad-af12-b0a61d6a27ca"
      id="F_d1a0a97f-ce10-434d-87ed-6a6a25f83681">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;17. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has evaluated subsequent events through the date these financial statements were issued. Except as noted below, the Company concluded that no subsequent events have occurred that require disclosure.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Public Offering of Common Shares and Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 12, 2025, the Company entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (collectively, the &#x201c;Underwriters&#x201d;) relating to the issuance and sale by the Company, in an underwritten public offering, of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,558,823&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares at an offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Common Share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,735,295&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares at an offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.4999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;pre-funded warrant,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;each case before underwriting discounts and commissions. The offering closed on November 14, 2025. The aggregate gross proceeds from the offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting the underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Company also granted to the Underwriters a 30-day option to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,294,117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional Common Shares at the public offering price, less underwriting discounts and commissions (the &#x201c;Option&#x201d;), which the Underwriters exercised in full pursuant to a Notice of Exercise dated November 14, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  The aggregate gross proceeds from the Option exercise were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting the underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The offering closed on November 18, 2025, with respect to the Option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and do not expire. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a pre-funded warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s outstanding Common Shares immediately after exercise, which percentage may be changed at the holder&#x2019;s election to a lower or higher percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#x2019; notice to the Company, subject to the terms of the pre-funded warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e634a878-3df9-460e-9159-d57cc1cb247d"
      decimals="INF"
      id="F_3c0714f5-a572-4936-927d-9b2db797ae35"
      unitRef="U_shares">12558823</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_5e0ae0ab-6ca4-4467-9077-b61b1010d728"
      decimals="INF"
      id="F_f7e55c35-908f-4a8b-a144-9ccdc15452c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_71db83b8-afac-440b-84f1-dbe6aa46e50c"
      decimals="INF"
      id="F_8d287aa7-c86f-48f3-ba32-1c97a215b187"
      unitRef="U_shares">2735295</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="C_5e0ae0ab-6ca4-4467-9077-b61b1010d728"
      decimals="INF"
      id="F_7a5e3d41-196d-4c55-93b1-0522c5961ecd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.4999</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e634a878-3df9-460e-9159-d57cc1cb247d"
      decimals="-5"
      id="F_8d002aac-9b08-4c75-aea8-48170c86a375"
      unitRef="U_USD">130000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_e634a878-3df9-460e-9159-d57cc1cb247d"
      decimals="-5"
      id="F_10b67764-55df-44e0-bc10-31180365a84a"
      unitRef="U_USD">8200000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_222a5d6f-14cb-46e4-a552-efc82189402f"
      decimals="INF"
      id="F_dce0b189-96ff-4a3b-9340-ab87d418bf1d"
      unitRef="U_shares">2294117</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc"
      decimals="-5"
      id="F_401c92fd-6c79-4c71-b80c-0e9e59b30771"
      unitRef="U_USD">19500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc"
      decimals="-5"
      id="F_a0b77a19-d36a-4821-b993-ba7afaee59af"
      unitRef="U_USD">1200000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c1ea2072-6521-49ac-9036-975bf2bea853"
      decimals="4"
      id="F_e2c6fb55-7a09-41cd-ae88-a5de148643ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <engn:PercentageOfOutstandingCommonSharesOwnedByTheHolder
      contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc"
      decimals="4"
      id="F_9abd894f-9eb1-40df-8d71-217a2a39776c"
      unitRef="U_pure">0.0999</engn:PercentageOfOutstandingCommonSharesOwnedByTheHolder>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0aad8347-fb07-4df8-ad44-efd7872041dc"
      decimals="4"
      id="F_48904250-c5a9-46b0-933a-5984f8bdebff"
      unitRef="U_pure">0.1999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
